<SEC-DOCUMENT>0001178879-20-000015.txt : 20200302
<SEC-HEADER>0001178879-20-000015.hdr.sgml : 20200302
<ACCEPTANCE-DATETIME>20200302160628
ACCESSION NUMBER:		0001178879-20-000015
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200302
DATE AS OF CHANGE:		20200302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		20676818

	BUSINESS ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		(609) 662-2000

	MAIL ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>amicus1231201910-k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:85C9FDC6E508590992BDFE9A40C3498C,x:e8e9afb5efcb40c2ba8d83ad3c175a9b-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:fold="http://www.amicustherapeutics.com/20191231" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:AmendmentFlag" id="Fact-40041F20A13A79DD65E36B8C2F5D2891-wk-Fact-40041F20A13A79DD65E36B8C2F5D2891" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-428231AD13EE75B4492B6B8C2F7ED9CB-wk-Fact-428231AD13EE75B4492B6B8C2F7ED9CB">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-6D8D0C899AF9BB9ADBC36B8C2FB6328F-wk-Fact-6D8D0C899AF9BB9ADBC36B8C2FB6328F">FY</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalYearFocus" id="Fact-F10ED4C7EAFFC8AAEFAA6B8C2F64EA88-wk-Fact-F10ED4C7EAFFC8AAEFAA6B8C2F64EA88">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:EntityCentralIndexKey" id="Fact-50D4889DEA448BBA86996B8C2F9825BD-wk-Fact-50D4889DEA448BBA86996B8C2F9825BD">0001178879</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2018Q4" name="fold:AccumulatedDepreciationOperatingRightOfUseLeases" id="Fact-C6D384C1592E8C6E0DDEF08ACBDDFA6F-wk-Fact-C6D384C1592E8C6E0DDEF08ACBDDFA6F">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2019Q4" name="fold:AccumulatedDepreciationOperatingRightOfUseLeases" id="Fact-E512B8C8F55CC3FD57DBF08ACBE2FF60-wk-Fact-E512B8C8F55CC3FD57DBF08ACBE2FF60">5342000</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_MeasurementInputTypeAxis_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember" name="fold:ContingentConsiderationMeasurementInput" id="Fact-533C87F94613460CBEA06B8C2FC3A472-wk-Fact-533C87F94613460CBEA06B8C2FC3A472">0.780</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_MeasurementInputTypeAxis_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember" name="fold:ContingentConsiderationMeasurementInput" id="Fact-BE010A11712751116FD76B8C2FC46AEC-wk-Fact-BE010A11712751116FD76B8C2FC46AEC">0.750</ix:nonFraction><ix:nonNumeric contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="fold:DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice" id="Fact-0484CB657AE27563867E5A61FC0FC16D-wk-Fact-0484CB657AE27563867E5A61FC0FC16D">P5D</ix:nonNumeric><ix:nonNumeric contextRef="D2018Q4Dec21-Dec21_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" id="Fact-D41A82CED90A17B6F69B5A658246CD99-wk-Fact-D41A82CED90A17B6F69B5A658246CD99">P2Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-374BBBB9FEC8829FE1346B8C2F922D60-wk-Fact-374BBBB9FEC8829FE1346B8C2F922D60">0.01</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-42B154C72991371E6B9E6B8C2F9293F7-wk-Fact-42B154C72991371E6B9E6B8C2F9293F7">500000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-60DFB7974CE3763A798D6B8C2FAF6B72-wk-Fact-60DFB7974CE3763A798D6B8C2FAF6B72">189383924</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-DC52D9E141E051AFAC626B8C2F7739D1-wk-Fact-DC52D9E141E051AFAC626B8C2F7739D1">255417869</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-BFB6E95C5F70B0BD69556B8C2F910441-wk-Fact-BFB6E95C5F70B0BD69556B8C2F910441">189383924</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-BB0C14EADDD2C4D911CF6B8C2FAC3D89-wk-Fact-BB0C14EADDD2C4D911CF6B8C2FAC3D89">255417869</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="Fact-50980E499B58E712E4336B8C2F66C8E1-wk-Fact-50980E499B58E712E4336B8C2F66C8E1">0.1633987</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:InventoryValuationReserves" id="Fact-A0A724C2028202AA55A0F4D6802F8783-wk-Fact-A0A724C2028202AA55A0F4D6802F8783">200000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact-42FF67C69BE0721E5D69F460271CE743-wk-Fact-42FF67C69BE0721E5D69F460271CE743">17600000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2017Q4YTD" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" id="Fact-AD2854D8727420F8BCA26B8C2FDA10AC-wk-Fact-AD2854D8727420F8BCA26B8C2FDA10AC">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2018Q4YTD" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" id="Fact-64B19F9E1649070BE93A6B8C2FDB7C1E-wk-Fact-64B19F9E1649070BE93A6B8C2FDB7C1E">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q4YTD" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" id="Fact-ACA7C1E538DB299082616B8C2FDB5A2F-wk-Fact-ACA7C1E538DB299082616B8C2FDB5A2F">889000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2017Q4YTD" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" id="Fact-6C0DA510324686047032F0A2B2058CBD-wk-Fact-6C0DA510324686047032F0A2B2058CBD">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2018Q4YTD" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" id="Fact-97AD78C9903932ADD5A4F0A2B1D1AC33-wk-Fact-97AD78C9903932ADD5A4F0A2B1D1AC33">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q4YTD" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" id="Fact-0C028B849EF26079BB34F0A2B1BDF711-wk-Fact-0C028B849EF26079BB34F0A2B1BDF711">182000</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-9BDA315E059F4DFE6FF3F4523C44EC67-wk-Fact-9BDA315E059F4DFE6FF3F4523C44EC67">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="fold-20191231.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Feb19">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_fold_UnderwrittenOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:UnderwrittenOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_fold_LargestCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:LargestCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_fold_LargestCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:LargestCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_IncomeStatementLocationAxis_fold_ChangesInFairValueOfContingentConsiderationPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">fold:ChangesInFairValueOfContingentConsiderationPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_fold_AssetAcquisitionAxis_fold_CelenexMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="fold:AssetAcquisitionAxis">fold:CelenexMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Jul01-Jul31_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_FixedAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:FixedAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Jul01-Jul31_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30_fold_AssetAcquisitionAxis_fold_CelenexMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="fold:AssetAcquisitionAxis">fold:CelenexMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_fold_AssetAcquisitionAxis_fold_CelenexMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="fold:AssetAcquisitionAxis">fold:CelenexMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_srt_CounterpartyNameAxis_fold_CallidusBiopharmaIncMember_srt_ProductOrServiceAxis_fold_MilestonePaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fold:MilestonePaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Apr1-Apr30_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_dei_LegalEntityAxis_fold_NationwideChildrensHospitalMember_fold_AssetAcquisitionAxis_fold_CelenexMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fold:NationwideChildrensHospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="fold:AssetAcquisitionAxis">fold:CelenexMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q1QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr01-Apr30_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1February28_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Jul1-Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlan2007AndDirectorOptionPlan2007Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Mar_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr30_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlan2007AndDirectorOptionPlan2007Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlan2007AndDirectorOptionPlan2007Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec21-Dec21_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-21</xbrli:startDate>
			<xbrli:endDate>2018-12-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_MeasurementInputTypeAxis_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_MeasurementInputTypeAxis_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:CommonStockCappedCallConfirmationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:CommonStockCappedCallConfirmationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Jun07">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb15-Feb15_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-15</xbrli:startDate>
			<xbrli:endDate>2018-02-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb16-Feb16_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-16</xbrli:startDate>
			<xbrli:endDate>2018-02-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Feb15">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb16-Feb16_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-16</xbrli:startDate>
			<xbrli:endDate>2018-02-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb15-Feb15_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-15</xbrli:startDate>
			<xbrli:endDate>2018-02-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Jun07_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:CommonStockCappedCallConfirmationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q4Dec01-Dec31_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TaxCreditCarryforwardAxis_fold_OrphanDrugTaxCreditCarryforwardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">fold:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec22-Dec22">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-22</xbrli:startDate>
			<xbrli:endDate>2017-12-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q4Nov1-Nov30_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-11-01</xbrli:startDate>
			<xbrli:endDate>2013-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3Oct31_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2013Q4Nov30_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:VestedRestrictedStockUnitsUnissuedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:VestedRestrictedStockUnitsUnissuedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:VestedRestrictedStockUnitsUnissuedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="unit">
		<xbrli:measure>fold:unit</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>fold:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="vote">
		<xbrli:measure>fold:vote</xbrli:measure>
	</xbrli:unit><xbrli:unit id="program">
		<xbrli:measure>fold:program</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="day">
		<xbrli:measure>fold:day</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="sB79C2D451FE75F8A9FD4F2A436AE86C3"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">_______________________________________________________________________________________</span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:inherit;font-size:14pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:inherit;font-size:14pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d23277494e730-wk-Fact-140CB0A7F4BC108BB3FFCC4A52D40C1A" name="dei:DocumentType" contextRef="FD2019Q4YTD"><span style="font-size:14pt;font-weight:bold;">10-K</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:14pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:inherit;font-size:14pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">_______________________________________________________________________________________</span></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d23277494e752-wk-Fact-56DFDE92D9E6246914CFCC4B4F48E24D" name="dei:DocumentAnnualReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the fiscal year ended </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d23277494e762-wk-Fact-CF89E379260ED9FE9DF0CC4E79071C1D" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q4YTD" format="ixt:datemonthdayyearen">December 31, 2019</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">OR</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d23277494e782-wk-Fact-F8BACA7CD13286DFBC90CC4C9F884D8E" name="dei:DocumentTransitionReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Commission File Number&#160;</span><span><ix:nonNumeric id="d23277494e797-wk-Fact-2356A5A46AD7EC68055CCC4D80DF11FF" name="dei:EntityFileNumber" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">001-33497</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">_______________________________________________________________________________________</span></div><div style="line-height:120%;text-align:center;font-size:20pt;"><span style="font-family:inherit;font-size:20pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:20pt;"><span><ix:nonNumeric id="d23277494e808-wk-Fact-DDA3429367135D7196B9CC4CFCBE0C8B" name="dei:EntityRegistrantName" contextRef="FD2019Q4YTD"><span style="font-size:20pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:20pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">_______________________________________________________________________________________</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:178px;"></td><td style="width:56px;"></td><td style="width:92px;"></td><td style="width:25px;"></td><td style="width:326px;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d23277494e836-wk-Fact-8787B187131F118897F75A1124C8A44D" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d23277494e856-wk-Fact-6F78C1736A5985CB15545A11826F08D6" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q4YTD">71-0869350</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(State or Other Jurisdiction of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(IRS Employer</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Incorporation or Organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Identification Number)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d23277494e914-wk-Fact-6A201BF34D020706BE3D5A11B253E404" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q4YTD">1 Cedar Brook Drive,</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d23277494e919-wk-Fact-3F41E9C8B66FBEB996615A1211117334" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q4YTD">Cranbury,</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d23277494e924-wk-Fact-0FE5D8AA775151AF78765A124718D217" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q4YTD">NJ</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d23277494e934-wk-Fact-7C7277C36D64F46A496C5A127F276472" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q4YTD">08512</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Address of Principal Executive Offices)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Zip Code)</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d23277494e966-wk-Fact-A5B24CF68B3504865FAA5FE2078F71E6" name="dei:CityAreaCode" contextRef="FD2019Q4YTD">(609)</ix:nonNumeric></span></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d23277494e981-wk-Fact-71A26DFA2D3DF45BD5085FE253AD033B" name="dei:LocalPhoneNumber" contextRef="FD2019Q4YTD">662-2000</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Registrant's Telephone Number, Including Area Code)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:285px;"></td><td style="width:112px;"></td><td style="width:285px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Trading Symbols(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23277494e1047-wk-Fact-2E3BC118988C50EF4ADBCC500C954F86" name="dei:Security12bTitle" contextRef="FD2019Q4YTD">Common Stock, par value $0.01 per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23277494e1052-wk-Fact-6B3F40C8AEE37EEF32ECCC5048F2F25F" name="dei:TradingSymbol" contextRef="FD2019Q4YTD">FOLD</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23277494e1057-wk-Fact-ED5F6428BDFAE624FA8ECC508DCEFDD9" name="dei:SecurityExchangeName" contextRef="FD2019Q4YTD" format="ixt-sec:exchnameen">NASDAQ Global Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">_______________________________________________________________________________________</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;</span><span><ix:nonNumeric id="d23277494e1068-wk-Fact-B705354ECFF338EA0AC8CC517922FB6E" name="dei:EntityWellKnownSeasonedIssuer" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span><span style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;Yes&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span><span style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d23277494e1088-wk-Fact-07D146A1BE780D62359ACC519A50309C" name="dei:EntityVoluntaryFilers" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">No</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><span><ix:nonNumeric id="d23277494e1100-wk-Fact-8BAB8AD26B49209C9DC6CC599AF3F169" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span><span style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;</span><span><ix:nonNumeric id="d23277494e1116-wk-Fact-206453E805DB4FAC7F83CC5A4223A12B" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span><span style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.41592920353983%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:5%;"></td><td style="width:4%;"></td><td style="width:34%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonNumeric id="d23277494e1148-wk-Fact-14C9BCEE9D25B8CADCD55A14838793B0" name="dei:EntityFilerCategory" contextRef="FD2019Q4YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer </ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated filer </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Wingdings;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-accelerated filer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Smaller reporting company </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;"><span><ix:nonNumeric id="d23277494e1198-wk-Fact-12A0CA74ACE6E547A5DE5A14D2E5BB2C" name="dei:EntitySmallBusiness" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Emerging growth company </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;"><span><ix:nonNumeric id="d23277494e1224-wk-Fact-1BC48AAAA6465A8A2F0E5A14FAAAB57B" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. </span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark if the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes </span><span><ix:nonNumeric id="d23277494e1239-wk-Fact-2A69F76F5125307143C7CC5710F20165" name="dei:EntityShellCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;"> No </span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The aggregate market value of the </span><span style="font-family:inherit;font-size:8pt;">252,198,093</span><span style="font-family:inherit;font-size:8pt;"> shares of voting common equity held by non-affiliates of the registrant, computed by reference to the closing price as reported on The NASDAQ Global Market, as of the last business day of the registrant's most recently completed second fiscal quarter (June&#160;30, 2019) was </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d23277494e1255-wk-Fact-782A8BC254E9AD91FF2ACC582FE1069B" name="dei:EntityPublicFloat" contextRef="FI2019Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,147,432,201</ix:nonFraction></span></span><span style="font-family:inherit;font-size:8pt;">. Shares of voting and non-voting stock held by executive officers, directors, and holders of more than 10% of the outstanding stock have been excluded from this calculation because such persons or institutions may be deemed affiliates. This determination of affiliate status is not a conclusive determination for other purposes.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">February&#160;19, 2020</span><span style="font-family:inherit;font-size:8pt;">, there were </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23277494e1268-wk-Fact-A51DB6BEE9F50C52C6ADCC53F3409124" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q1Feb19" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">257,244,659</ix:nonFraction></span></span><span style="font-family:inherit;font-size:8pt;"> shares of common stock outstanding.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="TextSelection-36A62316E19402049DAFF04AA0B19DA5-0-wk-Fact-BDFCCDFABCB8772262F2F04B55D9E387" escape="true"><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">DOCUMENTS INCORPORATED BY REFERENCE: Portions of the Proxy Statement for the registrant's 2020 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s8FF189164D085E6F8C1EBFBF040D88BF"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:87%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDDA49073CD6E5379AB6F51BCAA01BE3B"><span style="font-family:inherit;font-size:10pt;">Item&#160;1.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDDA49073CD6E5379AB6F51BCAA01BE3B"><span style="font-family:inherit;font-size:10pt;">BUSINESS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDDA49073CD6E5379AB6F51BCAA01BE3B">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB94A52326B345DDF9C0EE4509E0B0D8B"><span style="font-family:inherit;font-size:10pt;">Item&#160;1A.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB94A52326B345DDF9C0EE4509E0B0D8B"><span style="font-family:inherit;font-size:10pt;">RISK FACTORS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB94A52326B345DDF9C0EE4509E0B0D8B">23</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA4296979CE875A27B263A9FFFEEC0008"><span style="font-family:inherit;font-size:10pt;">Item&#160;1B.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA4296979CE875A27B263A9FFFEEC0008"><span style="font-family:inherit;font-size:10pt;">UNRESOLVED STAFF COMMENTS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA4296979CE875A27B263A9FFFEEC0008">66</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s71AD227DB3645D5FAB584D7D43A61421"><span style="font-family:inherit;font-size:10pt;">Item&#160;2.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s71AD227DB3645D5FAB584D7D43A61421"><span style="font-family:inherit;font-size:10pt;">PROPERTIES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s71AD227DB3645D5FAB584D7D43A61421">66</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s649C89903AD6545E9AE1F4E469F08820"><span style="font-family:inherit;font-size:10pt;">Item&#160;3.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s649C89903AD6545E9AE1F4E469F08820"><span style="font-family:inherit;font-size:10pt;">LEGAL PROCEEDINGS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s649C89903AD6545E9AE1F4E469F08820">66</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2BCE0D4E8C2D5908924D06D9EF7E5C2E"><span style="font-family:inherit;font-size:10pt;">Item&#160;4.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2BCE0D4E8C2D5908924D06D9EF7E5C2E"><span style="font-family:inherit;font-size:10pt;">MINE SAFETY DISCLOSURES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2BCE0D4E8C2D5908924D06D9EF7E5C2E">66</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5E448FCE35A65BA692BD8CBD208B8411"><span style="font-family:inherit;font-size:10pt;">Item&#160;5.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5E448FCE35A65BA692BD8CBD208B8411"><span style="font-family:inherit;font-size:10pt;">MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5E448FCE35A65BA692BD8CBD208B8411">67</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s107B5D7853ED5EEFA3A660A62C9EE4EE"><span style="font-family:inherit;font-size:10pt;">Item&#160;6.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s107B5D7853ED5EEFA3A660A62C9EE4EE"><span style="font-family:inherit;font-size:10pt;">SELECTED FINANCIAL DATA</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s107B5D7853ED5EEFA3A660A62C9EE4EE">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9C749DD4726B5EF4A983BE6301642A93"><span style="font-family:inherit;font-size:10pt;">Item&#160;7.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9C749DD4726B5EF4A983BE6301642A93"><span style="font-family:inherit;font-size:10pt;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9C749DD4726B5EF4A983BE6301642A93">70</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC1713476A23C558394D08E245F2ECB55"><span style="font-family:inherit;font-size:10pt;">Item&#160;7A.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC1713476A23C558394D08E245F2ECB55"><span style="font-family:inherit;font-size:10pt;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC1713476A23C558394D08E245F2ECB55">81</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEC58A22A3F745DC58EF2B1D908A75911"><span style="font-family:inherit;font-size:10pt;">Item&#160;8.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEC58A22A3F745DC58EF2B1D908A75911"><span style="font-family:inherit;font-size:10pt;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEC58A22A3F745DC58EF2B1D908A75911">82</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEE35BFFFF353513E849894B4C79ABA8B"><span style="font-family:inherit;font-size:10pt;">Item&#160;9.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEE35BFFFF353513E849894B4C79ABA8B"><span style="font-family:inherit;font-size:10pt;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEE35BFFFF353513E849894B4C79ABA8B">121</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC84CA4FDB7735C42B193939D5F0018E6"><span style="font-family:inherit;font-size:10pt;">Item&#160;9A.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC84CA4FDB7735C42B193939D5F0018E6"><span style="font-family:inherit;font-size:10pt;">CONTROLS AND PROCEDURES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC84CA4FDB7735C42B193939D5F0018E6">121</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s50143FCB25A65C42A1AD62541FF181E3"><span style="font-family:inherit;font-size:10pt;">Item&#160;9B.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s50143FCB25A65C42A1AD62541FF181E3"><span style="font-family:inherit;font-size:10pt;">OTHER INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s50143FCB25A65C42A1AD62541FF181E3">121</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9137634C9ACF582D88C6CE54C12E70DD"><span style="font-family:inherit;font-size:10pt;">Item&#160;10.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9137634C9ACF582D88C6CE54C12E70DD"><span style="font-family:inherit;font-size:10pt;">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9137634C9ACF582D88C6CE54C12E70DD">122</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1BCF264D0C1553D0BCA3C09F781BC606"><span style="font-family:inherit;font-size:10pt;">Item&#160;11.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1BCF264D0C1553D0BCA3C09F781BC606"><span style="font-family:inherit;font-size:10pt;">EXECUTIVE COMPENSATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1BCF264D0C1553D0BCA3C09F781BC606">122</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4FDEA3A8BE265ADE8A2B00BE72D4C7BA"><span style="font-family:inherit;font-size:10pt;">Item&#160;12.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4FDEA3A8BE265ADE8A2B00BE72D4C7BA"><span style="font-family:inherit;font-size:10pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4FDEA3A8BE265ADE8A2B00BE72D4C7BA">122</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE6385A5273545FFDACF9311A2008D47E"><span style="font-family:inherit;font-size:10pt;">Item&#160;13.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE6385A5273545FFDACF9311A2008D47E"><span style="font-family:inherit;font-size:10pt;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE6385A5273545FFDACF9311A2008D47E">122</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8C6C85D20121543FBA4EBC0D5ADD73D2"><span style="font-family:inherit;font-size:10pt;">Item&#160;14.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8C6C85D20121543FBA4EBC0D5ADD73D2"><span style="font-family:inherit;font-size:10pt;">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8C6C85D20121543FBA4EBC0D5ADD73D2">122</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDAF9C920F6345F51AB2FC0381E899555"><span style="font-family:inherit;font-size:10pt;">Item&#160;15.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDAF9C920F6345F51AB2FC0381E899555"><span style="font-family:inherit;font-size:10pt;">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDAF9C920F6345F51AB2FC0381E899555">123</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s68E31F390E9753EE988A636E5A4AF02B"><span style="font-family:inherit;font-size:10pt;">SIGNATURES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s68E31F390E9753EE988A636E5A4AF02B">128</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have filed applications to register certain trademarks in the United States and abroad, including AMICUS THERAPEUTICS and design, AMICUS ASSIST and design, CHART and design, AT THE FOREFRONT OF THERAPIES FOR RARE AND ORPHAN DISEASES, HEALING BEYOND DISEASE, OUR GOOD STUFF, and Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and design. FABRAZYME, MYOZYME, LUMIZYME, and REPLAGAL are the property of their respective owners.</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sC71CB25EDAF85DD5960512018B1D0F7E"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This annual report on Form&#160;10-K contains forward-looking statements that involve risks, uncertainties, and assumptions. Forward-looking statements are all statements, other than statements of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "can," "could," "estimate," "expect," "forecast," "intend," "likely," "may," "outlook," "plan," "potential," "predict," "project," "seek," "should," "will," "would," the negatives or plurals thereof, and other words and terms of similar meaning, although not all forward-looking statements contain these identifying words.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the progress and results of our preclinical and clinical trials of our drug candidates and gene therapy candidates, including but not limited to AT-GAA, CLN6 and CLN3;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of manufacturing drug supply for our clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200") and gene therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope, progress, results, and costs of preclinical development, laboratory testing, and clinical trials for our product candidates including those testing the use of a pharmacological chaperone co-administered with ERT for the treatment of Pompe disease ("AT-GAA") and gene therapies for the treatment of rare genetic metabolic diseases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the future results of on-going preclinical research and subsequent clinical trials for cyclin-dependent kinase-like 5 ("CDKL5") deficiency, Pompe gene therapy, Fabry gene therapy, Niemann- Pick Type C ("NPC"), Mucopolysaccharidosis Type IIIB ("MPSIIIB") and next generation Mucopolysaccharidosis Type IIIA ("MPSIIIA"), including our ability to obtain regulatory approvals and commercialize these gene therapies and obtain market acceptance for such therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs, timing, and outcome of regulatory review of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any changes in regulatory standards relating to the review of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number and development requirements of other product candidates that we pursue;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the emergence of competing technologies and other adverse market developments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to successfully commercialize Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> ("migalastat HCl");</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, AT-GAA and our gene therapy candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain reimbursement for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain market acceptance of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which we acquire or invest in businesses, products, and technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to establish collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to adjust to changes in the European and United Kingdom markets in the wake of the United Kingdom leaving the European Union; </span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">1</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which our business could be adversely impacted by the effects of the COVID-19 &#8220;coronavirus&#8221; outbreak or by other health epidemics or pandemics;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fluctuations in foreign currency exchange rates; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in accounting standards.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In light of these risks and uncertainties, we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in Part I, Item 1A "&#8212; Risk Factors", that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Those factors and the other risk factors described herein are not necessarily all of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations or investments we may make. Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">You should read this Annual Report on Form 10-K and the documents that we incorporate by reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. These forward-looking statements speak only as of the date of this report. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">2</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0365FA3E2C225137887A809C096749F0"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</span></div><div><a id="sDDA49073CD6E5379AB6F51BCAA01BE3B"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We have a portfolio of product opportunities led by our novel medicine for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic, and an industry leading rare disease gene therapy portfolio.</span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cornerstone of our portfolio is Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">(also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world.</span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lead biologics program of our pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation to AT-GAA for the treatment of late onset Pompe disease. </span></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("NCH") and an expanded collaboration with the University of Pennsylvania ("Penn"). Our pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, CLN8, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Niemann-Pick Type C ("NPC"), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). Our expanded collaboration with Penn also provides us with exclusive disease-specific access and the option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Strategy</span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our strategy is to create, manufacture, test, and deliver the highest quality medicines for people living with rare metabolic diseases through internally developed, acquired, or in-licensed products and product candidates that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. In addition to our programs in Fabry and Pompe, we have begun to leverage our global capabilities to develop and expand our robust pipeline through our recent entry into genomic medicine. We have made significant progress toward fulfilling our vision to build a leading global biotechnology company focused on rare metabolic diseases. </span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Highlights of our progress include:</span></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial and regulatory success in Fabry disease</span><span style="font-family:inherit;font-size:10pt;">. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> revenue totaled </span><span style="font-family:inherit;font-size:10pt;">$182.2 million</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$91.0 million</span><span style="font-family:inherit;font-size:10pt;"> compared to the prior year. We continue to see strong commercial momentum and continue to expand into additional geographies. In the countries we have been operating the longest, such as Germany and the United Kingdom, we see an increasing proportion of previously untreated patients come onto Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. In the U.S., we continue to see a significant increase in patients from a growing and very wide prescriber base. Across all markets, we see a high rate of compliance and adherence to this oral treatment option.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pompe clinical program milestones</span><span style="font-family:inherit;font-size:10pt;">. We completed enrollment in a global pivotal study of AT-GAA (ATB200-03, also known as PROPEL) and enrolled 123 participants with late-onset Pompe disease at 59 global sites. We reported positive data from a Phase 1/2 clinical study to evaluate Pompe disease patients treated with our novel treatment paradigm AT-GAA. The U.S. FDA also granted Breakthrough Therapy designation for AT-GAA for the treatment of late-onset Pompe disease. In the first quarter of 2020, the British Medicines and Healthcare Products Regulatory Agency issued a Promising Innovative Medicine designation for AT-GAA for the treatment of late-onset Pompe disease. </span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">3</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pipeline advancement and growth.</span><span style="font-family:inherit;font-size:10pt;"> We have established an industry leading gene therapy portfolio of medicines for people living with rare metabolic diseases through a license with NCH and an expanded collaboration with Penn. In 2019, we reported positive interim clinical data from the first eight patients in the CLN6 study. Additionally, in 2019, four programs were added to the pipeline through ongoing collaborations</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:10pt;">with Penn to pursue research and development of novel gene therapies for Pompe disease, Fabry disease, CDD, NPC, MPSIIIB, as well as a next generation program in MPSIIIA.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Manufacturing</span><span style="font-family:inherit;font-size:10pt;">. We continue to manufacture our Pompe biologic at commercial scale (1,000L) for our pivotal PROPEL study and commercial supply. Our supply agreement with WuXi Biologics and current capacity are expected to produce sufficient quantities to support commercial needs as quickly as possible after receipt of applicable regulatory approvals if obtained. For gene therapy, we have recently entered into strategic partnerships with two best-in-class contract development and manufacturing organizations: Catalent Biologics and Thermo Fisher Scientific. Catalent Biologics will support our clinical manufacturing capabilities and capacity for multiple active preclinical lysosomal disorder programs that are currently in development in collaboration with Penn. Thermo Fisher will assist with late-stage clinical and commercial-scale capabilities and provides us with immediate clinical and commercial manufacturing capabilities and capacity for the Amicus intrathecal AAV Batten disease gene therapy programs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial strength. </span><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents, and marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$452.7 million</span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$504.2 million</span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. The current cash position, including expected Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> revenues, is sufficient to fund ongoing Fabry, Pompe, and gene therapy program operations into the first half of 2022. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Commercial Product and Product Candidates</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Galafold</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(Migalastat HCl) for Fabry Disease</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our oral precision medicine Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> was granted accelerated approval by the FDA in August 2018 under the brand name Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ("GLA") variant based on in vitro assay data. The FDA approved Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for 348 amenable GLA variants. Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> was approved in the E.U. and U.K. in May 2016 as a first-line therapy for long-term treatment of adults and adolescents, aged 16 years and older, with a confirmed diagnosis of Fabry disease and who have an amenable mutation (variant). The approved E.U. and U.K. labels include 367 Fabry-causing mutations, which represent up to half of all patients with Fabry disease. Approvals have also been granted in over 40 countries around the world, including the U.S., E.U., U.K., Japan, and others. We plan to continue to launch Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in additional countries during 2020.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As an orally administered monotherapy, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is designed to bind to and stabilize an endogenous alpha-galactosidase A ("alpha-Gal A") enzyme in those patients with genetic variants identified as amenable in a GLP cell-based amenability assay. Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is an oral precision medicine intended to treat Fabry disease in patients who have amenable genetic variants, and at this time, it is not intended for concomitant use with ERT. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Gene Therapy for Fabry Disease</span></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are committed to continued innovation for all people living with Fabry disease. For people living with Fabry disease who have non-amenable variants, which are not suitable for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> as a monotherapy, our strategy is to develop a Fabry gene therapy. In October 2018, we further expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for Fabry disease and other indications. In October 2019, we disclosed preliminary data from a Fabry AAV gene therapy using an Amicus-engineered transgene that demonstrated high levels of GLA activity and robust GL-3 reduction in a mouse model of Fabry disease.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fabry Disease Background</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patients with Fabry disease have an inherited deficiency of the alpha-Gal A enzyme that would normally degrade the lipid substrate globotriaosylceramide in the lysosome. Genetic variants that cause changes in the amino acid sequence of alpha-Gal A result in an unstable enzyme that does not efficiently fold into its correct three-dimensional shape and cannot be trafficked properly in the cell, even if it has the potential for biological activity. Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is an oral small molecule pharmacological chaperone that </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">4</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">is designed to bind to and stabilize a patient&#8217;s own endogenous target protein. This is considered a precision medicine because Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> targets only patients with GLA variants amenable to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fabry disease is an X-linked disease caused by mutations in the GLA gene, which encodes the alpha-Gal A enzyme. These mutations can cause alpha-Gal A to be either absent or deficient. When alpha-Gal A is absent or deficient the substrates, GL-3 and lyso-Gb3 accumulate, leading to damage of cells within affected parts of the individual's body and causing the various pathologies seen in Fabry disease. Fabry disease leads to progressive, irreversible organ damage, typically involving the nervous, cardiac, and renal systems, as well as multiple other tissues. The symptoms can be severe, differ from patient to patient, and begin at an early age, resulting in significant clinical, humanistic, and healthcare costs. Fabry disease requires lifelong medical intervention to manage the complications of this devastating disease across multiple organ systems.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fabry disease is a relatively rare disorder. The annual incidence of Fabry disease in newborn males has been historically estimated to be 1:40,000-1:60,000 (Journal of the American Medical Association January 1999 and The Metabolic and Molecular Bases of Inherited Disease 8th&#160;edition 2001). However, more recent newborn screening studies in Italy, Taiwan, Austria, and the U.S., which collectively screened more than 500,000 newborns, found the incidence of Fabry disease mutations to be between 1:2,400 to 1:8,454, more than ten times higher than previous estimates for classic patients (American Journal of Human Genetics 2006, Human Mutation 2009, the Lancet 2011, Journal of Pediatrics 2017, and JAMA Pediatrics 2018).</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that approximately 35-50% of the Fabry disease patient population may benefit from treatment with Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> as a monotherapy. Additionally, we expect that as awareness of late-onset symptoms of Fabry disease grows, the number of patients diagnosed with the disease will increase. Increased awareness of Fabry disease, particularly for specialists not accustomed to treating Fabry disease patients, may lead to increased testing and diagnosis of patients with the disease.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currently, two other products, both ERTs, are approved for the treatment of Fabry disease: agalsidase beta by Sanofi Aventis and agalsidase alfa by Takeda. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Novel ERT for Pompe Disease</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are leveraging our biologics capabilities to develop AT-GAA, a novel treatment paradigm for Pompe disease. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with a pharmacological chaperone, AT2221, to improve activity and stability. We initiated a global Phase 3 clinical study ("ATB200-03" or "PROPEL") of AT-GAA in adult patients with late onset Pompe disease in December 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pharmacological chaperone, AT2221 is not an active ingredient that contributes directly to GAA substrate reduction but instead acts to stabilize ATB200. The small molecule pharmacological chaperone AT2221 binds and stabilizes ATB200 in circulation to improve the uptake of active enzyme in key disease-relevant tissues, resulting in increased clearance of accumulated substrate, glycogen.</span></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our strategy is to enhance the body of clinical data for AT-GAA in ongoing clinical studies. Based on regulatory feedback from both the U.S. FDA and the European Medicines Agency ("EMA"), the Phase 3 PROPEL study is expected to support approval for a broad indication, including ERT-switch and treatment-na&#239;ve patients, if the results are favorable.</span></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2019, we reported additional interim data from our clinical study ATB200-02 at the 24th International Annual Congress of the World Muscle Society. Highlights included muscle function, safety, and tolerability data in patients as well as pharmacodynamic data (muscle damage biomarker, creatine kinase, disease substrate biomarker, and urine hexose tetrasaccharide). Muscle function improved in 16 out of 18 patients at 24 months. Mean six-minute walk test ("6MWT") improved in both ERT-na&#239;ve and ERT-switch patients with continued benefit observed out to month 24. All 5 ERT-naive patients showed increases from baseline in 6MWT distance at all time points out to month 24. To date, adverse events have been generally mild and transient. AT-GAA has resulted in a low rate of infusion-associated reactions ("IARs") following over 1,500+ infusions (28 events of IARs in eight patients). The clinical pharmacokinetic profile has been consistent with previously reported preclinical data. Treatment with AT-GAA resulted in persistent and durable reductions in creatine kinase and urine hexose tetrasaccharide across all patient cohorts up to month 24.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">5</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Gene Therapy for Pompe Disease</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of our long-term commitment to provide multiple solutions to address the significant unmet needs of the Pompe community, we are also advancing a next-generation gene therapy treatment for Pompe disease. In October 2018, we further expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for Pompe disease and other indications.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019, we presented initial preclinical data from our investigational adeno-associated viral ("AAV") gene therapy program for Pompe disease. This initial preclinical study in Pompe knockout mice administered a single high dose of AAV gene therapy with either unmodified wild-type hGAA ("unmodified hGAA") or an Amicus/Penn engineered hGAA transgene with a Lysosomal-Targeting Cell receptor binding motif ("engineered hGAA"). The Amicus/Penn engineered hGAA AAV gene therapy demonstrated more robust and consistent glycogen reduction compared to unmodified hGAA AAV gene therapy, in all key tissues assessed in a Pompe mouse model. In the central nervous system, the engineered hGAA AAV gene therapy also showed robust glycogen reduction in neuronal cells, suggesting this may be an effective way to address neuronal aspects of Pompe disease. Unmodified hGAA AAV gene therapy showed minimal glycogen reduction in neuronal cells. This preclinical study provides initial validation for combining Amicus-engineered transgenes with Penn's AAV gene therapy technologies.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pompe Disease Background</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like Fabry disease, Pompe disease is an LD that results from a deficiency in an enzyme, GAA. Signs and symptoms of Pompe disease can be severe and debilitating and include progressive muscle weakness throughout the body, particularly the heart and skeletal muscles. GAA deficiency causes accumulation of glycogen in cells, which is believed to result in the clinical manifestations of Pompe disease. Pompe disease ranges from a rapidly fatal infantile form with severe cardiac involvement to a more slowly progressive, late-onset form primarily affecting skeletal muscle. All forms are characterized by severe muscle weakness that worsens over time. In the early-onset form, patients are usually diagnosed shortly after birth and often experience enlargement of the heart and severe muscle weakness. In late-onset Pompe disease, symptoms may not appear until late childhood or adulthood and patients often experience progressive muscle weakness.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">According to reported estimates of the Acid Maltase Deficiency Association, the United Pompe Foundation, and the Lysosomal Disease Program at Massachusetts General Hospital, there are 5,000-10,000 patients with Pompe disease worldwide.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currently, one product, an ERT, is approved for the treatment of Pompe disease: alglucosidase alfa by Sanofi Aventis.</span></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Gene Therapy for Various Types of Batten Disease </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are researching potential first-in-class gene therapies for multiple forms of Batten disease. Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell's ability to recycle certain molecules. Each gene is called CLN (ceroid lipofuscinosis, neuronal) and given a different number designation as its subtype. There are 13 known forms of Batten disease often referred to as CLN1-8; 10-14. The various types of Batten disease have similar features and symptoms but vary in severity and age of onset.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most forms of Batten disease/NCLs usually begin during childhood. The clinical course often involves progressive loss of independent adaptive skills such as mobility, feeding, and communication. Patients may also experience vision loss, personality changes, behavioral problems, learning impairment, and seizures. Patients typically experience progressive loss of motor function and eventually those affected become wheelchair-bound, are then bedridden, and die prematurely.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have two clinical programs in CLN6 and CLN3 Batten disease, and several preclinical programs including CLN8, CLN1 and other types of Batten disease. CLN6 Batten disease results from a mutation in the CLN6 gene which primarily affects the nervous system and results in a late-infantile form of Batten disease. CLN3 Batten disease, the most common form of Batten disease, results from a mutation in the CLN3 gene which primarily affects the nervous system and results in a juvenile form of Batten disease. CLN8 Batten disease results from a mutation in the CLN8 gene which primarily affects the nervous system and results in a late-infantile form of Batten disease. CLN1 Batten disease results from a mutation in the CLN1 gene which primarily affects the nervous system and results in an infantile form of Batten disease.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">6</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The CLN6 Batten disease Phase 1/2 study completed target enrollment, with thirteen patients receiving a single administration of adeno-associated virus serotype 9 AAV-CLN6 gene therapy. In August 2019, we reported positive interim clinical data from the first eight patients in the study. The AAV-CLN6 gene therapy demonstrated a positive impact on motor and language function. Seven out of eight patients maintained stable Hamburg Motor and Language scores or had an initial change (+1 to -1 points) followed by stabilization. In October 2019, we reported additional interim clinical data further supporting the impact of one-time intrathecal AAV gene therapy in children with CLN6 Batten disease. This interim data suggested stabilization of various components of the Hamburg Motor, Language, Seizure, and Vision scores in most patients from baseline to month 12 or 24, in particular those patients treated at a younger age, compared to the progression expected in matched untreated patients. The CLN6 Batten population is approximately 1,000 patients across our commercial landscape today and there are no approved therapies for this disorder.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2018, we announced the initiation of a Phase 1/2 study to evaluate the safety and efficacy of a single intrathecal administration of adeno-associated virus serotype 9 AAV-CLN3 gene therapy in children with CLN3 Batten disease. In the Phase 1/2 study, a total of three patients were dosed in the low dose group, and based on the safety profile to date, the data safety monitoring board cleared us to begin enrollment in the high dose cohort of up to three additional patients. One high dose patient has been dosed, with no serious adverse events to date following a single administration of AAV-CLN3 gene therapy. CLN3 impacts approximately 5,000 patients across our commercial landscape today and there are no approved therapies for this disorder.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">CDKL5 Deficiency Disorder </span></div><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are researching a potential first-in-class protein replacement therapy approach for CDD. In addition, through our collaboration with Penn, we are researching a gene therapy for CDD. CDKL5 is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development. Genetic mutations in the CDKL5 gene result in CDKL5 protein deficiency and CDD. This disorder manifests clinically as persistent seizures starting in infancy, followed by severe impairment in neurological development. Most children affected by CDD cannot walk or care for themselves and may also suffer from scoliosis, visual impairment, sensory issues, and gastrointestinal complications. </span></div><div style="line-height:174%;padding-bottom:16px;padding-top:4px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Preclinical Gene Therapies</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a number of additional gene therapies in active preclinical development, including gene therapies for NPC, MPSIIIB, as well as a next generation program in MPSIIIA. Our strategy is to develop first or best in class AAV gene therapies for these rare devastating pediatric neurological lysosomal storage diseases.</span></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Strategic Alliances and Arrangements</span></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will continue to evaluate business development opportunities as appropriate that build stockholder value and provide us with access to the financial, technical, clinical, and commercial resources necessary to develop and market technologies or products with a focus on rare metabolic diseases. We are exploring potential collaborations, alliances, and other business development opportunities on a regular basis. These opportunities may include the acquisition of preclinical-stage, clinical-stage or marketed products so long as such transactions are consistent with our strategic plan to develop and provide therapies to patients living with rare and orphan diseases.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">7</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisitions</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Celenex,&#160;Inc.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, we expanded our pipeline by acquiring the rights and related intellectual property of ten gene therapy programs through the acquisition of Celenex, Inc. ("Celenex"). Celenex is a private, clinical stage gene therapy company whose lead programs are ten gene therapy programs including CLN6 and CLN3, which are in clinical stage, and several programs in pre-clinical stage. Pursuant to the terms of the agreement, we acquired Celenex for cash consideration of $100 million. We also agreed to pay up to an additional $15 million in connection with the achievement of certain development milestones, $262 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments. Celenex has an exclusive license agreement with NCH. Under this license agreement, NCH is eligible to receive development and sales-based milestones of up to $7.8 million for each product.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">MiaMed,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2016, we acquired MiaMed,&#160;Inc., ("MiaMed"), which is a pre-clinical biotechnology company focused on developing protein replacement therapy for CDD and related diseases. As part of the transaction, we may be obligated to pay up to an additional $83.0&#160;million in connection with the achievement of certain clinical, regulatory, and commercial milestones, for a potential aggregate deal value of $89.5&#160;million. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Callidus Biopharma,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our acquisition of Callidus Biopharma, Inc. ("Callidus"), we agreed to issue an aggregate of 7.2&#160;million shares of our common stock to the former stockholders of Callidus. In addition, we may be obligated to make additional payments to the former stockholders of Callidus upon the achievement of certain clinical milestones of up to $35&#160;million and regulatory milestones of up to $80&#160;million set forth in the merger agreement, provided that the aggregate merger consideration shall not exceed $130&#160;million. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patents and Trade Secrets</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success depends in part on our ability to maintain proprietary protection surrounding our product candidates, technology, and know-how, to operate without infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by filing U.S. and foreign patent applications related to our proprietary technology, including both new inventions and improvements of existing technology, that are important to the development of our business, unless this proprietary position would be better protected using trade secrets. Our patent strategy includes obtaining patent protection, where possible, on compositions of matter, methods of manufacture, methods of use, combination therapies, dosing and administration regimens, formulations, therapeutic monitoring, screening methods, and assays. We also rely on trade secrets, know-how, continuing technological innovation, in-licensing, and partnership opportunities to develop and maintain our proprietary position. Lastly, we monitor third parties for activities that may infringe our proprietary rights, as well as the progression of third-party patent applications that may have the potential to create blocks to our products or otherwise interfere with the development of our business. We are aware, for example, of U.S. patents, and corresponding international counterparts, owned by third parties that contain claims related to ERTs, and small molecules for stabilizing enzymes. If any of these patents were to be asserted against us, there is no assurance that a court would find in our favor or that, if we choose or are required to seek a license, a license to any of these patents would be available to us on acceptable terms or at all.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We own or hold license rights to several issued patents and numerous pending and issued applications, filed in the U.S., Europe, Japan, and other jurisdictions that are related to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;"> and our ongoing clinical programs:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We own issued U.S. patents that cover the use of migalastat, the active pharmaceutical ingredients in Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, in the treatment of Fabry disease, which expire in 2027, 2029, 2037 or 2038 and are listed in the FDA Orange Book. Foreign counterparts of the U.S. patents are pending or issued in Europe, Japan, and certain other jurisdictions. Further, we have pending U.S. patent applications covering methods of treating a patient diagnosed with Fabry disease with migalastat and their foreign counterparts. Any patents issuing from these applications will expire in 2038, 2039, 2040, or 2041.and we anticipate listing these patents in the FDA Orange Book if issued.</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">8</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We own several issued U.S. patents that cover various aspects of our investigational new treatment for Pompe disease, AT-GAA (ATB200/AT2221, an ERT/pharmacological chaperone combination) as well as foreign counterparts to the issued patents, most of which are still pending. Issued U.S. patents cover ATB200 compositions-of-matter, formulations, methods of manufacturing and methods of treatment and will expire in 2034, 2035 or 2037. We also have pending U.S. patent applications covering compositions, methods of treatment, methods of manufacture, and formulations with anticipated expiry in 2033, 2035, 2036, 2037, 2038, or 2040.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From the Celenex acquisition, we acquired an exclusive license to composition-of-matter and intrathecal method of treatment patent applications covering the gene therapy for treating Batten disease that are pending in the U.S., Europe, Japan, and other jurisdictions.  Any patents issued from these applications will expire in 2033 or 2040. The patent covering an intrathecal method of treatment, which expires in 2033, has issued in Europe and Japan.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patent term extensions and adjustments, supplementary protection certificates, and pediatric exclusivity periods are not reflected in the expiration dates listed above and may extend protection. </span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to our clinical programs, we actively monitor and file patent applications in the U.S. and in foreign countries on relevant technologies and pre-clinical programs. For example, we own or hold license rights to U.S. and foreign patents or patent applications covering the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gene therapy protein engineering technology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gene therapy (e.g., Pompe and Fabry) and ERT (e.g., CDKL5) programs and the use to treat specified diseases.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot be certain, however, that issued patents will be enforceable or provide adequate protection or that pending patent applications will result in issued patents.</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Individual patents extend for varying periods depending on the effective date of filing of the patent application or the date of patent issuance, and the legal term of the patents in the countries in which they are obtained. Generally, patents issued in the U.S. are effective for 20&#160;years from the earliest effective filing date. This period may be shortened by terminal disclaimer or further extended by patent term adjustment or extension. The term of foreign patents varies in accordance with provisions of applicable local law, but typically is 20&#160;years from the earliest effective filing date.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. Drug Price Competition and Patent Term Restoration Act of 1984, and amendments thereto, more commonly known as the Hatch-Waxman Act, provides for an extension of one patent, known as a Hatch-Waxman statutory extension, for each New Chemical Entity ("NCE") to compensate for a portion of the time spent in clinical development and regulatory review. However, the maximum extension is five years and the extension cannot extend the patent beyond 14&#160;years from the new drug application ("NDA") approval. Similar extensions are available in European countries, known as Supplemental Protection Certificate (SPC) extensions, Japan, and other countries. However, in the U.S. we will not know what, if any, extensions are available until a drug is approved. In addition, in the U.S., under provisions of the Best Pharmaceuticals for Children Act, we may be entitled to an additional six-month period of patent protection or market exclusivity for completing pediatric clinical studies in response to an FDA issued Pediatric Written Request before said exclusivities expire.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The patent positions of companies like ours are generally uncertain and involve complex legal, technical, scientific, and factual questions. Our ability to maintain and solidify our proprietary position for our technology will depend on our success in promptly filing patent applications on new discoveries, and in obtaining effective claims and enforcing those claims once granted. We focus special attention on filing patent applications for formulations and delivery regimens for our products in development to further enhance our patent exclusivity for those products. We seek to protect our proprietary technology and processes, in part, by contracting with our employees, collaborators, scientific advisors, and our commercial consultants to ensure that any inventions resulting from the relationship are disclosed promptly, maintained in confidence until a patent application is filed, and preferably until publication of the patent application, and assigned to us or subject to a right to obtain a license. We do not know whether any of our owned patent applications or those patent applications that are licensed to us will result in the issuance of any patents. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, narrowed, invalidated, circumvented, or be found to be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products and reduce the term of patent protection that we may have for our products. Neither we nor our licensors can be certain that we were the first to invent the inventions claimed in our owned or licensed patents or patent applications. In addition, our competitors may independently develop similar technologies or duplicate any technology developed by us and the rights granted under any issued patents may not provide us with any meaningful competitive advantages against these competitors. Furthermore, because of the extensive time required for development, testing, and regulatory review of a potential product, it is possible that any related patent may expire prior to or shortly after commencing commercialization, thereby reducing the advantage of the patent to our business and products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets are difficult to protect. We seek to protect our trade secret technology and processes, in part, by entering into confidentiality agreements with commercial partners, collaborators, employees, consultants, scientific advisors, and other contractors, and by contracting with our employees and some of our commercial consultants to ensure that any trade secrets resulting from such employment or consulting are owned by us. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be discovered independently by others. To the extent that our consultants, contractors, or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration and License Agreements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have acquired rights to develop and commercialize our product candidates through licenses granted by various parties. The following summarizes our material rights and obligations under those licenses:</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Nationwide Children's Hospital</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, we expanded our pipeline by acquiring the rights and related intellectual property of ten gene therapy programs through our acquisition of Celenex. Celenex has an exclusive license agreement with NCH. Under this license agreement, NCH is eligible to receive development and sales-based milestones of up to $7.8 million for each product.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">University of Pennsylvania</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, we expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDD, and one additional undisclosed rare metabolic disorder. In May 2019, we further expanded the collaboration from three to six programs for rare genetic diseases and now includes specifically: NPC, MPSIIIB, as well as a next generation program in MPSIIIA. This expanded collaboration with Penn also provides us with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. Under the expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $86.5 million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country- by-country basis. We will provide $10.0 million each year during the five-year agreement to fund the discovery research program. In connection with the collaboration agreement, in 2018, we made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;">$7 million</span><span style="font-family:inherit;font-size:10pt;"> in cash to Penn that was expensed to research and development expense in the Consolidated Statements of Operations. </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">GlaxoSmithKline</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2013, we entered into a Revised Agreement (the "Revised Agreement") with GlaxoSmithKline ("GSK"), pursuant to which, we obtained global rights to develop and commercialize Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between us and GSK in July 2012. Under the terms of the Revised Agreement, for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> monotherapy, GSK is eligible to receive post-approval and sales-based milestones, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. There was no other consideration paid to GSK as part of the Revised Agreement.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continue to rely on contract manufacturers to supply the active biopharmaceutical ingredients and final drug product for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, other pharmacological chaperones, our next-generation ERT product candidates, and our gene therapy product candidates. The active biopharmaceutical ingredients and final formulations for these products are manufactured under current Good Manufacturing Practice ("cGMP"). The components in the final formulation for each product are commonly used in other biopharmaceutical products and are well characterized ingredients. Although we rely on contract manufacturers, we have personnel with extensive manufacturing and quality experience to oversee our contract manufacturers. We have implemented appropriate controls for assuring the quality of both active biopharmaceutical ingredients and final drug products. Product specifications will be established in concurrence with regulatory bodies at the time of product registration.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While our third-party manufacturers have met our current manufacturing requirements, we anticipate taking steps to increase our manufacturing capabilities for our gene therapy platform. Our current arrangement with third-party manufacturers provide sufficient quantities of our program materials to meet anticipated clinical trial demands.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. In addition, several large pharmaceutical companies are increasingly focused on developing therapies for the treatment of rare diseases through organic growth, acquisitions, and partnerships. While we believe that our technologies, knowledge, experience, and scientific resources, provide us with competitive advantages, we face potential competition from many different sources, including commercial enterprises, academic institutions, government agencies, and private and public research institutions. Any product candidates that we successfully develop and commercialize will compete with both existing and new therapies that may become available in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many of our competitors may have significantly greater financial resources and expertise associated with research and development, regulatory approvals, and marketing approved products. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient, and/or are less expensive than products that we may develop. In addition, our ability to compete may be affected because in some cases insurers or other third-party payors seek to encourage the use of generic products. This may have the effect of making branded products less attractive to buyers.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">11</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Major Competitors</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our major competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for LDs. Other competitors are pharmaceutical and biotechnology companies that have approved therapies or therapies in development for rare diseases for which pharmacological chaperone technology, or next-generation ERT may be applicable. Additionally, we are aware of several early-stage, niche pharmaceutical, and biotechnology companies whose core business revolves around protein misfolding; however, we are not aware that any of these companies are currently working to develop products that would directly compete with ours. We are also aware of several pharmaceutical and biotechnology companies who are developing various treatments for novel ERTs and gene therapy. The key competitive factors affecting the success of our product candidates are likely to be their efficacy, safety, convenience, and price.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The following table lists our principal competitors and publicly available information on the status of their clinical-stage product offerings:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.83820662768031%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Competitor </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Class of Product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Status</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 Sales</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sanofi Aventis</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fabry Disease</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fabrazyme</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">ERT</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Marketed</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8364;813</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Pompe Disease</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Myozyme</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">/ Lumizyme</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">ERT</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Marketed</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8364;918</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fabry Disease</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">GZ402671</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Oral GCS Inhibitor</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase&#160;2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Pompe Disease</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">GZ402666 ("neo GAA")</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">ERT</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase&#160;3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Takeda</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fabry Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Replagal</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">ERT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Marketed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Idorsia</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fabry Disease</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lucerastat</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Oral Therapy</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase&#160;3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Protalix Biotherapeutics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fabry Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">PRX-102</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">ERT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase&#160;2/3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Avrobio</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fabry Disease</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">AVR-RD-01</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gene Therapy</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase&#160;1/2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Freeline</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fabry Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">FLT190</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gene Therapy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase&#160;1/2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sangamo</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fabry Disease</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">ST-920</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gene Therapy</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase&#160;1/2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AskBio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Pompe Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">ACTUS-101</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gene Therapy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase&#160;1/2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Audentes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Pompe Disease</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">AT845</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gene Therapy</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase&#160;1/2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Roche (Spark)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Pompe Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">SPK3006</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gene Therapy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase&#160;1/2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/A</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:inherit;font-size:9pt;">Reflects commercial products and product candidates for which IND has been filed or are in clinical development.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FDA Approval Process</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the U.S., biopharmaceutical products, including gene therapies, are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, Public Health Services Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biopharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to file&#160;a marketing application, to issue Complete Response letters or to not approve pending NDAs or biologic product license applications ("BLAs"), or to issue warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, litigation, government investigation, and criminal prosecution.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">12</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharmaceutical product development in the U.S. typically involves nonclinical laboratory and animal tests, the submission to the FDA of an Investigational New Drug application ("IND"), which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required varies substantially based upon the type, complexity, and novelty of the product or disease. Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal studies to assess the characteristics, potential safety, and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including Good Laboratory Practice ("GLP"). The results of preclinical testing are submitted to the FDA as part of an IND along with other information including information about product chemistry, manufacturing and controls, and at least one proposed clinical trial protocol. Long-term preclinical safety evaluations, such as animal tests of reproductive toxicity and carcinogenicity, continue during the IND phase of development. Reproductive toxicity studies are required to allow inclusion of women of childbearing potential in clinical trials, whereas carcinogenicity studies are required for registration. The results of these long-term studies would eventually be described in product labeling.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A 30-day review period after the submission and receipt of an IND is required prior to the commencement of clinical testing in humans. The IND becomes effective 30&#160;days after its receipt by the FDA, and trials may begin at that point unless the FDA notifies the sponsor that the investigations are subject to a clinical hold.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical trials usually involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted in compliance with applicable government regulations, Good Clinical Practice ("GCP"), as well as under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to an Institutional Review Board ("IRB"), for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical trials to support an NDA or BLA for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase&#160;1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence on pharmacodynamics effects and effectiveness.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Phase&#160;2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication or indications, dosage tolerance, and optimum dosage, and identify common adverse effects and safety risks. If a compound demonstrates evidence of efficacy and an acceptable safety profile in Phase&#160;2 evaluations, Phase&#160;3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients over longer treatment periods, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has established the Office of Tissue and Advanced Therapies within the Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving gene therapies. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors that the FDA will consider at each of the above stages of development and relate to, among other things: the proper preclinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire. NIH and the FDA have a publicly accessible database, the Genetic Modification Clinical Research Information System, which includes information on gene therapy trials and serves as an electronic tool to facilitate the reporting and analysis of adverse events on these trials. </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">13</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After completion of the required clinical testing, an NDA or BLA is prepared and submitted to the FDA for the determination of efficacy and safety. FDA approval of the NDA or BLA is required before marketing of the product may begin in the U.S. The NDA or BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product's pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA or BLA is substantial. Under federal law, the submission of most NDAs and BLAs is additionally subject to a substantial application user fee; although for orphan drugs these fees are waived, and the holder of an approved NDA or BLA may also be subject to annual product and establishment user fees. These fees are typically increased annually.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has 60&#160;days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the agency's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Marketing applications are assigned review status during the filing period. Review status could be either standard or priority. Most such applications for standard review are reviewed within 12&#160;months under PDUFA V (two months for filing plus ten months for review). The FDA attempts to review a drug candidate that is eligible for priority review within six months, as discussed below. The review process may be extended by the FDA for three additional months to evaluate major amendments submitted during the pre-specified PDUFA V review clock. The FDA may also refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an Advisory Committee for public review, typically a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an Advisory Committee, but it generally follows such recommendations. Before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA may also undertake an audit of nonclinical and clinical trial sites. The FDA will not approve the product unless compliance with cGMP is satisfactory and the NDA or BLA contains data that provide substantial evidence that the drug is safe and effective in the indication studied and to be marketed. During the product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe use of the product candidate. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After the FDA evaluates the NDA or BLA and the manufacturing facilities, it issues an approval letter or a complete response letter. Complete response letters outline the deficiencies in the submission that prevent approval and may require substantial additional testing or information for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in an amendment submitted to the NDA or BLA, the FDA will then issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type and extent of information included.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require substantial post-approval commitments or requirements to conduct additional testing and/or surveillance to monitor the drug's safety or efficacy and may impose other conditions, including distribution and labeling restrictions which can materially affect the potential market and profitability of the drug. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained, problems are identified following initial marketing, or post-marketing commitments are not met.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Hatch-Waxman Act</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA certain patent(s) with claims that cover the applicant's product or approved method of use. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an Abbreviated New Drug Application ("ANDA"). An ANDA provides for marketing of a drug product that has the same route of administration, active ingredients strength, and dosage form as the listed drug and has been shown through bioequivalence testing to be, in most cases, therapeutically equivalent to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of their drug product, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as "generic equivalents" to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed "innovator" drug.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">14</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA's Orange Book. Specifically, the applicant must certify that: (i)&#160;the required patent information has not been filed; (ii)&#160;the listed patent has expired; (iii)&#160;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv)&#160;the listed patent is invalid or will not be infringed by the new product. A certification that the new product will not infringe the already approved product's listed patents or that such patents are invalid is called a Paragraph&#160;4 certification. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the ANDA applicant submits a Paragraph&#160;4 certification to the FDA, the applicant must also send notice of the Paragraph&#160;4 certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;4 certification. The filing of a patent infringement lawsuit within 45&#160;days of the receipt of a Paragraph&#160;4 certification automatically prevents the FDA from approving the ANDA until the earlier of 30&#160;months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patent term and data exclusivity run in parallel. An ANDA application also will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of an NCE, listed in the Orange Book for the referenced product has expired (New Chemical Entity Market Exclusivity). Federal law provides a period of five years following approval of a drug containing no previously approved active ingredients, during which ANDAs for generic versions of those drugs cannot be submitted unless the submission contains a Paragraph&#160;4 certification that challenges a listed patent, in which case the submission may be made four years following the original product approval.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal law provides for a period of three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration or combination, or for a new use, the approval of which was required to be supported by new clinical trials conducted by or for the sponsor, during which the FDA cannot grant effective approval of an ANDA based on that listed drug for the same new dosage form, route of administration or combination, or new use.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Regulatory Requirements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Once an NDA or BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, communications regarding unindicated uses, industry-sponsored scientific and educational activities, and promotional activities involving the internet.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Drugs may be promoted only for approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, new safety information, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA, NDA supplement, BLA, or BLA supplement before the change can be implemented. New efficacy claims require submission and approval of an NDA supplement and BLA supplement for each new indication.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The efficacy claims typically require new clinical data similar to those included in the original application. The FDA uses the same procedures and actions in reviewing NDA and BLA supplements as it does in reviewing NDAs and BLAs. Additional exclusivity may be granted for new efficacy claims. Generic ANDAs cannot be labeled for these types of claims until the new exclusivity period expires.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA or BLA. The FDA also may require post-marketing testing, known as Phase&#160;4 testing, risk evaluation and mitigation strategies, and surveillance to monitor the effects of an approved product, or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as drug manufacture, packaging, and labeling procedures must continue to conform to cGMP, after approval. Drug manufacturers and certain subcontractors are required to register their establishments with FDA and certain state agencies and are subject to routine inspections by the FDA during which the agency inspects manufacturing facilities to access compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">15</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Orphan Drugs</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. The first NDA or BLA applicant with FDA orphan drug designation for a particular active ingredient to receive FDA approval of the designated drug for the disease indication for which it has such designation, is entitled to a seven-year exclusive marketing period (Orphan Drug Exclusivity) in the U.S. for that product, for that indication. During the seven-year period, the FDA may not finally approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the license holder cannot supply sufficient quantities of the product. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition, provided that the sponsor has conducted appropriate clinical trials required for approval. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA or BLA application user fee for the orphan indication.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pediatric Information</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Pediatric Research Equity Act of 2007 ("PREA"), NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fast Track Designation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Fast Track program, the sponsor of an IND may request the FDA to designate the drug candidate as a Fast Track drug if it is intended to treat a serious condition and fulfill an unmet medical need. The FDA must determine if the drug candidate qualifies for Fast Track designation within 60&#160;days of receipt of the sponsor's request. Once the FDA designates a drug as a Fast Track candidate, it is required to facilitate the development and expedite the review of that drug by providing more frequent communication with and guidance to the sponsor.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to other benefits such as greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track drug's NDA or BLA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA's review period as specified under PDUFA V for filing and reviewing an application does not begin until the last section of the NDA or BLA has been submitted. Additionally, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Breakthrough Therapy Designation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A Breakthrough Therapy designation conveys all of the Fast Track program features, as well as more intensive FDA guidance on an efficient drug development program. The FDA also has an organizational commitment to involve senior management in such guidance.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Priority Review</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under FDA policies, a drug candidate is eligible for priority review, or review within six months from filing for a new molecular entity ("NME") or six months from submission for a non-NME if the drug candidate provides a significant improvement compared to marketed drugs in the treatment, diagnosis, or prevention of a disease. A Fast Track designated drug candidate would ordinarily meet the FDA's criteria for priority review. The FDA makes its determination of priority or standard review during the 60-day filing period after an initial NDA or BLA submission.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">16</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accelerated Approval</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the FDA's accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit. This approval mechanism is provided for under 21CRF314 Subpart&#160;H and Subpart&#160;E. In this case, clinical trials are conducted in which a surrogate endpoint is used as the primary outcome for approval. A surrogate endpoint is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. This surrogate endpoint substitutes for a direct measurement of how a patient feels, functions, or survives and is considered reasonably likely to predict clinical benefit. Such surrogate endpoints may be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. When the Phase&#160;4 commitment is successfully completed, the biomarker is deemed to be a surrogate endpoint. Failure to conduct required post-approval studies or confirm a clinical benefit during post-marketing studies, could lead the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Section&#160;505(b) (2)&#160;New Drug Applications</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most drug products obtain FDA marketing approval pursuant to an NDA, an ANDA, or a BLA. A fourth alternative is a special type of NDA, commonly referred to as a Section&#160;505(b) (2)&#160;NDA, which enables the applicant to rely, in part, on the safety and efficacy data of an existing product, or published literature, in support of its application.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">505(b) (2)&#160;NDAs often provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section&#160;505(b)(2) permits the submission of an NDA for which at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely upon certain preclinical or clinical studies conducted for an approved product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new product candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section&#160;505(b) (2)&#160;applicant.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the extent that the Section&#160;505(b) (2)&#160;applicant is relying on studies conducted for an already-approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent as an ANDA applicant. Thus approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of an NCE, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph&#160;4 certification and subsequent patent infringement suit, until the earlier of 30&#160;months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section&#160;505(b)(2) applicant.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">17</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patient Protection and Affordable Care Act of 2010</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), which was enacted as part of the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 ("PPACA") created an abbreviated approval pathway for biological products that are demonstrated to be "biosimilar" or "interchangeable" with an FDA-licensed reference biological product via an approved BLA. Biosimilarity to an approved reference product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity is demonstrated in steps beginning with rigorous analytical studies or "fingerprinting", in vitro studies, in vivo animal studies, and generally at least one clinical study, absent a waiver from the Secretary of Health and Human Services. The biosimilarity exercise tests the hypothesis that the investigational product and the reference product are the same. If at any point in the stepwise biosimilarity process a significant difference is observed, then the products are not biosimilar, and the development of a stand-alone NDA or BLA is necessary. In order to meet the higher hurdle of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being evaluated by the FDA. Under the BPCIA, a reference biologic is granted 12&#160;years of exclusivity from the time of first licensure of the reference product.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-Kickback, False Claims Laws,&#160;the Prescription Drug Marketing Act and Other Regulations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes as well as regulations related to payments and transfers of value to healthcare providers, the protection of the security and privacy of protected health information, and other compliance efforts. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Violations of the anti-kickback statute are punishable by imprisonment, criminal fines, civil monetary penalties, and exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services, reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Physician Drug Samples</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The Prescription Drug Marketing Act (the "PDMA") imposes requirements and limitations upon the provision of drug samples to physicians, as well as prohibits states from licensing distributors of prescription drugs unless the state licensing program meets certain federal guidelines that include minimum standards for storage, handling, and record keeping. In addition, the PDMA sets forth civil and criminal penalties for violations.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">18</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulation Outside the U.S.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to regulations in the U.S., we are subject to a variety of regulations in other jurisdictions governing clinical studies, commercial sales, and distribution of our products. Most countries outside the U.S. require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. In addition, whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of countries outside the U.S. before we can commence clinical studies or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To obtain regulatory approval of an orphan drug under the E.U. and U.K. regulatory systems, we are mandated to submit MAAs in Centralized Procedure. The centralized procedure, which came into operation in 1995, allows applicants to obtain a marketing authorization that is valid throughout the E.U. and U.K. It is compulsory for medicinal products manufactured using biotechnological processes, for orphan medicinal products and for human products containing a new active substance which was not authorized in the Community before 20&#160;May 2004 (date of entry into force of Regulation (EC) No 726/2004) and which are intended for the treatment of AIDS, cancer, neurodegenerative disorder or diabetes. The centralized procedure is optional for any other products containing new active substances not authorized in the Community before 20&#160;May 2004 or for products which constitute a significant therapeutic, scientific or technical innovation or for which a Community authorization is in the interests of patients at Community level. When a company wishes to place on the market a medicinal product that is eligible for the centralized procedure, it sends an application directly to the European Medicines Agency, to be assessed by the Committee for Medicinal Products for Human Use ("CHMP"). The procedure results in a Commission decision, which is valid in all E.U. Member States and the U.K. Centrally-authorized products may be marketed in all Member States. Centralized procedure: Full copies of the MA application are sent to a rapporteur and a co-rapporteur designated by the competent EMA scientific committee. They coordinate the EMA's assessment of the medicinal product and prepare draft reports. Once the draft reports are prepared (other experts might be called upon for this purpose), they are sent to the CHMP, whose comments or objections are communicated to the applicant. The rapporteur is therefore the privileged interlocutor of the applicant and continues to play this role, even after the MA has been granted.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The rapporteur and co-rapporteur then assess the applicant's replies, submit them for discussion to the CHMP and, taking into account the conclusions of this debate, prepare a final assessment report. Once the evaluation is completed, the CHMP gives a favorable or unfavorable opinion as to whether to grant the authorization. When the opinion is favorable, it shall include the draft summary of the product's characteristics, the package leaflet and the texts proposed for the various packaging materials. The time limit for the evaluation procedure is 210&#160;days. The EMA then has fifteen days to forward its opinion to the Commission. This is the start of the second phase of the procedure: the decision-making process. The Agency sends to the Commission its opinion and assessment report, together with annexes containing: the SmPC (Annex&#160;1); the particulars of the MAH responsible for batch release, the particulars of the manufacturer of the active substance and the conditions of the marketing authorization (Annex&#160;2); and the labelling and the package leaflet (Annex&#160;3). The annexes are translated into the 22 other official languages of the E.U. During the decision-making process, the Commission services verify that the marketing authorization complies with Union law. The Commission has fifteen days to prepare a draft decision. The medicinal product is assigned a Community registration number, which will be placed on its packaging if the marketing authorization is granted. During this period, various Commission directorates-general are consulted on the draft marketing authorization decision.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The draft decision is then sent to the Standing Committee on Medicinal Products for Human Use, (Member States have one representative each in both of these committees) for their opinions. The Centralized Procedure, which is compulsory for medicines produced by certain biotechnological processes and optional for those which are highly innovative, provides for the grant of a single marketing authorization that is valid for all E.U. member states and U.K. The Decentralized Procedure provides for approval by one or more other, or concerned, member states of an assessment of an application performed by one member state, known as the reference member state. Under this procedure, an applicant submits an application, or dossier, and related materials including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the related materials within 120&#160;days after receipt of a valid application. Within 90&#160;days of receiving the reference member state's assessment report, each concerned member state must decide whether to approve the assessment report and related materials. If a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to the public health, the disputed points may eventually be referred to the European Commission, whose decision is binding on all member states.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">19</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have obtained an orphan medicinal product designation in the E.U. and U.K. from the EMA for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Fabry disease and the combination product, ATB200/AT2221, for the treatment of Pompe disease. Applications from persons or companies seeking "orphan medicinal product designation" for products they intend to develop for the diagnosis, prevention, or treatment of life-threatening or very serious conditions that affect not more than 5 in 10,000 persons in the E.U. and U.K. are reviewed by the Committee for Orphan Medicinal Products ("COMP"). In addition, orphan drug designation can be granted if the drug is intended for a life threatening, seriously debilitating, or serious and chronic condition in the E.U. and U.K. and that without incentives it is unlikely that sales of the drug in the E.U. and U.K. would be sufficient to justify developing the drug. Orphan drug designation is only available if there is no other satisfactory method approved in the E.U. and U.K. of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orphan drug designation provides opportunities for fee reductions for protocol assistance and access to the centralized regulatory procedures before and during the first year after marketing approval, which reductions are not limited to the first year after marketing approval for small and medium enterprises. In addition, if a product which has an orphan drug designation subsequently receives EMA marketing approval for the indication for which it has such designation, the product is entitled to orphan drug exclusivity, which means the EMA may not approve any other application to market the same drug for the same indication for a period of 10&#160;years. The exclusivity period may be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Competitors may receive marketing approval of different drugs or biologics for the indications for which the orphan product has exclusivity. In order to do so, however, they must demonstrate that the new drugs or biologics provide a significant benefit over the existing orphan product. This demonstration of significant benefit may be done at the time of initial approval or in post-approval studies, depending on the type of marketing authorization granted.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have obtained a positive opinion for our pediatric investigation plan ("PIP") in the E.U. and U.K. for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Fabry disease as well. In May 2016, we announced that we had received full European Commission approval for migalastat HCl, under the product name Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, as a first-line therapy for long-term treatment of adults and adolescents aged 16&#160;years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. A PIP is a development plan aimed at ensuring that the necessary data are obtained to support the authorization of a medicine for children, through studies in children. All applications for marketing authorization for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral or waiver. This requirement also applies when a marketing-authorization holder wants to add a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized and covered by intellectual property rights. Several rewards and incentives for the development of pediatric medicines for children are available in the E.U. and U.K. Medicines authorized across the E.U. and U.K. with the results of studies from a PIP included in the product information are eligible for an extension of their supplementary protection certificate by six months. This is the case even when the studies' results are negative. For orphan medicines, the incentive is an additional two years of market exclusivity. Scientific advice and protocol assistance at the Agency are free of charge for questions relating to the development of pediatric medicines. Medicines developed specifically for children that are already authorized but are not protected by a patent or supplementary protection certificate are eligible for a pediatric-use marketing authorization ("PUMA"). If a PUMA is granted, the product will benefit from 10&#160;years of market protection as an incentive.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have obtained orphan drug designation in Japan for migalastat for the treatment of Fabry Disease. We also have other Orphan Drug applications approved in rest of world markets including Switzerland, Australia, South Korea and Taiwan. The Ministry of Health, Labor, and Welfare, based on the opinion of the Pharmaceutical Affairs and Food Sanitation Council, grants orphan status to drugs intended to address serious illnesses with high unmet medical need that affect fewer than 50,000 patients in Japan. Orphan designation provides certain benefits and incentives, including priority review for marketing authorization and a period of 10&#160;years of market exclusivity if the drug candidate is approved for the designated indication.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In a referendum held in U.K. on June 23, 2016, a majority of those voting voted for the U.K. to leave the E.U., commonly referred to as "Brexit". On March 29, 2017, the U.K. government delivered to the European Council notice of its intention to leave the E.U. The negotiation period (under Article 50 of the Treaty on European Union) had been extended repeatedly; however, on January 24, 2020, the U.K. and the E.U. entered into a withdrawal agreement pursuant to which the U.K. formally left the E.U. on January 31, 2020, but will, for a transition period ending on December 31, 2020, maintain access to the E.U. single market and to the global trade deals negotiated by the E.U. on behalf of its members and remain subject to E.U. law. The ultimate impact of Brexit will depend on the terms that are negotiated in relation to the U.K.&#8217;s future relationship with the E.U. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which E.U. laws to replicate or replace.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">20</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Foreign Corrupt Practices Act</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits U.S. corporations and individuals from engaging in certain activities to obtain or retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. Equivalent laws have been adopted in other foreign countries that impose similar obligations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmaceutical Pricing and Reimbursement</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the U.S. and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative authorities, managed care providers, private health insurers, and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare product candidates, and efforts are underway by the current U.S. administration and states to reduce the cost of prescription drugs overall. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. Our product candidates may not be considered cost-effective. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2003, the U.S. government enacted legislation providing a partial prescription drug benefit for Medicare recipients that began in 2006. Government payment for some of the costs of prescription drugs may increase demand for any products for which we receive marketing approval. However, to obtain payments under this program, we would be required to sell products to Medicare recipients through managed care organizations and other health care delivery systems operating pursuant to this legislation. These organizations would negotiate prices for our products, which are likely to be lower than we might otherwise obtain. Federal, state, and local governments in the U.S. continue to consider legislation to limit the growth of healthcare costs, including the cost of prescription drugs. Future legislation could limit payments for biopharmaceuticals such as the drug candidates that we are developing.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals. With the current administration and Congress, there have been efforts to make additional legislative changes, including repeal and replacement of certain provisions of the PPACA. It is unclear what impact such legislative changes will have on the availability of healthcare and/or containing or lowering the costs of healthcare.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the U.S. has increased and will continue to increase the pressure on pharmaceutical pricing.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had 584 full-time employees. None of our employees were represented by a labor union. We have not experienced any work stoppages and consider our employee relations to be good.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">21</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Corporate Information</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We were incorporated under the laws of the State of Delaware on February&#160;4, 2002. Our global headquarters are located at 1 Cedar Brook Drive, Cranbury, NJ 08512 and our telephone number is (609)&#160;662-2000. Our website address is </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">www.amicusrx.com</span><span style="font-family:inherit;font-size:10pt;">. We make available free of charge on our website our annual, quarterly, and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the U.S. Securities and Exchange Commission.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information relating to our corporate governance, including our Code of Business Conduct for Employees, Executive Officers and Directors, Corporate Governance Guidelines, and information concerning our senior management team, Board of Directors, including Board Committees and Committee charters, and transactions in our securities by directors and executive officers, is available on our website at </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">www.amicusrx.com</span><span style="font-family:inherit;font-size:10pt;"> under the "Investors&#160;&#8212; Corporate Governance" caption and in print to any stockholder upon request. Any waivers or material amendments to the Code will be posted promptly on our website.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">22</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB94A52326B345DDF9C0EE4509E0B0D8B"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following risk factors and other information included in this Annual Report on Form&#160;10-K should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Please see page&#160;1 of this Annual Report on Form&#160;10-K for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks occur, our business, financial condition, results of operations, and future growth prospects could be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to our Products and the Regulatory Approval and Clinical Development of our Product Candidates</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend heavily on sales of our first product, Galafold</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">, in Europe., the U.S. and Japan. Moreover, if we are unable to commercialize Galafold</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> successfully, or experience significant delays in doing so, our business could be materially harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have invested a significant portion of our efforts and financial resources in the development of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Fabry disease and rely upon sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> primarily in Europe. and growing sales in the U.S. and Japan. Our ability to generate material product revenues will depend heavily on the successful development, regulatory approval, and commercialization of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. We began the commercial launch of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the E.U. and U.K. in May 2016, in Japan in June 2018 and in the U.S. in August 2018 and continue to seek commercial approval in additional foreign jurisdictions. Approvals have been granted in over 40 countries around the world. We will continue to study Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in a confirmatory Phase 4 program and other supportive Phase 4 studies. If the results of the Phase 4 studies negatively change the benefit/risk profile of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, the commercial success of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> may be substantially diminished. Any adverse market event with respect to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, including failure to obtain sufficient market acceptance, could have a material adverse effect on our business, financial condition and results of operations. If our sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> were to decrease, or such sales were substantially or completely displaced in the market, or if we are unable to achieve sufficient market acceptance of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> by physicians, patients, third-party payors and others in the medical community, or if we fail to receive commercial approval in any additional jurisdictions, it could have a material adverse effect on our business, financial condition and results of operations. In addition, if Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> or similar products from our competitors were to become the subject of litigation and/or an adverse governmental action requiring us or such competitors, as applicable, to cease sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, such an event could have a material adverse effect on our business, financial condition and results of operations. In addition, the entry into the market of competitors with new or generic treatments, including oral, ERT and gene therapies, may erode the market for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and have a material impact on our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any delay or impediment in our ability to obtain regulatory approval in any region to commercialize, or, when approved, obtain coverage and adequate reimbursement from third parties, including government payors, for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> may cause us to be unable to meet our revenue guidance or to generate the revenues necessary to continue our research and development pipeline activities, thereby adversely affecting our business and our prospects for future growth.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, the success of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> will depend on a number of factors, including the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtaining a sufficiently broad label in each territory that would not unduly restrict patient access;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtaining additional foreign approvals for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continuing to build and maintain an infrastructure capable of supporting product sales, marketing, and distribution of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the U.S., Europe, Japan and other territories where we pursue commercialization directly;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintaining commercial manufacturing arrangements with third-party manufacturers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintaining commercial distribution agreements with third-party distributors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">launching commercial sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, where approved, whether alone or in collaboration with others;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acceptance of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, where approved, by patients, the medical community and third-party payors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">effectively competing with other therapies, including potential generics and potential gene therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a continued acceptable safety profile of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">23</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">protecting and enforcing our rights in our intellectual property portfolio; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtaining and maintaining a commercially viable price for our products.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, which would materially harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product or product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our product and product candidates, including Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and AT-GAA and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, commercialization and reimbursement are subject to comprehensive regulation by the EMA, the PMDA, the FDA, and other regulatory agencies in the U.S. and by comparable authorities in other countries. Failure to obtain regulatory approval for our product and product candidates will prevent us from commercializing our product in jurisdictions beyond those in which we have obtained regulatory approval for our product or in any jurisdictions for our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have also acquired a pipeline of gene therapies in development to treat rare metabolic diseases, in addition to development of AT-GAA for Pompe disease. Securing marketing approval for all our product candidates requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy. We will continue to rely on third parties to assist us with filing and supporting the applications necessary to obtain marketing approvals for product candidates in this process. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Regulatory authorities may determine that any of our products or product candidates are not effective or only moderately effective, or have undesirable or unintended side effects, toxicities, safety profiles or other characteristics that preclude us from obtaining marketing approval or that prevent or limit commercial use.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obtaining approval for all of our product candidates is highly uncertain and we may fail to obtain regulatory approval in any or all jurisdictions. The review processes and the processes of regulatory authorities, including the FDA, EMA and PMDA, are extensive, lengthy, expensive, and uncertain, and such regulatory authorities may delay, limit, or deny approval of any of our product candidates for many reasons, including, but not limited to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our failure to demonstrate to the satisfaction of the applicable regulatory authorities that any of our product candidates are safe and effective for a particular indication;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the results of clinical trials may not meet the level of statistical significance or other efficacy or safety parameters required by the applicable regulatory authorities for approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the applicable regulatory authority may disagree with the number, design, size, conduct, or implementation of our clinical trials or conclude that the data fail to meet statistical or clinical significance;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the applicable regulatory authority may not find the data from preclinical studies and clinical trials sufficient to demonstrate that the product candidate's clinical and other benefits outweigh its safety risks;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the applicable regulatory authority may disagree with our interpretation of data from preclinical studies or clinical trials, and may reject conclusions from preclinical studies or clinical trials, or determine that primary or secondary endpoints from clinical trials were not met, or reject safety conclusions from such studies or trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the applicable regulatory authority may not accept data generated at one or more of our clinical trial sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the applicable regulatory authority may determine that we did not properly oversee our clinical trials or follow the regulatory authority's advice or recommendations in designing and conducting our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an advisory committee, if convened by the applicable regulatory authority, may recommend against approval of our application or may recommend that the applicable regulatory authority require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve the product candidate; and</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">24</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the applicable regulatory authority may identify deficiencies in the chemistry, manufacturing, and control sections of our application, our manufacturing processes, facilities, or analytical methods or those of our third-party contract manufacturers, and this may lead to significant delays in the approval of our product candidates or to the rejection of our applications altogether.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The process of obtaining marketing approvals is expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our product or product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Undesirable side effects caused by our product, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> or product candidates including AT-GAA, CLN6 and CLN3, could interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA, EMA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing our product or product candidates and generating revenues from their sale. In addition, if we or others identify undesirable side effects caused by our products or product candidates after receipt of marketing approval:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory authorities may require the addition of restrictive labeling statements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory authorities may withdraw their approval of the product; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be required to change the way the product is administered, or additional clinical trials are conducted.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or product candidate or could substantially increase the costs and expenses of commercializing the product or product candidate, which in turn could delay or prevent us from generating significant revenues from its sale or adversely affect our reputation.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to establish and maintain sales and marketing capabilities or enter into agreements with third parties to market and sell our product or product candidates, we may not be successful in commercializing Galafold</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">, or any product candidate if and when they are approved.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To achieve commercial success for any approved product, we must continue to develop and maintain a sales and marketing organization or outsource commercialization to third parties. We have established our own sales and marketing capabilities to promote Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in Europe, Japan, the U.S. and other foreign jurisdictions with a targeted sales force. There are risks involved with establishing and maintaining our own sales and marketing capabilities and entering into arrangements with third parties to perform these services for any of our products or product candidates. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Similarly, if we enter into agreements with third parties, including the out licensing of our product or product candidates, we may choose to reduce or eliminate our sales and marketing operations and thereby lose our commercialization investment.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Factors that may inhibit our efforts to successfully commercialize Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, or our product candidates, if and when they are approved by regulatory authorities, including the FDA, PMDA and EMA, on our own include:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the inability of sales personnel to obtain access to adequate numbers of physicians to prescribe any future products;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">25</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">efforts by our competitors to commercialize products at or about the time when our product candidates would be coming to market.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also co-promote or out license our product or product candidates in various markets with pharmaceutical and biotechnology companies in instances where we believe that a larger sales and marketing presence will expand the market or accelerate penetration. If we do enter into co-promote or out licensing arrangements with third parties, our product revenues will be lower than if we directly sold and marketed our products and any revenues received under such arrangements will depend on the skills and efforts of others.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not be successful in entering into distribution arrangements and marketing alliances with third parties. Our failure to enter into these arrangements on favorable terms could delay or impair our ability to commercialize our product and product candidates and could increase our costs of commercialization. Dependence on distribution arrangements and marketing alliances to commercialize our products and product candidates will subject us to a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may not be able to control the amount and timing of resources that our distributors may devote to the commercialization of our product or product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our distributors may experience financial difficulties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our distributors may experience compliance related issues and associated government investigations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">business combinations or significant changes in a distributor's business strategy may also adversely affect a distributor's willingness or ability to complete its obligations under any arrangement; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">these arrangements are often terminated or allowed to expire, which could interrupt the marketing and sales of a product and decrease our revenue.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are unable to establish and maintain adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue at our current guidance and may not ever become profitable.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the market opportunities for our product or product candidates are smaller than we believe they are, then our revenues may be adversely affected, and our business may suffer.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each of the diseases that our product and most advanced product candidates are being developed to address is rare. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product and product candidates, are based on estimates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currently, most reported estimates of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas, which are then extrapolated to estimate the prevalence of the diseases in the broader world population. In addition, as new studies are performed the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Fabry disease, Pompe disease, Batten disease or other rare diseases in the study populations, particularly in these newer studies, accurately reflects the prevalence of these diseases in the broader world population. If our estimates of the prevalence of Fabry disease, Pompe disease, Batten disease, or other rare diseases or of the number of patients who may benefit from treatment with our product or product candidates prove to be incorrect, the market opportunities for our product and product candidates may be smaller than we believe they are, our prospects for generating revenue at our guidance levels may be adversely affected and our business may suffer.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">26</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Galafold</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> or any of our product candidates that receive regulatory approval may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and any of our other products or product candidates that receive regulatory approval may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the efficacy and potential advantages compared to alternative treatments, including generics and gene therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the prevalence and severity of any side effects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to offer our product and product candidates for sale at competitive prices;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">convenience and ease of administration compared to alternative treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">publicity concerning our products or competing products and treatments; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sufficient third-party coverage or reimbursement.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to negotiate, secure and maintain third-party coverage and reimbursement may be affected by political, economic and regulatory developments in the U.S., E.U., U.K. and other jurisdictions. Governments continue to impose cost containment measures, and third-party payors are increasingly challenging prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. These and other similar developments could significantly limit the degree of market acceptance of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">and any of our product candidates that receive marketing approval and we may fail to meet our revenue targets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product and product candidates and any products we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology and gene therapy companies worldwide. For example, several large pharmaceutical and biotechnology companies currently market and sell products for the treatment of lysosomal storage disorders, including Fabry disease. These products include Sanofi Aventis' Fabrazyme</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and Takeda&#8217;s Replagal</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, as well as other Fabry treatment products in development. In addition, Sanofi markets and sells Myozyme</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and Lumizyme</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Pompe disease and has another product for Pompe in development, Neo-GAA. We are also aware of other enzyme replacement and substrate reduction therapies in development by third parties for Pompe, as well as potential gene therapies for both Fabry and Pompe and our other product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or noncompetitive. Our competitors may also obtain FDA, EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours, could achieve regulatory exclusivity and block us from approval and marketing our products for a significant period of time. We may also face competition from off-label use of other approved therapies. There can be no assurance that developments by others will not render our product candidates or any acquired products obsolete or noncompetitive either during the research phase or once the products reaches commercialization.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that many competitors, including academic institutions, government agencies, public and private research organizations, large pharmaceutical companies and smaller more focused companies, are attempting to develop therapies for many of our target indications. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, prosecuting intellectual </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">27</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">property rights and marketing approved products than we do. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to or necessary for our programs or advantageous to our business. In addition, if we obtain regulatory approvals for our product candidates, manufacturing efficiency and marketing capabilities are likely to be significant competitive factors. We currently rely on third-party manufacturers for our product and all of our product candidates including our gene therapies. Further, many of our competitors have substantial resources and expertise in conducting collaborative arrangements, sourcing in-licensing arrangements, manufacturing and acquiring new business lines or businesses that are greater than our own.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A variety of risks associated with international operations could materially adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, and any of our other product candidates that may be approved in the future for commercialization in the E.U., U.K. or in other foreign countries, are or will be subject to additional risks related to international operations or entering into international business relationships, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">different regulatory requirements for maintaining approval of drugs in foreign countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reduced protection for contractual and intellectual property rights in some countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anti-corruption laws in other jurisdictions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">tighter restrictions on privacy and the collection and use of patient data; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">business interruptions resulting from geopolitical actions (including war and terrorism), pandemic diseases (such as the recent spread of COVID-19 &#8220;coronavirus&#8221;), or natural disasters (including earthquakes, typhoons, floods and fires).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, there are complex regulatory, tax, labor and other legal requirements imposed by the E.U., U.K., and many of the individual countries in Europe, Asia and Latin America with which we will need to comply. Many U.S.-based biopharmaceutical companies have found the process of marketing their own products in Europe and other international geographies to be very challenging.</span></div><div style="line-height:120%;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The impact of Brexit on our international operations is currently unknown but could have a material impact on our business.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In a referendum held in the U.K. on June 23, 2016, a majority of those voting voted for the U.K. to leave E.U., commonly referred to as "Brexit".&#160;On March 29, 2017, the U.K. government delivered to the European Council notice of its intention to leave the E.U. The negotiation period (under Article 50 of the Treaty on European Union) had been extended repeatedly; however, on January 24, 2020, the U.K. and the E.U. entered into a withdrawal agreement pursuant to which the U.K. formally left the E.U. on January 31, 2020, but will, for a transition period ending on December 31, 2020, maintain access to the E.U. single market and to the global trade deals negotiated by the E.U. on behalf of its members and remain subject to E.U. law. The ultimate impact of the "leave" vote will depend on the terms that are negotiated in relation to the U.K.&#8217;s future relationship with the E.U. Brexit could impair the Company&#8217;s ability to transact business in the U.K. and E.U. countries.&#160;Brexit has already and could continue to adversely affect European and/or worldwide economic and market conditions and could continue to contribute to instability in the global financial markets.&#160; The long-term effects of Brexit will depend in part on any new trade agreements the U.K. makes to retain access to E.U. markets following the U.K.&#8217;s withdrawal transition period from the E.U. Negotiations of a trade agreement may be unsuccessful, and the U.K. may not reach agreement with the E.U. on the future terms of the U.K.&#8217;s relationship with the E.U.&#160; </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">28</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Without an agreement, there will be a period of considerable uncertainty particularly in relation to the financial and banking markets and the regulation of the pharmaceutical industry, including the regulatory approval process.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which E.U. laws to replicate or replace.&#160; If the U.K. were to significantly alter its regulations affecting the pharmaceutical industry, we could face significant new costs relating to the development, manufacture, and marketing of our current and future products.&#160;It may also be time-consuming and expensive for us to alter our internal operations in order to comply with any new regulations. Altered regulations could also add time and expense to the process by which our current product or product candidates receive or maintain regulatory approval in the U.K. and the E.U.&#160;Following Brexit, approval of medications approved through the E.U. centralized procedure, such as Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, will remain in effect through grandfathering. Our international headquarters are in Marlow, U.K. Guidance from the EMA provides that the Company must transfer marketing authorization to a holder in the E.U. In compliance with such guidance, we have moved our regulatory portfolio to Ireland which is the marketing authorization holder in the E.U. We have also completed preparation for Brexit given what is currently known, which is subject to change after the transition period.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Among other outcomes, Brexit could disrupt the free movement of goods, services and people between the U.K. and the E.U., and result in increased legal and regulatory complexities, as well as potential higher costs of conducting business in the U.K. and the E.U.&#160; In addition, changes to U.K. immigration policy as a result of Brexit could adversely affect our ability to retain talent for our European operations. Given the lack of comparable precedent, it is unclear what financial, trade, regulatory, and legal implications the final withdrawal of the U.K. from the E.U. would have and how such withdrawal would affect us. Any of these effects, and others we cannot anticipate, could negatively affect our business and financial condition.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Following the receipt of marketing approval of our product or any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The regulations and practices that govern marketing approvals, pricing, commercialization, coverage and reimbursement for new drug products vary widely from country to country and product to product. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries, including almost all of the member states of the European Economic Area, require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, including the European market, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted and approved products are subject to re-reviews, class reviews and other governmental controls which can negatively impact pricing originally approved. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact any revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. This is particularly true in the case of gene therapies for which payors and manufacturers must develop different pricing models for this growing area. Current pricing for gene therapies may not be sustainable in the future which would have a negative impact on our revenues and business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to commercialize Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> or any product candidate successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the European and U.S. healthcare industries and elsewhere is cost containment. It is currently unknown what impact, if any, the current administration and Congress in the U.S. will have on pricing and reimbursement, particularly with respect to government programs such as Medicare and Medicaid and Pharmacy Benefit Managers for commercial plans, and including reimportation, reference pricing and limitations on manufacturer price increases. For the last several years government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">29</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, was enacted in the U.S. As discussed below, this legislation imposes cost-containment and other measures affecting the amount of reimbursement for our current and any future marketed products. The full effects of this legislation depend on a number of factors, many of which are beyond our control, including new regulations and guidance issued by Centers for Medicare &amp; Medicaid Services ("CMS") and other federal and state agencies. A majority of states have passed legislation and other states are considering legislation intended to control the price and reimbursement of prescription drugs. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any prescription drug for which supplemental rebates are not being paid. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform measures in the future that will impose additional constraints on prices and reimbursements for our marketed products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, there have been numerous efforts at all levels of federal and state government to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the out-of-pocket cost of prescription drugs, and reform government program reimbursement methodologies for drugs. At the federal level, there are proposals for drug price control measures that could be enacted in future legislation. Additionally, on May 11, 2018, President Trump laid out his administration&#8217;s "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs" to reduce the cost of prescription drugs while preserving innovation and cures. The Department of Health and Human Services has solicited feedback on some of these measures and may implement others impacting our business under its existing authority. There have been several recent U.S. Congressional inquiries and proposed legislation designed to address these issues, including legislation recently signed by President Trump to ban clauses in commercial health insurance that restrict pharmacists from sharing pricing information. CMS has also proposed a series of policy changes designed to promote prescription drug affordability and transparency. At the state level, legislatures are becoming increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures. In some cases, these measures are designed to encourage importation from other countries and bulk purchasing.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prices at which we or our customers seek reimbursement for our products can be subject to challenge, reduction or denial by the government and other payers. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will continue to be available for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> or any product that we commercialize, and in particular gene therapies, and, if coverage and reimbursement are available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and any product candidate for which we obtain marketing approval. Obtaining reimbursement for our product candidates when approved may be particularly difficult because of the higher prices typically associated with drugs directed at smaller orphan populations of patients and the pricing and reimbursement of competitive products. In addition, third-party payors are likely to impose strict requirements for reimbursement of a higher priced drug. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product for which we obtain marketing approval.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Any product or product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to penalties or other enforcement actions if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product or our product candidates, when and if any of them are approved.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any product or product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA, EMA, PMDA and other regulatory authorities. For example, the FDA's requirements include submissions of safety and other post-marketing information and reports, registration requirements, Current Good Manufacturing Practices, or cGMP, requirements relating to manufacturing, quality control, quality assurance and complaints and corresponding maintenance of records and documents, requirements regarding the distribution of samples to healthcare professionals and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or may be subject to significant conditions of approval, including the requirement of a REMS. The FDA also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The labeling, advertising, promotion, marketing and distribution of a drug or biologic product also must be in compliance with FDA requirements which include, among others, promotional activities, standards and regulations for direct-to-consumer advertising, promotional activities involving the internet, and industry sponsored scientific and educational activities. In general, all product promotion must be consistent with the labeling approved by the FDA for such product, contain a balanced presentation of information on the product's uses, benefits, risks, and important safety information and limitations on use, and otherwise not be false or misleading. The FDA has very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing a company to correct deviations from regulatory standards and enforcement actions that can include seizures, injunctions and criminal prosecution. Failure to comply with applicable FDA requirements and restrictions also may subject a company to adverse publicity and enforcement action by the FDA, the U.S. Department of Justice ("DOJ") or the Office of the Inspector General of the U.S. Department of Health and Human Services ("HHS") as well as state authorities. This could subject the company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes its products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">restrictions on such products, manufacturers or manufacturing processes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes to or restrictions on the labeling or marketing of a product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">restrictions on product distribution or use;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">requirements to implement a REMS;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">requirements to conduct post-marketing studies or clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">warning or untitled letters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">withdrawal of the products from the market;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">recall of products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fines, restitution or disgorgement of profits or revenues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspension or withdrawal of marketing approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refusal to permit the import or export of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">product seizure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">injunctions; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the imposition of civil or criminal penalties.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">31</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-compliance with E.U. and U.K. requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the E.U.'s and U.K.'s requirements regarding the protection of personal information, which are effective as of May&#160;25, 2018, can also lead to significant penalties and sanctions and business restrictions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we, or our suppliers, third-party contractors, clinical investigators or collaborators are slow to adapt, or are unable to adapt, to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, we or our collaborators may lose marketing approval for our products when and if any of them are approved, resulting in decreased revenue from milestones, product sales or royalties.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our relationships with customers, healthcare providers, patients, patient organizations, charitable foundations and third-party payors will be subject to applicable anti-kickback, fraud and abuse, anti-bribery and corruption and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which we may obtain marketing approval. Increasingly, patients, patient organizations and charitable foundations also can influence selection of and payment for therapies. Our future arrangements with payors, healthcare providers, patient organizations, charitable foundations and patients may expose us to broadly applicable fraud and abuse, anti-bribery and corruption, and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we may obtain marketing approval. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal, state and foreign healthcare laws and regulations pertaining to fraud and abuse, anti-bribery and corruption, interaction with patient organizations, charitable foundations, and patients' rights are and will be applicable to our business. Restrictions under applicable federal, state and foreign healthcare laws and regulations may affect our ability to operate and expose us to areas of risk, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Several other countries, including the U.K., have enacted similar anti-kickback, fraud and abuse, and healthcare laws and regulations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the U.S. federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. In addition, charitable contributions to foundations for use in supporting patients may expose those foundations and us to additional penalties and prosecution under the False Claims Act. There is also a separate false claims provision imposing criminal penalties. Applicable regulations of both the EMA and E.U. member states also impose liability for failing to comply with fraud and abuse laws or improperly using information obtained in in the course of clinical trials with the EMA or other regulatory authorities;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">32</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute to defraud any healthcare benefit program or specific intent to violate it in order to have committed a violation. This statute also may impose monetary penalties on any offers or transfers of remuneration to Medicare or Medicaid beneficiaries (patients) which is likely to influence the beneficiary's selection of particular supplier of government payable items. States, such as California have enacted their own privacy regulations and others may enact similar legislation. Similarly, the collection and use of personal health data in the E.U. is governed by the E.U. General Data Protection Regulation (the "GDPR"), with many requirements mandated by the GDPR for the consent of the individuals to whom the personal data relates, the information provided to the individuals, transfer of personal data within and outside of the E.U. and the security and confidentiality of the personal data. Enforcement of the GDPR began on May&#160;25, 2018, and failure to comply with the requirements of the GDPR may result in substantial fines and other administrative penalties. The GDPR increases our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may be onerous and adversely affect our business, financial condition, results of operations and prospects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. federal laws requiring drug manufacturers to report annually information related to certain payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership or investment interests held by physicians and their immediate family members, including under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign laws regulating marketing activities and requiring manufacturers to report marketing expenditures, payments and other transfers of value to physicians and other healthcare providers. Similarly, payments made to physicians in certain E.U. member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician's employer, his or her competent professional organization and/or the regulatory authorities of the individual E.U. member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the E.U. member states. In addition, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the E.U. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. federal government price reporting laws, which require us to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on our marketed drugs. Participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, potential liability for the failure to report such prices in an accurate and timely manner, and potentially limit our ability to offer certain marketplace discounts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Foreign Corrupt Practices Act, which prohibit us and third parties working on our behalf from making payments to foreign government officials to assist in obtaining or retaining business. Specifically, the anti-bribery provisions of the FCPA prohibit the willful use of the mails or any means of instrumentality of interstate commerce corruptly in furtherance of any offer, payment, promise to pay, or authorization of the payment of money or anything of value to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to a foreign official to influence the foreign official in his or her official capacity, induce the foreign official to do or omit to do an act in violation of his or her lawful duty, or to secure any improper advantage in order to assist in obtaining or retaining business for or with, or directing business to, any person; and</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">33</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">state and foreign equivalents of each of the above laws, including foreign anti-bribery and corruption laws and state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While we do not submit claims and our customers will make the ultimate decision on how to submit claims, in the U.S. we may provide reimbursement guidance and support regarding Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, and our other product candidates for which we receive regulatory approval, to our customers and patients. If a government authority were to conclude that we provided improper advice to our customers and patients and/or encouraged the submission of false claims for reimbursement, we could face action by government authorities. Similarly, if a government authority were to conclude that our patient support efforts or interactions with charitable foundations were improper, we could face action by government authorities. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">or any product candidates for which we obtain marketing approval.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or Medicare Modernization Act, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar reduction in payments from private payors.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pricing of pharmaceutical products, in general, and specialty drugs, in particular, has also been a topic of concern in the U.S. government, including by the current administration and Congress. There can be no assurance as to how this scrutiny on pricing of pharmaceutical products will impact future pricing of our products or orphan drugs or pharmaceutical products generally and government programs in particular.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act, was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the Affordable Care Act that have been implemented since enactment and are of importance to the pharmaceutical industry are the following: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs or biologic agents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">34</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expansion of healthcare fraud and abuse laws, including the U.S. Civil False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of- sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expansion of eligibility criteria for Medicaid programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">requirements to report certain financial arrangements with physicians and teaching hospitals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, other legislative changes have been proposed and adopted since passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April 2013. Subsequent litigation extended the 2% reduction, on average, to 2025.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have also been significant ongoing efforts to modify or eliminate the Affordable Care Act. For example, the Tax Cuts and Jobs Act ("Tax Act") enacted on December 22, 2017 repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code, commonly referred to as the individual mandate, beginning in 2019. The Joint Committee on Taxation estimates that the repeal will result in over 13 million fewer Americans maintaining their health insurance coverage over the next ten years and is likely to lead to increases in insurance premiums.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 20, 2017, the President signed an executive order directing federal agencies to exercise existing authorities to reduce burdens associated with the Affordable Care Act pending further action by Congress. In April 2018, the Centers for Medicare &amp; Medicaid Services, or CMS, issued a final rule and guidance documents which changed requirements for health plans sold through the Affordable Care Act marketplaces for 2019. These changes include, for example, (i) turning over responsibility for ensuring that marketplace plans have enough health care providers in their networks to the states that rely on the federal HealthCare.gov exchange; (ii) allowing states to alter aspects of the essential health benefits required of health plans sold through the federal and state insurance marketplaces; (iii) eliminating certain Small Business Health Options Program, or SHOP, regulatory requirements; and (iv) outlining criteria by which insurers may reduce the percentage of income allocated to patient care. The U.S. Department of Labor issued a final rule in June 2018 to expand the availability of association health plans available to small business owners and self-employed individuals, beginning on September 1, 2018. These association health plans will not be required to provide the essential health benefits mandated by the Affordable Care Act. These and other regulations may impact coverage of certain health care services.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that further changes to the Affordable Care Act, as well as other healthcare reform measures that have been proposed and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenue. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may compromise our ability to generate revenue, attain profitability or commercialize our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2017, President Trump signed into law the Food&#160;&amp; Drug Administration Reauthorization Act (FDARA). This legislation imposes significant new requirements for clinical trial sponsors which will affect, among other things, obtaining orphan drug designation, and the development of drugs and biological products for pediatric use. Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and ATB200/AT2221 have obtained orphan drug designations from the FDA, but this legislation may result in new regulations which might materially impact </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">35</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our business. Under the new legislation, an applicant for orphan drug designation must show that its product provides a significant therapeutic advantage over an already approved or licensed drug in terms of greater efficacy, greater safety, or by providing a major contribution to patient care.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2019, both the House and Senate passed comparable prescription drug price reduction legislation. While both bills would require pharmaceutical manufacturers to pay a rebate if drug prices outpace inflation, the House bill would empower the Secretary of Health and Human Services to negotiate prices directly with manufacturers. Both bills address the Medicare Part D coverage gap by capping out-of-pocket costs. Though the Congressional Budget Office estimates the House bill would result in a $456 billion decrease in federal health care expenditures, it also predicts that the legislation would cause fewer drugs to be introduced to the U.S. market over the next decade.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the E.U., similar political, economic and regulatory developments may affect our ability to profitably commercialize our products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the E.U. or member state level may result in significant additional requirements or obstacles that may increase our operating costs.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have promoted off-label uses, we may become subject to significant liability.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription drug products. In particular, a product may not be promoted in the U.S. for uses that are not approved by the FDA as reflected in the product's approved labeling. Further, any labeling approved by the FDA for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> or any of our other product candidates may include restrictions on use, or other limitations. The FDA may impose further requirements or restrictions on the distribution or use of any of our other product candidates as part of a REMS plan. Physicians may nevertheless prescribe such products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines and / or other penalties against companies for alleged improper promotion and has investigated and / or prosecuted several companies in relation to off-label promotion. The FDA has also requested that certain companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed, curtailed or prohibited.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk when we commercially sell any products that we develop, including those which may arise from misuse or malfunction of, or design flaws in, such products, whether or not such problems directly relate to the products and services we have provided. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reduced resources of our management to pursue our business strategy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">decreased demand for any product candidates or products that we may develop;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">injury to our reputation and significant negative media attention;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory investigations, prosecutions or enforcement actions that could require costly recalls or product modifications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significant costs to defend the related litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased insurance costs, or an inability to maintain appropriate insurance coverage;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">36</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">substantial monetary awards to trial participants or patients, including awards that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available, and would damage our ability to obtain liability insurance at reasonable costs, or at all, in the future;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">loss of revenue; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the inability to commercialize any products that we may develop.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. We have increased our insurance coverage for the commercialization of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and may increase insurance coverage when, and if, we begin commercializing any other product candidate that receives marketing approval. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or a series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our available cash and adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the FDA or other applicable regulatory authorities approve generic or biosimilar products with claims that compete with our product or any of our product candidates, it could reduce our sales of our product or those product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the U.S., after an NDA is approved, such as Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, the product covered thereby becomes a "listed drug" which can, in turn, be cited by potential competitors in support of approval of an abbreviated NDA, or ANDA. The Federal Food, Drug, and Cosmetic Act, or the FD&amp;C Act, FDA regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes. These manufacturers might only be required to conduct a relatively inexpensive study to show that their product has the same active ingredients, dosage form, strength, route of administration, and conditions of use, or product labeling, as our product or product candidate and that the generic product is absorbed in the body at the same rate and to the same extent as, or is bioequivalent to, our product or product candidate. These generic equivalents would be significantly less costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product are typically lost to the generic product. Accordingly, competition from generic equivalents to our product or product candidates, including Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, would substantially limit our ability to generate revenues and therefore to obtain a return on the investments we have made in our product or product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Biologics Price Competition and Innovation Act, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act of 2010, or the ACA, Pub. L. No.&#160;111-148 (2010). The BPCIA authorizes the FDA to approve "abbreviated" BLAs for products whose sponsors demonstrate they are "biosimilar" to reference products previously approved under BLAs. The FDA may also separately determine whether "biosimilar" products are "interchangeable" with their reference products. However, the FDA may not approve an "abbreviated" BLA for a biosimilar product until at least twelve years after the date on which the BLA for the reference product was approved. FDA approval of abbreviated BLAs could be further delayed if the reference products are subject to unexpired and otherwise valid patents.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the enactment of the BPCIA, information in approved BLAs could not be relied upon by other manufacturers to establish the safety and efficacy of their products for which they were seeking FDA approval. Accordingly, if our products are approved under a BLA, other manufacturers potentially could develop and seek FDA approval of "biosimilar" products at some point in the future, including a biosimilar of AT-GAA.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">37</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our gene therapy product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Only a few gene therapy products have been approved in the U.S., E.U., and U.K. We have acquired the rights to many potential gene therapies and are focusing a substantial effort in our research and development efforts on these gene therapy platforms, and our future success depends on the successful development of these therapeutic approaches. There can be no assurance that any development problems we experience in the future related to our gene therapies will not cause significant delays or unanticipated costs, or that such development problems can be solved. In addition, the clinical study requirements of the FDA, the EMA, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as our gene therapies can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. The number of gene therapy products approved in the Western world is rapidly increasing. Approved products include Spark&#8217;s gene therapy product, which received approval from the FDA in 2017, GlaxoSmithKline&#8217;s Strimvelis, and Novartis&#8217;s and Gilead&#8217;s CAR-T therapies, which received approval from the FDA in 2017, Avexis&#8217;s Zolgemsa which received FDA approval in 2019, and Bluebird Bio&#8217;s Zynteglo which received E.U. and U.K. approval in 2019. Given the few precedents of approved gene therapy products, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the U.S., the E.U., the U.K. or other jurisdictions. Approvals by the EMA and the European Commission may not be indicative of what the FDA may require for approval. Regulatory requirements governing gene and cell therapy products have evolved and may continue to change in the future. For example, the FDA has established the Office of Cellular, Tissue and Gene Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In addition, the FDA can put an investigational new drug application, or IND, on clinical hold if the information in an IND is not sufficient to assess the risks in patients or a safety issue emerges in preclinical or clinical studies. Before a clinical study can begin at any institution, that institution&#8217;s institutional review board, or IRB, and its Institutional Biosafety Committee will have to review the proposed clinical study to assess the safety of the study. Moreover, serious adverse events or developments in clinical trials of gene therapy product candidates conducted by others may cause the FDA or other regulatory bodies to initiate a clinical hold on our clinical trials or otherwise change the requirements for approval of any of our product candidates. These regulatory review agencies, committees and advisory groups and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates or lead to significant post-approval studies, limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business. </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">38</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may encounter difficulties manufacturing our gene therapy which could impact timing and availability of clinical and commercial supply.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may experience delays in developing a sustainable, reproducible and commercial-scale manufacturing process or transferring that process to commercial partners. There is intense competition for limited commercial manufacturing capacity in gene therapy and for base materials, such as plasmids, necessary to the manufacturing of gene therapy products. We do not currently have our own gene therapy manufacturing capacity and rely instead on commercial manufacturing partners. These commercial manufacturing partners are expanding rapidly and there can be no assurance that needed capacity will be available or that these partners will continue to meet evolving regulatory standards.  Any delay in securing supply of these materials and the manufacturing slots with commercial partners may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, FDA and other regulatory bodies  are continuing to evolve their guidance for gene therapy manufacturing and could impose rigorous requirements relating to the manufacturing and testing of clinical and commercial products that could add time, complexity and the risk that we or our manufacturing partners will be unable to meet these requirements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, EMA, PMDA or other foreign regulatory authorities, or do not otherwise produce favorable results, we may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with seeking marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. This is particularly the case with AT-GAA, as there can be no assurance of the outcome of the Phase 3 PROPEL study or that the study results will meet regulatory standards for approval.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the regulatory pathways for gene therapies are evolving. In some cases, the FDA will approve gene therapies based on Phase 2 clinical trial data. If, however, the FDA decides we need to complete Phase&#160;3 clinical trial(s), we may need to expend significantly more capital to pursue FDA approval of gene therapies. If we are required to conduct additional clinical trials or other testing of our product candidates, including AT-GAA, CLN6, CLN3 and other gene therapies, that we develop beyond those tests and trials that we contemplate; if we are unable to successfully complete our clinical trials or other testing; if the results of these trials or tests are not positive or are only modestly positive; or if there are safety concerns, we may:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">choose not to seek regulatory approval in the U.S., E.U., U.K. or other key jurisdictions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be delayed in obtaining marketing approval for our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">not obtain marketing approval at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be subject to additional post-marketing testing requirements, safety strategies or restrictions, such as a requirement of a risk evaluation and mitigation strategy, or REMS; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">have the product removed from the market after obtaining regulatory approval.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential regulatory approval or commercialization of our product candidates could be delayed or prevented.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may experience numerous unforeseen events during, or as a result of, clinical trials including ongoing clinical trials of AT-GAA, CLN6 and CLN3 that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including:</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">39</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or patients may drop out of these clinical trials at a higher rate than we anticipate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be unable to enroll a sufficient number of patients in our trials to ensure adequate statistical power to detect any statistically significant treatment effects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulators, institutional review boards, or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulators, institutional review boards, or independent ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, institutional review boards or independent ethics committees to suspend or terminate the trials.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our product development costs will increase if we experience delays in testing or regulatory approvals. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, allow our competitors to bring products to market before we do, or impair our ability to successfully commercialize our product candidates, and so may harm our business and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials, including the current CLN-3 study and other studies we may initiate. Each of the diseases that our lead product candidates are intended to treat are characterized by small patient populations, which could result in slow enrollment of clinical trial participants. In addition, our competitors have ongoing clinical trials for product candidates that could be competitive with our product candidates. As a result, potential clinical trial sites may elect to dedicate their limited resources to participation in our competitors' clinical trials and not ours, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors' product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient enrollment is affected by other factors including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">severity of the disease under investigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">eligibility criteria for the clinical trial in question;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">perceived risks and benefits of the product candidate under study;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">efforts to facilitate timely enrollment in clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patient referral practices of physicians;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">40</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to monitor patients adequately during and after treatment; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">proximity and availability of clinical trial sites for prospective patients.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the company to decline and limit our ability to obtain additional financing. Our inability to enroll a sufficient number of patients in any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product, product candidate or indication and fail to capitalize on a product, product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have historically been focused on the development of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, a small molecule for Fabry disease and in a next generation ERT treatment for Pompe disease, AT-GAA. In 2018 we also made a significant investment in potential gene therapies for Fabry, Pompe, CDD, Batten&#8217;s disease and other LDs. Notwithstanding our large investment in gene therapies and Pompe ERT to date and anticipated future expenditures in related proprietary technologies, we have not yet developed, and may never successfully develop, any marketed drugs using ERT and gene therapy approaches. As a result of pursuing the development of our product and product candidates using our proprietary and licensed technologies, we may fail to develop products or product candidates, or address indications based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success. Research programs to identify new product candidates require substantial technical, financial and human resources. These research programs may initially show promise in identifying potential product candidates yet fail to yield product candidates for clinical development.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial results from a clinical trial do not ensure that the trial will be successful and success in preclinical or early stage clinical trials does not ensure success in later-stage clinical trials.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will only obtain regulatory approval to commercialize a product candidate if we can demonstrate to the satisfaction of the FDA or the applicable non-U.S. regulatory authority, in well-designed and conducted clinical trials, that the product candidate is safe and effective and otherwise meets the appropriate standards required for approval for a particular indication. Clinical trials are lengthy, complex and extremely expensive processes with uncertain duration and results. A failure of one or more of our clinical trials may occur at any stage of testing.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful. Our product candidates may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials or preliminary stages of clinical trials. For some of our product candidates, we have no safety or efficacy data in humans. There can be no assurance that the results seen in preclinical studies for any product candidates, including AT-GAA, CLN6 and CLN3 will result in success in clinical trials. When administered in humans, the product candidates may perform differently than in preclinical studies. Product candidates may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies or animal studies, and may interact with human biological systems in unforeseen, ineffective or harmful ways. We may be unable to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">41</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Initial results from a clinical trial do not necessarily predict final results. We cannot be assured that these trials will ultimately be successful. In addition, patients may not be compliant with their dosing regimen or trial protocols or they may withdraw from the clinical trial at any time for any reason. For example, we have reported data from a Phase 1/2 clinical trial of AT-GAA in Pompe disease. The data is based on a small patient sample and therefore may not be predictive of future results in the Phase 3 PROPEL study. PROPEL study results may not support further development, or even if such results are favorable, we may not be able to successfully complete the development of, obtain accelerated, conditional or standard regulatory approval for, or successfully commercialize AT-GAA. Similarly, we recently reported preliminary results from initial patients in the CLN-6 trial. Results from these initial patients may not be predictive of results of the full data set, we may not be able to demonstrate safety and efficacy and the FDA, EMA and other regulatory authorities may not accept this data as sufficient for approval. In addition, while the clinical trials of our product candidates are designed based on the available relevant information, in view of the uncertainties inherent in drug development, such clinical trials may not be designed with focus on indications, patient populations, dosing regimens, safety or efficacy parameters or other variables that will provide the necessary safety or efficacy data to support regulatory approval to commercialize the resulting product candidates. This is particularly the case for emerging gene therapies where we do not yet have a defined regulatory pathway and there can be no assurance that regulators in the U.S., E.U., U.K., Japan or other jurisdictions will accept the existing CLN-6, CLN-3 or other gene therapy clinical data sets for approval and without additional clinical trials or that future trials will support approvals. In addition, individual patient responses to the dose administered of a product candidate may vary in a manner that is difficult to predict. Also, the methods we select to assess particular safety or efficacy parameters may not yield statistical precision in estimating our product candidates' effects on study participants. Even if we believe the data collected from clinical trials of our product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Preclinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay, limit or prevent regulatory approval.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, certain of our product candidates are based on gene therapy technology. The product candidates in our gene therapy program are being developed for the treatment of diseases in which there is little clinical experience, which increases the difficulty in selecting appropriate endpoints and the risk that regulatory authorities may not consider the endpoints of clinical trials to provide clinically meaningful results. As a result, if the FDA requires different endpoints than the endpoints we anticipate using or have used in our clinical trials, or a different analysis of those endpoints, it may be more difficult for us to obtain, or we may be delayed in obtaining, FDA approval of our product candidates. If we are not successful in commercializing any of our products or product candidates, or are significantly delayed in doing so, our business will be materially harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain or maintain orphan drug exclusivity for our product or product candidates. If our competitors are able to obtain orphan drug exclusivity for their products, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory authorities in some jurisdictions, including the E.U., U.K., and the U.S., may designate drugs for relatively small patient populations as orphan drugs. We obtained orphan drug designations from the FDA for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Fabry disease in February 2004. We also obtained orphan medicinal product designation in the E.U. and U.K. for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in May 2006. AT-GAA has also received this designation from the FDA and EMA. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of market exclusivity, which, subject to certain exceptions, precludes the EMA from approving another marketing application for a similar medicinal product or the FDA from approving another marketing application for the same drug for the same indication for that time period. The FDA defines &#8220;same drug&#8221; as a drug or biologic that contains the same active moiety and is intended for the same use. The applicable market exclusivity period for orphan drugs is ten years in the E.U. and U.K. and seven years in the U.S. The E.U. and U.K. exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation, including if the drug is sufficiently profitable so that market exclusivity is no longer justified.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the E.U. and U.K., a "similar medicinal product" is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. Obtaining orphan drug exclusivity for our product candidates, in the E.U., U.K. and U.S., may be important to the product candidate's success. If a competitor to AT-GAA or our other product candidates obtains orphan drug exclusivity for and approval of a product with the same indications as our product candidates as before we do and if the competitor's product is the same drug or a similar medicinal product as ours, we could be excluded from the market for a certain period of time.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we obtain orphan drug exclusivity for other product candidates in these indications, we may not be able to maintain it. For example, if a competitive product that is the same drug or a similar medicinal product as our product or product candidate </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">42</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">is shown to be clinically superior to our product or product candidate, as applicable, any orphan drug exclusivity we have obtained will not block the approval of such competitive product. In addition, orphan drug exclusivity will not prevent the approval of a product that is the same drug as our product or product candidate if the FDA finds that we cannot assure the availability of sufficient quantities of the drug to meet the needs of the persons with the disease or condition for which the drug was designated.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA Reauthorization Act, signed into law in August 2017, authorizes the FDA to impose additional clinical trial requirements on manufacturers seeking orphan drug designation and/or pediatric indications. Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and AT-GAA have obtained orphan drug designations from the FDA. The impact, however, of future regulations on other product candidates is uncertain and could result in the need for additional clinical trials.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure to obtain or maintain regulatory approval in foreign jurisdictions would prevent us from marketing our products abroad.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to market and sell our products in Europe and many other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, some countries outside the U.S. require approval of the sales price of a drug before it can be marketed. In many countries, separate procedures must be followed to obtain reimbursement. We may not obtain marketing, pricing or reimbursement approvals outside the U.S. on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the U.S. does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. Regulatory approvals in countries outside the U.S. do not ensure pricing approvals in those countries or in any other countries, and regulatory approvals and pricing approvals do not ensure that reimbursement will be obtained.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the future.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, we have focused on developing and commercializing our first product, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, and our pipeline product AT-GAA as well as our multiple gene therapies. Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. Although the European Commission, PMDA and FDA have granted approval for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, for the treatment of adults with a confirmed diagnosis of Fabry disease and who have an amenable genetic variant, and we are generating product sales, we continue to incur significant research, development, commercialization and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have a net loss of </span><span style="font-family:inherit;font-size:10pt;">$356.4 million</span><span style="font-family:inherit;font-size:10pt;">, and we have an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$1.8 billion</span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue our development and commercialization of, and seek regulatory approvals for, product candidates in the U.S., the E.U., U.K., Japan and other foreign countries, as applicable;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conduct additional clinical trials to support the full approval of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the U.S. and post-approval commitments or trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue communicating with the EMA, as necessary, regarding post-marketing requirements and clinical trials for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue to or initiate the regulatory submission process for marketing approval of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> outside of the U.S. and E.U. and other foreign jurisdictions where approved, as applicable;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">build and maintain our commercial infrastructure so that it is capable of supporting product sales, marketing and distribution of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and our other product candidates in Europe, Japan and the U.S. or other territories in which we have received or may receive regulatory approval;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">43</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue our preclinical studies and clinical trials on the use of AT-GAA for Pompe disease and our gene therapies for Fabry, Pompe, Batten&#8217;s, Niemann Pick-C, MPS and other LDs; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue our preclinical studies of and potentially conduct clinical studies of ERT and gene therapy for CDD.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. The size of our future losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If any of our product candidates fails in clinical trials or does not gain regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders' equity and working capital.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may never become profitable even though we currently generate revenue from the sale of products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We began the commercial launch of our first product, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, in May 2016, with the U.S. and Japan commercial launches in 2018 and are now approved in 40 countries. Our ability to generate material revenue and become profitable depends upon our ability to successfully commercialize our existing product and product candidates, or product candidates that we may in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for our product candidates, we do not know when any of these product candidates will generate revenue for us, if at all and we may not meet our current revenue and operating expense guidance. Our ability to generate revenue from our current or future product and product candidates depends on a number of factors, including our ability to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">successfully complete development activities and obtain additional regulatory and pricing and reimbursement approvals for, and continue to successfully commercialize, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">develop and maintain a commercial organization capable of sales, marketing, and distribution for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and any product candidates we intend to market, in the countries where we have chosen to commercialize the product candidates ourselves including the U.S. and Japan;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">manufacture commercial quantities of our products at acceptable cost levels;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain a commercially viable price for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain coverage and adequate reimbursement from third parties, including government payors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">successfully satisfy post-marketing requirements that the FDA, EMA, or other foreign regulatory authorities may impose for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">or any of our other product candidates that may receive regulatory approval, including pediatric trials and patient registries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">successfully complete development activities, including the necessary preclinical studies and clinical trials, with respect to product candidates, including AT-GAA and our gene therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">complete and submit regulatory submissions to the FDA and obtain regulatory approval for our product candidates including AT-GAA and our gene therapies; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, because of the numerous risks and uncertainties associated with product development, including that our product candidates may not advance through development or achieve the safety and efficacy endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. Furthermore, we anticipate incurring significant costs associated with commercializing these products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we are able to generate significant revenues from the sale of our products, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">44</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we require substantial additional capital to fund our operations and we fail to obtain necessary financing, we may be unable to complete the development and commercialization of our product and development and commercialization of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations have consumed substantial amounts of cash. We expect to continue to spend substantial amounts to advance the preclinical and clinical development of our product candidates, and launch and commercialize our product and product candidates for which we may receive regulatory approval, including continuing to build our own commercial organization. We believe that our current cash position, including expected Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> revenues, is sufficient to fund ongoing Fabry and Pompe, and gene therapy program operations into the first half of 2022. Potential future business development collaborations, restructurings, pipeline expansion, and investment in biologics or gene therapy manufacturing capabilities could impact our future capital requirements. However, we may require substantial additional capital for the development and commercialization of our product and further development and commercialization of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts, when required or on acceptable terms, we could also be required to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significantly delay, scale back, or discontinue the development or the commercialization of our product or product candidates or one or more of our other research and development initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek collaborators for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> or one or more of our current or future product candidates at an earlier stage than otherwise would be desirable, or on terms that are less favorable than might otherwise be available;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">relinquish or license on unfavorable terms our rights to our technologies, product or product candidates that we otherwise would seek to develop or commercialize ourselves;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significantly curtail operations; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">enter into strategic partnerships on unfavorable terms, including sale of our assets for less than full value.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this "Risk Factors" section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs of commercialization activities, including maintaining sales, marketing, and distribution capabilities for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope, progress, results, and costs of preclinical development, laboratory testing, and clinical trials for our product candidates and any other product candidates that we may in-license or acquire;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of manufacturing drug supply for our preclinical studies and clinical trials, including the significant cost of manufacturing AT-GAA and our gene therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of transferring manufacturing technologies for our gene therapies to CMOs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the outcome, timing, and cost of the regulatory approval process by the FDA, EMA, PMDA and other foreign regulatory authorities, including the potential for regulatory authorities to require that we perform more studies than those that we currently anticipate for our product and product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost and timing of completion of existing or expanded commercial-scale outsourced manufacturing activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of defending any claims asserted against us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the emergence of competing technologies and other adverse market developments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which we acquire or invest in additional businesses, products, and technologies.</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">45</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies, Galafold</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> or product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may seek additional capital through a combination of private and public equity offerings, debt financings, receivables or royalty financings, strategic collaborations and alliances, restructuring and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt, receivables, and royalty financings may be coupled with an equity component, such as warrants to purchase stock, which could also result in dilution of our existing stockholders' ownership. The incurrence of additional indebtedness beyond our existing indebtedness with the remaining convertible note holders and Pharmakon Debt Financing could also result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur further debt, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could have a material adverse effect on our ability to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to default on any of our indebtedness, we could lose such assets and intellectual property. If we raise additional funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> or our product candidates, or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market our technologies that we would otherwise prefer to develop and market ourselves.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;21, 2016, we issued $250&#160;million aggregate principal amount of 3.00% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes"), in a private offering to qualified institutional buyers pursuant to Rule&#160;144A under the Securities Act. The Convertible Notes bear interest at a fixed rate of 3.00% per year, payable semiannually on June&#160;15 and December&#160;15 of each year, beginning on June&#160;15, 2017. The Convertible Notes will mature on December&#160;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Convertible Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock, par value $0.01 per share, or a combination thereof and may be settled. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, we entered into a loan agreement with BioPharma Credit PLC, an investment fund managed by Pharmakon Advisors, L.P. (the "Pharmakon Debt Financing") as the lender, for a </span><span style="font-family:inherit;font-size:10pt;">$150.0 million</span><span style="font-family:inherit;font-size:10pt;"> non-dilutive senior secured term loan (the "Senior Secured Term Loan") with an interest rate equal to 3-month LIBOR plus </span><span style="font-family:inherit;font-size:10pt;">7.50%</span><span style="font-family:inherit;font-size:10pt;"> per annum, subject to a floor and ceiling on the rate, which matures in </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> years. We received net proceeds of </span><span style="font-family:inherit;font-size:10pt;">$146.6 million</span><span style="font-family:inherit;font-size:10pt;"> in September 2018, after deducting fees and estimated expenses payable by us. There are no warrants or any equity conversion features associated with the Senior Secured Term Loan. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first and second quarters of 2019, we entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with a limited number of holders (the "Holders") of the unsecured Convertible Senior Notes due in 2023 ("Convertible Notes"). Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of $247.2 million of Convertible Notes held by them in exchange for an aggregate of approximately 44.0 million shares of our common stock, par value $0.01 per share. Additionally, we terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for cash proceeds of $19.9 million.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There can be no assurance that our cash and cash equivalents, together with funds generated by our operations and any future financings, will be sufficient to satisfy our debt payment obligations or that we will have sufficient equity to satisfy these obligations. Our inability to generate funds or obtain financing sufficient to satisfy our debt payment obligations may result in such obligations being accelerated by our lenders, which would likely have a material adverse effect on our business, financial condition and results of operations.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">46</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate may adversely affect our financial results.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our outstanding debt is indexed to the London Interbank Offered Rate (&#8220;LIBOR&#8221;). On July 27, 2017, the Financial Conduct Authority (&#8220;FCA&#8221;), which regulates LIBOR, announced its intention to phase out LIBOR rates by the end of 2021. It is not possible to predict the further effect of the FCA&#8217;s announcement, any changes in the methods by which LIBOR is determined, or any other reforms to LIBOR that may be enacted in the U.K., the E.U. or elsewhere. Such developments may cause LIBOR to perform differently than in the past or cease to exist. In addition, any other legal or regulatory changes made by the FCA, ICE Benchmark Administration Limited, the European Money Markets Institute (formerly Euribor-EBF), the European Commission or any other successor governance or oversight body, or future changes adopted by such body, in the method by which LIBOR is determined or the transition from LIBOR to a successor benchmark may result in, among other things, a sudden or prolonged increase or decrease in LIBOR, a delay in the publication of LIBOR, and changes in the rules or methodologies in LIBOR, which may discourage market participants from continuing to administer or to participate in LIBOR&#8217;s determination, and, in certain situations, could result in LIBOR no longer being determined and published. If a published U.S. dollar LIBOR rate is unavailable after 2021, the interest rates on our debt which is indexed to LIBOR will be determined using alternative methods, which may result in interest obligations which are more than or do not otherwise correlate over time with the payments that would have been made on such debt if U.S. dollar LIBOR was available in its current form. Further, the same costs and risks that may lead to the unavailability of U.S. dollar LIBOR may make one or more of the alternative methods impossible or impracticable to determine. Any of these proposals or consequences could have a material adverse effect on our financing costs, and as a result, our financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign currency exchange rate fluctuations could harm our financial results.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conduct operations in many countries involving transactions denominated in a variety of currencies other than the U.S. dollar. Accordingly, changes in the value of currencies relative to the U.S. dollar may impact our consolidated revenues and operating results due to transactional and translational remeasurement that is reflected in our earnings. The current exposures arise primarily from cash, accounts receivable, intercompany receivables and payables, and net product sales denominated in foreign currencies. Fluctuations in currency exchange rates have had, and will continue to have, an impact on our results as expressed in U.S. dollars. We are not currently engaged in any foreign currency hedging activities and there can be no assurance that currency exchange rate fluctuations will not adversely affect our results of operations, financial condition and cash flows. In addition, our outlooks do not assume fluctuations in currency exchange rates. Adverse fluctuations in currency exchange rates from the date of our outlooks could cause our actual results to differ materially from those anticipated in our outlooks and adversely impact our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also face risks arising from the imposition of exchange controls and currency devaluations. Exchange controls may limit our ability to convert foreign currencies into U.S. dollars or to make payments by our foreign subsidiaries or businesses located in or conducted within a country imposing controls. Currency devaluations result in a diminished value of funds denominated in the currency of the country instituting the devaluation.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the announcement of Brexit and the continued uncertainty around the full impact of it and the exact trade arrangements upon exit has adversely impacted global markets, including currencies, and resulted in a decline and volatility in the value of the British pound and the Euro, as compared to the U.S. dollar and other currencies. Volatility in exchange rates and global financial markets is expected to continue due to a number of factors, including uncertainty surrounding Brexit trade arrangements and continued political and economic uncertainty globally. </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">47</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may acquire other assets or businesses, or form collaborations or make investments in other companies or technologies that could harm our operating results, dilute our stockholders' ownership, increase our debt, or cause us to incur significant expense.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of our business strategy, we may continue to pursue acquisitions or licenses of assets or businesses, or strategic alliances and collaborations, to expand our existing technologies and operations, such as our acquisition of Celenex in 2018 and the research collaboration with Penn to develop gene therapies in 2018 and expanded in 2019. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any such transaction, any of which could have a detrimental effect on our financial condition, results of operations, and cash flows. We may not be able to find suitable acquisition or licensing candidates, and if we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business and we may incur additional debt or assume unknown or contingent liabilities in connection therewith. Integration of an acquired company or assets may also disrupt ongoing operations, require the hiring of additional personnel and the implementation of additional internal systems and infrastructure, especially the acquisition of commercial assets, and require management resources that would otherwise focus on developing our existing business. We may not be able to find suitable collaboration partners or identify other investment opportunities, and we may experience losses related to any such investments.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To finance any acquisitions, licenses or collaborations, we may choose to issue debt or shares of our common stock as consideration. Any such issuance of shares would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other assets or companies or fund a transaction using our stock as consideration. Alternatively, it may be necessary for us to raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had federal, state, and foreign net operating loss carry forwards ("NOLs") of approximately </span><span style="font-family:inherit;font-size:10pt;">$1,036 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$897.8 million</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$30.6 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the 2017 Tax Act. Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through 2019 will expire in 2029 through 2039. The foreign NOLs are subject to differing expirations beginning in 2026. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended (the "Code"), as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past, and could occur again in the future Under Section&#160;382 of the Internal Revnue Code of 1986, as amended, or Section 382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership some of which are outside our control. We completed a detailed study of our NOLs and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on our ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">48</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to our Intellectual Property</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the U.S. and in certain foreign jurisdictions related to our novel technologies, product and product candidates that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, if we license technology or product candidates from third parties in the future, these license agreements may not permit us to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering this intellectual property. These agreements could also give our licensors the right to enforce the licensed patents without our involvement, or to decide not to enforce the patents at all. Therefore, in these circumstances, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we or our licensors were the first to make the inventions covered by each of our pending patent applications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we or our licensors were the first to file patent applications for these inventions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any patents issued to us or our licensors will provide a basis for commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">licenses from other third parties will not be required to commercialize patented products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we will develop additional proprietary technologies that are patentable;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we will file patent applications for new proprietary technologies promptly or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our patents will not expire prior to or shortly after commencing commercialization of a product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the patents of others will not have a negative effect on our ability to do business; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patent authorities will not identify deficiencies in our patent applications and refuse to grant our patents.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we cannot be assured that any of our pending patent applications will result in issued patents. In particular, we have filed patent applications in the U.S., the European Patent Office and other countries outside the U.S. that have not been issued as patents. These pending applications include, among others, some of the patent applications for ATB200, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, and our gene therapy platforms and product candidates. If patents are not issued in respect of our pending patent applications, we may not be able to stop competitors from marketing similar products in Europe and other countries in which we do not have issued patents.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">49</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The patents that we have licensed from Mt. Sinai School of Medicine relating to use of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> to treat Fabry disease expired in 2018 in the U.S. and expired in 2019 in all other jurisdictions. In addition to patent protection outside of the U.S., we intend to seek orphan medicinal product designation of our product candidates and to rely on statutory data exclusivity provisions in jurisdictions outside the U.S. where such protections are available, including Europe. The patent rights that we own or have licensed relating to our product candidates are limited in ways that may affect our ability to exclude third parties from competing against us if we obtain regulatory approval to market these product candidates. In particular:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not hold composition of matter patents covering Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> but we have several method of treatment patents issued. We do have composition of matter patents, method of manufacture and other patents issued for ATB200. We also have pending applications covering Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, ATB200 and gene therapy. There can be no assurance that these applications will be allowed or that allowed applications will be issued or that the scope of such patents, if they issue, will be sufficient to protect our product. Composition of matter patents can provide protection for pharmaceutical products to the extent that the specifically covered compositions are important. For our product candidates for which we do not hold composition of matter patents, competitors who obtain the requisite regulatory approval can offer products with the same composition as our products so long as the competitors do not infringe any method of use patents that we may hold.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For some of our product candidates the principal patent protection that covers or those we expect will cover our product candidate is a method of use patent. This type of patent only protects the product when used or sold for the specified method. However, this type of patent does not limit a competitor from making and marketing a product that is identical to our product that is labeled for an indication that is outside of the patented method, or for which there is a substantial use in commerce outside the patented method.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, physicians may prescribe such a competitive identical product for indications other than the one for which the product has been approved, or off-label indications, that are covered by the applicable patents. Although such off-label prescriptions may infringe or induce infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. In addition, we may not pursue or obtain patent protection in all major markets. Assuming the other requirements for patentability are met, currently, the first to file&#160;a patent application is generally entitled to the patent. However, prior to March&#160;16, 2013, in the U.S., the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office or become involved in opposition, derivation, reexamination, inter partes review, post grant review, interference proceedings or other patent office proceedings or litigation, in the U.S. or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. In addition, other companies may attempt to circumvent any regulatory data protection or market exclusivity that we obtain under applicable legislation, which may require us to allocate significant resources to preventing such circumvention. Legal and regulatory developments in the E.U. and elsewhere may also result in clinical trial data submitted as part of an MAA becoming publicly available. Such developments could enable other companies to circumvent our intellectual property rights and use our clinical trial data to obtain marketing authorizations in the E.U. and in other jurisdictions. Such developments may also require us to allocate significant resources to prevent other companies from circumventing or violating our intellectual property rights. Our attempts to prevent third parties from circumventing our intellectual property and other rights may ultimately be unsuccessful. We may also fail to take the required actions or pay the necessary fees to maintain our patents.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">50</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, litigation, interferences, oppositions, inter partes reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products. We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity. Litigation, interference, oppositions, inter partes reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, our products, or&#160;the technologies or processes used to formulate or manufacture those products may now, or in the future, infringe the patent rights of third parties. It is also possible that third parties will obtain patent or other proprietary rights that might be necessary or useful for the development, manufacture or sale of our products. We may need to obtain licenses for intellectual property rights from others and may not be able to&#160;obtain these licenses on commercially reasonable terms, if at all.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent's claims narrowly or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research, development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be accused of infringing one or more claims of an issued patent or may fall within the scope of one or more claims in a published patent application that may subsequently issue and to which we do not hold a license or other rights. Third parties may own or control these patents or patent applications in the U.S. and abroad. These third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we or they could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No assurance can be given that patents do not exist, have not been filed, or could not be filed or issued, which contain claims covering our product candidates, technology or methods. Because of the number of patents issued and patent applications filed in our field, we believe there is a risk that third parties may allege they have patent rights encompassing our product candidates, technology or methods.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">51</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any of these patents were to be asserted against us, while we do not believe that our product candidates would be found to infringe any valid claim of such patents, there is no assurance that a court would find in our favor. If we were to challenge the validity of any issued U.S. patent in court, we would need to overcome a presumption of validity that attaches to every patent. This burden is high and would require us to present clear and convincing evidence as to the invalidity of the patent's claims. There is no assurance that a court would find in our favor on infringement or validity. Furthermore, during the course of litigation, confidential information may be disclosed in the form of documents or testimony in connection with discovery requests, depositions or trial testimony. Disclosure of our confidential information and our involvement in intellectual property litigation could materially adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to avoid or settle potential claims with respect to any patent rights of third parties, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our collaborators were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. This could harm our business significantly. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference proceedings declared by the U.S. Patent and Trademark Office and opposition proceedings in the European Patent Office, regarding intellectual property rights with respect to our products and technology. Even if we prevail, the cost to us of any patent litigation or other proceeding could be substantial.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from any litigation could significantly limit our ability to continue our operations. Patent litigation and other proceedings may also absorb significant management time.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee's former employer. Litigation may be necessary to defend against these claims.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, while we typically require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">52</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intellectual property litigation could cause us to spend substantial resources and could distract our personnel from their normal responsibilities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be obtained or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to license agreements with NCH and Penn pursuant to which we license key intellectual property relating to our gene therapy product candidates. We expect to enter into additional licenses in the future. Our existing licenses impose, and we expect that future licenses will impose, various diligences, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license, in which event we might not be able to market any product that is covered by the licensed patents.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">53</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. Patent and Trademark Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents are required to be paid to the U.S. Patent and Trademark Office and foreign patent agencies in several stages over the lifetime of the patents. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our rights to develop and commercialize our gene therapy product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The biotechnology and pharmaceutical industries, especially in the gene therapy field, are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions. We are aware of companies focused on developing gene therapies in various indications as well as several companies addressing other methods for delivering or modifying genes and regulating gene expression. Any advances in gene therapy technology made by a competitor may be used to develop therapies that could compete against any of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources than we do, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to our own patents, we have acquired licenses to certain patent rights and proprietary technology from third parties, including our current partners at NCH and Penn, that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product and product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses. Licenses to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">54</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to our Dependence on Third Parties</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of third parties to manufacture our product or product candidates may increase the risk that we will not have sufficient quantities of our product or product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not currently own or operate manufacturing facilities for clinical or commercial production of our product or product candidates. We currently lack the resources and the capabilities to manufacture ourselves any of our product or product candidates on a clinical or commercial scale. If we choose in the future to manufacture ourselves, we would face all of the risks and uncertainties of third-party manufacture of our products. We currently outsource all manufacturing and packaging of our product and preclinical and clinical product candidates to third parties. The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. In particular, the manufacture of our biologic product candidate ATB200 for Pompe, is highly complex and we may encounter difficulties in production. These problems include difficulties with production costs and yields and quality control, including stability of the product or product candidate. Further, our gene therapies may require new or specialized manufacturing with limited third-party manufacturers available to provide these services. The occurrence of any of these problems could significantly delay our clinical trials or the commercial availability of our product or product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may be unable to enter into agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable terms. Even if we enter into these agreements, the manufacturers of each product candidate will be single source suppliers to us for a significant period of time.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reliance on the third party for regulatory compliance and quality assurance;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limitations on supply availability resulting from capacity and scheduling constraints of the third parties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inability to manufacture product that meets the regulatory requirements for product approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inability to manufacture batches that meet specifications and quality standards;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inability to hire and retain the skilled workers necessary to manufacture our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">impact on our reputation in the marketplace if manufacturers of our products, once commercialized, fail to meet the demands of our customers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the possible breach of the manufacturing agreement by the third party;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The failure of any of our contract manufacturers to maintain high manufacturing standards could result in injury or death of clinical trial participants or patients using products. Such failure could also result in product liability claims, product recalls, product seizures or withdrawals, delays or failures in testing or delivery, cost overruns or other problems that could seriously harm our business or profitability.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA and regulatory authorities in other jurisdictions require our contract manufacturers to comply with regulations setting forth cGMP. These regulations cover all aspects of the manufacturing, testing, quality control and recordkeeping relating to our product candidates and any products that we may commercialize, including Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. Our manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the U.S. Our failure or the failure of our third-party manufacturers, to comply with applicable regulations could significantly and adversely affect regulatory approval and supplies of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing our products.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">55</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the third parties that we engage to manufacture product for our preclinical tests and clinical trials should cease to continue to do so for any reason, we likely would experience delays in advancing these trials while we identify and qualify replacement suppliers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the drug substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive regulatory approval on a timely and competitive basis.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third parties to conduct certain preclinical development activities and our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not independently conduct clinical trials for our product candidates or certain preclinical development activities of our product candidates. We rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators and collaboration partners, to perform these functions. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our reliance on these third parties for certain preclinical and clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, or GCP, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register certain ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within particular timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Similar GCP and transparency requirements apply in the E.U. and U.K. Failure to comply with such requirements, including with respect to clinical trials conducted outside the E.U., U.K. and U.S., can also lead regulatory authorities to refuse to take into account clinical trial data submitted as part of an MAA.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, third parties that we rely on for our clinical development activities may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Our product development costs will increase if we experience delays in testing or obtaining marketing approvals.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also rely on other third parties to obtain, store and distribute drug supplies for our preclinical development activities and clinical trials. In addition, in some instances we are required to purchase clinical supplies from our competitors, who may refuse to allow this purchase or do so at prohibitively high prices. Any performance failure on the part of our distributors or inability to secure supply from our competitors could delay preclinical and clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Extensions, delays, suspensions or terminations of our preclinical development activities or our clinical trials as a result of the performance of our independent clinical investigators and CROs will delay, and make more costly, regulatory approval for any product candidates that we may develop. Any change in a CRO during an ongoing preclinical development activity or clinical trial could seriously delay that trial and potentially compromise the results of the activity or trial.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">56</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be successful in maintaining or establishing collaborations, which could adversely affect our ability to develop and, particularly in international markets, commercialize products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are collaborating with physicians, academic institutions, hospitals, patient advocacy groups, foundations and government agencies in order to assist with the development of our products and each of our product candidates. We plan to pursue similar activities in future programs and plan to evaluate the merits of retaining commercialization rights for ourselves or entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies. We also may seek to establish collaborations for the sales, marketing and distribution of our products in all or select geographies. If we elect to seek collaborators in the future but are unable to reach agreements with suitable collaborators, we may fail to meet our business objectives for the affected product or program. We face, and will continue to face, significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts, if any, to establish and implement collaborations or other alternative arrangements. The terms of any collaboration or other arrangements that we establish, if any, may not be favorable to us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any collaboration that we enter into may not be successful. The success of our collaboration arrangements, if any, will depend heavily on the efforts and activities of our collaborators. It is likely that any collaborators of ours will have significant discretion in determining the efforts and resources that they will apply to these collaborations. The risks that we may be subject to in possible future collaborations include the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaborators may not pursue development and commercialization of our product or product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disputes may arise between the collaborator and us as to the ownership of intellectual property arising during the collaboration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may grant exclusive rights to our collaborators, which would prevent us from collaborating with others;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">57</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaborations with pharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Such terminations or expirations may adversely affect us financially and could harm our business reputation in the event we elect to pursue collaborations that ultimately expire or are terminated.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Materials necessary to manufacture our product or product candidates may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our product or product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently rely on the manufacturers of our product and product candidates to purchase from third-party suppliers the materials necessary to produce the compounds for our preclinical studies and clinical trials, and we rely, or will rely, on these other manufacturers for commercial distribution of our product and, if we obtain marketing approval, for any of our product candidates. Suppliers may not sell these materials to our manufacturers at the time we need them or on commercially reasonable terms and all such prices are susceptible to fluctuations in price and availability due to transportation costs, government regulations, price controls and changes in economic climate or other foreseen circumstances. We do not have any control over the process or timing of the acquisition of these materials by our manufacturers. We may enter into agreements to purchase certain materials and provide them to our manufacturers, with all the risks and uncertainties of supply associated with those purchases. If we or our manufacturers are unable to obtain these materials for our preclinical studies and clinical trials, product testing and potential regulatory approval of our product candidates would be delayed, significantly impacting our ability to develop and commercialize our product candidates. If our manufacturers or we are unable to purchase these materials for commercial distribution of our product or, after regulatory approval has been obtained, our product candidates, the commercial launch of our product and product candidates would be delayed or there would be a shortage in supply, which would materially affect our ability to generate revenues from the sale of our product or product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing of our product and product candidates requires us or our manufacturing partners to conduct required stability and comparability testing. We or our partners may encounter product, packaging, equipment and process-related issues that may require refinement or resolution in order to successfully commercialize our product and proceed with our planned clinical trials and obtain regulatory approval for commercial marketing of our product candidates. In the future, we may identify impurities, which could result in increased scrutiny by regulatory authorities, delays in our clinical programs and regulatory approval, increases in our operating expenses or failure to obtain or maintain approval for our product or product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently rely on WuXi App Tec Biopharmaceuticals, a company based in the People's Republic of China (the "PRC"), as the sole supplier of our biologic product, ATB200. Accordingly, there is a risk that supplies of our product may be significantly delayed by or may become unavailable as a result of manufacturing, equipment, process, or business-related issues affecting that company. We may also face additional manufacturing and supply-chain risks due to the regulatory and political structure of the PRC, or as a result of the international relationship between the PRC and the U.S. or any of the other countries in which our products are marketed. In addition, the recent out-breaks of SARS, COVID-19 &#8220;coronavirus&#8221; or other similar illnesses in PRC could impact operations at Wuxi. Although currently there has been no impact on operations and we and Wuxi have robust mitigation plans in place, there can be no assurance that operations would not be impacted in the future with a negative impact on supply of our product.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">58</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business activities involve the use of hazardous materials, which require compliance with environmental and occupational safety laws regulating the use of such materials. If we violate these laws, we could be subject to significant fines, liabilities or other adverse consequences.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research and development programs involve the controlled use of hazardous materials, including microbial agents, corrosive, explosive and flammable chemicals and other hazardous compounds in addition to certain biological hazardous waste. Additionally, the activities of our third-party product manufacturers of our product, and of our product candidates if and when they reach commercialization, will also require the use of hazardous materials. Accordingly, we are subject to federal, state and local laws governing the use, handling and disposal of these materials. Although we believe that our safety procedures for handling and disposing of these materials comply in all material respects with the standards prescribed by local, state and federal regulations, we cannot completely eliminate the risk of accidental contamination or injury from these materials. In addition, our collaborators may not comply with these laws. In the event of an accident or failure to comply with environmental laws, we could be held liable for damages that result, and any such liability could exceed our assets and resources or we could be subject to limitations or stoppages related to our use of these materials which may lead to an interruption of our business operations or those of our third-party contractors. While we believe that our existing insurance coverage is generally adequate for our normal handling of these hazardous materials, it may not be sufficient to cover pollution conditions or other extraordinary or unanticipated events. Furthermore, an accident could damage or force us to shut down our operations. Changes in environmental laws may impose costly compliance requirements on us or otherwise subject us to future liabilities and additional laws relating to the management, handling, generation, manufacture, transportation, storage, use and disposal of materials used in or generated by the manufacture of our products or related to our clinical trials. In addition, we cannot predict the effect that these potential requirements may have on us, our suppliers and contractors or our customers.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to our Business, Employee Matters and Managing Growth</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our Chief Executive Officer and other key executives and to attract, retain and motivate qualified personnel.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are highly dependent on John F. Crowley, our Chairman and Chief Executive Officer, Bradley&#160;L. Campbell, our President and Chief Operating Officer, and Daphne Quimi, our Chief Financial Officer. These executives each have significant pharmaceutical industry experience. The loss of the services of any of these executives might impede the achievement of our research, development and commercialization objectives and materially adversely affect our business and we may not be able to replace these executives with candidates with similar background and experience in the event of the loss of their services. We do not maintain "key person" insurance on Mr.&#160;Crowley or on any of our other executive officers.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recruiting and retaining qualified scientific, clinical and sales and marketing personnel will also be critical to our success, including our Research and Gene Therapy Center of Excellence in Philadelphia. In addition, maintaining a qualified finance and legal department is key to our ability to meet our regulatory obligations as a public company and important in any potential capital raising activities. Our industry has experienced a high rate of turnover in recent years. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel, particularly in New Jersey and Philadelphia and their surrounding areas. Although we believe we offer competitive salaries and benefits, we may have to increase spending in order to retain personnel. If we fail to retain our remaining qualified personnel or replace them when they leave, we may be unable to recruit replacements nor continue our development and commercialization activities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">59</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had 584 full-time employees. As our development and commercialization strategies develop, we will need additional managerial, operational, sales, marketing, financial, technical operations and other resources. In particular, we are expanding our scientific and managerial support for gene therapy. Our management, personnel and systems currently in place may not be adequate to support this future growth. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our existing or future product candidates and we may not be able to replace key personnel in the event of turnover. Future growth would impose significant added responsibilities on members of management, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">managing the development and commercialization of any product candidates approved for marketing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">overseeing our ongoing preclinical studies and clinical trials effectively;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">identifying, recruiting, maintaining, motivating and integrating additional employees, including any sales and marketing personnel engaged in connection with the commercialization of any approved product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">managing our collaboration partners and associated joint steering committees;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">managing any clinical or commercial collaborations with third parties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">improving our managerial, development, operational and financial systems and procedures;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">monitoring and improving diversity, inclusion and pay-equity initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developing our compliance infrastructure and processes to ensure compliance with regulations applicable to public companies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developing biologics and gene therapy manufacturing expertise; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expanding our facilities.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company.</span></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Litigation may adversely affect our business, financial condition, results of operations or liquidity.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business is subject to the risk of litigation by employees, consumers, vendors, competitors, intellectual property rights holders, shareholders, government agencies and others through private actions, class actions, administrative proceedings, regulatory actions or other litigation. For example, we and certain of our current and former officers have previously been parties to securities class action lawsuits against us, all of which have been settled or dismissed. The outcome of litigation, particularly class action lawsuits, regulatory actions and intellectual property claims, is difficult to assess or quantify. Plaintiffs in these types of lawsuits may seek recovery of very large or indeterminate amounts, and the magnitude of the potential loss relating to these lawsuits may remain unknown for substantial periods of time. In addition, certain of these lawsuits, if decided against us or settled by us, may result in liability material to our Consolidated Financial Statements as a whole or may negatively affect our operating results if changes to our business operation are required. The cost to defend litigation may be significant. There also may be adverse publicity associated with litigation that could negatively affect customer perception of our business, regardless of whether the allegations are valid or whether we are ultimately found liable. As a result, litigation may adversely affect our business, financial condition, results of operations or liquidity.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be exposed to employment-related claims and losses which could have an adverse effect on our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we continue to increase the size of our workforce, the risk of potential employment-related claims will also increase. As such, we may be subject to claims, allegations or legal proceedings related to employment matters including, but not limited to, discrimination, harassment (sexual or otherwise), wrongful termination or retaliation, local, state or federal labor law violations, injury, and wage violations. In the event we are subject to one or more employment-related claims, allegations or legal proceedings, we may incur substantial costs, losses or other liabilities in the defense, investigation, settlement or other disposition of such claims. In addition to the economic impact, we may also suffer reputational harm as a result of such claims, allegations and legal proceedings and the investigation, defense and prosecution of such claims, allegations and legal proceedings could cause substantial disruption in our business and operations. While we do have policies and procedures in place to reduce our exposure to these risks, there can be no assurance that such policies and procedures will be effective or that we will not be exposed to such claims, allegations or legal proceedings.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in fraudulent conduct, harassment or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FDA or similar regulations of foreign regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">manufacturing standards;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal and state healthcare fraud and abuse laws and regulations, anti-bribery and corruption laws, anti-discrimination and harassment laws, privacy and similar laws and regulations established and enforced by foreign regulatory authorities; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">laws that require the reporting of financial information or data accurately.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, bribery and corruption and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">61</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of computer system failures or security breaches.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite the implementation of security measures, our internal computer systems, and those of our CROs, contract manufacturing organizations and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, security breaches, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations and could result in a material disruption of our clinical activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our commercialization of our product and our product candidate development programs. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruptions or security breach were to result in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur significant unexpected losses, expenses and liabilities, we could face litigation or suffer reputational harm and the further development of our product candidates could be delayed.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business and operations would suffer significant harm in the event of health epidemics and other outbreaks </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business could be adversely impacted by the effects of the COVID-19 &#8220;coronavirus&#8221; outbreak originating in the PRC, or by other health epidemics or pandemics.&#160; We currently rely on WuXi App Tec Biopharmaceuticals, a company based in the PRC, as the sole supplier of our biologic product, ATB200. &#160;Accordingly, there is a risk that supplies of our product may be significantly delayed by or may become unavailable as a result of COVID-19 or other health epidemic.&#160; </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our operations and sales channels are global and any travel bans or other restrictions that may be imposed in order to contain the spread of an outbreak may disrupt our and our other business partners&#8217; ability to conduct business around the world, could adversely impact our supply chain and may hinder the ability of our patients to receive treatment from their caregivers or in our on-going clinical trials.&#160; This may also result in our inability to obtain raw materials needed for the manufacture of our products, reduce the sales of our products for patient treatment and interfere with the conduct of our clinical trials.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although currently there has been no impact on operations and we, Wuxi and our other business partners have robust mitigation plans in place, there can be no assurance that operations would not be negatively impacted in the future, resulting in negative impacts on our financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to our Common Stock</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our executive officers, directors and principal stockholders maintain the ability to exert significant influence and control over matters submitted to our stockholders for approval.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our executive officers, directors and affiliated stockholders beneficially own shares representing approximately 43% of our common stock as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. As a result, if these stockholders were to choose to act together, they would be able to exert significant influence and control over matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could influence the election of directors and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination or reorganization. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire. The interests of this group of stockholders may not always coincide with the interests of other stockholders, and they may act, whether by meeting or written consent of stockholders, in a manner that advances their best interests and not necessarily those of other stockholders, including obtaining a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">62</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these provisions:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish a classified board of directors, and, as a result, not all directors are elected at one time;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limit the manner in which stockholders can remove directors from our board of directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limit who may call stockholder meetings;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">authorize our board of directors to issue preferred stock, without stockholder approval, which could be used to institute a "poison pill" that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">require the approval of the holders of at least 67% of the outstanding voting stock to amend or repeal certain provisions of our charter or bylaws.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The market price of our common stock is highly volatile and may be subject to wide fluctuations in response to numerous factors, some of which are beyond our control. In addition to the factors discussed in this Annual Report on Form&#160;10-K, these factors include:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success of competitive products or technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory actions with respect to our product or product candidates or our competitors' products or product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">actual or anticipated changes in our growth rate relative to our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the outcome of any patent infringement or other litigation that may be brought against us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">results of clinical trials of our product candidates or those of our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory or legal developments in the E.U., U.K., U.S. and other countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of Brexit on our operations, supply chain, regulatory approvals and personnel;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">63</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the recruitment or departure of key personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the level of expenses related to our product or any of our product candidates or clinical development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">actual or anticipated variations in our quarterly operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number and characteristics of our efforts to in-license or acquire additional product candidates or products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">introduction of new products or services by us or our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcement or expectation of additional financing efforts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sales of our common stock by us, our insiders or our other stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in accounting practices;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lawsuits and other claims asserted against us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in the structure of healthcare payment systems;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">general economic, industry and market conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">publication of research reports about us, our competitors or our industry, or positive or negative recommendations or withdrawal of research coverage by securities or industry analysts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">other events or factors, many of which are beyond our control; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the other factors described in this "Risk Factors" section.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks stated above could have a material adverse effect on the market price of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we operate in the pharmaceutical and biotechnology industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management's attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">64</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A significant portion of our total outstanding shares may be sold into the market. This could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain holders of our common stock have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also have registered on a Form&#160;S-8 registration statement all shares of common stock that we may issue under our equity compensation plans. As a result, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. In addition, certain of our employees, executive officers and directors have entered into, or may enter into, Rule&#160;10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule&#160;10b5-1 plan, a broker executes trades pursuant to parameters established by the employee, director or officer when entering into the plan, without further direction from the employee, officer or director. A Rule&#160;10b5-1 plan may be amended or terminated in some circumstances. Our employees, executive officers and directors may also buy or sell additional shares outside of a Rule&#160;10b5-1 plan when they are not in possession of material, nonpublic information.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may fail to qualify for continued listing on The NASDAQ Global Market which could make it more difficult for investors to sell their shares.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our common stock is listed on The NASDAQ Global Market, or NASDAQ. As a NASDAQ listed company, we are required to satisfy the continued listing requirements of NASDAQ for inclusion in the Global Market to maintain such listing, including, among other things, the maintenance of a minimum closing bid price of $1.00 per share and stockholders' equity of at least $10.0&#160;million. There can be no assurance that we will be able to maintain compliance with the continued listing requirements or that our common stock will not be delisted from NASDAQ in the future. If our common stock is delisted by NASDAQ, we could face significant material adverse consequences, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a limited availability of market quotations for our securities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reduced liquidity with respect to our securities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a determination that our shares are a "penny stock," which will require brokers trading in our shares to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a limited amount of news and analyst coverage for our company; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a decreased ability to issue additional securities or obtain additional financing in the future.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports or publish unfavorable research about our business, the price of our common stock and trading volume could decline.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If securities or industry analysts do not initiate or continue coverage of us, the trading price for our common stock would be negatively affected. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who covers us downgrades our common stock, the price of our common stock would likely decline. If one or more of these analysts ceases to cover us or fails to publish regular reports on us, interest in the purchase of our common stock could decrease, which could cause the price of our common stock or trading volume to decline.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have broad discretion in the use of our cash and cash equivalents, and investors must rely on the judgment of our management regarding the use of our cash and cash equivalents. Our management may not use cash and cash equivalents in ways that ultimately increase the value of your investment. Our failure to use our cash and cash equivalents effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product and product candidates. Pending their use, we may invest our cash and cash equivalents in short-term or long-term, investment-grade, interest-bearing securities. These investments may not yield favorable returns. If we do not invest or apply our cash and cash equivalents in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause the price of our common stock to decline.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">65</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These inherent limitations reflect the reality that judgments can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our capital in the foreseeable future, capital appreciation, if any, will be our stockholders sole source of gain.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the development and growth of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be our stockholders sole source of gain for the foreseeable future.</span></div><div><a id="sA4296979CE875A27B263A9FFFEEC0008"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><a id="s71AD227DB3645D5FAB584D7D43A61421"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table contains information about our current significant leased properties as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.48148148148148%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Approximate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Square Feet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Use</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Lease expiry date </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cranbury, New Jersey, U.S.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office and laboratory</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2026</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marlow, United Kingdom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,796</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2028</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Philadelphia, Pennsylvania, U.S.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50,816</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office and laboratory</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 2044</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Princeton, New Jersey, U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,922</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2022</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span><span style="font-family:inherit;font-size:9pt;">&#160; Includes renewal options on leases which the Company is reasonably certain to exercise.</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the above, we also maintain offices in other U.S. and international jurisdictions in which we operate. We believe that our current office and laboratory facilities are adequate and suitable for our current and anticipated needs. We believe that, to the extent required, we will be able to lease or buy additional facilities at commercially reasonable rates.</span></div><div><a id="s649C89903AD6545E9AE1F4E469F08820"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are not currently a party to any legal proceedings.</span></div><div><a id="s2BCE0D4E8C2D5908924D06D9EF7E5C2E"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">66</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFD20766B6D835FCA927D54EB223591CF"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></div><div><a id="s5E448FCE35A65BA692BD8CBD208B8411"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;5.&#160;&#160;&#160;&#160;MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Market For Our Common Stock</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our common stock has been traded on the NASDAQ Global Market under the symbol "FOLD" since May&#160;31, 2007. Prior to that time, there was no public market for our common stock. The closing price for our common stock as reported by the NASDAQ Global Market on </span><span style="font-family:inherit;font-size:10pt;">February&#160;19, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$10.81</span><span style="font-family:inherit;font-size:10pt;"> per share. As of </span><span style="font-family:inherit;font-size:10pt;">February&#160;19, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;">22</span><span style="font-family:inherit;font-size:10pt;"> holders of record of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividends</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never declared or paid any dividends on our capital stock. We currently intend to retain any future earnings to finance the development and growth of our business. We do not intend to declare or pay cash dividends to our stockholders in the foreseeable future.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Sales of Unregistered Securities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not sell any equity securities during the fiscal year ended December 31, 2019 in transactions that were not registered under the Securities Act.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">67</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Graph</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following performance graph compares the cumulative total return on our common stock during the last five fiscal years with the NASDAQ Composite Index (U.S.) and the NASDAQ Biotechnology Index during the same period. The graph shows the value at the end of each of the last five fiscal years, of $100 invested in our common stock. Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:24px;"><img src="chart-4f9a0d4e5d2c71b470b.jpg" alt="chart-4f9a0d4e5d2c71b470b.jpg" style="height:305px;width:653px;"></img></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.8635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:29%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12/31/2014</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12/31/2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12/31/2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12/31/2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12/31/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12/31/2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics, Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$100</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$117</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$60</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$173</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$115</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$117</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">NASDAQ Composite</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$100</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$106</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$114</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$146</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$140</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$189</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NASDAQ Biotechnology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$100</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$111</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$87</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$106</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$96</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$119</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not repurchase any shares of our common stock during the year ended December 31, 2019. We have not announced any plans or programs for the repurchase of our common stock. However, employees surrendered </span><span style="font-family:inherit;font-size:10pt;">301,059</span><span style="font-family:inherit;font-size:10pt;"> shares to the Company, during the year ended December 31, 2019 at a weighted average price of $</span><span style="font-family:inherit;font-size:10pt;">10.75</span><span style="font-family:inherit;font-size:10pt;"> per share for the payment of the minimum tax liability withholding obligations upon the vesting of restricted stock units. We do not consider this a share buyback program. </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">68</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s107B5D7853ED5EEFA3A660A62C9EE4EE"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;SELECTED FINANCIAL DATA</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Statement of Operations Data (in thousands except share and per share data)</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">182,237</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">91,245</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">36,930</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">4,958</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost of goods sold</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">21,963</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">14,404</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">6,236</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">833</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">160,274</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">76,841</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">30,694</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">4,125</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">286,378</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">270,902</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">149,310</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">104,793</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">76,943</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Selling, general, and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">169,861</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">127,200</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">88,671</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">71,151</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">47,269</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Changes in fair value of contingent consideration payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3,297</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3,300</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(234,322</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">6,760</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">4,377</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss on impairment of assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">465,427</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">69</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">15</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">4,775</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">4,216</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3,593</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3,242</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">1,833</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">464,311</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">405,618</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">472,679</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">186,015</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">130,437</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(304,037</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(328,777</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(441,985</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(181,890</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(130,437</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other income (expense):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">10,249</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">10,461</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">4,096</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">1,602</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">929</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(18,872</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(22,402</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(17,240</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(5,398</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1,578</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss on exchange of convertible notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(40,624</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Change in fair value of derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2,739</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss on extinguishment of debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(13,302</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(952</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other (expense) income </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2,626</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(5,632</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">6,008</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(4,793</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(80</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss before income tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(355,910</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(349,089</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(449,121</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(203,781</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(132,118</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income tax (expense) benefit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(478</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">94</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">165,119</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3,739</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(356,388</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(348,995</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(284,002</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(200,042</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(132,118</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss attributable to common stockholders per common share&#160;&#8212; basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1.48</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1.88</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1.85</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1.49</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1.20</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Weighted-average common shares outstanding&#160;&#8212; basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">240,421,001</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">185,790,021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">153,355,144</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">134,401,588</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">109,923,815</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Data (in thousands)</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash, cash equivalents, and marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">452,740</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">504,152</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">358,562</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">330,351</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">214,033</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Working capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">391,261</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">464,971</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">321,925</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">229,105</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">142,985</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">850,207</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">789,951</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">627,024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">1,036,845</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">908,384</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">373,782</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">447,039</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">274,174</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">676,694</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">560,550</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1,768,610</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1,412,222</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1,063,610</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(779,608</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(579,566</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total stockholders' equity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">476,425</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">342,912</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">352,850</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">360,151</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">347,834</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">69</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9C749DD4726B5EF4A983BE6301642A93"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a global, patient-dedicated biotechnology company focused on discovering, developing, and developing novel medicines for rare. We have a portfolio of product opportunities led by our novel medicine for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic, and an industry leading rare disease gene therapy portfolio.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cornerstone of our portfolio is Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lead biologics program of our pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation to AT-GAA for the treatment of late onset Pompe disease. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("NCH") and an expanded collaboration with the University of Pennsylvania ("Penn"). Our pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, CLN8, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Niemann-Pick Type C ("NPC"), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). Our expanded collaboration with Penn also provides us with exclusive disease-specific access and the option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second quarter of 2019, we completed an underwritten equity offering and issued </span><span style="font-family:inherit;font-size:10pt;">18.7 million</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock at </span><span style="font-family:inherit;font-size:10pt;">$10.75</span><span style="font-family:inherit;font-size:10pt;"> per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of </span><span style="font-family:inherit;font-size:10pt;">$189.0 million</span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first and second quarters of 2019, we entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with a limited number of holders (the "Holders") of the unsecured Convertible Senior Notes due in 2023 ("Convertible Notes"). Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;">$247.2 million</span><span style="font-family:inherit;font-size:10pt;"> of Convertible Notes held by them in exchange for an aggregate of approximately </span><span style="font-family:inherit;font-size:10pt;">44.0 million</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock, par value </span><span style="font-family:inherit;font-size:10pt;">$0.01</span><span style="font-family:inherit;font-size:10pt;"> per share. Additionally, we terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for cash proceeds of </span><span style="font-family:inherit;font-size:10pt;">$19.9 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">70</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Results of Operations</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following section generally discusses 2019 and 2018 items and year-to-year comparisons between 2019 and 2018. Discussions of 2017 items and year-to-year comparisons between 2018 and 2017 that are not included in this Form 10-K can be found in Part II, Item 7 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Year Ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Compared to Year Ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides selected financial information for the Company:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.29629629629629%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net product sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">182,237</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91,245</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">90,992</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,963</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,404</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7,559</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Cost of goods sold as a percentage of net product sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">12.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">15.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(3.7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Operating expenses:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Research and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">286,378</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">270,902</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">15,476</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Selling, general, and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">169,861</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">127,200</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">42,661</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Changes in fair value of contingent consideration payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,297</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,300</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,775</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,216</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">559</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Other income (expense):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,249</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,461</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(212</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(18,872</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(22,402</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3,530</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Loss on exchange of convertible notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(40,624</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(40,624</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Change in fair value of derivatives</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,739</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,739</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Other (expense) income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,626</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(5,632</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3,006</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Income tax (expense) benefit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(478</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">94</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(572</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(356,388</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(348,995</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(7,393</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Product Sales. </span><span style="font-family:inherit;font-size:10pt;">Net product sales increased </span><span style="font-family:inherit;font-size:10pt;">$91.0 million</span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to the same period in the prior year. The increase was primarily due to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> being approved for sale in the U.S. and Japan in the third and second quarters of 2018, respectively, as well as continued growth in the European market.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Goods Sold.</span><span style="font-family:inherit;font-size:10pt;"> Cost of goods sold includes manufacturing costs as well as royalties associated with sales of our product. Cost of goods sold as a percentage of net product sales was </span><span style="font-family:inherit;font-size:10pt;">12.1%</span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">15.8%</span><span style="font-family:inherit;font-size:10pt;"> during the same period in the prior year primarily due to the proportion of sales in countries subject to a higher royalty burden.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">71</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expense. </span><span style="font-family:inherit;font-size:10pt;">The following table summarizes our principal product development programs for each product candidate in development, and the out-of-pocket, third-party expenses incurred with respect to each product candidate:</span></div><div style="line-height:120%;text-align:center;text-indent:20px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.88109161793372%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Projects</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third-party direct project expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;(Fabry Disease)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20,347</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,665</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AT-GAA (Pompe Disease)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">103,884</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55,919</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gene therapy programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,836</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">137</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pre-clinical and other programs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,166</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,562</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total third-party direct project expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">165,233</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70,283</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other project costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Personnel costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81,496</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62,999</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,649</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30,620</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other project costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">121,145</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">93,619</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business development transactions</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">107,000</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total research and development costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">286,378</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">270,902</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">$15.5 million</span><span style="font-family:inherit;font-size:10pt;"> increase in research and development costs was primarily due to increases in clinical research and manufacturing costs with the advancement and enrollment of clinical studies in the Pompe program, an increase in gene therapy programs driven by the pipeline growth, as well as support for ongoing regulatory requirements, approval in new geographies, and pediatric and other studies to support label expansion of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. There were also increases in personnel and other costs associated with the advancement and enrollment of clinical studies and investments in manufacturing. This was primarily offset by $100 million in expenses associated with the acquisition of ten gene therapy assets with the Celenex transaction and the $7 million license upfront payment related to the collaboration agreement with Penn in 2018. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, General, and Administrative Expense. </span><span style="font-family:inherit;font-size:10pt;">Selling, general, and administrative increased </span><span style="font-family:inherit;font-size:10pt;">$42.7 million</span><span style="font-family:inherit;font-size:10pt;"> primarily due to the expanded geographic scope of the ongoing commercial launch of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">and related operational costs of our global business, including establishing commercial organizations and related teams in the U.S. and Japan.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Loss on Exchange of Convertible Notes.</span><span style="font-family:inherit;font-size:10pt;"> During the first and second quarters of 2019, the Company entered into separate, privately negotiated Exchange Agreements with a limited number of holders of the Convertible Notes. As a result of this exchange, the Company recognized a loss on exchange of debt of $40.6 million in the Consolidated Statements of Operations, and $215.0 million in additional paid-in-capital and common stock of $0.4 million in the Consolidated Balance Sheets for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Tax (Expense) Benefit. </span><span style="font-family:inherit;font-size:10pt;">The income tax expense for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$0.5 million</span><span style="font-family:inherit;font-size:10pt;">. We are subject to income taxes in various jurisdictions. Our tax liabilities are largely dependent on the distributions of pre-tax earnings among the many jurisdictions in which we operate. The income tax benefit for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$0.1 million</span><span style="font-family:inherit;font-size:10pt;"> was primarily related to provision to return variances.</span></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">72</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP"). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the following discussion represents our critical accounting policies.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our net product sales consist of sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:6pt;"> </span><span style="font-family:inherit;font-size:10pt;">for the treatment of Fabry disease. We have recorded revenue on sales where Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:6pt;"> </span><span style="font-family:inherit;font-size:10pt;">is available either on a commercial basis or through a reimbursed EAP. Orders for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:6pt;"> </span><span style="font-family:inherit;font-size:10pt;">are generally received from distributors and pharmacies with the ultimate payor often a government authority.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:3px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue when our performance obligation with our customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The transaction price is determined based on fixed consideration in our customer contracts and is recorded net of estimates for variable consideration, which are third-party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:6pt;"> </span><span style="font-family:inherit;font-size:10pt;">is recognized. We recognize revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. We evaluate these estimates each reporting period to reflect known changes.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We elected the portfolio approach practical expedient in applying ASC Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">, to our identified revenue streams. Contracts within each revenue stream have similar characteristics and we believe the results of this approach would not differ materially than if we applied ASC Topic 606 to each individual contract.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">73</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to continue to incur substantial research and development expenses as we continue to develop our product candidates. Research and development expense consists of:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">internal costs associated with our research and clinical development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fees owed to third-party contract research organizations in connection with preclinical, toxicology studies and clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">payments we make to contract manufacturers, investigative sites, and consultants in connection with clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">technology license costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">manufacturing development costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">personnel-related expenses, including salaries, benefits, travel, and related costs for the personnel involved in drug discovery and development;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">activities relating to regulatory filings and the advancement of our product candidates through preclinical studies and clinical trials; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">facilities and other allocated expenses, which include direct and allocated expenses for rent, facility maintenance, as well as laboratory and other supplies.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have multiple research and development projects ongoing at any one time. We utilize our internal resources, employees, and infrastructure across multiple projects. We record and maintain information regarding external, out-of-pocket research and development expenses on a project-specific basis.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expense research and development costs as incurred, including payments made to date under our license agreements. We believe that significant investment in product development is a competitive necessity and plan to continue these investments in order to realize the potential of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing, and costs of the efforts that will be necessary to complete the remainder of the development of our product candidates. As a result, we are not able to reasonably estimate the period, if any, in which material net cash inflows may commence from our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the conduct, duration, and cost of clinical trials, which vary significantly over the life of a project as a result of evolving events during clinical development, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number of clinical sites included in the trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the length of time required to enroll suitable patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number of patients that ultimately participate in the trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the results of our clinical trials; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any mandate by the FDA or other regulatory authority to conduct clinical trials beyond those currently anticipated.</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">74</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals, and the expense of filing, prosecuting, defending, and enforcing any patent claims or other intellectual property rights. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay, or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of the foregoing variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development, regulatory approval, and commercialization of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those which we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Drug development takes several years and millions of dollars in development costs.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-based Compensation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Option Grants</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with the applicable accounting guidance, we estimate the fair value of each equity award granted. We chose the "straight-line" attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007. We determine the average expected life using our actual historical data versus a "simplified" method used in prior quarters. The "simplified" method of estimating the expected exercise term uses the mid-point between the vesting date and the end of the contractual term. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on historical analysis of actual option forfeitures.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSU's")</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs awarded under the plan are generally subject to graded vesting and are contingent on an employee's continued service on such date. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. We expense the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. In addition, certain of our share-based awards are market- and performance-based and dependent upon achieving certain goals. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized on a straight-line basis over the vesting term. With respect to performance-based awards, we estimate the probability that the performance conditions will be achieved. </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">75</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We assign fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date of acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, we estimate the fair value of contingent acquisition consideration payments utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we believe the assumptions and estimates made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired businesses and are inherently uncertain. Examples of critical estimates in valuing any contingent acquisition consideration issued or which may be issued and the intangible assets we have acquired or may acquire in the future include but are not limited to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the feasibility and timing of achievement of development, regulatory, and commercial milestones;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expected costs to develop the in-process research and development into commercially viable products; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">future expected cash flows from product sales.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unanticipated events and circumstances may occur which may affect the accuracy or validity of such assumptions, estimates, or actual results.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets and Goodwill</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. No indicators of impairment were noted during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2018.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuation of Contingent Consideration Payable</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. Each period we reassess the fair value of the contingent acquisition consideration payable associated with certain acquisitions and record changes in the fair value as contingent consideration expense. Increases or decreases in the fair value of the contingent acquisition consideration payable can result from changes in estimated probability adjustments with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Significant judgment is employed in determining the appropriateness of these assumptions each period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described in the accounting for business combinations above can materially impact the amount of contingent consideration expense that we record in any given period.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">76</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of our significant research and development expenditures, as well as expenditures to build a commercial organization to support the launch of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, we have not been profitable and have generated operating losses since we were incorporated in 2002. We have historically funded our operations through stock offerings, debt issuances, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> revenues, collaborations, and other financing arrangements.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sources of Liquidity</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first and second quarters of 2019, we entered into separate, privately negotiated Exchange Agreements with a limited number of holders of the Convertible Notes. Under the terms of the Exchange Agreements, the limited number of holders agreed to exchange an aggregate principal amount of $247.2 million of Convertible Notes held by them in exchange for an aggregate of approximately 44.0 million shares of our common stock, par value $0.01 per share. Additionally, we terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for cash proceeds of $19.9 million.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second quarter of 2019, we completed an underwritten equity offering and issued 18.7 million shares of common stock at $10.75 per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of $189.0 million, after deducting underwriting discounts, commissions, and offering expenses.</span></div><div style="line-height:120%;text-align:justify;padding-left:2px;text-indent:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:2px;text-indent:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the third quarter of 2018, we entered into a loan agreement with BioPharma Credit PLC, as the lender, for a $150.0 million non-dilutive senior secured term loan (the "Senior Secured Term Loan") with an interest rate equal to 3-month LIBOR plus 7.50% per annum, subject to a floor and ceiling on the rate, which matures in five years. We received net proceeds of $146.6 million in September 2018, after deducting fees and expenses. There are no warrants or any equity conversion features associated with the Senior Secured Term Loan. For additional information, see " &#8212;Note 12. Debt" in our Notes to Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:2px;text-indent:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first quarter of 2018, we issued, through an underwritten offering, </span><span style="font-family:inherit;font-size:10pt;">20.2 million</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock resulting in net proceeds of $294.6 million after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="line-height:120%;text-align:justify;padding-left:2px;text-indent:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flow discussion</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents, and marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$452.7 million</span><span style="font-family:inherit;font-size:10pt;">. We invest cash in excess of our immediate requirements in regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such cash balances. For more details on the cash, cash equivalents, and marketable securities, refer to "-Note 5.&#160; Cash, Cash Equivalents, Marketable Securities, and Restricted Cash," in our Notes to Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Cash Used in Operating Activities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operations for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$250.4 million</span><span style="font-family:inherit;font-size:10pt;">. The components of net cash used in operations included the net loss for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$356.4 million</span><span style="font-family:inherit;font-size:10pt;"> and the net change in operating assets and liabilities of </span><span style="font-family:inherit;font-size:10pt;">$11.6 million</span><span style="font-family:inherit;font-size:10pt;">. The change in operating assets was primarily due to increases in accounts receivable by </span><span style="font-family:inherit;font-size:10pt;">$11.1 million</span><span style="font-family:inherit;font-size:10pt;"> due to increased commercial sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, an increase in prepaid and other current assets of </span><span style="font-family:inherit;font-size:10pt;">$3.3 million</span><span style="font-family:inherit;font-size:10pt;"> to support commercial activities for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> launch, and an increase in inventory of </span><span style="font-family:inherit;font-size:10pt;">$5.1 million</span><span style="font-family:inherit;font-size:10pt;">. The net cash used in operations was also impacted by an increase in accounts payable and accrued expenses of </span><span style="font-family:inherit;font-size:10pt;">$46.7 million</span><span style="font-family:inherit;font-size:10pt;">, mainly related to program expenses and support for the commercial launch of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. This was partially offset by a decrease in deferred reimbursement of </span><span style="font-family:inherit;font-size:10pt;">$5.5 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">77</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operations for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$300.0 million</span><span style="font-family:inherit;font-size:10pt;">. The components of net cash used in operations included the net loss for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$349.0 million</span><span style="font-family:inherit;font-size:10pt;">, and the net increase in operating assets of $16.1 million. The change in operating assets was primarily due to increases in accounts receivable by $13.3 million and inventory of $4.2 million due to commercial sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, partially offset by a decrease in prepaid and other current assets of $2.5 million for spending to support commercial activities for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> launch. The net cash used in operations was also impacted by an increase in accounts payable and accrued expenses of $17.1 million, mainly related to program expenses and support for the commercial launch of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, and a decrease in deferred reimbursement of $6.3 million due to payment of a milestone.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Cash Provided by (Used in) Investing Activities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by investing activities for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$95.2 million</span><span style="font-family:inherit;font-size:10pt;">. Our investing activities have consisted primarily of purchases, sales, and maturities of investments and capital expenditures. Net cash provided by investing activities reflects </span><span style="font-family:inherit;font-size:10pt;">$499.0 million</span><span style="font-family:inherit;font-size:10pt;"> for the sale and redemption of marketable securities, partially offset by </span><span style="font-family:inherit;font-size:10pt;">$383.9 million</span><span style="font-family:inherit;font-size:10pt;"> for the purchase of marketable securities and </span><span style="font-family:inherit;font-size:10pt;">$20.0 million</span><span style="font-family:inherit;font-size:10pt;"> for the acquisition of property and equipment.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$121.2 million</span><span style="font-family:inherit;font-size:10pt;">. Our investing activities have consisted primarily of purchases, sales, and maturities of investments and capital expenditures. Net cash used in investing activities reflects </span><span style="font-family:inherit;font-size:10pt;">$578.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the purchase of marketable securities, </span><span style="font-family:inherit;font-size:10pt;">$6.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the acquisition of property and equipment, partially offset by </span><span style="font-family:inherit;font-size:10pt;">$463.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the sale and redemption of marketable securities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Cash Provided by Financing Activities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$217.5 million</span><span style="font-family:inherit;font-size:10pt;">. Net cash provided by financing activities primarily reflects </span><span style="font-family:inherit;font-size:10pt;">$189.0 million</span><span style="font-family:inherit;font-size:10pt;"> from the issuance of common stock, net of issuance costs paid, </span><span style="font-family:inherit;font-size:10pt;">$19.9 million</span><span style="font-family:inherit;font-size:10pt;"> from termination of capped call and </span><span style="font-family:inherit;font-size:10pt;">$12.3 million</span><span style="font-family:inherit;font-size:10pt;"> from the exercise of stock options and warrants, partially offset by </span><span style="font-family:inherit;font-size:10pt;">$3.2 million</span><span style="font-family:inherit;font-size:10pt;"> from the purchase of vested restricted stock units.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$450.8 million</span><span style="font-family:inherit;font-size:10pt;">. Net cash provided by financing activities primarily reflects $294.6 million from the issuance of common stock, net of issuance costs, $146.6 million in proceeds from the Senior Secured Term Loan, net of issuance costs and estimated fees , $9.1 million from the exercise of stock options, and $3.6 million from the exercise of warrants, partially offset by $2.8 million from the purchase of vested RSU's.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">78</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Funding Requirements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to incur losses from operations for the foreseeable future primarily due to research and development expenses, including expenses related to conducting clinical trials.&#160;Our future capital requirements will depend on a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the progress and results of our preclinical and clinical trials of our drug candidates and gene therapy candidates, including but not limited to AT-GAA, CLN6 and CLN3;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of manufacturing drug and gene therapy supply for our clinical and preclinical studies, including the significant cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200") and gene therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope, progress, results, and costs of preclinical development, laboratory testing and clinical trials for our product candidates including those testing the use of a pharmacological chaperone co-administered with ERT for the treatment of AT-GAA and gene therapies for the treatment of rare genetic metabolic diseases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the future results of on-going preclinical research and subsequent clinical trials for CDD, Pompe gene therapy, Fabry gene therapy, NPC, MPSIIIB and next generation MPSIIIA, including our ability to obtain regulatory approvals and commercialize these gene therapies and obtain market acceptance for such therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs, timing, and outcome of regulatory review of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any changes in regulatory standards relating to the review of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number and development requirements of other product candidates that we pursue;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the emergence of competing technologies and other adverse market developments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to successfully commercialize Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> ("migalastat HCl");</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, AT-GAA and our gene therapy candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain reimbursement for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain market acceptance of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which we acquire or invest in businesses, products, and technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to establish collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to adjust to changes in the European and U.K. markets in the wake of the U.K. leaving the E.U.;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which our business could be adversely impacted by the effects of the COVID-19 &#8220;coronavirus&#8221; outbreak or by other health epidemics or pandemics;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fluctuations in foreign currency exchange rates; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in accounting standards.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While we continue to generate revenue from product sales, in the absence of additional funding, we expect our continuing operating losses to result in increases in our cash used in operations over the next several quarters and years.&#160;We may seek additional funding through public or private financings of debt or equity. We believe that our current cash position, including expected Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> revenues, is sufficient to fund ongoing Fabry, Pompe, and gene therapy program operations into the first half of 2022. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">79</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Uncertainties Related to Potential Future Payments</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Milestone Payments / Royalties</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Celenex - With our acquisition of Celenex in 2018, we agreed to pay up to an additional $15 million in connection with the achievement of certain development milestones, $262 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NCH - Celenex has an exclusive license agreement with NCH. Under this license agreement, NCH is eligible to receive development and sales-based milestones of up to $7.8 million from us for each product.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Penn - Under our expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty, and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $86.5 million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis. We will provide $10.0 million each year during the five-year agreement to fund the discovery research program.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GlaxoSmithKline - In November&#160;2013, we entered into the Revised Agreement (the "Revised Agreement") with GlaxoSmithKline ("GSK"), pursuant to which we have obtained global rights to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between us and GSK in July&#160;2012 (the "Original Collaboration Agreement"). Under the terms of the Revised Agreement, there was no upfront payment from us to GSK. For migalastat monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. In addition, because we reacquired worldwide rights to migalastat, we are no longer eligible to receive any milestones or royalties we would have been eligible to receive under the Original Collaboration Agreement.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our significant contractual obligations and commercial commitments at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the effects such obligations are expected to have on our liquidity and cash flows in future periods:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.5925925925926%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 1&#160;year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">1-3&#160;years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">3-5&#160;years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Over 5&#160;years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease obligations </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">215,641</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,738</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,246</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,391</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">163,266</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt obligations, including interest </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">206,715</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,708</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38,594</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">153,413</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase obligations </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74,753</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35,153</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,200</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17,600</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,800</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other contractual obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,500</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,500</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,000</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,000</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total fixed contractual obligations </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">513,609</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59,599</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80,540</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">198,404</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">175,066</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span><span style="font-family:inherit;font-size:9pt;"> This table does not include (a)&#160;any milestone payments which may become payable to third parties under license agreements as the timing and likelihood of such payments are not known, (b)&#160;any royalty payments to third parties as the amounts of such payments, timing, and/or the likelihood of such payments are not known, (c)&#160;amounts, if any, that may be committed in the future to construct additional facilities, (d)&#160;agreements with clinical research organizations and other outside contractors who are partially responsible for conducting and monitoring our clinical trials for our drug candidates including Galafold</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:9pt;">. These contractual obligations are not reflected in the table above because we may terminate them without penalty, and (e)&#160;contracts that are entered into in the ordinary course of business which are not material in the aggregate in any period presented above.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2) </sup></span><span style="font-family:inherit;font-size:9pt;">Represents the future payments on operating leases for properties, equipment, and vehicles. For more details, refer to "&#8212; Note&#160;13. Leases," in our Notes to Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3) </sup></span><span style="font-family:inherit;font-size:9pt;">Represents the future payments of principal and interest to be made on our $2.8&#160;million 3% unsecured Convertible Notes due 2023 (the "Convertible Notes") and our $150 million Secured Senior Term Loan due 2023 ("Senior Secured Term Loan"). The Convertible Notes bear interest at a fixed rate of 3.00% per year, payable semiannually on June&#160;15 and December&#160;15 of each year, beginning on June&#160;15, 2017 and will mature on December&#160;15, 2023. The Senior Secured Term Loan bears interest at a rate equal to the 3-month LIBOR plus 7.5% per year, payable quarterly of each year, beginning on December 31, 2019 and will mature on September 28, 2023. </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">80</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4) </sup></span><span style="font-family:inherit;font-size:9pt;">Represents minimum purchase commitments due to third parties. Contracts for which our commitment is variable, based on volumes, with no fixed minimum quantities, and contracts that can be canceled without payment penalties have been excluded. The purchase obligations included above are in addition to amounts included in total recorded on our </span><span style="font-family:inherit;font-size:9pt;">December 31, 2019</span><span style="font-family:inherit;font-size:9pt;"> Consolidated Balance Sheet.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have no other lines of credit or other committed sources of capital. To the extent our capital resources are insufficient to meet future capital requirements, we will need to raise additional capital or incur indebtedness to fund our operations. We cannot assure you that additional debt or equity financing will be available on acceptable terms, if at all.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had no off-balance sheet arrangements as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Please refer to "&#8212; Note&#160;2. Summary of Significant Accounting Policies," in our Notes to Consolidated Financial Statements.</span></div><div><a id="sC1713476A23C558394D08E245F2ECB55"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Market risk is the risk of change in fair value of a financial instrument due to changes in interest rates, equity prices, creditworthiness, financing, exchange rates or other factors. Our primary market risk exposure relates to changes in interest rates in our cash, cash equivalents, and marketable securities. We place our investments in high-quality financial instruments, primarily money market funds, corporate debt securities, asset backed securities, and U.S. government agency notes with maturities of less than one year, which we believe are subject to limited interest rate and credit risk. The securities in our investment portfolio are not leveraged, are classified as available-for-sale and, due to the short-term nature, are subject to minimal interest rate risk. We believe that a 1% (100 basis points) change in average interest rates would either increase or decrease the market value of our investment portfolio by $1.4&#160;million as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. We currently do not hedge interest rate exposure and consistent with our investment policy, we do not use derivative financial instruments in our investment portfolio. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to interest rate risk with respect to variable rate debt. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had a $150 million Senior Secured Term Loan that bears interest at a rate equal to the 3-month LIBOR plus 7.50% per year. We do not currently hedge our variable interest rate debt. The annual average variable interest rate for our variable rate debt as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was 9.95%. A hypothetical 100 basis point increase or decrease in the average interest rate on our variable rate debt would result in $1.5 million change in the interest expense as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Financial Conduct Authority has announced the intent to phase out the use of LIBOR by the end of 2021. If LIBOR is discontinued, we may need to renegotiate the terms of the Senior Secured Term Loan in order to replace LIBOR with the new standard that is established. As a result, we may incur incremental costs in transitioning to a new standard, and interest rates on our current or future indebtedness may be adversely affected by the new standard. There is currently no definitive information regarding the future utilization of LIBOR or of any particular replacement rate. As such, the potential effect of any such event on our cost of capital cannot yet be determined, but we do not expect it to have a material impact on our consolidated financial condition, results of operations, or cash flows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars. We are not currently engaged in any foreign currency hedging activities. The current exposures arise primarily from cash, accounts receivable, intercompany receivables and payables, and net product sales denominated in foreign currencies. Both positive and negative impacts to our international product sales from movements in foreign currency exchange rates may be partially mitigated by the natural, opposite impact that foreign currency exchange rates have on our international operating expenses. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our Consolidated Financial Statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">81</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="sEC58A22A3F745DC58EF2B1D908A75911"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Management's Report on Consolidated Financial Statements and</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The management of Amicus Therapeutics,&#160;Inc. has prepared, and is responsible for the Company's Consolidated Financial Statements and related footnotes. These Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S.&#160;GAAP").</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule&#160;13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of the Company's principal executive and principal financial officers and effected by the Company's board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S.&#160;GAAP and includes those policies and procedures that:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of Amicus Therapeutics,&#160;Inc.;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of Amicus therapeutics,&#160;Inc. are being made only in accordance with authorizations of management and directors of Amicus therapeutics,&#160;Inc.; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of Amicus Therapeutics,&#160;Inc. that could have a material effect on the financial statements.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We assessed the effectiveness of our internal control over financial reporting as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) ("COSO") in Internal Control&#160;&#8212; Integrated Framework. Based on our assessment we believe that, as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our internal control over financial reporting is effective based on those criteria.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effectiveness of the Company's internal control over financial reporting as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> has been audited by Ernst&#160;&amp; Young&#160;LLP, an independent registered public accounting firm, as stated in their report. This report appears on the following page.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dated </span><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.01559454191033%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:38%;"></td><td style="width:23%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;JOHN F. CROWLEY</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;DAPHNE QUIMI</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">82</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s7C8C22EB95335B51828D40B7638147C5"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the Stockholders and the Board of Directors of Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have audited Amicus Therapeutics,&#160;Inc.&#8217;s internal control over financial reporting as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, Amicus Therapeutics,&#160;Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, based on the COSO criteria.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity and cash flows for each of the three years in the period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and the related notes and our report dated </span><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span><span style="font-family:inherit;font-size:10pt;"> expressed an unqualified opinion thereon.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Consolidated Financial Statements and Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:47.953216374269005%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Iselin, New Jersey</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">83</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBD8E69A6F5EB5637B5849666EA77B647"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the Stockholders and the Board of Directors of Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Amicus Therapeutics,&#160;Inc. (the Company) as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity and cash flows for each of the three years in the period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and the results of its operations and its cash flows for each of the three years in the period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, in conformity with U.S. generally accepted accounting principles.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated </span><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span><span style="font-family:inherit;font-size:10pt;"> expressed an unqualified opinion thereon.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">84</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Audit Matter</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:17%;"></td><td style="width:83%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement of the Contingent Consideration</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Description of the Matter</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described in Note 3 to the consolidated financial statements, the Company has a $22.7 million contingent consideration liability recorded as of December 31, 2019 representing the fair value of additional amounts that management believes are likely to be paid to the former stockholders of Callidus Biopharma, Inc. The determination of the recorded amount of the contingent consideration liabilities requires the Company to make significant estimates and assumptions.</span></div><div style="padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We identified the measurement of the contingent consideration liability as a critical audit matter because auditing the Company&#8217;s valuation of the contingent consideration liability involved complex and challenging auditor judgment as the inputs to such valuation, such as the estimated probability of achieving milestones, the assumed timing of milestones and the discount rates, are largely unobservable. </span></div><div style="padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">How We Addressed the Matter in Our Audit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To test the estimated fair value of the contingent consideration liability, we performed audit procedures that included testing the operating effectiveness of internal controls relating to management&#8217;s fair value measurement of the contingent consideration liability including controls over the Company&#8217;s model, significant assumptions, and data. </span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our procedures also included, among others, assessing the terms of the arrangement, evaluating the methodology used, testing the significant assumptions discussed above and the completeness, accuracy and relevance of the underlying data used by management in its analysis. We also performed analyses of certain assumptions to assess the impact of changes in certain assumptions on the Company&#8217;s determination of the fair value of the contingent consideration liability. Evaluating the assumptions also involved evaluating whether the assumptions used by management were consistent with external market data and evidence obtained in other areas of the audit.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:47.953216374269005%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have served as the Company's auditor since 2003.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Iselin, New Jersey</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">85</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFFA8538BE1DF59708C90D88E9CE98E32"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share amounts)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e903-wk-Fact-5B00B5F16D67C7FD36126B8C2F621219" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e922-wk-Fact-E0F444372BF0213F4E0F6B8C2F5F9EC4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Investments in marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e937-wk-Fact-4A226FD07C14E5234D7F6B8C2F74207E" name="us-gaap:MarketableSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">309,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e956-wk-Fact-1D4272B56D92ABA819AA6B8C2F5E569F" name="us-gaap:MarketableSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">424,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e976-wk-Fact-BA912F98E8D1F6A0DFCB6B8C2F71A559" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,284</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e995-wk-Fact-2E32F6AAB833211133756B8C2F731405" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,962</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1015-wk-Fact-598359183EED6871AA2C6B8C2F5D1396" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1034-wk-Fact-1834396DC49735734D906B8C2F69C29C" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1054-wk-Fact-FB4E761A9DC63467F6796B8C2F63C2E9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1073-wk-Fact-C78980F9200619F0C34D6B8C2F64B373" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1093-wk-Fact-B0ADCE739AA5F7221E976B8C2F631854" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">520,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1112-wk-Fact-29EB9D173F3F9E7895726B8C2F69122D" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">551,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease right-of-use assets, less accumulated amortization of $5,342 and $0 at December 31, 2019 and December 31, 2018, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1132-wk-Fact-4BD6B73A59B6BF695169F646B8B5F75E" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property and equipment, less accumulated depreciation of $17,604 and $15,671 at December 31, 2019 and December 31, 2018, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1172-wk-Fact-F67F04CA72257459EC5C6B8C2F73F9EF" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1191-wk-Fact-22630A3A2EFD75C53BAC6B8C2F5F1448" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process research&#160;&amp; development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1211-wk-Fact-03B01ABC5931CEDDDEE06B8C2F6C699B" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1230-wk-Fact-5EFC3AB0BA2868FB3C3D6B8C2FD9FC4B" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1250-wk-Fact-364FF26B676C1588BCD86B8C2FDCFB4F" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">197,797</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1269-wk-Fact-CEAD39D57A9C217F62616B8C2F63BACC" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">197,797</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other non-current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1289-wk-Fact-7AF6EA197567122BF0A66B8C2F72AE80" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1308-wk-Fact-4893A24E7769DEFAB4696B8C2F687696" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1333-wk-Fact-23F277D0CD51901118126B8C2F6C9A4B" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">850,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1352-wk-Fact-2DD17AE8CD5BB0331C9B6B8C2F5DB374" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">789,951</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities and Stockholders' Equity</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts payable, accrued expenses, and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1454-wk-Fact-00D9324EC614ACA175846B8C2F705888" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">120,373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1473-wk-Fact-88FBC7147324CDFE62F06B8C2F5C7F02" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred reimbursements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1488-wk-Fact-85B34183A1BAB0E939B96B8C2F75461D" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1507-wk-Fact-21671084F18DF46E3C6F6B8C2F6B59A8" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1527-wk-Fact-EE5C5AABDF3F3EA76797F04F5FF883CB" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1566-wk-Fact-1423E69DBFAD094151066B8C2F6A4AEC" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128,812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1585-wk-Fact-3927BB33B0CED3187A7F6B8C2F609D91" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred reimbursements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1606-wk-Fact-3E5F2B685D8C4AC684536B8C2FD84CD5" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1625-wk-Fact-65566CB6011B20BB379E6B8C2F75B94B" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1645-wk-Fact-45A28D578D9871951C846B8C2F6523C6" name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1664-wk-Fact-32630FAC16D8974424506B8C2F60703E" name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">175,006</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Senior secured term loan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1684-wk-Fact-D76F68D335F2597C385A6B8C2F631674" name="us-gaap:SecuredLongTermDebt" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">147,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1703-wk-Fact-9E6E03BA69EA8B482DDE6B8C2F61C23E" name="us-gaap:SecuredLongTermDebt" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">146,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contingent consideration payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1723-wk-Fact-2C76AEA29938F40F94A96B8C2F6E264E" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1742-wk-Fact-C7D73D49F5FDA70E2A526B8C2FDF2EDB" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1762-wk-Fact-4ADD7C6F326DF36E4E006B8C2F66D061" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1781-wk-Fact-C30451D3C7E2C65D56616B8C2FD6F83D" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1801-wk-Fact-27EEB08844CA532CFF47F051C35D6512" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other non-current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1840-wk-Fact-BFB6B88FEFABECCA642F6B8C2FD9BABE" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1859-wk-Fact-482B04496298B8B229816B8C2F5C6138" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,853</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1879-wk-Fact-30701C7F5F623B7130166B8C2F69AD14" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">373,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1898-wk-Fact-02DF947039E9B909CEF66B8C2F5E248C" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">447,039</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Commitments and contingencies</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1918-wk-Fact-CBAA5205F6A16D6BE0B66B8C2F74FF02" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1937-wk-Fact-2CE529D9499330CB0B936B8C2F68A159" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stockholders' equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock, $.01 par value, 500,000,000 shares authorized, 255,417,869 and 189,383,924 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e1998-wk-Fact-2E4D8B5095C94CD22DEA6B8C2F68B118" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2017-wk-Fact-F358B90EFBB04F19525E6B8C2F6E963B" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2038-wk-Fact-9771010B5D436515AD836B8C2FDDE224" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,227,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2057-wk-Fact-003CE95CC9E2359D4B3F6B8C2F748542" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,740,061</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive loss:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2118-wk-Fact-91FC16488DCFE71832B96B8C2F5E6850" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,785</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2137-wk-Fact-B55C6547D1E7FCA28D3D6B8C2F77D41C" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized gain (loss) on available-for securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2157-wk-Fact-B7FB66E86646903CDCBA6B8C2F65BD78" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23288016e2176-wk-Fact-005DFC2E40FCC9D795036B8C2F6A67A4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Warrants</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2197-wk-Fact-7F01D812BDF3643902436B8C2F6DACFA" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2216-wk-Fact-5178B0C4973A999EE5106B8C2F67434A" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23288016e2236-wk-Fact-219EDF5D966D06A097816B8C2F671BA4" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,768,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23288016e2256-wk-Fact-92E3D153B42F2D85E6176B8C2F5D0952" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,412,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total stockholders' equity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2277-wk-Fact-7273512A0E79AC0E8AC96B8C2F60F4B4" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">476,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2296-wk-Fact-E7FD0993FBD1AF28A70F6B8C2F77FEF1" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">342,912</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Liabilities and Stockholders' Equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2321-wk-Fact-21F8E7E7D9BCC6742EEC6B8C2F6D65AE" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">850,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23288016e2340-wk-Fact-C39A2EDBE43DDCBD89EA6B8C2F680A29" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">789,951</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying Notes to Consolidated Financial Statements</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">86</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s36C5B7D902C35E9AADB8F813AB037C69"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e869-wk-Fact-DC4C2C439C61ED6A63236B8C2FB9BFAF" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e888-wk-Fact-D89C4138A9858DD9450E6B8C2FB1397B" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e907-wk-Fact-40820295652A1814D77F6B8C2FA61836" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e923-wk-Fact-35E115AA24D5710A28EF6B8C2FBD49B8" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e942-wk-Fact-1A2B44A15DD0CFB80D256B8C2FBA5097" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e961-wk-Fact-F71730BAAAF46B9083576B8C2FBEE548" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e982-wk-Fact-578F0FA71FB4F40DDC466B8C2FA8FD4E" name="us-gaap:GrossProfit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">160,274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1001-wk-Fact-34ABCBDBA20B82AD10746B8C2FB14CD3" name="us-gaap:GrossProfit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76,841</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1020-wk-Fact-E1C68C18789615DA8DCD6B8C2FA4B844" name="us-gaap:GrossProfit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,694</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1103-wk-Fact-E30918DA8FF3BF43108B6B8C2FACB792" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">286,378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1122-wk-Fact-60072610235C9A0EB3FE6B8C2FBAE7CB" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">270,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1141-wk-Fact-AE709E9500303273C8C26B8C2FAA6FDD" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">149,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general, and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1162-wk-Fact-7BF2E0C69DEBA6E1BB046B8C2FB19456" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">169,861</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1181-wk-Fact-7B12A9AB69980CAC57196B8C2FA919A2" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">127,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1200-wk-Fact-E11715E59A3703425DA46B8C2FABDF38" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in fair value of contingent consideration payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1221-wk-Fact-FB99FB171B33B0504A336B8C2FAA9303" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1240-wk-Fact-5BF3B505984CD70519BF6B8C2FB42BBF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1259-wk-Fact-6412DBABF29B3880516E6B8C2FAF627E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234,322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on impairment of assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1281-wk-Fact-CDEEE16656F8C54D15046B8C2FBC78B4" name="us-gaap:AssetImpairmentCharges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1300-wk-Fact-158CDB36E5BC291E5E126B8C2FB37ABC" name="us-gaap:AssetImpairmentCharges" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1319-wk-Fact-421008C66332774F04E96B8C2FB2588D" name="us-gaap:AssetImpairmentCharges" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">465,427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1340-wk-Fact-3B0DEA15683CDE6A13166B8C2FBAABE1" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1359-wk-Fact-C72A52BDFB132B2A7DFF6B8C2FAD7B5A" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1378-wk-Fact-5EDF63642521DC3B6F856B8C2FB25DE8" name="us-gaap:DepreciationAndAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,593</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1400-wk-Fact-2F756A13481E351FA7FA6B8C2FB0BE32" name="us-gaap:OperatingExpenses" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">464,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1419-wk-Fact-A294EDFCF04123616AEC6B8C2FB2D9AB" name="us-gaap:OperatingExpenses" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">405,618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1438-wk-Fact-0693C9D7C797D1E222926B8C2FAFAB4A" name="us-gaap:OperatingExpenses" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">472,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1459-wk-Fact-073DAB3CCCD667A6A8986B8C2FB5943B" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">304,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1479-wk-Fact-3FC73189E7F1B23E25DF6B8C2FA4FD1C" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">328,777</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1499-wk-Fact-582BAFF6935F78DC48D46B8C2FB54681" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">441,985</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expenses):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1583-wk-Fact-670C141A8834953AA6BC6B8C2FA79BDD" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1602-wk-Fact-9EDA13665BB8A16EE4446B8C2FA7544F" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1621-wk-Fact-B426CBAB3F8CD192DC7C6B8C2FAD0D19" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1642-wk-Fact-4D69E1E9417A264B41F66B8C2FB3D15D" name="us-gaap:InterestExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,872</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1662-wk-Fact-D43000A9337A6E8F3D176B8C2FB17BEB" name="us-gaap:InterestExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1682-wk-Fact-FD80FD50E03C7BB7D7166B8C2FA57388" name="us-gaap:InterestExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on exchange of convertible notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1704-wk-Fact-11BAC4E93BA6283AE60AF09A2E464CDD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40,624</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1724-wk-Fact-9190C43965384A029822F09A2DC9D88E" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1743-wk-Fact-E5DA14CDD8E3F849B47AF09A2E368636" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value of derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1764-wk-Fact-4DFA666D5541072D423E6B8C2FA5FF75" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1783-wk-Fact-3CD4EAB05566DE713D4C6B8C2FBB76CA" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1803-wk-Fact-9BC122649F618E2B74066B8C2FADCBB0" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (expense) income </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1824-wk-Fact-A2335624B2E238FDF6646B8C2FB73DC9" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,626</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1844-wk-Fact-E70AE8AD338BA820E4716B8C2FB87CF0" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1864-wk-Fact-72A46D84302E427AFA3A6B8C2FA82694" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before income tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1885-wk-Fact-39CB3DA7D0A5C09EE4246B8C2FAA0F9E" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">355,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1905-wk-Fact-815848D01C88BA2101DF6B8C2FA91CFB" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">349,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1925-wk-Fact-5152D2C671953CAC01836B8C2FB75F3C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">449,121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (expense) benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e1947-wk-Fact-3855EEFA4DD61B26A72F6B8C2FB86431" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1967-wk-Fact-CECB6F05ED5CE81CFF1C6B8C2FAEB61F" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e1986-wk-Fact-741CBE90FE3A6560C1116B8C2FAF165A" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">165,119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e2012-wk-Fact-A12C3F3D7CBD330E74976B8C2FA8F19A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">356,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e2032-wk-Fact-EE3BD9FBA254D383B3646B8C2FAB60A5" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">348,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e2052-wk-Fact-7624C92CE3E7F08A06F66B8C2FB8EA12" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">284,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders per common share&#160;&#8212; basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e2075-wk-Fact-6E1EA8AB2B5EE55BBAF96B8C2FBBFC22" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e2095-wk-Fact-D5333D21D9D2336967446B8C2FAE1D9A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.88</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23289528e2115-wk-Fact-8DAAF16771AA9BF6916B6B8C2FA59DE3" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average common shares outstanding&#160;&#8212; basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e2132-wk-Fact-D335D27D9B7976C780C46B8C2FBC3C1B" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">240,421,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e2151-wk-Fact-C04A907E3EAA92AB22546B8C2FA66E6E" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">185,790,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23289528e2170-wk-Fact-FD8F09C37B719A0A7D836B8C2FBD8BC0" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">153,355,144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying Notes to Consolidated Financial Statements</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">87</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s471E59E8CEDF50DAA0D61EC6EDE706C0"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share amounts)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23293640e869-wk-Fact-A12C3F3D7CBD330E74976B8C2FA8F19A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">356,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23293640e889-wk-Fact-EE3BD9FBA254D383B3646B8C2FAB60A5" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">348,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23293640e909-wk-Fact-7624C92CE3E7F08A06F66B8C2FB8EA12" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">284,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive gain (loss):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment gain (loss), net of tax impact of $889, $0, and $0, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23293640e988-wk-Fact-2497C471A4E5AEE308166B8C2F8FC877" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23293640e1007-wk-Fact-5E2F0C75B255D33D6DD16B8C2FDFAFC3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,537</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23293640e1026-wk-Fact-30212D5892122EAB4A2D6B8C2F8E8F78" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on available-for-sale securities, net of tax impact of $182, $0, and $0, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23293640e1048-wk-Fact-E257C540551A3DBFA26E6B8C2FE0580C" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23293640e1067-wk-Fact-35A4CEBC1E86D3AFC3DD6B8C2F8E89C0" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23293640e1086-wk-Fact-30089DF5E67CA8790E056B8C2FDF4D4D" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23293640e1108-wk-Fact-94BD6351E9A3EB0DD3E76B8C2F908DF9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23293640e1127-wk-Fact-835C7999A497D53BE0E46B8C2F5C84AA" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23293640e1146-wk-Fact-29E8B67988A0D0445EFE6B8C2F91AE95" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23293640e1173-wk-Fact-212C265F2A0F2C86CEDC6B8C2F905D41" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">353,631</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23293640e1193-wk-Fact-E9E0FEAA8DB54050439D6B8C2F8F35F3" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">346,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23293640e1213-wk-Fact-F92D3B9A49AA1C25B2256B8C2F905125" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">288,144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">88</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s00ADE69CBA4751D6AB4C0197779A6372"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share amounts)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:23%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional<br/>Paid-In<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other<br/>Comprehensive<br/>Gain (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total<br/>Stockholders'<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at December 31, 2016</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1034-wk-Fact-CB4CE02257B5D60D255AF0EA7EDB5A19" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">142,691,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1053-wk-Fact-7ECA77534ADC923D4A10F0EA7F3250AB" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,480</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1072-wk-Fact-6C6FC3584D73102679A2F0EA7FE4050C" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,120,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1092-wk-Fact-99D957CB57872214B041F0EA7F3A4135" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,076</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1111-wk-Fact-CF44EE2C1D2B0EBEE1D6F0EA7F4337C2" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e1130-wk-Fact-CB5FF14331816780AE64F0EA7FF2D8C6" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">779,608</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1151-wk-Fact-AF3D99E47E56894A15B3F9E4EA76076B" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">360,151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock issued from exercise of stock options, net</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1166-wk-Fact-06EEF3F743B81E68ACD96B8C2FB1E814" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,878,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1180-wk-Fact-0502C09373180BDA5A286B8C2FA19730" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1199-wk-Fact-B4CEE74027C2651C57146B8C2F917DA5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1277-wk-Fact-06563F35549DB683EC8DF9E4EB1AEF31" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock issued from equity financing</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1297-wk-Fact-CECDAB624F2A6814C8D16B8C2FA0EADF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">21,122,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1311-wk-Fact-30EBD03145E65DA23A236B8C2FB31D47" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1330-wk-Fact-45ECE7170057AB5699726B8C2FB58517" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">242,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1408-wk-Fact-1CA19A0DE922FA77EBC0F9E4EB40508E" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">243,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restricted stock tax vesting</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1428-wk-Fact-84183763C594799AF2A46B8C2FA36EF2" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">296,674</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e1461-wk-Fact-B36EF85169AECA7F15026B8C2FB8556B" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,596</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e1540-wk-Fact-0C0ABB6E3462EABB1FF1F9E4EAA9340E" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,596</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1594-wk-Fact-77FF9FA59189190003CC6B8C2FB28F76" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e1672-wk-Fact-DC95ABECCF69B9B53530F9E4EB2AF115" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unrealized holding loss on available-for-sale securities</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e1764-wk-Fact-FCCDEA7CE814B392C85F6B8C2F93C2D9" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">538</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e1804-wk-Fact-30089DF5E67CA8790E056B8C2FDF4D4D" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">538</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign currency translation adjustment</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e1897-wk-Fact-20FEF41E91CAA8F07EF36B8C2FA51D02" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,604</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e1937-wk-Fact-30212D5892122EAB4A2D6B8C2F8E8F78" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,604</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e2049-wk-Fact-8D06CD9FCB9F7F29A7CB6B8C2FA9D4B2" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">284,002</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e2070-wk-Fact-7624C92CE3E7F08A06F66B8C2FB8EA12" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">284,002</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2091-wk-Fact-E116F0EEEF6E38B7B7E3F9E4EB322812" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">166,989,790</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2105-wk-Fact-9FC99F99063D8477916AF9E4EB6A2902" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,721</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2124-wk-Fact-5EC3630415CCD31768B0F9E4EBFA76EE" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,400,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2144-wk-Fact-1CD7432BDD3EA6D386A5F9E4EB739AB4" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,076</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e2163-wk-Fact-95A86E66D98AE582F6FDF9E4EB11EC88" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,095</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e2183-wk-Fact-E5FF49CD2401CA6D5BEEF9E4EC32FF94" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,063,610</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2204-wk-Fact-B2D79F70DDEB23B418F1F9E4EA95B037" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">352,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock issued from exercise of stock options, net</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2225-wk-Fact-5DF2C956A4DED99D51126B8C2FA1CB1F" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,397,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2239-wk-Fact-182AB12C812C6FCE04106B8C2F959F9C" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2258-wk-Fact-1D3D86EE5F3B6BF2B7526B8C2F9EF0AF" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,130</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2336-wk-Fact-26540FD37A5DAA2D5D5FF9E4EBBBB260" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock issued from equity financing</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2356-wk-Fact-B13935D331D75A5E7B666B8C2FB8AB65" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">20,239,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2370-wk-Fact-6578B6B388ECBE3DFE696B8C2FA79E9B" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2389-wk-Fact-DD821DE10FBA1E913D116B8C2F99055A" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">294,381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2467-wk-Fact-86A330F0D24E11E344C2F9E4EC4C749C" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">294,583</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restricted stock tax vesting</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2487-wk-Fact-7C8E73380EF49CCC642B6B8C2FACF1D8" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">303,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e2520-wk-Fact-9E718180F8A32739FBD66B8C2F9DB20B" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,832</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e2599-wk-Fact-ADF31BCC69E2D9337D58F9E4EB48983F" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,832</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2653-wk-Fact-EB36FC772FD3009C194E6B8C2F9A9DCA" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2731-wk-Fact-5040736D1354400E18CDF9E4EB039404" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Reclassification upon ASU 2018-02 adoption</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e2823-wk-Fact-C1858CD1E791C7A23DBA6B8C2FB0D9BE" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">383</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2843-wk-Fact-A723192498A1E24CFEBF6B8C2FA54246" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Warrants exercised</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2883-wk-Fact-2D15C9099A30F65D18106B8C2F9F2D1C" name="fold:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">453,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2897-wk-Fact-B204E528F6EE417C92A26B8C2FADBA41" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2916-wk-Fact-3127660D0B9B444BC3186B8C2FAD3A8D" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e2936-wk-Fact-57DEFD5AFE450919FC6A6B8C2F9F702F" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,013</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e2995-wk-Fact-4317C909BB1DCAF6F1706B8C2FADBA78" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Change in fair value of derivatives</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3048-wk-Fact-7178637E143E617FE6D96B8C2FAE8A89" name="fold:AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3126-wk-Fact-7B958370E009E9DA2CEBF9E4EC0B4D6E" name="fold:AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unrealized holding gain on available-for-sale securities</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3218-wk-Fact-6BAC63F52D88E860ADC76B8C2FA7D762" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3257-wk-Fact-35A4CEBC1E86D3AFC3DD6B8C2F8E89C0" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign currency translation adjustment</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3349-wk-Fact-F0FB5F4398AE6E1330596B8C2F985A06" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,537</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3388-wk-Fact-5E2F0C75B255D33D6DD16B8C2FDFAFC3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,537</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e3499-wk-Fact-36892C62D8554F4DDA7C6B8C2F9503B4" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">348,995</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e3520-wk-Fact-EE3BD9FBA254D383B3646B8C2FAB60A5" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">348,995</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3541-wk-Fact-B3B4DB07B946C573D8DAF9E4EA66F6A5" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">189,383,924</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3555-wk-Fact-3342F1CE51C85A741C49F9E4EBB25D93" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3574-wk-Fact-149E5C89F93DF1E9F7DDF9E4EC29334A" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,740,061</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3594-wk-Fact-675CDC74381AE7D7898BF9E4EAB173F5" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3613-wk-Fact-6F771260732A78707861F9E4EBF1BF6E" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e3632-wk-Fact-31D554C3D91F58C12276F9E4EAD0A60C" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,412,222</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3653-wk-Fact-E7FD0993FBD1AF28A70F6B8C2F77FEF1" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">342,912</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock issued from exercise of stock options, net</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3674-wk-Fact-0455BB36CC84DC734C56F0EA7ECD2FEA" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,967,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3688-wk-Fact-92368690AD62C1FBC77CF0EA7F0CAF29" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3707-wk-Fact-95485FF63F3F281F721EF0EA7FA3B5D3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,456</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3785-wk-Fact-10934332BA4913248356F9E4EBD434BF" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock issued from equity financing</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3805-wk-Fact-1D256EEC5C1A7347E4D8F0EA7EC347AE" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">18,720,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3819-wk-Fact-BDCE41D70D5405CEC59DF0EA7EF59CA6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3838-wk-Fact-882DC04021EC07ED292EF0EA7FC88941" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3916-wk-Fact-01D0AD4899945F06F003F9E4EBCBC0A1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restricted stock tax vesting</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e3936-wk-Fact-475627558440E2B1AD45F0EA7FB00946" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">477,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e3969-wk-Fact-142A54CA33E258073097F0EA7EDE7E47" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,235</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e4048-wk-Fact-7A7CDAA2351AA9E05014F9E4EAFB5AB9" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,235</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock issued for contingent consideration</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4069-wk-Fact-1B7DB4B6D4DF2AE65BFEF0C33556F1D3" name="fold:StockIssuedDuringPeriodSharesContingentConsideration" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">771,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4083-wk-Fact-0E3AC98F406287B84F9DF0C310AC46D3" name="fold:StockIssuedDuringPeriodValueContingentConsideration" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4102-wk-Fact-EA780E2ED1C69775E15FF0EA7FB688D5" name="fold:StockIssuedDuringPeriodValueContingentConsideration" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4180-wk-Fact-07060A57817454DB10CFF9E4EBC39B52" name="fold:StockIssuedDuringPeriodValueContingentConsideration" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4233-wk-Fact-3181DC5BD7AAFE431437F9E4EB5041E1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4311-wk-Fact-3181DC5BD7AAFE431437F9E4EB5041E1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Warrants exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4331-wk-Fact-0F742D588111A4109D9CF0EA7F4D4879" name="fold:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">101,787</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4345-wk-Fact-D86C2944210D5DB73A19F0EA7F3540A9" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4364-wk-Fact-48582319C0E13D386B07F0EA7FC1DF9D" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,487</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e4384-wk-Fact-8030A0B4EEABD5020AB8F0EA7FDAD9F7" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">676</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4443-wk-Fact-F4EFAA8241AEEC1EF5DFF9E4EB9DAD3D" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Equity component of the convertible notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4463-wk-Fact-488DA091CCBA99611795F0C60C7315FF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">43,995,139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4477-wk-Fact-82C5F3C262689C6B695BF0C65174AB33" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4496-wk-Fact-924AE7EF10D4D8118855F0EA7F920F4A" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">215,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4574-wk-Fact-F427851617AE28A120FDF9E4EB7B32AE" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">215,476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Termination of capped call confirmations</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4627-wk-Fact-4BBE83A72416A48D96B5F0C6CDA6FB12" name="fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4705-wk-Fact-E5E4C9738C23D156F0EBF9E4EAEB48AC" name="fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unrealized holding gain on available-for-sale securities</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4797-wk-Fact-80BC958E54E2D07AA2F9F0EA7FA908CA" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4836-wk-Fact-E257C540551A3DBFA26E6B8C2FE0580C" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign currency translation adjustment</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4928-wk-Fact-23DC336BE914791899FCF0C88FE37FC5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e4967-wk-Fact-2497C471A4E5AEE308166B8C2F8FC877" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e5078-wk-Fact-A574CD9E2AB6AD485519F0EA7FE172B9" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">356,388</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e5099-wk-Fact-A12C3F3D7CBD330E74976B8C2FA8F19A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">356,388</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e5121-wk-Fact-058DCB3FD6820CFAD4BEF9E4EC43E729" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">255,417,869</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e5140-wk-Fact-E9E0C616C31562EC717BF9E4EC3BF338" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e5159-wk-Fact-E27C19FF065EF04C6330F9E4EAE22405" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,227,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e5179-wk-Fact-328132D6666CE8439535F9E4EC03E500" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e5198-wk-Fact-0E10DAC26043DEDA7C95F9E4EABACD7E" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d23300192e5217-wk-Fact-497BD0ACF7BF501CC93DF9E4EC13ABC1" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,768,610</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d23300192e5238-wk-Fact-7273512A0E79AC0E8AC96B8C2F60F4B4" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">476,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying Notes to Consolidated Financial Statements</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">89</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5F89C2F342D0599087B9185A4EBDCA93"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e932-wk-Fact-6BC49C4CC46616D540C46B8C2F93291F" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">356,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e952-wk-Fact-62A7EF9CA74D8C1A89926B8C2F8951DF" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">348,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e972-wk-Fact-203E20272F98B22DCBA46B8C2F88D814" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">284,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of debt discount and deferred financing</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1051-wk-Fact-B20E0EAC45FE94281D0E6B8C2F824998" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1070-wk-Fact-F0CE957B4D78C14BDF766B8C2F7D5B82" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1089-wk-Fact-E189BF43CAE7F5E53C4F6B8C2F84BDEE" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1110-wk-Fact-FFE1107513765E92EB0B6B8C2F83C0A7" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1129-wk-Fact-BA12E0CB739F7B734C786B8C2F84ACE8" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1148-wk-Fact-9DFD25175320039594DD6B8C2F8138D1" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,593</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1169-wk-Fact-A12D776EE9C11A9F0F7D6B8C2F8C00FF" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1188-wk-Fact-8AF7DE728BB551B8F8C66B8C2F920015" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1207-wk-Fact-F089EE3869BDA843F30C6B8C2F891B47" name="us-gaap:ShareBasedCompensation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss on exchange of convertible debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1228-wk-Fact-11BAC4E93BA6283AE60AF09A2E464CDD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40,624</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1247-wk-Fact-9190C43965384A029822F09A2DC9D88E" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1266-wk-Fact-E5DA14CDD8E3F849B47AF09A2E368636" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in fair value of derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1287-wk-Fact-E13B46924D4F3B8039CE6B8C2F99F7E5" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1306-wk-Fact-F79394BB2415E7878EB46B8C2F7ED9A5" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1325-wk-Fact-CEA03EB18B424CFC3B136B8C2FA53664" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-cash changes in the fair value of contingent consideration payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1347-wk-Fact-813BE3DA0C2D7DB84DA46B8C2F81A3E7" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1366-wk-Fact-08264A8AD1F16FA07A0F6B8C2F85602A" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1385-wk-Fact-F87E6C9A74DF1D533A3E6B8C2F9DB018" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">234,322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency remeasurement (gain) loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1408-wk-Fact-D44AFD56A1DC6FAC2BFF6B8C2F88D592" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1427-wk-Fact-230EF82DFD11F69B82E76B8C2F943F9A" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1446-wk-Fact-B4AEC08BE537A39774FC6B8C2F8792AE" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-cash deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1468-wk-Fact-3E1FA7D83E7BC9A1F1836B8C2F862481" name="fold:NonCashDeferredTaxesAndOtherTaxBenefits" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1488-wk-Fact-A401A251341B3AD747B76B8C2F8A0BB9" name="fold:NonCashDeferredTaxesAndOtherTaxBenefits" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1507-wk-Fact-AB9DA20DC7F25DD263086B8C2F9C787B" name="fold:NonCashDeferredTaxesAndOtherTaxBenefits" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">167,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss on impairment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1529-wk-Fact-CDEEE16656F8C54D15046B8C2FBC78B4" name="us-gaap:AssetImpairmentCharges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1548-wk-Fact-158CDB36E5BC291E5E126B8C2FB37ABC" name="us-gaap:AssetImpairmentCharges" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1567-wk-Fact-421008C66332774F04E96B8C2FB2588D" name="us-gaap:AssetImpairmentCharges" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">465,427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1588-wk-Fact-7AA6F863095FB412C75BF0DBA18D8C54" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1608-wk-Fact-5AC05363FC474F18B89EF0DBA1C6E0E1" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1627-wk-Fact-F085A73686F279E8BD2DF0DBA17FE745" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1711-wk-Fact-D39389DDF03D3FED0CAE6B8C2F8BFC55" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1731-wk-Fact-261D038B57628CFF03FC6B8C2F9E4E90" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1751-wk-Fact-469FE50A9B5F3EFA665C6B8C2F9C96E3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1773-wk-Fact-0E6DEA11585781728D346B8C2FA14D9C" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1793-wk-Fact-3ADFA9682D8E9DC154846B8C2F971028" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1813-wk-Fact-40A409E6762E148147F36B8C2F7EE304" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1835-wk-Fact-25E626787516C7ADD3996B8C2F95D071" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1855-wk-Fact-5AE175A6D1FE7B6661446B8C2F8C43B6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,488</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1874-wk-Fact-725209F5611A806E59506B8C2F915E69" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,329</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts payable, accrued expenses, and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1896-wk-Fact-EDF00278FBBADEBF52306B8C2FA3FDDF" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1915-wk-Fact-F11326D39F71BC0C9E846B8C2F8712E6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e1934-wk-Fact-1CB304E64D630CEDCD476B8C2F81C575" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,563</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other non-current assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1955-wk-Fact-988ADF8C07F3D50CCEC86B8C2F8FFFDF" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1975-wk-Fact-AB9105FAB697E7D8E56D6B8C2F8BB3F5" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e1995-wk-Fact-77774B4F8F2C67D2155F6B8C2FA203E3" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred reimbursements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2017-wk-Fact-935248A6F52A70C011666B8C2F868C7D" name="fold:IncreaseDecreaseInDeferredReimbursements" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2037-wk-Fact-E76290A0DCDD0A75F37A6B8C2F80955D" name="fold:IncreaseDecreaseInDeferredReimbursements" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2057-wk-Fact-FBB8BA0DCF3ECAD374D76B8C2F88E0D2" name="fold:IncreaseDecreaseInDeferredReimbursements" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash used in operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2085-wk-Fact-6E5C58C1B3990CC887446B8C2F9F47CA" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">250,416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2105-wk-Fact-803A15B97216F723248C6B8C2F8E681B" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">299,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2125-wk-Fact-9D738CF6BB0ADE13DEA06B8C2F95ABCB" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">213,695</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Investing activities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Sale and redemption of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2204-wk-Fact-2D1E876F12351D37F7966B8C2F8990B4" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">499,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2223-wk-Fact-0543E0EED44D7CF0B7CD6B8C2F7DB5D5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">463,502</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2242-wk-Fact-FB36614350A6EA19EFCB6B8C2F9F42AA" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">323,753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2263-wk-Fact-ED9FE3ABDE05EA04F4E86B8C2F881B6D" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">383,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2283-wk-Fact-3910D1B66193778CBE876B8C2F830DD6" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">578,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2303-wk-Fact-677964FC1ECBA81FD9AB6B8C2F9AE265" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">490,468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Capital expenditures</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2325-wk-Fact-37E668B8B686A4458B166B8C2F8858B6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2345-wk-Fact-0DAFC87E91E963E4E2AE6B8C2F7DC484" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2365-wk-Fact-4A7E1145A35A935C29F26B8C2F85BE9E" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,526</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash provided by (used in) investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2392-wk-Fact-475C119B965C01C411E26B8C2FA37FEE" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">95,153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2411-wk-Fact-A0FFBF6279FF8B38DB976B8C2F9DBF65" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">121,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2431-wk-Fact-01198EB4E7505E6CCADE6B8C2F891C67" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">171,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Financing activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from issuance of common stock and warrants, net of issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2510-wk-Fact-F2704EE118B7091F6FD66B8C2F977919" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2529-wk-Fact-B5F21D5ECFEAA89423966B8C2F9F2675" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">294,584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2548-wk-Fact-B784335B4DC51DF8C1366B8C2F96239A" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">243,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Payment of finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2569-wk-Fact-BAD41F786DE8D3B87FC66B8C2F82F9D7" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">420</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2589-wk-Fact-F2EE64BE5F98864897966B8C2F878542" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">334</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2609-wk-Fact-2719017B402EA5F6299E6B8C2F94174F" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase of vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2631-wk-Fact-DEE3BF9B877233E3C1A06B8C2F9CD59F" name="fold:PaymentsForRepurchaseOfRestrictedStockUnits" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2651-wk-Fact-D26F1B564BA17EAE41FB6B8C2FA3D0C1" name="fold:PaymentsForRepurchaseOfRestrictedStockUnits" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,832</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2671-wk-Fact-F6F863AFA26198A232026B8C2FA1D10B" name="fold:PaymentsForRepurchaseOfRestrictedStockUnits" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from termination of capped call confirmations </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2693-wk-Fact-AA01D8CD69767613B14FF0DF80D3D13B" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2712-wk-Fact-B2D22E4E2C4054A0EC87F0DF80B02E1B" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2731-wk-Fact-0A413E35E07861686891F0DF8112026B" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2753-wk-Fact-F07113C9E57965F7C4CF6B8C2F84E438" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2772-wk-Fact-30A55806F250E5A46EE06B8C2F9A6996" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2791-wk-Fact-10EC447DD577843DB9E66B8C2F93D1DF" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from exercise of warrants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2812-wk-Fact-5CB464F307184C271DCC6B8C2F8C4D4A" name="us-gaap:ProceedsFromWarrantExercises" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2831-wk-Fact-B484DCAB9F1E2EC336FA6B8C2F814972" name="us-gaap:ProceedsFromWarrantExercises" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2850-wk-Fact-6364C8A43D73032310D36B8C2F89C1B8" name="us-gaap:ProceedsFromWarrantExercises" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Payment of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2871-wk-Fact-AA2303C5565A021D06E96B8C2FA21D23" name="fold:PaymentOfContingentConsideration" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2890-wk-Fact-0EE0C4F5E85C8EEAEC416B8C2F7FD341" name="fold:PaymentOfContingentConsideration" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e2909-wk-Fact-AC957E5B05E36424D9306B8C2F8386E1" name="fold:PaymentOfContingentConsideration" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from loan agreements, net of issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2931-wk-Fact-8D38DD39AEA205E0CA9D6B8C2F81E052" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2950-wk-Fact-6F2228282511076E63126B8C2FA11663" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">146,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2969-wk-Fact-5B40723157BC3BF824166B8C2FA4BD4E" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash provided by financing activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e2995-wk-Fact-DAB8E41057AD5F6868A66B8C2F943266" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">217,502</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3014-wk-Fact-BE0C8474ABF4A020B82F6B8C2F9DFF68" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">450,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3033-wk-Fact-110000E7976C9BEF69C46B8C2FA3A6BE" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">247,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3054-wk-Fact-846DEF153FCCCAE58F926B8C2F8A0599" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,729</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3073-wk-Fact-A84C24A691625E3D6FE36B8C2F8BB70E" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3092-wk-Fact-A41657E5248B32ECA0586B8C2F803386" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3108-wk-Fact-AD4528390579D92F1D4B6B8C2F9698F3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,968</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3127-wk-Fact-5F77536A04002259C0B36B8C2F82DD69" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d23303121e3146-wk-Fact-231FB42B2D8F723DF2096B8C2F7ED4C0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">136,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash, cash equivalents, and restricted cash at the beginning of the year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3168-wk-Fact-DB4369335D59DC134A9D6B8C2F866261" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3187-wk-Fact-2832D32E859374AFC2286B8C2F8F7EAF" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3206-wk-Fact-16CED533A8AE75DDB1B16B8C2F7DBC89" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">187,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash, cash equivalents, and restricted cash at the end of the year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3232-wk-Fact-910F239777FED3FF4F746B8C2F7F1327" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">146,343</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3251-wk-Fact-DB4369335D59DC134A9D6B8C2F866261" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3270-wk-Fact-2832D32E859374AFC2286B8C2F8F7EAF" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">90</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Supplemental disclosures of cash flow information</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tenant improvements paid through lease incentive</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3497-wk-Fact-A7B96D6DBC76EB5CBE7E5E49B7E90D9F" name="us-gaap:PaymentsForTenantImprovements" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3516-wk-Fact-C94E2998746401BA4FE75E49B828E11A" name="us-gaap:PaymentsForTenantImprovements" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3535-wk-Fact-16D6BCC77848ECC7A33E5E49B80977E7" name="us-gaap:PaymentsForTenantImprovements" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash paid during the period for interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3556-wk-Fact-86091AB09D4E77F88A636B8C2F9374E2" name="us-gaap:InterestPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3575-wk-Fact-B3BE08222E528821B1FF6B8C2F99AF03" name="us-gaap:InterestPaidNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3594-wk-Fact-8F0872C79FDA11110CAB6B8C2F978C49" name="us-gaap:InterestPaidNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contingent consideration paid in shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3615-wk-Fact-0E6EC91FD946FDCCFE8F6B8C2F845A63" name="fold:ContingentConsiderationPaidInStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3634-wk-Fact-82E858F8C18688D80F8D6B8C2F7F3B97" name="fold:ContingentConsiderationPaidInStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3653-wk-Fact-7D22062009D79D9D847B6B8C2F802719" name="fold:ContingentConsiderationPaidInStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Capital expenditures unpaid at the end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3674-wk-Fact-BB85E2F4AF874FB3A4556B8C2F7EF40E" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3693-wk-Fact-4192F7BDB12BC73B43B66B8C2F96F603" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d23303121e3712-wk-Fact-8D72AE52D79371A1DA6A6B8C2FA0905F" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying Notes to Consolidated Financial Statements</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">91</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5B4233CAD1BA551195E5C01C54AA1D8A"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sFE09F007A05A5FA8ACD4F06016F536E0"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-636559182FD59C4ED16C6B8C2FE9DA6C-0-wk-Fact-5D3C118228AD30FD49C26B8C2FC0AC6D" continuedAt="TextSelection-636559182FD59C4ED16C6B8C2FE9DA6C-1" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="TextSelection-636559182FD59C4ED16C6B8C2FE9DA6C-1"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities led by the novel medicine for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic, and an industry leading rare disease gene therapy portfolio.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cornerstone of the Company&#8217;s portfolio is Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several other geographies around the world. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lead biologics program of the Company&#8217;s pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation to AT-GAA for the treatment of late onset Pompe disease. In the first quarter of 2020, the British Medicines and Healthcare Products Regulatory Agency issued a Promising Innovative Medicine designation for AT-GAA for the treatment of late-onset Pompe disease. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("NCH") and an expanded collaboration with the University of Pennsylvania ("Penn"). The Company's pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, CLN8 and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Niemann-Pick Type C ("NPC"), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. For additional information, see "&#8212;&#160;Note&#160;16. Collaboration Agreement."</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second quarter of 2019, the Company completed an underwritten equity offering and issued </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23294950e733-wk-Fact-4CD3463F939D863661B6F441E6784C03" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">18.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23294950e737-wk-Fact-43864E6CC5A7B8A09AC4F442508D5BE9" name="us-gaap:SaleOfStockPricePerShare" contextRef="FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_fold_UnderwrittenOfferingMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">10.75</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23294950e741-wk-Fact-2BE35686606668C4F05AF442E8185CE0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">189.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first and second quarters of 2019, the Company entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with a limited number of holders (the "Holders") of the unsecured Convertible Senior Notes due in 2023 ("Convertible Notes"). Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23294950e748-wk-Fact-4A8CFF7594107A63B4FEF44336C1516F" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">247.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Notes held by them in exchange for an aggregate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23294950e752-wk-Fact-4DF48FAD377A5BBDBBD7F443ABB9B03E" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" contextRef="FI2019Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">44.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23294950e756-wk-Fact-00CA33B6D7C853055C4C6B8C2FC67E47" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. For additional information, see "&#8212;&#160;Note&#160;12. Debt."</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had an accumulated deficit of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23294950e763-wk-Fact-FAF3435D709F3DA7AB3D5E3D52AC5C82" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and anticipates incurring losses through the fiscal year ending December&#160;31, 2020 and beyond. The Company has historically funded its operations through stock offerings, debt issuances, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> revenues, collaborations, and other financing arrangements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The current cash position, including expected Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> revenues, is sufficient to fund ongoing Fabry, Pompe, and gene therapy program operations into the first half of 2022. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">92</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="sEA5998B0AE725DD4BFB41C8E09E3013B"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-0-wk-Fact-5285E3B5D1D46CEF06876B8C2F7E70C7" continuedAt="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-1" continuedAt="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-8C71E148341AF573F89F6B8C2FE917A0-0-wk-Fact-9FE7E6700C906910B1B56B8C2F780D7A" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-3343EB1779E9A30E2F9B6B8C2FE9AF8B-0-wk-Fact-9AC21E923F3FF07366306B8C2F7CC954" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="TextSelection-14BD7248B5A5EF13C21E6B8C2FE93FD0-0-wk-Fact-8BDD425FC5D70DBC935D6B8C2F7B938F" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Transactions</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:UseOfEstimates" id="TextSelection-B1BEDBAA5C2BA3FCB95A6B8C2FECF963-0-wk-Fact-5FFC2CBEAAAB33B9C0476B8C2F79C20F" continuedAt="TextSelection-B1BEDBAA5C2BA3FCB95A6B8C2FECF963-1" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-B1BEDBAA5C2BA3FCB95A6B8C2FECF963-1">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates</ix:continuation>.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" id="TextSelection-7214BCBBDDF9E496101B6B8C2FEB79A4-0-wk-Fact-7537BCD706084DB470EF6B8C2F78E609" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company&#8217;s Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company&#8217;s Consolidated Balance Sheets. </span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ConcentrationRiskCreditRisk" id="TextSelection-7DC42E7D27D0E0CED7EA6B8C2FE9A96E-0-wk-Fact-521D12F038F0B2B2BA2B6B8C2F79894D" continuedAt="TextSelection-7DC42E7D27D0E0CED7EA6B8C2FE9A96E-1" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><ix:continuation id="TextSelection-7DC42E7D27D0E0CED7EA6B8C2FE9A96E-1" continuedAt="TextSelection-7DC42E7D27D0E0CED7EA6B8C2FE9A96E-2"><span style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The Company's accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-7DC42E7D27D0E0CED7EA6B8C2FE9A96E-2"> have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. </ix:continuation>As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded an allowance for doubtful accounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23303986e803-wk-Fact-53394349897BB9430E70F4548CC8CA31" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">93</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-2" continuedAt="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="TextSelection-E3B427D74813A74FCD276B8C2FEB7E2B-0-wk-Fact-4294ACCA309DB69526076B8C2F7991CA" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23303986e820-wk-Fact-8D6D1633680792660EFB6B8C2F78DBA5" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-5703905931FA413501816B8C2FEC44C1-0-wk-Fact-62517B085A042C3179386B8C2F7A65F4" continuedAt="TextSelection-5703905931FA413501816B8C2FEC44C1-1" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s net product sales consist of sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2019, one customer accounted for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e851-wk-Fact-0CCF68FC4D54E08F8CBD8071B7D03535" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_fold_LargestCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">22</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of net product sales and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e855-wk-Fact-52CDA64B376E7CDAB53D8071B7485360" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_fold_LargestCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of accounts receivable from product sales.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The transaction price is determined based on fixed consideration in the Company&#8217;s customer contracts and is recorded net of estimates for variable consideration, which are third-party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="TextSelection-DA852D43D2551BF4B4F3ECA6347620F8-0-wk-Fact-A7E50FCADD0F4D9CC037ECA81EBC9699" escape="true"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-5703905931FA413501816B8C2FEC44C1-1"></ix:continuation>The following table summarizes the Company's net product sales from Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> disaggregated by geographic area:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Year </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e1057-wk-Fact-540DDF2EB280E57377DDECAA212A3B63" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e1076-wk-Fact-8B6DF3BE79A57B7C71FCECAA2352837D" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ex-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e1116-wk-Fact-BC89AF6C9CEDDF3429ECECAA20F42CBF" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129,759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e1135-wk-Fact-939BBA72A9EDC1564DD1ECAA2216997D" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84,022</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,930</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net product sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e1185-wk-Fact-DC4C2C439C61ED6A63236B8C2FB9BFAF" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e1204-wk-Fact-D89C4138A9858DD9450E6B8C2FB1397B" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,930</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InventoryPolicyTextBlock" id="TextSelection-10FD1C38E38659F01EBD6B8C2FEA1F44-0-wk-Fact-84C4F1521A5E2501CA0E6B8C2F7A9D7A" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories and Cost of Goods Sold</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">94</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-3" continuedAt="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-4"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="TextSelection-8472714FD0685FC8BB346B8C2FEAFF47-0-wk-Fact-52CFF4D46B57187DF6AB6B8C2F79E373" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ContingentLiabilityReserveEstimatePolicy" id="TextSelection-70850AC051DFD6E5DFAE6B8C2FEBC5A4-0-wk-Fact-D6364A21241F63DF59996B8C2F799044" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Liabilities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="TextSelection-575749024514C75DC1706B8C2FE95858-0-wk-Fact-836459D8791C764CA0DC6B8C2FB67A4B" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="fold:InterestIncomeAndInterestExpensePolicyTextBlock" id="TextSelection-718928BE0BC05136A5016B8C2FEA5FE0-0-wk-Fact-0309953B443E3556E5516B8C2F7C2CAB" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Income and Interest Expense</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-6351A6C103F9695B95BE6B8C2FEA3E24-0-wk-Fact-CB4DEF24F61D4264A0576B8C2F79C5B3" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">95</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-4" continuedAt="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-5"><ix:nonNumeric contextRef="FD2019Q4YTD" name="fold:OtherComprehensiveIncomePolicyPolicyTextBlock" id="TextSelection-E6BB8317678B7FC3C35B6B8C2FEAC6A1-0-wk-Fact-3EBB9D4B5F16A9D724846B8C2F7E746F" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of other comprehensive income (loss) include unrealized gains and losses on available-for-sale securities and gain (loss) on foreign currency transactions and are included in the Statements of Comprehensive Loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeLeasesPolicyTextBlock" id="TextSelection-D18FF4496464951246F16B8C2FEAB18D-0-wk-Fact-A17417144C218F54DB8D6B8C2F7B60AD" continuedAt="TextSelection-D18FF4496464951246F16B8C2FEAB18D-1" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-D18FF4496464951246F16B8C2FEAB18D-1">The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods. For additional information, see " -Note 13. Leases" and "-Note 2. Summary of Significant Accounting Policies, Recent Accounting Developments - Guidance Adopted in 2019."</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="fold:NonqualifiedCashDeferralPlansPolicy" id="TextSelection-6749655221BB3AA38B786B8C2FEABDF7-0-wk-Fact-AA2EB03D0562C535DA8B6B8C2F7B75EF" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nonqualified Cash Deferral Plan</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code (the "Code"). All of the investments held in the Deferral Plan are classified as investments held-to-maturity and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="TextSelection-776E5806CA3ABEB55EAF6B8C2FEB3B27-0-wk-Fact-52AE44BEBD2DBB3241B86B8C2F7A53F5" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity-based Compensation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e1379-wk-Fact-2FAC5CDC964E24FFC1636B8C2F7AB347" name="fold:ShareBasedCompensationNumberOfPlans" contextRef="FI2019Q4" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> equity-based employee compensation plans, which are described more fully in "&#8212;&#160;Note&#160;9. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">96</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-5" continuedAt="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-6"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-1833A9DB0984C5BF47476B8C2FEBF259-0-wk-Fact-28FF2588390FB1AC37AE6B8C2F79DDA4" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss per Common Share</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs, and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#8212;&#160;Note&#160;17. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="TextSelection-D4528603DE03E8585B926B8C2FEB04EB-0-wk-Fact-03053A79A9F8BC94AE5E6B8C2F78EA1D" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company currently operates in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e1408-wk-Fact-E5A66F127A912EFAF4D06B8C2F7B488D" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q4YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23303986e1412-wk-Fact-9A431B26D08C4C8E99166B8C2F78ABB8" name="us-gaap:NumberOfReportingUnits" contextRef="FD2019Q4YTD" unitRef="unit" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> reporting unit.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessCombinationsPolicy" id="TextSelection-60A64CBD7C9AFB0A63DC6B8C2FE94674-0-wk-Fact-07AAB7D2192A8CCE9F696B8C2F7D0543" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock" id="TextSelection-98913C9DB62F84DC614F6B8C2FEB06D0-0-wk-Fact-641073630EC12E4EA7AD6B8C2F7AD127" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Consideration Payable</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="TextSelection-CFC6672625FA874C814C6B8C2FEB3306-0-wk-Fact-2F19E6F50385C7182C326B8C2F795727" continuedAt="TextSelection-CFC6672625FA874C814C6B8C2FEB3306-1" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets and Goodwill</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-CFC6672625FA874C814C6B8C2FEB3306-1">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.</ix:continuation> No indicators of impairment were noted during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2018.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">97</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-07F6699B8F24BDA845046B8C2FEBAFA9-0-wk-Fact-DE2B0D766BB6E033D49D6B8C2F7B1B3C" continuedAt="TextSelection-07F6699B8F24BDA845046B8C2FEBAFA9-1" escape="true"><ix:continuation id="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-6" continuedAt="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-7"><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Developments - Guidance Adopted in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-02 - In February 2016, the FASB issued ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> ("ASU 2016-02"). ASU 2016-02 requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. In August 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, ("ASU 2018-11"). ASU 2018-11 provided entities with an additional transition method for adoption, whereby, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Effective January 1, 2019 the Company adopted ASU 2016-02, along with the amendments issued in 2017 and 2018, and elected the transition method in ASU 2018-11. The Company elected the package of transition provisions available for expired or existing contracts, which allowed the Company to carry forward its historical assessments of (i) whether contracts are or contain leases, (ii) lease classification and (iii) initial direct costs. In addition, the Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and will apply the practical expedient not to separate lease and non-lease components for new and modified leases commencing after adoption. The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods. Upon adoption, the Company recorded a lease liability with a corresponding right-of-use asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23303986e1481-wk-Fact-BAECD2387D7B66988514F45E7B8A41D1" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The adoption did not have a material impact on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Developments - Guidance Not Yet Adopted</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2019-12 - In December 2019, the FASB issued ASU 2019-15,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following apply in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for public business entities for periods for which financial statements have not yet been issued. An entity that elects early adoption in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption should adopt all the amendments in the same period. The Company is currently assessing the impact that this standard will have on its Consolidated Financial Statements upon adoption.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2018-15 - In August 2018, the FASB issued&#160;ASU 2018-15,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)</span><span style="font-family:inherit;font-size:10pt;">: ("ASU 2018-15"), relating to a customer&#8217;s accounting for implementation, set-up, and other upfront costs incurred in a&#160;cloud computing&#160;arrangement that is hosted by a vendor. Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance does not affect the accounting for the service element of a hosting arrangement that is a service contract. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized software costs and related amortization expense and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for public companies. The Company will adopt this guidance prospectively on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2018-13 - In August 2018, the FASB issued ASU 2018-03, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement </span><span style="font-family:inherit;font-size:10pt;">("ASU 2018-13"). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on (i) changes in unrealized gains and losses, (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and (iii) the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div></ix:continuation></ix:nonNumeric><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">98</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-07F6699B8F24BDA845046B8C2FEBAFA9-1"><ix:continuation id="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-7"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2017-04 - In January 2017, the FASB issued ASU 2017-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </span><span style="font-family:inherit;font-size:10pt;">("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-13 - </span><span style="font-family:inherit;font-size:9pt;">I</span><span style="font-family:inherit;font-size:10pt;">n June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="font-family:inherit;font-size:10pt;">("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">basis to be presented at the net amount expected to be collected and amends guidance on the impairment of financial instruments.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13 is effective for public companies who are SEC filers for fiscal years beginning after December 15, 2019, including</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">interim periods within those years. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div></ix:continuation></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sC054CD575B73598287CC5E95C649426E"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-13F63466C1AED2E1AFDB6B8C2FECBB7C-0-wk-Fact-B1342E389A0057E725F06B8C2F7FB962" continuedAt="TextSelection-13F63466C1AED2E1AFDB6B8C2FECBB7C-1" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="TextSelection-13F63466C1AED2E1AFDB6B8C2FECBB7C-1" continuedAt="TextSelection-13F63466C1AED2E1AFDB6B8C2FECBB7C-2"><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Celenex</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company expanded its pipeline by acquiring the rights and related intellectual property of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23295074e716-wk-Fact-BDFC961784DFE295E5F66B8C2F82B9EB" name="fold:NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped" contextRef="D2018Q3Sep01-Sep30" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> gene therapy programs through its acquisition of Celenex, Inc., ("Celenex"). Celenex is a private, clinical stage gene therapy company whose lead programs are </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23295074e720-wk-Fact-BDFC961784DFE295E5F66B8C2F82B9EB" name="fold:NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped" contextRef="D2018Q3Sep01-Sep30" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> gene therapy programs including CLN6 and CLN3, which are in clinical stage, and several programs in pre-clinical stage. Pursuant to the terms of the agreement, the Company acquired Celenex for cash consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e724-wk-Fact-5447E630E2BDAE1D85FB6B8C2F84A882" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2018Q3Sep01-Sep30_fold_AssetAcquisitionAxis_fold_CelenexMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has also agreed to pay up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e728-wk-Fact-8434BD1CA8291FC7D2056B8C2F819028" name="fold:RevenueRecognitionMilestoneMethodContingentOnDevelopment" contextRef="FI2018Q3_fold_AssetAcquisitionAxis_fold_CelenexMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the achievement of certain development milestones, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e732-wk-Fact-32FD915B7E0C0C9694DF6B8C2F8352C6" name="fold:RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones" contextRef="FI2018Q3_fold_AssetAcquisitionAxis_fold_CelenexMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">262</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the achievement of certain regulatory approval milestones across multiple programs and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e737-wk-Fact-837343E2D59FF82549696B8C2F8264FA" name="fold:RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears" contextRef="FI2018Q3_fold_AssetAcquisitionAxis_fold_CelenexMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in tiered sales milestone payments. Celenex has an exclusive license agreement with Nationwide Children&#8217;s Hospital ("NCH"). Under this license agreement, NCH is eligible to receive development and sales-based milestones of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e741-wk-Fact-B4457837434349CD43BA6B8C2F8056D1" name="fold:RevenueRecognitionMilestoneMethodContingentOnDevelopment" contextRef="FI2018Q3_dei_LegalEntityAxis_fold_NationwideChildrensHospitalMember_fold_AssetAcquisitionAxis_fold_CelenexMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for each product.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the Celenex transaction and concluded that the transaction did not meet the definition of a business and was an asset acquisition. Given the fact that the license has no alternative future use, the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e750-wk-Fact-6A9B398B4F15E56CFEDF6B8C2F86360A" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q4YTD_fold_AssetAcquisitionAxis_fold_CelenexMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment was expensed to research and development expense in the Consolidated Statements of Operations for the year ended December 31, 2018</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of MiaMed,&#160;Inc</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2016, the Company entered into an Agreement and Plan of Merger (the "MiaMed Agreement") with MiaMed,&#160;Inc., ("MiaMed"). MiaMed is a pre-clinical biotechnology company focused on developing protein replacement therapy for CDD and related diseases. Under the terms of the MiaMed Agreement, the former holders of MiaMed's capital stock received an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e766-wk-Fact-1FB6B6B71D7447A309786B8C2F809EE7" name="fold:AssetAcquisitionConsiderationTransferred" contextRef="D2016Q3Jul01-Jul31_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, comprised of (i)&#160;approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e770-wk-Fact-5B2C6EDE3FFE9391E5AF6B8C2F829166" name="fold:PaymentsToAcquireBusinessAssets" contextRef="D2016Q3Jul01-Jul31_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash (plus MiaMed's cash and cash equivalents at closing and less any of MiaMed's unpaid third-party fees and expenses related to the transaction), and (ii)&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23295074e774-wk-Fact-A5F50F814199C634196C6B8C2F802D99" name="fold:BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="D2016Q3Jul01-Jul31_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">825,603</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock. In addition, the Company also agreed to pay up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e778-wk-Fact-AA672290D2E654C95E8C6B8C2F8300FC" name="fold:BusinessAssetAcquisitionContingentConsiderationMilestones" contextRef="I2016Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the achievement of certain clinical, regulatory, and commercial milestones, for a potential aggregate deal value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e782-wk-Fact-792EBE211D6645ABCB296B8C2F86E15F" name="fold:BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment" contextRef="D2016Q3Jul01-Jul31_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">89.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company evaluated the transaction and concluded that it only acquired inputs and did not acquire any processes. The Company will need to develop its own processes in order to produce an output. Therefore, the Company accounted for the transaction as an asset acquisition and accordingly </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e787-wk-Fact-878A4BC8792EAFC2ADA16B8C2F8535DA" name="fold:ResearchExpenseForStockIssuanceInAssetAcquisition" contextRef="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was expensed to research and development expense in the Consolidated Statements of Operation for the year ended December 31, 2016.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">99</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-13F63466C1AED2E1AFDB6B8C2FECBB7C-2"><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Scioderm,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2015, the Company acquired Scioderm&#160;Inc., ("Scioderm"), a privately-held biopharmaceutical company focused on developing innovative therapies for treating the rare disease, Epidermolysis Bullosa ("EB"). The acquisition potentially leveraged the Scioderm development team's EB expertise with the Company's global clinical infrastructure to advance SD-101toward regulatory approvals and the Company's commercial, patient advocacy, and medical affairs infrastructure to support a successful global launch. The acquisition of Scioderm was accounted for as a purchase of a business in accordance with ASC 805 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the end of the first quarter of 2017, the Company achieved </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23295074e804-wk-Fact-6AB57838556E88D2C5CC6B8C2F823FC1" name="fold:BusinessCombinationOfEnrollmentRate" contextRef="FD2017Q1QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> enrollment in the Phase&#160;3 clinical study of SD-101 and the milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e808-wk-Fact-5E5B180AE7FE933E1E3F6B8C2F81827B" name="fold:ContingentConsiderationMilestonePayment" contextRef="D2017Q2Apr1-Apr30_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> due for this event, was paid in April 2017. On September&#160;13, 2017, the Company reported that top-line data from the randomized, double-blind, placebo-controlled Phase&#160;3 clinical study ("ESSENCE, SD-5") to assess the efficacy and safety of the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in participants with EB. Based on these top-line data, the Company has no current plans to invest in any additional clinical studies or commercial preparation activities for SD-101. This event led the Company to assess the carrying amount of the program's tangible and intangible assets against their respective fair values. Based on the assessment, the Company recognized a loss on impairment of intangible assets in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e812-wk-Fact-A01520D7A22A68F7CB6C6B8C2F84518F" name="us-gaap:AssetImpairmentCharges" contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">463.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e816-wk-Fact-7885984B58AFE54E70046B8C2F84E3DD" name="us-gaap:AssetImpairmentCharges" contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_FixedAssetsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in fixed assets recorded within loss on impairment of assets within the Consolidated Statements of Operations. Since the study did not meet the primary and secondary endpoints, the Company concluded that they will not make the potential milestone payments indicated in the Asset Purchase Agreement to the former Scioderm holders. Accordingly, the Company recognized a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e820-wk-Fact-5A94841895C3C4D66B796B8C2F83A01B" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">254.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in changes in fair value of contingent consideration payable in the third quarter of 2017, in order to decrease the liability to zero. The Company also recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e825-wk-Fact-60DFD41B3B6627E0686B6B8C2F8306B0" name="fold:SellingGeneralAndAdministrativeCostsDueToWindDown" contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in selling, general, and administrative costs and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e829-wk-Fact-2BE2CBBEAD96990EBD7B6B8C2F85178F" name="fold:ResearchAndDevelopmentExpensesDueToWindDown" contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in research and development expenses related to the wind-down of operations for the Phase 3 ESSENCE study and ongoing extension studies SD-004 and SD-006, as well as income tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e833-wk-Fact-9A6FD4B48AC18551B64B6B8C2F811894" name="fold:IncomeTaxExpenseBenefitDueToWindDown" contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">164.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> due to the reduction of the deferred tax liability related to Scioderm IPR&amp;D, in the Consolidated Statements of Operations in the third quarter of 2017. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Callidus Biopharma,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2013, the Company acquired Callidus Biopharma, Inc., ("Callidus"), a privately-held biologics company focused on developing best-in-class ERTs for LDs with its lead ERT ATB200 for Pompe disease in late preclinical development. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the contingent acquisition consideration payments was estimated by applying a probability-based income approach utilizing an appropriate discount rate. Key assumptions include discount rate and various probability factors. This estimation was based on significant inputs that are not observable in the market, referred to as Level&#160;3 inputs. Some of the more significant assumptions used in the valuation include (i)&#160;the probability and timing related to the achievement of certain developmental milestones and (ii)&#160;and the discount rate. See "&#8212;&#160;Note&#160;11. Assets and Liabilities Measured at Fair Value", for additional discussion regarding fair value measurements of the contingent acquisition consideration payable. The Company determined the fair value of the contingent consideration to be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e847-wk-Fact-7B07BE014D5E095F66566B8C2F81C915" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which is payable beyond the next twelve months, resulting in an increase in the contingent consideration payable and related expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e855-wk-Fact-2B6DC90185DEB086A7FF6B8C2F80D2B7" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_IncomeStatementLocationAxis_fold_ChangesInFairValueOfContingentConsiderationPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The expense is recorded in the Consolidated Statement of Operations within the changes in fair value of contingent consideration line item.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2018, the Company reached a clinical milestone for Callidus, which was the dosing of the first patient in a Phase 3 study. The milestone payment for this event was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23295074e866-wk-Fact-60EBDC3ACF458DAEEE406B8C2F8443E6" name="us-gaap:ContractWithCustomerAssetNet" contextRef="FI2019Q1_srt_CounterpartyNameAxis_fold_CallidusBiopharmaIncMember_srt_ProductOrServiceAxis_fold_MilestonePaymentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> which was paid in the Company's stock during the first quarter of 2019.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For further information, see "&#8212;&#160;Note&#160;4. Goodwill and Intangible Assets."</span></div></ix:continuation><div><a id="sAAE203E383CB58B1AE43A132A92C7AC8"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="TextSelection-DF3E2F58ABFD7EAE14EC6B8C2FECA969-0-wk-Fact-DD21C2A788321ECBEF6E6B8C2F8DAC5C" continuedAt="TextSelection-DF3E2F58ABFD7EAE14EC6B8C2FECA969-1" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="TextSelection-DF3E2F58ABFD7EAE14EC6B8C2FECA969-1" continuedAt="TextSelection-DF3E2F58ABFD7EAE14EC6B8C2FECA969-2"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the acquisitions, the Company initially recognized IPR&amp;D of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23304539e713-wk-Fact-9832D92ADA363F93556CFE17C999FB73" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="FI2017Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">486.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and goodwill of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23304539e717-wk-Fact-C6450D6F257F5D42CCC5F0F22C279E4C" name="us-gaap:Goodwill" contextRef="FI2017Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Intangible assets related to IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D assets below their respective carrying amounts.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">100</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-DF3E2F58ABFD7EAE14EC6B8C2FECA969-2"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill and intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in "&#8212;&#160;Note&#160;3. Acquisitions", in September 2017, the Company reported that top-line data from the randomized, double-blind, placebo-controlled Phase&#160;3 clinical study ("ESSENCE, SD-005") to assess the efficacy and safety of the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in participants with EB. This event led to an assessment to determine if an impairment had occurred for goodwill and IPR&amp;D. Based on tests for impairment, the Company determined that IPR&amp;D had been impaired, however goodwill was not impaired based on qualitative and market capitalization tests performed. The loss on impairment of IPR&amp;D of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23304539e727-wk-Fact-F933D71B07D5500C378AF483FA4EC618" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">463.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded within loss on impairment of assets in the Consolidated Statements of Operations for the year ended December 31, 2017.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-00102C6CCA655B973C926B8C2FEC043F-0-wk-Fact-FEC7A87B0FC3750517C66B8C2F8C1012" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the changes in IPR&amp;D for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23304539e802-wk-Fact-7B83DD302D5AD6FB3EB0F0F235F2F6C4" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23304539e822-wk-Fact-61747BB0E7762E3A3CADF0F235FA2E8C" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23304539e852-wk-Fact-7E5EDE1883CBDE4D2812F0F23603B93C" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23304539e872-wk-Fact-0087BB04BEC76849389A6B8C2F7AE9E7" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23304539e902-wk-Fact-B0B536ED06743D2850386B8C2F78C618" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfGoodwillTextBlock" id="TextSelection-CC4811043DD829BAD5846B8C2FECC1FA-0-wk-Fact-6043CE11B4E7B93532E56B8C2F8DE2C9" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the changes in Goodwill for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23304539e983-wk-Fact-C6450D6F257F5D42CCC5F0F22C279E4C" name="us-gaap:Goodwill" contextRef="FI2017Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23304539e1003-wk-Fact-5F3FF69DD3BF8F254193F0F22C305557" name="us-gaap:GoodwillPeriodIncreaseDecrease" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23304539e1033-wk-Fact-CD8809FE0317F0DD941CF0F22C323721" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23304539e1053-wk-Fact-C3AEF96150F63F6F68C36B8C2FC47E5C" name="us-gaap:GoodwillPeriodIncreaseDecrease" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23304539e1083-wk-Fact-95CE8BCB22200E84EC7D6B8C2FD9501A" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="sFB5B02ADBA975533AA1CD14739D00FBF"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="TextSelection-41C442BD0CD55961C6366B8C2FEC3590-0-wk-Fact-1505B423F7361A9D38246B8C2FC993D5" continuedAt="TextSelection-41C442BD0CD55961C6366B8C2FEC3590-1" escape="true">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="TextSelection-41C442BD0CD55961C6366B8C2FEC3590-1" continuedAt="TextSelection-41C442BD0CD55961C6366B8C2FEC3590-2"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company held </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23308676e717-wk-Fact-71830DDDFE6281AC39316B8C2FC70FA0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">142.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23308676e721-wk-Fact-F0628342D38E0507C8336B8C2FC781A6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of available- for-sale debt securities which are reported at fair value on the Company&#8217;s Consolidated Balance Sheets. Unrealized holding gains and losses are reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company&#8217;s cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">101</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-41C442BD0CD55961C6366B8C2FEC3590-2" continuedAt="TextSelection-41C442BD0CD55961C6366B8C2FEC3590-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="TextSelection-8E9A1CABF1B7EF9A34CD6B8C2FEC7077-0-wk-Fact-7CC9E4B8902CC637CA836B8C2FC8B2B1" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e966-wk-Fact-5B00B5F16D67C7FD36126B8C2F621219" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1024-wk-Fact-C270CADE368FA1D155306B8C2F723D9A" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1044-wk-Fact-DE091A42E9261DE946436B8C2F73CB6B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1063-wk-Fact-782643CBC2B6029C562E6B8C2F7509D5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e1082-wk-Fact-381307D63B9083924BC86B8C2F6E49B9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1103-wk-Fact-BFB3F98B98399D8E557D6B8C2F6AC3D7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1128-wk-Fact-BD6009015B9F2DDB00646B8C2F6DF5B0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1147-wk-Fact-8BAD851580373610A8AC6B8C2F72D43F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e1166-wk-Fact-74D9472C264F847354FF6B8C2F6D7BA5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1187-wk-Fact-90179DB6AC13E7EB750C6B8C2F75D560" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,710</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1212-wk-Fact-204AEB45811B12B64F996B8C2F748CE7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1231-wk-Fact-7F3D51A6A2D625CE48C76B8C2F6F9359" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1250-wk-Fact-65D97F8923F569EA6DF06B8C2F6DF8B4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1270-wk-Fact-08F3465C00A07FE507356B8C2F6B9B28" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1295-wk-Fact-6181A41EAF1D88689B54F4BB800238EE" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1314-wk-Fact-41CCD20ED2901FF0AAC5F4BB830FE91A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e1333-wk-Fact-CECC7E4430459C04D59AF4BB85E1F8A4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1354-wk-Fact-AA020BFE4F967E948276F4BB88F0FD8F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1379-wk-Fact-62B063C0F96BA0D343C66B8C2F73864D" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1398-wk-Fact-B6754899B37AF67DA86F6B8C2F7128BB" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1417-wk-Fact-83FA7AF8EF83E3EA13886B8C2F6B74C8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1437-wk-Fact-AFF2F5C076B201DE9A966B8C2F6C1DF1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1462-wk-Fact-0C7E5DFB4AD09D71AB046B8C2F744D8F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1481-wk-Fact-8CC89087C0815C318B186B8C2F7085E5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1500-wk-Fact-676AA78073808DBDE3386B8C2F7104EB" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1520-wk-Fact-521880514C63ABBA9DDB6B8C2F6FDE3A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1550-wk-Fact-6B78C925F5D29D186CE96B8C2F6AB9EC" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452,502</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1569-wk-Fact-E4FEEDD888E9369C66006B8C2F706652" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e1589-wk-Fact-B8A7664B2C92083E58C36B8C2F72EDFA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1609-wk-Fact-BFC95B59B637A7D94BEE6B8C2F6E9CAD" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1634-wk-Fact-5B00B5F16D67C7FD36126B8C2F621219" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1692-wk-Fact-5B00B5F16D67C7FD36126B8C2F621219" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in marketable securities </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1715-wk-Fact-7D50C9DD3736619A93A16B8C2F757DBA" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">309,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1734-wk-Fact-E4FEEDD888E9369C66006B8C2F706652" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e1753-wk-Fact-B8A7664B2C92083E58C36B8C2F72EDFA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1774-wk-Fact-C007D8E5B1A5A692C2356B8C2F74485B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">309,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents, and marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1804-wk-Fact-6B78C925F5D29D186CE96B8C2F6AB9EC" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452,502</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1823-wk-Fact-E4FEEDD888E9369C66006B8C2F706652" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e1843-wk-Fact-B8A7664B2C92083E58C36B8C2F72EDFA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e1863-wk-Fact-BFC95B59B637A7D94BEE6B8C2F6E9CAD" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">December 31, 2019</span><span style="font-family:inherit;font-size:9pt;">, </span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d23308676e1881-wk-Fact-400FD84C6187A000BCC0F4CF9F4AD7C4" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;"> of marketable securities have maturity dates greater than 12 months and are available to convert into cash, if needed.&#160;</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2107-wk-Fact-E0F444372BF0213F4E0F6B8C2F5F9EC4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2165-wk-Fact-94E74268B7E5D8FDAE096B8C2FC171E7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2185-wk-Fact-F6239B0E65C8E3DE7CC96B8C2FC03AA6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2204-wk-Fact-68B7016CCB087663DACC6B8C2FBF65B5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e2223-wk-Fact-05F596B05B799111BAF36B8C2FBE9339" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2244-wk-Fact-715C729030DC757E88B76B8C2FDE552F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,726</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2269-wk-Fact-9B9F21F776762287E2356B8C2FB626F7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2288-wk-Fact-1FC13BF88D3A4ADA117F6B8C2FBFCDE2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e2307-wk-Fact-91DE03ACB91BACBB21CB6B8C2FDF67DE" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2328-wk-Fact-7721CFE973BEFC6825D16B8C2FBC0551" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2353-wk-Fact-C983AE549CBC4BA216496B8C2FDCB4A8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2372-wk-Fact-A036C8C6A4F350B3490F6B8C2FE0C8AC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e2391-wk-Fact-EB058F8ADA153AEEF8076B8C2FDDD4B2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2412-wk-Fact-26DE3DF8F734EB28284E6B8C2FBD577D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,135</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2437-wk-Fact-0FD1BE5A1FD8E958E5616B8C2FBC606C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2456-wk-Fact-07002C0C77DBC6D5C03C6B8C2FBB30FD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2475-wk-Fact-2D479C324616D19F7DD06B8C2FDEF8CB" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2495-wk-Fact-3FB4E72587657B2059E26B8C2FBBFC47" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2520-wk-Fact-4C2AA2A2455E0C5B39B26B8C2FDD9311" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2539-wk-Fact-28B7CDFC1912F3007EFC6B8C2FBA5C43" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2558-wk-Fact-6499C8AD09958E018EC86B8C2FBACAF0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2578-wk-Fact-FE9F9FECD74F4CFCBA316B8C2FBB697C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2608-wk-Fact-6F243344B5D04BF695E86B8C2F5B2536" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">504,579</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2627-wk-Fact-545A5542EB5615A0C92E6B8C2FC0CAB4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e2647-wk-Fact-9BABEFA438FA0D6D3B3B6B8C2FC1E712" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2667-wk-Fact-EEAC36866142424E3A786B8C2FDEA3FE" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">504,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2692-wk-Fact-E0F444372BF0213F4E0F6B8C2F5F9EC4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2750-wk-Fact-94E74268B7E5D8FDAE096B8C2FC171E7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2770-wk-Fact-1FC678478DDB8B1428276B8C2FB6A38B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">424,830</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2789-wk-Fact-545A5542EB5615A0C92E6B8C2FC0CAB4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e2808-wk-Fact-9BABEFA438FA0D6D3B3B6B8C2FC1E712" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2829-wk-Fact-A8AA31BD9ED97E2E19036B8C2FBD4F41" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">424,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents, and marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2860-wk-Fact-6F243344B5D04BF695E86B8C2F5B2536" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">504,579</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2879-wk-Fact-545A5542EB5615A0C92E6B8C2FC0CAB4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23308676e2899-wk-Fact-9BABEFA438FA0D6D3B3B6B8C2FC1E712" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2919-wk-Fact-EEAC36866142424E3A786B8C2FDEA3FE" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">504,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2938-wk-Fact-1EB75FF29637C588F8966B8C2FC55F8D" name="us-gaap:DebtSecuritiesRealizedGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> realized gains or losses. For the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e2946-wk-Fact-977662F1B8CD5803F3736B8C2FC9ABF2" name="us-gaap:DebtSecuritiesRealizedGainLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">minal realized gains. The cost of securities sold is based on the specific identification method.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized loss positions in the available-for-sale debt securities as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> reflect temporary impairments that have been in a loss position for less than twelve months and as such are recognized in other comprehensive gain (loss). The fair value of these available-for-sale debt securities in unrealized loss positions was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23308676e2962-wk-Fact-A650DA271F5E2043ABF56B8C2FC92FD2" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23308676e2966-wk-Fact-8ECC369781B2331D432F6B8C2FC6CCDA" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">403.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">102</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="TextSelection-3AA6CC8064D75ED5A4696B8C2FECA0B3-0-wk-Fact-195C1E6D49CB99CEF2576B8C2FC7EBAD" escape="true"><ix:continuation id="TextSelection-41C442BD0CD55961C6366B8C2FEC3590-3"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.15204678362574%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e3091-wk-Fact-5B00B5F16D67C7FD36126B8C2F621219" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e3110-wk-Fact-E0F444372BF0213F4E0F6B8C2F5F9EC4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e3130-wk-Fact-980FBEF7CC1BDC2421CE6B8C2F9FB7B2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e3150-wk-Fact-8DC1D437E5FAEDD56EF36B8C2F9C47F1" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e3169-wk-Fact-B1243CF993A2D97AA30F6B8C2FA8BC1B" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,626</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e3188-wk-Fact-E5911821A3DEB4C387A76B8C2FA27858" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e3219-wk-Fact-910F239777FED3FF4F746B8C2F7F1327" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">146,343</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e3238-wk-Fact-DB4369335D59DC134A9D6B8C2F866261" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308676e3258-wk-Fact-2832D32E859374AFC2286B8C2F8F7EAF" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="sC4A73322AF1F5A93BA293772CFBB4B71"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-7697FF89DA9E62B17B516B8C2FEDDC15-0-wk-Fact-0F06026F1E3C4F8CF6BF6B8C2F76942F" continuedAt="TextSelection-7697FF89DA9E62B17B516B8C2FEDDC15-1" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7697FF89DA9E62B17B516B8C2FEDDC15-1"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consist of raw materials, work in process, and finished goods related to the manufacture of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-06FA89F0008DB5A10A526B8C2FECC5E3-0-wk-Fact-5A48380470B14FB459E46B8C2F764627" continuedAt="TextSelection-06FA89F0008DB5A10A526B8C2FECC5E3-1" escape="true">The following table summarizes the components of inventories:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-06FA89F0008DB5A10A526B8C2FECC5E3-1"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.25341130604289%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308366e804-wk-Fact-601D04349EADE6AA45B96B8C2F7B2AC7" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308366e823-wk-Fact-F478C9FE19848115EE556B8C2F7CF0F7" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308366e843-wk-Fact-77E3815F734D370608CA6B8C2F7B19DF" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,660</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308366e862-wk-Fact-C90F0B424B39E43EB6B46B8C2F7C8BAF" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308366e887-wk-Fact-361A11C11128E0FAB23A6B8C2F7C617B" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308366e906-wk-Fact-DC128946E9DF39F27A5E6B8C2F7F9A3C" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308366e936-wk-Fact-598359183EED6871AA2C6B8C2F5D1396" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23308366e955-wk-Fact-1834396DC49735734D906B8C2F69C29C" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded a reserve for inventory of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23308366e971-wk-Fact-D9C8F27AA3C1967D59FDFE1CBAA16E80" name="us-gaap:InventoryValuationReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s5114D1FF42CF584CB9BE5008123C7040"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-427A5EE12365CEA5F2346B8C2FEDCAF6-0-wk-Fact-307645632A81B9BE2ABA6B8C2F87BA18" continuedAt="TextSelection-427A5EE12365CEA5F2346B8C2FEDCAF6-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="TextSelection-427A5EE12365CEA5F2346B8C2FEDCAF6-1"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-57F288B90C1B81348B3C6B8C2FED281B-0-wk-Fact-535D9C833A52CC8718BA6B8C2F87C6F0" escape="true"><div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e888-wk-Fact-2EEE6520CD29795BA5006B8C2FAC9345" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e907-wk-Fact-4DBD3CFE344991CF5D3B6B8C2FAEA3FF" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e927-wk-Fact-09F5A673102BCA4BBB8C6B8C2FB9C4D0" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,607</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e946-wk-Fact-85A556EBEB15155DB7306B8C2FAA53C9" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e971-wk-Fact-D382EDEA12846F3A79366B8C2FB591A2" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e990-wk-Fact-798EE9DD7D1E49065D5C6B8C2FB6A0E2" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,445</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1015-wk-Fact-52D307D67626685021306B8C2FB48CBC" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,157</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1034-wk-Fact-8EF5E6DC3EC6433ABD536B8C2FB048F0" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1059-wk-Fact-6EA08765345851C919C66B8C2FB2CBAD" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1078-wk-Fact-A4FA1DB88D20FA9704CB6B8C2FB406A9" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vehicles</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1103-wk-Fact-92C14A4CD6879CF175856B8C2FB77099" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1122-wk-Fact-5C5E9131940146AA1CAB6B8C2FB30FF0" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1147-wk-Fact-37CDD5F83D260305A687F4DAA41DF7FB" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1166-wk-Fact-9CE6C905166C860193AEF4DAA73C7B89" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1191-wk-Fact-93C5927FC2B32DC57C8A6B8C2FB8FD1A" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1210-wk-Fact-4264C8D37BC1F40DB6A26B8C2FB280BC" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1236-wk-Fact-746D9B7E5C55CC2EDE356B8C2FACFA18" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1255-wk-Fact-4385649138A4469301676B8C2FAB270C" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23306992e1280-wk-Fact-17F8D4944E489AE199326B8C2F6F9E3C" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23306992e1300-wk-Fact-62D5EE66AC2956E871286B8C2F7661AD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1331-wk-Fact-F67F04CA72257459EC5C6B8C2F73F9EF" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23306992e1350-wk-Fact-22630A3A2EFD75C53BAC6B8C2F5F1448" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23306992e1363-wk-Fact-FA1D709DF1F1CEBAFF136B8C2F87C650" name="us-gaap:Depreciation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23306992e1367-wk-Fact-1822A579B4B5F0C52FF36B8C2F87FA63" name="us-gaap:Depreciation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">103</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s68237A0585D656D19048385F65F3AB36"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="TextSelection-9916E088260D456E4A816B8C2FEDE4D3-0-wk-Fact-E8A0F65E2AD6CEF223B86B8C2FC2961F" continuedAt="TextSelection-9916E088260D456E4A816B8C2FEDE4D3-1" escape="true">Accounts Payable, Accrued Expenses, and Other Current Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="TextSelection-6B00730EDA1BC18131276B8C2FEDB313-0-wk-Fact-AC6EB517A4203702CA9C6B8C2FC3DFC9" escape="true"><ix:continuation id="TextSelection-9916E088260D456E4A816B8C2FEDE4D3-1"><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable, accrued expenses, and other current liabilities</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">consist of the following: </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e848-wk-Fact-76A958AF45849747BFF16B8C2F5F35CD" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e867-wk-Fact-81CB44D0291CDD2910E26B8C2F6334D1" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e887-wk-Fact-30C8CC481744915C05B86B8C2F605F55" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,832</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e906-wk-Fact-4D283C06813C237ED1556B8C2F68FE9E" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued contract manufacturing&#160;&amp; contract research costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e931-wk-Fact-F59F17AEDA4814B9ED426B8C2F62AEC7" name="fold:AccruedContractManufacturingAndContractResearchCostsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e950-wk-Fact-D8FAE76B6955D6CC6FCE6B8C2F5F2453" name="fold:AccruedContractManufacturingAndContractResearchCostsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e975-wk-Fact-D16282FE40EB5C9E9B026B8C2F663ABF" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e994-wk-Fact-DEF3D83FEE1187C15C286B8C2F64263B" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued program fees</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1019-wk-Fact-EF3EF3EEC6FBB3D83F566B8C2F64D1D2" name="fold:AccruedProgramFees" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,016</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1038-wk-Fact-F6E8301EFD2CD9C56CB36B8C2F618CF9" name="fold:AccruedProgramFees" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,674</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued royalties </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1063-wk-Fact-BD2EFF4736E434B2AD9B6B8C2F66082C" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1082-wk-Fact-3CB3A785AAE089BA436C6B8C2F5FBA77" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,463</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1107-wk-Fact-5DFA01953B4A0C5901946B8C2F67DD9C" name="us-gaap:InterestPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1126-wk-Fact-F2D84B5EAC479C82D6626B8C2F61A72D" name="us-gaap:InterestPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1151-wk-Fact-1DF5D9764B0F09386F746B8C2F63DD2F" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1170-wk-Fact-38ED9C389A1B3A2F49876B8C2F5F9D91" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued sales rebates and discounts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1195-wk-Fact-095688441A07997175F16B8C2F606A08" name="fold:AccruedSalesRebatesAndChargebacksCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1214-wk-Fact-E8AD0E063125749A343C6B8C2F61636E" name="fold:AccruedSalesRebatesAndChargebacksCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1240-wk-Fact-4A80E75D0536CF5DBAF5807669AB94A2" name="us-gaap:TaxesPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1259-wk-Fact-20B8D7B2EEF16283F0B98076699890CC" name="us-gaap:TaxesPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1284-wk-Fact-4AA4FC74F76DB35479B76B8C2F617A0A" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1303-wk-Fact-E667141DD1DE08AFE9966B8C2F6239BC" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,830</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1333-wk-Fact-00D9324EC614ACA175846B8C2F705888" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">120,373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309531e1352-wk-Fact-88FBC7147324CDFE62F06B8C2F5C7F02" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s2BD0D322DCCC53ADB58D4B488B3FA93B"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-578C9C881010BE5968316B8C2FEDA5FE-0-wk-Fact-876BC63A0935717069256B8C2F5BC9DA" continuedAt="TextSelection-578C9C881010BE5968316B8C2FEDA5FE-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="TextSelection-578C9C881010BE5968316B8C2FEDA5FE-1" continuedAt="TextSelection-578C9C881010BE5968316B8C2FEDA5FE-2"><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock and Warrants</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company was authorized to issue </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e734-wk-Fact-7704FE8FF618F9D2A5A96B8C2FCAA091" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e738-wk-Fact-BB0DC01B065B17E32F166B8C2FC0133F" name="fold:CommonStockVotingRightsForEachShareHeld" contextRef="FI2019Q4" unitRef="vote" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> vote for each share held.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e747-wk-Fact-17462F320EA863EE8864F9595693B507" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q1Mar_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">101,787</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> warrants were exercised at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e751-wk-Fact-057638893F235F4A72E2F9597A0D0CB4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.98</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock resulting in gross cash proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e755-wk-Fact-AC25BF811C168E4720ADF95A0B0735C5" name="us-gaap:ProceedsFromWarrantExercises" contextRef="D2019Q1Mar_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in "&#8212; Note 1. Business" during the second quarter of 2019, the Company completed an underwritten equity offering and issued </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e764-wk-Fact-4CD3463F939D863661B6F441E6784C03" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">18.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e768-wk-Fact-43864E6CC5A7B8A09AC4F442508D5BE9" name="us-gaap:SaleOfStockPricePerShare" contextRef="FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_fold_UnderwrittenOfferingMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">10.75</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e772-wk-Fact-2BE35686606668C4F05AF442E8185CE0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">189.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in "&#8212; Note 11. Assets and Liabilities Measured at Fair Value", the Company reached a clinical milestone, which was the dosing of the first patient in a Phase 3 study, related to the contingent consideration from the acquisition of Callidus. The milestone for this event was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e781-wk-Fact-F49D436D658119FEC9E6F95AF556C7E7" name="fold:ContingentConsiderationMilestonePayment" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was paid in Company common stock in the first quarter of 2019 and resulted in a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e785-wk-Fact-C32C215E245092FE298CF95B1214C8DF" name="fold:MilestonePaymentStockIssuedAsConsideration" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> impact on stockholder's equity.</span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> As discussed in ''&#8212; Note 12. Debt'', during the first and second quarters of 2019, the Company entered into separate, privately negotiated Exchange Agreements with the Holders of the Convertible Notes. Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e795-wk-Fact-B45190F1751000600DA8F95C3C463827" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">247.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Notes held by them in exchange for an aggregate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e799-wk-Fact-91BBA8E21CAD8952E731F95CB2CEF06C" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" contextRef="FI2019Q2" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">44.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Company's common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e803-wk-Fact-209D73E792B95831DFADF95D06B1901E" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="FI2019Q2" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the Company completed an underwritten offering of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e812-wk-Fact-EF5E78786355E3087CA55E3A86D43B2F" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2018Q1Feb_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">20.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e816-wk-Fact-46AF99920B8CC311CC116B8C2FBF88F8" name="us-gaap:SharePrice" contextRef="I2018Q1February28_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">15.50</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e820-wk-Fact-F55D2818823FEFBA1F166B8C2FD9BA2E" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2018Q1Feb_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">294.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e829-wk-Fact-804937D244542F3E127E6B8C2FD8C337" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2018Q2Apr01-Apr30_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">453,214</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> warrants were exercised at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e833-wk-Fact-C596C404389DBE15D0726B8C2FDB2584" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I2018Q2Apr30_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.98</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock resulting in gross cash proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e837-wk-Fact-C989E8B009D1B9B3DFED6B8C2FDB5A97" name="us-gaap:ProceedsFromWarrantExercises" contextRef="D2018Q2Apr01-Apr30_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">104</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-578C9C881010BE5968316B8C2FEDA5FE-2"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Restated Certificate of Incorporation to increase the number of shares of common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e846-wk-Fact-2F66A4E785AD7F6B013E6B8C2FB7456F" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="FI2018Q2" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, that the Company is authorized to issue from </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e850-wk-Fact-0624F178F2DE343E049A6B8C2FDD8C71" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2017Q4" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e854-wk-Fact-A7F51933C89FF59E7D5B6B8C2FDE70D9" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2018Q2" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares.</span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:2px;text-indent:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2017, the Company completed an underwriting offering of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e863-wk-Fact-64153E7C0581BDA0B7785E3AB653721A" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2017Q3Jul1-Jul31" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">21.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e867-wk-Fact-AD0E5D7C64EFD9BB1976F96686C1D383" name="us-gaap:SharePrice" contextRef="I2017Q3Jul31" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">12.25</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. This transaction resulted in net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e871-wk-Fact-D3F9EF911D0835DD2722F967EF5B1D64" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2017Q3Jul1-Jul31" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">243.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nonqualified Cash Plan</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's Deferral Plan, (the "Deferral Plan") provides certain key employees and members of the Board of Directors as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code of 1986 as amended.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had a deferred compensation investment balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e887-wk-Fact-36696387BDFD4BFEB2E26B8C2FD82C89" name="us-gaap:TradingSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23309752e891-wk-Fact-07C2219858E146C0FB766B8C2FB91F3A" name="us-gaap:TradingSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, with corresponding approximate amounts of liability. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferral Plan investment assets are classified as trading securities and are recorded at fair value with changes in the investments' fair value recognized in AOCI in the period they occur. Deferred compensation liability amounts under the Deferral Plan are included in other long-term liabilities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Incentive Plans </span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the &#8216;&#8216;Plan&#8217;&#8217;) and the 2007 Director Option Plan (the &#8216;&#8216;2007 Director Plan&#8217;&#8217;). The Plan provides for the granting of restricted stock and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company&#8217;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. Under the provisions of each plan, no option will have a term in excess of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23309752e915-wk-Fact-2B0D98E748B57F724FCE6B8C2FC37CD6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" format="ixt-sec:duryear">10</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e919-wk-Fact-06DBAAB2DE509B262DDE6B8C2FC14083" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> on the first year anniversary date of grant plus an additional 1/48th for each month thereafter and may be exercised in whole or in part for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e923-wk-Fact-3F41DCA9C8F1C90AC84C6B8C2FDCF862" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the shares vested at any time after the date of grant. Options under the 2007 Director Plan may be granted to new directors upon joining the Board of Directors and vest in the same manner as options under the Plan. In addition, options are granted to independent directors at each annual meeting of stockholders and vest on the date of the annual meeting of stockholders of the Company in the year following the year during which the options were granted. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has reserved up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23309752e931-wk-Fact-F354E847CBC1869008876B8C2FDE6923" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,667,216</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares for issuance under the Plan and the 2007 Director Plan.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sE93A586457905ADD9C2BA4D103673EDA"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-11EAF28FB00D6CB2974F6B8C2FEDFFD1-0-wk-Fact-95E0BF78658CFD2170056B8C2FBCB44B" continuedAt="TextSelection-11EAF28FB00D6CB2974F6B8C2FEDFFD1-1" escape="true">Share based Compensation </ix:nonNumeric></span></div><ix:continuation id="TextSelection-11EAF28FB00D6CB2974F6B8C2FEDFFD1-1" continuedAt="TextSelection-11EAF28FB00D6CB2974F6B8C2FEDFFD1-2"><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s Equity Incentive Plans consist of the Plan and the 2007 Director Plan. The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors. advisors, and consultants at a price to be determined by the Company&#8217;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">105</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-11EAF28FB00D6CB2974F6B8C2FEDFFD1-2" continuedAt="TextSelection-11EAF28FB00D6CB2974F6B8C2FEDFFD1-3"><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 21, 2018, the Board of Directors of the Company approved an amendment (the "Amendment") to the Plan. The Amendment provides for certain benefits to qualifying Plan Participants who separate from service with the Company due to death, disability or "Retirement" (as such term is defined under the Plan) ("Qualified Participants"). Options granted under the Plan ("Options") to a Qualified Participant shall continue to vest until the 2nd anniversary of the Qualified Participant&#8217;s separation and all vested Options held by such Qualified Participant shall remain exercisable until the earlier of the 4th anniversary of the Qualified Participant&#8217;s separation or the original expiration date of the Option. Options that are not exercised during this exercise period shall be forfeited. Time-based restricted stock units and restricted stock granted to a Qualified Participant under the Plan that was scheduled to vest within the </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> year period following the Qualified Participant's separation shall accelerate and be delivered upon such separation. Any time-based restricted stock units or restricted stock that would have vested after such </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> year period will be forfeited upon the Qualified Participant's separation. Also, per the Amendment, any performance-based restricted stock units under the Plan ("PRSUs") received by the Qualified Participant, shall remain eligible to vest after the Qualified Participant&#8217;s separation based on the actual performance of the Company through the end of the performance period applicable to any such PRSU. </span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Grants</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the fair value method of measuring stock-based compensation, using the fair value of each equity award granted. The Company chose the &#8216;&#8216;straight-line&#8217;&#8217; attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007. Beginning in the third quarter of 2017, the average expected life is determined using our actual historical data versus a &#8216;&#8216;simplified&#8217;&#8217; method used in prior quarters. The &#8216;&#8216;simplified&#8217;&#8217; method of estimating the Company did not have sufficient reliable exercise data to justify a change from the use of the &#8216;&#8216;simplified&#8217;&#8217; method of estimating the expected exercise term of employee stock option grants. The impact from this change was not material. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-C169596DA4EB79E400E26B8C2FEEB307-0-wk-Fact-84D72C7E2E84BC5055E96B8C2FA83773" escape="true"><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e919-wk-Fact-334566BF82E5406E41986B8C2FB63C5E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">74.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e939-wk-Fact-2346CCAAB20E0F7405556B8C2FC16FCD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">78.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e959-wk-Fact-603283EEB15B434AA9EB6B8C2FAD6EEA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">82.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e986-wk-Fact-6F4877164D897F9A8A3E6B8C2FB7D031" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1006-wk-Fact-180BD6C843CD4F4638BD6B8C2FAEF3E3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1026-wk-Fact-D9D181C2CD5B3838D4B86B8C2FAFBD7E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life of options (years) </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23321073e1055-wk-Fact-0FE01A116A2C53DE583D6B8C2FAEB726" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">5.68</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23321073e1074-wk-Fact-C414BBBB88D41B9DBCE76B8C2FB9C16F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">5.62</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23321073e1093-wk-Fact-4B975B0F2E3FE51804706B8C2FAC937B" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">6.18</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected annual dividend per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1124-wk-Fact-484D35B21DE01CFE7C316B8C2FBD66FB" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1143-wk-Fact-2DCADA7EF791271161936B8C2FB328B5" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1163-wk-Fact-49F7FA51173858F9ED5D6B8C2FAE94FD" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______________________________________</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:inherit;font-size:9pt;">The average expected life is determined using actual historical data. </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant-date fair value per share of options granted during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e1197-wk-Fact-8736E6C84C5A9D177F0B6B8C2FC11878" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.67</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e1201-wk-Fact-169B0E0B26230A2FC32B6B8C2FAD7AB9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.19</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e1206-wk-Fact-869D274AD36731D480536B8C2FBAD554" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.09</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">106</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-11EAF28FB00D6CB2974F6B8C2FEDFFD1-3" continuedAt="TextSelection-11EAF28FB00D6CB2974F6B8C2FEDFFD1-4"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-5779D4DDBCF51D5DA0EF6B8C2FED11C9-0-wk-Fact-CFFED8366577B22493FA6B8C2FA40819" escape="true"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company's stock options for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1412-wk-Fact-2854A020A413B8827FA76B8C2F6BA0AE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2016Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">15,497.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1431-wk-Fact-C6F20ACC2A0CE886DA4E6B8C2F6429A2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2016Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1477-wk-Fact-8E6B3829D146BEAFCD2D6B8C2F6987D6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">3,695.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1496-wk-Fact-88D2B0BB0397600DF0F96B8C2F697564" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e1542-wk-Fact-F1B30837C2A5155484116B8C2F68768A" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">2,878.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1562-wk-Fact-37DB44D2711654D656936B8C2F6AC6F0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e1608-wk-Fact-0FBEE9F5DA6453ADAA666B8C2F67F146" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">1,133.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1628-wk-Fact-AB8162858C1D5D12DDB96B8C2F669ABE" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1674-wk-Fact-907F2419D6D64060251B6B8C2F670529" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">15,181.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1693-wk-Fact-223D95748C8FBC9D6F116B8C2F68B93D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1739-wk-Fact-B246D3B4750C5B220CAA6B8C2F6AED4A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">2,348.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1758-wk-Fact-30AD57BB2EEBF00DA8B66B8C2F60DD2E" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e1804-wk-Fact-4AC93A04508889FED89A6B8C2F62690E" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">1,398.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1824-wk-Fact-556E2D36DCE423E4E2966B8C2F636D74" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e1870-wk-Fact-0AE2C4EE68F9D9A0C5766B8C2F67FB05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">313.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1890-wk-Fact-05DCED1C375B010737E16B8C2F621C29" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e1936-wk-Fact-5E92F59DC82AFF7B4641F107049F41F6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e1956-wk-Fact-66434F6085247546CD44F1070497BD32" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2003-wk-Fact-BCC614F3A31BAD74DDABF10704A32149" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">15,810.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2022-wk-Fact-18F0E2C17DDD1785CCA56B8C2F603621" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2068-wk-Fact-06403FBA0F323D5363ED6B8C2F66B2FC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">4,091.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2087-wk-Fact-99F69023E684C083ED3D6B8C2F699F1D" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e2133-wk-Fact-E21317772D04BE03F5B66B8C2F6BA9A5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">1,967.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2153-wk-Fact-579E3D2E91EB3AB9BACD6B8C2F6476DE" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e2199-wk-Fact-2C221FB81A0EC6B2ABA96B8C2F63009C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">879.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2219-wk-Fact-288930CF4C60038F10626B8C2F672866" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e2265-wk-Fact-AFDCEC4114C3560AF3FF6B8C2F66BC11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">331.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2285-wk-Fact-B727B5ACDBD1D3D316676B8C2F6156D3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2331-wk-Fact-B7CD0F2B3715033A3BD5F10704A802B4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">16,724.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2350-wk-Fact-DC7C0A1266CFAA5A68D86B8C2F636FD8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23321073e2364-wk-Fact-24CDBFDB1FADEFEA14C26B8C2F66FE0B" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">6.4</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2380-wk-Fact-2D94BF4CEBAA15CEEC316B8C2F62FEB9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and unvested expected to vest, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2395-wk-Fact-F8B2C0DE430B3FC26A8E6B8C2F65324D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">16,111.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2414-wk-Fact-6F63F4A09D4AA3FDDC2A6B8C2F61D956" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23321073e2428-wk-Fact-2A412CA30673313E57B16B8C2F61B2E5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">6.3</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2444-wk-Fact-452E1E0C735B539386A26B8C2F64E6CB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2459-wk-Fact-6B5099A3F2F4D22CD7A06B8C2F650A19" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">10,646.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2478-wk-Fact-FA33E95C047D425862946B8C2F681FC2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23321073e2492-wk-Fact-2B43CA11873C7A3CC73A6B8C2F65DBB1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">5.1</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2508-wk-Fact-044AE318C987D7B20F766B8C2F66B5C1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options exercised during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e2532-wk-Fact-C52AFC78286257757A326B8C2FBFD948" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e2536-wk-Fact-FCAD9C33DAB8EAC55DD26B8C2FA70507" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e2541-wk-Fact-31A2446F19E0F46853606B8C2FA6A78F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively. Cash proceeds from stock options exercised during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e2557-wk-Fact-5D555EAD57689EF131F46B8C2FB82B87" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e2561-wk-Fact-8B0EBC54E03CBB6849FC6B8C2F962E5F" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e2566-wk-Fact-B32A62681747FC0946CD6B8C2F938C56" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the total unrecognized compensation cost related to non-vested stock options granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e2574-wk-Fact-CAF2F64FEE207C986AC56B8C2FBE41AE" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23321073e2578-wk-Fact-7369085C268F31E8DC626B8C2FBB053B" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">2.5</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">107</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-11EAF28FB00D6CB2974F6B8C2FEDFFD1-4"><div style="line-height:120%;padding-top:3px;text-align:justify;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSU's")</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee&#8217;s continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-8D8648081C88943496D96B8C2FEE45BC-0-wk-Fact-1EC7FBBFC5D166DEC9166B8C2FA854A2" continuedAt="TextSelection-8D8648081C88943496D96B8C2FEE45BC-1" escape="true">A summary of non-vested RSU activity under the Plan for the year ended </ix:nonNumeric></span><ix:continuation id="TextSelection-8D8648081C88943496D96B8C2FEE45BC-1" continuedAt="TextSelection-8D8648081C88943496D96B8C2FEE45BC-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></ix:continuation></div><ix:continuation id="TextSelection-8D8648081C88943496D96B8C2FEE45BC-2"><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average Grant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested units as of December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2791-wk-Fact-AB4DC6AF410D5387FDA26B8C2F882870" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">2,575.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2810-wk-Fact-7DD21A2A94DBF4B87C3B6B8C2F9E0253" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2856-wk-Fact-A49FEB9988B1AB2584716B8C2FC5F4FB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">1,811.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2875-wk-Fact-E12AAD032DF6A2DB9E916B8C2FB01657" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e2921-wk-Fact-FE50B2AD64E6D9CCF89F6B8C2FB871F5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">530.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e2941-wk-Fact-B3EBE060F34E3C9C85E66B8C2FD91F17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e2987-wk-Fact-DDC00EA68B64794BF6D06B8C2F7F8310" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">145.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3007-wk-Fact-82F23EBABCAF1517C85F6B8C2FA28541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested units as of December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3053-wk-Fact-64470A1E4DDC79850F516B8C2F9639D8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">3,712.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3072-wk-Fact-78BDAA0022F9A4D641876B8C2FA1B8F4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3118-wk-Fact-4157C9329DFD58F645506B8C2FA79762" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">3,526.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3137-wk-Fact-933ED712907F40487C5C6B8C2FA03B99" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e3183-wk-Fact-F7FA368BD79CDB060D896B8C2FA44B7B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">921.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3203-wk-Fact-9E32FEFC38E0D29134A76B8C2F6C8E61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321073e3249-wk-Fact-122439D5AC571EEDCB7F6B8C2F965DD5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">525.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3269-wk-Fact-AB77580393075F32C72E6B8C2FA188EE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested units as of December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3315-wk-Fact-C874CAE23CD645A302306B8C2F86E062" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="shares" decimals="-2" scale="3" format="ixt:numdotdecimal">5,792.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3334-wk-Fact-27DD6F54A2C8827814CA6B8C2F7DF7BA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23321073e3348-wk-Fact-9E47C7A5BCE8138ED98E6B8C2FA2AF6C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" format="ixt-sec:duryear">2.4</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3364-wk-Fact-C1BF863728D52788DD2A6B8C2F68E65C" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3382-wk-Fact-A0A054AE10824057B1516B8C2F99C1BF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">920,782</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> RSUs have vested and all non-vested units are expected to vest over their normal term. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321073e3390-wk-Fact-B0CD7EC1B9634E0B9C356B8C2FA675C0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23321073e3394-wk-Fact-7D7E26E9159E1CB82C146B8C2FA9AB13" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" format="ixt-sec:duryear">2.4</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation Expense Related to Equity Awards</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-0EE5A7CD52C739EB50466B8C2FEEA1A4-0-wk-Fact-82BF33F2ACDDD35FEAD46B8C2F943E37" escape="true"><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity compensation expense recognized in:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3650-wk-Fact-0EEC8328C096952DC7A76B8C2FA0AEB3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3669-wk-Fact-BD51CCA018B9BA1FD8906B8C2F9C6E18" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3689-wk-Fact-68E2BEC4E6B7F33806FA6B8C2F9D4433" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,328</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general, and administrative expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3709-wk-Fact-568FD9079379AA0532DD6B8C2F9E116B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,855</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3728-wk-Fact-345BA38CEC69D5757E2F6B8C2F9CFCAF" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,520</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3747-wk-Fact-E8B9F9C4B16BF6CDAA096B8C2FAAA537" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,773</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total equity compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3778-wk-Fact-3D17075C0554D00CAE6D6B8C2F9C8DA1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3797-wk-Fact-26AF11B40A93A84DF2846B8C2F9DF885" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321073e3817-wk-Fact-40D99F47497183F8E95E6B8C2F9DE13A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="s34D496D16561512CA2D284600752B02A"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">11. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-EC3ACF956964C82C72FF6B8C2FEE21A0-0-wk-Fact-E930081D82B80FC20B726B8C2FD2D32C" continuedAt="TextSelection-EC3ACF956964C82C72FF6B8C2FEE21A0-1" escape="true">Assets and Liabilities Measured at Fair Value</ix:nonNumeric></span></div><ix:continuation id="TextSelection-EC3ACF956964C82C72FF6B8C2FEE21A0-1" continuedAt="TextSelection-EC3ACF956964C82C72FF6B8C2FEE21A0-2"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;1</span><span style="font-family:inherit;font-size:10pt;"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;2</span><span style="font-family:inherit;font-size:10pt;"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;3</span><span style="font-family:inherit;font-size:10pt;"> &#8212; Inputs that are unobservable for the asset or liability.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">108</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-EC3ACF956964C82C72FF6B8C2FEE21A0-2" continuedAt="TextSelection-EC3ACF956964C82C72FF6B8C2FEE21A0-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="TextSelection-56F1DBE1C6D650A8F66A6B8C2FEE3B4B-0-wk-Fact-FA0BBBE03090A70E039B6B8C2FD39C37" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are identified in the following table:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e865-wk-Fact-62D2B9935C4B76D0736E6B8C2FAF14A3" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,710</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e884-wk-Fact-FBA445FF93915393E7356B8C2FB0F89B" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,710</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-back securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e904-wk-Fact-9D22DAEB8ED75F6DAFC26B8C2FB02FD4" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e923-wk-Fact-D23316BA2ACDD59274576B8C2FB13E63" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e948-wk-Fact-CB231CD13FD9E28CE1A16B8C2FB08318" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e967-wk-Fact-F43A1306B519E02282EB6B8C2FB16B09" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Government Agency Bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e992-wk-Fact-31EFA70D78C3A4269487F51932460FC1" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1011-wk-Fact-5C35B3C7F6E7F515EC60F51936D40724" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1036-wk-Fact-88228F5425B592EC64416B8C2FC2DAC9" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1055-wk-Fact-8FDA42CA2BA3FCAD58AF6B8C2FB16B2D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1085-wk-Fact-306C7CF7EAB8535E7DF36B8C2FB0FD0D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">314,270</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1104-wk-Fact-59E779BD08D6ADF0FD146B8C2FB250A0" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">314,270</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1284-wk-Fact-A8126901DA0ED74CA5236B8C2FBE301A" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1303-wk-Fact-AC1C14A2E15744EEC9576B8C2FD08232" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1323-wk-Fact-043762B0B0647DE5D1E36B8C2FA51FDA" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred compensation plan liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1343-wk-Fact-137BB7BCEC6B7A71C9186B8C2FC55102" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1362-wk-Fact-7F3C403D282E06346EEC6B8C2F97DEF9" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1381-wk-Fact-CD51A036FA9AA7817B8E6B8C2FC2D26C" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1412-wk-Fact-0E6A72FFF324DCE980B26B8C2F952E99" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1431-wk-Fact-F094551D2B2367DC42296B8C2FBB2D55" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1451-wk-Fact-C8D5B6C96E65BFC6FBE16B8C2F9AFCE0" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are identified in the following table:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.40545808966861%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1591-wk-Fact-21494C4DD7EE1DD8029E6B8C2F989FD1" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1610-wk-Fact-F540D30470F11583D8996B8C2F9AE801" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-back securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1630-wk-Fact-7964A76A9DD4AB4791996B8C2F9BAB85" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,135</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1649-wk-Fact-4C7A39899E3861A5939B6B8C2F9B07D0" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,135</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1674-wk-Fact-FA86355F08A8A8179E1F6B8C2FA20909" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,726</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1693-wk-Fact-530284A611BECDC32D9B6B8C2F99BF26" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,726</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1718-wk-Fact-CDCE02C201FAC64736E96B8C2FA50B21" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1737-wk-Fact-BBBD87355D902D65A0276B8C2F991BB4" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1767-wk-Fact-2780EFF5CE8841BA80236B8C2F98639A" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">427,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1786-wk-Fact-DF0118932C215386FB926B8C2F9BC774" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">427,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1966-wk-Fact-076C70718BA9807DD34E6B8C2FC467C3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e1985-wk-Fact-C3D79DBF8DC8E250D8216B8C2F8FBED0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2005-wk-Fact-DD91337C9F7E65E2DE886B8C2FC3FE5F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred compensation plan liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2025-wk-Fact-399C5AC269023A2A6AEC6B8C2FC4AA20" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2044-wk-Fact-1D67C75E3B1429437BAD6B8C2FC067B2" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2063-wk-Fact-9E00E9139DD05FAD37426B8C2FBF39A1" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2094-wk-Fact-D580D6CD7D94DF3370F46B8C2FC40EAD" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2113-wk-Fact-1D79A78390BD13240B5B6B8C2FC08CC2" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2133-wk-Fact-3B0BB34B55C6B627376E6B8C2FC3E94B" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s Convertible Notes falls into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the Convertible Notes at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314355e2151-wk-Fact-B5D3E785C08D618126B46B8C2FD2A10A" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s Senior Secured Term Loan fall into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan approximates the fair value.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company did not have any Level 3 assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">109</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-EC3ACF956964C82C72FF6B8C2FEE21A0-3" continuedAt="TextSelection-EC3ACF956964C82C72FF6B8C2FEE21A0-4"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Money Market Funds and Marketable Securities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. No transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy occurred during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Consideration Payable</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contingent consideration payable resulted from the acquisition of Callidus, as discussed in "&#8212;&#160;Note&#160;3. Acquisitions." The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Using this approach, expected future cash flows are calculated over the expected life of the agreement, are discounted, and then exercise scenario probabilities are applied. The valuation is performed quarterly. Gains and losses are included in the Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contingent consideration payable for Callidus has been classified as a Level&#160;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. The Company may be required to record losses in future periods.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="TextSelection-CF9A1CA51A25CC5ACF9D6B8C2FEE98CC-0-wk-Fact-B506949ED8563FDE56936B8C2FD34DE2" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.64327485380117%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:23%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable Input</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Range</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2382-wk-Fact-CB7D08B2553A27760399F51F8FA959D6" name="fold:ContingentConsiderationMeasurementInput" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">9.6</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical and regulatory milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2403-wk-Fact-19B1EE601DCB5A352C066B8C2FBCCBF7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability weighted discounted cash flow</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of achievement of milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75% - 78%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected year of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021 - 2022</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reached a clinical milestone, which was the dosing of the first patient in a Phase 3 study, related to the contingent consideration from the acquisition of Callidus. The milestone for this event was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314355e2506-wk-Fact-AF81482B9D4E0B2F2D45F5281854A0A8" name="fold:MilestonePaymentStockIssuedAsConsideration" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was paid in Company common stock in the first quarter of 2019, resulting in </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314355e2510-wk-Fact-C32C215E245092FE298CF95B1214C8DF" name="fold:MilestonePaymentStockIssuedAsConsideration" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> impact on stockholder's equity.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">110</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-EC3ACF956964C82C72FF6B8C2FEE21A0-4"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="TextSelection-97FEA1D3A39BEA57B9A96B8C2FEE2581-0-wk-Fact-5521F2C6FC13058156266B8C2FD31206" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the change in the balance of contingent consideration payable for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, beginning of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2658-wk-Fact-340DBEA618E28155AFBC6B8C2FC2551D" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2677-wk-Fact-B992A0290929767D0F7B6B8C2FBDBC9A" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones payable, included in accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2697-wk-Fact-E20336D039B288BF7E676B8C2FC97609" name="fold:MilestonePayableAccruedDuringPeriod" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23314355e2716-wk-Fact-0D4BA3A5007CA6E174646B8C2FC38E58" name="fold:MilestonePayableAccruedDuringPeriod" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in fair value during the period, included in the Consolidated Statements of Operations </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2742-wk-Fact-FB99FB171B33B0504A336B8C2FAA9303" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2761-wk-Fact-5BF3B505984CD70519BF6B8C2FB42BBF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment for contingent consideration paid in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23314355e2786-wk-Fact-D166FC205994C7855A326B8C2FCB74A1" name="fold:ContingentConsiderationPaidInStockAdjustment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2806-wk-Fact-59F9F037EA50D56CAC3D6B8C2FCADE89" name="fold:ContingentConsiderationPaidInStockAdjustment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, end of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2836-wk-Fact-B390ECC61D128FFEA65D6B8C2FC22B24" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314355e2855-wk-Fact-340DBEA618E28155AFBC6B8C2FC2551D" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Compensation Plan - Investment and Liability</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Deferred Compensation Plan (the "Deferral Plan") provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant&#8217;s base salary, bonus and director&#8217;s fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investment&#8217;s fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these securities.</span></div></ix:continuation><div><a id="s847C0302A2875BDD9F71A7482901E3F0"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-F959C5629CEE77D28E886B8C2FEF52E7-0-wk-Fact-69054EA4CAD312C074C46B8C2FCC0C37" continuedAt="TextSelection-F959C5629CEE77D28E886B8C2FEF52E7-1" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="TextSelection-F959C5629CEE77D28E886B8C2FEF52E7-1" continuedAt="TextSelection-F959C5629CEE77D28E886B8C2FEF52E7-2"><div style="line-height:120%;text-align:left;padding-left:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Senior Secured Term Loan due 2023</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company entered into a loan agreement with BioPharma Credit PLC as the lender. The loan agreement provides for a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e718-wk-Fact-FF6D70C0EE2C4790FC796B8C2FCC46C8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="FI2018Q3_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> senior secured term loan ("Senior Secured Term Loan") with an interest rate equal to the 3-month LIBOR plus </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e722-wk-Fact-DB8503C1C233442235606B8C2FCBE52A" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">7.50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum and matures in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23313844e726-wk-Fact-22E1D6353C7B389F25CC6B8C2FC53B37" name="us-gaap:DebtInstrumentTerm" contextRef="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember" format="ixt-sec:duryear">5</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> from the maturity date. The Senior Secured Term Loan will be repaid in four quarterly payments equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e730-wk-Fact-E6DAAB3F7AF9B9D4B9A46B8C2FC59FDE" name="fold:DebtInstrumentPeriodicPaymentPrincipalPercentage" contextRef="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">12.50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> thereof starting on the forty-eight month anniversary of the date of the first credit extension with the balance due on the Maturity Date. Interest is payable quarterly in arrears. The Senior Secured Term Loan contains certain customary representations and warranties, affirmative and negative covenants, and events of default applicable to the Company and certain of its subsidiaries but does not include any financial covenants relating to the achievement or maintenance of revenue or cash flow. If an event of default occurs and is continuing, the lender may declare all amounts outstanding under the Senior Secured Term Loan to be immediately due and payable. The Company received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e734-wk-Fact-F9D0EBDE2026DB1AEB816B8C2FCD11CB" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">146.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in September 2018, after deducting fees and estimated expenses</span><span style="font-family:inherit;font-size:10pt;color:#661de7;">.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Notes due 2023</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2016, the Company issued at par value </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e751-wk-Fact-1A5BCD6FA61C935D35E46B8C2FC51676" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes, which included the exercise in full of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e755-wk-Fact-F738263E3F0B3159DE6F6B8C2FCA4CE5" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> over-allotment option granted to the initial purchasers of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act (the "Note Offering"). Interest is payable semiannually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Convertible Notes are convertible at the option of the Holders, under certain circumstances and during certain periods, into cash, shares of the Company&#8217;s common stock or a combination thereof. The net proceeds from the Note Offering were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e759-wk-Fact-AFBDABC2B472827081366B8C2FC9F17B" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">243.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting fees and estimated expenses. In addition, the Company used approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e763-wk-Fact-5B83B787931E7F6199DE6B8C2FC6D869" name="fold:PremiumsPaidForCappedCallConfirmations" contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The Convertible Notes were initially convertible into approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e767-wk-Fact-654A998EAA6953265B3F6B8C2FC9B725" name="fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt" contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">40.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock under certain circumstances prior to maturity at a conversion rate of </span><span style="font-family:inherit;font-size:10pt;">163.3987</span><span style="font-family:inherit;font-size:10pt;"> shares per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e776-wk-Fact-070D28372E735840193C6B8C2FC85BCB" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.12</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock, subject to adjustment under certain conditions. Holders may convert their Convertible Notes at their option at specified times prior to the maturity date of December 15, 2023, only if: </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">111</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-F959C5629CEE77D28E886B8C2FEF52E7-2" continuedAt="TextSelection-F959C5629CEE77D28E886B8C2FEF52E7-3"><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">during any fiscal quarter commencing after March 31, 2017, if the last reported sale price of the Company&#8217;s common stock for at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23313844e789-wk-Fact-614A79F9919D1D48570C6B8C2FBCBD82" name="fold:DebtInstrumentsConvertibleThresholdTradingDays" contextRef="D2016Q4Dec01-Dec31_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" format="ixt-sec:durday">20</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> trading days in the period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e793-wk-Fact-069AD8890E4E550C5D886B8C2FCF8CEB" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is equal to or more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e797-wk-Fact-7CC5796764790349B7BC6B8C2FCBE7A8" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price of the Convertible Notes on the last day of such preceding fiscal quarter; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a holder submits its Convertible Notes for conversion during the </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> business day period following any five consecutive trading day period in which the trading price for the Convertible Notes, per $1,000 principal amount of the Convertible Notes, for each such trading day was less than </span><span style="font-family:inherit;font-size:10pt;">98%</span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate of the Convertible Notes on such date; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Company issues to all or substantially all of the holders of common stock rights options or warrants entitling then them for a period of not more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23313844e824-wk-Fact-FBA1D3CE298256109EC56B8C2FCD68B4" name="fold:DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice" contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" format="ixt-sec:durday">60</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> calendar days after the date of such issuance to subscribe for or purchase shares of the common stock, at a price per share less than the average of the Last Reported Sale Prices of the common stock for the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23313844e828-wk-Fact-5FA0E637AD8AA7E2C96B6B8C2FCDC424" name="fold:DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice" contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" format="ixt-sec:durday">10</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance or distributes to all or substantially all holders of the common stock the Company&#8217;s assets, debt securities or rights to purchase the Company&#8217;s securities which distribution has a per share value of exceeding </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e832-wk-Fact-58B14D407CDD41D50F546B8C2FCEEE00" name="fold:DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent" contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Last Reported Sale Price of the common stock on the Trading Day immediately preceding the date of announcement of such distribution; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Company enters into specified corporate transactions; or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Company has had a call for redemption, the holder can convert up until the second trading day immediately preceding the redemption date.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes will be convertible, at the option of the note holders, regardless of whether any of the foregoing conditions have been satisfied, on or after September 15, 2023 at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date of December 15, 2023.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 15, 2018, the Company entered into an underwriting agreement relating to an underwritten public offering of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e858-wk-Fact-B150AE12010A6F0E7FA16B8C2FC359A7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2018Q1Feb15-Feb15_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">19.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock. Under the terms of the underwriting agreement, the Company granted the underwriters an option, exercisable for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23313844e862-wk-Fact-59D98E3469E8BE2D03CE6B8C2FCA52B0" name="fold:NumberOfDaysGrantedUnderwritersForPurchaseOfShares" contextRef="D2018Q1Feb15-Feb15_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" format="ixt-sec:durday">30</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> days after February 16, 2018, to purchase up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e866-wk-Fact-C01297DCB725BB446E936B8C2FCE0514" name="fold:MaximumNumberOfAdditionalSharesGrantedToUnderwriters" contextRef="D2018Q1Feb16-Feb16_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock, which was exercised with respect to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e870-wk-Fact-3E0A8567ECF286FC65ED6B8C2FCC77D2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2018Q1Feb16-Feb16_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">885,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:3px;text-align:justify;padding-left:8px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subsequent to the underwritten public offering on February 15, 2018, the Company did not have sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the Company accounted for the portion of the bifurcated conversion feature and of the Capped Call Confirmations that would not be able to be net share settled as a current derivative liability and as a derivative asset, respectively. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at February 15, 2018 was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e879-wk-Fact-4982F8077A63ED61CD736B8C2FD42960" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" contextRef="I2018Q1Feb15" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">507.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e883-wk-Fact-2585A1F718CCFBACDC896B8C2FC83DB1" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" contextRef="I2018Q1Feb15" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of which the portion that was determined to not be able to be net share settled was recorded with a corresponding impact to additional-paid-in-capital. Subsequent changes to fair value of the derivatives were recorded in the second quarter of 2018 through earnings on the Company&#8217;s Consolidated Statements of Operations resulting in a change in fair value of derivatives for the year ended December 31, 2018 of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e887-wk-Fact-382F5C639B319DEE9E736B8C2FCB4C69" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following the approval by the stockholders of the Company on June 7, 2018, to increase the authorized shares of common stock to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e896-wk-Fact-7AAFD508B95F463B58AD6B8C2FCE79B3" name="us-gaap:CommonStockSharesAuthorized" contextRef="I2018Q2Jun07" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, the Company has sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the derivative liability and derivative asset were reclassified into additional-paid-in-capital. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at June 7, 2018 was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e900-wk-Fact-A300EF905825F6AFED656B8C2FC81FB5" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" contextRef="I2018Q2Jun07" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e904-wk-Fact-189ABE58A2CCA97034FA6B8C2FCFE7FD" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" contextRef="I2018Q2Jun07_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">112</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-F959C5629CEE77D28E886B8C2FEF52E7-3"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Capped Call Confirmations were expected generally to reduce the potential dilution to the common stock upon any conversion of the Convertible Notes and/or offset the cash payments the Company is required to make in excess of the principal amount upon conversion of the Convertible Notes in the event that the market price of the common stock was greater than the strike price of the Capped Call Confirmations (which initially corresponded to the initial conversion price of the Convertible Notes and is subject to certain adjustments under the terms of the Capped Call Confirmations), with such reduction and/or offset subject to a cap based on the cap price of the Capped Call Confirmations. The Capped Call Confirmations had an initial cap price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e914-wk-Fact-5497BD2CA820CA3F29CCFE284125C2E6" name="fold:DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.20</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, which represented a premium of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e918-wk-Fact-10A394F1D0D24A663F9EFE28B0DAFBF5" name="fold:DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage" contextRef="FD2019Q4YTD_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> over the closing price of the Company&#8217;s common stock on The NASDAQ Global Market on December 15, 2016 and was subject to certain adjustments under the terms of the Capped Call Confirmations. The Capped Call Confirmations covered, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes, the number of shares of common stock that underlay the Convertible Notes. The Capped Call Confirmations did not meet the criteria for separate accounting as a derivative as they were indexed to the Company&#8217;s common stock. The premiums paid for the Capped Call Confirmations were included as a net reduction to additional paid-in capital.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first and second quarters of 2019, the Company entered into separate, privately negotiated Exchange Agreements with the Holders of the Convertible Notes. Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e927-wk-Fact-B45190F1751000600DA8F95C3C463827" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">247.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Notes held by them in exchange for an aggregate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e931-wk-Fact-91BBA8E21CAD8952E731F95CB2CEF06C" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" contextRef="FI2019Q2" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">44.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Company common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e935-wk-Fact-209D73E792B95831DFADF95D06B1901E" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="FI2019Q2" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. In addition, pursuant to the Exchange Agreements, the Company made aggregate cash payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e939-wk-Fact-1F5B7A94737DEA358528F5408D3044B5" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Holders to satisfy accrued and unpaid interest to the closing date of the transactions, along with cash in lieu of fractional shares. These transactions resulted in </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e943-wk-Fact-396C28C1E94507BF0BF2F5411D5F65DD" name="fold:GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in additional paid-in-capital and common stock of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e948-wk-Fact-5094DDD0E163A65FFBDAF540DD195F5A" name="fold:GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> on the Consolidated Balance Sheets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Additionally, the Company recognized a net loss on the exchange of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e956-wk-Fact-8A097E423BA39BB400C8F540FC57069F" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">40.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> on the Consolidated Statements of Operations during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. During the second half of the year there were no additional debt conversion transactions.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first and second quarter of 2019, the Company terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for proceeds of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23313844e969-wk-Fact-D99DFD97B7D3360AB9D9FE28DEDC64DB" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The last reported sale price of the Company&#8217;s common stock was equal to or more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e978-wk-Fact-82A399D0A8222FC4D6E06B8C2FCC4948" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price of the Convertible Notes for at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23313844e982-wk-Fact-A4E71847A9CC1F90FFB66B8C2FCBB2EE" name="fold:DebtInstrumentsConvertibleThresholdTradingDays" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" format="ixt-sec:durday">20</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> trading days of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e986-wk-Fact-DE8AD1F5AB7B094D94806B8C2FC5B348" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last day of the year. As a result, the Convertible Notes are currently convertible into the Company&#8217;s common stock.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ConvertibleDebtTableTextBlock" id="TextSelection-65A3CE65A60D02E674BA6B8C2FEE2141-0-wk-Fact-BD7B287089297DB84E946B8C2FCAB8AF" continuedAt="TextSelection-65A3CE65A60D02E674BA6B8C2FEE2141-1" escape="true"><div style="line-height:120%;text-align:left;padding-left:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes and Senior Secured Term Loan consist of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1124-wk-Fact-24DCFBA222D6DDC5331A6B8C2FDAB7F0" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1143-wk-Fact-A49155D3D83F7E5189616B8C2FC6D58B" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">400,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: debt discount </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23313844e1165-wk-Fact-31776D97A1480C350A3B6B8C2FD4FD9F" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,974</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23313844e1185-wk-Fact-AED4C09B57A701EFCE576B8C2F5D45C5" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: deferred financing </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23313844e1213-wk-Fact-79271BE2087D91BC98256B8C2FCC81E8" name="us-gaap:DeferredOfferingCosts" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23313844e1233-wk-Fact-99CFDF4B33B0F91109976B8C2F769919" name="us-gaap:DeferredOfferingCosts" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net carrying value of the debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1264-wk-Fact-5BD150A78593854B7C036B8C2F7C736A" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">149,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1283-wk-Fact-F9F1A4D99F1CC2367ED36B8C2F86AA44" name="us-gaap:LongTermDebt" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-65A3CE65A60D02E674BA6B8C2FEE2141-1" continuedAt="TextSelection-65A3CE65A60D02E674BA6B8C2FEE2141-2"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-65A3CE65A60D02E674BA6B8C2FEE2141-2"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in the Consolidated Balance Sheets within Convertible Notes and Senior Secured Term Loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div></ix:continuation></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="TextSelection-91166D466E18071C97436B8C2FEE5795-0-wk-Fact-4EBF939F978E8DDC6D8E6B8C2FAAAA73" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth interest expense recognized related to the Convertible Notes and Senior Secured Term Loan for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1401-wk-Fact-B633F20151B0B7E934176B8C2F8DA90A" name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,483</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1420-wk-Fact-57F52E083651E7343AF76B8C2F8E6824" name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1445-wk-Fact-F4AA3E25AED1F831FA35F558D4DDC44C" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1464-wk-Fact-96CE3492C9F6A083E60DF558D49D26D3" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of deferred financing</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1489-wk-Fact-95022225BC69EB35C0C86B8C2FC6B90F" name="fold:AmortizationDeferredFinancingCosts" contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1508-wk-Fact-6BF9AE3DDB2FBAD9C9D86B8C2F8DAA82" name="fold:AmortizationDeferredFinancingCosts" contextRef="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">555</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective interest rate of the liability component, Convertible debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1528-wk-Fact-BB3F118589D2FDE468496B8C2FC688E1" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">10.63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1548-wk-Fact-B765D77ABDB679D3E5CA6B8C2F8ED761" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">10.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective interest rate of the liability component, Senior Secured Term Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1574-wk-Fact-2C7F977DA607F957B1B46B8C2F8DF43A" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">10.16</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23313844e1594-wk-Fact-1CBA799669C39AF5A4076B8C2F8FB7B2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">10.48</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">113</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC2479D17811C5939B8481AA8430CC2D4"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">13. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-9BEBABECF6BAC46825B16B8C2FEF8841-0-wk-Fact-FDB0339FECC693E5F66B6B8C2FD1A2A1" continuedAt="TextSelection-9BEBABECF6BAC46825B16B8C2FEF8841-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9BEBABECF6BAC46825B16B8C2FEF8841-1" continuedAt="TextSelection-9BEBABECF6BAC46825B16B8C2FEF8841-2"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company currently has operating leases for office and research laboratory space, equipment, and vehicles under agreements expiring at various dates through 2044, which include renewal options on leases which the Company is reasonably certain to exercise.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, operating lease expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23310740e728-wk-Fact-2C1E1A67EF2F266F1A1EF5820B5A4DC1" name="us-gaap:OperatingLeaseExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company paid </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23310740e736-wk-Fact-CDFBD572792F40DF533DF58597568EE9" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for amounts included in the measurement of operating lease liabilities and recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23310740e740-wk-Fact-F63CD3F91A2157E56376F58628C0D2FA" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of&#160;right-of-use assets and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23310740e745-wk-Fact-7A8F1CC741F0352DDED95E4386412FDB" name="us-gaap:PaymentsForTenantImprovements" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of tenant improvements paid through lease incentives in exchange for new operating lease liabilities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commitments under finance leases are not significant.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-A543583BC7CCFC50A412F11A0EF14EC5-0-wk-Fact-1C5B981E8951A61A6B0DF11A45D68C19" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to operating leases was as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.270955165692%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except year and discount rate amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU asset</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e812-wk-Fact-4BD6B73A59B6BF695169F646B8B5F75E" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of the operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e863-wk-Fact-EE5C5AABDF3F3EA76797F04F5FF883CB" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current portion of the operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e883-wk-Fact-27EEB08844CA532CFF47F051C35D6512" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e913-wk-Fact-92260A302B4863A3D563F12FFDA892AC" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease terms (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d23310740e959-wk-Fact-7D97FD268F4F05DE5AFBF12FFED0ED72" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q4" format="ixt-sec:duryear">18.2</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e984-wk-Fact-6779B3EDECC548CC76A6F13000883DCD" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q4" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">13.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-D3FC531F0F6DA798EC50F11D3821DC08-0-wk-Fact-25D54E1B374D29E9D9ABF11D7103272B" escape="true"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the future minimum operating lease payments were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.22807017543859%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1065-wk-Fact-591FBE268DBA647D41D5F13193B50A99" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1085-wk-Fact-AB6E9B99A110471BADCEF1319461F873" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,787</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1110-wk-Fact-81BAD9407374C6757E17F13195030868" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1135-wk-Fact-A1B02EB6AFFA835280E2F13195AC74FC" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1160-wk-Fact-9F141E82640B9AA6C329F131967D4107" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1185-wk-Fact-E50DD1740E38C0C8BFE4F131974744BB" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">163,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1210-wk-Fact-5DD7018D8FA4A3855DA7F1319860F344" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">215,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less lease incentives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23310740e1235-wk-Fact-3A0CD3ACD441D14DCF71F13199CC8FAE" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,939</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Less imputed interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23310740e1261-wk-Fact-70C93D3BE79A79F6D9AC7881F867184F" name="fold:LesseeOperatingLeaseLiabilityTenantIncentives" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">125,982</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1292-wk-Fact-92260A302B4863A3D563F12FFDA892AC" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="TextSelection-25093EA098ABF712041F6B8C2FEFB829-0-wk-Fact-B43E3320C99BF7745A656B8C2FCBBE62" continuedAt="TextSelection-25093EA098ABF712041F6B8C2FEFB829-1" escape="true"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the future minimum operating lease payments were as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.64327485380117%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1367-wk-Fact-73D409374FA0CC967FD9F128C84B1614" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1387-wk-Fact-2A97566038DAD5A155B6F128DA6A916E" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1412-wk-Fact-A9C9398B779ABA0F3319F128E7BB9DB4" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,560</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1437-wk-Fact-1723A298EF75122D5B59F12900796ED3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1462-wk-Fact-02B2FFB3F7339C92583DF12947D5C0F8" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,611</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1487-wk-Fact-AF2EE63D3DE760C13D6FF1298A823CB1" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23310740e1517-wk-Fact-27BE5FEC2F3FF19B55FBF129EA73D302" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">114</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-9BEBABECF6BAC46825B16B8C2FEF8841-2"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-25093EA098ABF712041F6B8C2FEFB829-1"></ix:continuation>Rent expense, including fees for utilities and common area maintenances under ASC 840 for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23310740e1538-wk-Fact-2BD4BE44BD0445A1A8686B8C2FCD7E2E" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23310740e1542-wk-Fact-2848F407D0CABB88D4E36B8C2FD65D1C" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div><a id="s0352528E806752F5864C694312E2CD0E"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">14. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-65F2DCD53CF91B74D4EA6B8C2FF0FEE0-0-wk-Fact-16DA4D35CA075587B05D6B8C2FD551A5" continuedAt="TextSelection-65F2DCD53CF91B74D4EA6B8C2FF0FEE0-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-65F2DCD53CF91B74D4EA6B8C2FF0FEE0-1" continuedAt="TextSelection-65F2DCD53CF91B74D4EA6B8C2FF0FEE0-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="TextSelection-771DFF68B38622C834CF6B8C2FEFEA06-0-wk-Fact-985F98D9CF548B9883EC6B8C2FD5EEBC" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For financial reporting purposes, income (loss) before income taxes includes the following components:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e890-wk-Fact-1B62C5856E55328328816B8C2FC97DDE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">393,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e910-wk-Fact-8B0AE47788918F08CACD6B8C2FD1BE99" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">309,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e931-wk-Fact-D0C3B7C2B914CE0D273D6B8C2FD1DE3A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">440,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e952-wk-Fact-932DAB2A1D500F07D5F86B8C2FCF5C1E" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e971-wk-Fact-B90A662EF7133EEC0A8B6B8C2FCB59FB" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">39,906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e991-wk-Fact-BE264FA86A2454CC262E6B8C2FCDC0DE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1023-wk-Fact-39CB3DA7D0A5C09EE4246B8C2FAA0F9E" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">355,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1043-wk-Fact-815848D01C88BA2101DF6B8C2FA91CFB" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">349,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1064-wk-Fact-5152D2C671953CAC01836B8C2FB75F3C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">449,121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-698CDBEFF926BED040EA6B8C2FF0DA4E-0-wk-Fact-47B4792A80FE22F167F16B8C2FD702F8" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following were the components of income tax expense (benefit) for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1268-wk-Fact-3017EF3DD467528D67AF6B8C2FDBCB48" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1287-wk-Fact-6C2D8462C980510AC0566B8C2FDCE563" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1307-wk-Fact-CB91E7F12EA4CB174C106B8C2FD545BD" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1327-wk-Fact-50B90BCB2AFD53BFB66D6B8C2FD682B4" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1346-wk-Fact-E1693786881D256DA3FA6B8C2F5B3EE5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1365-wk-Fact-BB8CECA721E3E6027B126B8C2FD841D2" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1391-wk-Fact-DBADAC90D2EC97FDAD926B8C2F5E017F" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,877</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1410-wk-Fact-1C1DD8ABDEFDD908660C6B8C2FDF0EAB" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1430-wk-Fact-CD86F9F4B51EC5932EF06B8C2FD4675E" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1523-wk-Fact-F333304494EAD4D897EE6B8C2FD38244" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">984</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1543-wk-Fact-89FF48B82C2CA89C73886B8C2FD7FB6B" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1562-wk-Fact-B215553E2FCCBF8A6AF26B8C2FD922BB" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">150,015</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1589-wk-Fact-15848181ADC01F902A1C6B8C2FD52239" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1609-wk-Fact-7D11EC0D3A1915066F166B8C2FDA8E08" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1628-wk-Fact-EA38FC150B6EF7F2FF5B6B8C2FD37F16" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">17,389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1655-wk-Fact-0C3143F67700DA4E00C66B8C2FDB0965" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1674-wk-Fact-2E3194BADBBB0BF1202A6B8C2FD2FA1D" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1693-wk-Fact-48C7A957E9810B44842D6B8C2FD10E61" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1724-wk-Fact-3855EEFA4DD61B26A72F6B8C2FB86431" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1743-wk-Fact-CECB6F05ED5CE81CFF1C6B8C2FAEB61F" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1764-wk-Fact-741CBE90FE3A6560C1116B8C2FAF165A" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">165,119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-0DA40F01E329828AAF426B8C2FEF3BDD-0-wk-Fact-A222ECB5C7730250D4DC6B8C2FDCEFE0" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the statutory tax rates and the effective tax rates for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1928-wk-Fact-AA8D933C503D7D7165636B8C2FD4A315" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1943-wk-Fact-561B46DF8FA1E7FED5E66B8C2FCFB688" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1958-wk-Fact-96B79A3A3C4965C6A0276B8C2FC64480" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2017Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e1979-wk-Fact-164FD407967FBCA3DD686B8C2FD28581" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e1993-wk-Fact-3FD17995448F7480EA9D6B8C2FCD40A9" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e2008-wk-Fact-7C20802DC01281574AF26B8C2FC7E5F2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nondeductible IPR&amp;D</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2029-wk-Fact-8F7E3CFFA94DF87F3FE06B8C2FC490C6" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2043-wk-Fact-4FA00169E143BF5391EB6B8C2FC363D1" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e2057-wk-Fact-415DE3AFDD493DDEFB686B8C2FD01458" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2078-wk-Fact-67ECD3733E5D98D402076B8C2FCB709C" name="fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2092-wk-Fact-788C06563B436D5D60F56B8C2FCFF233" name="fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e2106-wk-Fact-16AE9D2876599208D8D86B8C2FC9308D" name="fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e2127-wk-Fact-7D440115F0147CB9A7F46B8C2FD37B00" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e2142-wk-Fact-AD6D85479F5FED16961F6B8C2F5E52DA" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e2157-wk-Fact-D02D0036049D0B857DA96B8C2F5B11A2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign income tax rate differential</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2178-wk-Fact-2CFBEB4DCC5752AD46086B8C2FCA315D" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2192-wk-Fact-6E3E3F30BDC57F643AD36B8C2FD10007" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2206-wk-Fact-76C2D18A6D13ECC997A56B8C2FC56659" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of 2017 Act</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2226-wk-Fact-85FB580CF826B39C80466B8C2FCC87E7" name="fold:EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2240-wk-Fact-FE60471FEF74411B8D946B8C2FCE6667" name="fold:EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2254-wk-Fact-F75F5F279AB3842549066B8C2FD022AE" name="fold:EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nondeductible debt conversion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e2274-wk-Fact-1FCC5BDCC1952E3BE704806C4173AFE3" name="fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2289-wk-Fact-688BF567C2646EDAD639806C4168A472" name="fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2303-wk-Fact-A34EEB2C5B9F045F0F89806C417EF5C8" name="fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2323-wk-Fact-882E73CA7F560274E3066B8C2FCA19D6" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2337-wk-Fact-27340BF2D1ACFC4BCB206B8C2FD65A3E" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2351-wk-Fact-07C09D60DC4DC21E93B76B8C2FC69DD0" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2372-wk-Fact-4D3F7D15C65F60EADF7D6B8C2FC77390" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2386-wk-Fact-D6422EC00323B691969D6B8C2FC89FB5" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e2400-wk-Fact-12F92DFE772AF0C93E2A6B8C2FC9D518" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2421-wk-Fact-7B7933CF781616BCA3846B8C2FC89D1A" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2436-wk-Fact-34F69AA6AD377C39C8AC6B8C2FCEDDE8" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e2451-wk-Fact-A0D3CAA093EF1472D29C6B8C2FD51D25" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2465-wk-Fact-33E7A91CB3328DEE01746B8C2FD90E91" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="D2017Q4Dec22-Dec22" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">115</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-65F2DCD53CF91B74D4EA6B8C2FF0FEE0-2" continuedAt="TextSelection-65F2DCD53CF91B74D4EA6B8C2FF0FEE0-3"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;">, requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the Tax Act's provisions, the SEC staff issued SAB&#160;118, which allows companies to record the tax effects of the Tax Act on a provisional basis based on a reasonable estimate, and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available. The measurement period ends when a company has obtained, prepared, and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from enactment. The Tax Act did not have a material impact on the Company's financial statements because its deferred temporary differences are fully offset by a valuation allowance. The Company did not have any significant offshore earnings from which to record the mandatory transition tax. During 2018 the Company operated in a consolidated loss position in its foreign operations and did not have a one-time tax on accumulated earnings of foreign subsidiaries.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2017, the Company provisionally recorded certain impacts of the Tax Act including the adjustment to our net deferred tax liability arising from the reduction in the federal tax rate as well as the impact of mandatory deemed repatriation. Adjustments to these provisional amounts that we recorded in 2018 did not have a significant impact on the Company's Consolidated Financial Statements. The Company's accounting for the effects of the enactment of the Tax Act are now complete.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded an income tax expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321069e2485-wk-Fact-D83C88EBB3E6BADEBCAC806D686FF67A" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2019 for taxes in foreign jurisdictions and a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321069e2489-wk-Fact-1637E1A3A2B5DF3468835B1107EF58C6" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> tax benefit in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> for taxes in U.S. federal and state jurisdictions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company did not recognize interest or penalties related to income tax during the period ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and did </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2504-wk-Fact-539A8AA3AF92ACCCD7266B8C2FD5A00D" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">t accrue for interest or penalties as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company does </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2512-wk-Fact-C154AE221CAF6FD46CB66B8C2FDB8126" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">t have an accrual for uncertain tax positions as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Tax returns for years 2015 through 2018 are open to examination by tax authorities. The Company is also subject to examination in any period for which it has net operating losses.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="TextSelection-F1B00804A46C6642C9D76B8C2FF08723-0-wk-Fact-63A77C6A554A8726F1E96B8C2FDC9723" continuedAt="TextSelection-F1B00804A46C6642C9D76B8C2FF08723-1" escape="true">The significant components of the deferred tax assets and liabilities are as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F1B00804A46C6642C9D76B8C2FF08723-1"><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intellectual property</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2702-wk-Fact-771D2CDFCE34CC0AC0606B8C2F73CBE9" name="fold:DeferredTaxAssetsIntellectualProperty" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2721-wk-Fact-7AB49B04AEB9AC387DE16B8C2F713AA9" name="fold:DeferredTaxAssetsIntellectualProperty" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization/depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2741-wk-Fact-950FDD1C1EE4E7389CC66B8C2F702ADD" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,329</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2760-wk-Fact-915D6DC834273BF367F86B8C2F72FA30" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research tax credit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2785-wk-Fact-8D965747E3F38262C59D6B8C2F6E870E" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">141,669</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2804-wk-Fact-E27AC989C5FB9A9D8F1A6B8C2F716E4E" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">96,509</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carry forwards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2829-wk-Fact-76AD0CD7000D695A7EA76B8C2F717666" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">286,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2848-wk-Fact-4BDFB5A080BCD05C48836B8C2F6E4118" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">248,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred reimbursement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2873-wk-Fact-50349FE870E9C5CB95746B8C2F6C3D2F" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2892-wk-Fact-4D676B30ECD5F6FF4F066B8C2F692AA1" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash stock issue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2917-wk-Fact-6E3FB4479B4A22F6CD0F6B8C2F705F6E" name="fold:DeferredTaxAssetsNonCashStockIssueNonCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2936-wk-Fact-1E0E903D7A04E69D55A26B8C2F6E0E1A" name="fold:DeferredTaxAssetsNonCashStockIssueNonCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest carry forward limitation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2961-wk-Fact-0F35B586F2FC4A5519A86B8C2F70576D" name="fold:DeferredTaxAssetsInterestCarryforwardLimitation" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e2980-wk-Fact-98D49B3AEBF4B7BDC6DC6B8C2F6D639F" name="fold:DeferredTaxAssetsInterestCarryforwardLimitation" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e3005-wk-Fact-3F7781D712A988179C736B8C2F6EE5E0" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e3024-wk-Fact-3CF879BE61D241C968FE6B8C2F73846D" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e3050-wk-Fact-7C672B227C93287DA1826B8C2F69B385" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">516,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e3069-wk-Fact-E4B1427FF2855D9AC6E86B8C2F702768" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">430,113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business acquisition</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3140-wk-Fact-B68C0F160AC9B55A4C526B8C2F702690" name="fold:DeferredTaxLiabilitiesBusinessAcquisition" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3160-wk-Fact-8A9D7B8D0E07FC0B6C656B8C2F6DB123" name="fold:DeferredTaxLiabilitiesBusinessAcquisition" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3186-wk-Fact-00C3B260231CE4B058D86B8C2F6AAEAF" name="fold:DeferredTaxLiabilitiesRoyaltyPayable" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3206-wk-Fact-46CA7336BAB2A5172E006B8C2F6F41A3" name="fold:DeferredTaxLiabilitiesRoyaltyPayable" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3232-wk-Fact-BF486A9101D6A25F29A56B8C2F6F68E7" name="fold:DeferredTaxLiabilitiesConvertibleNotes" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3252-wk-Fact-F4808C0C2D06E6CE0A806B8C2F6C4037" name="fold:DeferredTaxLiabilitiesConvertibleNotes" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Advanced R&amp;D payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3278-wk-Fact-6DDC655A3F21268CF4F26B8C2F6B6954" name="fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,611</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3298-wk-Fact-7999CD8A28AF3221C2CE6B8C2F720BA4" name="fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3324-wk-Fact-7B40FD860DAC7E15C795806E1FE12A58" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e3344-wk-Fact-E283FCF0E2951C88FDB3806E1FF29C24" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e3369-wk-Fact-5680E77C94D4F61428266B8C2F776DBE" name="fold:DeferredTaxAssetsLiabilitiesGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">461,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23321069e3388-wk-Fact-8604C4990F7F8F1628B66B8C2F707856" name="fold:DeferredTaxAssetsLiabilitiesGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">356,540</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: valuation allowance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3413-wk-Fact-C8BD887FCE88B9FA83966B8C2F6DC6A8" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">466,357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3433-wk-Fact-F7384C970602CB88EB406B8C2F70DEBA" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">363,005</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3464-wk-Fact-7D8351087B8D88CB6E596B8C2F71ED31" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23321069e3484-wk-Fact-EFD986F5DD4DD015506E6B8C2F6936D6" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">116</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-65F2DCD53CF91B74D4EA6B8C2FF0FEE0-3"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded valuation allowances of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321069e3506-wk-Fact-54D053EE631F70BD30F16B8C2FDADEA9" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">466.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321069e3510-wk-Fact-1D727B5C50080A1FA10F6B8C2FD825BE" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">363.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, representing an increase in the valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321069e3514-wk-Fact-AA5615B419AB3FE0870C6B8C2FDF75B7" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D that may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had federal, state, and foreign net operating loss carry forwards ("NOLs") of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321069e3530-wk-Fact-86A1268CE690F76D28A66B8C2FD4B823" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,036</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321069e3534-wk-Fact-878E6FA11354F78BD9AA6B8C2FDDA479" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">897.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321069e3538-wk-Fact-2BFF22EAF0794277BA446B8C2FD60226" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the 2017 Tax Act.&#160;Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> will expire in 2029 through 2039. The foreign NOLs are subject to differing expirations beginning in 2026. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended ( the "Code") as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past and could occur again in the future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership some of which are outside our control. We completed a detailed study of our NOLs and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on our ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also has research and experimentation and orphan drug credit carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321069e3549-wk-Fact-BA9478FDF0274A24C5CE6B8C2FD7CCF4" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="FI2019Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23321069e3553-wk-Fact-CFF6089AA80D3E0AA0A46B8C2FDB1AF7" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="FI2019Q4_us-gaap_TaxCreditCarryforwardAxis_fold_OrphanDrugTaxCreditCarryforwardMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">114.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which will expire in the years 2021 through 2039. Deferred tax assets for these carryforwards are subject to a full valuation allowance.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">117</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAA7C9305097C56B58DB3BA8D5E8062A9"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">15. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-1497BDC4FACD91DB9DC36B8C2FF0D9AE-0-wk-Fact-6CC02298C5A1E64B5CDE6B8C2F8B3CE9" continuedAt="TextSelection-1497BDC4FACD91DB9DC36B8C2FF0D9AE-1" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1497BDC4FACD91DB9DC36B8C2FF0D9AE-1" continuedAt="TextSelection-1497BDC4FACD91DB9DC36B8C2FF0D9AE-2"><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Penn</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, the Company expanded its gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDD and one additional undisclosed rare metabolic disorder. </span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company further expanded the collaboration from three to six programs for rare genetic diseases and now includes specifically: NPC, MPS IIIB, as well as a next generation program in MPS IIIA. This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. Under the expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314361e721-wk-Fact-914A7A9FA001D05867236B8C2F8FED2D" name="fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication" contextRef="I2018Q3Oct31_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">86.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country- by-country basis. The Company will provide </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314361e725-wk-Fact-13AF9A209FE6B6D3B7AE5A2F899F792B" name="fold:CollaborationAgreementAnnualContributionByCompany" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> each year during the five-year agreement to fund the discovery research program. In connection with the collaboration agreement, the Company made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314361e729-wk-Fact-5AA80ED9B4B64A5966D46B8C2F8A4025" name="fold:PaymentsForCollaborativeArrangement" contextRef="D2018Q4Oct_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash to Penn that was expensed to research and development expense in the Consolidated Statements of Operations. </span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">GlaxoSmithKline</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2013, Amicus entered into the Revised Agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus has obtained global rights to develop and commercialize Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between Amicus and GSK in July 2012 ("Expanded Collaboration Agreement"). Under the terms of the Revised Agreement, there was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314361e745-wk-Fact-4915FFA43553298649466B8C2F8CF22D" name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="D2013Q4Nov1-Nov30_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment from Amicus to GSK. For Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314361e753-wk-Fact-91880EAA908876D0BDFA6B8C2F8C056E" name="fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" contextRef="I2013Q4Nov30_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, as well as tiered royalties in the mid-teens in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23314361e757-wk-Fact-97E44BF3AC9B2DE7751D6B8C2F8EE763" name="fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" contextRef="D2013Q4Nov1-Nov30_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember" unitRef="number" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> major markets outside the U.S. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314361e766-wk-Fact-964291FBFF64F987C8E06B8C2F8CDFAC" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of royalty expenses under the revised agreement with GSK.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the Revised Agreement, GSK will no longer jointly fund development costs for all formulations of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In evaluating the impact of both the Expanded Collaboration Agreement and the Revised Agreement, the Company applied the accounting guidance regarding the impact of potential future payments it may make in its role as a vendor (i.e.,&#160;Amicus) to its customer (i.e.,&#160;GSK) and evaluated if these potential future payments could be a reduction of revenue from GSK. If the potential future payments to GSK are as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a payment for an identifiable benefit, and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the identifiable benefit is separable from the existing relationship between the Company and GSK, and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the identifiable benefit can be obtained from a party other than GSK, and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Company can reasonably estimate the fair value of the identifiable benefit,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">then the potential future payments would be treated separately from the collaboration and research revenue. However, if all these criteria are not satisfied, then the potential future payments are treated as a reduction of revenue.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, the Company did not believe that, for accounting purposes, the new U.S. licensing rights to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> obtained from GSK under the Expanded Collaboration Agreement, nor the ex U.S. licensing rights to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> obtained from GSK under the Revised Agreement, represented a separate, identifiable benefit from the licenses in the Original Collaboration Agreement entered into between Amicus and GSK in 2010. The contingent amounts payable to GSK were not sufficiently separable from GSK's original license and the research and development reimbursements such that Amicus could not have entered into a similar exchange transaction with another party. Additionally, the Company cannot reasonably estimate the fair value of the worldwide licensing rights to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">118</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1497BDC4FACD91DB9DC36B8C2FF0D9AE-2" continuedAt="TextSelection-1497BDC4FACD91DB9DC36B8C2FF0D9AE-3"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that the potential future payments to GSK would be treated as a reduction of revenue and that the total amount of revenue to be received under the arrangement is no longer fixed or determinable as the contingent milestone payments are subject to significant uncertainty.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result, the Company no longer recognized any of the upfront license fees and premiums on the equity purchase from GSK until such time as the arrangement consideration becomes fixed or determinable, because an indeterminable amount may ultimately be payable back to GSK. These amounts (the balance of the unrecognized upfront license fee and the premium on the equity purchases) are classified as deferred reimbursements on the balance sheet. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, under the GSK collaboration agreements, we paid </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314361e841-wk-Fact-F6607C3E645005EFD9006B8C2F8BACF4" name="fold:PaymentsForCollaborativeArrangement" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in sales-based milestones. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized another </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314361e849-wk-Fact-20E49CFEE805483AE05D5A2C20D3C0EA" name="fold:AccruedPaymentsForCollaborativeArrangement" contextRef="FI2019Q4_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for sales-based milestones that were met, invoiced and recorded in accounts payable, accrued expenses and other current liabilities and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314361e853-wk-Fact-E23A0085D26708E176FC6B8C2F8CCAB3" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" contextRef="FI2019Q4_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as deferred reimbursements in the Consolidated Balance Sheets. Additionally, the Company recognized a liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d23314361e858-wk-Fact-F8B8CF84E363BE4B910B6B8C2F8E80C9" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q4_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to royalties payable to GSK in accounts payable and accrued expenses in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recognition of Research Revenue was also affected by the determination that the overall total arrangement consideration was no longer fixed and determinable, despite the fact that the research activities continued and that the research expense reimbursements by GSK to Amicus were received as the research activities related to the reimbursement had been completed. Therefore, the research reimbursements from GSK were recorded as deferred reimbursements on the balance sheet and would not be recognized until the total arrangement consideration becomes fixed and determinable.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-1497BDC4FACD91DB9DC36B8C2FF0D9AE-3">As a result, all revenue recognition was suspended until the total arrangement consideration would become fixed and determinable. In addition, future milestone payments made by the Company will be applied against the balance of this deferred reimbursements account. Revenue recognition for research expense reimbursements, the original upfront license fee, and the equity premiums will resume once the total arrangement consideration becomes fixed and determinable which will occur when the balance of the deferred reimbursements account is sufficient to cover all the remaining contingent milestone payments.</ix:continuation> </span></div><div><a id="s3BF1C10E541E5F258A760E9C920F1A06"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">16. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-1183A685636062BAB9C06B8C2FF0EE82-0-wk-Fact-A6689DA7FF2D8776B4446B8C2F5CF69E" continuedAt="TextSelection-1183A685636062BAB9C06B8C2FF0EE82-1" escape="true">Basic and Diluted Net Loss per Common Share</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1183A685636062BAB9C06B8C2FF0EE82-1" continuedAt="TextSelection-1183A685636062BAB9C06B8C2FF0EE82-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-AB7A91445DFDCF58CA866B8C2FF0E7D6-0-wk-Fact-740F45CCD5AFF3C9DD166B8C2F5F52F2" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23322176e957-wk-Fact-A12C3F3D7CBD330E74976B8C2FA8F19A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">356,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23322176e977-wk-Fact-EE3BD9FBA254D383B3646B8C2FAB60A5" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">348,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23322176e998-wk-Fact-7624C92CE3E7F08A06F66B8C2FB8EA12" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">284,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1086-wk-Fact-D335D27D9B7976C780C46B8C2FBC3C1B" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">240,421,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1105-wk-Fact-C04A907E3EAA92AB22546B8C2FA66E6E" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">185,790,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1124-wk-Fact-FD8F09C37B719A0A7D836B8C2FBD8BC0" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">153,355,144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1147-wk-Fact-451D251E4BC847CA86296B8C2FD73DCA" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">462</ix:nonFraction> thousand</span></span><span style="font-family:inherit;font-size:10pt;"> potential common shares outstanding as a result of the Convertible Debt that were excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">119</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-9EE70B85AEE59FC60E9A6B8C2FF09E4A-0-wk-Fact-A8F8F06FFA1D7CA058756B8C2F5FC059" escape="true"><ix:continuation id="TextSelection-1183A685636062BAB9C06B8C2FF0EE82-2"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1291-wk-Fact-B0F3B94DBA13422B52666B8C2FD65629" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">16,724</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1305-wk-Fact-6AC75A5491E336EAC2576B8C2F5E631A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15,810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1319-wk-Fact-DC9931E8B30A4242E7926B8C2FDDCB18" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1339-wk-Fact-451D251E4BC847CA86296B8C2FD73DCA" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1353-wk-Fact-B543501FDD0A78AE88E96B8C2FDD6F77" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">40,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1367-wk-Fact-B5B07445FBA35699ED2D6B8C2FDF0481" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">40,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding warrants, convertible to common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1387-wk-Fact-068429365532503376166B8C2FD39D01" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,555</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1401-wk-Fact-6C7EDD7C7088D8F97D956B8C2F88392A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,657</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1415-wk-Fact-3B34FC38F89A67D8B0436B8C2FD7D577" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,110</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1435-wk-Fact-A45DC495EFE4FF7EC4246B8C2F736566" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,792</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1449-wk-Fact-01E949B14758B2D4EBFB6B8C2F5ECE82" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,712</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1463-wk-Fact-1B83CD77F3BA4BA7F0346B8C2FD7D269" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested restricted stock units, unissued</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1483-wk-Fact-6988649409D0E4C870336B8C2FD2BE6A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1497-wk-Fact-BDCD3D04D2C4C5D02E8C6B8C2F749E7B" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1511-wk-Fact-FA31F23D13B5039940196B8C2FD50BDB" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total number of potentially issuable shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1531-wk-Fact-16DC22FF590D0AF5E1E96B8C2F5E7900" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">25,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1545-wk-Fact-1BBAF4B2EC55279EA9736B8C2FDDD346" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">63,120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23322176e1559-wk-Fact-1F9B313FF09CAF41A2FE6B8C2F7FDF04" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">61,766</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="s12C5036634045BB09E34F453B9B99BDA"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">17. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="TextSelection-988223644A840CFBF49B6B8C2FF071B7-0-wk-Fact-53E922A3BE245411F5D06B8C2FD86F78" continuedAt="TextSelection-988223644A840CFBF49B6B8C2FF071B7-1" escape="true">Selected Quarterly Financial Data (Unaudited)</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="TextSelection-A29B1851B6E29EE68FC46B8C2FF1AE1F-0-wk-Fact-91EB35B5A4BEBFF93BCF6B8C2FD84F9C" escape="true"><ix:continuation id="TextSelection-988223644A840CFBF49B6B8C2FF071B7-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarters Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands except per share data)</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23323377e1019-wk-Fact-44902E0097C5CEB0FFE28DFAB213BFF8" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23323377e1038-wk-Fact-7024DCA7E52B12BBE1358DFAB1E96C72" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,130</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23323377e1058-wk-Fact-1EE24E38CFD4F00279558DFAB1FD2307" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23323377e1077-wk-Fact-4FAD3164B41E81BD56BB8DFAB1F98B87" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1102-wk-Fact-4F6C6F3770BFDE64B43A6B8C2F756313" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">120,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1122-wk-Fact-F1822C751D7B6D2B708F6B8C2F72319B" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1143-wk-Fact-5F683393F42F9BD1ED856B8C2F780502" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1163-wk-Fact-1C72C39461CD96AFF4D06B8C2F767482" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">89,729</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share&#160;</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1191-wk-Fact-FA5B15E085FC0D8F948E6B8C2F7627C8" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1211-wk-Fact-A0563B7683B60421C55D6B8C2F75A38D" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1232-wk-Fact-DB6B515B1B39FB7965F26B8C2F786C03" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1252-wk-Fact-CA126464B24305CA1D4E6B8C2F76B473" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23323377e1365-wk-Fact-A8CE90D84DB95BC4D8AA8DFAB2061F50" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23323377e1384-wk-Fact-88A9DA73B5C16B9DCFD68DFAB20AB288" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23323377e1404-wk-Fact-17F49E2BE4EED94867278DFAB20276F5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d23323377e1423-wk-Fact-8E5F1AEF9E0BD318EB388DFAB20FE127" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1448-wk-Fact-050BF3C54D8FEDC1ED1E6B8C2F779697" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">49,916</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1468-wk-Fact-46E2120879A46C1469D76B8C2F73ED0D" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1489-wk-Fact-CDE8CD41A6B379BC80566B8C2F7782B4" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">159,163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1509-wk-Fact-6A3E43D826425F080B096B8C2F75F20D" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">78,083</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share&#160;</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1537-wk-Fact-7E5BBD5C2A97C85F922C6B8C2F764B3C" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1557-wk-Fact-823B8B225542D8FCB6136B8C2F779A0C" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1578-wk-Fact-7F6FF23300FB091E830D6B8C2F744A59" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d23323377e1598-wk-Fact-3E6D2F9AE4C31A487F026B8C2F77F26F" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:inherit;font-size:9pt;">Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.</span></div></ix:continuation></ix:nonNumeric><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">120</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amicus Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div><a id="sEE35BFFFF353513E849894B4C79ABA8B"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><a id="sC84CA4FDB7735C42B193939D5F0018E6"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9A.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">CONTROLS AND PROCEDURES.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The term "disclosure controls and procedures," as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no changes in our internal controls over financial reporting during the fourth quarter of the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Management's Report on Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this section which includes the "Management's Report on Consolidated Financial Statements and Internal Control over Financial Reporting" and the "Report of Independent Registered Public Accounting Firm" are incorporated by reference from "Item&#160;8. Financial Statements and Supplementary Data."</span></div><div><a id="s50143FCB25A65C42A1AD62541FF181E3"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9B.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">OTHER INFORMATION.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">121</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s422BA29919465D8EA93C3144109BA62C"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain information required by Part&#160;III is omitted from this Annual Report on Form&#160;10-K as we intend to file our definitive proxy statement for our </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> annual meeting of stockholders, pursuant to Regulation&#160;14A of the Securities Exchange Act, not later than 120&#160;days after the end of the fiscal year covered by this Annual Report on Form&#160;10-K, and certain information to be included in the proxy statement is incorporated herein by reference.</span></div><div><a id="s9137634C9ACF582D88C6CE54C12E70DD"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;10.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DIRECTORS, EXECUTIVE OFFICERS OF THE REGISTRANT AND CORPORATE GOVERNANCE.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference from the Proxy Statement under the caption "Management," "Section&#160;16(a) Beneficial Ownership Reporting Compliance," and "Proposal No.&#160;1&#160;&#8212; Election of Directors"</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have adopted a Code of Business Ethics and Conduct for Employees, Executive Officers and Directors that applies to our employees, officers and directors and incorporate guidelines designed to deter wrongdoing and to promote the honest and ethical conduct and compliance with applicable laws and regulations. In addition, the code of ethics incorporates our guidelines pertaining to topics such as conflicts of interest and workplace behavior. We have posted the text of our code on our website at </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">www.amicusrx.com</span><span style="font-family:inherit;font-size:10pt;"> in connection with "Investors/Corporate Governance" materials. In addition, we intend to promptly disclose (1)&#160;the nature of any amendment to our code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions and (2)&#160;the nature of any waiver, including an implicit waiver, from provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date the waiver on our website in the future.</span></div><div><a id="s1BCF264D0C1553D0BCA3C09F781BC606"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;11.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EXECUTIVE COMPENSATION.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference from the Proxy Statement under the caption "Compensation Discussion and Analysis."</span></div><div><a id="s4FDEA3A8BE265ADE8A2B00BE72D4C7BA"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;12.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference from the Proxy Statement under the captions "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" and "Equity Compensation Plan Information."</span></div><div><a id="sE6385A5273545FFDACF9311A2008D47E"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;13.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference from the Proxy Statement under the captions "Certain Relationships and Related Transactions," "Director Independence," "Committee Compensation and Meetings of the Board of Directors," and "Compensation Committee Interlock and Insider Participation."</span></div><div><a id="s8C6C85D20121543FBA4EBC0D5ADD73D2"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;14.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">PRINCIPAL ACCOUNTING FEES AND SERVICES.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference from the Proxy Statement.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">122</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s77C3081FFA25545D8D6C64CA345AD056"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</span></div><div><a id="sDAF9C920F6345F51AB2FC0381E899555"></a></div><div style="line-height:120%;padding-bottom:16px;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;15.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EXHIBITS, FINANCIAL STATEMENT SCHEDULE</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidated Financial Statements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Consolidated Financial Statements are filed as part of this report.</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2. Consolidated Financial Statement Schedules</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All schedules are omitted because they are not required or because the required information is included in the Consolidated Financial Statements or notes thereto.</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">3. Exhibits </span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporated by Reference</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">to SEC Filing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed Exhibit Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed with this</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form&#160;10-K</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465914009064/a14-5772_1ex2d1.htm"><span style="font-family:inherit;font-size:10pt;">Agreement and Plan of Merger, dated November&#160;19, 2013, by and among Amicus Therapeutics,&#160;Inc., CB Acquisition Corp., Callidus BioPharma,&#160;Inc., and Cuong&#160;Do</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/12/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465915068317/a15-20301_1ex2d2.htm"><span style="font-family:inherit;font-size:10pt;">Amendment to Agreement and Plan of Merger, dated September&#160;30, 2015, by and among the Registrant, Titan Merger Sub Corp. and Scioderm,&#160;Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9/30/2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">+2.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916131264/a16-14342_2ex2d1.htm"><span style="font-family:inherit;font-size:10pt;">Agreement and Plan of Merger, dated July&#160;5, 2016, by and among MiaMed,&#160;Inc., the Registrant and Minervas Merger Sub,&#160;Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7/6/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">+2.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465918058298/a18-35026_1ex2d1.htm#Exhibit2_1_042023"><span style="font-family:inherit;font-size:10pt;">Agreement and Plan of Merger, dated as of September 19, 2018, by and among Amicus Therapeutics, Inc., Columbus Merger Sub Corp., Celenex, Inc. and Shareholder Representative Services LLC, solely in its capacity as the Shareholders&#8217; Representative</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9/25/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000119312512085717/d299897dex31.htm"><span style="font-family:inherit;font-size:10pt;">Restated Certificate of Incorporation of the Registrant.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/28/2012</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307006223/y32191a1exv3w4.htm"><span style="font-family:inherit;font-size:10pt;">Restated By-laws of the Registrant.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1/A (333-141700)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4/27/2007</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465915044580/a15-13880_1ex3d1.htm"><span style="font-family:inherit;font-size:10pt;">Certificate of Amendment to the Registrant's Restated Certificate of Incorporation, as amended.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6/10/2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465918039068/a18-15070_1ex3d1.htm#Exhibit3_1_045312"><span style="font-family:inherit;font-size:10pt;">Certificate of Amendment to the Restated Certificate of Incorporation</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6/8/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307007596/y32191a2exv4w1.txt"><span style="font-family:inherit;font-size:10pt;">Specimen Stock Certificate evidencing shares of common stock</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1 (333-141700)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3/30/2007</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307004755/y32191exv4w2.txt"><span style="font-family:inherit;font-size:10pt;">Third Amended and Restated Investor Rights Agreement, dated as of September&#160;13, 2006, as amended</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1 (333-141700)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3/30/2007</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465915068667/a15-20301_2ex4d1.htm"><span style="font-family:inherit;font-size:10pt;">Form of Warrant, issued on October&#160;1, 2015</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10/1/2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916098580/a16-4879_1ex4d1.htm"><span style="font-family:inherit;font-size:10pt;">Form of Warrant to Purchase Common Stock</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/22/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916130493/a16-14342_1ex4d1.htm"><span style="font-family:inherit;font-size:10pt;">Form of Warrant to Purchase Common Stock</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7/1/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916163271/a16-23115_4ex4d1.htm"><span style="font-family:inherit;font-size:10pt;">Indenture, dated December&#160;21, 2016, by and between the Registrant and Wilmington Trust, National Association</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/21/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916116168/a16-9905_1ex4d7.htm"><span style="font-family:inherit;font-size:10pt;">Form of Indenture</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;S-3ASR</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4/24/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit48descriptionof.htm"><span style="font-family:inherit;font-size:10pt;">Description of the Registrant's securities</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">123</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporated by Reference</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">to SEC Filing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed Exhibit Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed with this</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form&#160;10-K</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307006223/y32191a1exv10w1.txt"><span style="font-family:inherit;font-size:10pt;">2002 Equity Incentive Plan, as amended, and forms of option agreements thereunder</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1/A (333-141700)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4/27/2007</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">+10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000136231009001208/c80039exv10w3.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated License Agreement, dated October, 31, 2008, by and between the Registrant and Mount Sinai School of Medicine of New York University</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/6/2009</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">+10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307004755/y32191exv10w5.txt"><span style="font-family:inherit;font-size:10pt;">Exclusive License Agreement, dated as of June&#160;8, 2005, by and between the Registrant and Novo Nordisk, A/S</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1 (333-141700)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3/30/2007</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307004755/y32191exv10w17.txt"><span style="font-family:inherit;font-size:10pt;">Form of Director and Officer Indemnification Agreement</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1 (333-141700)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3/30/2007</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.17</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012310059110/c02571exv10w2.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated 2007 Director Option Plan and form of option agreement</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6/18/2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307007596/y32191a2exv10w24.txt"><span style="font-family:inherit;font-size:10pt;">2007 Employee Stock Purchase Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S-1/A (333-141700)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5/17/2007</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.24</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916126424/a16-13153_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Management Bonus Program Summary</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6/9/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012311077951/c21575exv10w1.htm"><span style="font-family:inherit;font-size:10pt;">Lease Agreement dated August&#160;16, 2011 between the Registrant and Cedar Brook 3 Corporate Center,&#160;L.P.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8/16/2011</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.9</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465913086132/a13-24764_2ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Securities Purchase Agreement, dated November&#160;20, 2013 by and among the Company and the purchasers identified therein</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11/20/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.10</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465913092766/a13-27232_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Credit and Security Agreement, by and between MidCap Funding III,&#160;LLC, as administrative agent, the Lenders listed in the Credit Facility Schedule thereto, the Registrant, and Callidus Biopharma,&#160;Inc., dated as of December&#160;27, 2013</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/30/2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">+10.11</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000104746914001702/a2218555zex-10_46.htm"><span style="font-family:inherit;font-size:10pt;">Second Restated Agreement, dated November&#160;19, 2013 by and between the Registrant and Glaxo Group Limited</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3/3/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.46</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465914027065/a14-10318_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Amicus Therapeutics, Inc. Restricted Stock Unit Deferral Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4/10/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465914030658/a14-11143_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Employment Agreement dated April&#160;23, 2014, between the Registrant and John&#160;F. Crowley</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4/25/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.14</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916126814/a16-13248_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated 2007 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6/13/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.15</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916152935/a16-20656_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Amicus Therapeutics,&#160;Inc. Cash Deferral Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10/28/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465915030977/a15-10123_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">First Amendment to Credit and Security Agreement by and between MidCap Funding III,&#160;LLC, as administrative agent, the Lenders listed in the Credit Facility Schedule thereto, the Registrant, and Callidus Biopharma, Inc., dated as of April&#160;27, 2015.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4/28/2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.17</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465915068667/a15-20301_2ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Note and Warrant Purchase Agreement by and among the Registrant and the purchasers identified on the signature pages thereto, dated October&#160;1, 2015</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10/1/2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465915064782/a15-19345_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">First Amendment to Lease, dated September&#160;9, 2015, by and between Cedar Brook&#160;3 Corporate Center,&#160;L.P. and the Registrant</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9/14/2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.19</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916105202/a16-6432_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Retention Bonus Letter, dated March&#160;10, 2016, by and between the Registrant and Jay Barth, M.D.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3/15/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916098580/a16-4879_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Note and Warrant Purchase Agreement by and among the Registrant and the purchasers identified on the signature pages thereto, dated February&#160;19, 2016.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/22/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">124</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporated by Reference</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">to SEC Filing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed Exhibit Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed with this</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form&#160;10-K</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.21</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916130493/a16-14342_1ex10d2.htm"><span style="font-family:inherit;font-size:10pt;">Joinder to and Amendment of Note and Warrant Purchase Agreement by and among Amicus Therapeutics,&#160;Inc., Amicus Therapeutics UK Limited, Amicus Therapeutics International Holding&#160;LTD and the purchasers identified on the signature pages thereto, dated as of June&#160;30, 2016</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7/1/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916135418/a16-15792_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Amendment No.&#160;1 to the Amended and Restated Amicus Therapeutics,&#160;Inc. 2007 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7/29/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916141049/a16-17325_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Secondment Letter, dated August&#160;22, 2016 by and between the Registrant and Bradley Campbell</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8/23/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.24</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916163271/a16-23115_4ex10d7.htm"><span style="font-family:inherit;font-size:10pt;">Note Purchase Agreement, dated December&#160;15, 2016, by and among the Registrant, Amicus Therapeutics International Holding&#160;LTD and P&#160;Redmile&#160;Ltd.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/21/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916163271/a16-23115_4ex10d8.htm"><span style="font-family:inherit;font-size:10pt;">Note Purchase Agreement, dated December&#160;15, 2016, by and among the Registrant, Amicus Therapeutics International Holding&#160;LTD and Redmile Capital Offshore Fund,&#160;Ltd.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/21/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.26</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916163271/a16-23115_4ex10d9.htm"><span style="font-family:inherit;font-size:10pt;">Note Purchase Agreement, dated December&#160;15, 2016, by among the Registrant, Amicus Therapeutics International Holding&#160;LTD and Redmile Capital Offshore Fund II,&#160;Ltd.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/21/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.9</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.27</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916163271/a16-23115_4ex10d10.htm"><span style="font-family:inherit;font-size:10pt;">Note Purchase Agreement, dated December&#160;15, 2016, by and among the Registrant, Amicus Therapeutics International Holding&#160;LTD and Redmile Special Opportunities Fund,&#160;Ltd.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/21/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.10</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.28</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916163271/a16-23115_4ex10d11.htm"><span style="font-family:inherit;font-size:10pt;">Note Purchase Agreement, dated December&#160;15, 2016, by and among the Registrant, Amicus Therapeutics International Holding&#160;LTD and Redmile Capital Fund,&#160;LP</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/21/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.11</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.29</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916163271/a16-23115_4ex10d12.htm"><span style="font-family:inherit;font-size:10pt;">Note Purchase Agreement, dated December&#160;15, 2016, by and between Amicus Therapeutics International Holding&#160;LTD and GCM Grosvenor Special Opportunities Master Fund,&#160;Ltd.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/21/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916164572/a16-23950_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">Form of Performance-Based Restricted Stock Unit Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/30/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465918058299/a18-34001_1ex10d1.htm#Exhibit10_1_121933"><span style="font-family:inherit;font-size:10pt;">Loan Agreement, dated as of September 19, 2018, by and among Amicus Therapeutics, Inc., as Borrower, certain subsidiaries of the Borrower, as Guarantors, and Biopharma Credit PLC, as Lender</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9/25/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.32</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000008/exhibit1012.htm"><span style="font-family:inherit;font-size:10pt;">Form of Exchange Agreements Relating to Company's 3.00% Convertible Senior Notes due 2023</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1/24/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.33</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000013/exhibit101.htm"><span style="font-family:inherit;font-size:10pt;">Form of Exchange Agreements Relating to Company's 3.00% Convertible Senior Notes due 2023</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/8/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.34</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000028/exhibit101_updated.htm"><span style="font-family:inherit;font-size:10pt;">Form of Exchange Agreements Relating to Company's 3.00% Convertible Senior Notes due 2023</span></a></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3/13/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">125</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporated by Reference</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">to SEC Filing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed Exhibit Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed with this</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form&#160;10-K</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.35</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000047/exhibit1011.htm"><span style="font-family:inherit;font-size:10pt;">Form of Exchange Agreements Relating to Company's 3.00% Convertible Senior Notes due 2023</span></a></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5/22/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.36</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000052/exhibit1012.htm"><span style="font-family:inherit;font-size:10pt;">Form of Exchange Agreements Relating to Company's 3.00% Convertible Senior Notes due 2023</span></a></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6/19/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.37</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887918000036/exhibit101.htm"><span style="font-family:inherit;font-size:10pt;">Amendment #1 to the Amended and Restated Amicus Therapeutics, Inc. 2007 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/26/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">++10.38</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000024/exhibit1048.htm"><span style="font-family:inherit;font-size:10pt;">Research, Collaboration and License Agreement with The Trustees of the University of Pennsylvania dated October 8, 2018</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form 10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/28/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.48</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.39</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000024/exhibit1049.htm"><span style="font-family:inherit;font-size:10pt;">Separation Agreement with William D. Baird III dated as of February 8, 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form 10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2/28/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.49</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.40</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000039/exhibit101toform10-q2.htm"><span style="font-family:inherit;font-size:10pt;">Form of Call Option Partial Termination</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form 10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5/9/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.41</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000063/a101formofcappedcallte.htm"><span style="font-family:inherit;font-size:10pt;">Form of Capped Call Transaction Termination Agreement</span></a></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form 10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8/8/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">**</sup></span><span style="font-family:inherit;font-size:10pt;">10.42</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000063/a102pennamicus.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated Research, Collaboration &amp; License Agreement, dated May 28, 2019, by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania</span></a></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form 10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8/8/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.43</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000072/exhibit101.htm"><span style="font-family:inherit;font-size:10pt;">Amendment #2 to the Amicus Therapeutics, Inc. Cash Deferral Plan.</span></a></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form&#160;8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12/19/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.44</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1044jfcamendagr.htm"><span style="font-family:inherit;font-size:10pt;">Amendment No. 1 to Employment Agreement dated April 23, 2014 between the Registrant and John F. Crowley</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.45</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1045ellenrosenb.htm"><span style="font-family:inherit;font-size:10pt;">Employment Agreement dated February 18, 2020, between the Registrant and Ellen S. Rosenberg</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.46</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1046bradleycamp.htm"><span style="font-family:inherit;font-size:10pt;">Employment Agreement dated February 18, 2020, between the Registrant and Bradley L. Campbell</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.47</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1047jaybarth-em.htm"><span style="font-family:inherit;font-size:10pt;">Employment Agreement dated February 18, 2020, between the Registrant and Jay Barth, M.D.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.48</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1048daphnequimi.htm"><span style="font-family:inherit;font-size:10pt;">Employment Agreement dated February 18, 2020, between the Registrant and Daphne Quimi</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*10.49</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1049hungdo-empl.htm"><span style="font-family:inherit;font-size:10pt;">Employment Agreement dated February 18, 2020 between the Registrant and Hung Do</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit21.htm"><span style="font-family:inherit;font-size:10pt;">List of Subsidiaries</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit231.htm"><span style="font-family:inherit;font-size:10pt;">Consent of Independent Registered Public Accounting Firm.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit311.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Rule&#160;13a-14(a) of the Securities Exchange Act of 1934.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit312.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Rule&#160;13a-14(a) of the Securities Exchange Act of 1934.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit321.htm"><span style="font-family:inherit;font-size:10pt;">Certificate of Principal Executive Officer pursuant to 18 U.S.C. Section&#160;1350 and Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">126</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporated by Reference</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">to SEC Filing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed Exhibit Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed with this</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form&#160;10-K</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit322.htm"><span style="font-family:inherit;font-size:10pt;">Certificate of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350 and Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following financial information from this Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019, formatted in Inline XBRL (Extensible Business Reporting Language) and filed electronically herewith: (i)&#160;the Consolidated Balance Sheets; (ii)&#160;the Consolidated Statements of Operations; (iii)&#160;the Consolidated Statements of Comprehensive Loss; (iv)&#160;the Consolidated Statements of Cash Flows; (v)&#160;and the Notes to the Consolidated Financial Statements.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cover page from the Annual Report on Form 10-K for the year ended December 31, 2019, formatted in Inline XBRL (included in Exhibit 101).</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">X</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">____________________________________________________________________</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">+</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Confidential treatment has been granted as to certain portions of the document, which portions have been omitted and filed separately with the Securities and Exchange Commission.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">++</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to confidential treatment request.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicates management contract or compensatory plan.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">**</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain confidential portions of this exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference from the Proxy Statement under the captions "Certain Relationships and Related Transactions," "Director Independence," "Committee Compensation and Meetings of the Board of Directors," and "Compensation Committee Interlock and Insider Participation."</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s66C6EF2B9E7258B38978B88E8E471D0D"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;16.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FORM 10-K SUMMARY.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">127</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><a id="s68E31F390E9753EE988A636E5A4AF02B"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on </span><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:28.460038986354775%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:14%;"></td><td style="width:86%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AMICUS THERAPEUTICS,&#160;INC.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Registrant)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ &#160;&#160;&#160;John F. Crowley</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">John F. Crowley</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Executive Officer</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Signature</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Title</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ &#160;&#160;&#160;John F. Crowley</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(John F. Crowley)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Daphne Quimi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer<br/>(Principal Financial Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Daphne Quimi)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Samantha Prout</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global Controller<br/>(Principal Accounting Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Samantha Prout)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Robert Essner</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Robert Essner)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Ted W. Love, M.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Ted W. Love, M.D.)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Margaret G. McGlynn, R.Ph.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Margaret G. McGlynn, R.Ph.)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Michael G. Raab</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Michael G. Raab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Glenn Sblendorio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Glenn Sblendorio)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">128</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FF189164D085E6F8C1EBFBF040D88BF"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Signature</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Title</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Craig Wheeler</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Craig Wheeler)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160; Lynn&#160;Bleil</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Lynn Bleil)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Burke Whitman</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Burke Whitman)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;">129</span><span style="font-family:inherit;font-size:10pt;">-</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>2
<FILENAME>exhibit48descriptionof.htm
<DESCRIPTION>EXHIBIT 4.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF0775ED0DF388A3DF2BC9C0416A8918B"></a></div><div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following description summarizes certain of the terms of the capital stock of Amicus Therapeutics, Inc. This description does not purport to be complete and is qualified in its entirety by reference to our restated certificate of incorporation, as amended, and our amended and restated bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit is a part. We encourage you to read our amended and restated certificate of incorporation, bylaws and the applicable provisions of Delaware law for additional information. Unless the context requires otherwise, all references to &#8220;we&#8221;, &#8220;us,&#8221; &#8220;our&#8221; and &#8220;Company&#8221; in this section refer solely to Amicus Therapeutics, Inc. and not to any subsidiaries that we may have from time to time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">DESCRIPTION OF OUR COMMON STOCK</font></div><div style="line-height:130%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">General</font></div><div style="line-height:130%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We are authorized to issue 500,000,000 shares of common stock, $0.01 par value per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any outstanding preferred stock.</font></div><div style="line-height:130%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font></div><div style="line-height:130%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Transfer Agent and Registrar</font></div><div style="line-height:130%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The transfer agent and registrar for our common stock is American Stock Transfer and Trust Company.</font></div><div style="line-height:130%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">The NASDAQ Global Market</font></div><div style="line-height:130%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our common stock is listed on the NASDAQ Global Market under the symbol "FOLD."</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">DESCRIPTION OF OUR PREFERRED STOCK</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We are authorized to issue up to 10,000,000 shares of preferred stock, par value $0.01 per share. Our board of directors may, without further action by our stockholders, from time to time, direct the issuance of shares of preferred stock in series and may, at the time of issuance, determine the rights, preferences and limitations of each series, including voting rights, dividend rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares of our preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares of our preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of the Company before any payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal of incumbent management. Upon the affirmative vote of our board of directors, without stockholder approval, we may issue shares of preferred stock with voting and conversion rights which could adversely affect the holders of shares of our common stock.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We currently do not have any shares of preferred stock outstanding. Should we choose to offer a specific series of preferred stock, we will describe the terms of the preferred stock in the prospectus supplement for such offering and will file&#160;a copy of the certificate establishing the terms of the preferred stock with the SEC.</font></div><div style="line-height:130%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.44
<SEQUENCE>3
<FILENAME>exhibit1044jfcamendagr.htm
<DESCRIPTION>EXHIBIT 10.44
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s199A48A082A3D17A6AB39C0612BE6AD4"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:center;padding-left:24px;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment to Employment Agreement</font></div><div style="line-height:120%;padding-top:13px;text-align:left;padding-left:24px;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Employment Agreement dated as of April 23, 2014, between AMICUS THERAPEUTICS, INC., a Delaware corporation having an office at 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (the &#8220;Company&#8221;), and JOHN F. CROWLEY, an individual residing at [&#8230;] (&#8220;Employee&#8221;) is amended as follows:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;Section 3.2:  The second sentence is amended to delete 60% and replace with 65%.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;Section 3.3 is renumbered as Section 3.4</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;New Section 3.3 is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Equity</font><font style="font-family:inherit;font-size:10pt;">.  Subject to the terms and conditions of the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan and such other equity plans as the Company may adopt from time to time during Employee&#8217;s employment with the Company, Employee will be eligible to receive stock options (&#8220;Options&#8221;), Restricted Stock Units (&#8220;RSUs&#8221;) and Performance Restricted Stock Units (PRSUs) and/or such other equity or equity-based grants, as the Company may elect, in any such case pursuant to any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  Unless otherwise provided in this Agreement, the terms and conditions of the applicable equity plan will govern all equity grants to Employee (including vesting of options and units), including with regard to the Employee&#8217;s cessation of employment on such equity grants.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;Section 5.2(b):  The second sentence is deleted and replaced with:  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, (i) the vesting of any unvested Options held by Employee immediately prior to such termination shall accelerate such that the portion of those Options that was otherwise scheduled to vest during the 12&#160;month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of such termination; (ii) the vesting of any unvested RSUs held by Employee immediately prior to such termination shall accelerate such that the portion of those RSUs that was otherwise scheduled to vest during the 12&#160;month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of such termination; (iii) the vesting of any unvested PRSUs held by Employee immediately prior to such termination shall accelerate such that the portion of those PRSUs that was otherwise scheduled to vest during the 12&#160;month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of termination unless a different date is set forth in the applicable equity award agreement. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;Section 5.4:&#160;&#160;&#160;&#160;The second sentence is deleted and replaced with: </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, all unvested the Options and RSUs, held by Employee immediately prior to his termination shall vest in full. Any unvested PRSUs held by Employee immediately prior to his termination shall vest at the target level or at such greater level as determined by the Compensation Committee of the Board of Directors, in its sole discretion.</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other provisions of the Employment Agreement remain unchanged and in full force and effect. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, the parties have executed this Amendment to Employment Agreement this 18</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;date of February, 2020.</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ John F. Crowley</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John F. Crowley</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mike Raab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mike Raab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lead Independent Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>4
<FILENAME>exhibit1045ellenrosenb.htm
<DESCRIPTION>EXHIBIT 10.45
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3DF38FBE86245B6F9FB29C032D14C3AF"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THIS EMPLOYMENT AGREEMENT</font><font style="font-family:inherit;font-size:12pt;">&#32;(this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), dated as of February 18, 2020 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), between AMICUS THERAPEUTICS, INC., a Delaware corporation having an office at 3675 Market Street, Philadelphia, PA 19104 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and [&#8230;], (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) (together, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">parties</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS,</font><font style="font-family:inherit;font-size:12pt;">&#32;the Company wishes to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">continue to</font><font style="font-family:inherit;font-size:12pt;">&#32;employ Employee, and Employee wishes to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">continue to</font><font style="font-family:inherit;font-size:12pt;">&#32;be employed by Company, on the terms and conditions set forth herein; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:inherit;font-size:12pt;">&#32;in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the sufficiency and receipt whereof is hereby acknowledged, the parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">Section 1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:12pt;">.  Unless otherwise defined herein, the following terms shall have the following respective meanings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accrued Amounts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, as of the termination of Employee&#8217;s employment:  (a)&#160;the total of any expenses properly incurred by Employee under Section 3.4(b) that have not previously been reimbursed as of the effective date of the termination; (b)&#160;the sum of Employee&#8217;s accrued, but unused, vacation time, if any, as of the effective date of the termination; and (c) any accrued and unpaid Base Salary through and including the effective date of Employee&#8217;s termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any other company, directly or indirectly, controlling, controlled by or under common control with the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cause</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Employee&#8217;s: (i)&#160;willful or deliberate misconduct that has or could reasonably be expected to have a materially adverse impact on the reputation or business of the Company (or an Affiliate), or that results in gain or personal enrichment of Employee to the detriment of the Company (or an Affiliate); (ii)&#160;violation of Company policy including, but not limited to, policies prohibiting harassment and other workplace misconduct, and policies governing corporate compliance; (iii) misappropriation of the funds or assets of the Company (or an Affiliate); (iv) conviction, plea of guilty, admission to facts sufficient for a finding of guilt, or plea of no contest (or nolo contendere) to: (a) any felony, or (b) any misdemeanor involving fraud, theft, dishonesty, wrongful taking of property, embezzlement, bribery, forgery or extortion; (v) material breach of this Agreement; (vi)&#160;material breach of the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">; (vii) breach of Employee&#8217;s duty of loyalty to the Company; (viii) disqualification, bar or suspension by any governmental authority from performing any of the duties contemplated by this Agreement; (ix)&#160;material failure to perform Employee&#8217;s duties or obligations hereunder (other than as a result of being Unable to Work); or (x)&#160;willful failure to adhere to or carry out lawful duties or directives of the Company&#8217;s Chief Executive Officer (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CEO</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or Board of Directors (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Notwithstanding anything to the contrary herein, the Company shall not be deemed to have terminated Employee for Cause for the events described above in subsections (ix) or (x) unless the CEO or Board, as applicable, has determined that such events are amenable to cure and given Employee written notice of the occurrence of the claimed event(s) constituting Cause and Employee has failed to cure such event(s) within fourteen (14) calendar days after Employee&#8217;s receipt of such notice (or such other period as may be deemed reasonable by the CEO or Board under the circumstances and communicated to Employee).  The other events described above are not subject to an opportunity to cure but the Company may, in its sole discretion, conduct an investigation into those events and provide the employee a full opportunity to participate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any of the following: (i)&#160;when any person or entity who is not currently a stockholder of the Company (as of the date of this Agreement) becomes the beneficial owner of greater than 50% of the then-outstanding voting power of the Company; (ii)&#160;when a merger or consolidation with another entity occurs that causes the voting securities of the Company outstanding immediately before the transaction to constitute less than a majority of the voting power of the voting securities of the Company or the surviving entity outstanding immediately after the transaction; or (iii)&#160;when a sale or disposition of all or substantially all of the Company&#8217;s assets occurs.  Notwithstanding the foregoing, no event shall be deemed to be a Change in Control Event unless such event would also be a Change in Control under Section 409A and the rules and regulations promulgated thereunder (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 409</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or would otherwise be a permitted distribution event under Section 409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">&#8221; means:  (i) payment of an amount equal to one and one-half (1.5) times Employee&#8217;s then current Base Salary, payable in installments over eighteen (18)&#160;months, commencing within sixty (60) calendar days after the resignation or termination (collectively, &#8220;termination&#8217;) of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices for its senior management personnel; (ii) payment of an amount equal to 100% of the target Bonus for the calendar year in which such termination occurs (such amount being payable in a lump sum), payable within seventy five (75) calendar days following such termination ; (iii) the accelerated vesting of stock options held by Employee immediately prior to such termination (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Options</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such that all Options will become vested as of the date of Employee&#8217;s termination; (iv) the accelerated vesting of restricted stock grants held by Employee immediately prior to such termination (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Grants</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such that all Grants will become vested as of the date of Employee&#8217;s termination; (v) the accelerated vesting of performance restricted stock units held by Employee immediately prior to such termination at the applicable performance targets or such greater amounts as determined by the Board of Directors in their sole discretion; and (vi) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of eighteen (18) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that  the Company will pay the full premiums otherwise payable for such coverage during such 18 month period.  Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Change in Control Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Good Reason</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the occurrence of one or both of the following events without Employee&#8217;s consent: (i)&#160;the Company&#8217;s material diminution of Employee&#8217;s authority, duties, or responsibilities as set forth in this Agreement; or (ii)&#160;the Company&#8217;s change in the principal geographic location at which Employee provides services to the Company to a location more than thirty (30) miles from Employee&#8217;s assigned primary office location, unless such relocation is only temporary, for a reasonable period of time, or unless such relocation merely constitutes travel reasonably required in connection with the performance of Employee&#8217;s duties.  Notwithstanding anything to the contrary herein, Employee shall not be deemed to have resigned for Good Reason unless: (a) Employee had provided to the Company written notice within thirty (30) calendar days of the occurrence of the claimed event(s) constituting Good Reason, specifying in detail the basis for such Good Reason; (b) the Company fails to cure the Good Reason within thirty (30) calendar days after its receipt of such notice, and (c) Employee terminates employment within sixty (60) calendar days after providing notice to Company of the claimed event(s) constituting Good Reason. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (i) payment of an amount equal to Employee&#8217;s then current Base Salary, payable in installments over twelve (12)&#160;months, commencing within sixty (60) calendar days of the termination of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices then in effect for its senior management personnel; (ii) payment of a bonus equal to 100% of the target Bonus for the calendar year in which such termination occurs pro-rated for the number of days actually worked in the year of termination, payable within seventy five (75) calendar days following such termination; (iii) the accelerated vesting of the Options, such that the portion of the Options that was otherwise scheduled to vest during the twelve (12)&#160;month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination;  (iv) the accelerated vesting of RSUs, such that the portion of RSUs that was otherwise scheduled to vest during the twelve (12) month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination; (v)  the accelerated vesting of PRSUs, such that the portion of PRSUs that was otherwise scheduled to vest during the twelve month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination; and (vi)in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.  Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Unable to Work&#8221; means the determination by the Company, following an interactive process, that Employee has become physically or mentally incapable of performing Employee&#8217;s essential job functions, with or without a reasonable accommodation, following any period during which such status would be protected under applicable law.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employment</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duties and Responsibilities</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of this Agreement, Employee will be employed by the Company as Chief Legal Officer and Corporate Secretary or in such other position as may be mutually agreed upon by the parties.  A Job Description setting forth Employee&#8217;s duties and responsibilities is attached as Exhibit C.  Employee accepts such employment, and agrees to perform all of the duties and accept all of the responsibilities accompanying such position.  Employee agrees to serve the Company faithfully and to the best of Employee&#8217;s abilities, and to devote all of Employee&#8217;s business time, skill and attention to such service.  Employee is expected to be available for meetings on a regular basis, upon request by the Company, at the Company&#8217;s Cranbury, New Jersey, and Philadelphia, Pennsylvania, locations or such other Company locations as needed including, but not limited to, the Company&#8217;s international offices.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Full Time and Attention</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall devote Employee&#8217;s full business time and best efforts to the performance of Employee&#8217;s duties and to the furtherance of the Company&#8217;s interests.  During Employee&#8217;s employment with the Company, Employee may not hold another position of employment, or be retained as a consultant, or engage in any other business activity (whether full-time or part-time, whether or not for compensation), unless the Company gives Employee prior written permission to do so.  Notwithstanding anything stated in this provision to the contrary, Employee is permitted to engage in charitable activities, as long as they do not interfere with Employee&#8217;s employment obligations to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Policies</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment with the Company, Employee will be subject to all applicable employment and other policies of the Company, as outlined in the Amicus Employee Handbook and as otherwise published by the Company in writing.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compensation and Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, the Company shall pay Employee a salary at the gross annual rate of $452,389 (less applicable withholding) or such greater amount as the Board or a committee thereof may from time to time establish pursuant to the terms hereof (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Such Base Salary shall be reviewed annually and may be increased, but not decreased, by the Board or a committee thereof in its sole discretion. The Base Salary shall be payable in accordance with the Company&#8217;s customary payroll practices for its senior management personnel.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee shall be eligible to participate in the Company&#8217;s bonus programs as may be in effect with respect to senior management personnel. Employee shall be eligible to earn an annual target bonus of 100% of the Base Salary in cash (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">&#8221;) such actual amount determined by the Company Compensation Committee in its absolute discretion and at 40% of base salary; provided, however, that notwithstanding anything to the contrary herein or in any bonus program, Employee must be employed by the Company as of December 31 of the applicable calendar year, in order to be eligible to earn a Bonus for such calendar year.  Any Bonus payment to which Employee becomes entitled hereunder shall be paid to Employee in a lump sum (less applicable withholding) on or before the 15</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of the third month following the end of the calendar year in which the Bonus was earned.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Equity</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan and such other equity plans as the Company may adopt from time to time including, but not limited to, an Employee Stock Purchase Plan, during Employee&#8217;s employment with the Company, Employee will be eligible to receive stock options, Restricted Stock Units and Performance Restricted Stock Units pursuant to any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  Unless otherwise provided in this Agreement, the terms and conditions of the applicable equity plan will govern all equity grants to Employee (including vesting of options and units), including with regard to the impact of the end of Employee&#8217;s employment on such equity grants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefit Plans</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee may participate in any benefit plans (including health and medical insurance) as may be in effect with respect to senior management personnel of the Company, including any equity plan, subject to the eligibility and contribution requirements, enrollment criteria and other terms and conditions of such plans.  The Company reserves the right to modify, amend and eliminate any such plans, in its sole and absolute discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reimbursement of Expenses</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, the Company shall pay or promptly reimburse Employee, upon submission of proper invoices or other documentation in accordance with the Company&#8217;s policies and procedures, for all reasonable out-of-pocket business, entertainment and travel expenses incurred by Employee in the performance of Employee&#8217;s duties.  Any taxable reimbursement of business or other expenses as specified under this Agreement shall be subject to the following conditions:  (i)&#160;the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year; (ii)&#160;the reimbursement of an eligible expense shall be made no later than the end of the calendar year after the year in which such expense was incurred; and (iii)&#160;the right to reimbursement shall not be subject to liquidation or exchange for another benefit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Vacation</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee shall be entitled to vacation in accordance with the policies of the Company applicable to senior management personnel as may be in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Withholding</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall withhold from all amounts payable or benefits accorded to Employee all federal, state and local income, employment and other taxes, as and in such amounts as may be required by applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duration of Employment</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s employment with the Company shall begin on the Effective Date and continue until Employee&#8217;s employment is terminated by either Employee or the Company.  At all times, Employee&#8217;s employment with the Company shall be &#8220;at-will,&#8221; meaning that either Employee or the Company may terminate the employment at any time, for no reason or any lawful reason.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination; Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notice of Termination</font><font style="font-family:inherit;font-size:12pt;">.  Any termination of Employee&#8217;s employment by the Company or by Employee (other than on account of death) shall be communicated to the other party by written notice that indicates the specific termination provision in this Agreement relied upon.  Except as otherwise expressly provided in this Agreement or the notice, the termination shall take effect immediately.  The parties agree that the notice requirements set forth in this Agreement do not alter the &#8220;at will&#8221; nature of Employee&#8217;s employment, as described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Generally</font><font style="font-family:inherit;font-size:12pt;">.  Upon termination of Employee&#8217;s employment for any reason, Employee shall be deemed simultaneously to have resigned as a member of the Board, if applicable, and from any other position or office Employee may at the time hold with the Company or any of its Affiliates.  Employee agrees to cooperate with the Company by signing any necessary documents and taking any other steps necessary to effectuate Employee&#8217;s resignation from the Board, if applicable, and from any other position or office Employee may hold with the Company or any of its Affiliates.  In addition, upon termination of Employee&#8217;s employment for any reason, the Company shall pay Employee the Accrued Amounts.  The Accrued Amounts will be paid within the time required by applicable law.  The impact of the termination of Employee&#8217;s employment on the Employee&#8217;s participation in the Company&#8217;s health plans is addressed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by Employee</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resignation Independent of a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If Employee resigns and a Change in Control Event has not occurred in the prior 12 months, then (irrespective of whether the resignation was with or without Good Reason):  (i)&#160;Employee shall receive no further compensation or remuneration of any kind other than the Accrued Amounts; and (ii)&#160;at the end of the month in which the resignation takes effect, Employee shall cease to be covered under or permitted to participate in or receive any of the benefits described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3.4</font><font style="font-family:inherit;font-size:12pt;">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Good Reason Resignation Within 12 Months of a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If Employee resigns for Good Reason within&#160;twelve (12)&#160;months after a Change in Control Event, Employee will be entitled to receive, in addition to the Accrued Amounts, </font><font style="font-family:inherit;font-size:12pt;">Change in Control Severance Benefits.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by the Company</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Without Cause Within 12 Months After a Change in Control Event.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;If the Company terminates Employee&#8217;s employment without Cause within 12 months after a Change in Control Event, then in lieu of any other payments, rights or benefits under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(a)</font><font style="font-family:inherit;font-size:12pt;">, Employee will be entitled to receive Change in Control Severance Benefits in addition to the Accrued Amounts.  All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Without Cause Not Within 12 Months After a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If the Company terminates Employee&#8217;s employment without Cause (other than within 12 months after a Change in Control Event), then Employee will be entitled to receive Severance Benefits in addition to the Accrued Amounts</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">For Cause</font><font style="font-family:inherit;font-size:12pt;">.  If the Company terminates Employee&#8217;s employment for Cause at any time, Employee shall: (i)&#160;receive no further compensation or remuneration of any kind (including any Base Salary or Bonus hereunder) other than the Accrued Amounts; and (ii)&#160;at the end of the month in which the termination takes effect, cease to be covered under or be permitted to participate in or receive any of the benefits described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;3.4</font><font style="font-family:inherit;font-size:12pt;">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination upon Death or Inability to Work</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Death.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Employee&#8217;s employment shall terminate immediately upon Employee&#8217;s death.  In the event of Employee&#8217;s death during the course of Employee&#8217;s employment with the Company, the Company will pay the Employee&#8217;s estate the Accrued Amounts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inability to Work.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Except as otherwise provided by applicable law, the Company may terminate Employee&#8217;s employment in the event Employee is Unable to Work.  In the event of Employee&#8217;s death or termination by the Company due to Employee being Unable to Work, Employee shall receive: (a) the Accrued Amounts, and (b) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Release and Compliance Required</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s receipt of any right, payment or benefit under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;is subject to and conditioned upon: (a)&#160;Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company; and (b) Employee&#8217;s reaffirmation of and continuing compliance with Employee&#8217;s contractual and legal obligations to the Company, as expressly set forth in the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="font-family:inherit;font-size:12pt;">.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;409A</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:12pt;">.  This section is intended to help ensure that compensation paid or delivered to Employee pursuant to this Agreement either is paid in compliance with, or is exempt from, IRC Section&#160;409A. However, the Company does not warrant to Employee that all compensation paid or delivered to Employee for Employee&#8217;s services will be exempt from, or paid in compliance with, Section&#160;409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Amounts Payable On Account of Termination</font><font style="font-family:inherit;font-size:12pt;">.  For the purposes of determining when amounts otherwise payable on account of Employee&#8217;s termination of employment under this Agreement will be paid, which amounts become due because of Employee&#8217;s termination of employment, &#8220;termination of employment&#8221; or words of similar import, as used in this Agreement, shall be construed as the date that Employee first incurs a &#8220;separation from service&#8221; for purposes of Section&#160;409A on or following termination of employment.  Furthermore, if Employee is a &#8220;specified employee&#8221; of a public company as determined pursuant to Section&#160;409A as of Employee&#8217;s termination of employment, any amounts payable on account of Employee&#8217;s termination of employment that constitute deferred compensation within the meaning of Section&#160;409A and that are otherwise payable during the first six months following Employee&#8217;s termination (or prior to Employee&#8217;s death after termination) shall be paid to Employee in a cash lump-sum on the earlier of: (i)&#160;the date of Employee&#8217;s death; or (ii)&#160;the first business day of the seventh calendar month immediately following the month in which Employee&#8217;s termination occurs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Series of Payments</font><font style="font-family:inherit;font-size:12pt;">.  Any right to a series of installment payments shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interpretative Rules</font><font style="font-family:inherit;font-size:12pt;">.  In applying Section&#160;409A to amounts paid pursuant to this Agreement, any right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Participation in Other Severance Plans.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Employee agrees and acknowledges that Employee shall not be eligible to participate in or have any right to compensation or benefits pursuant to the Company&#8217;s Change in Control Severance Plan (or any successor plan thereto) or any other Severance Plan issued by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exclusivity</font><font style="font-family:inherit;font-size:12pt;">. In the event Employee&#8217;s employment is terminated for any reason, Employee (and Employee&#8217;s eligible dependents, if any) shall not be entitled to any payments or benefits from the Company or any of its Affiliates except as specifically set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Federal Excise Tax</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Rule</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s payments and benefits under this Agreement and all other arrangements or programs related thereto shall not, in the aggregate, exceed the maximum amount that may be paid to Employee without triggering golden parachute penalties under Section&#160;280G of the Code, and the provisions related thereto with respect to such payments. If Employee&#8217;s benefits must be cut back to avoid triggering such penalties, such reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary, to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity derivative payments shall be reduced.  If an amount in excess of the limit set forth in this Section is paid to Employee, Employee must repay the excess amount to the Company upon demand, with interest at the rate provided in Section&#160;1274(b)(2)(B) of the Code.  Employee and the Company agree to cooperate with each other reasonably in connection with any administrative or judicial proceedings concerning the existence or amount of golden parachute penalties on payments or benefits Employee receives.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exception</font><font style="font-family:inherit;font-size:12pt;">.  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;shall apply only if it increases the net amount Employee would realize from payments and benefits subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;after payment of income and excise taxes by Employee on such payments and benefits.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Determinations</font><font style="font-family:inherit;font-size:12pt;">.  The determination of whether the golden parachute penalties under Section&#160;280G of the Code and the provisions related thereto shall be made by counsel chosen by Employee and reasonably acceptable to the Company. All other determinations needed to apply this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be made in good faith by the Company&#8217;s independent auditors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Computers, Property and Records</font><font style="font-family:inherit;font-size:12pt;">.  Employee agrees to handle all Company property in accordance with the Company&#8217;s policies and procedures.  Employee&#8217;s authorization to access the Company&#8217;s computer systems is limited and use of such systems to compete or prepare to compete with the Company constitutes unauthorized access that is strictly prohibited.  All records received or created by Employee in the course of employment related to the Company&#8217;s business (such as but not limited to, email, notes, files, contact lists, agendas, drawings, maps, specifications, and calendars) are the property of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resolution of Disputes</font><font style="font-family:inherit;font-size:12pt;">.  Employee and the Company hereby agree that, except for disputes regarding alleged or anticipated violations of the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, any and all disputes between them shall be resolved solely in accordance with the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">&#32;and, to the greatest extent permitted by law, Employee and the Company expressly waive their respective right to a trial by jury for any and all such disputes between them.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Conflict</font><font style="font-family:inherit;font-size:12pt;">.  Employee represents and warrants that Employee has not entered, nor will Employee enter, into any other agreements that restrict Employee&#8217;s ability to fulfill Employee&#8217;s obligations under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall be construed, interpreted and governed by the laws of the state of Employee&#8217;s assigned primary office location during the last six months of Employee&#8217;s employment with the Company, without regard to the conflicts of law principles.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Binding Effect</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall extend to and be binding upon Employee, Employee&#8217;s legal representatives, heirs and distributees and upon the Company, its successors and assigns regardless of any change in the business structure of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">.  The Company&#8217;s rights and obligations under this Agreement, including the restrictions in the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its assets, stock or business.  Employee consents to that transfer.  Employee may not assign any rights or obligations under this Agreement without the Company&#8217;s prior written consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the parties with respect thereto</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:12pt;">including Employee&#8217;s prior Agreement, dated February 8, 2016, except this Agreement does not supersede the Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A or the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as Exhibit B.  Nor does this Agreement supersede any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  No waiver, modification or change of any provision of this Agreement shall be valid unless in writing and signed by both parties.  </font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:12pt;">.  The waiver of any breach of any duty, term or condition of this Agreement shall not be deemed to constitute a waiver of any preceding or succeeding breach of the same or any other duty, term or condition of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Agreement shall be unenforceable in any jurisdiction in accordance with its terms, the provision shall be enforceable to the fullest extent permitted in that jurisdiction and shall continue to be enforceable in accordance with its terms in any other jurisdiction and the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.  All notices pursuant to this Agreement shall be in writing and shall be sent by prepaid certified mail, return receipt requested or by recognized air courier service addressed as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;If to the Company to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amicus Therapeutics, Inc. <br>1 Cedar Brook Drive <br>Cranbury, New Jersey 08512</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c/o&#160;&#160;&#160;&#160;CEO or General Counsel</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;If to Employee to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ellen Rosenberg <br>at the address identified herein or in Employee&#8217;s personnel records,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or to such other addresses as may hereinafter be specified by notice in writing by either of the parties, and shall be deemed given three (3)&#160;business days after the date so mailed or sent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance</font><font style="font-family:inherit;font-size:12pt;">. If reasonably requested in writing, Employee agrees within fifteen (15) business days to provide the Company with an executed IRS Form&#160;4669 (Statement of Payments Received) with respect to any taxable amount paid to Employee by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowing and Voluntary Nature of Agreement</font><font style="font-family:inherit;font-size:12pt;">. Employee acknowledges and agrees that Employee is executing this Agreement knowingly and voluntarily and without any duress or undue influence by the Company or anyone else.  Employee further acknowledges and agrees that Employee has carefully read this Agreement and fully understands it. Employee further agrees that Employee has been provided an opportunity to seek, and has received, the advice of an attorney of Employee&#8217;s choice (at Employee&#8217;s expense) before signing this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">[Signature Page Follows]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above written.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:12pt;">____________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ellen Rosenberg</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ David Clark               &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;David Clark</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: Chief People Officer</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s9FD0D81F192B4FFB49409C032D4C92EE"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFIDENTIALITY, NON-DISCLOSURE AND NON-COMPETITION AGREEMENT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITH</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ellen Rosenberg</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement is made as of February 18, 2020 between you and Amicus Therapeutics, Inc. (the &#8220;Company&#8221;).  You agree that you are receiving adequate consideration in exchange for entering into this Confidentiality, Non-Disclosure and Non-Competition Agreement (the &#8220;Agreement&#8221;) including:  (1)&#160;at-will employment and the benefits of that employment including any grant to you of certain restricted stock units and options to purchase shares of common stock in the Company; (2)&#160;access to Confidential Information belonging to the Company; and (3) access to the Company&#8217;s business relationships.  You acknowledge that entering into this Agreement is a condition of receiving those items.  Accordingly, you agree to the following terms and conditions:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the protections provided by this Agreement are necessary to safeguard the Company&#8217;s Confidential Information (as defined below), business relationships and other business interests, and that the Company is willing to employ you, and continue to employ you, on the condition that you execute this Agreement.  You agree that the Company has spent substantial resources developing its Confidential Information and business relationships.  You also agree that protecting these assets is critical to the Company&#8217;s survival and success, and a competitor with access to those assets would have an unfair competitive advantage over the Company. Therefore, you agree that the Company has a legitimate business interest in protecting those assets and that the commitments set forth in this Agreement are a reasonable means of doing so.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that as an integral part of the Company&#8217;s business, the Company has developed, and will develop, at a considerable investment of time and expense, non-public scientific data and methods, clinical development plans and strategies, business development plans and strategies, marketing and business plans and strategies, procedures, methods of operation and marketing, financial data, lists of actual and potential customers and suppliers including buying habits of those customers, and independent sales representatives and related data, technical procedures, engineering and product specifications, plans for development and expansion, and other confidential and sensitive information, and you acknowledge that the Company has a legitimate business interest in protecting the confidentiality of such information.  You acknowledge that you will be entrusted with such information as well as confidential non-public information belonging to customers, suppliers, and other third parties.  You, therefore, acknowledge a continuing responsibility to protect such information and agree to the provisions contained herein.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Trade Secrets&#8221; shall mean information belonging to the Company or licensed by it including, without limitation, data, reports, research, drawings, specifications, software, formulae, patterns, compilations, programs, devices, methods, techniques, or processes (including such information that has commercial value to the Company from a negative viewpoint, such as the results of research which proves that certain processes used to attempt to develop new technology will be unsuccessful) which are not commonly known by or available to the public, and which information: (a)&#160;derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from their disclosure or use; (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy; and (c) as otherwise defined by law.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Proprietary Information&#8221; shall mean any information, other than Trade Secrets, without regard to form, belonging to the Company or licensed by it including, without limitation, formulae, patterns, compilations, programs, devices, methods, techniques, or processes, which is not commonly known by or available to the public and which information is material to the Company and not generally known by the public, and all notes, analyses, compilations, studies, interpretations or other documents prepared by you which contain, reflect or are based upon, in whole or in part, the information furnished to you by the Company pursuant hereto; provided, however that &#8220;Proprietary Information&#8221; shall not include any information which you can show (i) becomes patented, published or otherwise part of the public domain through no act or fault of your own, (ii) is received in good faith from any third party who has the right to disclose such information and who has not received such information, either directly or indirectly, from the Company, or (iii) any information which you can show was in your legitimate possession prior to your commencing employment with the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Confidential Information&#8221; shall mean, collectively, the information outlined in Paragraph 2 of this Agreement, Trade Secrets outlined in Paragraph 3 and Proprietary Information outlined in Paragraph 4 and all other information protected by unauthorized disclosure by law. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">You will treat as confidential and will not, without the prior written approval of the Company, directly or indirectly, use (other than in the performance of duties of employment with the Company), publish, disclose, patent, copyright, or authorize anyone else to use, publish, disclose, patent, or copyright any Confidential Information during your employment and after your employment with the Company terminates, whether such termination is voluntary or involuntary, with or without cause.  You agree to take all action reasonably necessary to protect Confidential Information from being disclosed or used by anyone other than persons authorized by the Company.  Confidential information shall not include information that: (i) is or subsequently becomes publicly available without your, or any other person or entity&#8217;s, breach of any obligation owed to the Company; (ii) was lawfully received by you from a third party free of any obligation of confidentiality owed to the Company; or (iii) you are required to disclose in a judicial or administrative proceeding or as otherwise required by law.    </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company recognizes that you, as a former employee or independent contractor of another company, may previously have been privy to trade secrets and/or confidential information of such other company, and you may be under an obligation to such other company to maintain the confidentiality of such trade secrets or confidential information.  Accordingly, to the extent you are under such an obligation, you shall not: (a) bring any records, notes, files, drawings, documents, plans and like items, electronic or otherwise, provided to you in confidence by such other company, or any copies thereof, relating to or containing or disclosing confidential information or trade secrets of any such other company, on the premises of the Company or loaded onto the Company&#8217;s computer systems or otherwise use such documents and items in the performance of services for the Company; or (b) disclose any confidential information or trade secrets provided to you in confidence by such other company in the performance of your job duties for </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">.  You represent that you are &#8220;free and clear&#8221; of any legal restrictions that might interfere with your ability to begin or continue your employment with, or perform your duties and responsibilities for, </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">such as non-compete, non-solicitation or non-disclosure restrictions imposed by current or former employers or contractors.   You confirm that you have disclosed to </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">&#32;any agreements between you and your current or former employers or contractors describing any possible restrictions on your activities. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You acknowledge that all Confidential Information and any records, files, memoranda, computer programs, reports, claims reports or records, customer lists, contracts, marketing plans, programs or forecasts and other written or printed documents or materials or other data stored on computer disks or other electronic data storage methods (&#8220;Documents&#8221;) received, created or used by you during the course of your relationship with the Company are and will remain the sole property of the Company.  You agree to return all such Documents (including all copies) to the Company promptly upon the termination of your employment, or earlier upon </font><font style="font-family:inherit;font-size:11pt;">the Company&#8217;s </font><font style="font-family:inherit;font-size:12pt;">request,  and agree that, during or after your employment, you will not, under any circumstances, without the specific authorization in writing of an officer of the Company, disclose those Documents or any information contained in such Documents to anyone outside the Company&#8217;s organization or use those Documents for any purpose other than the advancement of the Company&#8217;s interests.  Upon termination of your employment for any reason, or upon the Company&#8217;s earlier request, you also agree to immediately return to </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">all equipment and property provided to you by </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">including, but not limited to, computers, phones, pagers, thumb drives or other storage devices, iPads and other tablet devices, and any other electronic devices.  You also agree to provide </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">with all usernames, passwords, passcodes, and other information for logging into and accessing the equipment, applications, platforms, software, hardware, devices and other systems that you used or accessed in the course of, and during, your employment.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protected Conduct</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement prohibits you from disclosing Confidential Information under any of the following circumstances:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure in confidence to an attorney solely for the purpose of reporting or investigating a suspected violation of law; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure, directly or indirectly, to a Federal, State or local government official in confidence solely for the purpose of reporting or investigating a suspected violation of law; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure in a complaint or other document filed under seal in a lawsuit or other proceeding; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure to your attorney in connection with a lawsuit you file against the Company for retaliation for reporting a suspected violation of law.  Under this scenario, you may use the Confidential Information in the court proceedings as long as you file any document containing the Confidential Information under seal and do not otherwise disclose the Confidential Information, except pursuant to a Court Order.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prohibits you from filing a charge or complaint with, reporting or making disclosures (including providing supporting documents or other information) of possible violations of any law or regulation to, and/or participating in any investigation or proceeding conducted by, any self-regulatory organization or governmental agency, authority, or legislative body including, but not limited to, the Securities and Exchange Commission and/or Equal Employment Opportunity Commission or as otherwise required or allowed by law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Is intended to interfere with your rights under Section 7 of the National Labor Relations Act, including the right of employees to communicate with each other regarding the terms and conditions of their employment and to engage in concerted activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prevents you from disclosing or requires you to conceal the details of any alleged discrimination, retaliation or harassment.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Disclosure and Assignment Of Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">.  You agree to promptly disclose to the Company all &#8220;Intellectual Property&#8221; conceived or developed by you while employed by the Company that relates to the Company&#8217;s business.  The term &#8220;Intellectual Property&#8221; means any and all (i) data, reports, formulas, techniques, research, drawings, specifications, software and any other copyrightable works; (ii) Trade Secrets; and (iii) ideas, creations, inventions, discoveries, designs, devices, methods, processes and innovations whether or not patentable, and all related know-how.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Assignment of Intellectual Property Rights</font><font style="font-family:inherit;font-size:11pt;">.  You agree that all Intellectual Property conceived or developed by you while employed by the Company after the date of this Agreement shall be the exclusive property of the Company.  You hereby assign and agree to assign in the future to the Company all of your right, title and interest in and to any and all Intellectual Property related to your work at the Company, whether or not registrable under patent, copyright, trademark or similar statutes, made or conceived or reduced to practice or learned by you, either alone or jointly with others, during the period and scope of your employment with the Company.  Such assignment is perpetual and irrevocable.  Intellectual Property assigned to the Company, or to a third party as directed by the Company pursuant to this paragraph, are hereinafter referred to as &#8220;Company Intellectual Property.&#8221;  You agree to assign all right, title and interest in and to any particular Company Intellectual Property to a third party as directed by the Company.  You further agree to assign to the Company or, to the extent assignment is not permissible, waive any so-called &#8220;moral rights&#8221; in the Intellectual Property to the extent permitted by law.  You will assist the Company in every proper way to obtain, perfect, and from time to time enforce, its patent, copyright, trade secret and other rights in the Intellectual Property relating to Company Intellectual Property in any and all countries.  You hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, that you now or may hereafter have for infringement of any Intellectual Property assigned hereunder to the Company.</font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Prior Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding the foregoing, the Company agrees that you will not be obligated to assign any invention that you developed entirely on your own time, without using any equipment, supplies, facilities or trade secret information of the Company, unless such invention either:  (i) relates (at the time of conception or reduction to practice of the invention) to the Company&#8217;s business or the Company&#8217;s actual or demonstrably anticipated research, or (ii) results from any work performed by you for the Company.  Intellectual Property, if any, that you made prior to the commencement of your employment with the Company, or made outside the scope of your employment, are excluded from the scope of this Agreement.  To preclude any possible uncertainty, you have set forth on Exhibit A attached to this Agreement a complete list of all Intellectual Property that you have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement</font><font style="font-family:inherit;font-size:12pt;">&#32;of your employment with </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">, that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Agreement (collectively referred to as &#8220;Prior Intellectual Property&#8221;).</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Obligation to Keep the Company Informed</font><font style="font-family:inherit;font-size:11pt;">.  During the period of your employment, you will promptly disclose to the Company fully and in writing all Intellectual Property authored, created, conceived or reduced to practice by you, either alone or jointly with others, whether or not patentable or copyrightable or believed by you to be patentable or copyrightable.  In addition, you will promptly disclose to the Company (to be held in confidence) all patent applications filed by you or on your behalf within six months after termination of your employment (whether voluntarily or involuntarily), and to cooperate fully with a review and determination by the Company as to whether such patent applications constitute or include the Company&#8217;s Intellectual Property or Confidential Information.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Works for Hire</font><font style="font-family:inherit;font-size:11pt;">.  You acknowledge and agree that all original works of authorship that are made by you (solely or jointly with others) within the scope of your employment by the Company and that are protectable by copyright including, but not limited to, drawings, sketches and designs, are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C. Section 101).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the Company has compelling business interests in preventing the use or disclosure of its Confidential Information, or the misappropriation of its business relationships, and to protect those interests it is reasonable to restrict you from working or becoming affiliated with, either during or after the end of your employment with the Company, a Competitive Business (as defined below).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also acknowledge that the Company is engaged in a highly competitive business and that by virtue of the nature of your employment with the Company, your engaging in or working for or with any Competitive Business will cause the Company great and irreparable harm.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accordingly, you agree that, during your employment with the Company and for a period of twelve (12) months after the date of termination of your employment with the Company for any reason, whether such termination is voluntary or involuntary, by wrongful discharge or otherwise, you will not, directly, or indirectly work for or with or have any interest in any Competitive Business, whether as an individual on your own account, as a partner or joint venturer, as an employee, agent or salesperson for any person, as an officer or director of any corporation, or as a consultant or otherwise, or engage in preparations for any activity prohibited by this paragraph or any other paragraph in this Agreement without the prior specific written consent by an officer of the Company to do so provided, that the foregoing shall not prohibit ownership of the securities of a publicly-traded entity which constitute less than 2% of the outstanding voting securities of the entity.  For purposes of this Agreement, &#8220;Competitive Business&#8221; shall mean any person or entity who engages in the business of researching, developing and/or commercializing products, including but not limited to small molecules, biologics and gene therapies in the areas of Fabry disease, Pompe disease, Battens Disease, CDKL-5 Deficiency Disorder and any other condition, or any other business, in which the Company is actively engaged during the last twenty-four months of your employment.   You acknowledge that the geographic scope of this restriction is reasonable given that: (1) the Company does business and has customers and competitors throughout the world; and (2) modern communication and transportation make it easy to compete in this industry from virtually any location on earth.   Further, you acknowledge and agree that given the nature of your responsibilities for the Company and your access to its Confidential Information and business relationships, if you were to work for any Competitive Business as described in this paragraph, you would inevitably disclose Confidential Information. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Solicitation</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also acknowledge that, by virtue of your relationship with the Company, you have gained or will gain knowledge of the identity, characteristics and preferences of its customers among other Confidential Information, and that you would inevitably have to draw on such Confidential Information if you were to solicit or service the Company&#8217;s customers on behalf of a Competitive Business.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accordingly, you agree that for twelve (12) months following the termination for any reason whatsoever of your employment with the Company, you will not solicit the business of or perform any services for an actual or prospective Customer of the Company (as defined below).  You also agree that, during this twelve-month period, you will not encourage or assist any person or entity engaged in a Competitive Business to solicit or service any actual or prospective Customer of the Company covered by this paragraph.  &#8220;Customer of the Company&#8221; means any person or company that, at any time during the twenty-four (24) months prior to the end of your employment with the Company, purchases &#8211; or enters into a contract to purchase &#8211; products or services from the Company.  Customer shall also mean any prospective customer to which the Company has submitted a proposal for purchase of products or services.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also agree that, for twelve (12) months following the end of your employment with the Company for any reason, you will not directly or indirectly hire or seek to hire or retain, whether on your own behalf or on behalf of some other person or entity, any Company Personnel (as defined below).  Nor will you, during this twelve (12) month period, directly or indirectly induce or encourage any Company Personnel to leave the Company.  You acknowledge that, even after the expiration of the twelve (12) month period described in this paragraph, you will be barred from soliciting or hiring Company Personnel if, in soliciting or hiring them, you would use or disclose Confidential Information belonging to the Company.  &#8220;Company Personnel&#8221; means any employee, independent contractor or other personnel employed, retained or engaged by the Company at any time during the twenty-four (24) months prior to the termination of your employment:  (1)&#160;with whom you interacted within the scope of your employment with the Company; (2)&#160;whom you directly or indirectly supervised during your employment with the Company; or&#160;(3)&#160;regarding whom you received non-public information about his or her job responsibilities, compensation or job performance by virtue of your employment with the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Return of Property</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon termination of your employment (by the Company or you) for any reason, or upon the earlier request of the Company, you agree to immediately return to the Company all Company records and other property in your possession, custody or control including (but not limited to) anything containing Confidential Information such as documents, papers, files, records, reports, binders, notebooks, books, notes, calendars, plans, drawings, maps, specifications, blueprints, studies, photographs, video recordings, audio recordings, computers, tablets, smartphones, mobile telephones, drives, discs, and any other devices used to store electronic data, and any and all electronic copies and/or hard-copies.  Notwithstanding the foregoing, nothing in this Agreement shall prohibit you from retaining paystubs and other records regarding your compensation and benefits that the Company is required by law to provide to you.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon termination of your employment (by the Company or you) for any reason, or upon the earlier request of the Company, you agree to provide the Company with all usernames, passwords, passcodes and other information that it may need to log into and access the equipment, applications, platforms, software, hardware, devices and other systems that you used or accessed in the course of, and during, your employment.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon the Company&#8217;s request, you agree to immediately provide the Company with a written affidavit confirming that you have returned all Company property and Confidential Information, and cooperate in providing the Company, at the Company&#8217;s request, a means through which it can promptly and independently verify (including by forensic analysis, if necessary) that all Confidential Information has been removed from electronic storage devices, cloud-based storage, and accounts in your possession or control.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If you are served with a subpoena, court order, or similar legal document requiring the production of Company records or other property or the disclosure of Confidential Information, you agree to provide the Company with as much notice as is possible (presumably seven (7) business days or more) through written notification to the Company&#8217;s General Counsel and the Company&#8217;s CEO, so that the Company may take permissible steps to protect the records and information, unless such notice is prohibited by law or court order; provided, however, that nothing in this Agreement prohibits you from engaging in the Protected Conduct described in Section 9 and Section 10 of this Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Terms</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the restrictions contained in this Agreement are fair, reasonable and necessary to protect the legitimate business interests of the Company and that the Company will suffer irreparable harm in the event of any actual or threatened breach by you of this Agreement.  You agree that enforcement of the restrictions in this Agreement will not cause you any hardship, and because of your background and experience will not in any manner preclude you from becoming gainfully employed in such manner and to such extent as will provide you with a standard of living of at least the sort and fashion to which you are accustomed. You therefore agree that the Company may seek a restraining order, preliminary injunction or other court order to enforce this Agreement without the necessity of posting a bond or any security that might otherwise be required in connection with such relief.  You also agree that any request for such relief by the Company shall be in addition and without prejudice to any claim for monetary damages which the Company might elect to assert.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If any provision of this Agreement is held to be unenforceable by a court, such unenforceability shall not affect the enforceability of the remaining provisions.  Such provision shall be reformed and construed to the extent permitted by law so that it would be valid, legal and enforceable to the maximum extent possible.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that this Agreement does not give you any rights to employment by or to be retained as a consultant of the Company and, unless otherwise provided in another writing, executed by an officer of the Company and you, your relationship with the Company shall be employment &#8220;at will.&#8221;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You agree that, if you, at any time during or within one year after your employment with the Company ends, you receive an offer of employment or retention from any person or entity other than the Company, you will provide that person or entity with a copy of this Agreement.  You also agree that, at any time during, or within one year after the end of, your employment with the Company, you will, in writing, immediately after accepting (orally or in writing) any offer of employment or retention with any person or entity other than the Company:  (1)&#160;notify the Company that you accepted the offer; and (2)&#160;inform the Company of the identity of the person or entity, and of your title, responsibilities, work location and anticipated start date.  You acknowledge that the requirements set forth in this paragraph are fair, reasonable and necessary in order for the Company to adequately protect its Confidential Information and business relationships.  The Company may also provide copies of this Agreement to others including, but not limited to, customers and potential customers, and your future employers and prospective employers.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">You understand nothing in this Agreement prohibits you reporting to any governmental authority information concerning violations of law or regulations, and that you may report trade secret information to a government official or to an attorney and use it in certain proceedings without fear of prosecution or liability provided such disclosure is consistent with 18 U.S.C. 1833. If you make the disclosure to your attorney in connection with a private lawsuit, you may use the Confidential Information in the court proceedings as long as you file any document containing the Confidential Information under seal and do not otherwise disclose the Confidential Information, except pursuant to a Court Order.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement represents the entire agreement of the parties with respect to the subject matter covered and cannot be modified or amended except in a writing signed by both parties.  The waiver by any party to this Agreement or a breach of any of the provisions of this Agreement shall not operate or be construed as a waiver of any subsequent or simultaneous breach.  This Agreement supersedes any confidentiality, non-competition and non-solicitation entered into by the Company and you prior to the date of this Agreement.  This Agreement does not supersede:  (1)&#160;the Employment Agreement between you and the Company; (2)&#160;the Mutual Agreement to Arbitrate Disputes on an Individual Basis between you and the Company; or (3)&#160;</font><font style="font-family:inherit;font-size:12pt;">any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">30.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement shall be construed, interpreted and governed by the laws of the state of your assigned primary office location during the last six months of your employment with the Company, without regard to the conflicts of law principles</font><font style="font-family:inherit;font-size:11pt;">.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">31.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The rights and obligations of the Company under this Agreement shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its or their assets, stock or business.  By signing this Agreement, you consent to any such transfer.  You may not assign any rights or obligations under this Agreement without the prior written consent of the Company&#8217;s Chief Legal Officer or designee. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">By signing below, you acknowledge that you:  (1)&#160;received this Agreement fourteen (14) business days before the date on which you must return an executed copy of it to the Company; (2) have had sufficient opportunity to read each provision of this Agreement; (e)&#160;understand the meaning, effect and implications of each provision of this Agreement; (4)&#160;have had an opportunity to consult with legal counsel of your choosing (at your expense) regarding this Agreement; and (5)&#160;are not relying on any promises or representations that are not set forth in this Agreement.  By signing this Agreement, you are indicating that you are doing so freely and voluntarily and with full understanding of its terms and conditions.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ David Clark___</font><font style="font-family:inherit;font-size:11pt;">______________________</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">David Clark </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief People Officer </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">__________________&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Signature:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">&#32;_______________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;February 24. 2020_________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Home Address:&#160;&#160;&#160;&#160;[&#8230;]_____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SCHEDULE 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">PRIOR INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">List below all Intellectual Property and works of authorship that you have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of your employment with Amicus that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Confidentiality, Non-Disclosure and Non-Competition Agreement:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If additional space is needed, attach and sign additional sheets and indicate here:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">___ Additional sheets are attached.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you are not listing any Intellectual Property or works of authorship, indicate here:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">X</font><font style="font-family:inherit;font-size:12pt;">_ No Intellectual Property or works of authorship claimed.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signature of Employee: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:12pt;">___________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Print Name of Employee: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Ellen Rosenberg_</font><font style="font-family:inherit;font-size:12pt;">___________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: February 24, 2020</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s7D55B7D3F41E38EF8AEC9C032D91EA51"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT B</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">MUTUAL AGREEMENT TO ARBITRATE DISPUTES ON AN INDIVIDUAL BASIS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Mutual Agreement to Arbitrate Disputes on an Individual Basis (&#8220;Arbitration Agreement&#8221;) is made and entered into as of February 18, 2020 (the &#8220;Effective Date&#8221;) by and between </font><font style="font-family:inherit;font-size:11pt;">Amicus Therapeutics, Inc. (the &#8220;Company&#8221;) </font><font style="font-family:inherit;font-size:12pt;">and Ellen Rosenberg (&#8220;you&#8221;).  In this Arbitration Agreement, the Company and you are sometimes referred to individually as a &#8220;Party&#8221; and sometimes referred to together as the &#8220;Parties.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:12pt;">.  The Parties are entering into this Arbitration Agreement because they want to resolve all disputes arising out of or relating to your employment by the Company, or the termination of your employment, by binding private arbitration in accordance with the provisions of this Arbitration Agreement.  Regarding any claims covered by this Arbitration Agreement, you and the Company understand that, by entering into this Arbitration Agreement, YOU AND THE COMPANY ARE EACH GIVING UP:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1)&#160;&#160;&#160;&#160;THE RIGHT TO A JURY TRIAL; AND</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THE RIGHT TO FILE A LAWSUIT IN COURT AGAINST THE OTHER PARTY; AND </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THE RIGHT TO BRING A CLASS OR COLLECTIVE ACTION AGAINST THE OTHER PARTY IN COURT OR IN ARBITRATION OR IN ANY OTHER FORUM.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Mandatory Arbitration</font><font style="font-family:inherit;font-size:12pt;">.  In exchange for the mutual promises contained in this Arbitration Agreement and as a condition of the Company hiring and employing you, you and the Company agree that:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any and all &#8220;Covered Claims&#8221; (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3</font><font style="font-family:inherit;font-size:12pt;">&#32;below) shall be submitted to and resolved by final and binding arbitration to be held in the American Arbitration Association (&#8220;AAA&#8221;) office located nearest to your employment location for the Company.  The arbitration shall proceed before a single arbitrator and administered by the AAA in accordance with AAA&#8217;s Employment Arbitration Rules and Mediation Procedures (the &#8220;AAA Rules&#8221;) in effect and applicable at the time the arbitration is commenced.  The AAA Rules may be amended from time to time and are available online at </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">https://www.adr.org/sites/default/files/Employment%20Rules.pdf</font></a><font style="font-family:inherit;font-size:12pt;">.  You may also call the AAA at 800-778-7879 with any questions about the arbitration process.  If the AAA Rules are inconsistent with the terms of this Arbitration Agreement, the terms of this Arbitration Agreement shall govern; AND </font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Arbitrator, and not any federal, state, or local court or agency, shall have exclusive authority to resolve any dispute relating to the interpretation, applicability, formation or enforceability of this Arbitration Agreement including, but not limited to, the arbitrability of any dispute between the parties; AND </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Arbitrator&#8217;s decision shall be final and binding only on the Parties to this Arbitration Agreement and the Parties agree that awards deciding issues for similarly-situated employees will have no preclusive effect in any arbitration between the Parties. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Covered Claims</font><font style="font-family:inherit;font-size:12pt;">.  Except as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">, &#8220;Covered Claims&#8221; under this Arbitration Agreement shall include all past, current and future grievances, disputes, claims or causes of action that otherwise could be brought in a federal, state or local court under applicable federal, state or local laws, arising out of or relating to your employment with the Company or the termination of your employment including claims arising out of or related to your hiring, recruitment, compensation and termination, and including claims you may have against the Company or its officers, directors, supervisors, managers, employees or agents, or that the Company may have against you.  Covered Claims include, but are not limited to, claims for breach of any contract or covenant (express or implied), tort claims, claims for wages or other compensation, claims for wrongful termination (constructive or actual), claims for discrimination, harassment or retaliation (including, but not limited to, harassment or discrimination based on race, age, color, sex, gender, gender identity, transgender status, sexual orientation, national origin, alienage or citizenship status, creed, religion, marital status, partnership status, familial status, domestic violence victim status, military status, predisposing genetic characteristics, medical condition including pregnancy, psychological condition, mental condition, criminal accusations and convictions, disability, or any other trait or characteristic protected by federal, state, or local law, claims for violation of any federal, state, local or other governmental law, statute, regulation, or ordinance, including, but not limited to, all claims arising under federal law such as:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:77px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Age Discrimination in Employment Act; the Older Workers Benefits Protection Act; Title VII of the Civil Rights of 1964; Sections 1981 through 1988 of Title 42 of the United States Code; the Civil Rights Act of 1991; the Equal Pay Act; the Americans with Disabilities Act; the Rehabilitation Act; the Employee Retirement Income Security Act; the Worker Adjustment and Retraining Notification Act; the National Labor Relations Act; the Fair Credit Reporting Act; the Occupational Safety and Health Act; the Uniformed Services Employment and Reemployment Act; the Employee Polygraph Protection Act; the Immigration Reform Control Act; the Family and Medical Leave Act; the Genetic Information Nondiscrimination Act; the Federal False Claims Act; the Patient Protection and Affordable Care Act; the Consolidated Omnibus Budget Reconciliation Act; and the Lilly Ledbetter Fair Pay Act;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and all claims arising under state and local law, such as:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:77px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The New Jersey Law Against Discrimination; the New Jersey Discrimination in Wages Law; the New Jersey Security and Financial Empowerment Act; the New Jersey Temporary Disability Benefits and Family Leave Insurance Law; the New Jersey Domestic Partnership Act; the New Jersey Conscientious Employee Protection Act; the New Jersey Family Leave Act; the New Jersey Wage Payment Act; the New Jersey Equal Pay Law; the New Jersey Occupational Safety and Health Law; the New Jersey False Claims Act; the New Jersey Smokers&#8217; Rights Law; the New Jersey Genetic Privacy Act; the New Jersey Fair Credit Reporting Act; the New Jersey Emergency Responder Leave Law; the New Jersey Millville Dallas Airmotive Plant Job Loss Notification Act (a/k/a the New Jersey WARN Act); Gender Inequity Law; and the New Jersey Earned Sick Leave Law.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The laws listed above should be interpreted as including all amendments to those laws and together with all of their respective implementing regulations, and any and all other federal, state and local laws that govern your employment with the Company or the termination of that employment for any reason.  Covered Claims under this Agreement include claims arising out of or related to acts or omissions that occurred before entering into this Arbitration Agreement and those that may occur in the future.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Claims Not Covered</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding any other provision of this Arbitration Agreement, this Arbitration Agreement does not mandate arbitration of:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">disputes arising under your Confidentiality, Non-Disclosure and Non-Competition Agreement with the Company; OR </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">claims for Workers&#8217; Compensation benefits;  OR</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">claims for unemployment compensation benefits;  OR</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any other claims that, as a matter of law, cannot be subject to mandatory arbitration.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings 3;font-size:12pt;">&#218;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding any other provision of this Arbitration Agreement, nothing in this Arbitration Agreement prevents you or shall be interpreted to mean that you are precluded from filing charges or complaints with the National Labor Relations Board (NLRB), the Equal Employment Opportunity Commission (EEOC), the Securities and Exchange Commission (SEC) or any equivalent state or local agency.  Nor does this Arbitration Agreement prevent you from testifying or participating in any proceedings before those administrative agencies.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver of Class and Collective Actions</font><font style="font-family:inherit;font-size:12pt;">.  You and the Company expressly intend and agree that:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">class and collective action procedures shall not be asserted and will not apply in any arbitration pursuant to this Agreement; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">neither you nor the Company will assert class or collective claims against the other in court, in arbitration or otherwise;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">each Party shall only submit individual claims in arbitration and will not seek to represent the interests of any other person; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any claims by you will not be joined, consolidated or heard together with the claims of any other employee; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">no decision or arbitral award determining an issue with a similarly-situated employee shall have any preclusive effect in any arbitration between the Parties, and the Arbitrator shall have no authority to give preclusive effect to the issues determined in any arbitration between the Company and any other employee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver of Trial by Jury</font><font style="font-family:inherit;font-size:12pt;">.  The Parties understand and fully agree that, by entering into this Arbitration Agreement, they are giving up their constitutional right to have a trial by jury, and are giving up their normal rights of appeal following the issuance of the arbitrator&#8217;s award except as otherwise provided by applicable law.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Claims Procedure</font><font style="font-family:inherit;font-size:12pt;">.  Arbitration shall be initiated by the express written notice of either you or the Company.  The Party initiating the arbitration must give written notice of any claim to the other Party.  Written notice of your claim shall be mailed by certified or registered mail, return receipt requested, to Employer&#8217;s General Counsel at Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512.  Written notice of a claim by the Company will be mailed to your last known address.  The written notice shall identify and describe the nature of all claims asserted and the facts supporting the claims.  Written notice of arbitration shall be initiated within the same time limitations that applicable federal and state law applies to those claims.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbitrator Selection</font><font style="font-family:inherit;font-size:12pt;">.  The Arbitrator shall be selected as provided in AAA Rules.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Discovery</font><font style="font-family:inherit;font-size:12pt;">.  The Arbitrator shall have the authority to order such discovery, by way of deposition, interrogatory, document production or otherwise, as the Arbitrator deems necessary to a full and fair exploration of the issues in dispute, consistent with the expedited nature of arbitration.  The Arbitrator shall have the authority to set deadlines for completion of discovery.  The Arbitrator shall decide all discovery disputes.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Governing Law; Substantive Law</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement and any arbitration shall be governed by the Federal Arbitration Act (FAA) to the exclusion of any state law inconsistent with the FAA.  The Arbitrator shall apply the substantive state or federal law as applicable to the claims asserted in arbitration.  Claims arising under federal law shall be determined in accordance with federal law.  Common law claims shall be determined in accordance with the substantive law of the state your assigned primary office location during the last six months of your employment with the Company, without regard to conflicts of law principles.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compelling Arbitration; Enforcing Award</font><font style="font-family:inherit;font-size:12pt;">.  Either Party may ask a court to stay any court proceeding to compel arbitration under this Arbitration Agreement, and to confirm, vacate or enforce an arbitration award.  Judgment on the award rendered by the Arbitrator may be entered in any state or federal court of competent jurisdiction located in the state of your employment location for the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbitration Fees and Costs</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall be responsible for the Arbitrator&#8217;s fees and arbitration expenses and any other costs unique to the arbitration hearing, except that you shall be responsible for paying the initial filing fees as provided by the AAA&#8217;s Rules.  Each Party shall pay its own deposition, witness, expert and attorneys&#8217; fees and all other expenses to the same extent as if the matter were proceeding in court.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Term of Agreement; Modification in Writing</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement shall survive the termination of your employment.  This Arbitration Agreement can only be revoked or modified in a writing that specifically states an intent to revoke or modify this Arbitration Agreement and is signed by both you and the President of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:12pt;">.  The Company may freely assign this Arbitration Agreement at any time.  This Arbitration Agreement shall inure to the benefit of the Company&#8217;s successors and assigns.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement represents the entire agreement of the parties with respect to the subject matter covered and cannot be modified or amended except in a writing signed by both parties.  The waiver by any party to this Arbitration Agreement or a breach of any of the provisions of this Arbitration Agreement shall not operate or be construed as a waiver of any subsequent or simultaneous breach.  This Arbitration Agreement supersedes any inconsistent agreements between the Parties with respect to the subject matter of the Arbitration Agreement.  This Agreement does not supersede:  (1) the Employment Agreement between you and the Company; (2) the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement </font><font style="font-family:inherit;font-size:12pt;">between you and the Company; or (3)&#160;any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Arbitration Agreement is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable provision shall be severed and that adjudication shall not affect the validity of the remainder of this Arbitration Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Voluntary Agreement</font><font style="font-family:inherit;font-size:12pt;">.  By executing this Arbitration Agreement, the Parties represent that they have been given the opportunity to fully review its terms.  You acknowledge and agree that you have had an opportunity to ask questions and consult with an attorney of your choice, at your expense, before signing this Arbitration Agreement.  The Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement.  YOU AND THE COMPANY FULLY UNDERSTAND AND AGREE THAT YOU AND THE COMPANY ARE GIVING UP CERTAIN RIGHTS OTHERWISE AFFORDED BY CIVIL COURT ACTIONS INCLUDING, BUT NOT LIMITED TO, THE RIGHT TO A JURY OR COURT TRIAL AND THE RIGHT TO BRING ANY CLAIM AS A CLASS OR COLLECTIVE ACTION.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">__________________&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Signature:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">&#32;_______________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;February 24, 2020_________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Home Address:&#160;&#160;&#160;&#160;[&#8230;]_</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ David Clark</font><font style="font-family:inherit;font-size:11pt;">___________________________</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">David Clark</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Chief People Officer</font></div><div><a name="s215439F1FC9DC8270B999C032DB6B10D"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT C</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;padding-bottom:16px;padding-top:9px;text-align:left;padding-left:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0e0e0e;">Reporting to the CEO, the </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Chief Legal Officer and Corporate Secretary</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0e0e0e;">will be the senior legal advisor to the CEO, the Board of Directors, and the senior management team. As such, the Chief Legal Officer and General Counsel will have global responsibility for management and oversight of all legal issues and the provision of legal services, counsel and advice to the leadership team including R&amp;D, Commercial, Corporate Development and Business Development, and general administration. The General Counsel will oversee and develop the internal legal leadership role, as well as be expected to grasp quickly and preside over legal and key operational aspects of the company's global activities, as well as contribute more broadly to other matters as required.</font></div><div style="line-height:126%;padding-bottom:16px;text-align:left;padding-left:65px;text-indent:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0e0e0e;">The Chief Legal Officer and General Counsel will be highly "solutions oriented" while providing constructive guidance that protects the company's and shareholders' interests and stimulates profitable growth. The Chief Legal Officer and General Counsel must possess a proven ability to navigate business challenges and provide substantive advice on issues such as: securities laws; corporate governance; litigation; competition/antitrust; regulatory and compliance issues; intellectual property; risks and strategies; labor and employment matters; government  affairs; pricing and reimbursement; transactions including mergers and acquisitions, licensing, and strategic alliances; and special projects. The General Counsel will have experience overseeing a company's commercial expansion in the U.S. and E.U., including both the creation of international entities in preparation for and the subsequent launch of pharmaceutical drug products, preferably of both small molecule and biologics and ideally for one or more orphan designated drugs.  The Chief Legal Officer and General Counsel must be an "enabler and facilitator'' as well as a strong and agile leader, and be viewed as such by all constituencies including senior management, the Board and outside counsel.</font></div><div style="line-height:126%;padding-bottom:16px;text-align:left;padding-left:65px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0e0e0e;">As a key guardian of the company's culture and its values, the Chief Legal Officer and General Counsel will ensure that the business practices, policies and activities of Amicus meet not only legal and regulatory requirements but the standards and best practices of a growing and successful company. S/he will be expected to be accessible, motivational and credible to the legal team as well as to senior management, peers and staff across the company.</font></div><div style="line-height:120%;padding-bottom:1px;padding-top:9px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0e0e0e;">KEY RESPONSIBILITIES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:9px;text-align:left;padding-left:65px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0e0e0e;">Areas of specific responsibility and attention include the following</font><font style="font-family:inherit;font-size:12pt;color:#545454;">:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:137px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:12pt;padding-left:113px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:125%;text-align:left;font-size:12pt;text-indent:-24px;"><font style="font-family:inherit;font-size:12pt;color:#0e0e0e;">Provide legal and business counsel to the Amicus Board of Directors, CEO and company, advising/handling major business issues/problems, including securities matters, litigation, intellectual property, regulatory and compliance issues, employment </font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">matters, and business transactions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:137px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:113px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Manage matters as they relate to the Board of Directors, including leading the preparation, review and documentation of board-related activities, such as meetings of the board and board committees, the annual meetings of shareholders and the preparation of proxy materials.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Provide international legal expertise necessary to support the establishment of E.U</font><font style="font-family:inherit;font-size:12pt;color:#464646;">.</font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">as well as U</font><font style="font-family:inherit;font-size:12pt;color:#464646;">.</font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">S</font><font style="font-family:inherit;font-size:12pt;color:#2a2a2a;">. </font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">commercial operations and product launch of Amicus</font><font style="font-family:inherit;font-size:12pt;color:#2a2a2a;">' </font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Migalastat and all future products.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Participate and contribute to the overall management of the company as a member of the Leadership Team. Senior executive management should expect to receive reliable information and insights into major legal issues facing the company, as well as the practicality of alternative strategies or decisions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Proactively identify potential problems and devise creative solutions; aggressively support legal/business needs; recruit and manage a small corporate legal staff to be determined</font><font style="font-family:inherit;font-size:12pt;color:#2a2a2a;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Manage a legal team including ability to attract, motivate, mentor and retain key talent.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Manage a network of outside law firms handling intellectual property, major litigation, securities matters, and acquisitions/divestitures requiring outside counsel, as well as municipal, state and federal government environmental, employment and labor relations issues</font><font style="font-family:inherit;font-size:12pt;color:#2a2a2a;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Continue oversight of the company</font><font style="font-family:inherit;font-size:12pt;color:#464646;">'</font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">s business ethics, values, and legal compliance training initiatives.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Determine corporate legal policies, protecting the legal interests of the corporation and ensuring that the business practices, policies, and activities of the corporation meet legal and regulatory requirements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Proactively monitor the regulatory environment concerning current mandates and future trends that will impact Amicus and provide advice regarding same, including issues of pricing and reimbursement, pharmaceutical advertising and promotion</font><font style="font-family:inherit;font-size:12pt;color:#2a2a2a;">, </font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">etc.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Facilitate development and closure of targeted transactions and strategic initiatives.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;font-weight:bold;">PROFESSIONAL EXPERIENCE/ QUALIFICATIONS</font></div><table cellpadding="0" cellspacing="0" style="padding-top:9px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">A minimum of fifteen years of experience as an attorney, preferably both, with a well-respected law firm and within a public biotechnology/pharmaceutical company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Credibility and stature to be a key member of senior management. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">S/He will be outwardly focused, proactive about company affairs, engaged in the business and able to perform well beyond the legal technical expertise. Importantly </font><font style="font-family:inherit;font-size:12pt;color:#282828;">, </font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">the selected candidate will share Amicus </font><font style="font-family:inherit;font-size:12pt;color:#282828;">' </font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">values of developing breakthrough therapies for patients with important unmet medical needs. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Will be a person of passion, inspired by the company</font><font style="font-family:inherit;font-size:12pt;color:#282828;">'</font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">s mission and able to inspire and reinforce the mission daily.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Will have the ability to act as both a legal and business advisor possessed of strategic and tactical vision who can function effectively across a broad range of issues</font><font style="font-family:inherit;font-size:12pt;color:#282828;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:25.333333333333332px;"><div style="line-height:125%;text-align:left;font-size:12pt;text-indent:-25.333333333333332px;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">A broad-based commercial legal experience with a sophisticated knowledge of complex financial transactions and securities matters and a strong knowledge of corporate governance and SEC requirements.</font></div></td></tr></table><div style="line-height:124%;text-align:left;padding-left:76px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:124%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:26.666666666666668px;"><div style="line-height:124%;text-align:left;font-size:12pt;text-indent:-26.666666666666668px;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">The ability and confidence to effectively represent the company to a variety of both internal and external constituencies.</font></div></td></tr></table><div style="line-height:126%;text-align:left;padding-left:76px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:26.666666666666668px;"><div style="line-height:126%;text-align:left;font-size:12pt;text-indent:-26.666666666666668px;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Experience overseeing a company</font><font style="font-family:inherit;font-size:12pt;color:#282828;">'</font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">s commercial expansion in the U</font><font style="font-family:inherit;font-size:12pt;color:#3d3d3d;">.</font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">S</font><font style="font-family:inherit;font-size:12pt;color:#4d4d4d;">. </font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">and E.U</font><font style="font-family:inherit;font-size:12pt;color:#4d4d4d;">.</font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">, including both the creation of international entities in preparation for and the subsequent launch of pharmaceutical drug products, preferably of both small molecule and biologics and for one or more orphan designated drugs.</font></div></td></tr></table><div style="line-height:126%;text-align:left;padding-left:76px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:26.666666666666668px;"><div style="line-height:126%;text-align:left;font-size:12pt;text-indent:-26.666666666666668px;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Proven success in building legal structures and the systems and processes required to have them function in an effective, responsive and timely fashion.</font></div></td></tr></table><div style="line-height:126%;text-align:justify;padding-left:76px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:26.666666666666668px;"><div style="line-height:126%;text-align:justify;font-size:12pt;text-indent:-26.666666666666668px;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Proven success in managing complex and multi-party legal and business relationships</font><font style="font-family:inherit;font-size:12pt;color:#282828;">,</font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">&#32;proven people skills and in-depth experience with successfully harmonizing diverse and competing interests</font><font style="font-family:inherit;font-size:12pt;color:#3d3d3d;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:76px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:26.666666666666668px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-26.666666666666668px;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Unimpeachable ethics.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:98px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:76px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:26.666666666666668px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-26.666666666666668px;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">A hands-on style and attitude as well as the ability to operate independently or in a team.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:21px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:124px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:100px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:26.666666666666668px;"><div style="line-height:126%;text-align:left;font-size:12pt;text-indent:-26.666666666666668px;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Experience in a biotech or pharmaceuticals company (required), and knowledge of multiple therapeutic areas</font><font style="font-family:inherit;font-size:12pt;color:#282828;">; </font><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">knowledge of therapeutic areas of rare diseases would be a plus.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:124%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:17.333333333333332px;"><div style="line-height:124%;text-align:left;font-size:12pt;text-indent:-17.333333333333332px;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Knowledge of compliance practices and mandates, including global pharmaceutical marketing.</font></div></td></tr></table><div style="line-height:124%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="sD4B0FE8BDE941C78FDCE9C032DE0392F"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:30px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">A working understanding of intellectual property as it relates to the compounds and medicines that are the products and assets of the Company, including experience with licensing.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:12pt;padding-left:42px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Proven experience in structuring, negotiating, and drafting documentation for relevant transactions including mergers and acquisitions, strategic alliances, and joint venture agreements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:40px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Experience assessing potential concerns, identifying and managing risk, and proactively managing outcomes with creativity and strategic planning.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:40px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">The ability to manage and work with outside counsel and appropriately assess when consultation with outside counsel is appropriate.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:40px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Depth of knowledge in the regulatory landscape of the pharmaceutical sector, particularly but not exclusively the U.S. regulatory arena.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:13px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">EDUCATION</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:9px;text-align:left;padding-left:73px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0f0f0f;">Law degree from a well-regarded American law school is required</font><font style="font-family:inherit;font-size:12pt;color:#5e5e5e;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:9px;text-align:left;padding-left:73px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LOCATION</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This position will be based at 3675 Market St., Philadelphia, PA</font><font style="font-family:inherit;font-size:12pt;color:#0070c0;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or as indicated in the Employment Contract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Travel &#8211; 15%</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>5
<FILENAME>exhibit1046bradleycamp.htm
<DESCRIPTION>EXHIBIT 10.46
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5B66ADCD68D701DE176B9C01CC332B09"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THIS EMPLOYMENT AGREEMENT</font><font style="font-family:inherit;font-size:12pt;">&#32;(this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), dated as of February 18, 2020 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), between AMICUS THERAPEUTICS, INC., a Delaware corporation having an office at 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and Bradley Campbell, an individual residing at [&#8230;], (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) (together, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">parties</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS,</font><font style="font-family:inherit;font-size:12pt;">&#32;the Company wishes to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">continue to</font><font style="font-family:inherit;font-size:12pt;">&#32;employ Employee, and Employee wishes to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">continue to</font><font style="font-family:inherit;font-size:12pt;">&#32;be employed by Company, on the terms and conditions set forth herein; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:inherit;font-size:12pt;">&#32;in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the sufficiency and receipt whereof is hereby acknowledged, the parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">Section 1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:12pt;">.  Unless otherwise defined herein, the following terms shall have the following respective meanings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accrued Amounts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, as of the termination of Employee&#8217;s employment:  (a)&#160;the total of any expenses properly incurred by Employee under Section 3.4(b) that have not previously been reimbursed as of the effective date of the termination; (b)&#160;the sum of Employee&#8217;s accrued, but unused, vacation time, if any, as of the effective date of the termination; and (c) any accrued and unpaid Base Salary through and including the effective date of Employee&#8217;s termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any other company, directly or indirectly, controlling, controlled by or under common control with the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cause</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Employee&#8217;s: (i)&#160;willful or deliberate misconduct that has or could reasonably be expected to have a materially adverse impact on the reputation or business of the Company (or an Affiliate), or that results in gain or personal enrichment of Employee to the detriment of the Company (or an Affiliate); (ii)&#160;violation of Company policy including, but not limited to, policies prohibiting harassment and other workplace misconduct, and policies governing corporate compliance; (iii) misappropriation of the funds or assets of the Company (or an Affiliate); (iv) conviction, plea of guilty, admission to facts sufficient for a finding of guilt, or plea of no contest (or nolo contendere) to: (a) any felony, or (b) any misdemeanor involving fraud, theft, dishonesty, wrongful taking of property, embezzlement, bribery, forgery or extortion; (v) material breach of this Agreement; (vi)&#160;material breach of the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">; (vii) breach of Employee&#8217;s duty of loyalty to the Company; (viii) disqualification, bar or suspension by any governmental authority from performing any of the duties contemplated by this Agreement; (ix)&#160;material failure to perform Employee&#8217;s duties or obligations hereunder (other than as a result of being Unable to Work); or (x)&#160;willful failure to adhere to or carry out lawful duties or directives of the Company&#8217;s Chief Executive Officer (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CEO</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or Board of Directors (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Notwithstanding anything to the contrary herein, the Company shall not be deemed to have terminated Employee for Cause for the events described above in subsections (ix) or (x) unless the CEO or Board, as applicable, has determined that such events are amenable to cure and given Employee written notice of the occurrence of the claimed event(s) constituting Cause and Employee has failed to cure such event(s) within fourteen (14) calendar days after Employee&#8217;s receipt of such notice (or such other period as may be deemed reasonable by the CEO or Board under the circumstances and communicated to Employee).  The other events described above are not subject to an opportunity to cure but the Company may, in its sole discretion, conduct an investigation into those events and provide the employee a full opportunity to participate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any of the following: (i)&#160;when any person or entity who is not currently a stockholder of the Company (as of the date of this Agreement) becomes the beneficial owner of greater than 50% of the then-outstanding voting power of the Company; (ii)&#160;when a merger or consolidation with another entity occurs that causes the voting securities of the Company outstanding immediately before the transaction to constitute less than a majority of the voting power of the voting securities of the Company or the surviving entity outstanding immediately after the transaction; or (iii)&#160;when a sale or disposition of all or substantially all of the Company&#8217;s assets occurs.  Notwithstanding the foregoing, no event shall be deemed to be a Change in Control Event unless such event would also be a Change in Control under Section 409A and the rules and regulations promulgated thereunder (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 409</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or would otherwise be a permitted distribution event under Section 409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">&#8221; means:  (i) payment of an amount equal to one and one-half (1.5) times Employee&#8217;s then current Base Salary, payable in installments over eighteen (18)&#160;months, commencing within sixty (60) calendar days after the resignation or termination (collectively, &#8220;termination&#8217;) of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices for its senior management personnel; (ii) payment of an amount equal to 100% of the target Bonus for the calendar year in which such termination occurs (such amount being payable in a lump sum), payable within seventy five (75) calendar days following such termination ; (iii) the accelerated vesting of stock options held by Employee immediately prior to such termination (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Options</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such that all Options will become vested as of the date of Employee&#8217;s termination; (iv) the accelerated vesting of restricted stock grants held by Employee immediately prior to such termination (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Grants</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such that all Grants will become vested as of the date of Employee&#8217;s termination; (v) the accelerated vesting of performance restricted stock units held by Employee immediately prior to such termination at the applicable performance targets or such greater amounts as determined by the Board of Directors in their sole discretion; and (vi) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of eighteen (18) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that  the Company will pay the full premiums otherwise payable for such coverage during such 18 month period.  Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Change in Control Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Good Reason</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the occurrence of one or both of the following events without Employee&#8217;s consent: (i)&#160;the Company&#8217;s material diminution of Employee&#8217;s authority, duties, or responsibilities as set forth in this Agreement; or (ii)&#160;the Company&#8217;s change in the principal geographic location at which Employee provides services to the Company to a location more than thirty (30) miles from Employee&#8217;s assigned primary office location, unless such relocation is only temporary, for a reasonable period of time, or unless such relocation merely constitutes travel reasonably required in connection with the performance of Employee&#8217;s duties.  Notwithstanding anything to the contrary herein, Employee shall not be deemed to have resigned for Good Reason unless: (a) Employee had provided to the Company written notice within thirty (30) calendar days of the occurrence of the claimed event(s) constituting Good Reason, specifying in detail the basis for such Good Reason; (b) the Company fails to cure the Good Reason within thirty (30) calendar days after its receipt of such notice, and (c) Employee terminates employment within sixty (60) calendar days after providing notice to Company of the claimed event(s) constituting Good Reason. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (i) payment of an amount equal to Employee&#8217;s then current Base Salary, payable in installments over twelve (12)&#160;months, commencing within sixty (60) calendar days of the termination of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices then in effect for its senior management personnel; (ii) payment of a bonus equal to 100% of the target Bonus for the calendar year in which such termination occurs pro-rated for the number of days actually worked in the year of termination, payable within seventy five (75) calendar days following such termination; (iii) the accelerated vesting of the Options, such that the portion of the Options that was otherwise scheduled to vest during the twelve (12)&#160;month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination;  (iv) the accelerated vesting of RSUs, such that the portion of RSUs that was otherwise scheduled to vest during the twelve (12) month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination; (v)  the accelerated vesting of PRSUs, such that the portion of PRSUs that was otherwise scheduled to vest during the twelve month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination; and (vi)in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.  Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Unable to Work&#8221; means the determination by the Company, following an interactive process, that Employee has become physically or mentally incapable of performing Employee&#8217;s essential job functions, with or without a reasonable accommodation, following any period during which such status would be protected under applicable law.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employment</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duties and Responsibilities</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of this Agreement, Employee will be employed by the Company as President &amp; Chief Operating Officer or in such other position as may be mutually agreed upon by the parties.  A Job Description setting forth Employee&#8217;s duties and responsibilities is attached as Exhibit C.  Employee accepts such employment, and agrees to perform all of the duties and accept all of the responsibilities accompanying such position.  Employee agrees to serve the Company faithfully and to the best of Employee&#8217;s abilities, and to devote all of Employee&#8217;s business time, skill and attention to such service.  Employee is expected to be available for meetings on a regular basis, upon request by the Company, at the Company&#8217;s Cranbury, New Jersey, and Philadelphia, Pennsylvania, locations or such other Company locations as needed including, but not limited to, the Company&#8217;s international offices.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Full Time and Attention</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall devote Employee&#8217;s full business time and best efforts to the performance of Employee&#8217;s duties and to the furtherance of the Company&#8217;s interests.  During Employee&#8217;s employment with the Company, Employee may not hold another position of employment, or be retained as a consultant, or engage in any other business activity (whether full-time or part-time, whether or not for compensation), unless the Company gives Employee prior written permission to do so.  Notwithstanding anything stated in this provision to the contrary, Employee is permitted to engage in charitable activities, as long as they do not interfere with Employee&#8217;s employment obligations to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Policies</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment with the Company, Employee will be subject to all applicable employment and other policies of the Company, as outlined in the Amicus Employee Handbook and as otherwise published by the Company in writing.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compensation and Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, the Company shall pay Employee a salary at the gross annual rate of $515,904 (less applicable withholding) or such greater amount as the Board or a committee thereof may from time to time establish pursuant to the terms hereof (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Such Base Salary shall be reviewed annually and may be increased, but not decreased, by the Board or a committee thereof in its sole discretion. The Base Salary shall be payable in accordance with the Company&#8217;s customary payroll practices for its senior management personnel.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee shall be eligible to participate in the Company&#8217;s bonus programs as may be in effect with respect to senior management personnel. Employee shall be eligible to earn an annual target bonus of 100% of the Base Salary in cash (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">&#8221;) such actual amount determined by the Company Compensation Committee in its absolute discretion and at 50% of base salary; provided, however, that notwithstanding anything to the contrary herein or in any bonus program, Employee must be employed by the Company as of December 31 of the applicable calendar year, in order to be eligible to earn a Bonus for such calendar year.  Any Bonus payment to which Employee becomes entitled hereunder shall be paid to Employee in a lump sum (less applicable withholding) on or before the 15</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of the third month following the end of the calendar year in which the Bonus was earned.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Equity</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan and such other equity plans as the Company may adopt from time to time including, but not limited to, an Employee Stock Purchase Plan, during Employee&#8217;s employment with the Company, Employee will be eligible to receive stock options, Restricted Stock Units and Performance Restricted Stock Units pursuant to any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  Unless otherwise provided in this Agreement, the terms and conditions of the applicable equity plan will govern all equity grants to Employee (including vesting of options and units), including with regard to the impact of the end of Employee&#8217;s employment on such equity grants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefit Plans</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee may participate in any benefit plans (including health and medical insurance) as may be in effect with respect to senior management personnel of the Company, including any equity plan, subject to the eligibility and contribution requirements, enrollment criteria and other terms and conditions of such plans.  The Company reserves the right to modify, amend and eliminate any such plans, in its sole and absolute discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reimbursement of Expenses</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, the Company shall pay or promptly reimburse Employee, upon submission of proper invoices or other documentation in accordance with the Company&#8217;s policies and procedures, for all reasonable out-of-pocket business, entertainment and travel expenses incurred by Employee in the performance of Employee&#8217;s duties.  Any taxable reimbursement of business or other expenses as specified under this Agreement shall be subject to the following conditions:  (i)&#160;the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year; (ii)&#160;the reimbursement of an eligible expense shall be made no later than the end of the calendar year after the year in which such expense was incurred; and (iii)&#160;the right to reimbursement shall not be subject to liquidation or exchange for another benefit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Vacation</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee shall be entitled to vacation in accordance with the policies of the Company applicable to senior management personnel as may be in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Withholding</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall withhold from all amounts payable or benefits accorded to Employee all federal, state and local income, employment and other taxes, as and in such amounts as may be required by applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duration of Employment</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s employment with the Company shall begin on the Effective Date and continue until Employee&#8217;s employment is terminated by either Employee or the Company.  At all times, Employee&#8217;s employment with the Company shall be &#8220;at-will,&#8221; meaning that either Employee or the Company may terminate the employment at any time, for no reason or any lawful reason.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination; Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notice of Termination</font><font style="font-family:inherit;font-size:12pt;">.  Any termination of Employee&#8217;s employment by the Company or by Employee (other than on account of death) shall be communicated to the other party by written notice that indicates the specific termination provision in this Agreement relied upon.  Except as otherwise expressly provided in this Agreement or the notice, the termination shall take effect immediately.  The parties agree that the notice requirements set forth in this Agreement do not alter the &#8220;at will&#8221; nature of Employee&#8217;s employment, as described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Generally</font><font style="font-family:inherit;font-size:12pt;">.  Upon termination of Employee&#8217;s employment for any reason, Employee shall be deemed simultaneously to have resigned as a member of the Board, if applicable, and from any other position or office Employee may at the time hold with the Company or any of its Affiliates.  Employee agrees to cooperate with the Company by signing any necessary documents and taking any other steps necessary to effectuate Employee&#8217;s resignation from the Board, if applicable, and from any other position or office Employee may hold with the Company or any of its Affiliates.  In addition, upon termination of Employee&#8217;s employment for any reason, the Company shall pay Employee the Accrued Amounts.  The Accrued Amounts will be paid within the time required by applicable law.  The impact of the termination of Employee&#8217;s employment on the Employee&#8217;s participation in the Company&#8217;s health plans is addressed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by Employee</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resignation Independent of a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If Employee resigns and a Change in Control Event has not occurred in the prior 12 months, then (irrespective of whether the resignation was with or without Good Reason):  (i)&#160;Employee shall receive no further compensation or remuneration of any kind other than the Accrued Amounts; and (ii)&#160;at the end of the month in which the resignation takes effect, Employee shall cease to be covered under or permitted to participate in or receive any of the benefits described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3.4</font><font style="font-family:inherit;font-size:12pt;">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Good Reason Resignation Within 12 Months of a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If Employee resigns for Good Reason within&#160;twelve (12)&#160;months after a Change in Control Event, Employee will be entitled to receive, in addition to the Accrued Amounts, </font><font style="font-family:inherit;font-size:12pt;">Change in Control Severance Benefits.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by the Company</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Without Cause Within 12 Months After a Change in Control Event.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;If the Company terminates Employee&#8217;s employment without Cause within 12 months after a Change in Control Event, then in lieu of any other payments, rights or benefits under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(a)</font><font style="font-family:inherit;font-size:12pt;">, Employee will be entitled to receive Change in Control Severance Benefits in addition to the Accrued Amounts.  All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Without Cause Not Within 12 Months After a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If the Company terminates Employee&#8217;s employment without Cause (other than within 12 months after a Change in Control Event), then Employee will be entitled to receive Severance Benefits in addition to the Accrued Amounts</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">For Cause</font><font style="font-family:inherit;font-size:12pt;">.  If the Company terminates Employee&#8217;s employment for Cause at any time, Employee shall: (i)&#160;receive no further compensation or remuneration of any kind (including any Base Salary or Bonus hereunder) other than the Accrued Amounts; and (ii)&#160;at the end of the month in which the termination takes effect, cease to be covered under or be permitted to participate in or receive any of the benefits described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;3.4</font><font style="font-family:inherit;font-size:12pt;">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination upon Death or Inability to Work</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Death.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Employee&#8217;s employment shall terminate immediately upon Employee&#8217;s death.  In the event of Employee&#8217;s death during the course of Employee&#8217;s employment with the Company, the Company will pay the Employee&#8217;s estate the Accrued Amounts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inability to Work.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Except as otherwise provided by applicable law, the Company may terminate Employee&#8217;s employment in the event Employee is Unable to Work.  In the event of Employee&#8217;s death or termination by the Company due to Employee being Unable to Work, Employee shall receive: (a) the Accrued Amounts, and (b) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Release and Compliance Required</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s receipt of any right, payment or benefit under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;is subject to and conditioned upon: (a)&#160;Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company; and (b) Employee&#8217;s reaffirmation of and continuing compliance with Employee&#8217;s contractual and legal obligations to the Company, as expressly set forth in the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="font-family:inherit;font-size:12pt;">.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;409A</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:12pt;">.  This section is intended to help ensure that compensation paid or delivered to Employee pursuant to this Agreement either is paid in compliance with, or is exempt from, IRC Section&#160;409A. However, the Company does not warrant to Employee that all compensation paid or delivered to Employee for Employee&#8217;s services will be exempt from, or paid in compliance with, Section&#160;409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Amounts Payable On Account of Termination</font><font style="font-family:inherit;font-size:12pt;">.  For the purposes of determining when amounts otherwise payable on account of Employee&#8217;s termination of employment under this Agreement will be paid, which amounts become due because of Employee&#8217;s termination of employment, &#8220;termination of employment&#8221; or words of similar import, as used in this Agreement, shall be construed as the date that Employee first incurs a &#8220;separation from service&#8221; for purposes of Section&#160;409A on or following termination of employment.  Furthermore, if Employee is a &#8220;specified employee&#8221; of a public company as determined pursuant to Section&#160;409A as of Employee&#8217;s termination of employment, any amounts payable on account of Employee&#8217;s termination of employment that constitute deferred compensation within the meaning of Section&#160;409A and that are otherwise payable during the first six months following Employee&#8217;s termination (or prior to Employee&#8217;s death after termination) shall be paid to Employee in a cash lump-sum on the earlier of: (i)&#160;the date of Employee&#8217;s death; or (ii)&#160;the first business day of the seventh calendar month immediately following the month in which Employee&#8217;s termination occurs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Series of Payments</font><font style="font-family:inherit;font-size:12pt;">.  Any right to a series of installment payments shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interpretative Rules</font><font style="font-family:inherit;font-size:12pt;">.  In applying Section&#160;409A to amounts paid pursuant to this Agreement, any right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Participation in Other Severance Plans.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Employee agrees and acknowledges that Employee shall not be eligible to participate in or have any right to compensation or benefits pursuant to the Company&#8217;s Change in Control Severance Plan (or any successor plan thereto) or any other Severance Plan issued by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exclusivity</font><font style="font-family:inherit;font-size:12pt;">. In the event Employee&#8217;s employment is terminated for any reason, Employee (and Employee&#8217;s eligible dependents, if any) shall not be entitled to any payments or benefits from the Company or any of its Affiliates except as specifically set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Federal Excise Tax</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Rule</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s payments and benefits under this Agreement and all other arrangements or programs related thereto shall not, in the aggregate, exceed the maximum amount that may be paid to Employee without triggering golden parachute penalties under Section&#160;280G of the Code, and the provisions related thereto with respect to such payments. If Employee&#8217;s benefits must be cut back to avoid triggering such penalties, such reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary, to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity derivative payments shall be reduced.  If an amount in excess of the limit set forth in this Section is paid to Employee, Employee must repay the excess amount to the Company upon demand, with interest at the rate provided in Section&#160;1274(b)(2)(B) of the Code.  Employee and the Company agree to cooperate with each other reasonably in connection with any administrative or judicial proceedings concerning the existence or amount of golden parachute penalties on payments or benefits Employee receives.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exception</font><font style="font-family:inherit;font-size:12pt;">.  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;shall apply only if it increases the net amount Employee would realize from payments and benefits subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;after payment of income and excise taxes by Employee on such payments and benefits.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Determinations</font><font style="font-family:inherit;font-size:12pt;">.  The determination of whether the golden parachute penalties under Section&#160;280G of the Code and the provisions related thereto shall be made by counsel chosen by Employee and reasonably acceptable to the Company. All other determinations needed to apply this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be made in good faith by the Company&#8217;s independent auditors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Computers, Property and Records</font><font style="font-family:inherit;font-size:12pt;">.  Employee agrees to handle all Company property in accordance with the Company&#8217;s policies and procedures.  Employee&#8217;s authorization to access the Company&#8217;s computer systems is limited and use of such systems to compete or prepare to compete with the Company constitutes unauthorized access that is strictly prohibited.  All records received or created by Employee in the course of employment related to the Company&#8217;s business (such as but not limited to, email, notes, files, contact lists, agendas, drawings, maps, specifications, and calendars) are the property of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resolution of Disputes</font><font style="font-family:inherit;font-size:12pt;">.  Employee and the Company hereby agree that, except for disputes regarding alleged or anticipated violations of the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, any and all disputes between them shall be resolved solely in accordance with the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">&#32;and, to the greatest extent permitted by law, Employee and the Company expressly waive their respective right to a trial by jury for any and all such disputes between them.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Conflict</font><font style="font-family:inherit;font-size:12pt;">.  Employee represents and warrants that Employee has not entered, nor will Employee enter, into any other agreements that restrict Employee&#8217;s ability to fulfill Employee&#8217;s obligations under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall be construed, interpreted and governed by the laws of the state of Employee&#8217;s assigned primary office location during the last six months of Employee&#8217;s employment with the Company, without regard to the conflicts of law principles.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Binding Effect</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall extend to and be binding upon Employee, Employee&#8217;s legal representatives, heirs and distributees and upon the Company, its successors and assigns regardless of any change in the business structure of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">.  The Company&#8217;s rights and obligations under this Agreement, including the restrictions in the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its assets, stock or business.  Employee consents to that transfer.  Employee may not assign any rights or obligations under this Agreement without the Company&#8217;s prior written consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the parties with respect thereto</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:12pt;">including Employee&#8217;s prior Agreement, dated April 23, 2014, except this Agreement does not supersede the Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A or the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as Exhibit B.  Nor does this Agreement supersede any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  No waiver, modification or change of any provision of this Agreement shall be valid unless in writing and signed by both parties.  </font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:12pt;">.  The waiver of any breach of any duty, term or condition of this Agreement shall not be deemed to constitute a waiver of any preceding or succeeding breach of the same or any other duty, term or condition of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Agreement shall be unenforceable in any jurisdiction in accordance with its terms, the provision shall be enforceable to the fullest extent permitted in that jurisdiction and shall continue to be enforceable in accordance with its terms in any other jurisdiction and the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.  All notices pursuant to this Agreement shall be in writing and shall be sent by prepaid certified mail, return receipt requested or by recognized air courier service addressed as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;If to the Company to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amicus Therapeutics, Inc. <br>1 Cedar Brook Drive <br>Cranbury, New Jersey 08512</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c/o&#160;&#160;&#160;&#160;CEO or General Counsel</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;If to Employee to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bradley Campbell <br>at the address identified herein or in Employee&#8217;s personnel records,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or to such other addresses as may hereinafter be specified by notice in writing by either of the parties, and shall be deemed given three (3)&#160;business days after the date so mailed or sent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance</font><font style="font-family:inherit;font-size:12pt;">. If reasonably requested in writing, Employee agrees within fifteen (15) business days to provide the Company with an executed IRS Form&#160;4669 (Statement of Payments Received) with respect to any taxable amount paid to Employee by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowing and Voluntary Nature of Agreement</font><font style="font-family:inherit;font-size:12pt;">. Employee acknowledges and agrees that Employee is executing this Agreement knowingly and voluntarily and without any duress or undue influence by the Company or anyone else.  Employee further acknowledges and agrees that Employee has carefully read this Agreement and fully understands it. Employee further agrees that Employee has been provided an opportunity to seek, and has received, the advice of an attorney of Employee&#8217;s choice (at Employee&#8217;s expense) before signing this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">[Signature Page Follows]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above written.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Bradley Campbell</font><font style="font-family:inherit;font-size:12pt;">__________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bradley Campbell</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ David Clark               &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;David Clark</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: Chief People Officer</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s7B4576857A0B352032999C01CC677E91"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFIDENTIALITY, NON-DISCLOSURE AND NON-COMPETITION AGREEMENT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITH</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Bradley Campbell</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement is made as of February 18, 2020 between you and Amicus Therapeutics, Inc. (the &#8220;Company&#8221;).  You agree that you are receiving adequate consideration in exchange for entering into this Confidentiality, Non-Disclosure and Non-Competition Agreement (the &#8220;Agreement&#8221;) including:  (1)&#160;at-will employment and the benefits of that employment including any grant to you of certain restricted stock units and options to purchase shares of common stock in the Company; (2)&#160;access to Confidential Information belonging to the Company; and (3) access to the Company&#8217;s business relationships.  You acknowledge that entering into this Agreement is a condition of receiving those items.  Accordingly, you agree to the following terms and conditions:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the protections provided by this Agreement are necessary to safeguard the Company&#8217;s Confidential Information (as defined below), business relationships and other business interests, and that the Company is willing to employ you, and continue to employ you, on the condition that you execute this Agreement.  You agree that the Company has spent substantial resources developing its Confidential Information and business relationships.  You also agree that protecting these assets is critical to the Company&#8217;s survival and success, and a competitor with access to those assets would have an unfair competitive advantage over the Company. Therefore, you agree that the Company has a legitimate business interest in protecting those assets and that the commitments set forth in this Agreement are a reasonable means of doing so.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that as an integral part of the Company&#8217;s business, the Company has developed, and will develop, at a considerable investment of time and expense, non-public scientific data and methods, clinical development plans and strategies, business development plans and strategies, marketing and business plans and strategies, procedures, methods of operation and marketing, financial data, lists of actual and potential customers and suppliers including buying habits of those customers, and independent sales representatives and related data, technical procedures, engineering and product specifications, plans for development and expansion, and other confidential and sensitive information, and you acknowledge that the Company has a legitimate business interest in protecting the confidentiality of such information.  You acknowledge that you will be entrusted with such information as well as confidential non-public information belonging to customers, suppliers, and other third parties.  You, therefore, acknowledge a continuing responsibility to protect such information and agree to the provisions contained herein.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Trade Secrets&#8221; shall mean information belonging to the Company or licensed by it including, without limitation, data, reports, research, drawings, specifications, software, formulae, patterns, compilations, programs, devices, methods, techniques, or processes (including such information that has commercial value to the Company from a negative viewpoint, such as the results of research which proves that certain processes used to attempt to develop new technology will be unsuccessful) which are not commonly known by or available to the public, and which information: (a)&#160;derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from their disclosure or use; (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy; and (c) as otherwise defined by law.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Proprietary Information&#8221; shall mean any information, other than Trade Secrets, without regard to form, belonging to the Company or licensed by it including, without limitation, formulae, patterns, compilations, programs, devices, methods, techniques, or processes, which is not commonly known by or available to the public and which information is material to the Company and not generally known by the public, and all notes, analyses, compilations, studies, interpretations or other documents prepared by you which contain, reflect or are based upon, in whole or in part, the information furnished to you by the Company pursuant hereto; provided, however that &#8220;Proprietary Information&#8221; shall not include any information which you can show (i) becomes patented, published or otherwise part of the public domain through no act or fault of your own, (ii) is received in good faith from any third party who has the right to disclose such information and who has not received such information, either directly or indirectly, from the Company, or (iii) any information which you can show was in your legitimate possession prior to your commencing employment with the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Confidential Information&#8221; shall mean, collectively, the information outlined in Paragraph 2 of this Agreement, Trade Secrets outlined in Paragraph 3 and Proprietary Information outlined in Paragraph 4 and all other information protected by unauthorized disclosure by law. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">You will treat as confidential and will not, without the prior written approval of the Company, directly or indirectly, use (other than in the performance of duties of employment with the Company), publish, disclose, patent, copyright, or authorize anyone else to use, publish, disclose, patent, or copyright any Confidential Information during your employment and after your employment with the Company terminates, whether such termination is voluntary or involuntary, with or without cause.  You agree to take all action reasonably necessary to protect Confidential Information from being disclosed or used by anyone other than persons authorized by the Company.  Confidential information shall not include information that: (i) is or subsequently becomes publicly available without your, or any other person or entity&#8217;s, breach of any obligation owed to the Company; (ii) was lawfully received by you from a third party free of any obligation of confidentiality owed to the Company; or (iii) you are required to disclose in a judicial or administrative proceeding or as otherwise required by law.    </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company recognizes that you, as a former employee or independent contractor of another company, may previously have been privy to trade secrets and/or confidential information of such other company, and you may be under an obligation to such other company to maintain the confidentiality of such trade secrets or confidential information.  Accordingly, to the extent you are under such an obligation, you shall not: (a) bring any records, notes, files, drawings, documents, plans and like items, electronic or otherwise, provided to you in confidence by such other company, or any copies thereof, relating to or containing or disclosing confidential information or trade secrets of any such other company, on the premises of the Company or loaded onto the Company&#8217;s computer systems or otherwise use such documents and items in the performance of services for the Company; or (b) disclose any confidential information or trade secrets provided to you in confidence by such other company in the performance of your job duties for </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">.  You represent that you are &#8220;free and clear&#8221; of any legal restrictions that might interfere with your ability to begin or continue your employment with, or perform your duties and responsibilities for, </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">such as non-compete, non-solicitation or non-disclosure restrictions imposed by current or former employers or contractors.   You confirm that you have disclosed to </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">&#32;any agreements between you and your current or former employers or contractors describing any possible restrictions on your activities. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You acknowledge that all Confidential Information and any records, files, memoranda, computer programs, reports, claims reports or records, customer lists, contracts, marketing plans, programs or forecasts and other written or printed documents or materials or other data stored on computer disks or other electronic data storage methods (&#8220;Documents&#8221;) received, created or used by you during the course of your relationship with the Company are and will remain the sole property of the Company.  You agree to return all such Documents (including all copies) to the Company promptly upon the termination of your employment, or earlier upon </font><font style="font-family:inherit;font-size:11pt;">the Company&#8217;s </font><font style="font-family:inherit;font-size:12pt;">request,  and agree that, during or after your employment, you will not, under any circumstances, without the specific authorization in writing of an officer of the Company, disclose those Documents or any information contained in such Documents to anyone outside the Company&#8217;s organization or use those Documents for any purpose other than the advancement of the Company&#8217;s interests.  Upon termination of your employment for any reason, or upon the Company&#8217;s earlier request, you also agree to immediately return to </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">all equipment and property provided to you by </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">including, but not limited to, computers, phones, pagers, thumb drives or other storage devices, iPads and other tablet devices, and any other electronic devices.  You also agree to provide </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">with all usernames, passwords, passcodes, and other information for logging into and accessing the equipment, applications, platforms, software, hardware, devices and other systems that you used or accessed in the course of, and during, your employment.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protected Conduct</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement prohibits you from disclosing Confidential Information under any of the following circumstances:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure in confidence to an attorney solely for the purpose of reporting or investigating a suspected violation of law; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure, directly or indirectly, to a Federal, State or local government official in confidence solely for the purpose of reporting or investigating a suspected violation of law; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure in a complaint or other document filed under seal in a lawsuit or other proceeding; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure to your attorney in connection with a lawsuit you file against the Company for retaliation for reporting a suspected violation of law.  Under this scenario, you may use the Confidential Information in the court proceedings as long as you file any document containing the Confidential Information under seal and do not otherwise disclose the Confidential Information, except pursuant to a Court Order.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prohibits you from filing a charge or complaint with, reporting or making disclosures (including providing supporting documents or other information) of possible violations of any law or regulation to, and/or participating in any investigation or proceeding conducted by, any self-regulatory organization or governmental agency, authority, or legislative body including, but not limited to, the Securities and Exchange Commission and/or Equal Employment Opportunity Commission or as otherwise required or allowed by law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Is intended to interfere with your rights under Section 7 of the National Labor Relations Act, including the right of employees to communicate with each other regarding the terms and conditions of their employment and to engage in concerted activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prevents you from disclosing or requires you to conceal the details of any alleged discrimination, retaliation or harassment.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Disclosure and Assignment Of Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">.  You agree to promptly disclose to the Company all &#8220;Intellectual Property&#8221; conceived or developed by you while employed by the Company that relates to the Company&#8217;s business.  The term &#8220;Intellectual Property&#8221; means any and all (i) data, reports, formulas, techniques, research, drawings, specifications, software and any other copyrightable works; (ii) Trade Secrets; and (iii) ideas, creations, inventions, discoveries, designs, devices, methods, processes and innovations whether or not patentable, and all related know-how.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Assignment of Intellectual Property Rights</font><font style="font-family:inherit;font-size:11pt;">.  You agree that all Intellectual Property conceived or developed by you while employed by the Company after the date of this Agreement shall be the exclusive property of the Company.  You hereby assign and agree to assign in the future to the Company all of your right, title and interest in and to any and all Intellectual Property related to your work at the Company, whether or not registrable under patent, copyright, trademark or similar statutes, made or conceived or reduced to practice or learned by you, either alone or jointly with others, during the period and scope of your employment with the Company.  Such assignment is perpetual and irrevocable.  Intellectual Property assigned to the Company, or to a third party as directed by the Company pursuant to this paragraph, are hereinafter referred to as &#8220;Company Intellectual Property.&#8221;  You agree to assign all right, title and interest in and to any particular Company Intellectual Property to a third party as directed by the Company.  You further agree to assign to the Company or, to the extent assignment is not permissible, waive any so-called &#8220;moral rights&#8221; in the Intellectual Property to the extent permitted by law.  You will assist the Company in every proper way to obtain, perfect, and from time to time enforce, its patent, copyright, trade secret and other rights in the Intellectual Property relating to Company Intellectual Property in any and all countries.  You hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, that you now or may hereafter have for infringement of any Intellectual Property assigned hereunder to the Company.</font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Prior Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding the foregoing, the Company agrees that you will not be obligated to assign any invention that you developed entirely on your own time, without using any equipment, supplies, facilities or trade secret information of the Company, unless such invention either:  (i) relates (at the time of conception or reduction to practice of the invention) to the Company&#8217;s business or the Company&#8217;s actual or demonstrably anticipated research, or (ii) results from any work performed by you for the Company.  Intellectual Property, if any, that you made prior to the commencement of your employment with the Company, or made outside the scope of your employment, are excluded from the scope of this Agreement.  To preclude any possible uncertainty, you have set forth on Exhibit A attached to this Agreement a complete list of all Intellectual Property that you have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement</font><font style="font-family:inherit;font-size:12pt;">&#32;of your employment with </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">, that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Agreement (collectively referred to as &#8220;Prior Intellectual Property&#8221;).</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Obligation to Keep the Company Informed</font><font style="font-family:inherit;font-size:11pt;">.  During the period of your employment, you will promptly disclose to the Company fully and in writing all Intellectual Property authored, created, conceived or reduced to practice by you, either alone or jointly with others, whether or not patentable or copyrightable or believed by you to be patentable or copyrightable.  In addition, you will promptly disclose to the Company (to be held in confidence) all patent applications filed by you or on your behalf within six months after termination of your employment (whether voluntarily or involuntarily), and to cooperate fully with a review and determination by the Company as to whether such patent applications constitute or include the Company&#8217;s Intellectual Property or Confidential Information.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Works for Hire</font><font style="font-family:inherit;font-size:11pt;">.  You acknowledge and agree that all original works of authorship that are made by you (solely or jointly with others) within the scope of your employment by the Company and that are protectable by copyright including, but not limited to, drawings, sketches and designs, are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C. Section 101).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the Company has compelling business interests in preventing the use or disclosure of its Confidential Information, or the misappropriation of its business relationships, and to protect those interests it is reasonable to restrict you from working or becoming affiliated with, either during or after the end of your employment with the Company, a Competitive Business (as defined below).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also acknowledge that the Company is engaged in a highly competitive business and that by virtue of the nature of your employment with the Company, your engaging in or working for or with any Competitive Business will cause the Company great and irreparable harm.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accordingly, you agree that, during your employment with the Company and for a period of twelve (12) months after the date of termination of your employment with the Company for any reason, whether such termination is voluntary or involuntary, by wrongful discharge or otherwise, you will not, directly, or indirectly work for or with or have any interest in any Competitive Business, whether as an individual on your own account, as a partner or joint venturer, as an employee, agent or salesperson for any person, as an officer or director of any corporation, or as a consultant or otherwise, or engage in preparations for any activity prohibited by this paragraph or any other paragraph in this Agreement without the prior specific written consent by an officer of the Company to do so provided, that the foregoing shall not prohibit ownership of the securities of a publicly-traded entity which constitute less than 2% of the outstanding voting securities of the entity.  For purposes of this Agreement, &#8220;Competitive Business&#8221; shall mean any person or entity who engages in the business of researching, developing and/or commercializing products, including but not limited to small molecules, biologics and gene therapies in the areas of Fabry disease, Pompe disease, Battens Disease, CDKL-5 Deficiency Disorder and any other condition, or any other business, in which the Company is actively engaged during the last twenty-four months of your employment.   You acknowledge that the geographic scope of this restriction is reasonable given that: (1) the Company does business and has customers and competitors throughout the world; and (2) modern communication and transportation make it easy to compete in this industry from virtually any location on earth.   Further, you acknowledge and agree that given the nature of your responsibilities for the Company and your access to its Confidential Information and business relationships, if you were to work for any Competitive Business as described in this paragraph, you would inevitably disclose Confidential Information. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Solicitation</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also acknowledge that, by virtue of your relationship with the Company, you have gained or will gain knowledge of the identity, characteristics and preferences of its customers among other Confidential Information, and that you would inevitably have to draw on such Confidential Information if you were to solicit or service the Company&#8217;s customers on behalf of a Competitive Business.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accordingly, you agree that for twelve (12) months following the termination for any reason whatsoever of your employment with the Company, you will not solicit the business of or perform any services for an actual or prospective Customer of the Company (as defined below).  You also agree that, during this twelve-month period, you will not encourage or assist any person or entity engaged in a Competitive Business to solicit or service any actual or prospective Customer of the Company covered by this paragraph.  &#8220;Customer of the Company&#8221; means any person or company that, at any time during the twenty-four (24) months prior to the end of your employment with the Company, purchases &#8211; or enters into a contract to purchase &#8211; products or services from the Company.  Customer shall also mean any prospective customer to which the Company has submitted a proposal for purchase of products or services.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also agree that, for twelve (12) months following the end of your employment with the Company for any reason, you will not directly or indirectly hire or seek to hire or retain, whether on your own behalf or on behalf of some other person or entity, any Company Personnel (as defined below).  Nor will you, during this twelve (12) month period, directly or indirectly induce or encourage any Company Personnel to leave the Company.  You acknowledge that, even after the expiration of the twelve (12) month period described in this paragraph, you will be barred from soliciting or hiring Company Personnel if, in soliciting or hiring them, you would use or disclose Confidential Information belonging to the Company.  &#8220;Company Personnel&#8221; means any employee, independent contractor or other personnel employed, retained or engaged by the Company at any time during the twenty-four (24) months prior to the termination of your employment:  (1)&#160;with whom you interacted within the scope of your employment with the Company; (2)&#160;whom you directly or indirectly supervised during your employment with the Company; or&#160;(3)&#160;regarding whom you received non-public information about his or her job responsibilities, compensation or job performance by virtue of your employment with the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Return of Property</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon termination of your employment (by the Company or you) for any reason, or upon the earlier request of the Company, you agree to immediately return to the Company all Company records and other property in your possession, custody or control including (but not limited to) anything containing Confidential Information such as documents, papers, files, records, reports, binders, notebooks, books, notes, calendars, plans, drawings, maps, specifications, blueprints, studies, photographs, video recordings, audio recordings, computers, tablets, smartphones, mobile telephones, drives, discs, and any other devices used to store electronic data, and any and all electronic copies and/or hard-copies.  Notwithstanding the foregoing, nothing in this Agreement shall prohibit you from retaining paystubs and other records regarding your compensation and benefits that the Company is required by law to provide to you.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon termination of your employment (by the Company or you) for any reason, or upon the earlier request of the Company, you agree to provide the Company with all usernames, passwords, passcodes and other information that it may need to log into and access the equipment, applications, platforms, software, hardware, devices and other systems that you used or accessed in the course of, and during, your employment.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon the Company&#8217;s request, you agree to immediately provide the Company with a written affidavit confirming that you have returned all Company property and Confidential Information, and cooperate in providing the Company, at the Company&#8217;s request, a means through which it can promptly and independently verify (including by forensic analysis, if necessary) that all Confidential Information has been removed from electronic storage devices, cloud-based storage, and accounts in your possession or control.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If you are served with a subpoena, court order, or similar legal document requiring the production of Company records or other property or the disclosure of Confidential Information, you agree to provide the Company with as much notice as is possible (presumably seven (7) business days or more) through written notification to the Company&#8217;s General Counsel and the Company&#8217;s CEO, so that the Company may take permissible steps to protect the records and information, unless such notice is prohibited by law or court order; provided, however, that nothing in this Agreement prohibits you from engaging in the Protected Conduct described in Section 9 and Section 10 of this Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Terms</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the restrictions contained in this Agreement are fair, reasonable and necessary to protect the legitimate business interests of the Company and that the Company will suffer irreparable harm in the event of any actual or threatened breach by you of this Agreement.  You agree that enforcement of the restrictions in this Agreement will not cause you any hardship, and because of your background and experience will not in any manner preclude you from becoming gainfully employed in such manner and to such extent as will provide you with a standard of living of at least the sort and fashion to which you are accustomed. You therefore agree that the Company may seek a restraining order, preliminary injunction or other court order to enforce this Agreement without the necessity of posting a bond or any security that might otherwise be required in connection with such relief.  You also agree that any request for such relief by the Company shall be in addition and without prejudice to any claim for monetary damages which the Company might elect to assert.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If any provision of this Agreement is held to be unenforceable by a court, such unenforceability shall not affect the enforceability of the remaining provisions.  Such provision shall be reformed and construed to the extent permitted by law so that it would be valid, legal and enforceable to the maximum extent possible.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that this Agreement does not give you any rights to employment by or to be retained as a consultant of the Company and, unless otherwise provided in another writing, executed by an officer of the Company and you, your relationship with the Company shall be employment &#8220;at will.&#8221;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You agree that, if you, at any time during or within one year after your employment with the Company ends, you receive an offer of employment or retention from any person or entity other than the Company, you will provide that person or entity with a copy of this Agreement.  You also agree that, at any time during, or within one year after the end of, your employment with the Company, you will, in writing, immediately after accepting (orally or in writing) any offer of employment or retention with any person or entity other than the Company:  (1)&#160;notify the Company that you accepted the offer; and (2)&#160;inform the Company of the identity of the person or entity, and of your title, responsibilities, work location and anticipated start date.  You acknowledge that the requirements set forth in this paragraph are fair, reasonable and necessary in order for the Company to adequately protect its Confidential Information and business relationships.  The Company may also provide copies of this Agreement to others including, but not limited to, customers and potential customers, and your future employers and prospective employers.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">You understand nothing in this Agreement prohibits you reporting to any governmental authority information concerning violations of law or regulations, and that you may report trade secret information to a government official or to an attorney and use it in certain proceedings without fear of prosecution or liability provided such disclosure is consistent with 18 U.S.C. 1833. If you make the disclosure to your attorney in connection with a private lawsuit, you may use the Confidential Information in the court proceedings as long as you file any document containing the Confidential Information under seal and do not otherwise disclose the Confidential Information, except pursuant to a Court Order.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement represents the entire agreement of the parties with respect to the subject matter covered and cannot be modified or amended except in a writing signed by both parties.  The waiver by any party to this Agreement or a breach of any of the provisions of this Agreement shall not operate or be construed as a waiver of any subsequent or simultaneous breach.  This Agreement supersedes any confidentiality, non-competition and non-solicitation entered into by the Company and you prior to the date of this Agreement.  This Agreement does not supersede:  (1)&#160;the Employment Agreement between you and the Company; (2)&#160;the Mutual Agreement to Arbitrate Disputes on an Individual Basis between you and the Company; or (3)&#160;</font><font style="font-family:inherit;font-size:12pt;">any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">30.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement shall be construed, interpreted and governed by the laws of the state of your assigned primary office location during the last six months of your employment with the Company, without regard to the conflicts of law principles</font><font style="font-family:inherit;font-size:11pt;">.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">31.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The rights and obligations of the Company under this Agreement shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its or their assets, stock or business.  By signing this Agreement, you consent to any such transfer.  You may not assign any rights or obligations under this Agreement without the prior written consent of the Company&#8217;s Chief Legal Officer or designee. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">By signing below, you acknowledge that you:  (1)&#160;received this Agreement fourteen (14) business days before the date on which you must return an executed copy of it to the Company; (2) have had sufficient opportunity to read each provision of this Agreement; (e)&#160;understand the meaning, effect and implications of each provision of this Agreement; (4)&#160;have had an opportunity to consult with legal counsel of your choosing (at your expense) regarding this Agreement; and (5)&#160;are not relying on any promises or representations that are not set forth in this Agreement.  By signing this Agreement, you are indicating that you are doing so freely and voluntarily and with full understanding of its terms and conditions.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">______________________</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ellen Rosenberg </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">General Counsel &amp; Corporate Secretary, Legal </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Bradley Campbell</font><font style="font-family:inherit;font-size:11pt;">_________________&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Signature:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Bradley Campbell</font><font style="font-family:inherit;font-size:11pt;">_______________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">February 28, 2020</font><font style="font-family:inherit;font-size:11pt;">__________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Home Address:&#160;&#160;&#160;&#160;[&#8230;]_____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SCHEDULE 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">PRIOR INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">List below all Intellectual Property and works of authorship that you have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of your employment with Amicus that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Confidentiality, Non-Disclosure and Non-Competition Agreement:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If additional space is needed, attach and sign additional sheets and indicate here:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">___ Additional sheets are attached.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you are not listing any Intellectual Property or works of authorship, indicate here:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">X</font><font style="font-family:inherit;font-size:12pt;">_ No Intellectual Property or works of authorship claimed.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signature of Employee: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Bradley Campbell</font><font style="font-family:inherit;font-size:12pt;">&#32;_________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Print Name of Employee: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Bradley Campbell___</font><font style="font-family:inherit;font-size:12pt;">________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: February 28, 2020</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s9FDE43B1782855C096189C01CC8895DC"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT B</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">MUTUAL AGREEMENT TO ARBITRATE DISPUTES ON AN INDIVIDUAL BASIS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Mutual Agreement to Arbitrate Disputes on an Individual Basis (&#8220;Arbitration Agreement&#8221;) is made and entered into as of February 18, 2020 (the &#8220;Effective Date&#8221;) by and between </font><font style="font-family:inherit;font-size:11pt;">Amicus Therapeutics, Inc. (the &#8220;Company&#8221;) </font><font style="font-family:inherit;font-size:12pt;">and Bradley Campbell (&#8220;you&#8221;).  In this Arbitration Agreement, the Company and you are sometimes referred to individually as a &#8220;Party&#8221; and sometimes referred to together as the &#8220;Parties.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:12pt;">.  The Parties are entering into this Arbitration Agreement because they want to resolve all disputes arising out of or relating to your employment by the Company, or the termination of your employment, by binding private arbitration in accordance with the provisions of this Arbitration Agreement.  Regarding any claims covered by this Arbitration Agreement, you and the Company understand that, by entering into this Arbitration Agreement, YOU AND THE COMPANY ARE EACH GIVING UP:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1)&#160;&#160;&#160;&#160;THE RIGHT TO A JURY TRIAL; AND</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THE RIGHT TO FILE A LAWSUIT IN COURT AGAINST THE OTHER PARTY; AND </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THE RIGHT TO BRING A CLASS OR COLLECTIVE ACTION AGAINST THE OTHER PARTY IN COURT OR IN ARBITRATION OR IN ANY OTHER FORUM.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Mandatory Arbitration</font><font style="font-family:inherit;font-size:12pt;">.  In exchange for the mutual promises contained in this Arbitration Agreement and as a condition of the Company hiring and employing you, you and the Company agree that:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any and all &#8220;Covered Claims&#8221; (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3</font><font style="font-family:inherit;font-size:12pt;">&#32;below) shall be submitted to and resolved by final and binding arbitration to be held in the American Arbitration Association (&#8220;AAA&#8221;) office located nearest to your employment location for the Company.  The arbitration shall proceed before a single arbitrator and administered by the AAA in accordance with AAA&#8217;s Employment Arbitration Rules and Mediation Procedures (the &#8220;AAA Rules&#8221;) in effect and applicable at the time the arbitration is commenced.  The AAA Rules may be amended from time to time and are available online at </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">https://www.adr.org/sites/default/files/Employment%20Rules.pdf</font></a><font style="font-family:inherit;font-size:12pt;">.  You may also call the AAA at 800-778-7879 with any questions about the arbitration process.  If the AAA Rules are inconsistent with the terms of this Arbitration Agreement, the terms of this Arbitration Agreement shall govern; AND </font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Arbitrator, and not any federal, state, or local court or agency, shall have exclusive authority to resolve any dispute relating to the interpretation, applicability, formation or enforceability of this Arbitration Agreement including, but not limited to, the arbitrability of any dispute between the parties; AND </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Arbitrator&#8217;s decision shall be final and binding only on the Parties to this Arbitration Agreement and the Parties agree that awards deciding issues for similarly-situated employees will have no preclusive effect in any arbitration between the Parties. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Covered Claims</font><font style="font-family:inherit;font-size:12pt;">.  Except as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">, &#8220;Covered Claims&#8221; under this Arbitration Agreement shall include all past, current and future grievances, disputes, claims or causes of action that otherwise could be brought in a federal, state or local court under applicable federal, state or local laws, arising out of or relating to your employment with the Company or the termination of your employment including claims arising out of or related to your hiring, recruitment, compensation and termination, and including claims you may have against the Company or its officers, directors, supervisors, managers, employees or agents, or that the Company may have against you.  Covered Claims include, but are not limited to, claims for breach of any contract or covenant (express or implied), tort claims, claims for wages or other compensation, claims for wrongful termination (constructive or actual), claims for discrimination, harassment or retaliation (including, but not limited to, harassment or discrimination based on race, age, color, sex, gender, gender identity, transgender status, sexual orientation, national origin, alienage or citizenship status, creed, religion, marital status, partnership status, familial status, domestic violence victim status, military status, predisposing genetic characteristics, medical condition including pregnancy, psychological condition, mental condition, criminal accusations and convictions, disability, or any other trait or characteristic protected by federal, state, or local law, claims for violation of any federal, state, local or other governmental law, statute, regulation, or ordinance, including, but not limited to, all claims arising under federal law such as:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:77px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Age Discrimination in Employment Act; the Older Workers Benefits Protection Act; Title VII of the Civil Rights of 1964; Sections 1981 through 1988 of Title 42 of the United States Code; the Civil Rights Act of 1991; the Equal Pay Act; the Americans with Disabilities Act; the Rehabilitation Act; the Employee Retirement Income Security Act; the Worker Adjustment and Retraining Notification Act; the National Labor Relations Act; the Fair Credit Reporting Act; the Occupational Safety and Health Act; the Uniformed Services Employment and Reemployment Act; the Employee Polygraph Protection Act; the Immigration Reform Control Act; the Family and Medical Leave Act; the Genetic Information Nondiscrimination Act; the Federal False Claims Act; the Patient Protection and Affordable Care Act; the Consolidated Omnibus Budget Reconciliation Act; and the Lilly Ledbetter Fair Pay Act;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and all claims arising under state and local law, such as:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:77px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The New Jersey Law Against Discrimination; the New Jersey Discrimination in Wages Law; the New Jersey Security and Financial Empowerment Act; the New Jersey Temporary Disability Benefits and Family Leave Insurance Law; the New Jersey Domestic Partnership Act; the New Jersey Conscientious Employee Protection Act; the New Jersey Family Leave Act; the New Jersey Wage Payment Act; the New Jersey Equal Pay Law; the New Jersey Occupational Safety and Health Law; the New Jersey False Claims Act; the New Jersey Smokers&#8217; Rights Law; the New Jersey Genetic Privacy Act; the New Jersey Fair Credit Reporting Act; the New Jersey Emergency Responder Leave Law; the New Jersey Millville Dallas Airmotive Plant Job Loss Notification Act (a/k/a the New Jersey WARN Act); Gender Inequity Law; and the New Jersey Earned Sick Leave Law.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The laws listed above should be interpreted as including all amendments to those laws and together with all of their respective implementing regulations, and any and all other federal, state and local laws that govern your employment with the Company or the termination of that employment for any reason.  Covered Claims under this Agreement include claims arising out of or related to acts or omissions that occurred before entering into this Arbitration Agreement and those that may occur in the future.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Claims Not Covered</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding any other provision of this Arbitration Agreement, this Arbitration Agreement does not mandate arbitration of:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">disputes arising under your Confidentiality, Non-Disclosure and Non-Competition Agreement with the Company; OR </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">claims for Workers&#8217; Compensation benefits;  OR</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">claims for unemployment compensation benefits;  OR</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any other claims that, as a matter of law, cannot be subject to mandatory arbitration.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings 3;font-size:12pt;">&#218;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding any other provision of this Arbitration Agreement, nothing in this Arbitration Agreement prevents you or shall be interpreted to mean that you are precluded from filing charges or complaints with the National Labor Relations Board (NLRB), the Equal Employment Opportunity Commission (EEOC), the Securities and Exchange Commission (SEC) or any equivalent state or local agency.  Nor does this Arbitration Agreement prevent you from testifying or participating in any proceedings before those administrative agencies.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver of Class and Collective Actions</font><font style="font-family:inherit;font-size:12pt;">.  You and the Company expressly intend and agree that:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">class and collective action procedures shall not be asserted and will not apply in any arbitration pursuant to this Agreement; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">neither you nor the Company will assert class or collective claims against the other in court, in arbitration or otherwise;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">each Party shall only submit individual claims in arbitration and will not seek to represent the interests of any other person; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any claims by you will not be joined, consolidated or heard together with the claims of any other employee; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">no decision or arbitral award determining an issue with a similarly-situated employee shall have any preclusive effect in any arbitration between the Parties, and the Arbitrator shall have no authority to give preclusive effect to the issues determined in any arbitration between the Company and any other employee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver of Trial by Jury</font><font style="font-family:inherit;font-size:12pt;">.  The Parties understand and fully agree that, by entering into this Arbitration Agreement, they are giving up their constitutional right to have a trial by jury, and are giving up their normal rights of appeal following the issuance of the arbitrator&#8217;s award except as otherwise provided by applicable law.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Claims Procedure</font><font style="font-family:inherit;font-size:12pt;">.  Arbitration shall be initiated by the express written notice of either you or the Company.  The Party initiating the arbitration must give written notice of any claim to the other Party.  Written notice of your claim shall be mailed by certified or registered mail, return receipt requested, to Employer&#8217;s General Counsel at Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512.  Written notice of a claim by the Company will be mailed to your last known address.  The written notice shall identify and describe the nature of all claims asserted and the facts supporting the claims.  Written notice of arbitration shall be initiated within the same time limitations that applicable federal and state law applies to those claims.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbitrator Selection</font><font style="font-family:inherit;font-size:12pt;">.  The Arbitrator shall be selected as provided in AAA Rules.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Discovery</font><font style="font-family:inherit;font-size:12pt;">.  The Arbitrator shall have the authority to order such discovery, by way of deposition, interrogatory, document production or otherwise, as the Arbitrator deems necessary to a full and fair exploration of the issues in dispute, consistent with the expedited nature of arbitration.  The Arbitrator shall have the authority to set deadlines for completion of discovery.  The Arbitrator shall decide all discovery disputes.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Governing Law; Substantive Law</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement and any arbitration shall be governed by the Federal Arbitration Act (FAA) to the exclusion of any state law inconsistent with the FAA.  The Arbitrator shall apply the substantive state or federal law as applicable to the claims asserted in arbitration.  Claims arising under federal law shall be determined in accordance with federal law.  Common law claims shall be determined in accordance with the substantive law of the state your assigned primary office location during the last six months of your employment with the Company, without regard to conflicts of law principles.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compelling Arbitration; Enforcing Award</font><font style="font-family:inherit;font-size:12pt;">.  Either Party may ask a court to stay any court proceeding to compel arbitration under this Arbitration Agreement, and to confirm, vacate or enforce an arbitration award.  Judgment on the award rendered by the Arbitrator may be entered in any state or federal court of competent jurisdiction located in the state of your employment location for the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbitration Fees and Costs</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall be responsible for the Arbitrator&#8217;s fees and arbitration expenses and any other costs unique to the arbitration hearing, except that you shall be responsible for paying the initial filing fees as provided by the AAA&#8217;s Rules.  Each Party shall pay its own deposition, witness, expert and attorneys&#8217; fees and all other expenses to the same extent as if the matter were proceeding in court.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Term of Agreement; Modification in Writing</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement shall survive the termination of your employment.  This Arbitration Agreement can only be revoked or modified in a writing that specifically states an intent to revoke or modify this Arbitration Agreement and is signed by both you and the President of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:12pt;">.  The Company may freely assign this Arbitration Agreement at any time.  This Arbitration Agreement shall inure to the benefit of the Company&#8217;s successors and assigns.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement represents the entire agreement of the parties with respect to the subject matter covered and cannot be modified or amended except in a writing signed by both parties.  The waiver by any party to this Arbitration Agreement or a breach of any of the provisions of this Arbitration Agreement shall not operate or be construed as a waiver of any subsequent or simultaneous breach.  This Arbitration Agreement supersedes any inconsistent agreements between the Parties with respect to the subject matter of the Arbitration Agreement.  This Agreement does not supersede:  (1) the Employment Agreement between you and the Company; (2) the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement </font><font style="font-family:inherit;font-size:12pt;">between you and the Company; or (3)&#160;any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Arbitration Agreement is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable provision shall be severed and that adjudication shall not affect the validity of the remainder of this Arbitration Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Voluntary Agreement</font><font style="font-family:inherit;font-size:12pt;">.  By executing this Arbitration Agreement, the Parties represent that they have been given the opportunity to fully review its terms.  You acknowledge and agree that you have had an opportunity to ask questions and consult with an attorney of your choice, at your expense, before signing this Arbitration Agreement.  The Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement.  YOU AND THE COMPANY FULLY UNDERSTAND AND AGREE THAT YOU AND THE COMPANY ARE GIVING UP CERTAIN RIGHTS OTHERWISE AFFORDED BY CIVIL COURT ACTIONS INCLUDING, BUT NOT LIMITED TO, THE RIGHT TO A JURY OR COURT TRIAL AND THE RIGHT TO BRING ANY CLAIM AS A CLASS OR COLLECTIVE ACTION.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Bradley Campbell</font><font style="font-family:inherit;font-size:11pt;">_________________&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Signature:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Bradley Campbell</font><font style="font-family:inherit;font-size:11pt;">_______________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">February 28, 2020</font><font style="font-family:inherit;font-size:11pt;">_________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Home Address:&#160;&#160;&#160;&#160;[&#8230;]</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">________________________</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ellen Rosenberg </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Legal Officer and Corporate Secretary, Legal </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s6EF1B496DF73D1D0DD829C01CCB9EC81"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT C</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;font-weight:bold;">President &amp; Chief Operating Officer</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The President and Chief Operating Officer (COO) is responsible to help lead the overall strategic direction and execution of the global corporate strategy.  The position partners with the CEO, the Senior Leadership Team, and the Board of Directors on development of corporate strategy and objectives.  In addition, the individual in this position will be responsible for building, leading and coordinating all Global strategic, operational and commercial activities for the company&#8217;s product portfolio.  To achieve this the President and COO will help oversee and be fully conversant with the full range of the company&#8217;s products in development as well as their benefits while also having a complete understanding of the evolving competitive, regulatory and reimbursement landscape. This position will externally interface with the patients, providers, payers, health authorities and regulators, existing and new strategic partners, and the public financial community. In addition to the commercial responsibilities, the President &amp; COO shall also oversee the Technical Operations function (Global internal and external manufacturing and supply chain) and Program Management function (Strategic Management of all R&amp;D Programs) as well as the Gene Therapy Center of Excellence (Cross Functional organization driving all Gene Therapy R&amp;D).   The President and COO will play a critical role in helping to ensure commercial success, advancing the company&#8217;s portfolio and taking the company to its next stage of future growth, thereby benefiting both patients and shareholders.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MAJOR ACTIVITIES AND RESPONSIBILITIES</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The President and COO will be responsible for the following:</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serve as a key member of the Senior Leadership Team in helping to shape the company&#8217;s vision and strategy</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Responsible for global operations in coordination with other corporate functions in compliance with company policies and applicable law</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Provide overall executive leadership in creating and executing proactive global business and commercial strategies for products in development and registration.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Responsible for leadership of and day to day leadership and management of the global Commercial, Manufacturing, and Program Management organizations, including Global Sales, Sales Operations, Marketing, Market Access, Technical Operations functions</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oversight of the Gene Therapy Center of Excellence which is the cross functional organization responsible for all Gene Therapy R&amp;D</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">P&amp;L responsibility for the Global commercialization of Galafold</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Help lead, drive and oversee the commercial operational activities in the company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Have full accountability for the day-to-day operations, be responsible for the organization meeting corporate goals and objectives and keeping in compliance with applicable policies and regulations.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Development and implementation of global commercial and manufacturing strategy</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Proactively build trusting relationships with key internal and external stakeholders and decision makers, on a global level. Interact with the Amicus Board of Directors as it pertains to the role&#8217;s area of responsibilities. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serve as one of the key spokespersons for the company. Represent the company in its relationships with suppliers, major customers and partners, the business and financial communities, as well as the public, to promote a positive image in the industry and contribute business growth and success.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Directly contribute to successful corporate development activities in support of corporate development and strategy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Provide hands-on leadership while managing multiple projects. Define goals and drive innovation while ensuring the correct team, processes and scalable infrastructure are in place to support rapid operational and commercial growth.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Corporate &amp; Governance Roles:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Member of the Amicus Therapeutics Inc. Corporate Board of Directors</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Chair of the Amicus Global Business Steering Team</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Member of Executive Committee</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Member of the UK Board of Directors</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Assistant Corporate Secretary of Amicus Therapeutics, Inc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Formal backup to the CEO when absent</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">ORGANIZATIONAL STRUCTURE</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Reports to the CEO</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">QUALIFICATIONS AND BACKGROUND REQUIREMENTS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Educational Requirements</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">An MBA is required (or equivalent work experience such as management consulting)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Graduate degree in science or medicine or healthcare business is highly desirable</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Professional Work Experience</font></div><div style="line-height:180%;text-align:left;padding-left:24px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15+ years of experience in the pharmaceutical/biotech industry including operations, development, sales, marketing, market access, investor relations, business development, etc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Strong interpersonal and communication skills.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Experience interacting with a wide range of stakeholders </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s8E87BCE080979CE7DFB19C01CCDB1A2B"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Location</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cranbury, NJ</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47
<SEQUENCE>6
<FILENAME>exhibit1047jaybarth-em.htm
<DESCRIPTION>EXHIBIT 10.47
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s63C5C3779E7F2A8C6D8A9C0578B55BD6"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THIS EMPLOYMENT AGREEMENT</font><font style="font-family:inherit;font-size:12pt;">&#32;(this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), dated as of February 18, 2020 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), between AMICUS THERAPEUTICS, INC., a Delaware corporation having an office at 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and Jay Barth, an individual residing at [&#8230;], (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) (together, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">parties</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS,</font><font style="font-family:inherit;font-size:12pt;">&#32;the Company wishes to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">continue to</font><font style="font-family:inherit;font-size:12pt;">&#32;employ Employee, and Employee wishes to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">continue to</font><font style="font-family:inherit;font-size:12pt;">&#32;be employed by Company, on the terms and conditions set forth herein; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:inherit;font-size:12pt;">&#32;in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the sufficiency and receipt whereof is hereby acknowledged, the parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">Section 1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:12pt;">.  Unless otherwise defined herein, the following terms shall have the following respective meanings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accrued Amounts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, as of the termination of Employee&#8217;s employment:  (a)&#160;the total of any expenses properly incurred by Employee under Section 3.4(b) that have not previously been reimbursed as of the effective date of the termination; (b)&#160;the sum of Employee&#8217;s accrued, but unused, vacation time, if any, as of the effective date of the termination; and (c) any accrued and unpaid Base Salary through and including the effective date of Employee&#8217;s termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any other company, directly or indirectly, controlling, controlled by or under common control with the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cause</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Employee&#8217;s: (i)&#160;willful or deliberate misconduct that has or could reasonably be expected to have a materially adverse impact on the reputation or business of the Company (or an Affiliate), or that results in gain or personal enrichment of Employee to the detriment of the Company (or an Affiliate); (ii)&#160;violation of Company policy including, but not limited to, policies prohibiting harassment and other workplace misconduct, and policies governing corporate compliance; (iii) misappropriation of the funds or assets of the Company (or an Affiliate); (iv) conviction, plea of guilty, admission to facts sufficient for a finding of guilt, or plea of no contest (or nolo contendere) to: (a) any felony, or (b) any misdemeanor involving fraud, theft, dishonesty, wrongful taking of property, embezzlement, bribery, forgery or extortion; (v) material breach of this Agreement; (vi)&#160;material breach of the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">; (vii) breach of Employee&#8217;s duty of loyalty to the Company; (viii) disqualification, bar or suspension by any governmental authority from performing any of the duties contemplated by this Agreement; (ix)&#160;material failure to perform Employee&#8217;s duties or obligations hereunder (other than as a result of being Unable to Work); or (x)&#160;willful failure to adhere to or carry out lawful duties or directives of the Company&#8217;s Chief Executive Officer (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CEO</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or Board of Directors (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Notwithstanding anything to the contrary herein, the Company shall not be deemed to have terminated Employee for Cause for the events described above in subsections (ix) or (x) unless the CEO or Board, as applicable, has determined that such events are amenable to cure and given Employee written notice of the occurrence of the claimed event(s) constituting Cause and Employee has failed to cure such event(s) within fourteen (14) calendar days after Employee&#8217;s receipt of such notice (or such other period as may be deemed reasonable by the CEO or Board under the circumstances and communicated to Employee).  The other events described above are not subject to an opportunity to cure but the Company may, in its sole discretion, conduct an investigation into those events and provide the employee a full opportunity to participate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any of the following: (i)&#160;when any person or entity who is not currently a stockholder of the Company (as of the date of this Agreement) becomes the beneficial owner of greater than 50% of the then-outstanding voting power of the Company; (ii)&#160;when a merger or consolidation with another entity occurs that causes the voting securities of the Company outstanding immediately before the transaction to constitute less than a majority of the voting power of the voting securities of the Company or the surviving entity outstanding immediately after the transaction; or (iii)&#160;when a sale or disposition of all or substantially all of the Company&#8217;s assets occurs.  Notwithstanding the foregoing, no event shall be deemed to be a Change in Control Event unless such event would also be a Change in Control under Section 409A and the rules and regulations promulgated thereunder (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 409</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or would otherwise be a permitted distribution event under Section 409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">&#8221; means:  (i) payment of an amount equal to one and one-half (1.5) times Employee&#8217;s then current Base Salary, payable in installments over eighteen (18)&#160;months, commencing within sixty (60) calendar days after the resignation or termination (collectively, &#8220;termination&#8217;) of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices for its senior management personnel; (ii) payment of an amount equal to 100% of the target Bonus for the calendar year in which such termination occurs (such amount being payable in a lump sum), payable within seventy five (75) calendar days following such termination ; (iii) the accelerated vesting of stock options held by Employee immediately prior to such termination (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Options</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such that all Options will become vested as of the date of Employee&#8217;s termination; (iv) the accelerated vesting of restricted stock grants held by Employee immediately prior to such termination (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Grants</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such that all Grants will become vested as of the date of Employee&#8217;s termination; (v) the accelerated vesting of performance restricted stock units held by Employee immediately prior to such termination at the applicable performance targets or such greater amounts as determined by the Board of Directors in their sole discretion; and (vi) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of eighteen (18) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that  the Company will pay the full premiums otherwise payable for such coverage during such 18 month period.  Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Change in Control Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Good Reason</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the occurrence of one or both of the following events without Employee&#8217;s consent: (i)&#160;the Company&#8217;s material diminution of Employee&#8217;s authority, duties, or responsibilities as set forth in this Agreement; or (ii)&#160;the Company&#8217;s change in the principal geographic location at which Employee provides services to the Company to a location more than thirty (30) miles from Employee&#8217;s assigned primary office location, unless such relocation is only temporary, for a reasonable period of time, or unless such relocation merely constitutes travel reasonably required in connection with the performance of Employee&#8217;s duties.  Notwithstanding anything to the contrary herein, Employee shall not be deemed to have resigned for Good Reason unless: (a) Employee had provided to the Company written notice within thirty (30) calendar days of the occurrence of the claimed event(s) constituting Good Reason, specifying in detail the basis for such Good Reason; (b) the Company fails to cure the Good Reason within thirty (30) calendar days after its receipt of such notice, and (c) Employee terminates employment within sixty (60) calendar days after providing notice to Company of the claimed event(s) constituting Good Reason. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (i) payment of an amount equal to Employee&#8217;s then current Base Salary, payable in installments over twelve (12)&#160;months, commencing within sixty (60) calendar days of the termination of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices then in effect for its senior management personnel; (ii) payment of a bonus equal to 100% of the target Bonus for the calendar year in which such termination occurs pro-rated for the number of days actually worked in the year of termination, payable within seventy five (75) calendar days following such termination; (iii) the accelerated vesting of the Options, such that the portion of the Options that was otherwise scheduled to vest during the twelve (12)&#160;month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination;  (iv) the accelerated vesting of RSUs, such that the portion of RSUs that was otherwise scheduled to vest during the twelve (12) month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination; (v)  the accelerated vesting of PRSUs, such that the portion of PRSUs that was otherwise scheduled to vest during the twelve month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination; and (vi)in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.  Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Unable to Work&#8221; means the determination by the Company, following an interactive process, that Employee has become physically or mentally incapable of performing Employee&#8217;s essential job functions, with or without a reasonable accommodation, following any period during which such status would be protected under applicable law.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employment</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duties and Responsibilities</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of this Agreement, Employee will be employed by the Company as Chief Medical Officer or in such other position as may be mutually agreed upon by the parties.  A Job Description setting forth Employee&#8217;s duties and responsibilities is attached as Exhibit C.  Employee accepts such employment, and agrees to perform all of the duties and accept all of the responsibilities accompanying such position.  Employee agrees to serve the Company faithfully and to the best of Employee&#8217;s abilities, and to devote all of Employee&#8217;s business time, skill and attention to such service.  Employee is expected to be available for meetings on a regular basis, upon request by the Company, at the Company&#8217;s Cranbury, New Jersey, and Philadelphia, Pennsylvania, locations or such other Company locations as needed including, but not limited to, the Company&#8217;s international offices.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Full Time and Attention</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall devote Employee&#8217;s full business time and best efforts to the performance of Employee&#8217;s duties and to the furtherance of the Company&#8217;s interests.  During Employee&#8217;s employment with the Company, Employee may not hold another position of employment, or be retained as a consultant, or engage in any other business activity (whether full-time or part-time, whether or not for compensation), unless the Company gives Employee prior written permission to do so.  Notwithstanding anything stated in this provision to the contrary, Employee is permitted to engage in charitable activities, as long as they do not interfere with Employee&#8217;s employment obligations to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Policies</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment with the Company, Employee will be subject to all applicable employment and other policies of the Company, as outlined in the Amicus Employee Handbook and as otherwise published by the Company in writing.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compensation and Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, the Company shall pay Employee a salary at the gross annual rate of $481,054 (less applicable withholding) or such greater amount as the Board or a committee thereof may from time to time establish pursuant to the terms hereof (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Such Base Salary shall be reviewed annually and may be increased, but not decreased, by the Board or a committee thereof in its sole discretion. The Base Salary shall be payable in accordance with the Company&#8217;s customary payroll practices for its senior management personnel.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee shall be eligible to participate in the Company&#8217;s bonus programs as may be in effect with respect to senior management personnel. Employee shall be eligible to earn an annual target bonus of 100% of the Base Salary in cash (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">&#8221;) such actual amount determined by the Company Compensation Committee in its absolute discretion and at 40% of base salary; provided, however, that notwithstanding anything to the contrary herein or in any bonus program, Employee must be employed by the Company as of December 31 of the applicable calendar year, in order to be eligible to earn a Bonus for such calendar year.  Any Bonus payment to which Employee becomes entitled hereunder shall be paid to Employee in a lump sum (less applicable withholding) on or before the 15</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of the third month following the end of the calendar year in which the Bonus was earned.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Equity</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan and such other equity plans as the Company may adopt from time to time including, but not limited to, an Employee Stock Purchase Plan, during Employee&#8217;s employment with the Company, Employee will be eligible to receive stock options, Restricted Stock Units and Performance Restricted Stock Units pursuant to any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  Unless otherwise provided in this Agreement, the terms and conditions of the applicable equity plan will govern all equity grants to Employee (including vesting of options and units), including with regard to the impact of the end of Employee&#8217;s employment on such equity grants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefit Plans</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee may participate in any benefit plans (including health and medical insurance) as may be in effect with respect to senior management personnel of the Company, including any equity plan, subject to the eligibility and contribution requirements, enrollment criteria and other terms and conditions of such plans.  The Company reserves the right to modify, amend and eliminate any such plans, in its sole and absolute discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reimbursement of Expenses</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, the Company shall pay or promptly reimburse Employee, upon submission of proper invoices or other documentation in accordance with the Company&#8217;s policies and procedures, for all reasonable out-of-pocket business, entertainment and travel expenses incurred by Employee in the performance of Employee&#8217;s duties.  Any taxable reimbursement of business or other expenses as specified under this Agreement shall be subject to the following conditions:  (i)&#160;the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year; (ii)&#160;the reimbursement of an eligible expense shall be made no later than the end of the calendar year after the year in which such expense was incurred; and (iii)&#160;the right to reimbursement shall not be subject to liquidation or exchange for another benefit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Vacation</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee shall be entitled to vacation in accordance with the policies of the Company applicable to senior management personnel as may be in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Withholding</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall withhold from all amounts payable or benefits accorded to Employee all federal, state and local income, employment and other taxes, as and in such amounts as may be required by applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duration of Employment</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s employment with the Company shall begin on the Effective Date and continue until Employee&#8217;s employment is terminated by either Employee or the Company.  At all times, Employee&#8217;s employment with the Company shall be &#8220;at-will,&#8221; meaning that either Employee or the Company may terminate the employment at any time, for no reason or any lawful reason.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination; Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notice of Termination</font><font style="font-family:inherit;font-size:12pt;">.  Any termination of Employee&#8217;s employment by the Company or by Employee (other than on account of death) shall be communicated to the other party by written notice that indicates the specific termination provision in this Agreement relied upon.  Except as otherwise expressly provided in this Agreement or the notice, the termination shall take effect immediately.  The parties agree that the notice requirements set forth in this Agreement do not alter the &#8220;at will&#8221; nature of Employee&#8217;s employment, as described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Generally</font><font style="font-family:inherit;font-size:12pt;">.  Upon termination of Employee&#8217;s employment for any reason, Employee shall be deemed simultaneously to have resigned as a member of the Board, if applicable, and from any other position or office Employee may at the time hold with the Company or any of its Affiliates.  Employee agrees to cooperate with the Company by signing any necessary documents and taking any other steps necessary to effectuate Employee&#8217;s resignation from the Board, if applicable, and from any other position or office Employee may hold with the Company or any of its Affiliates.  In addition, upon termination of Employee&#8217;s employment for any reason, the Company shall pay Employee the Accrued Amounts.  The Accrued Amounts will be paid within the time required by applicable law.  The impact of the termination of Employee&#8217;s employment on the Employee&#8217;s participation in the Company&#8217;s health plans is addressed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by Employee</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resignation Independent of a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If Employee resigns and a Change in Control Event has not occurred in the prior 12 months, then (irrespective of whether the resignation was with or without Good Reason):  (i)&#160;Employee shall receive no further compensation or remuneration of any kind other than the Accrued Amounts; and (ii)&#160;at the end of the month in which the resignation takes effect, Employee shall cease to be covered under or permitted to participate in or receive any of the benefits described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3.4</font><font style="font-family:inherit;font-size:12pt;">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Good Reason Resignation Within 12 Months of a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If Employee resigns for Good Reason within&#160;twelve (12)&#160;months after a Change in Control Event, Employee will be entitled to receive, in addition to the Accrued Amounts, </font><font style="font-family:inherit;font-size:12pt;">Change in Control Severance Benefits.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by the Company</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Without Cause Within 12 Months After a Change in Control Event.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;If the Company terminates Employee&#8217;s employment without Cause within 12 months after a Change in Control Event, then in lieu of any other payments, rights or benefits under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(a)</font><font style="font-family:inherit;font-size:12pt;">, Employee will be entitled to receive Change in Control Severance Benefits in addition to the Accrued Amounts.  All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Without Cause Not Within 12 Months After a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If the Company terminates Employee&#8217;s employment without Cause (other than within 12 months after a Change in Control Event), then Employee will be entitled to receive Severance Benefits in addition to the Accrued Amounts</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">For Cause</font><font style="font-family:inherit;font-size:12pt;">.  If the Company terminates Employee&#8217;s employment for Cause at any time, Employee shall: (i)&#160;receive no further compensation or remuneration of any kind (including any Base Salary or Bonus hereunder) other than the Accrued Amounts; and (ii)&#160;at the end of the month in which the termination takes effect, cease to be covered under or be permitted to participate in or receive any of the benefits described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;3.4</font><font style="font-family:inherit;font-size:12pt;">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination upon Death or Inability to Work</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Death.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Employee&#8217;s employment shall terminate immediately upon Employee&#8217;s death.  In the event of Employee&#8217;s death during the course of Employee&#8217;s employment with the Company, the Company will pay the Employee&#8217;s estate the Accrued Amounts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inability to Work.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Except as otherwise provided by applicable law, the Company may terminate Employee&#8217;s employment in the event Employee is Unable to Work.  In the event of Employee&#8217;s death or termination by the Company due to Employee being Unable to Work, Employee shall receive: (a) the Accrued Amounts, and (b) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Release and Compliance Required</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s receipt of any right, payment or benefit under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;is subject to and conditioned upon: (a)&#160;Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company; and (b) Employee&#8217;s reaffirmation of and continuing compliance with Employee&#8217;s contractual and legal obligations to the Company, as expressly set forth in the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="font-family:inherit;font-size:12pt;">.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;409A</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:12pt;">.  This section is intended to help ensure that compensation paid or delivered to Employee pursuant to this Agreement either is paid in compliance with, or is exempt from, IRC Section&#160;409A. However, the Company does not warrant to Employee that all compensation paid or delivered to Employee for Employee&#8217;s services will be exempt from, or paid in compliance with, Section&#160;409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Amounts Payable On Account of Termination</font><font style="font-family:inherit;font-size:12pt;">.  For the purposes of determining when amounts otherwise payable on account of Employee&#8217;s termination of employment under this Agreement will be paid, which amounts become due because of Employee&#8217;s termination of employment, &#8220;termination of employment&#8221; or words of similar import, as used in this Agreement, shall be construed as the date that Employee first incurs a &#8220;separation from service&#8221; for purposes of Section&#160;409A on or following termination of employment.  Furthermore, if Employee is a &#8220;specified employee&#8221; of a public company as determined pursuant to Section&#160;409A as of Employee&#8217;s termination of employment, any amounts payable on account of Employee&#8217;s termination of employment that constitute deferred compensation within the meaning of Section&#160;409A and that are otherwise payable during the first six months following Employee&#8217;s termination (or prior to Employee&#8217;s death after termination) shall be paid to Employee in a cash lump-sum on the earlier of: (i)&#160;the date of Employee&#8217;s death; or (ii)&#160;the first business day of the seventh calendar month immediately following the month in which Employee&#8217;s termination occurs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Series of Payments</font><font style="font-family:inherit;font-size:12pt;">.  Any right to a series of installment payments shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interpretative Rules</font><font style="font-family:inherit;font-size:12pt;">.  In applying Section&#160;409A to amounts paid pursuant to this Agreement, any right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Participation in Other Severance Plans.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Employee agrees and acknowledges that Employee shall not be eligible to participate in or have any right to compensation or benefits pursuant to the Company&#8217;s Change in Control Severance Plan (or any successor plan thereto) or any other Severance Plan issued by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exclusivity</font><font style="font-family:inherit;font-size:12pt;">. In the event Employee&#8217;s employment is terminated for any reason, Employee (and Employee&#8217;s eligible dependents, if any) shall not be entitled to any payments or benefits from the Company or any of its Affiliates except as specifically set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Federal Excise Tax</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Rule</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s payments and benefits under this Agreement and all other arrangements or programs related thereto shall not, in the aggregate, exceed the maximum amount that may be paid to Employee without triggering golden parachute penalties under Section&#160;280G of the Code, and the provisions related thereto with respect to such payments. If Employee&#8217;s benefits must be cut back to avoid triggering such penalties, such reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary, to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity derivative payments shall be reduced.  If an amount in excess of the limit set forth in this Section is paid to Employee, Employee must repay the excess amount to the Company upon demand, with interest at the rate provided in Section&#160;1274(b)(2)(B) of the Code.  Employee and the Company agree to cooperate with each other reasonably in connection with any administrative or judicial proceedings concerning the existence or amount of golden parachute penalties on payments or benefits Employee receives.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exception</font><font style="font-family:inherit;font-size:12pt;">.  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;shall apply only if it increases the net amount Employee would realize from payments and benefits subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;after payment of income and excise taxes by Employee on such payments and benefits.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Determinations</font><font style="font-family:inherit;font-size:12pt;">.  The determination of whether the golden parachute penalties under Section&#160;280G of the Code and the provisions related thereto shall be made by counsel chosen by Employee and reasonably acceptable to the Company. All other determinations needed to apply this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be made in good faith by the Company&#8217;s independent auditors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Computers, Property and Records</font><font style="font-family:inherit;font-size:12pt;">.  Employee agrees to handle all Company property in accordance with the Company&#8217;s policies and procedures.  Employee&#8217;s authorization to access the Company&#8217;s computer systems is limited and use of such systems to compete or prepare to compete with the Company constitutes unauthorized access that is strictly prohibited.  All records received or created by Employee in the course of employment related to the Company&#8217;s business (such as but not limited to, email, notes, files, contact lists, agendas, drawings, maps, specifications, and calendars) are the property of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resolution of Disputes</font><font style="font-family:inherit;font-size:12pt;">.  Employee and the Company hereby agree that, except for disputes regarding alleged or anticipated violations of the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, any and all disputes between them shall be resolved solely in accordance with the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">&#32;and, to the greatest extent permitted by law, Employee and the Company expressly waive their respective right to a trial by jury for any and all such disputes between them.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Conflict</font><font style="font-family:inherit;font-size:12pt;">.  Employee represents and warrants that Employee has not entered, nor will Employee enter, into any other agreements that restrict Employee&#8217;s ability to fulfill Employee&#8217;s obligations under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall be construed, interpreted and governed by the laws of the state of Employee&#8217;s assigned primary office location during the last six months of Employee&#8217;s employment with the Company, without regard to the conflicts of law principles.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Binding Effect</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall extend to and be binding upon Employee, Employee&#8217;s legal representatives, heirs and distributees and upon the Company, its successors and assigns regardless of any change in the business structure of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">.  The Company&#8217;s rights and obligations under this Agreement, including the restrictions in the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its assets, stock or business.  Employee consents to that transfer.  Employee may not assign any rights or obligations under this Agreement without the Company&#8217;s prior written consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the parties with respect thereto</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:12pt;">including Employee&#8217;s prior Agreement, dated April 23, 2014, except this Agreement does not supersede the Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A or the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as Exhibit B.  Nor does this Agreement supersede any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  No waiver, modification or change of any provision of this Agreement shall be valid unless in writing and signed by both parties.  </font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:12pt;">.  The waiver of any breach of any duty, term or condition of this Agreement shall not be deemed to constitute a waiver of any preceding or succeeding breach of the same or any other duty, term or condition of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Agreement shall be unenforceable in any jurisdiction in accordance with its terms, the provision shall be enforceable to the fullest extent permitted in that jurisdiction and shall continue to be enforceable in accordance with its terms in any other jurisdiction and the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.  All notices pursuant to this Agreement shall be in writing and shall be sent by prepaid certified mail, return receipt requested or by recognized air courier service addressed as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;If to the Company to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amicus Therapeutics, Inc. <br>1 Cedar Brook Drive <br>Cranbury, New Jersey 08512</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c/o&#160;&#160;&#160;&#160;CEO or General Counsel</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;If to Employee to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Jay Barth <br>at the address identified herein or in Employee&#8217;s personnel records,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or to such other addresses as may hereinafter be specified by notice in writing by either of the parties, and shall be deemed given three (3)&#160;business days after the date so mailed or sent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance</font><font style="font-family:inherit;font-size:12pt;">. If reasonably requested in writing, Employee agrees within fifteen (15) business days to provide the Company with an executed IRS Form&#160;4669 (Statement of Payments Received) with respect to any taxable amount paid to Employee by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowing and Voluntary Nature of Agreement</font><font style="font-family:inherit;font-size:12pt;">. Employee acknowledges and agrees that Employee is executing this Agreement knowingly and voluntarily and without any duress or undue influence by the Company or anyone else.  Employee further acknowledges and agrees that Employee has carefully read this Agreement and fully understands it. Employee further agrees that Employee has been provided an opportunity to seek, and has received, the advice of an attorney of Employee&#8217;s choice (at Employee&#8217;s expense) before signing this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">[Signature Page Follows]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above written.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Jay Barth</font><font style="font-family:inherit;font-size:12pt;">__________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Jay Barth</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ David Clark               &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;David Clark</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: Chief People Officer</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s0DED0CA691F3463F27C39C0578D56434"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFIDENTIALITY, NON-DISCLOSURE AND NON-COMPETITION AGREEMENT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITH</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Jay Barth</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement is made as of February 18, 2020 between you and Amicus Therapeutics, Inc. (the &#8220;Company&#8221;).  You agree that you are receiving adequate consideration in exchange for entering into this Confidentiality, Non-Disclosure and Non-Competition Agreement (the &#8220;Agreement&#8221;) including:  (1)&#160;at-will employment and the benefits of that employment including any grant to you of certain restricted stock units and options to purchase shares of common stock in the Company; (2)&#160;access to Confidential Information belonging to the Company; and (3) access to the Company&#8217;s business relationships.  You acknowledge that entering into this Agreement is a condition of receiving those items.  Accordingly, you agree to the following terms and conditions:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the protections provided by this Agreement are necessary to safeguard the Company&#8217;s Confidential Information (as defined below), business relationships and other business interests, and that the Company is willing to employ you, and continue to employ you, on the condition that you execute this Agreement.  You agree that the Company has spent substantial resources developing its Confidential Information and business relationships.  You also agree that protecting these assets is critical to the Company&#8217;s survival and success, and a competitor with access to those assets would have an unfair competitive advantage over the Company. Therefore, you agree that the Company has a legitimate business interest in protecting those assets and that the commitments set forth in this Agreement are a reasonable means of doing so.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that as an integral part of the Company&#8217;s business, the Company has developed, and will develop, at a considerable investment of time and expense, non-public scientific data and methods, clinical development plans and strategies, business development plans and strategies, marketing and business plans and strategies, procedures, methods of operation and marketing, financial data, lists of actual and potential customers and suppliers including buying habits of those customers, and independent sales representatives and related data, technical procedures, engineering and product specifications, plans for development and expansion, and other confidential and sensitive information, and you acknowledge that the Company has a legitimate business interest in protecting the confidentiality of such information.  You acknowledge that you will be entrusted with such information as well as confidential non-public information belonging to customers, suppliers, and other third parties.  You, therefore, acknowledge a continuing responsibility to protect such information and agree to the provisions contained herein.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Trade Secrets&#8221; shall mean information belonging to the Company or licensed by it including, without limitation, data, reports, research, drawings, specifications, software, formulae, patterns, compilations, programs, devices, methods, techniques, or processes (including such information that has commercial value to the Company from a negative viewpoint, such as the results of research which proves that certain processes used to attempt to develop new technology will be unsuccessful) which are not commonly known by or available to the public, and which information: (a)&#160;derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from their disclosure or use; (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy; and (c) as otherwise defined by law.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Proprietary Information&#8221; shall mean any information, other than Trade Secrets, without regard to form, belonging to the Company or licensed by it including, without limitation, formulae, patterns, compilations, programs, devices, methods, techniques, or processes, which is not commonly known by or available to the public and which information is material to the Company and not generally known by the public, and all notes, analyses, compilations, studies, interpretations or other documents prepared by you which contain, reflect or are based upon, in whole or in part, the information furnished to you by the Company pursuant hereto; provided, however that &#8220;Proprietary Information&#8221; shall not include any information which you can show (i) becomes patented, published or otherwise part of the public domain through no act or fault of your own, (ii) is received in good faith from any third party who has the right to disclose such information and who has not received such information, either directly or indirectly, from the Company, or (iii) any information which you can show was in your legitimate possession prior to your commencing employment with the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Confidential Information&#8221; shall mean, collectively, the information outlined in Paragraph 2 of this Agreement, Trade Secrets outlined in Paragraph 3 and Proprietary Information outlined in Paragraph 4 and all other information protected by unauthorized disclosure by law. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">You will treat as confidential and will not, without the prior written approval of the Company, directly or indirectly, use (other than in the performance of duties of employment with the Company), publish, disclose, patent, copyright, or authorize anyone else to use, publish, disclose, patent, or copyright any Confidential Information during your employment and after your employment with the Company terminates, whether such termination is voluntary or involuntary, with or without cause.  You agree to take all action reasonably necessary to protect Confidential Information from being disclosed or used by anyone other than persons authorized by the Company.  Confidential information shall not include information that: (i) is or subsequently becomes publicly available without your, or any other person or entity&#8217;s, breach of any obligation owed to the Company; (ii) was lawfully received by you from a third party free of any obligation of confidentiality owed to the Company; or (iii) you are required to disclose in a judicial or administrative proceeding or as otherwise required by law.    </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company recognizes that you, as a former employee or independent contractor of another company, may previously have been privy to trade secrets and/or confidential information of such other company, and you may be under an obligation to such other company to maintain the confidentiality of such trade secrets or confidential information.  Accordingly, to the extent you are under such an obligation, you shall not: (a) bring any records, notes, files, drawings, documents, plans and like items, electronic or otherwise, provided to you in confidence by such other company, or any copies thereof, relating to or containing or disclosing confidential information or trade secrets of any such other company, on the premises of the Company or loaded onto the Company&#8217;s computer systems or otherwise use such documents and items in the performance of services for the Company; or (b) disclose any confidential information or trade secrets provided to you in confidence by such other company in the performance of your job duties for </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">.  You represent that you are &#8220;free and clear&#8221; of any legal restrictions that might interfere with your ability to begin or continue your employment with, or perform your duties and responsibilities for, </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">such as non-compete, non-solicitation or non-disclosure restrictions imposed by current or former employers or contractors.   You confirm that you have disclosed to </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">&#32;any agreements between you and your current or former employers or contractors describing any possible restrictions on your activities. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You acknowledge that all Confidential Information and any records, files, memoranda, computer programs, reports, claims reports or records, customer lists, contracts, marketing plans, programs or forecasts and other written or printed documents or materials or other data stored on computer disks or other electronic data storage methods (&#8220;Documents&#8221;) received, created or used by you during the course of your relationship with the Company are and will remain the sole property of the Company.  You agree to return all such Documents (including all copies) to the Company promptly upon the termination of your employment, or earlier upon </font><font style="font-family:inherit;font-size:11pt;">the Company&#8217;s </font><font style="font-family:inherit;font-size:12pt;">request,  and agree that, during or after your employment, you will not, under any circumstances, without the specific authorization in writing of an officer of the Company, disclose those Documents or any information contained in such Documents to anyone outside the Company&#8217;s organization or use those Documents for any purpose other than the advancement of the Company&#8217;s interests.  Upon termination of your employment for any reason, or upon the Company&#8217;s earlier request, you also agree to immediately return to </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">all equipment and property provided to you by </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">including, but not limited to, computers, phones, pagers, thumb drives or other storage devices, iPads and other tablet devices, and any other electronic devices.  You also agree to provide </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">with all usernames, passwords, passcodes, and other information for logging into and accessing the equipment, applications, platforms, software, hardware, devices and other systems that you used or accessed in the course of, and during, your employment.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protected Conduct</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement prohibits you from disclosing Confidential Information under any of the following circumstances:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure in confidence to an attorney solely for the purpose of reporting or investigating a suspected violation of law; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure, directly or indirectly, to a Federal, State or local government official in confidence solely for the purpose of reporting or investigating a suspected violation of law; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure in a complaint or other document filed under seal in a lawsuit or other proceeding; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure to your attorney in connection with a lawsuit you file against the Company for retaliation for reporting a suspected violation of law.  Under this scenario, you may use the Confidential Information in the court proceedings as long as you file any document containing the Confidential Information under seal and do not otherwise disclose the Confidential Information, except pursuant to a Court Order.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prohibits you from filing a charge or complaint with, reporting or making disclosures (including providing supporting documents or other information) of possible violations of any law or regulation to, and/or participating in any investigation or proceeding conducted by, any self-regulatory organization or governmental agency, authority, or legislative body including, but not limited to, the Securities and Exchange Commission and/or Equal Employment Opportunity Commission or as otherwise required or allowed by law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Is intended to interfere with your rights under Section 7 of the National Labor Relations Act, including the right of employees to communicate with each other regarding the terms and conditions of their employment and to engage in concerted activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prevents you from disclosing or requires you to conceal the details of any alleged discrimination, retaliation or harassment.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Disclosure and Assignment Of Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">.  You agree to promptly disclose to the Company all &#8220;Intellectual Property&#8221; conceived or developed by you while employed by the Company that relates to the Company&#8217;s business.  The term &#8220;Intellectual Property&#8221; means any and all (i) data, reports, formulas, techniques, research, drawings, specifications, software and any other copyrightable works; (ii) Trade Secrets; and (iii) ideas, creations, inventions, discoveries, designs, devices, methods, processes and innovations whether or not patentable, and all related know-how.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Assignment of Intellectual Property Rights</font><font style="font-family:inherit;font-size:11pt;">.  You agree that all Intellectual Property conceived or developed by you while employed by the Company after the date of this Agreement shall be the exclusive property of the Company.  You hereby assign and agree to assign in the future to the Company all of your right, title and interest in and to any and all Intellectual Property related to your work at the Company, whether or not registrable under patent, copyright, trademark or similar statutes, made or conceived or reduced to practice or learned by you, either alone or jointly with others, during the period and scope of your employment with the Company.  Such assignment is perpetual and irrevocable.  Intellectual Property assigned to the Company, or to a third party as directed by the Company pursuant to this paragraph, are hereinafter referred to as &#8220;Company Intellectual Property.&#8221;  You agree to assign all right, title and interest in and to any particular Company Intellectual Property to a third party as directed by the Company.  You further agree to assign to the Company or, to the extent assignment is not permissible, waive any so-called &#8220;moral rights&#8221; in the Intellectual Property to the extent permitted by law.  You will assist the Company in every proper way to obtain, perfect, and from time to time enforce, its patent, copyright, trade secret and other rights in the Intellectual Property relating to Company Intellectual Property in any and all countries.  You hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, that you now or may hereafter have for infringement of any Intellectual Property assigned hereunder to the Company.</font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Prior Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding the foregoing, the Company agrees that you will not be obligated to assign any invention that you developed entirely on your own time, without using any equipment, supplies, facilities or trade secret information of the Company, unless such invention either:  (i) relates (at the time of conception or reduction to practice of the invention) to the Company&#8217;s business or the Company&#8217;s actual or demonstrably anticipated research, or (ii) results from any work performed by you for the Company.  Intellectual Property, if any, that you made prior to the commencement of your employment with the Company, or made outside the scope of your employment, are excluded from the scope of this Agreement.  To preclude any possible uncertainty, you have set forth on Exhibit A attached to this Agreement a complete list of all Intellectual Property that you have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement</font><font style="font-family:inherit;font-size:12pt;">&#32;of your employment with </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">, that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Agreement (collectively referred to as &#8220;Prior Intellectual Property&#8221;).</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Obligation to Keep the Company Informed</font><font style="font-family:inherit;font-size:11pt;">.  During the period of your employment, you will promptly disclose to the Company fully and in writing all Intellectual Property authored, created, conceived or reduced to practice by you, either alone or jointly with others, whether or not patentable or copyrightable or believed by you to be patentable or copyrightable.  In addition, you will promptly disclose to the Company (to be held in confidence) all patent applications filed by you or on your behalf within six months after termination of your employment (whether voluntarily or involuntarily), and to cooperate fully with a review and determination by the Company as to whether such patent applications constitute or include the Company&#8217;s Intellectual Property or Confidential Information.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Works for Hire</font><font style="font-family:inherit;font-size:11pt;">.  You acknowledge and agree that all original works of authorship that are made by you (solely or jointly with others) within the scope of your employment by the Company and that are protectable by copyright including, but not limited to, drawings, sketches and designs, are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C. Section 101).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the Company has compelling business interests in preventing the use or disclosure of its Confidential Information, or the misappropriation of its business relationships, and to protect those interests it is reasonable to restrict you from working or becoming affiliated with, either during or after the end of your employment with the Company, a Competitive Business (as defined below).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also acknowledge that the Company is engaged in a highly competitive business and that by virtue of the nature of your employment with the Company, your engaging in or working for or with any Competitive Business will cause the Company great and irreparable harm.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accordingly, you agree that, during your employment with the Company and for a period of twelve (12) months after the date of termination of your employment with the Company for any reason, whether such termination is voluntary or involuntary, by wrongful discharge or otherwise, you will not, directly, or indirectly work for or with or have any interest in any Competitive Business, whether as an individual on your own account, as a partner or joint venturer, as an employee, agent or salesperson for any person, as an officer or director of any corporation, or as a consultant or otherwise, or engage in preparations for any activity prohibited by this paragraph or any other paragraph in this Agreement without the prior specific written consent by an officer of the Company to do so provided, that the foregoing shall not prohibit ownership of the securities of a publicly-traded entity which constitute less than 2% of the outstanding voting securities of the entity.  For purposes of this Agreement, &#8220;Competitive Business&#8221; shall mean any person or entity who engages in the business of researching, developing and/or commercializing products, including but not limited to small molecules, biologics and gene therapies in the areas of Fabry disease, Pompe disease, Battens Disease, CDKL-5 Deficiency Disorder and any other condition, or any other business, in which the Company is actively engaged during the last twenty-four months of your employment.   You acknowledge that the geographic scope of this restriction is reasonable given that: (1) the Company does business and has customers and competitors throughout the world; and (2) modern communication and transportation make it easy to compete in this industry from virtually any location on earth.   Further, you acknowledge and agree that given the nature of your responsibilities for the Company and your access to its Confidential Information and business relationships, if you were to work for any Competitive Business as described in this paragraph, you would inevitably disclose Confidential Information. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Solicitation</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also acknowledge that, by virtue of your relationship with the Company, you have gained or will gain knowledge of the identity, characteristics and preferences of its customers among other Confidential Information, and that you would inevitably have to draw on such Confidential Information if you were to solicit or service the Company&#8217;s customers on behalf of a Competitive Business.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accordingly, you agree that for twelve (12) months following the termination for any reason whatsoever of your employment with the Company, you will not solicit the business of or perform any services for an actual or prospective Customer of the Company (as defined below).  You also agree that, during this twelve-month period, you will not encourage or assist any person or entity engaged in a Competitive Business to solicit or service any actual or prospective Customer of the Company covered by this paragraph.  &#8220;Customer of the Company&#8221; means any person or company that, at any time during the twenty-four (24) months prior to the end of your employment with the Company, purchases &#8211; or enters into a contract to purchase &#8211; products or services from the Company.  Customer shall also mean any prospective customer to which the Company has submitted a proposal for purchase of products or services.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also agree that, for twelve (12) months following the end of your employment with the Company for any reason, you will not directly or indirectly hire or seek to hire or retain, whether on your own behalf or on behalf of some other person or entity, any Company Personnel (as defined below).  Nor will you, during this twelve (12) month period, directly or indirectly induce or encourage any Company Personnel to leave the Company.  You acknowledge that, even after the expiration of the twelve (12) month period described in this paragraph, you will be barred from soliciting or hiring Company Personnel if, in soliciting or hiring them, you would use or disclose Confidential Information belonging to the Company.  &#8220;Company Personnel&#8221; means any employee, independent contractor or other personnel employed, retained or engaged by the Company at any time during the twenty-four (24) months prior to the termination of your employment:  (1)&#160;with whom you interacted within the scope of your employment with the Company; (2)&#160;whom you directly or indirectly supervised during your employment with the Company; or&#160;(3)&#160;regarding whom you received non-public information about his or her job responsibilities, compensation or job performance by virtue of your employment with the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Return of Property</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon termination of your employment (by the Company or you) for any reason, or upon the earlier request of the Company, you agree to immediately return to the Company all Company records and other property in your possession, custody or control including (but not limited to) anything containing Confidential Information such as documents, papers, files, records, reports, binders, notebooks, books, notes, calendars, plans, drawings, maps, specifications, blueprints, studies, photographs, video recordings, audio recordings, computers, tablets, smartphones, mobile telephones, drives, discs, and any other devices used to store electronic data, and any and all electronic copies and/or hard-copies.  Notwithstanding the foregoing, nothing in this Agreement shall prohibit you from retaining paystubs and other records regarding your compensation and benefits that the Company is required by law to provide to you.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon termination of your employment (by the Company or you) for any reason, or upon the earlier request of the Company, you agree to provide the Company with all usernames, passwords, passcodes and other information that it may need to log into and access the equipment, applications, platforms, software, hardware, devices and other systems that you used or accessed in the course of, and during, your employment.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon the Company&#8217;s request, you agree to immediately provide the Company with a written affidavit confirming that you have returned all Company property and Confidential Information, and cooperate in providing the Company, at the Company&#8217;s request, a means through which it can promptly and independently verify (including by forensic analysis, if necessary) that all Confidential Information has been removed from electronic storage devices, cloud-based storage, and accounts in your possession or control.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If you are served with a subpoena, court order, or similar legal document requiring the production of Company records or other property or the disclosure of Confidential Information, you agree to provide the Company with as much notice as is possible (presumably seven (7) business days or more) through written notification to the Company&#8217;s General Counsel and the Company&#8217;s CEO, so that the Company may take permissible steps to protect the records and information, unless such notice is prohibited by law or court order; provided, however, that nothing in this Agreement prohibits you from engaging in the Protected Conduct described in Section 9 and Section 10 of this Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Terms</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the restrictions contained in this Agreement are fair, reasonable and necessary to protect the legitimate business interests of the Company and that the Company will suffer irreparable harm in the event of any actual or threatened breach by you of this Agreement.  You agree that enforcement of the restrictions in this Agreement will not cause you any hardship, and because of your background and experience will not in any manner preclude you from becoming gainfully employed in such manner and to such extent as will provide you with a standard of living of at least the sort and fashion to which you are accustomed. You therefore agree that the Company may seek a restraining order, preliminary injunction or other court order to enforce this Agreement without the necessity of posting a bond or any security that might otherwise be required in connection with such relief.  You also agree that any request for such relief by the Company shall be in addition and without prejudice to any claim for monetary damages which the Company might elect to assert.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If any provision of this Agreement is held to be unenforceable by a court, such unenforceability shall not affect the enforceability of the remaining provisions.  Such provision shall be reformed and construed to the extent permitted by law so that it would be valid, legal and enforceable to the maximum extent possible.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that this Agreement does not give you any rights to employment by or to be retained as a consultant of the Company and, unless otherwise provided in another writing, executed by an officer of the Company and you, your relationship with the Company shall be employment &#8220;at will.&#8221;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You agree that, if you, at any time during or within one year after your employment with the Company ends, you receive an offer of employment or retention from any person or entity other than the Company, you will provide that person or entity with a copy of this Agreement.  You also agree that, at any time during, or within one year after the end of, your employment with the Company, you will, in writing, immediately after accepting (orally or in writing) any offer of employment or retention with any person or entity other than the Company:  (1)&#160;notify the Company that you accepted the offer; and (2)&#160;inform the Company of the identity of the person or entity, and of your title, responsibilities, work location and anticipated start date.  You acknowledge that the requirements set forth in this paragraph are fair, reasonable and necessary in order for the Company to adequately protect its Confidential Information and business relationships.  The Company may also provide copies of this Agreement to others including, but not limited to, customers and potential customers, and your future employers and prospective employers.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">You understand nothing in this Agreement prohibits you reporting to any governmental authority information concerning violations of law or regulations, and that you may report trade secret information to a government official or to an attorney and use it in certain proceedings without fear of prosecution or liability provided such disclosure is consistent with 18 U.S.C. 1833. If you make the disclosure to your attorney in connection with a private lawsuit, you may use the Confidential Information in the court proceedings as long as you file any document containing the Confidential Information under seal and do not otherwise disclose the Confidential Information, except pursuant to a Court Order.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement represents the entire agreement of the parties with respect to the subject matter covered and cannot be modified or amended except in a writing signed by both parties.  The waiver by any party to this Agreement or a breach of any of the provisions of this Agreement shall not operate or be construed as a waiver of any subsequent or simultaneous breach.  This Agreement supersedes any confidentiality, non-competition and non-solicitation entered into by the Company and you prior to the date of this Agreement.  This Agreement does not supersede:  (1)&#160;the Employment Agreement between you and the Company; (2)&#160;the Mutual Agreement to Arbitrate Disputes on an Individual Basis between you and the Company; or (3)&#160;</font><font style="font-family:inherit;font-size:12pt;">any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">30.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement shall be construed, interpreted and governed by the laws of the state of your assigned primary office location during the last six months of your employment with the Company, without regard to the conflicts of law principles</font><font style="font-family:inherit;font-size:11pt;">.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">31.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The rights and obligations of the Company under this Agreement shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its or their assets, stock or business.  By signing this Agreement, you consent to any such transfer.  You may not assign any rights or obligations under this Agreement without the prior written consent of the Company&#8217;s Chief Legal Officer or designee. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">By signing below, you acknowledge that you:  (1)&#160;received this Agreement fourteen (14) business days before the date on which you must return an executed copy of it to the Company; (2) have had sufficient opportunity to read each provision of this Agreement; (e)&#160;understand the meaning, effect and implications of each provision of this Agreement; (4)&#160;have had an opportunity to consult with legal counsel of your choosing (at your expense) regarding this Agreement; and (5)&#160;are not relying on any promises or representations that are not set forth in this Agreement.  By signing this Agreement, you are indicating that you are doing so freely and voluntarily and with full understanding of its terms and conditions.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">______________________</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ellen Rosenberg </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">General Counsel &amp; Corporate Secretary, Legal </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Jay Barth</font><font style="font-family:inherit;font-size:11pt;">________________________&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Signature:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Jay Barth</font><font style="font-family:inherit;font-size:11pt;">______________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">February 26, 2020</font><font style="font-family:inherit;font-size:11pt;">_________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Home Address:&#160;&#160;&#160;&#160;[&#8230;]_____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SCHEDULE 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">PRIOR INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">List below all Intellectual Property and works of authorship that you have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of your employment with Amicus that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Confidentiality, Non-Disclosure and Non-Competition Agreement:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If additional space is needed, attach and sign additional sheets and indicate here:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">___ Additional sheets are attached.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you are not listing any Intellectual Property or works of authorship, indicate here:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">X</font><font style="font-family:inherit;font-size:12pt;">_ No Intellectual Property or works of authorship claimed.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signature of Employee: /s/ Jay Barth_______________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Print Name of Employee: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Bradley Campbell</font><font style="font-family:inherit;font-size:12pt;">________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: February 26, 2020</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s9D410FDB0E904A82C6ED9C05790AC5D8"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT B</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">MUTUAL AGREEMENT TO ARBITRATE DISPUTES ON AN INDIVIDUAL BASIS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Mutual Agreement to Arbitrate Disputes on an Individual Basis (&#8220;Arbitration Agreement&#8221;) is made and entered into as of February 18, 2020 (the &#8220;Effective Date&#8221;) by and between </font><font style="font-family:inherit;font-size:11pt;">Amicus Therapeutics, Inc. (the &#8220;Company&#8221;) </font><font style="font-family:inherit;font-size:12pt;">and Jay Barth (&#8220;you&#8221;).  In this Arbitration Agreement, the Company and you are sometimes referred to individually as a &#8220;Party&#8221; and sometimes referred to together as the &#8220;Parties.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:12pt;">.  The Parties are entering into this Arbitration Agreement because they want to resolve all disputes arising out of or relating to your employment by the Company, or the termination of your employment, by binding private arbitration in accordance with the provisions of this Arbitration Agreement.  Regarding any claims covered by this Arbitration Agreement, you and the Company understand that, by entering into this Arbitration Agreement, YOU AND THE COMPANY ARE EACH GIVING UP:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1)&#160;&#160;&#160;&#160;THE RIGHT TO A JURY TRIAL; AND</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THE RIGHT TO FILE A LAWSUIT IN COURT AGAINST THE OTHER PARTY; AND </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THE RIGHT TO BRING A CLASS OR COLLECTIVE ACTION AGAINST THE OTHER PARTY IN COURT OR IN ARBITRATION OR IN ANY OTHER FORUM.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Mandatory Arbitration</font><font style="font-family:inherit;font-size:12pt;">.  In exchange for the mutual promises contained in this Arbitration Agreement and as a condition of the Company hiring and employing you, you and the Company agree that:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any and all &#8220;Covered Claims&#8221; (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3</font><font style="font-family:inherit;font-size:12pt;">&#32;below) shall be submitted to and resolved by final and binding arbitration to be held in the American Arbitration Association (&#8220;AAA&#8221;) office located nearest to your employment location for the Company.  The arbitration shall proceed before a single arbitrator and administered by the AAA in accordance with AAA&#8217;s Employment Arbitration Rules and Mediation Procedures (the &#8220;AAA Rules&#8221;) in effect and applicable at the time the arbitration is commenced.  The AAA Rules may be amended from time to time and are available online at </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">https://www.adr.org/sites/default/files/Employment%20Rules.pdf</font></a><font style="font-family:inherit;font-size:12pt;">.  You may also call the AAA at 800-778-7879 with any questions about the arbitration process.  If the AAA Rules are inconsistent with the terms of this Arbitration Agreement, the terms of this Arbitration Agreement shall govern; AND </font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Arbitrator, and not any federal, state, or local court or agency, shall have exclusive authority to resolve any dispute relating to the interpretation, applicability, formation or enforceability of this Arbitration Agreement including, but not limited to, the arbitrability of any dispute between the parties; AND </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Arbitrator&#8217;s decision shall be final and binding only on the Parties to this Arbitration Agreement and the Parties agree that awards deciding issues for similarly-situated employees will have no preclusive effect in any arbitration between the Parties. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Covered Claims</font><font style="font-family:inherit;font-size:12pt;">.  Except as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">, &#8220;Covered Claims&#8221; under this Arbitration Agreement shall include all past, current and future grievances, disputes, claims or causes of action that otherwise could be brought in a federal, state or local court under applicable federal, state or local laws, arising out of or relating to your employment with the Company or the termination of your employment including claims arising out of or related to your hiring, recruitment, compensation and termination, and including claims you may have against the Company or its officers, directors, supervisors, managers, employees or agents, or that the Company may have against you.  Covered Claims include, but are not limited to, claims for breach of any contract or covenant (express or implied), tort claims, claims for wages or other compensation, claims for wrongful termination (constructive or actual), claims for discrimination, harassment or retaliation (including, but not limited to, harassment or discrimination based on race, age, color, sex, gender, gender identity, transgender status, sexual orientation, national origin, alienage or citizenship status, creed, religion, marital status, partnership status, familial status, domestic violence victim status, military status, predisposing genetic characteristics, medical condition including pregnancy, psychological condition, mental condition, criminal accusations and convictions, disability, or any other trait or characteristic protected by federal, state, or local law, claims for violation of any federal, state, local or other governmental law, statute, regulation, or ordinance, including, but not limited to, all claims arising under federal law such as:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:77px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Age Discrimination in Employment Act; the Older Workers Benefits Protection Act; Title VII of the Civil Rights of 1964; Sections 1981 through 1988 of Title 42 of the United States Code; the Civil Rights Act of 1991; the Equal Pay Act; the Americans with Disabilities Act; the Rehabilitation Act; the Employee Retirement Income Security Act; the Worker Adjustment and Retraining Notification Act; the National Labor Relations Act; the Fair Credit Reporting Act; the Occupational Safety and Health Act; the Uniformed Services Employment and Reemployment Act; the Employee Polygraph Protection Act; the Immigration Reform Control Act; the Family and Medical Leave Act; the Genetic Information Nondiscrimination Act; the Federal False Claims Act; the Patient Protection and Affordable Care Act; the Consolidated Omnibus Budget Reconciliation Act; and the Lilly Ledbetter Fair Pay Act;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and all claims arising under state and local law, such as:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:77px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The New Jersey Law Against Discrimination; the New Jersey Discrimination in Wages Law; the New Jersey Security and Financial Empowerment Act; the New Jersey Temporary Disability Benefits and Family Leave Insurance Law; the New Jersey Domestic Partnership Act; the New Jersey Conscientious Employee Protection Act; the New Jersey Family Leave Act; the New Jersey Wage Payment Act; the New Jersey Equal Pay Law; the New Jersey Occupational Safety and Health Law; the New Jersey False Claims Act; the New Jersey Smokers&#8217; Rights Law; the New Jersey Genetic Privacy Act; the New Jersey Fair Credit Reporting Act; the New Jersey Emergency Responder Leave Law; the New Jersey Millville Dallas Airmotive Plant Job Loss Notification Act (a/k/a the New Jersey WARN Act); Gender Inequity Law; and the New Jersey Earned Sick Leave Law.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The laws listed above should be interpreted as including all amendments to those laws and together with all of their respective implementing regulations, and any and all other federal, state and local laws that govern your employment with the Company or the termination of that employment for any reason.  Covered Claims under this Agreement include claims arising out of or related to acts or omissions that occurred before entering into this Arbitration Agreement and those that may occur in the future.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Claims Not Covered</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding any other provision of this Arbitration Agreement, this Arbitration Agreement does not mandate arbitration of:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">disputes arising under your Confidentiality, Non-Disclosure and Non-Competition Agreement with the Company; OR </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">claims for Workers&#8217; Compensation benefits;  OR</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">claims for unemployment compensation benefits;  OR</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any other claims that, as a matter of law, cannot be subject to mandatory arbitration.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings 3;font-size:12pt;">&#218;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding any other provision of this Arbitration Agreement, nothing in this Arbitration Agreement prevents you or shall be interpreted to mean that you are precluded from filing charges or complaints with the National Labor Relations Board (NLRB), the Equal Employment Opportunity Commission (EEOC), the Securities and Exchange Commission (SEC) or any equivalent state or local agency.  Nor does this Arbitration Agreement prevent you from testifying or participating in any proceedings before those administrative agencies.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver of Class and Collective Actions</font><font style="font-family:inherit;font-size:12pt;">.  You and the Company expressly intend and agree that:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">class and collective action procedures shall not be asserted and will not apply in any arbitration pursuant to this Agreement; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">neither you nor the Company will assert class or collective claims against the other in court, in arbitration or otherwise;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">each Party shall only submit individual claims in arbitration and will not seek to represent the interests of any other person; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any claims by you will not be joined, consolidated or heard together with the claims of any other employee; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">no decision or arbitral award determining an issue with a similarly-situated employee shall have any preclusive effect in any arbitration between the Parties, and the Arbitrator shall have no authority to give preclusive effect to the issues determined in any arbitration between the Company and any other employee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver of Trial by Jury</font><font style="font-family:inherit;font-size:12pt;">.  The Parties understand and fully agree that, by entering into this Arbitration Agreement, they are giving up their constitutional right to have a trial by jury, and are giving up their normal rights of appeal following the issuance of the arbitrator&#8217;s award except as otherwise provided by applicable law.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Claims Procedure</font><font style="font-family:inherit;font-size:12pt;">.  Arbitration shall be initiated by the express written notice of either you or the Company.  The Party initiating the arbitration must give written notice of any claim to the other Party.  Written notice of your claim shall be mailed by certified or registered mail, return receipt requested, to Employer&#8217;s General Counsel at Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512.  Written notice of a claim by the Company will be mailed to your last known address.  The written notice shall identify and describe the nature of all claims asserted and the facts supporting the claims.  Written notice of arbitration shall be initiated within the same time limitations that applicable federal and state law applies to those claims.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbitrator Selection</font><font style="font-family:inherit;font-size:12pt;">.  The Arbitrator shall be selected as provided in AAA Rules.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Discovery</font><font style="font-family:inherit;font-size:12pt;">.  The Arbitrator shall have the authority to order such discovery, by way of deposition, interrogatory, document production or otherwise, as the Arbitrator deems necessary to a full and fair exploration of the issues in dispute, consistent with the expedited nature of arbitration.  The Arbitrator shall have the authority to set deadlines for completion of discovery.  The Arbitrator shall decide all discovery disputes.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Governing Law; Substantive Law</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement and any arbitration shall be governed by the Federal Arbitration Act (FAA) to the exclusion of any state law inconsistent with the FAA.  The Arbitrator shall apply the substantive state or federal law as applicable to the claims asserted in arbitration.  Claims arising under federal law shall be determined in accordance with federal law.  Common law claims shall be determined in accordance with the substantive law of the state your assigned primary office location during the last six months of your employment with the Company, without regard to conflicts of law principles.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compelling Arbitration; Enforcing Award</font><font style="font-family:inherit;font-size:12pt;">.  Either Party may ask a court to stay any court proceeding to compel arbitration under this Arbitration Agreement, and to confirm, vacate or enforce an arbitration award.  Judgment on the award rendered by the Arbitrator may be entered in any state or federal court of competent jurisdiction located in the state of your employment location for the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbitration Fees and Costs</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall be responsible for the Arbitrator&#8217;s fees and arbitration expenses and any other costs unique to the arbitration hearing, except that you shall be responsible for paying the initial filing fees as provided by the AAA&#8217;s Rules.  Each Party shall pay its own deposition, witness, expert and attorneys&#8217; fees and all other expenses to the same extent as if the matter were proceeding in court.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Term of Agreement; Modification in Writing</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement shall survive the termination of your employment.  This Arbitration Agreement can only be revoked or modified in a writing that specifically states an intent to revoke or modify this Arbitration Agreement and is signed by both you and the President of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:12pt;">.  The Company may freely assign this Arbitration Agreement at any time.  This Arbitration Agreement shall inure to the benefit of the Company&#8217;s successors and assigns.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement represents the entire agreement of the parties with respect to the subject matter covered and cannot be modified or amended except in a writing signed by both parties.  The waiver by any party to this Arbitration Agreement or a breach of any of the provisions of this Arbitration Agreement shall not operate or be construed as a waiver of any subsequent or simultaneous breach.  This Arbitration Agreement supersedes any inconsistent agreements between the Parties with respect to the subject matter of the Arbitration Agreement.  This Agreement does not supersede:  (1) the Employment Agreement between you and the Company; (2) the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement </font><font style="font-family:inherit;font-size:12pt;">between you and the Company; or (3)&#160;any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Arbitration Agreement is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable provision shall be severed and that adjudication shall not affect the validity of the remainder of this Arbitration Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Voluntary Agreement</font><font style="font-family:inherit;font-size:12pt;">.  By executing this Arbitration Agreement, the Parties represent that they have been given the opportunity to fully review its terms.  You acknowledge and agree that you have had an opportunity to ask questions and consult with an attorney of your choice, at your expense, before signing this Arbitration Agreement.  The Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement.  YOU AND THE COMPANY FULLY UNDERSTAND AND AGREE THAT YOU AND THE COMPANY ARE GIVING UP CERTAIN RIGHTS OTHERWISE AFFORDED BY CIVIL COURT ACTIONS INCLUDING, BUT NOT LIMITED TO, THE RIGHT TO A JURY OR COURT TRIAL AND THE RIGHT TO BRING ANY CLAIM AS A CLASS OR COLLECTIVE ACTION.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Jay Barth</font><font style="font-family:inherit;font-size:11pt;">________________________&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Signature:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Jay Barth</font><font style="font-family:inherit;font-size:11pt;">______________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">February 26, 2020</font><font style="font-family:inherit;font-size:11pt;">_________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Home Address:&#160;&#160;&#160;&#160;[&#8230;]</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">________________________</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ellen Rosenberg </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Legal Officer and Corporate Secretary, Legal </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s6FA6F837BA639E40F2779C0579272D3A"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT C</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Chief Medical Officer</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Chief Medical Officer will report directly to the Chief Executive Officer. The primary role of the CMO will be to provide leadership and direction for Amicus&#8217;s pipeline of clinical development programs. The CMO will be responsible for the strategy, direction and execution of the company&#8217;s clinical development plans. The CMO will be a key member of the senior management team as a member of the company&#8217;s Executive Committee which determines and oversees research and drug development at Amicus and sets the overall strategic direction of the company. </font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ROLES AND RESPONSIBILITIES</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Chief Medical Officer is responsible for: </font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Orchestrate and manage clinical aspects of regulatory strategies and interactions with Health Authorities </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oversee the analysis and interpretation of clinical trial data and the reporting of clinical trial results</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lead interactions with academic thought leaders, investigators, cooperative groups, and other clinical stakeholders </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Provide clinical support and work with other members of the management team to develop and communicate the overall corporate strategy </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Represent the Company and its programs to external audiences, including the investment, medical and regulatory communities, as well as pharmaceutical or biotechnology industry collaborators/partners </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In addition to leading and supervising the Clinical Research Department the CMO will have direct line responsibility for the Clinical Operations, Regulatory Affairs, Medical Affairs, and Drug Safety Departments.</font></div></td></tr></table><div style="line-height:180%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ORGANIZATIONAL STRUCTURE</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Reports to Chief Executive Officer</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUALIFICATIONS AND BACKGROUND REQUIREMENTS</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Educational Requirements</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">M.D with 15+ years of experience overall and 10+ years in a pharmaceutical and/or biotechnology setting.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Professional Work Experience </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Demonstrated clinical leadership as evidenced by strong track record of driving multiple successful project advancements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Proven track record developing and managing R&amp;D strategic and operating plans and budgets, as well as recruiting and managing a team in a biotech research environment</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Demonstrable expertise relating to all aspects of the drug development process and the ability to identify and resolve complex issues related to programs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Extensive working knowledge of oncology clinical landscape, regulatory guidance, and flexible resourcing models.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Successful track record in drafting and implementing clinical trial protocols required.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Demonstrated experience and capability to build strong external network of key opinion leaders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Proven ability to manage timelines and resources to drive projects toward key decision criteria.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Extensive experience interfacing with and providing scientific guidance to CRO partners and proven ability to work efficiently in a hybrid model.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Experience in interacting with relevant functions that are integral to successful clinical program advancements</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Must have the demonstrated ability to recruit, motivate, and lead successful teams with a history of developing a culture of teamwork, collaboration, transparency, and effective communication.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#2d2d2d;">Excellent written and oral communication skills.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-19px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;text-decoration:underline;">Location</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This position will be based at 1 Cedar Brook Drive, Cranbury, NJ, 08512</font><font style="font-family:inherit;font-size:12pt;color:#0070c0;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or as indicated in the Employment Contract.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="sEEA59F0B79C6B4BF2AB89C05795967D7"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.48
<SEQUENCE>7
<FILENAME>exhibit1048daphnequimi.htm
<DESCRIPTION>EXHIBIT 10.48
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s91D115DE94C5D49E994F9C0290F3AC05"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THIS EMPLOYMENT AGREEMENT</font><font style="font-family:inherit;font-size:12pt;">&#32;(this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), dated as of February 18, 2020 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), between AMICUS THERAPEUTICS, INC., a Delaware corporation having an office at 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and Daphne Quimi, an individual residing at [&#8230;], (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) (together, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">parties</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS,</font><font style="font-family:inherit;font-size:12pt;">&#32;the Company wishes to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">continue to</font><font style="font-family:inherit;font-size:12pt;">&#32;employ Employee, and Employee wishes to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">continue to</font><font style="font-family:inherit;font-size:12pt;">&#32;be employed by Company, on the terms and conditions set forth herein; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:inherit;font-size:12pt;">&#32;in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the sufficiency and receipt whereof is hereby acknowledged, the parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">Section 1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:12pt;">.  Unless otherwise defined herein, the following terms shall have the following respective meanings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accrued Amounts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, as of the termination of Employee&#8217;s employment:  (a)&#160;the total of any expenses properly incurred by Employee under Section 3.4(b) that have not previously been reimbursed as of the effective date of the termination; (b)&#160;the sum of Employee&#8217;s accrued, but unused, vacation time, if any, as of the effective date of the termination; and (c) any accrued and unpaid Base Salary through and including the effective date of Employee&#8217;s termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any other company, directly or indirectly, controlling, controlled by or under common control with the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cause</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Employee&#8217;s: (i)&#160;willful or deliberate misconduct that has or could reasonably be expected to have a materially adverse impact on the reputation or business of the Company (or an Affiliate), or that results in gain or personal enrichment of Employee to the detriment of the Company (or an Affiliate); (ii)&#160;violation of Company policy including, but not limited to, policies prohibiting harassment and other workplace misconduct, and policies governing corporate compliance; (iii) misappropriation of the funds or assets of the Company (or an Affiliate); (iv) conviction, plea of guilty, admission to facts sufficient for a finding of guilt, or plea of no contest (or nolo contendere) to: (a) any felony, or (b) any misdemeanor involving fraud, theft, dishonesty, wrongful taking of property, embezzlement, bribery, forgery or extortion; (v) material breach of this Agreement; (vi)&#160;material breach of the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">; (vii) breach of Employee&#8217;s duty of loyalty to the Company; (viii) disqualification, bar or suspension by any governmental authority from performing any of the duties contemplated by this Agreement; (ix)&#160;material failure to perform Employee&#8217;s duties or obligations hereunder (other than as a result of being Unable to Work); or (x)&#160;willful failure to adhere to or carry out lawful duties or directives of the Company&#8217;s Chief Executive Officer (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CEO</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or Board of Directors (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Notwithstanding anything to the contrary herein, the Company shall not be deemed to have terminated Employee for Cause for the events described above in subsections (ix) or (x) unless the CEO or Board, as applicable, has determined that such events are amenable to cure and given Employee written notice of the occurrence of the claimed event(s) constituting Cause and Employee has failed to cure such event(s) within fourteen (14) calendar days after Employee&#8217;s receipt of such notice (or such other period as may be deemed reasonable by the CEO or Board under the circumstances and communicated to Employee).  The other events described above are not subject to an opportunity to cure but the Company may, in its sole discretion, conduct an investigation into those events and provide the employee a full opportunity to participate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any of the following: (i)&#160;when any person or entity who is not currently a stockholder of the Company (as of the date of this Agreement) becomes the beneficial owner of greater than 50% of the then-outstanding voting power of the Company; (ii)&#160;when a merger or consolidation with another entity occurs that causes the voting securities of the Company outstanding immediately before the transaction to constitute less than a majority of the voting power of the voting securities of the Company or the surviving entity outstanding immediately after the transaction; or (iii)&#160;when a sale or disposition of all or substantially all of the Company&#8217;s assets occurs.  Notwithstanding the foregoing, no event shall be deemed to be a Change in Control Event unless such event would also be a Change in Control under Section 409A and the rules and regulations promulgated thereunder (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 409</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or would otherwise be a permitted distribution event under Section 409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">&#8221; means:  (i) payment of an amount equal to one and one-half (1.5) times Employee&#8217;s then current Base Salary, payable in installments over eighteen (18)&#160;months, commencing within sixty (60) calendar days after the resignation or termination (collectively, &#8220;termination&#8217;) of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices for its senior management personnel; (ii) payment of an amount equal to 100% of the target Bonus for the calendar year in which such termination occurs (such amount being payable in a lump sum), payable within seventy five (75) calendar days following such termination ; (iii) the accelerated vesting of stock options held by Employee immediately prior to such termination (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Options</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such that all Options will become vested as of the date of Employee&#8217;s termination; (iv) the accelerated vesting of restricted stock grants held by Employee immediately prior to such termination (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Grants</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such that all Grants will become vested as of the date of Employee&#8217;s termination; (v) the accelerated vesting of performance restricted stock units held by Employee immediately prior to such termination at the applicable performance targets or such greater amounts as determined by the Board of Directors in their sole discretion; and (vi) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of eighteen (18) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that  the Company will pay the full premiums otherwise payable for such coverage during such 18 month period.  Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Change in Control Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Good Reason</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the occurrence of one or both of the following events without Employee&#8217;s consent: (i)&#160;the Company&#8217;s material diminution of Employee&#8217;s authority, duties, or responsibilities as set forth in this Agreement; or (ii)&#160;the Company&#8217;s change in the principal geographic location at which Employee provides services to the Company to a location more than thirty (30) miles from Employee&#8217;s assigned primary office location, unless such relocation is only temporary, for a reasonable period of time, or unless such relocation merely constitutes travel reasonably required in connection with the performance of Employee&#8217;s duties.  Notwithstanding anything to the contrary herein, Employee shall not be deemed to have resigned for Good Reason unless: (a) Employee had provided to the Company written notice within thirty (30) calendar days of the occurrence of the claimed event(s) constituting Good Reason, specifying in detail the basis for such Good Reason; (b) the Company fails to cure the Good Reason within thirty (30) calendar days after its receipt of such notice, and (c) Employee terminates employment within sixty (60) calendar days after providing notice to Company of the claimed event(s) constituting Good Reason. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (i) payment of an amount equal to Employee&#8217;s then current Base Salary, payable in installments over twelve (12)&#160;months, commencing within sixty (60) calendar days of the termination of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices then in effect for its senior management personnel; (ii) payment of a bonus equal to 100% of the target Bonus for the calendar year in which such termination occurs pro-rated for the number of days actually worked in the year of termination, payable within seventy five (75) calendar days following such termination; (iii) the accelerated vesting of the Options, such that the portion of the Options that was otherwise scheduled to vest during the twelve (12)&#160;month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination;  (iv) the accelerated vesting of RSUs, such that the portion of RSUs that was otherwise scheduled to vest during the twelve (12) month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination; (v)  the accelerated vesting of PRSUs, such that the portion of PRSUs that was otherwise scheduled to vest during the twelve month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">unless a different date is set forth in the applicable equity award agreement; and (vi)in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.  Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Unable to Work&#8221; means the determination by the Company, following an interactive process, that Employee has become physically or mentally incapable of performing Employee&#8217;s essential job functions, with or without a reasonable accommodation, following any period during which such status would be protected under applicable law.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employment</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duties and Responsibilities</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of this Agreement, Employee will be employed by the Company as Chief Financial Officer or in such other position as may be mutually agreed upon by the parties.  A Job Description setting forth Employee&#8217;s duties and responsibilities is attached as Exhibit C.  Employee accepts such employment, and agrees to perform all of the duties and accept all of the responsibilities accompanying such position.  Employee agrees to serve the Company faithfully and to the best of Employee&#8217;s abilities, and to devote all of Employee&#8217;s business time, skill and attention to such service.  Employee is expected to be available for meetings on a regular basis, upon request by the Company, at the Company&#8217;s Cranbury, New Jersey, and Philadelphia, Pennsylvania, locations or such other Company locations as needed including, but not limited to, the Company&#8217;s international offices.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Full Time and Attention</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall devote Employee&#8217;s full business time and best efforts to the performance of Employee&#8217;s duties and to the furtherance of the Company&#8217;s interests.  During Employee&#8217;s employment with the Company, Employee may not hold another position of employment, or be retained as a consultant, or engage in any other business activity (whether full-time or part-time, whether or not for compensation), unless the Company gives Employee prior written permission to do so.  Notwithstanding anything stated in this provision to the contrary, Employee is permitted to engage in charitable activities, as long as they do not interfere with Employee&#8217;s employment obligations to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Policies</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment with the Company, Employee will be subject to all applicable employment and other policies of the Company, as outlined in the Amicus Employee Handbook and as otherwise published by the Company in writing.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compensation and Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, the Company shall pay Employee a salary at the gross annual rate of $452,000 (less applicable withholding) or such greater amount as the Board or a committee thereof may from time to time establish pursuant to the terms hereof (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Such Base Salary shall be reviewed annually and may be increased, but not decreased, by the Board or a committee thereof in its sole discretion. The Base Salary shall be payable in accordance with the Company&#8217;s customary payroll practices for its senior management personnel.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee shall be eligible to participate in the Company&#8217;s bonus programs as may be in effect with respect to senior management personnel. Employee shall be eligible to earn an annual target bonus of 100% of the Base Salary in cash (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">&#8221;) such actual amount determined by the Company Compensation Committee in its absolute discretion and at 40% of base salary; provided, however, that notwithstanding anything to the contrary herein or in any bonus program, Employee must be employed by the Company as of December 31 of the applicable calendar year, in order to be eligible to earn a Bonus for such calendar year.  Any Bonus payment to which Employee becomes entitled hereunder shall be paid to Employee in a lump sum (less applicable withholding) on or before the 15</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of the third month following the end of the calendar year in which the Bonus was earned.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Equity</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan and such other equity plans as the Company may adopt from time to time including, but not limited to, an Employee Stock Purchase Plan, during Employee&#8217;s employment with the Company, Employee will be eligible to receive stock options, Restricted Stock Units and Performance Restricted Stock Units pursuant to any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  Unless otherwise provided in this Agreement, the terms and conditions of the applicable equity plan will govern all equity grants to Employee (including vesting of options and units), including with regard to the impact of the end of Employee&#8217;s employment on such equity grants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefit Plans</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee may participate in any benefit plans (including health and medical insurance) as may be in effect with respect to senior management personnel of the Company, including any equity plan, subject to the eligibility and contribution requirements, enrollment criteria and other terms and conditions of such plans.  The Company reserves the right to modify, amend and eliminate any such plans, in its sole and absolute discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reimbursement of Expenses</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, the Company shall pay or promptly reimburse Employee, upon submission of proper invoices or other documentation in accordance with the Company&#8217;s policies and procedures, for all reasonable out-of-pocket business, entertainment and travel expenses incurred by Employee in the performance of Employee&#8217;s duties.  Any taxable reimbursement of business or other expenses as specified under this Agreement shall be subject to the following conditions:  (i)&#160;the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year; (ii)&#160;the reimbursement of an eligible expense shall be made no later than the end of the calendar year after the year in which such expense was incurred; and (iii)&#160;the right to reimbursement shall not be subject to liquidation or exchange for another benefit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Vacation</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee shall be entitled to vacation in accordance with the policies of the Company applicable to senior management personnel as may be in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Withholding</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall withhold from all amounts payable or benefits accorded to Employee all federal, state and local income, employment and other taxes, as and in such amounts as may be required by applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duration of Employment</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s employment with the Company shall begin on the Effective Date and continue until Employee&#8217;s employment is terminated by either Employee or the Company.  At all times, Employee&#8217;s employment with the Company shall be &#8220;at-will,&#8221; meaning that either Employee or the Company may terminate the employment at any time, for no reason or any lawful reason.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination; Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notice of Termination</font><font style="font-family:inherit;font-size:12pt;">.  Any termination of Employee&#8217;s employment by the Company or by Employee (other than on account of death) shall be communicated to the other party by written notice that indicates the specific termination provision in this Agreement relied upon.  Except as otherwise expressly provided in this Agreement or the notice, the termination shall take effect immediately.  The parties agree that the notice requirements set forth in this Agreement do not alter the &#8220;at will&#8221; nature of Employee&#8217;s employment, as described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Generally</font><font style="font-family:inherit;font-size:12pt;">.  Upon termination of Employee&#8217;s employment for any reason, Employee shall be deemed simultaneously to have resigned as a member of the Board, if applicable, and from any other position or office Employee may at the time hold with the Company or any of its Affiliates.  Employee agrees to cooperate with the Company by signing any necessary documents and taking any other steps necessary to effectuate Employee&#8217;s resignation from the Board, if applicable, and from any other position or office Employee may hold with the Company or any of its Affiliates.  In addition, upon termination of Employee&#8217;s employment for any reason, the Company shall pay Employee the Accrued Amounts.  The Accrued Amounts will be paid within the time required by applicable law.  The impact of the termination of Employee&#8217;s employment on the Employee&#8217;s participation in the Company&#8217;s health plans is addressed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by Employee</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resignation Independent of a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If Employee resigns and a Change in Control Event has not occurred in the prior 12 months, then (irrespective of whether the resignation was with or without Good Reason):  (i)&#160;Employee shall receive no further compensation or remuneration of any kind other than the Accrued Amounts; and (ii)&#160;at the end of the month in which the resignation takes effect, Employee shall cease to be covered under or permitted to participate in or receive any of the benefits described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3.4</font><font style="font-family:inherit;font-size:12pt;">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Good Reason Resignation Within 12 Months of a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If Employee resigns for Good Reason within&#160;twelve (12)&#160;months after a Change in Control Event, Employee will be entitled to receive, in addition to the Accrued Amounts, </font><font style="font-family:inherit;font-size:12pt;">Change in Control Severance Benefits.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by the Company</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Without Cause Within 12 Months After a Change in Control Event.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;If the Company terminates Employee&#8217;s employment without Cause within 12 months after a Change in Control Event, then in lieu of any other payments, rights or benefits under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(a)</font><font style="font-family:inherit;font-size:12pt;">, Employee will be entitled to receive Change in Control Severance Benefits in addition to the Accrued Amounts.  All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Without Cause Not Within 12 Months After a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If the Company terminates Employee&#8217;s employment without Cause (other than within 12 months after a Change in Control Event), then Employee will be entitled to receive Severance Benefits in addition to the Accrued Amounts</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">For Cause</font><font style="font-family:inherit;font-size:12pt;">.  If the Company terminates Employee&#8217;s employment for Cause at any time, Employee shall: (i)&#160;receive no further compensation or remuneration of any kind (including any Base Salary or Bonus hereunder) other than the Accrued Amounts; and (ii)&#160;at the end of the month in which the termination takes effect, cease to be covered under or be permitted to participate in or receive any of the benefits described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;3.4</font><font style="font-family:inherit;font-size:12pt;">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination upon Death or Inability to Work</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Death.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Employee&#8217;s employment shall terminate immediately upon Employee&#8217;s death.  In the event of Employee&#8217;s death during the course of Employee&#8217;s employment with the Company, the Company will pay the Employee&#8217;s estate the Accrued Amounts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inability to Work.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Except as otherwise provided by applicable law, the Company may terminate Employee&#8217;s employment in the event Employee is Unable to Work.  In the event of Employee&#8217;s death or termination by the Company due to Employee being Unable to Work, Employee shall receive: (a) the Accrued Amounts, and (b) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Release and Compliance Required</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s receipt of any right, payment or benefit under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;is subject to and conditioned upon: (a)&#160;Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company; and (b) Employee&#8217;s reaffirmation of and continuing compliance with Employee&#8217;s contractual and legal obligations to the Company, as expressly set forth in the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="font-family:inherit;font-size:12pt;">.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;409A</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:12pt;">.  This section is intended to help ensure that compensation paid or delivered to Employee pursuant to this Agreement either is paid in compliance with, or is exempt from, IRC Section&#160;409A. However, the Company does not warrant to Employee that all compensation paid or delivered to Employee for Employee&#8217;s services will be exempt from, or paid in compliance with, Section&#160;409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Amounts Payable On Account of Termination</font><font style="font-family:inherit;font-size:12pt;">.  For the purposes of determining when amounts otherwise payable on account of Employee&#8217;s termination of employment under this Agreement will be paid, which amounts become due because of Employee&#8217;s termination of employment, &#8220;termination of employment&#8221; or words of similar import, as used in this Agreement, shall be construed as the date that Employee first incurs a &#8220;separation from service&#8221; for purposes of Section&#160;409A on or following termination of employment.  Furthermore, if Employee is a &#8220;specified employee&#8221; of a public company as determined pursuant to Section&#160;409A as of Employee&#8217;s termination of employment, any amounts payable on account of Employee&#8217;s termination of employment that constitute deferred compensation within the meaning of Section&#160;409A and that are otherwise payable during the first six months following Employee&#8217;s termination (or prior to Employee&#8217;s death after termination) shall be paid to Employee in a cash lump-sum on the earlier of: (i)&#160;the date of Employee&#8217;s death; or (ii)&#160;the first business day of the seventh calendar month immediately following the month in which Employee&#8217;s termination occurs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Series of Payments</font><font style="font-family:inherit;font-size:12pt;">.  Any right to a series of installment payments shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interpretative Rules</font><font style="font-family:inherit;font-size:12pt;">.  In applying Section&#160;409A to amounts paid pursuant to this Agreement, any right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Participation in Other Severance Plans.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Employee agrees and acknowledges that Employee shall not be eligible to participate in or have any right to compensation or benefits pursuant to the Company&#8217;s Change in Control Severance Plan (or any successor plan thereto) or any other Severance Plan issued by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exclusivity</font><font style="font-family:inherit;font-size:12pt;">. In the event Employee&#8217;s employment is terminated for any reason, Employee (and Employee&#8217;s eligible dependents, if any) shall not be entitled to any payments or benefits from the Company or any of its Affiliates except as specifically set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Federal Excise Tax</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Rule</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s payments and benefits under this Agreement and all other arrangements or programs related thereto shall not, in the aggregate, exceed the maximum amount that may be paid to Employee without triggering golden parachute penalties under Section&#160;280G of the Code, and the provisions related thereto with respect to such payments. If Employee&#8217;s benefits must be cut back to avoid triggering such penalties, such reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary, to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity derivative payments shall be reduced.  If an amount in excess of the limit set forth in this Section is paid to Employee, Employee must repay the excess amount to the Company upon demand, with interest at the rate provided in Section&#160;1274(b)(2)(B) of the Code.  Employee and the Company agree to cooperate with each other reasonably in connection with any administrative or judicial proceedings concerning the existence or amount of golden parachute penalties on payments or benefits Employee receives.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exception</font><font style="font-family:inherit;font-size:12pt;">.  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;shall apply only if it increases the net amount Employee would realize from payments and benefits subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;after payment of income and excise taxes by Employee on such payments and benefits.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Determinations</font><font style="font-family:inherit;font-size:12pt;">.  The determination of whether the golden parachute penalties under Section&#160;280G of the Code and the provisions related thereto shall be made by counsel chosen by Employee and reasonably acceptable to the Company. All other determinations needed to apply this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be made in good faith by the Company&#8217;s independent auditors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Computers, Property and Records</font><font style="font-family:inherit;font-size:12pt;">.  Employee agrees to handle all Company property in accordance with the Company&#8217;s policies and procedures.  Employee&#8217;s authorization to access the Company&#8217;s computer systems is limited and use of such systems to compete or prepare to compete with the Company constitutes unauthorized access that is strictly prohibited.  All records received or created by Employee in the course of employment related to the Company&#8217;s business (such as but not limited to, email, notes, files, contact lists, agendas, drawings, maps, specifications, and calendars) are the property of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resolution of Disputes</font><font style="font-family:inherit;font-size:12pt;">.  Employee and the Company hereby agree that, except for disputes regarding alleged or anticipated violations of the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, any and all disputes between them shall be resolved solely in accordance with the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">&#32;and, to the greatest extent permitted by law, Employee and the Company expressly waive their respective right to a trial by jury for any and all such disputes between them.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Conflict</font><font style="font-family:inherit;font-size:12pt;">.  Employee represents and warrants that Employee has not entered, nor will Employee enter, into any other agreements that restrict Employee&#8217;s ability to fulfill Employee&#8217;s obligations under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall be construed, interpreted and governed by the laws of the state of Employee&#8217;s assigned primary office location during the last six months of Employee&#8217;s employment with the Company, without regard to the conflicts of law principles.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Binding Effect</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall extend to and be binding upon Employee, Employee&#8217;s legal representatives, heirs and distributees and upon the Company, its successors and assigns regardless of any change in the business structure of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">.  The Company&#8217;s rights and obligations under this Agreement, including the restrictions in the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its assets, stock or business.  Employee consents to that transfer.  Employee may not assign any rights or obligations under this Agreement without the Company&#8217;s prior written consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the parties with respect thereto</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:12pt;">including Employee&#8217;s prior Agreement, dated April 30, 2014, except this Agreement does not supersede the Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A or the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as Exhibit B.  Nor does this Agreement supersede any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  No waiver, modification or change of any provision of this Agreement shall be valid unless in writing and signed by both parties.  </font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:12pt;">.  The waiver of any breach of any duty, term or condition of this Agreement shall not be deemed to constitute a waiver of any preceding or succeeding breach of the same or any other duty, term or condition of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Agreement shall be unenforceable in any jurisdiction in accordance with its terms, the provision shall be enforceable to the fullest extent permitted in that jurisdiction and shall continue to be enforceable in accordance with its terms in any other jurisdiction and the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.  All notices pursuant to this Agreement shall be in writing and shall be sent by prepaid certified mail, return receipt requested or by recognized air courier service addressed as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;If to the Company to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amicus Therapeutics, Inc. <br>1 Cedar Brook Drive <br>Cranbury, New Jersey 08512</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c/o&#160;&#160;&#160;&#160;CEO or General Counsel</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;If to Employee to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Daphne Quimi <br>at the address identified herein or in Employee&#8217;s personnel records,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or to such other addresses as may hereinafter be specified by notice in writing by either of the parties, and shall be deemed given three (3)&#160;business days after the date so mailed or sent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance</font><font style="font-family:inherit;font-size:12pt;">. If reasonably requested in writing, Employee agrees within fifteen (15) business days to provide the Company with an executed IRS Form&#160;4669 (Statement of Payments Received) with respect to any taxable amount paid to Employee by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowing and Voluntary Nature of Agreement</font><font style="font-family:inherit;font-size:12pt;">. Employee acknowledges and agrees that Employee is executing this Agreement knowingly and voluntarily and without any duress or undue influence by the Company or anyone else.  Employee further acknowledges and agrees that Employee has carefully read this Agreement and fully understands it. Employee further agrees that Employee has been provided an opportunity to seek, and has received, the advice of an attorney of Employee&#8217;s choice (at Employee&#8217;s expense) before signing this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">[Signature Page Follows]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above written.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Daphne Quimi</font><font style="font-family:inherit;font-size:12pt;">_____________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Daphne Quimi</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ David Clark                   ______&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;David Clark</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: Chief People Officer</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s80A88F596CF3BA011BC69C0291268643"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFIDENTIALITY, NON-DISCLOSURE AND NON-COMPETITION AGREEMENT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITH</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Daphne Quimi</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement is made as of February 18, 2020 between you and Amicus Therapeutics, Inc. (the &#8220;Company&#8221;).  You agree that you are receiving adequate consideration in exchange for entering into this Confidentiality, Non-Disclosure and Non-Competition Agreement (the &#8220;Agreement&#8221;) including:  (1)&#160;at-will employment and the benefits of that employment including any grant to you of certain restricted stock units and options to purchase shares of common stock in the Company; (2)&#160;access to Confidential Information belonging to the Company; and (3) access to the Company&#8217;s business relationships.  You acknowledge that entering into this Agreement is a condition of receiving those items.  Accordingly, you agree to the following terms and conditions:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the protections provided by this Agreement are necessary to safeguard the Company&#8217;s Confidential Information (as defined below), business relationships and other business interests, and that the Company is willing to employ you, and continue to employ you, on the condition that you execute this Agreement.  You agree that the Company has spent substantial resources developing its Confidential Information and business relationships.  You also agree that protecting these assets is critical to the Company&#8217;s survival and success, and a competitor with access to those assets would have an unfair competitive advantage over the Company. Therefore, you agree that the Company has a legitimate business interest in protecting those assets and that the commitments set forth in this Agreement are a reasonable means of doing so.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that as an integral part of the Company&#8217;s business, the Company has developed, and will develop, at a considerable investment of time and expense, non-public scientific data and methods, clinical development plans and strategies, business development plans and strategies, marketing and business plans and strategies, procedures, methods of operation and marketing, financial data, lists of actual and potential customers and suppliers including buying habits of those customers, and independent sales representatives and related data, technical procedures, engineering and product specifications, plans for development and expansion, and other confidential and sensitive information, and you acknowledge that the Company has a legitimate business interest in protecting the confidentiality of such information.  You acknowledge that you will be entrusted with such information as well as confidential non-public information belonging to customers, suppliers, and other third parties.  You, therefore, acknowledge a continuing responsibility to protect such information and agree to the provisions contained herein.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Trade Secrets&#8221; shall mean information belonging to the Company or licensed by it including, without limitation, data, reports, research, drawings, specifications, software, formulae, patterns, compilations, programs, devices, methods, techniques, or processes (including such information that has commercial value to the Company from a negative viewpoint, such as the results of research which proves that certain processes used to attempt to develop new technology will be unsuccessful) which are not commonly known by or available to the public, and which information: (a)&#160;derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from their disclosure or use; (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy; and (c) as otherwise defined by law.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Proprietary Information&#8221; shall mean any information, other than Trade Secrets, without regard to form, belonging to the Company or licensed by it including, without limitation, formulae, patterns, compilations, programs, devices, methods, techniques, or processes, which is not commonly known by or available to the public and which information is material to the Company and not generally known by the public, and all notes, analyses, compilations, studies, interpretations or other documents prepared by you which contain, reflect or are based upon, in whole or in part, the information furnished to you by the Company pursuant hereto; provided, however that &#8220;Proprietary Information&#8221; shall not include any information which you can show (i) becomes patented, published or otherwise part of the public domain through no act or fault of your own, (ii) is received in good faith from any third party who has the right to disclose such information and who has not received such information, either directly or indirectly, from the Company, or (iii) any information which you can show was in your legitimate possession prior to your commencing employment with the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Confidential Information&#8221; shall mean, collectively, the information outlined in Paragraph 2 of this Agreement, Trade Secrets outlined in Paragraph 3 and Proprietary Information outlined in Paragraph 4 and all other information protected by unauthorized disclosure by law. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">You will treat as confidential and will not, without the prior written approval of the Company, directly or indirectly, use (other than in the performance of duties of employment with the Company), publish, disclose, patent, copyright, or authorize anyone else to use, publish, disclose, patent, or copyright any Confidential Information during your employment and after your employment with the Company terminates, whether such termination is voluntary or involuntary, with or without cause.  You agree to take all action reasonably necessary to protect Confidential Information from being disclosed or used by anyone other than persons authorized by the Company.  Confidential information shall not include information that: (i) is or subsequently becomes publicly available without your, or any other person or entity&#8217;s, breach of any obligation owed to the Company; (ii) was lawfully received by you from a third party free of any obligation of confidentiality owed to the Company; or (iii) you are required to disclose in a judicial or administrative proceeding or as otherwise required by law.    </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company recognizes that you, as a former employee or independent contractor of another company, may previously have been privy to trade secrets and/or confidential information of such other company, and you may be under an obligation to such other company to maintain the confidentiality of such trade secrets or confidential information.  Accordingly, to the extent you are under such an obligation, you shall not: (a) bring any records, notes, files, drawings, documents, plans and like items, electronic or otherwise, provided to you in confidence by such other company, or any copies thereof, relating to or containing or disclosing confidential information or trade secrets of any such other company, on the premises of the Company or loaded onto the Company&#8217;s computer systems or otherwise use such documents and items in the performance of services for the Company; or (b) disclose any confidential information or trade secrets provided to you in confidence by such other company in the performance of your job duties for </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">.  You represent that you are &#8220;free and clear&#8221; of any legal restrictions that might interfere with your ability to begin or continue your employment with, or perform your duties and responsibilities for, </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">such as non-compete, non-solicitation or non-disclosure restrictions imposed by current or former employers or contractors.   You confirm that you have disclosed to </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">&#32;any agreements between you and your current or former employers or contractors describing any possible restrictions on your activities. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You acknowledge that all Confidential Information and any records, files, memoranda, computer programs, reports, claims reports or records, customer lists, contracts, marketing plans, programs or forecasts and other written or printed documents or materials or other data stored on computer disks or other electronic data storage methods (&#8220;Documents&#8221;) received, created or used by you during the course of your relationship with the Company are and will remain the sole property of the Company.  You agree to return all such Documents (including all copies) to the Company promptly upon the termination of your employment, or earlier upon </font><font style="font-family:inherit;font-size:11pt;">the Company&#8217;s </font><font style="font-family:inherit;font-size:12pt;">request,  and agree that, during or after your employment, you will not, under any circumstances, without the specific authorization in writing of an officer of the Company, disclose those Documents or any information contained in such Documents to anyone outside the Company&#8217;s organization or use those Documents for any purpose other than the advancement of the Company&#8217;s interests.  Upon termination of your employment for any reason, or upon the Company&#8217;s earlier request, you also agree to immediately return to </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">all equipment and property provided to you by </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">including, but not limited to, computers, phones, pagers, thumb drives or other storage devices, iPads and other tablet devices, and any other electronic devices.  You also agree to provide </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">with all usernames, passwords, passcodes, and other information for logging into and accessing the equipment, applications, platforms, software, hardware, devices and other systems that you used or accessed in the course of, and during, your employment.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protected Conduct</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement prohibits you from disclosing Confidential Information under any of the following circumstances:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure in confidence to an attorney solely for the purpose of reporting or investigating a suspected violation of law; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure, directly or indirectly, to a Federal, State or local government official in confidence solely for the purpose of reporting or investigating a suspected violation of law; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure in a complaint or other document filed under seal in a lawsuit or other proceeding; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure to your attorney in connection with a lawsuit you file against the Company for retaliation for reporting a suspected violation of law.  Under this scenario, you may use the Confidential Information in the court proceedings as long as you file any document containing the Confidential Information under seal and do not otherwise disclose the Confidential Information, except pursuant to a Court Order.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prohibits you from filing a charge or complaint with, reporting or making disclosures (including providing supporting documents or other information) of possible violations of any law or regulation to, and/or participating in any investigation or proceeding conducted by, any self-regulatory organization or governmental agency, authority, or legislative body including, but not limited to, the Securities and Exchange Commission and/or Equal Employment Opportunity Commission or as otherwise required or allowed by law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Is intended to interfere with your rights under Section 7 of the National Labor Relations Act, including the right of employees to communicate with each other regarding the terms and conditions of their employment and to engage in concerted activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prevents you from disclosing or requires you to conceal the details of any alleged discrimination, retaliation or harassment.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Disclosure and Assignment Of Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">.  You agree to promptly disclose to the Company all &#8220;Intellectual Property&#8221; conceived or developed by you while employed by the Company that relates to the Company&#8217;s business.  The term &#8220;Intellectual Property&#8221; means any and all (i) data, reports, formulas, techniques, research, drawings, specifications, software and any other copyrightable works; (ii) Trade Secrets; and (iii) ideas, creations, inventions, discoveries, designs, devices, methods, processes and innovations whether or not patentable, and all related know-how.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Assignment of Intellectual Property Rights</font><font style="font-family:inherit;font-size:11pt;">.  You agree that all Intellectual Property conceived or developed by you while employed by the Company after the date of this Agreement shall be the exclusive property of the Company.  You hereby assign and agree to assign in the future to the Company all of your right, title and interest in and to any and all Intellectual Property related to your work at the Company, whether or not registrable under patent, copyright, trademark or similar statutes, made or conceived or reduced to practice or learned by you, either alone or jointly with others, during the period and scope of your employment with the Company.  Such assignment is perpetual and irrevocable.  Intellectual Property assigned to the Company, or to a third party as directed by the Company pursuant to this paragraph, are hereinafter referred to as &#8220;Company Intellectual Property.&#8221;  You agree to assign all right, title and interest in and to any particular Company Intellectual Property to a third party as directed by the Company.  You further agree to assign to the Company or, to the extent assignment is not permissible, waive any so-called &#8220;moral rights&#8221; in the Intellectual Property to the extent permitted by law.  You will assist the Company in every proper way to obtain, perfect, and from time to time enforce, its patent, copyright, trade secret and other rights in the Intellectual Property relating to Company Intellectual Property in any and all countries.  You hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, that you now or may hereafter have for infringement of any Intellectual Property assigned hereunder to the Company.</font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Prior Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding the foregoing, the Company agrees that you will not be obligated to assign any invention that you developed entirely on your own time, without using any equipment, supplies, facilities or trade secret information of the Company, unless such invention either:  (i) relates (at the time of conception or reduction to practice of the invention) to the Company&#8217;s business or the Company&#8217;s actual or demonstrably anticipated research, or (ii) results from any work performed by you for the Company.  Intellectual Property, if any, that you made prior to the commencement of your employment with the Company, or made outside the scope of your employment, are excluded from the scope of this Agreement.  To preclude any possible uncertainty, you have set forth on Exhibit A attached to this Agreement a complete list of all Intellectual Property that you have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement</font><font style="font-family:inherit;font-size:12pt;">&#32;of your employment with </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">, that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Agreement (collectively referred to as &#8220;Prior Intellectual Property&#8221;).</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Obligation to Keep the Company Informed</font><font style="font-family:inherit;font-size:11pt;">.  During the period of your employment, you will promptly disclose to the Company fully and in writing all Intellectual Property authored, created, conceived or reduced to practice by you, either alone or jointly with others, whether or not patentable or copyrightable or believed by you to be patentable or copyrightable.  In addition, you will promptly disclose to the Company (to be held in confidence) all patent applications filed by you or on your behalf within six months after termination of your employment (whether voluntarily or involuntarily), and to cooperate fully with a review and determination by the Company as to whether such patent applications constitute or include the Company&#8217;s Intellectual Property or Confidential Information.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Works for Hire</font><font style="font-family:inherit;font-size:11pt;">.  You acknowledge and agree that all original works of authorship that are made by you (solely or jointly with others) within the scope of your employment by the Company and that are protectable by copyright including, but not limited to, drawings, sketches and designs, are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C. Section 101).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the Company has compelling business interests in preventing the use or disclosure of its Confidential Information, or the misappropriation of its business relationships, and to protect those interests it is reasonable to restrict you from working or becoming affiliated with, either during or after the end of your employment with the Company, a Competitive Business (as defined below).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also acknowledge that the Company is engaged in a highly competitive business and that by virtue of the nature of your employment with the Company, your engaging in or working for or with any Competitive Business will cause the Company great and irreparable harm.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accordingly, you agree that, during your employment with the Company and for a period of twelve (12) months after the date of termination of your employment with the Company for any reason, whether such termination is voluntary or involuntary, by wrongful discharge or otherwise, you will not, directly, or indirectly work for or with or have any interest in any Competitive Business, whether as an individual on your own account, as a partner or joint venturer, as an employee, agent or salesperson for any person, as an officer or director of any corporation, or as a consultant or otherwise, or engage in preparations for any activity prohibited by this paragraph or any other paragraph in this Agreement without the prior specific written consent by an officer of the Company to do so provided, that the foregoing shall not prohibit ownership of the securities of a publicly-traded entity which constitute less than 2% of the outstanding voting securities of the entity.  For purposes of this Agreement, &#8220;Competitive Business&#8221; shall mean any person or entity who engages in the business of researching, developing and/or commercializing products, including but not limited to small molecules, biologics and gene therapies in the areas of Fabry disease, Pompe disease, Battens Disease, CDKL-5 Deficiency Disorder and any other condition, or any other business, in which the Company is actively engaged during the last twenty-four months of your employment.   You acknowledge that the geographic scope of this restriction is reasonable given that: (1) the Company does business and has customers and competitors throughout the world; and (2) modern communication and transportation make it easy to compete in this industry from virtually any location on earth.   Further, you acknowledge and agree that given the nature of your responsibilities for the Company and your access to its Confidential Information and business relationships, if you were to work for any Competitive Business as described in this paragraph, you would inevitably disclose Confidential Information. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Solicitation</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also acknowledge that, by virtue of your relationship with the Company, you have gained or will gain knowledge of the identity, characteristics and preferences of its customers among other Confidential Information, and that you would inevitably have to draw on such Confidential Information if you were to solicit or service the Company&#8217;s customers on behalf of a Competitive Business.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accordingly, you agree that for twelve (12) months following the termination for any reason whatsoever of your employment with the Company, you will not solicit the business of or perform any services for an actual or prospective Customer of the Company (as defined below).  You also agree that, during this twelve-month period, you will not encourage or assist any person or entity engaged in a Competitive Business to solicit or service any actual or prospective Customer of the Company covered by this paragraph.  &#8220;Customer of the Company&#8221; means any person or company that, at any time during the twenty-four (24) months prior to the end of your employment with the Company, purchases &#8211; or enters into a contract to purchase &#8211; products or services from the Company.  Customer shall also mean any prospective customer to which the Company has submitted a proposal for purchase of products or services.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also agree that, for twelve (12) months following the end of your employment with the Company for any reason, you will not directly or indirectly hire or seek to hire or retain, whether on your own behalf or on behalf of some other person or entity, any Company Personnel (as defined below).  Nor will you, during this twelve (12) month period, directly or indirectly induce or encourage any Company Personnel to leave the Company.  You acknowledge that, even after the expiration of the twelve (12) month period described in this paragraph, you will be barred from soliciting or hiring Company Personnel if, in soliciting or hiring them, you would use or disclose Confidential Information belonging to the Company.  &#8220;Company Personnel&#8221; means any employee, independent contractor or other personnel employed, retained or engaged by the Company at any time during the twenty-four (24) months prior to the termination of your employment:  (1)&#160;with whom you interacted within the scope of your employment with the Company; (2)&#160;whom you directly or indirectly supervised during your employment with the Company; or&#160;(3)&#160;regarding whom you received non-public information about his or her job responsibilities, compensation or job performance by virtue of your employment with the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Return of Property</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon termination of your employment (by the Company or you) for any reason, or upon the earlier request of the Company, you agree to immediately return to the Company all Company records and other property in your possession, custody or control including (but not limited to) anything containing Confidential Information such as documents, papers, files, records, reports, binders, notebooks, books, notes, calendars, plans, drawings, maps, specifications, blueprints, studies, photographs, video recordings, audio recordings, computers, tablets, smartphones, mobile telephones, drives, discs, and any other devices used to store electronic data, and any and all electronic copies and/or hard-copies.  Notwithstanding the foregoing, nothing in this Agreement shall prohibit you from retaining paystubs and other records regarding your compensation and benefits that the Company is required by law to provide to you.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon termination of your employment (by the Company or you) for any reason, or upon the earlier request of the Company, you agree to provide the Company with all usernames, passwords, passcodes and other information that it may need to log into and access the equipment, applications, platforms, software, hardware, devices and other systems that you used or accessed in the course of, and during, your employment.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon the Company&#8217;s request, you agree to immediately provide the Company with a written affidavit confirming that you have returned all Company property and Confidential Information, and cooperate in providing the Company, at the Company&#8217;s request, a means through which it can promptly and independently verify (including by forensic analysis, if necessary) that all Confidential Information has been removed from electronic storage devices, cloud-based storage, and accounts in your possession or control.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If you are served with a subpoena, court order, or similar legal document requiring the production of Company records or other property or the disclosure of Confidential Information, you agree to provide the Company with as much notice as is possible (presumably seven (7) business days or more) through written notification to the Company&#8217;s General Counsel and the Company&#8217;s CEO, so that the Company may take permissible steps to protect the records and information, unless such notice is prohibited by law or court order; provided, however, that nothing in this Agreement prohibits you from engaging in the Protected Conduct described in Section 9 and Section 10 of this Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Terms</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the restrictions contained in this Agreement are fair, reasonable and necessary to protect the legitimate business interests of the Company and that the Company will suffer irreparable harm in the event of any actual or threatened breach by you of this Agreement.  You agree that enforcement of the restrictions in this Agreement will not cause you any hardship, and because of your background and experience will not in any manner preclude you from becoming gainfully employed in such manner and to such extent as will provide you with a standard of living of at least the sort and fashion to which you are accustomed. You therefore agree that the Company may seek a restraining order, preliminary injunction or other court order to enforce this Agreement without the necessity of posting a bond or any security that might otherwise be required in connection with such relief.  You also agree that any request for such relief by the Company shall be in addition and without prejudice to any claim for monetary damages which the Company might elect to assert.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If any provision of this Agreement is held to be unenforceable by a court, such unenforceability shall not affect the enforceability of the remaining provisions.  Such provision shall be reformed and construed to the extent permitted by law so that it would be valid, legal and enforceable to the maximum extent possible.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that this Agreement does not give you any rights to employment by or to be retained as a consultant of the Company and, unless otherwise provided in another writing, executed by an officer of the Company and you, your relationship with the Company shall be employment &#8220;at will.&#8221;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You agree that, if you, at any time during or within one year after your employment with the Company ends, you receive an offer of employment or retention from any person or entity other than the Company, you will provide that person or entity with a copy of this Agreement.  You also agree that, at any time during, or within one year after the end of, your employment with the Company, you will, in writing, immediately after accepting (orally or in writing) any offer of employment or retention with any person or entity other than the Company:  (1)&#160;notify the Company that you accepted the offer; and (2)&#160;inform the Company of the identity of the person or entity, and of your title, responsibilities, work location and anticipated start date.  You acknowledge that the requirements set forth in this paragraph are fair, reasonable and necessary in order for the Company to adequately protect its Confidential Information and business relationships.  The Company may also provide copies of this Agreement to others including, but not limited to, customers and potential customers, and your future employers and prospective employers.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">You understand nothing in this Agreement prohibits you reporting to any governmental authority information concerning violations of law or regulations, and that you may report trade secret information to a government official or to an attorney and use it in certain proceedings without fear of prosecution or liability provided such disclosure is consistent with 18 U.S.C. 1833. If you make the disclosure to your attorney in connection with a private lawsuit, you may use the Confidential Information in the court proceedings as long as you file any document containing the Confidential Information under seal and do not otherwise disclose the Confidential Information, except pursuant to a Court Order.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement represents the entire agreement of the parties with respect to the subject matter covered and cannot be modified or amended except in a writing signed by both parties.  The waiver by any party to this Agreement or a breach of any of the provisions of this Agreement shall not operate or be construed as a waiver of any subsequent or simultaneous breach.  This Agreement supersedes any confidentiality, non-competition and non-solicitation entered into by the Company and you prior to the date of this Agreement.  This Agreement does not supersede:  (1)&#160;the Employment Agreement between you and the Company; (2)&#160;the Mutual Agreement to Arbitrate Disputes on an Individual Basis between you and the Company; or (3)&#160;</font><font style="font-family:inherit;font-size:12pt;">any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">30.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement shall be construed, interpreted and governed by the laws of the state of your assigned primary office location during the last six months of your employment with the Company, without regard to the conflicts of law principles</font><font style="font-family:inherit;font-size:11pt;">.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">31.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The rights and obligations of the Company under this Agreement shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its or their assets, stock or business.  By signing this Agreement, you consent to any such transfer.  You may not assign any rights or obligations under this Agreement without the prior written consent of the Company&#8217;s Chief Legal Officer or designee. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">By signing below, you acknowledge that you:  (1)&#160;received this Agreement fourteen (14) business days before the date on which you must return an executed copy of it to the Company; (2) have had sufficient opportunity to read each provision of this Agreement; (e)&#160;understand the meaning, effect and implications of each provision of this Agreement; (4)&#160;have had an opportunity to consult with legal counsel of your choosing (at your expense) regarding this Agreement; and (5)&#160;are not relying on any promises or representations that are not set forth in this Agreement.  By signing this Agreement, you are indicating that you are doing so freely and voluntarily and with full understanding of its terms and conditions.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">______________________</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ellen Rosenberg </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">General Counsel &amp; Corporate Secretary, Legal </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Daphne Quimi</font><font style="font-family:inherit;font-size:11pt;">____________________&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Signature:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Daphne Quimi</font><font style="font-family:inherit;font-size:11pt;">__________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">February 27, 2020</font><font style="font-family:inherit;font-size:11pt;">__________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Home Address:&#160;&#160;&#160;&#160;[&#8230;]_____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SCHEDULE 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">PRIOR INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">List below all Intellectual Property and works of authorship that you have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of your employment with Amicus that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Confidentiality, Non-Disclosure and Non-Competition Agreement:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If additional space is needed, attach and sign additional sheets and indicate here:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">___ Additional sheets are attached.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you are not listing any Intellectual Property or works of authorship, indicate here:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">X</font><font style="font-family:inherit;font-size:12pt;">_ No Intellectual Property or works of authorship claimed.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signature of Employee: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Daphne Quimi</font><font style="font-family:inherit;font-size:12pt;">____________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Print Name of Employee: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Daphne Quimi</font><font style="font-family:inherit;font-size:12pt;">_____________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: February 27, 2020</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="sADB3916FEF47A551B9F79C029148568D"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT B</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">MUTUAL AGREEMENT TO ARBITRATE DISPUTES ON AN INDIVIDUAL BASIS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Mutual Agreement to Arbitrate Disputes on an Individual Basis (&#8220;Arbitration Agreement&#8221;) is made and entered into as of February 18, 2020 (the &#8220;Effective Date&#8221;) by and between </font><font style="font-family:inherit;font-size:11pt;">Amicus Therapeutics, Inc. (the &#8220;Company&#8221;) </font><font style="font-family:inherit;font-size:12pt;">and Daphne Quimi (&#8220;you&#8221;).  In this Arbitration Agreement, the Company and you are sometimes referred to individually as a &#8220;Party&#8221; and sometimes referred to together as the &#8220;Parties.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:12pt;">.  The Parties are entering into this Arbitration Agreement because they want to resolve all disputes arising out of or relating to your employment by the Company, or the termination of your employment, by binding private arbitration in accordance with the provisions of this Arbitration Agreement.  Regarding any claims covered by this Arbitration Agreement, you and the Company understand that, by entering into this Arbitration Agreement, YOU AND THE COMPANY ARE EACH GIVING UP:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1)&#160;&#160;&#160;&#160;THE RIGHT TO A JURY TRIAL; AND</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THE RIGHT TO FILE A LAWSUIT IN COURT AGAINST THE OTHER PARTY; AND </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THE RIGHT TO BRING A CLASS OR COLLECTIVE ACTION AGAINST THE OTHER PARTY IN COURT OR IN ARBITRATION OR IN ANY OTHER FORUM.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Mandatory Arbitration</font><font style="font-family:inherit;font-size:12pt;">.  In exchange for the mutual promises contained in this Arbitration Agreement and as a condition of the Company hiring and employing you, you and the Company agree that:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any and all &#8220;Covered Claims&#8221; (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3</font><font style="font-family:inherit;font-size:12pt;">&#32;below) shall be submitted to and resolved by final and binding arbitration to be held in the American Arbitration Association (&#8220;AAA&#8221;) office located nearest to your employment location for the Company.  The arbitration shall proceed before a single arbitrator and administered by the AAA in accordance with AAA&#8217;s Employment Arbitration Rules and Mediation Procedures (the &#8220;AAA Rules&#8221;) in effect and applicable at the time the arbitration is commenced.  The AAA Rules may be amended from time to time and are available online at </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">https://www.adr.org/sites/default/files/Employment%20Rules.pdf</font></a><font style="font-family:inherit;font-size:12pt;">.  You may also call the AAA at 800-778-7879 with any questions about the arbitration process.  If the AAA Rules are inconsistent with the terms of this Arbitration Agreement, the terms of this Arbitration Agreement shall govern; AND </font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Arbitrator, and not any federal, state, or local court or agency, shall have exclusive authority to resolve any dispute relating to the interpretation, applicability, formation or enforceability of this Arbitration Agreement including, but not limited to, the arbitrability of any dispute between the parties; AND </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Arbitrator&#8217;s decision shall be final and binding only on the Parties to this Arbitration Agreement and the Parties agree that awards deciding issues for similarly-situated employees will have no preclusive effect in any arbitration between the Parties. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Covered Claims</font><font style="font-family:inherit;font-size:12pt;">.  Except as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">, &#8220;Covered Claims&#8221; under this Arbitration Agreement shall include all past, current and future grievances, disputes, claims or causes of action that otherwise could be brought in a federal, state or local court under applicable federal, state or local laws, arising out of or relating to your employment with the Company or the termination of your employment including claims arising out of or related to your hiring, recruitment, compensation and termination, and including claims you may have against the Company or its officers, directors, supervisors, managers, employees or agents, or that the Company may have against you.  Covered Claims include, but are not limited to, claims for breach of any contract or covenant (express or implied), tort claims, claims for wages or other compensation, claims for wrongful termination (constructive or actual), claims for discrimination, harassment or retaliation (including, but not limited to, harassment or discrimination based on race, age, color, sex, gender, gender identity, transgender status, sexual orientation, national origin, alienage or citizenship status, creed, religion, marital status, partnership status, familial status, domestic violence victim status, military status, predisposing genetic characteristics, medical condition including pregnancy, psychological condition, mental condition, criminal accusations and convictions, disability, or any other trait or characteristic protected by federal, state, or local law, claims for violation of any federal, state, local or other governmental law, statute, regulation, or ordinance, including, but not limited to, all claims arising under federal law such as:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:77px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Age Discrimination in Employment Act; the Older Workers Benefits Protection Act; Title VII of the Civil Rights of 1964; Sections 1981 through 1988 of Title 42 of the United States Code; the Civil Rights Act of 1991; the Equal Pay Act; the Americans with Disabilities Act; the Rehabilitation Act; the Employee Retirement Income Security Act; the Worker Adjustment and Retraining Notification Act; the National Labor Relations Act; the Fair Credit Reporting Act; the Occupational Safety and Health Act; the Uniformed Services Employment and Reemployment Act; the Employee Polygraph Protection Act; the Immigration Reform Control Act; the Family and Medical Leave Act; the Genetic Information Nondiscrimination Act; the Federal False Claims Act; the Patient Protection and Affordable Care Act; the Consolidated Omnibus Budget Reconciliation Act; and the Lilly Ledbetter Fair Pay Act;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and all claims arising under state and local law, such as:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:77px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The New Jersey Law Against Discrimination; the New Jersey Discrimination in Wages Law; the New Jersey Security and Financial Empowerment Act; the New Jersey Temporary Disability Benefits and Family Leave Insurance Law; the New Jersey Domestic Partnership Act; the New Jersey Conscientious Employee Protection Act; the New Jersey Family Leave Act; the New Jersey Wage Payment Act; the New Jersey Equal Pay Law; the New Jersey Occupational Safety and Health Law; the New Jersey False Claims Act; the New Jersey Smokers&#8217; Rights Law; the New Jersey Genetic Privacy Act; the New Jersey Fair Credit Reporting Act; the New Jersey Emergency Responder Leave Law; the New Jersey Millville Dallas Airmotive Plant Job Loss Notification Act (a/k/a the New Jersey WARN Act); Gender Inequity Law; and the New Jersey Earned Sick Leave Law.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The laws listed above should be interpreted as including all amendments to those laws and together with all of their respective implementing regulations, and any and all other federal, state and local laws that govern your employment with the Company or the termination of that employment for any reason.  Covered Claims under this Agreement include claims arising out of or related to acts or omissions that occurred before entering into this Arbitration Agreement and those that may occur in the future.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Claims Not Covered</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding any other provision of this Arbitration Agreement, this Arbitration Agreement does not mandate arbitration of:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">disputes arising under your Confidentiality, Non-Disclosure and Non-Competition Agreement with the Company; OR </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">claims for Workers&#8217; Compensation benefits;  OR</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">claims for unemployment compensation benefits;  OR</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any other claims that, as a matter of law, cannot be subject to mandatory arbitration.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings 3;font-size:12pt;">&#218;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding any other provision of this Arbitration Agreement, nothing in this Arbitration Agreement prevents you or shall be interpreted to mean that you are precluded from filing charges or complaints with the National Labor Relations Board (NLRB), the Equal Employment Opportunity Commission (EEOC), the Securities and Exchange Commission (SEC) or any equivalent state or local agency.  Nor does this Arbitration Agreement prevent you from testifying or participating in any proceedings before those administrative agencies.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver of Class and Collective Actions</font><font style="font-family:inherit;font-size:12pt;">.  You and the Company expressly intend and agree that:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">class and collective action procedures shall not be asserted and will not apply in any arbitration pursuant to this Agreement; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">neither you nor the Company will assert class or collective claims against the other in court, in arbitration or otherwise;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">each Party shall only submit individual claims in arbitration and will not seek to represent the interests of any other person; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any claims by you will not be joined, consolidated or heard together with the claims of any other employee; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">no decision or arbitral award determining an issue with a similarly-situated employee shall have any preclusive effect in any arbitration between the Parties, and the Arbitrator shall have no authority to give preclusive effect to the issues determined in any arbitration between the Company and any other employee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver of Trial by Jury</font><font style="font-family:inherit;font-size:12pt;">.  The Parties understand and fully agree that, by entering into this Arbitration Agreement, they are giving up their constitutional right to have a trial by jury, and are giving up their normal rights of appeal following the issuance of the arbitrator&#8217;s award except as otherwise provided by applicable law.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Claims Procedure</font><font style="font-family:inherit;font-size:12pt;">.  Arbitration shall be initiated by the express written notice of either you or the Company.  The Party initiating the arbitration must give written notice of any claim to the other Party.  Written notice of your claim shall be mailed by certified or registered mail, return receipt requested, to Employer&#8217;s General Counsel at Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512.  Written notice of a claim by the Company will be mailed to your last known address.  The written notice shall identify and describe the nature of all claims asserted and the facts supporting the claims.  Written notice of arbitration shall be initiated within the same time limitations that applicable federal and state law applies to those claims.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbitrator Selection</font><font style="font-family:inherit;font-size:12pt;">.  The Arbitrator shall be selected as provided in AAA Rules.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Discovery</font><font style="font-family:inherit;font-size:12pt;">.  The Arbitrator shall have the authority to order such discovery, by way of deposition, interrogatory, document production or otherwise, as the Arbitrator deems necessary to a full and fair exploration of the issues in dispute, consistent with the expedited nature of arbitration.  The Arbitrator shall have the authority to set deadlines for completion of discovery.  The Arbitrator shall decide all discovery disputes.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Governing Law; Substantive Law</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement and any arbitration shall be governed by the Federal Arbitration Act (FAA) to the exclusion of any state law inconsistent with the FAA.  The Arbitrator shall apply the substantive state or federal law as applicable to the claims asserted in arbitration.  Claims arising under federal law shall be determined in accordance with federal law.  Common law claims shall be determined in accordance with the substantive law of the state your assigned primary office location during the last six months of your employment with the Company, without regard to conflicts of law principles.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compelling Arbitration; Enforcing Award</font><font style="font-family:inherit;font-size:12pt;">.  Either Party may ask a court to stay any court proceeding to compel arbitration under this Arbitration Agreement, and to confirm, vacate or enforce an arbitration award.  Judgment on the award rendered by the Arbitrator may be entered in any state or federal court of competent jurisdiction located in the state of your employment location for the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbitration Fees and Costs</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall be responsible for the Arbitrator&#8217;s fees and arbitration expenses and any other costs unique to the arbitration hearing, except that you shall be responsible for paying the initial filing fees as provided by the AAA&#8217;s Rules.  Each Party shall pay its own deposition, witness, expert and attorneys&#8217; fees and all other expenses to the same extent as if the matter were proceeding in court.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Term of Agreement; Modification in Writing</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement shall survive the termination of your employment.  This Arbitration Agreement can only be revoked or modified in a writing that specifically states an intent to revoke or modify this Arbitration Agreement and is signed by both you and the President of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:12pt;">.  The Company may freely assign this Arbitration Agreement at any time.  This Arbitration Agreement shall inure to the benefit of the Company&#8217;s successors and assigns.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement represents the entire agreement of the parties with respect to the subject matter covered and cannot be modified or amended except in a writing signed by both parties.  The waiver by any party to this Arbitration Agreement or a breach of any of the provisions of this Arbitration Agreement shall not operate or be construed as a waiver of any subsequent or simultaneous breach.  This Arbitration Agreement supersedes any inconsistent agreements between the Parties with respect to the subject matter of the Arbitration Agreement.  This Agreement does not supersede:  (1) the Employment Agreement between you and the Company; (2) the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement </font><font style="font-family:inherit;font-size:12pt;">between you and the Company; or (3)&#160;any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Arbitration Agreement is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable provision shall be severed and that adjudication shall not affect the validity of the remainder of this Arbitration Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Voluntary Agreement</font><font style="font-family:inherit;font-size:12pt;">.  By executing this Arbitration Agreement, the Parties represent that they have been given the opportunity to fully review its terms.  You acknowledge and agree that you have had an opportunity to ask questions and consult with an attorney of your choice, at your expense, before signing this Arbitration Agreement.  The Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement.  YOU AND THE COMPANY FULLY UNDERSTAND AND AGREE THAT YOU AND THE COMPANY ARE GIVING UP CERTAIN RIGHTS OTHERWISE AFFORDED BY CIVIL COURT ACTIONS INCLUDING, BUT NOT LIMITED TO, THE RIGHT TO A JURY OR COURT TRIAL AND THE RIGHT TO BRING ANY CLAIM AS A CLASS OR COLLECTIVE ACTION.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Daphne Quimi</font><font style="font-family:inherit;font-size:11pt;">____________________&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Signature:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Daphne Quimi</font><font style="font-family:inherit;font-size:11pt;">__________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">February 27, 2020</font><font style="font-family:inherit;font-size:11pt;">__________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Home Address:&#160;&#160;&#160;&#160;[&#8230;]</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">________________________</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ellen Rosenberg </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Legal Officer and Corporate Secretary, Legal </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="sBFBC61449B7AC008F7FC9C02916729C3"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT C</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Chief Financial Officer will be a key member of the Executive Team and responsible for overall management of the Company&#8217;s Finance Department.  The successful candidate will also play a leadership role in the development of the company&#8217;s financing strategy and general corporate strategy.  He or she will have a significant role in shaping Company Guidance and public disclosures. Key aspects of position responsibilities include but are not limited to the following:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Advise senior management and the Board of Directors on the financial implications of business activities.  Make recommendations to strategically enhance financial performance.  Prepare special analyses/evaluations in support of major business decisions and collaboratively develop operating policies and procedures and improvement programs for the attainment of corporate objectives.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serve as key business partner and contributor to growth strategies, tactics and long-range planning, ensuring that current revenue-generating strategies create enterprise value.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contribute to the Company&#8217;s investor relations program. Act as primary liaison for company banking relationships and one of the liaisons to investor and analyst communities.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Collaborate with head of Investor Relations and CEO in the preparation of the quarterly earnings press releases, executive speeches, investor presentations and all corporate communications.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Build, develop and lead a strong finance function in a small-company organizational setting.  Ensure the efficient day-to-day operation of the accounting and finance functions through direct supervision and overall goal setting for the department. Focus on integration of finance function into mainstream business operations and planning. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Work with the CEO and the General Counsel to manage external reporting requirements and the preparation of Board packages.  Play a leadership role in support and management of the Audit Committee of the Board of Directors.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lead the Company&#8217;s financial and public disclosure compliance efforts.  Coordinate the review of SEC filings, including 10-Q, 10-K, and 8-K for compliance with generally accepted accounting principles and relevant SEC and PCAOB regulations, including Sarbanes-Oxley requirements.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oversee the audit of the Company&#8217;s financial records and work effectively with outside auditors and the Audit Committee.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Provide day-to-day leadership and management to the Company&#8217;s finance and accounting operations, including general accounting, financial reporting, asset usage, budget preparation, and financial analysis and forecasting.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lead special project teams and perform special projects as directed by the executive team.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">POSITION REQUIREMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Technical</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15-20 years progressive accounting/finance experience, including at least 5 years experience in a senior leadership role.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bachelor&#8217;s Degree in Accounting or Finance required.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MBA and/or CPA preferred.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Experience in a public biotechnology or life science organization is required.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prior experience with and/or exposure to investor relations, venture capital and M&amp;A activity preferred.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contacts/experience with life sciences financial community (bankers, venture capitalists, analysts, etc.), both buy-side and sell-side, a plus.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Experience working with executive management, boards of directors and audit committees.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Experience with public company reporting and SEC regulatory issues.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Experience managing and developing an accounting and finance organization, particularly in a growth environment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Experience in budgeting and forecasting with multiple programs and products.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Personality</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Hands on professional accustomed to very high growth and fast-paced environments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Demonstrated sense of urgency and ability to work independently, as part of a team and under tight deadlines.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Entrepreneurial with a self-starting personality; ability to prioritize and manage multiple responsibilities simultaneously.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Ability to handle multiple functions simultaneously and independently and to coordinate activities with rest of management team and other functional areas.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Ability to work collaboratively as part of a team both within the finance function and across the organization</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Strong drive, dedication and work ethic.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Ability to thrive in a small company environment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Articulate.  Open, transparent communicator, inquisitive and not afraid to challenge.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s0C078302A57CD7E4598E9C0291994EBC"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.49
<SEQUENCE>8
<FILENAME>exhibit1049hungdo-empl.htm
<DESCRIPTION>EXHIBIT 10.49
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s878B667D685F0DAB4FC19C04B5110872"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THIS EMPLOYMENT AGREEMENT</font><font style="font-family:inherit;font-size:12pt;">&#32;(this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), dated as of February 18, 2020 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), between AMICUS THERAPEUTICS, INC., a Delaware corporation having an office at 3675 Market Street, Philadelphia, PA 19104 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and Hung Do, an individual residing at [&#8230;], (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) (together, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">parties</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS,</font><font style="font-family:inherit;font-size:12pt;">&#32;the Company wishes to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">continue to</font><font style="font-family:inherit;font-size:12pt;">&#32;employ Employee, and Employee wishes to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">continue to</font><font style="font-family:inherit;font-size:12pt;">&#32;be employed by Company, on the terms and conditions set forth herein; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:inherit;font-size:12pt;">&#32;in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the sufficiency and receipt whereof is hereby acknowledged, the parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">Section 1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:12pt;">.  Unless otherwise defined herein, the following terms shall have the following respective meanings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Accrued Amounts&#8221; means, as of the termination of Employee&#8217;s employment:  (a)&#160;the total of any expenses properly incurred by Employee under Section 3.4(b) that have not previously been reimbursed as of the effective date of the termination; (b)&#160;the sum of Employee&#8217;s accrued, but unused, vacation time, if any, as of the effective date of the termination; and (c) any accrued and unpaid Base Salary through and including the effective date of Employee&#8217;s termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any other company, directly or indirectly, controlling, controlled by or under common control with the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cause</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Employee&#8217;s: (i)&#160;willful or deliberate misconduct that has or could reasonably be expected to have a materially adverse impact on the reputation or business of the Company (or an Affiliate), or that results in gain or personal enrichment of Employee to the detriment of the Company (or an Affiliate); (ii)&#160;violation of Company policy including, but not limited to, policies prohibiting harassment and other workplace misconduct, and policies governing corporate compliance; (iii) misappropriation of the funds or assets of the Company (or an Affiliate); (iv) conviction, plea of guilty, admission to facts sufficient for a finding of guilt, or plea of no contest (or nolo contendere) to: (a) any felony, or (b) any misdemeanor involving fraud, theft, dishonesty, wrongful taking of property, embezzlement, bribery, forgery or extortion; (v) material breach of this Agreement; (vi)&#160;material breach of the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">; (vii) breach of Employee&#8217;s duty of loyalty to the Company; (viii) disqualification, bar or suspension by any governmental authority from performing any of the duties contemplated by this Agreement; (ix)&#160;material failure to perform Employee&#8217;s duties or obligations hereunder (other than as a result of being Unable to Work); or (x)&#160;willful failure to adhere to or carry out lawful duties or directives of the Company&#8217;s Chief Executive Officer (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CEO</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or Board of Directors (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Notwithstanding anything to the contrary herein, the Company shall not be deemed to have terminated Employee for Cause for the events described above in subsections (ix) or (x) unless the CEO or Board, as applicable, has determined that such events are amenable to cure and given Employee written notice of the occurrence of the claimed event(s) constituting Cause and Employee has failed to cure such event(s) within fourteen (14) calendar days after Employee&#8217;s receipt of such notice (or such other period as may be deemed reasonable by the CEO or Board under the circumstances and communicated to Employee).  The other events described above are not subject to an opportunity to cure but the Company may, in its sole discretion, conduct an investigation into those events and provide the employee a full opportunity to participate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any of the following: (i)&#160;when any person or entity who is not currently a stockholder of the Company (as of the date of this Agreement) becomes the beneficial owner of greater than 50% of the then-outstanding voting power of the Company; (ii)&#160;when a merger or consolidation with another entity occurs that causes the voting securities of the Company outstanding immediately before the transaction to constitute less than a majority of the voting power of the voting securities of the Company or the surviving entity outstanding immediately after the transaction; or (iii)&#160;when a sale or disposition of all or substantially all of the Company&#8217;s assets occurs.  Notwithstanding the foregoing, no event shall be deemed to be a Change in Control Event unless such event would also be a Change in Control under Section 409A and the rules and regulations promulgated thereunder (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 409</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or would otherwise be a permitted distribution event under Section 409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">&#8221; means:  (i) payment of an amount equal to one and one-half (1.5) times Employee&#8217;s then current Base Salary, payable in installments over eighteen (18)&#160;months, commencing within sixty (60) calendar days after the resignation or termination (collectively, &#8220;termination&#8217;) of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices for its senior management personnel; (ii) payment of an amount equal to 100% of the target Bonus for the calendar year in which such termination occurs (such amount being payable in a lump sum), payable within seventy five (75) calendar days following such termination ; (iii) the accelerated vesting of stock options held by Employee immediately prior to such termination (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Options</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such that all Options will become vested as of the date of Employee&#8217;s termination; (iv) the accelerated vesting of restricted stock grants held by Employee immediately prior to such termination (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Grants</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such that all Grants will become vested as of the date of Employee&#8217;s termination; (v) the accelerated vesting of performance restricted stock units held by Employee immediately prior to such termination at the applicable performance targets or such greater amounts as determined by the Board of Directors in their sole discretion; and (vi) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of eighteen (18) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that  the Company will pay the full premiums otherwise payable for such coverage during such 18 month period.  Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Change in Control Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Good Reason</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the occurrence of one or both of the following events without Employee&#8217;s consent: (i)&#160;the Company&#8217;s material diminution of Employee&#8217;s authority, duties, or responsibilities as set forth in this Agreement; or (ii)&#160;the Company&#8217;s change in the principal geographic location at which Employee provides services to the Company to a location more than thirty (30) miles from Employee&#8217;s assigned primary office location, unless such relocation is only temporary, for a reasonable period of time, or unless such relocation merely constitutes travel reasonably required in connection with the performance of Employee&#8217;s duties.  Notwithstanding anything to the contrary herein, Employee shall not be deemed to have resigned for Good Reason unless: (a) Employee had provided to the Company written notice within thirty (30) calendar days of the occurrence of the claimed event(s) constituting Good Reason, specifying in detail the basis for such Good Reason; (b) the Company fails to cure the Good Reason within thirty (30) calendar days after its receipt of such notice, and (c) Employee terminates employment within sixty (60) calendar days after providing notice to Company of the claimed event(s) constituting Good Reason. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (i) payment of an amount equal to Employee&#8217;s then current Base Salary, payable in installments over twelve (12)&#160;months, commencing within sixty (60) calendar days of the termination of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices then in effect for its senior management personnel; (ii) payment of a bonus equal to 100% of the target Bonus for the calendar year in which such termination occurs pro-rated for the number of days actually worked in the year of termination, payable within seventy five (75) calendar days following such termination; (iii) the accelerated vesting of the Options, such that the portion of the Options that was otherwise scheduled to vest during the twelve (12)&#160;month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination;  (iv) the accelerated vesting of RSUs, such that the portion of RSUs that was otherwise scheduled to vest during the twelve (12) month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination; (v)  the accelerated vesting of PRSUs, such that the portion of PRSUs that was otherwise scheduled to vest during the twelve month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination; and (vi)in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.  Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Unable to Work&#8221; means the determination by the Company, following an interactive process, that Employee has become physically or mentally incapable of performing Employee&#8217;s essential job functions, with or without a reasonable accommodation, following any period during which such status would be protected under applicable law.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employment</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duties and Responsibilities</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of this Agreement, Employee will be employed by the Company as Chief Science Officer or in such other position as may be mutually agreed upon by the parties.  A Job Description setting forth Employee&#8217;s duties and responsibilities is attached as Exhibit C.  Employee accepts such employment, and agrees to perform all of the duties and accept all of the responsibilities accompanying such position.  Employee agrees to serve the Company faithfully and to the best of Employee&#8217;s abilities, and to devote all of Employee&#8217;s business time, skill and attention to such service.  Employee is expected to be available for meetings on a regular basis, upon request by the Company, at the Company&#8217;s Cranbury, New Jersey, and Philadelphia, Pennsylvania, locations or such other Company locations as needed including, but not limited to, the Company&#8217;s international offices.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Full Time and Attention</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall devote Employee&#8217;s full business time and best efforts to the performance of Employee&#8217;s duties and to the furtherance of the Company&#8217;s interests.  During Employee&#8217;s employment with the Company, Employee may not hold another position of employment, or be retained as a consultant, or engage in any other business activity (whether full-time or part-time, whether or not for compensation), unless the Company gives Employee prior written permission to do so.  Notwithstanding anything stated in this provision to the contrary, Employee is permitted to engage in charitable activities, as long as they do not interfere with Employee&#8217;s employment obligations to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Policies</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment with the Company, Employee will be subject to all applicable employment and other policies of the Company, as outlined in the Amicus Employee Handbook and as otherwise published by the Company in writing.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compensation and Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, the Company shall pay Employee a salary at the gross annual rate of $427,063 (less applicable withholding) or such greater amount as the Board or a committee thereof may from time to time establish pursuant to the terms hereof (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Such Base Salary shall be reviewed annually and may be increased, but not decreased, by the Board or a committee thereof in its sole discretion. The Base Salary shall be payable in accordance with the Company&#8217;s customary payroll practices for its senior management personnel.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee shall be eligible to participate in the Company&#8217;s bonus programs as may be in effect with respect to senior management personnel. Employee shall be eligible to earn an annual target bonus of 100% of the Base Salary in cash (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">&#8221;) such actual amount determined by the Company Compensation Committee in its absolute discretion and at 40% of base salary; provided, however, that notwithstanding anything to the contrary herein or in any bonus program, Employee must be employed by the Company as of December 31 of the applicable calendar year, in order to be eligible to earn a Bonus for such calendar year.  Any Bonus payment to which Employee becomes entitled hereunder shall be paid to Employee in a lump sum (less applicable withholding) on or before the 15</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of the third month following the end of the calendar year in which the Bonus was earned.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Equity</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan and such other equity plans as the Company may adopt from time to time including, but not limited to, an Employee Stock Purchase Plan, during Employee&#8217;s employment with the Company, Employee will be eligible to receive stock options, Restricted Stock Units and Performance Restricted Stock Units pursuant to any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  Unless otherwise provided in this Agreement, the terms and conditions of the applicable equity plan will govern all equity grants to Employee (including vesting of options and units), including with regard to the impact of the end of Employee&#8217;s employment on such equity grants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefit Plans</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee may participate in any benefit plans (including health and medical insurance) as may be in effect with respect to senior management personnel of the Company, including any equity plan, subject to the eligibility and contribution requirements, enrollment criteria and other terms and conditions of such plans.  The Company reserves the right to modify, amend and eliminate any such plans, in its sole and absolute discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reimbursement of Expenses</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, the Company shall pay or promptly reimburse Employee, upon submission of proper invoices or other documentation in accordance with the Company&#8217;s policies and procedures, for all reasonable out-of-pocket business, entertainment and travel expenses incurred by Employee in the performance of Employee&#8217;s duties.  Any taxable reimbursement of business or other expenses as specified under this Agreement shall be subject to the following conditions:  (i)&#160;the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year; (ii)&#160;the reimbursement of an eligible expense shall be made no later than the end of the calendar year after the year in which such expense was incurred; and (iii)&#160;the right to reimbursement shall not be subject to liquidation or exchange for another benefit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Vacation</font><font style="font-family:inherit;font-size:12pt;">.  During Employee&#8217;s employment, Employee shall be entitled to vacation in accordance with the policies of the Company applicable to senior management personnel as may be in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Withholding</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall withhold from all amounts payable or benefits accorded to Employee all federal, state and local income, employment and other taxes, as and in such amounts as may be required by applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duration of Employment</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s employment with the Company shall begin on the Effective Date and continue until Employee&#8217;s employment is terminated by either Employee or the Company.  At all times, Employee&#8217;s employment with the Company shall be &#8220;at-will,&#8221; meaning that either Employee or the Company may terminate the employment at any time, for no reason or any lawful reason.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination; Severance Benefits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notice of Termination</font><font style="font-family:inherit;font-size:12pt;">.  Any termination of Employee&#8217;s employment by the Company or by Employee (other than on account of death) shall be communicated to the other party by written notice that indicates the specific termination provision in this Agreement relied upon.  Except as otherwise expressly provided in this Agreement or the notice, the termination shall take effect immediately.  The parties agree that the notice requirements set forth in this Agreement do not alter the &#8220;at will&#8221; nature of Employee&#8217;s employment, as described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Generally</font><font style="font-family:inherit;font-size:12pt;">.  Upon termination of Employee&#8217;s employment for any reason, Employee shall be deemed simultaneously to have resigned as a member of the Board, if applicable, and from any other position or office Employee may at the time hold with the Company or any of its Affiliates.  Employee agrees to cooperate with the Company by signing any necessary documents and taking any other steps necessary to effectuate Employee&#8217;s resignation from the Board, if applicable, and from any other position or office Employee may hold with the Company or any of its Affiliates.  In addition, upon termination of Employee&#8217;s employment for any reason, the Company shall pay Employee the Accrued Amounts.  The Accrued Amounts will be paid within the time required by applicable law.  The impact of the termination of Employee&#8217;s employment on the Employee&#8217;s participation in the Company&#8217;s health plans is addressed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by Employee</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resignation Independent of a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If Employee resigns and a Change in Control Event has not occurred in the prior 12 months, then (irrespective of whether the resignation was with or without Good Reason):  (i)&#160;Employee shall receive no further compensation or remuneration of any kind other than the Accrued Amounts; and (ii)&#160;at the end of the month in which the resignation takes effect, Employee shall cease to be covered under or permitted to participate in or receive any of the benefits described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3.4</font><font style="font-family:inherit;font-size:12pt;">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Good Reason Resignation Within 12 Months of a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If Employee resigns for Good Reason within&#160;twelve (12)&#160;months after a Change in Control Event, Employee will be entitled to receive, in addition to the Accrued Amounts, </font><font style="font-family:inherit;font-size:12pt;">Change in Control Severance Benefits.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by the Company</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Without Cause Within 12 Months After a Change in Control Event.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;If the Company terminates Employee&#8217;s employment without Cause within 12 months after a Change in Control Event, then in lieu of any other payments, rights or benefits under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(a)</font><font style="font-family:inherit;font-size:12pt;">, Employee will be entitled to receive Change in Control Severance Benefits in addition to the Accrued Amounts.  All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Without Cause Not Within 12 Months After a Change in Control Event</font><font style="font-family:inherit;font-size:12pt;">.  If the Company terminates Employee&#8217;s employment without Cause (other than within 12 months after a Change in Control Event), then Employee will be entitled to receive Severance Benefits in addition to the Accrued Amounts</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All payments and benefits under this section, except for the Accrued Amounts, shall:  (1)&#160;require Employee to execute and return (and not revoke) a separation agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">containing a general release, the form and substance of which are acceptable to the Company; and (2)&#160;be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;5.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.7(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">For Cause</font><font style="font-family:inherit;font-size:12pt;">.  If the Company terminates Employee&#8217;s employment for Cause at any time, Employee shall: (i)&#160;receive no further compensation or remuneration of any kind (including any Base Salary or Bonus hereunder) other than the Accrued Amounts; and (ii)&#160;at the end of the month in which the termination takes effect, cease to be covered under or be permitted to participate in or receive any of the benefits described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;3.4</font><font style="font-family:inherit;font-size:12pt;">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination upon Death or Inability to Work</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Death.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Employee&#8217;s employment shall terminate immediately upon Employee&#8217;s death.  In the event of Employee&#8217;s death during the course of Employee&#8217;s employment with the Company, the Company will pay the Employee&#8217;s estate the Accrued Amounts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inability to Work.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Except as otherwise provided by applicable law, the Company may terminate Employee&#8217;s employment in the event Employee is Unable to Work.  In the event of Employee&#8217;s death or termination by the Company due to Employee being Unable to Work, Employee shall receive: (a) the Accrued Amounts, and (b) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Release and Compliance Required</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s receipt of any right, payment or benefit under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;is subject to and conditioned upon: (a)&#160;Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company; and (b) Employee&#8217;s reaffirmation of and continuing compliance with Employee&#8217;s contractual and legal obligations to the Company, as expressly set forth in the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="font-family:inherit;font-size:12pt;">.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;409A</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:12pt;">.  This section is intended to help ensure that compensation paid or delivered to Employee pursuant to this Agreement either is paid in compliance with, or is exempt from, IRC Section&#160;409A. However, the Company does not warrant to Employee that all compensation paid or delivered to Employee for Employee&#8217;s services will be exempt from, or paid in compliance with, Section&#160;409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Amounts Payable On Account of Termination</font><font style="font-family:inherit;font-size:12pt;">.  For the purposes of determining when amounts otherwise payable on account of Employee&#8217;s termination of employment under this Agreement will be paid, which amounts become due because of Employee&#8217;s termination of employment, &#8220;termination of employment&#8221; or words of similar import, as used in this Agreement, shall be construed as the date that Employee first incurs a &#8220;separation from service&#8221; for purposes of Section&#160;409A on or following termination of employment.  Furthermore, if Employee is a &#8220;specified employee&#8221; of a public company as determined pursuant to Section&#160;409A as of Employee&#8217;s termination of employment, any amounts payable on account of Employee&#8217;s termination of employment that constitute deferred compensation within the meaning of Section&#160;409A and that are otherwise payable during the first six months following Employee&#8217;s termination (or prior to Employee&#8217;s death after termination) shall be paid to Employee in a cash lump-sum on the earlier of: (i)&#160;the date of Employee&#8217;s death; or (ii)&#160;the first business day of the seventh calendar month immediately following the month in which Employee&#8217;s termination occurs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Series of Payments</font><font style="font-family:inherit;font-size:12pt;">.  Any right to a series of installment payments shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interpretative Rules</font><font style="font-family:inherit;font-size:12pt;">.  In applying Section&#160;409A to amounts paid pursuant to this Agreement, any right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Participation in Other Severance Plans.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Employee agrees and acknowledges that Employee shall not be eligible to participate in or have any right to compensation or benefits pursuant to the Company&#8217;s Change in Control Severance Plan (or any successor plan thereto) or any other Severance Plan issued by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exclusivity</font><font style="font-family:inherit;font-size:12pt;">. In the event Employee&#8217;s employment is terminated for any reason, Employee (and Employee&#8217;s eligible dependents, if any) shall not be entitled to any payments or benefits from the Company or any of its Affiliates except as specifically set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Federal Excise Tax</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Rule</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s payments and benefits under this Agreement and all other arrangements or programs related thereto shall not, in the aggregate, exceed the maximum amount that may be paid to Employee without triggering golden parachute penalties under Section&#160;280G of the Code, and the provisions related thereto with respect to such payments. If Employee&#8217;s benefits must be cut back to avoid triggering such penalties, such reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary, to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity derivative payments shall be reduced.  If an amount in excess of the limit set forth in this Section is paid to Employee, Employee must repay the excess amount to the Company upon demand, with interest at the rate provided in Section&#160;1274(b)(2)(B) of the Code.  Employee and the Company agree to cooperate with each other reasonably in connection with any administrative or judicial proceedings concerning the existence or amount of golden parachute penalties on payments or benefits Employee receives.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exception</font><font style="font-family:inherit;font-size:12pt;">.  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;shall apply only if it increases the net amount Employee would realize from payments and benefits subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;after payment of income and excise taxes by Employee on such payments and benefits.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Determinations</font><font style="font-family:inherit;font-size:12pt;">.  The determination of whether the golden parachute penalties under Section&#160;280G of the Code and the provisions related thereto shall be made by counsel chosen by Employee and reasonably acceptable to the Company. All other determinations needed to apply this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be made in good faith by the Company&#8217;s independent auditors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Computers, Property and Records</font><font style="font-family:inherit;font-size:12pt;">.  Employee agrees to handle all Company property in accordance with the Company&#8217;s policies and procedures.  Employee&#8217;s authorization to access the Company&#8217;s computer systems is limited and use of such systems to compete or prepare to compete with the Company constitutes unauthorized access that is strictly prohibited.  All records received or created by Employee in the course of employment related to the Company&#8217;s business (such as but not limited to, email, notes, files, contact lists, agendas, drawings, maps, specifications, and calendars) are the property of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resolution of Disputes</font><font style="font-family:inherit;font-size:12pt;">.  Employee and the Company hereby agree that, except for disputes regarding alleged or anticipated violations of the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, any and all disputes between them shall be resolved solely in accordance with the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">&#32;and, to the greatest extent permitted by law, Employee and the Company expressly waive their respective right to a trial by jury for any and all such disputes between them.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Conflict</font><font style="font-family:inherit;font-size:12pt;">.  Employee represents and warrants that Employee has not entered, nor will Employee enter, into any other agreements that restrict Employee&#8217;s ability to fulfill Employee&#8217;s obligations under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall be construed, interpreted and governed by the laws of the state of Employee&#8217;s assigned primary office location during the last six months of Employee&#8217;s employment with the Company, without regard to the conflicts of law principles.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Binding Effect</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall extend to and be binding upon Employee, Employee&#8217;s legal representatives, heirs and distributees and upon the Company, its successors and assigns regardless of any change in the business structure of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">.  The Company&#8217;s rights and obligations under this Agreement, including the restrictions in the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its assets, stock or business.  Employee consents to that transfer.  Employee may not assign any rights or obligations under this Agreement without the Company&#8217;s prior written consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the parties with respect thereto</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:12pt;">including Employee&#8217;s prior Agreement, dated November 16, 2013, except this Agreement does not supersede the Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A or the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as Exhibit B.  Nor does this Agreement supersede any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.  No waiver, modification or change of any provision of this Agreement shall be valid unless in writing and signed by both parties.  </font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:12pt;">.  The waiver of any breach of any duty, term or condition of this Agreement shall not be deemed to constitute a waiver of any preceding or succeeding breach of the same or any other duty, term or condition of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Agreement shall be unenforceable in any jurisdiction in accordance with its terms, the provision shall be enforceable to the fullest extent permitted in that jurisdiction and shall continue to be enforceable in accordance with its terms in any other jurisdiction and the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.  All notices pursuant to this Agreement shall be in writing and shall be sent by prepaid certified mail, return receipt requested or by recognized air courier service addressed as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;If to the Company to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amicus Therapeutics, Inc. <br>1 Cedar Brook Drive <br>Cranbury, New Jersey 08512</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c/o&#160;&#160;&#160;&#160;CEO or General Counsel</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;If to Employee to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Hung Do <br>at the address identified herein or in Employee&#8217;s personnel records,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or to such other addresses as may hereinafter be specified by notice in writing by either of the parties, and shall be deemed given three (3)&#160;business days after the date so mailed or sent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance</font><font style="font-family:inherit;font-size:12pt;">. If reasonably requested in writing, Employee agrees within fifteen (15) business days to provide the Company with an executed IRS Form&#160;4669 (Statement of Payments Received) with respect to any taxable amount paid to Employee by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowing and Voluntary Nature of Agreement</font><font style="font-family:inherit;font-size:12pt;">. Employee acknowledges and agrees that Employee is executing this Agreement knowingly and voluntarily and without any duress or undue influence by the Company or anyone else.  Employee further acknowledges and agrees that Employee has carefully read this Agreement and fully understands it. Employee further agrees that Employee has been provided an opportunity to seek, and has received, the advice of an attorney of Employee&#8217;s choice (at Employee&#8217;s expense) before signing this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">[Signature Page Follows]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above written.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Hung Do</font><font style="font-family:inherit;font-size:12pt;">_________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Hung Do</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ David Clark                &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;David Clark</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: Chief People Officer</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s0E802C8680626D54F43E9C04B5673CBD"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFIDENTIALITY, NON-DISCLOSURE AND NON-COMPETITION AGREEMENT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITH</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Hung Do</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement is made as of February 18, 2020 between you and Amicus Therapeutics, Inc. (the &#8220;Company&#8221;).  You agree that you are receiving adequate consideration in exchange for entering into this Confidentiality, Non-Disclosure and Non-Competition Agreement (the &#8220;Agreement&#8221;) including:  (1)&#160;at-will employment and the benefits of that employment including any grant to you of certain restricted stock units and options to purchase shares of common stock in the Company; (2)&#160;access to Confidential Information belonging to the Company; and (3) access to the Company&#8217;s business relationships.  You acknowledge that entering into this Agreement is a condition of receiving those items.  Accordingly, you agree to the following terms and conditions:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the protections provided by this Agreement are necessary to safeguard the Company&#8217;s Confidential Information (as defined below), business relationships and other business interests, and that the Company is willing to employ you, and continue to employ you, on the condition that you execute this Agreement.  You agree that the Company has spent substantial resources developing its Confidential Information and business relationships.  You also agree that protecting these assets is critical to the Company&#8217;s survival and success, and a competitor with access to those assets would have an unfair competitive advantage over the Company. Therefore, you agree that the Company has a legitimate business interest in protecting those assets and that the commitments set forth in this Agreement are a reasonable means of doing so.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that as an integral part of the Company&#8217;s business, the Company has developed, and will develop, at a considerable investment of time and expense, non-public scientific data and methods, clinical development plans and strategies, business development plans and strategies, marketing and business plans and strategies, procedures, methods of operation and marketing, financial data, lists of actual and potential customers and suppliers including buying habits of those customers, and independent sales representatives and related data, technical procedures, engineering and product specifications, plans for development and expansion, and other confidential and sensitive information, and you acknowledge that the Company has a legitimate business interest in protecting the confidentiality of such information.  You acknowledge that you will be entrusted with such information as well as confidential non-public information belonging to customers, suppliers, and other third parties.  You, therefore, acknowledge a continuing responsibility to protect such information and agree to the provisions contained herein.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Trade Secrets&#8221; shall mean information belonging to the Company or licensed by it including, without limitation, data, reports, research, drawings, specifications, software, formulae, patterns, compilations, programs, devices, methods, techniques, or processes (including such information that has commercial value to the Company from a negative viewpoint, such as the results of research which proves that certain processes used to attempt to develop new technology will be unsuccessful) which are not commonly known by or available to the public, and which information: (a)&#160;derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from their disclosure or use; (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy; and (c) as otherwise defined by law.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Proprietary Information&#8221; shall mean any information, other than Trade Secrets, without regard to form, belonging to the Company or licensed by it including, without limitation, formulae, patterns, compilations, programs, devices, methods, techniques, or processes, which is not commonly known by or available to the public and which information is material to the Company and not generally known by the public, and all notes, analyses, compilations, studies, interpretations or other documents prepared by you which contain, reflect or are based upon, in whole or in part, the information furnished to you by the Company pursuant hereto; provided, however that &#8220;Proprietary Information&#8221; shall not include any information which you can show (i) becomes patented, published or otherwise part of the public domain through no act or fault of your own, (ii) is received in good faith from any third party who has the right to disclose such information and who has not received such information, either directly or indirectly, from the Company, or (iii) any information which you can show was in your legitimate possession prior to your commencing employment with the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Confidential Information&#8221; shall mean, collectively, the information outlined in Paragraph 2 of this Agreement, Trade Secrets outlined in Paragraph 3 and Proprietary Information outlined in Paragraph 4 and all other information protected by unauthorized disclosure by law. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">You will treat as confidential and will not, without the prior written approval of the Company, directly or indirectly, use (other than in the performance of duties of employment with the Company), publish, disclose, patent, copyright, or authorize anyone else to use, publish, disclose, patent, or copyright any Confidential Information during your employment and after your employment with the Company terminates, whether such termination is voluntary or involuntary, with or without cause.  You agree to take all action reasonably necessary to protect Confidential Information from being disclosed or used by anyone other than persons authorized by the Company.  Confidential information shall not include information that: (i) is or subsequently becomes publicly available without your, or any other person or entity&#8217;s, breach of any obligation owed to the Company; (ii) was lawfully received by you from a third party free of any obligation of confidentiality owed to the Company; or (iii) you are required to disclose in a judicial or administrative proceeding or as otherwise required by law.    </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company recognizes that you, as a former employee or independent contractor of another company, may previously have been privy to trade secrets and/or confidential information of such other company, and you may be under an obligation to such other company to maintain the confidentiality of such trade secrets or confidential information.  Accordingly, to the extent you are under such an obligation, you shall not: (a) bring any records, notes, files, drawings, documents, plans and like items, electronic or otherwise, provided to you in confidence by such other company, or any copies thereof, relating to or containing or disclosing confidential information or trade secrets of any such other company, on the premises of the Company or loaded onto the Company&#8217;s computer systems or otherwise use such documents and items in the performance of services for the Company; or (b) disclose any confidential information or trade secrets provided to you in confidence by such other company in the performance of your job duties for </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">.  You represent that you are &#8220;free and clear&#8221; of any legal restrictions that might interfere with your ability to begin or continue your employment with, or perform your duties and responsibilities for, </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">such as non-compete, non-solicitation or non-disclosure restrictions imposed by current or former employers or contractors.   You confirm that you have disclosed to </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">&#32;any agreements between you and your current or former employers or contractors describing any possible restrictions on your activities. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You acknowledge that all Confidential Information and any records, files, memoranda, computer programs, reports, claims reports or records, customer lists, contracts, marketing plans, programs or forecasts and other written or printed documents or materials or other data stored on computer disks or other electronic data storage methods (&#8220;Documents&#8221;) received, created or used by you during the course of your relationship with the Company are and will remain the sole property of the Company.  You agree to return all such Documents (including all copies) to the Company promptly upon the termination of your employment, or earlier upon </font><font style="font-family:inherit;font-size:11pt;">the Company&#8217;s </font><font style="font-family:inherit;font-size:12pt;">request,  and agree that, during or after your employment, you will not, under any circumstances, without the specific authorization in writing of an officer of the Company, disclose those Documents or any information contained in such Documents to anyone outside the Company&#8217;s organization or use those Documents for any purpose other than the advancement of the Company&#8217;s interests.  Upon termination of your employment for any reason, or upon the Company&#8217;s earlier request, you also agree to immediately return to </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">all equipment and property provided to you by </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">including, but not limited to, computers, phones, pagers, thumb drives or other storage devices, iPads and other tablet devices, and any other electronic devices.  You also agree to provide </font><font style="font-family:inherit;font-size:11pt;">the Company </font><font style="font-family:inherit;font-size:12pt;">with all usernames, passwords, passcodes, and other information for logging into and accessing the equipment, applications, platforms, software, hardware, devices and other systems that you used or accessed in the course of, and during, your employment.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protected Conduct</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement prohibits you from disclosing Confidential Information under any of the following circumstances:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure in confidence to an attorney solely for the purpose of reporting or investigating a suspected violation of law; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure, directly or indirectly, to a Federal, State or local government official in confidence solely for the purpose of reporting or investigating a suspected violation of law; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure in a complaint or other document filed under seal in a lawsuit or other proceeding; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You make the disclosure to your attorney in connection with a lawsuit you file against the Company for retaliation for reporting a suspected violation of law.  Under this scenario, you may use the Confidential Information in the court proceedings as long as you file any document containing the Confidential Information under seal and do not otherwise disclose the Confidential Information, except pursuant to a Court Order.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prohibits you from filing a charge or complaint with, reporting or making disclosures (including providing supporting documents or other information) of possible violations of any law or regulation to, and/or participating in any investigation or proceeding conducted by, any self-regulatory organization or governmental agency, authority, or legislative body including, but not limited to, the Securities and Exchange Commission and/or Equal Employment Opportunity Commission or as otherwise required or allowed by law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Is intended to interfere with your rights under Section 7 of the National Labor Relations Act, including the right of employees to communicate with each other regarding the terms and conditions of their employment and to engage in concerted activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings;font-size:12pt;">&#x9f;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prevents you from disclosing or requires you to conceal the details of any alleged discrimination, retaliation or harassment.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Disclosure and Assignment Of Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">.  You agree to promptly disclose to the Company all &#8220;Intellectual Property&#8221; conceived or developed by you while employed by the Company that relates to the Company&#8217;s business.  The term &#8220;Intellectual Property&#8221; means any and all (i) data, reports, formulas, techniques, research, drawings, specifications, software and any other copyrightable works; (ii) Trade Secrets; and (iii) ideas, creations, inventions, discoveries, designs, devices, methods, processes and innovations whether or not patentable, and all related know-how.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Assignment of Intellectual Property Rights</font><font style="font-family:inherit;font-size:11pt;">.  You agree that all Intellectual Property conceived or developed by you while employed by the Company after the date of this Agreement shall be the exclusive property of the Company.  You hereby assign and agree to assign in the future to the Company all of your right, title and interest in and to any and all Intellectual Property related to your work at the Company, whether or not registrable under patent, copyright, trademark or similar statutes, made or conceived or reduced to practice or learned by you, either alone or jointly with others, during the period and scope of your employment with the Company.  Such assignment is perpetual and irrevocable.  Intellectual Property assigned to the Company, or to a third party as directed by the Company pursuant to this paragraph, are hereinafter referred to as &#8220;Company Intellectual Property.&#8221;  You agree to assign all right, title and interest in and to any particular Company Intellectual Property to a third party as directed by the Company.  You further agree to assign to the Company or, to the extent assignment is not permissible, waive any so-called &#8220;moral rights&#8221; in the Intellectual Property to the extent permitted by law.  You will assist the Company in every proper way to obtain, perfect, and from time to time enforce, its patent, copyright, trade secret and other rights in the Intellectual Property relating to Company Intellectual Property in any and all countries.  You hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, that you now or may hereafter have for infringement of any Intellectual Property assigned hereunder to the Company.</font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Prior Intellectual Property</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding the foregoing, the Company agrees that you will not be obligated to assign any invention that you developed entirely on your own time, without using any equipment, supplies, facilities or trade secret information of the Company, unless such invention either:  (i) relates (at the time of conception or reduction to practice of the invention) to the Company&#8217;s business or the Company&#8217;s actual or demonstrably anticipated research, or (ii) results from any work performed by you for the Company.  Intellectual Property, if any, that you made prior to the commencement of your employment with the Company, or made outside the scope of your employment, are excluded from the scope of this Agreement.  To preclude any possible uncertainty, you have set forth on Exhibit A attached to this Agreement a complete list of all Intellectual Property that you have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement</font><font style="font-family:inherit;font-size:12pt;">&#32;of your employment with </font><font style="font-family:inherit;font-size:11pt;">the Company</font><font style="font-family:inherit;font-size:12pt;">, that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Agreement (collectively referred to as &#8220;Prior Intellectual Property&#8221;).</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Obligation to Keep the Company Informed</font><font style="font-family:inherit;font-size:11pt;">.  During the period of your employment, you will promptly disclose to the Company fully and in writing all Intellectual Property authored, created, conceived or reduced to practice by you, either alone or jointly with others, whether or not patentable or copyrightable or believed by you to be patentable or copyrightable.  In addition, you will promptly disclose to the Company (to be held in confidence) all patent applications filed by you or on your behalf within six months after termination of your employment (whether voluntarily or involuntarily), and to cooperate fully with a review and determination by the Company as to whether such patent applications constitute or include the Company&#8217;s Intellectual Property or Confidential Information.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Works for Hire</font><font style="font-family:inherit;font-size:11pt;">.  You acknowledge and agree that all original works of authorship that are made by you (solely or jointly with others) within the scope of your employment by the Company and that are protectable by copyright including, but not limited to, drawings, sketches and designs, are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C. Section 101).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the Company has compelling business interests in preventing the use or disclosure of its Confidential Information, or the misappropriation of its business relationships, and to protect those interests it is reasonable to restrict you from working or becoming affiliated with, either during or after the end of your employment with the Company, a Competitive Business (as defined below).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also acknowledge that the Company is engaged in a highly competitive business and that by virtue of the nature of your employment with the Company, your engaging in or working for or with any Competitive Business will cause the Company great and irreparable harm.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accordingly, you agree that, during your employment with the Company and for a period of twelve (12) months after the date of termination of your employment with the Company for any reason, whether such termination is voluntary or involuntary, by wrongful discharge or otherwise, you will not, directly, or indirectly work for or with or have any interest in any Competitive Business, whether as an individual on your own account, as a partner or joint venturer, as an employee, agent or salesperson for any person, as an officer or director of any corporation, or as a consultant or otherwise, or engage in preparations for any activity prohibited by this paragraph or any other paragraph in this Agreement without the prior specific written consent by an officer of the Company to do so provided, that the foregoing shall not prohibit ownership of the securities of a publicly-traded entity which constitute less than 2% of the outstanding voting securities of the entity.  For purposes of this Agreement, &#8220;Competitive Business&#8221; shall mean any person or entity who engages in the business of researching, developing and/or commercializing products, including but not limited to small molecules, biologics and gene therapies in the areas of Fabry disease, Pompe disease, Battens Disease, CDKL-5 Deficiency Disorder and any other condition, or any other business, in which the Company is actively engaged during the last twenty-four months of your employment.   You acknowledge that the geographic scope of this restriction is reasonable given that: (1) the Company does business and has customers and competitors throughout the world; and (2) modern communication and transportation make it easy to compete in this industry from virtually any location on earth.   Further, you acknowledge and agree that given the nature of your responsibilities for the Company and your access to its Confidential Information and business relationships, if you were to work for any Competitive Business as described in this paragraph, you would inevitably disclose Confidential Information. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Solicitation</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also acknowledge that, by virtue of your relationship with the Company, you have gained or will gain knowledge of the identity, characteristics and preferences of its customers among other Confidential Information, and that you would inevitably have to draw on such Confidential Information if you were to solicit or service the Company&#8217;s customers on behalf of a Competitive Business.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accordingly, you agree that for twelve (12) months following the termination for any reason whatsoever of your employment with the Company, you will not solicit the business of or perform any services for an actual or prospective Customer of the Company (as defined below).  You also agree that, during this twelve-month period, you will not encourage or assist any person or entity engaged in a Competitive Business to solicit or service any actual or prospective Customer of the Company covered by this paragraph.  &#8220;Customer of the Company&#8221; means any person or company that, at any time during the twenty-four (24) months prior to the end of your employment with the Company, purchases &#8211; or enters into a contract to purchase &#8211; products or services from the Company.  Customer shall also mean any prospective customer to which the Company has submitted a proposal for purchase of products or services.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You also agree that, for twelve (12) months following the end of your employment with the Company for any reason, you will not directly or indirectly hire or seek to hire or retain, whether on your own behalf or on behalf of some other person or entity, any Company Personnel (as defined below).  Nor will you, during this twelve (12) month period, directly or indirectly induce or encourage any Company Personnel to leave the Company.  You acknowledge that, even after the expiration of the twelve (12) month period described in this paragraph, you will be barred from soliciting or hiring Company Personnel if, in soliciting or hiring them, you would use or disclose Confidential Information belonging to the Company.  &#8220;Company Personnel&#8221; means any employee, independent contractor or other personnel employed, retained or engaged by the Company at any time during the twenty-four (24) months prior to the termination of your employment:  (1)&#160;with whom you interacted within the scope of your employment with the Company; (2)&#160;whom you directly or indirectly supervised during your employment with the Company; or&#160;(3)&#160;regarding whom you received non-public information about his or her job responsibilities, compensation or job performance by virtue of your employment with the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Return of Property</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon termination of your employment (by the Company or you) for any reason, or upon the earlier request of the Company, you agree to immediately return to the Company all Company records and other property in your possession, custody or control including (but not limited to) anything containing Confidential Information such as documents, papers, files, records, reports, binders, notebooks, books, notes, calendars, plans, drawings, maps, specifications, blueprints, studies, photographs, video recordings, audio recordings, computers, tablets, smartphones, mobile telephones, drives, discs, and any other devices used to store electronic data, and any and all electronic copies and/or hard-copies.  Notwithstanding the foregoing, nothing in this Agreement shall prohibit you from retaining paystubs and other records regarding your compensation and benefits that the Company is required by law to provide to you.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon termination of your employment (by the Company or you) for any reason, or upon the earlier request of the Company, you agree to provide the Company with all usernames, passwords, passcodes and other information that it may need to log into and access the equipment, applications, platforms, software, hardware, devices and other systems that you used or accessed in the course of, and during, your employment.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Upon the Company&#8217;s request, you agree to immediately provide the Company with a written affidavit confirming that you have returned all Company property and Confidential Information, and cooperate in providing the Company, at the Company&#8217;s request, a means through which it can promptly and independently verify (including by forensic analysis, if necessary) that all Confidential Information has been removed from electronic storage devices, cloud-based storage, and accounts in your possession or control.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If you are served with a subpoena, court order, or similar legal document requiring the production of Company records or other property or the disclosure of Confidential Information, you agree to provide the Company with as much notice as is possible (presumably seven (7) business days or more) through written notification to the Company&#8217;s General Counsel and the Company&#8217;s CEO, so that the Company may take permissible steps to protect the records and information, unless such notice is prohibited by law or court order; provided, however, that nothing in this Agreement prohibits you from engaging in the Protected Conduct described in Section 9 and Section 10 of this Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Terms</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that the restrictions contained in this Agreement are fair, reasonable and necessary to protect the legitimate business interests of the Company and that the Company will suffer irreparable harm in the event of any actual or threatened breach by you of this Agreement.  You agree that enforcement of the restrictions in this Agreement will not cause you any hardship, and because of your background and experience will not in any manner preclude you from becoming gainfully employed in such manner and to such extent as will provide you with a standard of living of at least the sort and fashion to which you are accustomed. You therefore agree that the Company may seek a restraining order, preliminary injunction or other court order to enforce this Agreement without the necessity of posting a bond or any security that might otherwise be required in connection with such relief.  You also agree that any request for such relief by the Company shall be in addition and without prejudice to any claim for monetary damages which the Company might elect to assert.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If any provision of this Agreement is held to be unenforceable by a court, such unenforceability shall not affect the enforceability of the remaining provisions.  Such provision shall be reformed and construed to the extent permitted by law so that it would be valid, legal and enforceable to the maximum extent possible.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge that this Agreement does not give you any rights to employment by or to be retained as a consultant of the Company and, unless otherwise provided in another writing, executed by an officer of the Company and you, your relationship with the Company shall be employment &#8220;at will.&#8221;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You agree that, if you, at any time during or within one year after your employment with the Company ends, you receive an offer of employment or retention from any person or entity other than the Company, you will provide that person or entity with a copy of this Agreement.  You also agree that, at any time during, or within one year after the end of, your employment with the Company, you will, in writing, immediately after accepting (orally or in writing) any offer of employment or retention with any person or entity other than the Company:  (1)&#160;notify the Company that you accepted the offer; and (2)&#160;inform the Company of the identity of the person or entity, and of your title, responsibilities, work location and anticipated start date.  You acknowledge that the requirements set forth in this paragraph are fair, reasonable and necessary in order for the Company to adequately protect its Confidential Information and business relationships.  The Company may also provide copies of this Agreement to others including, but not limited to, customers and potential customers, and your future employers and prospective employers.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">You understand nothing in this Agreement prohibits you reporting to any governmental authority information concerning violations of law or regulations, and that you may report trade secret information to a government official or to an attorney and use it in certain proceedings without fear of prosecution or liability provided such disclosure is consistent with 18 U.S.C. 1833. If you make the disclosure to your attorney in connection with a private lawsuit, you may use the Confidential Information in the court proceedings as long as you file any document containing the Confidential Information under seal and do not otherwise disclose the Confidential Information, except pursuant to a Court Order.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement represents the entire agreement of the parties with respect to the subject matter covered and cannot be modified or amended except in a writing signed by both parties.  The waiver by any party to this Agreement or a breach of any of the provisions of this Agreement shall not operate or be construed as a waiver of any subsequent or simultaneous breach.  This Agreement supersedes any confidentiality, non-competition and non-solicitation entered into by the Company and you prior to the date of this Agreement.  This Agreement does not supersede:  (1)&#160;the Employment Agreement between you and the Company; (2)&#160;the Mutual Agreement to Arbitrate Disputes on an Individual Basis between you and the Company; or (3)&#160;</font><font style="font-family:inherit;font-size:12pt;">any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">30.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement shall be construed, interpreted and governed by the laws of the state of your assigned primary office location during the last six months of your employment with the Company, without regard to the conflicts of law principles</font><font style="font-family:inherit;font-size:11pt;">.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">31.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The rights and obligations of the Company under this Agreement shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its or their assets, stock or business.  By signing this Agreement, you consent to any such transfer.  You may not assign any rights or obligations under this Agreement without the prior written consent of the Company&#8217;s Chief Legal Officer or designee. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">By signing below, you acknowledge that you:  (1)&#160;received this Agreement fourteen (14) business days before the date on which you must return an executed copy of it to the Company; (2) have had sufficient opportunity to read each provision of this Agreement; (e)&#160;understand the meaning, effect and implications of each provision of this Agreement; (4)&#160;have had an opportunity to consult with legal counsel of your choosing (at your expense) regarding this Agreement; and (5)&#160;are not relying on any promises or representations that are not set forth in this Agreement.  By signing this Agreement, you are indicating that you are doing so freely and voluntarily and with full understanding of its terms and conditions.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">______________________</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ellen Rosenberg </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">General Counsel &amp; Corporate Secretary, Legal </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Hung Do</font><font style="font-family:inherit;font-size:11pt;">________________________&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Signature:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Hung Do</font><font style="font-family:inherit;font-size:11pt;">_____________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">February 26, 2020</font><font style="font-family:inherit;font-size:11pt;">_________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Home Address:&#160;&#160;&#160;&#160;[&#8230;]_____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SCHEDULE 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">PRIOR INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">List below all Intellectual Property and works of authorship that you have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of your employment with Amicus that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Confidentiality, Non-Disclosure and Non-Competition Agreement:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If additional space is needed, attach and sign additional sheets and indicate here:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">___ Additional sheets are attached.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you are not listing any Intellectual Property or works of authorship, indicate here:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">X</font><font style="font-family:inherit;font-size:12pt;">_ No Intellectual Property or works of authorship claimed.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signature of Employee: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Hung Do</font><font style="font-family:inherit;font-size:12pt;">________________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Print Name of Employee: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Hung Do</font><font style="font-family:inherit;font-size:12pt;">_________________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: February 26, 2020</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="sBFE6AE091DA0C36035A39C04B580C6D5"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT B</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">MUTUAL AGREEMENT TO ARBITRATE DISPUTES ON AN INDIVIDUAL BASIS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Mutual Agreement to Arbitrate Disputes on an Individual Basis (&#8220;Arbitration Agreement&#8221;) is made and entered into as of February 18, 2020 (the &#8220;Effective Date&#8221;) by and between </font><font style="font-family:inherit;font-size:11pt;">Amicus Therapeutics, Inc. (the &#8220;Company&#8221;) </font><font style="font-family:inherit;font-size:12pt;">and Hung Do (&#8220;you&#8221;).  In this Arbitration Agreement, the Company and you are sometimes referred to individually as a &#8220;Party&#8221; and sometimes referred to together as the &#8220;Parties.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:12pt;">.  The Parties are entering into this Arbitration Agreement because they want to resolve all disputes arising out of or relating to your employment by the Company, or the termination of your employment, by binding private arbitration in accordance with the provisions of this Arbitration Agreement.  Regarding any claims covered by this Arbitration Agreement, you and the Company understand that, by entering into this Arbitration Agreement, YOU AND THE COMPANY ARE EACH GIVING UP:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1)&#160;&#160;&#160;&#160;THE RIGHT TO A JURY TRIAL; AND</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THE RIGHT TO FILE A LAWSUIT IN COURT AGAINST THE OTHER PARTY; AND </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THE RIGHT TO BRING A CLASS OR COLLECTIVE ACTION AGAINST THE OTHER PARTY IN COURT OR IN ARBITRATION OR IN ANY OTHER FORUM.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Mandatory Arbitration</font><font style="font-family:inherit;font-size:12pt;">.  In exchange for the mutual promises contained in this Arbitration Agreement and as a condition of the Company hiring and employing you, you and the Company agree that:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any and all &#8220;Covered Claims&#8221; (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3</font><font style="font-family:inherit;font-size:12pt;">&#32;below) shall be submitted to and resolved by final and binding arbitration to be held in the American Arbitration Association (&#8220;AAA&#8221;) office located nearest to your employment location for the Company.  The arbitration shall proceed before a single arbitrator and administered by the AAA in accordance with AAA&#8217;s Employment Arbitration Rules and Mediation Procedures (the &#8220;AAA Rules&#8221;) in effect and applicable at the time the arbitration is commenced.  The AAA Rules may be amended from time to time and are available online at </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">https://www.adr.org/sites/default/files/Employment%20Rules.pdf</font></a><font style="font-family:inherit;font-size:12pt;">.  You may also call the AAA at 800-778-7879 with any questions about the arbitration process.  If the AAA Rules are inconsistent with the terms of this Arbitration Agreement, the terms of this Arbitration Agreement shall govern; AND </font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Arbitrator, and not any federal, state, or local court or agency, shall have exclusive authority to resolve any dispute relating to the interpretation, applicability, formation or enforceability of this Arbitration Agreement including, but not limited to, the arbitrability of any dispute between the parties; AND </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Arbitrator&#8217;s decision shall be final and binding only on the Parties to this Arbitration Agreement and the Parties agree that awards deciding issues for similarly-situated employees will have no preclusive effect in any arbitration between the Parties. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Covered Claims</font><font style="font-family:inherit;font-size:12pt;">.  Except as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">, &#8220;Covered Claims&#8221; under this Arbitration Agreement shall include all past, current and future grievances, disputes, claims or causes of action that otherwise could be brought in a federal, state or local court under applicable federal, state or local laws, arising out of or relating to your employment with the Company or the termination of your employment including claims arising out of or related to your hiring, recruitment, compensation and termination, and including claims you may have against the Company or its officers, directors, supervisors, managers, employees or agents, or that the Company may have against you.  Covered Claims include, but are not limited to, claims for breach of any contract or covenant (express or implied), tort claims, claims for wages or other compensation, claims for wrongful termination (constructive or actual), claims for discrimination, harassment or retaliation (including, but not limited to, harassment or discrimination based on race, age, color, sex, gender, gender identity, transgender status, sexual orientation, national origin, alienage or citizenship status, creed, religion, marital status, partnership status, familial status, domestic violence victim status, military status, predisposing genetic characteristics, medical condition including pregnancy, psychological condition, mental condition, criminal accusations and convictions, disability, or any other trait or characteristic protected by federal, state, or local law, claims for violation of any federal, state, local or other governmental law, statute, regulation, or ordinance, including, but not limited to, all claims arising under federal law such as:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:77px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Age Discrimination in Employment Act; the Older Workers Benefits Protection Act; Title VII of the Civil Rights of 1964; Sections 1981 through 1988 of Title 42 of the United States Code; the Civil Rights Act of 1991; the Equal Pay Act; the Americans with Disabilities Act; the Rehabilitation Act; the Employee Retirement Income Security Act; the Worker Adjustment and Retraining Notification Act; the National Labor Relations Act; the Fair Credit Reporting Act; the Occupational Safety and Health Act; the Uniformed Services Employment and Reemployment Act; the Employee Polygraph Protection Act; the Immigration Reform Control Act; the Family and Medical Leave Act; the Genetic Information Nondiscrimination Act; the Federal False Claims Act; the Patient Protection and Affordable Care Act; the Consolidated Omnibus Budget Reconciliation Act; and the Lilly Ledbetter Fair Pay Act;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and all claims arising under state and local law, such as:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:77px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The New Jersey Law Against Discrimination; the New Jersey Discrimination in Wages Law; the New Jersey Security and Financial Empowerment Act; the New Jersey Temporary Disability Benefits and Family Leave Insurance Law; the New Jersey Domestic Partnership Act; the New Jersey Conscientious Employee Protection Act; the New Jersey Family Leave Act; the New Jersey Wage Payment Act; the New Jersey Equal Pay Law; the New Jersey Occupational Safety and Health Law; the New Jersey False Claims Act; the New Jersey Smokers&#8217; Rights Law; the New Jersey Genetic Privacy Act; the New Jersey Fair Credit Reporting Act; the New Jersey Emergency Responder Leave Law; the New Jersey Millville Dallas Airmotive Plant Job Loss Notification Act (a/k/a the New Jersey WARN Act); Gender Inequity Law; and the New Jersey Earned Sick Leave Law.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The laws listed above should be interpreted as including all amendments to those laws and together with all of their respective implementing regulations, and any and all other federal, state and local laws that govern your employment with the Company or the termination of that employment for any reason.  Covered Claims under this Agreement include claims arising out of or related to acts or omissions that occurred before entering into this Arbitration Agreement and those that may occur in the future.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Claims Not Covered</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding any other provision of this Arbitration Agreement, this Arbitration Agreement does not mandate arbitration of:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">disputes arising under your Confidentiality, Non-Disclosure and Non-Competition Agreement with the Company; OR </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">claims for Workers&#8217; Compensation benefits;  OR</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">claims for unemployment compensation benefits;  OR</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any other claims that, as a matter of law, cannot be subject to mandatory arbitration.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Wingdings 3;font-size:12pt;">&#218;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding any other provision of this Arbitration Agreement, nothing in this Arbitration Agreement prevents you or shall be interpreted to mean that you are precluded from filing charges or complaints with the National Labor Relations Board (NLRB), the Equal Employment Opportunity Commission (EEOC), the Securities and Exchange Commission (SEC) or any equivalent state or local agency.  Nor does this Arbitration Agreement prevent you from testifying or participating in any proceedings before those administrative agencies.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver of Class and Collective Actions</font><font style="font-family:inherit;font-size:12pt;">.  You and the Company expressly intend and agree that:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">class and collective action procedures shall not be asserted and will not apply in any arbitration pursuant to this Agreement; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">neither you nor the Company will assert class or collective claims against the other in court, in arbitration or otherwise;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">each Party shall only submit individual claims in arbitration and will not seek to represent the interests of any other person; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any claims by you will not be joined, consolidated or heard together with the claims of any other employee; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">no decision or arbitral award determining an issue with a similarly-situated employee shall have any preclusive effect in any arbitration between the Parties, and the Arbitrator shall have no authority to give preclusive effect to the issues determined in any arbitration between the Company and any other employee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver of Trial by Jury</font><font style="font-family:inherit;font-size:12pt;">.  The Parties understand and fully agree that, by entering into this Arbitration Agreement, they are giving up their constitutional right to have a trial by jury, and are giving up their normal rights of appeal following the issuance of the arbitrator&#8217;s award except as otherwise provided by applicable law.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Claims Procedure</font><font style="font-family:inherit;font-size:12pt;">.  Arbitration shall be initiated by the express written notice of either you or the Company.  The Party initiating the arbitration must give written notice of any claim to the other Party.  Written notice of your claim shall be mailed by certified or registered mail, return receipt requested, to Employer&#8217;s General Counsel at Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512.  Written notice of a claim by the Company will be mailed to your last known address.  The written notice shall identify and describe the nature of all claims asserted and the facts supporting the claims.  Written notice of arbitration shall be initiated within the same time limitations that applicable federal and state law applies to those claims.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbitrator Selection</font><font style="font-family:inherit;font-size:12pt;">.  The Arbitrator shall be selected as provided in AAA Rules.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Discovery</font><font style="font-family:inherit;font-size:12pt;">.  The Arbitrator shall have the authority to order such discovery, by way of deposition, interrogatory, document production or otherwise, as the Arbitrator deems necessary to a full and fair exploration of the issues in dispute, consistent with the expedited nature of arbitration.  The Arbitrator shall have the authority to set deadlines for completion of discovery.  The Arbitrator shall decide all discovery disputes.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Governing Law; Substantive Law</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement and any arbitration shall be governed by the Federal Arbitration Act (FAA) to the exclusion of any state law inconsistent with the FAA.  The Arbitrator shall apply the substantive state or federal law as applicable to the claims asserted in arbitration.  Claims arising under federal law shall be determined in accordance with federal law.  Common law claims shall be determined in accordance with the substantive law of the state your assigned primary office location during the last six months of your employment with the Company, without regard to conflicts of law principles.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compelling Arbitration; Enforcing Award</font><font style="font-family:inherit;font-size:12pt;">.  Either Party may ask a court to stay any court proceeding to compel arbitration under this Arbitration Agreement, and to confirm, vacate or enforce an arbitration award.  Judgment on the award rendered by the Arbitrator may be entered in any state or federal court of competent jurisdiction located in the state of your employment location for the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbitration Fees and Costs</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall be responsible for the Arbitrator&#8217;s fees and arbitration expenses and any other costs unique to the arbitration hearing, except that you shall be responsible for paying the initial filing fees as provided by the AAA&#8217;s Rules.  Each Party shall pay its own deposition, witness, expert and attorneys&#8217; fees and all other expenses to the same extent as if the matter were proceeding in court.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Term of Agreement; Modification in Writing</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement shall survive the termination of your employment.  This Arbitration Agreement can only be revoked or modified in a writing that specifically states an intent to revoke or modify this Arbitration Agreement and is signed by both you and the President of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:12pt;">.  The Company may freely assign this Arbitration Agreement at any time.  This Arbitration Agreement shall inure to the benefit of the Company&#8217;s successors and assigns.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Arbitration Agreement represents the entire agreement of the parties with respect to the subject matter covered and cannot be modified or amended except in a writing signed by both parties.  The waiver by any party to this Arbitration Agreement or a breach of any of the provisions of this Arbitration Agreement shall not operate or be construed as a waiver of any subsequent or simultaneous breach.  This Arbitration Agreement supersedes any inconsistent agreements between the Parties with respect to the subject matter of the Arbitration Agreement.  This Agreement does not supersede:  (1) the Employment Agreement between you and the Company; (2) the </font><font style="font-family:inherit;font-size:11pt;">Confidentiality, Non-Disclosure and Non-Competition Agreement </font><font style="font-family:inherit;font-size:12pt;">between you and the Company; or (3)&#160;any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Arbitration Agreement is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable provision shall be severed and that adjudication shall not affect the validity of the remainder of this Arbitration Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Voluntary Agreement</font><font style="font-family:inherit;font-size:12pt;">.  By executing this Arbitration Agreement, the Parties represent that they have been given the opportunity to fully review its terms.  You acknowledge and agree that you have had an opportunity to ask questions and consult with an attorney of your choice, at your expense, before signing this Arbitration Agreement.  The Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement.  YOU AND THE COMPANY FULLY UNDERSTAND AND AGREE THAT YOU AND THE COMPANY ARE GIVING UP CERTAIN RIGHTS OTHERWISE AFFORDED BY CIVIL COURT ACTIONS INCLUDING, BUT NOT LIMITED TO, THE RIGHT TO A JURY OR COURT TRIAL AND THE RIGHT TO BRING ANY CLAIM AS A CLASS OR COLLECTIVE ACTION.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Hung Do</font><font style="font-family:inherit;font-size:11pt;">________________________&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Signature:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Hung Do</font><font style="font-family:inherit;font-size:11pt;">_____________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">February 26, 2020</font><font style="font-family:inherit;font-size:11pt;">__________________</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Home Address:&#160;&#160;&#160;&#160;[&#8230;]</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMICUS THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ellen Rosenberg</font><font style="font-family:inherit;font-size:11pt;">_______________________</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ellen Rosenberg </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Legal Officer and Corporate Secretary, Legal </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s3755179971FD47E45E289C04B58E6B76"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT C</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#222222;">The </font><font style="font-family:inherit;font-size:12pt;color:#222222;font-weight:bold;">Chief Scientific Officer</font><font style="font-family:inherit;font-size:12pt;color:#222222;">&#32;will oversee the scientific and technological operations at the Global Research and Gene Therapy of Excellence located in Philadelphia, PA. The Chief Scientific Officer will guide the company research and scientific priorities to drive discovery and innovation so that they line up with the overall mission and goals of the organization.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ROLES AND RESPONSIBILITIES</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Chief Scientific Officer is responsible for: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Providing exemplary scientific input into the Company&#8217;s research and development programs in order to support the overall corporate strategy and objectives set by the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Building a robust pipeline of products by creating and developing novel, differentiated and effective medicines in-house that overcome challenges as potential treatments for various genetic diseases.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Thorough assessments of external therapeutic approaches and molecules to determine technical feasibility and merit as potential treatments for various disease programs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Continually assess and acquire the necessary technical capabilities, subject matter experts and personnel, equipment and resources to form a highly innovative and capable research team to drive innovation and achieve departmental and corporate goals.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Setting short- and long-term scientific goals and objectives with effective strategies to attain defined goals within Science.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ensure that staff is properly trained and provide opportunities for continual growth and development in both technical and non-technical areas.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Provide needed support to other departments including Clinical/Translational Research, Regulatory, Medical Affairs, Legal, Technical Operations, etc. for advancing programs and attaining new intellectual property.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Work closely with Business Development, Finance, Investor Relations, etc. to support other business needs and corporate initiatives.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ensure that staff is adhering to best practices and proper procedures in conducting research to ensure safety, data integrity, obtaining high quality results and compliance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Work with Program Management and Finance for planning objectives, anticipated timelines and annual departmental budgets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Assemble effective Scientific Advisory Board of scientific experts for various disciplines to get their independent assessment and guidance on current programs on annual basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Meet personal and organizational goals set by Executive Committee and Board of Directors.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ORGANIZATIONAL STRUCTURE</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:24px;"><font style="font-family:inherit;font-size:14pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:12pt;">Reports to the Chief Executive Officer</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUALIFICATIONS AND BACKGROUND REQUIREMENTS</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Educational Requirements</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PhD and/or MD</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Professional Work Experience </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#333333;">Minimum of 10-15 years of relevant industry experience required</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#333333;">Highly creative and innovative thinker with experience in drug development</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#333333;">Proven track record of accomplishments in creating new medicines and innovations</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#333333;">Excellent communication and critical thinking skills required</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#333333;">Experience with global pharmaceutical companies desired</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LOCATION</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This position will be based at 3675 Market St, Philadelphia, PA 19104</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Domestic and international travel is required</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s8E0CD76EC689E14BB13C9C04B5B74BDD"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>9
<FILENAME>exhibit21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2A2FA3C0DC975658AAE0E815F11B7D8D"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 21</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">List of Subsidiaries of the Registrant&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Callidus Biopharma,&#160;Inc. (Delaware)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Celenex, Inc. (Delaware)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scioderm,&#160;Inc. (Delaware)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scioderm Limited (Ireland)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MiaMed,&#160;Inc. (Delaware)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics International Holding Limited (UK)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics UK Limited (UK)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics UK Operations Limited (UK)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics SAS (France)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics&#160;B.V. (Netherlands)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics&#160;GmbH (Germany)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics S.L.U. (Spain)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics&#160;S.r.l. (Italy)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics K.K. (Japan)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics Canada&#160;Inc. (Canada)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics PTY&#160;LTD (Australia)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics US, Inc. (Delaware)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Biologics, Inc. (Florida)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics ApS (Denmark)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics Europe Limited (Ireland)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics Switzerland GmbH (Switzerland)</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>exhibit231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s142E37037DD8509C8A9DDFEF1139686D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">EXHIBIT 23.1&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We consent to the incorporation by reference in the following Registration Statements:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-233153) pertaining to the Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-3ASR No. 333-231017) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-3ASR No. 333-212414) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-3ASR No. 333-207210) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-197202) pertaining to the Amicus Therapeutics, Inc. Cash Deferral Plan</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-195194) pertaining to the Amicus Therapeutics, Inc. Restricted Stock Unit Deferral Plan</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-174900) pertaining to the: 1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. Amended and Restated 2007 Director Option Plan</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-157219) pertaining to the:  1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. 2007 Director Option Plan</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-145305) pertaining to the: 1) Amicus Therapeutics, Inc. 2002 Equity Incentive Plan, as Amended, 2) Amicus Therapeutics, Inc. 2007 Equity Incentive Plan, 3) Amicus Therapeutics, Inc. 2007 Director Option Plan, 4) Amicus Therapeutics, Inc. 2007 Employee Stock Purchase Plan</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-3 No. 333-192747), pertaining to the acquisition of Callidus Biopharma, Inc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-3 No. 333-192876), pertaining to the issuance of warrants</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of our reports dated </font><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;with respect to the consolidated financial statements of Amicus Therapeutics,&#160;Inc., and the effectiveness of internal control over financial reporting of Amicus Therapeutics,&#160;Inc. included in this Annual Report (Form&#160;10-K) of Amicus Therapeutics,&#160;Inc. for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Iselin, New Jersey</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7212BC70AEBA51E4BFD420E879FAA709"></a></div><div><div style="line-height:120%;padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, John F. Crowley, certify that:</font></div><div style="line-height:120%;padding-bottom:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this annual report on Form&#160;10-K of Amicus Therapeutics,&#160;Inc.;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:16px;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:31.4453125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ John F. Crowley</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John F. Crowley</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4BBFA2C2868B5FDF80A2E4363AC6D9FD"></a></div><div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Daphne Quimi, certify that:</font></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this annual report on Form&#160;10-K of Amicus Therapeutics,&#160;Inc.;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:16px;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:31.4453125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Daphne Quimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Daphne Quimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7BD18B7304045192B38F3B5FCD606450"></a></div><div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by the Principal Executive Officer Pursuant to 18 U. S. C. Section&#160;1350, as</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to 18 U. S. C. Section&#160;1350, I, John F. Crowley, hereby certify that, to the best of my knowledge, Amicus Therapeutics&#160;Inc., (the "Company") Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;(the "Report"), as filed with the Securities and Exchange Commission on </font><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font><font style="font-family:inherit;font-size:10pt;">, fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:31.4453125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ John F. Crowley</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John F. Crowley</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>14
<FILENAME>exhibit322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4E01E04AEBB759AB8578BC7D4C5B1C0A"></a></div><div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by the Principal Financial Officer Pursuant to 18 U. S. C. Section&#160;1350, as</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to 18 U. S. C. Section&#160;1350, I, Daphne Quimi, hereby certify that, to the best of my knowledge, the Amicus Therapeutics&#160;Inc. (the "Company") Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;(the "Report"), as filed with the Securities and Exchange Commission on </font><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font><font style="font-family:inherit;font-size:10pt;">, fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:31.4453125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Daphne Quimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Daphne Quimi</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>fold-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amicustherapeutics.com/20191231" xmlns:fold="http://www.amicustherapeutics.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccountsPayableAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>2108100 - Disclosure - Accounts Payable, Accrued Expenses, and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>2408402 - Disclosure - Accounts Payable, Accrued Expenses, and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>2308301 - Disclosure - Accounts Payable, Accrued Expenses, and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.amicustherapeutics.com/role/Acquisitions">
        <link:definition>2103100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetails" roleURI="http://www.amicustherapeutics.com/role/AcquisitionsDetails">
        <link:definition>2403401 - Disclosure - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsAndLiabilitiesDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails">
        <link:definition>2411402 - Disclosure - - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsAndLiabilitiesMeasuredAtFairValue" roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue">
        <link:definition>2111100 - Disclosure - Assets and Liabilities Measured at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails">
        <link:definition>2411403 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsAndLiabilitiesMeasuredAtFairValueTables" roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables">
        <link:definition>2311301 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicAndDilutedNetLossPerCommonShare" roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare">
        <link:definition>2116100 - Disclosure - Basic and Diluted Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicAndDilutedNetLossPerCommonShareDetails" roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails">
        <link:definition>2416402 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicAndDilutedNetLossPerCommonShareTables" roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables">
        <link:definition>2316301 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash">
        <link:definition>2105100 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails">
        <link:definition>2405403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetailsCalc2" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetailsCalc2">
        <link:definition>2405403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails">
        <link:definition>2405402 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2405404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables">
        <link:definition>2305301 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreements">
        <link:definition>2115100 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails">
        <link:definition>2415401 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>1004000 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1003000 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLossParenthetical" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical">
        <link:definition>1003001 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.amicustherapeutics.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.amicustherapeutics.com/role/Debt">
        <link:definition>2112100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertibleNotesAndSeniorSecuredTermLoanDetails" roleURI="http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails">
        <link:definition>2412403 - Disclosure - Debt - Convertible Notes and Senior Secured Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails">
        <link:definition>2412404 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails">
        <link:definition>2412402 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.amicustherapeutics.com/role/DebtTables">
        <link:definition>2312301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusiness" roleURI="http://www.amicustherapeutics.com/role/DescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessDetails" roleURI="http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails">
        <link:definition>2401401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssets" roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets">
        <link:definition>2104100 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsDetails" roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails">
        <link:definition>2404402 - Disclosure - Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails">
        <link:definition>2404403 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsTables" roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables">
        <link:definition>2304301 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxes">
        <link:definition>2114100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredAndValuationDetails" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails">
        <link:definition>2414403 - Disclosure - Income Taxes - Deferred and Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossCarryforwardsDetails" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails">
        <link:definition>2414404 - Disclosure - Income Taxes - Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesStatutoryRateDetails" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails">
        <link:definition>2414402 - Disclosure - Income Taxes - Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesTables">
        <link:definition>2314301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.amicustherapeutics.com/role/Inventories">
        <link:definition>2106100 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails">
        <link:definition>2406402 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.amicustherapeutics.com/role/InventoriesTables">
        <link:definition>2306301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.amicustherapeutics.com/role/Leases">
        <link:definition>2113100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.amicustherapeutics.com/role/LeasesDetails">
        <link:definition>2413402 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetailsCalc2" roleURI="http://www.amicustherapeutics.com/role/LeasesDetailsCalc2">
        <link:definition>2413402 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.amicustherapeutics.com/role/LeasesTables">
        <link:definition>2313301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipment">
        <link:definition>2107100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails">
        <link:definition>2407402 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables">
        <link:definition>2307301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited">
        <link:definition>2117100 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedDetails" roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails">
        <link:definition>2417402 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>2317301 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation">
        <link:definition>2110100 - Disclosure - Share based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationExpenseSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails">
        <link:definition>2410406 - Disclosure - Share based Compensation - Expense Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2410402 - Disclosure - Share based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRsusAndPbrsusSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails">
        <link:definition>2410405 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails">
        <link:definition>2410404 - Disclosure - Share based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>2310301 - Disclosure - Share based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>2410403 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity">
        <link:definition>2109100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockAndWarrantsDetails" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails">
        <link:definition>2409401 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails">
        <link:definition>2409402 - Disclosure - Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails">
        <link:definition>2402406 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails">
        <link:definition>2402408 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails">
        <link:definition>2402407 - Disclosure - Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="fold_AccruedContractManufacturingAndContractResearchCostsCurrent" name="AccruedContractManufacturingAndContractResearchCostsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_AccruedPaymentsForCollaborativeArrangement" name="AccruedPaymentsForCollaborativeArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_AccruedProgramFees" name="AccruedProgramFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_AccruedSalesRebatesAndChargebacksCurrent" name="AccruedSalesRebatesAndChargebacksCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_AccumulatedDepreciationOperatingRightOfUseLeases" name="AccumulatedDepreciationOperatingRightOfUseLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives" name="AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" name="AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_AmortizationDeferredFinancingCosts" name="AmortizationDeferredFinancingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_AssetAcquisitionAxis" name="AssetAcquisitionAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_AssetAcquisitionConsiderationTransferred" name="AssetAcquisitionConsiderationTransferred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_AssetAcquisitionDomain" name="AssetAcquisitionDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment" name="BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_BusinessAssetAcquisitionContingentConsiderationMilestones" name="BusinessAssetAcquisitionContingentConsiderationMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" name="BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_BusinessCombinationOfEnrollmentRate" name="BusinessCombinationOfEnrollmentRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_CallidusBiopharmaIncMember" name="CallidusBiopharmaIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" name="CashCashEquivalentsAndAvailableforsaleDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" name="CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_CelenexMember" name="CelenexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_ChangesInFairValueOfContingentConsiderationPayableMember" name="ChangesInFairValueOfContingentConsiderationPayableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_CollaborationAgreementAnnualContributionByCompany" name="CollaborationAgreementAnnualContributionByCompany" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" name="CollaborativeAgreementConditionalAggregatePaymentsPerIndication" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" name="CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="fold_CollaborativeArrangementDisclosureAbstract" name="CollaborativeArrangementDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_CommonStockCappedCallConfirmationMember" name="CommonStockCappedCallConfirmationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_CommonStockVotingRightsForEachShareHeld" name="CommonStockVotingRightsForEachShareHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" name="ContingentAcquisitionConsiderationPayablePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" name="ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" name="ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_ContingentConsiderationMeasurementInput" name="ContingentConsiderationMeasurementInput" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant" />
  <xsd:element id="fold_ContingentConsiderationMilestonePayment" name="ContingentConsiderationMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_ContingentConsiderationPaidInStock" name="ContingentConsiderationPaidInStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_ContingentConsiderationPaidInStockAdjustment" name="ContingentConsiderationPaidInStockAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_ConvertibleSeniorNotes2016Due2023Member" name="ConvertibleSeniorNotes2016Due2023Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare" name="DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage" name="DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent" name="DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice" name="DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice" name="DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" name="DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" name="DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" name="DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice" name="DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_DebtInstrumentPeriodicPaymentPrincipalPercentage" name="DebtInstrumentPeriodicPaymentPrincipalPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_DebtInstrumentsConvertibleThresholdTradingDays" name="DebtInstrumentsConvertibleThresholdTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_DeferredTaxAssetsIntellectualProperty" name="DeferredTaxAssetsIntellectualProperty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="fold_DeferredTaxAssetsInterestCarryforwardLimitation" name="DeferredTaxAssetsInterestCarryforwardLimitation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="fold_DeferredTaxAssetsLiabilitiesGross" name="DeferredTaxAssetsLiabilitiesGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" name="DeferredTaxAssetsNonCashStockIssueNonCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" name="DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_DeferredTaxLiabilitiesBusinessAcquisition" name="DeferredTaxLiabilitiesBusinessAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_DeferredTaxLiabilitiesConvertibleNotes" name="DeferredTaxLiabilitiesConvertibleNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_DeferredTaxLiabilitiesRoyaltyPayable" name="DeferredTaxLiabilitiesRoyaltyPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" name="EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent" name="EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_EmployeeAndDirectorsStockOptionsMember" name="EmployeeAndDirectorsStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_FixedAssetsMember" name="FixedAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_ForeignCurrencyRemeasurementGainLossBeforeTax" name="ForeignCurrencyRemeasurementGainLossBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" name="GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" name="GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_GlaxoSmithKlinePLCMember" name="GlaxoSmithKlinePLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_IncomeTaxExpenseBenefitDueToWindDown" name="IncomeTaxExpenseBenefitDueToWindDown" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="fold_IncreaseDecreaseInDeferredReimbursements" name="IncreaseDecreaseInDeferredReimbursements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" name="IncreaseDecreaseInNoncurrentOperatingLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="fold_InterestIncomeAndInterestExpensePolicyTextBlock" name="InterestIncomeAndInterestExpensePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_LargestCustomerMember" name="LargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_LesseeOperatingLeaseLiabilityTenantIncentives" name="LesseeOperatingLeaseLiabilityTenantIncentives" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters" name="MaximumNumberOfAdditionalSharesGrantedToUnderwriters" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_MeasurementInputProbabilityOfMilestoneAchievementMember" name="MeasurementInputProbabilityOfMilestoneAchievementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_MiamedIncMember" name="MiamedIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_MilestonePayableAccruedDuringPeriod" name="MilestonePayableAccruedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_MilestonePaymentMember" name="MilestonePaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_MilestonePaymentStockIssuedAsConsideration" name="MilestonePaymentStockIssuedAsConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_NationwideChildrensHospitalMember" name="NationwideChildrensHospitalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_NonCashDeferredTaxesAndOtherTaxBenefits" name="NonCashDeferredTaxesAndOtherTaxBenefits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_NonqualifiedCashDeferralPlansPolicy" name="NonqualifiedCashDeferralPlansPolicy" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares" name="NumberOfDaysGrantedUnderwritersForPurchaseOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped" name="NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" name="NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" name="NumberOfSharesIssuedPerIncrementOfConvertibleDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_OrphanDrugTaxCreditCarryforwardMember" name="OrphanDrugTaxCreditCarryforwardMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_OtherComprehensiveIncomePolicyPolicyTextBlock" name="OtherComprehensiveIncomePolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_PaymentOfContingentConsideration" name="PaymentOfContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_PaymentsForCollaborativeArrangement" name="PaymentsForCollaborativeArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_PaymentsForRepurchaseOfRestrictedStockUnits" name="PaymentsForRepurchaseOfRestrictedStockUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_PaymentsToAcquireBusinessAssets" name="PaymentsToAcquireBusinessAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_PremiumsPaidForCappedCallConfirmations" name="PremiumsPaidForCappedCallConfirmations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_PrivatePlacementPurchaseAgreementMember" name="PrivatePlacementPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_ProbabilityWeightedDiscountedCashFlowMember" name="ProbabilityWeightedDiscountedCashFlowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" name="ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_ResearchAndDevelopmentExpensesDueToWindDown" name="ResearchAndDevelopmentExpensesDueToWindDown" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_ResearchEquipmentMember" name="ResearchEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_ResearchExpenseForStockIssuanceInAssetAcquisition" name="ResearchExpenseForStockIssuanceInAssetAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment" name="RevenueRecognitionMilestoneMethodContingentOnDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones" name="RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears" name="RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="fold_RevisedCollaborationAgreementMember" name="RevisedCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_SciodermIncMember" name="SciodermIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_SellingGeneralAndAdministrativeCostsDueToWindDown" name="SellingGeneralAndAdministrativeCostsDueToWindDown" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_ShareBasedCompensationNumberOfPlans" name="ShareBasedCompensationNumberOfPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="fold_ShortTermCorporateDebtSecuritiesMember" name="ShortTermCorporateDebtSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_StockIssuedDuringPeriodSharesContingentConsideration" name="StockIssuedDuringPeriodSharesContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="fold_StockIssuedDuringPeriodValueContingentConsideration" name="StockIssuedDuringPeriodValueContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="fold_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" name="StockOptionPlan2007AndDirectorOptionPlan2007Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" name="StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_TB200PompeProgramMember" name="TB200PompeProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_UnderwrittenOfferingMember" name="UnderwrittenOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="fold_VestedRestrictedStockUnitsUnissuedMember" name="VestedRestrictedStockUnitsUnissuedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>fold-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities" xlink:href="fold-20191231.xsd#AccountsPayableAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="fold-20191231.xsd#AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="fold-20191231.xsd#AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Acquisitions" xlink:href="fold-20191231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AcquisitionsDetails" xlink:href="fold-20191231.xsd#AcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesMeasuredAtFairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare" xlink:href="fold-20191231.xsd#BasicAndDilutedNetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails" xlink:href="fold-20191231.xsd#BasicAndDilutedNetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables" xlink:href="fold-20191231.xsd#BasicAndDilutedNetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetailsCalc2" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreements" xlink:href="fold-20191231.xsd#CollaborativeAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:href="fold-20191231.xsd#CollaborativeAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:href="fold-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="fold-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CoverPage" xlink:href="fold-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:href="fold-20191231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails" xlink:href="fold-20191231.xsd#DebtConvertibleNotesAndSeniorSecuredTermLoanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:href="fold-20191231.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:href="fold-20191231.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:href="fold-20191231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionOfBusiness" xlink:href="fold-20191231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails" xlink:href="fold-20191231.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxes" xlink:href="fold-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails" xlink:href="fold-20191231.xsd#IncomeTaxesDeferredAndValuationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:href="fold-20191231.xsd#IncomeTaxesLossCarryforwardsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:href="fold-20191231.xsd#IncomeTaxesStatutoryRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesTables" xlink:href="fold-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:href="fold-20191231.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:href="fold-20191231.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:href="fold-20191231.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Leases" xlink:href="fold-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesDetails" xlink:href="fold-20191231.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesDetailsCalc2" xlink:href="fold-20191231.xsd#LeasesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesTables" xlink:href="fold-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipment" xlink:href="fold-20191231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails" xlink:href="fold-20191231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables" xlink:href="fold-20191231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="fold-20191231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="fold-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="fold-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:href="fold-20191231.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationRsusAndPbrsusSummaryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:href="fold-20191231.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:href="fold-20191231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails" xlink:href="fold-20191231.xsd#StockholdersEquityCommonStockAndWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails" xlink:href="fold-20191231.xsd#StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:label="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_3f7618bd-d074-4469-ab19-6b8c429e9fa1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_3f7618bd-d074-4469-ab19-6b8c429e9fa1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedProgramFees" xlink:label="loc_fold_AccruedProgramFees_2613ff7c-e58d-ed47-439e-6b8c42782b55" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_fold_AccruedProgramFees_2613ff7c-e58d-ed47-439e-6b8c42782b55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_7d4777c3-e41b-9b63-699f-d86dc2fc13b0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_7d4777c3-e41b-9b63-699f-d86dc2fc13b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_44d274ec-089d-7b00-4cf5-06d0b5a846fb" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_InterestPayableCurrent_44d274ec-089d-7b00-4cf5-06d0b5a846fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:label="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_5b862d76-fe22-efe2-d9e5-6b8c42da8633" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_5b862d76-fe22-efe2-d9e5-6b8c42da8633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="locator" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_61043dfa-aeb8-0b07-593f-a2357b7b89ac" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_61043dfa-aeb8-0b07-593f-a2357b7b89ac" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_79395791-5fb1-8c7a-d3e8-d7e3e5037f5b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_79395791-5fb1-8c7a-d3e8-d7e3e5037f5b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_79395791-5fb1-8c7a-d3e8-d7e3e5037f5b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_e70b772f-0d77-255b-9d30-d7e3e4f28a45" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_79395791-5fb1-8c7a-d3e8-d7e3e5037f5b" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_e70b772f-0d77-255b-9d30-d7e3e4f28a45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_554f95d2-cb4f-eb2c-68b3-7e12c8578a72" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_e70b772f-0d77-255b-9d30-d7e3e4f28a45" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_554f95d2-cb4f-eb2c-68b3-7e12c8578a72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_e70b772f-0d77-255b-9d30-d7e3e4f28a45" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_7A6FA3E5927A9BDC157B06E59B5001A3_79395791-5fb1-8c7a-d3e8-d7e3e5037f5b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7A6FA3E5927A9BDC157B06E59B5001A3_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_7A6FA3E5927A9BDC157B06E59B5001A3_79395791-5fb1-8c7a-d3e8-d7e3e5037f5b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7A6FA3E5927A9BDC157B06E59B5001A3_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A6FA3E5927A9BDC157B06E59B5001A3_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_7A6FA3E5927A9BDC157B06E59B5001A3_79395791-5fb1-8c7a-d3e8-d7e3e5037f5b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A6FA3E5927A9BDC157B06E59B5001A3_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_ae11e3b1-839b-d0b0-a04b-b35611528b8c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_ae11e3b1-839b-d0b0-a04b-b35611528b8c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e5ed56be-b332-3e5a-5302-f555a962d258" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e5ed56be-b332-3e5a-5302-f555a962d258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_9f9a6981-86f6-4247-b428-2476fffdd764" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_9f9a6981-86f6-4247-b428-2476fffdd764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_97d19ab6-417d-df40-82ab-78413bc8bbd0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_97d19ab6-417d-df40-82ab-78413bc8bbd0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_3fda818c-6b39-e088-a39a-b3bff4b8a17e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_3fda818c-6b39-e088-a39a-b3bff4b8a17e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_35cec4c3-4d76-5677-c897-f4a7c5f95a66" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_SecuredLongTermDebt_35cec4c3-4d76-5677-c897-f4a7c5f95a66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eaedbb6a-5feb-d7b5-74ff-83d9e06de663" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eaedbb6a-5feb-d7b5-74ff-83d9e06de663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9a00ddef-ccc2-f99c-735a-66b1e1849bbf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9a00ddef-ccc2-f99c-735a-66b1e1849bbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_4d245d7e-ad6c-dd35-41be-465e2f0e7195" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_4d245d7e-ad6c-dd35-41be-465e2f0e7195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58dbb131-3dd4-8ecf-cb87-48dc5113246d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58dbb131-3dd4-8ecf-cb87-48dc5113246d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_d3b228b2-7eb9-f739-11a1-2268f8c30c19" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_d3b228b2-7eb9-f739-11a1-2268f8c30c19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c839a0d8-dfea-e1a5-fc91-ef95e7aed9cb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c839a0d8-dfea-e1a5-fc91-ef95e7aed9cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d385978f-69ad-b055-896a-51e9bbc23743" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d385978f-69ad-b055-896a-51e9bbc23743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_3575bb55-f9ac-46fc-4fdd-3912f64b14f5" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_3575bb55-f9ac-46fc-4fdd-3912f64b14f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64118bb2-1b72-460a-8e47-0026dedd2749" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64118bb2-1b72-460a-8e47-0026dedd2749" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_7b45f80f-9814-0790-1324-d7e3e4b819d4" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_7b45f80f-9814-0790-1324-d7e3e4b819d4" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NonCashDeferredTaxesAndOtherTaxBenefits" xlink:label="loc_fold_NonCashDeferredTaxesAndOtherTaxBenefits_5777280b-56c1-6b02-a41f-6b8c4276aa08" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_fold_NonCashDeferredTaxesAndOtherTaxBenefits_5777280b-56c1-6b02-a41f-6b8c4276aa08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_b5495221-c933-5c88-514e-d2731414949c" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AssetImpairmentCharges_b5495221-c933-5c88-514e-d2731414949c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_8b336d93-6f62-28d9-cbe5-d7e3e5162c8a" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_8b336d93-6f62-28d9-cbe5-d7e3e5162c8a" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_IncreaseDecreaseInDeferredReimbursements" xlink:label="loc_fold_IncreaseDecreaseInDeferredReimbursements_32e092c0-2497-8d25-c1eb-d7e3e4a1af87" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_fold_IncreaseDecreaseInDeferredReimbursements_32e092c0-2497-8d25-c1eb-d7e3e4a1af87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f6cd34b6-f238-abf8-9b6c-ac9d5fcdd140" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f6cd34b6-f238-abf8-9b6c-ac9d5fcdd140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_331bb1f4-b37f-a29c-873f-d7e3e4da443a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_331bb1f4-b37f-a29c-873f-d7e3e4da443a" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_e0f10fda-796d-3dfe-130a-d7e3e4e2aee4" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_e0f10fda-796d-3dfe-130a-d7e3e4e2aee4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_a88ea9da-fe15-25d5-e7ed-084f1843cf38" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_a88ea9da-fe15-25d5-e7ed-084f1843cf38" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentOfContingentConsideration" xlink:label="loc_fold_PaymentOfContingentConsideration_da28b561-6e0f-5985-9bf3-d7e3e4bd3f96" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_fold_PaymentOfContingentConsideration_da28b561-6e0f-5985-9bf3-d7e3e4bd3f96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_5656d2a9-7814-506a-4f08-df2c0f722a69" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_5656d2a9-7814-506a-4f08-df2c0f722a69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_b1c71806-d6c9-66f0-9d97-067835486fa9" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_b1c71806-d6c9-66f0-9d97-067835486fa9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_138d7df8-0ec2-04f9-f9f7-0e5a0ff1d684" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_138d7df8-0ec2-04f9-f9f7-0e5a0ff1d684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd7c3da-2a5b-cbc6-d33a-bb097a23c2f6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd7c3da-2a5b-cbc6-d33a-bb097a23c2f6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_71d11517-34f8-505e-4c4b-e25ef3111aee" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_71d11517-34f8-505e-4c4b-e25ef3111aee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bab93ab9-d249-c671-e786-575d618bea25" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bab93ab9-d249-c671-e786-575d618bea25" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ee6f6897-b14b-45ca-c6e4-4fc17aaf1e37" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ee6f6897-b14b-45ca-c6e4-4fc17aaf1e37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_b5495221-c933-5c88-514e-d2731414949c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_AssetImpairmentCharges_b5495221-c933-5c88-514e-d2731414949c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_9f9b2594-efaa-e1fa-01db-e194221f432f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_DepreciationAndAmortization_9f9b2594-efaa-e1fa-01db-e194221f432f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d385978f-69ad-b055-896a-51e9bbc23743" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d385978f-69ad-b055-896a-51e9bbc23743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_0bcab6d8-2bb7-f099-a199-f96923f23f8b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_0bcab6d8-2bb7-f099-a199-f96923f23f8b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_736d2dab-e6d0-241f-ea81-d597b26683aa" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_736d2dab-e6d0-241f-ea81-d597b26683aa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_4bfbe561-36eb-5a4b-3221-ec5e4f11e905" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DeferredOfferingCosts_4bfbe561-36eb-5a4b-3221-ec5e4f11e905" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:type="locator" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsLiabilitiesGross" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross_bca55d2d-1c95-578f-eedb-6b8c42a22349" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_fold_DeferredTaxAssetsLiabilitiesGross_bca55d2d-1c95-578f-eedb-6b8c42a22349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_bca55d2d-1c95-578f-eedb-6b8c42a22349" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsIntellectualProperty" xlink:label="loc_fold_DeferredTaxAssetsIntellectualProperty_e501a54c-5ef3-449a-6914-6b8c42d7bd2f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_fold_DeferredTaxAssetsIntellectualProperty_e501a54c-5ef3-449a-6914-6b8c42d7bd2f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_06fdd8fa-20aa-c385-b288-61c16515fae0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_06fdd8fa-20aa-c385-b288-61c16515fae0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2923c663-d6ea-ecbc-ca18-63a6f8140ce1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2923c663-d6ea-ecbc-ca18-63a6f8140ce1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:label="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_3f444215-88b4-5938-8872-6b8c4271e69f" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_3f444215-88b4-5938-8872-6b8c4271e69f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:label="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_bb5a8fbe-5af6-51c3-65dd-6b8c426897b3" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_bb5a8fbe-5af6-51c3-65dd-6b8c426897b3" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:label="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_0212217d-a10d-24e3-0291-6b8c42667f53" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_bca55d2d-1c95-578f-eedb-6b8c42a22349" xlink:to="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_0212217d-a10d-24e3-0291-6b8c42667f53" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" xlink:label="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_47819219-029a-9464-f9f8-6b8c4237c867" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_bca55d2d-1c95-578f-eedb-6b8c42a22349" xlink:to="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_47819219-029a-9464-f9f8-6b8c4237c867" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:label="loc_fold_DeferredTaxLiabilitiesConvertibleNotes_e4413535-eba1-848b-2deb-6b8c4240df9d" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_bca55d2d-1c95-578f-eedb-6b8c42a22349" xlink:to="loc_fold_DeferredTaxLiabilitiesConvertibleNotes_e4413535-eba1-848b-2deb-6b8c4240df9d" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:label="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_0e6e29c0-bfdb-6495-b2d8-6b8c42c1739a" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_bca55d2d-1c95-578f-eedb-6b8c42a22349" xlink:to="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_0e6e29c0-bfdb-6495-b2d8-6b8c42c1739a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_4c5a1085-469a-cd6c-e26f-53287b62aa26" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_bca55d2d-1c95-578f-eedb-6b8c42a22349" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_4c5a1085-469a-cd6c-e26f-53287b62aa26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3ce82195-ed3e-f261-3529-b3a868ecf6c4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3ce82195-ed3e-f261-3529-b3a868ecf6c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89ebd542-78ee-71d0-be95-65de1bb3ef82" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89ebd542-78ee-71d0-be95-65de1bb3ef82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dbb037c2-04c0-fa14-65e6-8ccd12d2a855" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dbb037c2-04c0-fa14-65e6-8ccd12d2a855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8caef893-a841-2be2-863f-e20b53026f02" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8caef893-a841-2be2-863f-e20b53026f02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_d9df7d3d-b9dd-e868-b078-e2e03ba315bc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_d9df7d3d-b9dd-e868-b078-e2e03ba315bc" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_60f5ad21-a26e-3ffe-d029-6b8c424925d2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_60f5ad21-a26e-3ffe-d029-6b8c424925d2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_35576b1d-4191-d890-6c5b-6b8c4289f44a" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_35576b1d-4191-d890-6c5b-6b8c4289f44a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_77b9f787-6596-82cb-4698-f0991c80113b" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_77b9f787-6596-82cb-4698-f0991c80113b" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_99A804B095F438465154806C36A69110" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_99A804B095F438465154806C36A69110" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a142eb63-af8d-4212-6321-d7c0ac27f958" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a142eb63-af8d-4212-6321-d7c0ac27f958" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_832fb73d-9886-a0dd-5905-8e2ec54304d6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_832fb73d-9886-a0dd-5905-8e2ec54304d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e71cbb67-0324-15b7-66dc-376e90f3ca60" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e71cbb67-0324-15b7-66dc-376e90f3ca60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1f2c68db-a374-1412-5f1f-4edca1431bbb" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1f2c68db-a374-1412-5f1f-4edca1431bbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00C53811DEC7E28B134B7857B58112C1_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_00C53811DEC7E28B134B7857B58112C1_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00C53811DEC7E28B134B7857B58112C1_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_00C53811DEC7E28B134B7857B58112C1_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:label="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_00C53811DEC7E28B134B7857B58112C1_befaec6b-f43b-cc96-bbcc-d7e3e4afc866" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00C53811DEC7E28B134B7857B58112C1_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_00C53811DEC7E28B134B7857B58112C1_befaec6b-f43b-cc96-bbcc-d7e3e4afc866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_00C53811DEC7E28B134B7857B58112C1_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00C53811DEC7E28B134B7857B58112C1_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_00C53811DEC7E28B134B7857B58112C1_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>fold-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities" xlink:href="fold-20191231.xsd#AccountsPayableAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="fold-20191231.xsd#AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="fold-20191231.xsd#AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Acquisitions" xlink:href="fold-20191231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AcquisitionsDetails" xlink:href="fold-20191231.xsd#AcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesMeasuredAtFairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare" xlink:href="fold-20191231.xsd#BasicAndDilutedNetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails" xlink:href="fold-20191231.xsd#BasicAndDilutedNetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables" xlink:href="fold-20191231.xsd#BasicAndDilutedNetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreements" xlink:href="fold-20191231.xsd#CollaborativeAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:href="fold-20191231.xsd#CollaborativeAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:href="fold-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="fold-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CoverPage" xlink:href="fold-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:href="fold-20191231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails" xlink:href="fold-20191231.xsd#DebtConvertibleNotesAndSeniorSecuredTermLoanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:href="fold-20191231.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:href="fold-20191231.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:href="fold-20191231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionOfBusiness" xlink:href="fold-20191231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails" xlink:href="fold-20191231.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxes" xlink:href="fold-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails" xlink:href="fold-20191231.xsd#IncomeTaxesDeferredAndValuationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:href="fold-20191231.xsd#IncomeTaxesLossCarryforwardsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:href="fold-20191231.xsd#IncomeTaxesStatutoryRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesTables" xlink:href="fold-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:href="fold-20191231.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:href="fold-20191231.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:href="fold-20191231.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Leases" xlink:href="fold-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesDetails" xlink:href="fold-20191231.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesTables" xlink:href="fold-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipment" xlink:href="fold-20191231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails" xlink:href="fold-20191231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables" xlink:href="fold-20191231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="fold-20191231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="fold-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="fold-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:href="fold-20191231.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationRsusAndPbrsusSummaryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:href="fold-20191231.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:href="fold-20191231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails" xlink:href="fold-20191231.xsd#StockholdersEquityCommonStockAndWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails" xlink:href="fold-20191231.xsd#StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AssetAcquisitionAxis" xlink:label="loc_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AssetAcquisitionDomain" xlink:label="loc_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:to="loc_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358_default" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AssetAcquisitionDomain" xlink:label="loc_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:to="loc_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CelenexMember" xlink:label="loc_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:to="loc_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:to="loc_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:to="loc_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NationwideChildrensHospitalMember" xlink:label="loc_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:to="loc_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MiamedIncMember" xlink:label="loc_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:to="loc_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_SciodermIncMember" xlink:label="loc_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:to="loc_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="loc_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:to="loc_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:to="loc_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:to="loc_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ParentCompanyMember" xlink:label="loc_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:to="loc_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_4DC1884E5A227457153BF438F6203547" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_srt_RangeAxis_4DC1884E5A227457153BF438F6203547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_743549F8EB631323E452F438F6207CE2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4DC1884E5A227457153BF438F6203547" xlink:to="loc_srt_RangeMember_743549F8EB631323E452F438F6207CE2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_743549F8EB631323E452F438F6207CE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4DC1884E5A227457153BF438F6203547" xlink:to="loc_srt_RangeMember_743549F8EB631323E452F438F6207CE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B262BF12837A80ACA992F438F6203480" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_743549F8EB631323E452F438F6207CE2" xlink:to="loc_srt_MaximumMember_B262BF12837A80ACA992F438F6203480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:to="loc_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:to="loc_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:to="loc_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_FixedAssetsMember" xlink:label="loc_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:to="loc_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ChangesInFairValueOfContingentConsiderationPayableMember" xlink:label="loc_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:to="loc_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:to="loc_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:to="loc_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MilestonePaymentMember" xlink:label="loc_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:to="loc_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="loc_fold_CallidusBiopharmaIncMember_01BF166FEB5F6F5612E0F438F620BD46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:to="loc_fold_CallidusBiopharmaIncMember_01BF166FEB5F6F5612E0F438F620BD46" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped" xlink:label="loc_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment" xlink:label="loc_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones" xlink:label="loc_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears" xlink:label="loc_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AssetAcquisitionConsiderationTransferred" xlink:label="loc_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentsToAcquireBusinessAssets" xlink:label="loc_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessAssetAcquisitionContingentConsiderationMilestones" xlink:label="loc_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment" xlink:label="loc_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ResearchExpenseForStockIssuanceInAssetAcquisition" xlink:label="loc_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessCombinationOfEnrollmentRate" xlink:label="loc_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationMilestonePayment" xlink:label="loc_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_SellingGeneralAndAdministrativeCostsDueToWindDown" xlink:label="loc_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ResearchAndDevelopmentExpensesDueToWindDown" xlink:label="loc_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_IncomeTaxExpenseBenefitDueToWindDown" xlink:label="loc_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_256BDCD8D41F0A55591D06E59AC828E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_256BDCD8D41F0A55591D06E59AC828E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6D62FC78AF95E750553106E59AC85BE7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_256BDCD8D41F0A55591D06E59AC828E6" xlink:to="loc_us-gaap_EquityComponentDomain_6D62FC78AF95E750553106E59AC85BE7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6D62FC78AF95E750553106E59AC85BE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_256BDCD8D41F0A55591D06E59AC828E6" xlink:to="loc_us-gaap_EquityComponentDomain_6D62FC78AF95E750553106E59AC85BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A1A16C002F301BAF468B06E59AC961D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6D62FC78AF95E750553106E59AC85BE7" xlink:to="loc_us-gaap_CommonStockMember_A1A16C002F301BAF468B06E59AC961D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_99411C76C516B7479AC506E59ACA9105" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_99411C76C516B7479AC506E59ACA9105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_99411C76C516B7479AC506E59ACA9105" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_99411C76C516B7479AC506E59ACA9105" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_E8BEEED3A48EBE2B590506E59ACAF4EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_E8BEEED3A48EBE2B590506E59ACAF4EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_FA9D2C06A546F82AEE5E06E59ACB74FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_FA9D2C06A546F82AEE5E06E59ACB74FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2760E630EA877897924506E59ACB8FC2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2760E630EA877897924506E59ACB8FC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_852C45003812C247467606E59ACB7C5E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_852C45003812C247467606E59ACB7C5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FB93AD08CF2525BCDBF806E59ACB07DD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FB93AD08CF2525BCDBF806E59ACB07DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4943E6D1703B7E380CD206E59ACB6DA4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FB93AD08CF2525BCDBF806E59ACB07DD" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4943E6D1703B7E380CD206E59ACB6DA4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4943E6D1703B7E380CD206E59ACB6DA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FB93AD08CF2525BCDBF806E59ACB07DD" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4943E6D1703B7E380CD206E59ACB6DA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_F5E009322C273A9E81D106E59ACC2D44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4943E6D1703B7E380CD206E59ACB6DA4" xlink:to="loc_us-gaap_ConvertibleDebtMember_F5E009322C273A9E81D106E59ACC2D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_386D8D7F60F41744740006E59ACCEA62" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_DebtInstrumentAxis_386D8D7F60F41744740006E59ACCEA62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D1481F0912C1EB3D6F7C06E59ACCEADE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_386D8D7F60F41744740006E59ACCEA62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D1481F0912C1EB3D6F7C06E59ACCEADE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D1481F0912C1EB3D6F7C06E59ACCEADE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_386D8D7F60F41744740006E59ACCEA62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D1481F0912C1EB3D6F7C06E59ACCEADE" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_362D6CB30E0CE50823C106E59ACC9529" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D1481F0912C1EB3D6F7C06E59ACCEADE" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_362D6CB30E0CE50823C106E59ACC9529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_398EAB39EEC1FDEA53A006E59ACD5BE3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_398EAB39EEC1FDEA53A006E59ACD5BE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ADC6F92CC72BA46074206E59ACDD0F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_398EAB39EEC1FDEA53A006E59ACD5BE3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ADC6F92CC72BA46074206E59ACDD0F4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ADC6F92CC72BA46074206E59ACDD0F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_398EAB39EEC1FDEA53A006E59ACD5BE3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ADC6F92CC72BA46074206E59ACDD0F4" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_TB200PompeProgramMember" xlink:label="loc_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ADC6F92CC72BA46074206E59ACDD0F4" xlink:to="loc_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_BBDEA5FE7A608AF319EF06E59ACEDF45" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_srt_RangeAxis_BBDEA5FE7A608AF319EF06E59ACEDF45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3242353424424C53A20906E59ACEBC7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_BBDEA5FE7A608AF319EF06E59ACEDF45" xlink:to="loc_srt_RangeMember_3242353424424C53A20906E59ACEBC7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3242353424424C53A20906E59ACEBC7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_BBDEA5FE7A608AF319EF06E59ACEDF45" xlink:to="loc_srt_RangeMember_3242353424424C53A20906E59ACEBC7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B6E919E227CF4BC2F78A06E59ACE2D71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3242353424424C53A20906E59ACEBC7C" xlink:to="loc_srt_MinimumMember_B6E919E227CF4BC2F78A06E59ACE2D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D909E0F9DE5B1879B0C506E59ACEF559" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3242353424424C53A20906E59ACEBC7C" xlink:to="loc_srt_MaximumMember_D909E0F9DE5B1879B0C506E59ACEF559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_3225E1B03D6B92ECA98906E59ACE7FEB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_3225E1B03D6B92ECA98906E59ACE7FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_A54682EFC656C075A48506E59ACEB627_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3225E1B03D6B92ECA98906E59ACE7FEB" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_A54682EFC656C075A48506E59ACEB627_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_A54682EFC656C075A48506E59ACEB627" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3225E1B03D6B92ECA98906E59ACE7FEB" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_A54682EFC656C075A48506E59ACEB627" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_A54682EFC656C075A48506E59ACEB627" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C7DB0DFA5CC07F72DF5606E59AD0FDBA" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C7DB0DFA5CC07F72DF5606E59AD0FDBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5E3832D9044D492748F806E59AD00AA1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C7DB0DFA5CC07F72DF5606E59AD0FDBA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5E3832D9044D492748F806E59AD00AA1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5E3832D9044D492748F806E59AD00AA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C7DB0DFA5CC07F72DF5606E59AD0FDBA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5E3832D9044D492748F806E59AD00AA1" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="loc_fold_CallidusBiopharmaIncMember_DCB45C35D9B5DD7C02F806E59AD04ED6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5E3832D9044D492748F806E59AD00AA1" xlink:to="loc_fold_CallidusBiopharmaIncMember_DCB45C35D9B5DD7C02F806E59AD04ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_DB69BB8C2542E49DC38906E59AD2CEFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_DB69BB8C2542E49DC38906E59AD2CEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationMeasurementInput" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MilestonePaymentStockIssuedAsConsideration" xlink:label="loc_fold_MilestonePaymentStockIssuedAsConsideration_4344C138D500B1779D5D06E59AD344F3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_fold_MilestonePaymentStockIssuedAsConsideration_4344C138D500B1779D5D06E59AD344F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_289F93C101D9BD0F47C2F4CA95E57717" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_289F93C101D9BD0F47C2F4CA95E57717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="loc_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_VestedRestrictedStockUnitsUnissuedMember" xlink:label="loc_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="loc_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_76B3F1B22B802007E8FA06E59B557006" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:to="loc_us-gaap_FinancialInstrumentAxis_76B3F1B22B802007E8FA06E59B557006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_76B3F1B22B802007E8FA06E59B557006" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_76B3F1B22B802007E8FA06E59B557006" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ShortTermCorporateDebtSecuritiesMember" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EFB98BD3BF7FBA612B4E06E59B567FE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EFB98BD3BF7FBA612B4E06E59B567FE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B0188D078A0FC09CADE75AE6059A3E7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B0188D078A0FC09CADE75AE6059A3E7C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B0188D078A0FC09CADE75AE6059A3E7C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_RevisedCollaborationAgreementMember" xlink:label="loc_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:to="loc_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_9FC163C46F71661603BC5AE6059C383D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B0188D078A0FC09CADE75AE6059A3E7C" xlink:to="loc_srt_CounterpartyNameAxis_9FC163C46F71661603BC5AE6059C383D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4AC615F4001CFC35EA9D5AE6059CC450_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9FC163C46F71661603BC5AE6059C383D" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4AC615F4001CFC35EA9D5AE6059CC450_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4AC615F4001CFC35EA9D5AE6059CC450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9FC163C46F71661603BC5AE6059C383D" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4AC615F4001CFC35EA9D5AE6059CC450" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_GlaxoSmithKlinePLCMember" xlink:label="loc_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4AC615F4001CFC35EA9D5AE6059CC450" xlink:to="loc_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:label="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborationAgreementAnnualContributionByCompany" xlink:label="loc_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentsForCollaborativeArrangement" xlink:label="loc_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedPaymentsForCollaborativeArrangement" xlink:label="loc_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:label="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:label="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6C32BBAB621D4ACA0E0A5AE6059EA3F4" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6C32BBAB621D4ACA0E0A5AE6059EA3F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:to="loc_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_CE8C7DB74B995899A2E68065CB71E0C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_CE8C7DB74B995899A2E68065CB71E0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CE8C7DB74B995899A2E68065CB71E0C8" xlink:to="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CE8C7DB74B995899A2E68065CB71E0C8" xlink:to="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DC21306B6C29553DF9878065CB72703C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:to="loc_us-gaap_CommonStockMember_DC21306B6C29553DF9878065CB72703C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_EE4344F1A6C21AC5B3298065CB7292C0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:to="loc_us-gaap_WarrantMember_EE4344F1A6C21AC5B3298065CB7292C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:to="loc_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1DEE58F5AD26DDDA3D7D8065CB740F96" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1DEE58F5AD26DDDA3D7D8065CB740F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:label="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_FB46E4422C8F95F5A3818065CB769B50" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_FB46E4422C8F95F5A3818065CB769B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_90BC437A239F698485D38065CB76CAB4" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_90BC437A239F698485D38065CB76CAB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_66F5C0463CCF44E0FD268065CB77F8F5" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_NetIncomeLoss_66F5C0463CCF44E0FD268065CB77F8F5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:to="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:to="loc_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:to="loc_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:to="loc_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:to="loc_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8E1D8D56E4CE683818FF9C2B24BB00CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_008DA5A29850AF6817D09C2B24B9F7A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8E1D8D56E4CE683818FF9C2B24BB00CD" xlink:to="loc_us-gaap_DebtInstrumentTable_008DA5A29850AF6817D09C2B24B9F7A0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1D0574122F4AEAFD01BC9C2B24B95F70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_008DA5A29850AF6817D09C2B24B9F7A0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1D0574122F4AEAFD01BC9C2B24B95F70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6AAA0459369A8FA0DD399C2B24BAEF4B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1D0574122F4AEAFD01BC9C2B24B95F70" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6AAA0459369A8FA0DD399C2B24BAEF4B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6AAA0459369A8FA0DD399C2B24BAEF4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1D0574122F4AEAFD01BC9C2B24B95F70" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6AAA0459369A8FA0DD399C2B24BAEF4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_F1E8FC67F8ED3BAC15769C2B24BA8DEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6AAA0459369A8FA0DD399C2B24BAEF4B" xlink:to="loc_us-gaap_ConvertibleDebtMember_F1E8FC67F8ED3BAC15769C2B24BA8DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_5FD0A5FCF2806CE694FC9C2B24BB1841" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6AAA0459369A8FA0DD399C2B24BAEF4B" xlink:to="loc_us-gaap_SeniorNotesMember_5FD0A5FCF2806CE694FC9C2B24BB1841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_07C508C02087244063099C2B24BB451F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_008DA5A29850AF6817D09C2B24B9F7A0" xlink:to="loc_us-gaap_DebtInstrumentAxis_07C508C02087244063099C2B24BB451F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F93285081B65E0185C4C9C2B24BBF9F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_07C508C02087244063099C2B24BB451F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F93285081B65E0185C4C9C2B24BBF9F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F93285081B65E0185C4C9C2B24BBF9F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_07C508C02087244063099C2B24BB451F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F93285081B65E0185C4C9C2B24BBF9F3" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_64858C7EFC92E7C434E59C2B24BB1E8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F93285081B65E0185C4C9C2B24BBF9F3" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_64858C7EFC92E7C434E59C2B24BB1E8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8E1D8D56E4CE683818FF9C2B24BB00CD" xlink:to="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AmortizationDeferredFinancingCosts" xlink:label="loc_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:to="loc_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:to="loc_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:to="loc_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:to="loc_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:to="loc_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:to="loc_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3C41D9213C2B1B3D18E05A1074CE3472" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3C41D9213C2B1B3D18E05A1074CE3472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_EBF3C7B524591C07FF9B5A1074CE3C1E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3C41D9213C2B1B3D18E05A1074CE3472" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_EBF3C7B524591C07FF9B5A1074CE3C1E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_EBF3C7B524591C07FF9B5A1074CE3C1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3C41D9213C2B1B3D18E05A1074CE3472" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_EBF3C7B524591C07FF9B5A1074CE3C1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_9ACE4153E503BB0F13335A1074CEAF4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_EBF3C7B524591C07FF9B5A1074CE3C1E" xlink:to="loc_us-gaap_ConvertibleDebtMember_9ACE4153E503BB0F13335A1074CEAF4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_EBF3C7B524591C07FF9B5A1074CE3C1E" xlink:to="loc_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_AB744A961CE994BB57F95A1074CF04EF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_DebtInstrumentAxis_AB744A961CE994BB57F95A1074CF04EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B509427952999A78CB775A1074CF1260_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_AB744A961CE994BB57F95A1074CF04EF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B509427952999A78CB775A1074CF1260_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B509427952999A78CB775A1074CF1260" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_AB744A961CE994BB57F95A1074CF04EF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B509427952999A78CB775A1074CF1260" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_4E09D13F7BF4A7CEE36A5A1074CFF3C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B509427952999A78CB775A1074CF1260" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_4E09D13F7BF4A7CEE36A5A1074CFF3C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_68C9A3449486064BFBBC5A1074CF9E0A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_68C9A3449486064BFBBC5A1074CF9E0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49A21B354B72550567815A1074CFF87E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_68C9A3449486064BFBBC5A1074CF9E0A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49A21B354B72550567815A1074CFF87E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49A21B354B72550567815A1074CFF87E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_68C9A3449486064BFBBC5A1074CF9E0A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49A21B354B72550567815A1074CFF87E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49A21B354B72550567815A1074CFF87E" xlink:to="loc_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_96B0B8BE0E25DC0B99E65A1074D0EFBC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_96B0B8BE0E25DC0B99E65A1074D0EFBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BBC538A68BE4F101162A5A1074D0F9D6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_96B0B8BE0E25DC0B99E65A1074D0EFBC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BBC538A68BE4F101162A5A1074D0F9D6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BBC538A68BE4F101162A5A1074D0F9D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_96B0B8BE0E25DC0B99E65A1074D0EFBC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BBC538A68BE4F101162A5A1074D0F9D6" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="loc_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BBC538A68BE4F101162A5A1074D0F9D6" xlink:to="loc_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D7EE94C6B97FCD83FFB85A1074D1DA37" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_srt_RangeAxis_D7EE94C6B97FCD83FFB85A1074D1DA37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2230B1F25ECF5460806B5A1074D1A4F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_D7EE94C6B97FCD83FFB85A1074D1DA37" xlink:to="loc_srt_RangeMember_2230B1F25ECF5460806B5A1074D1A4F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2230B1F25ECF5460806B5A1074D1A4F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_D7EE94C6B97FCD83FFB85A1074D1DA37" xlink:to="loc_srt_RangeMember_2230B1F25ECF5460806B5A1074D1A4F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2230B1F25ECF5460806B5A1074D1A4F1" xlink:to="loc_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_020F6B249100D0C05E9F5A1074D1524F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_StatementClassOfStockAxis_020F6B249100D0C05E9F5A1074D1524F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A1BF0B1DFFEB7DCE6DB05A1074D167AB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_020F6B249100D0C05E9F5A1074D1524F" xlink:to="loc_us-gaap_ClassOfStockDomain_A1BF0B1DFFEB7DCE6DB05A1074D167AB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A1BF0B1DFFEB7DCE6DB05A1074D167AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_020F6B249100D0C05E9F5A1074D1524F" xlink:to="loc_us-gaap_ClassOfStockDomain_A1BF0B1DFFEB7DCE6DB05A1074D167AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B0C00EDC3E2F75E8804D5A1074D27098" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A1BF0B1DFFEB7DCE6DB05A1074D167AB" xlink:to="loc_us-gaap_CommonStockMember_B0C00EDC3E2F75E8804D5A1074D27098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CommonStockCappedCallConfirmationMember" xlink:label="loc_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:to="loc_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentPeriodicPaymentPrincipalPercentage" xlink:label="loc_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PremiumsPaidForCappedCallConfirmations" xlink:label="loc_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:label="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:label="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice" xlink:label="loc_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice" xlink:label="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice" xlink:label="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent" xlink:label="loc_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42FCE10AAA89FC2C82CF5A1074D6FFFC" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42FCE10AAA89FC2C82CF5A1074D6FFFC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares" xlink:label="loc_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters" xlink:label="loc_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_D6BC90715063822A46C95A1074D75030" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_D6BC90715063822A46C95A1074D75030" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_E7B415EF1A06C06A0E2A5A1074D73865" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_E7B415EF1A06C06A0E2A5A1074D73865" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_5B9ECC59F94D1FCF9B705A1074D7092A" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_5B9ECC59F94D1FCF9B705A1074D7092A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7DA0F42673F8E3F50565A1074D89CD8" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7DA0F42673F8E3F50565A1074D89CD8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9DB44D7A085092D4D9035A1074D890C7" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9DB44D7A085092D4D9035A1074D890C7" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare" xlink:label="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage" xlink:label="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A247A9281574CE2C6A9B5E3E77C458AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A247A9281574CE2C6A9B5E3E77C458AF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6A21B3DE3009C13D0DD05E3E77C43A6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A247A9281574CE2C6A9B5E3E77C458AF" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6A21B3DE3009C13D0DD05E3E77C43A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_CCDFE690D998708265DA5E3E77C4FAA2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6A21B3DE3009C13D0DD05E3E77C43A6E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_CCDFE690D998708265DA5E3E77C4FAA2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_CCDFE690D998708265DA5E3E77C4FAA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6A21B3DE3009C13D0DD05E3E77C43A6E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_CCDFE690D998708265DA5E3E77C4FAA2" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_UnderwrittenOfferingMember" xlink:label="loc_fold_UnderwrittenOfferingMember_4FD0FDE0374B48E54AD75E3E77C5EFEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_CCDFE690D998708265DA5E3E77C4FAA2" xlink:to="loc_fold_UnderwrittenOfferingMember_4FD0FDE0374B48E54AD75E3E77C5EFEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D0A7B38C8E8809F824285E3E77C59E97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D0A7B38C8E8809F824285E3E77C59E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1E86998F4D468DE7EF2D5E3E77C57D90" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1E86998F4D468DE7EF2D5E3E77C57D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D9FEFD3B4A7D37B824F15E3E77C5E92C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D9FEFD3B4A7D37B824F15E3E77C5E92C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_1F6B481A2F35AAB0E3D05E3E77C6098C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_1F6B481A2F35AAB0E3D05E3E77C6098C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_61BBCD63D3059377E3BF5E3E77C64CDB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_61BBCD63D3059377E3BF5E3E77C64CDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2F5B681B9E6353A221555E3E77C66B13" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2F5B681B9E6353A221555E3E77C66B13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:to="loc_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:to="loc_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:to="loc_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_OrphanDrugTaxCreditCarryforwardMember" xlink:label="loc_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:to="loc_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:to="loc_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/LeasesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44C6046FA48D4E243697F4CA96DAE5FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44C6046FA48D4E243697F4CA96DAE5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44C6046FA48D4E243697F4CA96DAE5FB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44C6046FA48D4E243697F4CA96DAE5FB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ResearchEquipmentMember" xlink:label="loc_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0FBC601C58BF4B432A04F4CA96DDACEF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0FBC601C58BF4B432A04F4CA96DDACEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:to="loc_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C99530CB325952F00E70F4CA968338F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0C43FF8003579E3372BEF4CA9682E2BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C99530CB325952F00E70F4CA968338F5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0C43FF8003579E3372BEF4CA9682E2BA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0AA1E1EA5CFD59732D01F4CA9682230F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0C43FF8003579E3372BEF4CA9682E2BA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0AA1E1EA5CFD59732D01F4CA9682230F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6FC8C567248DB68AE82BF4CA968278A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0AA1E1EA5CFD59732D01F4CA9682230F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6FC8C567248DB68AE82BF4CA968278A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6FC8C567248DB68AE82BF4CA968278A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0AA1E1EA5CFD59732D01F4CA9682230F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6FC8C567248DB68AE82BF4CA968278A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6FC8C567248DB68AE82BF4CA968278A7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6FC8C567248DB68AE82BF4CA968278A7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C99530CB325952F00E70F4CA968338F5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BBDD24977964BF5870E45A1075280CB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BBDD24977964BF5870E45A1075280CB8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_71007BA0362D29B495005A10752838C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BBDD24977964BF5870E45A1075280CB8" xlink:to="loc_us-gaap_AwardTypeAxis_71007BA0362D29B495005A10752838C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC859A5EA4678B2DC86A5A1075282EB7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_71007BA0362D29B495005A10752838C8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC859A5EA4678B2DC86A5A1075282EB7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC859A5EA4678B2DC86A5A1075282EB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_71007BA0362D29B495005A10752838C8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC859A5EA4678B2DC86A5A1075282EB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_39BFBDF60223D999C4AD5A107528CF92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC859A5EA4678B2DC86A5A1075282EB7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_39BFBDF60223D999C4AD5A107528CF92" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_BDEA4BB0F7E63A8945635A10752917C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC859A5EA4678B2DC86A5A1075282EB7" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_BDEA4BB0F7E63A8945635A10752917C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_7DF6611CF4899FD208125A1075297F8E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BBDD24977964BF5870E45A1075280CB8" xlink:to="loc_us-gaap_PlanNameAxis_7DF6611CF4899FD208125A1075297F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7AAB71BBFDC91F3E66955A1075297E07_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7DF6611CF4899FD208125A1075297F8E" xlink:to="loc_us-gaap_PlanNameDomain_7AAB71BBFDC91F3E66955A1075297E07_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7AAB71BBFDC91F3E66955A1075297E07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7DF6611CF4899FD208125A1075297F8E" xlink:to="loc_us-gaap_PlanNameDomain_7AAB71BBFDC91F3E66955A1075297E07" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7AAB71BBFDC91F3E66955A1075297E07" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A0E4A552DD985013374EF4CA9689E2CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32EDCCABC059196020A0F4CA96876303" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A0E4A552DD985013374EF4CA9689E2CA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32EDCCABC059196020A0F4CA96876303" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_C45A93806BD488E80343F4CA9688980B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32EDCCABC059196020A0F4CA96876303" xlink:to="loc_us-gaap_PlanNameAxis_C45A93806BD488E80343F4CA9688980B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_767D1B98894A4EB2EC0AF4CA96880879_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_C45A93806BD488E80343F4CA9688980B" xlink:to="loc_us-gaap_PlanNameDomain_767D1B98894A4EB2EC0AF4CA96880879_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_767D1B98894A4EB2EC0AF4CA96880879" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_C45A93806BD488E80343F4CA9688980B" xlink:to="loc_us-gaap_PlanNameDomain_767D1B98894A4EB2EC0AF4CA96880879" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_679EA055E22ECC41DBBCF4CA9688058B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_767D1B98894A4EB2EC0AF4CA96880879" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_679EA055E22ECC41DBBCF4CA9688058B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_989ECD003446AADDE028F4CA96885A63" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32EDCCABC059196020A0F4CA96876303" xlink:to="loc_us-gaap_AwardTypeAxis_989ECD003446AADDE028F4CA96885A63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1909B48BB5BF0B3AF3D7F4CA96891AEC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_989ECD003446AADDE028F4CA96885A63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1909B48BB5BF0B3AF3D7F4CA96891AEC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1909B48BB5BF0B3AF3D7F4CA96891AEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_989ECD003446AADDE028F4CA96885A63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1909B48BB5BF0B3AF3D7F4CA96891AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_CED1ACB296D6AF589CF7F4CA9689D296" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1909B48BB5BF0B3AF3D7F4CA96891AEC" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_CED1ACB296D6AF589CF7F4CA9689D296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A0E4A552DD985013374EF4CA9689E2CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3E23C2637145AB0474DDF4CA968ADA23" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3E23C2637145AB0474DDF4CA968ADA23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A0E4A552DD985013374EF4CA9689E2CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A0E4A552DD985013374EF4CA9689E2CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9454C802A246A016936F4CA969258A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9454C802A246A016936F4CA969258A7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_81C9D6FCCF24CC5A2B46F4CA9692E50B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9454C802A246A016936F4CA969258A7" xlink:to="loc_us-gaap_AwardTypeAxis_81C9D6FCCF24CC5A2B46F4CA9692E50B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863F710C1804E9660D8EF4CA9693506B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_81C9D6FCCF24CC5A2B46F4CA9692E50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863F710C1804E9660D8EF4CA9693506B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863F710C1804E9660D8EF4CA9693506B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_81C9D6FCCF24CC5A2B46F4CA9692E50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863F710C1804E9660D8EF4CA9693506B" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_80E9849487D0119FCB2DF4CA969356EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863F710C1804E9660D8EF4CA9693506B" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_80E9849487D0119FCB2DF4CA969356EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3E5B63BA347ACFEF23ECF4CA9694200B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3E5B63BA347ACFEF23ECF4CA9694200B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30945E3CC311DD40B16F4CA96A9B266" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30945E3CC311DD40B16F4CA96A9B266" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5DF96950A1882F53B127F4CA96A926AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30945E3CC311DD40B16F4CA96A9B266" xlink:to="loc_us-gaap_AwardTypeAxis_5DF96950A1882F53B127F4CA96A926AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7D0897F89C4410ADDCA1F4CA96A972F8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5DF96950A1882F53B127F4CA96A926AE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7D0897F89C4410ADDCA1F4CA96A972F8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7D0897F89C4410ADDCA1F4CA96A972F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5DF96950A1882F53B127F4CA96A926AE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7D0897F89C4410ADDCA1F4CA96A972F8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_D3E1E1D0B7E220F99789F4CA96AA7B95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7D0897F89C4410ADDCA1F4CA96A972F8" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_D3E1E1D0B7E220F99789F4CA96AA7B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5C8A6D74694D7E607A6C5E3B9DDFE13F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5C8A6D74694D7E607A6C5E3B9DDFE13F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7DBD74F48EFFB5BC77C85E3B9DDFC4AC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5C8A6D74694D7E607A6C5E3B9DDFE13F" xlink:to="loc_us-gaap_EquityComponentDomain_7DBD74F48EFFB5BC77C85E3B9DDFC4AC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7DBD74F48EFFB5BC77C85E3B9DDFC4AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5C8A6D74694D7E607A6C5E3B9DDFE13F" xlink:to="loc_us-gaap_EquityComponentDomain_7DBD74F48EFFB5BC77C85E3B9DDFC4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_25D544CD7DD9A26035515E3B9DDF6ED6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7DBD74F48EFFB5BC77C85E3B9DDFC4AC" xlink:to="loc_us-gaap_CommonStockMember_25D544CD7DD9A26035515E3B9DDF6ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:to="loc_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:to="loc_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0805E96978230F2C63C05E3B9DE561EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:to="loc_us-gaap_CommonStockMember_0805E96978230F2C63C05E3B9DE561EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_UnderwrittenOfferingMember" xlink:label="loc_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:to="loc_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_529F042DFCF0CF6E50475E3B9DE73B00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:to="loc_us-gaap_WarrantMember_529F042DFCF0CF6E50475E3B9DE73B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CommonStockVotingRightsForEachShareHeld" xlink:label="loc_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationMilestonePayment" xlink:label="loc_fold_ContingentConsiderationMilestonePayment_60E4D1113AF6FA0EF6665E3B9DE9C5D9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_fold_ContingentConsiderationMilestonePayment_60E4D1113AF6FA0EF6665E3B9DE9C5D9" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MilestonePaymentStockIssuedAsConsideration" xlink:label="loc_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:to="loc_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_71A450859D2E014B13586B8C7486C162_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:to="loc_srt_RangeMember_71A450859D2E014B13586B8C7486C162_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:to="loc_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:to="loc_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:to="loc_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:to="loc_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:to="loc_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" xlink:label="loc_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:to="loc_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:to="loc_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:to="loc_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:to="loc_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:to="loc_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradingSecurities" xlink:label="loc_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:to="loc_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B2322CA7589B6653FA6A06E59B9BCB18" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D3B76C56E1FE671BF48A06E59B9A4BF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B2322CA7589B6653FA6A06E59B9BCB18" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D3B76C56E1FE671BF48A06E59B9A4BF3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_57A64FE6181903DC6E8306E59B9AC67D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D3B76C56E1FE671BF48A06E59B9A4BF3" xlink:to="loc_srt_RangeAxis_57A64FE6181903DC6E8306E59B9AC67D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DCCEDAC04EB6346611E606E59B9A8A33_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_57A64FE6181903DC6E8306E59B9AC67D" xlink:to="loc_srt_RangeMember_DCCEDAC04EB6346611E606E59B9A8A33_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DCCEDAC04EB6346611E606E59B9A8A33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_57A64FE6181903DC6E8306E59B9AC67D" xlink:to="loc_srt_RangeMember_DCCEDAC04EB6346611E606E59B9A8A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5FD4FB4230C9810C691906E59B9B26FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_DCCEDAC04EB6346611E606E59B9A8A33" xlink:to="loc_srt_MinimumMember_5FD4FB4230C9810C691906E59B9B26FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E3510819730789D3F88B06E59B9B824D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_DCCEDAC04EB6346611E606E59B9A8A33" xlink:to="loc_srt_MaximumMember_E3510819730789D3F88B06E59B9B824D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B2322CA7589B6653FA6A06E59B9BCB18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_55077C6D9D5BEA82093B06E59B8C5A39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:to="loc_us-gaap_OperatingLeaseLiability_55077C6D9D5BEA82093B06E59B8C5A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_F81525777F3FB337256E06E59B8C1980" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_F81525777F3FB337256E06E59B8C1980" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:to="loc_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:to="loc_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:to="loc_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_LargestCustomerMember" xlink:label="loc_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:to="loc_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:to="loc_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:to="loc_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:to="loc_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:to="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:to="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_4E07D8A9B2243407B00D8065CB07A2BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:to="loc_country_US_4E07D8A9B2243407B00D8065CB07A2BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:to="loc_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_72FB274570EA9761A0E78065CB07D889" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_72FB274570EA9761A0E78065CB07D889" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>fold-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_9C948231F2FCE62471A9F438F6012495_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_9C948231F2FCE62471A9F438F6012495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_9C948231F2FCE62471A9F438F6012495" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_9C948231F2FCE62471A9F438F6012495" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_9C948231F2FCE62471A9F438F6012495" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0AF5E2C1BA9B1180A014F438F6018D32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0AF5E2C1BA9B1180A014F438F6018D32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0AF5E2C1BA9B1180A014F438F6018D32_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0AF5E2C1BA9B1180A014F438F6018D32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0AF5E2C1BA9B1180A014F438F6018D32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0AF5E2C1BA9B1180A014F438F6018D32" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0AF5E2C1BA9B1180A014F438F6018D32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9BFD9D2DA29C54A25E82F438F60193C2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9BFD9D2DA29C54A25E82F438F60193C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9BFD9D2DA29C54A25E82F438F60193C2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9BFD9D2DA29C54A25E82F438F60193C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9BFD9D2DA29C54A25E82F438F60193C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9BFD9D2DA29C54A25E82F438F60193C2" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9BFD9D2DA29C54A25E82F438F60193C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0D1BBDF68ECC5BB909956B8C7465280E_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_0D1BBDF68ECC5BB909956B8C7465280E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0D1BBDF68ECC5BB909956B8C7465280E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0D1BBDF68ECC5BB909956B8C7465280E" xlink:to="lab_us-gaap_DebtDisclosureAbstract_0D1BBDF68ECC5BB909956B8C7465280E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_DC0D7B9C85E72AB4189A6B8C74655790_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_DC0D7B9C85E72AB4189A6B8C74655790" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_DC0D7B9C85E72AB4189A6B8C74655790_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_DC0D7B9C85E72AB4189A6B8C74655790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_DC0D7B9C85E72AB4189A6B8C74655790" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_DC0D7B9C85E72AB4189A6B8C74655790" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_DC0D7B9C85E72AB4189A6B8C74655790" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_A5319FAE8853E39553E08065C8BB2117_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_A5319FAE8853E39553E08065C8BB2117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A5319FAE8853E39553E08065C8BB2117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A5319FAE8853E39553E08065C8BB2117" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_A5319FAE8853E39553E08065C8BB2117" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant components of the deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:type="arc" />
    <link:label id="lab_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Intellectual Property</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsIntellectualProperty" xlink:label="loc_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B" xlink:to="lab_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_F3CFBFB74070B7C269BA8065C8BCB837_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_F3CFBFB74070B7C269BA8065C8BCB837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization/depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_F3CFBFB74070B7C269BA8065C8BCB837_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_F3CFBFB74070B7C269BA8065C8BCB837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_F3CFBFB74070B7C269BA8065C8BCB837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_F3CFBFB74070B7C269BA8065C8BCB837" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_F3CFBFB74070B7C269BA8065C8BCB837" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_45DE845E20AC28BF38388065C8BDB445_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_45DE845E20AC28BF38388065C8BDB445" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_45DE845E20AC28BF38388065C8BDB445_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_45DE845E20AC28BF38388065C8BDB445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_45DE845E20AC28BF38388065C8BDB445" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_45DE845E20AC28BF38388065C8BDB445" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_45DE845E20AC28BF38388065C8BDB445" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_385EA0D1DE4D7F2A174A8065C8BDD3FA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_385EA0D1DE4D7F2A174A8065C8BDD3FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carry forwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_385EA0D1DE4D7F2A174A8065C8BDD3FA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_385EA0D1DE4D7F2A174A8065C8BDD3FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_385EA0D1DE4D7F2A174A8065C8BDD3FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_385EA0D1DE4D7F2A174A8065C8BDD3FA" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_385EA0D1DE4D7F2A174A8065C8BDD3FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_E515807DFB09F9DDC97B8065C8BDBE72_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_E515807DFB09F9DDC97B8065C8BDBE72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred reimbursement</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_E515807DFB09F9DDC97B8065C8BDBE72_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_E515807DFB09F9DDC97B8065C8BDBE72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_E515807DFB09F9DDC97B8065C8BDBE72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_E515807DFB09F9DDC97B8065C8BDBE72" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_E515807DFB09F9DDC97B8065C8BDBE72" xlink:type="arc" />
    <link:label id="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock issue</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Non Cash Stock Issue Non Current</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carry forwards expected to be realized or consumed within one year or operating cycle, if longer.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:label="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382" xlink:to="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382" xlink:type="arc" />
    <link:label id="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest carry forward limitation</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Interest Carryforward Limitation</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Interest Carryforward Limitation</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:label="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C" xlink:to="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5EAA877063F69CEF6DCE8065C8BD6773_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_5EAA877063F69CEF6DCE8065C8BD6773" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5EAA877063F69CEF6DCE8065C8BD6773_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_5EAA877063F69CEF6DCE8065C8BD6773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5EAA877063F69CEF6DCE8065C8BD6773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_5EAA877063F69CEF6DCE8065C8BD6773" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_5EAA877063F69CEF6DCE8065C8BD6773" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_8707118815911E0A230D8065C8BE1595_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_8707118815911E0A230D8065C8BE1595" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_8707118815911E0A230D8065C8BE1595_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_8707118815911E0A230D8065C8BE1595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8707118815911E0A230D8065C8BE1595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8707118815911E0A230D8065C8BE1595" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_8707118815911E0A230D8065C8BE1595" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:type="arc" />
    <link:label id="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1_negatedLabel_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Business acquisition</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1_label_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Business Acquisition</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1_documentation_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Business Acquisition</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:label="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1" xlink:to="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1" xlink:type="arc" />
    <link:label id="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995_negatedLabel_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Royalty payable</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995_label_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Royalty Payable</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995_documentation_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from royalty payable</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:label="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995" xlink:to="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995" xlink:type="arc" />
    <link:label id="lab_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923_negatedLabel_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923_label_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Convertible Notes</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923_documentation_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax consequences attributable to taxable temporary differences derived from convertible notes.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:label="loc_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923" xlink:to="lab_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923" xlink:type="arc" />
    <link:label id="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF_negatedLabel_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Advanced R&amp;D payments</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF_label_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Advanced Research and Development Payments</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF_documentation_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from advanced Research and Development payments.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" xlink:label="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF" xlink:to="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_CA33709024E87DB02069806E1FA4880A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_CA33709024E87DB02069806E1FA4880A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_CA33709024E87DB02069806E1FA4880A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_CA33709024E87DB02069806E1FA4880A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_CA33709024E87DB02069806E1FA4880A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther_CA33709024E87DB02069806E1FA4880A" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther_CA33709024E87DB02069806E1FA4880A" xlink:type="arc" />
    <link:label id="lab_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4_totalLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net deferred tax assets</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Liabilities Gross</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carry forwards, net of deferred tax liability attributable to taxable temporary differences.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsLiabilitiesGross" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4" xlink:to="lab_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_A91419BBED7D141B6C198065C8BFF5D2_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_A91419BBED7D141B6C198065C8BFF5D2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_A91419BBED7D141B6C198065C8BFF5D2_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_A91419BBED7D141B6C198065C8BFF5D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_A91419BBED7D141B6C198065C8BFF5D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_A91419BBED7D141B6C198065C8BFF5D2" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_A91419BBED7D141B6C198065C8BFF5D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_48422641F5E7333F27848065C8BF438D_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_48422641F5E7333F27848065C8BF438D" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_48422641F5E7333F27848065C8BF438D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_48422641F5E7333F27848065C8BF438D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_48422641F5E7333F27848065C8BF438D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_48422641F5E7333F27848065C8BF438D" xlink:to="lab_us-gaap_DeferredTaxLiabilities_48422641F5E7333F27848065C8BF438D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6F32F3F9FA244DD4F5F58065C8BF2EEA_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6F32F3F9FA244DD4F5F58065C8BF2EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in the valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6F32F3F9FA244DD4F5F58065C8BF2EEA_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6F32F3F9FA244DD4F5F58065C8BF2EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6F32F3F9FA244DD4F5F58065C8BF2EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6F32F3F9FA244DD4F5F58065C8BF2EEA" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6F32F3F9FA244DD4F5F58065C8BF2EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_FA2B3E5FBEEC6A0333AB6B8C73F5AD24_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_FA2B3E5FBEEC6A0333AB6B8C73F5AD24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_FA2B3E5FBEEC6A0333AB6B8C73F5AD24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FA2B3E5FBEEC6A0333AB6B8C73F5AD24" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_FA2B3E5FBEEC6A0333AB6B8C73F5AD24" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_24BA39DC0A59F3CE0E3B6B8C73F5DEC1_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_24BA39DC0A59F3CE0E3B6B8C73F5DEC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_24BA39DC0A59F3CE0E3B6B8C73F5DEC1_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_24BA39DC0A59F3CE0E3B6B8C73F5DEC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_24BA39DC0A59F3CE0E3B6B8C73F5DEC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_24BA39DC0A59F3CE0E3B6B8C73F5DEC1" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_24BA39DC0A59F3CE0E3B6B8C73F5DEC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3A9942225052822466DA6B8C74DECF14_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_3A9942225052822466DA6B8C74DECF14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3A9942225052822466DA6B8C74DECF14_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_3A9942225052822466DA6B8C74DECF14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3A9942225052822466DA6B8C74DECF14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_3A9942225052822466DA6B8C74DECF14" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_3A9942225052822466DA6B8C74DECF14" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_178FF5FE372BEA852CDB6B8C74858507_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_178FF5FE372BEA852CDB6B8C74858507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_178FF5FE372BEA852CDB6B8C74858507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_178FF5FE372BEA852CDB6B8C74858507" xlink:to="lab_us-gaap_EquityAbstract_178FF5FE372BEA852CDB6B8C74858507" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE_label_en-US" xlink:label="lab_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:to="lab_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_71A450859D2E014B13586B8C7486C162_terseLabel_en-US" xlink:label="lab_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_71A450859D2E014B13586B8C7486C162_label_en-US" xlink:label="lab_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:to="lab_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58_label_en-US" xlink:label="lab_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58" xlink:to="lab_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:to="lab_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:to="lab_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:type="arc" />
    <link:label id="lab_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067_terseLabel_en-US" xlink:label="lab_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Plan and 2007 Director Plan</link:label>
    <link:label id="lab_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067_label_en-US" xlink:label="lab_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Plan2007 And Director Option Plan2007 [Member]</link:label>
    <link:label id="lab_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067_documentation_en-US" xlink:label="lab_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the 2007 Plan and the 2007 Director Plan.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" xlink:label="loc_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067" xlink:to="lab_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44_label_en-US" xlink:label="lab_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:to="lab_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7_label_en-US" xlink:label="lab_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:to="lab_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Anniversary</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:to="lab_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:type="arc" />
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F_terseLabel_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F_label_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee And Directors Stock Options [Member]</link:label>
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F_documentation_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F" xlink:to="lab_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation investment</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F_label_en-US" xlink:label="lab_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradingSecurities" xlink:label="loc_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F" xlink:to="lab_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares reserved for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_57851EDB06F2C3C25B5B6B8C754856E7_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_57851EDB06F2C3C25B5B6B8C754856E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_57851EDB06F2C3C25B5B6B8C754856E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_57851EDB06F2C3C25B5B6B8C754856E7" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_57851EDB06F2C3C25B5B6B8C754856E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_F3E42608C13CA8428CB66B8C75482BAB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_F3E42608C13CA8428CB66B8C75482BAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_F3E42608C13CA8428CB66B8C75482BAB_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_F3E42608C13CA8428CB66B8C75482BAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_F3E42608C13CA8428CB66B8C75482BAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_F3E42608C13CA8428CB66B8C75482BAB" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_F3E42608C13CA8428CB66B8C75482BAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_3DC63E24C6ADBDFB8E9FF438F6100726_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_3DC63E24C6ADBDFB8E9FF438F6100726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3DC63E24C6ADBDFB8E9FF438F6100726" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3DC63E24C6ADBDFB8E9FF438F6100726" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_3DC63E24C6ADBDFB8E9FF438F6100726" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:type="arc" />
    <link:label id="lab_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8_terseLabel_en-US" xlink:label="lab_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8_label_en-US" xlink:label="lab_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8_documentation_en-US" xlink:label="lab_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AssetAcquisitionAxis" xlink:label="loc_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:to="lab_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:type="arc" />
    <link:label id="lab_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358_terseLabel_en-US" xlink:label="lab_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358_label_en-US" xlink:label="lab_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358_documentation_en-US" xlink:label="lab_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Asset Acquisition [Axis]</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AssetAcquisitionDomain" xlink:label="loc_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:to="lab_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:type="arc" />
    <link:label id="lab_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E_terseLabel_en-US" xlink:label="lab_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Celenex</link:label>
    <link:label id="lab_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E_label_en-US" xlink:label="lab_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Celenex [Member]</link:label>
    <link:label id="lab_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E_documentation_en-US" xlink:label="lab_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Celenex [Member]</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_CelenexMember" xlink:label="loc_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E" xlink:to="lab_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301_label_en-US" xlink:label="lab_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:to="lab_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160_label_en-US" xlink:label="lab_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:to="lab_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:type="arc" />
    <link:label id="lab_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1_terseLabel_en-US" xlink:label="lab_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nationwide Children's Hospital</link:label>
    <link:label id="lab_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1_label_en-US" xlink:label="lab_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nationwide Children's Hospital [Member]</link:label>
    <link:label id="lab_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1_documentation_en-US" xlink:label="lab_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nationwide Children's Hospital [Member]</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_NationwideChildrensHospitalMember" xlink:label="loc_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1" xlink:to="lab_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:type="arc" />
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical, Regulatory and Commercial milestones</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B_label_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Liability Clinical Regulatory And Commercial Milestones [Member]</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to clinical, regulatory and commercial contingent consideration milestones.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B" xlink:to="lab_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:type="arc" />
    <link:label id="lab_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7_terseLabel_en-US" xlink:label="lab_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MiaMed Inc</link:label>
    <link:label id="lab_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7_label_en-US" xlink:label="lab_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miamed Inc [Member]</link:label>
    <link:label id="lab_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7_documentation_en-US" xlink:label="lab_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to MiaMed Inc.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_MiamedIncMember" xlink:label="loc_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7" xlink:to="lab_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7" xlink:type="arc" />
    <link:label id="lab_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5_terseLabel_en-US" xlink:label="lab_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scioderm</link:label>
    <link:label id="lab_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5_label_en-US" xlink:label="lab_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scioderm Inc [Member]</link:label>
    <link:label id="lab_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5_documentation_en-US" xlink:label="lab_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to Scioderm, Inc.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_SciodermIncMember" xlink:label="loc_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5" xlink:to="lab_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5" xlink:type="arc" />
    <link:label id="lab_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D_terseLabel_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Callidus</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D_label_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Callidus Biopharma Inc [Member]</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D_documentation_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to Callidus Biopharma, Inc.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="loc_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:to="lab_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:to="lab_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:to="lab_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:type="arc" />
    <link:label id="lab_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amicus</link:label>
    <link:label id="lab_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8_label_en-US" xlink:label="lab_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ParentCompanyMember" xlink:label="loc_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8" xlink:to="lab_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:to="lab_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310" xlink:to="lab_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:type="arc" />
    <link:label id="lab_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5_terseLabel_en-US" xlink:label="lab_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5_label_en-US" xlink:label="lab_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Assets [Member]</link:label>
    <link:label id="lab_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5_documentation_en-US" xlink:label="lab_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Assets [Member]</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_FixedAssetsMember" xlink:label="loc_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5" xlink:to="lab_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:type="arc" />
    <link:label id="lab_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4_terseLabel_en-US" xlink:label="lab_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of contingent consideration payable</link:label>
    <link:label id="lab_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4_label_en-US" xlink:label="lab_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Contingent Consideration Payable [Member]</link:label>
    <link:label id="lab_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4_documentation_en-US" xlink:label="lab_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the location on the Statement of Operations, Changes in fair value of contingent consideration payable.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ChangesInFairValueOfContingentConsiderationPayableMember" xlink:label="loc_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4" xlink:to="lab_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:to="lab_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:to="lab_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:type="arc" />
    <link:label id="lab_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E_terseLabel_en-US" xlink:label="lab_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E_label_en-US" xlink:label="lab_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment [Member]</link:label>
    <link:label id="lab_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E_documentation_en-US" xlink:label="lab_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment [Member]</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_MilestonePaymentMember" xlink:label="loc_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E" xlink:to="lab_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:to="lab_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:type="arc" />
    <link:label id="lab_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2_terseLabel_en-US" xlink:label="lab_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of gene therapy programs for neurologic LSDs developed</link:label>
    <link:label id="lab_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2_label_en-US" xlink:label="lab_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Gene Therapy Programs For Neurologic LSDs Developed</link:label>
    <link:label id="lab_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2_documentation_en-US" xlink:label="lab_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Gene Therapy Programs For Neurologic LSDs Developed</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped" xlink:label="loc_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2" xlink:to="lab_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F" xlink:type="arc" />
    <link:label id="lab_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F_terseLabel_en-US" xlink:label="lab_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration based on the achievement of certain milestones</link:label>
    <link:label id="lab_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F_label_en-US" xlink:label="lab_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent On Development</link:label>
    <link:label id="lab_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F_documentation_en-US" xlink:label="lab_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent On Development</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment" xlink:label="loc_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F" xlink:to="lab_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F" xlink:type="arc" />
    <link:label id="lab_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95_terseLabel_en-US" xlink:label="lab_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration based on the achievement of regulatory milestones</link:label>
    <link:label id="lab_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95_label_en-US" xlink:label="lab_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent On Submission And Approval Milestones</link:label>
    <link:label id="lab_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95_documentation_en-US" xlink:label="lab_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent On Submission And Approval Milestones</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones" xlink:label="loc_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95" xlink:to="lab_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95" xlink:type="arc" />
    <link:label id="lab_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14_terseLabel_en-US" xlink:label="lab_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum payment under contingent consideration</link:label>
    <link:label id="lab_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14_label_en-US" xlink:label="lab_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Maximum Expected Payment Over Next Four Years</link:label>
    <link:label id="lab_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14_documentation_en-US" xlink:label="lab_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Maximum Expected Payment Over Next Four Years</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears" xlink:label="loc_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14" xlink:to="lab_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14" xlink:type="arc" />
    <link:label id="lab_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299_terseLabel_en-US" xlink:label="lab_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, total consideration, stock and cash</link:label>
    <link:label id="lab_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299_label_en-US" xlink:label="lab_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:label id="lab_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299_documentation_en-US" xlink:label="lab_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AssetAcquisitionConsiderationTransferred" xlink:label="loc_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299" xlink:to="lab_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299" xlink:type="arc" />
    <link:label id="lab_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B_terseLabel_en-US" xlink:label="lab_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, cash consideration paid</link:label>
    <link:label id="lab_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B_label_en-US" xlink:label="lab_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business Assets</link:label>
    <link:label id="lab_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B_documentation_en-US" xlink:label="lab_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentsToAcquireBusinessAssets" xlink:label="loc_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B" xlink:to="lab_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B" xlink:type="arc" />
    <link:label id="lab_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631_terseLabel_en-US" xlink:label="lab_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration paid in common stock (in shares)</link:label>
    <link:label id="lab_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631_label_en-US" xlink:label="lab_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Asset Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued</link:label>
    <link:label id="lab_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631_documentation_en-US" xlink:label="lab_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of equity interests issued or issuable to acquire entity.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631" xlink:to="lab_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631" xlink:type="arc" />
    <link:label id="lab_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51_terseLabel_en-US" xlink:label="lab_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payable upon achievement of milestones</link:label>
    <link:label id="lab_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51_label_en-US" xlink:label="lab_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Asset Acquisition Contingent Consideration Milestones</link:label>
    <link:label id="lab_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51_documentation_en-US" xlink:label="lab_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of contingent consideration payable in a business asset acquisition upon achievement of certain clinical, regulatory and commercial milestones.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessAssetAcquisitionContingentConsiderationMilestones" xlink:label="loc_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51" xlink:to="lab_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51" xlink:type="arc" />
    <link:label id="lab_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F_terseLabel_en-US" xlink:label="lab_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, potential aggregate deal value</link:label>
    <link:label id="lab_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F_label_en-US" xlink:label="lab_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Asset Acquisition Consideration Transferred Including Milestone Payment</link:label>
    <link:label id="lab_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F_documentation_en-US" xlink:label="lab_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment" xlink:label="loc_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F" xlink:to="lab_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F" xlink:type="arc" />
    <link:label id="lab_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518_terseLabel_en-US" xlink:label="lab_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges to research expense for stock issued in asset acquisition</link:label>
    <link:label id="lab_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518_label_en-US" xlink:label="lab_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Expense For Stock Issuance In Asset Acquisition</link:label>
    <link:label id="lab_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518_documentation_en-US" xlink:label="lab_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of research expense charged to statement of operations for stock issued in assets acquisition transaction.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ResearchExpenseForStockIssuanceInAssetAcquisition" xlink:label="loc_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518" xlink:to="lab_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518" xlink:type="arc" />
    <link:label id="lab_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B_terseLabel_en-US" xlink:label="lab_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enrollment rate</link:label>
    <link:label id="lab_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B_label_en-US" xlink:label="lab_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination of Enrollment Rate</link:label>
    <link:label id="lab_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B_documentation_en-US" xlink:label="lab_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The company enrollment percent achieved during the year.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessCombinationOfEnrollmentRate" xlink:label="loc_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B" xlink:to="lab_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B" xlink:type="arc" />
    <link:label id="lab_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D_label_en-US" xlink:label="lab_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration, Milestone Payment</link:label>
    <link:label id="lab_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of milestone payment.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationMilestonePayment" xlink:label="loc_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D" xlink:to="lab_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss on impairment of assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB" xlink:to="lab_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A" xlink:type="arc" />
    <link:label id="lab_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4_terseLabel_en-US" xlink:label="lab_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling , general and administrative costs due to wind-down</link:label>
    <link:label id="lab_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4_label_en-US" xlink:label="lab_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling , General and Administrative Costs Due to Wind-down</link:label>
    <link:label id="lab_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4_documentation_en-US" xlink:label="lab_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of selling, general and administrative costs due to wind-down of operations.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_SellingGeneralAndAdministrativeCostsDueToWindDown" xlink:label="loc_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4" xlink:to="lab_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4" xlink:type="arc" />
    <link:label id="lab_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809_terseLabel_en-US" xlink:label="lab_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses due to wind-down</link:label>
    <link:label id="lab_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809_label_en-US" xlink:label="lab_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expenses due to wind-down</link:label>
    <link:label id="lab_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809_documentation_en-US" xlink:label="lab_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of research and development expenses due to wind-down of operations.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ResearchAndDevelopmentExpensesDueToWindDown" xlink:label="loc_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809" xlink:to="lab_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809" xlink:type="arc" />
    <link:label id="lab_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7_negatedLabel_en-US" xlink:label="lab_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit due to wind-down</link:label>
    <link:label id="lab_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7_label_en-US" xlink:label="lab_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit) Due To Wind-Down</link:label>
    <link:label id="lab_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7_documentation_en-US" xlink:label="lab_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit) Due To Wind-Down</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_IncomeTaxExpenseBenefitDueToWindDown" xlink:label="loc_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7" xlink:to="lab_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_DC3F1226FCE4EB34CD22F4CA95E34D75_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_DC3F1226FCE4EB34CD22F4CA95E34D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DC3F1226FCE4EB34CD22F4CA95E34D75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DC3F1226FCE4EB34CD22F4CA95E34D75" xlink:to="lab_us-gaap_EarningsPerShareAbstract_DC3F1226FCE4EB34CD22F4CA95E34D75" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_A3FAF63273DD8A670C92F4CA95E413DA_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_A3FAF63273DD8A670C92F4CA95E413DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_A3FAF63273DD8A670C92F4CA95E413DA_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_A3FAF63273DD8A670C92F4CA95E413DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_A3FAF63273DD8A670C92F4CA95E413DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_A3FAF63273DD8A670C92F4CA95E413DA" xlink:to="lab_us-gaap_NetIncomeLossAbstract_A3FAF63273DD8A670C92F4CA95E413DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_A3ED8D3FB28B691BE929F4CA95E44C07_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_A3ED8D3FB28B691BE929F4CA95E44C07" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_A3ED8D3FB28B691BE929F4CA95E44C07_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_A3ED8D3FB28B691BE929F4CA95E44C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A3ED8D3FB28B691BE929F4CA95E44C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_A3ED8D3FB28B691BE929F4CA95E44C07" xlink:to="lab_us-gaap_NetIncomeLoss_A3ED8D3FB28B691BE929F4CA95E44C07" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E2BA7E9CA1F335FB50E4F4CA95E415D1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E2BA7E9CA1F335FB50E4F4CA95E415D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E2BA7E9CA1F335FB50E4F4CA95E415D1_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E2BA7E9CA1F335FB50E4F4CA95E415D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E2BA7E9CA1F335FB50E4F4CA95E415D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E2BA7E9CA1F335FB50E4F4CA95E415D1" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E2BA7E9CA1F335FB50E4F4CA95E415D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1A103E459C8EC2515F04F4CA95E44DB1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1A103E459C8EC2515F04F4CA95E44DB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1A103E459C8EC2515F04F4CA95E44DB1_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1A103E459C8EC2515F04F4CA95E44DB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1A103E459C8EC2515F04F4CA95E44DB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1A103E459C8EC2515F04F4CA95E44DB1" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1A103E459C8EC2515F04F4CA95E44DB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding warrants, convertible to common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375_label_en-US" xlink:label="lab_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375" xlink:to="lab_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916" xlink:type="arc" />
    <link:label id="lab_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9_terseLabel_en-US" xlink:label="lab_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested restricted stock units, unissued</link:label>
    <link:label id="lab_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9_label_en-US" xlink:label="lab_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested Restricted Stock Units Unissued [Member]</link:label>
    <link:label id="lab_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9_documentation_en-US" xlink:label="lab_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent the information pertaining to vested restricted stock units, unissued.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_VestedRestrictedStockUnitsUnissuedMember" xlink:label="loc_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9" xlink:to="lab_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_93963682E9AE17F562BD8065C89DF0D1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_93963682E9AE17F562BD8065C89DF0D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_93963682E9AE17F562BD8065C89DF0D1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_93963682E9AE17F562BD8065C89DF0D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_93963682E9AE17F562BD8065C89DF0D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_93963682E9AE17F562BD8065C89DF0D1" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_93963682E9AE17F562BD8065C89DF0D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9405EBF7A870DF1B69DE8065C89D60D4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9405EBF7A870DF1B69DE8065C89D60D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9405EBF7A870DF1B69DE8065C89D60D4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9405EBF7A870DF1B69DE8065C89D60D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9405EBF7A870DF1B69DE8065C89D60D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9405EBF7A870DF1B69DE8065C89D60D4" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9405EBF7A870DF1B69DE8065C89D60D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_1AC2B8A0BD9E09DB8D8CFE14A08922A0_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_1AC2B8A0BD9E09DB8D8CFE14A08922A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1AC2B8A0BD9E09DB8D8CFE14A08922A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1AC2B8A0BD9E09DB8D8CFE14A08922A0" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_1AC2B8A0BD9E09DB8D8CFE14A08922A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_802D1B1914953E55DD88FE14A0899F02_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_802D1B1914953E55DD88FE14A0899F02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Expenses, and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_802D1B1914953E55DD88FE14A0899F02_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_802D1B1914953E55DD88FE14A0899F02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_802D1B1914953E55DD88FE14A0899F02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_802D1B1914953E55DD88FE14A0899F02" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_802D1B1914953E55DD88FE14A0899F02" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FE4C28BF345F9240B077FE14A0C7AF8A_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FE4C28BF345F9240B077FE14A0C7AF8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FE4C28BF345F9240B077FE14A0C7AF8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FE4C28BF345F9240B077FE14A0C7AF8A" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FE4C28BF345F9240B077FE14A0C7AF8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_BCF71DCCA0ACC9DB6180FE14A0C79F78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_BCF71DCCA0ACC9DB6180FE14A0C79F78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_BCF71DCCA0ACC9DB6180FE14A0C79F78_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_BCF71DCCA0ACC9DB6180FE14A0C79F78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_BCF71DCCA0ACC9DB6180FE14A0C79F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_BCF71DCCA0ACC9DB6180FE14A0C79F78" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_BCF71DCCA0ACC9DB6180FE14A0C79F78" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5A0A0949D7C47646E445FE14A0C7B943_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_5A0A0949D7C47646E445FE14A0C7B943" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5A0A0949D7C47646E445FE14A0C7B943_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_5A0A0949D7C47646E445FE14A0C7B943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_5A0A0949D7C47646E445FE14A0C7B943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_5A0A0949D7C47646E445FE14A0C7B943" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_5A0A0949D7C47646E445FE14A0C7B943" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EFC0EF2EBE9620C4193AF4CA96A99CA0_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EFC0EF2EBE9620C4193AF4CA96A99CA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EFC0EF2EBE9620C4193AF4CA96A99CA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EFC0EF2EBE9620C4193AF4CA96A99CA0" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EFC0EF2EBE9620C4193AF4CA96A99CA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905" xlink:type="arc" />
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected annual dividend per share</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:to="lab_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:to="lab_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:type="arc" />
    <link:label id="lab_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED_terseLabel_en-US" xlink:label="lab_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Offering</link:label>
    <link:label id="lab_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED_label_en-US" xlink:label="lab_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Offering [Member]</link:label>
    <link:label id="lab_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED_documentation_en-US" xlink:label="lab_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwritten Offering [Member]</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_UnderwrittenOfferingMember" xlink:label="loc_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED" xlink:to="lab_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_529F042DFCF0CF6E50475E3B9DE73B00_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_529F042DFCF0CF6E50475E3B9DE73B00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_529F042DFCF0CF6E50475E3B9DE73B00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_529F042DFCF0CF6E50475E3B9DE73B00" xlink:to="lab_us-gaap_WarrantMember_529F042DFCF0CF6E50475E3B9DE73B00" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B_label_en-US" xlink:label="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5" xlink:type="arc" />
    <link:label id="lab_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA_terseLabel_en-US" xlink:label="lab_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voting right for each share held, number</link:label>
    <link:label id="lab_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA_label_en-US" xlink:label="lab_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Voting Rights for Each Share Held</link:label>
    <link:label id="lab_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA_documentation_en-US" xlink:label="lab_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of votes entitled for each share held.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_CommonStockVotingRightsForEachShareHeld" xlink:label="loc_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA" xlink:to="lab_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued from equity financing (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross cash proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from the issuance of common stock after deducting underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C" xlink:type="arc" />
    <link:label id="lab_fold_ContingentConsiderationMilestonePayment_60E4D1113AF6FA0EF6665E3B9DE9C5D9_verboseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationMilestonePayment_60E4D1113AF6FA0EF6665E3B9DE9C5D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration, milestone payment</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationMilestonePayment" xlink:label="loc_fold_ContingentConsiderationMilestonePayment_60E4D1113AF6FA0EF6665E3B9DE9C5D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationMilestonePayment_60E4D1113AF6FA0EF6665E3B9DE9C5D9" xlink:to="lab_fold_ContingentConsiderationMilestonePayment_60E4D1113AF6FA0EF6665E3B9DE9C5D9" xlink:type="arc" />
    <link:label id="lab_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD_terseLabel_en-US" xlink:label="lab_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment, stock issued as consideration</link:label>
    <link:label id="lab_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD_label_en-US" xlink:label="lab_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Stock Issued As Consideration</link:label>
    <link:label id="lab_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD_documentation_en-US" xlink:label="lab_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Stock Issued As Consideration</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_MilestonePaymentStockIssuedAsConsideration" xlink:label="loc_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD" xlink:to="lab_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange agreement, aggregate principal amount</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3" xlink:to="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange agreement, authorized (in shares)</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E" xlink:to="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share of common stock issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5_label_en-US" xlink:label="lab_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5" xlink:to="lab_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_4DC3EE18173CE16E4F42F4CA96E8300D_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_4DC3EE18173CE16E4F42F4CA96E8300D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4DC3EE18173CE16E4F42F4CA96E8300D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4DC3EE18173CE16E4F42F4CA96E8300D" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_4DC3EE18173CE16E4F42F4CA96E8300D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C290E2C643728DB1F995F4CA96E8C241_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C290E2C643728DB1F995F4CA96E8C241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventories for the Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C290E2C643728DB1F995F4CA96E8C241_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C290E2C643728DB1F995F4CA96E8C241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C290E2C643728DB1F995F4CA96E8C241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C290E2C643728DB1F995F4CA96E8C241" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C290E2C643728DB1F995F4CA96E8C241" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47CB1EF6A2D466FFC1AC785A432F8870_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47CB1EF6A2D466FFC1AC785A432F8870" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47CB1EF6A2D466FFC1AC785A432F8870_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47CB1EF6A2D466FFC1AC785A432F8870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47CB1EF6A2D466FFC1AC785A432F8870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47CB1EF6A2D466FFC1AC785A432F8870" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47CB1EF6A2D466FFC1AC785A432F8870" xlink:type="arc" />
    <link:label id="lab_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0_negatedTerseLabel_en-US" xlink:label="lab_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Milestones payable, included in accrued expenses</link:label>
    <link:label id="lab_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0_label_en-US" xlink:label="lab_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payable Accrued During Period</link:label>
    <link:label id="lab_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0_documentation_en-US" xlink:label="lab_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payable Accrued During Period</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_MilestonePayableAccruedDuringPeriod" xlink:label="loc_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0" xlink:to="lab_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_53ED4DD32069164A6F94785A4332608E_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_53ED4DD32069164A6F94785A4332608E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value during the period, included in the Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_53ED4DD32069164A6F94785A4332608E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_53ED4DD32069164A6F94785A4332608E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_53ED4DD32069164A6F94785A4332608E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_53ED4DD32069164A6F94785A4332608E" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_53ED4DD32069164A6F94785A4332608E" xlink:type="arc" />
    <link:label id="lab_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36_negatedLabel_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustment for contingent consideration paid in stock</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36_label_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Paid In Stock, Adjustment</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration Paid In Stock, Adjustment</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationPaidInStockAdjustment" xlink:label="loc_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36" xlink:to="lab_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2E1CC3093D11EDF41792785A433299FB_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2E1CC3093D11EDF41792785A433299FB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2E1CC3093D11EDF41792785A433299FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2E1CC3093D11EDF41792785A433299FB" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2E1CC3093D11EDF41792785A433299FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:to="lab_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED" xlink:to="lab_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:to="lab_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:type="arc" />
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A_terseLabel_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Convertible Notes</link:label>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A_label_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes2016 Due2023 [Member]</link:label>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A_documentation_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes).</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A" xlink:to="lab_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:to="lab_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instruments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instruments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:to="lab_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: deferred financing</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7" xlink:to="lab_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net carrying value of the debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E" xlink:to="lab_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="lab_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseExpense_84FD69ACFCFFEE16348F7882C0667FD0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_84FD69ACFCFFEE16348F7882C0667FD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_84FD69ACFCFFEE16348F7882C0667FD0_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_84FD69ACFCFFEE16348F7882C0667FD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_84FD69ACFCFFEE16348F7882C0667FD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_84FD69ACFCFFEE16348F7882C0667FD0" xlink:to="lab_us-gaap_OperatingLeaseExpense_84FD69ACFCFFEE16348F7882C0667FD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_0601DB451D768DDDC8227882C067C1D4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_0601DB451D768DDDC8227882C067C1D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_0601DB451D768DDDC8227882C067C1D4_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_0601DB451D768DDDC8227882C067C1D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_0601DB451D768DDDC8227882C067C1D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_0601DB451D768DDDC8227882C067C1D4" xlink:to="lab_us-gaap_OperatingLeaseCost_0601DB451D768DDDC8227882C067C1D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_60D3A5EB96491F8240AB7882C067669F_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_60D3A5EB96491F8240AB7882C067669F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_60D3A5EB96491F8240AB7882C067669F_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_60D3A5EB96491F8240AB7882C067669F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_60D3A5EB96491F8240AB7882C067669F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_60D3A5EB96491F8240AB7882C067669F" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_60D3A5EB96491F8240AB7882C067669F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_C18DAC9931528D985FA97882C067E2C6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_C18DAC9931528D985FA97882C067E2C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease ROU asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_C18DAC9931528D985FA97882C067E2C6_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_C18DAC9931528D985FA97882C067E2C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C18DAC9931528D985FA97882C067E2C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_C18DAC9931528D985FA97882C067E2C6" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_C18DAC9931528D985FA97882C067E2C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_FC13FAF7AF7D1BF48F9C7882C067BCD5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_FC13FAF7AF7D1BF48F9C7882C067BCD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of the operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_FC13FAF7AF7D1BF48F9C7882C067BCD5_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_FC13FAF7AF7D1BF48F9C7882C067BCD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_FC13FAF7AF7D1BF48F9C7882C067BCD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_FC13FAF7AF7D1BF48F9C7882C067BCD5" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_FC13FAF7AF7D1BF48F9C7882C067BCD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_F4E25CAC27C1D9D6CEF77882C0677839_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_F4E25CAC27C1D9D6CEF77882C0677839" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of the operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_F4E25CAC27C1D9D6CEF77882C0677839_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_F4E25CAC27C1D9D6CEF77882C0677839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_F4E25CAC27C1D9D6CEF77882C0677839" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_F4E25CAC27C1D9D6CEF77882C0677839" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_F4E25CAC27C1D9D6CEF77882C0677839" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_13069144F9553D3C3FE97882C068E874_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_13069144F9553D3C3FE97882C068E874" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_13069144F9553D3C3FE97882C068E874_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_13069144F9553D3C3FE97882C068E874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_13069144F9553D3C3FE97882C068E874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_13069144F9553D3C3FE97882C068E874" xlink:to="lab_us-gaap_OperatingLeaseLiability_13069144F9553D3C3FE97882C068E874" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9A62DBC7E0B967F832D17882C06809B2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9A62DBC7E0B967F832D17882C06809B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease terms (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9A62DBC7E0B967F832D17882C06809B2_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9A62DBC7E0B967F832D17882C06809B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9A62DBC7E0B967F832D17882C06809B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9A62DBC7E0B967F832D17882C06809B2" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9A62DBC7E0B967F832D17882C06809B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5EFD52D25B09D5497B2E7882C068CB83_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5EFD52D25B09D5497B2E7882C068CB83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5EFD52D25B09D5497B2E7882C068CB83_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5EFD52D25B09D5497B2E7882C068CB83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5EFD52D25B09D5497B2E7882C068CB83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5EFD52D25B09D5497B2E7882C068CB83" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5EFD52D25B09D5497B2E7882C068CB83" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_A1321ABFD78C15539EA17882C06868C4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_A1321ABFD78C15539EA17882C06868C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_A1321ABFD78C15539EA17882C06868C4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_A1321ABFD78C15539EA17882C06868C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_A1321ABFD78C15539EA17882C06868C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_A1321ABFD78C15539EA17882C06868C4" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_A1321ABFD78C15539EA17882C06868C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9670396DD6EECDF787DF7882C069156D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9670396DD6EECDF787DF7882C069156D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9670396DD6EECDF787DF7882C069156D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9670396DD6EECDF787DF7882C069156D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9670396DD6EECDF787DF7882C069156D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9670396DD6EECDF787DF7882C069156D" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9670396DD6EECDF787DF7882C069156D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FA9167DEAB47E8864D647882C0690915_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FA9167DEAB47E8864D647882C0690915" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FA9167DEAB47E8864D647882C0690915_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FA9167DEAB47E8864D647882C0690915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FA9167DEAB47E8864D647882C0690915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FA9167DEAB47E8864D647882C0690915" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FA9167DEAB47E8864D647882C0690915" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CB7DE3BE0A81DCED018E7882C0693B47_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CB7DE3BE0A81DCED018E7882C0693B47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CB7DE3BE0A81DCED018E7882C0693B47_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CB7DE3BE0A81DCED018E7882C0693B47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CB7DE3BE0A81DCED018E7882C0693B47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CB7DE3BE0A81DCED018E7882C0693B47" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CB7DE3BE0A81DCED018E7882C0693B47" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7EA7858A5904B744E1A77882C069B8F7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7EA7858A5904B744E1A77882C069B8F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7EA7858A5904B744E1A77882C069B8F7_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7EA7858A5904B744E1A77882C069B8F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7EA7858A5904B744E1A77882C069B8F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7EA7858A5904B744E1A77882C069B8F7" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7EA7858A5904B744E1A77882C069B8F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4CA263A7974D629C46617882C0694D75_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4CA263A7974D629C46617882C0694D75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4CA263A7974D629C46617882C0694D75_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4CA263A7974D629C46617882C0694D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4CA263A7974D629C46617882C0694D75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4CA263A7974D629C46617882C0694D75" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4CA263A7974D629C46617882C0694D75" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36309D15CD4F85F5451E7882C0696E35_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36309D15CD4F85F5451E7882C0696E35" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36309D15CD4F85F5451E7882C0696E35_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36309D15CD4F85F5451E7882C0696E35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36309D15CD4F85F5451E7882C0696E35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36309D15CD4F85F5451E7882C0696E35" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36309D15CD4F85F5451E7882C0696E35" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37F96170CBD1B9F4D2DF7882C06ABDE8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37F96170CBD1B9F4D2DF7882C06ABDE8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less lease incentives</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37F96170CBD1B9F4D2DF7882C06ABDE8_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37F96170CBD1B9F4D2DF7882C06ABDE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37F96170CBD1B9F4D2DF7882C06ABDE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37F96170CBD1B9F4D2DF7882C06ABDE8" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37F96170CBD1B9F4D2DF7882C06ABDE8" xlink:type="arc" />
    <link:label id="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D_negatedTerseLabel_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D_label_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Incentives</link:label>
    <link:label id="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D_documentation_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Incentives</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:label="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D" xlink:to="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_99F6CCC8147C8ABDDD487882C06A4510_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_99F6CCC8147C8ABDDD487882C06A4510" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_99F6CCC8147C8ABDDD487882C06A4510" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_99F6CCC8147C8ABDDD487882C06A4510" xlink:to="lab_us-gaap_OperatingLeaseLiability_99F6CCC8147C8ABDDD487882C06A4510" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_067B0DC19BF3B955A47D7882C06AE8A6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_067B0DC19BF3B955A47D7882C06AE8A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_067B0DC19BF3B955A47D7882C06AE8A6_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_067B0DC19BF3B955A47D7882C06AE8A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_067B0DC19BF3B955A47D7882C06AE8A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_067B0DC19BF3B955A47D7882C06AE8A6" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_067B0DC19BF3B955A47D7882C06AE8A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1CA4533D7297FEB8C64F7882C06AFFDF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1CA4533D7297FEB8C64F7882C06AFFDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1CA4533D7297FEB8C64F7882C06AFFDF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1CA4533D7297FEB8C64F7882C06AFFDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1CA4533D7297FEB8C64F7882C06AFFDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1CA4533D7297FEB8C64F7882C06AFFDF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1CA4533D7297FEB8C64F7882C06AFFDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_BB61A974338E2BA8B0D77882C06B9C2B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_BB61A974338E2BA8B0D77882C06B9C2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_BB61A974338E2BA8B0D77882C06B9C2B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_BB61A974338E2BA8B0D77882C06B9C2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_BB61A974338E2BA8B0D77882C06B9C2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_BB61A974338E2BA8B0D77882C06B9C2B" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_BB61A974338E2BA8B0D77882C06B9C2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_97A44209FF2D5BFE68677882C06BD7E7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_97A44209FF2D5BFE68677882C06BD7E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_97A44209FF2D5BFE68677882C06BD7E7_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_97A44209FF2D5BFE68677882C06BD7E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_97A44209FF2D5BFE68677882C06BD7E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_97A44209FF2D5BFE68677882C06BD7E7" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_97A44209FF2D5BFE68677882C06BD7E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A62E98682ED82A96C29A7882C06B6A1A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A62E98682ED82A96C29A7882C06B6A1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A62E98682ED82A96C29A7882C06B6A1A_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A62E98682ED82A96C29A7882C06B6A1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A62E98682ED82A96C29A7882C06B6A1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A62E98682ED82A96C29A7882C06B6A1A" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A62E98682ED82A96C29A7882C06B6A1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E91E4056896B05D3FE687882C06BB120_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E91E4056896B05D3FE687882C06BB120" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E91E4056896B05D3FE687882C06BB120_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E91E4056896B05D3FE687882C06BB120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E91E4056896B05D3FE687882C06BB120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E91E4056896B05D3FE687882C06BB120" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E91E4056896B05D3FE687882C06BB120" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1444D304BFBFDD8685467882C06B4B23_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1444D304BFBFDD8685467882C06B4B23" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1444D304BFBFDD8685467882C06B4B23_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1444D304BFBFDD8685467882C06B4B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1444D304BFBFDD8685467882C06B4B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1444D304BFBFDD8685467882C06B4B23" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1444D304BFBFDD8685467882C06B4B23" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_8788DF9F5CEB4F1A05D47882C06B3C4E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_8788DF9F5CEB4F1A05D47882C06B3C4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense, including fees for utilities and common area maintenances</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_8788DF9F5CEB4F1A05D47882C06B3C4E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_8788DF9F5CEB4F1A05D47882C06B3C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_8788DF9F5CEB4F1A05D47882C06B3C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_8788DF9F5CEB4F1A05D47882C06B3C4E" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_8788DF9F5CEB4F1A05D47882C06B3C4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_31A36554131537E30A057882C06C050F_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements_31A36554131537E30A057882C06C050F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvements paid through lease incentive</link:label>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_31A36554131537E30A057882C06C050F_label_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements_31A36554131537E30A057882C06C050F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Tenant Improvements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_31A36554131537E30A057882C06C050F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForTenantImprovements_31A36554131537E30A057882C06C050F" xlink:to="lab_us-gaap_PaymentsForTenantImprovements_31A36554131537E30A057882C06C050F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2060D555856B9A2CA9C95E3E77C3B54D_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2060D555856B9A2CA9C95E3E77C3B54D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2060D555856B9A2CA9C95E3E77C3B54D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2060D555856B9A2CA9C95E3E77C3B54D" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2060D555856B9A2CA9C95E3E77C3B54D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate Information, Status of Operations and Management Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_D9FEFD3B4A7D37B824F15E3E77C5E92C_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_D9FEFD3B4A7D37B824F15E3E77C5E92C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D9FEFD3B4A7D37B824F15E3E77C5E92C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D9FEFD3B4A7D37B824F15E3E77C5E92C" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_D9FEFD3B4A7D37B824F15E3E77C5E92C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_724808BBCDFBA11624315A1076D03736_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_724808BBCDFBA11624315A1076D03736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_724808BBCDFBA11624315A1076D03736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_724808BBCDFBA11624315A1076D03736" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_724808BBCDFBA11624315A1076D03736" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_6ADD8E950120A2116F455A1076D112B4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_6ADD8E950120A2116F455A1076D112B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6ADD8E950120A2116F455A1076D112B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_6ADD8E950120A2116F455A1076D112B4" xlink:to="lab_us-gaap_NetIncomeLoss_6ADD8E950120A2116F455A1076D112B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive gain (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4FE0C452432B0D4510DA5A1076D131D7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4FE0C452432B0D4510DA5A1076D131D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment gain (loss), net of tax impact of $889, $0, and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4FE0C452432B0D4510DA5A1076D131D7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4FE0C452432B0D4510DA5A1076D131D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4FE0C452432B0D4510DA5A1076D131D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4FE0C452432B0D4510DA5A1076D131D7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4FE0C452432B0D4510DA5A1076D131D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_DEDE18FD0B3889F9056B5A1076D188BE_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_DEDE18FD0B3889F9056B5A1076D188BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities, net of tax impact of $182, $0, and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_DEDE18FD0B3889F9056B5A1076D188BE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_DEDE18FD0B3889F9056B5A1076D188BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_DEDE18FD0B3889F9056B5A1076D188BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_DEDE18FD0B3889F9056B5A1076D188BE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_DEDE18FD0B3889F9056B5A1076D188BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_414D937F78AFAF47080D5A1076D229E9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_414D937F78AFAF47080D5A1076D229E9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_414D937F78AFAF47080D5A1076D229E9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_414D937F78AFAF47080D5A1076D229E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_414D937F78AFAF47080D5A1076D229E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_414D937F78AFAF47080D5A1076D229E9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_414D937F78AFAF47080D5A1076D229E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_BFCCCF0E713CBDD49D125A1076D287C0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_BFCCCF0E713CBDD49D125A1076D287C0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_BFCCCF0E713CBDD49D125A1076D287C0_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_BFCCCF0E713CBDD49D125A1076D287C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_BFCCCF0E713CBDD49D125A1076D287C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_BFCCCF0E713CBDD49D125A1076D287C0" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_BFCCCF0E713CBDD49D125A1076D287C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_30D12D6D977D5237EECF06E59B9D7744_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_30D12D6D977D5237EECF06E59B9D7744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_30D12D6D977D5237EECF06E59B9D7744_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_30D12D6D977D5237EECF06E59B9D7744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_30D12D6D977D5237EECF06E59B9D7744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_30D12D6D977D5237EECF06E59B9D7744" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_30D12D6D977D5237EECF06E59B9D7744" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F95E133B6A05E4A71FE6F4CA96E0414D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F95E133B6A05E4A71FE6F4CA96E0414D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F95E133B6A05E4A71FE6F4CA96E0414D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F95E133B6A05E4A71FE6F4CA96E0414D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F95E133B6A05E4A71FE6F4CA96E0414D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_00113CECF71B0ECFF478F4CA96E00DC1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_00113CECF71B0ECFF478F4CA96E00DC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_00113CECF71B0ECFF478F4CA96E00DC1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_00113CECF71B0ECFF478F4CA96E00DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_00113CECF71B0ECFF478F4CA96E00DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_00113CECF71B0ECFF478F4CA96E00DC1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_00113CECF71B0ECFF478F4CA96E00DC1" xlink:type="arc" />
    <link:label id="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971_terseLabel_en-US" xlink:label="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Plan Amended Restated 2007 Equity Incentive Plan</link:label>
    <link:label id="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971_label_en-US" xlink:label="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Plan Amended Restated2007 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971_documentation_en-US" xlink:label="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertaining to the Company's Amended and Restated 2007 Equity Incentive Plan.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971" xlink:to="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971" xlink:type="arc" />
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period following separation for accelerated vesting</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value, options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation costs, period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs vested and non-vested units expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="lab_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9C10CF480A54E3A593748065CB8A511A_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9C10CF480A54E3A593748065CB8A511A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9C10CF480A54E3A593748065CB8A511A_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9C10CF480A54E3A593748065CB8A511A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9C10CF480A54E3A593748065CB8A511A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9C10CF480A54E3A593748065CB8A511A" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9C10CF480A54E3A593748065CB8A511A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_95A8073839D574DE114A8065CB8AD041_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_95A8073839D574DE114A8065CB8AD041" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_95A8073839D574DE114A8065CB8AD041_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_95A8073839D574DE114A8065CB8AD041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_95A8073839D574DE114A8065CB8AD041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_95A8073839D574DE114A8065CB8AD041" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_95A8073839D574DE114A8065CB8AD041" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_9CDE7924F78E5BAC1EBE8065CB8A6DBE_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_9CDE7924F78E5BAC1EBE8065CB8A6DBE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_9CDE7924F78E5BAC1EBE8065CB8A6DBE_label_en-US" xlink:label="lab_us-gaap_GrossProfit_9CDE7924F78E5BAC1EBE8065CB8A6DBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_9CDE7924F78E5BAC1EBE8065CB8A6DBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_9CDE7924F78E5BAC1EBE8065CB8A6DBE" xlink:to="lab_us-gaap_GrossProfit_9CDE7924F78E5BAC1EBE8065CB8A6DBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:to="lab_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_35502A350253563C1CBF8065CB8AD854_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_35502A350253563C1CBF8065CB8AD854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_35502A350253563C1CBF8065CB8AD854_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_35502A350253563C1CBF8065CB8AD854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_35502A350253563C1CBF8065CB8AD854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_35502A350253563C1CBF8065CB8AD854" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_35502A350253563C1CBF8065CB8AD854" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_80205FA659A584FD5C548065CB8B8B68_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_80205FA659A584FD5C548065CB8B8B68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_80205FA659A584FD5C548065CB8B8B68_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_80205FA659A584FD5C548065CB8B8B68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_80205FA659A584FD5C548065CB8B8B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_80205FA659A584FD5C548065CB8B8B68" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_80205FA659A584FD5C548065CB8B8B68" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89AB4C07BBB15FFB6F578065CB8B8973_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89AB4C07BBB15FFB6F578065CB8B8973" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of contingent consideration payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89AB4C07BBB15FFB6F578065CB8B8973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89AB4C07BBB15FFB6F578065CB8B8973" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89AB4C07BBB15FFB6F578065CB8B8973" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_BD60618A1F29110159BA8065CB8B9739_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_BD60618A1F29110159BA8065CB8B9739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_BD60618A1F29110159BA8065CB8B9739_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_BD60618A1F29110159BA8065CB8B9739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_BD60618A1F29110159BA8065CB8B9739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_BD60618A1F29110159BA8065CB8B9739" xlink:to="lab_us-gaap_DepreciationAndAmortization_BD60618A1F29110159BA8065CB8B9739" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_6A91026E3151247916FD8065CB8B0F1D_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_6A91026E3151247916FD8065CB8B0F1D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_6A91026E3151247916FD8065CB8B0F1D_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_6A91026E3151247916FD8065CB8B0F1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_6A91026E3151247916FD8065CB8B0F1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_6A91026E3151247916FD8065CB8B0F1D" xlink:to="lab_us-gaap_OperatingExpenses_6A91026E3151247916FD8065CB8B0F1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_870D3EB4219F9310A5E58065CB8CAB31_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_870D3EB4219F9310A5E58065CB8CAB31" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_870D3EB4219F9310A5E58065CB8CAB31_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_870D3EB4219F9310A5E58065CB8CAB31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_870D3EB4219F9310A5E58065CB8CAB31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_870D3EB4219F9310A5E58065CB8CAB31" xlink:to="lab_us-gaap_OperatingIncomeLoss_870D3EB4219F9310A5E58065CB8CAB31" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expenses):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_D291E90B8FDDD46DD47C8065CB8CA754_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_D291E90B8FDDD46DD47C8065CB8CA754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_D291E90B8FDDD46DD47C8065CB8CA754_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_D291E90B8FDDD46DD47C8065CB8CA754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_D291E90B8FDDD46DD47C8065CB8CA754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_D291E90B8FDDD46DD47C8065CB8CA754" xlink:to="lab_us-gaap_InvestmentIncomeInterest_D291E90B8FDDD46DD47C8065CB8CA754" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_31E77B8F9C42DA6AD6C28065CB8C24E3_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_31E77B8F9C42DA6AD6C28065CB8C24E3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_31E77B8F9C42DA6AD6C28065CB8C24E3_label_en-US" xlink:label="lab_us-gaap_InterestExpense_31E77B8F9C42DA6AD6C28065CB8C24E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_31E77B8F9C42DA6AD6C28065CB8C24E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_31E77B8F9C42DA6AD6C28065CB8C24E3" xlink:to="lab_us-gaap_InterestExpense_31E77B8F9C42DA6AD6C28065CB8C24E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_D5B4BA328C02AA54E1AB8065CB8CFAF8_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_D5B4BA328C02AA54E1AB8065CB8CFAF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on exchange of convertible notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_D5B4BA328C02AA54E1AB8065CB8CFAF8_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_D5B4BA328C02AA54E1AB8065CB8CFAF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D5B4BA328C02AA54E1AB8065CB8CFAF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D5B4BA328C02AA54E1AB8065CB8CFAF8" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_D5B4BA328C02AA54E1AB8065CB8CFAF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_854C11095B13B0007D2D8065CB8D9F09_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_854C11095B13B0007D2D8065CB8D9F09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivatives</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_854C11095B13B0007D2D8065CB8D9F09_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_854C11095B13B0007D2D8065CB8D9F09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_854C11095B13B0007D2D8065CB8D9F09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_854C11095B13B0007D2D8065CB8D9F09" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_854C11095B13B0007D2D8065CB8D9F09" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_69292D82C7EF1F7D79918065CB8D69C4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_69292D82C7EF1F7D79918065CB8D69C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_69292D82C7EF1F7D79918065CB8D69C4_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_69292D82C7EF1F7D79918065CB8D69C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_69292D82C7EF1F7D79918065CB8D69C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_69292D82C7EF1F7D79918065CB8D69C4" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_69292D82C7EF1F7D79918065CB8D69C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6F39E8ED534B8E681E598065CB8D29CA_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6F39E8ED534B8E681E598065CB8D29CA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6F39E8ED534B8E681E598065CB8D29CA_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6F39E8ED534B8E681E598065CB8D29CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6F39E8ED534B8E681E598065CB8D29CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6F39E8ED534B8E681E598065CB8D29CA" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6F39E8ED534B8E681E598065CB8D29CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_07BE433BEA627B68671E8065CB8DD25D_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_07BE433BEA627B68671E8065CB8DD25D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_07BE433BEA627B68671E8065CB8DD25D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_07BE433BEA627B68671E8065CB8DD25D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_07BE433BEA627B68671E8065CB8DD25D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_07BE433BEA627B68671E8065CB8DD25D" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_07BE433BEA627B68671E8065CB8DD25D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_11494C532F9F977AAEC28065CB8DFC59_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_11494C532F9F977AAEC28065CB8DFC59" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_11494C532F9F977AAEC28065CB8DFC59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_11494C532F9F977AAEC28065CB8DFC59" xlink:to="lab_us-gaap_NetIncomeLoss_11494C532F9F977AAEC28065CB8DFC59" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_AB66654B1B021B9450738065CB8DCEC8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_AB66654B1B021B9450738065CB8DCEC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_AB66654B1B021B9450738065CB8DCEC8_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_AB66654B1B021B9450738065CB8DCEC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_AB66654B1B021B9450738065CB8DCEC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_AB66654B1B021B9450738065CB8DCEC8" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_AB66654B1B021B9450738065CB8DCEC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FE0A4F646C105458497B6B8C73D538E7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FE0A4F646C105458497B6B8C73D538E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FE0A4F646C105458497B6B8C73D538E7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FE0A4F646C105458497B6B8C73D538E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FE0A4F646C105458497B6B8C73D538E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FE0A4F646C105458497B6B8C73D538E7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FE0A4F646C105458497B6B8C73D538E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_22B3E78AD388CD684FF28065C8CBB6BA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_22B3E78AD388CD684FF28065C8CBB6BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_22B3E78AD388CD684FF28065C8CBB6BA_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_22B3E78AD388CD684FF28065C8CBB6BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_22B3E78AD388CD684FF28065C8CBB6BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_22B3E78AD388CD684FF28065C8CBB6BA" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_22B3E78AD388CD684FF28065C8CBB6BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9663C877623F15AA582E8065C8CBC05C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9663C877623F15AA582E8065C8CBC05C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9663C877623F15AA582E8065C8CBC05C_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9663C877623F15AA582E8065C8CBC05C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9663C877623F15AA582E8065C8CBC05C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9663C877623F15AA582E8065C8CBC05C" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9663C877623F15AA582E8065C8CBC05C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_E0CDC6F990D16873397B8065C8CC1769_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_E0CDC6F990D16873397B8065C8CC1769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_E0CDC6F990D16873397B8065C8CC1769_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_E0CDC6F990D16873397B8065C8CC1769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_E0CDC6F990D16873397B8065C8CC1769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_E0CDC6F990D16873397B8065C8CC1769" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_E0CDC6F990D16873397B8065C8CC1769" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BE36FCB073F1D571D34E8065C8CC8DD4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BE36FCB073F1D571D34E8065C8CC8DD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BE36FCB073F1D571D34E8065C8CC8DD4_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BE36FCB073F1D571D34E8065C8CC8DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BE36FCB073F1D571D34E8065C8CC8DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BE36FCB073F1D571D34E8065C8CC8DD4" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BE36FCB073F1D571D34E8065C8CC8DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9B544C962E1E39FD41058065C8CCFDF3_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9B544C962E1E39FD41058065C8CCFDF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9B544C962E1E39FD41058065C8CCFDF3_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9B544C962E1E39FD41058065C8CCFDF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9B544C962E1E39FD41058065C8CCFDF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9B544C962E1E39FD41058065C8CCFDF3" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9B544C962E1E39FD41058065C8CCFDF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_42F7EF9887EED9B79B068065C8CC5670_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_42F7EF9887EED9B79B068065C8CC5670" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_42F7EF9887EED9B79B068065C8CC5670_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_42F7EF9887EED9B79B068065C8CC5670" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_42F7EF9887EED9B79B068065C8CC5670" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_42F7EF9887EED9B79B068065C8CC5670" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_42F7EF9887EED9B79B068065C8CC5670" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_AB72D7831A698793F4208065C8CD9EE9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_AB72D7831A698793F4208065C8CD9EE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_AB72D7831A698793F4208065C8CD9EE9_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_AB72D7831A698793F4208065C8CD9EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_AB72D7831A698793F4208065C8CD9EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_AB72D7831A698793F4208065C8CD9EE9" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_AB72D7831A698793F4208065C8CD9EE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_F6C74DDC67A6EA2F0F368065C8CDEF0E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_F6C74DDC67A6EA2F0F368065C8CDEF0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_F6C74DDC67A6EA2F0F368065C8CDEF0E_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_F6C74DDC67A6EA2F0F368065C8CDEF0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_F6C74DDC67A6EA2F0F368065C8CDEF0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_F6C74DDC67A6EA2F0F368065C8CDEF0E" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_F6C74DDC67A6EA2F0F368065C8CDEF0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E102AC54DBB02887DBB48065C8CDA51E_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E102AC54DBB02887DBB48065C8CDA51E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E102AC54DBB02887DBB48065C8CDA51E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E102AC54DBB02887DBB48065C8CDA51E" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E102AC54DBB02887DBB48065C8CDA51E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the statutory tax rates and the effective tax rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2AFC149E8CFED70449D28065C8CDACCE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2AFC149E8CFED70449D28065C8CDACCE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2AFC149E8CFED70449D28065C8CDACCE_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2AFC149E8CFED70449D28065C8CDACCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2AFC149E8CFED70449D28065C8CDACCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2AFC149E8CFED70449D28065C8CDACCE" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2AFC149E8CFED70449D28065C8CDACCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_75CBCF60F3178A07B4168065C8CE4F17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_75CBCF60F3178A07B4168065C8CE4F17" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_75CBCF60F3178A07B4168065C8CE4F17_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_75CBCF60F3178A07B4168065C8CE4F17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_75CBCF60F3178A07B4168065C8CE4F17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_75CBCF60F3178A07B4168065C8CE4F17" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_75CBCF60F3178A07B4168065C8CE4F17" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_F3A68A94FBE97CECD85D8065C8CE85ED_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_F3A68A94FBE97CECD85D8065C8CE85ED" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Nondeductible IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_F3A68A94FBE97CECD85D8065C8CE85ED_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_F3A68A94FBE97CECD85D8065C8CE85ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_F3A68A94FBE97CECD85D8065C8CE85ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_F3A68A94FBE97CECD85D8065C8CE85ED" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_F3A68A94FBE97CECD85D8065C8CE85ED" xlink:type="arc" />
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB_negatedTerseLabel_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB_label_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB_documentation_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of contingent consideration.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB" xlink:to="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1879FC0ABC27641C90418065C8CE78BF_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1879FC0ABC27641C90418065C8CE78BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1879FC0ABC27641C90418065C8CE78BF_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1879FC0ABC27641C90418065C8CE78BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1879FC0ABC27641C90418065C8CE78BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1879FC0ABC27641C90418065C8CE78BF" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1879FC0ABC27641C90418065C8CE78BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5A431CECDBD0B100781F8065C8CEE55C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5A431CECDBD0B100781F8065C8CEE55C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign income tax rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5A431CECDBD0B100781F8065C8CEE55C_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5A431CECDBD0B100781F8065C8CEE55C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5A431CECDBD0B100781F8065C8CEE55C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5A431CECDBD0B100781F8065C8CEE55C" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5A431CECDBD0B100781F8065C8CEE55C" xlink:type="arc" />
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F_negatedTerseLabel_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of 2017 Act</link:label>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F_label_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Impact of 2017 Act, Percent</link:label>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F_documentation_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impact of 2017 Act.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F" xlink:to="lab_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F" xlink:type="arc" />
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF_negatedTerseLabel_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Nondeductible debt conversion</link:label>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF_label_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Conversion</link:label>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF_documentation_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Conversion</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF" xlink:to="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_F6A01EC7DEF9FA5DD81F8065C8CE801A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_F6A01EC7DEF9FA5DD81F8065C8CE801A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_F6A01EC7DEF9FA5DD81F8065C8CE801A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_F6A01EC7DEF9FA5DD81F8065C8CE801A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_F6A01EC7DEF9FA5DD81F8065C8CE801A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_F6A01EC7DEF9FA5DD81F8065C8CE801A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_F6A01EC7DEF9FA5DD81F8065C8CE801A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_FE52A7D803D05B691CA68065C8CFAF68_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_FE52A7D803D05B691CA68065C8CFAF68" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_FE52A7D803D05B691CA68065C8CFAF68_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_FE52A7D803D05B691CA68065C8CFAF68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_FE52A7D803D05B691CA68065C8CFAF68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_FE52A7D803D05B691CA68065C8CFAF68" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_FE52A7D803D05B691CA68065C8CFAF68" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BC3CA7218F9729C7D3F38065C8CF8AA1_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BC3CA7218F9729C7D3F38065C8CF8AA1" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BC3CA7218F9729C7D3F38065C8CF8AA1_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BC3CA7218F9729C7D3F38065C8CF8AA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BC3CA7218F9729C7D3F38065C8CF8AA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BC3CA7218F9729C7D3F38065C8CF8AA1" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BC3CA7218F9729C7D3F38065C8CF8AA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ED212A189A6E48E97F8F8065C8CF1464_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ED212A189A6E48E97F8F8065C8CF1464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual for interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ED212A189A6E48E97F8F8065C8CF1464_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ED212A189A6E48E97F8F8065C8CF1464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ED212A189A6E48E97F8F8065C8CF1464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ED212A189A6E48E97F8F8065C8CF1464" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ED212A189A6E48E97F8F8065C8CF1464" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_337695229C5387CA06998065C8CF36A1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_337695229C5387CA06998065C8CF36A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual for uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_337695229C5387CA06998065C8CF36A1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_337695229C5387CA06998065C8CF36A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_337695229C5387CA06998065C8CF36A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_337695229C5387CA06998065C8CF36A1" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_337695229C5387CA06998065C8CF36A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_84B4305CBDE7345936E78065C8CF1802_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_84B4305CBDE7345936E78065C8CF1802" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current federal and state tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_84B4305CBDE7345936E78065C8CF1802_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_84B4305CBDE7345936E78065C8CF1802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_84B4305CBDE7345936E78065C8CF1802" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_84B4305CBDE7345936E78065C8CF1802" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_84B4305CBDE7345936E78065C8CF1802" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_211266F442E1B4E174FF8065CB717821_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_211266F442E1B4E174FF8065CB717821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_211266F442E1B4E174FF8065CB717821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_211266F442E1B4E174FF8065CB717821" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_211266F442E1B4E174FF8065CB717821" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F_label_en-US" xlink:label="lab_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:to="lab_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0" xlink:to="lab_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23" xlink:to="lab_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:to="lab_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8" xlink:to="lab_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued from exercise of stock options, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued from exercise of stock options, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34_positiveLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US">Stock issued from equity financing</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock tax vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock tax vesting</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF" xlink:type="arc" />
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for contingent consideration (in shares)</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Contingent Consideration</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Contingent Consideration</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:label="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305" xlink:to="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305" xlink:type="arc" />
    <link:label id="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for contingent consideration</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Contingent Consideration</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Contingent Consideration</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33" xlink:to="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification upon ASU 2018-02 adoption</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2" xlink:type="arc" />
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents Stock issued from exercise of warrants (in shares).</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8" xlink:to="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8" xlink:type="arc" />
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents Stock issued from exercise of warrants.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D" xlink:to="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of the convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of the convertible notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5" xlink:type="arc" />
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C_terseLabel_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivatives</link:label>
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C_label_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid-In Capital, Change In Fair Value Of Derivatives</link:label>
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C_documentation_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid-In Capital, Change In Fair Value Of Derivatives</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C" xlink:to="lab_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C" xlink:type="arc" />
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0_terseLabel_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination of capped call confirmations</link:label>
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0_label_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations</link:label>
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0_documentation_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from Termination of Capped Call Confirmations.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0" xlink:to="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_FB46E4422C8F95F5A3818065CB769B50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_FB46E4422C8F95F5A3818065CB769B50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding loss on available-for-sale securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_FB46E4422C8F95F5A3818065CB769B50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_FB46E4422C8F95F5A3818065CB769B50" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_FB46E4422C8F95F5A3818065CB769B50" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_90BC437A239F698485D38065CB76CAB4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_90BC437A239F698485D38065CB76CAB4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_90BC437A239F698485D38065CB76CAB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_90BC437A239F698485D38065CB76CAB4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_90BC437A239F698485D38065CB76CAB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1BC8AA90569BE8E362318065CB77111E_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1BC8AA90569BE8E362318065CB77111E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1BC8AA90569BE8E362318065CB77111E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_1BC8AA90569BE8E362318065CB77111E" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1BC8AA90569BE8E362318065CB77111E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_A2278ACA94E9B86F831D8065CB772D92_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A2278ACA94E9B86F831D8065CB772D92" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A2278ACA94E9B86F831D8065CB772D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_A2278ACA94E9B86F831D8065CB772D92" xlink:to="lab_us-gaap_StockholdersEquity_A2278ACA94E9B86F831D8065CB772D92" xlink:type="arc" />
    <link:label id="lab_fold_CollaborativeArrangementDisclosureAbstract_BE17BBE1FCDFE296D7865AE6059ADE40_label_en-US" xlink:label="lab_fold_CollaborativeArrangementDisclosureAbstract_BE17BBE1FCDFE296D7865AE6059ADE40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_fold_CollaborativeArrangementDisclosureAbstract_BE17BBE1FCDFE296D7865AE6059ADE40_documentation_en-US" xlink:label="lab_fold_CollaborativeArrangementDisclosureAbstract_BE17BBE1FCDFE296D7865AE6059ADE40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborativeArrangementDisclosureAbstract" xlink:label="loc_fold_CollaborativeArrangementDisclosureAbstract_BE17BBE1FCDFE296D7865AE6059ADE40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborativeArrangementDisclosureAbstract_BE17BBE1FCDFE296D7865AE6059ADE40" xlink:to="lab_fold_CollaborativeArrangementDisclosureAbstract_BE17BBE1FCDFE296D7865AE6059ADE40" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:to="lab_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710" xlink:to="lab_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710" xlink:type="arc" />
    <link:label id="lab_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610_terseLabel_en-US" xlink:label="lab_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revised Agreement</link:label>
    <link:label id="lab_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610_label_en-US" xlink:label="lab_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revised Collaboration Agreement [Member]</link:label>
    <link:label id="lab_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610_documentation_en-US" xlink:label="lab_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the License and Collaboration Agreement entered into by the entity on November 19, 2013.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_RevisedCollaborationAgreementMember" xlink:label="loc_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610" xlink:to="lab_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610" xlink:type="arc" />
    <link:label id="lab_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09_terseLabel_en-US" xlink:label="lab_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09_label_en-US" xlink:label="lab_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline P L C [Member]</link:label>
    <link:label id="lab_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09_documentation_en-US" xlink:label="lab_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Glaxo Group Limited, an affiliate of GlaxoSmithKline PLC (GSK).</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_GlaxoSmithKlinePLCMember" xlink:label="loc_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09" xlink:to="lab_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09" xlink:type="arc" />
    <link:label id="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059_terseLabel_en-US" xlink:label="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conditional aggregate payments per indication</link:label>
    <link:label id="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059_label_en-US" xlink:label="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Conditional Aggregate Payments Per Indication</link:label>
    <link:label id="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059_documentation_en-US" xlink:label="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Conditional Aggregate Payments Per Indication</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:label="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059" xlink:to="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059" xlink:type="arc" />
    <link:label id="lab_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A_terseLabel_en-US" xlink:label="lab_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Discovery Program Fee</link:label>
    <link:label id="lab_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A_label_en-US" xlink:label="lab_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Annual Contribution By Company</link:label>
    <link:label id="lab_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A_documentation_en-US" xlink:label="lab_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Annual Contribution By Company</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborationAgreementAnnualContributionByCompany" xlink:label="loc_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A" xlink:to="lab_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A" xlink:type="arc" />
    <link:label id="lab_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7_terseLabel_en-US" xlink:label="lab_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for collaborative agreement</link:label>
    <link:label id="lab_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7_label_en-US" xlink:label="lab_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Collaborative Arrangement</link:label>
    <link:label id="lab_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7_documentation_en-US" xlink:label="lab_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Collaborative Arrangement</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentsForCollaborativeArrangement" xlink:label="loc_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7" xlink:to="lab_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7" xlink:type="arc" />
    <link:label id="lab_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4_terseLabel_en-US" xlink:label="lab_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payments for collaborative arrangement</link:label>
    <link:label id="lab_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4_label_en-US" xlink:label="lab_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Payments For Collaborative Arrangement</link:label>
    <link:label id="lab_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4_documentation_en-US" xlink:label="lab_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Payments For Collaborative Arrangement</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedPaymentsForCollaborativeArrangement" xlink:label="loc_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4" xlink:to="lab_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC" xlink:type="arc" />
    <link:label id="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0_terseLabel_en-US" xlink:label="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments upon achievement of post-approval and sales-based milestones</link:label>
    <link:label id="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0_label_en-US" xlink:label="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Achievement of Post Approval and Sales Based Milestones Potential Payments</link:label>
    <link:label id="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0_documentation_en-US" xlink:label="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:label="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0" xlink:to="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0" xlink:type="arc" />
    <link:label id="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D_terseLabel_en-US" xlink:label="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones</link:label>
    <link:label id="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D_label_en-US" xlink:label="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Major Markets Outside United States from Whom Parties to Contractual Arrangement is Eligible to Receive Post Approval and Sales Based Milestones</link:label>
    <link:label id="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D_documentation_en-US" xlink:label="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:label="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D" xlink:to="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6C32BBAB621D4ACA0E0A5AE6059EA3F4_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6C32BBAB621D4ACA0E0A5AE6059EA3F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6C32BBAB621D4ACA0E0A5AE6059EA3F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6C32BBAB621D4ACA0E0A5AE6059EA3F4" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6C32BBAB621D4ACA0E0A5AE6059EA3F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Credits and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses, and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_F4EBE52986F50E6091D9F034C1597E12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_F4EBE52986F50E6091D9F034C1597E12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation gain (loss), tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_F4EBE52986F50E6091D9F034C1597E12_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_F4EBE52986F50E6091D9F034C1597E12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_F4EBE52986F50E6091D9F034C1597E12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_F4EBE52986F50E6091D9F034C1597E12" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_F4EBE52986F50E6091D9F034C1597E12" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_BC8C52C48083640E5578F0A2B5F826BE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_BC8C52C48083640E5578F0A2B5F826BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_BC8C52C48083640E5578F0A2B5F826BE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_BC8C52C48083640E5578F0A2B5F826BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_BC8C52C48083640E5578F0A2B5F826BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_BC8C52C48083640E5578F0A2B5F826BE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_BC8C52C48083640E5578F0A2B5F826BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_C6FB7BC0D37DC8CE0A690F0C2273203F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_C6FB7BC0D37DC8CE0A690F0C2273203F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_C6FB7BC0D37DC8CE0A690F0C2273203F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_C6FB7BC0D37DC8CE0A690F0C2273203F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_C6FB7BC0D37DC8CE0A690F0C2273203F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_C6FB7BC0D37DC8CE0A690F0C2273203F" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_C6FB7BC0D37DC8CE0A690F0C2273203F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:type="arc" />
    <link:label id="lab_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844_terseLabel_en-US" xlink:label="lab_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization, operating lease right-of-use assets</link:label>
    <link:label id="lab_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844_label_en-US" xlink:label="lab_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Operating Right-Of-Use Leases</link:label>
    <link:label id="lab_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844_documentation_en-US" xlink:label="lab_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Operating Right-Of-Use Leases</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AccumulatedDepreciationOperatingRightOfUseLeases" xlink:label="loc_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844" xlink:to="lab_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29311DB3AC16197F6B670F0C23EA285B_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29311DB3AC16197F6B670F0C23EA285B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29311DB3AC16197F6B670F0C23EA285B_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29311DB3AC16197F6B670F0C23EA285B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29311DB3AC16197F6B670F0C23EA285B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29311DB3AC16197F6B670F0C23EA285B" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29311DB3AC16197F6B670F0C23EA285B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_960D468863072E76E1E60F0C23EA468F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_960D468863072E76E1E60F0C23EA468F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_960D468863072E76E1E60F0C23EA468F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_960D468863072E76E1E60F0C23EA468F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_960D468863072E76E1E60F0C23EA468F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_960D468863072E76E1E60F0C23EA468F" xlink:to="lab_us-gaap_CommonStockSharesIssued_960D468863072E76E1E60F0C23EA468F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_45930812871761CA9F3F0F0C23EA6DB9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_45930812871761CA9F3F0F0C23EA6DB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_45930812871761CA9F3F0F0C23EA6DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_45930812871761CA9F3F0F0C23EA6DB9" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_45930812871761CA9F3F0F0C23EA6DB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_925B57E706D6B482DF2D6B8C7632E303_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_925B57E706D6B482DF2D6B8C7632E303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_925B57E706D6B482DF2D6B8C7632E303_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_925B57E706D6B482DF2D6B8C7632E303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_925B57E706D6B482DF2D6B8C7632E303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_925B57E706D6B482DF2D6B8C7632E303" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_925B57E706D6B482DF2D6B8C7632E303" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_035649593555A0C87F496B8C74FBFDC6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_035649593555A0C87F496B8C74FBFDC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_035649593555A0C87F496B8C74FBFDC6_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_035649593555A0C87F496B8C74FBFDC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_035649593555A0C87F496B8C74FBFDC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_035649593555A0C87F496B8C74FBFDC6" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_035649593555A0C87F496B8C74FBFDC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:to="lab_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:to="lab_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590" xlink:to="lab_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:to="lab_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:to="lab_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE" xlink:to="lab_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED" xlink:to="lab_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED" xlink:type="arc" />
    <link:label id="lab_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0_terseLabel_en-US" xlink:label="lab_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement Purchase Agreement</link:label>
    <link:label id="lab_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0_label_en-US" xlink:label="lab_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Purchase Agreement [Member]</link:label>
    <link:label id="lab_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0_documentation_en-US" xlink:label="lab_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to private placement purchase agreements.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="loc_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0" xlink:to="lab_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE_label_en-US" xlink:label="lab_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE" xlink:to="lab_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:to="lab_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:type="arc" />
    <link:label id="lab_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8_terseLabel_en-US" xlink:label="lab_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Capped Call Confirmation</link:label>
    <link:label id="lab_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8_label_en-US" xlink:label="lab_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capped Call Confirmation [Member]</link:label>
    <link:label id="lab_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8_documentation_en-US" xlink:label="lab_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Capped Call Confirmation [Member]</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_CommonStockCappedCallConfirmationMember" xlink:label="loc_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8" xlink:to="lab_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="lab_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New credit facility borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2" xlink:to="lab_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Periodic payment, percentage</link:label>
    <link:label id="lab_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324_label_en-US" xlink:label="lab_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal Percentage</link:label>
    <link:label id="lab_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324_documentation_en-US" xlink:label="lab_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal Percentage</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentPeriodicPaymentPrincipalPercentage" xlink:label="loc_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324" xlink:to="lab_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds after deducting fees and estimated expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1" xlink:type="arc" />
    <link:label id="lab_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124_terseLabel_en-US" xlink:label="lab_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds for capped call confirmations</link:label>
    <link:label id="lab_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124_label_en-US" xlink:label="lab_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premiums Paid for Capped Call Confirmations</link:label>
    <link:label id="lab_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124_documentation_en-US" xlink:label="lab_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow for premiums paid for capped call confirmations.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_PremiumsPaidForCappedCallConfirmations" xlink:label="loc_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124" xlink:to="lab_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124" xlink:type="arc" />
    <link:label id="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80_terseLabel_en-US" xlink:label="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued per increment of convertible debt (in shares)</link:label>
    <link:label id="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80_label_en-US" xlink:label="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued Per Increment Of Convertible Debt</link:label>
    <link:label id="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80_documentation_en-US" xlink:label="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of shares per increment of convertible debt that will be issued upon conversion. For example, X number of shares may be issued for every $1,000 of convertible debt principal.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:label="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80" xlink:to="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion ratio (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75_label_en-US" xlink:label="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instruments, Convertible, Threshold Trading Days</link:label>
    <link:label id="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75_documentation_en-US" xlink:label="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:label="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75" xlink:to="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period following 5 consecutive trading day period, trading price less than 98% of product of sales price</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Period Following Five Consecutive Trading Day Period, Trading Price Less Than Ninety-Eight Percent Of Product Of Sales Price</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Period Following Five Consecutive Trading Day Period, Trading Price Less Than Ninety-Eight Percent Of Product Of Sales Price</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice" xlink:label="loc_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F" xlink:to="lab_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period following issuance of stock rights options or warrants with price per share less than last reported sales price</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Restriction, Period Following Issuance Of Stock Rights Options Or Warrants With Price Per Share Less Than Last Reported Sales Price</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Restriction, Period Following Issuance Of Stock Rights Options Or Warrants With Price Per Share Less Than Last Reported Sales Price</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice" xlink:label="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC" xlink:to="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for measurement of sales price</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Restriction, Period For Measurement Of Sales Price</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Restriction, Period For Measurement Of Sales Price</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice" xlink:label="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6" xlink:to="lab_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess of value per share for triggering event, percent</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Restriction, Excess Of Value Per Share For Triggering Event, Percent</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Restriction, Excess Of Value Per Share For Triggering Event, Percent</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent" xlink:label="loc_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B" xlink:to="lab_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42FCE10AAA89FC2C82CF5A1074D6FFFC_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42FCE10AAA89FC2C82CF5A1074D6FFFC" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Common stock issued from underwriting agreement (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42FCE10AAA89FC2C82CF5A1074D6FFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42FCE10AAA89FC2C82CF5A1074D6FFFC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42FCE10AAA89FC2C82CF5A1074D6FFFC" xlink:type="arc" />
    <link:label id="lab_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979_verboseLabel_en-US" xlink:label="lab_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of days granted underwriters for purchase of shares</link:label>
    <link:label id="lab_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979_label_en-US" xlink:label="lab_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Days Granted Underwriters For Purchase Of Shares</link:label>
    <link:label id="lab_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979_documentation_en-US" xlink:label="lab_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Days Granted Underwriters For Purchase Of Shares</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares" xlink:label="loc_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979" xlink:to="lab_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979" xlink:type="arc" />
    <link:label id="lab_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21_verboseLabel_en-US" xlink:label="lab_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of additional shares granted to underwriters (in shares)</link:label>
    <link:label id="lab_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21_label_en-US" xlink:label="lab_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Number Of Additional Shares Granted To Underwriters</link:label>
    <link:label id="lab_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21_documentation_en-US" xlink:label="lab_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Number Of Additional Shares Granted To Underwriters</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters" xlink:label="loc_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21" xlink:to="lab_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivatives</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and unpaid interest on exchange agreement</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9" xlink:to="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9" xlink:type="arc" />
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20_terseLabel_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on extinguishment of debt, additional paid-in capital</link:label>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20_label_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Additional Paid-In Capital</link:label>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20_documentation_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Additional Paid-In Capital</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20" xlink:to="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20" xlink:type="arc" />
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66_terseLabel_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on extinguishment of debt, fair value of common shares issued</link:label>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66_label_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued</link:label>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66_documentation_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66" xlink:to="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9DB44D7A085092D4D9035A1074D890C7_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9DB44D7A085092D4D9035A1074D890C7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on exchange of convertible debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9DB44D7A085092D4D9035A1074D890C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9DB44D7A085092D4D9035A1074D890C7" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9DB44D7A085092D4D9035A1074D890C7" xlink:type="arc" />
    <link:label id="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C_terseLabel_en-US" xlink:label="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from capped call confirmations, exchange of convertible debt</link:label>
    <link:label id="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C_label_en-US" xlink:label="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</link:label>
    <link:label id="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C_documentation_en-US" xlink:label="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C" xlink:to="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capped call confirmations, initial cap price (in dollars per share)</link:label>
    <link:label id="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309_label_en-US" xlink:label="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Call Feature, Capped Call Confirmation, Initial Cap Price Per Share</link:label>
    <link:label id="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309_documentation_en-US" xlink:label="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Call Feature, Capped Call Confirmation, Initial Cap Price Per Share</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare" xlink:label="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309" xlink:to="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309" xlink:type="arc" />
    <link:label id="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capped call confirmations, premium percentage</link:label>
    <link:label id="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64_label_en-US" xlink:label="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Call Feature, Capped Call Confirmation, Premium Percentage</link:label>
    <link:label id="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64_documentation_en-US" xlink:label="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Call Feature, Capped Call Confirmation, Premium Percentage</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage" xlink:label="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64" xlink:to="lab_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8E555E9FAA22258891F089D88B0288D3_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8E555E9FAA22258891F089D88B0288D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8E555E9FAA22258891F089D88B0288D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8E555E9FAA22258891F089D88B0288D3" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8E555E9FAA22258891F089D88B0288D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329_terseLabel_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329_label_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_98FD1B9B9FD418A48A6389D88B06ABF8_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_98FD1B9B9FD418A48A6389D88B06ABF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_98FD1B9B9FD418A48A6389D88B06ABF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_98FD1B9B9FD418A48A6389D88B06ABF8" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_98FD1B9B9FD418A48A6389D88B06ABF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_F3DA09C934BAB99BD6AB5A1076B0EDA1_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_F3DA09C934BAB99BD6AB5A1076B0EDA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_F3DA09C934BAB99BD6AB5A1076B0EDA1_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_F3DA09C934BAB99BD6AB5A1076B0EDA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_F3DA09C934BAB99BD6AB5A1076B0EDA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_F3DA09C934BAB99BD6AB5A1076B0EDA1" xlink:to="lab_us-gaap_ProfitLoss_F3DA09C934BAB99BD6AB5A1076B0EDA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B2F1E7865F1336AA8AF95A1076B15674_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B2F1E7865F1336AA8AF95A1076B15674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and deferred financing</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B2F1E7865F1336AA8AF95A1076B15674_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B2F1E7865F1336AA8AF95A1076B15674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B2F1E7865F1336AA8AF95A1076B15674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B2F1E7865F1336AA8AF95A1076B15674" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B2F1E7865F1336AA8AF95A1076B15674" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_236D15FC4E012CEA5A0C5A1076B112FF_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_236D15FC4E012CEA5A0C5A1076B112FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_236D15FC4E012CEA5A0C5A1076B112FF_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_236D15FC4E012CEA5A0C5A1076B112FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_236D15FC4E012CEA5A0C5A1076B112FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_236D15FC4E012CEA5A0C5A1076B112FF" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_236D15FC4E012CEA5A0C5A1076B112FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_5AC7102B8CF576C3E9835A1076B19DD4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5AC7102B8CF576C3E9835A1076B19DD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5AC7102B8CF576C3E9835A1076B19DD4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5AC7102B8CF576C3E9835A1076B19DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5AC7102B8CF576C3E9835A1076B19DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_5AC7102B8CF576C3E9835A1076B19DD4" xlink:to="lab_us-gaap_ShareBasedCompensation_5AC7102B8CF576C3E9835A1076B19DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_381A1E98ECA73A0DC2935A1076B2CE25_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_381A1E98ECA73A0DC2935A1076B2CE25" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivatives</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_381A1E98ECA73A0DC2935A1076B2CE25_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_381A1E98ECA73A0DC2935A1076B2CE25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_381A1E98ECA73A0DC2935A1076B2CE25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_381A1E98ECA73A0DC2935A1076B2CE25" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_381A1E98ECA73A0DC2935A1076B2CE25" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_B2992E29BB5833F81B3E5A1076B2ADA7_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_B2992E29BB5833F81B3E5A1076B2ADA7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash changes in the fair value of contingent consideration payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_B2992E29BB5833F81B3E5A1076B2ADA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_B2992E29BB5833F81B3E5A1076B2ADA7" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_B2992E29BB5833F81B3E5A1076B2ADA7" xlink:type="arc" />
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E_negatedLabel_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign currency remeasurement (gain) loss</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E_label_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E_documentation_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E" xlink:to="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E" xlink:type="arc" />
    <link:label id="lab_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E_negatedTerseLabel_en-US" xlink:label="lab_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash deferred taxes</link:label>
    <link:label id="lab_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E_label_en-US" xlink:label="lab_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Deferred Taxes And Other Tax Benefits</link:label>
    <link:label id="lab_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E_documentation_en-US" xlink:label="lab_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The portion of the non-cash component of deferred taxes and other tax benefits for the period.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_NonCashDeferredTaxesAndOtherTaxBenefits" xlink:label="loc_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E" xlink:to="lab_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_62F10153A1729FC78F3C5A1076B2F2A3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_62F10153A1729FC78F3C5A1076B2F2A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on impairment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_62F10153A1729FC78F3C5A1076B2F2A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_62F10153A1729FC78F3C5A1076B2F2A3" xlink:to="lab_us-gaap_AssetImpairmentCharges_62F10153A1729FC78F3C5A1076B2F2A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_5A88F304BD8E4F7F36765A1076B2D5C7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_5A88F304BD8E4F7F36765A1076B2D5C7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_5A88F304BD8E4F7F36765A1076B2D5C7_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_5A88F304BD8E4F7F36765A1076B2D5C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5A88F304BD8E4F7F36765A1076B2D5C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_5A88F304BD8E4F7F36765A1076B2D5C7" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_5A88F304BD8E4F7F36765A1076B2D5C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_E1F7C675AD8BC9E489755A1076B378A8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_E1F7C675AD8BC9E489755A1076B378A8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_E1F7C675AD8BC9E489755A1076B378A8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_E1F7C675AD8BC9E489755A1076B378A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_E1F7C675AD8BC9E489755A1076B378A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_E1F7C675AD8BC9E489755A1076B378A8" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_E1F7C675AD8BC9E489755A1076B378A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1FE7810C9034CB39EFDC5A1076B397B3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_1FE7810C9034CB39EFDC5A1076B397B3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1FE7810C9034CB39EFDC5A1076B397B3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_1FE7810C9034CB39EFDC5A1076B397B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1FE7810C9034CB39EFDC5A1076B397B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_1FE7810C9034CB39EFDC5A1076B397B3" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_1FE7810C9034CB39EFDC5A1076B397B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_AE867926F61E125AF50D5A1076B34C94_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_AE867926F61E125AF50D5A1076B34C94" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_AE867926F61E125AF50D5A1076B34C94_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_AE867926F61E125AF50D5A1076B34C94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_AE867926F61E125AF50D5A1076B34C94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_AE867926F61E125AF50D5A1076B34C94" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_AE867926F61E125AF50D5A1076B34C94" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_46DD10AD27C8C82FA0685A1076B33D31_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_46DD10AD27C8C82FA0685A1076B33D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses, and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_46DD10AD27C8C82FA0685A1076B33D31_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_46DD10AD27C8C82FA0685A1076B33D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_46DD10AD27C8C82FA0685A1076B33D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_46DD10AD27C8C82FA0685A1076B33D31" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_46DD10AD27C8C82FA0685A1076B33D31" xlink:type="arc" />
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B_terseLabel_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets and liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B_label_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Noncurrent Operating Liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B_documentation_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B" xlink:to="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B" xlink:type="arc" />
    <link:label id="lab_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20_terseLabel_en-US" xlink:label="lab_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20_label_en-US" xlink:label="lab_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Deferred Reimbursements</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20_documentation_en-US" xlink:label="lab_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of deferred reimbursements.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_IncreaseDecreaseInDeferredReimbursements" xlink:label="loc_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20" xlink:to="lab_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1D8E44FE23FE227B9315A1076B4C723_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1D8E44FE23FE227B9315A1076B4C723" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1D8E44FE23FE227B9315A1076B4C723_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1D8E44FE23FE227B9315A1076B4C723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1D8E44FE23FE227B9315A1076B4C723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1D8E44FE23FE227B9315A1076B4C723" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1D8E44FE23FE227B9315A1076B4C723" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2EB220937FF97B84ED1E5A1076B4D6FA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2EB220937FF97B84ED1E5A1076B4D6FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale and redemption of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2EB220937FF97B84ED1E5A1076B4D6FA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2EB220937FF97B84ED1E5A1076B4D6FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2EB220937FF97B84ED1E5A1076B4D6FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2EB220937FF97B84ED1E5A1076B4D6FA" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2EB220937FF97B84ED1E5A1076B4D6FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_F01FD1A94031AC8DE16E5A1076B40A72_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_F01FD1A94031AC8DE16E5A1076B40A72" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_F01FD1A94031AC8DE16E5A1076B40A72_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_F01FD1A94031AC8DE16E5A1076B40A72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_F01FD1A94031AC8DE16E5A1076B40A72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_F01FD1A94031AC8DE16E5A1076B40A72" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_F01FD1A94031AC8DE16E5A1076B40A72" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_248323DA79C0E7B53C835A1076B575F1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_248323DA79C0E7B53C835A1076B575F1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_248323DA79C0E7B53C835A1076B575F1_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_248323DA79C0E7B53C835A1076B575F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_248323DA79C0E7B53C835A1076B575F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_248323DA79C0E7B53C835A1076B575F1" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_248323DA79C0E7B53C835A1076B575F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1878DFE768D2B105BE645A1076B5F84F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1878DFE768D2B105BE645A1076B5F84F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1878DFE768D2B105BE645A1076B5F84F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1878DFE768D2B105BE645A1076B5F84F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1878DFE768D2B105BE645A1076B5F84F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1878DFE768D2B105BE645A1076B5F84F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1878DFE768D2B105BE645A1076B5F84F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_530D0A9FAC2A58F619E15A1076B5EE5D_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments_530D0A9FAC2A58F619E15A1076B5EE5D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_530D0A9FAC2A58F619E15A1076B5EE5D_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments_530D0A9FAC2A58F619E15A1076B5EE5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_530D0A9FAC2A58F619E15A1076B5EE5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments_530D0A9FAC2A58F619E15A1076B5EE5D" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments_530D0A9FAC2A58F619E15A1076B5EE5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C31A0AD1082F23E69D285A1076B5A0F8_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C31A0AD1082F23E69D285A1076B5A0F8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of finance leases</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C31A0AD1082F23E69D285A1076B5A0F8_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C31A0AD1082F23E69D285A1076B5A0F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt and Lease Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C31A0AD1082F23E69D285A1076B5A0F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C31A0AD1082F23E69D285A1076B5A0F8" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C31A0AD1082F23E69D285A1076B5A0F8" xlink:type="arc" />
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719_negatedLabel_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of vested restricted stock units</link:label>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719_label_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Repurchase Of Restricted Stock Units</link:label>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719_documentation_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow to reacquire restricted stock units during the period.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719" xlink:to="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719" xlink:type="arc" />
    <link:label id="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_21B6708D37B8F020B6C85A1076B68278_negatedTerseLabel_en-US" xlink:label="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_21B6708D37B8F020B6C85A1076B68278" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from termination of capped call confirmations</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_21B6708D37B8F020B6C85A1076B68278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_21B6708D37B8F020B6C85A1076B68278" xlink:to="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_21B6708D37B8F020B6C85A1076B68278" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_BA3A65432A0FA934EF1B5A1076B64933_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_BA3A65432A0FA934EF1B5A1076B64933" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_BA3A65432A0FA934EF1B5A1076B64933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_BA3A65432A0FA934EF1B5A1076B64933" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_BA3A65432A0FA934EF1B5A1076B64933" xlink:type="arc" />
    <link:label id="lab_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224_negatedTerseLabel_en-US" xlink:label="lab_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224_label_en-US" xlink:label="lab_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Contingent Consideration</link:label>
    <link:label id="lab_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224_documentation_en-US" xlink:label="lab_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow associated with the payment of contingent consideration liabilities.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentOfContingentConsideration" xlink:label="loc_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224" xlink:to="lab_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_BC9187B21B382A0068645A1076B6034D_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_BC9187B21B382A0068645A1076B6034D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from loan agreements, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_BC9187B21B382A0068645A1076B6034D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_BC9187B21B382A0068645A1076B6034D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_BC9187B21B382A0068645A1076B6034D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_BC9187B21B382A0068645A1076B6034D" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_BC9187B21B382A0068645A1076B6034D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6B78839E25A8B5398DE55A1076B7EC7B_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6B78839E25A8B5398DE55A1076B7EC7B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6B78839E25A8B5398DE55A1076B7EC7B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6B78839E25A8B5398DE55A1076B7EC7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6B78839E25A8B5398DE55A1076B7EC7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6B78839E25A8B5398DE55A1076B7EC7B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6B78839E25A8B5398DE55A1076B7EC7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_EF7A2E4B256A22C7BA975A1076B700C5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_EF7A2E4B256A22C7BA975A1076B700C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_EF7A2E4B256A22C7BA975A1076B700C5_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_EF7A2E4B256A22C7BA975A1076B700C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_EF7A2E4B256A22C7BA975A1076B700C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_EF7A2E4B256A22C7BA975A1076B700C5" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_EF7A2E4B256A22C7BA975A1076B700C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6E87429F1392DEB4A5D25A1076B75241_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6E87429F1392DEB4A5D25A1076B75241" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6E87429F1392DEB4A5D25A1076B75241_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6E87429F1392DEB4A5D25A1076B75241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6E87429F1392DEB4A5D25A1076B75241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6E87429F1392DEB4A5D25A1076B75241" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6E87429F1392DEB4A5D25A1076B75241" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_485D79F80BC7433EA3945A1076B7DF86_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_485D79F80BC7433EA3945A1076B7DF86" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_485D79F80BC7433EA3945A1076B7DF86_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_485D79F80BC7433EA3945A1076B7DF86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_485D79F80BC7433EA3945A1076B7DF86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_485D79F80BC7433EA3945A1076B7DF86" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_485D79F80BC7433EA3945A1076B7DF86" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1D61B227E5BA73041E5A1076B70FDC_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1D61B227E5BA73041E5A1076B70FDC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at the end of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1D61B227E5BA73041E5A1076B70FDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1D61B227E5BA73041E5A1076B70FDC" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1D61B227E5BA73041E5A1076B70FDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_26C190D3C84A5C1E74ED5A1076B8A323_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_26C190D3C84A5C1E74ED5A1076B8A323" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_26C190D3C84A5C1E74ED5A1076B8A323_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_26C190D3C84A5C1E74ED5A1076B8A323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_26C190D3C84A5C1E74ED5A1076B8A323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_26C190D3C84A5C1E74ED5A1076B8A323" xlink:to="lab_us-gaap_InterestPaidNet_26C190D3C84A5C1E74ED5A1076B8A323" xlink:type="arc" />
    <link:label id="lab_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration paid in shares</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23_label_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Paid In Stock</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment of contingent consideration liability in stock during the period.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationPaidInStock" xlink:label="loc_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23" xlink:to="lab_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08AEC86729A2C58CF47B5A1076B81D10_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08AEC86729A2C58CF47B5A1076B81D10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures unpaid at the end of period</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08AEC86729A2C58CF47B5A1076B81D10_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08AEC86729A2C58CF47B5A1076B81D10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08AEC86729A2C58CF47B5A1076B81D10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08AEC86729A2C58CF47B5A1076B81D10" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08AEC86729A2C58CF47B5A1076B81D10" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72F753367475931D4031F4CA96ADE872_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72F753367475931D4031F4CA96ADE872" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72F753367475931D4031F4CA96ADE872_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72F753367475931D4031F4CA96ADE872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72F753367475931D4031F4CA96ADE872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72F753367475931D4031F4CA96ADE872" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72F753367475931D4031F4CA96ADE872" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15BE1CA68024B4671B14F4CA96ADFD1F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15BE1CA68024B4671B14F4CA96ADFD1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15BE1CA68024B4671B14F4CA96ADFD1F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15BE1CA68024B4671B14F4CA96ADFD1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15BE1CA68024B4671B14F4CA96ADFD1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15BE1CA68024B4671B14F4CA96ADFD1F" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15BE1CA68024B4671B14F4CA96ADFD1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AF5171050A1C0109067DF4CA96AEEE7D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AF5171050A1C0109067DF4CA96AEEE7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Non-Vested RSU Activity under the Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AF5171050A1C0109067DF4CA96AEEE7D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AF5171050A1C0109067DF4CA96AEEE7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AF5171050A1C0109067DF4CA96AEEE7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AF5171050A1C0109067DF4CA96AEEE7D" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AF5171050A1C0109067DF4CA96AEEE7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_22A648FCA37E1EB83502F4CA96AEB836_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_22A648FCA37E1EB83502F4CA96AEB836" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Compensation Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_22A648FCA37E1EB83502F4CA96AEB836_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_22A648FCA37E1EB83502F4CA96AEB836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_22A648FCA37E1EB83502F4CA96AEB836" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_22A648FCA37E1EB83502F4CA96AEB836" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_22A648FCA37E1EB83502F4CA96AEB836" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_38D53409FB481F0C0F2B06E59BA05D16_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_38D53409FB481F0C0F2B06E59BA05D16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Disaggregated by Geographical Area</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_38D53409FB481F0C0F2B06E59BA05D16_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_38D53409FB481F0C0F2B06E59BA05D16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_38D53409FB481F0C0F2B06E59BA05D16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_38D53409FB481F0C0F2B06E59BA05D16" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_38D53409FB481F0C0F2B06E59BA05D16" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EA4AFCD91857607412046B8C74B3A361_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EA4AFCD91857607412046B8C74B3A361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EA4AFCD91857607412046B8C74B3A361_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EA4AFCD91857607412046B8C74B3A361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EA4AFCD91857607412046B8C74B3A361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EA4AFCD91857607412046B8C74B3A361" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EA4AFCD91857607412046B8C74B3A361" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6" xlink:to="lab_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D" xlink:type="arc" />
    <link:label id="lab_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A_terseLabel_en-US" xlink:label="lab_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A_label_en-US" xlink:label="lab_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A_documentation_en-US" xlink:label="lab_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tangible property used for research.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ResearchEquipmentMember" xlink:label="loc_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A" xlink:to="lab_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101" xlink:type="arc" />
    <link:label id="lab_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A_label_en-US" xlink:label="lab_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A" xlink:to="lab_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84_label_en-US" xlink:label="lab_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84" xlink:to="lab_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6" xlink:to="lab_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0FBC601C58BF4B432A04F4CA96DDACEF_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0FBC601C58BF4B432A04F4CA96DDACEF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0FBC601C58BF4B432A04F4CA96DDACEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0FBC601C58BF4B432A04F4CA96DDACEF" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0FBC601C58BF4B432A04F4CA96DDACEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E_label_en-US" xlink:label="lab_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E" xlink:to="lab_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5C37C328BC1A7E4198E5F4CA95DE4D2B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5C37C328BC1A7E4198E5F4CA95DE4D2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Selected Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5C37C328BC1A7E4198E5F4CA95DE4D2B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5C37C328BC1A7E4198E5F4CA95DE4D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5C37C328BC1A7E4198E5F4CA95DE4D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5C37C328BC1A7E4198E5F4CA95DE4D2B" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5C37C328BC1A7E4198E5F4CA95DE4D2B" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9_label_en-US" xlink:label="lab_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="lab_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_FB5DFE7B89F812C350785FE1BF4605C3_terseLabel_en-US" xlink:label="lab_dei_DocumentType_FB5DFE7B89F812C350785FE1BF4605C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_FB5DFE7B89F812C350785FE1BF4605C3_label_en-US" xlink:label="lab_dei_DocumentType_FB5DFE7B89F812C350785FE1BF4605C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FB5DFE7B89F812C350785FE1BF4605C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_FB5DFE7B89F812C350785FE1BF4605C3" xlink:to="lab_dei_DocumentType_FB5DFE7B89F812C350785FE1BF4605C3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentAnnualReport_3FB39C4850309E31327B5FE1BF46A9FC_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport_3FB39C4850309E31327B5FE1BF46A9FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_3FB39C4850309E31327B5FE1BF46A9FC_label_en-US" xlink:label="lab_dei_DocumentAnnualReport_3FB39C4850309E31327B5FE1BF46A9FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_3FB39C4850309E31327B5FE1BF46A9FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_3FB39C4850309E31327B5FE1BF46A9FC" xlink:to="lab_dei_DocumentAnnualReport_3FB39C4850309E31327B5FE1BF46A9FC" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_C5B62CE816D8A6A2C9CF5FE1BF461A6A_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_C5B62CE816D8A6A2C9CF5FE1BF461A6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_C5B62CE816D8A6A2C9CF5FE1BF461A6A_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_C5B62CE816D8A6A2C9CF5FE1BF461A6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_C5B62CE816D8A6A2C9CF5FE1BF461A6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_C5B62CE816D8A6A2C9CF5FE1BF461A6A" xlink:to="lab_dei_DocumentPeriodEndDate_C5B62CE816D8A6A2C9CF5FE1BF461A6A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_0C46C8C87A322793582A5FE1BF474576_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_0C46C8C87A322793582A5FE1BF474576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_0C46C8C87A322793582A5FE1BF474576_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_0C46C8C87A322793582A5FE1BF474576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_0C46C8C87A322793582A5FE1BF474576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_0C46C8C87A322793582A5FE1BF474576" xlink:to="lab_dei_DocumentTransitionReport_0C46C8C87A322793582A5FE1BF474576" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_3F2ACEC6D182C1ACF4E15FE1BF478B2E_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_3F2ACEC6D182C1ACF4E15FE1BF478B2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_3F2ACEC6D182C1ACF4E15FE1BF478B2E_label_en-US" xlink:label="lab_dei_EntityFileNumber_3F2ACEC6D182C1ACF4E15FE1BF478B2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_3F2ACEC6D182C1ACF4E15FE1BF478B2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_3F2ACEC6D182C1ACF4E15FE1BF478B2E" xlink:to="lab_dei_EntityFileNumber_3F2ACEC6D182C1ACF4E15FE1BF478B2E" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_8022DB0711C77C4ED16B5FE1BF473B0A_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_8022DB0711C77C4ED16B5FE1BF473B0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_8022DB0711C77C4ED16B5FE1BF473B0A_label_en-US" xlink:label="lab_dei_EntityRegistrantName_8022DB0711C77C4ED16B5FE1BF473B0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_8022DB0711C77C4ED16B5FE1BF473B0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_8022DB0711C77C4ED16B5FE1BF473B0A" xlink:to="lab_dei_EntityRegistrantName_8022DB0711C77C4ED16B5FE1BF473B0A" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_FBBA85465756467F195F5FE1BF4740E9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_FBBA85465756467F195F5FE1BF4740E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_FBBA85465756467F195F5FE1BF4740E9_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_FBBA85465756467F195F5FE1BF4740E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_FBBA85465756467F195F5FE1BF4740E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_FBBA85465756467F195F5FE1BF4740E9" xlink:to="lab_dei_EntityIncorporationStateCountryCode_FBBA85465756467F195F5FE1BF4740E9" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_EF562BAE77FF1C56AC365FE1BF471B85_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_EF562BAE77FF1C56AC365FE1BF471B85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_EF562BAE77FF1C56AC365FE1BF471B85_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_EF562BAE77FF1C56AC365FE1BF471B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_EF562BAE77FF1C56AC365FE1BF471B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_EF562BAE77FF1C56AC365FE1BF471B85" xlink:to="lab_dei_EntityTaxIdentificationNumber_EF562BAE77FF1C56AC365FE1BF471B85" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_92AC6FCB1626B9E5C29F5FE1BF47EF28_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_92AC6FCB1626B9E5C29F5FE1BF47EF28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_92AC6FCB1626B9E5C29F5FE1BF47EF28_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_92AC6FCB1626B9E5C29F5FE1BF47EF28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_92AC6FCB1626B9E5C29F5FE1BF47EF28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_92AC6FCB1626B9E5C29F5FE1BF47EF28" xlink:to="lab_dei_EntityAddressAddressLine1_92AC6FCB1626B9E5C29F5FE1BF47EF28" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_3422DFCC988D283E58065FE1BF48F2F1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_3422DFCC988D283E58065FE1BF48F2F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_3422DFCC988D283E58065FE1BF48F2F1_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_3422DFCC988D283E58065FE1BF48F2F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_3422DFCC988D283E58065FE1BF48F2F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_3422DFCC988D283E58065FE1BF48F2F1" xlink:to="lab_dei_EntityAddressCityOrTown_3422DFCC988D283E58065FE1BF48F2F1" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_7FED752E914CB953F2265FE1BF48C273_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_7FED752E914CB953F2265FE1BF48C273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7FED752E914CB953F2265FE1BF48C273_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_7FED752E914CB953F2265FE1BF48C273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_7FED752E914CB953F2265FE1BF48C273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_7FED752E914CB953F2265FE1BF48C273" xlink:to="lab_dei_EntityAddressStateOrProvince_7FED752E914CB953F2265FE1BF48C273" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_5B04A7F2CCEB1665C9D75FE1BF48E3BD_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_5B04A7F2CCEB1665C9D75FE1BF48E3BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5B04A7F2CCEB1665C9D75FE1BF48E3BD_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_5B04A7F2CCEB1665C9D75FE1BF48E3BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_5B04A7F2CCEB1665C9D75FE1BF48E3BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_5B04A7F2CCEB1665C9D75FE1BF48E3BD" xlink:to="lab_dei_EntityAddressPostalZipCode_5B04A7F2CCEB1665C9D75FE1BF48E3BD" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_02BFDC19413C9F91E5135FE20A37BD10_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_02BFDC19413C9F91E5135FE20A37BD10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_02BFDC19413C9F91E5135FE20A37BD10_label_en-US" xlink:label="lab_dei_CityAreaCode_02BFDC19413C9F91E5135FE20A37BD10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_02BFDC19413C9F91E5135FE20A37BD10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_02BFDC19413C9F91E5135FE20A37BD10" xlink:to="lab_dei_CityAreaCode_02BFDC19413C9F91E5135FE20A37BD10" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_E682777FA548764FD9CD5FE2537A792A_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_E682777FA548764FD9CD5FE2537A792A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_E682777FA548764FD9CD5FE2537A792A_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_E682777FA548764FD9CD5FE2537A792A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_E682777FA548764FD9CD5FE2537A792A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_E682777FA548764FD9CD5FE2537A792A" xlink:to="lab_dei_LocalPhoneNumber_E682777FA548764FD9CD5FE2537A792A" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_FEDC2B61D8E8CDD2E0225FE1BF489D59_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_FEDC2B61D8E8CDD2E0225FE1BF489D59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_FEDC2B61D8E8CDD2E0225FE1BF489D59_label_en-US" xlink:label="lab_dei_Security12bTitle_FEDC2B61D8E8CDD2E0225FE1BF489D59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_FEDC2B61D8E8CDD2E0225FE1BF489D59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_FEDC2B61D8E8CDD2E0225FE1BF489D59" xlink:to="lab_dei_Security12bTitle_FEDC2B61D8E8CDD2E0225FE1BF489D59" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_325B79A725821E6CE7D45FE1BF4827CB_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_325B79A725821E6CE7D45FE1BF4827CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_325B79A725821E6CE7D45FE1BF4827CB_label_en-US" xlink:label="lab_dei_TradingSymbol_325B79A725821E6CE7D45FE1BF4827CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_325B79A725821E6CE7D45FE1BF4827CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_325B79A725821E6CE7D45FE1BF4827CB" xlink:to="lab_dei_TradingSymbol_325B79A725821E6CE7D45FE1BF4827CB" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_69FCA2046B3E4CB4CC505FE1BF48519B_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_69FCA2046B3E4CB4CC505FE1BF48519B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_69FCA2046B3E4CB4CC505FE1BF48519B_label_en-US" xlink:label="lab_dei_SecurityExchangeName_69FCA2046B3E4CB4CC505FE1BF48519B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_69FCA2046B3E4CB4CC505FE1BF48519B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_69FCA2046B3E4CB4CC505FE1BF48519B" xlink:to="lab_dei_SecurityExchangeName_69FCA2046B3E4CB4CC505FE1BF48519B" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4E46AA743DC6EEF951915FE1BF48BAF9_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_4E46AA743DC6EEF951915FE1BF48BAF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4E46AA743DC6EEF951915FE1BF48BAF9_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_4E46AA743DC6EEF951915FE1BF48BAF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_4E46AA743DC6EEF951915FE1BF48BAF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_4E46AA743DC6EEF951915FE1BF48BAF9" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_4E46AA743DC6EEF951915FE1BF48BAF9" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_D204AEA1C9C59C6E87785FE1BF49B0F0_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_D204AEA1C9C59C6E87785FE1BF49B0F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_D204AEA1C9C59C6E87785FE1BF49B0F0_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_D204AEA1C9C59C6E87785FE1BF49B0F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_D204AEA1C9C59C6E87785FE1BF49B0F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_D204AEA1C9C59C6E87785FE1BF49B0F0" xlink:to="lab_dei_EntityVoluntaryFilers_D204AEA1C9C59C6E87785FE1BF49B0F0" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_9CDB847679A72C32B5C75FE1BF492ED5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_9CDB847679A72C32B5C75FE1BF492ED5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9CDB847679A72C32B5C75FE1BF492ED5_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_9CDB847679A72C32B5C75FE1BF492ED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9CDB847679A72C32B5C75FE1BF492ED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_9CDB847679A72C32B5C75FE1BF492ED5" xlink:to="lab_dei_EntityCurrentReportingStatus_9CDB847679A72C32B5C75FE1BF492ED5" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_D22A5D907F30E135B4725FE1BF494F36_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_D22A5D907F30E135B4725FE1BF494F36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_D22A5D907F30E135B4725FE1BF494F36_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_D22A5D907F30E135B4725FE1BF494F36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_D22A5D907F30E135B4725FE1BF494F36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_D22A5D907F30E135B4725FE1BF494F36" xlink:to="lab_dei_EntityInteractiveDataCurrent_D22A5D907F30E135B4725FE1BF494F36" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_D2AE3F3A647A1BED7F555FE1BF49244C_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_D2AE3F3A647A1BED7F555FE1BF49244C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_D2AE3F3A647A1BED7F555FE1BF49244C_label_en-US" xlink:label="lab_dei_EntityFilerCategory_D2AE3F3A647A1BED7F555FE1BF49244C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D2AE3F3A647A1BED7F555FE1BF49244C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_D2AE3F3A647A1BED7F555FE1BF49244C" xlink:to="lab_dei_EntityFilerCategory_D2AE3F3A647A1BED7F555FE1BF49244C" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_E0449B4C4B0CC9A82DE35FE1BF49D40A_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_E0449B4C4B0CC9A82DE35FE1BF49D40A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_E0449B4C4B0CC9A82DE35FE1BF49D40A_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_E0449B4C4B0CC9A82DE35FE1BF49D40A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_E0449B4C4B0CC9A82DE35FE1BF49D40A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_E0449B4C4B0CC9A82DE35FE1BF49D40A" xlink:to="lab_dei_EntitySmallBusiness_E0449B4C4B0CC9A82DE35FE1BF49D40A" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2B6D2680ED0985A8D0555FE1BF499AC1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_2B6D2680ED0985A8D0555FE1BF499AC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2B6D2680ED0985A8D0555FE1BF499AC1_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_2B6D2680ED0985A8D0555FE1BF499AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_2B6D2680ED0985A8D0555FE1BF499AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_2B6D2680ED0985A8D0555FE1BF499AC1" xlink:to="lab_dei_EntityEmergingGrowthCompany_2B6D2680ED0985A8D0555FE1BF499AC1" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_B7E524BAB6582AD77DFC5FE1BF499A3F_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_B7E524BAB6582AD77DFC5FE1BF499A3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_B7E524BAB6582AD77DFC5FE1BF499A3F_label_en-US" xlink:label="lab_dei_EntityShellCompany_B7E524BAB6582AD77DFC5FE1BF499A3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_B7E524BAB6582AD77DFC5FE1BF499A3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_B7E524BAB6582AD77DFC5FE1BF499A3F" xlink:to="lab_dei_EntityShellCompany_B7E524BAB6582AD77DFC5FE1BF499A3F" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_433F897EA448EACC40FE5FE1BF4A39F9_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_433F897EA448EACC40FE5FE1BF4A39F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_433F897EA448EACC40FE5FE1BF4A39F9_label_en-US" xlink:label="lab_dei_EntityPublicFloat_433F897EA448EACC40FE5FE1BF4A39F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_433F897EA448EACC40FE5FE1BF4A39F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_433F897EA448EACC40FE5FE1BF4A39F9" xlink:to="lab_dei_EntityPublicFloat_433F897EA448EACC40FE5FE1BF4A39F9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_083AEB62EA462ACB5A495FE1BF4A607A_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_083AEB62EA462ACB5A495FE1BF4A607A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_083AEB62EA462ACB5A495FE1BF4A607A_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_083AEB62EA462ACB5A495FE1BF4A607A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_083AEB62EA462ACB5A495FE1BF4A607A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_083AEB62EA462ACB5A495FE1BF4A607A" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_083AEB62EA462ACB5A495FE1BF4A607A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_466552B348E7034A434C5FE1BF4A4327_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_466552B348E7034A434C5FE1BF4A4327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_466552B348E7034A434C5FE1BF4A4327_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_466552B348E7034A434C5FE1BF4A4327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_466552B348E7034A434C5FE1BF4A4327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock_466552B348E7034A434C5FE1BF4A4327" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock_466552B348E7034A434C5FE1BF4A4327" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_7DFC831ABC595B29AE515FE1BF4AE860_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7DFC831ABC595B29AE515FE1BF4AE860" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_7DFC831ABC595B29AE515FE1BF4AE860_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7DFC831ABC595B29AE515FE1BF4AE860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7DFC831ABC595B29AE515FE1BF4AE860" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7DFC831ABC595B29AE515FE1BF4AE860" xlink:to="lab_dei_EntityCentralIndexKey_7DFC831ABC595B29AE515FE1BF4AE860" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_9AA3FFAF9D2CBD2DDBDD5FE1BF4A0DFC_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_9AA3FFAF9D2CBD2DDBDD5FE1BF4A0DFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_9AA3FFAF9D2CBD2DDBDD5FE1BF4A0DFC_label_en-US" xlink:label="lab_dei_AmendmentFlag_9AA3FFAF9D2CBD2DDBDD5FE1BF4A0DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9AA3FFAF9D2CBD2DDBDD5FE1BF4A0DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_9AA3FFAF9D2CBD2DDBDD5FE1BF4A0DFC" xlink:to="lab_dei_AmendmentFlag_9AA3FFAF9D2CBD2DDBDD5FE1BF4A0DFC" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_28A5D3087D829054D70D5FE1BF4AD361_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_28A5D3087D829054D70D5FE1BF4AD361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_28A5D3087D829054D70D5FE1BF4AD361_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_28A5D3087D829054D70D5FE1BF4AD361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_28A5D3087D829054D70D5FE1BF4AD361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_28A5D3087D829054D70D5FE1BF4AD361" xlink:to="lab_dei_CurrentFiscalYearEndDate_28A5D3087D829054D70D5FE1BF4AD361" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_13DA6EF5BF7E30C447605FE1BF4B7B06_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_13DA6EF5BF7E30C447605FE1BF4B7B06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_13DA6EF5BF7E30C447605FE1BF4B7B06_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_13DA6EF5BF7E30C447605FE1BF4B7B06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13DA6EF5BF7E30C447605FE1BF4B7B06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_13DA6EF5BF7E30C447605FE1BF4B7B06" xlink:to="lab_dei_DocumentFiscalYearFocus_13DA6EF5BF7E30C447605FE1BF4B7B06" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6008555300A26C8048095FE1BF4B87AE_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_6008555300A26C8048095FE1BF4B87AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6008555300A26C8048095FE1BF4B87AE_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_6008555300A26C8048095FE1BF4B87AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6008555300A26C8048095FE1BF4B87AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_6008555300A26C8048095FE1BF4B87AE" xlink:to="lab_dei_DocumentFiscalPeriodFocus_6008555300A26C8048095FE1BF4B87AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2DE031D946238B846D265FD4960DDE48_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2DE031D946238B846D265FD4960DDE48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2DE031D946238B846D265FD4960DDE48_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2DE031D946238B846D265FD4960DDE48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2DE031D946238B846D265FD4960DDE48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2DE031D946238B846D265FD4960DDE48" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2DE031D946238B846D265FD4960DDE48" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5B43F2C18B965FFC093D5FD4960F412F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5B43F2C18B965FFC093D5FD4960F412F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5B43F2C18B965FFC093D5FD4960F412F_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5B43F2C18B965FFC093D5FD4960F412F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5B43F2C18B965FFC093D5FD4960F412F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5B43F2C18B965FFC093D5FD4960F412F" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5B43F2C18B965FFC093D5FD4960F412F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_3F721B1A30F8A9B417965FD4960F56B1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_3F721B1A30F8A9B417965FD4960F56B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_3F721B1A30F8A9B417965FD4960F56B1_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_3F721B1A30F8A9B417965FD4960F56B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3F721B1A30F8A9B417965FD4960F56B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3F721B1A30F8A9B417965FD4960F56B1" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_3F721B1A30F8A9B417965FD4960F56B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_E28C49ACA18B9D20B4875FD4961018FC_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_E28C49ACA18B9D20B4875FD4961018FC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_E28C49ACA18B9D20B4875FD4961018FC_label_en-US" xlink:label="lab_us-gaap_InventoryNet_E28C49ACA18B9D20B4875FD4961018FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E28C49ACA18B9D20B4875FD4961018FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_E28C49ACA18B9D20B4875FD4961018FC" xlink:to="lab_us-gaap_InventoryNet_E28C49ACA18B9D20B4875FD4961018FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryValuationReserves_AC5DAD063209726069C15FD496109FC5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves_AC5DAD063209726069C15FD496109FC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve for inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_AC5DAD063209726069C15FD496109FC5_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves_AC5DAD063209726069C15FD496109FC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_AC5DAD063209726069C15FD496109FC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves_AC5DAD063209726069C15FD496109FC5" xlink:to="lab_us-gaap_InventoryValuationReserves_AC5DAD063209726069C15FD496109FC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545" xlink:to="lab_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733" xlink:to="lab_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and experimentation tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90_label_en-US" xlink:label="lab_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90" xlink:to="lab_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90" xlink:type="arc" />
    <link:label id="lab_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9_terseLabel_en-US" xlink:label="lab_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orphan drug tax credit carryforwards</link:label>
    <link:label id="lab_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9_label_en-US" xlink:label="lab_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orphan Drug Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9_documentation_en-US" xlink:label="lab_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent the information pertaining to orphan drug tax credit carryforward.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_OrphanDrugTaxCreditCarryforwardMember" xlink:label="loc_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9" xlink:to="lab_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of net operating loss carry forwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71" xlink:to="lab_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested units as of the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3E23C2637145AB0474DDF4CA968ADA23_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3E23C2637145AB0474DDF4CA968ADA23" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3E23C2637145AB0474DDF4CA968ADA23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3E23C2637145AB0474DDF4CA968ADA23" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3E23C2637145AB0474DDF4CA968ADA23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_067E86918123750E2DCCF4CA968A1F94_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_067E86918123750E2DCCF4CA968A1F94" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested units as of the end of the period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_067E86918123750E2DCCF4CA968A1F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_067E86918123750E2DCCF4CA968A1F94" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_067E86918123750E2DCCF4CA968A1F94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested units as of the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_733620390872E2954FF9F4CA968B6702_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_733620390872E2954FF9F4CA968B6702" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested units as of the end of the period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_733620390872E2954FF9F4CA968B6702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_733620390872E2954FF9F4CA968B6702" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_733620390872E2954FF9F4CA968B6702" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-vested units, weighted average remaining years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-vested units, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7DE3AD809CC5BD5F0E116B8C745B384E_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7DE3AD809CC5BD5F0E116B8C745B384E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7DE3AD809CC5BD5F0E116B8C745B384E_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7DE3AD809CC5BD5F0E116B8C745B384E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7DE3AD809CC5BD5F0E116B8C745B384E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7DE3AD809CC5BD5F0E116B8C745B384E" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7DE3AD809CC5BD5F0E116B8C745B384E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E955D54B89E1E93437B55A7138DF61CB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E955D54B89E1E93437B55A7138DF61CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E955D54B89E1E93437B55A7138DF61CB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E955D54B89E1E93437B55A7138DF61CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E955D54B89E1E93437B55A7138DF61CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E955D54B89E1E93437B55A7138DF61CB" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E955D54B89E1E93437B55A7138DF61CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_A927B441A3414782E6FA5A7138E237C6_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_A927B441A3414782E6FA5A7138E237C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_A927B441A3414782E6FA5A7138E237C6_label_en-US" xlink:label="lab_us-gaap_Goodwill_A927B441A3414782E6FA5A7138E237C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A927B441A3414782E6FA5A7138E237C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_A927B441A3414782E6FA5A7138E237C6" xlink:to="lab_us-gaap_Goodwill_A927B441A3414782E6FA5A7138E237C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_43951AD4B439B9F51D655A7138E54F6D_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_43951AD4B439B9F51D655A7138E54F6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss of impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_43951AD4B439B9F51D655A7138E54F6D_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_43951AD4B439B9F51D655A7138E54F6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_43951AD4B439B9F51D655A7138E54F6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_43951AD4B439B9F51D655A7138E54F6D" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_43951AD4B439B9F51D655A7138E54F6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_30A56DCA4CDE626B93C7F438F6013EC4_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_30A56DCA4CDE626B93C7F438F6013EC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_30A56DCA4CDE626B93C7F438F6013EC4_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_30A56DCA4CDE626B93C7F438F6013EC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_30A56DCA4CDE626B93C7F438F6013EC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_30A56DCA4CDE626B93C7F438F6013EC4" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_30A56DCA4CDE626B93C7F438F6013EC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_EBFDE47D8A8B15E807A06B8C74177A4C_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_EBFDE47D8A8B15E807A06B8C74177A4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_EBFDE47D8A8B15E807A06B8C74177A4C_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_EBFDE47D8A8B15E807A06B8C74177A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_EBFDE47D8A8B15E807A06B8C74177A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_EBFDE47D8A8B15E807A06B8C74177A4C" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_EBFDE47D8A8B15E807A06B8C74177A4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3E5B63BA347ACFEF23ECF4CA9694200B_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3E5B63BA347ACFEF23ECF4CA9694200B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3E5B63BA347ACFEF23ECF4CA9694200B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3E5B63BA347ACFEF23ECF4CA9694200B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3E5B63BA347ACFEF23ECF4CA9694200B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C35BC97780761B4A9721F4CA969445DC_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C35BC97780761B4A9721F4CA969445DC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C35BC97780761B4A9721F4CA969445DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C35BC97780761B4A9721F4CA969445DC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C35BC97780761B4A9721F4CA969445DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and unvested expected to vest as of the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23862FFA4AADC32DDD79F4CA9696233B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23862FFA4AADC32DDD79F4CA9696233B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23862FFA4AADC32DDD79F4CA9696233B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23862FFA4AADC32DDD79F4CA9696233B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23862FFA4AADC32DDD79F4CA9696233B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and unvested expected to vest as of the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and unvested expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options vested and unvested expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5BAB9750C4008D9E49150F0C23695DA8_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5BAB9750C4008D9E49150F0C23695DA8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5BAB9750C4008D9E49150F0C23695DA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5BAB9750C4008D9E49150F0C23695DA8" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5BAB9750C4008D9E49150F0C23695DA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9E1EC4117D001C611D240F0C23695185_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9E1EC4117D001C611D240F0C23695185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in IPR&amp;D</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9E1EC4117D001C611D240F0C23695185" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9E1EC4117D001C611D240F0C23695185" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9E1EC4117D001C611D240F0C23695185" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6EBCD275C8A28E400F240F0C23697BB5_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6EBCD275C8A28E400F240F0C23697BB5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6EBCD275C8A28E400F240F0C23697BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6EBCD275C8A28E400F240F0C23697BB5" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6EBCD275C8A28E400F240F0C23697BB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696" xlink:to="lab_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_FE726B9B05E74DF31D3C0F0C236AFF1F_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_FE726B9B05E74DF31D3C0F0C236AFF1F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_FE726B9B05E74DF31D3C0F0C236AFF1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_FE726B9B05E74DF31D3C0F0C236AFF1F" xlink:to="lab_us-gaap_Goodwill_FE726B9B05E74DF31D3C0F0C236AFF1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_05F492A7ABFEC1C5582E0F0C236ABC5B_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease_05F492A7ABFEC1C5582E0F0C236ABC5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_05F492A7ABFEC1C5582E0F0C236ABC5B_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease_05F492A7ABFEC1C5582E0F0C236ABC5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_05F492A7ABFEC1C5582E0F0C236ABC5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease_05F492A7ABFEC1C5582E0F0C236ABC5B" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease_05F492A7ABFEC1C5582E0F0C236ABC5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_AFDDC1EDE9FA9FFD9C640F0C236A9998_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_AFDDC1EDE9FA9FFD9C640F0C236A9998" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_AFDDC1EDE9FA9FFD9C640F0C236A9998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_AFDDC1EDE9FA9FFD9C640F0C236A9998" xlink:to="lab_us-gaap_Goodwill_AFDDC1EDE9FA9FFD9C640F0C236A9998" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_A22D53CFDBA2BF29CDAA6B8C740701A6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_A22D53CFDBA2BF29CDAA6B8C740701A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_A22D53CFDBA2BF29CDAA6B8C740701A6_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_A22D53CFDBA2BF29CDAA6B8C740701A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_A22D53CFDBA2BF29CDAA6B8C740701A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_A22D53CFDBA2BF29CDAA6B8C740701A6" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_A22D53CFDBA2BF29CDAA6B8C740701A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8CE43E3E67E82C4540A906E59B4C5F0A_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8CE43E3E67E82C4540A906E59B4C5F0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8CE43E3E67E82C4540A906E59B4C5F0A_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8CE43E3E67E82C4540A906E59B4C5F0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8CE43E3E67E82C4540A906E59B4C5F0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8CE43E3E67E82C4540A906E59B4C5F0A" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8CE43E3E67E82C4540A906E59B4C5F0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_E691FD2CDFF8AA39D26206E59B4C6252_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_E691FD2CDFF8AA39D26206E59B4C6252" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_E691FD2CDFF8AA39D26206E59B4C6252_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_E691FD2CDFF8AA39D26206E59B4C6252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_E691FD2CDFF8AA39D26206E59B4C6252" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_E691FD2CDFF8AA39D26206E59B4C6252" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_E691FD2CDFF8AA39D26206E59B4C6252" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44A26DA936435DEFEE1F06E59B4C1C1A_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44A26DA936435DEFEE1F06E59B4C1C1A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44A26DA936435DEFEE1F06E59B4C1C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44A26DA936435DEFEE1F06E59B4C1C1A" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44A26DA936435DEFEE1F06E59B4C1C1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:to="lab_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:to="lab_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:type="arc" />
    <link:label id="lab_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356_terseLabel_en-US" xlink:label="lab_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Largest Customer</link:label>
    <link:label id="lab_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356_label_en-US" xlink:label="lab_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest Customer [Member]</link:label>
    <link:label id="lab_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356_documentation_en-US" xlink:label="lab_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Largest Customer [Member]</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_LargestCustomerMember" xlink:label="loc_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356" xlink:to="lab_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61" xlink:to="lab_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A" xlink:to="lab_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:to="lab_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:to="lab_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:type="arc" />
    <link:label id="lab_country_US_4E07D8A9B2243407B00D8065CB07A2BF_terseLabel_en-US" xlink:label="lab_country_US_4E07D8A9B2243407B00D8065CB07A2BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_4E07D8A9B2243407B00D8065CB07A2BF_label_en-US" xlink:label="lab_country_US_4E07D8A9B2243407B00D8065CB07A2BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_4E07D8A9B2243407B00D8065CB07A2BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_4E07D8A9B2243407B00D8065CB07A2BF" xlink:to="lab_country_US_4E07D8A9B2243407B00D8065CB07A2BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ex-U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB_label_en-US" xlink:label="lab_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB" xlink:to="lab_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0E7968F212AC5B455DFFF4CA962457B7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0E7968F212AC5B455DFFF4CA962457B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income (Loss) before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0E7968F212AC5B455DFFF4CA962457B7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0E7968F212AC5B455DFFF4CA962457B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0E7968F212AC5B455DFFF4CA962457B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0E7968F212AC5B455DFFF4CA962457B7" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0E7968F212AC5B455DFFF4CA962457B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_097FA3744FC60167C87EF4CA9624D01B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_097FA3744FC60167C87EF4CA9624D01B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_097FA3744FC60167C87EF4CA9624D01B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_097FA3744FC60167C87EF4CA9624D01B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_097FA3744FC60167C87EF4CA9624D01B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_097FA3744FC60167C87EF4CA9624D01B" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_097FA3744FC60167C87EF4CA9624D01B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E419D0863BDB10323CF7F4CA9624FEEE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E419D0863BDB10323CF7F4CA9624FEEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of the Statutory Tax Rates and the Effective Tax Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E419D0863BDB10323CF7F4CA9624FEEE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E419D0863BDB10323CF7F4CA9624FEEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E419D0863BDB10323CF7F4CA9624FEEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E419D0863BDB10323CF7F4CA9624FEEE" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E419D0863BDB10323CF7F4CA9624FEEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_10105552F86874C4ACFAF4CA96246745_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_10105552F86874C4ACFAF4CA96246745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Components of the Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_10105552F86874C4ACFAF4CA96246745_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_10105552F86874C4ACFAF4CA96246745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_10105552F86874C4ACFAF4CA96246745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_10105552F86874C4ACFAF4CA96246745" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_10105552F86874C4ACFAF4CA96246745" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:type="arc" />
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B_terseLabel_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B_label_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B_documentation_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ShortTermCorporateDebtSecuritiesMember" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B" xlink:to="lab_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246" xlink:to="lab_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F" xlink:to="lab_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2" xlink:type="arc" />
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost, cash balances and debt securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, cash balances</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E" xlink:type="arc" />
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair value, cash balances and debt securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities with maturity date greater than 12 months</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_1D110BF8BB80E64C1CD4F4CA95E02863_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_1D110BF8BB80E64C1CD4F4CA95E02863" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_1D110BF8BB80E64C1CD4F4CA95E02863_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_1D110BF8BB80E64C1CD4F4CA95E02863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1D110BF8BB80E64C1CD4F4CA95E02863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1D110BF8BB80E64C1CD4F4CA95E02863" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_1D110BF8BB80E64C1CD4F4CA95E02863" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_6C874772D1E8C9E10DEAF4CA96629E8B_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_6C874772D1E8C9E10DEAF4CA96629E8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Liability Components of the Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_6C874772D1E8C9E10DEAF4CA96629E8B_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_6C874772D1E8C9E10DEAF4CA96629E8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_6C874772D1E8C9E10DEAF4CA96629E8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_6C874772D1E8C9E10DEAF4CA96629E8B" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_6C874772D1E8C9E10DEAF4CA96629E8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_DB5ACCDC5F06BA30DEDDF4CA96632A64_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_DB5ACCDC5F06BA30DEDDF4CA96632A64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Total Interest Expense Recognized Related to the Convertible Notes</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_DB5ACCDC5F06BA30DEDDF4CA96632A64_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_DB5ACCDC5F06BA30DEDDF4CA96632A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_DB5ACCDC5F06BA30DEDDF4CA96632A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_DB5ACCDC5F06BA30DEDDF4CA96632A64" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_DB5ACCDC5F06BA30DEDDF4CA96632A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_7CDAC3086C7462874E29F4CC291B0E6A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss_7CDAC3086C7462874E29F4CC291B0E6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, realized gain (loss)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_7CDAC3086C7462874E29F4CC291B0E6A_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss_7CDAC3086C7462874E29F4CC291B0E6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_7CDAC3086C7462874E29F4CC291B0E6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesRealizedGainLoss_7CDAC3086C7462874E29F4CC291B0E6A" xlink:to="lab_us-gaap_DebtSecuritiesRealizedGainLoss_7CDAC3086C7462874E29F4CC291B0E6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_E22BB21C705FF5379478F4CC298F29C2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_E22BB21C705FF5379478F4CC298F29C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of available-for-sale debt securities in unrealized loss positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_E22BB21C705FF5379478F4CC298F29C2_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_E22BB21C705FF5379478F4CC298F29C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_E22BB21C705FF5379478F4CC298F29C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_E22BB21C705FF5379478F4CC298F29C2" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_E22BB21C705FF5379478F4CC298F29C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:to="lab_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:to="lab_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_AD84902415A769223A515A1077157B5A_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_AD84902415A769223A515A1077157B5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_AD84902415A769223A515A1077157B5A_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_AD84902415A769223A515A1077157B5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_AD84902415A769223A515A1077157B5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_AD84902415A769223A515A1077157B5A" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_AD84902415A769223A515A1077157B5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_137449E12EC16618D2265A10771608DA_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_137449E12EC16618D2265A10771608DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_137449E12EC16618D2265A10771608DA_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_137449E12EC16618D2265A10771608DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_137449E12EC16618D2265A10771608DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_137449E12EC16618D2265A10771608DA" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_137449E12EC16618D2265A10771608DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_8D149F2A95DD62831D8C5A10771662AA_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_8D149F2A95DD62831D8C5A10771662AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_8D149F2A95DD62831D8C5A10771662AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_8D149F2A95DD62831D8C5A10771662AA" xlink:to="lab_us-gaap_InventoryNet_8D149F2A95DD62831D8C5A10771662AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44881851DBCDC16B09935A10771601B7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44881851DBCDC16B09935A10771601B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44881851DBCDC16B09935A10771601B7_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44881851DBCDC16B09935A10771601B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44881851DBCDC16B09935A10771601B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44881851DBCDC16B09935A10771601B7" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44881851DBCDC16B09935A10771601B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_7764DC38042947D3904D5A107716D4AE_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_7764DC38042947D3904D5A107716D4AE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_7764DC38042947D3904D5A107716D4AE_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_7764DC38042947D3904D5A107716D4AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7764DC38042947D3904D5A107716D4AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_7764DC38042947D3904D5A107716D4AE" xlink:to="lab_us-gaap_AssetsCurrent_7764DC38042947D3904D5A107716D4AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_FF11C0680C73A0C715855A107716405C_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_FF11C0680C73A0C715855A107716405C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets, less accumulated amortization of $5,342 and $0 at December 31, 2019 and December 31, 2018, respectively</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_FF11C0680C73A0C715855A107716405C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_FF11C0680C73A0C715855A107716405C" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_FF11C0680C73A0C715855A107716405C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_12C799AF1655D7BCB3FF5A1077161A00_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_12C799AF1655D7BCB3FF5A1077161A00" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, less accumulated depreciation of $17,604 and $15,671 at December 31, 2019 and December 31, 2018, respectively</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12C799AF1655D7BCB3FF5A1077161A00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_12C799AF1655D7BCB3FF5A1077161A00" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_12C799AF1655D7BCB3FF5A1077161A00" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1B4AFDEF26E5AEBA98905A107717EB9B_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1B4AFDEF26E5AEBA98905A107717EB9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research &amp; development</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1B4AFDEF26E5AEBA98905A107717EB9B_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1B4AFDEF26E5AEBA98905A107717EB9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1B4AFDEF26E5AEBA98905A107717EB9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1B4AFDEF26E5AEBA98905A107717EB9B" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1B4AFDEF26E5AEBA98905A107717EB9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2FB6D7F18C356F545D375A107717D459_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_2FB6D7F18C356F545D375A107717D459" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2FB6D7F18C356F545D375A107717D459_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_2FB6D7F18C356F545D375A107717D459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2FB6D7F18C356F545D375A107717D459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_2FB6D7F18C356F545D375A107717D459" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_2FB6D7F18C356F545D375A107717D459" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_569ABB8B0731DC78D32C5A1077173E07_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_569ABB8B0731DC78D32C5A1077173E07" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_569ABB8B0731DC78D32C5A1077173E07_label_en-US" xlink:label="lab_us-gaap_Assets_569ABB8B0731DC78D32C5A1077173E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_569ABB8B0731DC78D32C5A1077173E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_569ABB8B0731DC78D32C5A1077173E07" xlink:to="lab_us-gaap_Assets_569ABB8B0731DC78D32C5A1077173E07" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_599D1743656847EFFFEC5A10771858D3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_599D1743656847EFFFEC5A10771858D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_599D1743656847EFFFEC5A10771858D3_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_599D1743656847EFFFEC5A10771858D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Credits and Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_599D1743656847EFFFEC5A10771858D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_599D1743656847EFFFEC5A10771858D3" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_599D1743656847EFFFEC5A10771858D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_AFA33B0C72857264755E5A107718D321_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_AFA33B0C72857264755E5A107718D321" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_AFA33B0C72857264755E5A107718D321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_AFA33B0C72857264755E5A107718D321" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_AFA33B0C72857264755E5A107718D321" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_A215638D252C0B6A9A015A1077189C74_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A215638D252C0B6A9A015A1077189C74" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_A215638D252C0B6A9A015A1077189C74_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A215638D252C0B6A9A015A1077189C74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A215638D252C0B6A9A015A1077189C74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_A215638D252C0B6A9A015A1077189C74" xlink:to="lab_us-gaap_LiabilitiesCurrent_A215638D252C0B6A9A015A1077189C74" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_1DC8DB922FAD4C75749D5A107719AA69_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable_1DC8DB922FAD4C75749D5A107719AA69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_1DC8DB922FAD4C75749D5A107719AA69_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable_1DC8DB922FAD4C75749D5A107719AA69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_1DC8DB922FAD4C75749D5A107719AA69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_1DC8DB922FAD4C75749D5A107719AA69" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable_1DC8DB922FAD4C75749D5A107719AA69" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredLongTermDebt_EC3740DB914D228BB5105A107719F09B_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt_EC3740DB914D228BB5105A107719F09B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured term loan</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_EC3740DB914D228BB5105A107719F09B_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt_EC3740DB914D228BB5105A107719F09B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_EC3740DB914D228BB5105A107719F09B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt_EC3740DB914D228BB5105A107719F09B" xlink:to="lab_us-gaap_SecuredLongTermDebt_EC3740DB914D228BB5105A107719F09B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A2DAEB4F5242BF262D7E5A107719AD18_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A2DAEB4F5242BF262D7E5A107719AD18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A2DAEB4F5242BF262D7E5A107719AD18_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A2DAEB4F5242BF262D7E5A107719AD18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A2DAEB4F5242BF262D7E5A107719AD18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A2DAEB4F5242BF262D7E5A107719AD18" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A2DAEB4F5242BF262D7E5A107719AD18" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1CB17DBC7C3DA4E7B3DF5A1077198B1C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1CB17DBC7C3DA4E7B3DF5A1077198B1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1CB17DBC7C3DA4E7B3DF5A1077198B1C_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1CB17DBC7C3DA4E7B3DF5A1077198B1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1CB17DBC7C3DA4E7B3DF5A1077198B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1CB17DBC7C3DA4E7B3DF5A1077198B1C" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1CB17DBC7C3DA4E7B3DF5A1077198B1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_CEEB8A882CD4D42655D35A10771936A6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_CEEB8A882CD4D42655D35A10771936A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_CEEB8A882CD4D42655D35A10771936A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_CEEB8A882CD4D42655D35A10771936A6" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_CEEB8A882CD4D42655D35A10771936A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7BFA969878A0F11C88105A10771926EC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_7BFA969878A0F11C88105A10771926EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7BFA969878A0F11C88105A10771926EC_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_7BFA969878A0F11C88105A10771926EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7BFA969878A0F11C88105A10771926EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_7BFA969878A0F11C88105A10771926EC" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_7BFA969878A0F11C88105A10771926EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_50A2D33EF6D61D539C475A1077196A5A_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_50A2D33EF6D61D539C475A1077196A5A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_50A2D33EF6D61D539C475A1077196A5A_label_en-US" xlink:label="lab_us-gaap_Liabilities_50A2D33EF6D61D539C475A1077196A5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_50A2D33EF6D61D539C475A1077196A5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_50A2D33EF6D61D539C475A1077196A5A" xlink:to="lab_us-gaap_Liabilities_50A2D33EF6D61D539C475A1077196A5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7C2EA4D7EA1B0CF5CF955A10771A1181_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_7C2EA4D7EA1B0CF5CF955A10771A1181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7C2EA4D7EA1B0CF5CF955A10771A1181_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_7C2EA4D7EA1B0CF5CF955A10771A1181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7C2EA4D7EA1B0CF5CF955A10771A1181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_7C2EA4D7EA1B0CF5CF955A10771A1181" xlink:to="lab_us-gaap_CommitmentsAndContingencies_7C2EA4D7EA1B0CF5CF955A10771A1181" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:to="lab_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_BAD0822D44F45EA91D145A10771A434A_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_BAD0822D44F45EA91D145A10771A434A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $.01 par value, 500,000,000 shares authorized, 255,417,869 and 189,383,924 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_BAD0822D44F45EA91D145A10771A434A_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_BAD0822D44F45EA91D145A10771A434A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_BAD0822D44F45EA91D145A10771A434A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_BAD0822D44F45EA91D145A10771A434A" xlink:to="lab_us-gaap_CommonStockValue_BAD0822D44F45EA91D145A10771A434A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_BB5E8ADC98EB2B1180305A10771AEF92_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_BB5E8ADC98EB2B1180305A10771AEF92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_BB5E8ADC98EB2B1180305A10771AEF92_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_BB5E8ADC98EB2B1180305A10771AEF92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_BB5E8ADC98EB2B1180305A10771AEF92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_BB5E8ADC98EB2B1180305A10771AEF92" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_BB5E8ADC98EB2B1180305A10771AEF92" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_D50F8194BAF97D01BA345A10771BDD72_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_D50F8194BAF97D01BA345A10771BDD72" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_D50F8194BAF97D01BA345A10771BDD72_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_D50F8194BAF97D01BA345A10771BDD72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_D50F8194BAF97D01BA345A10771BDD72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_D50F8194BAF97D01BA345A10771BDD72" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_D50F8194BAF97D01BA345A10771BDD72" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C7C72C0B157CA906B84A5A10771B3240_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C7C72C0B157CA906B84A5A10771B3240" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on available-for securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C7C72C0B157CA906B84A5A10771B3240_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C7C72C0B157CA906B84A5A10771B3240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C7C72C0B157CA906B84A5A10771B3240" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C7C72C0B157CA906B84A5A10771B3240" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C7C72C0B157CA906B84A5A10771B3240" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_232459848D7EEBA785CE5A10771B979E_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_232459848D7EEBA785CE5A10771B979E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_232459848D7EEBA785CE5A10771B979E_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_232459848D7EEBA785CE5A10771B979E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_232459848D7EEBA785CE5A10771B979E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_232459848D7EEBA785CE5A10771B979E" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_232459848D7EEBA785CE5A10771B979E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_02E40DECE1AF6437AABF5A10771BE8D5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_02E40DECE1AF6437AABF5A10771BE8D5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_02E40DECE1AF6437AABF5A10771BE8D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_02E40DECE1AF6437AABF5A10771BE8D5" xlink:to="lab_us-gaap_StockholdersEquity_02E40DECE1AF6437AABF5A10771BE8D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6C709C5B45C992C5C8195A10771C6297_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_6C709C5B45C992C5C8195A10771C6297" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6C709C5B45C992C5C8195A10771C6297_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_6C709C5B45C992C5C8195A10771C6297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6C709C5B45C992C5C8195A10771C6297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6C709C5B45C992C5C8195A10771C6297" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_6C709C5B45C992C5C8195A10771C6297" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:to="lab_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_55077C6D9D5BEA82093B06E59B8C5A39_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_55077C6D9D5BEA82093B06E59B8C5A39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_55077C6D9D5BEA82093B06E59B8C5A39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_55077C6D9D5BEA82093B06E59B8C5A39" xlink:to="lab_us-gaap_OperatingLeaseLiability_55077C6D9D5BEA82093B06E59B8C5A39" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_76EC8BF314C40E1EE3C306E59B91BF03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract_76EC8BF314C40E1EE3C306E59B91BF03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_76EC8BF314C40E1EE3C306E59B91BF03_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract_76EC8BF314C40E1EE3C306E59B91BF03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_76EC8BF314C40E1EE3C306E59B91BF03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_76EC8BF314C40E1EE3C306E59B91BF03" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract_76EC8BF314C40E1EE3C306E59B91BF03" xlink:type="arc" />
    <link:label id="lab_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of equity-based employee compensation plans</link:label>
    <link:label id="lab_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792_label_en-US" xlink:label="lab_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Number of Plans</link:label>
    <link:label id="lab_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of plans under the equity-based arrangements.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ShareBasedCompensationNumberOfPlans" xlink:label="loc_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792" xlink:to="lab_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_D94FAEF0182049283D238065CA117000_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_D94FAEF0182049283D238065CA117000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_D94FAEF0182049283D238065CA117000_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_D94FAEF0182049283D238065CA117000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_D94FAEF0182049283D238065CA117000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_D94FAEF0182049283D238065CA117000" xlink:to="lab_us-gaap_AccountsPayableCurrent_D94FAEF0182049283D238065CA117000" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_B6B6E4049F73A2DCACCC8065CA12F529_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_B6B6E4049F73A2DCACCC8065CA12F529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_B6B6E4049F73A2DCACCC8065CA12F529_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_B6B6E4049F73A2DCACCC8065CA12F529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_B6B6E4049F73A2DCACCC8065CA12F529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_B6B6E4049F73A2DCACCC8065CA12F529" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_B6B6E4049F73A2DCACCC8065CA12F529" xlink:type="arc" />
    <link:label id="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6_terseLabel_en-US" xlink:label="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued contract manufacturing &amp; contract research costs</link:label>
    <link:label id="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6_label_en-US" xlink:label="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Contract Manufacturing and Contract Research Costs Current</link:label>
    <link:label id="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6_documentation_en-US" xlink:label="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:label="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6" xlink:to="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_52637272F518A71CE2BB8065CA12DDE5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_52637272F518A71CE2BB8065CA12DDE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_52637272F518A71CE2BB8065CA12DDE5_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_52637272F518A71CE2BB8065CA12DDE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_52637272F518A71CE2BB8065CA12DDE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_52637272F518A71CE2BB8065CA12DDE5" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_52637272F518A71CE2BB8065CA12DDE5" xlink:type="arc" />
    <link:label id="lab_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83_terseLabel_en-US" xlink:label="lab_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued program fees</link:label>
    <link:label id="lab_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83_label_en-US" xlink:label="lab_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Program Fees</link:label>
    <link:label id="lab_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83_documentation_en-US" xlink:label="lab_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable related to a pharmaceutical program, including but not limited to clinical studies or commercial preparation activities.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedProgramFees" xlink:label="loc_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83" xlink:to="lab_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_F919DAE66D0AB4FFB0F78065CA12D75A_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_F919DAE66D0AB4FFB0F78065CA12D75A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_F919DAE66D0AB4FFB0F78065CA12D75A_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_F919DAE66D0AB4FFB0F78065CA12D75A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_F919DAE66D0AB4FFB0F78065CA12D75A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_F919DAE66D0AB4FFB0F78065CA12D75A" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_F919DAE66D0AB4FFB0F78065CA12D75A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_39493592E3203C92EEC18065CA1283E2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_39493592E3203C92EEC18065CA1283E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_39493592E3203C92EEC18065CA1283E2_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_39493592E3203C92EEC18065CA1283E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_39493592E3203C92EEC18065CA1283E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_39493592E3203C92EEC18065CA1283E2" xlink:to="lab_us-gaap_InterestPayableCurrent_39493592E3203C92EEC18065CA1283E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_CD06CB3F0CF6042A0BE98065CA1319F1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_CD06CB3F0CF6042A0BE98065CA1319F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued milestones</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_CD06CB3F0CF6042A0BE98065CA1319F1_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_CD06CB3F0CF6042A0BE98065CA1319F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_CD06CB3F0CF6042A0BE98065CA1319F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_CD06CB3F0CF6042A0BE98065CA1319F1" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_CD06CB3F0CF6042A0BE98065CA1319F1" xlink:type="arc" />
    <link:label id="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94_terseLabel_en-US" xlink:label="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued sales rebates and discounts</link:label>
    <link:label id="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94_label_en-US" xlink:label="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Rebates And Chargebacks, Current</link:label>
    <link:label id="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94_documentation_en-US" xlink:label="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Sales Rebates And Chargebacks, Current</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:label="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94" xlink:to="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_D9EE9BA2A55EAA0B43B080766CA3D95C_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_D9EE9BA2A55EAA0B43B080766CA3D95C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_D9EE9BA2A55EAA0B43B080766CA3D95C_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_D9EE9BA2A55EAA0B43B080766CA3D95C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_D9EE9BA2A55EAA0B43B080766CA3D95C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_D9EE9BA2A55EAA0B43B080766CA3D95C" xlink:to="lab_us-gaap_TaxesPayableCurrent_D9EE9BA2A55EAA0B43B080766CA3D95C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_638256014392644FC9D48065CA13E5C0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_638256014392644FC9D48065CA13E5C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_638256014392644FC9D48065CA13E5C0_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_638256014392644FC9D48065CA13E5C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_638256014392644FC9D48065CA13E5C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_638256014392644FC9D48065CA13E5C0" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_638256014392644FC9D48065CA13E5C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_977D8AA7EFE539F232578065CA1317B8_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_977D8AA7EFE539F232578065CA1317B8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_977D8AA7EFE539F232578065CA1317B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_977D8AA7EFE539F232578065CA1317B8" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_977D8AA7EFE539F232578065CA1317B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82D12F3BDDC3FE2072E506E59BA41342_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82D12F3BDDC3FE2072E506E59BA41342" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82D12F3BDDC3FE2072E506E59BA41342_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82D12F3BDDC3FE2072E506E59BA41342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82D12F3BDDC3FE2072E506E59BA41342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82D12F3BDDC3FE2072E506E59BA41342" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82D12F3BDDC3FE2072E506E59BA41342" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_E264E5A89D243D2726E306E59BA41004_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_E264E5A89D243D2726E306E59BA41004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_E264E5A89D243D2726E306E59BA41004_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_E264E5A89D243D2726E306E59BA41004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_E264E5A89D243D2726E306E59BA41004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_E264E5A89D243D2726E306E59BA41004" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_E264E5A89D243D2726E306E59BA41004" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_EB9B02A2247BDF53C6B906E59BA447C8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_EB9B02A2247BDF53C6B906E59BA447C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_EB9B02A2247BDF53C6B906E59BA447C8_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_EB9B02A2247BDF53C6B906E59BA447C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_EB9B02A2247BDF53C6B906E59BA447C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_EB9B02A2247BDF53C6B906E59BA447C8" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_EB9B02A2247BDF53C6B906E59BA447C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_8073ACF56E46602A974A06E59BA53EBC_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_8073ACF56E46602A974A06E59BA53EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_8073ACF56E46602A974A06E59BA53EBC_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_8073ACF56E46602A974A06E59BA53EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_8073ACF56E46602A974A06E59BA53EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_8073ACF56E46602A974A06E59BA53EBC" xlink:to="lab_us-gaap_UseOfEstimates_8073ACF56E46602A974A06E59BA53EBC" xlink:type="arc" />
    <link:label id="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43_terseLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities [Policy Text Block]</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43" xlink:to="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_DEC54CDE6B5F0143572406E59BA5934E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_DEC54CDE6B5F0143572406E59BA5934E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_DEC54CDE6B5F0143572406E59BA5934E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_DEC54CDE6B5F0143572406E59BA5934E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_DEC54CDE6B5F0143572406E59BA5934E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_DEC54CDE6B5F0143572406E59BA5934E" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_DEC54CDE6B5F0143572406E59BA5934E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4BFCADED9B07BE850DC606E59BA54CB3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4BFCADED9B07BE850DC606E59BA54CB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4BFCADED9B07BE850DC606E59BA54CB3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4BFCADED9B07BE850DC606E59BA54CB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4BFCADED9B07BE850DC606E59BA54CB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4BFCADED9B07BE850DC606E59BA54CB3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4BFCADED9B07BE850DC606E59BA54CB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_F0D42A22594863806E1706E59BA5DFCD_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_F0D42A22594863806E1706E59BA5DFCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_F0D42A22594863806E1706E59BA5DFCD_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_F0D42A22594863806E1706E59BA5DFCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_F0D42A22594863806E1706E59BA5DFCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_F0D42A22594863806E1706E59BA5DFCD" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_F0D42A22594863806E1706E59BA5DFCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_03FED454C487F7BA2D1A06E59BA51463_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_03FED454C487F7BA2D1A06E59BA51463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories and Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_03FED454C487F7BA2D1A06E59BA51463_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_03FED454C487F7BA2D1A06E59BA51463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_03FED454C487F7BA2D1A06E59BA51463" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_03FED454C487F7BA2D1A06E59BA51463" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_03FED454C487F7BA2D1A06E59BA51463" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0FBCDD4A9EAFC602AA7606E59BA65A6C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0FBCDD4A9EAFC602AA7606E59BA65A6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0FBCDD4A9EAFC602AA7606E59BA65A6C_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0FBCDD4A9EAFC602AA7606E59BA65A6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0FBCDD4A9EAFC602AA7606E59BA65A6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0FBCDD4A9EAFC602AA7606E59BA65A6C" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0FBCDD4A9EAFC602AA7606E59BA65A6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_80552152FA2476C40CC106E59BA6A5BD_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_80552152FA2476C40CC106E59BA6A5BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Liabilities</link:label>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_80552152FA2476C40CC106E59BA6A5BD_label_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_80552152FA2476C40CC106E59BA6A5BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_80552152FA2476C40CC106E59BA6A5BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_80552152FA2476C40CC106E59BA6A5BD" xlink:to="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_80552152FA2476C40CC106E59BA6A5BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_96B3550638B5F2F4D5F606E59BA69636_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_96B3550638B5F2F4D5F606E59BA69636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_96B3550638B5F2F4D5F606E59BA69636_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_96B3550638B5F2F4D5F606E59BA69636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_96B3550638B5F2F4D5F606E59BA69636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_96B3550638B5F2F4D5F606E59BA69636" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_96B3550638B5F2F4D5F606E59BA69636" xlink:type="arc" />
    <link:label id="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76_terseLabel_en-US" xlink:label="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense</link:label>
    <link:label id="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76_label_en-US" xlink:label="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense [Policy Text Block]</link:label>
    <link:label id="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76_documentation_en-US" xlink:label="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for interest income and interest expense.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:label="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76" xlink:to="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9F531953F8E001EBC5E106E59BA62AE2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_9F531953F8E001EBC5E106E59BA62AE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9F531953F8E001EBC5E106E59BA62AE2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_9F531953F8E001EBC5E106E59BA62AE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9F531953F8E001EBC5E106E59BA62AE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_9F531953F8E001EBC5E106E59BA62AE2" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_9F531953F8E001EBC5E106E59BA62AE2" xlink:type="arc" />
    <link:label id="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A_terseLabel_en-US" xlink:label="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A_label_en-US" xlink:label="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income Policy [Policy Text Block]</link:label>
    <link:label id="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A_documentation_en-US" xlink:label="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for other comprehensive income.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A" xlink:to="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_07DFC17E7946B081497006E59BA7C8AB_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_07DFC17E7946B081497006E59BA7C8AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_07DFC17E7946B081497006E59BA7C8AB_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_07DFC17E7946B081497006E59BA7C8AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_07DFC17E7946B081497006E59BA7C8AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_07DFC17E7946B081497006E59BA7C8AB" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_07DFC17E7946B081497006E59BA7C8AB" xlink:type="arc" />
    <link:label id="lab_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB_terseLabel_en-US" xlink:label="lab_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonqualified Cash Deferral Plan</link:label>
    <link:label id="lab_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB_label_en-US" xlink:label="lab_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonqualified Cash Deferral Plans Policy</link:label>
    <link:label id="lab_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB_documentation_en-US" xlink:label="lab_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_NonqualifiedCashDeferralPlansPolicy" xlink:label="loc_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB" xlink:to="lab_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64B11EE7DDA01CFEF4A606E59BA718AE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64B11EE7DDA01CFEF4A606E59BA718AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64B11EE7DDA01CFEF4A606E59BA718AE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64B11EE7DDA01CFEF4A606E59BA718AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64B11EE7DDA01CFEF4A606E59BA718AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64B11EE7DDA01CFEF4A606E59BA718AE" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64B11EE7DDA01CFEF4A606E59BA718AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_4A1CBEB4804CE5CDF53B06E59BA78B33_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_4A1CBEB4804CE5CDF53B06E59BA78B33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_4A1CBEB4804CE5CDF53B06E59BA78B33_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_4A1CBEB4804CE5CDF53B06E59BA78B33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_4A1CBEB4804CE5CDF53B06E59BA78B33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_4A1CBEB4804CE5CDF53B06E59BA78B33" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_4A1CBEB4804CE5CDF53B06E59BA78B33" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_F6FD0EC7749B625F326606E59BA7311F_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_F6FD0EC7749B625F326606E59BA7311F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_F6FD0EC7749B625F326606E59BA7311F_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_F6FD0EC7749B625F326606E59BA7311F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_F6FD0EC7749B625F326606E59BA7311F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_F6FD0EC7749B625F326606E59BA7311F" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_F6FD0EC7749B625F326606E59BA7311F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_7EE80494CCAF4644142A06E59BA76C32_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_7EE80494CCAF4644142A06E59BA76C32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_7EE80494CCAF4644142A06E59BA76C32_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_7EE80494CCAF4644142A06E59BA76C32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_7EE80494CCAF4644142A06E59BA76C32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_7EE80494CCAF4644142A06E59BA76C32" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_7EE80494CCAF4644142A06E59BA76C32" xlink:type="arc" />
    <link:label id="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2_terseLabel_en-US" xlink:label="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Payable</link:label>
    <link:label id="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2_label_en-US" xlink:label="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Acquisition Consideration Payable [Policy Text Block]</link:label>
    <link:label id="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2_documentation_en-US" xlink:label="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:label="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2" xlink:to="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_E91F2DC8FA971A41F49306E59BA8CCA2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_E91F2DC8FA971A41F49306E59BA8CCA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_E91F2DC8FA971A41F49306E59BA8CCA2_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_E91F2DC8FA971A41F49306E59BA8CCA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_E91F2DC8FA971A41F49306E59BA8CCA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_E91F2DC8FA971A41F49306E59BA8CCA2" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_E91F2DC8FA971A41F49306E59BA8CCA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295451EDF3048C0BA5EF06E59BA8CB68_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295451EDF3048C0BA5EF06E59BA8CB68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Developments</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295451EDF3048C0BA5EF06E59BA8CB68_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295451EDF3048C0BA5EF06E59BA8CB68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295451EDF3048C0BA5EF06E59BA8CB68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295451EDF3048C0BA5EF06E59BA8CB68" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295451EDF3048C0BA5EF06E59BA8CB68" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:to="lab_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07" xlink:type="arc" />
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853_terseLabel_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred financing</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853_label_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Deferred Financing Costs</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853_documentation_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_AmortizationDeferredFinancingCosts" xlink:label="loc_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853" xlink:to="lab_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate of the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_B331BC341BD19BF34843F4CA963EA91D_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_B331BC341BD19BF34843F4CA963EA91D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_B331BC341BD19BF34843F4CA963EA91D_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_B331BC341BD19BF34843F4CA963EA91D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_B331BC341BD19BF34843F4CA963EA91D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_B331BC341BD19BF34843F4CA963EA91D" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_B331BC341BD19BF34843F4CA963EA91D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10DD4D717384D8E80EEDF4CA963E9C3F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10DD4D717384D8E80EEDF4CA963E9C3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Minimum Lease Payments, Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10DD4D717384D8E80EEDF4CA963E9C3F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10DD4D717384D8E80EEDF4CA963E9C3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10DD4D717384D8E80EEDF4CA963E9C3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10DD4D717384D8E80EEDF4CA963E9C3F" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10DD4D717384D8E80EEDF4CA963E9C3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E9D2571BCAF941DF482CF4CA963E2337_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E9D2571BCAF941DF482CF4CA963E2337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E9D2571BCAF941DF482CF4CA963E2337_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E9D2571BCAF941DF482CF4CA963E2337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E9D2571BCAF941DF482CF4CA963E2337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E9D2571BCAF941DF482CF4CA963E2337" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E9D2571BCAF941DF482CF4CA963E2337" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74E01337F4EEBC279E2EFE14A0877FAC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74E01337F4EEBC279E2EFE14A0877FAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74E01337F4EEBC279E2EFE14A0877FAC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74E01337F4EEBC279E2EFE14A0877FAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74E01337F4EEBC279E2EFE14A0877FAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74E01337F4EEBC279E2EFE14A0877FAC" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74E01337F4EEBC279E2EFE14A0877FAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_365A1A48F13DD425C4F5F4CA967C1FB8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_365A1A48F13DD425C4F5F4CA967C1FB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Assets and Liabilities Subject to Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_365A1A48F13DD425C4F5F4CA967C1FB8_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_365A1A48F13DD425C4F5F4CA967C1FB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_365A1A48F13DD425C4F5F4CA967C1FB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_365A1A48F13DD425C4F5F4CA967C1FB8" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_365A1A48F13DD425C4F5F4CA967C1FB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_70B00742343AA6F9B497F4CA967DA9F0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_70B00742343AA6F9B497F4CA967DA9F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_70B00742343AA6F9B497F4CA967DA9F0_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_70B00742343AA6F9B497F4CA967DA9F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_70B00742343AA6F9B497F4CA967DA9F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_70B00742343AA6F9B497F4CA967DA9F0" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_70B00742343AA6F9B497F4CA967DA9F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_DA8732B94CE07819DD53F4CA967D0B32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_DA8732B94CE07819DD53F4CA967D0B32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Contingent Consideration Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_DA8732B94CE07819DD53F4CA967D0B32_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_DA8732B94CE07819DD53F4CA967D0B32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_DA8732B94CE07819DD53F4CA967D0B32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_DA8732B94CE07819DD53F4CA967D0B32" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_DA8732B94CE07819DD53F4CA967D0B32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total equity compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7" xlink:type="arc" />
    <link:label id="lab_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0_terseLabel_en-US" xlink:label="lab_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATB-200 Pompe Program</link:label>
    <link:label id="lab_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0_label_en-US" xlink:label="lab_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">T B200 Pompe Program [Member]</link:label>
    <link:label id="lab_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0_documentation_en-US" xlink:label="lab_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to ATB-200 Pompe program.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_TB200PompeProgramMember" xlink:label="loc_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0" xlink:to="lab_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0" xlink:type="arc" />
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical and Regulatory Approval Milestones</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860_label_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Liability Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to clinical and regulatory contingent consideration milestones.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860" xlink:to="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:to="lab_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:to="lab_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:type="arc" />
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094_terseLabel_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability Weighted Discounted Cash Flow</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094_label_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probability Weighted Discounted Cash Flow [Member]</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094_documentation_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to valuation technique of probability weighted discounted cash flow.</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094" xlink:to="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB" xlink:type="arc" />
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3_terseLabel_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of Milestone Achievement</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3_label_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3_documentation_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3" xlink:to="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities subject to fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation plan liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair value of liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of the debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7" xlink:type="arc" />
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration, measurement input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541_label_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationMeasurementInput" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541" xlink:to="lab_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1877A8A6DBC811CFA0C106E59B8FE813_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_1877A8A6DBC811CFA0C106E59B8FE813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1877A8A6DBC811CFA0C106E59B8FE813_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_1877A8A6DBC811CFA0C106E59B8FE813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1877A8A6DBC811CFA0C106E59B8FE813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_1877A8A6DBC811CFA0C106E59B8FE813" xlink:to="lab_us-gaap_NumberOfOperatingSegments_1877A8A6DBC811CFA0C106E59B8FE813" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportingUnits_C959832D0C5C846A7AD106E59B8F0AE0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits_C959832D0C5C846A7AD106E59B8F0AE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_C959832D0C5C846A7AD106E59B8F0AE0_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits_C959832D0C5C846A7AD106E59B8F0AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_C959832D0C5C846A7AD106E59B8F0AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits_C959832D0C5C846A7AD106E59B8F0AE0" xlink:to="lab_us-gaap_NumberOfReportingUnits_C959832D0C5C846A7AD106E59B8F0AE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_609125FABB33296645236B8C7480F666_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_609125FABB33296645236B8C7480F666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_609125FABB33296645236B8C7480F666_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_609125FABB33296645236B8C7480F666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_609125FABB33296645236B8C7480F666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_609125FABB33296645236B8C7480F666" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_609125FABB33296645236B8C7480F666" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_B2FED7700321B2BE9E796B8C74B7DED4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_B2FED7700321B2BE9E796B8C74B7DED4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_B2FED7700321B2BE9E796B8C74B7DED4_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_B2FED7700321B2BE9E796B8C74B7DED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_B2FED7700321B2BE9E796B8C74B7DED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_B2FED7700321B2BE9E796B8C74B7DED4" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_B2FED7700321B2BE9E796B8C74B7DED4" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>fold-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities" xlink:href="fold-20191231.xsd#AccountsPayableAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="fold-20191231.xsd#AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="fold-20191231.xsd#AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Acquisitions" xlink:href="fold-20191231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AcquisitionsDetails" xlink:href="fold-20191231.xsd#AcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesMeasuredAtFairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:href="fold-20191231.xsd#AssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare" xlink:href="fold-20191231.xsd#BasicAndDilutedNetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails" xlink:href="fold-20191231.xsd#BasicAndDilutedNetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables" xlink:href="fold-20191231.xsd#BasicAndDilutedNetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables" xlink:href="fold-20191231.xsd#CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreements" xlink:href="fold-20191231.xsd#CollaborativeAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:href="fold-20191231.xsd#CollaborativeAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:href="fold-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="fold-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations" xlink:href="fold-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CoverPage" xlink:href="fold-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:href="fold-20191231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails" xlink:href="fold-20191231.xsd#DebtConvertibleNotesAndSeniorSecuredTermLoanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:href="fold-20191231.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:href="fold-20191231.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:href="fold-20191231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionOfBusiness" xlink:href="fold-20191231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails" xlink:href="fold-20191231.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="fold-20191231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxes" xlink:href="fold-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails" xlink:href="fold-20191231.xsd#IncomeTaxesDeferredAndValuationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:href="fold-20191231.xsd#IncomeTaxesLossCarryforwardsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:href="fold-20191231.xsd#IncomeTaxesStatutoryRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesTables" xlink:href="fold-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:href="fold-20191231.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:href="fold-20191231.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:href="fold-20191231.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Leases" xlink:href="fold-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesDetails" xlink:href="fold-20191231.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesTables" xlink:href="fold-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipment" xlink:href="fold-20191231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails" xlink:href="fold-20191231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables" xlink:href="fold-20191231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="fold-20191231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="fold-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="fold-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:href="fold-20191231.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationRsusAndPbrsusSummaryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:href="fold-20191231.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:href="fold-20191231.xsd#ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:href="fold-20191231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails" xlink:href="fold-20191231.xsd#StockholdersEquityCommonStockAndWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails" xlink:href="fold-20191231.xsd#StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="fold-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1AC2B8A0BD9E09DB8D8CFE14A08922A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_802D1B1914953E55DD88FE14A0899F02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1AC2B8A0BD9E09DB8D8CFE14A08922A0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_802D1B1914953E55DD88FE14A0899F02" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4F7A55351BCEECBBF1498065CA115F88" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4F7A55351BCEECBBF1498065CA115F88" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_D94FAEF0182049283D238065CA117000" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_us-gaap_AccountsPayableCurrent_D94FAEF0182049283D238065CA117000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_B6B6E4049F73A2DCACCC8065CA12F529" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_B6B6E4049F73A2DCACCC8065CA12F529" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:label="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6B391DDFE9ABDA5053588065CA12D1C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_52637272F518A71CE2BB8065CA12DDE5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_52637272F518A71CE2BB8065CA12DDE5" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedProgramFees" xlink:label="loc_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_fold_AccruedProgramFees_8BE9C9143F9477115A918065CA126B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_F919DAE66D0AB4FFB0F78065CA12D75A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_F919DAE66D0AB4FFB0F78065CA12D75A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_39493592E3203C92EEC18065CA1283E2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_us-gaap_InterestPayableCurrent_39493592E3203C92EEC18065CA1283E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_CD06CB3F0CF6042A0BE98065CA1319F1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_CD06CB3F0CF6042A0BE98065CA1319F1" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:label="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_C4FC42467137162285658065CA13CF94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_D9EE9BA2A55EAA0B43B080766CA3D95C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_us-gaap_TaxesPayableCurrent_D9EE9BA2A55EAA0B43B080766CA3D95C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_638256014392644FC9D48065CA13E5C0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_638256014392644FC9D48065CA13E5C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_977D8AA7EFE539F232578065CA1317B8" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_C3EE13D9D98BB9A50B028065CA119BD6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_977D8AA7EFE539F232578065CA1317B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_FC4A597342DBF59F2F5AFE14A087B5EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74E01337F4EEBC279E2EFE14A0877FAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_FC4A597342DBF59F2F5AFE14A087B5EF" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74E01337F4EEBC279E2EFE14A0877FAC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_BD75B30EE13F0663AC686B8C74075D20" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_A22D53CFDBA2BF29CDAA6B8C740701A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_BD75B30EE13F0663AC686B8C74075D20" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_A22D53CFDBA2BF29CDAA6B8C740701A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3DC63E24C6ADBDFB8E9FF438F6100726" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3DC63E24C6ADBDFB8E9FF438F6100726" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AssetAcquisitionAxis" xlink:label="loc_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AssetAcquisitionDomain" xlink:label="loc_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_AssetAcquisitionAxis_ECA1C61009D6532C909FF438F610EFD8" xlink:to="loc_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CelenexMember" xlink:label="loc_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_AssetAcquisitionDomain_AA20BD1937EACAECE9E1F438F610F358" xlink:to="loc_fold_CelenexMember_857189D13E3DD50C7B8FF438F610310E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_813053E38A4DCFE2F5E7F438F610C301" xlink:to="loc_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NationwideChildrensHospitalMember" xlink:label="loc_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_EE862914C58855CEDAF1F438F610F160" xlink:to="loc_fold_NationwideChildrensHospitalMember_AD0B30A3B294B45AADAFF438F6104BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4DB03A173DCA13B5621BF438F6105DE1" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_E8EB13F7BBFE2A6372AEF438F610C621" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_B24F56F86D41EEDC4CDCF438F610711B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1104AD98C7A23809C75DF438F6104106" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MiamedIncMember" xlink:label="loc_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:to="loc_fold_MiamedIncMember_2285C22D3D6BC1D3E900F438F61037A7" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_SciodermIncMember" xlink:label="loc_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:to="loc_fold_SciodermIncMember_A7ABF7E3047501367F4AF438F6103FE5" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="loc_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EBE7944BF322314E2DBBF438F6106292" xlink:to="loc_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1A0C230DE81031C0204CF438F6101036" xlink:to="loc_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ParentCompanyMember" xlink:label="loc_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_911253171A7E34FA574EF438F620C2B3" xlink:to="loc_srt_ParentCompanyMember_21BE9A2A9BAB9739FB73F438F620E0F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_4DC1884E5A227457153BF438F6203547" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_srt_RangeAxis_4DC1884E5A227457153BF438F6203547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_743549F8EB631323E452F438F6207CE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4DC1884E5A227457153BF438F6203547" xlink:to="loc_srt_RangeMember_743549F8EB631323E452F438F6207CE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B262BF12837A80ACA992F438F6203480" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_743549F8EB631323E452F438F6207CE2" xlink:to="loc_srt_MaximumMember_B262BF12837A80ACA992F438F6203480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_247D946D5909F3661B2FF438F6205A80" xlink:to="loc_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B5F5F8A3C0C742AADA24F438F620AB5D" xlink:to="loc_us-gaap_CommonStockMember_20568226EFC5F7C75524F438F6207310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D474CE0441CC7928A5E2F438F6207947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_FixedAssetsMember" xlink:label="loc_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF4D9F328964410F0B86F438F620C1BE" xlink:to="loc_fold_FixedAssetsMember_7F13F5A91730A153FD3FF438F62082E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_389ECB871F12777C2B98F438F620B600" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ChangesInFairValueOfContingentConsiderationPayableMember" xlink:label="loc_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F3BBAE70D5BE98434BB1F438F6202F68" xlink:to="loc_fold_ChangesInFairValueOfContingentConsiderationPayableMember_B83346385D2D44AA02F3F438F620F8A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B0742E6062437E21B6E0F438F620FB3E" xlink:to="loc_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MilestonePaymentMember" xlink:label="loc_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CD48085D17507572F0B9F438F6204EDC" xlink:to="loc_fold_MilestonePaymentMember_29CC0632EF790A46C45AF438F6201B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0614AB5BC2E16AE4DB3FF438F620E7BD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86594AAB6DBABCCDAE40F438F620578D" xlink:to="loc_fold_CallidusBiopharmaIncMember_4BD67CA1EB6AD36331D3F438F610AD4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07BB51F4AC1A9DCFF578F438F610B2CD" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped" xlink:label="loc_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped_F52E91E9EB94A0C6984FF438F62088F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0ED6D6A149B21BB95319F438F620551F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment" xlink:label="loc_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment_DA567C64D3B05F726A4EF438F6207A4F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones" xlink:label="loc_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones_3E67979D201321A0CD7CF438F6202B95" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears" xlink:label="loc_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears_3A36405FA1E0DD124E62F438F6209E14" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AssetAcquisitionConsiderationTransferred" xlink:label="loc_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_AssetAcquisitionConsiderationTransferred_E1A1FCF3211C6683AFBEF438F6204299" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentsToAcquireBusinessAssets" xlink:label="loc_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_PaymentsToAcquireBusinessAssets_5DEFE4173124202B4340F438F620F41B" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0D4C4AF6AFBE7A70B839F438F620F631" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessAssetAcquisitionContingentConsiderationMilestones" xlink:label="loc_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_BusinessAssetAcquisitionContingentConsiderationMilestones_E93EA18A73B959456576F438F6206D51" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment" xlink:label="loc_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment_0D27FC0447B17E091780F438F620C12F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ResearchExpenseForStockIssuanceInAssetAcquisition" xlink:label="loc_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_ResearchExpenseForStockIssuanceInAssetAcquisition_3D14806520F9283AC4F5F438F6205518" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_BusinessCombinationOfEnrollmentRate" xlink:label="loc_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_BusinessCombinationOfEnrollmentRate_0D8DEA8B507A7067B2E0F438F6205A5B" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationMilestonePayment" xlink:label="loc_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_ContingentConsiderationMilestonePayment_F9CD511D896ADE4C3977F438F6203E0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_AssetImpairmentCharges_283CCCE6AA0A0A24FAA8F438F62055DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_533306F36DF6CE60FFFAF438F6201B9A" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_SellingGeneralAndAdministrativeCostsDueToWindDown" xlink:label="loc_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_SellingGeneralAndAdministrativeCostsDueToWindDown_C40B3A9D7643FE8732CCF438F620B9C4" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ResearchAndDevelopmentExpensesDueToWindDown" xlink:label="loc_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_ResearchAndDevelopmentExpensesDueToWindDown_D1348023AAB648538AF8F438F6209809" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_IncomeTaxExpenseBenefitDueToWindDown" xlink:label="loc_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_fold_IncomeTaxExpenseBenefitDueToWindDown_410F9316D1C4DC2878B8F438F620D3B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9E606821142A89843259F438F6202704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B5FC3EAE6B30ADA5E58F438F620944A" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_5FE9DDE88BF893ECC6DEF438F6206536" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D57F2DF47AC512BC6D7F06E59AC871AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D57F2DF47AC512BC6D7F06E59AC871AC" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_256BDCD8D41F0A55591D06E59AC828E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_256BDCD8D41F0A55591D06E59AC828E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6D62FC78AF95E750553106E59AC85BE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_256BDCD8D41F0A55591D06E59AC828E6" xlink:to="loc_us-gaap_EquityComponentDomain_6D62FC78AF95E750553106E59AC85BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A1A16C002F301BAF468B06E59AC961D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6D62FC78AF95E750553106E59AC85BE7" xlink:to="loc_us-gaap_CommonStockMember_A1A16C002F301BAF468B06E59AC961D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17325C904EBE4E68DBAA06E59AC9DBB5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_CD4AAF10C519D7D29A9E06E59AC9A87B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35A616B33B4732CD2A3206E59AC965B9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_F336D9B21AAF7AEC819706E59ACA9314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_99411C76C516B7479AC506E59ACA9105" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_99411C76C516B7479AC506E59ACA9105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_99411C76C516B7479AC506E59ACA9105" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_E8BEEED3A48EBE2B590506E59ACAF4EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_E8BEEED3A48EBE2B590506E59ACAF4EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_FA9D2C06A546F82AEE5E06E59ACB74FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_FA9D2C06A546F82AEE5E06E59ACB74FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_EF5AC1CFE98B9DF0F8EB06E59ACB7EE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2760E630EA877897924506E59ACB8FC2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2760E630EA877897924506E59ACB8FC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_852C45003812C247467606E59ACB7C5E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A670A0E3DC6D85B76DC806E59ACA44D4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_852C45003812C247467606E59ACB7C5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FB93AD08CF2525BCDBF806E59ACB07DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FB93AD08CF2525BCDBF806E59ACB07DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4943E6D1703B7E380CD206E59ACB6DA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FB93AD08CF2525BCDBF806E59ACB07DD" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4943E6D1703B7E380CD206E59ACB6DA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_F5E009322C273A9E81D106E59ACC2D44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4943E6D1703B7E380CD206E59ACB6DA4" xlink:to="loc_us-gaap_ConvertibleDebtMember_F5E009322C273A9E81D106E59ACC2D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_386D8D7F60F41744740006E59ACCEA62" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_DebtInstrumentAxis_386D8D7F60F41744740006E59ACCEA62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D1481F0912C1EB3D6F7C06E59ACCEADE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_386D8D7F60F41744740006E59ACCEA62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D1481F0912C1EB3D6F7C06E59ACCEADE" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_362D6CB30E0CE50823C106E59ACC9529" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D1481F0912C1EB3D6F7C06E59ACCEADE" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_362D6CB30E0CE50823C106E59ACC9529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_398EAB39EEC1FDEA53A006E59ACD5BE3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_398EAB39EEC1FDEA53A006E59ACD5BE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ADC6F92CC72BA46074206E59ACDD0F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_398EAB39EEC1FDEA53A006E59ACD5BE3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ADC6F92CC72BA46074206E59ACDD0F4" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_TB200PompeProgramMember" xlink:label="loc_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ADC6F92CC72BA46074206E59ACDD0F4" xlink:to="loc_fold_TB200PompeProgramMember_086D5EF534CB0CCF2C7A06E59ACD69D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_BBDEA5FE7A608AF319EF06E59ACEDF45" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_srt_RangeAxis_BBDEA5FE7A608AF319EF06E59ACEDF45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3242353424424C53A20906E59ACEBC7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_BBDEA5FE7A608AF319EF06E59ACEDF45" xlink:to="loc_srt_RangeMember_3242353424424C53A20906E59ACEBC7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B6E919E227CF4BC2F78A06E59ACE2D71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3242353424424C53A20906E59ACEBC7C" xlink:to="loc_srt_MinimumMember_B6E919E227CF4BC2F78A06E59ACE2D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D909E0F9DE5B1879B0C506E59ACEF559" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3242353424424C53A20906E59ACEBC7C" xlink:to="loc_srt_MaximumMember_D909E0F9DE5B1879B0C506E59ACEF559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_3225E1B03D6B92ECA98906E59ACE7FEB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_3225E1B03D6B92ECA98906E59ACE7FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_A54682EFC656C075A48506E59ACEB627" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3225E1B03D6B92ECA98906E59ACE7FEB" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_A54682EFC656C075A48506E59ACEB627" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_A54682EFC656C075A48506E59ACEB627" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_CAFD4C32A3CE278FBE0306E59ACFE860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_D2CEA58AE114CAFD697506E59ACF0776" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_9BAB55C162ED579C834406E59ACF4917" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_97B27FADD4A43EB3659106E59AD09094" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C7DB0DFA5CC07F72DF5606E59AD0FDBA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C7DB0DFA5CC07F72DF5606E59AD0FDBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5E3832D9044D492748F806E59AD00AA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C7DB0DFA5CC07F72DF5606E59AD0FDBA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5E3832D9044D492748F806E59AD00AA1" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="loc_fold_CallidusBiopharmaIncMember_DCB45C35D9B5DD7C02F806E59AD04ED6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5E3832D9044D492748F806E59AD00AA1" xlink:to="loc_fold_CallidusBiopharmaIncMember_DCB45C35D9B5DD7C02F806E59AD04ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C725986A6A6FAF31EBC106E59AD1F36B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_C0F9DD291A91B3079C1B06E59AD1A7DB" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B6FBB06FEDC86E2C19A806E59AD18134" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_667AB0F0BBF0E9802BF806E59AD1D5C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B4B0864F81B4BBF783A06E59AC84BA3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_46ED9A2FEABF58AD457B06E59AD11A1C" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_BC5B6411899C6F9BBA8206E59AD2ABDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_DB69BB8C2542E49DC38906E59AD2CEFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_DB69BB8C2542E49DC38906E59AD2CEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_354616960478B1A48E0E06E59AD37D6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CF787FA721E2712C6FA306E59AD23010" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_E88000730085946A1AC806E59AD3FC97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_94A2464B1196AFBC628D06E59AD3A8C7" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationMeasurementInput" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_EBFF2EC8166EA4D7F77E06E59AD3C541" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MilestonePaymentStockIssuedAsConsideration" xlink:label="loc_fold_MilestonePaymentStockIssuedAsConsideration_4344C138D500B1779D5D06E59AD344F3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93AA445F94FEDD58E9CB06E59AD1EAAF" xlink:to="loc_fold_MilestonePaymentStockIssuedAsConsideration_4344C138D500B1779D5D06E59AD344F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_57851EDB06F2C3C25B5B6B8C754856E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_F3E42608C13CA8428CB66B8C75482BAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_57851EDB06F2C3C25B5B6B8C754856E7" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_F3E42608C13CA8428CB66B8C75482BAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_288B14705DA948BBD0A7785A432C30FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_288B14705DA948BBD0A7785A432C30FD" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47CB1EF6A2D466FFC1AC785A432F8870" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47CB1EF6A2D466FFC1AC785A432F8870" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MilestonePayableAccruedDuringPeriod" xlink:label="loc_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:to="loc_fold_MilestonePayableAccruedDuringPeriod_168AE15853C3D9BD1E65785A433085B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_53ED4DD32069164A6F94785A4332608E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_53ED4DD32069164A6F94785A4332608E" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationPaidInStockAdjustment" xlink:label="loc_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:to="loc_fold_ContingentConsiderationPaidInStockAdjustment_6925BCFA3515F428AAF9785B40B03D36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2E1CC3093D11EDF41792785A433299FB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_06F7F6B081CDB0036031785A432FAAC4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2E1CC3093D11EDF41792785A433299FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63EE5D432E8810C5AB62F4CA967C82CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_365A1A48F13DD425C4F5F4CA967C1FB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63EE5D432E8810C5AB62F4CA967C82CF" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_365A1A48F13DD425C4F5F4CA967C1FB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_70B00742343AA6F9B497F4CA967DA9F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63EE5D432E8810C5AB62F4CA967C82CF" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_70B00742343AA6F9B497F4CA967DA9F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_DA8732B94CE07819DD53F4CA967D0B32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63EE5D432E8810C5AB62F4CA967C82CF" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_DA8732B94CE07819DD53F4CA967D0B32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_A720943C635335798FDC6B8C74B7E841" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_B2FED7700321B2BE9E796B8C74B7DED4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A720943C635335798FDC6B8C74B7E841" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_B2FED7700321B2BE9E796B8C74B7DED4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DC3F1226FCE4EB34CD22F4CA95E34D75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_A3FAF63273DD8A670C92F4CA95E413DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DC3F1226FCE4EB34CD22F4CA95E34D75" xlink:to="loc_us-gaap_NetIncomeLossAbstract_A3FAF63273DD8A670C92F4CA95E413DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A3ED8D3FB28B691BE929F4CA95E44C07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_A3FAF63273DD8A670C92F4CA95E413DA" xlink:to="loc_us-gaap_NetIncomeLoss_A3ED8D3FB28B691BE929F4CA95E44C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E2BA7E9CA1F335FB50E4F4CA95E415D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DC3F1226FCE4EB34CD22F4CA95E34D75" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E2BA7E9CA1F335FB50E4F4CA95E415D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1A103E459C8EC2515F04F4CA95E44DB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E2BA7E9CA1F335FB50E4F4CA95E415D1" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1A103E459C8EC2515F04F4CA95E44DB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DC3F1226FCE4EB34CD22F4CA95E34D75" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_864CC057759AE33685B9F4CA95E59513" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_289F93C101D9BD0F47C2F4CA95E57717" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_289F93C101D9BD0F47C2F4CA95E57717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_26814BD80589A8D12EAEF4CA95E62B70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="loc_us-gaap_WarrantMember_41A679AAACC92479E90EF4CA95E62375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_E519041B4D550E9A43C2F4CA95E62916" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_VestedRestrictedStockUnitsUnissuedMember" xlink:label="loc_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B200674550588BEE86E7F4CA95E564CC" xlink:to="loc_fold_VestedRestrictedStockUnitsUnissuedMember_50F1E7171AABE8F7E189F4CA95E617C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4B950464EEB9829FA375F4CA95E5A282" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_443CE3B3D25EAC56428AF4CA95E632CA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BBC312CAB28C9F99A629F4CA95E6149D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2B6797B4DAC56C5D03C88065C89DCF12" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_93963682E9AE17F562BD8065C89DF0D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2B6797B4DAC56C5D03C88065C89DCF12" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_93963682E9AE17F562BD8065C89DF0D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9405EBF7A870DF1B69DE8065C89D60D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2B6797B4DAC56C5D03C88065C89DCF12" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9405EBF7A870DF1B69DE8065C89D60D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_A752A6663D89AFCF2866F438F601C89F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_30A56DCA4CDE626B93C7F438F6013EC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_A752A6663D89AFCF2866F438F601C89F" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_30A56DCA4CDE626B93C7F438F6013EC4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C6B8611724AF160E7C5506E59B54559B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C6B8611724AF160E7C5506E59B54559B" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_76B3F1B22B802007E8FA06E59B557006" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:to="loc_us-gaap_FinancialInstrumentAxis_76B3F1B22B802007E8FA06E59B557006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_76B3F1B22B802007E8FA06E59B557006" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ShortTermCorporateDebtSecuritiesMember" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_3F3B96F4DA5935CC636006E59B55CA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_C0FBDC8B1697ED82987B06E59B554B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_8696BB2B49AB93A3C5A506E59B560981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DA40EF17641D156748BB06E59B568590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_DA463876F942EF81788306E59B56B246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6A54FCC7931D8F43E81A06E59B559C4F" xlink:to="loc_us-gaap_CertificatesOfDepositMember_668DEF305E76D56A324406E59B561C2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8DD35CC16164FA39F12A06E59B544C9A" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EFB98BD3BF7FBA612B4E06E59B567FE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EFB98BD3BF7FBA612B4E06E59B567FE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64088860389D640D60DA06E59B57C2C2" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ADBAFBB3EA02F2934D9D06E59B576B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8CAA97C71EBA9C37EC4B06E59B57A9CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9B1D19A9F0BC8B2456DE06E59B571467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89CFCADEE5269E4AD4E606E59B58308F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2904CAFD368976C2E20F06E59B58839E" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_FBF13EDE057527AD787906E59B582A07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_549CA8E56C7E4ABECFCB06E59B56C105" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_B8E3D1A4EDD80E8F4B3306E59B58BA5B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_51D07AD444FEC1F337A8F4CC27A9F3DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4E1BEF972FC8985FD9A2F4CC28A5EDFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_51D07AD444FEC1F337A8F4CC27A9F3DB" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4E1BEF972FC8985FD9A2F4CC28A5EDFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_37A1B9C868F4BC34960AF4CC28DC61A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_51D07AD444FEC1F337A8F4CC27A9F3DB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_37A1B9C868F4BC34960AF4CC28DC61A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_7CDAC3086C7462874E29F4CC291B0E6A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_51D07AD444FEC1F337A8F4CC27A9F3DB" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_7CDAC3086C7462874E29F4CC291B0E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_E22BB21C705FF5379478F4CC298F29C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_51D07AD444FEC1F337A8F4CC27A9F3DB" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_E22BB21C705FF5379478F4CC298F29C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_3A82C2469312158F4F2A06E59B4C5E40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8CE43E3E67E82C4540A906E59B4C5F0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_3A82C2469312158F4F2A06E59B4C5E40" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8CE43E3E67E82C4540A906E59B4C5F0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_E691FD2CDFF8AA39D26206E59B4C6252" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_3A82C2469312158F4F2A06E59B4C5E40" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_E691FD2CDFF8AA39D26206E59B4C6252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44A26DA936435DEFEE1F06E59B4C1C1A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_3A82C2469312158F4F2A06E59B4C5E40" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44A26DA936435DEFEE1F06E59B4C1C1A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_9C948231F2FCE62471A9F438F6012495" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0AF5E2C1BA9B1180A014F438F6018D32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_9C948231F2FCE62471A9F438F6012495" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0AF5E2C1BA9B1180A014F438F6018D32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9BFD9D2DA29C54A25E82F438F60193C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_9C948231F2FCE62471A9F438F6012495" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9BFD9D2DA29C54A25E82F438F60193C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborativeArrangementDisclosureAbstract" xlink:label="loc_fold_CollaborativeArrangementDisclosureAbstract_2D052AB880C1AB9427B16B8C7480FC26" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_609125FABB33296645236B8C7480F666" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_CollaborativeArrangementDisclosureAbstract_2D052AB880C1AB9427B16B8C7480FC26" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_609125FABB33296645236B8C7480F666" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborativeArrangementDisclosureAbstract" xlink:label="loc_fold_CollaborativeArrangementDisclosureAbstract_BE17BBE1FCDFE296D7865AE6059ADE40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B0188D078A0FC09CADE75AE6059A3E7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_CollaborativeArrangementDisclosureAbstract_BE17BBE1FCDFE296D7865AE6059ADE40" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B0188D078A0FC09CADE75AE6059A3E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B0188D078A0FC09CADE75AE6059A3E7C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E14598E78FDD3B4F4E375AE6059A1667" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_14E32FE04247A50074BE5AE6059BD710" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_RevisedCollaborationAgreementMember" xlink:label="loc_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_290DB1BCE0B03BE391D05AE6059BDEF3" xlink:to="loc_fold_RevisedCollaborationAgreementMember_69EA30C27BB0ABBAB2E55AE6059B1610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_9FC163C46F71661603BC5AE6059C383D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B0188D078A0FC09CADE75AE6059A3E7C" xlink:to="loc_srt_CounterpartyNameAxis_9FC163C46F71661603BC5AE6059C383D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4AC615F4001CFC35EA9D5AE6059CC450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9FC163C46F71661603BC5AE6059C383D" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4AC615F4001CFC35EA9D5AE6059CC450" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_GlaxoSmithKlinePLCMember" xlink:label="loc_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4AC615F4001CFC35EA9D5AE6059CC450" xlink:to="loc_fold_GlaxoSmithKlinePLCMember_31EF106A90F9431E96A15AE6059C0A09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B0188D078A0FC09CADE75AE6059A3E7C" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:label="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_76443A7E5607458D75C55AE6059C0059" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborationAgreementAnnualContributionByCompany" xlink:label="loc_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_CollaborationAgreementAnnualContributionByCompany_AEB0E0456B63851992F55AE6059D5D2A" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentsForCollaborativeArrangement" xlink:label="loc_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_PaymentsForCollaborativeArrangement_6FCFC9D6A26097C047155AE6059D88F7" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AccruedPaymentsForCollaborativeArrangement" xlink:label="loc_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_AccruedPaymentsForCollaborativeArrangement_BE14F6DEFD31D64E2B2B5AE6059D58B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_3C6B7DE0B04769BE01AB5AE6059DF4EC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:label="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_9FAC0A6F806D4442084F5AE6059DB0A0" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:label="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_333732CB2BA25E7B43845AE6059DF35D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6C32BBAB621D4ACA0E0A5AE6059EA3F4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6C32BBAB621D4ACA0E0A5AE6059EA3F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_380C9605FDADDF0220D85AE6059ED1D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7386689EE9BD2C4B5B215AE6059C8AF1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7DE6588EC990904433435AE6059E5816" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2F72F7CC89EBE25B9A785A1077143599" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2F72F7CC89EBE25B9A785A1077143599" xlink:to="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:to="loc_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EFC434D2943DFC1665185A107715D96B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EFC434D2943DFC1665185A107715D96B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_AD84902415A769223A515A1077157B5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_AD84902415A769223A515A1077157B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_137449E12EC16618D2265A10771608DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_137449E12EC16618D2265A10771608DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_8D149F2A95DD62831D8C5A10771662AA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:to="loc_us-gaap_InventoryNet_8D149F2A95DD62831D8C5A10771662AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44881851DBCDC16B09935A10771601B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44881851DBCDC16B09935A10771601B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7764DC38042947D3904D5A107716D4AE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_60D6FCB14BD0A51012FB5A107715F85A" xlink:to="loc_us-gaap_AssetsCurrent_7764DC38042947D3904D5A107716D4AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_FF11C0680C73A0C715855A107716405C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_FF11C0680C73A0C715855A107716405C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12C799AF1655D7BCB3FF5A1077161A00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12C799AF1655D7BCB3FF5A1077161A00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1B4AFDEF26E5AEBA98905A107717EB9B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1B4AFDEF26E5AEBA98905A107717EB9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C122AF75E9381A114CCF5A1077177C31" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:to="loc_us-gaap_Goodwill_C122AF75E9381A114CCF5A1077177C31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2FB6D7F18C356F545D375A107717D459" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2FB6D7F18C356F545D375A107717D459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_569ABB8B0731DC78D32C5A1077173E07" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_180C2D1B1F53421A91D75A1077157741" xlink:to="loc_us-gaap_Assets_569ABB8B0731DC78D32C5A1077173E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2F72F7CC89EBE25B9A785A1077143599" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A6A0A4427F15E245839D5A1077180A03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A6A0A4427F15E245839D5A1077180A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_599D1743656847EFFFEC5A10771858D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_599D1743656847EFFFEC5A10771858D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_AFA33B0C72857264755E5A107718D321" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_AFA33B0C72857264755E5A107718D321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A215638D252C0B6A9A015A1077189C74" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_933B4CB4197A0C4E72ED5A107717D524" xlink:to="loc_us-gaap_LiabilitiesCurrent_A215638D252C0B6A9A015A1077189C74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_647217D9FBFE1039D3E75A1077188266" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_647217D9FBFE1039D3E75A1077188266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_1DC8DB922FAD4C75749D5A107719AA69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_1DC8DB922FAD4C75749D5A107719AA69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_EC3740DB914D228BB5105A107719F09B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_SecuredLongTermDebt_EC3740DB914D228BB5105A107719F09B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A2DAEB4F5242BF262D7E5A107719AD18" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A2DAEB4F5242BF262D7E5A107719AD18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1CB17DBC7C3DA4E7B3DF5A1077198B1C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1CB17DBC7C3DA4E7B3DF5A1077198B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_CEEB8A882CD4D42655D35A10771936A6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_CEEB8A882CD4D42655D35A10771936A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7BFA969878A0F11C88105A10771926EC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7BFA969878A0F11C88105A10771926EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_50A2D33EF6D61D539C475A1077196A5A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_Liabilities_50A2D33EF6D61D539C475A1077196A5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7C2EA4D7EA1B0CF5CF955A10771A1181" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7C2EA4D7EA1B0CF5CF955A10771A1181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_BAD0822D44F45EA91D145A10771A434A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:to="loc_us-gaap_CommonStockValue_BAD0822D44F45EA91D145A10771A434A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_BB5E8ADC98EB2B1180305A10771AEF92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_BB5E8ADC98EB2B1180305A10771AEF92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_D50F8194BAF97D01BA345A10771BDD72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_D50F8194BAF97D01BA345A10771BDD72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C7C72C0B157CA906B84A5A10771B3240" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92F528E22D47EE5224085A10771AA2B8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C7C72C0B157CA906B84A5A10771B3240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_232459848D7EEBA785CE5A10771B979E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_232459848D7EEBA785CE5A10771B979E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15A9DC08B08EC511F0B15A10771B1528" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15A9DC08B08EC511F0B15A10771B1528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_02E40DECE1AF6437AABF5A10771BE8D5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64B9E00F7CE448508F155A10771A921E" xlink:to="loc_us-gaap_StockholdersEquity_02E40DECE1AF6437AABF5A10771BE8D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6C709C5B45C992C5C8195A10771C6297" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B8968DA573416D62538A5A1077179621" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6C709C5B45C992C5C8195A10771C6297" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:type="locator" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AccumulatedDepreciationOperatingRightOfUseLeases" xlink:label="loc_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:to="loc_fold_AccumulatedDepreciationOperatingRightOfUseLeases_9A375DD05E08CE25502C0F1C8BB9B844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29311DB3AC16197F6B670F0C23EA285B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29311DB3AC16197F6B670F0C23EA285B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_C22E85136E128022B6290F0C23EA2563" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_C22E85136E128022B6290F0C23EA2563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_AC8CCCC82C290041B0370F0C23EA08F4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_AC8CCCC82C290041B0370F0C23EA08F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_960D468863072E76E1E60F0C23EA468F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:to="loc_us-gaap_CommonStockSharesIssued_960D468863072E76E1E60F0C23EA468F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_45930812871761CA9F3F0F0C23EA6DB9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CCD9A1DCB4167E748D3E0F0C23E94146" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_45930812871761CA9F3F0F0C23EA6DB9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_F3DA09C934BAB99BD6AB5A1076B0EDA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:to="loc_us-gaap_ProfitLoss_F3DA09C934BAB99BD6AB5A1076B0EDA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B2F1E7865F1336AA8AF95A1076B15674" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B2F1E7865F1336AA8AF95A1076B15674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_236D15FC4E012CEA5A0C5A1076B112FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_236D15FC4E012CEA5A0C5A1076B112FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5AC7102B8CF576C3E9835A1076B19DD4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="loc_us-gaap_ShareBasedCompensation_5AC7102B8CF576C3E9835A1076B19DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_76D01D315BBE7BF207F15A1076B1C81F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_76D01D315BBE7BF207F15A1076B1C81F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_381A1E98ECA73A0DC2935A1076B2CE25" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_381A1E98ECA73A0DC2935A1076B2CE25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_B2992E29BB5833F81B3E5A1076B2ADA7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_B2992E29BB5833F81B3E5A1076B2ADA7" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_462B1A4BE0229F6DD6695A1076B2780E" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NonCashDeferredTaxesAndOtherTaxBenefits" xlink:label="loc_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="loc_fold_NonCashDeferredTaxesAndOtherTaxBenefits_4992623D649962D43A825A1076B29E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_62F10153A1729FC78F3C5A1076B2F2A3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="loc_us-gaap_AssetImpairmentCharges_62F10153A1729FC78F3C5A1076B2F2A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5A88F304BD8E4F7F36765A1076B2D5C7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9CA16F8F92957F98C5025A1076B1B3B4" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5A88F304BD8E4F7F36765A1076B2D5C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_E1F7C675AD8BC9E489755A1076B378A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_E1F7C675AD8BC9E489755A1076B378A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1FE7810C9034CB39EFDC5A1076B397B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1FE7810C9034CB39EFDC5A1076B397B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_AE867926F61E125AF50D5A1076B34C94" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_AE867926F61E125AF50D5A1076B34C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_46DD10AD27C8C82FA0685A1076B33D31" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_46DD10AD27C8C82FA0685A1076B33D31" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_A4A5E80A5A9DBC1188505A1076B3CE2B" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_IncreaseDecreaseInDeferredReimbursements" xlink:label="loc_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5069E0FFBEE146F8BF515A1076B3F6C8" xlink:to="loc_fold_IncreaseDecreaseInDeferredReimbursements_130051BD9656F61FB78F5A1076B4DC20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1D8E44FE23FE227B9315A1076B4C723" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_394243E6E147CFB240A85A1076B07347" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1D8E44FE23FE227B9315A1076B4C723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2EB220937FF97B84ED1E5A1076B4D6FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2EB220937FF97B84ED1E5A1076B4D6FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_F01FD1A94031AC8DE16E5A1076B40A72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_F01FD1A94031AC8DE16E5A1076B40A72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_248323DA79C0E7B53C835A1076B575F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_248323DA79C0E7B53C835A1076B575F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1878DFE768D2B105BE645A1076B5F84F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_009FB7CD338B5CA94BE25A1076B4D60F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1878DFE768D2B105BE645A1076B5F84F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2C25438638A90061CB345A1076B578B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2C25438638A90061CB345A1076B578B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_530D0A9FAC2A58F619E15A1076B5EE5D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_530D0A9FAC2A58F619E15A1076B5EE5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C31A0AD1082F23E69D285A1076B5A0F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C31A0AD1082F23E69D285A1076B5A0F8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_7FC06E2951FB14AB11125A1076B69719" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_21B6708D37B8F020B6C85A1076B68278" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_21B6708D37B8F020B6C85A1076B68278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_06BD1BCAC98971D1837B5A1076B64D78" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_06BD1BCAC98971D1837B5A1076B64D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_BA3A65432A0FA934EF1B5A1076B64933" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_BA3A65432A0FA934EF1B5A1076B64933" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PaymentOfContingentConsideration" xlink:label="loc_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="loc_fold_PaymentOfContingentConsideration_0F79841FC49D51A8985E5A1076B66224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_BC9187B21B382A0068645A1076B6034D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_BC9187B21B382A0068645A1076B6034D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6B78839E25A8B5398DE55A1076B7EC7B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7588EBAD8FB1B6589CBE5A1076B5BE9C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6B78839E25A8B5398DE55A1076B7EC7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_EF7A2E4B256A22C7BA975A1076B700C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_EF7A2E4B256A22C7BA975A1076B700C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6E87429F1392DEB4A5D25A1076B75241" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6E87429F1392DEB4A5D25A1076B75241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_485D79F80BC7433EA3945A1076B7DF86" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_485D79F80BC7433EA3945A1076B7DF86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1D61B227E5BA73041E5A1076B70FDC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1D61B227E5BA73041E5A1076B70FDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3E211F27AF9A3315CA735A1076B0E8A7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_DDA343D355EBD34773195A1F70C6FDEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_DDA343D355EBD34773195A1F70C6FDEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_26C190D3C84A5C1E74ED5A1076B8A323" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:to="loc_us-gaap_InterestPaidNet_26C190D3C84A5C1E74ED5A1076B8A323" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationPaidInStock" xlink:label="loc_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:to="loc_fold_ContingentConsiderationPaidInStock_CED4F01B0DC54B1B25F45A1076B8BA23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08AEC86729A2C58CF47B5A1076B81D10" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F6DF73ADEB02254BA5365A1076B7359A" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08AEC86729A2C58CF47B5A1076B81D10" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_211266F442E1B4E174FF8065CB717821" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_211266F442E1B4E174FF8065CB717821" xlink:to="loc_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_CE8C7DB74B995899A2E68065CB71E0C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_CE8C7DB74B995899A2E68065CB71E0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CE8C7DB74B995899A2E68065CB71E0C8" xlink:to="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DC21306B6C29553DF9878065CB72703C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:to="loc_us-gaap_CommonStockMember_DC21306B6C29553DF9878065CB72703C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9B6860EA330585DE33898065CB723D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_EE4344F1A6C21AC5B3298065CB7292C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:to="loc_us-gaap_WarrantMember_EE4344F1A6C21AC5B3298065CB7292C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_EA5150B1A70D44F5A1CD8065CB72D5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6529198BE0F457D8E1248065CB71501B" xlink:to="loc_us-gaap_RetainedEarningsMember_1039B5391E402FC1BD928065CB738E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_541D21AE77A4841163E18065CB71ED0F" xlink:to="loc_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EC73189271658C810DB68065CB73BA9B" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9617A7DAE4230610A1298065CB73F7D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockholdersEquity_1395EE5A7E47FEB7518A8065CB7300A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CE45244EB1D707D43A9D8065CB7488E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A4263515AD9B82A141988065CB7447AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1DEE58F5AD26DDDA3D7D8065CB740F96" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1DEE58F5AD26DDDA3D7D8065CB740F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_667AEC92E5968745CFF58065CB746A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_DF6CE80D681ADCF09D888065CB741811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_E1FDB492C7850D7D9B158065CB75CCDF" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:label="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_D456A3BACE713AFA0EF68065CB75A305" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_A2DC556EBE5A538584688065CB756A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_390B1481EB6663979E588065CB75A8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_D1BACC2FBC312F0DA43B8065CB7594B2" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_3A388C3E687FDAAC553E8065CB7553A8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_A1BC07EB244D79786AD58065CB758B3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_98A31EDF5C47F000B02D8065CB7641F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2AD4D4F1669B5D44C0A68065CB7626E5" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives_9697C1C26C7CF66EAF1A8065CB76927C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_155BBDCAE224A218C2CF8065CB763CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_FB46E4422C8F95F5A3818065CB769B50" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_FB46E4422C8F95F5A3818065CB769B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_90BC437A239F698485D38065CB76CAB4" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_90BC437A239F698485D38065CB76CAB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_66F5C0463CCF44E0FD268065CB77F8F5" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_NetIncomeLoss_66F5C0463CCF44E0FD268065CB77F8F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1BC8AA90569BE8E362318065CB77111E" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1BC8AA90569BE8E362318065CB77111E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A2278ACA94E9B86F831D8065CB772D92" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_D0890976F8CABE6BDCBF8065CB73F0FC" xlink:to="loc_us-gaap_StockholdersEquity_A2278ACA94E9B86F831D8065CB772D92" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_724808BBCDFBA11624315A1076D03736" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6ADD8E950120A2116F455A1076D112B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_724808BBCDFBA11624315A1076D03736" xlink:to="loc_us-gaap_NetIncomeLoss_6ADD8E950120A2116F455A1076D112B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_724808BBCDFBA11624315A1076D03736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4FE0C452432B0D4510DA5A1076D131D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4FE0C452432B0D4510DA5A1076D131D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_DEDE18FD0B3889F9056B5A1076D188BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_DEDE18FD0B3889F9056B5A1076D188BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_414D937F78AFAF47080D5A1076D229E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C6BE6A9E86D93016C1CD5A1076D1171B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_414D937F78AFAF47080D5A1076D229E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_BFCCCF0E713CBDD49D125A1076D287C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_724808BBCDFBA11624315A1076D03736" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_BFCCCF0E713CBDD49D125A1076D287C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9900D76A21F9F8E4737DF034C1593BFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_F4EBE52986F50E6091D9F034C1597E12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9900D76A21F9F8E4737DF034C1593BFA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_F4EBE52986F50E6091D9F034C1597E12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_BC8C52C48083640E5578F0A2B5F826BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9900D76A21F9F8E4737DF034C1593BFA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_BC8C52C48083640E5578F0A2B5F826BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9C10CF480A54E3A593748065CB8A511A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9C10CF480A54E3A593748065CB8A511A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_95A8073839D574DE114A8065CB8AD041" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_95A8073839D574DE114A8065CB8AD041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_9CDE7924F78E5BAC1EBE8065CB8A6DBE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_GrossProfit_9CDE7924F78E5BAC1EBE8065CB8A6DBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_35502A350253563C1CBF8065CB8AD854" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_35502A350253563C1CBF8065CB8AD854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_80205FA659A584FD5C548065CB8B8B68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_80205FA659A584FD5C548065CB8B8B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89AB4C07BBB15FFB6F578065CB8B8973" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89AB4C07BBB15FFB6F578065CB8B8973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_A828D143408532109C428065CB8B33B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:to="loc_us-gaap_AssetImpairmentCharges_A828D143408532109C428065CB8B33B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_BD60618A1F29110159BA8065CB8B9739" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:to="loc_us-gaap_DepreciationAndAmortization_BD60618A1F29110159BA8065CB8B9739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_6A91026E3151247916FD8065CB8B0F1D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_BA28CC1237F09BBDC7408065CB8AC851" xlink:to="loc_us-gaap_OperatingExpenses_6A91026E3151247916FD8065CB8B0F1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_870D3EB4219F9310A5E58065CB8CAB31" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_OperatingIncomeLoss_870D3EB4219F9310A5E58065CB8CAB31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_D291E90B8FDDD46DD47C8065CB8CA754" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:to="loc_us-gaap_InvestmentIncomeInterest_D291E90B8FDDD46DD47C8065CB8CA754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_31E77B8F9C42DA6AD6C28065CB8C24E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:to="loc_us-gaap_InterestExpense_31E77B8F9C42DA6AD6C28065CB8C24E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D5B4BA328C02AA54E1AB8065CB8CFAF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D5B4BA328C02AA54E1AB8065CB8CFAF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_854C11095B13B0007D2D8065CB8D9F09" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_854C11095B13B0007D2D8065CB8D9F09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_69292D82C7EF1F7D79918065CB8D69C4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1CC746BA6B82156E4F348065CB8CCD3D" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_69292D82C7EF1F7D79918065CB8D69C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6F39E8ED534B8E681E598065CB8D29CA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6F39E8ED534B8E681E598065CB8D29CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_07BE433BEA627B68671E8065CB8DD25D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_07BE433BEA627B68671E8065CB8DD25D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_11494C532F9F977AAEC28065CB8DFC59" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_NetIncomeLoss_11494C532F9F977AAEC28065CB8DFC59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_AB66654B1B021B9450738065CB8DCEC8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_AB66654B1B021B9450738065CB8DCEC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_23BC4EB383A5DE4855A38065CB8E2B6F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AAB5F79DE87B5F3EBD548065CB8A281C" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_23BC4EB383A5DE4855A38065CB8E2B6F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FB5DFE7B89F812C350785FE1BF4605C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_DocumentType_FB5DFE7B89F812C350785FE1BF4605C3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_3FB39C4850309E31327B5FE1BF46A9FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_DocumentAnnualReport_3FB39C4850309E31327B5FE1BF46A9FC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_C5B62CE816D8A6A2C9CF5FE1BF461A6A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_DocumentPeriodEndDate_C5B62CE816D8A6A2C9CF5FE1BF461A6A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_0C46C8C87A322793582A5FE1BF474576" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_DocumentTransitionReport_0C46C8C87A322793582A5FE1BF474576" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_3F2ACEC6D182C1ACF4E15FE1BF478B2E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityFileNumber_3F2ACEC6D182C1ACF4E15FE1BF478B2E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_8022DB0711C77C4ED16B5FE1BF473B0A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityRegistrantName_8022DB0711C77C4ED16B5FE1BF473B0A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_FBBA85465756467F195F5FE1BF4740E9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_FBBA85465756467F195F5FE1BF4740E9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_EF562BAE77FF1C56AC365FE1BF471B85" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityTaxIdentificationNumber_EF562BAE77FF1C56AC365FE1BF471B85" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_92AC6FCB1626B9E5C29F5FE1BF47EF28" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityAddressAddressLine1_92AC6FCB1626B9E5C29F5FE1BF47EF28" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_3422DFCC988D283E58065FE1BF48F2F1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityAddressCityOrTown_3422DFCC988D283E58065FE1BF48F2F1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_7FED752E914CB953F2265FE1BF48C273" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityAddressStateOrProvince_7FED752E914CB953F2265FE1BF48C273" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_5B04A7F2CCEB1665C9D75FE1BF48E3BD" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityAddressPostalZipCode_5B04A7F2CCEB1665C9D75FE1BF48E3BD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_02BFDC19413C9F91E5135FE20A37BD10" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_CityAreaCode_02BFDC19413C9F91E5135FE20A37BD10" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_E682777FA548764FD9CD5FE2537A792A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_LocalPhoneNumber_E682777FA548764FD9CD5FE2537A792A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_FEDC2B61D8E8CDD2E0225FE1BF489D59" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_Security12bTitle_FEDC2B61D8E8CDD2E0225FE1BF489D59" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_325B79A725821E6CE7D45FE1BF4827CB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_TradingSymbol_325B79A725821E6CE7D45FE1BF4827CB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_69FCA2046B3E4CB4CC505FE1BF48519B" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_SecurityExchangeName_69FCA2046B3E4CB4CC505FE1BF48519B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_4E46AA743DC6EEF951915FE1BF48BAF9" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_4E46AA743DC6EEF951915FE1BF48BAF9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_D204AEA1C9C59C6E87785FE1BF49B0F0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityVoluntaryFilers_D204AEA1C9C59C6E87785FE1BF49B0F0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9CDB847679A72C32B5C75FE1BF492ED5" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityCurrentReportingStatus_9CDB847679A72C32B5C75FE1BF492ED5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_D22A5D907F30E135B4725FE1BF494F36" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityInteractiveDataCurrent_D22A5D907F30E135B4725FE1BF494F36" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D2AE3F3A647A1BED7F555FE1BF49244C" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityFilerCategory_D2AE3F3A647A1BED7F555FE1BF49244C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_E0449B4C4B0CC9A82DE35FE1BF49D40A" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntitySmallBusiness_E0449B4C4B0CC9A82DE35FE1BF49D40A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_2B6D2680ED0985A8D0555FE1BF499AC1" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityEmergingGrowthCompany_2B6D2680ED0985A8D0555FE1BF499AC1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_B7E524BAB6582AD77DFC5FE1BF499A3F" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityShellCompany_B7E524BAB6582AD77DFC5FE1BF499A3F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_433F897EA448EACC40FE5FE1BF4A39F9" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityPublicFloat_433F897EA448EACC40FE5FE1BF4A39F9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_083AEB62EA462ACB5A495FE1BF4A607A" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_083AEB62EA462ACB5A495FE1BF4A607A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_466552B348E7034A434C5FE1BF4A4327" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_466552B348E7034A434C5FE1BF4A4327" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7DFC831ABC595B29AE515FE1BF4AE860" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_EntityCentralIndexKey_7DFC831ABC595B29AE515FE1BF4AE860" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9AA3FFAF9D2CBD2DDBDD5FE1BF4A0DFC" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_AmendmentFlag_9AA3FFAF9D2CBD2DDBDD5FE1BF4A0DFC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_28A5D3087D829054D70D5FE1BF4AD361" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_CurrentFiscalYearEndDate_28A5D3087D829054D70D5FE1BF4AD361" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13DA6EF5BF7E30C447605FE1BF4B7B06" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_DocumentFiscalYearFocus_13DA6EF5BF7E30C447605FE1BF4B7B06" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6008555300A26C8048095FE1BF4B87AE" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_13717F139F41AB56D50F5FE1BF4545D9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6008555300A26C8048095FE1BF4B87AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0D1BBDF68ECC5BB909956B8C7465280E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_DC0D7B9C85E72AB4189A6B8C74655790" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0D1BBDF68ECC5BB909956B8C7465280E" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_DC0D7B9C85E72AB4189A6B8C74655790" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_FAB88ADFFCA8883EBC72FE2CA5B56546" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_FAB88ADFFCA8883EBC72FE2CA5B56546" xlink:to="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58B4769F590E8580A3D0FE2D647A334D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_552252890C1A52414306FE2D647B7333" xlink:to="loc_us-gaap_ConvertibleDebtMember_229F432D751A84C1F6B5FE2D647C42ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:to="loc_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_11E38E3AC3D431C480A0FE2D64821904" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88D6DF43C979AEF29B87FE2D64832357" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_1029014EF5F10F9CC1A9FE2D6483971A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4F8DAB8EC48BF29EF92BFE2CA8B464C7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_088D675B8C0F6592E74FFE2CA8C1F395" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_332F48F1B021ABE40CFDFE2D1DA6E47D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F3C6C7BFD62EDAD217BDFE2D1DA7706F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:to="loc_us-gaap_DeferredOfferingCosts_3942547A820B96A75CCBFE2D1DA753D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_12CF31523D6128D31B11FE2D1DA542B7" xlink:to="loc_us-gaap_LongTermDebt_5BBCE4CADA75FE32D7C5FE2D1DA7939E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_EA83773738FE147FD8779C2B24B62685" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_008DA5A29850AF6817D09C2B24B9F7A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_EA83773738FE147FD8779C2B24B62685" xlink:to="loc_us-gaap_DebtInstrumentTable_008DA5A29850AF6817D09C2B24B9F7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1D0574122F4AEAFD01BC9C2B24B95F70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_008DA5A29850AF6817D09C2B24B9F7A0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1D0574122F4AEAFD01BC9C2B24B95F70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6AAA0459369A8FA0DD399C2B24BAEF4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1D0574122F4AEAFD01BC9C2B24B95F70" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6AAA0459369A8FA0DD399C2B24BAEF4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_F1E8FC67F8ED3BAC15769C2B24BA8DEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6AAA0459369A8FA0DD399C2B24BAEF4B" xlink:to="loc_us-gaap_ConvertibleDebtMember_F1E8FC67F8ED3BAC15769C2B24BA8DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_5FD0A5FCF2806CE694FC9C2B24BB1841" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6AAA0459369A8FA0DD399C2B24BAEF4B" xlink:to="loc_us-gaap_SeniorNotesMember_5FD0A5FCF2806CE694FC9C2B24BB1841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_07C508C02087244063099C2B24BB451F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_008DA5A29850AF6817D09C2B24B9F7A0" xlink:to="loc_us-gaap_DebtInstrumentAxis_07C508C02087244063099C2B24BB451F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F93285081B65E0185C4C9C2B24BBF9F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_07C508C02087244063099C2B24BB451F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F93285081B65E0185C4C9C2B24BBF9F3" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_64858C7EFC92E7C434E59C2B24BB1E8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F93285081B65E0185C4C9C2B24BBF9F3" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_64858C7EFC92E7C434E59C2B24BB1E8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8E1D8D56E4CE683818FF9C2B24BB00CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_008DA5A29850AF6817D09C2B24B9F7A0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8E1D8D56E4CE683818FF9C2B24BB00CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8E1D8D56E4CE683818FF9C2B24BB00CD" xlink:to="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_B8B7181DF91BED89F2A69C2B24BC3C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_863008870608E6ABAF599C2B24BE5D07" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_AmortizationDeferredFinancingCosts" xlink:label="loc_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:to="loc_fold_AmortizationDeferredFinancingCosts_D6716BF124256A4DFBA49C2B24BE3853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_64A46964450BB312A7409C2B24BC87FC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_156A0CE488A4C71B8D2E9C2B24BEDD35" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4F59202CCE3A7A25C5885A1074CCD278" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4F59202CCE3A7A25C5885A1074CCD278" xlink:to="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_CB566AC5F52A91A60F9F5A1074CC941E" xlink:to="loc_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0B928CDE2AE149058A555A1074CCF242" xlink:to="loc_us-gaap_LineOfCreditMember_4DA6D747A3EB6F618C985A1074CD2590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_15A20C3DF3641DDF4BFD5A1074CD9DD3" xlink:to="loc_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4B06FAB4239A786E0B305A1074CD1B5A" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_BF1323F3F1CFAB4DBFCB5A1074CDACDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3C41D9213C2B1B3D18E05A1074CE3472" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3C41D9213C2B1B3D18E05A1074CE3472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_EBF3C7B524591C07FF9B5A1074CE3C1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3C41D9213C2B1B3D18E05A1074CE3472" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_EBF3C7B524591C07FF9B5A1074CE3C1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_9ACE4153E503BB0F13335A1074CEAF4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_EBF3C7B524591C07FF9B5A1074CE3C1E" xlink:to="loc_us-gaap_ConvertibleDebtMember_9ACE4153E503BB0F13335A1074CEAF4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_EBF3C7B524591C07FF9B5A1074CE3C1E" xlink:to="loc_us-gaap_SeniorNotesMember_092FDE048FD1DB4908795A1074CEC9BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_AB744A961CE994BB57F95A1074CF04EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_DebtInstrumentAxis_AB744A961CE994BB57F95A1074CF04EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B509427952999A78CB775A1074CF1260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_AB744A961CE994BB57F95A1074CF04EF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B509427952999A78CB775A1074CF1260" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_4E09D13F7BF4A7CEE36A5A1074CFF3C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B509427952999A78CB775A1074CF1260" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_4E09D13F7BF4A7CEE36A5A1074CFF3C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_68C9A3449486064BFBBC5A1074CF9E0A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_68C9A3449486064BFBBC5A1074CF9E0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49A21B354B72550567815A1074CFF87E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_68C9A3449486064BFBBC5A1074CF9E0A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49A21B354B72550567815A1074CFF87E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49A21B354B72550567815A1074CFF87E" xlink:to="loc_us-gaap_OverAllotmentOptionMember_C06192CDB4DA0C36D8905A1074D075ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_96B0B8BE0E25DC0B99E65A1074D0EFBC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_96B0B8BE0E25DC0B99E65A1074D0EFBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BBC538A68BE4F101162A5A1074D0F9D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_96B0B8BE0E25DC0B99E65A1074D0EFBC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BBC538A68BE4F101162A5A1074D0F9D6" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="loc_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BBC538A68BE4F101162A5A1074D0F9D6" xlink:to="loc_fold_PrivatePlacementPurchaseAgreementMember_99C32E2C7CBA24E274105A1074D07FB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D7EE94C6B97FCD83FFB85A1074D1DA37" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_srt_RangeAxis_D7EE94C6B97FCD83FFB85A1074D1DA37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2230B1F25ECF5460806B5A1074D1A4F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_D7EE94C6B97FCD83FFB85A1074D1DA37" xlink:to="loc_srt_RangeMember_2230B1F25ECF5460806B5A1074D1A4F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2230B1F25ECF5460806B5A1074D1A4F1" xlink:to="loc_srt_MinimumMember_CEB7B5CB1F535C6E388E5A1074D1E0FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_020F6B249100D0C05E9F5A1074D1524F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_StatementClassOfStockAxis_020F6B249100D0C05E9F5A1074D1524F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A1BF0B1DFFEB7DCE6DB05A1074D167AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_020F6B249100D0C05E9F5A1074D1524F" xlink:to="loc_us-gaap_ClassOfStockDomain_A1BF0B1DFFEB7DCE6DB05A1074D167AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B0C00EDC3E2F75E8804D5A1074D27098" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A1BF0B1DFFEB7DCE6DB05A1074D167AB" xlink:to="loc_us-gaap_CommonStockMember_B0C00EDC3E2F75E8804D5A1074D27098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4989977D27C383F110B05A1074D24A4A" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CommonStockCappedCallConfirmationMember" xlink:label="loc_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F0604EE3EC5D6C8443A05A1074D2833C" xlink:to="loc_fold_CommonStockCappedCallConfirmationMember_7A54C5878E1DB5A617315A1074D206B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BBD940C5C801998C95E75A1074CC8E6F" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_576AE2EB5882CBD6DE605A1074D38372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_276B730304F3A599A9C05A1074D3C579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_DebtInstrumentTerm_68E7A0620B3C7D5752F55A1074D327E2" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentPeriodicPaymentPrincipalPercentage" xlink:label="loc_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage_40029C217DA3E0EF18B95A1074D48324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_717B28CF055D7ADAB0865A1074D4B725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACD6507760B51282DCF75A1074D39CAF" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_348A93776004696C99985A1074D458E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5FA2C01B09361BE479AC5A1074D4A4B1" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_PremiumsPaidForCappedCallConfirmations" xlink:label="loc_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_PremiumsPaidForCappedCallConfirmations_7D7CF446D14F6F5737185A1074D4E124" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:label="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_87BC256323FC4FB434845A1074D58C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_47A66FC32DE7F2441D7D5A1074D5663E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_31A67079F803583E5A165A1074D5F53F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:label="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_C50BE5FF78596226EC975A1074D57A75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_EEB3F1B646BC6AA76B0F5A1074D5DAA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4B3BF2EE13ED75BB30A45A1074D5BDCB" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice" xlink:label="loc_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice_BE8E6DD48378424F7FDF5A1074D6B41F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice" xlink:label="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice_523427872C7A6941E6DA5A1074D69ABC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice" xlink:label="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice_9A737FB45F6795099C765A1074D61BB6" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent" xlink:label="loc_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent_4F4616106EEDC127D6275A1074D6098B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42FCE10AAA89FC2C82CF5A1074D6FFFC" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42FCE10AAA89FC2C82CF5A1074D6FFFC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares" xlink:label="loc_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares_96D7E89EC42E522499E65A1074D6A979" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters" xlink:label="loc_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters_D71285B2BABEBD6BAC135A1074D69B21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_BD026C36331672DCBF7A5A1074D75E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1DC917477A335FCF61085A1074D71490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_56958B9A421BC3CFD95D5A1074D72C90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_D6BC90715063822A46C95A1074D75030" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_D6BC90715063822A46C95A1074D75030" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_E7B415EF1A06C06A0E2A5A1074D73865" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_E7B415EF1A06C06A0E2A5A1074D73865" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_5B9ECC59F94D1FCF9B705A1074D7092A" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_5B9ECC59F94D1FCF9B705A1074D7092A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7DA0F42673F8E3F50565A1074D89CD8" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7DA0F42673F8E3F50565A1074D89CD8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_7B6E23D9ABC69220742F5A1074D853E9" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_F85375E1B8765BE532B95A1074D84B20" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_306435364FBDE9A7270B5A1074D8BA66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9DB44D7A085092D4D9035A1074D890C7" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9DB44D7A085092D4D9035A1074D890C7" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_A91971C05AF325AE36605A1074D8889C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare" xlink:label="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare_BC3E3922E6D100220F475A1074D93309" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage" xlink:label="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_CED8E6C459764A3CD88B5A1074D4C779" xlink:to="loc_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage_0F5962671347E5F75E615A1074D90B64" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_39395D2634E039314856F4CA9662E426" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_6C874772D1E8C9E10DEAF4CA96629E8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_39395D2634E039314856F4CA9662E426" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_6C874772D1E8C9E10DEAF4CA96629E8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_DB5ACCDC5F06BA30DEDDF4CA96632A64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_39395D2634E039314856F4CA9662E426" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_DB5ACCDC5F06BA30DEDDF4CA96632A64" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ADCE1637AA351E4BEBFE6B8C7632EEC0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_925B57E706D6B482DF2D6B8C7632E303" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ADCE1637AA351E4BEBFE6B8C7632EEC0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_925B57E706D6B482DF2D6B8C7632E303" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2060D555856B9A2CA9C95E3E77C3B54D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A247A9281574CE2C6A9B5E3E77C458AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2060D555856B9A2CA9C95E3E77C3B54D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A247A9281574CE2C6A9B5E3E77C458AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6A21B3DE3009C13D0DD05E3E77C43A6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A247A9281574CE2C6A9B5E3E77C458AF" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6A21B3DE3009C13D0DD05E3E77C43A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_CCDFE690D998708265DA5E3E77C4FAA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6A21B3DE3009C13D0DD05E3E77C43A6E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_CCDFE690D998708265DA5E3E77C4FAA2" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_UnderwrittenOfferingMember" xlink:label="loc_fold_UnderwrittenOfferingMember_4FD0FDE0374B48E54AD75E3E77C5EFEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_CCDFE690D998708265DA5E3E77C4FAA2" xlink:to="loc_fold_UnderwrittenOfferingMember_4FD0FDE0374B48E54AD75E3E77C5EFEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A247A9281574CE2C6A9B5E3E77C458AF" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D0A7B38C8E8809F824285E3E77C59E97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D0A7B38C8E8809F824285E3E77C59E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1E86998F4D468DE7EF2D5E3E77C57D90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1E86998F4D468DE7EF2D5E3E77C57D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D9FEFD3B4A7D37B824F15E3E77C5E92C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D9FEFD3B4A7D37B824F15E3E77C5E92C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_1F6B481A2F35AAB0E3D05E3E77C6098C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_1F6B481A2F35AAB0E3D05E3E77C6098C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_61BBCD63D3059377E3BF5E3E77C64CDB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_61BBCD63D3059377E3BF5E3E77C64CDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2F5B681B9E6353A221555E3E77C66B13" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2F5B681B9E6353A221555E3E77C66B13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B60118A25F70292D5BF95E3E77C56E53" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_969B1FC9AD58129BBC0D5E3E77C66867" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3400034A6E2EA60EC546B8C74FB83A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_035649593555A0C87F496B8C74FBFDC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3400034A6E2EA60EC546B8C74FB83A9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_035649593555A0C87F496B8C74FBFDC6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A29A3E92C86B4824E3FA0F0C23686634" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A29A3E92C86B4824E3FA0F0C23686634" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5BAB9750C4008D9E49150F0C23695DA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5BAB9750C4008D9E49150F0C23695DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9E1EC4117D001C611D240F0C23695185" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9E1EC4117D001C611D240F0C23695185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6EBCD275C8A28E400F240F0C23697BB5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_C9C79C47DAB1E6AD90FD0F0C2369843A" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6EBCD275C8A28E400F240F0C23697BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A29A3E92C86B4824E3FA0F0C23686634" xlink:to="loc_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_FE726B9B05E74DF31D3C0F0C236AFF1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696" xlink:to="loc_us-gaap_Goodwill_FE726B9B05E74DF31D3C0F0C236AFF1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_05F492A7ABFEC1C5582E0F0C236ABC5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_05F492A7ABFEC1C5582E0F0C236ABC5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_AFDDC1EDE9FA9FFD9C640F0C236A9998" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_A442FB012FF117DB913A0F0C2369D696" xlink:to="loc_us-gaap_Goodwill_AFDDC1EDE9FA9FFD9C640F0C236A9998" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59AAB58CDE837C80C2A95A7138DB7631" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E955D54B89E1E93437B55A7138DF61CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59AAB58CDE837C80C2A95A7138DB7631" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E955D54B89E1E93437B55A7138DF61CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A927B441A3414782E6FA5A7138E237C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59AAB58CDE837C80C2A95A7138DB7631" xlink:to="loc_us-gaap_Goodwill_A927B441A3414782E6FA5A7138E237C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_43951AD4B439B9F51D655A7138E54F6D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59AAB58CDE837C80C2A95A7138DB7631" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_43951AD4B439B9F51D655A7138E54F6D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FE4C28BF345F9240B077FE14A0C7AF8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_BCF71DCCA0ACC9DB6180FE14A0C79F78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FE4C28BF345F9240B077FE14A0C7AF8A" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_BCF71DCCA0ACC9DB6180FE14A0C79F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_5A0A0949D7C47646E445FE14A0C7B943" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FE4C28BF345F9240B077FE14A0C7AF8A" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_5A0A0949D7C47646E445FE14A0C7B943" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_75DAE5B6E049177F730B6B8C74DE8E0A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3A9942225052822466DA6B8C74DECF14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75DAE5B6E049177F730B6B8C74DE8E0A" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3A9942225052822466DA6B8C74DECF14" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A5319FAE8853E39553E08065C8BB2117" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A5319FAE8853E39553E08065C8BB2117" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsIntellectualProperty" xlink:label="loc_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:to="loc_fold_DeferredTaxAssetsIntellectualProperty_0E073FDD5C7CF9F9BBD98065C8BC1B6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_F3CFBFB74070B7C269BA8065C8BCB837" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_F3CFBFB74070B7C269BA8065C8BCB837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_45DE845E20AC28BF38388065C8BDB445" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_45DE845E20AC28BF38388065C8BDB445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_385EA0D1DE4D7F2A174A8065C8BDD3FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_385EA0D1DE4D7F2A174A8065C8BDD3FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_E515807DFB09F9DDC97B8065C8BDBE72" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_E515807DFB09F9DDC97B8065C8BDBE72" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:label="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:to="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_E359511995EA86813BDA8065C8BD9382" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:label="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:to="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_96C3C08B7996AD3616488065C8BD088C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5EAA877063F69CEF6DCE8065C8BD6773" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_5EAA877063F69CEF6DCE8065C8BD6773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8707118815911E0A230D8065C8BE1595" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_F393096AD8B0B948B4E28065C8BC583C" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8707118815911E0A230D8065C8BE1595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:label="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:to="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_61824FD78D2209A50CF58065C8BE79F1" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:label="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:to="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_FF83D0641304A9D81B858065C8BEB995" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:label="loc_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:to="loc_fold_DeferredTaxLiabilitiesConvertibleNotes_A33D31F9E31D88C3BEFC8065C8BE0923" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" xlink:label="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:to="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_03FE4761A7E5D5A06CA08065C8BE9FFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_CA33709024E87DB02069806E1FA4880A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_CA33709024E87DB02069806E1FA4880A" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DeferredTaxAssetsLiabilitiesGross" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A12248FC14AC5596E79A8065C8BE5E5E" xlink:to="loc_fold_DeferredTaxAssetsLiabilitiesGross_0CDE70BBB61FBACE9A788065C8BF11E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_A91419BBED7D141B6C198065C8BFF5D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_A91419BBED7D141B6C198065C8BFF5D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_48422641F5E7333F27848065C8BF438D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:to="loc_us-gaap_DeferredTaxLiabilities_48422641F5E7333F27848065C8BF438D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6F32F3F9FA244DD4F5F58065C8BF2EEA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_E41F2B0B3F307DD2F9838065C8BCE459" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6F32F3F9FA244DD4F5F58065C8BF2EEA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E17F0C17267D712970196B8C73BC1955" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E17F0C17267D712970196B8C73BC1955" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5BD98A6D77B5928DF52D6B8C73BD8C8D" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:to="loc_us-gaap_DomesticCountryMember_D6AA64A4A430644E57C76B8C73BDB545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_C8DF703FAD3A32B7DB736B8C73BDA042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69BAB46EB8062486EF3D6B8C73BD2F50" xlink:to="loc_us-gaap_ForeignCountryMember_788698BE82D059B64B486B8C73BED733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_7FEAEDD6D53AC7BB598C6B8C73BE1F21" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:to="loc_us-gaap_ResearchMember_6AD8BBE802EAF5D5A62E6B8C73BE2D90" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_OrphanDrugTaxCreditCarryforwardMember" xlink:label="loc_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7A72550E957A5C851F516B8C73BE51D3" xlink:to="loc_fold_OrphanDrugTaxCreditCarryforwardMember_231164FA3C16B887F54A6B8C73BFAAC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B5D8825B6768CB21739C6B8C73BC5F33" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:to="loc_us-gaap_OperatingLossCarryforwards_38553B0AECD59488F13F6B8C73BF6C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_81132E967199597BAD4E6B8C73BFD208" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_B765F9A85D366F1571516B8C73BF3030" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_DE3C192D6B3223F0101A8065C8CAEF78" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE3C192D6B3223F0101A8065C8CAEF78" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_22B3E78AD388CD684FF28065C8CBB6BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_22B3E78AD388CD684FF28065C8CBB6BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9663C877623F15AA582E8065C8CBC05C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9663C877623F15AA582E8065C8CBC05C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1CFC22D27378E52CEED28065C8CB9A4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_66705C15D4F2C94260288065C8CA7C6B" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1CFC22D27378E52CEED28065C8CB9A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE3C192D6B3223F0101A8065C8CAEF78" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_E0CDC6F990D16873397B8065C8CC1769" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_E0CDC6F990D16873397B8065C8CC1769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BE36FCB073F1D571D34E8065C8CC8DD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BE36FCB073F1D571D34E8065C8CC8DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9B544C962E1E39FD41058065C8CCFDF3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55C6158A5B32A5284FEB8065C8CC9EF5" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9B544C962E1E39FD41058065C8CCFDF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE3C192D6B3223F0101A8065C8CAEF78" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_42F7EF9887EED9B79B068065C8CC5670" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_42F7EF9887EED9B79B068065C8CC5670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_AB72D7831A698793F4208065C8CD9EE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_647782B6688E84320D2A8065C8CC8549" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_AB72D7831A698793F4208065C8CD9EE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_F6C74DDC67A6EA2F0F368065C8CDEF0E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE3C192D6B3223F0101A8065C8CAEF78" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_F6C74DDC67A6EA2F0F368065C8CDEF0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E102AC54DBB02887DBB48065C8CDA51E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE3C192D6B3223F0101A8065C8CAEF78" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E102AC54DBB02887DBB48065C8CDA51E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE3C192D6B3223F0101A8065C8CAEF78" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2AFC149E8CFED70449D28065C8CDACCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2AFC149E8CFED70449D28065C8CDACCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_75CBCF60F3178A07B4168065C8CE4F17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_75CBCF60F3178A07B4168065C8CE4F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_F3A68A94FBE97CECD85D8065C8CE85ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_F3A68A94FBE97CECD85D8065C8CE85ED" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_2D622DB5FB2D13FC28048065C8CEB4DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1879FC0ABC27641C90418065C8CE78BF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1879FC0ABC27641C90418065C8CE78BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5A431CECDBD0B100781F8065C8CEE55C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5A431CECDBD0B100781F8065C8CEE55C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent_5399A4609FCF180E58B88065C8CE850F" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_9D35C5E78643D2238FF0806C452BDEBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_F6A01EC7DEF9FA5DD81F8065C8CE801A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_F6A01EC7DEF9FA5DD81F8065C8CE801A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_FE52A7D803D05B691CA68065C8CFAF68" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_FE52A7D803D05B691CA68065C8CFAF68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BC3CA7218F9729C7D3F38065C8CF8AA1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EAF13366F4EF21211C388065C8CDA359" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BC3CA7218F9729C7D3F38065C8CF8AA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ED212A189A6E48E97F8F8065C8CF1464" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE3C192D6B3223F0101A8065C8CAEF78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ED212A189A6E48E97F8F8065C8CF1464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_337695229C5387CA06998065C8CF36A1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE3C192D6B3223F0101A8065C8CAEF78" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_337695229C5387CA06998065C8CF36A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_84B4305CBDE7345936E78065C8CF1802" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE3C192D6B3223F0101A8065C8CAEF78" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_84B4305CBDE7345936E78065C8CF1802" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_17F3F4095B5585A7F627F4CA96244546" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0E7968F212AC5B455DFFF4CA962457B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17F3F4095B5585A7F627F4CA96244546" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0E7968F212AC5B455DFFF4CA962457B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_097FA3744FC60167C87EF4CA9624D01B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17F3F4095B5585A7F627F4CA96244546" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_097FA3744FC60167C87EF4CA9624D01B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E419D0863BDB10323CF7F4CA9624FEEE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17F3F4095B5585A7F627F4CA96244546" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E419D0863BDB10323CF7F4CA9624FEEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_10105552F86874C4ACFAF4CA96246745" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17F3F4095B5585A7F627F4CA96244546" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_10105552F86874C4ACFAF4CA96246745" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_B513BF9EA067B861F5366B8C74176D0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_EBFDE47D8A8B15E807A06B8C74177A4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B513BF9EA067B861F5366B8C74176D0F" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_EBFDE47D8A8B15E807A06B8C74177A4C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_38B2EE3D7E88FF3684665FD4960AFB2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2DE031D946238B846D265FD4960DDE48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_38B2EE3D7E88FF3684665FD4960AFB2E" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2DE031D946238B846D265FD4960DDE48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5B43F2C18B965FFC093D5FD4960F412F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_38B2EE3D7E88FF3684665FD4960AFB2E" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5B43F2C18B965FFC093D5FD4960F412F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3F721B1A30F8A9B417965FD4960F56B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_38B2EE3D7E88FF3684665FD4960AFB2E" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3F721B1A30F8A9B417965FD4960F56B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E28C49ACA18B9D20B4875FD4961018FC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_38B2EE3D7E88FF3684665FD4960AFB2E" xlink:to="loc_us-gaap_InventoryNet_E28C49ACA18B9D20B4875FD4961018FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_AC5DAD063209726069C15FD496109FC5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_38B2EE3D7E88FF3684665FD4960AFB2E" xlink:to="loc_us-gaap_InventoryValuationReserves_AC5DAD063209726069C15FD496109FC5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4DC3EE18173CE16E4F42F4CA96E8300D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C290E2C643728DB1F995F4CA96E8C241" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4DC3EE18173CE16E4F42F4CA96E8300D" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C290E2C643728DB1F995F4CA96E8C241" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_31F3838C922D9A7FF4340F0C22734488" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_C6FB7BC0D37DC8CE0A690F0C2273203F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_31F3838C922D9A7FF4340F0C22734488" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_C6FB7BC0D37DC8CE0A690F0C2273203F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_84FD69ACFCFFEE16348F7882C0667FD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeaseExpense_84FD69ACFCFFEE16348F7882C0667FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_0601DB451D768DDDC8227882C067C1D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeaseCost_0601DB451D768DDDC8227882C067C1D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_60D3A5EB96491F8240AB7882C067669F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_60D3A5EB96491F8240AB7882C067669F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C18DAC9931528D985FA97882C067E2C6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_C18DAC9931528D985FA97882C067E2C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_FC13FAF7AF7D1BF48F9C7882C067BCD5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_FC13FAF7AF7D1BF48F9C7882C067BCD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_F4E25CAC27C1D9D6CEF77882C0677839" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_F4E25CAC27C1D9D6CEF77882C0677839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_13069144F9553D3C3FE97882C068E874" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeaseLiability_13069144F9553D3C3FE97882C068E874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9A62DBC7E0B967F832D17882C06809B2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9A62DBC7E0B967F832D17882C06809B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5EFD52D25B09D5497B2E7882C068CB83" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5EFD52D25B09D5497B2E7882C068CB83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_A1321ABFD78C15539EA17882C06868C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_A1321ABFD78C15539EA17882C06868C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9670396DD6EECDF787DF7882C069156D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9670396DD6EECDF787DF7882C069156D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FA9167DEAB47E8864D647882C0690915" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FA9167DEAB47E8864D647882C0690915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CB7DE3BE0A81DCED018E7882C0693B47" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CB7DE3BE0A81DCED018E7882C0693B47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7EA7858A5904B744E1A77882C069B8F7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7EA7858A5904B744E1A77882C069B8F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4CA263A7974D629C46617882C0694D75" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4CA263A7974D629C46617882C0694D75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36309D15CD4F85F5451E7882C0696E35" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36309D15CD4F85F5451E7882C0696E35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37F96170CBD1B9F4D2DF7882C06ABDE8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37F96170CBD1B9F4D2DF7882C06ABDE8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:label="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_8611951736A2437BDA6D7882C06A9C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_99F6CCC8147C8ABDDD487882C06A4510" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E64649CE2A2E8A28D8A87882C0685601" xlink:to="loc_us-gaap_OperatingLeaseLiability_99F6CCC8147C8ABDDD487882C06A4510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_067B0DC19BF3B955A47D7882C06AE8A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_067B0DC19BF3B955A47D7882C06AE8A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1CA4533D7297FEB8C64F7882C06AFFDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1CA4533D7297FEB8C64F7882C06AFFDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_BB61A974338E2BA8B0D77882C06B9C2B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_BB61A974338E2BA8B0D77882C06B9C2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_97A44209FF2D5BFE68677882C06BD7E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_97A44209FF2D5BFE68677882C06BD7E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A62E98682ED82A96C29A7882C06B6A1A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A62E98682ED82A96C29A7882C06B6A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E91E4056896B05D3FE687882C06BB120" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E91E4056896B05D3FE687882C06BB120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1444D304BFBFDD8685467882C06B4B23" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_0C6ADBA406AFCBDCF7047882C06A5AE3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1444D304BFBFDD8685467882C06B4B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_8788DF9F5CEB4F1A05D47882C06B3C4E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_8788DF9F5CEB4F1A05D47882C06B3C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_31A36554131537E30A057882C06C050F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83AD3A767BF8F72937E87882C066E401" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_31A36554131537E30A057882C06C050F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_5DD5A561CA7081B5F261F4CA963E22FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_B331BC341BD19BF34843F4CA963EA91D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5DD5A561CA7081B5F261F4CA963E22FA" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_B331BC341BD19BF34843F4CA963EA91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10DD4D717384D8E80EEDF4CA963E9C3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5DD5A561CA7081B5F261F4CA963E22FA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10DD4D717384D8E80EEDF4CA963E9C3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E9D2571BCAF941DF482CF4CA963E2337" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5DD5A561CA7081B5F261F4CA963E22FA" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E9D2571BCAF941DF482CF4CA963E2337" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_EEF14ECEB8C22A3B91346B8C73D5CBC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FE0A4F646C105458497B6B8C73D538E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_EEF14ECEB8C22A3B91346B8C73D5CBC4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FE0A4F646C105458497B6B8C73D538E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A542914AB945A0ABF7E6F4CA96DAC3F7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A542914AB945A0ABF7E6F4CA96DAC3F7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44C6046FA48D4E243697F4CA96DAE5FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44C6046FA48D4E243697F4CA96DAE5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44C6046FA48D4E243697F4CA96DAE5FB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_ComputerEquipmentMember_9C1A1B0F952A93F80072F4CA96DBB4B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_D9B0CD02BC691E844D80F4CA96DB0B0D" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ResearchEquipmentMember" xlink:label="loc_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_fold_ResearchEquipmentMember_5F86296D86FBAEF077D0F4CA96DBF50A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_339B29A01CF425330C5BF4CA96DCEF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_90D1E9DA8D0A700BC183F4CA96DC3101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_VehiclesMember_FF7E53C833ABE575B403F4CA96DCCA5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_LandMember_5699FEB124A6A71636DCF4DB921ECE84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DBDE71297B932CBD313AF4CA96DB6437" xlink:to="loc_us-gaap_ConstructionInProgressMember_DD6C098F620D9EB469F3F4CA96DC5BC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6F99D3E045765E7DA11AF4CA96DAFEB9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_79B382DAAB88E2489B84F4CA96DCA2F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0FBC601C58BF4B432A04F4CA96DDACEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0FBC601C58BF4B432A04F4CA96DDACEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_519C28ACAF4C54F9C86AF4CA96DD1D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5CFF80469737D7E577A4F4CA96DC0880" xlink:to="loc_us-gaap_Depreciation_25154067A6612D5A97C8F4CA96DD653E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F95E133B6A05E4A71FE6F4CA96E0414D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_00113CECF71B0ECFF478F4CA96E00DC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F95E133B6A05E4A71FE6F4CA96E0414D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_00113CECF71B0ECFF478F4CA96E00DC1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5D71D38EAE495326CC01F4CA95E06044" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1D110BF8BB80E64C1CD4F4CA95E02863" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5D71D38EAE495326CC01F4CA95E06044" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1D110BF8BB80E64C1CD4F4CA95E02863" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8E555E9FAA22258891F089D88B0288D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8E555E9FAA22258891F089D88B0288D3" xlink:to="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9562584EB6D9ADE81CE189D88B3BA015" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9562584EB6D9ADE81CE189D88B3BA015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_806EEE4D50959EA4048089D88B050181" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329" xlink:to="loc_us-gaap_NetIncomeLoss_806EEE4D50959EA4048089D88B050181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_98FD1B9B9FD418A48A6389D88B06ABF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B6CC941AB1845A639389D88B043329" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_98FD1B9B9FD418A48A6389D88B06ABF8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_563248E3803F2B2C7427F4CA95DE431E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5C37C328BC1A7E4198E5F4CA95DE4D2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_563248E3803F2B2C7427F4CA95DE431E" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5C37C328BC1A7E4198E5F4CA95DE4D2B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_940CAEF5594DE38B3E2C6B8C745B645D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7DE3AD809CC5BD5F0E116B8C745B384E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_940CAEF5594DE38B3E2C6B8C745B645D" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7DE3AD809CC5BD5F0E116B8C745B384E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3799AF3CF3BAC31BA507F4CA9681F34C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0C43FF8003579E3372BEF4CA9682E2BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3799AF3CF3BAC31BA507F4CA9681F34C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0C43FF8003579E3372BEF4CA9682E2BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0AA1E1EA5CFD59732D01F4CA9682230F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0C43FF8003579E3372BEF4CA9682E2BA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0AA1E1EA5CFD59732D01F4CA9682230F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6FC8C567248DB68AE82BF4CA968278A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0AA1E1EA5CFD59732D01F4CA9682230F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6FC8C567248DB68AE82BF4CA968278A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6FC8C567248DB68AE82BF4CA968278A7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A20ED17BE21A30D89936F4CA968245FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6FC8C567248DB68AE82BF4CA968278A7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_86B8C551969ACBCDA52CF4CA9683D391" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C99530CB325952F00E70F4CA968338F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0C43FF8003579E3372BEF4CA9682E2BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C99530CB325952F00E70F4CA968338F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C99530CB325952F00E70F4CA968338F5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_669339189913F711BD04F4CA9683F036" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DB57EDBFF3C4CF3F1FD85A107527C601" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BBDD24977964BF5870E45A1075280CB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DB57EDBFF3C4CF3F1FD85A107527C601" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BBDD24977964BF5870E45A1075280CB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_71007BA0362D29B495005A10752838C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BBDD24977964BF5870E45A1075280CB8" xlink:to="loc_us-gaap_AwardTypeAxis_71007BA0362D29B495005A10752838C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC859A5EA4678B2DC86A5A1075282EB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_71007BA0362D29B495005A10752838C8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC859A5EA4678B2DC86A5A1075282EB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_39BFBDF60223D999C4AD5A107528CF92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC859A5EA4678B2DC86A5A1075282EB7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_39BFBDF60223D999C4AD5A107528CF92" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_BDEA4BB0F7E63A8945635A10752917C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC859A5EA4678B2DC86A5A1075282EB7" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_BDEA4BB0F7E63A8945635A10752917C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_7DF6611CF4899FD208125A1075297F8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BBDD24977964BF5870E45A1075280CB8" xlink:to="loc_us-gaap_PlanNameAxis_7DF6611CF4899FD208125A1075297F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7AAB71BBFDC91F3E66955A1075297E07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7DF6611CF4899FD208125A1075297F8E" xlink:to="loc_us-gaap_PlanNameDomain_7AAB71BBFDC91F3E66955A1075297E07" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7AAB71BBFDC91F3E66955A1075297E07" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_8215DD490C5D2B2463755A107529D971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BBDD24977964BF5870E45A1075280CB8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_15A11AD7FFA5EDECAF8B5A10752A392D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_AC585A74D17F392719F95A10752AD397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E2B92C65C19E851C55BA5A10752A9F72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_973F50070B0BE7716B555A10752AECF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4426656888E90B4AE0F75A10752A1FCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E4754E290F483601B7625A10752B5447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DBA9E5F515469F58D9DD5A10752BECB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FB253E6AC7173BAEA2295A107529CACA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_C86553DBDB33B2B6D31E5A10752B115B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8F3C92BEAEDED221D6C9F4CA9687BDFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32EDCCABC059196020A0F4CA96876303" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8F3C92BEAEDED221D6C9F4CA9687BDFF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32EDCCABC059196020A0F4CA96876303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_C45A93806BD488E80343F4CA9688980B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32EDCCABC059196020A0F4CA96876303" xlink:to="loc_us-gaap_PlanNameAxis_C45A93806BD488E80343F4CA9688980B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_767D1B98894A4EB2EC0AF4CA96880879" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_C45A93806BD488E80343F4CA9688980B" xlink:to="loc_us-gaap_PlanNameDomain_767D1B98894A4EB2EC0AF4CA96880879" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_679EA055E22ECC41DBBCF4CA9688058B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_767D1B98894A4EB2EC0AF4CA96880879" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_679EA055E22ECC41DBBCF4CA9688058B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_989ECD003446AADDE028F4CA96885A63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32EDCCABC059196020A0F4CA96876303" xlink:to="loc_us-gaap_AwardTypeAxis_989ECD003446AADDE028F4CA96885A63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1909B48BB5BF0B3AF3D7F4CA96891AEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_989ECD003446AADDE028F4CA96885A63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1909B48BB5BF0B3AF3D7F4CA96891AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_CED1ACB296D6AF589CF7F4CA9689D296" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1909B48BB5BF0B3AF3D7F4CA96891AEC" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_CED1ACB296D6AF589CF7F4CA9689D296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A0E4A552DD985013374EF4CA9689E2CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32EDCCABC059196020A0F4CA96876303" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A0E4A552DD985013374EF4CA9689E2CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A0E4A552DD985013374EF4CA9689E2CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DD583025BB7AF362D3C4F4CA968A8145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97420D1C3195A1030A1DF4CA968A326C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3E23C2637145AB0474DDF4CA968ADA23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3E23C2637145AB0474DDF4CA968ADA23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9A093486D55C38ECD19CF4CA968A035F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_067E86918123750E2DCCF4CA968A1F94" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FF9DE260827D29D2C740F4CA9689C6A0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_067E86918123750E2DCCF4CA968A1F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A0E4A552DD985013374EF4CA9689E2CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8B8E699126953534A825F4CA968BDB39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E3E442467B86014C9529F4CA968BC9D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E94A386ED42DCE08AEC3F4CA968BE8A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5F60A5E52A341372CB18F4CA968B9AF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_733620390872E2954FF9F4CA968B6702" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70C12551DF4555C2433DF4CA968ABD81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_733620390872E2954FF9F4CA968B6702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A0E4A552DD985013374EF4CA9689E2CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9282CE27E94C75C33093F4CA968CE7FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_C0FB267D8453FD4F6396F4CA968B1AF1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_F3ECC3DCE20A1CFB29E5F4CA968CBA93" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4B75EEB5454285ABB500F4CA9692D762" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9454C802A246A016936F4CA969258A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4B75EEB5454285ABB500F4CA9692D762" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9454C802A246A016936F4CA969258A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_81C9D6FCCF24CC5A2B46F4CA9692E50B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9454C802A246A016936F4CA969258A7" xlink:to="loc_us-gaap_AwardTypeAxis_81C9D6FCCF24CC5A2B46F4CA9692E50B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863F710C1804E9660D8EF4CA9693506B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_81C9D6FCCF24CC5A2B46F4CA9692E50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863F710C1804E9660D8EF4CA9693506B" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_80E9849487D0119FCB2DF4CA969356EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863F710C1804E9660D8EF4CA9693506B" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_80E9849487D0119FCB2DF4CA969356EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9454C802A246A016936F4CA969258A7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B661A2AEA175EF8DE013F4CA969327F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A47D84EE100D9E1F8E45F4CA96941712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3E5B63BA347ACFEF23ECF4CA9694200B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3E5B63BA347ACFEF23ECF4CA9694200B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6DAB725D1F108D022396F4CA9694335D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6E22500A11E93B780003F4CA9694AED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C35BC97780761B4A9721F4CA969445DC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_812D66D74FDFA2A26719F4CA9693E153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C35BC97780761B4A9721F4CA969445DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_521C585272ED1931A8D9F4CA9695DFB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_65706D901C49F6E5532EF4CA96950C31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CB7BCA632FDBE572574EF4CA9695DDBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8F63B15C6C3246A3E8B8F4CA969559DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CA76BDEA7EE39BB67317F4CA9695F0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_C3C7E614FE9B0F6E95E6F4CA96962D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5F326F8EAE083355667EF4CA96967F2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23862FFA4AADC32DDD79F4CA9696233B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_98FD1A8658FDB4F58749F4CA9695AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23862FFA4AADC32DDD79F4CA9696233B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8004872852F6D24C2EFBF4CA96967FED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_466E7CF0356B9D772496F4CA9696553F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F7D2152712FA7942D78F4CA96937FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47F45C68694B9ADD720EF4CA96960782" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1D0B0A56B074DC1CC0E4F4CA9697A2EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D3AD1521F1396C51D6EDF4CA9697A116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_A041DCCA211D3136990BF4CA969709F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7A1A493F0B0FF55466B9F4CA96979B73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0A45BD5DAA5510133BDAF4CA9696F099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1927EC0B53B6F70598A7F4CA96976781" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C35371B8948A11554C9DF4CA96AD021D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72F753367475931D4031F4CA96ADE872" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C35371B8948A11554C9DF4CA96AD021D" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72F753367475931D4031F4CA96ADE872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15BE1CA68024B4671B14F4CA96ADFD1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C35371B8948A11554C9DF4CA96AD021D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15BE1CA68024B4671B14F4CA96ADFD1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AF5171050A1C0109067DF4CA96AEEE7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C35371B8948A11554C9DF4CA96AD021D" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AF5171050A1C0109067DF4CA96AEEE7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_22A648FCA37E1EB83502F4CA96AEB836" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C35371B8948A11554C9DF4CA96AD021D" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_22A648FCA37E1EB83502F4CA96AEB836" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EFC0EF2EBE9620C4193AF4CA96A99CA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30945E3CC311DD40B16F4CA96A9B266" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EFC0EF2EBE9620C4193AF4CA96A99CA0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30945E3CC311DD40B16F4CA96A9B266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5DF96950A1882F53B127F4CA96A926AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30945E3CC311DD40B16F4CA96A9B266" xlink:to="loc_us-gaap_AwardTypeAxis_5DF96950A1882F53B127F4CA96A926AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7D0897F89C4410ADDCA1F4CA96A972F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5DF96950A1882F53B127F4CA96A926AE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7D0897F89C4410ADDCA1F4CA96A972F8" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_D3E1E1D0B7E220F99789F4CA96AA7B95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7D0897F89C4410ADDCA1F4CA96A972F8" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_D3E1E1D0B7E220F99789F4CA96AA7B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30945E3CC311DD40B16F4CA96A9B266" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9CF966C7700E59DC97A8F4CA96AAEC91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A36661F72CC6D72F19CF4CA96AA5126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7D01E2EBEECE28ECB67FF4CA96AAC905" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_121D5C7B0D80631E55BAF4CA96AA88A9" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_B122FF8A23687274A4EAF4CA96AB23B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4B293D1AE9C810E7A11E6B8C74B32073" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EA4AFCD91857607412046B8C74B3A361" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4B293D1AE9C810E7A11E6B8C74B32073" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EA4AFCD91857607412046B8C74B3A361" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3DC63674FC6C70037B095E3B9DDE7FF6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3DC63674FC6C70037B095E3B9DDE7FF6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5C8A6D74694D7E607A6C5E3B9DDFE13F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5C8A6D74694D7E607A6C5E3B9DDFE13F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7DBD74F48EFFB5BC77C85E3B9DDFC4AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5C8A6D74694D7E607A6C5E3B9DDFE13F" xlink:to="loc_us-gaap_EquityComponentDomain_7DBD74F48EFFB5BC77C85E3B9DDFC4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_25D544CD7DD9A26035515E3B9DDF6ED6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7DBD74F48EFFB5BC77C85E3B9DDFC4AC" xlink:to="loc_us-gaap_CommonStockMember_25D544CD7DD9A26035515E3B9DDF6ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FADF5C0249C39145E65B5E3B9DE59CF4" xlink:to="loc_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31F8CE24F46AA107DA2C5E3B9DE51D29" xlink:to="loc_us-gaap_CommonStockMember_25D544CD7DD9A26035515E3B9DDF6ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2467323550721F5141C25E3B9DE664FC" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_UnderwrittenOfferingMember" xlink:label="loc_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_725BD41817ED6D09784F5E3B9DE69AEA" xlink:to="loc_fold_UnderwrittenOfferingMember_283104795594830360DC5E3B9DE663ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_24D6483E5BBD6008B4185E3B9DE641BA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_529F042DFCF0CF6E50475E3B9DE73B00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6596017250EE6DFC35715E3B9DE72760" xlink:to="loc_us-gaap_WarrantMember_529F042DFCF0CF6E50475E3B9DE73B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0EACFAFAA20EA08499045E3B9DDE6C2B" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0641D7DEE2F0486D8D1C5E3B9DE7243F" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_95FEC08ADFF50C7BCAF25E3B9DE8CAB5" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CommonStockVotingRightsForEachShareHeld" xlink:label="loc_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_fold_CommonStockVotingRightsForEachShareHeld_4093C7957AAF2D71A4555E3B9DE8BCCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DA2C52CB656108665DF65E3B9DE8D7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980A5EC81888245BB03A5E3B9DE8B370" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_368223B446B0E30B380E5E3B9DE861EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_DF7C1FC1207115F37A1F5E3B9DE82A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_35242BD246BE584CAD545E3B9DE93A8C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentConsiderationMilestonePayment" xlink:label="loc_fold_ContingentConsiderationMilestonePayment_60E4D1113AF6FA0EF6665E3B9DE9C5D9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_fold_ContingentConsiderationMilestonePayment_60E4D1113AF6FA0EF6665E3B9DE9C5D9" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_MilestonePaymentStockIssuedAsConsideration" xlink:label="loc_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_fold_MilestonePaymentStockIssuedAsConsideration_77C66C6F2B0F151523805E3B9DE992CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6A1B295800E1228053B75E3B9DE94C17" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_C2823AE57F8B32D9E7805E3B9DE924B3" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_DC9857C31EF9D98A94DA5E3B9DE9947E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_776FA75B81C81A24764D5E3B9DE73F6B" xlink:to="loc_us-gaap_SharePrice_C16674817A15DD2035F65E3B9DEAF7F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_178FF5FE372BEA852CDB6B8C74858507" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_178FF5FE372BEA852CDB6B8C74858507" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:to="loc_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_EF233ACEC457DC55752B6B8C748620BE" xlink:to="loc_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_71A450859D2E014B13586B8C7486C162" xlink:to="loc_srt_MaximumMember_C54E800C1B637ACAB64A6B8C7487BC58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:to="loc_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_DC992F6113C6A66D19806B8C7487FEBD" xlink:to="loc_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" xlink:label="loc_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_70023AA36599892335F06B8C7487C485" xlink:to="loc_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_9956B698181E262884306B8C74872067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:to="loc_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_9005440F89F2AAED52096B8C7487CE44" xlink:to="loc_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_34850424E88FD14E1C826B8C748827A7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5D40E70F24C0F5C1930C6B8C7488F9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:to="loc_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B230A0E38881FD1140816B8C7488CC2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04783055FB6F5F33FB646B8C74888943" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_16C2E03A9C54DB229CB46B8C74892C1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74DD12A3893ABFE3F3156B8C74863373" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradingSecurities" xlink:label="loc_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:to="loc_us-gaap_TradingSecurities_72B8AE5C897703F8FFE56B8C74895B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_D1B56EEA06611AA47AAD6B8C748AC74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_E7456530BD148B14DA406B8C748A648E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7AB1F5CB82A012E869CD6B8C7489CA49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DBB0566EA8EBCB096EBC6B8C748A9456" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_FA2B3E5FBEEC6A0333AB6B8C73F5AD24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_24BA39DC0A59F3CE0E3B6B8C73F5DEC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FA2B3E5FBEEC6A0333AB6B8C73F5AD24" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_24BA39DC0A59F3CE0E3B6B8C73F5DEC1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CC14D2D74A98EE51EF3506E59B9DC9EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_30D12D6D977D5237EECF06E59B9D7744" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CC14D2D74A98EE51EF3506E59B9DC9EF" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_30D12D6D977D5237EECF06E59B9D7744" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3DA79C86DADEEE741B0F06E59B91AB6B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_76EC8BF314C40E1EE3C306E59B91BF03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3DA79C86DADEEE741B0F06E59B91AB6B" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_76EC8BF314C40E1EE3C306E59B91BF03" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ShareBasedCompensationNumberOfPlans" xlink:label="loc_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_76EC8BF314C40E1EE3C306E59B91BF03" xlink:to="loc_fold_ShareBasedCompensationNumberOfPlans_3FD14BDA9120B9F07FBC06E59B922792" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82D12F3BDDC3FE2072E506E59BA41342" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82D12F3BDDC3FE2072E506E59BA41342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_E264E5A89D243D2726E306E59BA41004" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_E264E5A89D243D2726E306E59BA41004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_EB9B02A2247BDF53C6B906E59BA447C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_EB9B02A2247BDF53C6B906E59BA447C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_8073ACF56E46602A974A06E59BA53EBC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_UseOfEstimates_8073ACF56E46602A974A06E59BA53EBC" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_DDE7AE390FCB12A31E8C06E59BA53A43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_DEC54CDE6B5F0143572406E59BA5934E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_DEC54CDE6B5F0143572406E59BA5934E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4BFCADED9B07BE850DC606E59BA54CB3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4BFCADED9B07BE850DC606E59BA54CB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_F0D42A22594863806E1706E59BA5DFCD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_F0D42A22594863806E1706E59BA5DFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_03FED454C487F7BA2D1A06E59BA51463" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_03FED454C487F7BA2D1A06E59BA51463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0FBCDD4A9EAFC602AA7606E59BA65A6C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0FBCDD4A9EAFC602AA7606E59BA65A6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_80552152FA2476C40CC106E59BA6A5BD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_80552152FA2476C40CC106E59BA6A5BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_96B3550638B5F2F4D5F606E59BA69636" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_96B3550638B5F2F4D5F606E59BA69636" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:label="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock_35404AF7BB840648A6EC06E59BA67D76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9F531953F8E001EBC5E106E59BA62AE2" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9F531953F8E001EBC5E106E59BA62AE2" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_E793FECFDC6540AA0AE506E59BA6FB7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_07DFC17E7946B081497006E59BA7C8AB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_07DFC17E7946B081497006E59BA7C8AB" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_NonqualifiedCashDeferralPlansPolicy" xlink:label="loc_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_fold_NonqualifiedCashDeferralPlansPolicy_E509FEE3430BAF58C83F06E59BA71ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64B11EE7DDA01CFEF4A606E59BA718AE" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64B11EE7DDA01CFEF4A606E59BA718AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_4A1CBEB4804CE5CDF53B06E59BA78B33" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_4A1CBEB4804CE5CDF53B06E59BA78B33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_F6FD0EC7749B625F326606E59BA7311F" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_F6FD0EC7749B625F326606E59BA7311F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_7EE80494CCAF4644142A06E59BA76C32" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_7EE80494CCAF4644142A06E59BA76C32" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:label="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7A3D9D4F7C6B9F14AF8806E59BA748D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_E91F2DC8FA971A41F49306E59BA8CCA2" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_E91F2DC8FA971A41F49306E59BA8CCA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295451EDF3048C0BA5EF06E59BA8CB68" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A51344C6C52B45AFC5D06E59BA45D77" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295451EDF3048C0BA5EF06E59BA8CB68" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2D0B092923B9B24F868806E59B9AF9FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D3B76C56E1FE671BF48A06E59B9A4BF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2D0B092923B9B24F868806E59B9AF9FD" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D3B76C56E1FE671BF48A06E59B9A4BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_57A64FE6181903DC6E8306E59B9AC67D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D3B76C56E1FE671BF48A06E59B9A4BF3" xlink:to="loc_srt_RangeAxis_57A64FE6181903DC6E8306E59B9AC67D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DCCEDAC04EB6346611E606E59B9A8A33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_57A64FE6181903DC6E8306E59B9AC67D" xlink:to="loc_srt_RangeMember_DCCEDAC04EB6346611E606E59B9A8A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5FD4FB4230C9810C691906E59B9B26FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_DCCEDAC04EB6346611E606E59B9A8A33" xlink:to="loc_srt_MinimumMember_5FD4FB4230C9810C691906E59B9B26FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E3510819730789D3F88B06E59B9B824D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_DCCEDAC04EB6346611E606E59B9A8A33" xlink:to="loc_srt_MaximumMember_E3510819730789D3F88B06E59B9B824D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B2322CA7589B6653FA6A06E59B9BCB18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D3B76C56E1FE671BF48A06E59B9A4BF3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B2322CA7589B6653FA6A06E59B9BCB18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B2322CA7589B6653FA6A06E59B9BCB18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_F3CB87DBB389B02BC3E206E59B9B275F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D52AAB58508B39DBEF2206E59B8A2E5B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D52AAB58508B39DBEF2206E59B8A2E5B" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A58EA1B15833F006297506E59B8BF880" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0E473A63468B4B8E633C06E59B8BAD99" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_24E9AA47BA4694F98ECA06E59B8BF295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_89D87552F592E2559D8406E59B8AEF10" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_55077C6D9D5BEA82093B06E59B8C5A39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:to="loc_us-gaap_OperatingLeaseLiability_55077C6D9D5BEA82093B06E59B8C5A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_F81525777F3FB337256E06E59B8C1980" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6C753D1B898EEF2DB69506E59B8CC557" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_F81525777F3FB337256E06E59B8C1980" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_85CE6AB6A84816214A648065CB067E31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_85CE6AB6A84816214A648065CB067E31" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:to="loc_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_EC470CE5455532D27FFA807204B1CED6" xlink:to="loc_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:type="arc" />
    <link:loc xlink:href="fold-20191231.xsd#fold_LargestCustomerMember" xlink:label="loc_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_15F0C698883E5C8185508072901E7B9C" xlink:to="loc_fold_LargestCustomerMember_9D559FBD747A573FAFE5807364D84356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2D2C65B949027E53E3C68071E91C19E7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D3BA5F0B7D0EF486B5B780726588F0AF" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_B771DF163435EAD8A7C580731BB1CD40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3608BD799A076D106EA48071D95CDEA3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:to="loc_us-gaap_SalesRevenueNetMember_F174603AD1AD324F5B6380746D48DF61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_F5AAB2E447C5D4CA555080723A6DE376" xlink:to="loc_us-gaap_AccountsReceivableMember_E0322092CD34697C7B238072F4A16C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:to="loc_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_D951FE71BC175EC1D3AB8065CB068566" xlink:to="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_4E07D8A9B2243407B00D8065CB07A2BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:to="loc_country_US_4E07D8A9B2243407B00D8065CB07A2BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_F07362D5B5F3CADCAAF38065CB079938" xlink:to="loc_us-gaap_NonUsMember_3A782D3F1250EBD480288065CB07CFFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53FE86937B75E4B966DE8065CB0687E5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6AB6104336A8DF4437DA8071B6350CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_72FB274570EA9761A0E78065CB07D889" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4BA5DE5068672111CC228065CB079F0F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_72FB274570EA9761A0E78065CB07D889" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7E5B21B5E1187373CFE006E59B8F108B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1877A8A6DBC811CFA0C106E59B8FE813" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7E5B21B5E1187373CFE006E59B8F108B" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1877A8A6DBC811CFA0C106E59B8FE813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_C959832D0C5C846A7AD106E59B8F0AE0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7E5B21B5E1187373CFE006E59B8F108B" xlink:to="loc_us-gaap_NumberOfReportingUnits_C959832D0C5C846A7AD106E59B8F0AE0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BA7186A7BEC46404329006E59B9FF53C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_38D53409FB481F0C0F2B06E59BA05D16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BA7186A7BEC46404329006E59B9FF53C" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_38D53409FB481F0C0F2B06E59BA05D16" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>chart-4f9a0d4e5d2c71b470b.jpg
<TEXT>
begin 644 chart-4f9a0d4e5d2c71b470b.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Q HT# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?EE@EEB?&,H[#/->A5R?C7_D 2_]A+P]_P"I'I% %W_A&M*_N7O_ (-]9_\
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MR&K_ /(V>$_^N'B3_P!(K"@#0_X1K2O[E[_X-]9_^6-'_"-:5_<O?_!OK/\
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M!K1M3\1? +XK_"?QU-J>IQ?&+2?C=I-MI-KXNNM%TB[M/AMXEUR^\,>+]/\
MA]XC\)V^A^-OJ[]GG]H[XG:Q\=+3]GWXQKX7U7Q3XH_9.^%?[5FCZ]X,TF[T
M72=)D\7^+=<\$?$'X=26M]JNIW%_IOA/6X/#-YX.\27#0:IK6D:SJ-KKEN;[
M1DOK]+__ ()Y?"3Q1J!L/B)?W_C_ .'VFZQ^U/J_A?PGK>F:5!K6EP?MF67C
M'3_CQX5U;X@V*Q>*/$G@G7+3Q]XFATG0+HV<]LS^'[KQ!JOBG4/!GA"\T?U7
MX&_LK:#\'_&%Q\1]7\7^(?B5\0X_A!\./V?M%\7>*+32+._TGX/_  IO_$.K
M>&-",6D6T$-]XAUC6_$^I>(/'GBF7RI/%6L1Z6]OI6A:9H^GZ5" ?5=> _$/
M]H+X<>#+[Q#X4US_ (3_ /M?3=/E%U_8OP;^,OBC2\W6D?;H?L_B#PM\/]9\
M/7JB"XC,[66JW(M9?,M[GRKJ":"/WZLS61_Q*M3Z_P#(/ONY_P"?2;WH _$#
M_@W+UFRL_P#@BM^P3#/]LW_\*W\;M^ZTS5+E"/\ A=WQ27B6VLIHCRI! <D8
MY&,$_MI_PDFF?]1#_P $NM__ "MK\8/^#<#_ )0H?L$_]DX\<?\ J[/BC7[>
MT 8/_"2:9_U$/_!+K?\ \K:/^$DTS_J(?^"76_\ Y6UO44 8/_"2:9_U$/\
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M4 8/_"2:9_U$/_!+K?\ \K:/^$DTS_J(?^"76_\ Y6UO44 8/_"2:9_U$/\
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M8TZL54C&<XQFI*,YQM)X/_"2:9_U$/\ P2ZW_P#*VC_A)-,_ZB'_ ()=;_\
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M_P!^M3_^/48\3?W]#_[]:G_\>H Z"BN?QXF_OZ'_ -^M3_\ CU&/$W]_0_\
MOUJ?_P >H Z"BN?QXF_OZ'_WZU/_ ./48\3?W]#_ ._6I_\ QZ@#H**Y_'B;
M^_H?_?K4_P#X]1CQ-_?T/_OUJ?\ \>H Z"L#Q7_R+'B+_L!:Q_Z;;JDQXF_O
MZ'_WZU/_ ./5A^)AXB_X1SQ!YKZ-Y?\ 8>L;_+CU'?M_LVZSLWRE=V.F>,T
M==I?_(-T[_KQM/\ TGCJ]7)Z</$G]GV&Q]$V_8;3;NBU+=C[/'C.V7&?7'\Z
MN8\3?W]#_P"_6I__ !Z@#H**Y_'B;^_H?_?K4_\ X]1CQ-_?T/\ []:G_P#'
MJ .@HKG\>)O[^A_]^M3_ /CU&/$W]_0_^_6I_P#QZ@#H**Y_'B;^_H?_ 'ZU
M/_X]1CQ-_?T/_OUJ?_QZ@#H**Y_'B;^_H?\ WZU/_P"/48\3?W]#_P"_6I__
M !Z@#H**Y_'B;^_H?_?K4_\ X]1CQ-_?T/\ []:G_P#'J .@KD_&O_( E_["
M7A[_ -2/2*N8\3?W]#_[]:G_ /'JY?QB/$/]@S><^C[/[0T''EQZ@&W?\)#I
M.S[\I&W=C=CG;D#DY !Z116 1XFR</H>,G'[K4NGX38_+CTI,>)O[^A_]^M3
M_P#CU '045S^/$W]_0_^_6I__'J,>)O[^A_]^M3_ /CU '045S^/$W]_0_\
MOUJ?_P >HQXF_OZ'_P!^M3_^/4 =!17/X\3?W]#_ ._6I_\ QZC'B;^_H?\
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M7MCO]F/L-CG?NE+YSC&W@<]3B@#TFBN?QXF_OZ'_ -^M3_\ CU&/$W]_0_\
MOUJ?_P >H Z"BN?QXF_OZ'_WZU/_ ./4A_X24=9-#'_;+4^W4X\W.!W/;J:
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M8\3?W]#_ ._6I_\ QZM3B.@KD4_Y'FX_[%6S_P#3W?5>QXF_OZ'_ -^M3_\
MCU8FGC4!XVNO[0-F9/\ A%K+9]C6X5-O]MZAG>+AG8G[N"".^1TH [NBBB@
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M0H?L$_\ 9./''_J[/BC7[>U^(7_!N!_RA0_8)_[)QXX_]79\4:_;V@ HHHH
M**** "BBB@ HHHH **** "L#Q7_R+'B+_L!:Q_Z;;JM^L#Q7_P BQXB_[ 6L
M?^FVZH T=+_Y!NG?]>-I_P"D\=7JHZ7_ ,@W3O\ KQM/_2>.KU !1110 444
M4 %%%% !1110 4444 %<GXU_Y $O_82\/?\ J1Z1765R?C7_ ) $O_82\/?^
MI'I% '64444 %%%% !1110 4444 %%%<CX[\=^%/AIX3UKQOXVUFUT'PUH%F
MUYJ.HW;'"J"$AM[>% T]Y?WL[1VFGZ?:QRW=_>30VMK%+/*B'?#8;$8W$4,'
MA*%;%8O%5J>'PV&P].=:OB*]::IT:-&E34IU*M6I*,*=.$7*<I*,4VTC#$XG
M#8+#5\9C*]'"X3"T:N(Q.)Q%6%'#X?#T82J5J]>M4E&G2I4J<93J5)RC"$(N
M4FDFS,^*'Q-\)_"+P;J?C?QC=SP:78-;6MK9V%L^H:UKVLZC.MIHWASP[I4/
M^DZMK^MW\D5CI>GVXW33R;Y7AMHIYXO$O@W\,?%WB3Q7_P -"?'.T2'XDZAI
M]YIW@'P"6M[K2?@CX+U&82'1;&2,RQWOCS7;>.VF\=>*%?S'E_XI_3#!I-HZ
MW.7\+O GBGXO^,-+_:&^-FC3:/\ V?%YWP,^$6IEY%^&FE7:/GQMXLLV(M;C
MXL^([.2/S!Y+CP1I9CTBQE_M)[Z=/;_BC\;_ (._!'1TU[XO_%#P%\,M)E6;
M[)>>./%6B^&5U"2!=SVVEPZK>6UUJUX0,166F07=W,V$AA=V53]EFN.P7!67
M8W(\#B\+/.<71EA^*L_IUJ+PV!P\TE7X9R?&*;IRP]VZ?$&;T:GL\TJ1>5Y?
M4EDM+$XK/OC\BRG-?$'-\NS6MEN/JY70Q$:_!_#,,)BIYAF6*C+GP_$V;Y=&
MFZ[Q/*E5X>R:I2E4RNDUFV84XYW5PV$X?]3Z>U?!7[2G_!0?]C']G'XA^%OA
MS\:/V@_ W@GQS::KI^MZEX7G.M:WJ^B:5?:-JD5E>^(K;PSI&M?\(W%>C4+.
MXLAK[:=)=6,W]HP(]@CW*VV_;2U;Q^IA_9H_9H^/'QSCFCMY;/QMKOAI?V??
MA!+%-DM.OCGXX#PKX@UVQ50#]M\ _#WQO#*KC[.937\:W_!0_P#8=_;OM?VO
MOBWXT\9?L]^/O%-]\;OB)JGC[0-9^#FE>,_C'X'G;Q:8K^S\'Z/XNT_POIVI
M2WW@VT$?A5K3Q#X=\+W9M]#%UIFECP^+*Y/X#QGQGCLERZABN'<O><5*F+A1
MK5WA,?7R^E1E";4X8C#1I4<1*I.*IQ=+$RA3D_?3<H1E_;_@'X \/\?<5YAD
MOBGQ1'@3#8;)JV-P660SSAK+N*,;CZ>(PT)4*V6YK4QF-RREA<-5J8JM#&Y/
M"MB*<;T'"G2Q%6G_ 'Y>$_%OA?QYX:T/QEX*\0Z+XL\)^)M,M-:\/>)?#NIV
M>LZ'K>DW\2SV6I:5JEA+/9WUE=1,'AN;>:2)U/#9! Z&OQ3_ .":?[*7[=OP
M _8[^$G@/6OC3\/OAGJ$=OXEUV7X3_$#X'7WQ0U+X=6WBOQ3J?B.T\//XH\/
M?'+P0AU""*^:\U#28K6;3-$O-3NM(MVGEL9+V;[DDT;]ORQBC$'Q%_9%\2/&
MWDN+KX-_&GP@]Q& P6]:YL_C?XPB@F)5&DT^/3WA8RN([Z)85$WTV79OC<3E
M^"Q6,R/,<)7Q&%P]:M1_V.?L:M6E3G4IJ'UQ8E*$IN*C5H4ZRMRU*<*B<%^1
M<4<#\/Y3Q/Q!DV1^(G"N=9=E>=9GE^7YA)YW0>.P>$QM?#X7%.NLDGE51UZ5
M.%253 YCBL#*4U/#8JOAY4ZTOLBN3\:>!/!_Q$T*X\->-_#FD^)M#N725[#5
MK1+F.*YA.Z"]LY#MN+#4;5_WEGJ5A-;7]G,%FM;F&55<?,,&H_M_V3H+CPC^
MR!XE2&0^8T'Q#^-W@J348B6P4CN/ACX[CT>5%9<I)<ZVDIB;#Q?:%%M9G^(7
M[;^EQSBX_9A^ _B.2)//27PS^U;XFLUN(RH)M+>#Q/\ LU:9_IZ$.%-U=6EA
M*S1 W<*&62/T\-GLL%6HXO#QSC!8K#U(5:-?#8',5B*%:#4H5*5;!4:DH3A)
M7C4IS332E%ZIGS6*X%JX^C5P<\?P;F>$Q-.5*M1Q'%/#5##5Z-1<LJ=:CG.8
M8)3ISC)<].K3LX2<9QO&I&'1'PM\:?@X/-^'^K77QK^']N"6^'?CS68[?XE:
M%:*'(A\$?$R__P!&\3P0AE6WT#XDJ+^1(EC7X@P+Y< ]+^'?QD\#?$N6_P!,
MT6]O-+\6:(J'Q)X!\4V$_ASQYX9+D*K:SX8U'9?)9R.P6UUFQ^W:#J((DTW5
M+R$B0^##XX?M8VI=-0_8AUF\) >%_#'[1'P8U*#8-P>.Z;Q)-X,GAN20IC2"
MWO;9XW#27D,@:(<+\1/&VO\ Q!33)?B!^P1^U#:ZOI+/-X5\9>"_%7[-,OCC
MPIJ *.\^@>)_"W[1]GK_ (>W$J[JMV-*U3RC:ZA97<.Z%_IEQ=P_G7N<28#,
M\+C)?\U'E.0X^CB92=O?S;*IX7"9=FKDTU/%X>ME>8SJ5:F*QV,S.HH49?+/
MPPXPR-J7#&:\*XW!I7_U9S/Q X1Q>'C%)>YE&:4,]QV994HJ5X82O0S7+:=*
MC#"8#!99252O']!Z*_,_X?\ [4GQS\(^(=/\*^.?V=/VIO&_@>YDGMH_'NL_
M![0-*\=^$OLZ2&.V\96?@7Q?XE\*^.H"D)!\5^$8M"\XI@Z3J-S<VTUYZGX;
M_P""@/P&\3VM[?6&A_M"M9:3JEUHNNWL/[*_[16J66@:I:3M;R66LWGA[X;:
MU:V,[/Y1CC>9V9+B!B%W.(^+,<)3P&$69T\=@LPR6=;ZO#.<'.M'!1KVBU0Q
MD,91PN,RK%33<J6$S;"X'$XBE&>(P]*MATJSZ<LP.<YEF,\C_L+-<-Q%2PT,
M94R"I1HXO,)X6<Y4_K> GEE?'X'.<#&K'V57'Y+B\PP>'KSIX7$UJ.+J1PY]
MNT5\<3_M\?LO63O'JOC3Q?X>>,(\R>+/@C\>?",EO X#"\N8_$OPPTMK;3@A
M,C:E<>58)''-(]PJ03,ENV_;Z_8PN6E23]IGX/:;)"$9H]=\9:?X=EDCD,@6
M6WCU\Z8]U"&B=7GMEFBC<;)'1BH/@?VSD[=EFN6MWM98[#-W]/:]-;]K.^S/
MIGP%QTH\SX+XL4=/>?#N;J.KBD[O!I6;E&S\UW/KRBOGJR_:W_94U-F33/VF
M/V?=2D2,321V'QG^&]T\<3,%661(?$S,D;,0H=@%+$+G)KTC1OBI\,O$;6Z^
M'_B'X%UQKNV^V6JZ/XO\.:HUS:!%E-U;BQU.<S6XC99//B#Q;&5]^T@UTT\;
M@ZKM2Q>&JO32G7I3>KLM(S>[T7F>5B>'\]P:<L9DN;82*O=XG+L9ATK)-MNK
M1@DDG=M[+78[VN0U?_D;/"?_ %P\2?\ I%85U$%S;W,*W%M-%<P29V2V\B3Q
MOABAV21,Z-AP58AL*0=Q&#C^?_XL_P#!P-^QOX%^/1\"V?A/XP^-_#'@7Q!X
MA\*^(OBAX2T7PW<>&9;V*=M'U6^\-Z3J'B2R\2>*-&TN]L'5=0LM/MCJ\2R7
M&@V^JP&U>[X,VS_)LBIT*N;YCAL!#$U'2P[KR:=6:47+EC&,I<L%*+J5&E3I
MJ<>>4>:-_HN"?#3CSQ'Q.8X3@?A;->),1E.&CB\RAE]*#6#HU)3A25:I6J4:
M2K5Y4ZL<-A5-XK$NE66'HU72J<O] ]07-U;6=O/=7<\-M;6T,EQ<W$\B0P6\
M$*-)+//-(RQPPQ1HSR2R,L:*I9F !-?G_:_MMZ[\=+>SMOV(?@_KOQULM5BC
M=?CGX[&N?!W]F71()4 DNX_'6O:!<^,OB?=V,SK#-HOPA\#>*[87D5UIVK>)
MO#L]O/+#<M?V+-9^+D]MKW[:WQ:U;]H:7[5%J4?P3T.PN/AM^RKH5S&\-Q:V
MA^$NGZEJ&L_%1=-G614OOCCXP\?6EVY%[;>&]$<QVD!_:WUK3*<.\Q3VQ?M%
M0RM7LTUCG"I]9BU=)Y?0QJC-<E5TKW5/@K^QVY\;YG#A:4&^;)%A_P"T^,)M
M74J;X=A7PJRFK%N$I0XHS#A^52A/V^"CC4E3E=US]N/1/&6K:EX,_9&^'GB+
M]K/QGIU_+H^I>(O!-[;>'/V>O!^JP$?:X?''[16LV\_@@S::I)U+P]\-H/B9
MXXMY5^RMX56=CLS#^RC\7_CN);O]LOXUWFO>&+QQYG[-O[/MWXB^%WP,6R'F
M*=+\=^+5N;?XR_&E9@(&U"'7/$'@GP)JH5[>Y^&8MG=)/NO0]!T/PQI.G:!X
M<T?2] T+1[2&PTC1=%T^TTK2=+L;==D%EINFV$-O96%I F$BMK2"&&- %1 !
M6M1_9E3%:YMB7C(O?!48RPV6I=8U,.JDZN,36E2..KXC#S:4X86B]$O]<,-D
MUH<%9/3R"K#;B#'5J><<62DK-5<-F=3#X?!9#.%1.>&K<.Y;EF:4(3>'Q&;X
M^"YY<AX&^'_@7X8^&=,\%_#GP=X7\!^$-&C,6D^%_!V@:7X:\/::C$,XL=&T
M:UL]/MC(_P \CQ6ZO+(2\CNY+'KZ**]:$(4X1ITX1A"$5&$(1480C%6C&,8I
M*,4M$DDDM$CXJO7KXJM5Q.)K5<1B*]2=:OB*]2=:M6JU).52K5JU)2J5*DY-
MRG.<I2E)MR;;N%%%%49!1110 4444 %<BG_(\W'_ &*MG_Z>[ZNNKD4_Y'FX
M_P"Q5L__ $]WU '74444 %%%% !1110 5\?_ !"\'>.=3_;<_9F^(&F>"M9U
M'X=^"?@1^U-X.\8>-X+SPU'I&@>)/BAXG_9MU;P9I5SIUYKUMXIOCJ=G\*/%
MIGO-'\/:EINER)ID6I7=JVIPE?L"C ZXY]: /PE^,_\ P3J_:Y^+/Q2UGP[X
MI^.O@#Q3\*_BA^PK_P %%OV>_'7Q"TKX,1_#WQ3I_C/]J^?X*V/A@ZK/;_&S
MQ3JVIZM*_A6+68?$F@^%HM$T'PI\+3X$71]/'BK0+G1?KW]G'X$_%E_VC;#]
MHOXI^&(OAS)X3_8N^#_[*]AX-76]#\13:UXOT'QMX@\>_%#QA;:CH%_?6J>"
M8;U?"6B?#V6_.G^(M9MQXEU/7/#WAU?[-M;G]':* "OGSXB_LZ?"GQOJ'B+Q
M=XBTOQ-<:YJ>GRF[GT_XE?%#0;-S::0+"W\K2/#_ (TTK1;4+;V\2R+::= )
MW#SS^9<2RS/]!UFZQ_R"=3_[!]]_Z234 ?A__P &YFBV%]_P16_8)FN4G:0?
M#;QN@*7M_ H4?&[XIN (X+J*,?,[$D)DYZXP!^V?_",Z1_SQN?\ P9ZK_P#)
MU?C#_P &X'_*%#]@G_LG'CC_ -79\4:_;V@# _X1G2/^>-S_ .#/5?\ Y.H_
MX1G2/^>-S_X,]5_^3JWZ* ,#_A&=(_YXW/\ X,]5_P#DZC_A&=(_YXW/_@SU
M7_Y.K?HH P/^$9TC_GC<_P#@SU7_ .3J/^$9TC_GC<_^#/5?_DZM^B@# _X1
MG2/^>-S_ .#/5?\ Y.H_X1G2/^>-S_X,]5_^3JWZ* ,#_A&=(_YXW/\ X,]5
M_P#DZC_A&=(_YXW/_@SU7_Y.K?HH P/^$9TC_GC<_P#@SU7_ .3JP_$WAW2X
MO#GB"1(K@.FAZNRDZCJ; $:=<D95[UE8>H8$$9!&":[NL#Q7_P BQXB_[ 6L
M?^FVZH IZ=X;TI]/L&:*Y):QM"?^)EJ@Y^SQ] +X #T   JY_P (SI'_ #QN
M?_!GJO\ \G5HZ7_R#=._Z\;3_P!)XZO4 8'_  C.D?\ /&Y_\&>J_P#R=1_P
MC.D?\\;G_P &>J__ "=6_10!@?\ ",Z1_P \;G_P9ZK_ /)U'_",Z1_SQN?_
M  9ZK_\ )U;]% &!_P (SI'_ #QN?_!GJO\ \G4?\(SI'_/&Y_\ !GJO_P G
M5OT4 8'_  C.D?\ /&Y_\&>J_P#R=1_PC.D?\\;G_P &>J__ "=6_10!@?\
M",Z1_P \;G_P9ZK_ /)U'_",Z1_SQN?_  9ZK_\ )U;]% &!_P (SI'_ #QN
M?_!GJO\ \G5R_C'P]I<.A3,D5P&.H:"O.HZFXVOXATE6!5[UAR"<'&0<,"&
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MEX"&O7-WJ%K+K$OA[2H+.[U(6D-XL=G#?7RW-U;V2EQ96\L-IYDGD^8WL_\
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M1_PC.D?\\;G_ ,&>J_\ R=6_10!@?\(SI'_/&Y_\&>J__)U'_",Z1_SQN?\
MP9ZK_P#)U;]% &!_PC.D?\\;G_P9ZK_\G5AZ?86VG^-KJ.V615?PM9%A)<7-
MP<C6]0QM:YFF91\QR%(!/)!XQW=<BG_(\W'_ &*MG_Z>[Z@#KJ*** "BBB@
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M5+34X,=FN5Y9%3S+,L!E\)7Y9X[&8?"0E;>TL14IQ>_1GHG_  D6F_W=4_\
M!#KO_P K:/\ A(M-_NZI_P""'7?_ )6UY(WQ]T:],?\ PBOP]^,WC-)MODW&
MD_"_Q%H5A-N[QZKX_C\&:4R ]9OM@AYRLC+S2?\ "=?&_596BT7X(:=H,3+F
M.\^(WQ1T+2WCS@J\FF^ M)^(<K\'F(WT# Y!=2,'T_\ 5;.H?[U1PF6RM=TL
MXS7*LGQ"2:3:PF9XW"XJ7+?6,*,I=%%O0\O_ %LR2;_V6OC,RBVDJN3Y3FV<
M89MJZ7UO*\#B\+&_1SK1CU;2U/7/^$BTW^[JG_@AUW_Y6U\W?M'?M4_"+X&^
M'%L_&FH:V^M>+-.U:VT/P]I.@7UQK5W +:2TGU1[>_&FV]MI5K<SPP37MS=1
M(\[_ &>V6XG5XT[3^Q?VC=8C8:AX]^%G@I&8E8?"_@#Q%XOOE4X^4:OXE\7:
M/8DKV=O"V"<DQC("_D-_P48^$'B?_A/? >K/\0-:^)WBVX\'7%GK-CJ^F^'-
M"ETC2K36;R;1)M'M=!TW1M-6RO;BZUE)K.Y^V:L);47<M_/;O'#!])PAEWA7
M@>(\K?BSXE<+\*\*5J\L+B\;B<VK9-A_K]:E*.782OQ#FV6T,@P-'$XKDIRQ
M,\PDI->PI2A.JJU+\Z\5..N-.'N"<TSC@S@_,\3FU&6#CAJN94,OKT(T:V+H
MTL16I93A,X><XK$0HSDZ>'>"I\GO8FM&5'#U*53]7?@'^U#\)?CSX<N;WP)J
M.M/=^'!8V6O:#J>@:C!KNDM/"RV=S=6ME'J%NUC?FWN!97UM=W%M-);SP&1+
MB"6)?>?^$BTW^[JG_@AUW_Y6U^%G_!/32_B!\*_$OQ!\:6G@N7QNSZ#I.D:_
MX'T'7+:U\=V/AT:H]\?%>@:3J"0^'/%,EK>Q_P!GW?AZ;Q%HNMQ131W&E-J$
MMY]@?]K/A[\5? GQ1L+N]\&:]#J$^ES+::]HEU!=:3XG\,Z@5).F>*/#&JPV
M>N^'M07:X^RZK86S2!#) 9H2LC8<;Y1P7/-<USCPEXDP''GAQ2Q2PN$XFR+.
M,MXCP&'QE'EPN/P.)S/**M6@E0S2GB\+@\37A0IXZG2YL)4QD(2Q%3J\(^/L
MUXKX5R6?&N&I9'QEC*>,G5RNKA,5E?U^AA\36C2QF P^.7[Z7U.-&KF%#"5\
M2\#5G;$QPOM:="'3_P#"1:;_ '=4_P#!#KO_ ,K:/^$BTW^[JG_@AUW_ .5M
M;E%? 'Z\8?\ PD6F_P!W5/\ P0Z[_P#*VC_A(M-_NZI_X(==_P#E;6YD#J<4
MWS$)P'3.<8W#.?3&>M &+_PD6F_W=4_\$.N__*VC_A(M-_NZI_X(==_^5M;9
M8#KG\%9OY TQI8T1Y';RTC5G=Y 8T5%!9F9I JA54$L20% )) YH'9]G]WI_
MFOO1C_\ "1:;_=U3_P $.N__ "MH_P"$BTW^[JG_ ((==_\ E;7)>(?C+\(_
M"0D;Q3\4/AUX:6*.":5M?\<^%=&6.*Z?R[:60ZEJUKLCN)/W<#MA97^2,LW%
M>3:M^V[^QSHA9-0_:G_9[CF1YXY+:#XO^ [^ZBDMAF:.6UT[7+RXC=#\A5XU
M9I2(4#2L$/)5Q^!H75;&X2BUO[7$4:?E]N:ZZ>NFY[6#X:XCS!*67Y!G6.C+
MX98/*\=B4]%+1T:$T_=:?H[GT-_PD6F_W=4_\$.N_P#RMH_X2+3?[NJ?^"'7
M?_E;7RC%^W_^RC=RK#HWQ)U+Q9([1HD?@/X8?&#Q_))/*"RVD2>"_A]KIDOA
M&//DL4S>0VQ%U-"EN1(9Y_VU/ ,R++X<^$_[5_BZ"1I6BN=&_9+^/ME:3V\6
M5^UV]WXK\$>&+6>&24>1$L4SW+N&?[.MNCS+S_VSE#3Y<RP-1K>-+%4:LNGV
M*<Y2TOKI^)Z3X"XVBTJW"7$6%3M:>,R?'X*EJKJ];%T*-)-I-I.:;2=CZG_X
M2+3?[NJ?^"'7?_E;7+^,-<L9]"E2*/578:AH#$#0=<  7Q!I;G).G  E4;:"
M07(VH&8@'Y^M_P!JGQUJJLOA[]B[]K74YV:**$ZMHOP0\#VGVB7#+'//XU^.
MFBSPPI%^\FO4LY[2(D0-+]I#PI_(C_P6W_:F_:I\6_M;W7PZ\8Q_%OX#> ?"
M?@GP3JW@3X03^-K"Q%U!K-C=3:E\0-8N/A9XOUOPGXEU75M<&JZ1:WT&O:PN
M@V.C0Z,!INIQZI#+\[Q1QM@>&LK_ +2^J8S'\V(I8:G2A0Q.%I.=55)WGC*V
M&=&$5"E.RBJDY3Y8J'*Y3A^J>#OT>N(O%KC'_51YWD7#2I97C,VQ6+KYEE.<
MXZGA\)4PM'DP^19?FT<?7J3K8RA>=66$PU*BJM2>)]I&G1K?W+'Q'IBYW#5%
MP<'=H.NJ01U!!TT8/L:YWQ9\4_A[X"T*\\4>._%>E>!O#.GQM+?>(_&DLGA/
M0+2-4:0M/K7B"+3M-C^1&;:USN*J2%.*_G5_X(N:S^VA^UI^R_KEEXR_:P^)
MW@CX5_#;XD:GX!\.Z[HOA/PKXF^+OB[31H6@ZSJ>C6_QH^*$'CA++0/!UU?C
M0-/AL?!5UXETIKBYLCXN\JSL-.TO]I?!_P"P?^S/X;UJS\7^)/ UU\9_B':(
M"GQ(_:%\2^(?CMXTAN1()#>Z3??$S4/$&F>%)BRH%A\%Z1X;LH(T6&VM((E"
M5W9/GV,S_+,%F67Y6\-0QE"-55,RQ5.E&-WRR]C2PL,55Q$834DG66!56,5*
M,E&46?/<=>&V0^&?%N?\)<4<91S3,<AS">#GAN$LFQ6+J5.50K4UF&+SJKDV
M"RRI7PU2G*:R^?$<L'6G*C6I3J4:D#DIO^"@?PM\5QI'^SM\/_C=^U5=33FS
MBU'X)?#36)/AU#<LADB:^^-'Q _X0;X116FT!YY=/\8ZM<Q1D%+*9RJ'+EU;
M]O/XJ?)<7OP8_9&\.W=L'V:5H'B_]J+XOV[&7A#J-UI?PX^#?A?4A!\S"/3O
MBUIT%PP4/=QQ$2?H#'%'$JI&@1$551% "(J*%54081%50%54554#  '%25Z/
M]GXNNO\ ;LSKS3TE0R^']F4));/VD*E?,HS3W=/,:<);.FEH?*?ZS9+ES_XQ
MWA'+:%2*3IYCQ16?%N90G?WU]6Q&&R[A.K1DM(T\5PIB*U/=8ER]X^ (OV)_
M@CXGN8M3_:!\4_&[]JW5(KI;Y(/C_KWBC7O $-V8U21K/X(>$-!\%? ZVB)4
M^2)?AW=W,2$JUW(Q:1OL+PQ9^!/!.B6/AKP;X:M?"?AS3(A!IOA_PSX)O- T
M/3X  HALM(TC1+/3[6(* JQPVZ*% 4  8KO:*ZL-E^"P<I3PV%HTJM1)5*R@
MI8BMMK6Q$^:O6EHKRJU)R;2NV>/FW$_$&>TZ5#-<WQV+PF&DY83+Y5I4\KP-
MUR\N7Y71]GEV7T[:*E@L-0II-I02;,$^(]*12S?VC&B*S,[Z'K<<:(H+.[N^
MG*D<:*"[R.RHB!G=E521\2:CK1_:_P#$CZ<KZU9_LH>%]1VZE=VFE:N&_:+\
M4:1J!#Z3:W-I:2RCX/\ AZ_LRFK3H8&\;:Q =/C)T:UEDDV_%6LZI^UCXIU?
MX7>"-1N-/_9\\):HNF_&#XA:5<W=O/\ $[6;.8G4/A!X#U2T> ?\(];,BV_Q
M(\56-S)YB2'POI3B26_G'V7HVC:3X=TG3=!T'3;+1]%T>RMM-TK2M-MHK.PT
M^PLXE@M;.SM8%2&WM[>%%CBBC5515  ZD_I]./\ J#AZ>)J67'.,HPJX*C**
M<N#L%7IJI2S"JF_W?%6,I3A4R^G*//P[AI+'M1SNO@IY-^.59/Q Q-3"TV_]
M1,%6J4L;6A)J/&>.P]7DJY?2E&W/PI@ZL)T\QJ1DX<1XF#P"<LBHXV&=4+?6
MM&M((;6UM[^WMK>*."WMX/#NMQ0P0Q((XH88H],6.***-5CCCC54C151%55
M$W_"1:;_ '=4_P#!#KO_ ,K:W**_/6VVVVVVVVV[MMZMMO5MO5M[GZ*DDDDD
MDDDDE9)+1)):)):)+8P_^$BTW^[JG_@AUW_Y6T?\)%IO]W5/_!#KO_RMK<HI
M#,/_ (2+3?[NJ?\ @AUW_P"5M<OXBUVPDO/";(NI8C\40,V[1-:0X.AZ^H"A
M]/4R,2PPD89R S;=J,1Z)7)^)?\ C^\(>WBJ'/M_Q(O$'6@#0_X2+3?[NJ?^
M"'7?_E;1_P )%IO]W5/_  0Z[_\ *VMSKTHH P_^$BTW^[JG_@AUW_Y6T?\
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M:;_=U3_P0Z[_ /*VO+_^$9_: _Z*]\-?_#):W_\ /GJO-X/^/MPRE_C7X,M
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MH/38XK=RK)=.=#_9YT*2.TE>2)8&BO)2X 5,P/*'^ZO)\3_\]M#_ ._>J_\
MR92^7XH'_+;0O^_.IG^=W7F+@Y-.-;,<3B:<OBI8K,N+<91EL[.AC>+<5AVF
MUK%T7&VECU)+P_WAPYQC)[N.*X]PN(I-Z?%37!M%VWVG&]ETNCX$D^-7@34
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MY?E.5Y12=#*LMP&64&^9T<OP>'P=)R_F=/#4Z<&_-J_F;TJ%&A'EHT:5&/\
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MWQ3? 2"YB0?,[$G;DD]<8 _;/_A&=(_YX3_^#'4__DVOQA_X-P/^4*'[!/\
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MG2/^>$__ (,=3_\ DVM^B@# _P"$9TC_ )X3_P#@QU/_ .3:/^$9TC_GA/\
M^#'4_P#Y-K?HH P/^$9TC_GA/_X,=3_^3:/^$9TC_GA/_P"#'4__ )-K?HH
MP/\ A&=(_P">$_\ X,=3_P#DVC_A&=(_YX3_ /@QU/\ ^3:WZ* ,#_A&=(_Y
MX3_^#'4__DVC_A&=(_YX3_\ @QU/_P"3:WZ* ,#_ (1G2/\ GA/_ .#'4_\
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M*Z^::Z^*GB/2I?VA'\1:MK$DGBG7(]-GD\1SW$NG6IC /VTK-UC_ )!.I_\
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M%_\ %6_P4_\ GX4 ?M!17XO_ /#%W_!8O_I-3X%_\5;_  4_^?A1_P ,7?\
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M\"_^*M_@I_\ /PKP7]I7X"_\%AO@M\)[[Q[/_P %A/ ?BV.W\9_"+PT=$?\
MX)G?!;1%D;X@_&/X?_#R._-^GQ@U-@=#E\5IKRVOV1AJ#Z8NGM/9K=&]MP#^
MAJBOQ?\ ^&,/^"Q;9)_X+4^!<[F!S_P2X^"A)PQ&2?\ A>'.<9H_X8N_X+%_
M])J? O\ XJW^"G_S\* /V@HK\7_^&+O^"Q?_ $FI\"_^*M_@I_\ /PH_X8N_
MX+%_])J? O\ XJW^"G_S\* /V@HK\7_^&+O^"Q?_ $FI\"_^*M_@I_\ /PH_
MX8N_X+%_])J? O\ XJW^"G_S\* /V@HK\7_^&+O^"Q?_ $FI\"_^*M_@I_\
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MB_\ \,7?\%B_^DU/@7_Q5O\ !3_Y^%'_  Q=_P %B_\ I-3X%_\ %6_P4_\
MGX4 ?M!17XO_ /#%W_!8O_I-3X%_\5;_  4_^?A1_P ,7?\ !8O_ *34^!?_
M !5O\%/_ )^% '[045^+_P#PQ=_P6+_Z34^!?_%6_P %/_GX4?\ #%W_  6+
M_P"DU/@7_P 5;_!3_P"?A0!^T%<AJ_\ R-GA/_KAXD_](K"OR._X8N_X+%_]
M)J? O_BK?X*?_/PKP#Q]\"O^"POA/X\? 'X5/_P6"\":G+\6-.^,UW#XD/\
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MRV34E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)M6U*PTR&2011S:A>VMC$\I5G$22W4L,;R%%9_+5B^Q2VW:":T$=9%5T8,K
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MVL,]O;2W,$5S=^<+6"2:))KDP1^;.+>)F$DWDQD22^4K^6GSOM7FOQN\*?\
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M]0>Q[]12U^?W[+6K_M 77PHL_P"P].\&ZSX=@U?4X/#][X[\1>*-/U0Z='Y
M>#3QIVB:O'<Z':WINH=/GEN4=&6XM8(OL=O;L?HS[;^TC_T+/P8_\+/QQ_\
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MO:6EI86MO96-M;V5G:0QV]K:6D,=M:VT$*!(H+>WA5(888T4)'%$B1HH"JH
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M2:G+X[\4:9+916]S8:UXZ;6]<'C>^M9XI?&$>NZW%XD_M2+5]22ZV=:_9V^
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<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812602592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories for the Period</a></td>
<td class="text">The following table summarizes the components of inventories:<div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.25341130604289%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,544</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,485</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812508928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Subject to Fair Value Measurements</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are identified in the following table:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,710</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,710</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-back securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Government Agency Bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,681</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,681</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred compensation plan liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,419</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are identified in the following table:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.40545808966861%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-back securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240,726</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240,726</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred compensation plan liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.64327485380117%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:23%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:12%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable Input</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Range</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.6%</span></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical and regulatory milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,390</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability weighted discounted cash flow</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of achievement of milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75% - 78%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected year of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021 - 2022</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Changes in Contingent Consideration Payable</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the change in the balance of contingent consideration payable for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, beginning of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones payable, included in accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,000</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in fair value during the period, included in the Consolidated Statements of Operations </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,297</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment for contingent consideration paid in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(316</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, end of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>23
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*NQZ8_?V'QM?!&4+O^Y"?@%02P,$%     @ RX!B4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    " #+@&)0&KC"<GT#   O$0  &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;(U8;6^;,!C\*X@?,/ +)*V22$VC:9,VJ>JT[3--G 05< 8D
MZ?[]C*&4^CE7^Q+ N7O.]OG,R^*JZ^?FJ%0;O)1%U2S#8]N>;J.HV1Y5F36?
M]$E5YI^]KLNL-9?U(6I.M<IVEE06$8_C-"JSO I7"]OV4*\6^MP6>:4>ZJ Y
MEV56_UVK0E^7(0M?&Q[SP['M&J+5XI0=U _5_CP]U.8J&JOL\E)53:ZKH%;[
M97C';C<B[0@6\2M7UV9R'G1#>=+ZN;OXNEN&<=<C5:AMVY7(S.&B[E51=)5,
M/_X,1<-1LR-.SU^K?[:#-X-YRAIUKXO?^:X]+L-Y&.S4/CL7[:.^?E'#@)(P
M&$;_35U48>!=3XS&5A>-_0VVYZ;5Y5#%=*7,7OIC7MGCM?]'RH&&"7P@\)$P
MCS\DB($@1@+[6$$.!/E&2.QL]4.Q<[/)VFRUJ/4UJ'M[3UFWBMBM-+._[1KM
M9-O_S/0TIO6RBA?1I2LS(-8]@D\0;$1$IO8HP)' FA,Z?R]P3Q'B/6)#$1)W
M0< Q"DL7$WJ"Z1+2I:7+"3UUIH@B9E@@@0()H<\= 8JXP0(I%$@)G;DN XC'
MYAF4F%&^X_,:0 26F$.).>5+1P) /%;?0(D;RG>]!A"/V2S&B8MI!==OA/$X
MSCRY9J0")\D&&(_I#(;[CG%:P;4=83R^,YQ?)F@%UWF$\5C/<,P933%WS4<8
MG_LXZXQ&F1/W <;G/@X\HW$6Q'V \;F/,\]HH@5Q'V!\[N/8,QIJ0=P'&)_[
M./F,YEH0]P'&XS['V><TU\)U'V$\[G.<?4YS+5WW$<9W7\?9YS37TG4?83SN
M<YQ]3G,M7?<1QC<6G'U.<RT35P5@?"HX^YSF6KIK#&%\:PQGG]-<2[+&P.W>
MYPO./J>YEC>NRO_?\3G./J>Y3LA*!C=]GPK./J>Y3MA[E<V 22RF&G9+.9."
M\]BS"@3> P3-=^(^$@^8=*+&DQF7,DT\6X' 6X&@,4^<I^LUPOB>K_%6(&C,
M$S<^")-Z5#R/\33FR<Q5H1C?8A!X*Q TYHD;'X3Q^8*W D%CGKH+&V%\2PUO
M!8+&/'6W:(1Q9RR:O$V6JC[8-_4FV.IS93\33%K'KP%WW+Z-OL'[3PG?L_J0
M5TWPI%OS3FO?//=:M\IT)?YD!GQ4V6Z\*-2^[4YGYKSN7^'[BU:?AL\3T?B-
M9/4/4$L#!!0    ( ,N 8E#;%8[SC00  !(6   8    >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&ULA9AOC^(V$,:_"N+]73QC.[97@%125:W42JNKVK[.+MX%
M72 TR2[7;U\GL AFQG=OR!^>L1\GGI\G7IS:[FN_C7&8?=LWAWXYWP[#\:$H
M^N=MW-?]Y_88#^F?E[;;UT.Z[%Z+_MC%>C,%[9L"E2J+?;T[S%>+Z=YCMUJT
M;T.S.\3';M:_[?=U]]\Z-NUI.8?YQXTON]?M,-XH5HMC_1K_C,-?Q\<N7177
M5C:[?3STN_8PZ^++<OX3/%3:CP&3XN]=//4WY[-Q*$]M^W6\^&VSG*O146SB
M\S V4:?#>ZQBTXPM)1__7AJ=7_L< V_//UK_91I\&LQ3W<>J;?[9;8;M<N[G
MLTU\J=^:X4M[^C5>!F3GL\OH?X_OL4GRT4GJX[EM^NEW]OS6#^W^TDJRLJ^_
MG8^[PW0\7=K_"),#\!* UP PWPW0EP!- HJSLVFH/]=#O5IT[6G6G=_6L1XG
M!3SH]#"?QYO3LYO^2Z/MT]WW56D6Q?O8SD6R/DOP1H+WBHHK2GN5%*G_JPD4
M3> 4KV_C2SE>B_%ZBC>W\8X,XBRQD^0P2<"@UT16<9D+S@39C!'-&&[&$S-G
M27G3BU8A*$W,<)E!8VYD=VZLZ,9R-X&XL=R-1D]F0<55"*%$V4LI>BF9%Z>(
MEY+U D89(%ZXRNN@9"M.M.*X%=+)VO$!*Z7(JZRX"DH;,H_%BUX\]T(2;.U9
M+S:9<73""#(+*F1R*8AN G=#NED'8<)HR&0\*)D[BO?#P*-X CBG+*4/EP%H
ME_.3X2!P/Y;Z 3XE=)H3U,^/9/=^9"0"<C\E]8-\X,$E8%%#/]3=.Y(A"YRR
MCE+VHKD;NM? #'%96?H,UT#&+'#..LI9X 3U5J%B?KC.^1 L9!S)J 7+EC&7
M63E !B1P0GI*2! 0B4HS%@@ZKTK,986,2>"<])23(" 0+4L*KK(VFQ,R*(&3
MTE-2 F>@ Y][#3("@3/04P8"AR"@]\!*(Z[S)>1> \JP1 Y+]AJ04] '19!1
M"2I08#,K!,JL1,Y*6BZL48 @:+J0"RIP:5KD_&3*1\Y*3]F- @.-TW3-J41=
MZ;3).))9B9R5GM(;!59B2=]K)<@2O'.9@S(LD</24W8CAZ!5EMGAJM)DJWT9
ME,B+4I;'R.M-JZW.$!EEGJ+ 4[I&(.>DQ<#RAJO0V\R*A3),48 IK<618S*A
MW=''4PDZ8YS2&="A#%3D0 UTO9$T;%)\5W/O1$8N!K9VYHIH+3-2<T8&"FW-
MZ8<VT))>4$$P.3<R(C5'9*"(U (B$1TB+7 %(3B3*)EYQEK&I.:?V2&3N#KS
MG<VQ1C-EK06L.8KC2E"9K!F9:9HSC5:^:RU\0M/*1-!\,IBIC;5,-,V)1J?5
M6G.B 6J*X4J2:55F4*-E\&D.OD!1HSG2/H$K4W7"GI"D-) F:RXI9 !J#D"@
M7T]K+9#-E88GA4!*@P%REF0":DZN5 ]12V?1[:Z0^!DAZ,3/B.)F<V[<+?VC
M[EYWAW[VU Y#NY]VXU[:=HBI3?4YM;:-]>9ZT<2783QUZ;P[[U*>+X;V>-F!
M+:[;P*O_ 5!+ P04    " #+@&)0_M@MP"4"  "F!@  &    'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;(V5W8Z;,!"%7P7Q #'_D(@@-515*[52M%6WUTXR
M!+0&4]L)V[>O;5A$C-MN+F)[?.;X&T#C?*#LA=< PGEM2<?W;BU$OT.(GVMH
M,=_0'CJY4U'68B&7[(IXSP!?=%)+4.!Y"6IQT[E%KF-'5N3T)DC3P9$Y_-:V
MF/T^ *'#WO7=M\!3<ZV%"J B[_$5OH/XT1^97*'9Y=*TT/&&=@Z#:N]^\'=E
MIO1:\-S P!=S1U5RHO1%+;Y<]JZG@(# 62@'+(<[E$"(,I(8OR9/=SY2)2[G
M;^Z?=.VREA/F4%+RL[F(>N]FKG.!"M^(>*+#9YCJB5UG*OXKW(%(N2*19YPI
MX?K?.=^XH.WD(E%:_#J.3:?'8=Q)MU.:/2&8$H(YP8_^F1!.":&1@$8R7>I'
M+'"1,SHX;'Q9/5;?A+\+Y<,\JZ!^=GI/5LME]%[X7I"CNS*:-(=1$RPTAJ)<
M*Y)XEB ),%,$5HI YX</%*'=(+0:A-H@>C"(C#)&3:PUG=;$8616LA9Y=H[(
MRA%9.&*#(UH=X:>)25M:5'&2^G:8V H36V 2 V;4I,MZ-YYOL/Q']("26%$2
M"TIJH(R:9/E^O.EG\+Q'^0"56J%2"U1F0*6KHX(XCOPT2[8&U%KI9]LP"[=!
M9(?*K%"9!<HXZI"]&VJM_!L46G0,U<&_879M.NZ<J)#-1[>(BE(!TM7;R ^B
MEI?&O"!0"35-Y9R-K7-<"-I/MP*:KZ;B#U!+ P04    " #+@&)0Y 8:U$<$
M   &$P  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(68VV[C-A"&7T7P
MO2-R2/$0V 9B"XL6:(%@BVVO%9L^8"7+E>1X^_:E#O%:PU'V)I:4C\-_*&I^
MDHM;67VOC\XUT8\B/]?+V;%I+L]Q7&^/KLCJI_+BSOX_^[(JLL;?5H>XOE0N
MVW6-BCP&QE1<9*?S;+7HGKU6JT5Y;?+3V;U647TMBJSZ;^WR\K:<\=G'@Z^G
MP[%I'\2KQ24[N+]<\^WR6OF[^!YE=RK<N3Z5YZAR^^7LA3^GD+0-.N+OD[O5
M#]=1F\I;67YO;W[?+6>L5>1RMVW:$)G_>7<;E^=M)*_CWR'H[-YGV_#Q^B/Z
MERYYG\Q;5KM-F?]SVC7'Y<S,HIW;9]>\^5K>?G-#0LDL&K+_P[V[W..M$M_'
MMLSK[F^TO=9-60Q1O)0B^]'_GL[=[VV(_]&,;@!# [@WX.K3!F)H('XVD)\V
MD$,#B1K$?2K=V*19DZT657F+JO[U7K)V%O%GZ4=_VS[L!KO[GQ^>VC]]7W'.
M%O%[&VA@UCT#C\R=B'WT>Q= =;&&H#F,.]B$A$K&2!HBG$^H$&2BH@L@1@&
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M=',O<VAE970U+GAM;'U5T8Z;,!#\%<1[#C#&0$20CD15*[72Z:JVSPYQ CK
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M!MQB9H0GV><2P%:B (MT<%]@NT0@0\-N"0F"!RI"J]%0$X1W1I&= %H)H":
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M[#W5U?WAS:)^:+<O0WJ]WO]^8O^F;9Z[WX:,#S]0N?H/4$L#!!0    ( ,N
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MS8?L[:EM[D\?UNU#/[R-^?WN</9_^-!WS\??-<Q//ZZX_1]02P,$%     @
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M8(NAH/;A>(MG.XW99'C3SS^(+=^X^ -02P,$%     @ RX!B4 \UC/BS 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL?5-A;]P@#/TKB!]0
M<N2V5:<D4J_3M$JK=.JT[3.7. DJA!3(I?WW,R3-LBWM%\#&[_G9F&PT]M&U
M )X\:]6YG+;>]P?&7-F"%N[*]-#A36VL%AY-VS#76Q!5!&G%>))\9%K(CA99
M])ULD9G!*]G!R1(W:"WLRQ&4&7.ZHZ^.!]FT/CA8D?6B@>_@?_0GBQ9;6"JI
MH7/2=,1"G=.;W>&X#_$QX*>$T:W.)%1R-N8Q&'=53I,@"!24/C (W"YP"TH%
M(I3Q-'/2)64 KL^O[%]B[5C+63BX->J7K'R;TVM**JC%H/R#&;_"7,\'2N;B
MO\$%%(8')9BC-,K%E92#\T;/+"A%B^=IEUW<Q^DF36?8-H#/ +X KF,>-B6*
MRC\++XK,FI'8J?>]"$^\.W#L31F<L17Q#L4[]%X*SI.,70+1''.<8O@J9K=$
M,&1?4O"M%$?^'YQOP]--A6F$IW\I?"/_?I-@'PGV[Y:X%?.O2K;JJ0;;Q&ER
MI#1#%R=YY5T&]H;'-_D3/DW[O;"-[!PY&X\O&_M?&^,!I217.$(M?K#%4%#[
M</R$9SN-V61XT\\_B"W?N/@-4$L#!!0    ( ,N 8E#WS9])M $  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;'U386_<( S]*X@?4.Y(;JM.
M2:1>IVF55NG4:=MG+G$25 @ID$O[[V=(FF5;M"^ C=_SLS'9:.RS:P$\>=6J
M<SEMO>^/C+FR!2W<C>FAPYO:6"T\FK9AKK<@J@C2BO'=[@/30G:TR*+O;(O,
M#%[)#LZ6N$%K8=].H,R8TSU]=SS)IO7!P8JL%PU\ _^]/UNTV,)220V=DZ8C
M%NJ<WNV/IS3$QX ?$D:W.I-0R<68YV \5#G=!4&@H/2!0>!VA7M0*A"AC)>9
MDRXI W!]?F?_'&O'6B["P;U1/V7EVYS>4E)!+0;EG\SX!>9Z#I3,Q7^%*R@,
M#THP1VF4BRLI!^>-GEE0BA:OTRZ[N(_3S2&98=L /@/X KB->=B4*"K_)+PH
M,FM&8J?>]R(\\?[(L3=E<,96Q#L4[]![+3A/,G8-1'/,:8KAJYC]$L&0?4G!
MMU*<^#]PO@U/-A4F$9[\H3#=)D@W"=)(D/ZWQ*V8PU])V*JG&FP3I\F1T@Q=
MG.25=QG8.Q[?Y'?X-.V/PC:R<^1B/+YL[']MC >4LKO!$6KQ@RV&@MJ'XT<\
MVVG,)L.;?OY!;/G&Q2]02P,$%     @ RX!B4$CZU9>U 0  T@,  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL?5-A;]L@$/TKB!]0$I(E461;:EI-
MG;1)4:>MGXE]ME'!YP*.NW\_P*[K=M:^ '?<>_?N.)(>S;.M 1QYU:JQ*:V=
M:X^,V;P&+>P-MM#XFQ*-%LZ;IF*V-2"*"-**\=5JQ[20#<V2Z#N;+,'.*=G
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M!1@7\#K]^P)V'+>U^@+,,.?,F6%(!S1OM@%PY%U);3/:.-<=&+-% TK8*^Q
M^YL*C1+.FZ9FMC,@R@A2DO'-9L^4:#7-T^@[F3S%WLE6P\D0VRLES*\C2!PR
MNJ4?CJ>V;EQPL#SM1 T_P#UW)^,M-K.4K0)M6]3$0)71N^WAF(3X&/#2PF 7
M9Q(J.2.^!>-;F=%-$ 02"A<8A-\N< ]2!B(OX^?$2>>4 ;@\?[!_B;7[6L["
MPCW*U[9T349O*2FA$KUT3SA\A:F>:TJFXA_A M*'!R4^1X'2QI44O76H)A8O
M18GW<6]UW(?Q9K^?8.L /@'X#+B->=B8*"I_$$[DJ<&!F+'WG0A/O#UPWYLB
M.&,KXIT7;[WWDO-=DK)+()IBCF,,7\1LYPCFV><4?"W%D?\#Y^OPW:K"783O
M_E!XO4Z0K!(DD2#Y;XEK,?N_DK!%3Q68.DZ3)07V.D[RPCL/[!V/;_(9/D[[
M=V'J5EMR1N=?-O:_0G3@I6RN_ @U_H/-AH3*A>.-/YMQS$;#83?](#9_X_PW
M4$L#!!0    ( ,N 8E 1L!9CM0$  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;'U386_;(!#]*X@?4&*2M5ED6VHZ59NT25&GM9^)?;91P7B
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MOVSL?XWHP$M)KOP(M?Z#+8:$VH7C)W\VTYA-AL-^_D%L^<;%;U!+ P04
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M0?00I.QNP@AUX8,MAH+&Q^.[<+;3F$V&QW[^06SYQN4O4$L#!!0    ( ,N
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MDG159%MJ6DV;M$E1IVV?B7VV48'S ,?=OQ]@U_,VKU^ .^Z]>W<<V8#VV;4
MGKQH95Q.6^^[(V.N;$$+=X,=F'!3H]7"!],VS'461)5 6C&^V=PR+:2A199\
M9UMDV'LE#9PM<;W6POX\@<(AIUOZZGB23>NC@Q59)QKX OYK=[;!8C-+)348
M)]$0"W5.[[?'TS[&IX!O$@:W.)-8R07Q.1H?JYQNHB!04/K((,)VA0=0*A(%
M&3\F3CJGC,#E^97]?:H]U'(1#AY0?9>5;W-Z1TD%M>B5?\+A TSU'"B9BO\$
M5U A/"H).4I4+JVD[)U'/;$$*5J\C+LT:1_&&WZ88.L /@'X#+A+>=B8*"E_
M%%X4F<6!V+'WG8A/O#WRT)LR.E,KTET0[X+W6O##(6/72#3%G,88OHC9SA$L
ML,\I^%J*$_\'SM?ANU6%NP3?_4?A'P3[58)](MB_6>):S.U?2=BBIQILDZ;)
MD1)[DR9YX9T']IZG-_D=/D[[9V$;:1RYH \OF_I?(WH(4C8W883:\,%F0T'M
MX_%=.-MQS$;#8S?](#9_X^(74$L#!!0    ( ,N 8E !<#DLM0$  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;'U386_;(!#]*X@?4!+BKEED
M6VHZ3:O42E&G;9^)?;91P><!CMM_/\"NY[76O@!WW'OW[CC2 <VS;0 <>=&J
MM1EMG.L.C-FB 2WL%7;0^IL*C1;.FZ9FMC,@R@C2BO'-YA/30K8T3Z/O9/(4
M>Z=D"R=#;*^U,*]'4#AD=$O?'$^R;EQPL#SM1 W?P?WH3L9;;&8II8;62FR)
M@2JCM]O#,0GQ,>"GA,$NSB14<D9\#L9]F=%-$ 0*"A<8A-\N< =*!2(OX_?$
M2>>4 ;@\O[%_C;7[6L["PAVJ7[)T34;WE)10B5ZY)QR^P53/-253\0]P >7#
M@Q*?HT!EXTJ*WCK4$XN7HL7+N,LV[L-XDR03;!W )P"? ?N8AXV)HO(OPHD\
M-3@0,_:^$^&)MP?N>U,$9VQ%O//BK?=><GY]D[)+()IBCF,,7\1LYPCFV><4
M?"W%D7^ \W7X;E7A+L)W_RC<KQ,DJP1))$C^6^):S.=W2=BBIQI,':?)D@+[
M-D[RPCL/["V/;_(W?)SV1V%JV5IR1N=?-O:_0G3@I6RN_ @U_H/-AH+*A>.-
M/YMQS$;#83?](#9_X_P/4$L#!!0    ( ,N 8E J,DC8LP$  -(#   9
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MH;5^^][M]?*6%\.J<1U3LOTKJC]02P,$%     @ RX!B4/>@ >?$ 0  -P0
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M>[08#&IMMWNSE]-43H86P_S@D.75*_X 4$L#!!0    ( ,N 8E"7K!)DT $
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MK/IB04,6)_J.3L/T.%AA[.GQFIXD88$D*)!X@>2?%A\V+88P'\(F^Z#)_KU
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M8\^H/TFUE 9L*=&=;;BU3\4:<*B-FWZR<S5?F#DP<EC> K(^2,5?4$L#!!0
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M.-5J*S&9P#1R.<!$2V5E@D VN9)+;)42FU)RK79+B8F'4J+0]WU-C D#66[
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MF,@>2$XH;E5_Y_5-YN(_4$L#!!0    ( ,R 8E!G@%\?G0$  %H#   9
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MG;4!D"];X57V^-"70$$7HGN'OINN>PJ"'>:7S);?J?X/4$L#!!0    ( ,R
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M2V\-*#12;Q.UY_.O/P>2C<NMAM:KM?@+4$L#!!0    ( ,R 8E G64,CJP0
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M2R3)4LY:A]OCT!!]ZOQEK+8KUT:S.^:?JJ=0UFL6X2!%5RW48=86$PPP?H]
M2KUW$<RY6 <3^LC!9HK \2UD.X7XOG^+V4TQ$0[G(PUGBQ$:@7 8:1#-"T2S
M I$1B&XBB$;5M)C88&KK)/0\;U22NU#;NU"[*2I:X&0 N\DLGLTLGF26X%%B
M%H(';OS')'E,1IG=!]O%DZ 5;/&OH/%LT'AF.T8':XTG?L9;\5_$=HI0!V]:
M8#2XE!7PL^F0PLG9I9;ZW ZL?1-^"O2E'MG7_G)K>^F[C.WLWP@_E[5P#DRJ
MEF$N]HDQ"2I*[T$%6*C'I%]0.$D]3=2<VY9J%Y(UW6N!^B<K^PM02P,$%
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MGI7I9KHOAC=L&"C>C<\SF/XCRK]02P,$%     @ S(!B4!2A[\83 @  _04
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M=YB48J_,,-7CIK_J]1,E3_8:&PUWZ?4_4$L#!!0    ( ,R 8E S%AV*, (
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M?P9N2VHF'2YH409!\$TPWPF4+/BF@1SV]/Q!9?5"F"1!A-0Z)U'"T12 [@I
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MIE>:(@LTN8LJCO.@5*=^N$WT?3N=_*=!W]S,6XUP?K6R^P]02P,$%     @
MS(!B4%'L:EP, P  T L  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N>&UL
MC59=CYLP$/PKB/<":S ?IR32)5752JUTNJKM,Y<X"3K %)SD^N]K&T+!7JI[
M";8S.SMK[&%7-]Z^=F?&A/-6E76W=L]"- ^^W^W/K,H[CS>LEO\<>5OE0D[;
MD]\U+<L/.J@J?1($L5_E1>UN5GKMJ=VL^$641<V>6J>[5%7>_MFRDM_6+KCW
MA>?B=!9JP=^LFOS$OC/QHWEJY<P?60Y%Q>JNX+73LN/:?82''0E4@$;\+-BM
MFXP=5<H+YZ]J\N6P=@.EB)5L+Q1%+A]7MF-EJ9BDCM\#J3OF5('3\9W]DRY>
M%O.2=VS'RU_%09S7;NHZ!W;,+Z5XYK?/;"B(NLY0_5=V9:6$*R4RQYZ7G?YU
M]I=.\&I@D5*J_*U_%K5^W@;^>Q@>0(8 ,@80^M^ < @(QP"(=/&],EWJQUSD
MFU7+;T[;OZTF5X<"'D*YF7NUJ/=._R>K[>3J=1,#7?E7131@MCV&3# P(GS)
M/J8@6(HML<+)/,'.1L04SQ"B180Z/IP5$>,$$4H0:8)H1I 8N]!C8HVI->9#
M1H(D)7@BBB:B2*(4)XA1@OC]I28H08(HR(Q2$ZO4, %I#8'QWFP<H0F%"6XF
M*$4%I;8@8B3:IK8@2F);D(V#%"!;$I2A@K)W'(8,.PQ@"T)P- R")4$0X)<T
M0/8(S%L:(+D(M35A0(CHLJ@%YP!$%#%%@96+)AERE!"@>>;FHE"O>01BWP\2
M+E#@9@(A4E=DUM6#DNE)"SR:F579,.JE"]X&N#<!8D[$LN@>I%[M5%!F.BV*
MBSU8,'3 70P0&R.Q*8G:J5(OLK8(@<5>L"0(=T6($4'FG1U YAY1:X\07.8M
M?9$ MUE ?):DIJ+$/D7@06H*0F"SPS87A-LLI,C-6*+ C1$09PQ-JT9 -%[X
M0A'<[@AB=Z%I=P,HFUZMV(N,1/ZD#ZI8>](M8^?L^:46JN.8K(YMZ2-1?92Q
MOI7M:M]<_J/I>]UO>7LJZLYYX4)V:;J7.G(NF!0I7Y+KG&5[/4Y*=A1JF,AQ
MV_>8_43P9NB?_;&)W_P%4$L#!!0    ( ,R 8E"H_1M*50(  %$'   9
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MV=YTY%R!SC)XT/F5^GT;%PR.RDQ3/1=]D^\7BK?# X;&5S3_#U!+ P04
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M''+>%R&.!"&91VN&78())F+Z?A0P5#P*^?6.[#%#I[*;3>!0(!188\&(P,%
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MFC 8SP3M49\PHC\*@LP":<0)AY%L4$?XO&7>C_%S(41!(**0")@+!H+[Y4]
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M]PIX=U'EV^[U=G1XQS[]'U!+ P04    " #,@&)0M[ Y6@,"  !_!0  &0
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M[5Z:43"RG*H:&E6)QI-PWOB?R,..)#; (7Y7T*E)W[-6#D(\V\&WT\8/;4;
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M^[)L&(\+?>$1'5FZ&VXRMF_:RXA?5_V7E/ZF*<_B*Y$W?*J:_P]02P,$%
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M8%=)YGB2>3?),)H1[ZSS+0A]"DY@C&""!/"@)I@;XYR /",8H2X-@=T4X?S
M#4 )/F)V/"0"<#-\$Q[ Y@C&0F,'THU@'A=> $I_@7$L".%WU!+A:,!<E^(Y
M%WC.12?G 0>/V:AF_,N5W#L/Q#-&*0H>LPGN!<[J :6X<"__0)%,40V#N4>I
M $0YPZ.$B<=W#/+YA%#D#OY0+U *UL82ISC(N'/10J0RWU;-<F&MU"'3Y<_
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MP>F+UF5G<-C"1:8Y N4OX7!AL-HR9=M_!EI0.P%LI&<_=VX[N,)7!XRSP4'
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M5EXC")F5L'-;F429O\B&UTSVAAFZ07?K0TGFNC$I-?.3(H(<3A$/9^(9DRN
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MK&*2PCQ[B268)FNF'#+<*Y.,6D\L5&@%]F+GVXJ?J_[^L,  ;\1P/.A,W*7
M68,F-[':2M".S*4SBG>J^<7RL/-@G5TQ=(OYJ1QD)V)O)41V+M3H+]RBNF5V
M]*XMJ@*E(9VN5+=Z72&)BSU1(9,K!S)VAH)'L][MV*PHX"<JA(.#))!#/)?^
M:!@>@TVE:ZN6:RE%DYPO5)SKW-=J5,MT4:1:;>@35>&3_TB+O((<A,JOF?M%
MMS.T\RW3-3*66!,DM4D<8J25>XDI^CR$BZEID4CFT6E]JJ;J/\!175%GEWQE
M>YVK+J7L5+BG$!CEP B^-D%$4?&Y,A+@#]WND!ZB'\<5Q'R7EBB8>"QCQO;D
MEKZ:.NAV)9X C\K9B'?LE3.M.HN?9G6?.ON:!GD#2E2V!(OMA6IY7I=\CW48
MHDH.VAQQ+=\GUZ5\UJ95@N6<+<I'M$F$P+[*ME>4Z1*]^O29C_?MR]*'P\BQ
M"1]%UY]?]+M=>N CHIJH@HE[0F7XV"-314> !_RY%GTCWG]F^2<? ]D'K@1Z
MSEG\Q[]U2>H?TV.EK0I#N 6/$?TJ++QMP"0(]2K_>+9JW'CH;Y-@4&T20>@*
M-N6 =2\"C$"35>D;A6BE.0,P>T$YY42 (JS)MZM2,&E\T(/DZEHO)5/!KHRT
M0 SHWE79Q.,>VHHC57T&JEA63J !A:37L>6N%L__G8E^^9289V*U>XW&8)&@
M\4YBH[5YT1/)TT-=U6JQEPUQY\K0X7 <@;OH]ZT*T0R3Y-IJJ%2:I\=<MG0+
MG#?: UO%UB14@A*;6F3-=171Y&K/'Y%ZUH>F-CBRYT%G$+B]3YO9,W&-."N^
M7JW9S(@K?-BH0D\7Y [#LA.]]*6:JQR1:RI,?5K5+8#>2;%PG,XK.>1M%+:L
M!_0@F/Y+=L8%AIM:JI06JN*4Q"CO4=WD"NTK&OQB9GQA_IUJ=85V,GLH37EJ
MDP4Y8Z0_Q?&IP_P%MW-8*4NNU:AWGE4CBJ>??]K3-DNN/8;YR!@MP"#MR!^^
MB-$H;+Z0G>R Z;AB![A4%U)J9C9L$I3V.\O \5D_LBGL-MTYF&WX@O K+@CW
M9?%2 $]JB2M0MWA<,&Z._:TIB:M-45RM$&DHN#,><:YE:M5)Q16K89Z:M(7Y
MP9?#[QDPJU*L3ENIZ6R<X(#35'1[^0"_6U;AFUU##DK8I<+RHZMW1[ \6A2:
MNIZ?A$7P##$FX.%2#V][KM8;_2@ 8?7\YBGF%]>,UBH(?ZWB_YL*_&%F'T O
M(5?+/ZK]GU#M?UVJXL"#AXQO$*C[Y3,R) (/\7\-CU:W^]_&IU5U&^5*#M)Y
MBBQJH25!W#?T@!!^?)&%;]P%7%_OH'4'$9\(KTL%;:Q"NOXFX]NXSDC@.>+H
M/G^@:^7>^R!ULOJ(MP%L?C^YIQD2SM46B#I(\Q.$1&U@W.PAJ@B?P GUD#S1
MS_2WCD-/FILD.ZS_LJK'^=78T4_C:%"\.S;L='W\@1HCRS:4SQT"4(-*C5V,
M^QA6Y"3\<!)Z[T]\?_H;OS_3[S]MHYQ\^,_<)]9=_$(=O9^Y3[_E^S/]?E7%
MNZ&.0%1+_<IV!'KGNP'=NOXG[#O[E&*K>4IUQ.^=.R)YKSQLP!L#^]NN@?[V
MZ:$X0@SHQR!ST?]ST1OV&]('FE,%T%DXZ,XZ,_<\<@+7/B9R_6.H'Y)I(N.S
MU9QH"Y&-\\#^<,E*)U&Y?O8E'.CJQ4M0:V\3O%(8FH>#7#8VT6%MX=RF-6\8
M/&[!EF*37I<T])DZ>L6NMFB3DEM1B4AY-VT_86JP-,+:)BSNIO=4FV\+?F83
M'*0 IJ4/=@KJ? G5(1PR99]O!9W.H:0DS0GP5:!]C-H65%G_A628-@!WF#A$
MAN0GVH%EK$K )OF%4GYM.G&V/X@%M@%3V*&GKD Q*:G;<^JP5 1-G9K9^^+M
MP,?,P1=Q#UK$;MP1^N(<O2@R.D'IYJYOD&MVN,3>13L'849:5$XM@,GO[3HK
MJV"OY&:8K&%1AV5115;^&O;2("05O@?JF2K3YH1K I/E?H$47T*4SJ/_CNW^
MA/U*N(N$J7&?)XM?4T)_R;7K\-T]1@BE@Q>?7"=@>%(/BO7 17:7H:]-(,_Q
M/0$<"N-X"R+*G+":2!M-&-*7U(<ZJ+I$+3O1S5,[OK4/!H8QO1N7D.5;91@/
MF+K %UC2<K ]7.JC[1YJH(T57W)^^:&$ :BU%^S>3Y0X:MC:3^@?K?V5$)5-
M6=]-*\,& 3CLQ],!BF*5F/8G_?0F+Y"/[.N,NS<<Q=/)*.KU>]'E*'I.?YC-
M>H3FK%%>Q+.()H-X/)I%HT%TV8?GX-=)K\MNDRNA%S/N9!)/!KUH,G.S@;],
MX0N5&TF&!%@?>-5@-CUX]RSJ1Y?PY'/^M1>]LY=],.JZ(?5?_-L-)IQ0@2YG
MG0DWB4:]VN/PIXMH..K'HVX?=:W1"/Y["?K,<_G[9-C%X(IC>>T2\]P#L*,U
MD^AE[WD$HC<>CT<T(YX/_F76'42?&8_QR83_^#K_OY/_HVFU:QL7-M$-"Q<;
M)T%,P;4_6-()G8!'(D^&0Z/BSF- +GM.0.4] (L/$]H(U*%Q=M,3%Y#_>^8%
MF\Q@FV8MQRL?ME^O_K ;S\:S: *79H0DC7^8],?UZ]7KC>+^<.0&AQLPI"LP
MBGO#7NL]&T_C?F\4#:/+*3X.O_8&H[_/C1EUA_%H0EHW_GHY'$R)DO#OO5'_
M[!MSSHX^?E^&_2'<K"[.16:"?QG^IKORV I?/V[?$@Y<D2H$9%0I0D;L,,'*
MT<%LI6U;[G9<&75#XC4<6QM\,&ZP61>I(]5&X0YU26%:%XJ?K(U(W>B,U9]K
MW8^ZUNI-):O$G[3P#6=Z*IR*4W.--FD5"G:N;#491^<B4&RJ.@11+N8DVDRY
MUERMR2PP33!;XM3E6<L.B\\KNT=Q&K#(QF%>$-"MR=%X=.-"F[W9I>(:%"6T
M]BTV%795.Z=N1^&-37J@:E[5_$&AW<;G5AXV+E&<[J-H3@1$PH<BW649ROEQ
M/Y/%1JOP]OI.U:]0W7MQGEKEN-5P%G?'76N*T_<&(%W'43\>]_&_O<GDI'I:
MW=NG+YXF-XX'PP'\-.W'@PE*]5$O[@\F54\#JN=;RI@]*S2FCR,1VY^U-S9B
M928/KF(1 YMY\2O7G5$2.:\18SQD\* SIY9+!);( 9,C#AQY^0EH9X4,ZG?_
MU)L,?XR::;FD9F%4<ZTQ+-\G-_-3_>%;*..371/LY3@>#8>XS7$?E,\_(QR'
MZ3  6C!0P2 >3D=8EVE7.B"2@0=Z0Q%"9FIT;G%WB()E&@]FW0:,;HHFHWNO
MD,K8S!T@NG*[G?XWLXCJ67_4 DK\PBOMI=OV5$QE/OOPX1.4U#QZ%/S9-?"U
M]%4QKH+U58Z6EDM+??*P-X2XA%$O]S >>V^*5VD8C]G\X4<<KD\O'G<G1!13
MWT[>#P"'.QI/X6B'H,2]/A3;C)NHTX7XBC^7$:ARHPF\8#H9,SCO/8EF@\0+
M"C^\8!A-XF%_%/U)FAJ#@CR$I<ZBMSC<(.[-O$:'3(-RU\6[1_FR2*B@LH!*
MV /5G_7=7?,NC4<Q&!E1?P*TB;,JR\!_MD1_\T($!]@.L FH9UZ"6CJ>]. G
M; '4,C3L)5B!W1'I4\2H7MK1-.^#1:(Q)%@B&F+_31[MAHIH:00J33%BS!\M
MT&DD_>B%CTF_;G$4F%RC&K7S.*QST%C(2$Z54?_&"41NA)V.D,@(:3""J#F5
M[@@5GOY-=ZXZ [0O>V#9].DFC4$DZIJ .%8I)5PAK Q6E4V 3_9!6/8G_BG7
M%-O+!V3_%#7Q'[J$!$YN!7*<=KMPK:9P(?Q(IA$<9P1(4V6@\=YH3/,<].S\
M,,&<IP8C=GOCJ =+F S=(T5^3-:T;7"#9V.X6L/QP'U*X +H' /.#\8#WKN9
M^]"DNP'WA\G.Z+_Z,9<$%^G<M<C1'#A\UZR+DF8\\-O$4)83N+)@^<0#L'^8
M2,"6G_0CMHC@MO6[<-U(0>B"8C*J$F!3D[OJ,_S7$U3<-(CK 4;)1;B</VMO
ML_-"%E0Y<P"**TAY1E\V^G/! O.93;ZR,*PE?)FAOHMN),K-,\W7-)&$,J$P
MY4% &U8Q.?:3PCN,Y]I@4QM:8M]"3!OEE5;?2I73"# C0>HOF Z =+<F[R=U
MM'<9G3;9%%E:Z7<0OZ@5FI4AT2-*P[J":N[8AM$=2A]^1S>"(2]Z72#NZ<2T
ME$NI(36W[J6@S,6D Q+,=WZKKBC(#KPCT4&J*BE F!O!JHC-6#J='='SC;*>
MV80SS@>H9IQ5RPRD74>D#=LUUB$M#7-$RO4[1[[_WM1$O#VU$*"/72EN1J_;
M ;GD=D- 0[37DJ:G',T6^K['KI[+I)?*ZUP2A^)IZ3PEL\'62/*&\\YM69KZ
MC09>8I+Z8@$[67*B$6$%R9Y0AS?'.[2*-2L%W9TJQ62K5$8\>G#?D&U[;H;D
M;TN*C*M616M^ISN(*OZ')&=6TRL?2ZN,&Q(K#;$:QK!MSZI44] =>X(O,;FS
M#@K&L(CO2Z'Y^K%]_WUX;GU@ANE\__WW<3W!TU?WZ*S*YJL7E/TK;G'LRPN
M5N^ :=$IO-+&H]>^7;O+G?PW7R<O5BYZ<REW#:?;7GW?,&H<C.CKPUWGTZ#2
M7G##L=;35V7UAQ.C6E+0MS(A#IRS0-A0R+/:5]76\H>U^L-AITE2-=>_8X6J
M>IB I79[MB7FF[!CR_1<QNBN.9VJ6>ICG'#4&77_"W-",(N,U^QOS0G?F*I4
MV.KA:!#WP8S_>\O10=!ZX(T'(PN/VZ4.&'Y02ADTDX #8U2.6/WF)^W-8-S^
ME"VV74CT0L[250-0"N"!M#5T*#=J72<H./8A;8,SW:3<$8E@>*1"J?! 7>\+
MD$HFYUP*O@OF4O2,J_6Q2]'O]$?V5CZ19H>#OZ/TKK>V;^AH'W3TCIN[V?\G
M-[/_1Q/ZIB;T\&%O-AW3G#<THZ:VU,WS\=DKMK'1Q="4C9)3)2@F>IH'40XM
M[*AB9)_SY\.@KMZR4]UN/T];(Q!D9L#EHK%M($FBPMY+&N26\<1,[X/[()_G
M>_ML& :Z_G#S1K_AZQ>.G#NLDZ]NMJ\FU27[]C;A<AF]S4<RV1V#;:"DS9#7
MJ#MJ00,_1NL/I.Y'JL[_W,#+6QZM^'2NF8I< B%Q_WZW.VG^/K,&>L?X1_D'
M_RYOE7]\L1Z-I+<_^L"Z0-M X<,-PS*MT]<=,U*W'W6G%^9M BBE<S+DOI^*
MTT2:E'$#/."86^PM_1B!0K(R5\1JW$_@[8F@*"72%9CYA$G;,\S.GE*=19I%
M5AA/"E+XP+#3KL$+\CZ:_;S*B^W$0H E/IU<]]#J8YF>MMO8C3RYR?<"#,!H
M)Y4QW8+"5N#U(ZTNR@X-CQ6'S/DXL$7W5FTQ3"X#>>Z9KL.B6WKA@F;+ODBW
M=WO? QA/..%VKROOAM,*H.J7C>:$.RH[3G1E]SP@G' GK*42LGD&NB,)N\U5
M,?8=,A(R;,24D!WN=2WR:)U8J(&H*B4B-[G%\@[ON79J4SIT#3N ,\/1DPN:
M*96NCU/7Q83RBIU>GI0[3>NW>?:"8,;?D67Q+3!ZGG($58]-XSP:5*'#/\B;
M=$*["C(ET9#OA4B0)/W1=YJRP/8K)P=NMS"KHD3;:"F*+(T:$2I:B!'6^_UP
MNK_W[C-*$."$"FF(1BDAF(MI-'R"D,[7U(A.JE1H" +/T6 V*X]?N#XMX;XP
M^PRKS5=[H9-@>GX/O,AHN$<R&=TGV![,V?7T3)CIO^3^T)NT,2Q,%U 7%WC?
MP,:E!;>DK,X#WUP!9-.'4(Z9R6 AWPYO.>RWN61[WEXIO,-:(.'9H=&B\Y)3
MU?TA'\WIKU98G:TP-@%C_9-X/GSAEZZ&3#E93EOZ6"V5/BDU,*L8G[UN/!Y/
MP$H<.U,72:5$DEZDE8UMD9JTYS7'.IF3G*UC%>C&YP3DX*-4!5^;%BDG7/<M
M;_@-RL9CB_Q6\8ZV0?FW%/*=?PCY?PCYTT+^_S?RV':&E&R8N$V>5$FPT??$
MWH5K_9V+3;UP^:Q6"3T<, )U/+A@+7R1:85J=8GR/@:5HO>F/2IYD+015!5R
M4'&"EFFROT=.4*K]!N]]]@ED#<-]/(LN-6&0M;62\83398698R_L?W=T;&>%
M((I5+:<B""Z?R0-2B1LUCH1'B571%-;@Z9/0]'7\_>TR4(/D?!I'\^Y# ]>&
MWX=7B/*BLU;7-VW#J:G!GB6DSQ*-40J GQSVI\M25STR)&_/M\]5!(6K*Z'N
MQ/R151\^5/3, $K':W8N)()1GLH5X;7-Z2JOTHPTA,^@T(F8/2&>:A\9A:GM
MD"NDP: "2(,8-CMH2!G/W:1>[A]R5G!DRJ'JT_BB[X/=Y#5BI_%UZC",2-@A
M+$.12D\>H@#_->R>R,KMZ;V@M@253PQ: IE#JC"3DLP7KK(HC=B[8W!]@LY8
M(38I*O.86.+>LIR8%'0IHD8M[?12:C?WXZ?;G_'>.EQG40H:IQ17+HK!5Z<C
M]2;"V?<@R.!.I!."7TV51VO[ [J1'BK4?D.VVSM)N=)>[C^NMR/)'.+@^8G#
M(=8Q>2CK776D.WFNO:RXWS.,(SMN'6JQU,I5AE!I)8'^A$!@G=IN)["@K@MU
MIQ-JO]3R&4LW0W\3J'IPXO.#R7G7/F;4K9?:G1O%V#;U<P[$E@F+4B']/[A#
MK)F(-H?](J>/Q$#@Y4Y(LRHEO0-QV96:0;?A+]8)[.CM NW4TJH#.-XFAPO-
M[8,5?DPVF2UEXIQF^BXC18Y(W_RS M9Z># >VG6B 5)*[AQ2(X$_JCBW4&,D
ME\6ES,W-)5C PRETV2OM0?,EQTZ<W,[;@J:!1F<[RIO'2H*XQ,\UV"BM95SP
M),-TF2.IM9WHA6LA<QK&D6Z;=(5S'7+@QJ:5\ETF8WR]W$TS2X+V0/F'[HDJ
MG6JOK66%2(4P%:.-F[!KU)YIXFDC(8F&M.!T)-OHO#P@* CE7@ =9L07G*2D
ME<#Q8?=;[""81!H<UTCOH72LZ+=.SVVW>SVI9OB@&$OA=2/2EJV1+ J9%O:X
MY7DJ%(?F?//36&][M<*Z5&=CD'"TA3-4N_BY((YVC FX\PH,#)1,%,ET[:*9
MY],B<+KI7PF** ^71!1$%R1UO9@JWJ+7+/XH>9@J=3WJH<X)R!_T+M2JF Y%
M4J1PD$ M0<%S8@F2FJ%+EVHA5]G#E7]I&UZCW7.OZ6:VZKSBWF&>PS<D.8MQ
MJ1;O]1MMT7BEE]%PEQ^BOU!R\*N6Y&"*:%'9A^,OO BVG@P3F0P[O>B[:#+M
MC.&?*8(G?!=]PFKL!NKH=X;PJ?ZW"_]]%1ROL><NR=O[G"HJ1YWQ%/_3C\8=
MF)?[CCC EI+):+(++J)NI]NM_'.Z=C.HX?S\)![6S+^8&FJ-,NEHKZKB)$B,
MJ%**J.#B:)-HHP0>)^R@NQAWQA,L,>UU._04!3!'G>ZL5OUT+?4AQXH"Y%#N
M]/5GX-/,^.T(#T!T!X3UWIGFM^SG^[/NP+7LP"ME3A^)F&J??W+L@(GTVN4/
MO=F"&K(M041Q)6HEWSK$8E&[)@<YB5VX"0*XUKP &Z -9Y,.IMU/.H,)JVPI
MU@V,9Z/.@/Y,]T -HLM^/)U@SB35.N*VOW9J]V4O[@TPB0$_FW5&H_-F,<%9
M]*:8:8&O&T[=+/KQ8#CM4);RL#,;VVGTXL%L*J\:=T9#.XU!#PODW"1>H06(
M?]?G,8]S?-[<ICBW::]+DX!;/G!S&\;=68_GUNWT9^'<9N.)O&O4F0[LW*:3
MF<X"OCWQDQL,>OK!H#.8GC>]&6:?3_I#FL>LTQO!7F YT@!S;O\DEM,6_0IB
M1MFF??BGEB%[,+D^#=F=PI #'M(=  -[-J'LH*-[."9ZFG8& U@^'FI_(@A%
M/ADN<\3LA(5S9M6M[\?*.>2L/%? 5,R>;843T^\SFU]#20XV.3GD%#=! A9[
MC0(.\>WSK/$OF)KM\7,Q,UE',M/>V"1]UKC:R< $%U5BG:DS1VH&BTV2W>;;
M*Z&79N%-VSOH5S)&LK+:$]*\D$R8I"X0O"73ARW@W>O8PDFV*']VOI./QB)G
M1+:6AR^E(R7W%'X&YNGW:(^C6<[V2MW?1K$K%U,L#_-?Q/R A>/C:GYICHG)
M)&:$254T#7P/.^66ZG'LR 3:WN05*L0MX/&D80IK;&DINKU#,U^GTB=$IZ<N
MBBS?5JQ!!]K.[G(?DL%)&7#@&LZ0,U\%)R#4\!K3_7ASUZZ_,*^[076-43T"
MEG+T=JY012TLU[3":)WLRK0BV0T)PWNUW\2Q>N!G"?FL/"7BZQ*<)$3T$I=H
M<"/^7H+^O5^I.!@;><$$A.EHPNP89-+(R;$>B#=DC"!W0+_LJ=2X' VZ3KQV
M>X&4'XZ<C!^/SIW -$(0F+Y*S-',Z!JC_EC_/NN[&<SZ*A&GG>',SF#4'WE1
M/NJ?.X59-(HG,YE"#Y7I/DG+$0K-L_ :XFC6[\:3:9^I.7!0BH]\6YM+D=;$
MKJ-T((\M<K,UW>]'&'DA]8^#F1%:> >?R-^=-D"+(.-)N).X<_2:8>9_YME(
MZ1I%5);T=%8_=*P^B"E+32/<#3=9"2E?DX?IL8)O SIM%QSLAI:2AME]; J<
M UQ9J2:Q+L=3EF5K=20;FCS*XQ/]P=<3UX"6Y?D+K$P<3:24%G%[\)[$@_XT
MNCVG&8B.TQ_'4U"?<;!^-^IAV: "IJ0GIGL1#8?QD&H+^[.X/Z8?!G&OVZO5
MMCZE7JCZ9<-:/6#!R4K:I[RMDAA=ZY]-J()F%+P1MJ>VQ='#^+S/6C71&?/0
M?0;' 8=ZM#*8XXE6]G#K!H^Y\^^'G)*CT)24YF!TA (?QUDF!-JR\'-'(!0S
M]5KF_;V469FV,PFG 2CJG.E4OJ3N"SROOIO7&^Y/8= )__K(3%W\S;2Q4.G,
M<,MFVL=8<>@XI+\^<N:5_M9Q/2XJ$W)O.6S/>D^#OZ#NX/)D4J2*!]Y&)BKC
M73AH31,]21!,,*H$8?@BZ#NQ2MACUYR@C7JDH/9X1E?AH#4D##U.ONQ\<7ZH
MPU!=*+#;11WAK8+OAFAN\L]I?#G$<--_R87ZDX=_NV;XMQ<>_JW7"/M&*(Q@
MH$_&4_DOF*^]8=R?=,U/+6M6RN&U&TZ!&_!(KPL+3M7OQ^-IS__0G!].Q0$^
M21P89\^CX/%O%^Y?/^0DQD[:_ZUI<_KWIDU%0[MHP$6KH*(A#)K\<QJ>#='8
M]-\&DAO$75 -^;]P;(B3,1V:G_[.)->;Q1-R^,H/9Y$<B/6!9]S\VX7[UPT)
MM#>$OS0E_=5K(O'82RX&Q2/5=6(9V1T"U#3+0"8W1URU> +JOC7O\[S(?TT+
M%B\L5T@##Z0+,7@7D6R+4]27T>CA>DC*:LOE4:>EJ[W;HMMTBR8[037#U#]C
MH.=MC@8H7I#?N%$NA^NQO0IE,,5P,YAW$NH#-=E<:;86"M(&,>IIZ[)- 7@N
M&,5)&<9(F@?FTJD-M3>68>A;V-55D.RT3T-PHJV[;LZOFHU0:<ED(YWX![VJ
MRD-;Q"Z\M:FI.J-],>-@!._H-3$./,%&2.\P=T&U2.XY016BCZF3KM]7+V*U
MK@RZ@-#CS?3!_9[J%ZFF3[9JA<'<A7OQU"V"<BMJ(UZT.H)>H$Y75R07H8[X
M?/X^]:4A!4(U^_9O3V<S0H0!@C*68=KB,_\PM:W/_GK@KJERR5Q7BHI_^42/
M+!B?"DY7D@/O&L=P!JPC!32"9+EUW<&>I-^A;YB-D5XW@?02,"-!H7Q$Q+FJ
MV<?P&8A1G=]ZI?.,\1S8.X*YT.9 &AEHT#+0.SBT&#<5H+X58D'[H;2;(*;'
MN&1"_6/L'2FK [E]W1!2\)BL%XI/K^[1M!HWIDU1X(,XDC;>,BF7Y+OUF1$E
M+!<[$9H%J1E+^5V:-F7:_)F.(II7@I;63TTH^[:0\6S/2N<\<K#MTLA6)<3/
ML"XT<8S:J[VF%).9D%^;RTXJ#W,,ME$ZT"^'Y1U7GR)0F6_*"'.6AHUATJ@@
M9Z$MVM*)D?H#+#/,+THKK14I#$2Y.RI%M5&D"MQ<_EJE*@[Q-"+X+RB+<AXT
M=(3I$3Y[P?"R#QYF/6 !0;J/NP8A2Y?*(]D\<HAQT:U2 G;68YIFUY^FB#@-
MWS::#"QR6;3?E5K7R?R1EHA*+88]N*V]_OSB"EN2<CM2P?3ZH9U;O764\SIH
MC] H^O_DIOA9>7KTLUT;N2*B3Y1>5$6@#-J%SCKC[Z(;1</A?$+7UMY@A9%R
MCB"1'\]F3O9)RND)FG&:L2>C[Z*K:#+]#K_R"S,=8OKPF.NQVN_V>_ 4_--O
M-UBJWC*4+^(OP["7WUC*BV0<69/JR PX:/I9QA7NY>?$+&_GIJR-$ E/O&/6
M8NA'G]%";>L_;CD$]I;;+J4!XZ76" YU2/NHV_4DS<=#64U87\?H&G23PJ4[
M58<J"+&T1F:/EY(%9D3MFO""MW0LM2^@8A3S-M<"(B]3SX+N4M3G8RESS$I*
MA,*DW/"M287A\"SR0CE/\WR(.10I=W CYE@DW(5<BB7]E9>@A+O0#0W#-2E\
MD^ZK34;^ 335"#15Z?7Z))"IQK#,/:HPM ^N91/^9D GSI+UC^J9+2 4'(MI
M^E9K*$; J6,@',WV]7GP>&NM0V04#^&'=_[R.WQ-J_U4L38]9C^#.SZ7AE;5
M/K1&R>9WQ]^F5$6#N#]#H&%$@;Q>8B*N:PE[8ON9AIAH+@>],<RSTF4KKI0)
M\/8X%V75!16$^2CV?F4ZP@11F:/!7FG\YM\1E^:W@,WXLL@:Y$R ...>:\2=
MJ:""/!'YY)M03_R$VK!/S!GO#>;)9Q<TL0:]J?85PU@QT> $#I0L2C;Y_R$'
M@3)I;P^<[QN(_Y[.@6K $F'YFOYV'D [/=GJ <,R1]#7!EC#'S0?G9X ]L.6
M"H1H)X8FD]6++ <Q6&R2Z(8;/GU\>R.^IFB-W+?0!I3!=X.*S@0AY0QZ%T^[
ME&DS_DU.955M*P(&H'<WS+H.\ND'5PSH\/;-BP^?&/]ATAEUOZ,,9$RHW@C
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M(UH*CGO*UJ5#S@UMJ(=K:IFK,BVG:JIK1D\4D,9.TC29P\<F-N(E<'.Z6=O
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M]D3-U>#LVQ"\[7")WYYV_JT3SY?3#1NWNMHGA)I1M'L&<NW%K1D#BI79".8
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MMMY\76LB<X;;&C.S-EM%'#V7,_B'#6J'[V"43[^C%UT2:3RD(R"S*L<GA3.
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M<Q0%8;+,+KGV+W-W,Q<J%^(L6>D^$>B$QM@QJ5&H<H?]V:6.4K[:A(X9EM$
M8RO(+9_'0:D!(N[C-TDS/.KWG>\WYY:D$G$&Q2%M>I-:C077UO?^VA@E8:0+
M\4FYQZ1^PBHIZ]L6<<$;3D)-/:F9*0JZ MMC/F\A--"!RR>A4J'\* G=^P7;
M^<)\":VT5!##G)>^&=VIZ>+:>1@<;/#K[>H*(TP;*Q4+[_I(24%>;T GFUV
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M03*HD;:K>^>]'Q1;?;G8W%G!4C!-+]]]H/JGY_T*+@.1_6IYM3T@EQ!^REN
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MD?5@1POU!>>FX$5,Z,?_+XP:?Q=OGW^I((>#P\GJ:Q(B"<D>+T"22"0W;#)
M(5"RN!MR%48F1=67WNX#0V!D^M/0^_8L?Z!91^\FG2B'Z,8" YEQ'IPBIOJ#
MHI>GP3"/3(5JM2MW\&H+VQ1)XLZ?RTDNVJ:[YJUG".7*SOEG.,$V8 T\.A/(
M3+RWP+"T'O&/FJX]Q:/;#T.RW/#0B<[J/W?])6\#DXPZGU. 6M(TQ)- 7C_F
ML4:CO X^0$Q:5$$P34%78(+6[=;,]496C*"3D_!&@<;[FD23+7"/)G&5"QT]
MB/HMXLU$X-ZUB'PB(-^R$:EC3U+<ZR,)$EG])VY"8@<8(=;H9'/#GW9LN]Q'
M71.,2P(VB6*PMJ0628Y'HSCY[R- )N?](0L0[3!^V"A!\/)(T4&3/U%U5):
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M(\""<(Y(PIDU89*+:)F\6ZZ1B(+ 6C!H[Y&LXZ?-?-T2"L@ -EK"7$0T -(
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M]\[MWN:S^8^U5\]02P$"% ,4    " #+@&)0'R// \     3 @  "P
M        @ $     7W)E;',O+G)E;'-02P$"% ,4    " #+@&)0)^B'#H(
M  "Q    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( ,N 8E +!'ID[P   "L"   1              "  9D!  !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,N 8E"97)PC$ 8  )PG   3
M          "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MRX!B4!JXPG)] P  +Q$  !@              ( !^ @  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,N 8E#;%8[SC00  !(6   8
M          "  :L,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #+@&)0_M@MP"4"  "F!@  &               @ %N$0  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ RX!B4.0&&M1'!   !A,
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M965T."YX;6Q02P$"% ,4    " #+@&)0YD0\\K !  #2 P  &
M    @ %3*@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MRX!B4)P=/$JU 0  T@,  !D              ( !.2P  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #+@&)0#S6,^+,!  #2 P  &0
M            @ $E+@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( ,N 8E#WS9])M $  -(#   9              "  0\P  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ RX!B4$CZU9>U 0
MT@,  !D              ( !^C$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #+@&)0GLZC)K4!  #0 P  &0              @ 'F
M,P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,N 8E ]
M7>/1LP$  -(#   9              "  =(U  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ RX!B4 $.C>*U 0  T@,  !D
M     ( !O#<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,N 8E"IC?X.M $  -(#   9              "
M 55!  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ RX!B
M4,]9[1&T 0  T@,  !D              ( !0$,  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #+@&)0#^AU%K0!  #2 P  &0
M        @ $K10  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( ,N 8E !<#DLM0$  -(#   9              "  19'  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ RX!B4"HR2-BS 0  T@,
M !D              ( ! DD  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " #+@&)0AO;V'/("   <#0  &0              @ 'L2@
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,N 8E!(UW(I
MM@$  -(#   9              "  15.  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ RX!B4+#HME[% 0  -P0  !D
M ( ! E   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #+
M@&)0]Z !Y\0!   W!   &0              @ '^40  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,N 8E##D\LUM@$  -(#   9
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M970S-"YX;6Q02P$"% ,4    " #,@&)0,8MT",(!   W!   &0
M    @ 'A70  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M ,R 8E!1(<CJT@$  )P$   9              "  =I?  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ S(!B4'% KNW< 0   04  !D
M             ( !XV$  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " #,@&)0U:&%(\,!   W!   &0              @ 'V8P  >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,R 8E#6PH'-MP$
M -(#   9              "  ?!E  !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ S(!B4&1S53W: @  < H  !D              ( !
MWF<  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #,@&)0
M9X!?'YT!  !: P  &0              @ 'O:@  >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,R 8E"]'+!\WP$  /H$   9
M      "  <-L  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ S(!B4-G(LR@G P  !@T  !D              ( !V6X  'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #,@&)0W=5=3)D!  !8 P
M&0              @ $W<@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( ,R 8E#R8=(4R@$  #4$   9              "  0=T  !X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ S(!B4-WIH(/H
M 0  9@4  !D              ( !"'8  'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " #,@&)0)UE#(ZL$  !?&   &0
M@ $G>   >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,R
M8E UJ6)%60(  -P'   9              "  0E]  !X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ S(!B4%I]#8T] @  O@8  !D
M         ( !F7\  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M    " #,@&)07N+4-$$"  "8!@  &0              @ $-@@  >&PO=V]R
M:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,R 8E %"_;'DP0  &,8
M   9              "  86$  !X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
M4$L! A0#%     @ S(!B4$F,)],@ @  +P8  !D              ( !3XD
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #,@&)0%*'O
MQA,"  #]!0  &0              @ &FBP  >&PO=V]R:W-H965T<R]S:&5E
M=#4S+GAM;%!+ 0(4 Q0    ( ,R 8E!K@OY67 ,  *X.   9
M  "  ?"-  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
MS(!B4(\VP^:K @  Z0D  !D              ( !@Y$  'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " #,@&)00O'IN%<$  "J%0  &0
M            @ %EE   >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( ,R 8E#R9!-A2 (  '8'   9              "  ?.8  !X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ S(!B4(/3CQC0 @
M5PL  !D              ( !<IL  'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    " #,@&)0,Q8=BC "  #<!@  &0              @ %Y
MG@  >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( ,R 8E"(
M1\";[@,  &81   9              "  >"@  !X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ S(!B4%'L:EP, P  T L  !D
M     ( !!:4  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,R 8E"WL#E: P(  '\%   9              "
M 76X  !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ S(!B
M4 QEC.U+ @  5P<  !D              ( !K[H  'AL+W=O<FMS:&5E=',O
M<VAE970V-RYX;6Q02P$"% ,4    " #,@&)0(/1R9KX#  ">$   &0
M        @ $QO0  >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0
M   ( ,R 8E!CXAQ%!00  .P4   9              "  2;!  !X;"]W;W)K
M<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ S(!B4&<&#,AK P  ^@T
M !D              ( !8L4  'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q0
M2P$"% ,4    " #,@&)0<+D!"BL"  !.!P  &0              @ $$R0
M>&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( ,R 8E X07M"
M]0,  +82   9              "  6;+  !X;"]W;W)K<VAE971S+W-H965T
M-S(N>&UL4$L! A0#%     @ S(!B4('DV?S8 P  ;!$  !D
M ( !DL\  'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " #,
M@&)0] Q'SD(#  #A#   &0              @ &ATP  >&PO=V]R:W-H965T
M<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( ,R 8E#K:ZBO@+8  %/+ @ 4
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !3 %, MQ8   6; 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983140336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(356,388</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(348,995</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(284,002</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240,421,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,790,021</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153,355,144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,724</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding warrants, convertible to common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,657</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,712</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested restricted stock units, unissued</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total number of potentially issuable shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,719</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,766</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983327184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock and Warrants</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company was authorized to issue </span><span style="font-family:inherit;font-size:10pt;"><span>500 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> vote for each share held.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, </span><span style="font-family:inherit;font-size:10pt;"><span>101,787</span></span><span style="font-family:inherit;font-size:10pt;"> warrants were exercised at </span><span style="font-family:inherit;font-size:10pt;"><span>$7.98</span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock resulting in gross cash proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in "&#8212; Note 1. Business" during the second quarter of 2019, the Company completed an underwritten equity offering and issued </span><span style="font-family:inherit;font-size:10pt;"><span>18.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$10.75</span></span><span style="font-family:inherit;font-size:10pt;"> per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$189.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in "&#8212; Note 11. Assets and Liabilities Measured at Fair Value", the Company reached a clinical milestone, which was the dosing of the first patient in a Phase 3 study, related to the contingent consideration from the acquisition of Callidus. The milestone for this event was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was paid in Company common stock in the first quarter of 2019 and resulted in a </span><span style="font-family:inherit;font-size:10pt;"><span>$9.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> impact on stockholder's equity.</span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> As discussed in ''&#8212; Note 12. Debt'', during the first and second quarters of 2019, the Company entered into separate, privately negotiated Exchange Agreements with the Holders of the Convertible Notes. Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$247.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Notes held by them in exchange for an aggregate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>44.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Company's common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the Company completed an underwritten offering of </span><span style="font-family:inherit;font-size:10pt;"><span>20.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$15.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$294.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, </span><span style="font-family:inherit;font-size:10pt;"><span>453,214</span></span><span style="font-family:inherit;font-size:10pt;"> warrants were exercised at </span><span style="font-family:inherit;font-size:10pt;"><span>$7.98</span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock resulting in gross cash proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Restated Certificate of Incorporation to increase the number of shares of common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share, that the Company is authorized to issue from </span><span style="font-family:inherit;font-size:10pt;"><span>250 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares to </span><span style="font-family:inherit;font-size:10pt;"><span>500 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares.</span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:2px;text-indent:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2017, the Company completed an underwriting offering of </span><span style="font-family:inherit;font-size:10pt;"><span>21.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$12.25</span></span><span style="font-family:inherit;font-size:10pt;"> per share. This transaction resulted in net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$243.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nonqualified Cash Plan</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's Deferral Plan, (the "Deferral Plan") provides certain key employees and members of the Board of Directors as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code of 1986 as amended.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had a deferred compensation investment balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, with corresponding approximate amounts of liability. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferral Plan investment assets are classified as trading securities and are recorded at fair value with changes in the investments' fair value recognized in AOCI in the period they occur. Deferred compensation liability amounts under the Deferral Plan are included in other long-term liabilities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Incentive Plans </span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the &#8216;&#8216;Plan&#8217;&#8217;) and the 2007 Director Option Plan (the &#8216;&#8216;2007 Director Plan&#8217;&#8217;). The Plan provides for the granting of restricted stock and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company&#8217;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. Under the provisions of each plan, no option will have a term in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> on the first year anniversary date of grant plus an additional 1/48th for each month thereafter and may be exercised in whole or in part for </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the shares vested at any time after the date of grant. Options under the 2007 Director Plan may be granted to new directors upon joining the Board of Directors and vest in the same manner as options under the Plan. In addition, options are granted to independent directors at each annual meeting of stockholders and vest on the date of the annual meeting of stockholders of the Company in the year following the year during which the options were granted. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has reserved up to </span><span style="font-family:inherit;font-size:10pt;"><span>10,667,216</span></span><span style="font-family:inherit;font-size:10pt;"> shares for issuance under the Plan and the 2007 Director Plan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0001178879-20-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178879-20-000015-xbrl.zip
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M-'V&;:^&!;DU@H,S(;=.:%1$>",L%D<MFVBUME#/FBK?@--ZQ$I@5,U$3M0
M WA0,YS\<"?UW\(G-2^$[FS<(-3IHR5[6[ZG1BFQ0D(T2X=:9L,?U$KVD3?V
M@$C  NG,G*A&07XPI![A:[]:QX%SJI26T' # 0,4.DV4R)XU*CUU"\R5GKJ%
MDNF_&\0[/JG[#BP@3F<SMWE]]''=M_Y*O63>\#7ZK([V?S0!4 +&&?A>0-!L
M+);7M*XZO  >>M,@1O!1W1Y&39P(G]2\T&30U=IP*$B62IEZ_ ;U\*9&CG+-
M\::.*P'?!#NP^6/%<PKIA>^%?E4T.5//3>-D0B)G1M($B/?(#:?TLY)<O#=I
M@MVD%G2X]F9;]J8.G4'A:-:8&M6E!DMK5&=GD28N3&JY<-E>:!9#U4%U3(_K
MBF'HWB_7)G%$@]K4K##5B>E9 T;!@UI=CGT^3J>3,G;4KI$/6J+=R<N5.[E.
M?"43WW,:R)D_;.";Y';:S#?AX;+]3L(H><2.LV'U*VC\>AVV>I,FU1Z>U#*5
M)BK")TOVMGI;#3L*TFD]TQXET4?4"S_""!)Y[@(W:M0'BN<UW.@'R(#OS:XV
M?+IHK"P:> \,EF;'STV#X+NIDWCHR5INE18#:MQ=J*@M-T;+(YJY_-(E5,?4
MP#=R&[8,#^H81Q/?J,7]\:R3NDO=0O1Q'2-.&[Q"\*!>M#:*U3IE>U8_N5.G
MF2.;B(BW1/G"I_42;AK6:95<QN'#!AT,9JQS<14Z8KV3ZP&M5"U1?'SCQ*3\
M)3<8C;T&$5D\K]67&UZJ&YP;0*N-M69OPJC1$\T>UA_!>.(WB W^L%YUG#6K
MCK.Z5S(O02,QEP;4JS8-UG;VI $HM0Z\#"CU3CSV9.1%-9*F>!.?UW'(.!R/
M&Y@D/FJP59=SJ?*(.N'?P N6^(>7["Y_7N="@E5Y2RAHT7F4ZV5)/&D@A]*(
M!A;9C-?L81V"-C#M6IX=A,$C9#98Q@MR&U ]OFG@E.Q9K0(3A[,&UL6>U7J-
MQ@2IGS2"GIO3^<!\C8TF?Z.AS[6 1O6@P1G68'GDCY:8!ROO&^I](0%)5L$#
MACR@ZA5$70=^/VBR>^BC.L.WX8B3.CAD>M=2I:R>+Q:W"2M<GLW6%>!,(QC[
MB%$5&;,,?O700\:^E.LW[*R!J06U3 TD<;,ND3VM$X#>^*[)>8"/ZDTMH+$?
M#82?/6V0*W6>K0Q\]9XM6/O=7\W[NONKT4U58]853JHZLXZ*F>7:]C)->YF&
M7:-9-VE5]=K4A+A-AB(^JCO:T&W2+>%)K62LD1I,)-::-WA)LTSEJK_\]P(W
M<7XT;)T^JWEI-FMPI,&#)8QUI<^EGB-X/T -(VZ%*Q3'F3D=/R:1$\3C,)I2
MOS'.T^N(:F4908-T9,,;[,6EH1$E%5%ZL.IZ/K9JR7)'[M?8C*OL\=)*%CV$
M<?T-?'&974=\35H!J54)\"*V 4KPY./#*UG/N6VZ18(G=3CG-'BKX4']Z36>
M6LUI)5Z39I(]J;-+7=*@V.&3)9*5(+:?AU[0<'M2/ZY! 1XMV-*YK&0/<P'6
MP'UJ;R+BNBL%RDCJ+Q.0%R\W%QJN8T=U2AK%@E&]#<6N-)::V^QY T4O]?[4
M>WY^^/6$3$V,?YZ47%H1N0T;!#%]U&!1N'Y3? Q[6,M2&[RDF:N_SBFRS"52
M;U;?DB:629\MLQX;;U?+(^H4+7*[XK:=J]*WY6LZTN1_JA/%E#"26JKI,:I)
M#C[_S__QRX0X(_CO__AE2A)'P-$=O!H#"]X(@P2W< 6VV('@LM_^?I"0'\E'
M%D[XD;Z8>(E//F=QC+]\9+_#U!_YW+_<A*/YYU]&WIT0)W,?CF@,DW7&SM3S
MYY^NO"F)A5-R+UR$4R?XF3Z+O?^03Y(X2WZ&19;?A/W.?&>.!B0Y^/R+]^,3
M?H1$[$=O-"(!_1&>GS+3D:W\1W*!.K=M(J1^Z_YY91X(@3/%&8GW28>5CW#U
MMN_<'@@>G(SMN$FG*XI=R99%75+T@6::_9ZE](>J(=L]4U8UJ7/_O?.H@0<"
MDX!_/P"1^>DFA--U@K'CQ[ )^I]?/E86_80]&-1;E=A>[#K^G\2)K&!D OJ4
MMR.KLB+IIJ18UJ W['8U><A6.;!,S1@6VUDQ\.!SIR/)@&W/7W:&-VS=Y_!:
M.++A;W%IW7U3-45#U33=UH9#33>'!H?NL*_(JIVO>]7 @\_VGYM>,H)Z<<&V
M)%IFUQA8NFT;JJY;MJZS=?2[EJZJ^8)7#3SXC"MX_I*M *AR;J"L=?SC8$1^
M_$KFI07W1+.KJIIIZ=VN.ASJ:E_3V#HT5>X-S7S!JP8>?!9%$"X#51TT+=N.
M8")0!841&!%3!^5"1SD0TL!C6TCCT4%U3\>H6OW6S3:$M\&?=!<.(?61/YHT
MH,&C^N79C$3P0W![@<'29^/KF)P0)R;ETS'ZIJ)V#:FGR99J]"W1-"U;5'5C
M:)JVWB_0:=5 V&RVQVQ3S]NDMKE-6CU)AG-1[5[/,!3;[ W,(5N[)=MV7\PW
MN6K@P>>>T@6IL<Y6RSL-TND-B>HW^Z\X2OYUX02W1/_AQ?2W;\X/;YI.OQ%\
MZU]<2?S7$*/B21SK+LBFV,//T3<02O\R0*7Q1FD\],+9Q $V>QRX"^^C+ -X
M ?[#3S'H71$%Y'".PJTT4_VP$\^Y\7PD(+!J/*!Y/1A=D%L\F#":?_-\L$U
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MV!<W8+>,W0VVGMV]@++_U/N>5N3OG:/OR>C0LLK7995O[P]^4@! ZQ_8M8"
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M%E" 5FO84-HYF]':^_!0%L4!"%C3BXB;A%'U :\S4-B+,18_J[H1)TY$AB"
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MO=XSJ78OK[U? F:_78.N>WP%Y/:[1>D0_G"2_5YRH0CZ\.SZ2N#J,EZ6;Q&
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M'V(7R@/'FQX>P'_@/%QO!I/A;S?$]V"E^*/K!/0_8>J/\ <">#?EPQC@\"=
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M!#\ PF=E=>"W?X= '0*>/;P"OU?=)(7'N40 <W[&8"#PK#Q_?L@JQ6!0$>J
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M$2(KB$(%T@1$!S><41T  V9&U1.V]SP8%!9>"'DO@P$MT$)GKI9:R:Q%FJ'
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MA*4UIZ  H!91Z!U@)O*&6SPGA*;2H?9';\_!3/M"HBD*[,P.JCH:J0Z#2RX
MSLL>HL&"B@%+H[[SPC3&6(& :EZHS7&M2F!%@G']>T$,.;C1W<6:)RV<KE-1
MKW(T!6Z7PX1EBPFW$>N!A+"'_<SI]1*"D\7(1;3E% 9$1B%:JF!7\T2@XEBH
MUBY$/!"$!J^P,"1J7HXF//"%XJ47,]]^R8=&C=Z5D:^MZ'Z^.-QM8<Y<3'E!
MM<R3D^=&QL^@)\H@6= 56#Q!%/H^14X,Q\R,C)EWA[)'P+XPU$''W<(?F,>[
M(RJ+KO#SB[-SZX2Y_]BD,+LD*SR\UILY+&8([%AT(W=JW,@"V)L]+5M"#'R1
M73:S2"OD<32N\HX&8CD949]/\%7IHRQ4NMFP]-0[QT^15JO?R?E"QCSILHHK
MZAJO/-L_#1SCCG=39Q!XM',=K?I5WO4ZL.0<D%T@_I4"0+'?VAB4)5ED=P%#
M.&O,POV6^Q#P'+[23!X7[<'SS-B_*/1"_9;Z)[TXQH)+#HZ9>E3>' < "-JM
M,)]Q0UO9]YQ(I<V)?%\YD3LE*'=>+&;>.&=TAUH7Y3>T=Q)H=LGDZ.D6Q?-O
MWI[MOEV\;C.^/N8N#2]CJ(1@%\/W=>*2.H:]:2$@"_E9R!5ZG(5HY($3M-<@
ME:>@%^?V$"8D>-DGQQ6_[#VF*0"JEHRS!R[4@/4CJN9"/.'L)'9V3S[UXC:+
MQE]C1X)J8Z1RBP,X8J8=U/3I6G4C:!X*I^?&H<!O[M:XMV.W<JW%T#+""B/\
M5F[(^%Q;H#"G*R6>TPRO\[A*F@B6^U!B@ P1/DB'HBB"XI_WV..F S,(N"Y>
M[9+%:T>SFV9>1]JYC0CCYY0J_TC_Z0G#/&B'OL_OFO "Q\4+,^2G>>91$O([
M+%(N20W*,NPNN^K!3V$"2FDE 2'8;3N&D9[[G65[L#)+&-*%BA:][?%F+/N+
MA7#AL]IF8-Z85[$A(^8CK?8ZR_Q$[/X(/D855L+=3?PF$>!<J9W#(B;NPX7(
M(3RV")/2RCR*5<HK]^H,HULGX#TUXD^"X23LCKL*6C17IJ%@H]R+A$L*.W2H
M'-6]0/,^,E!6NHI6/UVY:*,'F!T<O9?/X^9H^_A*<[J'81N%?&'9;A$IQ3$"
MGRP#@7;H;I"3U8W2G0 PO3@I6:8T9*O:*K5 F [#^@=[>Q )X4U1(4#;LV&F
MM:"%<I1'IWEX[O [SJCKOR]$I]0'Q[RH_"CN_EL!LC,"Q/8"4* I+P;+/;@%
MY?GI>M059?BN$T\.Z;\"IGRQ8!I^R\_\J!3)L-1GQ-#\63<)W9Y\-'C^50)P
MDRVXN:K<:#P=)CVQNX'KGHW"1'V&=D)S"'*I#WB5)5:7@[)R#6 OKCNRNS^,
M.XO+F@S@Q3BEN0/,>*(VQF$6^?*@J7P>Y3PC45ZQA1MDS-Z;./Z8.Q'E(Y@G
M"^_A>:-YX:&R:'U0Y"\S[:B%&N<YKT5.NT"+6S<*.I:LGZ77IWG6*@RB0:7E
M O'/*ABR(LEOL[SV80A;Z7*>>V)9W!+_V<BCKIX7@?<JF>,/Q4G-II])C(_Z
MQA9D_SQJG1^^59HJ_53*?#.KD1A;?.H,CYMRE?:#]]X[I8P=%[1?Y)UD5#2@
MX(76\.X'^)J>WF*(( JY4@K5340;4>]/"E7M#8\SHK4"J*GCH#$*0@6P <P0
MYS:@P>4PJ)JJQIV91:(:0,=-8.R(/O5G$X?)L \'7TXP;85GL-%;>1K9"#"_
M\Y*(%C]QYM2+R90$>AF79;/M#]25KEJ "V!2RNG;CTTBP>7GEM5E/;H^8C59
MCWX]HCY0AV8]]9FSE 4+<W\RTW405!AGTTD(I@/4H"D+S@A]$KO<)KG%V^D^
M#1GB?2!](.##M1&ZR+\L8?8T37@"%C^PGQB:YENM[A%4*N+GP:6"TA^P#W6P
MWA*J3-E\&(="*T-&!(-6<(]PB$F8ZW(8LI)[\!]FBQX)>NZJ8HO&"VP:M92Q
M/2P]A@'J7;$4W[28C;A8EYR%YN"F#NF.#K,,R;S!)KO(QWIA-$B^Y'+TG32
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M*6&!A?IGEU*T@/@EK)Y[VDO7X]7I*Q%?7%NA7B8GOV'.DL5+$6N9K^H>K+6
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M7(=_@V6#SF(&ON?CO&*ND2T\)GV)0&.G;X ,Y^EM$?D3'1UG;E4*T9)(>BF
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M'O-Q(-4T1BJX0>@F7-\@>GZ)?B"L<;<";46E(6O=QP].E7[S@\[UPUD2,+.
M7+*P!GQ_4'0V)>7E@]P;KQ+YD._V M=$)<'NY%4+_^/)C7Y?B;H<ZU.RU:GN
MH\-=KONFY[H_NV7Z<Y&^K5XM027\"T>U+>;H;\@_)O;H/;9'\4"QCX9IOI?N
M(D<EX.,9R1T\Z'N#W^_=98786XCDSM[/K_Z%E)DKPWA-R2RN/!&X97)>5-/@
MZ5\9=[@5)!ML2BZKLE)[3#+_EMR,5A1Q[V@[1$8V1TZ&NT. 0?6VB9*7[OP<
MT;E@%-;8_"]@+^TE&&W\U+67V)Q/LEBPA?@4I1D^MK97Q%P^&!!C!6_'CIG-
MFO"2C%N1*["8]SUU^>;80$RAQB3E;&X*SHRPC7FVCWV V72CI/LR_<N#V#!0
MUC;2O(11?:^)Y NO\+(*>0W#A;I"#!KR/,$4TIB%>;!_'QF7_32ZML?2;4O<
MMT+1_NFBOD5*&ZA!>EL 7S,I&.(_UY9V:*ITQ*/,0UQ%2.!PA&2J]7QKCMY$
MY'@C74/#V1;TS/>-9XZJ<XS#5.$\_5AC[X.L9-]S!R+@5&B+%F 7&/<(&ZYX
M@%E7UZB&?ZZJ+(E$/#FC].,,[]+9SR_.L!G&ZX6SO9<5J-(?P"#.* V2!#O>
M26M9Z?PTF& $%<%ODK*"1<<!.8S39W81#I*3 FE?SQ?<YOHJ*;>L2W6#3E6A
MP0_%(PRI+/[=<<H2O8XZITP@YO&I4:S3)-C(R\A1I)?E2\%5,X6>[P=&WZL$
M>4S,B.HOZCM!01*/ZT><1QC'F6R#CS69LBK$-E-[\KQ9>,@7BX567QC8Q;2B
M!*2P7Q-V@WIJ\?,1HZ?LIUL"9Z!<+Z5,#7-HK!EI"Y=.\IUR8&(Q$?R*U-K'
M'%=M^H:23*U;-0PW0I;1QDFNR3YFEJX86J5QT:&VD.@9(\IT,&GHH:?Q@4V3
MT9@%M@2E_J<MRAJ"V_/ $J^A1<V$T;B7SK41(XK'J+>4+<O<$CL5W\"KV]3!
MW/QTP\CX?P=5@VBGK3A1>$?$K3P8F]'36AD,@:J]Z&J(=#N"J=)5GB$ "W%4
MLYC(F$.]+06 9F%G!3Z:8*06\<M+>&634]2O1SLN2C$"32@]5)'6YP.VQ0 <
MYQ9,='YA4,6F]B1Q<F/ :1C%K4..D7 D,VRR?MF"FVKRC4K,$0B:+4QE"MZ
MNW !DQ&O%4(?"I=AJZAP@TFT.^"2?+-(7[SE$P/CR#_.DL B1:T>0\&9X$#+
M->&X'.DI_XH0JC=18W(%5XCKP/G.T@P+O!)$%^9M)\MPCM=NR3[G.8+R/&D)
MM^;B?Q/<.(0/[2.$VG ,/\#X4 '3S[O"@#*'T0!I"XKSE5N2[FE/IDYY'F0)
M"\T=%>4K )RH+BL ?K?CWGQA8-5]7"O=EXCB)E.#<$3GQ*M=APZFICDIH;50
M,%M&]#35+*?[17,;HS%@VS/'U\")+ 3TL9:(F6/_N@]4Y718M)6= (EF=9?[
MW:R=PM'(.*,2?POLHQ>7J5S#WKZ,W&TJ;?4P!9L XR(3Y>?!@DOL?.[[MH(>
MF=BK&2;R"FF[N1H7PRIKZ5X:E)5O_TUK(%!OLR]V$2:,C:%T%[F K)-,C@$/
MOVG5RPO%ZI)VT-B0?@C;(<N_Q_C)F/I^IBSAC%DG6)E#)'S)F)+A$=BL,[QC
MXRL*FG1.'0@J6\X]$;B[N\2&.:B)^4\HW>C%<2$N8MAR.@CPHN^$$9VZ+W!V
M).<;H>R]5<"%,L@1Z*#!]NN9$)1BZ$(O6&X/_Z5[+">@:1UH\I.8C'^-BZ-(
M45#=\#*45\-]3"XT-LLUAS4W.B44\#-_']G5TYISL'Z:M 9IR^A9D?MNC?[8
M+4L '>T20%]Y F@T3(E1VM.@C[9&!7-\V6I2[>+=,\<)(3_2+-"$KSUW6$K
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MAX7EO^&GB3$PF<NS\#=(Y^OHOQT>'_Q5& 6,]9PD#KZ]K& F_/UV ;."O^$
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M!0*#/)M$4"A9$^^HL$)'':<H1?SV3_$QZXLP?AN%%=-+J6[(W/M1VY'+//&
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MPH\:=YY3?%)!SC$'0R1!^4^$**-A[@L&-Y!<Z6##0"5'WE_<4:YQ+HI@&+9
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MS!!B=@^L=;]0KW?^*'[]J3(D)"^1<1[A6KUA'ATBL/7LY!2&B6!GCD9CL^O
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M6;B$!,V"KUFHS)IR^_8Z4$IARBZG4"(?5K#ZT'4W[69,+82RU.O!7/-$ZJI
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M]26MC3A?6N&*<MSZ:#QA2])98%*FUWI!F*X]$4\C07:=="63GA 4RQ^7WOD
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M]UXMZ-5 ,4\DOXJ.&86@64MS"\3W>@[YA%'\A(E$V9[!;M 9_N#*;%7EI=(
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M)\>\+KP3C!".J5A,TFSAEJ@]UY,XIZ\-'<JVK@IT($4##ZX,;M0RBAW A&F
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M;BV0PL .6OG<CVF4\=46G:FP89&(ZY7F;2C;%CT@U=^FB2\Q9L8BM&M6;KK
MB[<S/+*4-,RXA1$<NC6)@H9'ML,9?QWZ&HZT+%5'KQ_R86'")KZV0E)BHCV2
M^E'1K^KSM/3-H+&JM^4FYB/%V11_-^)/Y9D42O%GS3$A075YC8,&C^/Z\%O"
ME1'Z@0O!_20N*F=/?K1A,NN6-#CPO'A($>2H*D[()@@.Z\/E_"V_]F-L,-?>
M#.8DPNI(#KA6FYC3K>Y;N1KK5>6R;ER- !L3E;A.<>A!\@PU[ML4DP9$-5!W
MN:=):NO0RR8L293UX,^!L8M'H.F6 <,3+E.K-9B<V?=-'NT4/A+QI5GY4GH9
M9F]8M(C^VMFPTC!V&A0'@K,*6W[!35#-9EWMEX[+ )DI)+0D!(-@F6**C5NH
M=J76+N=LGW0UV92T&\/CJY8*"I1DYJ9LR13KP"4"P@53H%0)OQD#U_ 9">'
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M[T"J&H3.@(PSY=@WU>3FON%L:9I["Q9&_1AR]3YKK/>2*<H@@40.%3*DK1,
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M,7.3--]R:W4VL'MM8*HE0Y:TI':\SL19N*,9RTRM.7[6>"V:!5/1;0\A 1Q
M(?O?I5C.K3:^7O7#UWV1$<J,HL]EH<8JF0E@62'$G LVLQV/Y$XI:+):0@V
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ME55)B7F!\4<QN"TF> /WV.]N:CHFUAAD34]W/#6U!R]G%.XHJAGX0H$M: [
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MLR,=)Y$GJ*O+?(G9OC&R1)JBR9EW3/8#4X,(F1VF)RN2+LB9,9&$"C7+Q/'
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MFLU%KMRWJM[CF= 1$;7,PC1,_QS2&B6MI@)GMZ=F/";T1A(=%[8WPY1(8KC
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M@7Z4PL**'KX6L0J1BO/4S!$>@B[\UTI[J&.ESV'&,K(@"*C[-,9FX;U0::E
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M6603'*D+SWBF$%FD5(L-*RQ[.GOM1OA8F!40B)&?\1\\>Q/)=&L!6, H%,,
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M !O<O@ME3C&AA/>\3O\;PJMM75VWEWUV*%',(7#;)4R0@"N0;%,ZA"&EQUH
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M<9,QQ[9;A"OK#TTD-/$>*D.UA=VPAH]AMJ/K3"F3CVR-,]*H3^MU(5DN@<#
MT8FTE2!I%0.>$V,X<F=1BO)_9FZA^X.-9P -2E+.,F4(G&7N:*I51S?VSJ:[
M+.;21H<UVQ[F,9][;4%:<R:P^DZD-Z8H<*V7&SF:9TNZUY:$ ^^@B@]!I99/
MY B0(70K$,(F; SAU6:A^7MN/Z9,95AYT,#05%+E&Z1LR)2,.H(2&-*UE4FU
M502*).)HW1?/1X@@]SSH>K_MCNHYZSJ]9MK\'C#,BUK,3(KWW4XB&17JVH"$
MG)-&GO'AY#V,H\T&<Z\-QJIXAWDM"'@CQG9_-EU1/^Z&LO*^SN-I#L6IW'V2
MS6]F#.-,LCF[H-_FS#+%1A+A!LXNI4$0;GT-8AP$R=(*LZ5>_0X%V>:BU,+_
MN,JR=508#05*0U/OM7,8D=92];D_Q90>N'K,G2DI:3%R2">O&%C/UV!YLCZ\
M1+1Y1FYB@7F^M*E*-OK@BZ%=[B4G>8QE/KWO]=8I*B[$RPS/S$0SFP1S!$3\
MDQ:^]HFMRY,AA:$^O#"68#17O:D^HFC@T" @S2<;E$^Z=MY=FG0KG@8HXH:P
M72;TQX"+1<\NA,_DX$<H#Y0C9;2/?#<@/#H8:BC\!\M ?5P^%?,-FHV8,8Y6
MA0&IARE(C4ZZ8_:S&5.U(VZE_N\R+H9NRWT4@0"QK[HKX!5:*Y"!:9_AC#P$
MG<#]LYGARH8OQYI3X]YTLSDPGBMPPGI55&I%GRU>.UM8K=(&&&/&Q?R[6V\9
MF604'"FZ82291SEXI3<CLW:9$HTQA3[0.075T3H3AAI2GC$=Y9%H".U:Q!L8
MGN5NG?1PEQCJ;Z? %;0%FK9:?="!7>))0:M^C?@H/)6)QX;KG/2UVQ [^:EV
MMU*7PN0$^JPB@O#Z(:,[ W)YZ='D 0]E*+0M<-)P?PCNB\=\23<,FBL>)QW4
MN6ANPV '"*>4M1G_@XV78Z#>*'8^E+99[(G, =,'O2_!)1(JXX3GB!4/ZIS:
MIN4)LI_<&\H#L#.(!M\)-Y]8!(LGM29KS):*#*2)._>B@'XCC_1 "5O2DO.6
MKBX3#'+DPO"PKUI/ET2&EX-FD3#L(EW.?/%&]-=YZJ4+=YG$YB>:MW7F=.[^
MAV#Q!'5(8]N)B(.RT%VSRVCR3[7.>$]AION"_]@;23'@Y.%V\Q^ KE>>!6I(
MHI4K6:L2QTEO,HV)X:2W0T925J4SSPV-;]!I1BY-M<!2!BW#C9)86ZL0Z-Z*
MT-,/?(,GPE</@(P8U(.>.JW'\(_Q8_!.]7)>!1>F@H<$+-X9G1ZFSI"Z-8+-
M,) IB%6QETMAKVK272;(>G>!+4V%<1:_KAH)EW8)P3ZR<MM>)@MWX+2,N8TF
M[@,S8M[J:BD,N#\ @]&9GOL91A<\"2^3%KID^C':U<NFJI<!R+VL:%:T#0]5
M^ZM4X8^@>G/KQAF\NXSSP;2N[MTQZB6Y\<[T7>D]A:_K4"3AA:-Y(L"SI*\(
MVCZ"B[%2'Q!QE<[.B82V %/Q^/S[XS]'J&$CO"@1$TM!1*\;(RL%IB=Y](4>
M@J3?V5=RBL)#?1Y2Z7\Q.(*D-\ ;T^_P(LOQ0D=34!SC)82DW6%/SI(6A8(U
M>3>]]^MBHM6J B5L<4C\#7C1^+&U$ 3!L3<7U:;NR!G %A<7UQ@H>P.]2*-<
M$ZPV:VI@Y%3H8%#0/??5A>]+TBP,=>3ES4M^&O$#'53?"[,&L5=1L'QAK(Z6
MZF59.A<?R7-^_^;BY3GK;RJWH1DS:#])/53H2Q_YL_#\PEWZ3;<\6_QXMOBI
M.F/.D\>/'S]\_-7?%I_39[\0+E2Z#0TV_T<&B.GP)!(Q"3L?F%/ZP>+['\]E
MSM3'G8C_/*/).MNQ+"@?<"Q'^2 $K ^8RVY#(.65P='2P*3P^_A!!\;*TT_&
M\Q] YS<9.'0S0&EIFM]9A8?R1C\87!G="B92&5A/R_C #UCD]<A]G2U^<,[O
MBD9Y6G,'9E"(CNW!&HENS3!.=\_4TIQ$2\2(Y,:N"?RKY(G>I^(@JU2^A_ZB
M%^76;^\V84BZ;&<\LF0#"Q-GX06N]+31$1K,K=*1N!G_ 5X[,RW24<B H,+'
M5M>$QG:_2.(4:7LZXZ=OB*A9SY.@O2K[4':J91W7INE5O)R>)ZV@B8YNSRR+
M',D-@D?G%YWUY<VE''[$-,$Z8$)#(;]O3^)-50>#.#B/"MZS[ ,=2O:5]P[!
MO*?-#,G<>(NE]!S)Z+WZL![CLYS,H[PHR/?LP\#<)C9?NVAHY @J4WV^,=/Y
ML9O&7>S\_<._GY\/+>FTF\[?SDWG/PEQSDWEH:_^]K]6'GK=<8HG]#:CF&C:
MO+Y4Z,**K%BX\."R1 2"Z0\9C_E XSKMPN6F&YJ,95P^4W?PL$^^R\(8NYD3
M"HF4I1+#9O<<V,11ZBG);-E*/=#M'?_OTSJ1MW\"I\]K2M)3XDH9??=1V5B=
M=FZ+5DR;0._G7V?_#.V,=*5)_R6X&R];K6+84HWY29V7XX'2%15?R1O;ECXS
M?FOTKN(#K*UA;$6)P3D+D(0W/)BS%; :\DT;'D<I9KMK$>^,']TU->X>N1U?
M/2*#HB5*5Y=2&*DQ>D6G<DFLVU$GB1;"7L]/?%TS\TV=9ZPC;PXJ.S%7Q;LU
MSPQ=*A?1;<*+  MPA[B@'T !@G5PZSEZ5_(<354@Q(O83-"54B I%W#BF6A?
M=^;//G]UGMQ$F2 H0\_QV0I#OWRTP00U$(D:>Q\)9-(1[W)%V) X_4PU;/$3
MB8<]<ZCOB^QC3EQ<<'GR"Q3)HTR@E%7*(\2/&ZP\!//O+[,Q?^4975AR]2HK
MQGRO%H%'WKR\'1"XA%H:%M%YX@5)>*CPPD;+>U0^;2G@_U!6UQA*EZ^W_'4:
MCW3O$N/!,:E/-3VMSH]8=N 5(7:S49_2]R0_TYAS3>Q-=0'^=GJL=7$P'3<7
M5/;(63V;]N*=R\0^> &(L9_4<TF:?NNP\I9P43COOTT6?R_2C]6[G<O,_DG.
MVE_[75OG.[<TN7B/G]PUZC9O@OJ$^^/?<R*=]W^Z.'_[\'UX5Y]Z*^=7Q,CN
MK_;_5<76[<>T?Y4H",Z55XUNY_NBRY9YO:8Z0;C,P1GOMJCZEP$SC'?F_0N>
MN6>CP5IX)'=B[.E[:]WC_JV.OG1T=?(FC@C"[J5J+Y1F\I;]& R7F-C=/^S(
M\O4?5E)^DZ+/R';B?30]0QP.K\#[PW_[YUDP;IIG;=;"XZ#F1Q<7]@SGQ;R;
M>MX168#;79!( $V:;0D3)_:*AX#<.GF^*<WF=8 #2;M/HMZ.$X\+"P)Y*:PS
M8B@:8QX_N;,K>&S?6A=>(<8HH H1'S$C^AA*2N!S1CG5A?Z- F+W^\Q^\AY<
MY+P-Z.[>F\.)V&3!KLCD_GC<4+MZ[AZZ"Q-4;[T $9'[?__\;2+M W<":1<?
M)<'<V6'?T3"M3B%JP6I_^K)N<[?GZZN\H:4/FA=4DZ*_9K@=B@Z8O)[N8.1
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M5E5-,2J=@[?^;9DO]->V3SOX$5[(P#] [\+95F^"$GWL1!$M0?C@9C60/VT
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MD*6A&A%O:.!94$6-/@3@Q/O!IT=^4U(ZEWYW*S:H)O^H%]OHJI1$VU.2%$T
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M&ZZG84P?6P%^^^*U$J!")HGPU(MX7DP1VP8U(B5':X*W:;">]@#6U_, UCR
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M&W!%C8MD$2G2*GFE."GF[ F@OT"?"[>E55,ONQ-V0=%ICXEN-SVQ>KBQ&ZK
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MB91#W2S9*+BE06^_!_W@E.>O;#!$4)8OP05,%=JB$NB!8G^)6MZ*BRNB$)J
MX84+):'F]H0*E*^X?X_A,0N?1: P,@.\%*\"&?QRMLE^WF_&PT0TDS21V'C-
M9.(9PJT6SJ"8X2GV60I)SV 5\":V'Z<%PX.(:K=\YL3BCKBE9&T=BU7VRI#P
M:1T8E"0*KX5;2DIHC-;%1#90&*1AL1098A<2+^J!F)N.22=$W:[>CCG9\3=9
M[+3L9_8P;(@3B+:.%)YIFAEQN! P%9<07'"Y378D\]DN9,KIEE3_3^WAED*?
M/9YG5.J>3(@KWN/,(MJ')U0D"T" I/6W4&@TSJ+CE")A3'N2IJ&1 V1\]$I;
M=KIL 3 [_G7,"#P\7S3Q/?R9"D\\"30:;MNH8 B ,H.>1$T=E0($/J+(F?*K
M^(J-*U^TGWTQLB?J5=C;)=C 53FQ^ZQO?#E6#>J&=;V)EN5Y&;59ABXQ!U=
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M  ]"_9 F3]PC0S@?P9&#QV;I$U7:8?#X6WT:_F]PO];NB4H<]%)^2^+7 U_
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M7<E%@;K[TO.ISFK[E.Y@18,50=)_E>.?VPE;:E/V#[,Y>'P.X3N8U%:;E,X
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MZPXMF=U82<'!3@9;7]8_C79K]I@Q@'G@9[/.#+G*)+;12 $J7(3>8GK,Q.[
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M1)^&9.%<SH)3''U9I!4Q6,N0NW3BN K!"Z>$"&=;])DX;\K)=8Q*TWPM_S"
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M_/%E/+_.S>A_&GO,1FKZ7@ER1SXNRI9JWM O[1#:M+!)=CCMZ)8+13=-W$I
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M&!Q57 #6T01;X,=4N[:C-U19[6*<<>:4N9JYTB %":;Q R\G)^ WD"@[ET$
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ME]T9O4)RW!@ZA"/A)Y%F<Y%#)P@.)07LQHM- -1A0;A76+^PU6<+HD 1'E\
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MTB[R2M4,5H,*'N/B_GB/FA48T[5]6GM,!Z/89;!%V@L97*GZ<;T'P4,Y*"(
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MO2%O^ZY,\XFI 4GV (GFIV[;C_-8W=^+SO;WAXCS:=O1$'$.\_>%[_??<=X
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M.ID'"QPL\&'VP)-H_W =',M@@8,%/H@%'D4'9^NTT0T&.!C@PVR!T=')4S;
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MP))Y5I;&<P,+QQ$[1N $QJ!8@>H-I!M$Z-9A?Y.B:LD(WJO=:?NJ9-A8<WO
MS_K&(WQR6$G"L2U.N>&%>2(,Y:^_'5E']!E>Z:G/2S9^&4QA(Y_%C?$MGKH+
MJ4<W@9]-WO<[#:??T?[_%S43DQQLLU2\5W\L,)VC(FF]G%=/.1EWY+3S&]N]
M7SZHB^9_LU?[:<7;]N9EKUH_L.M38[9L?R4IV:\P(??.1+H%2ZG?:#^Y/(1N
MN4.BIU+BZ5)IK58*+S(_^%F+A99 ZBVIK'&>@F:;KE(8MT\4LE<CI#=)3[JV
M6N/&=LQ9?\&S7Z4B^)#._I5%P[,>_Y <NOO0@VA5H!S][3/'!"E]-'7#E6;
M[W,!^<89P9W 6HT_;LJC]=)S&5?;[7SQS,K;M7N.Z30W.ESC=<^O[LY=T^Z!
MT"Y.O=QL[_R:=&O27>OLUU# =I-XU]APWS+[_8VVR=M.\MW61C6KG]P0TW#C
ML7$5QWZ*8/8/W'A^U<+QE;>&\U@[JTPLWUI)6./4:^.4W3);UDYU(ZAQZH5P
M:@V!TS7;[9V:VG% CL-%98 +F&8B0:>MRYFR4>U>W.7^E&O@A^TT-CH==/'@
MUMGHYNC@EQJC#P6CVXW=Z1]<8W2-T0^>]-MF8Z,AD&W%Z'?+4'K__#.R)$*K
MB7Q_X(;/RV2V[)>G?,OV5Y_E_NSO8,YRPWX >YNESC>1"C?Q)GH7.ZS:KK7(
M7=(B5X\F]#IFL[M1PVAK?<(U?NX@?G8MLV]M--Y<XV>-GQOU*YFM[D9G^6Q_
M_&-WU)L+$88!-NF5]?NRA:W6 O%Z60KY(6GS.QJR[O3-7J<>RE CU2:1RNF:
MCE4/CZF1:J,J0LLQ.[O%J@[) \)U9-2]=NP&JOE9/ :\B] =C_U(X<\T\(NN
MKNXM=JJH5?Q=4O%7WG/3=/H;C;-MK:RHL7,7L;.YDL)28V>-G2^3I' 0*0J'
MX4TY%33PA;4@<J1,8]C1?^F+VCC908NW97:[]4CG&J4VBE*.O8H_O$:I?4>I
M-21/74FRK3K!%QJH$D1>/!7&6YFZ^&Z5U,6#4/ ?[-BTQT XV(W7IU^?_B&?
M_AZ:PA]IL$^:2<E7JY4[:*G8ENFT=DJOK'%J!W"JM5NQWAJGMM_\?>O8J^3
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MR*[+. .AE3U+WD--SL^4;KDYJNVT3:>Y?GWR%@6&:Z1\7J1\Y8+ZKF4ZO>=
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M6RFRWQDG('#'0;;F,*> 'YW!HZ5^^"RHLZG!>6O-% 0:6M_D;!A_@K:<"'W
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M$=F2''DI'"]+5PIP4_2OH/' >G>#]#Y58:SS(TJ6@)]SAJ7"DBJ%W-(Y [R
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M;Q-AJD>3_!K98KJ6]4+DOFD&V^HT-^"+7$E6[+?F>5[4-NV#OJE5:NVYONF
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MMW$N;;GRT3ZUCTU(^\]N@<Q))P<]@%8$1.Q>@\[//!UHS?- [+,+!G04Z8*
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MEIFCXB>\KE BR^_+[<68Y@ &)UT@YBS.\I&C& UH>),?@+Z+4113(S=3*QZ
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M#UR,G1681(UD-E6W]$2G^Q:%!NK:O[KV;SMJ_YZI^$Z5$J YPIZ):A*3,JY
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M/!5/<U"X'JKE'".8:0MFB1RVD&)-D$=64,="_+DNN%@@::<)XB P]QPPPI3
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MNDZKPM/0V-](;DIEG\1HPT/CV(9NUWN#EYW1VU>($D]A+)[L9%^0Y[3R4HF
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MTSXJ;0Q($>DU SFXNG<,<,X4BPRTA$[2604Q8U1KH2!SCI -80:GA'2F<9^
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M1G,L/0]_$\/%QF8JXSH!W8&@[,W])"F"?7J?$901E,, )6D'P:4-H*&04XP
MP))*8FT#2HB%[5!D' C*WIQ8G%+9IQ,[/%".+/U9,P>\N<RJ*E@U')XORC[\
MU],%'_MNMX7EG#DG#81*>N#Y!GP& -]I;JFY[W5UE&;G)(_JF)*4X%$LUXTI
MF#& 1[262ZB %L>1T)I2J$7 3)/1E,&4P2[[\+[@Z<V!1#)%+((G@F<8X$&
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MG[2W>V7=[]>-X+[3/'J!%+0]UY(P\E/;T!TO3)P,<^%#D=]D6Z;;2Q/<T:Q
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M/@$S;$H9M]7SD\BVW,"RG,0)DMBP[+9"QW5-U]BKE-D0&F^9$K /."-S8)W
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MQ@A')T)>5Y2C;1B.1-%V#&?63@G/FN;UH[K)G9P@SRH?7*-5,?343>/ R)+
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M"%2J+$CMP#5T0Y@AD1>$MB*9/,?RHAAT+E?W[22R/3W-A-V?NGKPBD0++N]
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MPW6-L0Q0%GBE1M,"_;XY2[$<XT+[P% [<0->QX+A\= 6J#"_J4A&'2/L+Y[
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M,7:VZ^X)1?^A<_>W)Y)DW!7\#T3_W+(D]Z;M0RS'7;2Q.U5J7\OSABRH:MV
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M9>:'5 "ZM7LT'5;C(55_Y5E_5J_MPB=@K@GF%F]8,O GR.L1&"AL'^"M<+:
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M$CYXU2@*($E9G-3]PT7Z,5A^43.JRR&6GV&BS&2-GDX0<V<\",Z( W5C]E<
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M7-5MZYZBH_T,E)%ON@N(34>P&FC'T!Q&^9+V@U+PNA,2;?8P],^K0P4DQ>8
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M$NY]*R1T_< %$FJ[8DJJH;TGRV^9WV#"*J5$J_DLA][;%M[:MRT[2HPX],W
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M'D8MK-1(+1&U,'S3BW9T.=_NG-OIK/#^;H;+VCB'?RS]Z63P^-SMPUETX[4
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MR][UT%/"RV,27FX'#L\B)]+-,(G"P',<RPI#(TX,V[."1-<SPFP\+N!PY['
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MCH/4COQ -V.8EA>'OE#"_<B,>D;]L2H9S-FP:=$,%&1Q59431]W6$P4,!3J
M<+%A-85F>UTV!=<TR7C"QCO4-T?TH10%2 ^HF/E1JV,"\\+43<\,=-L&$] R
MGE8=8WAWEL?8_M[+8_2]/_'TLJ=7&;WV&-PKF%_+M\XQ94H<K$:(^6)O=ZD^
M*DY_5 5U^ZRH6DVK=0.G[-:2JA^)0W[4LKJX:E:GK?\AM_[7NFJ:G2KT<XR@
M=89_UV'\FI>+$P^<>.!'YH%WO74X\< /P@-97M;?E?8HSO_CYM$RG]K61(%3
MSNRI\NJ'K[RB?); ==NJV4C7(R<SW,3U8B]++-?@#?U<TS"-X'GRC"R9S&+=
ME6<T\*U^P\<?IB[K)+%.$NN522Q9S'3BW1/OGGCWQ+LGWCWQ[HEWC\)2,'33
M;DNC34^/PR2U7#\+C<1P'$OG@-.FE02]VKCMI@)Z2,A(2,IF-*N:=7TR%PXF
MMEX7C -&V&K,=U_U"@Q^<'?K7> -+Q*<@4L@NY5 2:H'1FB;:6"Z1I(&MFOS
MO#_/BB,WNJOXIEMR$\XK6*M_%V.,VT98Z[!=$/W!'_>'3/]\*[/4PV]E\\>D
MFHW_D$F/DD:[;_N-\BCV(M2<@>\Y>Q1J1ZM5G5CT9;"HVQ;0>[X)3!E'L1FY
MNAG$CFNFG$4=/<!RW0>Q:%NI1='%-L"'<>:H #8I/N??7@;?FL:)9T\\^UP\
M^^8NIO7;5C*6;UBZE[A6%.B^%9AV%/-6,FYJ!U$O"/!8IL7 ^,MBVGT>LWTJ
M?PJY[(O/?_1DQ9?,XW>PN*&@XT999&6!'P7 WT'BIXXC@&W<,+:2'CKNT^K6
MCXR+464.@E=Q_/XX>1S5?%[45&RWS)=%?7+*/DY^[741CD6PF7XKV!)7UP/=
M<*(@,Y,DTG67XP.Y2>9$/:"49_()B-];,OZ(5/R^6KWE6 G_6ZZFVUVD>Y-[
MGC5PG3[XQP'<GT=KCIQDP&N5 78+EN1'8>([AN/K%J*$Z:$?QB(RD=A6=DQ.
MAZ,0#(YU$@HGH? "A<)=7@U#26WT["2P/3,V73OS;<]R["P3FH$7A7MS1>[#
MJW$44L%\#J'P>KP@)RGR4J7(74+$;U4+L"R\((G<,#:LU$LCS]&%:N$DCGNG
M>;%GO\E1R DP*SQCKUVXCTZ#>&V)$]2F_9Q#HIW2)EZ_[]<TVO".J=MA&MF.
M;QB184:@#@4!EV&V'Z=W^GX/["(AVHR(- _@^_6\@6>]"M?OB3-?!V=:+9JP
MEUF)8X1N:":NZ<0IL*/'390LL)R]!5[WZ;@X,+ONTUUY8M43JSZ)59T6<]!U
MDL#+_,"T,L<-TM!-,EW&&?S(/D9OPIY9]9 -J$ZL>F+5)[&JU[*J[F>6[3JQ
MKH>ZEZ6.[ED.9]4HB$S_.]GL!]=S_;T:Y<=O>[_T%(<-8'<MORH6HQM";#^A
M59S\D:UL"YQ6#3%\([2--,R,Q/==/X@<.[.CR-=UT_+3]#O;\K]?_BKI661U
M8;>#_\_>MS<GDESY?I6*MF<]CD!ROA\]<1V1E5GIVS=V>L;=;6_L7PY:*K7P
M(-!2T!KMI[^9]: *@02" A60L[N] NJ1CW-^>=Y'C:Z5IV[WSGW$=\&>E"'.
M(3#_"3(_AG7^$X%:&P02@R2 U@*E-,V9'P.;R.7NA%TP%[P-(AS$E1G ((#!
M@>,;,&ZTJDZTY@DAOH^IU( 8*E6.!C2!5JA.6B3>2#XXB+,R1#8$_'AK_%@'
M'[06)I0"",0V(58RGD@B$&<Y? @+K!%K@R;W9"5Y0PVB32]A]X2&4PMI^+G1
M/B_8=4_5KHNYK&T?* 8,:^  *U; 8((UJ\H_"$:6^E0=V/:1$V31)]KZ?HNM
M@1.F)V'7#1QY&API&\E7C%,BI(PQ5Y9QHP0K0ZPY1")^;4&6@Q@DVF/3X \-
M7-I5+B6-7O("6^7X4R16X 0G"F)1E7>(.=%K_:%O82@(7!JX] RX%-=<JJQ%
MEFK 6>QXQ212R5*Z91H:"]]('P]2;8A6* HR^%G=N'GYSLCCFZK5?3 O!O/B
M',Y8G70 -$^HL3%1!DC#H8H!J9(.R ;FQ7W796A0\R\WIJ#E]O*K3]N4&!C\
M7!E<U+D+0FLA@> :"$@UAB*&I5;!@:!)IRH][HGK]ZE:!*X/7-\1KJ>@D0;!
MF5)< (X%$"8V"<85UT- DM8L?JT650A<'[A^OUR_IIWE2:("JE&!(B@$H)!H
MAE4<*VE,7.4Q.HA8&YBXKRH)1R3D;TM!W3=\G  0G/7\%DD3.]*\'L\<[^[4
MK/<(6_ULN@Q'WO*'-I->8RZT1-12@Z1Q^IU.9%4U.):)KG#=E_/-^_T\[0LZ
MNIY#O4/2;$D W%OK'T)1CX)6P\#7[7\W6P %] KH=4[HQ>IXL838)#%&")%(
MS*1F#%0-RP!C%!W00M5&2@MMLQE!0+. 9@'-WAS-UN7[4%'#62P49XS$R$ED
M0."$"EUU/T.)L:UE_VU@>FLCXK[5MHR;TL.K<G/>EB_.M#%+@+\S@K\UZ,=
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M,7R=[I; ? + ? 8E%! 4-0!9AK",0<*H%@DV"=>Z B" E6)[*,TE-NCCZJ.
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MD?]!QCW2>( N%6X]WXF'3O"[K<^IU[QEH"&M640P)B2F!I#8,DF34EJCL=/
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M@H&0 +55V%0GHZ,">@7T.B?TXL'\$\ L@%D LV, L[66,2F#9:Q-@CCQ_*"
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M,!6D+HK)F9)4*$NH()(3'EL+*S<QIGJ=P:HTUNPMD 7!'D>M9D9V+O,Q0$F
MDN.%DH9[5T =$V( DE ;X_X%297A@#$Q<&LH:2?6A/48"!7TCRDDN?(2W$_&
M-VF6N>WJ#Z.;=*NZN"< EJ>=0%W B6@4I -::$T$Y(1(2#6@E9.* 6HI70$G
MGEI^;1"+=;2R;PF%]P1N4T#IK!P2..@8.$B"N@(!,4A@#9B 6"/,$P-I68&
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M[K']:>3>$?7O[R?C^\F@/_5M9R?%$\KGNAL="!7#6GSDGHFK+A$2Q\!H &/
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M<".8IJ,HS?5T=]=-.JF%2G^R[?GX98TX&&TP8=A*+(T[?QF#,;.$P(1Q033
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M41]<X0AN@?R*8[YT>WDH*Y2W7%@<W*6E<3^OM=&DQ1HE:]5JA5Q44EZ%I Y
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M;VV:/:@8@ "HLT5CK1DD%BL,8V4X,4;%A1B@W.7D37+?1:=RWX4[Y$,ZR1%
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M$%R&JEG!1A0\(*?B 7$(6 .@$!(#;8EF &!A(6"HJJ:!!'M]SMO^$]:[IY]
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M7"L2D+IH'FK&$TY3'$."),$\5KI$ L!X_(J]T$_'00H=D ,,7 ,,L+K$7J8
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ML4KJKGR-W.1&O[DB<-79K_-4%-S!_="NU4DX$5N"DYIHREB'R,20PQCC&%!
M%"[[(RDE,<!M^4,;W"'76^VG<9Y_*(7ZPRCM3ERX-C_8*''Y__:S9W$5=ZP7
M&#@Q@I)?H)(S6*>YQ0;'%% I2*(YH%#&92I?3% <FU-2\I?93+LI.7Z=F$@(
M>[0T3M5W*?&^ELPE(3Z3J5B4E?B*@N"V7:[;)FJW34/&3((LF$F2<$&IPJAT
MVV).%-R%&?.3E9L/1?%,+6JM1D&6(0BN\B=>@_<6%/"-TO!>U]80C2I(*HTT
M /-44: I2U2"R]ZLB=*ID&WJY_[QE6-&*;<M].F;"><>2YEG_V2C?LC[::>/
M&;9RW!_/7%W (8AUH@>*>QV;;YN?2S]7%[B&_1A+D"8)@QHB84RJ&*U@'Z$8
MD;<Z5Y?MG*NC#A/P:'O$2V3G- _> X@&$ T@NA>(4AK2+P.(7CMK5_&G^_F/
M@ZE]6&]=58/.[K*)8^MRI"C9*"^B@)^LL1^]CSZ,OF5ET-!5!V_H6G^2@R]J
MN)\9W0_.@WE7_* [])^]^XOC%OMF?>8\ZEGUZ Y&T>_94Y0]/ ['3UE)S_7@
M"^7RR@F*Q]V)]XCT8)+UIN.)(ZF:WMN?1N-'QW;FE/S)\3+UW;/\-?:'V>#1
MDRKGL]Y]]-AUNCBP(YQZWYG_-?<D9%%NO:[)4R>Z'8]FQ=/[Y5/FO[O+'&-:
MUW[[^&C7V$GZ3;0P+$>ZE4T+%K/>T/XQN!LX%JH\FDZZ;G6BW&%7R>'FJ=!Z
M3IGM3Z;-@W,_K%Y]INY&,IA+2/U"]17N1E]'=DWF)^LE39K]UZ=HW+-/+?BF
M_!LV;I874>F\X)WN3GZWWV9_%,^V*S";SNS8[BP(E7Q5-0E2$?*P[S?-%^YG
MGU_<IZCE;PS8_O=;=S!TG[^W4/O>SGGFIV$^5[[J/\_F\^BGJ*#;JNCOGOSL
M5+1+]0S<5XUSW'-\;YP(.7X["]\3*[W1;&JO_J=;@]O)^'<K'O^8>9X*3_%E
M$>9]UU?%5W/@0O??YNWB"PG,F\.Y6<6I-30T7;]CYH+P!&" %!*<QEI+PZ'B
M1" )8(H-<"7.^["2>"UO![X6P0JBFV@_?@R=W?JF0L.QV]2?Y;HPDLJ$,B23
M-.5<(Y$*47)=&(I2WN"Z8!)0DBJ2*,=MD0!.DBK?*0$)YN_*<Q;'635]\7/@
M,E6&&T2TLO<L+/AV#I)='GO(6Z-WS\O*\N:_8*QC_FH;W^=L-+#:]-FICE7D
M+]GD(?II;)_3MVJ+ ,+[\5"!QU6&DN/8-SM.\EHFK/DV7.VYLIT]]\/(3NCC
MU.^0CHY$=,I\J@*>?6FFWPSL=MB-AFZZNU\G6=%BP.\O\6#\R3>6B1+[R\$T
M^O13$I6<B$-7JU[N&$O7SO=MAY#=XY':84%(QF%=WF4,TQPD($U10K@$)N&R
M@@#"$K$,1#_9I?IX5XS-WL#O'3]W_Q@\S![B\63B"6>2KF,$6=NH1_P=UWQU
M"S=9H+)K/F4;E]V'7\R.9':0'H_:T.YA7A_S4A^G3A_](O_P;I.J6GNM,K4&
M7K+R@D;5$>!9^Z"DPL3O'^S#[J.?/L0??XT>A[.#&2RW2 >J4\%T+"C "4SL
MMX0@A"D#U<EJ2M%*:8Q#^ ^CW,*]DVKO27Y^G&3=_L?1?UJ#P=DHKB4>7)2,
MXMP&6\T#\+W])P;[R4BC45[]K,5KQJ/^>/3!3?9M=_3[Q[L[I\_N9WYV=^B/
MUY2V+1WR^,T:>5MND?=R0;,FJ)48^ZS"FN].K5#E+3!A+ADFRT)1QW412J%F
MF.*$QUA(@VA2A20HCO%*BZ]%H7#2?YSE7UB,]U81?^S/)HZIZMV_TV6KPS-8
MY0>OQ9R-UB^#,Z-=SFV!\!LWZ(H#>))5R2IWX]FDHCFU1O6<+7B. \=5>%Q;
MA"G32L78<&6D8ZV-I:HL0BJ-3A>.:A<7MDAY'_1*OM-/D\'(N81#^[GC-.A^
MS8ZU[.VHJS7.CZ*OCILZ<Y[RM%M0AX]++\OZUD_OO=$3%0AOM=KZ2I/<NLR5
M=^[$:9%$N5>8%786,^LKCD?%%M(D<G,&8/F,GRNQU%XL/U2[S&!>/-80.^>S
M329.+[8(L%O%[F!4!QEZUD8;/[C7MC)M'^"6N\@Q=Q#UO>O:VCGOSOKY=W84
M=@6<3^B^&V5?BS]ZXV_9R/XJ+SC2/5NSCU'TL[NN(_"NPP/5QEA99=[7+=_$
M7N \YWQV:_WH@=T&+#3>SJ91?YPY_NYIE2KOF;OOYN2)\Z<7CK'/KQ^7--.-
M'E(3J^=NIQY5A'D3]YYNNB<U3;J=YCNWI1>$TXT1^'A!,26#O/)1[*,Z#>/0
M4Y9;D1RZ8$?7XD1%^SZ>3:T C7RX8^9_.7UNB>S;6X09/#Q88;%+;U?7285G
MGR_6?3'NX ,ZWS*W'MX6[659W\_^D0U13&I#5&J0QCJUK@O3,51I+&")/!K"
M)%[>53Z5;VDL!#M:9;<D'^\<)!T=9O8E4X:$K6F:VQZ=\JKSXNEH[:OV9STO
MU'=5$-""@'VGZ9HZT1<^MPRB,P;[&;=OL2=K\\FYG6_JVR?CD3_><&!7\+Y>
MHU./UW-;[N/45_1P3BW8HD\_\)3L+E3\V*VBGD=&/5JGX4-%XT0SHQA,)*8:
MTW1N;T'&V?.VM+U%IOP&L<;59HV>N(N7+32QK02MV$J\M+F+]2QS\K;D6%G_
MZ:OS;-W]5IJ@-V[FOF_/;T?']-N[7[].G!&2N:AV8;&6FV[)<KVHB54+@WG)
MG9.E[ ]KXPY\2Y+H;F9W[=)B.[8<U<?$AF.!&'91[QA#*G7*3)5B29*4GKT<
MU;T0*M/NZ7/7\447*:'-ZS_:J]5P./8G)Q\?W<SMWFW9NBW?K#!\&MHI\6[,
M;-)SG4I4%:IK4ZR/)]4NW\5B;3D)T=C/0O35V>%UDY6!'8*S?A_+,=:'@JL;
MD#_0>2PFQ_[J+IN41K)S48L#.>L13 ?3F7N2O>GM[,G=T-[;V693]]-?9_9V
MD!"U8,'.3[)4;UJ>:KI'1A_+A[S[RWK')<\>!BX.8D?YY/R=_S<;V;M3;][,
M\=[^;8?D>S<YCW^!_&U^B6>>YI5%O#QR[ZX7819W3>/6';\E=^QHAEENO?7N
M9#BP7U@?J)S0OF.&[CNYZ?ON1+WBYG.BCO&D[SV)RH4;3'S<,-_T*OX$M/&I
MW;3<?)6K6Z[=?_@V&GFGG.2YCS:8]&8/SH?HE39@64A<_: XVLP[173;N3.=
M*+_O3K*&5/@M<WY2NM"RQ<>M>W47]\KO+<:RX%?,HR8+ZQQ]=VV6C@V9LM&;
M)]8J3E!,.!*( P$QJR@S#.3/.AP.EW[)IA_O*L\C&>?3?-7QL-AIY<4Z'O:?
M&)X C+;@Q2""C]HBZ 4^BP.&R)F01;NOIEDW<RW0NH]6YO[P%UF,.+)H,=PH
MKA0XYH)+#%-N&)1N/RY$BVG!%@L>/DTLD%G-=!4.9CQ)[$MG?=?.RBY@&2P9
MCZY$MB"^.>:F6,#8>BP:E)J\>0LLVMF5[<F*U [_[W[![/_8;6)J-]B\>.T\
M^N%=L9:^-UFTN)I_*?K';3Q<'/@HVZ@XM*Y#?%M?LM"(GF_)YY6G;-BP]<)%
M[<DSZPP5_=@V6 /V'>O<$:^=OFF3VP'*WE1E&\)B)QA,RLC:MZSPL3;N<7X7
M*"V3X=/"=E<<N[:IT]M4NB988I0H*46J%),4(T9C7!G8,N:(+JCT+SX.;6U3
MOWT63;\^91/?U] ;I7=+"G1>VEU8!?L9O03<B",>PNYNKSQG'5D[U^G-N#[6
M<;T>2UGT0?=)&9??OQT5PS=8"G[P6-UQX+] 1P;T,@=V'JG/%T=F;U+ Q*MN
MGKQ!PL2!1@)SE'),!0%0XNIX4=!X-1"\J!*-\2;S07UR8X(GZ]LN;IP6*#QN
M-/4+S;4+/*M=[ :B;=G4^YTX>VDK>@352M1Q!RVN9:W3E6Y=H;^D6_/.J#>5
M<^*/.4IH+[>'-=Y.]57IW]B_79>=PMF<^JXR<T5=.8/U&:VKKMIXY ZZ[GY<
M)C^ZP'9W,+2["^WN0KN[ ]K=[9 K>E"J*=XEU;0Z#&DE)WGMF<V+.GLM"82H
MWFI#LZ]H]076M=H2I*C8*VM\=BY.GXX?M\SATO,73_18\=0]2O\$0NQ%M7_V
M3?^ZRW(OGH^UL.!EE*_(=W!&Q+R?LMO)LU'/?^MC+C^[3/^H[,3'.W:?+#(3
MNBXOT7>^MRKHRPOF1N)6,]OGLTZC8>9N<M0,-5&']A@DBDLC)90::B(H!Z4)
M:>U'+= S64QYPP[Y8G>6W'4E_E+4F6BWRVWSU/+)]']^=><*WNYS?_ULO=F'
MV<.2F?B6YN::/+E^]\FUB-F8G;]W]E-9HF/OGR\5T1R>7K+%J9!U1 XPJ:P1
M($%*4DI!0G6%Q8FU$]+=G8JY3+A]*>O-7$2C(1YK,EM/V9-WJ[[!C7_>T<!;
MBS9?+BJ]>D87Q28KTI[*G#8/1XWO*QAJ)CL]NH0F_X,ES!LTDBI=.M?8.C73
M^VY;R;,;);$.)/$DH5PRSERV/28RYO."WCCE:B7A?KLDU@F6Y6FH=W>_3 9?
MO[K%/B=Y/"R!<XU0'IZ^645YUT1(UL=&FV):BF=1)+E!)O^ZCHAWH>XW&&B7
M;*!UHWL?%'&QE =?]FG_?U6L[N;GQUX(&RS0>\OVG47:_17CMFS4[86\W-+K
MGM.%O>D3>]>B>G6%-0F*>*0;2?5]H6'5V<6:$.:6H.>&J]P-?2J U\?FRWSO
MYI$_PS]L+Y#BSP<#S>-D[$X^JS\/,K[=N<P2>$T:">5KL<O/C?.V RY=-RZM
M)$GZ$U!WE#GV6.4.2\I#NFZ=\G9?!GB7(L619U#)RU!N[FY1E@4X\VXZF Y+
M-/.;YT-9!ED["BYUOVUC;;T?*5 C)SU64.,D15(@RB"0:4*KG'0F8O*,'[GV
M'.+7S'X]\)9)42UC*KRL,]B]!?>KGZTB=RW_./FO<JH<D8LW[JHS@I\L9GVQ
M,_*318E?2Y!P:7&Y_]59V'Z;?%'6OB_JK,A1OSLIO(HBYM$LLO'0-S\IM\+N
MI+PW&=P6>Y'];Y78M730N'@FXL\*"Y"N3T[JW<57E=B9L/9Z=;U;OJA:O\@M
M8.07<.T#YOOB<;6@+A&F1H&486X=:*5XBA+)XDH+$H+:T())@ZW(JL!E2# \
M@@0WC*DRZA#IVIB:.\I%$561HSRO,&I>L-Y9;BI#=S2RYE2OK'Q:5@XK@OV!
M6\;;V73+QM#8$59$>9T%4["4=*P/>#MM$IW8FY>;B$O$J11QW1T:%Q6VY?Q5
MG05T[QA3&II9I/R[+-$_7$J0FX>C!@,$KNNKJ8@AT03P1&L"-06&5NG_:9H"
M<(!JI78T>?[QSA-X5?N%U;0R+F"'F7XKJC9[*TRZ)ZIH+84)CA@EV 3D:X6_
M#!2TH)9-^0YF>S#;%U(*RVR].G6B-YY8 77RU$Q7_*L#V&.*3LVJ%&3G#&3'
M;9/WW;Y+#G.[N#,Z72W#PV.=:UW&K7I%2;C/Y9D]1B[S=.B_SQW#9'\AT+(9
MX.J;%QP*VT3Q%"L-GRD@N5VHW.BL+]T8N7J(^ZI^PY6E3?K><;#??[_/7$6%
M#ZQ5A #6(?XZ]C4<\Q0KNV;6-KS-K"/MV )SI_$N[<G79WB/IZX1KM*BO,=B
M;^MRJA93JAS?F-]VYL&^<M,JES;OW6?]V3#;=9'SJ4_CV)ZI=2EEQ*_*7O5Q
M%)GL=C)S1 QE5=.S!%:C(E'ON[.57<AVSD;5)$%H_FIJI>IQ=CNT[N*\!.S8
MI[B"UIYH#"E0J9UC"!0S(.5&51P!F$JUPCSC8RE%^G6S+6>1EFTW'O_5FB-]
M\7=H)Q+2]_Z?=>EAE7.4.&;%=:6'B;?O_.>M9DU#>4-.(6OZ)OIM7KGG*]6J
MB]8+TJ+PS:L/F[_//"-&B8.=JI+6FQEW#8/D*#$.UG#$I)8BQ83)5,0IT@ G
M5<6.HB@&:]/[W8'_WXI!_=88CW6RJJK1J@3@F"+61F7LYB &;C^(T8B^U7#%
MYG#5<.ZM-5$@4%7CU1T>&6Q8G8>> (@DUXFK[HAC0E@J<>6; PH7PUXE!5XE
M&6K^OL7ZEU+R9=R4DXU"P;Q0L+<7BE:P"]W(4X"NJN[!'?55]?K]HK+*WN&Q
M3&(_KG3QFF@+IT )RGB:&"2821A-J^88B4L6;7DK:T&D=A:'YS.'A*"[=*X^
MZBYV^J;<"RW.I@V,UU.4+[RV.-)K.[3)_C'+BGK_A8U^K>VXU6#M#_K^[,][
M-?GL[F[0&Q05)A5ORVQZ/YYXBNY2 %SQNJ,_6"QKVEPPJ5PXV%XX&R[9*V49
M9=:?G[BXN%[C9K>#.[M3>8^F\:2[K. *Z-:-IC;6@195H-_'LV$Q3.LE5@QG
MMT6A:A&CSK/I=%APGMM1S283-P=V8AT=@SL+6"S%]+]J?.LCZIT*YNPGPZ>B
M^K)!]%WQS:V[9S7\#8-<?E*=N+%QV';0*POOD;F?.;/2BG>_G(/CUIT)7B<-
M$RF0$8!SQ;#%8IAH7N[WFB#)P&IB7C7L>5^!>?.-OTW&>=U#XT-U#F,E[G-1
M,/5E_',WMT/]Q2ZL_:)!1;((X1\:IF(+]=44\&,Z$DX:CKQ@HL[I1510!0V'
M(DE,K!*=B(JZ6& =P\T+IIR8+BZ6_^AT%@KB(S+%+4)!IX@N53E8%<85R+2B
MDKN@E+MJWH.A8#AV06?WT'%Q0CFP"%M5#5:6\GO'AFHWI/>][J.C1KN)&KM)
MU;;!7O$<:)7EX_.'#Q:B5542L+W, \[T?C*>?;UWQ"V^]705W%JV'19*D!J%
M1_8^'Q_+_I1YN87XT3FNG.*-/2/4P@LW7[8"2D=-XPYOLP9S35F&(8[/PBA$
MG9V,+0;2A&$98RAUFLJT L$D)DG-7#%O-S2>6#-DE/@MJ??TI3Y0J#I\QYD+
M4W[I_K%/L\Z=.4EN^-&TY:)#D<<R!.>)346ZBRLE_^9(H9[*,+"UPI?R BJK
MJZ)EXHV P, 1)U2G_:L6WW*NV='].%E'";A21E,@8DD-83BF0E5^7,JM%BTK
M3,.M*GPW-1_.N@T%V;D O"77BP+@7*^CN%^+IK,[/'HE:WVC%;QBEE9;0]U"
MJ B#/[,#O;61W-2$M["/):@C%@H#D!H)J$#4,&6LC5PE0PIHXC44@Z]F'Z]H
MR;[[B! W^)S-8PGJY%4HI(I3BT<H293D !.CJI*WE)LU+8:.;AX7ZS0/,<VK
MN=<G%,V!<CTEUBGP5:$C>E-+#OM!>_YQ#(]+9,U @34CL&8$UHQCLF;L1'OQ
M.OTU-QM?WEAT/),]-X-?LY$5"9?1;*VNB:.FS,I@B1-O-[/]P;!(+ZXR9Q:X
MQAX=?='H:1<3UUD)_^:J#>[NG)E8, SF]W53F,6Z'/LV_Y@-)H4]^-#]W4<<
M,I_[6U>4+57(^=?9Y57*\$G1R6).6%CV<GS<F-CJ#-6O%NF*^HJRY,%EJ/Z^
M7+RV<?I_J%BV:Q[ *GZTRE^\>VUNV7NCP5I5D535[%5Y@YUX(<=AX]O^I5-$
MN7PN[J0@+O4+WES()E.6XXQ<H$?T'^PV-25OXL:9\SE[HWINFC<^LO$):^.3
M$LECC1(E$$@4-A8-K-6)!(&()BAESR6VVS&9PG-:;_A]*(9FOURHA5I#[R8;
M]&YM&)OM$;7Q&W2$(]!Y4<,*R9_SO5TNGF.:;9W<;YM8U E<$"@LB8$::$04
M8]C(U(E%#+2R-@<]1"Q*'MU-[:8:S56/)1,'E24<I?>4CZQ4B9QU9?5.?-XC
M#S2_J,]:_3WZVW!\:]'DYP+Z5VG0(2M;/;4.KMOPSD>/7(YK$V#MGOQ^OB,W
MG[Y8GI0/[/QURVQ7E^FZKLG46J+<8JE] <:&&*3;+?U8AR5G\)I@UO,CJ\Z^
M'[+*#O!Y0X.NCQU5%+U-MM_5@U]WW5/%J=O/_J@WS^?3_+YXNZ$@IHY\F[KM
M\:KR*65?#/\N[FRHWA 7@FU1&6R+JF#;00[N,0S$PT/MQW@K71,_% WAG-XM
M'G#EY0F7?";YMQ*?3M74P:K#*/LZG@Z\RY"6S<JC>=^+O&:A_H_ER/V*8&_(
M$EUSU\["'7WFJ!?1JENZS_Y[MD7+D8T:5!^.Q81""0SD% ( &+";EK#>3H(3
MPK! ?+=J/?=%-1'S>5#5$.=M$S?V8Y%_1ZVP^%L3Y*A4ZZO6]WTV[)='0 ^E
MFU*LL:_V;Z[S*ULHN&[()&$<*Y$BF"@MI/-7,71K'*,D-8 E!ZSQ\GF/&4^J
MLO^MR[QZ[+/S2A-RQ'8-C>VO@IG%I,O7:JHE<=T,"0&I.4ZY1+&D D-ME+9K
MJ &+K?["])DSN4_=R<>)CY+T%PIG=]'#=?[ [H=SX ; (WH$2ZTRFFUYGD7F
M:E4?NJYIYEQ!%T,2QT=A7.=I04-CKB3AF.M482HH$H82(#0&A,3/^A#;4+C7
MFS@JUU'_MY$S3ZJV0VL]"=1.Z@(\YHE3N;K5]NKV?5\4YI,;)_Y$UIH-LU'9
MB+ALLM0H_BI*NFK*H&;%:"?J#L>N;X^S"[Q 6$P?#K*9^_%=.1:[51<0X6W*
M?/$.Y4%ND:AS9 DB=>(8EBQ!+LXM"04\-B VR$H0A)H:1K5>D* JC^7C*/W#
M&=FS07Y?T%0X$:H3_3]Y>4D*8W:CZ]G&S@WI,0%],%ICI%<GXD6OW04W\>BJ
M3QI,)$ 2K35((<.*4>,Z.#G5UQI*:JAZP<+-CS==+PX/_XU>'<=</G#,!,QY
M ELC^A^7;:$_WUL_TM%K'+1FR_EI<O^\JJA6'I>%V-QM7 +?UY'/$RF<2 M%
M\_2\N=GHL^EN7\,)H'7"CU! \I0@'"LLXY@ D/CMQR24 R;-LG'AQ#!W<IAM
MD,2#A2VW+J?];%O;E2-V'EXG=AOS)!O,A8V\QY,0R(9O77K4]]WA7;7W^;=U
M-=A9$>H8+80SO"0V3B*:^UR(;;06VU@?VBB2HNJ&51MC5+ZRN0Z"-:%D_8F1
M<TV;#=%?LRN.9+75JZ741DL><XTQ RJ66KK(N4YUPHB.EUK*U:T*-_23JVS?
M+:VH6K9UY1%K 8.2[7[N?1"KJ*^@?'T2;<EK0U @N_E*#91 ")F$:):"JGJ2
M6(OQJ"3:ZTZ2+H 6ZS38LU^M7X04=?6_(BF'@G EDP0:":QC4;6"C6.4IJWU
MBVB*3F@4L;E11#O]T[?@B:B->IT*I:'U(&,>.Q_30DB%)S3&^^#)3NTA3A9)
MSK8O1*,?A#/7UU;WKNVJ7=34KFLXVF(U^=O4!RVBX$9G<SDFOB A/J/3Y?G%
M0SOD=VO2_AA5CC.%*@8T0"GC)"[3S=,400+?UY4$L>8Q$AP(Z0@V8D%26;%>
MJE@H\VQ7K:W/L3J665E]M(.Q2I3MGFSHEV"A.HK 8_*".>>F4&7[/U8 K27V
MQ2IL]-.X(%3+!W63X3FQ_H][V9,;4TX;UR^,'"S5A;F_FP\8.0@8+@@T! 5#
MWHLX IO3M\P'N/2V#]W)U\&H>+WN;#JN/O"DL,4G)4&@O"$<,T$0!!0QC/[\
MUUM7#CIYW[.SV'W,LQ^K?UE9_IIST/[$3?3_?2<KKL$U%(/% [E]0DU(N/@=
MW.^K/2\[YL.V,RP6Z<Z+*H2L4#2EI/EWF1[=_*A83%1(4D,X79+/G=6 '^\'
M?2N0;2AED=C]$E[&RQG?7+CYN^?'6BI.1>'Y^$?D(WS1GX#_SUYSL3CRYU!*
MO'3H8D->?]XD&2PF!L/.)HK)783\&!.S34@VFPMM3=0//N-[/,OMWI0OUP-<
MFV[@-]"-%XC T;2E&40/2W]M2R\.0L5N[_>OD_%LU'>VUGCRXY]ZO2R[NWME
M.-Q;..;9=WO(_ZN._=SMH8V356J6=RA6U.KHZ_\OQUCWYZ9AK]%ZH6@E6+!#
MF S"1D,D1+2C6D((::9U0NV/2N=;JYB;-1Q9BR4<D\F3JQ+?G-I*3BL.MGS0
MA>=A,/Q\,)VBCD!T6RRL#2E[6X595Q4>P#* Y=6"92/-4!$)*=58"VQX2J&0
MK&(K9YJ*;3VGMX&EN!2P)+M1$ETN6+YI9*V%<;DNA#\6"5#]0>ZKT0XYNIL]
M;I@%UQ?EF:8M_''Z[M]_@"YL,7O<1VPN8.^9>[!HBP?;:N"N98S]81O(LKK6
M T/.F99<02) @BE0.*Y86XU>3<=<1,K?[)>.[_*?65^7DGO)9BGJ2+Z:?;P_
MSJX*_R%2U!;,7GO<\J)57]2JKU)-$B!CRA4',#5)2GFA^E03FJPAI'NYZE^,
MD<5)!Y(V'=+ST?W3C%ZV:'?=91.7/'!7L%D<UK_TS8RO2XX([ S-K4["J6 V
M@K5/S"7B,$X1$%Q+&">^L7J9N"M@NB;1KA#NCV7+B&2<3Y=S*B_*1,-DM4[G
M"([P^:!WP(VKQ0U<XX:4B=&&Q!C'P$@(@92EK<>9E'"%EWY7W+@8^\Z:=_!5
MSAO.!SG>-*QVA#'^DDVC7AD57B8DOYU>I]/[@BP-_/A'U!_/7'+J(6D:9WCF
MLNLTG/G9"V(-_LE8NUZQ7%")!24Q3T#9QX0G'#.UO%\XS/Y28O8EFY>0R X%
MK6X4VZ3K-,]< C8&;+PF;&ST33/20$6TM/^3) @SGNH2&P53BI 78N/%F- 8
MP0XGK9Y#GR<V>L/YWWP=S_SSP[I.R)>^87'!_SS[G]5F%,UZU-;*D*+5>5M7
M!.3+\^LRFIU]$+OV[W:AU=^E[NV0LCFTI5!N<6U6BL7V6-W]@\UL(=B\=@]<
M:4WRO,*Z![:S#-OF\1AZ\J$BW1ULYW]R;&WV9R\L1_1M9:OSLJ(E6TD6YWHD
MC/*LIIJ>9 _=@>NG& T'=UNX^#<^;^:9YSQ%R]U=T0.G?J2G/7[(IO?C_LU.
MR[X :"?1.F>OFMR*CM N]_@A4Z,Y/V%:K($[QQR.\YEKM[BM7%="R)@FC*50
M  X3R0FNY)AR21OENB2-C<322"Y2H77"M$B+GRK['XY?5&^[9#_!E0;:+;*<
MW-5-"/UFD#OYMP; ]'Y5?!N,8TL<02^4W&9/S[PM<JMYR=IA#%>'=2!K%H>\
M_-'-9E8O*&+>*"^AL#D4-K]R87.H^;S44$DH_ LUGU>\]%==\^GZW[E0CR.T
M6S8+0SY"J&P*E4T^@DQ W20C9A@;BQL4QB#FJ<0$EMD80BL)5D[7EOW4@GN_
MZ"6LBJB"=]?/A!UM[\,WUB%BE>W_:NJ< G0&Z+Q*Z$1U,(URUP07",PH3#DF
M6)D*.E,FT,KAVP'0*2X).F&'H%?)C#U-Z+RT7+:FZ,[[.%3%H]?IB+8^OI/$
M^A/*/]Z&VJ0N-3-$*9PBJE(-C<#0*$P-I4(3K1-"DF74;HIWT>6CJC$KN]1>
MN*6+.EAL[6;V JDY69,UX$[ G;9QIY'&*EF28B)1(@U3UFA,&= %[DB-F,9M
MX,Y%F8G FHD7 3Q7$WY=M027RUE#).&-(@DG">2'! M.!>%%W==)4H#L?VB<
M,)G&F"8@$15)5"R!66@]TM25JL+-5&JRKL3MTNQ*R%ZEQNUDS<V :P'73A?7
M**@[=+'82)5BK6-D8J5E(K68'Q$I@0['M4NR6RF];%R[M/!ENB$IN4QV'@ZZ
MMX/A8.JZ"3T\CD=6(#L+>:376[![$2Q5VW 0U3@8Q]@XUBIA'7:C4\($D95]
M)T0*GR>IJDY_?K7"-9>YNE7A.52JKC8E)#NW) 0WK,WC\E55.(5HUI\#$%PL
M$#1ZU\><4<VYBG7,N-0XI8FJ#GXU9ZT#P<F591X&!.+RN>O6 <%VP^G!:NLP
M._LPX#X6U:8:G.!8OQ!ICR%#IP+!O-&](N%&<JX5 _9?*(]A3"J?U!"\DK;8
MIBWV+'0VP+=EV(2MY,SL*A^GCZ<!!ZX5!V2- S")%9>2,9E@J0Q5!%0Y>";F
M,3JF*?9&.$!$P($M%!>M!+N6FZ*OU*/[GQ475K6OAW?Q??&KO]^[CA="O/>U
M[Y<FR__S?E+=X]%JS_O;2=;]_7WWS@[TQ^[P>_<I=V6:]Y-RIKI>K_,$$>M#
M02X@3*C$,A9$0*4$P2!)D";NFNX^4[Q!YKHO&6=T/W$*^Z=<& .%A(QH(&C*
MC$A@&IO8  *T$+'9JZ[=%R%;J]B5+5EYR.=SVASOQJ$NZ9\KMC^"@/D_EUJP
M/@QZLSSZ8G_??<QF%E7R3K%9?1CU]FBA_NH#*$K_OXP7R37*4XKN,/H\M1^X
M_2&/?)MX]-?HAV1<\K$LE]76<KD(!;L.VY?!'V.4$-]$^Y%3.#+R+/OX:-?7
MCOGK3UDWS_+G*2CB-%9QFA@6JX0P@6A<]D=*C1 +'>.-C@'&TJ1)PB1.J6&L
MZO(!%5+/4]]L?<Y*Q_CBY5?1O+F&VZEB=GGN(:^]C6EFG<RL(3@Y%OM&8AWU
M[L@Z[+/)Q-Y[^!3==_-H7 E(-/23[/DRQG=W@U[FV2FL995U)[W[:-B]'=M?
MCB=/D7U\+^M$V3]F@\<'[_F[7W[+[@>]H;V#M4.R2=3].LE*_<O^>!PXTM^H
M.XV^=2>#L04>IZYY-+VW9LO7^P@!0CK1=WL#1P7BR7/LDT?9=ZO(XT<W_?9-
M1]4K%K^;-L8TR.W/N_EX9-'8CM!:25U713^VC[:&X"#/]D>TUUPFT^ J:8NJ
M)#J8I:2S+"1SDI;O5H .Z&W@KON7C7X"X 1DO'%T@^QV#17CJ4$&,6:@@JFA
M H'8>@PZ68G8+F)?6;"S,2'GF5-C.C?LV=:PZ(I9']E9&-I_63+O7SQ=-]&I
M2D=3$1^[@P/>:C>1P&PN$HDVL:8<<8D,<:FX&-M_""HY92)-5VC(%T7"93(<
M4Q[(C3R:.'B<[OI>A'D%F7.^L0<[NMG$HZ\S39?5MPK>#DKN),>U-#E(G'9;
M.-(P(!A.-#;26@N0\I0RS)E=.(9$ C0R*Z&_7QT^?[S[+<^4-6NF'V\=P&?]
M#Z/TC]Y]=_0UL\JQN+@_51'J8ZXP@D?4>+MTA47NW??WX[OW,[MXW=S39AW$
M'+7C<M7U-EP)1T[*"30 4Z1UJB5-"1:,0&OSK;3._-1]\EN_794OF;7(IQ\>
M'B?C;X4]<%0(EC>K#=5:7)!HZH<3#1KC*4"O,F4*%;,::;\:?,N<<MK]LA!2
MK[36JGE.(\_#4K%X_S"8%L,O[+TB/3RK;+3N)(M&XVF4VS<96&O23MK-BL&^
MCU=3XO9V1CU%":8"QPE/$I-0H)RH0JA :B!)DR:C'DQH+%V[&TFM@>%::-N]
MQ/Z44,U$XKI9M,&H=_Q5^3Q[?!QZH;1V\VW),YD[GDDKA876.#UO$.JMF/_.
MI.OF)55?WCHQW$+$>AWWV^HL7")SG.0WB -)*624R0-YX^B[S8?3)5$=:9W*
M#0<JM^U43@M4;AVW#62/T\)^=_OWO#FO/UDOC;EK9WS;VEKI")*R\YE86X*Q
MT?W:F\S\'+D1SCU'YN.2%??KQ]\*\SP<= >NG5<H,SEMKAWO1 J(:M[J6+.8
M8T5ES&+#K*W-I&$NXR>FAM/T^6#-4@1@?7I/&UTG< >_3N>VP&RS%9@J!X.W
MXQ^]*DB=\%AWYEB]I'%?C5F2% =\T:,KXBN*^%U0^)F84[!70N7KA52^%E8'
MJ[MKI2E-J%*Q-MC@5''&)3> &&J,$#A9"5UO.$4HE>IH9@?O0+%Z6A1J3D\7
M9G\9C][W7@-J+P!1SR.Z<UQ,:G3\0SQ-8R $(8FB&"7&$(M)%":8:D;A2L+S
M!DRR$M@[,BQ1W*&X30*G$+5Z:]SZ,I[ZK*KU$/44;,%]A;FMIJVG&2\X2C?7
M"X]^25ACOD2( 84!BHDU3Q76E&$#D3%:"8G4"F7I;MDL[2$] QV.7K?9ZFD*
M^DG:KR$P%@)C(3!VX S\EY_0K/^^:\?7_;K0&M4;0:X0,(]^\*TB]SF'OV1#
M:'<7[HRK5:MLM*5MG-;\D%Q+;C1BPA#KL>F4*A/[;3S5(-5\B^M62: J!/#7
M2O[\EXXO 6[:WQL[]_L\Z_W8GTV<F+[[=RANT,;*F! V.GT06L@".M$M^%2P
MY0P@9),K(.IZ=\:YC'&JTR2A1"0)9XH9B*UU*P36R4K2Z[,84A&*N_+WLNI]
MJX^P6KN.=ZY=QS=MAH-"A?H2<K=6ZSGW&'_N3F?V;9ZV9TQK;!**H0&&:<6E
M2!,*#(0:"P1U D0C8QI134D*8\R)1C*56JK8_91#@!%'\4$9T^CU,J;5]'1J
MJ.YF=J&RZ,%:! ^SAY4(W6-94Q%]SR;9?CG:U]JH6\(;A 3@ ')*L* R)%Q?
M0<+UM6=27VL#Y3HMUV^$UQSQ0,"%=$,<(R3W7$YR#P2L+DRE$IHX14SH6#'"
M-8&:6E<*2AQ3H.1* ?BSEG)5M:IGV2]V<%^^9\-OV<_V'>^7:U;;.W:1'8Y;
MX0(+ 9S7PU1XY9;%Y89I(! UN*B8I3*64D$("(>QTDGJP84P: 1?Z?:V*[C\
M=]:=?/D^/AJF0-#A@H>N:^=EJ*%@J%W?@=,F&+*(,X<AX9!'$L Q)PGCE*>0
M>QBB  /!Q$$P=#_)-E EM]3^D8:LYC.S;G"P;B[5NH&X8=W &* T9LH8)3!%
M J2H@!65<&)6$M)> BMF/)L<$U4$:!-53A\\+L"\(<&\">;-'(=8;=Y( PE,
M!6($Q%(IEF D/0XQ%\X!_" <&GP[JG5#!0K6S1E9-X[N.O-DYL'&>?6SH5/!
MGD:$)Z5 :V@_3K%PG9YCDQ*//9QP0N*5XM!=L4<Y$3L^ #'<0:R5CC*A.NLD
M$.J9': HVUI,!0DF53"I*EA#C8@1U9H#*+0PBB@L*-6JB!@)!@PF9%]8.QJ2
M(4@[C+1:9WHAMA0\5:AR71GR?(7N-MA59QL[^F$;PC2"1UB!1&.5:$*@AD0G
MAD./,#))+.JL<'D]BS"_C:H<^*R?_M&S/U6>"_-X<",Z$K<903K--.9U"7 M
M&U(G"T_/X+_'K<'#XVSJ&?.+[G'!E#J.HWB6IM96)&2P+@@#B<0:QRF7BDO#
MM%0)%P(:P3@4Q%1(Z!H\/P^#)5/^?"L]GM^(:$>V&[DZ5 HN"#C/PM$\!@W(
M!<#>"X2\);:/TTP2W76D)X#5VZ!:HD#!L7$=W]89/GXUW:'%4&V\TUX5?9][
M]UE_-LP^WAE?%?9S413VJV_MT>BNL]S?<6N-'Z) XE0!*51L?38$"#15%\-8
M(-FH\8L)3C%&UKZ1]J><4,5H\=,DCE.&GNV6N/4Y*TT>7UPBV 2AI;ZCYU(R
M*$Z^9'!YXD-;E^?J#,$-(QAQ(B@6 $)^]#I#VGJ=(0IUAJ'.,-09ACK#E^5W
M[=?"YH(C:*VK?Z@S?&77$3->1_FP)M:@Y<0HD"22<:.E=1U%(D@,&5PY45VR
MRQ>,^,:!ZF96<=&.1]E!9+4?9CA5/64DW:MB^P( \R+.4+=!BJ@A!2G7I9H!
M++325$%*8^8@12NF)&1;VB%MA)0/HR_?QR[U;-WY03NH0CJ X9!_?U;VV5XU
MRY=LGUUULAAIM&53,I%8BIASJ6(%C/V1-VU2'L=2Q_N:-A:'7&WA<9$(=RAK
M-6 >[)O3+'2^)L Y9US!M7T#.<(*29$:3B%"FL;4X8H$@$N6ZA7VA)UQQ147
M'AM6,&\S&?7TT>,"#)Q]RI:#@7.I!@ZK#1R 8F1,C W'V-HZB JL'1 1KFD"
MS I_PNY -/AV=/N&P9 5?T[V3:@PO (KIQ'%40:E*<,:ZY0SD$"LF7'@(I1
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M]]W15_L#G=UEDTG6MS]2>9Y-\[EDJ4JP7BNC'(64\J!S;ZISHDXATXP@E"8
M6"\Y9A)*-N=P%]+$>S5C.TSGCI-=WF9Y>-"YH',O/@4FH,X,@\A(I$W*.5(&
M)!*G2%7D,9K"O;@9#U.Z5HEDKK.9PM4$U7_)0A+Z2P:^T/X8/_X1]<<SE_53
M-2=N=6;V:X/\NO8'075H@<?<]8(U7$ &F6O/),C<_M!P1[:*@C%K9N?BXV/)
MEG5>8?B#9>1%^+B?D+2%'X4FA:Z2 4,.P1!<^S"8&":58DICSA-7!Z.2*M%>
MZW1'<VI'##G=\X* (0%# H:\R"=KG'$HH'&B%+#.F(&$(XUD"2+6(]-HQT#(
MCB#2IKN%6\W\OR80V=SZ]M^F73OHZO-6XC?%$OTR>["7]!9&-AR,LO?WF9\W
MB,"?ER<*,CM3C>&[([/!W5/QT6!D<<7.-[&_:2-A:A3IK)<Y82R !J&.+SWN
M1-/[+/KMYO--]-6AVL@=VD79R$I<UO??.7[19#;-H^ZH'_V_\6WNJI6C']ZY
MS^V_O?O+3?2E_)G[PD7M!G=6 D?3X5,TR;X-\BPO'N#8@X;=_Y^]+^]N'#GR
M_"IX:O>Z>H>2D+A1/?9[.-NRJU0UDMJ]\U<_B$Q)<), #8"EDC_]1F0"!'CI
MH$ )(-,[6RV2.#(SKE]$1D;<2]</ RF:I,FME.)FH33-4K@*16H@@5*%&<!/
M\V%5_7SSJH?T2C&B(I4JHNP(E!AZ#4K4P'1LXKGPJ^4' :QA55;3E@-[JSXY
M+^J37>H9(*>B'+-_VVJ7K:SF_/^XI')>O+X#*9Y,TQPI&DD38*&(D3 %T2AB
M)&(6)7G,%AWI"?^9(L^DLQRX9U3&O'#0K P5C;($'@5\@LQ(Q_$D3B*LJ2RE
M&?#::#;$OX>@ J-XH6A5F5T*+':R*K]#KMPCKF/9UUS0V9_5/QO%NB'">#*,
M9FT([/'6*TZ(OO6]QTN+P_Z]RZIG3*-;>GR=T>B/X^@&)OHQ&M]'#SG,[_0N
M>]E*;=#UT4N&*]UER/,_Y%88$LLFAN;+EAX8H>61P W=4-9D'T\";$. *[04
M6* !33\F,LR7)FIPQG-UO;:HZMOB$_;QGK_V.AV/X!'.)![.<E3)632E,\ "
M^8"K?- I2\S?R0F<IP48C*L4%YX!AP@M40B"#@H3[ !K8,I22Z32V9(^E/",
MCI8#N+4$-R1Z2>29MK^"N5W2,65*XMC00\7W?%WU0INXIN9K01G(#^40=#XJ
MTF'U3J=X\>WJ46>1@G/I2:8F#[8UJ?PC7OXQ+F"X0W@FMV82ZS/["DN2T7_/
MX@R8 [$!978U1PD=LBV2'/1]!3%RQ 37%.X8I@!'_@,,A#_";8#>XY1]NK^+
MAW?LNS&]C?-QR0MY!7Y.I+\!%@%(-)!&,P8R\%J8R'1,O\?% S-!-=H9,F51
MU$CHS_D"L,%?+@,/8<S-#;PF!\Z1+AV7RR8AUJ <$4N(R=F+HB2F;"HXCXS#
M,9QA8^Z-%Z+QC.IW@JA<1SG,!_Z%5[$?077G\ MJ-@HL!$" <E,*CTG 5-](
M":#$/(\R@&CY[#J'%:<,R$4LHPN^PQ%.P$^ UX]F&;?K:(=12"?P^%G&A+-:
MZ"B7)F"\8<$Y\, UOJ;(#@ HOT7Q& ?#$>2:NVDRRF%9*(Z=+\B#= >/3*_1
MP-/1 -'"-,KP+YQ&!+-^^$\)7)NOG$\+5_,&=,D8F$**$=4.AS@;F,A NIX5
M$I R20$!?P>E/X*A/J0)+AZ5'@!\2#=9.N$,@L-<1+XC\''PUKOH&V5@!S0D
M*JRXK/7#&=#CTP#NN)FKM+Q6:; VT2SG0YO#'_AQFF8X^JKNYA"7#Y;U9C8&
MXJ0W-SDM %?#:[^M9E;Q898O7AHF?-% [.Q)=TBO"FGQ&9>RLL"(-9A;Q' G
MDL_Y H-JS2E+*7.=N2Q&K"_87+V/TQS$)2V?@M@-YE^AOG3N<C,B+ZUS#24Y
M?@2"SB:S,7OL?!8@*=73D*WC41QE(%LOL(=OI7[96"M?35))TTVK%K(AX\S'
M0IK ;.>XES'<BGH .#R>C2K?*IJG:")=TUD&,E(T6 X5:1Q=@XN"JBZ+&81G
MS(!W9Q6>KO1JY:7-G3*0TGLZ'N-_F3#."U[5?#.BP/0C"26XR+@G="(U4D=+
MG0O2T%1JE?8I[J("7E%/'T;"6&Z)/YKLO4D4GX0:"R+TYZ;60+Y:-DCL8Z4D
MELF 8IND]Z4E*6CW>'!-F*.C8*6IU^9\$"UX?I2?)D0JO#)(\*>GH@16'27P
M+=6SK,!UU<!P'3]P/<>S9,,W+",,#7-E^].;95@OL"PF"*Q2'H)T:4)OXF=5
MZIKEHZ;??ZS/W7[C<:__9#5O48+U&#<K5FRY<*5,VEQ($/[A-Y4F_A?8B7P4
M#VO5'NV>1G:CU9-J!L11'<75_5#5#,M2L?2ZC(=8K=6&Y!6-ZE -=9+1IQ06
MN7V"/2OY[60U(Z<URJ'L7//)(,VV?A#.?/M1+/#-0CB0H6^DP2(;;>_AOI?>
MJLS5W%>!J0)R!'R.02U@JFA<H!N048YIP"@V UNS>;2TQLQPU=9+OA@F+O''
M*RA8(;;=1FAUN:[%HJNV8SD@UZ&M.)[G^:9258#2'5E>J5K^:U*[B2#(I03G
M\Q#LUXH$(.UG)6F<X3 #!VY)S,^XF&^6<7DNXO*"9!_G=(C2?0\6+*?)T5^3
M]*G-GQ>O8X&@!0;-9&H]BT7YJ\QDRZRSY+:D,, =,Q&ISRQX1-><0%&(YX1&
MZ&N&YU9,Y%I$63$.GRJL#";\UZ1$XL@\I4^3E]:C7QQ3^HB<<T#I(NO,JMDQ
M_5/Y;!UD'O1$:#'+$N9),O\]QX?JH"VS='9[Q]T%Q./@82:H6.GWB.\H8)3B
M@4TPFA7@$,<H'XL,&<.4QWF*_N2_ /@OWXX^+KIJ7"GC +@3'1<L@H'.5NG7
M@OI&]_=%WNA&V]6RH:JRCALFAYFBFS&;,BP'3H2[/LS161.I !A1W%/*?:YA
ME&4/+&I4NG%P4\3RF9FEJ%Q.U$:X9G6,!+S$-&.+-9UEP'4TKP)7\T?-<KY5
MU+2/U<4GTG\O[-1NQF>+<GTYO -7=TR_W*PD8"/XJX?+]@LP#.R.T^$?1VN"
MRB%Q9=F2-0>4B6%HBF?[9A45MDQ%/:X3R0W5,4W/<'100O"3$9*@[ WD>S9<
M^FCT^<GWD".)@E*9XNX[& 0.1YIN,KJF:4*3VIM=B MLH!<*4H1D8P',CRM;
MXPO,_70,_AG3>!6^V[B%T7CF0H:,O"1C^+GYT@2U\W@A/8+(/'6(I1U(0SH>
ME[\R=8Z?84V&U><U@GD58Z#TG-Y+%^DD6DDTFD39;9SPX8&B2JLO>+(&^^8^
M'A5W'RW[1#-5P]+ U.F*H2H_5CD:0R!7-,WIQ^J/E5VZHWGZ.UR"-/S+D7VT
M.3F>O]"$-U07+?]&MOMIR]MV^;)W/9;;I22T/9C?G+G-H\?GNIA+M9K?U.II
MIA4M9;UTZM;Z;5; J=+_,D@4H,.X$7J\Q5A6L-^KCN'L@#S;G\9I:XD^L#A[
M.LO!ZN8'6KER+J'J.TCHZEILE^2X,R%JNDMOSA<O6 O!--UB&NN0SSSZJWZ-
M.'NPI?SL\2(<[,0%];=S\4AW51YN88PQR((!W6F&0<CBX3 !9>OSVSGQ_O2*
MB72@F,83&S"F7&_ F";Q%<\/O4#5/$]V/-DHRT::JN<&]D*-Z978;)/)OY8\
M_M*MEV-UOO>B/KH/KQD#?<W9"5&(1LB\D/DG9;Y9-,)Q-=N5-2=P;<=3+=,/
M2"GS1'6<=F3>:D?FK8&J[D7!MY9]O0XC'V>".XC_81M.IR,ZS8"8[(, _>M!
MO_*6H+\K^DBK]9&MRZ'O$X\$@1:8JF5[7ID$ DC%\5<VBU=44J6&OHZCI'"2
M4?#O63R=;)$&\FR]I S45NM0=J\4KI#,0Y5,HTZ0L(GN&[YGJ9IBJFZH&F9H
ME9*IA(ZZ4E+V59+9#F)0!Z:J[+5D[EVHY(+F-,KPY%/T71H"^\3;5,@[)+W3
M9_72.+YA^;:AFYH9J*%J*8;BZ57U7".P3'FE9\6*>H$_/,8O'N:[@5:XC[)1
M7O'3SJP_T<C ,/;"+1%2M1=29342\P/%=#P;4+0>@G]O^U9(G,J]-P!AMR]5
M[5ANVQCH\EX(U>'X^N<K^=4\]5BJN$9X%L*SF"LII3X5:!J.+WN^*<NR;]BZ
M8P:.62DITS!6#GZL**DO%==] J9;4%2[<_HM8V#I\EX[%T(X#U4X-:ON)./Z
MH:L[LB6[GB_KGF99:H7+-;):8/]UPMD.>E!PJ\"V]EHX]\[SG^>%932>7,^R
MG)6!$&[*WKHI9MU+5I=5S0Z9GP^NBN?:>E7AT?!47PF?5#+5%_P$\0Y#_8K:
MILWOK&D7,M0/&;*;+=\,0,VJ''B^'AIAJ(55/V;#5AQGI4KJRV6HI6W\@2;O
M1>;. 7GV:7(\C/([N"D=_L$KZ0E_0?@+E1JR2=U[V@C4T-4TTW8U1T'[[<MA
MM8$/>BEX/*$(.,T#1KM$/CM#-L,OMBOC\/P(OCV0]?UV%H1D'JID-GJ[D #0
MM:SZIB-K@6'[NNXHE2<O!W5_J#8DLQVH0/8_QK9W;GQ5KFDQ]L_KU6Z;^7=(
M6JC/RL9H]+D/5=W5+2-40D]S=)W8CC6' :;A/YU7C$S4#!=^FG/0+MU[I<V.
MFYVU]T*@^B%05B/]SO(UVU6=P TUUW1]S_#+IDJ&;ZAVV+) M63 !W*K"7C=
M-].]]_6_8'\@X4((%Z)40JHL-SHQA:9I$=\DBF-;%C%MSYQO!@9Z\'0.,..N
MW7GR^L"VVFQ/WSU_08CAH8JA4F?UJ5YHF;8;&,17-.+9AA4&U4%=2S.>/B2S
M20Q;LOHRN.TB[WYG2'L'\_PEPW2]-24GA7/1^EP[T<_U*6VCUYZ'Z1FFXBJ*
MZ=FJ8IF^0ZPJ;@@.B;72SG5%VS#FVIG1US%*:.R@<^L[M5(5/OT!BYU19\4&
MFDLTQ0Q#Q=)UWW8\(YA'T!33>#KQ;I/8M;2-K\H#0M2]%[O#K,O6*#(MG)#U
M.NI@RW,)ZA\R]?=NP]*=Y7%"<VPP]^]9S%MK"/C5VRV5#T] +*+5GHUK6)X<
MPH(XGNWJNJ-YNC*'6(8M;]I3:?2@J+C'J9EG=Y[.0-;;S)Q<9;_7T+$M>3ST
M2MM[+7R->B*68_NF:_ER()NA)[N&9^C5AJ9+L.%*2\+7CK]C##1#/TCA.YR]
MSXOT(1H7#](T>L#N,0+['M#VRY.JRZHS*6794UW%D!65>('FRKKEEZ$9PW$"
M9V,N1D-UE:SVE7-:?^JD/DG;[NLS(<.'*L.*7,NP9GB.J:J&Z[B*HQ-3">2R
MV+$1:L1Y#OQX4H8[6O=T#V1X[Z(07IJP"6#3NB0MM@J['I)^ZK4:4NM3FVZH
M689C$YGXAJ/HH6([E1<4&E9@/D,--5CG'#EG9V#"T-O<[NF/LA%RMR=RI]=R
M!V(G6Y[L*;YL!(87R(Y5F7]/D]66Y*ZU8U"&T69:8W]$[W!B#\[H6Y0,Z4BZ
M^#_19/JSCT$(+( B]E^%!]-0869=F<GP?<_0=4<-%:(8EA=J8967Y1JVKCU#
MA55,5]5S=)*13[_1<<KJ,G\M.7"'YZT,(H(30K2%:*-HV[5HF[9M>[[E*)83
MJHI"/,6K$KP5V75V*MHME6 ;$+G5Y+#^B_;>Q2RV/2IV2*JJSQI);1PY,5U-
M#GW+D'W',P.B>Z:M@\<4D# @BJ,_EHW:4$J[/?YE*H>Y02ODK1_R]I2X:<VZ
M[98:>J$<*+9./,L*?5?EXA8JMJ=HKQ.W+4W\?VB6CJ+\#DEE@<_QLSC9W:/\
M[JNTB,920HN6CGD)3Z3M1>C#"16U<4)%-RPY,$W/UGPM-(BF6$K5J\TT?/>)
M4F\-/;7; V*:00:J_";'PKMYA$5(LI#D-9)LU?$&P/6:I]FV')JA%1)#L=QY
MUT73THU72W)+_=QT8Z!K;U(0KIN2O&_'SC_1//\H?8O&,U:'2(K&H!DP;"6\
MG-YZ.4]%%312UWWW+->W+#/T LMR[="Q5+NJ6>U[AO/T&==_5JSC5)RS0QAA
M#%2]S7/F(L(@9.^-94^M98_5BO%L4S9DQ7,M*W UN;+Y?N Z[<A>2X;?4 >R
M?)C1O8,)4)POAR:J0^@/PJ=Y<16%<O0J8-=1.L.LT@J\;N7/=!,F_VD7Z_,D
MYW3=[WO2"!B-;1W?4G4B6W@0S[(\UPATNVJ]%_CJ8TU#&EY?;TZ\OI[X+[(7
M[RL=(KU$J$VA-MM3FU9C>R[T;<L(==_7?%\FNHY)Q&5)--7P'^M8^KC:[.99
MY8-7FPR#GQ9XS*OZOI68'E (62!.N".U[AMV(;^5_5G]4[U['"?T^(ZR]26*
M_.//C2494BS[W<:B'%<#?_&=A!A;WWN\M%SLW[NL>L8TNJ7'UQF-_CB.;F"B
M'Z/Q??20P_Q.[[*7K=0&YHE>,ESI+D.A_2&WPI!8-C$T7[;TP @MCP1NZ(:R
M)@/(<L.M=F^1]Z3T1O)09333PJ,&9VR<ZI*4:2!E.^ 3]O&>O_8Z'8\PK7T2
M#V>Y= 771U,Z ^62#[B1/DN&)XOT[>0$V-$.Z2K%A6>:*"K /0WC)$J&<326
M+@OX@N522F56A/3!XQ),1\NZI);@AD0OB3RS.U<PMTLZIDQS'QMZJ/B>KZM>
M:!/7U'PM<+BY">4P"&0P#"]:/6(L+M^_9GD1WSSPK^($L!CH:ESB-M(.[B@L
MW01N>Y R.@35GDO1NI _&C0)EG*:9E'V((WB&["9%'[(V2_W=_'P3HH+*<ZE
M29I1:1S_0<</4G$' TK2 O_ ?^JWW<?C,?L%7DOC;_""63&#&S&T<$T3>A,7
M^8GD%-+6^LF'!T^N:<896B4#"3V?K1\G1<EH^\$@>MCZYL'"RG$Z 9NO(5..
M2FCK]W"H]:<GH);>.*>M@Q;5U2 P5!*:LNNK6+")\;[O^(%CO\46@3['7<93
M6P0GJ_UC)%B2<;.HV+NPQS-7GM0%>HAO*J:K>[HL6[)#0H=4G?Q\2]'K](Y=
M!HB?N_*JH9ZL[@NWM?(#D(A\BLKX&Z@<_#2%+RCJ[%N@BA0G0T A.84_F!RM
MTVYO(#6D=E <1S>([FK$=EPU#&3+E,MN,7YHZJZY3+M54BU3TP,]>TO/$F<"
M,'^YY9O/1>A_K_P6:$ED=9=2!#1ZC8[=7KT/I-$,K$_*6&0&2YP549P4J&YO
MHPSM,_L%.&D<_X>S#S!-/@.SMR9C;X!/2F]NX&]V6V71\!Y,\DNG@+@8@XY3
MN"&7;N&"C(&7T2SC+TN!91]HE($91#.]/O@. QJSV^!]UVMJ)>;2E,\DK^9V
M'>5@I&L#CDM^]K4ZU\ANQ;=</S2-#A]"^>'/\%# 6L,'M/;P5&Z0 #<\/<3Y
MX^LW,F0PB1XD^@UD=@8R^0#+52XT7$ECS).59E,46, 616/Y<81LP0& T*0D
M$#]1@V,;PGC'%%X]8-HYDJ99.IH-&4H!RH&YS&]F^+YQ!!2_@Y<AR(&'W .+
MT&.@W^)+XIL2XD37\+PTX3?,DOI9VV/FMT1]SNM@0LO :A'=W$4CZ8:.0!C&
M W@,, XG'J@D6+QDC?0L]C+,I0]'YU\^Y4<_X1RC*9#\.VBN M'HKE6\VJB?
M9SCLV&=@8-J6X2N64^9.^)IKU?7S*A7_I9K2)YA1LP_8AO#][^6-O_-^X&@'
M9J R8/0/SO<XG__LPX_ 2$,/[4+V\)D1[A$S8#S7# QD=35ILSV3OG-2U=;8
M,JW  /Q$5%T+3<OU;:?TWWS?T<P5#+LK4C%?U4E&GU(@P-_!"N2CF W^2:(]
MUW9;MGFRVDJY/:*]!016Z[Q(Q0U#10F<4#9M33%-U]&TDG"&K"@K<=Y=$2[D
MJNFY(O9LU"R?[%+"FJ"9F_=2[2[UAD7W?@6D3+,8366*FM_BOCS]/@7+CFA"
MD14;='J6SF[OX(-JGDAA^>BUV < ^HS!!G8O/ _Y*$W8V^^B;Y2#>  7,2PI
MY2_B$& &WW*+#?>9$E!(<H;%"3=,G].\J.PW,R3+AF+M=&2;OY-/9]28!S'X
M,F5T G@*Q[_VJ3";\6Q40[CZ+6QZ<KTT[P-TGZ*673)#:6_1EDH17)K/KO\%
M_(*KQ,$C3K&F10Z@[39.V+KPI\)R_5K$3;3,GH50[WKA<1%^@+4$CPU8I.Y%
M+$UG63Z#K_&B2QYM*S&'I5249;TS$[CO O'C#('$B/ESQ+8,4$DP^ E-,%SR
M@5U_A+\#.( ?[BDL!/PWAS>.HZPD)_X[*QA;LAL8+&58 N9P#[3,[^*I-&0.
MUXETB0[ \M<Y9Z%T6/,U/FD: 4,B;P_3V7C$?Y:B6V"FZ@H> X-U8WS]ZBD/
M$)XN/V6 ,#:",608RZO%Z#:%<<,<CY9G,S@J>1B1,I-"F!*^1+H%D%XP 83[
M=/G'\@;I S@/Z&73GW!BZ/90@/W@"=2/QMUE> +P':7'Z.6@GQ*G(PX&&X/[
M,Z)M[D< %\S0C8?G@8=_7+Z,,RAJ#.8G-'YA[EA19/$UH^<'YJS!P.<N MXU
MJH_=LQN&0#!XPT\-!XZ]$)1)]=R8F8.*D1F_TM&)]!O_"D0"9L(\JU6^6* S
M7T08S6S,& RNO"G8->D,N3$=_M%X1([OA*MXJ!4E,IT5>8R4AZO1?F7IF(UB
M[O8PEPR<OS'%+<39Z 'OQZOG:P8_TVS"*%I%:.'!]S P#,VNX7@<'?V.W@X^
M"VA^(GU9-\MRAIRH7.BGXPC6!+T>I&LEZ? </M\FE9G:H.NP/@ZZ)M.2[CT!
MT9B_  2A:.C^,=)Y4$ZP)%TUNM+EYBO+_/^<SO45\Q7!5#(= O+$V.P^SN>4
M'Y0W<JF.P!4<,X6/%\,;)E$"O 6B,X]#\0'!+#!<>P^LTPNGL;E5 $ F!1VW
M)$J<\U&2RO :"F4V1>4PRF:W"S2;F\LW=]*T^HB<Z]B::85^*"NFYBB:IU>%
M/'S3\\*5<[R +SPVAR9X7!MR6T:0Z^]L@LBJ$DAK\%$Q=P@?WP3JZXVC"&%H
MR!8X9I;LJX'L.+)307V7..%*Q'07E,+C5;]_8?SL SNOO; UZA&BO6'(G"NP
M)6"(BI#%'Q',D26(Z*_&//D6X1WP\9*(+Z''2,*@V[HP_)(BW,=T"_,]TRTB
M)F*YXV"S2%F7;=/3#5>W?%=U'<O7 TLV%,<^6LI;$'D:[YWF(/(TGLS3>"EJ
MVL4LB7XBE4;M?#:!FX:;-^(6[967CL?1-7-YOE$GRQ!'XW+X<3X$W M0&G-.
MW#&X!$=K4E"(9INN[VFAX_DV\5W;]]0J!<6WG>"X#DP;GB<KBFUYND,"0W-U
MSR\QC^6J7F!S\\C6W2E>_!YR)%&P;U-,_LMF%"MG-R8F.> QTK)NYL(Z+:7>
M/9UT\YR1O&8B2CLY.PMYR6I[?,<N_Q@7\+8A/.,K39+G:X&GQCF?2^5!V.UX
M$."<?1D6*0 D%N9;W/<!W!$Q%PM=0HPW,%<MFH+?F&8%8*\XG4,0C%[,V0H!
M1,56 &&*.PE7 X$&"Q_1S>X^[L6F\+'YNKA,:+IA+FGMJ\)2Q$,>Z!HT0GQ?
M8?14&H$W"([=0 JC:Y8<57[T?+^,92[XO3-X%A-KF&V&X&@"3OHU[JCBK2R]
M]D3J/CG7I,QV<9C =9_!W4?5N\AQ-[.,18SFG,<C3TW&NLG2"8]1(3_E\7?<
M0;[-H@EG$D8\9)Z"DPZISD,427I?<@E\@4@[OL'$;1BG=/[5&TB?OUY*9V=G
M[J 9AXRD!.9?!8Q9 )2_#=%X>8>#T=DXKP>]..":_YF+#O=_BW$(BYEW< W]
M#H/+42>7XSZN1LDB&&6D)9VRI[+\<+;57XH/R"3"IYB'!.,\FTV9?D_H_9+L
MCJ,"O1RIH,.[)!VGMW&Y0@L+.<%0_2<_+[?IK[,TP@!H+?D@JFRQJT5NRN %
M+0KI\B$9 ;% Z!PPG>,),$G]U>>'M$@3F)K_D!=9.KU[X'M5.;,'9>!P,LN'
M,PP#C\J+8*15));%@=>O^!K=,^ 40"H!N[.F$3Q+@N4YEIDEZ,K1'(8%X\O*
MSE9,08%JP.#H0ZVWJEK3_ VEYX:/!(U!DYSM7["\!KZ8-,+LA[F^.I$^5V^J
MGX1K6?;1@GO0_ZH27.#F&(A<*<AJM$V]R4/8$S#<#+O-)\)#Y2S\MS2&@32;
M,M</U^L6,VJ*G>9<$4TU"#45,H<]-M$<T[%#1Y:)+^N682JEP;?"P%?\A1HJ
MBVBL(C#@T4J%.]4DJDJM7VEV-I_M8H2!I]&I8/E44D<9'J;TRTT#Z"W$@C:A
MP?8V@HV3U1,HK<6&IB Q3?YK-&ZKN>\Z0L9->4)'#F-FH<!5CD816_GZ^/KA
M>/F[:F<%]V"/);B@_)LG/"TD,/%(1ZD<=\Z$>IVSJ3JA[2BR'0+D-GS5-9U
M=X %;3LT;<7=Q(1I,F=")P%,/$;7B&UKP$_N0SFKIP);[\MR1-YA/(OK&[:-
M-$^? \4&4^%[2[62!B5T,TNXK5^G:KE58AL)L)H)=Q>XXEV%!_/'+@*+"1@O
M5'6S*> '>&?)]V^A\!KEWS!6&OBVJ[F&YNBV8?AEQ-1R-%G1%WBM4F-AFFUB
MA$7N\GEN,"BU7?/7<Q.25DN_M)F3.HSR.^0=[EK@3AGND>&&!U-!S+QO\#+*
MBZJ(ZD( I!'V .8H\U/@@CV$_]URF'\91]_3RPF(]3]PI+W8@ .5= [J:E+Z
MSRI 71X69&$[EF90IOA>T&\QLJ6SB$V7)BU]./KE\A]'/PT6\BSX5D#Y9-SB
M2Z\1 ,+3;L?I-<"]56=@$0_BQNTOT3A"Q?(*=0> <?VIUR*=_KQ"EOH!YK1@
M!\U-#0^:SZ:OV>-"EVR2)FGES>!$41FDD^LX:3A<P<450]X+[C]''*ND8+D9
MW-/)*-L3S^=9$N!29;3@F=>@3<8Q;=JN!3I?T^*>TJ2B%#X.J(E/^OMLS-Q=
M!0@<5$[+ IJH1W/T4]/%P5R O,HR61GYH)$=\$H[]H09TVK(I-E$#T-'P]U
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M)%#PF."QC3PVA >!Q9N']AF;H>K*\) >2X=A9_H$'PD^*OFH4B_(.GB,+4V
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M8AJB[$B18Z6$HFQ< >ZR5':XR!L6M#*=2P#Y,=,XK,E6UH5ZX)<NXLX9Z[C
MJM%@TX99]E ^>T(!"8Q$582MJB)8]HG6+(N@O+(J@OS(2?VR*H*URP(!?7BB
M*&*P/_.;<[YU,#4,2F>_]R4,WKA<P8'F@#X[V'VHAXP/O2B!X(OU?''H10D$
M7ZSGBX,N2O"%;[3@^<QY9YVFHRG2"-]IXMO)R=ON22MVW7[&E4/5M37?=8BJ
M*8H+OF]Y_,$W=$-9K6??_QT;5OL^F$S'Z0.E;-\\H\,BS?)+E)Q2LMK<M2'&
MP%3:W"[?R+';<=][I[((S7,HFD=MY)P9CF?JCJ[9)%!5(W \12^/;.N!H9(W
MVRNV]EGSZ .+K+8>$II':)Y#TSRD[ESF>[:MDL!R5=G1%$T)3%LI,8_ON<1Z
M*\UC[K?F(5:;B;@]TSS[=FS'6TKH.\R@S+YF*:NJ+7+XWC&'KX>9TT+:^ROM
MC5::KJZINDP ^<B.:3F!9065M/M&:)I[Z(6]K;3+ TMOTP,3 B\$_L4";Y@-
M@7=E4]/TT'54W;#MP%?\4N!#6;/('CH_0N!WZ\+T?C.M<;ZA.I>T>(1IJ0SJ
M>P=<^J0V6YUX5_2I5>M3&7-&;=70=571954UC:K5FZ_:OOQF^O0=W*7?N*RT
MJ3V5@:ZW609Q(_=U%D8)1;%'BD*3ZYUVPS,#WS<]4[8LWPIMT[?+ Q.6I=K*
M/NYW[511&+HI%(50%'NB*$B],:ZZJA9ZJA5:MF.8ON7*FEH%8'W][4(R[^"A
M[4!1J /R-CO@W??3>N*._0I^5UZPYN=YD<5#_).?<&-%)$1H:I]"4YI:*SY'
MTWU/L_4@#+0P- -/4\HJ5";X5X:QQZ[4Q9S5V8;\K\CH%Y>_MJD(L3J6V'D2
MTOZNTJ[5^\PR"6S-=HEFZI:K^!J63*CR_[S 6BF\OD?^T!M(NSHPB9!V(>WO
M*NU&O<],7$OU?-,,5=?17,<,956;.S6*\6;G#-[!J7D#:5<&NMEFV+3[ODS?
M]YS^^9B+,\#_Y/ELJR+7(BZT3W$AJU:AAFU9AF9KLNW+@>99IJQ6<2'%#8Q]
M3,QC:<M<5-9IT5]+*6DU<=DR]CI:)-3'(:D/NY'XXWN^ZLN:KWB:I_NR$EA>
M&5W1[,!<J:2_!_[6.Z@/^TW./ CM(;3'[K6'3NK=Z]!12:BH/E%=759M0"&D
MRA/69==_,^WQUF>FWE9[M)HXV#WML>5.E=Q9+^XJ+:*QE+#"_%CK<=HH5X[<
MP:H:<GX0H:TG*M>HT^_2*)WABKVF=$T?#J/J:JU8B>%[BA*&NBW[LA/J :D.
M8.B!:<LK32%VZ]6U%([2!R;6\VI/E3W%*=T\!"H$_% %7-,;D6_7"357"3Q=
M5TP[<&RS"MOXOJJ]V:[V,UHM/5O #75 E%:QBA!P(>!]$G"]WL@FH>VJ1,42
MZ1Y(.G&4,"@#*^Q,U=NZ1BT).!F81JN!T'X*^ [[0RVV_5C3,0K;42#;Y43Q
MP.<V#%63-=UU93M0M5#35==V;=OU'7C%5ETA6,'W5R\>^[A8G9&8)])V;0[^
M9Q9E!<W&#_.&"V<)9U-8I<=;%UB6HJB&ICF6)GNA&VJV6S4/,(EK-EH7Z&I@
M*XJCNH&BZ1HAH>Z7?09\RPA-B\L6:^C@%"]^#UGN?,#OI2-I/KE&.PD_*B+I
MPZ])-!O%!6L@L<0("WSSRM81CZ\N,OFC2^PHMDLLG;A&H-A!8%AAU8LU)$Y
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M@G'"=,#BSK@75LY9<RI,>PD.";P O;K%\ ONU*+#C0XYC V8@-\[ ET@,<7
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MC6'G;+:-L4^YGF;!DA3^;XHWL)!4Q +V-_#J@F?-((*IQGV?9G],Q]$08S5
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M'(^\:"J%,&M83^GL[*P*KW[R>(G_T21.6'"6E?Z/;ME3$--^PL-5 &C'\"N
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MD^%98P7/KBM=$#U(;I05=P/I\XDO4@TZP\4"L/:(AFU6>R6Z2-SM,1(0@%4
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MJNBQFJ-0 5:?#AM%E;&>\D(5NG5%/K9.2?C*/U[0$0RY3"OX5(Q$98_.2(%
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M#4F;Z6PR8&YX5K4LMQ8H7YV3\/9RWH];Y,:2M)C\V>S=DK/.-Y]9'I>I+,W
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M?F><<\^Y97PWC#T&C$S6?IXYYWK6G'NOQ9AA+ (G3 R-#0$F)@!@.O@!&'.
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MW25*-L]>A)YR1:B.=[C7K.[9N*F Z5[XN7W4,;B%84-[H4[=B37<QPZU=;E
MKBL)/RTG1".:$X[Z&2 +#,HWL_:=9JBF%AG\Z$8CK%^77'\5UTFEY%+R2HIB
M_'*CHMZ8VB^J%BX5#%W7?]L!F:U9Q!2W)!9V,X#7A#&[::]6ZFX:]?*[6[>E
MF.)K'M0\M>O#1@08QD?;S MPL5[6_6%M%59E7=!F@WJ3]D0XV]=-DUY$XOG6
MWMNEL^1B]'PQC,K"OACJU'C>078V!Y;6A]$<JN>MFJ3PKAB&>R9VX[-E0_J(
M8N0(/_,.<8LCCMARJ3VXI0NDYTMP+_T<Z$?:[8U1'T7C3Y,ST(O(8^LQ\B3*
M!W%Z-UFQ!K^I>6VZ\?KCABO%II.U01N7VU6+8CVY!\PBLW>WERLO\XF5%%N=
MS+-*37O\V,K$,AIK?-%CQWQU#:GJ<>MG#R%$T.EQN>Q3_YU;.Y(F)?YC3[Y-
M9%\PR7;0//[D\\O/LI=:/VH\<38[PFMI=_W/2HCO)U=:C!RXCEEH6GE7%ZN!
M)J5^("T0D._J<#K];=,%)6OI1#D+02J$C-P@EX!WJ]5+I@6,8!SSWPZ"K[XS
M&?X6H7.N_%RI>ZFK<\ U7,UPVH*%_7UXU6+-;C+2=R$. N'!2EG$XJ$89!J$
MLYCD0%JJ^:Q-:\%>=,;'-%3[M^B)9=DD[)JWCP7%<,.]U*KNF&D[^R2L.SF3
MPW<U5/R*(,_V& "5%XV%<>K>V7=T G\:C?'O4RZ#=_<=J#[@+,E\WU2/?WH;
M=F_A:&.@12\,Z)*C2I$G<(7E E@%*>+MK, 2'-BV;C"FN*DG#,]UZ2+UIVXS
M@,1Y<5)!5R(QN KM@\+I$&[7D\?&*7=!;)? ),*:D#FK@X=M.A:OS[./!6V[
M2AEG]=$5IG5/DEGP$SDMN-KR$&09:.$<B]$LY"1+8BY5!C@9-KS"K><L[QN:
MKF^C#^J=*(0$V;#HIIX8; %D 'A*?G7,Q!XZGBI5LYIG(S25R[+YS(LH B7V
MQT<$)VG(":3H&B\6A([WSY]+-/ZDF/Z<,D2'M)&/5A$*]+L+3W2,TNP7@S=J
MB@Y"$=_?>Q?61S\+9I,YH7$03JC/ID#?O'3CF/S6-NI HH\'4_6KX)Z7E?WX
M/^G?)8AX.I/U2@E<H@<MAJP%7\#)U>#@4E\G[\SRU6OW[MJ[,9.Y* _ D,7!
MK1.@M<N!G#" ?9C9^)( ; 9]E*X"%IL.3SVB?(L9(7"Q(:!3B(O1+]F2AC:]
M*C^G.B(&[Z!DUUB+,A>J5!TA9-F)@VB]U]M_RP!0QIW?F,G,=([!J9L'2K.8
MLO#ZJBJM 4F50PJW?&\<MEHZQ@#BOY"-X3FX =],V4M,'P2_>AZFXY ]QF7(
M"7T&<+AM@0'(!9!CZ1P'(O=$.J8;2C'7#6$ 50V$])CY3T>YJ!)Y/K2_04FF
M-0=2UIP)&JN-["4A%W.=#U0L,-CR#T$HZ;$?:N?$@9(IMC"  1P4+S$.73M[
M$!W78 :0W=1YL# P@-]O^.?*D'65 ;Q*I+-&H.EV4SN\3 =.93WWC %8<E&Y
MUY'4FF(ZMYDJ_24$E)QB +^<G2>N_1? 8,C0)+55A";AV/CF/DI_\MV7XG5I
ME?#UPNJ]Z)>9=M['BR4>,M6NO=:U9P!B_4GHC2/5R-7FM7NR?O-BX];FXY/H
M1B9^C0-4R1J-1M0[6+BX^9G,RZR'P^S_2O-%Z4%4-,T90)VP!4TJH^Z_@O:?
MRG5+5,^ZU1_?5&7OMHM?^R2\/*8>)P@[L2H?XZ>VX[)XHOB"]UE>?B^6T:HL
M<AWUGN2!Z.<FHG?$QZ0/_2*+/F6%D,\O$NE__#?,?O]4Q/YW@:F%]3K1"R17
MXF9COB11+9DUPM/=S3F3Z\H'1+M-FQW<3ZB>?%O?Y)!I6+=B3VF@O=&#(GMH
MY(5$A#*QP/X=_3083'2UQG2)C#8>:_S&E(OYH9&OV%#IXCKC\MD_,J_DY?*J
M1YM/?7-]>\9'-JL$QUJH&:F]IV.W#T$4>7+CZ5 #\.,S"R5!B2_/MO=RFI_V
M-FF[PCI!@"NESJK)*=L:UIZN91UO;/XRMZ'<^L<6'\+^O:[$A]>GL'=BAWX>
M>;;,IMCCKE+I$#6=;7"Y[%R-4U:?Q_E&F;%2DRR+W<=5VEGE@E9/+M:8P#[Y
M_+L.1NSOBR!@9&@_USU1#O)6&K%%5+HUUW4T(G70%+ZQ&7&GCBM ,\^"TLMO
M*8OQCA"L*2Y<QBW0A(0;;C4/\HJZ*-,NP7A07UOGA4=48R!#V9)/;[S-T93#
MWCE>.!7;NQC"=WZRU+ X3<3$JL+<_/G2,9-K?@,GL@E=*XD_A[AX;CA"3RQE
M5 W^'&I@SEOL[(1ZN;K7@_[P2N4:BSP3/D_S:MLKV+ T[Y+B"]@Q^'^<"%$L
MK_^Y\S(@>U)]\R+5$N]H ]N\@K@BK&WXFDO#3FK)\#4GR*QHZ7"FVX/IU';*
M5W7D+V%=*0;@HFO, $KL>)F*_WFFTN'['\YP6?=;W_]5J-?X#[XL K-,@2Q:
M$? UZ^4ZG'F" ?0V=T@1+3;]2$:+;A7E<-,^/<EV,E<?1Q0SZ+Q8A[DK8 VF
MDXO[[F0-&:O!$KIX8BW)8G[Q4:WD<_6!)7!KL\OG)B/FA!$#ND8#M!:T[];.
M3X<8#(HUN'29S9 TT@?%C<!&/XC?;"D)0#-W'7-9TQA[\"$ @D5S^^%OY<9
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M%291]AR?K(9#>,EJ-Y8>#(5,O/D(J=-J"_OX;6 S>KHO<TYS<1<#Y8?VT$Z
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M R%#S>K[#Y7*5_*]3'G@>N]""WICLG1=LXN;!$UM"LXLO%A_38H$V9C#6YQ
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M!*F"@'14>I?>04&Z]%XCO3=IH4;I'>E*%2DA=*37"*%(ERX@)8F -$DH,4"
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MY^0XCZ;:'F)#W6AN[:&C2)("R4% E'P'7V.JZ>/A%Z^86'P3BG@-X%=DR&M
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MBF6AMZ'U@9K^/87(&.=!0TXBZLZN >7A7$9-"R<]DN:SY<<GEQ;]4X:-^:Y
MF<FK9;XN\\ BT_%(EW773;^HF6:^(G1:W&MT6HR<*$++,L'KH%L4<?D(OO#7
M%,#_]YE+IV?=1YJ!/BWN')<#$W, .Z$3('W"7_R,Z1-T9-88E6BT$CDPE-R
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M,APM+A3;ULO="WP@F(*@H,.KS:4EB9.)>[.WH[V3P\S]O$M 7LO+RP2SI\Q
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M4]S0X_B\U6:T8ZUW&<[5$>4=D_O%3(,H6%Q;ZWD'+-2<C3_O;N",V+01>GN
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MMX!S%O_-Z_AL,5Z!QD<MX>1-IYQ]MM%P35Z/!8ZX/<Q+Z)9-QD"5%DU<0$-
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M]W,WZS)2ZQ:VI%<EE-P1C!VS+8+B.S)'C"HC+*@=C-?NY9\0?]*N9SC-#CJ
M.5%K)WNVASR!X6^EN$-'5SQL@XL\_8X>AKY>%['G^VAI@CG8[WQM1SK'/IF+
MCA?1 U)2D+[A6L-4TXYS@WS+8"2/E*97M4@9N_ T1%'LJ5(SWY3X($?VFXJE
MU(8+MZ3@ZV1N;+9:LP@3:XV"H?/(&_QXV:LPOFPRSR.9S4K[0X15J@J\'B@1
MS<"DCR-Z0UA;^6:"7,*98CY!4%34VQ0,.K1T:6?%$VP!LB,@&&.UO@EJ=:LJ
M9]NJGA5%'%4/=#MQ33_9"JR+7\Y966-363_;,/$ 1$?_8JV#RI!R!*S:WF3&
M,J_\SYUU7>T.?"]P\7L*<2\?/;@X9G9B<*]0E>\/'A^D@#[-]UA3;A%30@4P
M[7'A*$/[86KE6-=GSJ[HARX]CFFNCD?B6N_\CFJ^6.VX[X81[-$(K#@*UBR\
M+"S>&27_?WA@^5BGE'SOQ^M:UT9;:0%M-:8=4D[@W85W!FE'M'9O>GWJQQ&]
MBX_?GK9S>>[M=+9"3'=M1<4:I[/[+"6B-TS$M&Q7AHE8?R81+>P4H3]IXA'Y
M)2:=:(*O9R/B^(9>.'0L3:F+.^=PM-=\#WW+S@$"J=@O_'A<?H3?K8OL*?V0
M8P-SB_HG=?6%JL 0KZ;BB)%\EF?-BIH?HF8\$;"=(,>CMN*76L;-!-G$]01=
M*!\\Z@C.QZ=68#<M8F7XQT'G-@NT*[F55RGKQ\-N;C+<3E:M#+'8] %3@ ]K
MS5)>GW[YI\OG(Y<%IUVXV,:DIHR'IXOU8)=.M&A%K;&P7Q^^Z72"TJ-=4A,2
M%_9]4-@1MN]W6O>)\WD'VW>)+1CSK(#I29'Y*,PQN>0:OC3HW )/ODY8!V5-
M4-)(DK]4*)*3:CMZ+D#!'/1:?_2F)B]>N@*^O 6EWP!9BY(&<0CCAMAJ;K@S
MU;O*%RM;^4N?=*RZ$6@R:R!]1GWK9)*J=?BRF&9E?>:;]A2Z&$H!$D5%TG#&
M2&5L72R ;1U'>!C;A"9<K;O/XJ2*"+N,:T#RVW1&XYO\)..:QQ<$;KMB73?M
MMA)W/2%^\EYT(4;\A(YNRO:\0P8]<B>9F0921]>VG-N_>?3+UO7V/)4<]*V&
M0^;=$@M4L(N)K4'/>14(A^96UO*QHEB'& ECL ![]$@-#P>I BL3*8V1K#9I
MMZZV^D%E5@K5@CC*<.)ER6=?11T"ZN^8(X&,E9-X;C6HD]ADRTDUF@LTO^ZC
M*7 '(OF&G/016=X#Z#$P_>D]@^<J8FBWA!_HTHONI;_HL^GK/$6\091]S"$J
M_=54,SM/U\;8V^'8%%'8D\,C&4+SFH83.L 7Y<$8MG3X!HK!+8.Y@XNS,!.Q
M%"_5ZDF)PZ@'?=N]796V/8Q3<@ET4OVIHO['??OP:KT;-EIBH J;&&OT<&4G
MJ467Y(^6F@E72+HJ7$=DAF-N4S&WRY]Z0L5GH'?%!'=(&@AB#(5;,W"J:PQ5
M%B$ZFR0+B=D WV*+C6(B"L<G/??\^7+5YA;;3/<W_VA1Y,(J;)T ,@81/((@
M&7V%%(-60%YX#=T#EM@*=_AHSHJ[+ECFEZ<VP*5&-!"V/9O&6;R?5H9'77P=
MT[PL/7W>3G4PG3VZFW./<T]10-1(\-KRM.7&AM,;#AA-;3XLL92Z8"-8Z+S<
M_P#V]T(A_[X'WB<=2??;97[<@"3%/PA@SP%/:VOV>4"C[2BCGE >75=GE)O)
M. K<I!87/@_Z*FES5E#T\%2<[[,=1\,/7?$P[Y,!^D%7XN:3#\I6SG>JQG4"
M<U:GDZ,I2;FF]N7?F_P6@D_NSSG9$W#KS[9R>QAZ=J=V>J6DE+5FO>S<9Y+"
MD'G"/;2[4='E7$GI7JO",QWW#SS0& FV;AAP+Y\QD]OJ.3;J9O6Q^G)CGBY^
MF)?Y6<WGF#[5M2[FM:]^REK<-\P<9M1:>(<\+$K&-QNWL81AAE#P"@F'59JG
MF6**"?[))_NT7P(_XI&Q!IC-TR.TXHD3M;?F7+Y,JVU_-70UY'%0X ^J9:3\
MFPBCQ^*S87>3)?2] B[])-+9Y&@JWY*#G=WSQ)71$+KKPGZ3Y8<O^40Q5/LG
MDUNGBTHO_ORR%PTW33M+43I7:MH_U5.P*2/0X4PQLKT) ]+BXY\<%- Q=_ 9
M!\K-&9)9??F/O"%^C+C2I8MN%&K;%9>*]1IRO:D;C^2:G"X]6^G:%WTZ^0%;
M8*BK"WM_=#<L;IV,I=*?;:%E++>+?LIN_&C!;?[1%3=/PH84O/4)*)2#%G>%
M"IQJ@+Q\T)DI-.HUO-SW+.[#N*NO;@'DTW;&$W+K/&=\W6])]GRK_H]/!<7#
MK8-&=U]&5@M*5WQ)W1DKAB1V.R3*IS]]HX4E$0XPKPUM\3DDQO&49385([#B
MBTF/>:Y1Y8YGR'M" 4?P1F5,F];OZXIN&4]>+!:<S:HMR9]#]%XK3C*QUV$W
M924H2(&!LBM8)(-+K,2H?P!_E9KVV)4I3BNZ]+1?' UT(9S;86^2M+78?;CO
M^[7X_EIG:8!'2C16EGP'8DX!GAD<TIQDH2UVS8SI>$-^KIX>^M)#2JA Y2A-
MX>?^5PJG)36#9%Q2'-Y[\*ZQ:JW;5,/8+(:JTT)+HV<AA7 $U!Z+CQ:J3KKI
MUY$CRJ=12%"OTL\OV-N[W%_9/NLF3:G/P0DL*MR<7S8U&&\%?'K>-WZD/./W
M)Z2TWLZ==<J.UQ:_'GE>VOCJY"_0Q3\-[9^FD5)XDFK,\]EHTEF MFGA>*6T
M=C.M,C7NX/I277J8W:6Q;7UGG?^@Q%<J.A:<B2PYE^*MT&C]*GK#VTD2_+LM
M-IHL1O=;A2617[)FO5<\"1H!2+=^X0%2"]K<_?DP)(81/)NG2N.8-%-!%DT/
M(F/ L%F0(^);T^/RH+3@4TV%3E1HD")?_0VHFO?:8&G<'#I4/IW]]9G]<N8#
MBPX/ 97N2]] N 1E3.A[]DU\HK/G[V#KYV>9*WMGEI1),?SK3W%J2 BWX@XA
MV1()?-WRJ;-?"%:@=%:L>0 @(D&<+_(C<U\'ZI-JD8D\M^WI/L_X!J_H")_O
MII@AW3\[NNZG-D1/N'^QPQV*]OTF\V6T[A\M76\%MZ["]%[0AC6#'@Y@MEVB
MJ_&E5RX0;$!X&W:+L(L,%V7O:+XA5,/%_+F?]\R]B:ZMT\L2"7I-$IS=I,MT
M);Y>]Z]'38[Y4Z8_<BMG2%N(FN3D;%'LB:3XC;35&XUO!\+2S(\636:EJB;4
M?!Y$!Z:GCJN!R';XYFDA C+^SM>'1D4(W@41M;J+0"+].0ZE)JAML@;Z6M%;
MVU,YDKGNC*[*,<C=&20VD( AINY3/WDWVN/BJ;M0<JM=L/YLPIKE81LRA=A1
MW3+W.SS-ZCA!!T#R[D/I7/*(+8?<+)HUY6WQC#%,ZS(IE6\SP=K@"2';)(W3
M4 A?[-9*@@Z;G$27INV?&M\-2C HB7EP>G>HZD:B.MZOEBY.L(<<N!])=MT$
M=[:*A:9#-U7:]BLIB5P#GUT,%1&)W2)Z*18&!+/GOL?2U(7MHCP<(X_O.T4#
M/N40:'O F_E@)\\@E^]*.3]N:3%>RDFV!EDI]ED<E7??!@U.\*W++)][NK3@
MP1<2L_=M5&J3TM)Z3-(<G9SVOSVCM5%]W8/@[?=>.:VI,S4R>GE_F6\'70>Q
M(AY?P^J@IVW!.YP 'J["6EF)HKDY-R_#UP&[XM;?YIC-)X0Y*R_Q99?8.FT>
M:"9->N@JWW)S=N,'M5U0I'1>*7M,Q&$T&L NOE9]?35>1&F936>F@RW_[-\K
M*%TD1>T3]H;#6^DQW?Q]HE ZRCL'I0,1;D--'L7^#M3O[90T+)RFAE]J-5Y&
M,%9A";3= WR[I[[C$E!\X8RG(I2N@=_ZK:M]T+0X3I0)R=>O:)9(S'EO^XT!
M-7GM$ L@\VY#6*#X# U"@#K'FP1/T3ZKL&$N)T0HV<WWR\>-6%' OA8U%!B-
MCW>.<02O4 OXAX9J7_U*%Q_'![,?%E' (,>A)I62,7P'4WDHNH+@R-XU2_,%
M*/QM:&Y7/%&2KRQX1M3#R[)]$IK6@"3>24$URM@#"F+3LK@(^ Q]<U/ BM:T
M?-8-VPHHJXV(!*VRROD'058\DE]Y1<@584H^T.'Z(ND;]QQ(?%ANOVPB,1^I
M>>!9YI5-_UC0=CSG_2@C"K;]/EXL YMY1CB(I1K'HC0(RL!0&RD>*UG+DN!?
M$%3PX0")X2:HHA:QH)SS(E.:'V9P6,QCH!8- 3BW=2$F:3*@1#Q1DZ"7P5@V
M*HW@8&0FZ5L(DI5N./EE9.QB9\2C]$<$N*"*[H=-0\L1E:C?ZH%D.R"0LK*/
M.$;;#3K?#D"I0<EG>OFV7-8PBU?;1UN#=_"@#GV'DI8S,Y[[A\M4OZ%W%]8,
M%=P9@\IZ]B*U!WZ9L39%$3M'OUB&K5-PJCE^/2!8*DQ^2>9$AJ6YK,8[N>Z/
MLN8WF'I7*=OOU6@6K+?:8WG0^0_KV845+[X#-, .BB/"H3/L^2BR)-]ZHFM8
M1;AQ:>4X?JAE_& -J!/;M*8<.LC+JQ^")YN; 86_)%>266LA!W9'+%^"8X%H
M#J=VQ/-]BEGX:3NQ%E-F74:1WW):<>@OYV;ZB ,'F4;R@R>QUA%U)F^BX:'H
M39^AOC:B-!"Z%-UT.,O3"+I50#B9W.JI )4#WSG"' YY"]\$RID06!^F=5NG
M-YEFDV)HVB)/^/'&2Y2X*T#VG3;]M2J"$V(_6M_3\;?[A6*EJ*@PG=M?DMSX
M(FX;_70J_$HAF_*YS=\T,A? 0+OAL];^R6%K[<7K2D%_%J9_[L2UHZ/^1EMM
M?4@!ZA$1H\Z^>Y]E:M:]<J>,UG#)L7S7<IRG%D!G5 :ST^/0..S(*HQWO9^_
M>V)>&AH)2AP9BJ>)$S^@95=A?NCX\5T K_X6I[-R&]^]K+CU]2IL#93>BF&;
ME4L'KK3=-/T64SE9661TF[AF&3Q.2%S1);A"Y6 Z(T\5RN*,82?J*$ ?IZL%
M&8U5%"J06AM?@YN@U[99G+WQI3/$W3WFEK@2CQDWG41SE6*W+WB,4"8H8<2H
MN- #G_TC:)OK]#B\YUFO0>>8[4PC;!<E#74 AZAGDM/F+T#B@$AL.Q$">O?5
M%O4MHI/1VVA[(8?VE_X4L=Q E8\*K0A)@N.SHQ?%NS(;+P,S![Z<;_;X\;3N
M[AZ$'DI#I$?*!)>-G)40917?>3&KL.\*GG;GQW.5J;O--P<8V]^(R=6K43C[
MY(G'D]+^5!VEEFGNKGHE78.1,&Q ],153[.-<>U'$_"Z\.UVRJ'<HTK,WVJR
M"E:&%Y7*\$_T">=U+\ZTH-P>^%L=+#9@:V7?%&SHIZ;J6B?N'*#J2A]0TMIB
M;90?@?.2?>_XY-C],5NIH!W'?7X.),^>';T9C;-4O>P8<N%]\X$7ZM$;ULE8
MBSC8NLNB(UJ:1#;FRZ<S252GFI7+T\O(.>\@]MS:59@U$!3S%0IE(\6@#*::
M.F3FQ];]J.WVW16*C."JZC+JW:C?BCEK*CJXTI[?&3S3VO"O38V&[7.Z]CTC
MF!$DI&F=AIXH<JN?]2X2P7,=0&\FJ_+W]!$B.94'V47T%6O^&>@U.UV.O'GT
M>)'D'++5EAT4/VY"':"I3@HU MRZ&".Q@\57>?4%+CVUG4X](9U*HHG)TW;X
M@"?O9W^_=\6 &[W\/DY#IAR[[=!%_R-/OF*1<<J&^_J+_OBR<_IC>6_J"6;_
M$OH9]'KR81*;M &/98ISC#=QRD )WJD9[T?9G_7J=Q5B3!B.;=W%F=?M""-%
M<",FFVN;^49Q N@NR4\NC:\\JWAL9A6&,7#^CN1K80''5=BR%OT%0H@@CXAL
M^8E'9"A@M<!],Q^=PJJUOPT4,\@R]+I0 ^6P%I8<5,\4R@B;'8($Z=="@Y0@
MKU:W+EY3\Y=5F.\(R3LR[4L%XDKCJP6MW4N?S[]7;*2]-SG5'O-'\'?FA>LF
MX6XW5FB]E28=CQ?\5,:>S];>%/I^PMO*WI\0OG8V99\G6-3N6I$B)]YX,J04
MGF2'F7ZE9^<VWFZ>:D_1T5*)SK#W4Z.Y6L+R,);]W*&TJ*UK=*).K/LCR7CO
M7(-*(Y<>!$JH7K.</$[070DEK*^'?K/GH\=5>YN\*00=*.<YX6JO^5$@G8N-
M*8C#*/!U06'L!"8A>RE^<<7,YFMT%U--H6' ($<?S4$P<@,=V.F)GA*OALQ5
M..ML[1R#]/@Z/%_!<X-Y>?YA03XA"!QBM\< KWG/!=E$"4BAF4R%WZF5C,CI
MD19D):)V0?&M0FW(G>)_U]T?I2?*8CN.OTQFLL2I8M>-2J\'&>2M!TU=H946
MHD9/[?RQWPZ+=V2"TSH0J4>R9$[T/K-5,9#:&KKY>>O7K8<S8,&RC_ZP/I>!
M.W#@E;B++/1U91O?&B(#=!X5>@>8<3-SP*.,T\)^VH8Z00UJ&ZGU<\[ANR)*
MN[5V'<!BD$>^L^%1@2%D1:AQ U\!$$90HHF' &P<D]DT&.Z<VN08'.!ED9D;
M1A J 9O@6_C24!;0QPL5%-.V01(<[:5TX09A=QWV9=?<5P![5L%SNZ"T:>,J
M;$,<F=NE@ _FE4#7R\S'U44@TV%AVYQMG\@M3U?\6$ZP@7Q N ,5-"IE!VV!
MD X#@>9*^#6"M8%*8O?NW7NH'KE1$[:P9",]9__VK=H;]":AAQ QQ4-O6(5-
M/& !5I345=C:#WE;!%4$C#%?-HA!W%@-1/8O&Q6OG$"V2UNS;V:M6$-P3M[#
MXJX@!!,M[4\6"Z3IB @NL9S3&1 XW_P2OQ.1E.F6EEJ*OV1Q"5F+#J2D(610
MJ@0_ #&'9;]1X#2QQ.F7$(G*Z'CB ?]PJ>Q#$(8#CUZ%R<WUM2*HY"2"ZX4\
MW9=#U$KK";7'581]4"Q[Y7.384DZ'"NRJ(=%HW9Z*/4A[=[#Z*M%#?7UF_H^
MRNWIVGZR]VUUN>W!!$[*P8<.6E4MFBFJ/_=O2NI(>B!C98WYN4']YP9SF5L2
M,1^)&,+^.&PJ%C@+'ZUI(=?*IQ9"?:W8330EX;OKQ$ZA))B6ZU,![19NX=L"
M/BF&]$2Z+&$_N_),8*TJU@T,:Z]$> +PI*9+!J-C5ITGH%MLM/3.<K^+NJ[G
M0<3+H#;*B.X1$7P3A".F2[<O#M)VXD1\G+9K%=9RA']P1=H#-Z0<GQR*3<1*
M$67PKSG:Y-G10E0ER:BP%-]E4SL4$@,,M3;.#;07!'.Z-D!>A^FX-[9S,Z'7
MUJQH[0WX\#%P9\*GDOL&:_H_5)_X=.\]N/:RR_.04!O78X'OCU2K]R_^3E^1
M)\A XJ MST20BMKM[\1#;#'W*L,K\$C04C#8=;K_^RLH@TM)43"UC^5&XMKS
M]H"S80$47#@EP3R@%'<7-Z[8OZB;NU4Q,-!<12W9N]"OSLT[_F-X%U^.RSV&
M%A/*$;M12H /(]>KE5Q+GNT0T9C+D!\[)]68V>$,[>>2ALO9M'K0NI6F!#64
MN$/1"J!GXO_6WMG',[W__W^=+B1GEA )Z\)%CMBI7)RTMB3$CA9"R)84S6(Y
MR&*V$',1/JDX$:,(,>/8"&.QX913Y#*3B\U)+O-^GUR\#S/??7^WW^]V^WW_
M__WY^^/U_^OV>CV>C\?]\<_KQ9FAZP^@U4 3;C[J36-G',;8WO\YR=&O=N#W
MF4)DPV,OJ4"$'YE<R8%BHL"5J5C41 ;G)0T!=,YO 4LJKP&L3.[Z)DQ-9KE1
MW7* ^D)2GRK7@=O*#Q%:7RI(R5J^<U"&DXRG8H=S&JUJ*>4DNFZ_7/-3<_Z4
M(.RC[3J5WK.;9BMH;@2ZV]A$!5<H]%YJ,SZO4@4YVO70R$A1WJ(R>>Q'8*I^
M@I+::)QJ""85/5=DC;WD=)3? ^K75G>J3JRUJ$#-Q='W(]]>@ELPTK.^"-M(
M>O6/GUAXNIE;_[-]>-17E<L&N0:Y?[<B\WZI3_G=R?K1OCVX+Z;_DKZW#$P)
M]O--%(5@F\+'@A24-]0I5X+\)X@IGN-U7O,,T%W1L4Y,L%1<&,4*Q2#X0< L
MZG[N<FE;]W[JHW:,<1_:3'IW>5Q%YF$#&^!,05XA_F!:VT/(VK6QSP*I8\^A
M6L<(B75:J7(C*F?E,O/7/KHF&7,(BF/31PBJ_32[26P\'0LXBL;C"ZPARPGU
M5S?I^Q4!J2!^-7*+"GCC><<:HL-L+T+M,PEC5:-#+YU [AF!''WZ(DU@6,(T
M1\A)'*]'+$0JAE4 HQE*4'!%D>U>=YYC5%/>,$90[8W9#9@XX$5KP?$^C&%P
ME(YG>=&HHQ256I?+3%B(2$:?9B.U:,Y ,RMS:1Q.31"U*&5]EW0\>1%<31(S
MO_V(GW+(NAIWR/2>\[$M_3]OZUC<=T!W3\;T^7?'W. PI__U!(;FEP*3!NBC
M?JT-]<0YB!Q3N#,DG=>9@L9)TZT]27_=;?)F6PA4@ZU(>W#M325]_(>R7H.0
M?X;R<J<B_GEF$6;Y\]-LJ^/L79@NTR[P9+;AR8[?5K*$$I/^"AW7B\$>5^X>
M-CEK5OK+N,[ DYTFKSW+GCV^>[,WGU3Q\IMDVY=W[ K>(U*D8WF_^JBOSZOF
MOX"1"JL!TI<,S<#64Q[%-]P^;5O8]NR'L%0062?O)2X=E6DK]-/=B91U#GWY
MNN!5+K-O@MBQ)-#D5N4W,XO1H]/1H8\8902(H/>3[[F R"*75[Z?NGX;LHZ?
M6[\PBSMB3A=G^;Q#I\7<9FB"^$X??=W;?YU8HR%%3Y_X-&1KF9?:'7\3J'LJ
M[GZ-1HUFOL^_!2B4J$VW6GA!8[HMT9GWZL,S+X.3LW9O/E S3GJJ70N(:Q]X
M7'$V*SW8X_;COF=!IN^X,RZF1RR>/_]</,!M(M9-Q&]14ICDM&/9LE+-8K_;
MT-?5>5Z%O$>+N.OH)JQZ:7'''$8OP:M_ MA8S)#92].QEVPBZ&>H%F#IS5Q^
ME(T>>Z:1B2_P?1QQXS4O'E4S,E*S=F)!P,W<4,'NP *U8.<F[-CR\A53:;9Z
M"D0QD&YODQ'O>W?X)OZ%8>.9M;_&_H3U+M')L C[1#.X.7E[\6D7(JU$VU'=
MMJ^RO&_EV</YUJ\6(/57C,E5$%A9*O)ZXF\Z\."NE-7DJ?%OL)UO1YC3!:LG
M3WI/#^;^'UIY>5YO!_7H[2T'U+-,<X''!3_G.,$GTU"JG\@L4@-<*7%9#W^I
M5]ZQC_ZG=,ZC;VE$P+59M%;+HYA;[3J<=<8)J4<?Q6Y1GQQ+ [#G>M D-LT
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M]A*T:_):QY"@?HFE;,P<8"8MF45/?7>S>=C2((O=2%C&[Z&90K:;L!URFL.
M[*!D/+%%#:HOM0>:1((]=#6HRQM$B3(S"XY#3]=/R.P$ /Z>_+0,S6IKV5;=
M#.RM94@J.*F$ U""%0>L($ QDRRF'%''Y?58P!DBXFZ+0L3LV-C4V+<39I7
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M1G==,:\I$3L9)N;+K&[XX_4W%,%Q#<DD_B%HQ<)E/S5S@4Q1",,9Z'R UN)
M:XPMPS>M]<T S@,9F0.->/<LZ^U:]0*O>(I#V65D]B9,V3Q_;P6&)<WK,HUU
MO\S+_G(-QZA37&UN!/+3T(HK4"_<CTC0W[>1+U>%8B07GDS"3:4['BFLU@Y
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M-ZG1[]G06LEH4F+)C$WL%*?BBMBI[/-:[/]X6___K_\'2VES^+\ 4$L#!!0
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MSLR]9DC::>"!WA<L5#HF5RN5/1(OBYSXF/\@8I)S%Z(<]@LCRR$"9I.$Q9W
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ML+R1ND*&JQ)8B$$4:$\5WM[KGUYYGU3V51?>10%K7OC>V2B*5:CCR2A2\.G
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MX>!7N+VZ(+6V&IBGB@(&P2K$/8<PU\G#D0;OX-X<C)8.B+E:K9:H#\MBBC_
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M4@E^,E[C*C#+!&L6N?H=""8!.M5.76EWU5;7X").06-P+_&+YRO!5E=#R'U
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MUU)57 ]5!_"IS6=N)<K[-Q*1ZP6I"("7E6&:R%DBOTFIG<N5-RKH2"=/RE1
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MLSXM&EN>9?YF)2SSLV8@X93,JRK'DJ#+EQF--0@JW$/Z:Y)>QSH<ZKRAK=7
M8N<T90(!2! R-9)L)B-5\9U&![96@^4Y:?_4>V-#8$KR,D"0%M008DY-@G.:
M;EIXE(Y5!"4O+UNM?E:"EM^N!"WWO@4QZ#U7BW5R.>Z*E=Z,US@3 FGCKE'
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M2K* >?[*>-)6(W>@@B)=I/)WX*8*5R*ZHA&_E6(I:#6#"/8:FY7OO-KTZE2
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MAW1VO:\4ZOFW*(6IN(0S&4DG4ZQ;5GCQZS3>'^,(KU)!F)/!RY5/G1G\ F.
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MSG @80D3JWEU\25T>>6I3EQD)S4A9"=J8<"@9-3GHFA,EL"]N88@E+6P3R9
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MH-6/"F QW$+9/"0 CA$B!0.'IR>,@>RQE9ZY #7[1&>UFXA[1<Y%83I&#T-
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M; +*$'1H_!W;.@+5@Z@^$"V^+E:$O567MJ7.%U*RX1&M:RU[Q0W]0'H%*G_
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M&)=4$BE":1ALRI3&0Y8DBW! WC:\;3AH?T2A85+" RHO".'AAIZ0HB-W,8:
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M_*VY^\QU=3GT3*ZT*6N12\#_?U!WKM/HX>./OVT-BM'PXW]02P,$%     @
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M^^?D0_/J>KIF/=K@-!%;)EZR52\ ='%*X#;&.+"H$MMW$5YQH_CU\,K">,I
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M5E8ZO#^)P)9!<9ZIJ2Z!=( !@H;YU/MYD/VRZ_4T5M9_R-+TFW>0H=*)W_?
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M(A2XHM#G(6Q/C)7?F-9TXB* 84T$]YFDW&2J7ZNAB/GP *Q>,?U"8ZF/X=(
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M%\-HX+#4"<^0$JN*57V0TU*1KT-I5F\KA+YFA$0@6H*')IBOLJ6_(S8U#8Y
MN'6X#2HG]H7C!]4>> GCSROX?'>%Z]=E:3(:EG%MJ[>D%0>G]N%B4-G+=NU.
M;&*61=4VC56F\MQI-0H<4!YWA=I<O[/^7&^@$$H"_H %09R*D49ZB='$R/5W
MWQNAZR8S_]HNHM)#0+[%(U+F=$=)7?$B _'M>_P>_G84(;W!TB))T.I'!; 8
M[OAL'A( QPB1@H'#TQ,F0/;8^<]<@)I]HK/:3<2](N>B,)V@AR&@=H#HG8(_
M8+TG]@*\'D%$J\<";7$7!#@&,#&-=P>X> 'FX>2<'HG]8IEKF/!#=7;@"2.@
M)32TIODL&,,RCNH7X_W4Q=#Y1G8C1G]?F0LPNB"-TYBI9R$,S1I8Y#JTK60S
M%3$EUX9J.IZ*,W6>A0C<K$9UMGFB.2O-._DV2_BUUHST,%K.@GK'FI:+]+X4
MTZ60J?M7F7DH&QH,C[FSC(4:P%"[")7_,$&;9<;Y^O5J1D7.VQ%E/KLL(DIJ
M[N:@>$_<^CC&/?F:9M^P!>T'.#!#E @G3'<D_/'2<^PD[/WS\-#&Z:*+*/9.
MI8_'T-M]^^K%>T\4E!P^OMF%ZTARXX<W> T_Y,6>><:7A*CE#&D2P6%"_;[]
M[/V@X.>_W>5?^_^BXD*0+G82)FH@+?(.S"E#0\E>=*K'_*VJIE6U5--X02']
MC#%]&E'/8#HEN53LQ;Q0WGZ(6V@-,[@SDY:71]CW65H_5+<=&?;Y20W@%)V:
MKL35%1]5E'D]9%X%_&Q:IU;;!%QE:AYRIH9:0(M^TRK&H(*Y#I84'3>XJBB\
M0?ER=YW'JCO(P"["21K/N&USDP3PLL/))!J9*(6F)M4]%,-I[,X$Z=.&+Y#1
M?-*H!]@K?A6V['8#/4)66B/8ZH'",#ZJ&-1"T1OLKR=P-4[%&2Z^>G\XQ+ +
MZH ]5"OL]3!>;.87DL)U/$FB00ET7X8CC0N/.$R1$<ETCS&\/T68>/Y)AV $
M8Z=%VC!#A7>8_/= N=6=)2F:8&FG[& M'B]Q!%^W$'D,FT BXRXV 64(.C1^
MQRZ40/4@JO=%BZ^+%6%OU:5MJ?.5E&QX1.M:RUYQ0S^27H'*'_"B]!(4[1J#
M<FX[!P8&UG$VJQC]K))<]"QF0<QV#I.\S"C^VC6& Z-AGCCZ:-=;D6]0^Z (
M^XM6_+*#2SIWU4;2=0&N#K*1N;.MQ%W7\*^0"UVW=+-1=ULF*2H#XM T<KCK
M48:1GV!V?C";LP(+!9L[4Y#B%.& ZT"#IP//"]?U[L_ CT%-B+&J*HX53"7*
M)JEM^%EXOZ<#[U,*IF!3)'M;ZMFW9ZJU$_NG1_CS]GN<%[[\,-'<2Y3>;P2!
M.V)%_1;/HN!;-=(5-C!9%SZT2K9#72L1( 2[6F*?'R\?&T]0K>-E[MALU#0/
M\Q,FW$P97>G8.IP>1AMGJK\X=LT]\+CYG3141L)!CP$I@/C,5K-Y-Y6'[::&
M=ZDFEP1ND4VKV_J2Z!'.;4,Q&C.M\C1I>U,Z.^@9;]UUW$\JD+9\DRC/J^9>
M:4 ./IL'<^V*(CXTW,5=%>03HF>9?!_V%:[ZR&SB _<>'VABZOT \0$^+B ]
MS"E;)D8 C\$S;SO25:Z?CK: \W)>YAXSVSA\0EF_]2R<=/C#^%<VD?,?(BFV
M54;*<HN$Y%(8P2VY^AZK.C81ZL=!_6N2!.8XZL7O:DRMGAOB&XA%^]X#&MZ0
M\.,@X35)?7)(N$P<^R38$/ C)^!P/0BX4K^%E!FO@6K2)HH<_*"-<UQ5):A9
M<Z7+GY@9!R;OQ%;7.9KVG=:*;HC\OHG\*UR)5^?>\ZY2J+W=-^_7@M978'K"
M 1BSNV>1%3K-] 7YWS#O"+-/30*LZ[?#PZ-54N_MSMFGMKIH&,64Q316F23H
MH&"!@XH/MRK^W*#JAU1EH;=U].GTP[;OQ(R=2.CQ%#W198+>7="ZQ-OE;?7[
MQSVY1Z(3IN-)W]2^NI>?]7O;)I$#?<47*J8LN7JR&>?MDQ,@8U/]ZD6DI>%2
M*TV40"Z[C!/B@VC*66J2HRM5:D2KXJ%CIYNI2\.W4"86# 23=C>,ZC'XY)I]
M'AXD?[J13^ZK C(FT=R+5<X'LY<2XG3$ 39D ,OXZ?[HJ"Z7G,)X1HR,(@'A
MIN3\1Q7[:^]="^S1"*JC(3G6TZJ,F*6SJ+9P!XQ>,VE380B5I4VG1/2M0I!I
MF>6EX,/5HTWO-]ZV1W(:UL3;ENB(=%W4IY)ZU3\3.I.^QZ>&5$U[:$S$U,F<
M9\49C@05'/AT.-Q82U95,'19!YN3\ .>A#5QVE'Q!*'E"N^G*D2&[W#@=0W5
M-RB[)AARK;]QG3%J1@2Z;"J*P5K)3=JY6)DZRS%3;',<'L=Q6",7H)#Z8":]
M3"N%"#N\8@%+X*8+ W<?:_0MU-.)J ^KU+6YA&]*I2AW;$/]CX/Z]7I0?Y)6
MA>KHP&).'W,Q.?S$B6CL+N2*<DF=6U13[B)3L%_J=D7EOC7!J_IZ]]DP^!K<
MQ0C?T'Z9 ;K@>G@S)Z[.730*%Y2^?9HWSK-'X3QK-@E]D.?XELZS\PSS[$'J
M_5YFLU4AS3O@YUP%3HT:K)?LAF#H!$&/H0$XVY0A-)5T7:JZ!<8COO\,YVX;
MD"NO,%/[$Z;F6VBRYE,2+#R2NUEJ3Z<:OAB"\9=>4@&X< ZJ')""-=5&^V!^
MJ2T"0%6_;K$ L-%'59$>MS+$-P[#'Y.#--OLKC\'D918BT6X#.O8;V$M4J P
M*B)55""*IIS_,D.(R02U\XC/H^/6Z<1R9$-7'F@.M"OQ)["$K#FT'VYM Z-#
ML I SX3G?VW=0*F+?(>=S$1%,<\DP*T>1FQ!9'IDD"+Q"BRQ+LHL0; ''0$3
MR33!ZJ'Q 2^70J.*X6#-#2IJO;1,<ATC.-_<#D"^M^OU=*@R[T.6IM^\@PRF
MZWN]3"4#8H].+<O.FY>[>YUS4S*Q>A</MI:J:1KLBEC!LGY+TDMJ')PQ_!]N
M2&.5!4F$,CV'K&N%&FO'!@Q/637%=*L!73<UU0]0P4)>3DUA466+=<]E,=6A
MBBN5"3FV<21X2ZIJE] R RZU\$6X[Q!%?;&LG2[03AV*C&C#]Q\#WV^V%U]_
MON]886<ZYG+'9=7&EF6'"5;T<"[N<J&4+&SHY@0]BA/T]H<[05C @$5$2UM;
MW0X1TFU<CTB:4;D\5L:'YM5D@5TJPML,-4+D,*P+N>VS=$3YC(BY$Y22B92&
M9= *:_FF@YXSE!#,MMQ+-*+]8F$V5A*2!<BF()8 @R87IYE3V6@=,W# I2"$
MW:U-0&"X$ZN'$=F[T@F<K,L;+4RN"QBM"G%?.(&94LNT&9==K7F/)9A%VPV-
MK[7X9AO^]"CXT^[.#\>@?J4Z9=2@J=C]K!R@*X>BX/#%<EQK<1N0AB/6*@-<
M.5V9@@8&IO8HK.;_N+^_;>PTP4.ND*\JI;P;;1QNGG?2.?N%; %G-6QNIXMC
MA7GCE5$@8VG:+/6 *A9O7PF/9=:BX;MNM!1P;J&2\,D$YH_WRPBN^9CF3/$)
MPJEYTF3?P72 2N$)TRR:(*]WNR_@PH=E9@PQL@7SZ+L' RK&>1<Z8K-@SZ=O
ML#8]H^:,N)BP;T-86W;4X:C@U4D033<*X:-AN#]>?R:J]8LIS]WA:.^]/D&M
MT]?H6EX*ES:JO%;<VB'_1CV7$"H5=:$"OR,H3?RFRB+G0X?CJ['FJ]!A)6S'
M!S;*)KYWH0+AEH(@C]'$6E8)SA&&^GL9CAC;DKTO[%;/"(?%::E2L6AI2E(U
MXW:XO<.<!3M_R-,AUO\G\*<\9$A&VS/&.'WX_C:;FMLX9L-_'@7_^?'@K]T3
M_%%KDTN?%TNESY\[#F*K=F0$YY1'Y#"5\],!G#\THW 9!!I_26Y^J*KV<*#
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MS@R70>-##<QF8=23]<5F)H%/J9VQ5IFQE(4V3&<$!Y^>N\J37DI.S2'0)RN
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MC7-BP%('+W>N=#5M1]UNQ&I*=1S2$= V]K.H+0.4H9FT-AZDZ1?\CO^19L=
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MY%4O0>>]OI0^-=YDFFH1DU<C%25YT9P!X:TS"CEM%+P3I!EBKF.KEXLHIP_
MUT#[Q+\J^2$:*>*STTJH^K-;+X;1P&&I$YXA)585JSH<IW,A7X?2K-Z]!WW-
M"#U M 0/33!?94M_10AH&AQA7>MP&U1.;+_&#ZH]\!+&GU<H]>X*UZ_+TF0T
M+./:5F])QPO.Z</%H/*2[=J=V"LLBZIM&JM,Y;G3T1,XH#SN"K6Y?F?]N=Y
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MKH@5+.N7)+VD!KT9P__AAC1669!$*--SR+I6J+%V;,#PE%7S2;<:T'534_T
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MG?]3HQ*94KAE"BI+ 0]E7DWKA"J32X<P?A]I)D)-(H5Q _<.,LU\V^BD%,(
MWE,(2X1/1.-I;LF0U*8LO0 )R=1I]@KTD1(HO3$6\J4%T11F^W-;'2!)1G1H
M]\4HZU^L(/HH=H@C-ZV#R[5%QII-3-;E2>$"]09VZ'*<HBL428H/*QJ<"D:2
M!E_':8Q4W%1F*^=$Y9)P93)H%K $F 2!UPQTHE%K1?_-9<*/&U%^ADC7YSO_
M8=T:,,Q'(!4MH[U(B3%,T\O6.%PC@J<'2X'J))M3"9!X%#(-D_4+BBR?*YXW
M\::<.5Z ?(='*R\$IEK"JD<M(>RYHXLFP E0GR=[#;@U'X@"TUH4NYV*M&)Q
MVA.FK&BPZD]6@>0%75.]>C29^+JSBXCT<S.[.:-D5M@8)*LN47,U<V"BK)#D
MTY33=,@#%\>LX0WP#848HW$\3ULQ%A&M=X<L99+-]"@E0P^L%N(S(C9K(G.
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M*^?2# S/KKM/K<,GB.4.GO>\N>+.<[!LDF:Z%5FI1F1A[;2STK1*J)I2(Z+
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MFVTI([7HN<#AT7NJ2G9AV:9A:3/3A50@"3W"44 G+3J1I+8\+\$6SW6(XH7
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MQ"[.Y\/*3]HD[F1L<@"6RZQTAVV_-0.O\NK?>-[6KFU@_8@JWIRZ(..+M:A
M%*."B=8:/+H]M4>F;0DN!5R-Z0C84-#D[F.Q,:6=H_=*R@"FMM73M,Q@47*"
MX,T8@3E()Q-,[:&;ZMF6;[VM/3-V@51(:\L&.XAMKZ11I([39$1>JZ[^5D^W
MO>HA"Y$2"%$!1SR.IKFA@<I=* O4WM :=:IZ4EM%,-S_.4+,"<P2H?PB\G[Z
M3%T&^JR.R-?5!/$&H>.[.9-MZ<7P-X&.8]&H_O;+SB_T.9^JP'SN>,=Y- %R
MP R&TW2B$FR.T9"7OQ;PLB(T-U]&83%^\W(/-#744HH0?Y0_GM"EM<LO,&LF
M4+$L0I%.?[FV1H.3K2N(S_BM-UZPW88,E6'/'^3;*T9Y-_O:2?"2B5=HJ<]Q
M.\DV?>*9KA 2R8&MAGI44IUA%S#VO!.]I:H\;#S=E]O^G%/JM NU%QB<PMP@
M<C9Z@T;<'TD8!C,\/(*^V^5.-W]+#12+.=Q6+HCWMNDS;\F0&GX&8R53>KHM
MYB'8!F"4&F=_ ?.>$I\I%JP4%?HMY%]QGKJ#,#O)E5?8=)-JAG!1 @Q* Q7.
MXY,@G"ZB"VGH)Z5^O&9*L'(0Y$DBT0['3:NW,$B=8*N#I!AR:IK(N0N*:L!:
MH/<>*VGK&?0HPRE*46.872NK,/$2'CA!^=RB"Q0VM65P!E@C&)1042%(G2W(
MS3K9JRK6SSUFN -32IBL:=?Q)V;UA!CG$C9KTP6Q.I9^KR;KC6RP>:=A16Z
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M<2&99'234&5Z.!"4'CF\@QHK<0-T[-.#H@S?3DM. S>+)EVG*Q^";':8H@S
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MM%2^!.:?I[A@?I6@"TH"NV-G]"X^$%2K-Z3$AB%R!9N;/W\>]MSB4P0!LS;
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M2_\[<S"!5<:AY-&22(#53)S:'@,R"R<DR3'=E[^BNG8X8C#&F10#(=2UY0+
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M'/9MR%8Y#PY!3#K&]?@>\&HW\N)!R(M[AFY>7I-TF..U!,4U#WC+GUMCK-V
MGY3PP>=&?Z7$7_F,4 J1XQ-V_:=&4\OJ:EN>3DRKBB:W]JV)C?^>T*^)CKNE
MR)'1BRGIL2T^G)6R,F3.[-"?P3GEE5SI'@E,/=:D\K;;N[0T?PRMN]'F;],H
MJQ5ES!OH-;P)$==\#A1E4!-W%2DF46[8H8@0O9M3B(;D(.N\&@8U<=T5]7R
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MC[W^S 6HV2<ZJ]U$W"MR+@K3"7H8 FH B-XI^ /6>V(OP.L1-K1Z+- 6]SV
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MKW_9?;'S%C>,')G.6[>4)%*AZHP*J-/WNDN8]1F%^3 )=&(!GK?MPEHL[L9
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MN)+)'AXR3A/S*V@T(/L=[>Q1[]^^@K.W\-X1=VL=DO?>1B2\X#**XT$9XYZ
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M5V=L O:X&@HI&0KCBK7>F=;[U])KL>F2?44'B U'VF8$13B?H?D<FV]F^N/
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MSCK9JRH/@+O/<&^FE-!:TZ[C3\SJ.3'.!<S5IO=A>2S]7JW5&YE?LT[#DCP
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MXD(RR>@FH<KT<" H/7)X![5<XM;HV,$'11F^G9:<!FX63?I15SX$V>PP11F
M)61I.1S!VU$T4A-Q!8H!7@RO@V=<PII1'Z;(01^O _JSRI%,'7-G2J)N9)0-
M W4K8DUW6S'F%EP)^ZKFE;XIDPLCN ;!TFDCS2>_U870E_;4,(5K+.NEHFI]
MFKMCKTY2/%R$*V";<=,UI(XE*#+FH2BN[:['(#9?K938G.7Z;LM-9-1QS+#5
M>,*:W!(D6VSPCTY4ID!H34;>3AOJPZ]+V1DWOB!F,(-GSKCG9:-3H#L\\9RP
ML*BU7W"T;*/=K@_J@SVH.TLXJ&P0O+[?@WISNZ6*#I 53=W)6PY*Z]>G/I<N
MA&(=,E%-4#M1<2.(X,^4H-CTQ&V#*!DU8,32H4JXCBPL"VF-/D?P;5J5Q+?"
MWQ=]!=G*9$JZ <EH>S#=FCP4M"7=,_LQ! HE3_*XN\V,&+?@(I/D;J0P<;E\
M\Y=6*Q?;;-F!"205Q6U&!3SOPM93TN+:C](:48+;N&&!*JGT\/=:YH[ZSOUR
M%,,$.97AM:P(XQ6>.6/2AMAI818N%)<"\4-9:F>WC:_"X9.-HFVO_CJ7U[95
MV:83BYN%1KG!)<4Z]P2)T"JSI)^B<\6:*6:I<'?\.C88C];C]+BHL*$QOX%K
M5D&0@DK;:H(CK491^0,I8*HX10,5$T,<:ZZ..\#=ZGC!H!V[Z'JGU4NKE,!_
ME5'&5UI5&;&CJH:4./EZN\JJ127]Z+IN[/.L[V9IWIM;";BU ^>>!-R;AR[@
MI,;&8:P6>RJW(3R?0N'D*-&&*VLQW"L/+QK]&;#)5' &3?A2A!P"&$PR?1&E
M)39CH80A*:2.+HB'%J23YJ*3@BQXGC;"GS5E=^""OMC7F#"HX"6PZY4\O98M
MU.%B HLW53ECYT4]ZZ.<,\)F1JAP'8&Z,ZR&!\@1 7>4G!!EV3AYUX&5FM1=
M \?3: !6!4VLB\9WPO-Q]%W25<%Z1T,B2Y,HJ+DH_"H94%PNW*R7ILB%^UW+
M+K( Q'_$K4X1(-B7]#5VTO%2%0*8EUK?.GZ:O<M9<\&9RW>.0=2C3(^C7.<-
M-8L<@ZG"B:7)C'2X5A>ZFO.F-/Z2ROU%&03<KZY3-Q/$-@[WMV1.?[.2+M*>
M[IJK<(L]FC%"4K3^2/M&C<2!WAK!W9GA(BA\J('9+(QZLK[8S"3P*;4SUBHS
MEK+0AFF*X$#3<T-YTDO)J3D ^F0%D.;O-(+IZR'#8=FDT2Y5E'V]O))\@2P?
M)XLX.0.RIK>"CVXMZNU!@$W(D?JL<WM$3B;*J9]C8>D,OW/,\3K _WB2BKIJ
M&L"CG[(F%C+#$T468+8%;2C19S:NMI,D0*4+WZZK\?+H3GJ.3=W^0<W*$_8T
M7GOJ7JCS( ,Z$*:-SLL(]:7:JJ;BY40+XR+B!)6[5 Y?-JM=G^XL"7%NK1[>
M<,'>KH9ZV)T=24UDY^2PU]04T4_&>IQF\*/R*UE;1==L%D@0JVB<F\]XJNR#
M3*:7Z7%JCELM.Y$TGBIN)T=5!RHOW/("IZT =DVB!#\KVN%+$VYS(U^8:0DC
MR$B-J"8!?.R[<YFC7-D[, />Y$%NB!P[,*^SU5X56I!I*^LX"9 /.2VEJNZR
MQ$#<6H&VPT1)&1IYJABXF',8, 8WL]-KW1LBL+6V&:(=OILRP_C,J =N-N.4
M\)KQ!'T,M@M1HW5X0]:2F 4!C_E\?,\R1(15]VXM*P04T/?<I#_JI2J[@^IP
MEQ_+KS(BR5EHS)-I/3.D[D4T^4^-ALH.9B6C27'SL:S#O2@Z)B? 'K@DWHS$
M58F*"%Q=WV-&%B0O55GD#23#JF%>-E2)&2/3;NO%IK/FI,Q0HW"]7H*1A<O@
M-B=I-RF7@B @T:]$3',)R;Z1_7=$5\U.6!6XEA"<W>5IH^@F!4UHK,,(CB?Y
MI^A0+$E_N3U14B.Q?Y51E4]L3W737.C?ZC5+'*N3DM'5W-JP5>3A(R X_!?8
M9T;Y]>48C!5.,+/\UO!7FY\1G:C09?6DB!35[T9 M=DU7]%1:E4!>/ZY:\?%
M6+#9<+(RQ'V@U<GS2Q:0^&>0AF:2[3#<@ SAX= 6O-):4&:@$2R6C'P,6L2U
MW/4"GU3+PARI+.2_9/&<%]M>[4;K+\7OS2^L>K586<;#9C[J-\_QG<;O[U,Q
MOF\ECCY>MQCKQ 9J0<'#&H:%QKXNQ'H(IL:[U3 UCE($4AYV5&0"\Z5^47D5
M!'(<B#,MD4K#$DVBJL.OJ5SO[S8B\_/0/:'SWCO=T_K-6;!O<"4UF.MR[/QX
M-_BP$M3_.P4NOK-B[7CAZNY=$MD5=BP:</'4>IBM3CT0^UGL$:XLI.@"&FF@
MW!->.##YBRB-K>(<JTMT3M_E67CWNBEG'\CIZ +!79^853PQLW-J\/!X'S76
MV\:^=\:MO3/JV!U+%W"Q.P<<Z*^?O3_EL*V)^%$2,6><H"T<8V"ZG7Y/7M70
MA) U$ZNBWO5EY%Q?9::LJ6U-;;.HS6326\6".5_"($&" 6.)BY3P"!N,#+&S
M<+W,?$ >>P1XKUP.%7^<QP[1G5<UILX#G:@L2GV;TL'>1#U;WW?<"85#^-0,
M""N&\-]J[-BCP!PF)SEA[AN<XT:>BI3<5TZ=7N5NG?T4V]#7[3*GL%\6#/LX
M@S=<Z>I8&[QSR=SI%O.@C^-,B_>.+5+N,[96P]<R90D[?M)VS@"#968?C%0V
MU)P:8509SJ&IJ<QC:OKN"*1:4)%=[UR1/S%WU8*U+4?W)HH4FW)A!8U-(0-I
MPY'E81F;Q$#?I!T25$@035B!CTS)JM7JT\16>W+*;\">4HK3^IRBIN/!4WEZ
M2OGG]<!896R@)!F">8$W<HBOX)0Z+'S+8TXO[J?AU+LB;H(2YTP'91;99*2>
M02[=1^0SKIR3.?;^A17XO2I(=NRTL7$NGYG-C#^@,ZU*;%[KEH^;#QQR9#:1
M6&-7KAU5A^2B19V)<OG&>&>/Z'@ 67Y6?2"O4Y/2X.T&A>^ .U75K+;N13.B
M A:"EHC.5,A;N?J N ,7D9O[NW!891Q1JRP%H2.3(<8862U&O EL_E0E;:UI
M_W'3_DFF+T@8=<4GTLRP3?Z="!6("&OYT0P#8RF*K6@"KJJ'4A>912:OP:_9
M5/!$$*PJS^\B+NI,;DG@X_/BC0V@[-T<VYFQ1!J T51H*GI%874B&0VWCL S
M2/\::WFU"KJW5P)L^48TOURR;B;JV42[RAG10 R)8Y-+WSD2DU)/3(JJ[RJ\
MPAK:!Y"MB-]F>2+G?#!RXI5 [3"!<Q')UQH7 SL9[!.<#58S-L#$!-FE@=)R
M$XBQ1IZ0K6[E:L@T^YY+Q6*MGEX G*BD, HU#H"2.?G9:$4D\C=N#YH!!+<2
M:N1[G2@S%>X78U8FZ87H1:;VE5+W"RG%Q>%5<"\&O!(3>)^.TJNU]-6HK9\U
MRJVKVUG>,OWG'MB"(_O2&;+/.R4->DF\PJ1R=[]JD>/?Z'O> J&H>A1S61RH
M]KG4T<[)1<;*,BR7IG6J8V[*=^(!'I2%>+6;?,_F2W/%>X$-QN1<51BHHO.[
M'*9[B<SI,NYSY I>'7;5;Y[2#.WZ(G/ X3HJ\:GB"W/:J4(;M,!88:*CPL;,
ME.T>BE/%V2*PRLN !S/!K'AJ-8M^!)4E=M\L<H^**9D7Z[\B*OWFDGC\+??=
M1'.8:92&C#X+(]1=&;8MJ!W/.^.B(TO1L/OPI(FV<+Y1!CIS&N ZP.7=Z\OW
MMZJVR3]"/G.W$!P!ERG4VR9'U]%.A#@QH"4^Y<8S,"L3;:;!:)7Z;WADO:-,
M]SB?&<E4%\2&3I$-7Y/<V/54XF[/?>--9B^'I];9V!E>"T*M6:U:WT02-)AO
MS;XU(&]%0/_H]$J?!FB]A&;1L-Y#YFY!1>6$SIR5\V)Z35&XI?,6C0,'U0@\
M(98CB%.+_WBIZ($,\^A3Q9Y&1P)U@29\*D38QE?BOQJ=AP',!QV9LTZDU& Z
M.:[BT9@[*[<0=OZNBJ_1,!UJ\IY9U&+#_\R*AQX8E075R[1!X9RG4$&-;^Q+
M:;=\"<P_3W'!_"I!%Y0$=L=.Z5U\(*A6;T")#0/D"C8W?_8\[+G%IP@"9FV
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MR=+_SAQ,8)5Q*'FT)!)@-1.GML> S,()27),]^6OJ*X=CAB,<2K%0 AU;;D
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M%JR&)"A'7%G^HQL01D^-UJ(+"I\.4)N/M1(4S3S-N AQH&".+ =9?3<J!6C
MG-(2/J,E1AZC44EW%[LI\2CTKGC!Q7\HR@=,/Z;V!AEZI_\HD\#$V$S!A)5@
MW("#=G%>00^3;L0X8* 92,.Y?IJ$IN9"RF$$XFW,341,/1*&IJT3LJ,!'BTV
MCEH/NO/!Q,/#7AST^#AW-*.Z%@ YJA"':/W-C&!]_@!;R/3\G3*.)SUVG"::
MRM5"-:;:FG9^$4^-+!T!> 36M:XG?11";$7JO \')F?N(LIM?DGM=,,'@M1B
M=*TR$29@,&,4,PF?SYGS,X;OIT[YG1H,C!AK7&,%PMA$-\QP<@-B70W0GEGB
M>PC-*0V$@+F5%4KU#/AB:Q5$A22JP),N8%E!+V?SB^2&,T5YWEC]B,;EV#Y7
M;)X[]GBNS_-#.<\K4A\^0RFM'6BJ#,03B35S5K$2$&V4\C7LJ-2@?MHLJ58Y
M<4OMM%9R)=:-^<OZ%VL7 F:(K5A!)9!#.KO>5PKU_&N4PE1<PIF,I),IUBTK
MO/AU&N_C.,*K5!#F9/!RY5-G!K_ &" ,2@(G62L#471E)J].,"CIY.C)N>-3
MY]S)F;J"]6W!L5O%$GR@J12^NVZD<BFJHJ-&G4TDQ)^;;4TV4YO;"^+/7I$J
MS;D5M9Q3[N([F*M^+5[$3\4PZ81,G ULLV 2*\TMFYQJ<M6R6L2::RZKFS)*
M;M..MD]<+HVCT^PCI5'8@FZ^F1V;]5AYO3;0?.[*MZYRQJFEAM^1N4D%T+:N
MF]-H*A1VL(C!ND1PD1F)T*(6DC7(?68KT/%6>O-UW"D$&(3&;+,(',VS$%YD
M@X'D<KEE';CTTG)-<")><P8D9ZBM:F.G#-SQ_"K\Q7H9_R0M9'SV>[\J:Y<^
M/.+$,+<X13+VEWL-G/U)O:U71>XMKP_[SCV7.]ZNJP?+/?*?DZ/LVG&1JH>U
MN&CJ;9U-.^=:L@VWCR53L]Z6NM62.F]4,>-9YC?.[IM!=6[5*%B=C<2'FE(E
M9%&D6:)9I47_941^2>FRX'2USJTG:H"BC$O1T']FW'1Q9(QHJV"3'>Z$_2+&
M?H[RPLJZ[;<&3G7[[8L7SSR)61)X1R-H:+IJV2%W^.2P<BZZ0*<TK%]>1I)G
M@6M5X:S-JNNN\HN*VL3!RL#"$/R7?+-1S)4U-CSJI+_.?0.WOLFUV/9A2MRT
MLDPJ./$Y3T$;!85I#;(6RT)QV,<H4M9^O5LQ4].:^'Z9Z=9M;8A[+@6\+2\]
MKW-,X%@(\Y04DC]('818EW8C,J9A!QUJ5.;$<4VAB;+_!WX<(_A29DN6R?>F
M$NEG-$[#:!!)!N&8NY#+N:$J:M.]0!I3@;7?3[%TC=\K:A-UULK8%3"5QFKM
M7C($7R=A*(E4F5E8Y^',EH?$ "31BA!@'?\A>3=D#/)@F'N. 06!9HO&Y/C0
M:9G+"&CD]?=@156N.=]S:GL1(%LA[1D+HBQ,IBB3^%WN0,YPY32Y3- #TX;Q
M1KY8JS3K[O/8'IWU -EANB8%/JE7F2K5;7U=7&(B%[N,:JD73K$9?ONEI*!A
M3;/=S4!FTY(?1#FF\1,H!TC#PPI$;T^!G)K_'IBM+3F[=6\;7,'=2PS&.2UF
ME$F)QQZX454W&G7G%/:P\1NV# EP7T&//HE5LFD'WY.2Q.8,UB@C/[FD8 I[
M<<\55K<UIYI\R_A-+4/T.<%@@NX*YO>LVE8ULJCT623%0E@0*XVF!2%PJ3%!
M>Y)GM_((-%'TG$XKUP*<,-HQU[Q4C;F2 ;#1PJKT6'D41)-8+]2T=ZW@/0)K
M^<4]U\'<7L/3)F1#GCC;UZJ5!B2M/[O..5C'*=HW ;DN"<H17976'XDHM'[U
MO4T+ 9-IDN:124;EWB:D)F% *&)$1V[T'!6F3V-$_(!K]HHTH*[*3O?YO2FI
MA1:*P0%!-2WH1)%@E0QS+61@XCVDTIFT<!MIR@KAP)T%ZER1-BIM$XRV#;W#
MR:8CS"SY3,'C8P>4EWJA:'V76(S+\Z']Z07G3WYU"("0.MJ0G\8+XRJK%F*@
ML9T(R5"@'K:Q_;*9@]SGC*E*8TZ<+*LQ3-&4^2(VLPE-FMA$5#2RDTGUY?*/
MD0HIMXY@:-'$0$=1F41LP8"I .:0JF4SM)1U>)J6J3G.,,I T"KA:"DG4E!F
M\MCI\(41AJN?_E*>;@>,@9_Z0"6VRWR LR("R;@V4CD8I2DUF=W@+<DHUPXN
MV73J3YOOIMC#*WD_>NNY%7L\I5B616\:1SEWIK5FJTS0MBTBTZ45"7 -GBNX
M"3X$\2\"Z0EM(R;P?<BPT:DW@%ND4L9MY&;RPZA;F^.QE(0^JJS%I%^3E\)I
M995S_<:LGM>K_=]EG>#5Y2)/?CT\\KX=GA_USLZ\;Y]ZI[WCC]Q]F;=%^E]S
MJU$YQ\T<7"LOB14,(MC,JN*K#ZKN-=MD/Y1$^*LTS7>O[TJS7$S_78K"VR%6
M=K\<[G\]\\Z!.G9/>E_/#_?/?._P:'^Q;;V+P2]]3=_>6:W:@UBMO>G[JUCC
M#9\YKYSC>?[<Z\4Q<(73%&127V?#6W/T?W;^[P'N?&/"W@,<8K,F[*]J//D
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M<L_H7S_/,5@M.^*>^^7>AT,)FU<5:39UU<U%K(I#Q%8)1BH9:HO&/6:7B\4
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MWC:>JUP_'=W_9N6\S#QFMC_XF+)^ZUDXZ>"G\:^L(^<_15)LJXR4Y18)R84
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MI@5GM'H%OI33>[%(\T*!(E#FWA!T$E@[U &TRJ\! [&FZ$=#T>>C-$O+X8B
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M;"(3V(S,?V>C,MP)<BR;E7693!#QG!HD? Y4%N),^&'%(&7X4!HU9RG,2!%
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M+K*P@R'M]E1$!L(SXT5>V-Q8+[P12X@T:9XHKX3,(H$EOQ8P-M8X.+!!>R<
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M&1>%<Y%79F\;E^[>?/8%><)>'-24>=)]V/VLS07CF,R26,M=WLK/68KPLZP
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MAF4I]BQO?S16:K8\77&EC>2&P-3I)2+1&11H@H49##NG#<<BMN')S[7+VPV
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M0LVV5;JLOHH*.Z5H0C@HA:@0#IG \*I/>*+:\A9^0OVZ'I9EXHEA+^85L#6
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MA:!DBX6G>'"I+FC4)WBG4<@/"#:^NV#E# DTP?NT &,UF>00HP(C*BUWQ#$
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MM8$>+.?-DAD-4>OJBB<%0#V>+G>X>VZ_?,D3\WA\/IVD4;W";K:9>Y=>A9M
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M< BA=M=444.9EY*A(*,%J]]Y0)WD'04KDR8\'XATLD?RQ%G5.8PGH];WO+D
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MSY?O78O=%OW4^% (PRY8<F=7Z>/TQH[!@K,W>8N_ 34>+5MA2B@EH#I9@D$
M'AG"U)!-6Z1*8KAN:CUNO_6)8,=L. O7.15"V'X!?D=6BM9U5EQI8FA>P*BQ
MR'#)<YX%O6X[4U[+%J9,SQX$IV%/;\AVS*H?G0,/X\^/I:O(.6&""11A+LX:
MN$,TQ V*'(?4QGKA/R-3.L"P8TYL? ^6031FHX9ZR>X**AQEI"9G@4D9*V[R
MKF/8,-T3Q4P+KS3Q,S*C&QA/8,K<:<,!]LR/I2KN!2RV6B"P[6V.V>)1I#(A
MP2@H\)):2X>;"+#LF6$'V)W,Y+WUYC@;CZ=?\ZIYB/W[L'0EA%,Z)(^2M1HQ
M#\:!$CF*G=1",:*#("UX4_R(J*T+0K_0%?6#O.,.]&"WN*@_UAU!<DCL!9#G
M)J=L.K5#TO\&CRY[P^.(EK^$#S-@4[=X;FJMF(\:# K0'@.+*-'LTRRH08Y9
M+77T2?H6V07_VF&2R_9+V<N0![5JG;>D6PJO*ZVTB2X(3I'*5P\5":#L1@!.
MBA")<RPF38>^?/]$##Z^6_ZZMWG[:>?Z.&N9@^-L$M["J\>'M+I1^4HEIJQC
M#AE#8X[T9E$"NP11+S#,6#RH^$06D);]^V.P[)[0*S5*UO*OA_,1O'FL9!6<
MPTPM,_!Z#)9#]DL442+M?2 T4*O%X',?]<B8#G$K;:._CB%'13U\@FU6 2"
M:930;L.B LTH) 1U860%8&"YSF;GT-WN^F!.;_"5)M"]V?)X&C6IIO)6>*)@
M_!!ILVX2027BA*' B P:1I/A+?3&DJ&N^B%33R 6GY-6TVF+.6EG!97V%E19
MPY#5G"#J(D5:LH0BQ4XP3&7"+6A4,GQ53W-2U_"55H!6<^HQ"M C)2N"L0HF
M101#A"$OO40Q)H,\-1HS1WCT+<['2T:;ZD<!Z@ZW4EQYE5+T\]LLE"!ZWMW=
M9B_OH$WS2BH+$#OM89@('  .D=/M,(DLUCS%"'B81D97233N1Q,_VW3S[7[X
MO8</ANF@VBL1$_;:BZQ*B[P3DI4@ RR-@*Q/AC(W>*.U+[I,AP#W:0?N_=9M
M5X1VWMMN4VV5+-7"PQ3J.2R$$K"#CDH4>0:SG]")IC8[*F7LXP&1LT.<A\3*
M=]-\1KCP2T^@_7%_CZVR"B8D%5A SH2 HI8:.:PT*&@1UES+B'#=9-#X:["Q
M(XR/=N%J(N-MAI"<4#IC=)&CI0$ZH[#&Z3'_KFYJKR1.P@9*D*425@FH% 5,
MS<:ES5 1!F^:]\RYT\(]I(GP]HYIVP7Y>T65DC@2'\" (1JCB#U'1.7HIC%1
M3C6WQ+>(!]RS]^$ 9[U6T Z);#_N9BR=>$8Y-AR,JI$=MZ3@ONHK[Q071C%D
MF(%%@D2-L-,<:>,X3LX0+%K,C&6V#@;$RQ[P[G5ESHF5_/Q]@M+JS,\_Q-KO
MN#5Z?(T5$T))1P+B("8*VF DO=CXF6J3.&_A?EWF@N!05N#.(![21+AT&SX+
M_[U89=YIN_;^6%WE\X%"=/G65+!@G%F,#(D*,8H94S0IDEK<#"ES(W% $UT'
M^ Z)?>>7%O38-Y-VSN$=OZE2RIFDM$)2&(DT]2Z[T^ME*@/B-2:$M= :S5^-
ML_U"W^LZO<W*_QY;?];2@MY?>V7,F<;\!3;B-6>:YSA-7&-YSN29-(2T"'F5
MRSY]'IX.ZU-=@"@;]_4:%IEI/3K!"T]_I6(ERLV[N"]3Y.:QRGM%,>A[B'O0
M H7U'M&H(G):1XT3M0W#<?3<HM<YT?5E##FZ<,[;\S[EZ\KU]<ZCD :E*QI@
MF"I-D6;2("&90)R[A 0).&IK<2(MLLZ5\B$]MD.WI+/L'K!RSM5KZ?^8UG^^
MF7RHIS[.#B?+XZ6KQ W%2@L4I,?(4J)0Q-G-(.*8!#62LV[R53PILG0*6'&R
M?+1??X.EMQ[9\>%<>;1P90FGT4F&;-)@9U-"D604C&WEL?54)2-:A#DJY2_:
M-56ZQ*NP-G.[RI?49MY&.RO[KE/K,-]C+&9Q-A>*MT5SWE.B<D8SGP,.:$8T
MPA:X2JSP2%I'#6-)N=C(8[MH.Q\/QM>L(+2:!)K@?5IXFB.TY/0P B,J+7?$
M,>/%X/693GKTQPRX7<-6:J%Z1/!\X^Y8KGPO6P6BDU$&,.0\(!,-A1_:($I\
M"H01:GB+9:J,1E.0+JV0.PUC9J\7\T4=?P.-_FIQM0GG]'*Q,U-WLQHJZQ,,
M#N<0M\(AHCU'UBE8M"6U$=OHDVVTW7-2' Z=<O=55'&?%&'4(,6#S)$O&/(V
M.&2]4XE@R1)K$=3C%%-P1PS8.<9Z@'5@ ^[-Y//7Z?^+MMYE6AQ<5P6JMU#Y
M5A55$0PM1PAHSEXBSR56C#D1;3<!$_\:=&N%[/ 8!V^-W7'NMK:*P>*J<U ?
MIX1$ (U%)%H.AJ'P@3-%?9O0!V7LVV&QK@VV@^/=Z^FB[HQVMY55FM'D% -]
M2^M\RA("$@8+I".-7G"&86D8NG?FH%C7!MJ!D>[S9:RC3?.=0?P.KJN*BGCG
MI$*848Z(< I)&3QB2D:#$_-6MCC2+'/)<D"4:X7LP!@'PV=TW=WJ>EM911+U
M4F?=EBF>;S53)!))B,?@+>$L]]'072T'Q+EVT)8BW=LXF\7XR,9#,[N]:145
M\=0'(A*2UL#XRY\<H1*1@"U6 DNC&Q'LM$B\B]_FG[_&\77\;3J97^X:A,=6
M60D;N+<@H_." DA+5]P44(YA&20PB;0)*%[&F.^'%M.3(3RT$9EG%C :.Z#?
MNJ;*.,RQ\P0ESCQ23 2$18+U49G$B D4ULVAV_2#8MWQP Z2;-E6[(INN:Z*
MIAR0EW'$$\5(86-03([!(,36\8 I#RU\GLN8\\,CW)'0#I%RV5#LB'&YJHK$
MH 1Q!+0ODZ&1H(*1F*'1BGF3J+,M5-PREOS@"'<DLH/D&VCL7?$-JJJTU2%2
M4/2MS2:FA3E?>R-1$-PG3AW'I)MKE7\IOAV'[-#X=I:W(SHDW;WZ*L<)B=$;
M1"VVB GI4(0!BES 4B^7@#:>8&6,^4$QKRV\11W'[GE5G4-]/^S<%W2M*KG!
M@/&Y8)J0EZ_.U2NJ7Q#&7R@MU L!7])S\I1W('Z?A-',3Q>3>0ROOF6GU[.K
M_-NQN#U6WWX0L=( 7+)($ K<)XRAX)U#3$<,MHRDTIGCIY:!;4YT2ZE#YIZ2
M'73TW;"=+?@<)W8R?S/)MW]'VWV;#Z]D?_-=3#9ZF)'!VG;(9ZW .>]14)%%
M;I/7\N?9QNB%G\/HE1/[.A[A_+L?A(Z\@Y_$AD>O4V?!+CB!YE;2V_]#/04L
MYS=GD_#JGXO1,O_FZ=Y\ZIL &YD^C&%^NRO8[MN-NXI5G'(9?3YMMMPCDD.>
M"06V Z.!6UB3O;.-+G 5;O$R =\Q;5YE[C/<!V440280A8B7$4G)*0H\,)V<
MU+3-:4(9-;&[;IWVC%VIQ?+,^\55[HX87L8O=?2K6^/P>1R7730)H*;6\]'_
M++]_M)T[>-75*RKEE&56!Q0="PA[+9#4H'+ ;SP0S5.BW?BH]AG4K#<*GA#F
MHBOJME6FY/KZ*8ZC!Y#_<V'K>:S'^9JSG0#:XY=V;G^?V$4 !H1!"5,T5V1#
MF8KVV:6MXPO0Q,+Y]"J'P+!W@X">XMWK2!R?\JQ1WY3MGZT"O;-U5L"O]Z3T
M+"++Q]EB!L/[@ZOAPW @^C2?^C_??UE.ICGL"M@G Y#J]./HC^6R&</9-92Y
MB&<S6 N7*)7-4;OLGLOI&%;S65X9OIO\I=\+X%RMZ0(T_B./K&Q#GQ:,=]/)
M/Q=V/$HCZ#T[N\P+_WH-G=_<[OSD;PM+NAK?[].GT<4$I/-9'_'+C=+1Y.+#
M=#SRQ<+P-)/E?+I$:Q6^Z7U:!8;].)K].4#<MG0O=/J2'0_&\0#%'V+W'[[-
M<1(Q/\;<YP^_'Z2HUW&RB"]N?HW3"ZCE$IX;G]71#E#63_$B=_B;29K6*X,/
M>/"$L-ZK+JQ-N/S#P0SQ[__R_P%02P,$%     @ S(!B4/N _#!*9P  M"4%
M !4   !F;VQD+3(P,3DQ,C,Q7V1E9BYX;6SL?6MWVS:WYO?Y%9W.Y[[%_?*N
MTYF%:R<S:9))TK<SG[@8B;9U*HL^E)3$Y]</0(F*[5@2Q9LHMZM-8DL$B/WL
M#6!CW_!O_^/K[?R'SUFQG.6+7WZ$_P __I M)OETMKC^Y<??/_RD/IA7KW[\
M'__]O_S;?_WII_^KW[_^P>:3]6VV6/U@BBQ=9=,?OLQ6-S_\,<V6?_YP5>2W
M/_R1%W_./J<__;1I]$/YPWRV^/.?\:]/Z3+[X>MR]L_EY":[35_GDW15OOMF
MM;K[Y\\_?_GRY1]?/Q7S?^3%]<\( /SSKM7>)^)O/U6/_10_^@FBGS#\Q]?E
M],<? H6+9?GN&B^I'H_?3E>[!@\?IC]OOMP]^EW77W#Y+)12_EQ^NWMT.7ON
MP= I_/G__O;Z0PG)3[/%<I4N)MF/__V__/##!KDBGV?OLZL?XK^_OW_UJ)/T
M=C99+U<W69'>9>O5;++\QR2__3D^^K.:3/+U8K5\E]ZGG^99^+589U/W]2Y;
M++.E6DS?QG9F712!HZ]GZ:?9?+::9<LPX/*]-T5V]<N/5_E\&F"%$J(-J/^M
M;;^K^[OLEQ^7L]N[>8#\Y_,1:K-5.IOW1N^3[D=#]L?X=&]4/^Z]!Z+_8SU;
MSN*R48.$[Y_M=4"U!6IOD^Z'MUQFJ\BN!G)_O.D@P_TM2Y?K(INJE4]GQ;_2
M^3IK,O0#W9R+C-?9YVR.W^?SN<^++VDQ;<&9!MV?B^R:"U"3SCHG2:?+V20,
MPL[FZZ#PO,E6K_/E\EU8^?+;VWSQX28MCDKC*7V<A8":8M>@J[.04T^^3N^I
M<V),NKR)?US8#SZG\["1+G]+BS\#A.&U'[+)NBBE/@SR?;9<%;-)&&=\_AAI
M;?L=#:'Q3_A0?0XR%1\-Z]B']&&+FI([U/M' ]R;M"C"V>ISW:G=]7M& \3[
M;)(O)F'[*$^:;Z^V''W2U7?->H:MFU&-!N1Z"VXWO7=/=-"/TD_Y1HS5=9%E
MT<)QG)K#S88:9EU!K=6ZAT$OEOE\-HVV(IW.HV'CPTV6U4'W2,/AAOHNC2?<
MFRP\GLX;C_O97GHEXL,J_%UR>;.^^'G^Y23<#W8PW-!OTL5UMGRU^+#*)W_>
MA!%GQ3(N(:O[QL0<[W(X\O+;NR*[R1;+,#&C MJ8J'T=G8^4QC/G]%X'(_+M
M75:DM:Q/]7OH8?"?L^)=>GWT9/K=@YT/Q6:?5L=&\?"97@806!'H7,V"'O$F
M7Y4JQH=L,0O*?-0ZLNG'K+A]G:>+FIMIBRY[(>_58I45067:&F=/H.)PRUX&
M>^K)Y%";7@983YG]_LD>!K.<%+.[S0E!KY>S179\>SC8:)@AUF;L\;:=#_C7
M/)]^F<WG8;H&V0]J0)S &TOCL?'6:#KD<&NB7+^'(0=_ZB+0H*LAR:FW9-3N
MH/.AOUJ$'[./Z=?C@WSFT3Z'8[.KK(@&_<4T6O-+O:BF3)S62Y]$1*W4!#&\
MO]JX6>K.S1.ZZ'/X43E=K_+B_GU04D\?^J'F?0Z[WJ3;VZ"'H7T."GY>U(B@
M>.;1/H=3FZ?[6O0YN+ILW-.@\Z&]SM+E\?$\?JJG0=3DV[,/]S2D>MQZ[MG.
M!_2NR,-)>G4?%OUHN[F+Q^MC SO49I !UF1IC::##+<>NX^W['RP'[)Y%OT#
M_V>=%N$(.[_WLT6ZF,S2N4U7Z>^+=#V=A:^/C?S$;LY%1DVI:=;;N8BJ)UN-
M.NN>I!@,H,.B-HWFR&RQ+%7,HV,_V&J@06Y-.Q_6M[=I<5]7DD[O:B!R3CTY
MGM;+0$2\7ZZCP?#=IR+\T 5G:G0X$&FE2^5M:=51DX#P;-6.LN/]#418S>6J
M1MN!!OQ'-KN^"4NC^AS:7$=#P_KV[I0PU9;==D_FR0[  ?U[W[]J&T86/P]3
M\X^XXM3WUS?L;@"RWN2+_UBG\]G5;!.=\6Z>+K:*W^H^G+:#[A?6U?AI<UJ;
MOZ-[ #:+Z=NK#[/K11C0)*"^#8V?+:[?Y?/9I,:!_[1>SD2$R4MDBRHFJ<B"
M:O5^MORS+A\[?<N90'A&QJ)K+XKH=TMAI[BT>/&9H.I6^$<R"5H<VCM[P9E(
M?Y]%V?O^\T[)K_F2LT'P.5NL,WW_:Y9?AUYN8HR)*K*T8PSJO>5,('S(KJ-0
MOEI<Y<5MN=Z4(9D#"$>;-Y\)K)K'@@9][24H+2853=L?'Y*URU:=+58_3V>W
M/V^?^3F=/XG!VI,/6Z6XQEQ:6H[^0<NN!Q5^CI%=^>*G:7:5KN>KAD/<VT^/
M \YOT]FB_7@?==/Y<,O>?[K-;C]E1=.Q/M='UP.]"?T5D_6G[*<=- V'>Z"G
MO8,.0C-;E F9K\.OVZ?CN 9+MMX,+?NZRA;3:' >Q>">76)'-L;G%LW>AK@O
MGWB %Q[F17QK]=YY/GENYI2SYBI=?BJGSGKYTW6:WOT<MZF?L_EJ67U2;EP_
M ;@MH?#?MA\G5836@S$%LK)7J^QV-ZAY^BF;__)C&$!2IUD"-?4&.^68QD!9
M11T5GF#A&0*2$/68V'DL%Y$76XS[I3968YBNY]FWR+2'O-#W#WXK!?   J=V
ME0"N-86>* .5M,9[RK>H0*"1L750^29[JIC\D!?3K/CE1UBUW"ZZ)^D,L;Q'
M'ZS-!T4K$!8^*'>,?T[F>3A7__+CJB@SP;<?YHM5F%5N7H9KA\UBHY(>$;KO
M-;[X25(&=ST8L?HZ>VZN['TV<49!$P@!TC**D9% ^HHXYZT84!0.;*O?BT9_
M7,R[A:R4ARY8:Q^I<<>8NWDZ40H!;:'$W"FCG''2P6JL'E.1/*O,]LKFO8KT
M-R9W@/TA+K;"9MS\/ \?'U$R-C9VQ#Z3S;-%]O6W1V>4IUQ[]% B*(="6H@=
MMI8"P[7848D#H4,RZ[D3UA%.G8IOWA$0QUD4J5U6Y"ZSR3^N\\\_3[/91OL*
M/SQ5NL)'R>OL.IV[Q6JVNM^S2S[S5"(@!C2,6R@2-@V'/'6\&KK! #;F(;KP
M_;$]6#WQ>3.>O:OKTT<2YP1#$A)#A:#4.*O\-_F&#(QSBVP%?]XI%!?"QU%M
MC6=A7T<[X9O2;OYE-LW,S6P^+0*I_S-?WLU6Z?SP[GBT8:(LB(<YK)$DFE 5
MCG6[C8)HW7RU[7S'; Y^WB,B]:9B>^.%R4NW0CBVQASD,/R-LUW??PS#V+.[
MUFZ;$*L!5I!C&]1$K"E#4%<T4^N:2P&^\#VW+PC/+#9QU'O7^=IM$R><AM@'
M3,/BJ1CF2+G=^AD &.=&W@-/ZTE+:^3^&E(S*K7A$H2EJ_/V\P.I_#+W)G01
MHQK>9]?K>>1)C'>)(8QAO9Z%[7,VSY:K?!$K.AX\L7?[FD0CXBGS@ED"G;.&
MF+"N;]'A$.KQ:# ]<#P?#;!#K4W/;/1'U)\]+1(8]#EEI3!<(2R -)S:G:('
M 6LL..2%*#W= '=.P8@_%MGQ3>MHV\1IQR4AVF,4%DWBD-6[U3V<0M"X59W6
MG*PA&5W@]=>0E5$J..,3D8[4FM]FZ6TV?;68'%9+GCR6("2H0<ABR[2!%CL)
MP,Z"SA4?GUK1(>)Y9\ T9MN'R2P/>-T>9=QW#R:**^VYPX!P"B!F/&Q]NQ%Z
M1P?T()R7=6VA:7Z42.?SV72]U+/\[B8M;M.C7-S?(B':,A[.5$XS93'#. A=
M-69E2?/8F=.-4^=E9V<8-=QFE\7JP18;?GNZO8:/DH<E$DMS;2S_^[R"?NCQ
M!"I@$ ;6B>BQ-  !LCM]A$^::^?T9*Z/2SOO$+6AY6"O;G6X02(A1!1##E58
MNHA7E!-7!9X9I/$XE>]N&'6$ZZT0>BG\'Y5"/2:V#\?N307?F-"8+N[W;O5[
MGDP0U$XJI*166G(LO>:XHL,!/VB0U>$MOBN&Y%T"TB=CW\>ZV@<V\-WW";$&
M"D$<50AQ0CFD6%=CQI0T/S&Q%[!C-X6I=]8>G*L/GD@X":.37@05$T.,L",4
M5>/FQHW4 M80^Z><:X7!Y?!P=!OI<*P;CF6_I5]GM^O;@TQ[]$RB$4/:0R0P
M5P(HHZ3<C1T3,6B@U?'ML1'J>3>T#V5 WA7_WQ5RN<L7Y?T^AWU1!]LEB' K
M";,T1F=CQJ!&OJ*5JA9\YA>^@_8!WU"B\F2H1_T+SSZ?:.JI%PH;8#A!,2@-
MD8HVI:D=Y^[;,=_R_I!Z6=(PJGU\C$)PKKBJ7;VOO;O_WF>3@ ,3"#'G#?7<
M<$J_T<0Q')$6T!%OO@N4:H?(4%RNJ@'%<D^KAR6!:@7KUFB=6,*)<8 0: R7
M2"CJOFE5LL5)6[P0/:%[$,\N/+6"+VNT3JPG-JRP2$@6: <>:,%V)BJHW;@U
MB4XY6U=J6J/WUY&>46H>8Q>:CKSN?O8UFVXNGSGL;/_NP81[B#U5$G(,%*38
M6[S3O@1J$3+1FV[1*>YYA^ ,-=<WMZ#LE.K7D2?'@V$/M$JPD,YHP:&'B'-N
MD):[^AZ:@>8*IGPA:D5WX)U92(YN!0?;)1YKK1P'EFHG!<$Q+:ZB%7DVTAH7
MG7*QGF2TPNMER\@H%87QB497 7G5]<@^G17Q/K4LWL+[;+[(MEC;D7"]AOTE
M6F!,&!;4(DN(4H'(G6/;"T7&IVATQ+]\>/1ZC?<H\NEZLGI;?,B*S[/)H0B!
MYQY--. $.088(I@[!#5S8$>)QBW.$>#"E8V.(!N ^9L+DLL!'@[MVOM\8BP1
M((@SY!1PRE%0T65%$W'6C%.3:,^B[WG=&3@O@_&C4@]&PN^.=(%=HF?86^*.
M=BPOYKFG$R2- 0PCY[D$BC!#J*K&"ENMWWV$)'2 >=XU)OT&WZ[C+?!W:;&Z
M?Y/>'MJ=GWLT 0P2I:DVR$&F'+'ZF\7#<=W"OWCI12H[@JS7D+#L;EU,;M)E
MIJZ+K%1:GX[XX*)=NWTB&)5!"]7,:J6-L8'LW?(7<!QI4$)[%N;#@?77$)31
M[?8CE(^N+ %=IN:%;<U#QKS3U#-/&43?]!]M2?,DK7X"$[OG1<WTO--P:LS;
M-^OXMK=7OV:+[&-9??X^:#[717J[]'GQ)EL'I/+KV>3U![NTV>=LGM]]NPCW
MN]IQ33I+/$5.0B>=#@ "PZ0@WWPEP@\:8=PX6?-UXY+G@R$WE''X?;;,PKMN
M@N:\'6H9P;6YPN& <?A@NP0XRRQ3D$@=#DU:4@QW6C<-ZEAC*1DR0[NYE/0!
M4N-%8WMSU?MLDE]O\-P=;W[+5C?Y])ME\NWBP3#WK1M-^TL";HP;1BS6@'J.
MF/J6.\45:2X40^9YMUPZ!@)O&&'YL/YT.UM&72L(N+J[*_+/#\M,=2) 1]Z1
M8,>XY-(&4C"*V9>6FYU]/LRIQD)U>I&GRQ"J;@'M3]"V62)QL8QWR6\M,6\_
M9V&#_;KR^;KX?V%M;2YD-?M/L,*,A"FGH /60D0<V\4-20>;.[1.KU,P7@'K
M!\S&PO6T[O[C,GQ%NEA>946Q7S6NVSYQ4$%O?)@HT# FL/)ZMRH3)&5CX3@]
M)?9LPM$36(V9OQ6^Y<=\6Y-E1W(9\[6/YT>:)=0Z[PCD.$AM7 D)_G9D]*1%
M&<K3<[?.QNIN,6K,X4=O?4!==1US./"'Q6GY:KE<9].W1?PWVH*K8]N'<'C/
MMM_NDX8.7Y$ 2PQ1GD5YYXH#+?!.S_<,-Z^'>WHT_]DDYWQX=BYE>P(YCNN]
MC3M,G QX0Z$X#@J8))11OHMS998VEZ#3 S=')T%=H]>'O#R['[Y:3.;K:1CZ
M4V]C _DY[05A!B'N#2"$:\@=D)"+W3IM(&I^$F\0G#-&@>H5SA9'IHTU:6L_
M\GE1YLJ5:^5BDKU:/*5D_]GHQ(X2;"$1@-&PP$H4-#=#/'U@JFH1['E!9M^^
M86N]\IC\]M-L4<KMVRNW"&C-HWR^3U?/67+K-@WB+:Q30E,0=UO&]0/G!E6T
M10'VR[#F]@14<P_?D1WOR#92LWGBI0F;([1",F4=,5AROBO,$8[OS=E^0?;:
M?L :RKE3+DBO;N_265$Z0X,6??VL?GJX01+6+F.,8TJ!\!\B7BGQ;1VS+5:
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MAJR,4N,8GXAT91))Y_/9=+W4L_SN)BUNTU>+R1$[Q]X6B36:4(.IE9I:RPU
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M[5F8#P?67T-01J65CE0^.M(O?IVG7_,/M[/5S?\.#V?O7IO#2L6^YQ,,G8>
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MY?TA];*D85216V,4@G-E#Y3WT$4=K%8=_D?/)M8@B '3S"!)*;9>"KZE"7&
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MSB@%[NMDOIYNG+W1OW>L^G/=+A(M-(<"6B^A=E9(CU1UL#'8H.;!E#VF6';
MS^,RT@5<0PG,PR'&>B6?5I7W=UM#XH"D'&V;B+#% B$X8$ XIK3RM-IQ';6@
MN9.UQ^*0W8M(US@UKPWS8""5]]?/%NEB<L"-7K-E8AF'3'N("*),$>NU(A4-
M6-#F6F*/91R[XW4_*)WGM%#A\CY=99L"I+//L8KN)'SW(,'WZ!'B2#\)# @
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M8I)BBHD2B&XY%^.$1W@C\AA@:R3[(YS#)[+_\B?N"(IH=#W&Q&%'""*,:\$
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MMR]QEXU.P=GKVM8E#X_5L-W-;-()/!.5U6;S</](@Y_U==M-XA!!2PW7P K
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M13/O<$^C/$-X>V+_G'*#,+@<&F85:IN6=.E(]LOBC^7]PWTKT9X\4QA*G #
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MWU_]_C>K_6T8!,$O[4_'7ZWS4[](/A;^\G]^??^E]?-=7M1-6JRS/_W/_P)
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MNH_BP=.YU/R>M+OK)GNH5QX*8>+@T#>1 <W8=P,<#< PLH/54U;=E,H&2_*
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MQDSR[]FF>QJY+R:]!%J)@P+H60:"CI5$UCBWY9L<>]CY/UJSEK6 0-HBXMA
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M<%DW=;3+OI9_Y,4F*K\5*VP;H86"R'-M*XE]SS+Q>,%9&&#V2\34F]:<^'K
MX*I]:*>B._2*#4B/4)/,1\_F;';M89QO!/F[#8'.,;FA(2(,4TGS!H,O$>WC
M\->#.!P#!BUB$'5Q^&,9<>"8;IHW'BI6Q^O. X'.<KQD+CM)Q<WDN>DJ?2%9
MP,251N?*29JUP*:PDR]DO# ?0<OV#=.B+V_:OF/Y*-F_<><;[/=MJ32J.<^]
M]>B.5'I32C['GJ^I>1?<[;5XR@5V>$U-O=*]7<P!49NU.+A[:[^62OH7D*FT
MN'5JCY9ZWIBRTW6Q+A^RK^GWWF)(<N5MWAS;M:&1!!9T(XCM")N^YX>CW<@*
MO571'AS:,"0F)?:8NF?0=<]#:,R]LT,)FO0[N.D RBBB&HX9LL]TY JEG9Y5
M@F_<9OQ3#_'G=NSTM1\[17/PRY%J)N=9+,>HX9LM@[!0<BYU**5S 3E#K3^E
MKH:G:XELG$)<!;%KN+X)H6TB/_!MRW3&BSI,SV":O--I7_?2U4PK5!P!4+W:
MI(=[G2M'/\#RSPA0R5(.?XA^M&49 0^%EUA$V62576JV2M?-'WESCW=U0^2_
M:K=&?,B:E9/$013%OA\F?F#%&+O1>'^OZU@NC[Y*&5KF#EDU'+))Y&3T\6GA
M *N[Q'4 =M4=Y*/7I9)H +3=EM_:(W[TO!BNL@T9[] ]:-,*XB4*+RB?$N:7
M(7%J7"DUM$P^T8K3JB!:67_*JO;B-G13MQ!6$;82:)IN@F,[#BT;1Z:9V!@%
M3FS9D??6(X/2GZ^OHPV0 ,'477<)_C; ^K_3]J-S[%SH0]*$+J/_R+M1*FYH
M?/V&],ANA$?%=[2%K 0EKF5Z5A3YR/4,' RV;&A%7)L&Q2QH3N\?=@^TFBJK
MO_#E=4&ZV#1&/U-\ O.!;FSN)G1^HI!^!JAIJOQFUPQWL7XB#92,;N:2G9.$
M7= <.8*7(3B2/I0JFYR$U! ;<>1'5A*:?N@&,(P#,QALV-CP^(Y5\'TV3Y<1
M.DU!>\Z6GJA(7W28PWO'[\LM:2N<IRLX2100'J7LZ1&<&56&55V865R@JK!C
MOZ0FG RPJL@?67YWWV0;1#IF>O?BMN:/NZ9NTH)>OC2*66R&R(L#C&!B64X2
M.D9LCV+F1$RW)6LSKKG,B;*B?*"S2=R%CGJ:V:1H5H;YU&J "GJL8'^I??_X
MP '>*Q#EVQW][;F*)5YF+RB=MB M0PSUN5=.U-C52>H!BC"M\S7=,](UY!5$
MT+!BVPFP'V/3@4YBC&#L*%0FK!(0-,OK@/I=VBO 4-[U;UKL@8-WX(9B[W9;
M]4K _>Z,[H#)2_1$L=(JU.$8J![Z<G3Z/+V":JT@7LO7;!5.<BBW,DY9]?O+
M^C[;[+;9QUM4-'FK+OE3]B5;[ZKVWMWX>WMA[B8AK.'RX7'7#!?PO)AK_$J'
M62L[#!S#=NTX#@.?E.S(\IP>I(-,W^31]8FA:=;[P1NJ'(?^@+U#8/ (T#8*
M#GQJ+PP[,67?>G:^%EQ$Q-D2PX*#S9<PYHBSEERB-B(7<LQ,H5]&[IG+^7(1
MW8_SDATY:.'SZ0] W_-ZY;LVQH;C>4Z 8LMR?2<<)IR<P($63^*:$Z?F+'9.
MT?Y&P7$FHEG#R9:5?I1(\J4HP2#JN7Q('\,74LX2XKJ,_+,()E[>I;0$3 HR
MTX?T(8O*AS0O5B&)C>O9CF,XOA_&L>_&WF"6(I)/+QS&YLD15X!"!'_K0"K)
M%3P$RPB^)FZ5J#8KK1.J]YXN;@D68'K).BKB#I,8"O/$L9'[*:N:G%3S47;3
M["W_FM'IJI7I^M .(Y\8#9 ?03-&<6_5-4//X-S++65+LYX=P ,;@H][-[<<
MD6S"-26'?+IU2!^%=E1Q=N@F5JTWN+J\>5L)R\O0+&7>O-["K9 EYI7(E%X?
MUO0V;(A<+T (81R8MA?$@;&W87D.WQ8QOL_6OD7L8)4 ?.N@U>WS>V-'>[%=
MC'.)D(])QI4_;11R+NAU.&:2GB,6+JV[";&U#%D1Q/YRE4R" 5;)^)S5396O
MFVS3/C3T6Y$W]><OO_4V8P<&A@U#.R*U51P@V\+F:#. 7,?5Y"QI+G!^([I1
MTS7N:D39/\.UHSCYQ$.24S8QF8Y./G'9X^I?HVN1@9\(MOKGF23G(E<7)$@-
MQ\N0)$6^E#I:(<?M-[^WW?246?(_[8MYO6W'2&#L00\B%,9^XL70'V:Y7.AA
M]HO9E%G4+&&_7Q*P*_J?%BS'+2WJN+XL:?/1S"=M/<-G%&Z ^;;&Z62:XTZ<
M61B7?+*F?;$F+V[+ZJ&_F*-[J+I]SZP$%Y/XO@_(7K[&RMR)U**'^05<H:/>
MIU)G6YUTV?U]7F373?90KVR2 F,KM"+3B1%V7-OTT0#/,C'7R=#)0$VY6%*/
MCDRZDLX1H4F6S?4$1\T:.??6+>H,:+U9Q-H,?Q#T+:/SQWD9HXGIW5:[0"[*
M^T0)HWOR816&V(($0VCZ.$B" +GF/IG9 =.[FM,BFB=5@.Q(DM;'DC2<%\D&
M:2(U8W=P1/P(R43QG237: CM+(GFJG\ZZ(?*,1UD?0F&,[C_*;(+K\]J4XL0
MX_QG55YM^3H^*]-N0OZ:?6]"0NS?5X$5N);KFW& 8N@ECFO2Q4?7P7X0)0;?
M*6Y=&#3GCL-3"9\SVA+S;3[*"9U7&&^UZ4ZO[0]_@]]JHD(D5W2!IY,-KTZY
M 7K[0OL,*!4DW*T\MJR(GDU1'&&V7+*$X/)EC\.XGDH*KR/5G24!%#QHT<]V
MK(2+XPM)0G?4EI$6M'MY]D2(3E:G/Z:X!VH;3APF'O(](TI@Z 91/ !UC8CK
MMN<9X$V8,#Z534;<2K?#D>?V><I.X]L9YN8^;<"WC(PICJM6FE<.*]>T?73]
MN?M5RM2[:*A\?ZO;66SR!U^K+*UWU7/_V;]FS7W)N' S9VOAS3"+;"CBR4?M
M4<<EI"=5 6+*7).WAJ4EM>D)T'8"4C 6K*GP4W<;?TW?AUNOJUVZW5^^!Q$V
M0Q\9813$1A"%?N3C)(8V,OS -!'K9F(9$_KD9D#5/6C9XYKM2J0+'%WH\2J8
M74;75>))J;[=<4Y5K]=TPJ+N+0^&L\UP43[I^5%>K[<E*4D.NK9OF!$,80#M
MP+%BQXDBWQ_0!(G!=<^%+@RZIZ-[V*#'?05ZV,/K/?55VU,_DJ*N GA7M=>]
M'OC$.>FL*U*,T\P+"!+GQ/*+^.QEDX3H #78PR;5UUQUER"_E^:.-4=L&3*L
MW<N7\\.3L,HJWW\MR\VW?$O?RKTN&M+ZZ>&']K6  Q!C"DEB&YM^F%BVDP2F
M;82&YW48L(<2GW5W@UJC^@1@P-EV_#W2[C&-XVX_4PW%Q>2%KJXG(LOHX)I\
M*Z=HTZ)S?-?%)KO-B[S)WI,QV"M$+V8<0YQX,,(8&?1T2!2ZT#<&-$'B^6(3
M>6HQ3#A;A^_)3TA:SPMP_>GS?T\?'O]')#I]IC@0O'-D\\5 ?")LC_E="_J$
M\BYGCHN+8*:)+#TA6X84:_?R[)243E;YY7E(%GN+#C%E!'80>=CV7-N-;9(9
M>HMA8'/=GB5C9QZ9'7"*JJP G[Q*JI=*<;4<:]3E:.(KJIAT3YS@I6F;A"=G
M]4N6'5:-VM>J'V_I)'U6U.TL_>=L2U]5QV7=U.TD_4U:9YM/W>N,^SG&.,%&
MG)AQ& >N:6 ;!E:W'=9%08"9I\\UH]#8,RFH=RTJT,,"B![#OLL>YGRK28[0
M"_UWHD@MHXM/Y6PY2V_@+&;ZC2S4_A[205L/G_>_TF-"W])J\W[<.P]-&#E$
MK RZO<6"L>.$ S#D^XCIC.V$<'271@?2<>C#D7[</(.3$D,]F?&DC#S[ETJ$
MZ4*[#)F9TN&7!<?47&N7FR3-J]_3[8X.]'8/C_2O:KJ\1H^!_EX2 6T?\_Y,
MA'05X"1P7>QYAA$[080##_D#\A@'?+N<%X!7LV -J/I#TH]5OL[ TPB1<RRW
M +Y8QX0+@#I-!2N4AJX ]1.TCH(#3Z_ V&#VS@+J[0^2J]C#IR.9:6@\/WBV
MT\&(JG2H+5JSY,O/>?WWI,JRZX*DB:QN6MPFLES7A8EGTD?D/3.!Q),>MP--
MKLN]YD>K.5=23."6@ )YCPI4EY1OJ3&=(4-J#^=B\F/;2*BK8/#U1T^/IV(W
M57*4:C?_"5.C'!\Z$Z."2'&EQ9NW<=_P)/2O6?4 5UYDP)C.LL4X-OT8AZZ7
M#(!Q8#C<^7 >F%,-&K?Y;;M^578@P4_/65KQWJ,P9S@Y4N'R([F8'#BV#^KC
M#)E/2ZC>2GGSMH\%Y;J9B3B5Y)80&Z:K3;6,5:/\*=]DQ68XFK4*H6DFB8],
MR_4]T[.1'0^SNZ%IA4S[5!8$=ZILEQ;%+MV"38]O?X<0QRV?RV",Y3+692#5
MG/] R);_^M]CRG_[]#=XNS_8^^.U%([+9)>!F*?%2-Y$VY[C!V2PDS_0-?P3
MRD OI+W)P&.:;\!/V= NAM^K?Z8_OR?<$54:;J#9%>2K[3.]!Z#N[QEX(A]'
M?]25V?]"S)+\(WN![231.E$T+;"I+.#JW(414BZV6XONUL7EEOR@K%)ZGOT
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MXN11S9<N,0MHF&[IS.X5N,GN\J*@*DGJ<CK<>108[LP44,X\N-@HBN>^ Y?
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M5PO]77G[;D=$*:7H:U#V^*EN9;T'K; 5V3=U0J8U>&R*MY2X\4GC&#*"&[3
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M[#0B2E O6$0).E4BRA.>'U!$N=R3$5%^'E6+*+HEHC-BL3$R70MY@4?J83/
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MN[JAM1Z#+RL[B0UL.Z2^,T,CHI=B1FCPP8(1WX'J12'77.3U3H%U[Q5H]HZ
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M0H<.^@SL1&9HVJ[E=7O"'3,@11"3^FD'H5L3VR/,'?:V_X(>/1C@ XH?= Z
MT8/V=]GD4G^<+HOHHD+$)ZUO1^=\<,#?.OCG]7;B*&W*]>YAN'_EQXC6$63V
MA$AD,,WI*4HZC]C<9^U:3EH\_TL]QH\F288>]F?69$EI:U,@-/L$*$ODB;0X
M66SF39;3N5E.W.9Y$NM]6F5A6F?M"<*LJ+OM=?N+2<+G_:_TM[BA;VFU(:T_
M+S=)2><<2!?XDCVFW5T[25FA]3K;TJMWLLWOQ#'RXQ4]< A1Y"4)<N(HQBCQ
MPQXZL@(S8D_""P&L.6%W:,'M !?4(]YV9B_=(P9/'62>!+ 0$IE2^D*P:DS_
M%/Z[%C\X]!$<. G"9W#X>[VCH/64#,FZYC(Z"_;>TFWHX,!?\/N/VUQX:HN%
M8-9?ARRL^3!6+-.$YVQUL[#6L81*:&F4E ONS9QWGXBB[^K$^J_MI6/71>?,
M'UE^=T\PHR>"_2YK?Q@1)Y(TKWY/M[MLA;#C.\BS(^@E!+4'@R08O(BL@.L<
MX-*P:ZZ[!H @[1"".PKQW8;>,GE+0((GBO(*E)UWX*>\ !MZIU]5@\>L C7E
M@G,GY=(H9KU:9V&P=1=H-Y<S[,V086].9=C>YRO0>4W?1^S\O@)CD^M=[WX%
M4.<!]1ZT[D]\Y<^TL;TP-[_45K:,B?[%LO/RRJ*EXIPTC\??LVJ=U]GH2/LX
MV'715'E1Y^L.>FR&@8E=!\,@]AV('2=$ _0@\<PID[<2P+IWF]W=5=D=%<M\
MP-4E:;K^.Z3IK'=D,VUF5A/P:=+QY+&>+P>/KAZFX='3'S'?L@1/8Y)5VG;^
M<V16M90H3J<:XB5R^?C!6L@(:;,*/"MQ#,,S0B.,/0^ZH3.L<J 8)UP;IN6M
MZ9[G/[I\?$A3-'5UMX[W"8Q[QY(LQ\P;EB:DEWN_T@&SATOL]9@ SI<#VF]L
M/TG7Y3U*BJA>AKXJ].?"C>TJF&)5MOCA<5L^9]F7K'K*U]EIC?Y0%G2YCHQ=
MJ!S7K>X>_AR7=?.A;/X]:SYGZ_*NH/=9'#JQLFW3=1W7]_TX,$(;Q4;B#=AA
M@KF>9E@&8LT*VSW O"NJ$5U[!GJL'R^_W+#D2+-I]#+ 3C,P& O^?25T!4;?
MCL<!]!6SNB$_;<!SUH"]7U< /= S$]/FADG"="&_+*N9+"-'+8R3<LD=>R&Y
M<ECOJ_IOT=^#J]CV'#LV R.Q?<LU8.BY9N]$Z-@VUX+8PJ!KSIZ_7<Z;5W31
MJ]NH5(%JC[M=%WO.THKW5I&%L3MWCM7?)G0GV[-)]M.^X1PX]Y\DZ9Z,VQS9
M5ZX!_2=/PY+D3)6/5<10^Q+7L&NY;JIV#UO=WC'S]3XM^DKB]];M8<)Q%84H
MB)W$@8[M!HGC1T$4#?!C''(^;+H8V#S2*W3-Y><OO]6@EUAZNJ HBW?]ESO2
M-.A2%[VFDGS9E.WOM:FXW9;"FXL70ZKN%; Y&\'DJV#C 9316]#=1-80?_=K
M9)W+^P6R'V0]C#.4.M;$=+6F923CY=&B:FU,;]QF'QGO/ZG[HY?>K;#O.HX5
MA5%H6:$9NI$%X\$?")UP$8-D:2]F'2\O9"PLWQ3FGGJ>LA7H'B''W]?;W8:>
MNOC_V<3T&T&<9;):5<-:1K+^ 7B:;%);;619TWEW$^'X8N=X%Q!"H9-X013[
M'OF'%8>18_N&Z^#01Z8/61?W1#]>G_[U5V_N7[.=Z]:K,]1<4!59,I?1YZ6]
M*-4V,=YG[Y^R8I?1O1NX+%I+?^3-/=[5#4%1$3!=KD1UG9'_V]#K/0,,#9P0
MX\BQ8PLY@>6-2!P($4_AJL.^YI*3WF[[6)6;W;H!] )_SLT,6AAG4Z^YR>93
MMAYMMY]LP N^$<!@0$QW$0_%W ":7CL\K?()T'I!%74&:1F*J=7#<KHFSWO;
M>MU\O/UK66YJ5&SZ>JO^0D_;!@[R#<_RK2!R/#N*(;318# R;,@W-R]A2/ML
M>CO2*F_!'44':H*)][YU<1+9-'(B]OBD<*"MA=4N0PS P)=+'&JZ3?T<0Q=4
M30&MRQ O%8Z\NDI=$3>L4O37JJSK3U5YFS=$[*+8"TP[\?S8"1&&<1@/%MPH
MC'D>>N#Y7*XBC?]AAQ8*+=,(%CZ)X2*'35-T\<(G(ATEGRY3HD4Q#OR_(!$B
M+"U#$X20E_)MA/-IKT=Z]P:I=>+O=.8FJ\>A94@&D!A#T_(2(PC#"'NV,=C#
MOL-U7[&X%<W#MA%8NV)/D?V%\P$N<?[89&(:ZOA$8\_: &JV"::S]%S0%'E*
MEZ$P"OQX^225(F;8)YKJC/SN/:EP(C(FVY;M)<:]\7%)!JW_L<NK=M&7GBJJ
M:UH;K2S',4QDD?]Q+,>U,,1A,E9!OL-U0E$G#LT*-D!O!P";/7C>^2>-@6"=
MAUI&#'CGHP[H/\ ]*"/X:;^R^/^Q]Z[-D>-(MN!?X8?=G2HS52_?C]U/ $C4
MU4Y62C=3U;VS9=?"J A*XG2(U"4C,E/]ZQ< 'T$]@@) @&3.KLU4IU)2!HX?
M)X\[' Z@P\[Z>1KT;)7Q?$>8ILJ4--&C%2K][EN'[,YBZ9N*U5SL<O>H9GOR
MT_O?LX*$C#W!!7:/>9'3<$$/S&VA;4+3-CT,?"\"7NCBV$/] @7Y/S\4.DA%
MS9":!;E%>6'<-SB;R\O3%U %6T 54<VGPPNP+-C<T1'<0F3\O@39J>_,_9)<
MS(UU.ZJE?AURJ=JHUYV&.CCC%<'^K*L_LK0^5FQMEJXD_%F4MW56L:N^+HNG
M([OZB]"5[W/6&_&%7N]=$=@PK?/Z4Y[>DI\<GG]/\X)>$]<L0% =3]**GFU?
M;\((0!>9 830\C"&/O:"'G\4.)N"';^TN^&7T_6 Y]**J-&*-W;RU\L?:/\7
M.V[H=(@D+: 3X^B<AV9MY,LZWV7MJ;M/Z?/H!8E:5&0VMXP(T?H>C75HV0IY
M*=?^4HLI:IP]5=FVP43%_)%>@/VOYJAQ&/NF;X7 PG9D6:;E1;!;]X!DP$@D
MEYPRCN8$<@BMR1T'X,0RQTEL\J6+<Q$IEB,.45V0>?G3/NOI'$)DG<!MW\[L
M&U]'J!O19A6$KT--E5A2JG\<)ZZ@;'P06:;M)X[E6;8;1):/XVX<$UNQR.JI
M^*=K7D-M3O(IWZR;3%PV^9@TR>42I7Q-7299>&U$9$V$F[=U:,D$_!^M@0@R
M(:P;36\OS;(V86#&3@)=FQZ5[%@F\!*O'0D!Z%A2RB'P^9JU@V)H.C=;_1 ^
M5%&*-$'ET,27K':TO?R_4$ SKQ2\0PF/A$@0N#(1D;'@G(Q(L\$K)"2#+5\.
MUBI7OWAK(12X/@0^I)?7^8F+G:[XA5#L<-W[IFXTW2T=;!]]WKXU77KRJV!?
MAP)2^61G7C[%1&B(K=>A%MZOB[5\?,C8B$:I8WL=BJ70GE+7<RFZ5X_N*J1E
MJV;4RX)H /G.)B:3-GKZ78CC.'9]\E^ >O$,Q/H]I ?1K%T=CE:^Q"1+GCD^
MI9J%-#&!.D%JY8G=(,!0S;W/\7UN1J1H,IWK4*#I9KS9ZJB$%WZ]:3Z^6RAT
MK"0(R!@1<NT8^"#VD=V-8KM)O]#&*S1BGRZQ$B:I,-D'*^1JR.)5%@TL20I*
M2\\B#02O>!@5#SG&UJ(9DNC?2,44%K@WQJ1Y4=/Y6U9?%<D/FA =\_J!*M35
M79S=$F7RH N!8X?(M '='V@!V(V+ 19J<IH^FN8<A15QRH((R)8MJ+<KZ-^R
MZI#?[C.C* ^BU6 %#/,)S;SDBDD/Q=96>2B]+]%1DBF^F;?H?$37B$*IHWH=
MFJ70GM>;?!0S):)K=-BK(LZJ_!MKEQH<O/8Y.UQ7V2']L0D]%UF6&7G0<J!I
MFD%L=_7O.,*FT+J[LD$UJUS3+/2V5VC7HY;0.#5L\TO=[$1/4KP3SN&YF!<&
M@7IA-&#GES\>"C]00:5>6(\8JC7K'4W4P!OWVARM(9^M@&W\R([(,#8*$FSA
M( ZBR.H&]4GR*;0U<MI0LQ33NRKZKU)UJ:ED<B[?S<>CX$H>HW"TE#[SJMXH
M4V,+?&HH7H>$J3+F];*?2H[$SK>C>MD=:9,71S+V5;_*#K.[LLJ:W[M)?V0U
MR3.KE)"<%VGU?'G('FL"FC9"$P[W#'9;=?.Q$R5A$GN."\/$#ZW$BSK$=H2
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M6=1C6CG# [V:U8A^[X'O!Z:'+"]VL8TBU_9-.V123UN!D2]T3=X:\&J6YZ[
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M>]W8/G#<3;,'^9L"N>4?5&A^/L0W166;2>A=7I!9^UC-2R?9T[54#\G*]9/
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MS<<J [<UR0VWAPU,K "2_\$HQHD=^7$0^AY(?-.+0)RX7+5VA</IJYZ_ &F
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M732Y_Z?+9'3Q()_7:/4,;T,VJ]4TI[;$1SIFDVTUI[E\SKZS']4;U\8HL4P
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MGYHN1[B8EHYR/135I914B,@1'=7CD'6HJ";;7I\'K9%!7@5-TJK(B_NZ*X'
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ML<L]+Z'3H8=R3\BNF\3X<WG(XGX;SVG\!+@ HSBR0B_PS<"U;-/U88@"%SK
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M<C1"T8@>J2!V'8*DQ))2_6,G)DE_SQ[R[;[7/8R#Q'-0Z#@ )E[@0=?L!T'
M$SKY5O"C-0M/AT9,:D3IX5,7C<R("4H'9"$)><G#B&I($K8.H9 %7RIY: 0S
M%)+G=K,Q/XIP BW;!3X(+-\A'XS=&$:VE: D=(42$OZ/U9U_$"2"V88 )9S)
MA1XV!',).J-9*'/H[1]+%,1)6L?K+@/\=1H@:SM_,T!1'ZKCEM;8+HOKJKPG
M3TI?!8]]9$8A]FTSCA+H^A'NE<6#2+ C8,) VM?A3MCH"95/+3K1YH I5/()
MQFPLBDG(:P([8(LU"YQG:;1C0 &YZY >-::\Z1U0Q@^O/)UMD/J4%]GE(7NL
M-Q[".#3)>($3Q"03"@+@=@.;82ATZJ>"X31+58?P90NAF%"I()5/KF;F4TRT
M/FC*I! -AG%F]?J8M!$-4\CX.I1,I4&EMJ=3D:K]7I5UO0DBZ(1V#  ,P\1V
MPPB&_:# QD)]Z!.'FE/-^OZ "^.>@E,D:IR<3A0T]70J%+,+X_=10N>5,89%
M1L+$.%ZY? D:PRM=,ASQRA;8;H^/QSW=W!S3+HMMSEHSR-?[C&UE+W;@L:P.
M^;^:D^'/8=R8F"2$IH6\$&(7NHX-S Y>#%""-T6SA9I/XF:#Q?7V1LW;.[1
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M_/:_$YN:]XY\\?IU>V/O.Z^0/"?+OA83<)=3GP;^QS=N-[S=D'^QP="+<1+
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MDRA5HE@O<#4@6[)8UD.[I%F3J^F+HLG4.K]/OR8_X6%_E[,[%.#/C$U*D3"
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M6J+VJXM7HSPQ5ZAZ>M3^;T5>EBO(!G\@BBS3)&%DQ4$$FH+YD X!K7D.>9V
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MV')"#[L6\2+266)9WIS)B0K\&BRCSYML*.D$\V052_M?UW7TMY(AC/"OPE1
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M=HUO-<KY:]!?9FZX#$,B\WI(F&2;GI=*2&=,]73DAVR7OM^G]R6;)G4=8J&
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M@1":L#M_Q(N1SW4WDX)F%6M3?6[@$[1M)O?+![930R!/D\PW1YJ\'-5BHC;
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MX %@L6O4FP8][(C=[S2^&<6ZUB(S^M $[W2:P"&?G,U$GYB&G65.&QF[3-F
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M&S[0[_[W_V@_H?]A]3'_^W_\_U!+ P04    " #,@&)0I/=%JVRS   Z] @
M%0   &9O;&0M,C Q.3$R,S%?<')E+GAM;.R]6Y?;.+(F^CZ_HD[/<W7A?MEK
M]\S"M<8S+J>/[=HU<UZX9(F9R2FEF*U+EG/_^@-(HO)B72B!I)AR=Y?M3(D
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ML*:D8NAI[2"R5M:/MVZNM@FY9C%_DM!Z& AUYHLW3<9!(1TL 1X4MP@#0RW
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M-)((A*%'WCB&"(=!Y5\GD$)$GK&$\M-YQ1&)L8[/(GIJYQE0GCIDH%920RB
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M'P64+R:!\8%_\\=8%G2'YK7KT4QZ QDVA'D>%G#( I_,FA*#!4ZY7=Y# /5
MZ6I($FUBZE-^OY@.;P>S)X_!ZQ'O3(I^5/N,*,,@]00 :+S!U"EI*YH-H1>R
M\Z6+O&R?N2?O<+^.!]_*SW?%_/9_A8?SC^_-_FUMU_,9ALY#P)0$7I+PBV0*
M5N,%"J14=NX9&%J08=D\A\^M5A^Q%+^OD:2OR==D' O&A'0N*!+($$TUVG!2
M*']AR9][L&WV0(JGW_/>ZH0WY62TC)T>C-5-^##F(/DX>%P2\S&?O@O?#@<[
M N>;Z#;CC!"LN*,L&#]46$X-W:P&X:_+6&_/"YSR;/)J JW/#!\UF2P&XS#8
M^;3XNHA?Z<=81',P>:R!SWH=9<II$"QRRC3#@D(ID:\HM-2BE C!'AHCO4)D
M*Q(Z&8/5!/#E=!>7=J&N1M.,^:!,2<L48D!R PB'&RJ$\"DG#3W<O<^/L^9E
M<C*RU' X7>2C!(#5[R$>'!+/K/,60\N(0QKIS6P1.J6H:A^OJ)T=9ZV)IBM3
MZ..T'.;Y:!9+5+\OAOEDEOL\W@H=YF'\HSW6S8&6&39,<QL=H80SJ1V :D.O
M)R[E9+^'%1C."L5V1-*0]?'L0"_P,']8_GAU_;&<S=7]_;1\"&KH9!0O>L[T
M8):/?BO"3_-RDL\^EO/PZ+(BU..+J,&ZD3S)+\RD5P8HY@5@\5HK H+XBF,:
MJ!1W85)2OOMI44Z+^>/2\+E 1/=*K"=/A ^+Z 2[NOYM\'_+Z>H6R>QJ,9\5
MH_SW23'/1Y_GL71%G*Y_W)9W'P?3>+7D2[G4A ,/@U+\C.QW,S<N;HH8H%ZN
MIW0-XG?-F3Z,+<,8<XQ,V ECV#+7! NR69 P33D+ZF'.P?//J#<H].YNRS[D
MDT4>2:^H718>7(11WT6O2"Q&6$QN8D6X\-]H?\KB$WK+F,$HGNPR!"U11@6S
M5ZWYXA3V*;K[T5D/'_+IU_*2IT-W@NHN0\I*OB;\*99,O(H1VN^+P==B7#__
MX3'=9%@ (P/=WBIK/4 (6%%QPD*;4E@H*?/ADWI$+AJ]+0JKL_#*X3 >1,Z"
M;A:/:6):TI5-_8P(<SAK9_U>LF !,2J$,U(""0C!F."*#U3 I(LKX%^H/8S:
M]H35^5V7R:P<%Z.8WUX/QH/),/]\F^<G76]KZ#I(U-]6AM&FWEZ5,:G&Q>\Z
MS3/D>?C/F"!Y[1#54O&PCD# .0RRD;5.\5I:2V*UWCH7W%\^F,&P,B(+-?04
M$P25A):O*:*<DY2S]1Z>2S8KY&T%DT_E;&=[SG*0ZR6F-EQ>/9\Q8)DW&A)M
M@_X' 41>5[3YP*S+0LVI@MV*CS16=IG4IHM"B89@8I$DV,;H/$9A-=.HE2PE
M>W@2C#K01A+!<&)UQ&/8W174MJ68.:SU[FF5*2N(!(@$C8PSB1 .K-Q,4)VT
M.O4PLJ%9)#7'UZZMJ)4;+H[\0SZO;S9M:Y9!S F1#B(7IPD4%B&VII0!8<^6
M@/=I8:)O TX-<KDK/,6<)I,@SL<PTCWX>?Y8)BPDTB,EJ;4,B5C+VU24,*12
M\)(4>_"$%_$V\)+ U>["!O+[03%RW^[C(7/E=WK!AKVA P=;9X0($79F:+6Q
M869H("7>S NHNRG7]T;WK^;Y>Q;+K*Y%EG'.B#58 !+4.FZQ!,16M%BB4FIC
M'']*WWJ>QX8WIP1.=H6*J_L\NB0G-^_SP2S_5-S<SJ^N?P_(CF/?@Y*][3+O
M(32 !4.68Q7^@E30BE8":$J TM$:<A?G;0U9\$TRM<,HMS#J^>/'\2!&&X^B
M?7@?76#[U9M]S3*(#)=2><@HM5P;C;VO*(4*I(0&':T>OR'X-,C3[I3A^6"R
MC'-8\2",U'U;GPO_6I:COXKQ>*^2?+AY!C51WCJ/6,P)H)44$JPIYT[+%"]0
M#P-W&\)2"YSM"E,U<+.AP$"$E.?422R@@I 84\T*S@U..9[HK2J<C(T3N=>9
M2O.DD=<*R]CZ?!9T/&:YA\)@RCPEU.**.=R2I MU/:P9W90"TP KN[6'#AI"
M&652:2TTX!A:PV-NXLI+P+%+JIA[?"!E1Q900V=11_*N*\D_BX6(@93S<OCG
M;3D.$IE%C6G^6./8LFX7F1:2":LHQR28>0Q1+%3% <E0R@;3P[."5L^_6^+Y
M&5!7_WA\=Z-,8JR)T01*'JQ!XCAR=K.J4I02T]K#,_+FA;\;76F<OMSH/L44
M4(2@L)53AP@56%9\B/G[+RQI8A. 2(C..X[9_8F$/@RYVGUD83.PD!/,*!.$
M.^^]J]0'08,R<5F;9PN :XO5Y_%.5\-^/(RQ_0TSY57@*# <"<H1(YQ25U$;
M=-1.,_YTX6!L 5J-<OA\.MA1NE>F$*0,"XLH,D S)16H(E2$-+S;' "MVX(M
MH":9I_W9Z)J_\A-F"0KLDUY[!T'8[[&KC&TA4%+9CWYO=^UH]"WROKML>I.P
M/<RC&_Y].;F))9$^E/.\4B#W!<CN;YE!:X35$B&O+#&<<K)1+Z52+,6]V5 $
M6FNAL:T#KUG>=X6U93QF+ 2^&G$L'+X'7UN>SIS!G(! &206(:$UA=5QD/3@
MT@[:6H=1.HN[@HY>S(I)/IN9\NYK,5G*+M[X#<IAOLR)%R_!3]?7P=9Z8JW=
M,ZG?H%A8Y33Q01U!VB.&+'>;:6:A2(!CTME>!T&3K6.S2\ETK?*]FPS+N_S+
MX-MS36%O,,N!EADT.N@6VG"#K0K*LL:V.B>50L.4<*@>GB5VIM@UP^XS^S+J
M'5$?:IL9Y[10054UEEB"8I!/%7,J,5,IML/1IY0=>S3: 5G3+.\T^N%8,W6/
M8<2U5Y))L4SN#*$1XDGC0"PIU]S1J5,N8.UJC--G<)G5\Y5E%(3]'6/G U^@
MI5@:4IG2DJFDZW''9R[ITDG6^L'DD:SMSDMQ=U?,JUP7&SUPN!\R>UIEW""G
M2- *%=3 >&J\K$*=%80B*6M 4AZ1-XJAYGC=F3?BE*B</9QC1$L'@.?&$2(H
M$!YNJ)0(IMQC@?T^O&[).=$4J[M<I,K)<M@'DPN\>C33R@*!D"7$DUBU!5I(
M*HH()IVFH^A"N6Y"N%M6H 2>=A94,ZKJ-WP<%,' -(/[8A[SYV]&OR^6YF#C
M3&OJA+)&"J>1#LLKP)6.IYR7Z+*.>%K 4>,\[C!<:W&W&,=\5DL;(!9AF.:W
M^616/.0K3\;[<A;]%U?77P;?ZJ3..:W'+)9Y0,+%N<>=HP@14,5?*H5TBE^T
MH:,?])8 V8D4>H927T[SXF:R.L(?/BYSV(U78!C]W\5LOKYTMJ0X'<''O"VS
M%'@!)='*2VX!U I7^XJVEJ>LL(E[]1.^>5OX;AV,IX&_10'V;&*HAT$QCH>\
M@>28H?DIR4T;$^.8MV6&&QXC;"#E1DG M""5IJ]Q$'B7JL>_)D;K NQJ8ORQ
MK-J\]"LL+ZPODY[/!Y-X470/PO<URU @ATI!A U,U_%ZB*G.![7D,L58;RC=
M36OID5K04!ID=5>@^I3/!\4D'[G!=!)&.7LVG6Q^70R+?7KQX<89I$I: X0&
MPAD*H8^S:DTU#!/^_*$!^ T!K'&&G\_)>)1S,0/($6"=<5!Y1C!72E<'S=J)
MI!SM2<EQ.BAATP*,DAG<E_NC]<[)MC;-F.% &JH)-5(B0TU0A=<4&X9DRFUC
M>+R'Z*).SYI@^!/$SIL%_>.2N[=Y>'PP?CG$"TN);HR5"MIXUX!QQX.B@AWP
MP"#L)(&D5F#+:^IWEY-\VK>"^,)XXE VD2!/"9F6,2$[ZS\=VT\F%>;46D =
M$,8A2D'0\STT0FL9M/P+N\K;K-C+[AA_!E_#<S+"S^-\R:3)2-V5TWGQG\O/
M=Z9]JN=@2'I%AB2&T&JL#&10<L\TXVLY*21H2LQW+P\T6H#NF65RA@/8L'M=
M39>\'"T/ S_FT\^W00#USF1WM<X,0DY0B)F#2 "$=-B_-W13EG)=N(>5H%O%
M8O/L/@/,EL.<J<7\-EA#_[FWXNZ>5IDRPH3_"60"?8! #?!F.@7CYL(*/W<%
MJT0VGPU.[V:SQ7%06K7() .6,"$8!APY'F:-8Q5]X7-_+I_3)<#H)!:?#4+U
M/.3[FF6$2@Q$6'>#^<N@4=)C7U'*K+ZP['3=@NET/I_1.[!AT>SJ.I9I\>/R
MKU[42ML,YCB'P'?-,NP0A!YQY8/5AB$UBJ^N6S -G%"U/&/M4!M+3H3A!H7\
MH0C\U8_!P!R]>S([U7!>/*Q<4(=Y<'QG&98$$>S"<D>X\1H1H$3%&8Y)DL^P
MUXM! DC*CKG>U683*+@NYO%L>0_&GA[*/+8*2",QT4I+J2U3>L,PJ\Y6GZ^#
M/ !MROS[S-RG,;R[N-<JW&"V+#A>ACUV64OG*5;A2]G<(M?&ZS)I%&1>>(DD
MY5X*0P%:<Q9JK%/LM!ZZHCI$;P^DU=D\>.9@VRB;DQM3SI;Q$[:8K3+X[<-V
MS2XRC3QT7##J(<9,*1$VK8H#E"4ED^KAMGU>$+U&=#LRZBY3P6'W\!Z$UFF>
M(<PLI-X0!R R3E$%3$4Y1#[%7='#U;17Z&Q!/IU%U$0+6@\":V+$8SZ9'<+B
M]@89589#@+0PGG)F@@DO*CT>2FM3UL:&[BBT%EG3*R@V(IZNP/?KH)C,(G_R
MV=7$?8NL6!2SVY6M>""?U<&V&6<60!ML2JT=UQZ!F)EW3;,1,&5!K'\,(%>0
MG.0WT>G374*A7H&R:5EUA4\_**;+([3 -YM/BX? F(=5?9U-?I'?\L$L9OVZ
MFGR*L>#30%N8?L7,W XF-_F[R>^3:3X8QP.3R(4#=GX[+\R6Q5["E'?1NZ*
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M0E!0T6<<2KGIW%#.H-;./%L$71>R:!!KU4+]*2_NOBZ"$)9^A?H8V]X^@Q@
M"K65C,95WFLN_)H>8@U*R<V7=)VK@W"G[K'5B RZVF7KNP@:N5,4K*_H?R+>
M(1S^(*XEKGA,#$<I%DD/*]QVZ(!I309G1F(TJ&9-W7+;TUD6C($P)XW%6&AJ
ME"3:H<W\9.#" I*[O.76'-<[O.4VS//1S >^Q;RI02/];3"/J5,?KZYW)U7=
M?R7NE!XSY#1"0&+NO>1:$&>A>^*/[[0TQ-D<UHT Z/LK<QT(I#/ #A[7)U!J
M^,]%,<U_&TS_S.>1A'KPK-,^\P!Z"P./ 8;*".L@V] .5%+N\T1WXMN'8PL"
M.!OX3LD85K^3#!&!$;:*2P,<UQ2;S>T RJE/\<@D>@X[L&?.B<FF1-(_E;(1
M53*#@@OK'6?"(@T!U8Z1B@M>D&ZN<)S;N&D#B:W)X,Q(W-P,;<*XV=-9QJD0
M3BLKO(::42&-KC:.P"&94F6UAW$/71HWS7']',9-3&P5L_[&&/(Z)<@.MLV0
M091@P;!0$@ &C<:;^<>%_@$3?C2"D#W62Q-RZ.R*VI(7J_2X'Z=%8,M]K+3V
MN,O-7:M=1C&P0$FO#%)4> :EJQQ:U#EJ?Q"[I V@-<GXKD#V*;]?#W!U73.6
MI%VY^I=D7'T=%S=+.>]#7/U.,A.,,: L! )YA!V3%E4N6ZJ [R:H\( ]TEKP
M=8=8;$TD)Q_@51/!E],PN,5T>!O'<?TI:*738KA,FQ?6XM\G>VZ<'-%%QKT!
MS"%)8> <41I"6*G/3'*8DI6QL2OB;WEW;5D@I\/LV6X?$'^?!]R/QZ:<7!?3
MNQ7BW;?A\E+@\C+@0S#2BZ_C?$=.@N0^,P1CRF]A,=?" P0T,]7T8@+Q;NH;
M=1WHWQD NY/,6<Y3XO2YNE_3D4^'Q6QOON.#;3/ M(7:*"-%F'06BD!\13.Q
M26AL*+JAM5MX9S(YFI##.;"W+E57#;GN@=WK9IE66+%@7J&@2RB)B?/PB5*)
M4Z(8ZE\Z[K!@^YE@ELCW5+5NY\7Z [K<SG89\%P* KTATE*HA!2T8@IC"*7$
M/#=[;;BU^I,=:W%-B>*\OKGE"6"LVK(WQ=3!MIDV$@JN@XZ 19A"@(F-;YP!
M3%+\)$??$>Z\1._9O7.G2Z)_IQ2-G$YD3',AL(QG0$)3+(5UU54L[@Q/"7D^
MXL+PN0_,VD!@:T+H"HKN^CH?AN6[LG0^A;WJ:IGG(?Z)!\\/@W&^O-E7V>7Q
MBUB#^,4'SY[<@]D6WI8YSQ5R1"/*%$*!D4KRBJ\ F)0L9CV\-]+*D=OYQ=(5
MW)-H^IB'W7/T?2#Z<+R(14:><V_%T3TSH=N!9,P)3I#T$$MDG2:*VLJ!QBDB
M*:>%QU]Z:7T#:&62]%IB;V+^M#4=,B*HY=(+H TG&#N%9:7E<>M%K=JR33FF
M[I>2#@B<SG\PC!\IAA\;LL! RZ!&B#NJ@W0 V80W<^!M2J#0T9ZM%63=I-W#
M]!X"]C@A= 78SXO[^_&24X-QQ:EWD^MR?2A1I_Y6O1XRSZSG6(7M!2!$B584
M5[F* OMERJ6'^FZRMZTZM\/JKB/*?3G]D@>3-294"Z;LSMNPM=IEUBI,L,64
M.FTQX1S#F(+2<V"8M^["[M(TCH =T>%-\+J[G!*![V'9_3@H1A_R_3G%7CR9
M(6:@!!8;$31> QTGKLJ1(11.NK?:Q]N!+6,GC;LGG^OL. N(HWBW,_2U9LO,
M.$L\@!I8$S@1=F_J*RU3:)6$D(9*BK06FM,67-IA?7<*_C(V;9ES9U3,%[&.
M\"KKQ$@OYA_*^?_)EQ-@KRY?KXL,".6,8!Q)A0P5QI/-T;N %J8D>$AR-KYA
M\+4L@R<4GK>6[]*_,UO/I-LPX8+THBTR?WPYWO-4]_U^5,>5^=W=/@MZ-6+,
M$X(<U,1!3KP7@%&C.>0"U7(]MDS_EP-))U\^F%$"+8+*<:Z((! R[&!%D;-)
M&0SZJ-\V*^77]E,*:SNSR*M!KHB.);3*29S7ZENQSTS:VR[LIL)PJSG14E(A
MPVKFV(96D)0CM\\P.E+0N_#2 $L[.V-].51;W@V*?;7TMCZ?,8HDE$([$)0N
M;H6#B%2TT:"472A<TN3\^J"S <YVIM8^73+[+;_[FD_WZ:^OG\VL01 #IIE!
MDE)LO11\31/B *?XEWN(ED2YOM9$$[G9%4+4*.C)03;QHE@TTM8:]$&T[&V7
M2<T$ TYA#*B@UF$L9$4KMBAE6^JA!Z99Y#3)V:Y0M [^/8B:%\]ESA%,B(<J
M3 FH#-48;6B1R*08PCV\Z-XL2E(XV>'N$X1PFT]FQ4.^JG!19Q?:WB9SB@:.
M:*@XL('68*T;6]%HJ3N;V^0MH*4IKG9W*W@>R,U';C"=%).;V4'8;&^008!E
MC).$C@#D3<SHB=;48>&2_+Q)>7K? F8:86GGUO7[,.1WX<=:)O7FX<P9CJ&0
MB$-&A1$06%T9 U@KF6(8]5!A:=J./I6/W1TEOHZ9^]X+]:D<CWTY_6LPW>?D
M/[*GS (A@>3,"Z.T8]H:7;FTL ?^PDRH%$ <3#S?)*//8']_O@TLG%TMYK/Y
M8!+C->N9XM\URR2#7'&K'$'!G(1 P8VNASVW*8D%CH;4]X&*'5Q+:PT:NTWX
M5"ETMPWN.AC:N@V^?CB#6,9<,(H[PKW3G$*A*JH 2"IZ=?0VN ];'58W: =;
MR;SO%%'Q7EP^LHM8+WX5A;Z:$,>F!SB^L\PX0A$A3D/+ 8^%8&5EGQ A7$I8
M=M\C-3K%8IM2.3-6_V,P7N0-075W7YDBB.%8A,)*+9"")!A=%4\(5RDF1$-A
M'1W6[>@4J8T)I1>+ZH?\K^57^RW8.AUDT(8-)58NL8C9&.5I^6:: B]3%L^C
MW1^[[I#C"P5EFBSZL&0F /%E^XPQKIR1R%')!"?4>$\KVIG"*:DTCK];5<Z*
M>?'PXP Q21:]6!%?I7-3D4L?\OG5=>#8=;X*\SMUL:S3=V8],TX RP14UG@0
ME)W-+@(%3+GYFIA"Z/+AVYJ8NCMAW]2<_Y2/EVE\RB^#;W\4\]O(PT!H+%P2
MJ=2!NZ/HOL\GLUVYBQKH-595MII(9+B@(&Q#4L-J":#&V)38PV8S&[66"+4K
M3'<GI9/O6>R==D?FU#JEK\P2&O8=K8SC$"NO@/.5AY@J#%)R;QR=Z.C"[*:N
MA-(T^)8J2S/8V]=5II UE#(7\_10+*@@K-HP(ODIQ\,GY#3Z<;#7H%#.L(M_
M*7>$:"VGU-?7"_FG// RV!SYYWSZ4 SS%0L^Y</R9K+L9<F->EM]*Z_.L 0:
M$@&=9HQAR64P5#>37=BD,A -U8%H+2GK&32!/@BQJVD3E!VSF,_49/0_RZ\S
M%1-$A2=Y&/UX,)L5U\5P26-,OJ?*8?&E?!UU$CHXF >IN9=D%H8]SR"O#8;(
M ZL(UA47)=$I5?-@#P-!ND+_V234CEJ\#K[<>Y!P0B\95E@(@QT3W%NEPC:(
M744;Q4G'K["'$;'G5W]31="*XIN*KNV=9 IJ [C3B!#+)1=,V8T]*31.22@+
M?_0#JM;%T0L_[*I^P2S(_D4M@UI%:],ZSJ10&#KKJ2'< P T0-7I"2/0)^W+
M/8SD[87/M6FI],E4>Q4J7:<22Y/=9TA98HF'C$E-+2$&J,J_PA!S*4XOV% =
MC#<?UW(&09VL#]09ZRK]P[N)'Q33Y:82*VM-BX=!/,[<6;,JO>=,,LD--(@9
M;CQC3GE81:8QB7A2$//1YU]O?_$]CUA:A>;':7Y7+.YF\<-HQ'W)IW?%9"GL
MF"AO:UVD%,">\KX,4JJ#<)1#B"@$A4&FDA/#QJ=<((-)J0HO10'NB>2ZTC.N
M8O:>+3?KU,.@&,>+-=?E=#9XKC ],6AY=OUE\.UC.5U":3Z?%E\7\]CJ2_EQ
M*=(]*DC+;\Z\)LP1@I 17E)/@TT,-RN+IDDSI:$SN3=_--PO&9Y[S@1NYL7-
MQ,1479/AXY=@+,\&PR5QD]'RM_$*22W/H%;&D4F@#<%<(2P]DR+FN,:5+ )J
M4N+?T-'GC+L"B-[\?9T^R[2K^15&OB+Z?3D[4/CGZ;F,L6#" Q+V4N,)<<!;
M5!DYW N?8HVBA@X 6RLUU14Z4SC^EJ\K0FV$4A+0L.LXX3 +QD5%*830I6#K
MQ#ME3UGJ+VCU:U (;^6VHD*("V64)$YJ$3B&8>5^Y,C*%*<P.OJX;#>TWKPC
M+9GU3X Z;_[4Y[K!\PWRG%E3UUK_9+3-%C@J?VJ=GC(>DW\(K8WU6D'($,%P
ME?C6 LQQK2M!O5)=E+7"20H@ @H%@CQ95\2S$*(DU;K/"1::EO9^9>4H'I_;
ME(Q#KJ' UYA;#;TA,RRLMDHZP:S$ #(#C=WPCR=EW3Q: ^JB G57*#V/?,Z-
M[\MVE1#O@(F7RS'2P!(*@565+(*.P<^UGG?@>>P<SF?UGQPGZ'-/NK?OT[?.
M.BB\!1H+(7VT!77%;R%TDAW>^WKB?9U:YQ'NN2=33:ZWIYEE!)(@0.Z##>N5
M)QP(4,D1(>E2<F@='V?;>BG;OJ*_'6F=,;MM1<Q^7^FN5IGVQA@/XI4[HZTE
MTD)4T2EXQ_F0NRRPW*J5T!S'^^K&6DV3VSPT'XQ?#OF'\&E)"8#E3"'HI1>.
M<,RM!Y@82"76OE:MR//;<"LE^M=!,8DR5=-B5DQNGD?E[E]8FGY5YDF\@HFD
M8)X"QX"$5E9<Y0XFA5R_?<]:;<PE&%DMB*D/JM]&Z8VY#UXHO:<A_&"?F3;"
M4&3B_H$9 8Y2+CQ02%,O$.O6]KE\*#<MCYYLNU?WZQOJYSLV6O%W,Z@:6^F.
M%IE2@==<6B=X^ $[;>DZ*;Q02,!:(=WMT/@I?\@GBSS&AL8, 7&T,5V*">(*
ME$P#0>-%/--6LUD>_CNP*Y[06R8-!,8'=BA*'%9A$O -;RB$%U9Z.ADAWY4-
M:)OCW1EXL["$_EJ6HWAQ>7W[?O:Y'&^[D'FX42:I$H!C@:6EG%@'(5$5E1:0
ME#0+O3P&:AI9C;&V*P#].HW&V;2\+O8MT<^>"A/!.BX1\5PXJI6!0;>KZ& V
M25'IH0>@:8"<SLG.U.*5#C&Y658H#@M@G5/H76TR';AA#$28>R#C!0E.0$6C
M$31E0>EA1:2FT=(47[O"SJ<@J/"NV[#VV;#'CLO[96G+U>#=MVI;'?YS402A
MO9N$B1"6QUE<-?<J2"?WFF%* 5(X_$4Q9=C 33Q96'4%O;#8FP;P\IVJU!7O
M.XOHS,>ASYM?\TG@U3C0I49WQ:2(?(IW%M>D[7/]U>H@$P !ZA6C4E%!O*5F
M,^?#_]G9ZDMV$/39/ Q;X7E7B-O<C?TM'\P6T^76$.V-WR?EUUE0$:,/XMWD
M?A$3< [+R; 8%^NL6L/%-'K2]&!6S-X7@Z_AF_ECY6Q;F2EQTE49B/: MK,Q
M9$(J30S@6FM(O=?,4[Z1@>0I"0OKZX=GS=S://S[*KW.TF4$*WS^[NX^L"&2
M;FX'TYN]J5RV-\B40,)"@@/7*4802$-011W&NE-M=%> R1M:E1OA<E<8LGF0
MSW U+^(&<A=/\__S4 [K/:TR;1E@4"CHD8000"IU9='K,%52(C22\OUTD)*R
M>2PUQ^BS&<K'&,@94Q("Q!R&%"+")63>5C0!#U-2G1V?7*?]\)[&\9+*T<Y1
M4NOBR):G,\&!Q4X3!*67& )%W3H+6[PCA5,VK>.7F3?G<$OG:&?WHLM)^7*P
M:VC7<, =;)M!$V86TXII@2!ECGA<\<\8FY1:,2F9U]M 4=/\[0I3[R8/^2I$
M=S7J=Y/ ^WROMVU7D\R&S==)H(6WUA(6_G"SF37\TEQI#4K\N[+!C3"X.PBM
MAG?8,?;JR0Q#QWF@)NK_5C%EF:GL (.(2_$$U/> O?0$O%G(I'"VL[/$03&9
MQ0TVGUU-W+?(AD4QNUV%^1S(6'FP;6:I)EKAH"T"I.(A/%2ZHMDKG^)/[6'>
MZ?:PU#2GNT17'/;5Y"G!X+M)8,9B&?ST(9]_G.;SO9$V=;O(!"4F&)J2:H@U
M (#;*FFLB)&+*99]#T\MV\5:"PSO-$)T)W<.A8'N;)@QB62@#QGN//3<<BEA
M12T+:_KY'4>M.2';PUJC/.].N:J,TBH8K9@LPMB? CEUO'>WCEK],OB6S\*2
M/1T$:1>3P?3Q7;!O9H'H80QC*Y=G9+54_-;>FC&/I1/.4DRT<$Q 1V7%9R1-
M2F3B\7EXWYRWHC^2Z78&Q-HIJXFJ\TF^/QAM1XL,<.T(QMHIAKAF@G%8A5-9
MBVB*A^/4DI%O$'NI?.UW%D$(B22&8N2EEYPKY3:&D_6&IBAVQR>-?7.K4PHO
MN\)%=9+],=\4+2V&,7JI&"_F6^O4U&R9J5BUC!(--4!02T)C-.^:7N-,4N6C
MI$J,;P,\S;*W*SC]D1<WMV%XZB%LP#?YA\7=UWQZ=;VDX%GVPOHH.ZW##&%M
MB--88$6M(X+&9,DK[CBD64H]Y+3ZAV\#?)UPO?-+8(&8CX&:EZ.H?==K5LV.
M63[\^TWY\,LH+U83(_SP>CZ$C[+E"_<<1GWW3 8QA]Q#+#V!07+,4N"I=U![
M0@FUM;;;1H9NR^'2Y? EO&C'R)\_DGE-K7=<"^D%1 :'Q4BL!\X -4E5=_LS
MVQ($5C;"N'JK^,G25I/)8C#^E-^7TUUXW?9HAKW&TH3I#C"0#D.,XFJS(D+)
M9TE(W_1=W&:EG\# EE'PL<IZ:\-N<@ &+Y[-#-4,&2<@LT(QA8PT%3\8#!]<
MQI%#LSA(X6#+0%@F+"A6<;$UEH37CV? $&:$$5QAA+C$5""U)H83RFOEI>W_
MJ4##FT(:$UM"A)O,B_FC+\9K37 '$EX_%M8UI((M$C.6(0.5\<3!:O!"HY2[
MCSVJ\-@, A*9UZKD/^4WR[LCD_F'P=VN/6';H_&&";(:< @-Y\$VL)!5.QO'
M&J1L"3T*HVH2 4D,;!4%T<B<AD5I*8BEK6G*Q60^?33E:#\H]K8,.K!6@A)&
M.66$!:[%VD;5$@>2,O?UJ!1ADQAIDI^M0N;+X-N[46#*IAQ\C?UC1YO,><J0
M5HYS[Z&A3!G,*K*@%BD5;9)*_?47)LUPLE6 J-$HB&2V_N=],<GA7G!L>3Z3
M89]DWFC($-/248/D!N_.HQ1'<U)EN_X"(YV+78#"A!^OIE_*O[9=.-KS=(9)
MV#.],5((BP1>!:NO2!$>^90; 'TZ>6@!$2<SL0L\+#>ZJ^G':?E03(;[-8[M
M33+NG>44.0F)T9(&%1MMB#(HZ;)MGXX%6D!&&B>[@,?'<C8?C/^_XOZ@.KJM
M048U((I[9(P+:R"C1@;ZU@0YK%/"(>#%>3$;XV-+P(CKF)KF@SU0>/Y(!I#V
MUD!)(#;22^@HQ&'0""C,M85)U7$OSG69P+F6Q/T^"&3\\;:<[/=/O7XL<TP@
M'K1@18G@C'@KC8V#IY@K'A2B%+%?G(LRD7LMB7Z=A?01HJ]?BOEXUVQ__5@6
MMB^#-(-6.&&L10X@5"U3TB9%-L&+\TTF<J\ET7^9#F(0PN?'NZ_E>(?<7SR3
M840UEXHC*A!TS#AN235LQ$U*U2YX<>[(%-:U/-G=M^'M8'*3[_%&;WLT8](;
MA0!A&KN@MA)C**B(H% FR?_B7(T-<+!5M?^/?#S^7Y-@JG[.![.P*XW>S6:+
M [[%'6VR_Y^]-UUR(T?6!=]H+O;%;/Y@[=$=E5*C4G7;^06CF)$IWF:2:BXJ
MJ9]^ )+!7$D& [&1DIUC7:E, @3</P?<';X01YA2G&!KF'->QJV4;RU"*Y]U
M&URI<[$94K:*D'_.I^O(D,7F56WQ5M3SP<\&&T&NG()&&BKC3@3?!^9(#7R6
M17"E7L4\$K:*A&T/AM7V33U=:I$IZ^. >'M(*D*K!>%L<Q<:C#0UI7DKD;,Y
MKQ#H2GV+C5"RY9?-2,G4__![84>KT6[!)YXTWQH2,8]4) ;@'@,7+6%->*D8
M2^*K]6(^!(\K=3 V0LG6 U\69K0J[N>+M_K9'_ADW()RV&/%"%=0.\L]I7N$
M$Y(5%WFE+L4< K:*@3\?1M.I7B\GL^+-_*D#GPP.D'C;$4,T,$8J@:S#Y18L
MR0J 05?G6<PG8*L8< _%XCZ5U5W,_UY]36UR1K/CY\&;(P+2S"(F@+- "JJ$
M!8^PELID=8VX.K=C<X1L]WSX&NVA*I!X^L&@N:.(:*59BNNTG*=,P/T&<$Z:
M$KHZ+V0V_5H%P,?UE^ED[*?ST7'%\<GG L'8"\F=(D0X90P!WNV6KR)I<MP.
MZ.K\D;GD:]? G#\\I%"\^?C?FR2YY9,LN>-FYI&! 0BLG&8H[I A93151)8;
M9(!G*0]7YZ]LG)XMIU<L'Z,XBUO]\U/B13$;%Y^+'RL=O^G?!W!3>7P@C%&*
M-([2P0$FBF!2GH[Q9\1SX'-U7LVVR-KNL5.D=FS3=[/;XL?_6QQ7/%Y\-J2[
M4N!('T,EU4@J1TM'K7*"Y7@XT95Z./-(V!(25$3M;4*NGXX.W37//A.DBJJ1
M5UY:9+1%UFIKRV4#FY6OB:_.AYE#NK:BF[8N,C]9CD?3_RE&B^/)FH<^'I!0
MU&(@N!5( DHL!_O-6,QR[%!\=<[*AJC8LE+QN#P??W/(477@TY$N5C'GJ?;<
M86 (X:Q\W=5<@QSO-;XZAV4S1.P$#]LDX^J(>/+YP  0E%(,@$+,"$ $*'5F
M+;C*ZE]Y=0[,ILCXB(I.2J,\+3;<>0?L].4VTFLZ3ZV:*A3O?WM  !9J;3T3
MSABJM0124J9%JHY)D0"5@-K%#H_9=R=&!&N Y5H:01U'2A,HI"KW2+G,BDH8
MCBPVQ>A7+7.:(&H/HFGFLW@PK29?IL6'^:K8MDJ>3>:+38C6IE_;P_OY:&:+
MU6@R[:^7?5.2[)460EGOC1)"8*<-1]XAHV@\ABFII(:TM\/'@LR?4Q^Y$]M[
M\>E O+!Q>\X0H3V2SDND-WL3FC!B<GPRER/!E1G\A@3G$;2:NI4/E/?SV7TD
M[T-:<2KTI'Y,CE7=?.OC@<8=<"8]E< )*H#"%L2=V?0:CC')RD@:>+^T+$;/
M&Z=M7ZBQ\X?1Y%B[O;<'!$H1BE>A! 8JB@@D&+#=[C3'^$K*L37#X!-HJ471
MKO#R1#%(Z_VC.)#\=/3S :%HXF!D.85*$ /]IL+(9F^&(-?;.=,-6LYE\+QY
MDG8%E^>GZHDKZ?6' X0."X>5P99@&,]AH'8R)1"4(*</PX"\0VW<0=G$[ <B
M*>7CY!UT:$@0PC(;Q<!(+I6+Y-*"[W:($:97J.K69?%1M-2FZ&G,W,VGMQLD
M0+3#0?K-TS-M:V=NK,[X.6;7!0(('[QHSAD>($ 20.(\]1!X:>+)*\O=2 ZS
MLF^'CH\Z3)VW3N-^3IGWDUFQ:<11^9#9CP@@48]3+0SPC$KD./'; SE>NECF
MI&,,R#G=_I54EZ+](&99T;?TQH@ D?$84H0M@TA8##6$22*@590@?=6W4@TN
M'T5-7:KV@QHS6BQ^3F;WZB$5RZL,G>?# L8H54#:M%U0VA%@O-WME#G"!^"5
M::T963;SCX(IB\[](.JOV>@AY;3]M[A-7LZS8/7&V."Q889K;UFT$95%D.MR
MSYR#K*X5=3O ?N[XB&H:5?ED[@Y:6^[<W,7_1CDP\^7JN$KTQN<#E@11PI5
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MJQX,'& 4=__B=RFL[E@<%W\4H]3];.O0;$N4#GU+D(IC[C6AGG%)@92&EWX
M!K7.>N8=8.3EP,6@(39U!&'W8URDU,E_CJ;KO2S&3>RTS"C/[OLV2"Q=E<T
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MZ2FT;"=(CA+/*M60:$I+ZR)KJ!L@=LB2X2AY/1<][$>U\XX8)+3'A'J)"-"
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MG#"O0>KR#?#]54IF8^3M3W[[+RS?M!ACH9%SV'(GA$])U80QZBV1#"@?_S0
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MOS,H0* U1B$(+8:820E*YQ8'TN?$S5SAZWR+LC4 [EZ*!)V^\@\4;._U+>'
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M^XOTY6.Q*O_[K_\#4$L! A0#%     @ S(!B4&#S=XBP&P0 @=TL !8
M         ( !     &%M:6-U<S$R,S$R,#$Y,3 M:RYH=&U02P$"% ,4
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M;&5Y8V%M<"YH=&U02P$"% ,4    " #,@&)0[UFKU&YT  #.(0, &@
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M              "  ?5=!P!E>&AI8FET,C,Q+FAT;5!+ 0(4 Q0    ( ,R
M8E X 2MYVP<  )8?   .              "  4AC!P!E>&AI8FET,S$Q+FAT
M;5!+ 0(4 Q0    ( ,R 8E +W@2JQP<  ) ?   .              "  4]K
M!P!E>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( ,R 8E :D!_^400  # .   .
M              "  4)S!P!E>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( ,R
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M &9O;&0M,C Q.3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,R 8E"D]T6K;+,
M #KT"  5              "  0I:"0!F;VQD+3(P,3DQ,C,Q7W!R92YX;6Q0
52P4&     !0 %  Y!0  J0T*

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983227632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company held </span><span style="font-family:inherit;font-size:10pt;"><span>$142.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents and </span><span style="font-family:inherit;font-size:10pt;"><span>$309.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of available- for-sale debt securities which are reported at fair value on the Company&#8217;s Consolidated Balance Sheets. Unrealized holding gains and losses are reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company&#8217;s cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,710</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,999</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in marketable securities </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,903</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents, and marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">December 31, 2019</span><span style="font-family:inherit;font-size:9pt;">, </span><span style="font-family:inherit;font-size:9pt;"><span>$9.5 million</span></span><span style="font-family:inherit;font-size:9pt;"> of marketable securities have maturity dates greater than 12 months and are available to convert into cash, if needed.&#160;</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,749</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,749</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(250</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240,726</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,749</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,749</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>424,830</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>424,403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents, and marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> realized gains or losses. For the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">minal realized gains. The cost of securities sold is based on the specific identification method.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized loss positions in the available-for-sale debt securities as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> reflect temporary impairments that have been in a loss position for less than twelve months and as such are recognized in other comprehensive gain (loss). The fair value of these available-for-sale debt securities in unrealized loss positions was </span><span style="font-family:inherit;font-size:10pt;"><span>$42.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$403.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.15204678362574%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,749</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,343</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6748313744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (356,388)<span></span>
</td>
<td class="num">$ (348,995)<span></span>
</td>
<td class="num">$ (284,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment gain (loss), net of tax impact of $889, $0, and $0, respectively</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
<td class="num">(3,604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities, net of tax impact of $182, $0, and $0, respectively</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(538)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,757<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
<td class="num">(4,142)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (353,631)<span></span>
</td>
<td class="num">$ (346,449)<span></span>
</td>
<td class="num">$ (288,144)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6825957776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 19, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amicus Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">71-0869350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 Cedar Brook Drive,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranbury,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">662-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FOLD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,147,432,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,244,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">DOCUMENTS INCORPORATED BY REFERENCE: Portions of the Proxy Statement for the registrant's 2020 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6988602848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,293,000<span></span>
</td>
<td class="nump">$ 48,768,000<span></span>
</td>
<td class="nump">$ 44,130,000<span></span>
</td>
<td class="nump">$ 34,046,000<span></span>
</td>
<td class="nump">$ 32,644,000<span></span>
</td>
<td class="nump">$ 20,596,000<span></span>
</td>
<td class="nump">$ 21,309,000<span></span>
</td>
<td class="nump">$ 16,696,000<span></span>
</td>
<td class="nump">$ 182,237,000<span></span>
</td>
<td class="nump">$ 91,245,000<span></span>
</td>
<td class="nump">$ 36,930,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,906,000<span></span>
</td>
<td class="nump">10,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued expenses, and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,373,000<span></span>
</td>
<td class="nump">$ 80,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication', window );">Conditional aggregate payments per indication</a></td>
<td class="nump">$ 86,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborationAgreementAnnualContributionByCompany', window );">Collaboration Agreement, Discovery Program Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentsForCollaborativeArrangement', window );">Payments for collaborative agreement</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentsForCollaborativeArrangement', window );">Payments for collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccruedPaymentsForCollaborativeArrangement', window );">Accrued payments for collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember', window );">Revised Agreement | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments', window );">Potential milestone payments upon achievement of post-approval and sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones', window );">Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued expenses, and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedPaymentsForCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Payments For Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedPaymentsForCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborationAgreementAnnualContributionByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Annual Contribution By Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborationAgreementAnnualContributionByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Conditional Aggregate Payments Per Indication</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentsForCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentsForCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fold_GlaxoSmithKlinePLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fold_GlaxoSmithKlinePLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983252592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities led by the novel medicine for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic, and an industry leading rare disease gene therapy portfolio.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cornerstone of the Company&#8217;s portfolio is Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several other geographies around the world. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lead biologics program of the Company&#8217;s pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation to AT-GAA for the treatment of late onset Pompe disease. In the first quarter of 2020, the British Medicines and Healthcare Products Regulatory Agency issued a Promising Innovative Medicine designation for AT-GAA for the treatment of late-onset Pompe disease. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("NCH") and an expanded collaboration with the University of Pennsylvania ("Penn"). The Company's pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, CLN8 and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Niemann-Pick Type C ("NPC"), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. For additional information, see "&#8212;&#160;Note&#160;16. Collaboration Agreement."</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second quarter of 2019, the Company completed an underwritten equity offering and issued </span><span style="font-family:inherit;font-size:10pt;"><span>18.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$10.75</span></span><span style="font-family:inherit;font-size:10pt;"> per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$189.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first and second quarters of 2019, the Company entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with a limited number of holders (the "Holders") of the unsecured Convertible Senior Notes due in 2023 ("Convertible Notes"). Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$247.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Notes held by them in exchange for an aggregate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>44.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share. For additional information, see "&#8212;&#160;Note&#160;12. Debt."</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had an accumulated deficit of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and anticipates incurring losses through the fiscal year ending December&#160;31, 2020 and beyond. The Company has historically funded its operations through stock offerings, debt issuances, Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> revenues, collaborations, and other financing arrangements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The current cash position, including expected Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> revenues, is sufficient to fund ongoing Fabry, Pompe, and gene therapy program operations into the first half of 2022. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6809461728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Weighted-average Assumptions (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">74.10%<span></span>
</td>
<td class="nump">78.60%<span></span>
</td>
<td class="nump">82.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 8 months 4 days<span></span>
</td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare', window );">Expected annual dividend per share</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6827278512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable, Accrued Expenses, and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 21,722<span></span>
</td>
<td class="nump">$ 6,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">7,832<span></span>
</td>
<td class="nump">2,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccruedContractManufacturingAndContractResearchCostsCurrent', window );">Accrued contract manufacturing &amp; contract research costs</a></td>
<td class="nump">17,800<span></span>
</td>
<td class="nump">5,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">27,156<span></span>
</td>
<td class="nump">21,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccruedProgramFees', window );">Accrued program fees</a></td>
<td class="nump">17,016<span></span>
</td>
<td class="nump">16,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">5,196<span></span>
</td>
<td class="nump">4,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">3,679<span></span>
</td>
<td class="nump">4,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Accrued milestones</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccruedSalesRebatesAndChargebacksCurrent', window );">Accrued sales rebates and discounts</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">3,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes</a></td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 120,373<span></span>
</td>
<td class="nump">$ 80,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedContractManufacturingAndContractResearchCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedContractManufacturingAndContractResearchCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedProgramFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable related to a pharmaceutical program, including but not limited to clinical studies or commercial preparation activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedProgramFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedSalesRebatesAndChargebacksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Rebates And Chargebacks, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedSalesRebatesAndChargebacksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6828322720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,837<span></span>
</td>
<td class="nump">$ 79,749<span></span>
</td>
<td class="nump">$ 49,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, debt securities</a></td>
<td class="nump">309,665<span></span>
</td>
<td class="nump">424,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities', window );">Cost, cash balances and debt securities</a></td>
<td class="nump">452,502<span></span>
</td>
<td class="nump">504,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value, cash balances</a></td>
<td class="nump">142,837<span></span>
</td>
<td class="nump">79,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">309,903<span></span>
</td>
<td class="nump">424,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure', window );">Fair value, cash balances and debt securities</a></td>
<td class="nump">452,740<span></span>
</td>
<td class="nump">504,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities with maturity date greater than 12 months</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, debt securities</a></td>
<td class="nump">145,875<span></span>
</td>
<td class="nump">240,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">145,991<span></span>
</td>
<td class="nump">240,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, debt securities</a></td>
<td class="nump">73,659<span></span>
</td>
<td class="nump">115,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">73,710<span></span>
</td>
<td class="nump">115,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, debt securities</a></td>
<td class="nump">77,731<span></span>
</td>
<td class="nump">68,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">77,810<span></span>
</td>
<td class="nump">68,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, debt securities</a></td>
<td class="nump">11,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">11,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, debt securities</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, debt securities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6827538528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 16,483<span></span>
</td>
<td class="nump">$ 11,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">10,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AmortizationDeferredFinancingCosts', window );">Amortization of deferred financing</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="nump">10.63%<span></span>
</td>
<td class="nump">10.85%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="nump">10.16%<span></span>
</td>
<td class="nump">10.48%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AmortizationDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AmortizationDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6816311792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>- Assets and Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314,270<span></span>
</td>
<td class="nump">$ 427,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,681<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,100<span></span>
</td>
<td class="nump">22,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_MilestonePaymentStockIssuedAsConsideration', window );">Milestone payment, stock issued as consideration</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember', window );">ATB-200 Pompe Program | Clinical and Regulatory Approval Milestones | Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember', window );">ATB-200 Pompe Program | Minimum | Clinical and Regulatory Approval Milestones | Callidus | Probability of Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember', window );">ATB-200 Pompe Program | Maximum | Clinical and Regulatory Approval Milestones | Callidus | Probability of Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,710<span></span>
</td>
<td class="nump">115,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,810<span></span>
</td>
<td class="nump">68,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,991<span></span>
</td>
<td class="nump">240,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
<td class="nump">3,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,270<span></span>
</td>
<td class="nump">427,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,710<span></span>
</td>
<td class="nump">115,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,810<span></span>
</td>
<td class="nump">68,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,991<span></span>
</td>
<td class="nump">240,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
<td class="nump">3,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,681<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,681<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | ATB-200 Pompe Program | Clinical and Regulatory Approval Milestones | Probability Weighted Discounted Cash Flow | Callidus | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_MilestonePaymentStockIssuedAsConsideration', window );">Milestone payment, stock issued as consideration</a></td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_MilestonePaymentStockIssuedAsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Stock Issued As Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_MilestonePaymentStockIssuedAsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6826284880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="nump">21.1<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants, net of issuance costs</a></td>
<td class="nump">$ 243,000<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="nump">$ 188,994<span></span>
</td>
<td class="nump">$ 294,584<span></span>
</td>
<td class="nump">$ 243,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount', window );">Exchange agreement, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,200<span></span>
</td>
<td class="nump">$ 247,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance', window );">Exchange agreement, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,768,610)<span></span>
</td>
<td class="num">$ (1,412,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fold_UnderwrittenOfferingMember', window );">Underwritten Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fold_UnderwrittenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fold_UnderwrittenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983258752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>program</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationNumberOfPlans', window );">Number of equity-based employee compensation plans</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of plans under the equity-based arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806254944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Changes in IPR&amp;D</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Change in IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 463,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Change in goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 197,797<span></span>
</td>
<td class="nump">$ 197,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812489392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and Available for Sale Securities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,710</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,999</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in marketable securities </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,903</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents, and marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">December 31, 2019</span><span style="font-family:inherit;font-size:9pt;">, </span><span style="font-family:inherit;font-size:9pt;"><span>$9.5 million</span></span><span style="font-family:inherit;font-size:9pt;"> of marketable securities have maturity dates greater than 12 months and are available to convert into cash, if needed.&#160;</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,749</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,749</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(250</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240,726</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,749</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,749</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>424,830</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>424,403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents, and marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.15204678362574%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,749</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,343</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983222560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text">Selected Quarterly Financial Data (Unaudited)<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarters Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands except per share data)</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(120,299</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84,551</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(89,729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share&#160;</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49,916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(159,163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share&#160;</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.28</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.33</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:inherit;font-size:9pt;">Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812480080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company currently has operating leases for office and research laboratory space, equipment, and vehicles under agreements expiring at various dates through 2044, which include renewal options on leases which the Company is reasonably certain to exercise.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, operating lease expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$10.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company paid </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> for amounts included in the measurement of operating lease liabilities and recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$21.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of&#160;right-of-use assets and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of tenant improvements paid through lease incentives in exchange for new operating lease liabilities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commitments under finance leases are not significant.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to operating leases was as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.270955165692%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except year and discount rate amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU asset</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of the operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,189</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current portion of the operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,531</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease terms (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the future minimum operating lease payments were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.22807017543859%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,787</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,582</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163,266</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>215,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less lease incentives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,939</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Less imputed interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(125,982</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the future minimum operating lease payments were as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.64327485380117%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,063</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,038</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,887</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rent expense, including fees for utilities and common area maintenances under ASC 840 for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$5.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806500992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Convertible Notes and Senior Secured Term Loan (Details) - Convertible Notes - 2016 Convertible Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">$ 152,825<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="num">(2,974)<span></span>
</td>
<td class="num">(74,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Less: deferred financing</a></td>
<td class="num">(346)<span></span>
</td>
<td class="num">(4,115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value of the debt</a></td>
<td class="nump">$ 149,505<span></span>
</td>
<td class="nump">$ 321,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808110608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Expense Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 44,430<span></span>
</td>
<td class="nump">$ 29,260<span></span>
</td>
<td class="nump">$ 23,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">17,575<span></span>
</td>
<td class="nump">11,740<span></span>
</td>
<td class="nump">10,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 26,855<span></span>
</td>
<td class="nump">$ 17,520<span></span>
</td>
<td class="nump">$ 12,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amicus1231201910-k.htm": {
   "axisCustom": 1,
   "axisStandard": 33,
   "contextCount": 211,
   "dts": {
    "calculationLink": {
     "local": [
      "fold-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fold-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "amicus1231201910-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fold-20191231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fold-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "fold-20191231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 673,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 16,
    "http://www.amicustherapeutics.com/20191231": 6,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 27
   },
   "keyCustom": 84,
   "keyStandard": 420,
   "memberCustom": 27,
   "memberStandard": 45,
   "nsprefix": "fold",
   "nsuri": "http://www.amicustherapeutics.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.amicustherapeutics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Acquisitions",
     "role": "http://www.amicustherapeutics.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Inventories",
     "role": "http://www.amicustherapeutics.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Property and Equipment",
     "role": "http://www.amicustherapeutics.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Accounts Payable, Accrued Expenses, and Other Current Liabilities",
     "role": "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accounts Payable, Accrued Expenses, and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Stockholders' Equity",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Share based Compensation",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensation",
     "shortName": "Share based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Assets and Liabilities Measured at Fair Value",
     "role": "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue",
     "shortName": "Assets and Liabilities Measured at Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated Balance Sheets",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Debt",
     "role": "http://www.amicustherapeutics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Leases",
     "role": "http://www.amicustherapeutics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Income Taxes",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115100 - Disclosure - Collaborative Agreements",
     "role": "http://www.amicustherapeutics.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - Basic and Diluted Net Loss per Common Share",
     "role": "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare",
     "shortName": "Basic and Diluted Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117100 - Disclosure - Selected Quarterly Financial Data (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited",
     "shortName": "Selected Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Inventories (Tables)",
     "role": "http://www.amicustherapeutics.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Accounts Payable, Accrued Expenses, and Other Current Liabilities (Tables)",
     "role": "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accounts Payable, Accrued Expenses, and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Share based Compensation (Tables)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables",
     "shortName": "Share based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)",
     "role": "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables",
     "shortName": "Assets and Liabilities Measured at Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Debt (Tables)",
     "role": "http://www.amicustherapeutics.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313301 - Disclosure - Leases (Tables)",
     "role": "http://www.amicustherapeutics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314301 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316301 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)",
     "role": "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables",
     "shortName": "Basic and Diluted Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317301 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables",
     "shortName": "Selected Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated Statements of Operations",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "D2017Q3Jul1-Jul31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - Description of Business (Details)",
     "role": "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD_srt_StatementGeographicalAxis_country_US",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fold:ShareBasedCompensationNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails",
     "shortName": "Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fold:ShareBasedCompensationNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402408 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Policies (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies - Recent Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "D2018Q3Sep01-Sep30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fold:NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Acquisitions (Details)",
     "role": "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
     "shortName": "Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "D2018Q3Sep01-Sep30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fold:NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Goodwill and Intangible Assets (Details)",
     "role": "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2017Q3",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Inventories (Details)",
     "role": "http://www.amicustherapeutics.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Accounts Payable, Accrued Expenses, and Other Current Liabilities (Details)",
     "role": "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accounts Payable, Accrued Expenses, and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409401 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails",
     "shortName": "Stockholders' Equity - Common Stock and Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "lang": null,
      "name": "fold:CommonStockVotingRightsForEachShareHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails",
     "shortName": "Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Share based Compensation - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails",
     "shortName": "Share based Compensation - Weighted-average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003001 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Share based Compensation - Stock Option Activity (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
     "shortName": "Share based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2016Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "-2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails",
     "shortName": "Share based Compensation - RSUs and PBRSUs Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember",
      "decimals": "-2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Share based Compensation - Expense Summary (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
     "shortName": "Share based Compensation - Expense Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - - Assets and Liabilities (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
     "shortName": "- Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "fold:MilestonePayableAccruedDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "D2017Q3Jul1-Jul31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "I2018Q1Feb15",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Debt - Convertible Notes and Senior Secured Term Loan (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails",
     "shortName": "Debt - Convertible Notes and Senior Secured Term Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413402 - Disclosure - Leases (Details)",
     "role": "http://www.amicustherapeutics.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414402 - Disclosure - Income Taxes - Statutory Rate (Details)",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails",
     "shortName": "Income Taxes - Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fold:DeferredTaxAssetsIntellectualProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414403 - Disclosure - Income Taxes - Deferred and Valuation (Details)",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails",
     "shortName": "Income Taxes - Deferred and Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fold:DeferredTaxAssetsIntellectualProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414404 - Disclosure - Income Taxes - Loss Carryforwards (Details)",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails",
     "shortName": "Income Taxes - Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FI2019Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415401 - Disclosure - Collaborative Agreements (Details)",
     "role": "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "I2018Q3Oct31_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember",
      "decimals": "-5",
      "lang": null,
      "name": "fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416402 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)",
     "role": "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails",
     "shortName": "Basic and Diluted Net Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417402 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)",
     "role": "http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails",
     "shortName": "Selected Quarterly Financial Data (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Description of Business",
     "role": "http://www.amicustherapeutics.com/role/DescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amicus1231201910-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fold_AccruedContractManufacturingAndContractResearchCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).",
        "label": "Accrued Contract Manufacturing and Contract Research Costs Current",
        "terseLabel": "Accrued contract manufacturing &amp; contract research costs"
       }
      }
     },
     "localname": "AccruedContractManufacturingAndContractResearchCostsCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AccruedPaymentsForCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Payments For Collaborative Arrangement",
        "label": "Accrued Payments For Collaborative Arrangement",
        "terseLabel": "Accrued payments for collaborative arrangement"
       }
      }
     },
     "localname": "AccruedPaymentsForCollaborativeArrangement",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AccruedProgramFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable related to a pharmaceutical program, including but not limited to clinical studies or commercial preparation activities.",
        "label": "Accrued Program Fees",
        "terseLabel": "Accrued program fees"
       }
      }
     },
     "localname": "AccruedProgramFees",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AccruedSalesRebatesAndChargebacksCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Sales Rebates And Chargebacks, Current",
        "label": "Accrued Sales Rebates And Chargebacks, Current",
        "terseLabel": "Accrued sales rebates and discounts"
       }
      }
     },
     "localname": "AccruedSalesRebatesAndChargebacksCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AccumulatedDepreciationOperatingRightOfUseLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated Depreciation, Operating Right-Of-Use Leases",
        "label": "Accumulated Depreciation, Operating Right-Of-Use Leases",
        "terseLabel": "Accumulated depreciation and amortization, operating lease right-of-use assets"
       }
      }
     },
     "localname": "AccumulatedDepreciationOperatingRightOfUseLeases",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments To Additional Paid-In Capital, Change In Fair Value Of Derivatives",
        "label": "Adjustments To Additional Paid-In Capital, Change In Fair Value Of Derivatives",
        "terseLabel": "Change in fair value of derivatives"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from Termination of Capped Call Confirmations.",
        "label": "Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations",
        "terseLabel": "Termination of capped call confirmations"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AmortizationDeferredFinancingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Amortization Deferred Financing Costs",
        "terseLabel": "Amortization of deferred financing"
       }
      }
     },
     "localname": "AmortizationDeferredFinancingCosts",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AssetAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fold_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Asset acquisition, total consideration, stock and cash"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AssetAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones.",
        "label": "Business Asset Acquisition Consideration Transferred Including Milestone Payment",
        "terseLabel": "Asset acquisition, potential aggregate deal value"
       }
      }
     },
     "localname": "BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_BusinessAssetAcquisitionContingentConsiderationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contingent consideration payable in a business asset acquisition upon achievement of certain clinical, regulatory and commercial milestones.",
        "label": "Business Asset Acquisition Contingent Consideration Milestones",
        "terseLabel": "Contingent consideration payable upon achievement of milestones"
       }
      }
     },
     "localname": "BusinessAssetAcquisitionContingentConsiderationMilestones",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Asset Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued",
        "terseLabel": "Consideration paid in common stock (in shares)"
       }
      }
     },
     "localname": "BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_BusinessCombinationOfEnrollmentRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The company enrollment percent achieved during the year.",
        "label": "Business Combination of Enrollment Rate",
        "terseLabel": "Enrollment rate"
       }
      }
     },
     "localname": "BusinessCombinationOfEnrollmentRate",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_CallidusBiopharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Callidus Biopharma, Inc.",
        "label": "Callidus Biopharma Inc [Member]",
        "terseLabel": "Callidus"
       }
      }
     },
     "localname": "CallidusBiopharmaIncMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities",
        "totalLabel": "Cost, cash balances and debt securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecurities",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure",
        "totalLabel": "Fair value, cash balances and debt securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents and Marketable Securities [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_CelenexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Celenex [Member]",
        "label": "Celenex [Member]",
        "terseLabel": "Celenex"
       }
      }
     },
     "localname": "CelenexMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ChangesInFairValueOfContingentConsiderationPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertains to the location on the Statement of Operations, Changes in fair value of contingent consideration payable.",
        "label": "Changes In Fair Value Of Contingent Consideration Payable [Member]",
        "terseLabel": "Changes in fair value of contingent consideration payable"
       }
      }
     },
     "localname": "ChangesInFairValueOfContingentConsiderationPayableMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_CollaborationAgreementAnnualContributionByCompany": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Annual Contribution By Company",
        "label": "Collaboration Agreement, Annual Contribution By Company",
        "terseLabel": "Collaboration Agreement, Discovery Program Fee"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualContributionByCompany",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Conditional Aggregate Payments Per Indication",
        "label": "Collaborative Agreement, Conditional Aggregate Payments Per Indication",
        "terseLabel": "Conditional aggregate payments per indication"
       }
      }
     },
     "localname": "CollaborativeAgreementConditionalAggregatePaymentsPerIndication",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.",
        "label": "Collaborative Arrangement Achievement of Post Approval and Sales Based Milestones Potential Payments",
        "terseLabel": "Potential milestone payments upon achievement of post-approval and sales-based milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CollaborativeArrangementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureAbstract",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "xbrltype": "stringItemType"
    },
    "fold_CommonStockCappedCallConfirmationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Capped Call Confirmation [Member]",
        "label": "Common Stock Capped Call Confirmation [Member]",
        "terseLabel": "Common Stock Capped Call Confirmation"
       }
      }
     },
     "localname": "CommonStockCappedCallConfirmationMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_CommonStockVotingRightsForEachShareHeld": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of votes entitled for each share held.",
        "label": "Common Stock Voting Rights for Each Share Held",
        "terseLabel": "Voting right for each share held, number"
       }
      }
     },
     "localname": "CommonStockVotingRightsForEachShareHeld",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.",
        "label": "Contingent Acquisition Consideration Payable [Policy Text Block]",
        "terseLabel": "Contingent Consideration Payable"
       }
      }
     },
     "localname": "ContingentAcquisitionConsiderationPayablePolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to clinical and regulatory contingent consideration milestones.",
        "label": "Contingent Consideration Liability Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and Regulatory Approval Milestones"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to clinical, regulatory and commercial contingent consideration milestones.",
        "label": "Contingent Consideration Liability Clinical Regulatory And Commercial Milestones [Member]",
        "terseLabel": "Clinical, Regulatory and Commercial milestones"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ContingentConsiderationMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Consideration, Measurement Input",
        "label": "Contingent Consideration, Measurement Input",
        "terseLabel": "Contingent consideration, measurement input"
       }
      }
     },
     "localname": "ContingentConsiderationMeasurementInput",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "fold_ContingentConsiderationMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of milestone payment.",
        "label": "Contingent Consideration, Milestone Payment",
        "terseLabel": "Milestone payment",
        "verboseLabel": "Contingent consideration, milestone payment"
       }
      }
     },
     "localname": "ContingentConsiderationMilestonePayment",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ContingentConsiderationPaidInStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment of contingent consideration liability in stock during the period.",
        "label": "Contingent Consideration Paid In Stock",
        "terseLabel": "Contingent consideration paid in shares"
       }
      }
     },
     "localname": "ContingentConsiderationPaidInStock",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ContingentConsiderationPaidInStockAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Consideration Paid In Stock, Adjustment",
        "label": "Contingent Consideration Paid In Stock, Adjustment",
        "negatedLabel": "Adjustment for contingent consideration paid in stock"
       }
      }
     },
     "localname": "ContingentConsiderationPaidInStockAdjustment",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ConvertibleSeniorNotes2016Due2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the \"Convertible Notes).",
        "label": "Convertible Senior Notes2016 Due2023 [Member]",
        "terseLabel": "2016 Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2016Due2023Member",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Call Feature, Capped Call Confirmation, Initial Cap Price Per Share",
        "label": "Debt Instrument, Call Feature, Capped Call Confirmation, Initial Cap Price Per Share",
        "terseLabel": "Capped call confirmations, initial cap price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Call Feature, Capped Call Confirmation, Premium Percentage",
        "label": "Debt Instrument, Call Feature, Capped Call Confirmation, Premium Percentage",
        "terseLabel": "Capped call confirmations, premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Conversion Restriction, Excess Of Value Per Share For Triggering Event, Percent",
        "label": "Debt Instrument, Convertible, Conversion Restriction, Excess Of Value Per Share For Triggering Event, Percent",
        "terseLabel": "Excess of value per share for triggering event, percent"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Conversion Restriction, Period Following Issuance Of Stock Rights Options Or Warrants With Price Per Share Less Than Last Reported Sales Price",
        "label": "Debt Instrument, Convertible, Conversion Restriction, Period Following Issuance Of Stock Rights Options Or Warrants With Price Per Share Less Than Last Reported Sales Price",
        "terseLabel": "Period following issuance of stock rights options or warrants with price per share less than last reported sales price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Conversion Restriction, Period For Measurement Of Sales Price",
        "label": "Debt Instrument, Convertible, Conversion Restriction, Period For Measurement Of Sales Price",
        "terseLabel": "Period for measurement of sales price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest",
        "label": "Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest",
        "terseLabel": "Accrued and unpaid interest on exchange agreement"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount",
        "label": "Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount",
        "terseLabel": "Exchange agreement, aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance",
        "label": "Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance",
        "terseLabel": "Exchange agreement, authorized (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Period Following Five Consecutive Trading Day Period, Trading Price Less Than Ninety-Eight Percent Of Product Of Sales Price",
        "label": "Debt Instrument, Convertible, Period Following Five Consecutive Trading Day Period, Trading Price Less Than Ninety-Eight Percent Of Product Of Sales Price",
        "terseLabel": "Period following 5 consecutive trading day period, trading price less than 98% of product of sales price"
       }
      }
     },
     "localname": "DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_DebtInstrumentPeriodicPaymentPrincipalPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Principal Percentage",
        "label": "Debt Instrument, Periodic Payment, Principal Percentage",
        "terseLabel": "Periodic payment, percentage"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipalPercentage",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_DebtInstrumentsConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instruments, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentsConvertibleThresholdTradingDays",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_DeferredTaxAssetsIntellectualProperty": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.",
        "label": "Deferred Tax Assets Intellectual Property",
        "terseLabel": "Intellectual property"
       }
      }
     },
     "localname": "DeferredTaxAssetsIntellectualProperty",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsInterestCarryforwardLimitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Interest Carryforward Limitation",
        "label": "Deferred Tax Assets, Interest Carryforward Limitation",
        "terseLabel": "Interest carry forward limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestCarryforwardLimitation",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsLiabilitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carry forwards, net of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Assets Liabilities Gross",
        "totalLabel": "Total net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesGross",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsNonCashStockIssueNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carry forwards expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Deferred Tax Assets Non Cash Stock Issue Non Current",
        "terseLabel": "Non-cash stock issue"
       }
      }
     },
     "localname": "DeferredTaxAssetsNonCashStockIssueNonCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 3.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from advanced Research and Development payments.",
        "label": "Deferred Tax Liabilities Advanced Research and Development Payments",
        "negatedLabel": "Advanced R&amp;D payments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxLiabilitiesBusinessAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 5.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Business Acquisition",
        "label": "Deferred Tax Liabilities, Business Acquisition",
        "negatedLabel": "Business acquisition"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesBusinessAcquisition",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxLiabilitiesConvertibleNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 4.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from convertible notes.",
        "label": "Deferred Tax Liabilities, Convertible Notes",
        "negatedLabel": "Convertible notes"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesConvertibleNotes",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxLiabilitiesRoyaltyPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 2.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from royalty payable",
        "label": "Deferred Tax Liabilities, Royalty Payable",
        "negatedLabel": "Royalty payable"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRoyaltyPayable",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of contingent consideration.",
        "label": "Effective Income Tax Rate Reconciliation, Fair Value of Contingent Consideration",
        "negatedTerseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impact of 2017 Act.",
        "label": "Effective Income Tax Rate Reconciliation Impact of 2017 Act, Percent",
        "negatedTerseLabel": "Impact of 2017 Act"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Conversion",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Conversion",
        "negatedTerseLabel": "Nondeductible debt conversion"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_EmployeeAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee And Directors Stock Options [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeAndDirectorsStockOptionsMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_FixedAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fixed Assets [Member]",
        "label": "Fixed Assets [Member]",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "FixedAssetsMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ForeignCurrencyRemeasurementGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "label": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "negatedLabel": "Foreign currency remeasurement (gain) loss"
       }
      }
     },
     "localname": "ForeignCurrencyRemeasurementGainLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (Loss) On Extinguishment Of Debt, Additional Paid-In Capital",
        "label": "Gain (Loss) On Extinguishment Of Debt, Additional Paid-In Capital",
        "terseLabel": "Gain (loss) on extinguishment of debt, additional paid-in capital"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued",
        "label": "Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued",
        "terseLabel": "Gain (loss) on extinguishment of debt, fair value of common shares issued"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_GlaxoSmithKlinePLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Glaxo Group Limited, an affiliate of GlaxoSmithKline PLC (GSK).",
        "label": "Glaxo Smith Kline P L C [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlinePLCMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_IncomeTaxExpenseBenefitDueToWindDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Tax Expense (Benefit) Due To Wind-Down",
        "label": "Income Tax Expense (Benefit) Due To Wind-Down",
        "negatedLabel": "Income tax benefit due to wind-down"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitDueToWindDown",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_IncreaseDecreaseInDeferredReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of deferred reimbursements.",
        "label": "Increase (Decrease) In Deferred Reimbursements",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredReimbursements",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_IncreaseDecreaseInNoncurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.",
        "label": "Increase (Decrease) In Noncurrent Operating Liabilities",
        "terseLabel": "Other non-current assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncurrentOperatingLiabilities",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_InterestIncomeAndInterestExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for interest income and interest expense.",
        "label": "Interest Income and Interest Expense [Policy Text Block]",
        "terseLabel": "Interest Income and Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpensePolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_LargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Largest Customer [Member]",
        "label": "Largest Customer [Member]",
        "terseLabel": "Largest Customer"
       }
      }
     },
     "localname": "LargestCustomerMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_LesseeOperatingLeaseLiabilityTenantIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Incentives",
        "label": "Lessee, Operating Lease, Liability, Tenant Incentives",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantIncentives",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum Number Of Additional Shares Granted To Underwriters",
        "label": "Maximum Number Of Additional Shares Granted To Underwriters",
        "verboseLabel": "Maximum number of additional shares granted to underwriters (in shares)"
       }
      }
     },
     "localname": "MaximumNumberOfAdditionalSharesGrantedToUnderwriters",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_MeasurementInputProbabilityOfMilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "label": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "terseLabel": "Probability of Milestone Achievement"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfMilestoneAchievementMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_MiamedIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to MiaMed Inc.",
        "label": "Miamed Inc [Member]",
        "terseLabel": "MiaMed Inc"
       }
      }
     },
     "localname": "MiamedIncMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_MilestonePayableAccruedDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payable Accrued During Period",
        "label": "Milestone Payable Accrued During Period",
        "negatedTerseLabel": "Milestones payable, included in accrued expenses"
       }
      }
     },
     "localname": "MilestonePayableAccruedDuringPeriod",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_MilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payment [Member]",
        "label": "Milestone Payment [Member]",
        "terseLabel": "Milestone Payment"
       }
      }
     },
     "localname": "MilestonePaymentMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_MilestonePaymentStockIssuedAsConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payment, Stock Issued As Consideration",
        "label": "Milestone Payment, Stock Issued As Consideration",
        "terseLabel": "Milestone payment, stock issued as consideration"
       }
      }
     },
     "localname": "MilestonePaymentStockIssuedAsConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_NationwideChildrensHospitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nationwide Children's Hospital [Member]",
        "label": "Nationwide Children's Hospital [Member]",
        "terseLabel": "Nationwide Children's Hospital"
       }
      }
     },
     "localname": "NationwideChildrensHospitalMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_NonCashDeferredTaxesAndOtherTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of the non-cash component of deferred taxes and other tax benefits for the period.",
        "label": "Non Cash Deferred Taxes And Other Tax Benefits",
        "negatedTerseLabel": "Non-cash deferred taxes"
       }
      }
     },
     "localname": "NonCashDeferredTaxesAndOtherTaxBenefits",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_NonqualifiedCashDeferralPlansPolicy": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.",
        "label": "Nonqualified Cash Deferral Plans Policy",
        "terseLabel": "Nonqualified Cash Deferral Plan"
       }
      }
     },
     "localname": "NonqualifiedCashDeferralPlansPolicy",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Days Granted Underwriters For Purchase Of Shares",
        "label": "Number Of Days Granted Underwriters For Purchase Of Shares",
        "verboseLabel": "Number of days granted underwriters for purchase of shares"
       }
      }
     },
     "localname": "NumberOfDaysGrantedUnderwritersForPurchaseOfShares",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Gene Therapy Programs For Neurologic LSDs Developed",
        "label": "Number Of Gene Therapy Programs For Neurologic LSDs Developed",
        "terseLabel": "Number of gene therapy programs for neurologic LSDs developed"
       }
      }
     },
     "localname": "NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.",
        "label": "Number of Major Markets Outside United States from Whom Parties to Contractual Arrangement is Eligible to Receive Post Approval and Sales Based Milestones",
        "terseLabel": "Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones"
       }
      }
     },
     "localname": "NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of shares per increment of convertible debt that will be issued upon conversion. For example, X number of shares may be issued for every $1,000 of convertible debt principal.",
        "label": "Number Of Shares Issued Per Increment Of Convertible Debt",
        "terseLabel": "Shares issued per increment of convertible debt (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesIssuedPerIncrementOfConvertibleDebt",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_OrphanDrugTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represent the information pertaining to orphan drug tax credit carryforward.",
        "label": "Orphan Drug Tax Credit Carryforward [Member]",
        "terseLabel": "Orphan drug tax credit carryforwards"
       }
      }
     },
     "localname": "OrphanDrugTaxCreditCarryforwardMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_OtherComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for other comprehensive income.",
        "label": "Other Comprehensive Income Policy [Policy Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_PaymentOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the payment of contingent consideration liabilities.",
        "label": "Payment Of Contingent Consideration",
        "negatedTerseLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentOfContingentConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_PaymentsForCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Collaborative Arrangement",
        "label": "Payments For Collaborative Arrangement",
        "terseLabel": "Payments for collaborative agreement"
       }
      }
     },
     "localname": "PaymentsForCollaborativeArrangement",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_PaymentsForRepurchaseOfRestrictedStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire restricted stock units during the period.",
        "label": "Payments For Repurchase Of Restricted Stock Units",
        "negatedLabel": "Purchase of vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRestrictedStockUnits",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_PaymentsToAcquireBusinessAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).",
        "label": "Payments To Acquire Business Assets",
        "terseLabel": "Asset acquisition, cash consideration paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessAssets",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_PremiumsPaidForCappedCallConfirmations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for premiums paid for capped call confirmations.",
        "label": "Premiums Paid for Capped Call Confirmations",
        "terseLabel": "Proceeds for capped call confirmations"
       }
      }
     },
     "localname": "PremiumsPaidForCappedCallConfirmations",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_PrivatePlacementPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information related to private placement purchase agreements.",
        "label": "Private Placement Purchase Agreement [Member]",
        "terseLabel": "Private Placement Purchase Agreement"
       }
      }
     },
     "localname": "PrivatePlacementPurchaseAgreementMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ProbabilityWeightedDiscountedCashFlowMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to valuation technique of probability weighted discounted cash flow.",
        "label": "Probability Weighted Discounted Cash Flow [Member]",
        "terseLabel": "Probability Weighted Discounted Cash Flow"
       }
      }
     },
     "localname": "ProbabilityWeightedDiscountedCashFlowMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt",
        "label": "Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt",
        "negatedTerseLabel": "Proceeds from termination of capped call confirmations",
        "terseLabel": "Proceeds from capped call confirmations, exchange of convertible debt"
       }
      }
     },
     "localname": "ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ResearchAndDevelopmentExpensesDueToWindDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of research and development expenses due to wind-down of operations.",
        "label": "Research and development expenses due to wind-down",
        "terseLabel": "Research and development expenses due to wind-down"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesDueToWindDown",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ResearchEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents tangible property used for research.",
        "label": "Research Equipment [Member]",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ResearchExpenseForStockIssuanceInAssetAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of research expense charged to statement of operations for stock issued in assets acquisition transaction.",
        "label": "Research Expense For Stock Issuance In Asset Acquisition",
        "terseLabel": "Charges to research expense for stock issued in asset acquisition"
       }
      }
     },
     "localname": "ResearchExpenseForStockIssuanceInAssetAcquisition",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent On Development",
        "label": "Revenue Recognition, Milestone Method, Contingent On Development",
        "terseLabel": "Contingent consideration based on the achievement of certain milestones"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentOnDevelopment",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent On Submission And Approval Milestones",
        "label": "Revenue Recognition, Milestone Method, Contingent On Submission And Approval Milestones",
        "terseLabel": "Contingent consideration based on the achievement of regulatory milestones"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Maximum Expected Payment Over Next Four Years",
        "label": "Revenue Recognition, Milestone Method, Maximum Expected Payment Over Next Four Years",
        "terseLabel": "Maximum payment under contingent consideration"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_RevisedCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the License and Collaboration Agreement entered into by the entity on November 19, 2013.",
        "label": "Revised Collaboration Agreement [Member]",
        "terseLabel": "Revised Agreement"
       }
      }
     },
     "localname": "RevisedCollaborationAgreementMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_SciodermIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Scioderm, Inc.",
        "label": "Scioderm Inc [Member]",
        "terseLabel": "Scioderm"
       }
      }
     },
     "localname": "SciodermIncMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_SellingGeneralAndAdministrativeCostsDueToWindDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of selling, general and administrative costs due to wind-down of operations.",
        "label": "Selling , General and Administrative Costs Due to Wind-down",
        "terseLabel": "Selling , general and administrative costs due to wind-down"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeCostsDueToWindDown",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share",
        "terseLabel": "Expected annual dividend per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting",
        "terseLabel": "Period following separation for accelerated vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_ShareBasedCompensationNumberOfPlans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of plans under the equity-based arrangements.",
        "label": "Share Based Compensation Number of Plans",
        "terseLabel": "Number of equity-based employee compensation plans"
       }
      }
     },
     "localname": "ShareBasedCompensationNumberOfPlans",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_ShortTermCorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Short Term Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "ShortTermCorporateDebtSecuritiesMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockIssuedDuringPeriodSharesContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period Shares Contingent Consideration",
        "label": "Stock Issued During Period Shares Contingent Consideration",
        "terseLabel": "Stock issued for contingent consideration (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesContingentConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants (in shares).",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_StockIssuedDuringPeriodValueContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period Value Contingent Consideration",
        "label": "Stock Issued During Period Value Contingent Consideration",
        "terseLabel": "Stock issued for contingent consideration"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueContingentConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_StockOptionPlan2007AndDirectorOptionPlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2007 Plan and the 2007 Director Plan.",
        "label": "Stock Option Plan2007 And Director Option Plan2007 [Member]",
        "terseLabel": "2007 Plan and 2007 Director Plan"
       }
      }
     },
     "localname": "StockOptionPlan2007AndDirectorOptionPlan2007Member",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to the Company's Amended and Restated 2007 Equity Incentive Plan.",
        "label": "Stock Option Plan Amended Restated2007 Equity Incentive Plan [Member]",
        "terseLabel": "Stock Option Plan Amended Restated 2007 Equity Incentive Plan"
       }
      }
     },
     "localname": "StockOptionPlanAmendedRestated2007EquityIncentivePlanMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_TB200PompeProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to ATB-200 Pompe program.",
        "label": "T B200 Pompe Program [Member]",
        "terseLabel": "ATB-200 Pompe Program"
       }
      }
     },
     "localname": "TB200PompeProgramMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_UnderwrittenOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwritten Offering [Member]",
        "label": "Underwritten Offering [Member]",
        "terseLabel": "Underwritten Offering"
       }
      }
     },
     "localname": "UnderwrittenOfferingMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_VestedRestrictedStockUnitsUnissuedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represent the information pertaining to vested restricted stock units, unissued.",
        "label": "Vested Restricted Stock Units Unissued [Member]",
        "terseLabel": "Vested restricted stock units, unissued"
       }
      }
     },
     "localname": "VestedRestrictedStockUnitsUnissuedMember",
     "nsuri": "http://www.amicustherapeutics.com/20191231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r59",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r150",
      "r229",
      "r233",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails",
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Amicus"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r147",
      "r229",
      "r231",
      "r408",
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails",
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails",
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r149",
      "r229",
      "r232",
      "r410",
      "r414",
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable, accrued expenses, and other current liabilities",
        "totalLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable, Accrued Expenses, and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r20",
      "r151",
      "r152",
      "r230"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r45"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r45"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r201"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "terseLabel": "Accumulated depreciation of property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized gain (loss) on available-for securities"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r60",
      "r63",
      "r66",
      "r67",
      "r343",
      "r350",
      "r352"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Accumulated other comprehensive loss:"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Restricted stock tax vesting"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of the convertible notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r238",
      "r240",
      "r275",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r240",
      "r269",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total equity compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r153",
      "r165",
      "r167",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r82",
      "r98",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r98",
      "r356"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and deferred financing"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r162",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r98",
      "r198"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Loss on impairment",
        "verboseLabel": "Loss on impairment of assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r145",
      "r385",
      "r399"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r57"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r158",
      "r173"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r155",
      "r159",
      "r173"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r157",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities with maturity date greater than 12 months"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r241",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r97",
      "r315"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Changes in fair value of contingent consideration payable",
        "verboseLabel": "Non-cash changes in the fair value of contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r311",
      "r312",
      "r314"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r311",
      "r313"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Intangible assets other than goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r106",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures unpaid at the end of period"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r34",
      "r100"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair value, cash balances"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r11",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r93",
      "r100",
      "r105"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at the end of the year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at the beginning of the year",
        "totalLabel": "Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r93",
      "r349"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r116",
      "r223",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r317",
      "r318",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Agreements",
        "verboseLabel": "Corporate Information, Status of Operations and Management Plans"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r235",
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r51",
      "r205",
      "r389",
      "r405"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $.01 par value, 500,000,000 shares authorized, 255,417,869 and 189,383,924 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Significant components of the deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income [Member]",
        "terseLabel": "Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r70",
      "r72",
      "r73"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r344",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r344",
      "r345",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r344",
      "r345",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r132",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r136",
      "r137",
      "r344",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r344",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r323",
      "r329",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r106",
      "r382",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.",
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Contingent Liabilities"
       }
      }
     },
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r225",
      "r227",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r225",
      "r226",
      "r230"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Accrued milestones"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Fair value of the debt"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Liability Components of the Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r235",
      "r237",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Current federal and state tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r299",
      "r303"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r301"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r299",
      "r303"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r386",
      "r387",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r209",
      "r387",
      "r398"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r48",
      "r217",
      "r218",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt conversion ratio (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r355",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r47",
      "r212",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate of the liability component"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Debt Instruments"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r49",
      "r111",
      "r217",
      "r219",
      "r220",
      "r221",
      "r354",
      "r355",
      "r357",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r354",
      "r357"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less: debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Instruments [Abstract]",
        "terseLabel": "Debt Instruments"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r163",
      "r174",
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair value of available-for-sale debt securities in unrealized loss positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Realized Gain (Loss)",
        "terseLabel": "Debt securities, realized gain (loss)"
       }
      }
     },
     "localname": "DebtSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation plan liability"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).",
        "label": "Deferred Credits and Other Liabilities, Current",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).",
        "label": "Deferred Credits and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r300",
      "r303"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r300",
      "r303"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r284",
      "r293"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r56",
      "r186"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "negatedLabel": "Less: deferred financing"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r300",
      "r303"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r280",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred reimbursement"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 1.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r279",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r280",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Amortization/depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r295",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research tax credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r284",
      "r293"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r280",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails": {
       "order": 6.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r98",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r98",
      "r199"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r98",
      "r143"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Fair value of derivative asset"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)",
        "verboseLabel": "Basic and diluted net loss per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r113",
      "r285",
      "r286"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of the statutory tax rates and the effective tax rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r285",
      "r286",
      "r302"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedTerseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r285",
      "r286",
      "r302"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r285",
      "r286",
      "r302"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedTerseLabel": "Foreign income tax rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r285",
      "r286",
      "r302"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "negatedTerseLabel": "Nondeductible IPR&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r285",
      "r286",
      "r302"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r285",
      "r286",
      "r302"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedTerseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r285",
      "r286",
      "r302"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation costs, period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial assets and liabilities subject to fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r341",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Subject to Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r334",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r334",
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r334",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Changes in fair value during the period, included in the Consolidated Statements of Operations",
        "negatedTerseLabel": "Changes in fair value of contingent consideration payable"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of the period",
        "periodStartLabel": "Balance, beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held.",
        "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "negatedLabel": "Change in fair value of derivatives"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r366",
      "r369"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r166",
      "r169",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r346",
      "r347",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Change in fair value of derivatives"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r348",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Change in fair value of derivatives"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r98",
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on exchange of convertible debt",
        "terseLabel": "Loss on exchange of convertible notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r189",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Change in goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r98",
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Change in IPR&amp;D",
        "verboseLabel": "Loss of impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r76",
      "r120",
      "r381",
      "r392",
      "r407"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Income (loss) before income taxes:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r144",
      "r304"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r106",
      "r282",
      "r283",
      "r289",
      "r290",
      "r294",
      "r305",
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Indefinite-lived Intangible Assets [Roll Forward]",
        "terseLabel": "Changes in IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r191",
      "r193"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "In-process research &amp; development"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r75",
      "r142",
      "r353",
      "r356",
      "r394"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Interest Expense, Debt [Abstract]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Components of Total Interest Expense Recognized Related to the Convertible Notes"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r91",
      "r95",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r45"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r184"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r54",
      "r180"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r55",
      "r106",
      "r127",
      "r181",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories and Cost of Goods Sold"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r184"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r54",
      "r117",
      "r180",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Reserve for inventory"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r184"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r81",
      "r141"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Lease Payments, Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/LeasesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less lease incentives"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r388",
      "r403"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Fair value of liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as current.",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Accrual for uncertain tax positions"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "New credit facility borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r210",
      "r387",
      "r400"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net carrying value of the debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Convertible Debt [Abstract]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "LongtermConvertibleDebtCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r49",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r4",
      "r44"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r93",
      "r96",
      "r99"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r68",
      "r71",
      "r77",
      "r99",
      "r124",
      "r393",
      "r406"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to common stockholders",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r119",
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Developments"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Ex-U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expenses):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r368",
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Cash paid for amounts included in operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Lease"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/LeasesDetailsCalc2": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Total operating lease liability",
        "verboseLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails",
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of the operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion of the operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease ROU asset",
        "verboseLabel": "Operating lease right-of-use assets, less accumulated amortization of $5,342 and $0 at December 31, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/LeasesDetails",
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r372",
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r371",
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease terms (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense, including fees for utilities and common area maintenances"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Amount of net operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r45"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r321",
      "r322",
      "r326"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized holding loss on available-for-sale securities",
        "verboseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax impact of $182, $0, and $0, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r321",
      "r322",
      "r326"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment gain (loss), net of tax impact of $889, $0, and $0, respectively",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": {
     "auth_ref": [
      "r60",
      "r64",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Foreign currency translation gain (loss), tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r61",
      "r62",
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax",
        "terseLabel": "Available-for-sale securities, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r69",
      "r72",
      "r321",
      "r322",
      "r326"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Tenant improvements paid through lease incentive"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r241",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds after deducting fees and estimated expenses"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock and warrants, net of issuance costs",
        "verboseLabel": "Net proceeds from the issuance of common stock after deducting underwriting discounts and commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "verboseLabel": "Proceeds from loan agreements, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r86",
      "r87",
      "r156"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sale and redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r89",
      "r272"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Gross cash proceeds from warrant exercises",
        "verboseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r68",
      "r71",
      "r92",
      "r145",
      "r146",
      "r321",
      "r324",
      "r325",
      "r327",
      "r328"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r37",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r36",
      "r200"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails",
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r202",
      "r404"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, less accumulated depreciation of $17,604 and $15,671 at December 31, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r106",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.",
        "label": "Repayments of Debt and Lease Obligation",
        "negatedLabel": "Payment of finance leases"
       }
      }
     },
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r278",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r106",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and experimentation tax credit carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r11",
      "r100",
      "r105",
      "r384",
      "r401"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r222",
      "r402"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Net product sales",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails",
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue Disaggregated by Geographical Area"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r370",
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock issued (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contingent Consideration Payable"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash and Available for Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of the Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Statutory Tax Rates and the Effective Tax Rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r240",
      "r268",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Equity Compensation Expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r189",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r194",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Changes in IPR&amp;D"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories for the Period"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r37",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails",
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Selected Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r11",
      "r105",
      "r384",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r241",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r247",
      "r258",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested RSU Activity under the Plan"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-term Debt, Noncurrent",
        "terseLabel": "Senior secured term loan"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelectedQuarterlyFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Selected Quarterly Financial Information [Abstract]",
        "terseLabel": "Selected Quarterly Financial Data"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80",
      "r179"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested units as of the end of the period (in shares)",
        "periodStartLabel": "Non-vested units as of the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested units as of the end of the period (in dollars per share)",
        "periodStartLabel": "Non-vested units as of the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Non-vested units, weighted average remaining years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "verboseLabel": "RSUs vested and non-vested units expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options, Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r249",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options vested and unvested expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and unvested expected to vest as of the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and unvested expected to vest as of the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award",
        "terseLabel": "Award term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r239",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "First Anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r106",
      "r241",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Price per share of common stock issued (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "verboseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Non-vested units, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r265",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and unvested expected to vest at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r53",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AcquisitionsDetails",
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r216",
      "r217",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Equity component of the convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r216",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "netLabel": "Common stock issued from underwriting agreement (in shares)",
        "verboseLabel": "Stock issued from equity financing (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r18",
      "r19",
      "r216",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Restricted stock tax vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r216",
      "r222",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, Exercised (in shares)",
        "terseLabel": "Stock issued from exercise of stock options, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r216",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "positiveLabel": "Stock issued from equity financing"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r216",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock issued from exercise of stock options, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r154"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect",
        "terseLabel": "Reclassification upon ASU 2018-02 adoption"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Deferred compensation investment"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government agency bonds"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrual for interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r130",
      "r131",
      "r133",
      "r134",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in the valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "verboseLabel": "Outstanding warrants, convertible to common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares outstanding - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(b))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r419": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r421": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r422": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r423": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r424": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r425": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL116659650-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6716254896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 486,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="nump">197,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Loss of impairment of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 463,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812599856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>211</ContextCount>
  <ElementCount>504</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Accounts Payable, Accrued Expenses, and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accounts Payable, Accrued Expenses, and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Share based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Assets and Liabilities Measured at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Basic and Diluted Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Inventories</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/PropertyAndEquipment</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Accounts Payable, Accrued Expenses, and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accounts Payable, Accrued Expenses, and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Share based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Debt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DescriptionOfBusiness</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRevenueByGeographicalAreaDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndRecentAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2402408 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Recent Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AcquisitionsDetails</Role>
      <ShortName>Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Acquisitions</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillAndIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashNarrativeDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashCashAndAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/InventoriesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Accounts Payable, Accrued Expenses, and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accounts Payable, Accrued Expenses, and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanAndEquityIncentivePlansDetails</Role>
      <ShortName>Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Share based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share based Compensation - Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Share based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails</Role>
      <ShortName>Share based Compensation - RSUs and PBRSUs Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Share based Compensation - Expense Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails</Role>
      <ShortName>Share based Compensation - Expense Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesDetails</Role>
      <ShortName>- Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollForwardDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Debt - Convertible Notes and Senior Secured Term Loan (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtConvertibleNotesAndSeniorSecuredTermLoanDetails</Role>
      <ShortName>Debt - Convertible Notes and Senior Secured Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/LeasesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Income Taxes - Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Income Taxes - Deferred and Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesDeferredAndValuationDetails</Role>
      <ShortName>Income Taxes - Deferred and Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Income Taxes - Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2415401 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CollaborativeAgreements</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="amicus1231201910-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SelectedQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="amicus1231201910-k.htm">amicus1231201910-k.htm</File>
    <File>exhibit1044jfcamendagr.htm</File>
    <File>exhibit1045ellenrosenb.htm</File>
    <File>exhibit1046bradleycamp.htm</File>
    <File>exhibit1047jaybarth-em.htm</File>
    <File>exhibit1048daphnequimi.htm</File>
    <File>exhibit1049hungdo-empl.htm</File>
    <File>exhibit21.htm</File>
    <File>exhibit231.htm</File>
    <File>exhibit311.htm</File>
    <File>exhibit312.htm</File>
    <File>exhibit321.htm</File>
    <File>exhibit322.htm</File>
    <File>exhibit48descriptionof.htm</File>
    <File>fold-20191231.xsd</File>
    <File>fold-20191231_cal.xml</File>
    <File>fold-20191231_def.xml</File>
    <File>fold-20191231_lab.xml</File>
    <File>fold-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>chart-4f9a0d4e5d2c71b470b.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983194496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>unit </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | unit</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812216800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text">Basic and Diluted Net Loss per Common Share<div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(356,388</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(348,995</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(284,002</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240,421,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,790,021</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153,355,144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> there were </span><span style="font-family:inherit;font-size:10pt;"><span>462 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> potential common shares outstanding as a result of the Convertible Debt that were excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,724</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding warrants, convertible to common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,657</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,712</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested restricted stock units, unissued</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total number of potentially issuable shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,719</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,766</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812479504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="line-height:120%;text-align:left;padding-left:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Senior Secured Term Loan due 2023</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company entered into a loan agreement with BioPharma Credit PLC as the lender. The loan agreement provides for a </span><span style="font-family:inherit;font-size:10pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:10pt;"> senior secured term loan ("Senior Secured Term Loan") with an interest rate equal to the 3-month LIBOR plus </span><span style="font-family:inherit;font-size:10pt;"><span>7.50%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum and matures in </span><span style="font-family:inherit;font-size:10pt;"><span>5 years</span></span><span style="font-family:inherit;font-size:10pt;"> from the maturity date. The Senior Secured Term Loan will be repaid in four quarterly payments equal to </span><span style="font-family:inherit;font-size:10pt;"><span>12.50%</span></span><span style="font-family:inherit;font-size:10pt;"> thereof starting on the forty-eight month anniversary of the date of the first credit extension with the balance due on the Maturity Date. Interest is payable quarterly in arrears. The Senior Secured Term Loan contains certain customary representations and warranties, affirmative and negative covenants, and events of default applicable to the Company and certain of its subsidiaries but does not include any financial covenants relating to the achievement or maintenance of revenue or cash flow. If an event of default occurs and is continuing, the lender may declare all amounts outstanding under the Senior Secured Term Loan to be immediately due and payable. The Company received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$146.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in September 2018, after deducting fees and estimated expenses</span><span style="font-family:inherit;font-size:10pt;color:#661de7;">.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Notes due 2023</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2016, the Company issued at par value </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes, which included the exercise in full of the </span><span style="font-family:inherit;font-size:10pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:10pt;"> over-allotment option granted to the initial purchasers of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act (the "Note Offering"). Interest is payable semiannually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Convertible Notes are convertible at the option of the Holders, under certain circumstances and during certain periods, into cash, shares of the Company&#8217;s common stock or a combination thereof. The net proceeds from the Note Offering were </span><span style="font-family:inherit;font-size:10pt;"><span>$243.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting fees and estimated expenses. In addition, the Company used approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$13.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The Convertible Notes were initially convertible into approximately </span><span style="font-family:inherit;font-size:10pt;"><span>40.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock under certain circumstances prior to maturity at a conversion rate of </span><span style="font-family:inherit;font-size:10pt;">163.3987</span><span style="font-family:inherit;font-size:10pt;"> shares per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$6.12</span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock, subject to adjustment under certain conditions. Holders may convert their Convertible Notes at their option at specified times prior to the maturity date of December 15, 2023, only if: </span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">during any fiscal quarter commencing after March 31, 2017, if the last reported sale price of the Company&#8217;s common stock for at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days in the period of </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is equal to or more than </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price of the Convertible Notes on the last day of such preceding fiscal quarter; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a holder submits its Convertible Notes for conversion during the </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> business day period following any five consecutive trading day period in which the trading price for the Convertible Notes, per $1,000 principal amount of the Convertible Notes, for each such trading day was less than </span><span style="font-family:inherit;font-size:10pt;">98%</span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate of the Convertible Notes on such date; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Company issues to all or substantially all of the holders of common stock rights options or warrants entitling then them for a period of not more than </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> calendar days after the date of such issuance to subscribe for or purchase shares of the common stock, at a price per share less than the average of the Last Reported Sale Prices of the common stock for the </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance or distributes to all or substantially all holders of the common stock the Company&#8217;s assets, debt securities or rights to purchase the Company&#8217;s securities which distribution has a per share value of exceeding </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Last Reported Sale Price of the common stock on the Trading Day immediately preceding the date of announcement of such distribution; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Company enters into specified corporate transactions; or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Company has had a call for redemption, the holder can convert up until the second trading day immediately preceding the redemption date.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes will be convertible, at the option of the note holders, regardless of whether any of the foregoing conditions have been satisfied, on or after September 15, 2023 at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date of December 15, 2023.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 15, 2018, the Company entered into an underwriting agreement relating to an underwritten public offering of </span><span style="font-family:inherit;font-size:10pt;"><span>19.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock. Under the terms of the underwriting agreement, the Company granted the underwriters an option, exercisable for </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> days after February 16, 2018, to purchase up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>2.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock, which was exercised with respect to </span><span style="font-family:inherit;font-size:10pt;"><span>885,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:3px;text-align:justify;padding-left:8px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subsequent to the underwritten public offering on February 15, 2018, the Company did not have sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the Company accounted for the portion of the bifurcated conversion feature and of the Capped Call Confirmations that would not be able to be net share settled as a current derivative liability and as a derivative asset, respectively. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at February 15, 2018 was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$507.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$13.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of which the portion that was determined to not be able to be net share settled was recorded with a corresponding impact to additional-paid-in-capital. Subsequent changes to fair value of the derivatives were recorded in the second quarter of 2018 through earnings on the Company&#8217;s Consolidated Statements of Operations resulting in a change in fair value of derivatives for the year ended December 31, 2018 of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following the approval by the stockholders of the Company on June 7, 2018, to increase the authorized shares of common stock to </span><span style="font-family:inherit;font-size:10pt;"><span>500,000,000</span></span><span style="font-family:inherit;font-size:10pt;">, the Company has sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the derivative liability and derivative asset were reclassified into additional-paid-in-capital. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at June 7, 2018 was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$88.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Capped Call Confirmations were expected generally to reduce the potential dilution to the common stock upon any conversion of the Convertible Notes and/or offset the cash payments the Company is required to make in excess of the principal amount upon conversion of the Convertible Notes in the event that the market price of the common stock was greater than the strike price of the Capped Call Confirmations (which initially corresponded to the initial conversion price of the Convertible Notes and is subject to certain adjustments under the terms of the Capped Call Confirmations), with such reduction and/or offset subject to a cap based on the cap price of the Capped Call Confirmations. The Capped Call Confirmations had an initial cap price of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.20</span></span><span style="font-family:inherit;font-size:10pt;"> per share, which represented a premium of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> over the closing price of the Company&#8217;s common stock on The NASDAQ Global Market on December 15, 2016 and was subject to certain adjustments under the terms of the Capped Call Confirmations. The Capped Call Confirmations covered, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes, the number of shares of common stock that underlay the Convertible Notes. The Capped Call Confirmations did not meet the criteria for separate accounting as a derivative as they were indexed to the Company&#8217;s common stock. The premiums paid for the Capped Call Confirmations were included as a net reduction to additional paid-in capital.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first and second quarters of 2019, the Company entered into separate, privately negotiated Exchange Agreements with the Holders of the Convertible Notes. Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$247.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Notes held by them in exchange for an aggregate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>44.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Company common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share. In addition, pursuant to the Exchange Agreements, the Company made aggregate cash payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Holders to satisfy accrued and unpaid interest to the closing date of the transactions, along with cash in lieu of fractional shares. These transactions resulted in </span><span style="font-family:inherit;font-size:10pt;"><span>$215.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in additional paid-in-capital and common stock of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the Consolidated Balance Sheets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Additionally, the Company recognized a net loss on the exchange of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$40.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the Consolidated Statements of Operations during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. During the second half of the year there were no additional debt conversion transactions.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first and second quarter of 2019, the Company terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for proceeds of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$19.9 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The last reported sale price of the Company&#8217;s common stock was equal to or more than </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price of the Convertible Notes for at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days of the </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last day of the year. As a result, the Convertible Notes are currently convertible into the Company&#8217;s common stock.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes and Senior Secured Term Loan consist of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152,825</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>400,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: debt discount </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,974</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74,145</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: deferred financing </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net carrying value of the debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149,505</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in the Consolidated Balance Sheets within Convertible Notes and Senior Secured Term Loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth interest expense recognized related to the Convertible Notes and Senior Secured Term Loan for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,381</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of deferred financing</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective interest rate of the liability component, Convertible debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.63</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective interest rate of the liability component, Senior Secured Term Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.16</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.48</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812560560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Changes in IPR&amp;D</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the changes in IPR&amp;D for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the changes in Goodwill for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>amicus1231201910-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:fold="http://www.amicustherapeutics.com/20191231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fold-20191231.xsd" xlink:type="simple"/>
    <context id="FD2019Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2020Q1Feb19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2020-02-19</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_fold_UnderwrittenOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_fold_LargestCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_fold_LargestCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_IncomeStatementLocationAxis_fold_ChangesInFairValueOfContingentConsiderationPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">fold:ChangesInFairValueOfContingentConsiderationPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_fold_AssetAcquisitionAxis_fold_CelenexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fold:AssetAcquisitionAxis">fold:CelenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="D2016Q3Jul01-Jul31_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_FixedAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:FixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2016Q3Jul01-Jul31_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2016Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30_fold_AssetAcquisitionAxis_fold_CelenexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fold:AssetAcquisitionAxis">fold:CelenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_fold_AssetAcquisitionAxis_fold_CelenexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fold:AssetAcquisitionAxis">fold:CelenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_srt_CounterpartyNameAxis_fold_CallidusBiopharmaIncMember_srt_ProductOrServiceAxis_fold_MilestonePaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fold:MilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q2Apr1-Apr30_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_dei_LegalEntityAxis_fold_NationwideChildrensHospitalMember_fold_AssetAcquisitionAxis_fold_CelenexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fold:AssetAcquisitionAxis">fold:CelenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fold:NationwideChildrensHospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2017Q1QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="FI2017Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2018Q2Apr01-Apr30_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="I2018Q1February28_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="D2017Q3Jul1-Jul31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlan2007AndDirectorOptionPlan2007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Feb_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2019Q1Mar_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="I2018Q2Apr30_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlan2007AndDirectorOptionPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlan2007AndDirectorOptionPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2017Q3Jul31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="FI2018Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2018Q4Dec21-Dec21_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-21</startDate>
            <endDate>2018-12-21</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_MeasurementInputTypeAxis_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_MeasurementInputTypeAxis_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:CommonStockCappedCallConfirmationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:CommonStockCappedCallConfirmationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q2Jun07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2018-06-07</instant>
        </period>
    </context>
    <context id="D2018Q1Feb15-Feb15_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-15</startDate>
            <endDate>2018-02-15</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Feb16-Feb16_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-16</startDate>
            <endDate>2018-02-16</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="I2018Q1Feb15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2018-02-15</instant>
        </period>
    </context>
    <context id="D2018Q1Feb16-Feb16_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-16</startDate>
            <endDate>2018-02-16</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="D2018Q1Feb15-Feb15_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-15</startDate>
            <endDate>2018-02-15</endDate>
        </period>
    </context>
    <context id="I2018Q2Jun07_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:CommonStockCappedCallConfirmationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-07</instant>
        </period>
    </context>
    <context id="D2016Q4Dec01-Dec31_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TaxCreditCarryforwardAxis_fold_OrphanDrugTaxCreditCarryforwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">fold:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2017Q4Dec22-Dec22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2017-12-22</startDate>
            <endDate>2017-12-22</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2013Q4Nov1-Nov30_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-11-01</startDate>
            <endDate>2013-11-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2018Q3Oct31_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="I2013Q4Nov30_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-11-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q4Oct_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:VestedRestrictedStockUnitsUnissuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:VestedRestrictedStockUnitsUnissuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:VestedRestrictedStockUnitsUnissuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="unit">
        <measure>fold:unit</measure>
    </unit>
    <unit id="segment">
        <measure>fold:segment</measure>
    </unit>
    <unit id="vote">
        <measure>fold:vote</measure>
    </unit>
    <unit id="program">
        <measure>fold:program</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="day">
        <measure>fold:day</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q4YTD"
      id="Fact-40041F20A13A79DD65E36B8C2F5D2891-wk-Fact-40041F20A13A79DD65E36B8C2F5D2891">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q4YTD"
      id="Fact-428231AD13EE75B4492B6B8C2F7ED9CB-wk-Fact-428231AD13EE75B4492B6B8C2F7ED9CB">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q4YTD"
      id="Fact-6D8D0C899AF9BB9ADBC36B8C2FB6328F-wk-Fact-6D8D0C899AF9BB9ADBC36B8C2FB6328F">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q4YTD"
      id="Fact-F10ED4C7EAFFC8AAEFAA6B8C2F64EA88-wk-Fact-F10ED4C7EAFFC8AAEFAA6B8C2F64EA88">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q4YTD"
      id="Fact-50D4889DEA448BBA86996B8C2F9825BD-wk-Fact-50D4889DEA448BBA86996B8C2F9825BD">0001178879</dei:EntityCentralIndexKey>
    <fold:AccumulatedDepreciationOperatingRightOfUseLeases
      contextRef="FI2018Q4"
      decimals="-3"
      id="Fact-C6D384C1592E8C6E0DDEF08ACBDDFA6F-wk-Fact-C6D384C1592E8C6E0DDEF08ACBDDFA6F"
      unitRef="usd">0</fold:AccumulatedDepreciationOperatingRightOfUseLeases>
    <fold:AccumulatedDepreciationOperatingRightOfUseLeases
      contextRef="FI2019Q4"
      decimals="-3"
      id="Fact-E512B8C8F55CC3FD57DBF08ACBE2FF60-wk-Fact-E512B8C8F55CC3FD57DBF08ACBE2FF60"
      unitRef="usd">5342000</fold:AccumulatedDepreciationOperatingRightOfUseLeases>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_MeasurementInputTypeAxis_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember"
      decimals="3"
      id="Fact-533C87F94613460CBEA06B8C2FC3A472-wk-Fact-533C87F94613460CBEA06B8C2FC3A472"
      unitRef="number">0.780</fold:ContingentConsiderationMeasurementInput>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_MeasurementInputTypeAxis_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember"
      decimals="3"
      id="Fact-BE010A11712751116FD76B8C2FC46AEC-wk-Fact-BE010A11712751116FD76B8C2FC46AEC"
      unitRef="number">0.750</fold:ContingentConsiderationMeasurementInput>
    <fold:DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice
      contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      id="Fact-0484CB657AE27563867E5A61FC0FC16D-wk-Fact-0484CB657AE27563867E5A61FC0FC16D">P5D</fold:DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting
      contextRef="D2018Q4Dec21-Dec21_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact-D41A82CED90A17B6F69B5A658246CD99-wk-Fact-D41A82CED90A17B6F69B5A658246CD99">P2Y</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-374BBBB9FEC8829FE1346B8C2F922D60-wk-Fact-374BBBB9FEC8829FE1346B8C2F922D60"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-42B154C72991371E6B9E6B8C2F9293F7-wk-Fact-42B154C72991371E6B9E6B8C2F9293F7"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-60DFB7974CE3763A798D6B8C2FAF6B72-wk-Fact-60DFB7974CE3763A798D6B8C2FAF6B72"
      unitRef="shares">189383924</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-DC52D9E141E051AFAC626B8C2F7739D1-wk-Fact-DC52D9E141E051AFAC626B8C2F7739D1"
      unitRef="shares">255417869</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-BFB6E95C5F70B0BD69556B8C2F910441-wk-Fact-BFB6E95C5F70B0BD69556B8C2F910441"
      unitRef="shares">189383924</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-BB0C14EADDD2C4D911CF6B8C2FAC3D89-wk-Fact-BB0C14EADDD2C4D911CF6B8C2FAC3D89"
      unitRef="shares">255417869</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="Fact-50980E499B58E712E4336B8C2F66C8E1-wk-Fact-50980E499B58E712E4336B8C2F66C8E1"
      unitRef="number">0.1633987</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:InventoryValuationReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-A0A724C2028202AA55A0F4D6802F8783-wk-Fact-A0A724C2028202AA55A0F4D6802F8783"
      unitRef="usd">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="Fact-42FF67C69BE0721E5D69F460271CE743-wk-Fact-42FF67C69BE0721E5D69F460271CE743"
      unitRef="usd">17600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="Fact-AD2854D8727420F8BCA26B8C2FDA10AC-wk-Fact-AD2854D8727420F8BCA26B8C2FDA10AC"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="Fact-64B19F9E1649070BE93A6B8C2FDB7C1E-wk-Fact-64B19F9E1649070BE93A6B8C2FDB7C1E"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="Fact-ACA7C1E538DB299082616B8C2FDB5A2F-wk-Fact-ACA7C1E538DB299082616B8C2FDB5A2F"
      unitRef="usd">889000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="Fact-6C0DA510324686047032F0A2B2058CBD-wk-Fact-6C0DA510324686047032F0A2B2058CBD"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="Fact-97AD78C9903932ADD5A4F0A2B1D1AC33-wk-Fact-97AD78C9903932ADD5A4F0A2B1D1AC33"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="Fact-0C028B849EF26079BB34F0A2B1BDF711-wk-Fact-0C028B849EF26079BB34F0A2B1BDF711"
      unitRef="usd">182000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-9BDA315E059F4DFE6FF3F4523C44EC67-wk-Fact-9BDA315E059F4DFE6FF3F4523C44EC67">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="FD2019Q4YTD"
      id="d23277494e730-wk-Fact-140CB0A7F4BC108BB3FFCC4A52D40C1A">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="FD2019Q4YTD"
      id="d23277494e752-wk-Fact-56DFDE92D9E6246914CFCC4B4F48E24D">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q4YTD"
      id="d23277494e762-wk-Fact-CF89E379260ED9FE9DF0CC4E79071C1D">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q4YTD"
      id="d23277494e782-wk-Fact-F8BACA7CD13286DFBC90CC4C9F884D8E">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q4YTD"
      id="d23277494e797-wk-Fact-2356A5A46AD7EC68055CCC4D80DF11FF">001-33497</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q4YTD"
      id="d23277494e808-wk-Fact-DDA3429367135D7196B9CC4CFCBE0C8B">Amicus Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q4YTD"
      id="d23277494e836-wk-Fact-8787B187131F118897F75A1124C8A44D">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q4YTD"
      id="d23277494e856-wk-Fact-6F78C1736A5985CB15545A11826F08D6">71-0869350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q4YTD"
      id="d23277494e914-wk-Fact-6A201BF34D020706BE3D5A11B253E404">1 Cedar Brook Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q4YTD"
      id="d23277494e919-wk-Fact-3F41E9C8B66FBEB996615A1211117334">Cranbury,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q4YTD"
      id="d23277494e924-wk-Fact-0FE5D8AA775151AF78765A124718D217">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q4YTD"
      id="d23277494e934-wk-Fact-7C7277C36D64F46A496C5A127F276472">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q4YTD"
      id="d23277494e966-wk-Fact-A5B24CF68B3504865FAA5FE2078F71E6">(609)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q4YTD"
      id="d23277494e981-wk-Fact-71A26DFA2D3DF45BD5085FE253AD033B">662-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q4YTD"
      id="d23277494e1047-wk-Fact-2E3BC118988C50EF4ADBCC500C954F86">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q4YTD"
      id="d23277494e1052-wk-Fact-6B3F40C8AEE37EEF32ECCC5048F2F25F">FOLD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q4YTD"
      id="d23277494e1057-wk-Fact-ED5F6428BDFAE624FA8ECC508DCEFDD9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="FD2019Q4YTD"
      id="d23277494e1068-wk-Fact-B705354ECFF338EA0AC8CC517922FB6E">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="FD2019Q4YTD"
      id="d23277494e1088-wk-Fact-07D146A1BE780D62359ACC519A50309C">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q4YTD"
      id="d23277494e1100-wk-Fact-8BAB8AD26B49209C9DC6CC599AF3F169">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q4YTD"
      id="d23277494e1116-wk-Fact-206453E805DB4FAC7F83CC5A4223A12B">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q4YTD"
      id="d23277494e1148-wk-Fact-14C9BCEE9D25B8CADCD55A14838793B0">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q4YTD"
      id="d23277494e1198-wk-Fact-12A0CA74ACE6E547A5DE5A14D2E5BB2C">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q4YTD"
      id="d23277494e1224-wk-Fact-1BC48AAAA6465A8A2F0E5A14FAAAB57B">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q4YTD"
      id="d23277494e1239-wk-Fact-2A69F76F5125307143C7CC5710F20165">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="FI2019Q2"
      decimals="0"
      id="d23277494e1255-wk-Fact-782A8BC254E9AD91FF2ACC582FE1069B"
      unitRef="usd">3147432201</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q1Feb19"
      decimals="INF"
      id="d23277494e1268-wk-Fact-A51DB6BEE9F50C52C6ADCC53F3409124"
      unitRef="shares">257244659</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-36A62316E19402049DAFF04AA0B19DA5-0-wk-Fact-BDFCCDFABCB8772262F2F04B55D9E387">&lt;div style="line-height:120%;text-align:justify;text-indent:36px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;DOCUMENTS INCORPORATED BY REFERENCE: Portions of the Proxy Statement for the registrant's 2020 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e903-wk-Fact-5B00B5F16D67C7FD36126B8C2F621219"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e922-wk-Fact-E0F444372BF0213F4E0F6B8C2F5F9EC4"
      unitRef="usd">79749000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e937-wk-Fact-4A226FD07C14E5234D7F6B8C2F74207E"
      unitRef="usd">309903000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e956-wk-Fact-1D4272B56D92ABA819AA6B8C2F5E569F"
      unitRef="usd">424403000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e976-wk-Fact-BA912F98E8D1F6A0DFCB6B8C2F71A559"
      unitRef="usd">33284000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e995-wk-Fact-2E32F6AAB833211133756B8C2F731405"
      unitRef="usd">21962000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1015-wk-Fact-598359183EED6871AA2C6B8C2F5D1396"
      unitRef="usd">14041000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1034-wk-Fact-1834396DC49735734D906B8C2F69C29C"
      unitRef="usd">8390000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1054-wk-Fact-FB4E761A9DC63467F6796B8C2F63C2E9"
      unitRef="usd">20008000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1073-wk-Fact-C78980F9200619F0C34D6B8C2F64B373"
      unitRef="usd">16592000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1093-wk-Fact-B0ADCE739AA5F7221E976B8C2F631854"
      unitRef="usd">520073000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1112-wk-Fact-29EB9D173F3F9E7895726B8C2F69122D"
      unitRef="usd">551096000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1132-wk-Fact-4BD6B73A59B6BF695169F646B8B5F75E"
      unitRef="usd">33315000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1172-wk-Fact-F67F04CA72257459EC5C6B8C2F73F9EF"
      unitRef="usd">47705000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1191-wk-Fact-22630A3A2EFD75C53BAC6B8C2F5F1448"
      unitRef="usd">11375000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1211-wk-Fact-03B01ABC5931CEDDDEE06B8C2F6C699B"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1230-wk-Fact-5EFC3AB0BA2868FB3C3D6B8C2FD9FC4B"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1250-wk-Fact-364FF26B676C1588BCD86B8C2FDCFB4F"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1269-wk-Fact-CEAD39D57A9C217F62616B8C2F63BACC"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1289-wk-Fact-7AF6EA197567122BF0A66B8C2F72AE80"
      unitRef="usd">28317000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1308-wk-Fact-4893A24E7769DEFAB4696B8C2F687696"
      unitRef="usd">6683000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1333-wk-Fact-23F277D0CD51901118126B8C2F6C9A4B"
      unitRef="usd">850207000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1352-wk-Fact-2DD17AE8CD5BB0331C9B6B8C2F5DB374"
      unitRef="usd">789951000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1454-wk-Fact-00D9324EC614ACA175846B8C2F705888"
      unitRef="usd">120373000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1473-wk-Fact-88FBC7147324CDFE62F06B8C2F5C7F02"
      unitRef="usd">80625000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1488-wk-Fact-85B34183A1BAB0E939B96B8C2F75461D"
      unitRef="usd">1250000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1507-wk-Fact-21671084F18DF46E3C6F6B8C2F6B59A8"
      unitRef="usd">5500000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1527-wk-Fact-EE5C5AABDF3F3EA76797F04F5FF883CB"
      unitRef="usd">7189000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1566-wk-Fact-1423E69DBFAD094151066B8C2F6A4AEC"
      unitRef="usd">128812000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1585-wk-Fact-3927BB33B0CED3187A7F6B8C2F609D91"
      unitRef="usd">86125000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1606-wk-Fact-3E5F2B685D8C4AC684536B8C2FD84CD5"
      unitRef="usd">8906000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1625-wk-Fact-65566CB6011B20BB379E6B8C2F75B94B"
      unitRef="usd">10156000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1645-wk-Fact-45A28D578D9871951C846B8C2F6523C6"
      unitRef="usd">2131000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1664-wk-Fact-32630FAC16D8974424506B8C2F60703E"
      unitRef="usd">175006000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:SecuredLongTermDebt
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1684-wk-Fact-D76F68D335F2597C385A6B8C2F631674"
      unitRef="usd">147374000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1703-wk-Fact-9E6E03BA69EA8B482DDE6B8C2F61C23E"
      unitRef="usd">146734000</us-gaap:SecuredLongTermDebt>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1723-wk-Fact-2C76AEA29938F40F94A96B8C2F6E264E"
      unitRef="usd">22681000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1742-wk-Fact-C7D73D49F5FDA70E2A526B8C2FDF2EDB"
      unitRef="usd">19700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1762-wk-Fact-4ADD7C6F326DF36E4E006B8C2F66D061"
      unitRef="usd">5051000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1781-wk-Fact-C30451D3C7E2C65D56616B8C2FD6F83D"
      unitRef="usd">6465000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1801-wk-Fact-27EEB08844CA532CFF47F051C35D6512"
      unitRef="usd">53531000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1840-wk-Fact-BFB6B88FEFABECCA642F6B8C2FD9BABE"
      unitRef="usd">5296000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1859-wk-Fact-482B04496298B8B229816B8C2F5C6138"
      unitRef="usd">2853000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1879-wk-Fact-30701C7F5F623B7130166B8C2F69AD14"
      unitRef="usd">373782000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e1898-wk-Fact-02DF947039E9B909CEF66B8C2F5E248C"
      unitRef="usd">447039000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d23288016e1918-wk-Fact-CBAA5205F6A16D6BE0B66B8C2F74FF02"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d23288016e1937-wk-Fact-2CE529D9499330CB0B936B8C2F68A159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e1998-wk-Fact-2E4D8B5095C94CD22DEA6B8C2F68B118"
      unitRef="usd">2598000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e2017-wk-Fact-F358B90EFBB04F19525E6B8C2F6E963B"
      unitRef="usd">1942000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e2038-wk-Fact-9771010B5D436515AD836B8C2FDDE224"
      unitRef="usd">2227225000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e2057-wk-Fact-003CE95CC9E2359D4B3F6B8C2F748542"
      unitRef="usd">1740061000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e2118-wk-Fact-91FC16488DCFE71832B96B8C2F5E6850"
      unitRef="usd">2785000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e2137-wk-Fact-B55C6547D1E7FCA28D3D6B8C2F77D41C"
      unitRef="usd">495000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e2157-wk-Fact-B7FB66E86646903CDCBA6B8C2F65BD78"
      unitRef="usd">40000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e2176-wk-Fact-005DFC2E40FCC9D795036B8C2F6A67A4"
      unitRef="usd">-427000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e2197-wk-Fact-7F01D812BDF3643902436B8C2F6DACFA"
      unitRef="usd">12387000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e2216-wk-Fact-5178B0C4973A999EE5106B8C2F67434A"
      unitRef="usd">13063000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e2236-wk-Fact-219EDF5D966D06A097816B8C2F671BA4"
      unitRef="usd">-1768610000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e2256-wk-Fact-92E3D153B42F2D85E6176B8C2F5D0952"
      unitRef="usd">-1412222000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e2277-wk-Fact-7273512A0E79AC0E8AC96B8C2F60F4B4"
      unitRef="usd">476425000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e2296-wk-Fact-E7FD0993FBD1AF28A70F6B8C2F77FEF1"
      unitRef="usd">342912000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23288016e2321-wk-Fact-21F8E7E7D9BCC6742EEC6B8C2F6D65AE"
      unitRef="usd">850207000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23288016e2340-wk-Fact-C39A2EDBE43DDCBD89EA6B8C2F680A29"
      unitRef="usd">789951000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e869-wk-Fact-DC4C2C439C61ED6A63236B8C2FB9BFAF"
      unitRef="usd">182237000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e888-wk-Fact-D89C4138A9858DD9450E6B8C2FB1397B"
      unitRef="usd">91245000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e907-wk-Fact-40820295652A1814D77F6B8C2FA61836"
      unitRef="usd">36930000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e923-wk-Fact-35E115AA24D5710A28EF6B8C2FBD49B8"
      unitRef="usd">21963000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e942-wk-Fact-1A2B44A15DD0CFB80D256B8C2FBA5097"
      unitRef="usd">14404000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e961-wk-Fact-F71730BAAAF46B9083576B8C2FBEE548"
      unitRef="usd">6236000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e982-wk-Fact-578F0FA71FB4F40DDC466B8C2FA8FD4E"
      unitRef="usd">160274000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1001-wk-Fact-34ABCBDBA20B82AD10746B8C2FB14CD3"
      unitRef="usd">76841000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1020-wk-Fact-E1C68C18789615DA8DCD6B8C2FA4B844"
      unitRef="usd">30694000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1103-wk-Fact-E30918DA8FF3BF43108B6B8C2FACB792"
      unitRef="usd">286378000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1122-wk-Fact-60072610235C9A0EB3FE6B8C2FBAE7CB"
      unitRef="usd">270902000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1141-wk-Fact-AE709E9500303273C8C26B8C2FAA6FDD"
      unitRef="usd">149310000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1162-wk-Fact-7BF2E0C69DEBA6E1BB046B8C2FB19456"
      unitRef="usd">169861000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1181-wk-Fact-7B12A9AB69980CAC57196B8C2FA919A2"
      unitRef="usd">127200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1200-wk-Fact-E11715E59A3703425DA46B8C2FABDF38"
      unitRef="usd">88671000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1221-wk-Fact-FB99FB171B33B0504A336B8C2FAA9303"
      unitRef="usd">-3297000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1240-wk-Fact-5BF3B505984CD70519BF6B8C2FB42BBF"
      unitRef="usd">-3300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1259-wk-Fact-6412DBABF29B3880516E6B8C2FAF627E"
      unitRef="usd">234322000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1281-wk-Fact-CDEEE16656F8C54D15046B8C2FBC78B4"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1300-wk-Fact-158CDB36E5BC291E5E126B8C2FB37ABC"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1319-wk-Fact-421008C66332774F04E96B8C2FB2588D"
      unitRef="usd">465427000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1340-wk-Fact-3B0DEA15683CDE6A13166B8C2FBAABE1"
      unitRef="usd">4775000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1359-wk-Fact-C72A52BDFB132B2A7DFF6B8C2FAD7B5A"
      unitRef="usd">4216000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1378-wk-Fact-5EDF63642521DC3B6F856B8C2FB25DE8"
      unitRef="usd">3593000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1400-wk-Fact-2F756A13481E351FA7FA6B8C2FB0BE32"
      unitRef="usd">464311000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1419-wk-Fact-A294EDFCF04123616AEC6B8C2FB2D9AB"
      unitRef="usd">405618000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1438-wk-Fact-0693C9D7C797D1E222926B8C2FAFAB4A"
      unitRef="usd">472679000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1459-wk-Fact-073DAB3CCCD667A6A8986B8C2FB5943B"
      unitRef="usd">-304037000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1479-wk-Fact-3FC73189E7F1B23E25DF6B8C2FA4FD1C"
      unitRef="usd">-328777000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1499-wk-Fact-582BAFF6935F78DC48D46B8C2FB54681"
      unitRef="usd">-441985000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1583-wk-Fact-670C141A8834953AA6BC6B8C2FA79BDD"
      unitRef="usd">10249000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1602-wk-Fact-9EDA13665BB8A16EE4446B8C2FA7544F"
      unitRef="usd">10461000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1621-wk-Fact-B426CBAB3F8CD192DC7C6B8C2FAD0D19"
      unitRef="usd">4096000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1642-wk-Fact-4D69E1E9417A264B41F66B8C2FB3D15D"
      unitRef="usd">18872000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1662-wk-Fact-D43000A9337A6E8F3D176B8C2FB17BEB"
      unitRef="usd">22402000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1682-wk-Fact-FD80FD50E03C7BB7D7166B8C2FA57388"
      unitRef="usd">17240000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1704-wk-Fact-11BAC4E93BA6283AE60AF09A2E464CDD"
      unitRef="usd">-40624000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1724-wk-Fact-9190C43965384A029822F09A2DC9D88E"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1743-wk-Fact-E5DA14CDD8E3F849B47AF09A2E368636"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1764-wk-Fact-4DFA666D5541072D423E6B8C2FA5FF75"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1783-wk-Fact-3CD4EAB05566DE713D4C6B8C2FBB76CA"
      unitRef="usd">-2739000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1803-wk-Fact-9BC122649F618E2B74066B8C2FADCBB0"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1824-wk-Fact-A2335624B2E238FDF6646B8C2FB73DC9"
      unitRef="usd">-2626000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1844-wk-Fact-E70AE8AD338BA820E4716B8C2FB87CF0"
      unitRef="usd">-5632000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1864-wk-Fact-72A46D84302E427AFA3A6B8C2FA82694"
      unitRef="usd">6008000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1885-wk-Fact-39CB3DA7D0A5C09EE4246B8C2FAA0F9E"
      unitRef="usd">-355910000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1905-wk-Fact-815848D01C88BA2101DF6B8C2FA91CFB"
      unitRef="usd">-349089000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1925-wk-Fact-5152D2C671953CAC01836B8C2FB75F3C"
      unitRef="usd">-449121000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e1947-wk-Fact-3855EEFA4DD61B26A72F6B8C2FB86431"
      unitRef="usd">478000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e1967-wk-Fact-CECB6F05ED5CE81CFF1C6B8C2FAEB61F"
      unitRef="usd">-94000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e1986-wk-Fact-741CBE90FE3A6560C1116B8C2FAF165A"
      unitRef="usd">-165119000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23289528e2012-wk-Fact-A12C3F3D7CBD330E74976B8C2FA8F19A"
      unitRef="usd">-356388000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23289528e2032-wk-Fact-EE3BD9FBA254D383B3646B8C2FAB60A5"
      unitRef="usd">-348995000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23289528e2052-wk-Fact-7624C92CE3E7F08A06F66B8C2FB8EA12"
      unitRef="usd">-284002000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23289528e2075-wk-Fact-6E1EA8AB2B5EE55BBAF96B8C2FBBFC22"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23289528e2095-wk-Fact-D5333D21D9D2336967446B8C2FAE1D9A"
      unitRef="usdPerShare">-1.88</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23289528e2115-wk-Fact-8DAAF16771AA9BF6916B6B8C2FA59DE3"
      unitRef="usdPerShare">-1.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q4YTD"
      decimals="0"
      id="d23289528e2132-wk-Fact-D335D27D9B7976C780C46B8C2FBC3C1B"
      unitRef="shares">240421001</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="0"
      id="d23289528e2151-wk-Fact-C04A907E3EAA92AB22546B8C2FA66E6E"
      unitRef="shares">185790021</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="0"
      id="d23289528e2170-wk-Fact-FD8F09C37B719A0A7D836B8C2FBD8BC0"
      unitRef="shares">153355144</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23293640e869-wk-Fact-A12C3F3D7CBD330E74976B8C2FA8F19A"
      unitRef="usd">-356388000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23293640e889-wk-Fact-EE3BD9FBA254D383B3646B8C2FAB60A5"
      unitRef="usd">-348995000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23293640e909-wk-Fact-7624C92CE3E7F08A06F66B8C2FB8EA12"
      unitRef="usd">-284002000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23293640e988-wk-Fact-2497C471A4E5AEE308166B8C2F8FC877"
      unitRef="usd">2290000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23293640e1007-wk-Fact-5E2F0C75B255D33D6DD16B8C2FDFAFC3"
      unitRef="usd">2537000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23293640e1026-wk-Fact-30212D5892122EAB4A2D6B8C2F8E8F78"
      unitRef="usd">-3604000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23293640e1048-wk-Fact-E257C540551A3DBFA26E6B8C2FE0580C"
      unitRef="usd">467000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23293640e1067-wk-Fact-35A4CEBC1E86D3AFC3DD6B8C2F8E89C0"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23293640e1086-wk-Fact-30089DF5E67CA8790E056B8C2FDF4D4D"
      unitRef="usd">-538000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23293640e1108-wk-Fact-94BD6351E9A3EB0DD3E76B8C2F908DF9"
      unitRef="usd">2757000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23293640e1127-wk-Fact-835C7999A497D53BE0E46B8C2F5C84AA"
      unitRef="usd">2546000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23293640e1146-wk-Fact-29E8B67988A0D0445EFE6B8C2F91AE95"
      unitRef="usd">-4142000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23293640e1173-wk-Fact-212C265F2A0F2C86CEDC6B8C2F905D41"
      unitRef="usd">-353631000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23293640e1193-wk-Fact-E9E0FEAA8DB54050439D6B8C2F8F35F3"
      unitRef="usd">-346449000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23293640e1213-wk-Fact-F92D3B9A49AA1C25B2256B8C2F905125"
      unitRef="usd">-288144000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e1034-wk-Fact-CB4CE02257B5D60D255AF0EA7EDB5A19"
      unitRef="shares">142691986</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e1053-wk-Fact-7ECA77534ADC923D4A10F0EA7F3250AB"
      unitRef="usd">1480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e1072-wk-Fact-6C6FC3584D73102679A2F0EA7FE4050C"
      unitRef="usd">1120156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember"
      decimals="-3"
      id="d23300192e1092-wk-Fact-99D957CB57872214B041F0EA7F3A4135"
      unitRef="usd">16076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e1111-wk-Fact-CF44EE2C1D2B0EBEE1D6F0EA7F4337C2"
      unitRef="usd">2047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d23300192e1130-wk-Fact-CB5FF14331816780AE64F0EA7FF2D8C6"
      unitRef="usd">-779608000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4"
      decimals="-3"
      id="d23300192e1151-wk-Fact-AF3D99E47E56894A15B3F9E4EA76076B"
      unitRef="usd">360151000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e1166-wk-Fact-06EEF3F743B81E68ACD96B8C2FB1E814"
      unitRef="shares">2878681</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e1180-wk-Fact-0502C09373180BDA5A286B8C2FA19730"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e1199-wk-Fact-B4CEE74027C2651C57146B8C2F917DA5"
      unitRef="usd">16272000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23300192e1277-wk-Fact-06563F35549DB683EC8DF9E4EB1AEF31"
      unitRef="usd">16301000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e1297-wk-Fact-CECDAB624F2A6814C8D16B8C2FA0EADF"
      unitRef="shares">21122449</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e1311-wk-Fact-30EBD03145E65DA23A236B8C2FB31D47"
      unitRef="usd">212000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e1330-wk-Fact-45ECE7170057AB5699726B8C2FB58517"
      unitRef="usd">242825000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23300192e1408-wk-Fact-1CA19A0DE922FA77EBC0F9E4EB40508E"
      unitRef="usd">243037000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e1428-wk-Fact-84183763C594799AF2A46B8C2FA36EF2"
      unitRef="shares">296674</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e1461-wk-Fact-B36EF85169AECA7F15026B8C2FB8556B"
      unitRef="usd">1596000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23300192e1540-wk-Fact-0C0ABB6E3462EABB1FF1F9E4EAA9340E"
      unitRef="usd">1596000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e1594-wk-Fact-77FF9FA59189190003CC6B8C2FB28F76"
      unitRef="usd">23101000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23300192e1672-wk-Fact-DC95ABECCF69B9B53530F9E4EB2AF115"
      unitRef="usd">23101000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e1764-wk-Fact-FCCDEA7CE814B392C85F6B8C2F93C2D9"
      unitRef="usd">-538000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23300192e1804-wk-Fact-30089DF5E67CA8790E056B8C2FDF4D4D"
      unitRef="usd">-538000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e1897-wk-Fact-20FEF41E91CAA8F07EF36B8C2FA51D02"
      unitRef="usd">-3604000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23300192e1937-wk-Fact-30212D5892122EAB4A2D6B8C2F8E8F78"
      unitRef="usd">-3604000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d23300192e2049-wk-Fact-8D06CD9FCB9F7F29A7CB6B8C2FA9D4B2"
      unitRef="usd">-284002000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23300192e2070-wk-Fact-7624C92CE3E7F08A06F66B8C2FB8EA12"
      unitRef="usd">-284002000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e2091-wk-Fact-E116F0EEEF6E38B7B7E3F9E4EB322812"
      unitRef="shares">166989790</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e2105-wk-Fact-9FC99F99063D8477916AF9E4EB6A2902"
      unitRef="usd">1721000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e2124-wk-Fact-5EC3630415CCD31768B0F9E4EBFA76EE"
      unitRef="usd">1400758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember"
      decimals="-3"
      id="d23300192e2144-wk-Fact-1CD7432BDD3EA6D386A5F9E4EB739AB4"
      unitRef="usd">16076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e2163-wk-Fact-95A86E66D98AE582F6FDF9E4EB11EC88"
      unitRef="usd">-2095000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d23300192e2183-wk-Fact-E5FF49CD2401CA6D5BEEF9E4EC32FF94"
      unitRef="usd">-1063610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d23300192e2204-wk-Fact-B2D79F70DDEB23B418F1F9E4EA95B037"
      unitRef="usd">352850000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e2225-wk-Fact-5DF2C956A4DED99D51126B8C2FA1CB1F"
      unitRef="shares">1397908</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e2239-wk-Fact-182AB12C812C6FCE04106B8C2F959F9C"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e2258-wk-Fact-1D3D86EE5F3B6BF2B7526B8C2F9EF0AF"
      unitRef="usd">9130000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23300192e2336-wk-Fact-26540FD37A5DAA2D5D5FF9E4EBBBB260"
      unitRef="usd">9144000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e2356-wk-Fact-B13935D331D75A5E7B666B8C2FB8AB65"
      unitRef="shares">20239839</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e2370-wk-Fact-6578B6B388ECBE3DFE696B8C2FA79E9B"
      unitRef="usd">202000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e2389-wk-Fact-DD821DE10FBA1E913D116B8C2F99055A"
      unitRef="usd">294381000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23300192e2467-wk-Fact-86A330F0D24E11E344C2F9E4EC4C749C"
      unitRef="usd">294583000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e2487-wk-Fact-7C8E73380EF49CCC642B6B8C2FACF1D8"
      unitRef="shares">303173</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e2520-wk-Fact-9E718180F8A32739FBD66B8C2F9DB20B"
      unitRef="usd">2832000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23300192e2599-wk-Fact-ADF31BCC69E2D9337D58F9E4EB48983F"
      unitRef="usd">2832000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e2653-wk-Fact-EB36FC772FD3009C194E6B8C2F9A9DCA"
      unitRef="usd">29260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23300192e2731-wk-Fact-5040736D1354400E18CDF9E4EB039404"
      unitRef="usd">29260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e2823-wk-Fact-C1858CD1E791C7A23DBA6B8C2FB0D9BE"
      unitRef="usd">-383000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d23300192e2843-wk-Fact-A723192498A1E24CFEBF6B8C2FA54246"
      unitRef="usd">383000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <fold:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e2883-wk-Fact-2D15C9099A30F65D18106B8C2F9F2D1C"
      unitRef="shares">453214</fold:StockIssuedDuringPeriodSharesWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e2897-wk-Fact-B204E528F6EE417C92A26B8C2FADBA41"
      unitRef="usd">5000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e2916-wk-Fact-3127660D0B9B444BC3186B8C2FAD3A8D"
      unitRef="usd">6625000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember"
      decimals="-3"
      id="d23300192e2936-wk-Fact-57DEFD5AFE450919FC6A6B8C2F9F702F"
      unitRef="usd">-3013000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23300192e2995-wk-Fact-4317C909BB1DCAF6F1706B8C2FADBA78"
      unitRef="usd">3617000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e3048-wk-Fact-7178637E143E617FE6D96B8C2FAE8A89"
      unitRef="usd">2739000</fold:AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives>
    <fold:AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23300192e3126-wk-Fact-7B958370E009E9DA2CEBF9E4EC0B4D6E"
      unitRef="usd">2739000</fold:AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e3218-wk-Fact-6BAC63F52D88E860ADC76B8C2FA7D762"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23300192e3257-wk-Fact-35A4CEBC1E86D3AFC3DD6B8C2F8E89C0"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e3349-wk-Fact-F0FB5F4398AE6E1330596B8C2F985A06"
      unitRef="usd">2537000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23300192e3388-wk-Fact-5E2F0C75B255D33D6DD16B8C2FDFAFC3"
      unitRef="usd">2537000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d23300192e3499-wk-Fact-36892C62D8554F4DDA7C6B8C2F9503B4"
      unitRef="usd">-348995000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23300192e3520-wk-Fact-EE3BD9FBA254D383B3646B8C2FAB60A5"
      unitRef="usd">-348995000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e3541-wk-Fact-B3B4DB07B946C573D8DAF9E4EA66F6A5"
      unitRef="shares">189383924</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e3555-wk-Fact-3342F1CE51C85A741C49F9E4EBB25D93"
      unitRef="usd">1942000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e3574-wk-Fact-149E5C89F93DF1E9F7DDF9E4EC29334A"
      unitRef="usd">1740061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember"
      decimals="-3"
      id="d23300192e3594-wk-Fact-675CDC74381AE7D7898BF9E4EAB173F5"
      unitRef="usd">13063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e3613-wk-Fact-6F771260732A78707861F9E4EBF1BF6E"
      unitRef="usd">68000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d23300192e3632-wk-Fact-31D554C3D91F58C12276F9E4EAD0A60C"
      unitRef="usd">-1412222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23300192e3653-wk-Fact-E7FD0993FBD1AF28A70F6B8C2F77FEF1"
      unitRef="usd">342912000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e3674-wk-Fact-0455BB36CC84DC734C56F0EA7ECD2FEA"
      unitRef="shares">1967087</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e3688-wk-Fact-92368690AD62C1FBC77CF0EA7F0CAF29"
      unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e3707-wk-Fact-95485FF63F3F281F721EF0EA7FA3B5D3"
      unitRef="usd">11456000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e3785-wk-Fact-10934332BA4913248356F9E4EBD434BF"
      unitRef="usd">11476000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e3805-wk-Fact-1D256EEC5C1A7347E4D8F0EA7EC347AE"
      unitRef="shares">18720930</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e3819-wk-Fact-BDCE41D70D5405CEC59DF0EA7EF59CA6"
      unitRef="usd">187000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e3838-wk-Fact-882DC04021EC07ED292EF0EA7FC88941"
      unitRef="usd">188807000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e3916-wk-Fact-01D0AD4899945F06F003F9E4EBCBC0A1"
      unitRef="usd">188994000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e3936-wk-Fact-475627558440E2B1AD45F0EA7FB00946"
      unitRef="shares">477198</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e3969-wk-Fact-142A54CA33E258073097F0EA7EDE7E47"
      unitRef="usd">3235000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e4048-wk-Fact-7A7CDAA2351AA9E05014F9E4EAFB5AB9"
      unitRef="usd">3235000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <fold:StockIssuedDuringPeriodSharesContingentConsideration
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e4069-wk-Fact-1B7DB4B6D4DF2AE65BFEF0C33556F1D3"
      unitRef="shares">771804</fold:StockIssuedDuringPeriodSharesContingentConsideration>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e4083-wk-Fact-0E3AC98F406287B84F9DF0C310AC46D3"
      unitRef="usd">8000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e4102-wk-Fact-EA780E2ED1C69775E15FF0EA7FB688D5"
      unitRef="usd">9308000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e4180-wk-Fact-07060A57817454DB10CFF9E4EBC39B52"
      unitRef="usd">9316000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e4233-wk-Fact-3181DC5BD7AAFE431437F9E4EB5041E1"
      unitRef="usd">44430000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e4311-wk-Fact-3181DC5BD7AAFE431437F9E4EB5041E1"
      unitRef="usd">44430000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <fold:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e4331-wk-Fact-0F742D588111A4109D9CF0EA7F4D4879"
      unitRef="shares">101787</fold:StockIssuedDuringPeriodSharesWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e4345-wk-Fact-D86C2944210D5DB73A19F0EA7F3540A9"
      unitRef="usd">1000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e4364-wk-Fact-48582319C0E13D386B07F0EA7FC1DF9D"
      unitRef="usd">1487000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember"
      decimals="-3"
      id="d23300192e4384-wk-Fact-8030A0B4EEABD5020AB8F0EA7FDAD9F7"
      unitRef="usd">-676000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e4443-wk-Fact-F4EFAA8241AEEC1EF5DFF9E4EB9DAD3D"
      unitRef="usd">812000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e4463-wk-Fact-488DA091CCBA99611795F0C60C7315FF"
      unitRef="shares">43995139</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e4477-wk-Fact-82C5F3C262689C6B695BF0C65174AB33"
      unitRef="usd">440000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e4496-wk-Fact-924AE7EF10D4D8118855F0EA7F920F4A"
      unitRef="usd">215036000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e4574-wk-Fact-F427851617AE28A120FDF9E4EB7B32AE"
      unitRef="usd">215476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e4627-wk-Fact-4BBE83A72416A48D96B5F0C6CDA6FB12"
      unitRef="usd">19875000</fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations>
    <fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e4705-wk-Fact-E5E4C9738C23D156F0EBF9E4EAEB48AC"
      unitRef="usd">19875000</fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e4797-wk-Fact-80BC958E54E2D07AA2F9F0EA7FA908CA"
      unitRef="usd">467000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e4836-wk-Fact-E257C540551A3DBFA26E6B8C2FE0580C"
      unitRef="usd">467000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e4928-wk-Fact-23DC336BE914791899FCF0C88FE37FC5"
      unitRef="usd">2290000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e4967-wk-Fact-2497C471A4E5AEE308166B8C2F8FC877"
      unitRef="usd">2290000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d23300192e5078-wk-Fact-A574CD9E2AB6AD485519F0EA7FE172B9"
      unitRef="usd">-356388000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23300192e5099-wk-Fact-A12C3F3D7CBD330E74976B8C2FA8F19A"
      unitRef="usd">-356388000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23300192e5121-wk-Fact-058DCB3FD6820CFAD4BEF9E4EC43E729"
      unitRef="shares">255417869</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d23300192e5140-wk-Fact-E9E0C616C31562EC717BF9E4EC3BF338"
      unitRef="usd">2598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d23300192e5159-wk-Fact-E27C19FF065EF04C6330F9E4EAE22405"
      unitRef="usd">2227225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember"
      decimals="-3"
      id="d23300192e5179-wk-Fact-328132D6666CE8439535F9E4EC03E500"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember"
      decimals="-3"
      id="d23300192e5198-wk-Fact-0E10DAC26043DEDA7C95F9E4EABACD7E"
      unitRef="usd">2825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d23300192e5217-wk-Fact-497BD0ACF7BF501CC93DF9E4EC13ABC1"
      unitRef="usd">-1768610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23300192e5238-wk-Fact-7273512A0E79AC0E8AC96B8C2F60F4B4"
      unitRef="usd">476425000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e932-wk-Fact-6BC49C4CC46616D540C46B8C2F93291F"
      unitRef="usd">-356388000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e952-wk-Fact-62A7EF9CA74D8C1A89926B8C2F8951DF"
      unitRef="usd">-348995000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e972-wk-Fact-203E20272F98B22DCBA46B8C2F88D814"
      unitRef="usd">-284002000</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1051-wk-Fact-B20E0EAC45FE94281D0E6B8C2F824998"
      unitRef="usd">2546000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1070-wk-Fact-F0CE957B4D78C14BDF766B8C2F7D5B82"
      unitRef="usd">10976000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1089-wk-Fact-E189BF43CAE7F5E53C4F6B8C2F84BDEE"
      unitRef="usd">9703000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1110-wk-Fact-FFE1107513765E92EB0B6B8C2F83C0A7"
      unitRef="usd">4775000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1129-wk-Fact-BA12E0CB739F7B734C786B8C2F84ACE8"
      unitRef="usd">4216000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1148-wk-Fact-9DFD25175320039594DD6B8C2F8138D1"
      unitRef="usd">3593000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1169-wk-Fact-A12D776EE9C11A9F0F7D6B8C2F8C00FF"
      unitRef="usd">44430000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1188-wk-Fact-8AF7DE728BB551B8F8C66B8C2F920015"
      unitRef="usd">29260000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1207-wk-Fact-F089EE3869BDA843F30C6B8C2F891B47"
      unitRef="usd">23101000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1228-wk-Fact-11BAC4E93BA6283AE60AF09A2E464CDD"
      unitRef="usd">-40624000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1247-wk-Fact-9190C43965384A029822F09A2DC9D88E"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1266-wk-Fact-E5DA14CDD8E3F849B47AF09A2E368636"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1287-wk-Fact-E13B46924D4F3B8039CE6B8C2F99F7E5"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1306-wk-Fact-F79394BB2415E7878EB46B8C2F7ED9A5"
      unitRef="usd">-2739000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1325-wk-Fact-CEA03EB18B424CFC3B136B8C2FA53664"
      unitRef="usd">265000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1347-wk-Fact-813BE3DA0C2D7DB84DA46B8C2F81A3E7"
      unitRef="usd">3297000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1366-wk-Fact-08264A8AD1F16FA07A0F6B8C2F85602A"
      unitRef="usd">3300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1385-wk-Fact-F87E6C9A74DF1D533A3E6B8C2F9DB018"
      unitRef="usd">-234322000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1408-wk-Fact-D44AFD56A1DC6FAC2BFF6B8C2F88D592"
      unitRef="usd">-254000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1427-wk-Fact-230EF82DFD11F69B82E76B8C2F943F9A"
      unitRef="usd">-3217000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1446-wk-Fact-B4AEC08BE537A39774FC6B8C2F8792AE"
      unitRef="usd">5620000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:NonCashDeferredTaxesAndOtherTaxBenefits
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1468-wk-Fact-3E1FA7D83E7BC9A1F1836B8C2F862481"
      unitRef="usd">1415000</fold:NonCashDeferredTaxesAndOtherTaxBenefits>
    <fold:NonCashDeferredTaxesAndOtherTaxBenefits
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1488-wk-Fact-A401A251341B3AD747B76B8C2F8A0BB9"
      unitRef="usd">0</fold:NonCashDeferredTaxesAndOtherTaxBenefits>
    <fold:NonCashDeferredTaxesAndOtherTaxBenefits
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1507-wk-Fact-AB9DA20DC7F25DD263086B8C2F9C787B"
      unitRef="usd">167305000</fold:NonCashDeferredTaxesAndOtherTaxBenefits>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1529-wk-Fact-CDEEE16656F8C54D15046B8C2FBC78B4"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1548-wk-Fact-158CDB36E5BC291E5E126B8C2FB37ABC"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1567-wk-Fact-421008C66332774F04E96B8C2FB2588D"
      unitRef="usd">465427000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1588-wk-Fact-7AA6F863095FB412C75BF0DBA18D8C54"
      unitRef="usd">149000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1608-wk-Fact-5AC05363FC474F18B89EF0DBA1C6E0E1"
      unitRef="usd">-59000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1627-wk-Fact-F085A73686F279E8BD2DF0DBA17FE745"
      unitRef="usd">8000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1711-wk-Fact-D39389DDF03D3FED0CAE6B8C2F8BFC55"
      unitRef="usd">11114000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1731-wk-Fact-261D038B57628CFF03FC6B8C2F9E4E90"
      unitRef="usd">13294000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1751-wk-Fact-469FE50A9B5F3EFA665C6B8C2F9C96E3"
      unitRef="usd">7725000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1773-wk-Fact-0E6DEA11585781728D346B8C2FA14D9C"
      unitRef="usd">5114000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1793-wk-Fact-3ADFA9682D8E9DC154846B8C2F971028"
      unitRef="usd">4205000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1813-wk-Fact-40A409E6762E148147F36B8C2F7EE304"
      unitRef="usd">897000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1835-wk-Fact-25E626787516C7ADD3996B8C2F95D071"
      unitRef="usd">3287000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1855-wk-Fact-5AE175A6D1FE7B6661446B8C2F8C43B6"
      unitRef="usd">-2488000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1874-wk-Fact-725209F5611A806E59506B8C2F915E69"
      unitRef="usd">15329000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1896-wk-Fact-EDF00278FBBADEBF52306B8C2FA3FDDF"
      unitRef="usd">46742000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1915-wk-Fact-F11326D39F71BC0C9E846B8C2F8712E6"
      unitRef="usd">17115000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1934-wk-Fact-1CB304E64D630CEDCD476B8C2F81C575"
      unitRef="usd">12563000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e1955-wk-Fact-988ADF8C07F3D50CCEC86B8C2F8FFFDF"
      unitRef="usd">-10117000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e1975-wk-Fact-AB9105FAB697E7D8E56D6B8C2F8BB3F5"
      unitRef="usd">-581000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e1995-wk-Fact-77774B4F8F2C67D2155F6B8C2FA203E3"
      unitRef="usd">-9000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInDeferredReimbursements
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2017-wk-Fact-935248A6F52A70C011666B8C2F868C7D"
      unitRef="usd">-5500000</fold:IncreaseDecreaseInDeferredReimbursements>
    <fold:IncreaseDecreaseInDeferredReimbursements
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2037-wk-Fact-E76290A0DCDD0A75F37A6B8C2F80955D"
      unitRef="usd">-6250000</fold:IncreaseDecreaseInDeferredReimbursements>
    <fold:IncreaseDecreaseInDeferredReimbursements
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2057-wk-Fact-FBB8BA0DCF3ECAD374D76B8C2F88E0D2"
      unitRef="usd">-12600000</fold:IncreaseDecreaseInDeferredReimbursements>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2085-wk-Fact-6E5C58C1B3990CC887446B8C2F9F47CA"
      unitRef="usd">-250416000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2105-wk-Fact-803A15B97216F723248C6B8C2F8E681B"
      unitRef="usd">-299955000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2125-wk-Fact-9D738CF6BB0ADE13DEA06B8C2F95ABCB"
      unitRef="usd">-213695000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2204-wk-Fact-2D1E876F12351D37F7966B8C2F8990B4"
      unitRef="usd">499047000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2223-wk-Fact-0543E0EED44D7CF0B7CD6B8C2F7DB5D5"
      unitRef="usd">463502000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2242-wk-Fact-FB36614350A6EA19EFCB6B8C2F9F42AA"
      unitRef="usd">323753000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2263-wk-Fact-ED9FE3ABDE05EA04F4E86B8C2F881B6D"
      unitRef="usd">383882000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2283-wk-Fact-3910D1B66193778CBE876B8C2F830DD6"
      unitRef="usd">578394000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2303-wk-Fact-677964FC1ECBA81FD9AB6B8C2F9AE265"
      unitRef="usd">490468000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2325-wk-Fact-37E668B8B686A4458B166B8C2F8858B6"
      unitRef="usd">20012000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2345-wk-Fact-0DAFC87E91E963E4E2AE6B8C2F7DC484"
      unitRef="usd">6308000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2365-wk-Fact-4A7E1145A35A935C29F26B8C2F85BE9E"
      unitRef="usd">4526000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2392-wk-Fact-475C119B965C01C411E26B8C2FA37FEE"
      unitRef="usd">95153000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2411-wk-Fact-A0FFBF6279FF8B38DB976B8C2F9DBF65"
      unitRef="usd">-121200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2431-wk-Fact-01198EB4E7505E6CCADE6B8C2F891C67"
      unitRef="usd">-171241000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2510-wk-Fact-F2704EE118B7091F6FD66B8C2F977919"
      unitRef="usd">188994000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2529-wk-Fact-B5F21D5ECFEAA89423966B8C2F9F2675"
      unitRef="usd">294584000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2548-wk-Fact-B784335B4DC51DF8C1366B8C2F96239A"
      unitRef="usd">243037000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2569-wk-Fact-BAD41F786DE8D3B87FC66B8C2F82F9D7"
      unitRef="usd">420000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2589-wk-Fact-F2EE64BE5F98864897966B8C2F878542"
      unitRef="usd">334000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2609-wk-Fact-2719017B402EA5F6299E6B8C2F94174F"
      unitRef="usd">308000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <fold:PaymentsForRepurchaseOfRestrictedStockUnits
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2631-wk-Fact-DEE3BF9B877233E3C1A06B8C2F9CD59F"
      unitRef="usd">3235000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
    <fold:PaymentsForRepurchaseOfRestrictedStockUnits
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2651-wk-Fact-D26F1B564BA17EAE41FB6B8C2FA3D0C1"
      unitRef="usd">2832000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
    <fold:PaymentsForRepurchaseOfRestrictedStockUnits
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2671-wk-Fact-F6F863AFA26198A232026B8C2FA1D10B"
      unitRef="usd">1596000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2693-wk-Fact-AA01D8CD69767613B14FF0DF80D3D13B"
      unitRef="usd">-19875000</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2712-wk-Fact-B2D22E4E2C4054A0EC87F0DF80B02E1B"
      unitRef="usd">0</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2731-wk-Fact-0A413E35E07861686891F0DF8112026B"
      unitRef="usd">0</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2753-wk-Fact-F07113C9E57965F7C4CF6B8C2F84E438"
      unitRef="usd">11476000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2772-wk-Fact-30A55806F250E5A46EE06B8C2F9A6996"
      unitRef="usd">9144000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2791-wk-Fact-10EC447DD577843DB9E66B8C2F93D1DF"
      unitRef="usd">16301000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2812-wk-Fact-5CB464F307184C271DCC6B8C2F8C4D4A"
      unitRef="usd">812000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2831-wk-Fact-B484DCAB9F1E2EC336FA6B8C2F814972"
      unitRef="usd">3617000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2850-wk-Fact-6364C8A43D73032310D36B8C2F89C1B8"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <fold:PaymentOfContingentConsideration
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2871-wk-Fact-AA2303C5565A021D06E96B8C2FA21D23"
      unitRef="usd">0</fold:PaymentOfContingentConsideration>
    <fold:PaymentOfContingentConsideration
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2890-wk-Fact-0EE0C4F5E85C8EEAEC416B8C2F7FD341"
      unitRef="usd">0</fold:PaymentOfContingentConsideration>
    <fold:PaymentOfContingentConsideration
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2909-wk-Fact-AC957E5B05E36424D9306B8C2F8386E1"
      unitRef="usd">10000000</fold:PaymentOfContingentConsideration>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2931-wk-Fact-8D38DD39AEA205E0CA9D6B8C2F81E052"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e2950-wk-Fact-6F2228282511076E63126B8C2FA11663"
      unitRef="usd">146596000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e2969-wk-Fact-5B40723157BC3BF824166B8C2FA4BD4E"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e2995-wk-Fact-DAB8E41057AD5F6868A66B8C2F943266"
      unitRef="usd">217502000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e3014-wk-Fact-BE0C8474ABF4A020B82F6B8C2F9DFF68"
      unitRef="usd">450775000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e3033-wk-Fact-110000E7976C9BEF69C46B8C2FA3A6BE"
      unitRef="usd">247434000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e3054-wk-Fact-846DEF153FCCCAE58F926B8C2F8A0599"
      unitRef="usd">1729000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e3073-wk-Fact-A84C24A691625E3D6FE36B8C2F8BB70E"
      unitRef="usd">1518000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e3092-wk-Fact-A41657E5248B32ECA0586B8C2F803386"
      unitRef="usd">1326000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e3108-wk-Fact-AD4528390579D92F1D4B6B8C2F9698F3"
      unitRef="usd">63968000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e3127-wk-Fact-5F77536A04002259C0B36B8C2F82DD69"
      unitRef="usd">31138000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e3146-wk-Fact-231FB42B2D8F723DF2096B8C2F7ED4C0"
      unitRef="usd">-136176000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23303121e3168-wk-Fact-DB4369335D59DC134A9D6B8C2F866261"
      unitRef="usd">82375000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d23303121e3187-wk-Fact-2832D32E859374AFC2286B8C2F8F7EAF"
      unitRef="usd">51237000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2016Q4"
      decimals="-3"
      id="d23303121e3206-wk-Fact-16CED533A8AE75DDB1B16B8C2F7DBC89"
      unitRef="usd">187413000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23303121e3232-wk-Fact-910F239777FED3FF4F746B8C2F7F1327"
      unitRef="usd">146343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23303121e3251-wk-Fact-DB4369335D59DC134A9D6B8C2F866261"
      unitRef="usd">82375000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d23303121e3270-wk-Fact-2832D32E859374AFC2286B8C2F8F7EAF"
      unitRef="usd">51237000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e3497-wk-Fact-A7B96D6DBC76EB5CBE7E5E49B7E90D9F"
      unitRef="usd">19388000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e3516-wk-Fact-C94E2998746401BA4FE75E49B828E11A"
      unitRef="usd">0</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e3535-wk-Fact-16D6BCC77848ECC7A33E5E49B80977E7"
      unitRef="usd">0</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e3556-wk-Fact-86091AB09D4E77F88A636B8C2F9374E2"
      unitRef="usd">16966000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e3575-wk-Fact-B3BE08222E528821B1FF6B8C2F99AF03"
      unitRef="usd">7500000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e3594-wk-Fact-8F0872C79FDA11110CAB6B8C2F978C49"
      unitRef="usd">7424000</us-gaap:InterestPaidNet>
    <fold:ContingentConsiderationPaidInStock
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e3615-wk-Fact-0E6EC91FD946FDCCFE8F6B8C2F845A63"
      unitRef="usd">9316000</fold:ContingentConsiderationPaidInStock>
    <fold:ContingentConsiderationPaidInStock
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e3634-wk-Fact-82E858F8C18688D80F8D6B8C2F7F3B97"
      unitRef="usd">0</fold:ContingentConsiderationPaidInStock>
    <fold:ContingentConsiderationPaidInStock
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e3653-wk-Fact-7D22062009D79D9D847B6B8C2F802719"
      unitRef="usd">0</fold:ContingentConsiderationPaidInStock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303121e3674-wk-Fact-BB85E2F4AF874FB3A4556B8C2F7EF40E"
      unitRef="usd">1865000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303121e3693-wk-Fact-4192F7BDB12BC73B43B66B8C2F96F603"
      unitRef="usd">106000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23303121e3712-wk-Fact-8D72AE52D79371A1DA6A6B8C2FA0905F"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-636559182FD59C4ED16C6B8C2FE9DA6C-0-wk-Fact-5D3C118228AD30FD49C26B8C2FC0AC6D">Description of Business&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities led by the novel medicine for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic, and an industry leading rare disease gene therapy portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The cornerstone of the Company&#x2019;s portfolio is Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several other geographies around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The lead biologics program of the Company&#x2019;s pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation to AT-GAA for the treatment of late onset Pompe disease. In the first quarter of 2020, the British Medicines and Healthcare Products Regulatory Agency issued a Promising Innovative Medicine designation for AT-GAA for the treatment of late-onset Pompe disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("NCH") and an expanded collaboration with the University of Pennsylvania ("Penn"). The Company's pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, CLN8 and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Niemann-Pick Type C ("NPC"), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. For additional information, see "&#x2014;&#160;Note&#160;16. Collaboration Agreement."&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the second quarter of 2019, the Company completed an underwritten equity offering and issued &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.75&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$189.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the first and second quarters of 2019, the Company entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with a limited number of holders (the "Holders") of the unsecured Convertible Senior Notes due in 2023 ("Convertible Notes"). Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$247.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of Convertible Notes held by them in exchange for an aggregate of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock, par value &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.01&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. For additional information, see "&#x2014;&#160;Note&#160;12. Debt."&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company had an accumulated deficit of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and anticipates incurring losses through the fiscal year ending December&#160;31, 2020 and beyond. The Company has historically funded its operations through stock offerings, debt issuances, Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; revenues, collaborations, and other financing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The current cash position, including expected Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; revenues, is sufficient to fund ongoing Fabry, Pompe, and gene therapy program operations into the first half of 2022. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d23294950e733-wk-Fact-4CD3463F939D863661B6F441E6784C03"
      unitRef="shares">18700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_fold_UnderwrittenOfferingMember"
      decimals="INF"
      id="d23294950e737-wk-Fact-43864E6CC5A7B8A09AC4F442508D5BE9"
      unitRef="usdPerShare">10.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d23294950e741-wk-Fact-2BE35686606668C4F05AF442E8185CE0"
      unitRef="usd">189000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23294950e748-wk-Fact-4A8CFF7594107A63B4FEF44336C1516F"
      unitRef="usd">247200000</fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23294950e752-wk-Fact-4DF48FAD377A5BBDBBD7F443ABB9B03E"
      unitRef="shares">44000000.0</fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="d23294950e756-wk-Fact-00CA33B6D7C853055C4C6B8C2FC67E47"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-8"
      id="d23294950e763-wk-Fact-FAF3435D709F3DA7AB3D5E3D52AC5C82"
      unitRef="usd">-1800000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-2510598904BC1F10AC336B8C2FEB54BD-0-wk-Fact-5285E3B5D1D46CEF06876B8C2F7E70C7">Summary of Significant Accounting Policies&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company&#x2019;s Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company&#x2019;s Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company's accounts receivable at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded an allowance for doubtful accounts of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or the lesser of the related initial term of the lease or useful life for leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s net product sales consist of sales of Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2019, one customer accounted for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of net product sales and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of accounts receivable from product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The transaction price is determined based on fixed consideration in the Company&#x2019;s customer contracts and is recorded net of estimates for variable consideration, which are third-party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company's net product sales from Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Ex-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;129,759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84,022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;36,930&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;182,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;36,930&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Interest Income and Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Components of other comprehensive income (loss) include unrealized gains and losses on available-for-sale securities and gain (loss) on foreign currency transactions and are included in the Statements of Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods. For additional information, see " -Note 13. Leases" and "-Note 2. Summary of Significant Accounting Policies, Recent Accounting Developments - Guidance Adopted in 2019."&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Nonqualified Cash Deferral Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code (the "Code"). All of the investments held in the Deferral Plan are classified as investments held-to-maturity and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; equity-based employee compensation plans, which are described more fully in "&#x2014;&#160;Note&#160;9. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Loss per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs, and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#x2014;&#160;Note&#160;17. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company currently operates in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. No indicators of impairment were noted during the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Developments - Guidance Adopted in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2016-02 - In February 2016, the FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ("ASU 2016-02"). ASU 2016-02 requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. In August 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, ("ASU 2018-11"). ASU 2018-11 provided entities with an additional transition method for adoption, whereby, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Effective January 1, 2019 the Company adopted ASU 2016-02, along with the amendments issued in 2017 and 2018, and elected the transition method in ASU 2018-11. The Company elected the package of transition provisions available for expired or existing contracts, which allowed the Company to carry forward its historical assessments of (i) whether contracts are or contain leases, (ii) lease classification and (iii) initial direct costs. In addition, the Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and will apply the practical expedient not to separate lease and non-lease components for new and modified leases commencing after adoption. The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods. Upon adoption, the Company recorded a lease liability with a corresponding right-of-use asset of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The adoption did not have a material impact on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Developments - Guidance Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2019-12 - In December 2019, the FASB issued ASU 2019-15,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following apply in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#x2019; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for public business entities for periods for which financial statements have not yet been issued. An entity that elects early adoption in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption should adopt all the amendments in the same period. The Company is currently assessing the impact that this standard will have on its Consolidated Financial Statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2018-15 - In August 2018, the FASB issued&#160;ASU 2018-15,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;: ("ASU 2018-15"), relating to a customer&#x2019;s accounting for implementation, set-up, and other upfront costs incurred in a&#160;cloud computing&#160;arrangement that is hosted by a vendor. Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance does not affect the accounting for the service element of a hosting arrangement that is a service contract. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized software costs and related amortization expense and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for public companies. The Company will adopt this guidance prospectively on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2018-13 - In August 2018, the FASB issued ASU 2018-03, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;("ASU 2018-13"). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on (i) changes in unrealized gains and losses, (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and (iii) the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2017-04 - In January 2017, the FASB issued ASU 2017-04, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2016-13 - &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;I&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;n June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;basis to be presented at the net amount expected to be collected and amends guidance on the impairment of financial instruments.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2016-13 is effective for public companies who are SEC filers for fiscal years beginning after December 15, 2019, including&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;interim periods within those years. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8C71E148341AF573F89F6B8C2FE917A0-0-wk-Fact-9FE7E6700C906910B1B56B8C2F780D7A">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3343EB1779E9A30E2F9B6B8C2FE9AF8B-0-wk-Fact-9AC21E923F3FF07366306B8C2F7CC954">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-14BD7248B5A5EF13C21E6B8C2FE93FD0-0-wk-Fact-8BDD425FC5D70DBC935D6B8C2F7B938F">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q4YTD"
      id="TextSelection-B1BEDBAA5C2BA3FCB95A6B8C2FECF963-0-wk-Fact-5FFC2CBEAAAB33B9C0476B8C2F79C20F">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates</us-gaap:UseOfEstimates>
    <fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7214BCBBDDF9E496101B6B8C2FEB79A4-0-wk-Fact-7537BCD706084DB470EF6B8C2F78E609">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company&#x2019;s Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company&#x2019;s Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;</fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="FD2019Q4YTD"
      id="TextSelection-7DC42E7D27D0E0CED7EA6B8C2FE9A96E-0-wk-Fact-521D12F038F0B2B2BA2B6B8C2F79894D">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company's accounts receivable at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt; have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23303986e803-wk-Fact-53394349897BB9430E70F4548CC8CA31"
      unitRef="usd">100000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E3B427D74813A74FCD276B8C2FEB7E2B-0-wk-Fact-4294ACCA309DB69526076B8C2F7991CA">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or the lesser of the related initial term of the lease or useful life for leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d23303986e820-wk-Fact-8D6D1633680792660EFB6B8C2F78DBA5">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5703905931FA413501816B8C2FEC44C1-0-wk-Fact-62517B085A042C3179386B8C2F7A65F4">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s net product sales consist of sales of Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2019, one customer accounted for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of net product sales and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of accounts receivable from product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The transaction price is determined based on fixed consideration in the Company&#x2019;s customer contracts and is recorded net of estimates for variable consideration, which are third-party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_fold_LargestCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d23303986e851-wk-Fact-0CCF68FC4D54E08F8CBD8071B7D03535"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_fold_LargestCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d23303986e855-wk-Fact-52CDA64B376E7CDAB53D8071B7485360"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-DA852D43D2551BF4B4F3ECA6347620F8-0-wk-Fact-A7E50FCADD0F4D9CC037ECA81EBC9699">&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company's net product sales from Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Ex-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;129,759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84,022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;36,930&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;182,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;36,930&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d23303986e1057-wk-Fact-540DDF2EB280E57377DDECAA212A3B63"
      unitRef="usd">52478000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d23303986e1076-wk-Fact-8B6DF3BE79A57B7C71FCECAA2352837D"
      unitRef="usd">7223000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-3"
      id="d23303986e1116-wk-Fact-BC89AF6C9CEDDF3429ECECAA20F42CBF"
      unitRef="usd">129759000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-3"
      id="d23303986e1135-wk-Fact-939BBA72A9EDC1564DD1ECAA2216997D"
      unitRef="usd">84022000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23303986e1185-wk-Fact-DC4C2C439C61ED6A63236B8C2FB9BFAF"
      unitRef="usd">182237000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23303986e1204-wk-Fact-D89C4138A9858DD9450E6B8C2FB1397B"
      unitRef="usd">91245000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-10FD1C38E38659F01EBD6B8C2FEA1F44-0-wk-Fact-84C4F1521A5E2501CA0E6B8C2F7A9D7A">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8472714FD0685FC8BB346B8C2FEAFF47-0-wk-Fact-52CFF4D46B57187DF6AB6B8C2F79E373">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-70850AC051DFD6E5DFAE6B8C2FEBC5A4-0-wk-Fact-D6364A21241F63DF59996B8C2F799044">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.&lt;/span&gt;&lt;/div&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-575749024514C75DC1706B8C2FE95858-0-wk-Fact-836459D8791C764CA0DC6B8C2FB67A4B">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <fold:InterestIncomeAndInterestExpensePolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-718928BE0BC05136A5016B8C2FEA5FE0-0-wk-Fact-0309953B443E3556E5516B8C2F7C2CAB">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Interest Income and Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.&lt;/span&gt;&lt;/div&gt;</fold:InterestIncomeAndInterestExpensePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6351A6C103F9695B95BE6B8C2FEA3E24-0-wk-Fact-CB4DEF24F61D4264A0576B8C2F79C5B3">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <fold:OtherComprehensiveIncomePolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E6BB8317678B7FC3C35B6B8C2FEAC6A1-0-wk-Fact-3EBB9D4B5F16A9D724846B8C2F7E746F">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Components of other comprehensive income (loss) include unrealized gains and losses on available-for-sale securities and gain (loss) on foreign currency transactions and are included in the Statements of Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</fold:OtherComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D18FF4496464951246F16B8C2FEAB18D-0-wk-Fact-A17417144C218F54DB8D6B8C2F7B60AD">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.&lt;/span&gt;&lt;/div&gt;The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods. For additional information, see " -Note 13. Leases" and "-Note 2. Summary of Significant Accounting Policies, Recent Accounting Developments - Guidance Adopted in 2019."</us-gaap:LesseeLeasesPolicyTextBlock>
    <fold:NonqualifiedCashDeferralPlansPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-6749655221BB3AA38B786B8C2FEABDF7-0-wk-Fact-AA2EB03D0562C535DA8B6B8C2F7B75EF">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Nonqualified Cash Deferral Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code (the "Code"). All of the investments held in the Deferral Plan are classified as investments held-to-maturity and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</fold:NonqualifiedCashDeferralPlansPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-776E5806CA3ABEB55EAF6B8C2FEB3B27-0-wk-Fact-52AE44BEBD2DBB3241B86B8C2F7A53F5">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; equity-based employee compensation plans, which are described more fully in "&#x2014;&#160;Note&#160;9. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <fold:ShareBasedCompensationNumberOfPlans
      contextRef="FI2019Q4"
      decimals="INF"
      id="d23303986e1379-wk-Fact-2FAC5CDC964E24FFC1636B8C2F7AB347"
      unitRef="program">3</fold:ShareBasedCompensationNumberOfPlans>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1833A9DB0984C5BF47476B8C2FEBF259-0-wk-Fact-28FF2588390FB1AC37AE6B8C2F79DDA4">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Loss per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs, and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#x2014;&#160;Note&#160;17. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D4528603DE03E8585B926B8C2FEB04EB-0-wk-Fact-03053A79A9F8BC94AE5E6B8C2F78EA1D">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company currently operates in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reporting unit.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d23303986e1408-wk-Fact-E5A66F127A912EFAF4D06B8C2F7B488D"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportingUnits
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d23303986e1412-wk-Fact-9A431B26D08C4C8E99166B8C2F78ABB8"
      unitRef="unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-60A64CBD7C9AFB0A63DC6B8C2FE94674-0-wk-Fact-07AAB7D2192A8CCE9F696B8C2F7D0543">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-98913C9DB62F84DC614F6B8C2FEB06D0-0-wk-Fact-641073630EC12E4EA7AD6B8C2F7AD127">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CFC6672625FA874C814C6B8C2FEB3306-0-wk-Fact-2F19E6F50385C7182C326B8C2F795727">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-07F6699B8F24BDA845046B8C2FEBAFA9-0-wk-Fact-DE2B0D766BB6E033D49D6B8C2F7B1B3C">&lt;div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Developments - Guidance Adopted in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2016-02 - In February 2016, the FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ("ASU 2016-02"). ASU 2016-02 requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. In August 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, ("ASU 2018-11"). ASU 2018-11 provided entities with an additional transition method for adoption, whereby, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Effective January 1, 2019 the Company adopted ASU 2016-02, along with the amendments issued in 2017 and 2018, and elected the transition method in ASU 2018-11. The Company elected the package of transition provisions available for expired or existing contracts, which allowed the Company to carry forward its historical assessments of (i) whether contracts are or contain leases, (ii) lease classification and (iii) initial direct costs. In addition, the Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and will apply the practical expedient not to separate lease and non-lease components for new and modified leases commencing after adoption. The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods. Upon adoption, the Company recorded a lease liability with a corresponding right-of-use asset of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The adoption did not have a material impact on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Developments - Guidance Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2019-12 - In December 2019, the FASB issued ASU 2019-15,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following apply in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#x2019; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for public business entities for periods for which financial statements have not yet been issued. An entity that elects early adoption in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption should adopt all the amendments in the same period. The Company is currently assessing the impact that this standard will have on its Consolidated Financial Statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2018-15 - In August 2018, the FASB issued&#160;ASU 2018-15,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;: ("ASU 2018-15"), relating to a customer&#x2019;s accounting for implementation, set-up, and other upfront costs incurred in a&#160;cloud computing&#160;arrangement that is hosted by a vendor. Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance does not affect the accounting for the service element of a hosting arrangement that is a service contract. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized software costs and related amortization expense and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for public companies. The Company will adopt this guidance prospectively on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2018-13 - In August 2018, the FASB issued ASU 2018-03, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;("ASU 2018-13"). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on (i) changes in unrealized gains and losses, (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and (iii) the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2017-04 - In January 2017, the FASB issued ASU 2017-04, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2016-13 - &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;I&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;n June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;basis to be presented at the net amount expected to be collected and amends guidance on the impairment of financial instruments.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASU 2016-13 is effective for public companies who are SEC filers for fiscal years beginning after December 15, 2019, including&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;interim periods within those years. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d23303986e1481-wk-Fact-BAECD2387D7B66988514F45E7B8A41D1"
      unitRef="usd">17600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-13F63466C1AED2E1AFDB6B8C2FECBB7C-0-wk-Fact-B1342E389A0057E725F06B8C2F7FB962">Acquisitions&lt;div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Acquisition of Celenex&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2018, the Company expanded its pipeline by acquiring the rights and related intellectual property of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; gene therapy programs through its acquisition of Celenex, Inc., ("Celenex"). Celenex is a private, clinical stage gene therapy company whose lead programs are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; gene therapy programs including CLN6 and CLN3, which are in clinical stage, and several programs in pre-clinical stage. Pursuant to the terms of the agreement, the Company acquired Celenex for cash consideration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$100 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company has also agreed to pay up to an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in connection with the achievement of certain development milestones, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$262 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in connection with the achievement of certain regulatory approval milestones across multiple programs and up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in tiered sales milestone payments. Celenex has an exclusive license agreement with Nationwide Children&#x2019;s Hospital ("NCH"). Under this license agreement, NCH is eligible to receive development and sales-based milestones of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for each product.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:21px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the Celenex transaction and concluded that the transaction did not meet the definition of a business and was an asset acquisition. Given the fact that the license has no alternative future use, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment was expensed to research and development expense in the Consolidated Statements of Operations for the year ended December 31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:21px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Acquisition of MiaMed,&#160;Inc&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2016, the Company entered into an Agreement and Plan of Merger (the "MiaMed Agreement") with MiaMed,&#160;Inc., ("MiaMed"). MiaMed is a pre-clinical biotechnology company focused on developing protein replacement therapy for CDD and related diseases. Under the terms of the MiaMed Agreement, the former holders of MiaMed's capital stock received an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, comprised of (i)&#160;approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash (plus MiaMed's cash and cash equivalents at closing and less any of MiaMed's unpaid third-party fees and expenses related to the transaction), and (ii)&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;825,603&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock. In addition, the Company also agreed to pay up to an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$83.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in connection with the achievement of certain clinical, regulatory, and commercial milestones, for a potential aggregate deal value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$89.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company evaluated the transaction and concluded that it only acquired inputs and did not acquire any processes. The Company will need to develop its own processes in order to produce an output. Therefore, the Company accounted for the transaction as an asset acquisition and accordingly &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was expensed to research and development expense in the Consolidated Statements of Operation for the year ended December 31, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Acquisition of Scioderm,&#160;Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2015, the Company acquired Scioderm&#160;Inc., ("Scioderm"), a privately-held biopharmaceutical company focused on developing innovative therapies for treating the rare disease, Epidermolysis Bullosa ("EB"). The acquisition potentially leveraged the Scioderm development team's EB expertise with the Company's global clinical infrastructure to advance SD-101toward regulatory approvals and the Company's commercial, patient advocacy, and medical affairs infrastructure to support a successful global launch. The acquisition of Scioderm was accounted for as a purchase of a business in accordance with ASC 805 &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Business Combinations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the end of the first quarter of 2017, the Company achieved &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; enrollment in the Phase&#160;3 clinical study of SD-101 and the milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; due for this event, was paid in April 2017. On September&#160;13, 2017, the Company reported that top-line data from the randomized, double-blind, placebo-controlled Phase&#160;3 clinical study ("ESSENCE, SD-5") to assess the efficacy and safety of the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in participants with EB. Based on these top-line data, the Company has no current plans to invest in any additional clinical studies or commercial preparation activities for SD-101. This event led the Company to assess the carrying amount of the program's tangible and intangible assets against their respective fair values. Based on the assessment, the Company recognized a loss on impairment of intangible assets in the amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$463.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in fixed assets recorded within loss on impairment of assets within the Consolidated Statements of Operations. Since the study did not meet the primary and secondary endpoints, the Company concluded that they will not make the potential milestone payments indicated in the Asset Purchase Agreement to the former Scioderm holders. Accordingly, the Company recognized a gain of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$254.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in changes in fair value of contingent consideration payable in the third quarter of 2017, in order to decrease the liability to zero. The Company also recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in selling, general, and administrative costs and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in research and development expenses related to the wind-down of operations for the Phase 3 ESSENCE study and ongoing extension studies SD-004 and SD-006, as well as income tax benefit of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$164.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; due to the reduction of the deferred tax liability related to Scioderm IPR&amp;amp;D, in the Consolidated Statements of Operations in the third quarter of 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Acquisition of Callidus Biopharma,&#160;Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2013, the Company acquired Callidus Biopharma, Inc., ("Callidus"), a privately-held biologics company focused on developing best-in-class ERTs for LDs with its lead ERT ATB200 for Pompe disease in late preclinical development. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of the contingent acquisition consideration payments was estimated by applying a probability-based income approach utilizing an appropriate discount rate. Key assumptions include discount rate and various probability factors. This estimation was based on significant inputs that are not observable in the market, referred to as Level&#160;3 inputs. Some of the more significant assumptions used in the valuation include (i)&#160;the probability and timing related to the achievement of certain developmental milestones and (ii)&#160;and the discount rate. See "&#x2014;&#160;Note&#160;11. Assets and Liabilities Measured at Fair Value", for additional discussion regarding fair value measurements of the contingent acquisition consideration payable. The Company determined the fair value of the contingent consideration to be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$22.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is payable beyond the next twelve months, resulting in an increase in the contingent consideration payable and related expense of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The expense is recorded in the Consolidated Statement of Operations within the changes in fair value of contingent consideration line item.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the fourth quarter of 2018, the Company reached a clinical milestone for Callidus, which was the dosing of the first patient in a Phase 3 study. The milestone payment for this event was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; which was paid in the Company's stock during the first quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For further information, see "&#x2014;&#160;Note&#160;4. Goodwill and Intangible Assets."&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <fold:NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped
      contextRef="D2018Q3Sep01-Sep30"
      decimals="INF"
      id="d23295074e716-wk-Fact-BDFC961784DFE295E5F66B8C2F82B9EB"
      unitRef="program">10</fold:NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped>
    <fold:NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped
      contextRef="D2018Q3Sep01-Sep30"
      decimals="INF"
      id="d23295074e720-wk-Fact-BDFC961784DFE295E5F66B8C2F82B9EB"
      unitRef="program">10</fold:NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2018Q3Sep01-Sep30_fold_AssetAcquisitionAxis_fold_CelenexMember"
      decimals="-6"
      id="d23295074e724-wk-Fact-5447E630E2BDAE1D85FB6B8C2F84A882"
      unitRef="usd">100000000</us-gaap:ResearchAndDevelopmentExpense>
    <fold:RevenueRecognitionMilestoneMethodContingentOnDevelopment
      contextRef="FI2018Q3_fold_AssetAcquisitionAxis_fold_CelenexMember"
      decimals="-6"
      id="d23295074e728-wk-Fact-8434BD1CA8291FC7D2056B8C2F819028"
      unitRef="usd">15000000</fold:RevenueRecognitionMilestoneMethodContingentOnDevelopment>
    <fold:RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones
      contextRef="FI2018Q3_fold_AssetAcquisitionAxis_fold_CelenexMember"
      decimals="-6"
      id="d23295074e732-wk-Fact-32FD915B7E0C0C9694DF6B8C2F8352C6"
      unitRef="usd">262000000</fold:RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones>
    <fold:RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears
      contextRef="FI2018Q3_fold_AssetAcquisitionAxis_fold_CelenexMember"
      decimals="-6"
      id="d23295074e737-wk-Fact-837343E2D59FF82549696B8C2F8264FA"
      unitRef="usd">75000000</fold:RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears>
    <fold:RevenueRecognitionMilestoneMethodContingentOnDevelopment
      contextRef="FI2018Q3_dei_LegalEntityAxis_fold_NationwideChildrensHospitalMember_fold_AssetAcquisitionAxis_fold_CelenexMember"
      decimals="-5"
      id="d23295074e741-wk-Fact-B4457837434349CD43BA6B8C2F8056D1"
      unitRef="usd">7800000</fold:RevenueRecognitionMilestoneMethodContingentOnDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q4YTD_fold_AssetAcquisitionAxis_fold_CelenexMember"
      decimals="-5"
      id="d23295074e750-wk-Fact-6A9B398B4F15E56CFEDF6B8C2F86360A"
      unitRef="usd">100000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <fold:AssetAcquisitionConsiderationTransferred
      contextRef="D2016Q3Jul01-Jul31_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember"
      decimals="-5"
      id="d23295074e766-wk-Fact-1FB6B6B71D7447A309786B8C2F809EE7"
      unitRef="usd">6500000</fold:AssetAcquisitionConsiderationTransferred>
    <fold:PaymentsToAcquireBusinessAssets
      contextRef="D2016Q3Jul01-Jul31_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember"
      decimals="-5"
      id="d23295074e770-wk-Fact-5B2C6EDE3FFE9391E5AF6B8C2F829166"
      unitRef="usd">1800000</fold:PaymentsToAcquireBusinessAssets>
    <fold:BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="D2016Q3Jul01-Jul31_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23295074e774-wk-Fact-A5F50F814199C634196C6B8C2F802D99"
      unitRef="shares">825603</fold:BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <fold:BusinessAssetAcquisitionContingentConsiderationMilestones
      contextRef="I2016Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember"
      decimals="-5"
      id="d23295074e778-wk-Fact-AA672290D2E654C95E8C6B8C2F8300FC"
      unitRef="usd">83000000.0</fold:BusinessAssetAcquisitionContingentConsiderationMilestones>
    <fold:BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment
      contextRef="D2016Q3Jul01-Jul31_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember"
      decimals="-5"
      id="d23295074e782-wk-Fact-792EBE211D6645ABCB296B8C2F86E15F"
      unitRef="usd">89500000</fold:BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment>
    <fold:ResearchExpenseForStockIssuanceInAssetAcquisition
      contextRef="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember"
      decimals="-5"
      id="d23295074e787-wk-Fact-878A4BC8792EAFC2ADA16B8C2F8535DA"
      unitRef="usd">6500000</fold:ResearchExpenseForStockIssuanceInAssetAcquisition>
    <fold:BusinessCombinationOfEnrollmentRate
      contextRef="FD2017Q1QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember"
      decimals="INF"
      id="d23295074e804-wk-Fact-6AB57838556E88D2C5CC6B8C2F823FC1"
      unitRef="number">1</fold:BusinessCombinationOfEnrollmentRate>
    <fold:ContingentConsiderationMilestonePayment
      contextRef="D2017Q2Apr1-Apr30_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember"
      decimals="-6"
      id="d23295074e808-wk-Fact-5E5B180AE7FE933E1E3F6B8C2F81827B"
      unitRef="usd">10000000</fold:ContingentConsiderationMilestonePayment>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember"
      decimals="-5"
      id="d23295074e812-wk-Fact-A01520D7A22A68F7CB6C6B8C2F84518F"
      unitRef="usd">463700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_FixedAssetsMember"
      decimals="-5"
      id="d23295074e816-wk-Fact-7885984B58AFE54E70046B8C2F84E3DD"
      unitRef="usd">1700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember"
      decimals="-5"
      id="d23295074e820-wk-Fact-5A94841895C3C4D66B796B8C2F83A01B"
      unitRef="usd">254700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <fold:SellingGeneralAndAdministrativeCostsDueToWindDown
      contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember"
      decimals="-5"
      id="d23295074e825-wk-Fact-60DFD41B3B6627E0686B6B8C2F8306B0"
      unitRef="usd">400000</fold:SellingGeneralAndAdministrativeCostsDueToWindDown>
    <fold:ResearchAndDevelopmentExpensesDueToWindDown
      contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember"
      decimals="-5"
      id="d23295074e829-wk-Fact-2BE2CBBEAD96990EBD7B6B8C2F85178F"
      unitRef="usd">8100000</fold:ResearchAndDevelopmentExpensesDueToWindDown>
    <fold:IncomeTaxExpenseBenefitDueToWindDown
      contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember"
      decimals="-5"
      id="d23295074e833-wk-Fact-9A6FD4B48AC18551B64B6B8C2F811894"
      unitRef="usd">-164700000</fold:IncomeTaxExpenseBenefitDueToWindDown>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember"
      decimals="-5"
      id="d23295074e847-wk-Fact-7B07BE014D5E095F66566B8C2F81C915"
      unitRef="usd">22700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_IncomeStatementLocationAxis_fold_ChangesInFairValueOfContingentConsiderationPayableMember"
      decimals="-5"
      id="d23295074e855-wk-Fact-2B6DC90185DEB086A7FF6B8C2F80D2B7"
      unitRef="usd">3300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="FI2019Q1_srt_CounterpartyNameAxis_fold_CallidusBiopharmaIncMember_srt_ProductOrServiceAxis_fold_MilestonePaymentMember"
      decimals="-5"
      id="d23295074e866-wk-Fact-60EBDC3ACF458DAEEE406B8C2F8443E6"
      unitRef="usd">9000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-DF3E2F58ABFD7EAE14EC6B8C2FECA969-0-wk-Fact-DD21C2A788321ECBEF6E6B8C2F8DAC5C">Goodwill and Intangible Assets&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with the acquisitions, the Company initially recognized IPR&amp;amp;D of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$486.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and goodwill of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$197.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Intangible assets related to IPR&amp;amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D assets below their respective carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill and intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As discussed in "&#x2014;&#160;Note&#160;3. Acquisitions", in September 2017, the Company reported that top-line data from the randomized, double-blind, placebo-controlled Phase&#160;3 clinical study ("ESSENCE, SD-005") to assess the efficacy and safety of the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in participants with EB. This event led to an assessment to determine if an impairment had occurred for goodwill and IPR&amp;amp;D. Based on tests for impairment, the Company determined that IPR&amp;amp;D had been impaired, however goodwill was not impaired based on qualitative and market capitalization tests performed. The loss on impairment of IPR&amp;amp;D of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$463.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was recorded within loss on impairment of assets in the Consolidated Statements of Operations for the year ended December 31, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table represents the changes in IPR&amp;amp;D for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table represents the changes in Goodwill for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Change in goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Change in goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="FI2017Q3"
      decimals="-5"
      id="d23304539e713-wk-Fact-9832D92ADA363F93556CFE17C999FB73"
      unitRef="usd">486700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2017Q3"
      decimals="-5"
      id="d23304539e717-wk-Fact-C6450D6F257F5D42CCC5F0F22C279E4C"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d23304539e727-wk-Fact-F933D71B07D5500C378AF483FA4EC618"
      unitRef="usd">463700000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-00102C6CCA655B973C926B8C2FEC043F-0-wk-Fact-FEC7A87B0FC3750517C66B8C2F8C1012">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table represents the changes in IPR&amp;amp;D for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="FI2017Q4"
      decimals="-5"
      id="d23304539e802-wk-Fact-7B83DD302D5AD6FB3EB0F0F235F2F6C4"
      unitRef="usd">23000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d23304539e822-wk-Fact-61747BB0E7762E3A3CADF0F235FA2E8C"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d23304539e852-wk-Fact-7E5EDE1883CBDE4D2812F0F23603B93C"
      unitRef="usd">23000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23304539e872-wk-Fact-0087BB04BEC76849389A6B8C2F7AE9E7"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23304539e902-wk-Fact-B0B536ED06743D2850386B8C2F78C618"
      unitRef="usd">23000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CC4811043DD829BAD5846B8C2FECC1FA-0-wk-Fact-6043CE11B4E7B93532E56B8C2F8DE2C9">&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table represents the changes in Goodwill for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Change in goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Change in goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="FI2017Q3"
      decimals="-5"
      id="d23304539e983-wk-Fact-C6450D6F257F5D42CCC5F0F22C279E4C"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d23304539e1003-wk-Fact-5F3FF69DD3BF8F254193F0F22C305557"
      unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d23304539e1033-wk-Fact-CD8809FE0317F0DD941CF0F22C323721"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23304539e1053-wk-Fact-C3AEF96150F63F6F68C36B8C2FC47E5C"
      unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23304539e1083-wk-Fact-95CE8BCB22200E84EC7D6B8C2FD9501A"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-41C442BD0CD55961C6366B8C2FEC3590-0-wk-Fact-1505B423F7361A9D38246B8C2FC993D5">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$142.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash and cash equivalents and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$309.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of available- for-sale debt securities which are reported at fair value on the Company&#x2019;s Consolidated Balance Sheets. Unrealized holding gains and losses are reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company&#x2019;s cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,731&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,999&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in marketable securities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;309,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;309,903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$9.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of marketable securities have maturity dates greater than 12 months and are available to convert into cash, if needed.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240,726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;115,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;115,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;504,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;504,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;424,830&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;424,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;504,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;504,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; there were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; realized gains or losses. For the fiscal year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;minal realized gains. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrealized loss positions in the available-for-sale debt securities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflect temporary impairments that have been in a loss position for less than twelve months and as such are recognized in other comprehensive gain (loss). The fair value of these available-for-sale debt securities in unrealized loss positions was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$42.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$403.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.15204678362574%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,626&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;146,343&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23308676e717-wk-Fact-71830DDDFE6281AC39316B8C2FC70FA0"
      unitRef="usd">142800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23308676e721-wk-Fact-F0628342D38E0507C8336B8C2FC781A6"
      unitRef="usd">309900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8E9A1CABF1B7EF9A34CD6B8C2FEC7077-0-wk-Fact-7CC9E4B8902CC637CA836B8C2FC8B2B1">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,731&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,999&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in marketable securities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;309,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;309,903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$9.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of marketable securities have maturity dates greater than 12 months and are available to convert into cash, if needed.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240,726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;115,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;115,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;504,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;504,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;424,830&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;424,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;504,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;504,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e966-wk-Fact-5B00B5F16D67C7FD36126B8C2F621219"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1024-wk-Fact-C270CADE368FA1D155306B8C2F723D9A"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23308676e1044-wk-Fact-DE091A42E9261DE946436B8C2F73CB6B"
      unitRef="usd">145875000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23308676e1063-wk-Fact-782643CBC2B6029C562E6B8C2F7509D5"
      unitRef="usd">121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23308676e1082-wk-Fact-381307D63B9083924BC86B8C2F6E49B9"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23308676e1103-wk-Fact-BFB3F98B98399D8E557D6B8C2F6AC3D7"
      unitRef="usd">145991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23308676e1128-wk-Fact-BD6009015B9F2DDB00646B8C2F6DF5B0"
      unitRef="usd">73659000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23308676e1147-wk-Fact-8BAD851580373610A8AC6B8C2F72D43F"
      unitRef="usd">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23308676e1166-wk-Fact-74D9472C264F847354FF6B8C2F6D7BA5"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23308676e1187-wk-Fact-90179DB6AC13E7EB750C6B8C2F75D560"
      unitRef="usd">73710000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23308676e1212-wk-Fact-204AEB45811B12B64F996B8C2F748CE7"
      unitRef="usd">77731000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23308676e1231-wk-Fact-7F3D51A6A2D625CE48C76B8C2F6F9359"
      unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23308676e1250-wk-Fact-65D97F8923F569EA6DF06B8C2F6DF8B4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23308676e1270-wk-Fact-08F3465C00A07FE507356B8C2F6B9B28"
      unitRef="usd">77810000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="d23308676e1295-wk-Fact-6181A41EAF1D88689B54F4BB800238EE"
      unitRef="usd">11999000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="d23308676e1314-wk-Fact-41CCD20ED2901FF0AAC5F4BB830FE91A"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="d23308676e1333-wk-Fact-CECC7E4430459C04D59AF4BB85E1F8A4"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="d23308676e1354-wk-Fact-AA020BFE4F967E948276F4BB88F0FD8F"
      unitRef="usd">11991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23308676e1379-wk-Fact-62B063C0F96BA0D343C66B8C2F73864D"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23308676e1398-wk-Fact-B6754899B37AF67DA86F6B8C2F7128BB"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23308676e1417-wk-Fact-83FA7AF8EF83E3EA13886B8C2F6B74C8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23308676e1437-wk-Fact-AFF2F5C076B201DE9A966B8C2F6C1DF1"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d23308676e1462-wk-Fact-0C7E5DFB4AD09D71AB046B8C2F744D8F"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d23308676e1481-wk-Fact-8CC89087C0815C318B186B8C2F7085E5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d23308676e1500-wk-Fact-676AA78073808DBDE3386B8C2F7104EB"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d23308676e1520-wk-Fact-521880514C63ABBA9DDB6B8C2F6FDE3A"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1550-wk-Fact-6B78C925F5D29D186CE96B8C2F6AB9EC"
      unitRef="usd">452502000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1569-wk-Fact-E4FEEDD888E9369C66006B8C2F706652"
      unitRef="usd">255000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1589-wk-Fact-B8A7664B2C92083E58C36B8C2F72EDFA"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1609-wk-Fact-BFC95B59B637A7D94BEE6B8C2F6E9CAD"
      unitRef="usd">452740000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1634-wk-Fact-5B00B5F16D67C7FD36126B8C2F621219"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1692-wk-Fact-5B00B5F16D67C7FD36126B8C2F621219"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1715-wk-Fact-7D50C9DD3736619A93A16B8C2F757DBA"
      unitRef="usd">309665000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1734-wk-Fact-E4FEEDD888E9369C66006B8C2F706652"
      unitRef="usd">255000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1753-wk-Fact-B8A7664B2C92083E58C36B8C2F72EDFA"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1774-wk-Fact-C007D8E5B1A5A692C2356B8C2F74485B"
      unitRef="usd">309903000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1804-wk-Fact-6B78C925F5D29D186CE96B8C2F6AB9EC"
      unitRef="usd">452502000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1823-wk-Fact-E4FEEDD888E9369C66006B8C2F706652"
      unitRef="usd">255000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1843-wk-Fact-B8A7664B2C92083E58C36B8C2F72EDFA"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e1863-wk-Fact-BFC95B59B637A7D94BEE6B8C2F6E9CAD"
      unitRef="usd">452740000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23308676e1881-wk-Fact-400FD84C6187A000BCC0F4CF9F4AD7C4"
      unitRef="usd">9500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2107-wk-Fact-E0F444372BF0213F4E0F6B8C2F5F9EC4"
      unitRef="usd">79749000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2165-wk-Fact-94E74268B7E5D8FDAE096B8C2FC171E7"
      unitRef="usd">79749000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23308676e2185-wk-Fact-F6239B0E65C8E3DE7CC96B8C2FC03AA6"
      unitRef="usd">240969000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23308676e2204-wk-Fact-68B7016CCB087663DACC6B8C2FBF65B5"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23308676e2223-wk-Fact-05F596B05B799111BAF36B8C2FBE9339"
      unitRef="usd">250000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_fold_ShortTermCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23308676e2244-wk-Fact-715C729030DC757E88B76B8C2FDE552F"
      unitRef="usd">240726000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23308676e2269-wk-Fact-9B9F21F776762287E2356B8C2FB626F7"
      unitRef="usd">115245000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23308676e2288-wk-Fact-1FC13BF88D3A4ADA117F6B8C2FBFCDE2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23308676e2307-wk-Fact-91DE03ACB91BACBB21CB6B8C2FDF67DE"
      unitRef="usd">104000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23308676e2328-wk-Fact-7721CFE973BEFC6825D16B8C2FBC0551"
      unitRef="usd">115141000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23308676e2353-wk-Fact-C983AE549CBC4BA216496B8C2FDCB4A8"
      unitRef="usd">68215000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23308676e2372-wk-Fact-A036C8C6A4F350B3490F6B8C2FE0C8AC"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23308676e2391-wk-Fact-EB058F8ADA153AEEF8076B8C2FDDD4B2"
      unitRef="usd">84000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23308676e2412-wk-Fact-26DE3DF8F734EB28284E6B8C2FBD577D"
      unitRef="usd">68135000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23308676e2437-wk-Fact-0FD1BE5A1FD8E958E5616B8C2FBC606C"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23308676e2456-wk-Fact-07002C0C77DBC6D5C03C6B8C2FBB30FD"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23308676e2475-wk-Fact-2D479C324616D19F7DD06B8C2FDEF8CB"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23308676e2495-wk-Fact-3FB4E72587657B2059E26B8C2FBBFC47"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d23308676e2520-wk-Fact-4C2AA2A2455E0C5B39B26B8C2FDD9311"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d23308676e2539-wk-Fact-28B7CDFC1912F3007EFC6B8C2FBA5C43"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d23308676e2558-wk-Fact-6499C8AD09958E018EC86B8C2FBACAF0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d23308676e2578-wk-Fact-FE9F9FECD74F4CFCBA316B8C2FBB697C"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2608-wk-Fact-6F243344B5D04BF695E86B8C2F5B2536"
      unitRef="usd">504579000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2627-wk-Fact-545A5542EB5615A0C92E6B8C2FC0CAB4"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2647-wk-Fact-9BABEFA438FA0D6D3B3B6B8C2FC1E712"
      unitRef="usd">438000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2667-wk-Fact-EEAC36866142424E3A786B8C2FDEA3FE"
      unitRef="usd">504152000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2692-wk-Fact-E0F444372BF0213F4E0F6B8C2F5F9EC4"
      unitRef="usd">79749000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2750-wk-Fact-94E74268B7E5D8FDAE096B8C2FC171E7"
      unitRef="usd">79749000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2770-wk-Fact-1FC678478DDB8B1428276B8C2FB6A38B"
      unitRef="usd">424830000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2789-wk-Fact-545A5542EB5615A0C92E6B8C2FC0CAB4"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2808-wk-Fact-9BABEFA438FA0D6D3B3B6B8C2FC1E712"
      unitRef="usd">438000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2829-wk-Fact-A8AA31BD9ED97E2E19036B8C2FBD4F41"
      unitRef="usd">424403000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2860-wk-Fact-6F243344B5D04BF695E86B8C2F5B2536"
      unitRef="usd">504579000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2879-wk-Fact-545A5542EB5615A0C92E6B8C2FC0CAB4"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2899-wk-Fact-9BABEFA438FA0D6D3B3B6B8C2FC1E712"
      unitRef="usd">438000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e2919-wk-Fact-EEAC36866142424E3A786B8C2FDEA3FE"
      unitRef="usd">504152000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d23308676e2938-wk-Fact-1EB75FF29637C588F8966B8C2FC55F8D"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d23308676e2946-wk-Fact-977662F1B8CD5803F3736B8C2FC9ABF2"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23308676e2962-wk-Fact-A650DA271F5E2043ABF56B8C2FC92FD2"
      unitRef="usd">42600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4"
      decimals="-5"
      id="d23308676e2966-wk-Fact-8ECC369781B2331D432F6B8C2FC6CCDA"
      unitRef="usd">403100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3AA6CC8064D75ED5A4696B8C2FECA0B3-0-wk-Fact-195C1E6D49CB99CEF2576B8C2FC7EBAD">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.15204678362574%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,626&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;146,343&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e3091-wk-Fact-5B00B5F16D67C7FD36126B8C2F621219"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e3110-wk-Fact-E0F444372BF0213F4E0F6B8C2F5F9EC4"
      unitRef="usd">79749000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d23308676e3130-wk-Fact-980FBEF7CC1BDC2421CE6B8C2F9FB7B2"
      unitRef="usd">49060000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e3150-wk-Fact-8DC1D437E5FAEDD56EF36B8C2F9C47F1"
      unitRef="usd">3506000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e3169-wk-Fact-B1243CF993A2D97AA30F6B8C2FA8BC1B"
      unitRef="usd">2626000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d23308676e3188-wk-Fact-E5911821A3DEB4C387A76B8C2FA27858"
      unitRef="usd">2177000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308676e3219-wk-Fact-910F239777FED3FF4F746B8C2F7F1327"
      unitRef="usd">146343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308676e3238-wk-Fact-DB4369335D59DC134A9D6B8C2F866261"
      unitRef="usd">82375000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d23308676e3258-wk-Fact-2832D32E859374AFC2286B8C2F8F7EAF"
      unitRef="usd">51237000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7697FF89DA9E62B17B516B8C2FEDDC15-0-wk-Fact-0F06026F1E3C4F8CF6BF6B8C2F76942F">Inventories&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories consist of raw materials, work in process, and finished goods related to the manufacture of Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The following table summarizes the components of inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.25341130604289%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recorded a reserve for inventory of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-06FA89F0008DB5A10A526B8C2FECC5E3-0-wk-Fact-5A48380470B14FB459E46B8C2F764627">The following table summarizes the components of inventories:&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.25341130604289%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308366e804-wk-Fact-601D04349EADE6AA45B96B8C2F7B2AC7"
      unitRef="usd">6544000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308366e823-wk-Fact-F478C9FE19848115EE556B8C2F7CF0F7"
      unitRef="usd">1291000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308366e843-wk-Fact-77E3815F734D370608CA6B8C2F7B19DF"
      unitRef="usd">3660000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308366e862-wk-Fact-C90F0B424B39E43EB6B46B8C2F7C8BAF"
      unitRef="usd">3485000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308366e887-wk-Fact-361A11C11128E0FAB23A6B8C2F7C617B"
      unitRef="usd">3837000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308366e906-wk-Fact-DC128946E9DF39F27A5E6B8C2F7F9A3C"
      unitRef="usd">3614000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23308366e936-wk-Fact-598359183EED6871AA2C6B8C2F5D1396"
      unitRef="usd">14041000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23308366e955-wk-Fact-1834396DC49735734D906B8C2F69C29C"
      unitRef="usd">8390000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23308366e971-wk-Fact-D9C8F27AA3C1967D59FDFE1CBAA16E80"
      unitRef="usd">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-427A5EE12365CEA5F2346B8C2FEDCAF6-0-wk-Fact-307645632A81B9BE2ABA6B8C2F87BA18">Property and Equipment&lt;div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,607&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,568&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,876&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,294&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vehicles&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Land&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17,604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(15,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-57F288B90C1B81348B3C6B8C2FED281B-0-wk-Fact-535D9C833A52CC8718BA6B8C2F87C6F0">&lt;div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,607&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,568&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,876&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,294&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vehicles&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Land&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17,604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(15,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="d23306992e888-wk-Fact-2EEE6520CD29795BA5006B8C2FAC9345"
      unitRef="usd">6185000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="d23306992e907-wk-Fact-4DBD3CFE344991CF5D3B6B8C2FAEA3FF"
      unitRef="usd">4691000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="d23306992e927-wk-Fact-09F5A673102BCA4BBB8C6B8C2FB9C4D0"
      unitRef="usd">1607000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="d23306992e946-wk-Fact-85A556EBEB15155DB7306B8C2FAA53C9"
      unitRef="usd">1298000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember"
      decimals="-3"
      id="d23306992e971-wk-Fact-D382EDEA12846F3A79366B8C2FB591A2"
      unitRef="usd">14568000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember"
      decimals="-3"
      id="d23306992e990-wk-Fact-798EE9DD7D1E49065D5C6B8C2FB6A0E2"
      unitRef="usd">8445000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d23306992e1015-wk-Fact-52D307D67626685021306B8C2FB48CBC"
      unitRef="usd">5157000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d23306992e1034-wk-Fact-8EF5E6DC3EC6433ABD536B8C2FB048F0"
      unitRef="usd">4876000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d23306992e1059-wk-Fact-6EA08765345851C919C66B8C2FB2CBAD"
      unitRef="usd">30294000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d23306992e1078-wk-Fact-A4FA1DB88D20FA9704CB6B8C2FB406A9"
      unitRef="usd">7425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember"
      decimals="-3"
      id="d23306992e1103-wk-Fact-92C14A4CD6879CF175856B8C2FB77099"
      unitRef="usd">124000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember"
      decimals="-3"
      id="d23306992e1122-wk-Fact-5C5E9131940146AA1CAB6B8C2FB30FF0"
      unitRef="usd">209000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"
      decimals="-3"
      id="d23306992e1147-wk-Fact-37CDD5F83D260305A687F4DAA41DF7FB"
      unitRef="usd">3190000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"
      decimals="-3"
      id="d23306992e1166-wk-Fact-9CE6C905166C860193AEF4DAA73C7B89"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d23306992e1191-wk-Fact-93C5927FC2B32DC57C8A6B8C2FB8FD1A"
      unitRef="usd">4184000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d23306992e1210-wk-Fact-4264C8D37BC1F40DB6A26B8C2FB280BC"
      unitRef="usd">102000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23306992e1236-wk-Fact-746D9B7E5C55CC2EDE356B8C2FACFA18"
      unitRef="usd">65309000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23306992e1255-wk-Fact-4385649138A4469301676B8C2FAB270C"
      unitRef="usd">27046000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23306992e1280-wk-Fact-17F8D4944E489AE199326B8C2F6F9E3C"
      unitRef="usd">17604000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23306992e1300-wk-Fact-62D5EE66AC2956E871286B8C2F7661AD"
      unitRef="usd">15671000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23306992e1331-wk-Fact-F67F04CA72257459EC5C6B8C2F73F9EF"
      unitRef="usd">47705000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23306992e1350-wk-Fact-22630A3A2EFD75C53BAC6B8C2F5F1448"
      unitRef="usd">11375000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23306992e1363-wk-Fact-FA1D709DF1F1CEBAFF136B8C2F87C650"
      unitRef="usd">4500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d23306992e1367-wk-Fact-1822A579B4B5F0C52FF36B8C2F87FA63"
      unitRef="usd">4200000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9916E088260D456E4A816B8C2FEDE4D3-0-wk-Fact-E8A0F65E2AD6CEF223B86B8C2FC2961F">Accounts Payable, Accrued Expenses, and Other Current Liabilities&lt;div style="line-height:120%;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts payable, accrued expenses, and other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,832&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued contract manufacturing&#160;&amp;amp; contract research costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,731&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Accrued program fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,674&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued royalties &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,463&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Accrued interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Accrued sales rebates and discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,772&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,830&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120,373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6B00730EDA1BC18131276B8C2FEDB313-0-wk-Fact-AC6EB517A4203702CA9C6B8C2FC3DFC9">&lt;div style="line-height:120%;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts payable, accrued expenses, and other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,832&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued contract manufacturing&#160;&amp;amp; contract research costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,731&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Accrued program fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,674&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued royalties &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,463&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Accrued interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Accrued sales rebates and discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,772&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,830&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120,373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e848-wk-Fact-76A958AF45849747BFF16B8C2F5F35CD"
      unitRef="usd">21722000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e867-wk-Fact-81CB44D0291CDD2910E26B8C2F6334D1"
      unitRef="usd">6606000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e887-wk-Fact-30C8CC481744915C05B86B8C2F605F55"
      unitRef="usd">7832000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e906-wk-Fact-4D283C06813C237ED1556B8C2F68FE9E"
      unitRef="usd">2276000</us-gaap:AccruedProfessionalFeesCurrent>
    <fold:AccruedContractManufacturingAndContractResearchCostsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e931-wk-Fact-F59F17AEDA4814B9ED426B8C2F62AEC7"
      unitRef="usd">17800000</fold:AccruedContractManufacturingAndContractResearchCostsCurrent>
    <fold:AccruedContractManufacturingAndContractResearchCostsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e950-wk-Fact-D8FAE76B6955D6CC6FCE6B8C2F5F2453"
      unitRef="usd">5890000</fold:AccruedContractManufacturingAndContractResearchCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e975-wk-Fact-D16282FE40EB5C9E9B026B8C2F663ABF"
      unitRef="usd">27156000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e994-wk-Fact-DEF3D83FEE1187C15C286B8C2F64263B"
      unitRef="usd">21731000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <fold:AccruedProgramFees
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e1019-wk-Fact-EF3EF3EEC6FBB3D83F566B8C2F64D1D2"
      unitRef="usd">17016000</fold:AccruedProgramFees>
    <fold:AccruedProgramFees
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e1038-wk-Fact-F6E8301EFD2CD9C56CB36B8C2F618CF9"
      unitRef="usd">16674000</fold:AccruedProgramFees>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e1063-wk-Fact-BD2EFF4736E434B2AD9B6B8C2F66082C"
      unitRef="usd">5196000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e1082-wk-Fact-3CB3A785AAE089BA436C6B8C2F5FBA77"
      unitRef="usd">4463000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e1107-wk-Fact-5DFA01953B4A0C5901946B8C2F67DD9C"
      unitRef="usd">3679000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e1126-wk-Fact-F2D84B5EAC479C82D6626B8C2F61A72D"
      unitRef="usd">4189000</us-gaap:InterestPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e1151-wk-Fact-1DF5D9764B0F09386F746B8C2F63DD2F"
      unitRef="usd">4000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e1170-wk-Fact-38ED9C389A1B3A2F49876B8C2F5F9D91"
      unitRef="usd">9000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <fold:AccruedSalesRebatesAndChargebacksCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e1195-wk-Fact-095688441A07997175F16B8C2F606A08"
      unitRef="usd">5900000</fold:AccruedSalesRebatesAndChargebacksCurrent>
    <fold:AccruedSalesRebatesAndChargebacksCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e1214-wk-Fact-E8AD0E063125749A343C6B8C2F61636E"
      unitRef="usd">3636000</fold:AccruedSalesRebatesAndChargebacksCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e1240-wk-Fact-4A80E75D0536CF5DBAF5807669AB94A2"
      unitRef="usd">7300000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e1259-wk-Fact-20B8D7B2EEF16283F0B98076699890CC"
      unitRef="usd">1330000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e1284-wk-Fact-4AA4FC74F76DB35479B76B8C2F617A0A"
      unitRef="usd">2772000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e1303-wk-Fact-E667141DD1DE08AFE9966B8C2F6239BC"
      unitRef="usd">4830000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23309531e1333-wk-Fact-00D9324EC614ACA175846B8C2F705888"
      unitRef="usd">120373000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23309531e1352-wk-Fact-88FBC7147324CDFE62F06B8C2F5C7F02"
      unitRef="usd">80625000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-578C9C881010BE5968316B8C2FEDA5FE-0-wk-Fact-876BC63A0935717069256B8C2F5BC9DA">Stockholders' Equity&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company was authorized to issue &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;500 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; vote for each share held.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2019, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101,787&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; warrants were exercised at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.98&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share of common stock resulting in gross cash proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As discussed in "&#x2014; Note 1. Business" during the second quarter of 2019, the Company completed an underwritten equity offering and issued &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.75&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$189.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As discussed in "&#x2014; Note 11. Assets and Liabilities Measured at Fair Value", the Company reached a clinical milestone, which was the dosing of the first patient in a Phase 3 study, related to the contingent consideration from the acquisition of Callidus. The milestone for this event was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was paid in Company common stock in the first quarter of 2019 and resulted in a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; impact on stockholder's equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; As discussed in ''&#x2014; Note 12. Debt'', during the first and second quarters of 2019, the Company entered into separate, privately negotiated Exchange Agreements with the Holders of the Convertible Notes. Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$247.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of Convertible Notes held by them in exchange for an aggregate of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of Company's common stock, par value &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.01&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2018, the Company completed an underwritten offering of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$294.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2018, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;453,214&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; warrants were exercised at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.98&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share of common stock resulting in gross cash proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s Restated Certificate of Incorporation to increase the number of shares of common stock, par value &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.01&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, that the Company is authorized to issue from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;500 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:2px;text-indent:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2017, the Company completed an underwriting offering of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. This transaction resulted in net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$243.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Nonqualified Cash Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's Deferral Plan, (the "Deferral Plan") provides certain key employees and members of the Board of Directors as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code of 1986 as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company had a deferred compensation investment balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, with corresponding approximate amounts of liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferral Plan investment assets are classified as trading securities and are recorded at fair value with changes in the investments' fair value recognized in AOCI in the period they occur. Deferred compensation liability amounts under the Deferral Plan are included in other long-term liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity Incentive Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the &#x2018;&#x2018;Plan&#x2019;&#x2019;) and the 2007 Director Option Plan (the &#x2018;&#x2018;2007 Director Plan&#x2019;&#x2019;). The Plan provides for the granting of restricted stock and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company&#x2019;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#x2019;s business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. Under the provisions of each plan, no option will have a term in excess of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the first year anniversary date of grant plus an additional 1/48th for each month thereafter and may be exercised in whole or in part for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the shares vested at any time after the date of grant. Options under the 2007 Director Plan may be granted to new directors upon joining the Board of Directors and vest in the same manner as options under the Plan. In addition, options are granted to independent directors at each annual meeting of stockholders and vest on the date of the annual meeting of stockholders of the Company in the year following the year during which the options were granted. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has reserved up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,667,216&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares for issuance under the Plan and the 2007 Director Plan.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="d23309752e734-wk-Fact-7704FE8FF618F9D2A5A96B8C2FCAA091"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <fold:CommonStockVotingRightsForEachShareHeld
      contextRef="FI2019Q4"
      decimals="INF"
      id="d23309752e738-wk-Fact-BB0DC01B065B17E32F166B8C2FC0133F"
      unitRef="vote">1</fold:CommonStockVotingRightsForEachShareHeld>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2019Q1Mar_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember"
      decimals="INF"
      id="d23309752e747-wk-Fact-17462F320EA863EE8864F9595693B507"
      unitRef="shares">101787</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="d23309752e751-wk-Fact-057638893F235F4A72E2F9597A0D0CB4"
      unitRef="usdPerShare">7.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="D2019Q1Mar_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember"
      decimals="-5"
      id="d23309752e755-wk-Fact-AC25BF811C168E4720ADF95A0B0735C5"
      unitRef="usd">800000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d23309752e764-wk-Fact-4CD3463F939D863661B6F441E6784C03"
      unitRef="shares">18700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_fold_UnderwrittenOfferingMember"
      decimals="INF"
      id="d23309752e768-wk-Fact-43864E6CC5A7B8A09AC4F442508D5BE9"
      unitRef="usdPerShare">10.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d23309752e772-wk-Fact-2BE35686606668C4F05AF442E8185CE0"
      unitRef="usd">189000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <fold:ContingentConsiderationMilestonePayment
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d23309752e781-wk-Fact-F49D436D658119FEC9E6F95AF556C7E7"
      unitRef="usd">9000000.0</fold:ContingentConsiderationMilestonePayment>
    <fold:MilestonePaymentStockIssuedAsConsideration
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d23309752e785-wk-Fact-C32C215E245092FE298CF95B1214C8DF"
      unitRef="usd">9300000</fold:MilestonePaymentStockIssuedAsConsideration>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount
      contextRef="FI2019Q2"
      decimals="-5"
      id="d23309752e795-wk-Fact-B45190F1751000600DA8F95C3C463827"
      unitRef="usd">247200000</fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance
      contextRef="FI2019Q2"
      decimals="-5"
      id="d23309752e799-wk-Fact-91BBA8E21CAD8952E731F95CB2CEF06C"
      unitRef="shares">44000000.0</fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q2"
      decimals="INF"
      id="d23309752e803-wk-Fact-209D73E792B95831DFADF95D06B1901E"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2018Q1Feb_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d23309752e812-wk-Fact-EF5E78786355E3087CA55E3A86D43B2F"
      unitRef="shares">20200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="I2018Q1February28_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23309752e816-wk-Fact-46AF99920B8CC311CC116B8C2FBF88F8"
      unitRef="usdPerShare">15.50</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D2018Q1Feb_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d23309752e820-wk-Fact-F55D2818823FEFBA1F166B8C2FD9BA2E"
      unitRef="usd">294600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2018Q2Apr01-Apr30_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember"
      decimals="INF"
      id="d23309752e829-wk-Fact-804937D244542F3E127E6B8C2FD8C337"
      unitRef="shares">453214</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I2018Q2Apr30_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="d23309752e833-wk-Fact-C596C404389DBE15D0726B8C2FDB2584"
      unitRef="usdPerShare">7.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="D2018Q2Apr01-Apr30_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember"
      decimals="-5"
      id="d23309752e837-wk-Fact-C989E8B009D1B9B3DFED6B8C2FDB5A97"
      unitRef="usd">3600000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q2"
      decimals="INF"
      id="d23309752e846-wk-Fact-2F66A4E785AD7F6B013E6B8C2FB7456F"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2017Q4"
      decimals="INF"
      id="d23309752e850-wk-Fact-0624F178F2DE343E049A6B8C2FDD8C71"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q2"
      decimals="INF"
      id="d23309752e854-wk-Fact-A7F51933C89FF59E7D5B6B8C2FDE70D9"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2017Q3Jul1-Jul31"
      decimals="-5"
      id="d23309752e863-wk-Fact-64153E7C0581BDA0B7785E3AB653721A"
      unitRef="shares">21100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="I2017Q3Jul31"
      decimals="INF"
      id="d23309752e867-wk-Fact-AD0E5D7C64EFD9BB1976F96686C1D383"
      unitRef="usdPerShare">12.25</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D2017Q3Jul1-Jul31"
      decimals="-5"
      id="d23309752e871-wk-Fact-D3F9EF911D0835DD2722F967EF5B1D64"
      unitRef="usd">243000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:TradingSecurities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23309752e887-wk-Fact-36696387BDFD4BFEB2E26B8C2FD82C89"
      unitRef="usd">4400000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d23309752e891-wk-Fact-07C2219858E146C0FB766B8C2FB91F3A"
      unitRef="usd">2700000</us-gaap:TradingSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member"
      id="d23309752e915-wk-Fact-2B0D98E748B57F724FCE6B8C2FC37CD6">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="d23309752e919-wk-Fact-06DBAAB2DE509B262DDE6B8C2FC14083"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member"
      decimals="INF"
      id="d23309752e923-wk-Fact-3F41DCA9C8F1C90AC84C6B8C2FDCF862"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member"
      decimals="INF"
      id="d23309752e931-wk-Fact-F354E847CBC1869008876B8C2FDE6923"
      unitRef="shares">10667216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-11EAF28FB00D6CB2974F6B8C2FEDFFD1-0-wk-Fact-95E0BF78658CFD2170056B8C2FBCB44B">Share based Compensation &lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s Equity Incentive Plans consist of the Plan and the 2007 Director Plan. The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors. advisors, and consultants at a price to be determined by the Company&#x2019;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#x2019;s business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 21, 2018, the Board of Directors of the Company approved an amendment (the "Amendment") to the Plan. The Amendment provides for certain benefits to qualifying Plan Participants who separate from service with the Company due to death, disability or "Retirement" (as such term is defined under the Plan) ("Qualified Participants"). Options granted under the Plan ("Options") to a Qualified Participant shall continue to vest until the 2nd anniversary of the Qualified Participant&#x2019;s separation and all vested Options held by such Qualified Participant shall remain exercisable until the earlier of the 4th anniversary of the Qualified Participant&#x2019;s separation or the original expiration date of the Option. Options that are not exercised during this exercise period shall be forfeited. Time-based restricted stock units and restricted stock granted to a Qualified Participant under the Plan that was scheduled to vest within the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;two&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; year period following the Qualified Participant's separation shall accelerate and be delivered upon such separation. Any time-based restricted stock units or restricted stock that would have vested after such &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;two&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; year period will be forfeited upon the Qualified Participant's separation. Also, per the Amendment, any performance-based restricted stock units under the Plan ("PRSUs") received by the Qualified Participant, shall remain eligible to vest after the Qualified Participant&#x2019;s separation based on the actual performance of the Company through the end of the performance period applicable to any such PRSU. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Option Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company uses the fair value method of measuring stock-based compensation, using the fair value of each equity award granted. The Company chose the &#x2018;&#x2018;straight-line&#x2019;&#x2019; attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007. Beginning in the third quarter of 2017, the average expected life is determined using our actual historical data versus a &#x2018;&#x2018;simplified&#x2019;&#x2019; method used in prior quarters. The &#x2018;&#x2018;simplified&#x2019;&#x2019; method of estimating the Company did not have sufficient reliable exercise data to justify a change from the use of the &#x2018;&#x2018;simplified&#x2019;&#x2019; method of estimating the expected exercise term of employee stock option grants. The impact from this change was not material. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected life of options (years) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;______________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:24px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The average expected life is determined using actual historical data. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:24px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The weighted average grant-date fair value per share of options granted during &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.67&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.19&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.09&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of the Company's stock options for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding, December 31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,497.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,695.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,878.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,133.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,181.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,348.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,398.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(313.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,810.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,091.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,967.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(879.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(331.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,724.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and unvested expected to vest, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,111.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,646.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The aggregate intrinsic value of options exercised during the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; respectively. Cash proceeds from stock options exercised during the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$16.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the total unrecognized compensation cost related to non-vested stock options granted was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$32.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:3px;text-align:justify;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSU's")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee&#x2019;s continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-vested units as of December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,575.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,811.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(530.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(145.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-vested units as of December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,712.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,526.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(921.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(525.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-vested units as of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,792.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;920,782&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; RSUs have vested and all non-vested units are expected to vest over their normal term. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$39.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.4 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation Expense Related to Equity Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity compensation expense recognized in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,328&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,855&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,520&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,773&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total equity compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,430&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C169596DA4EB79E400E26B8C2FEEB307-0-wk-Fact-84D72C7E2E84BC5055E96B8C2FA83773">&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected life of options (years) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;______________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:24px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The average expected life is determined using actual historical data. &lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="3"
      id="d23321073e919-wk-Fact-334566BF82E5406E41986B8C2FB63C5E"
      unitRef="number">0.741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="3"
      id="d23321073e939-wk-Fact-2346CCAAB20E0F7405556B8C2FC16FCD"
      unitRef="number">0.786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="3"
      id="d23321073e959-wk-Fact-603283EEB15B434AA9EB6B8C2FAD6EEA"
      unitRef="number">0.828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="3"
      id="d23321073e986-wk-Fact-6F4877164D897F9A8A3E6B8C2FB7D031"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="3"
      id="d23321073e1006-wk-Fact-180BD6C843CD4F4638BD6B8C2FAEF3E3"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="3"
      id="d23321073e1026-wk-Fact-D9D181C2CD5B3838D4B86B8C2FAFBD7E"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      id="d23321073e1055-wk-Fact-0FE01A116A2C53DE583D6B8C2FAEB726">P5Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      id="d23321073e1074-wk-Fact-C414BBBB88D41B9DBCE76B8C2FB9C16F">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      id="d23321073e1093-wk-Fact-4B975B0F2E3FE51804706B8C2FAC937B">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="INF"
      id="d23321073e1124-wk-Fact-484D35B21DE01CFE7C316B8C2FBD66FB"
      unitRef="usdPerShare">0.00</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="INF"
      id="d23321073e1143-wk-Fact-2DCADA7EF791271161936B8C2FB328B5"
      unitRef="usdPerShare">0.00</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="INF"
      id="d23321073e1163-wk-Fact-49F7FA51173858F9ED5D6B8C2FAE94FD"
      unitRef="usdPerShare">0.00</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1197-wk-Fact-8736E6C84C5A9D177F0B6B8C2FC11878"
      unitRef="usdPerShare">6.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1201-wk-Fact-169B0E0B26230A2FC32B6B8C2FAD7AB9"
      unitRef="usdPerShare">10.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1206-wk-Fact-869D274AD36731D480536B8C2FBAD554"
      unitRef="usdPerShare">5.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5779D4DDBCF51D5DA0EF6B8C2FED11C9-0-wk-Fact-CFFED8366577B22493FA6B8C2FA40819">&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of the Company's stock options for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding, December 31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,497.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,695.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,878.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,133.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,181.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,348.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,398.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(313.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,810.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,091.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,967.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(879.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(331.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,724.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and unvested expected to vest, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,111.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,646.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2016Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e1412-wk-Fact-2854A020A413B8827FA76B8C2F6BA0AE"
      unitRef="shares">15497500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2016Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1431-wk-Fact-C6F20ACC2A0CE886DA4E6B8C2F6429A2"
      unitRef="usdPerShare">7.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e1477-wk-Fact-8E6B3829D146BEAFCD2D6B8C2F6987D6"
      unitRef="shares">3695300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1496-wk-Fact-88D2B0BB0397600DF0F96B8C2F697564"
      unitRef="usdPerShare">7.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e1542-wk-Fact-F1B30837C2A5155484116B8C2F68768A"
      unitRef="shares">2878700</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1562-wk-Fact-37DB44D2711654D656936B8C2F6AC6F0"
      unitRef="usdPerShare">5.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e1608-wk-Fact-0FBEE9F5DA6453ADAA666B8C2F67F146"
      unitRef="shares">1133000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1628-wk-Fact-AB8162858C1D5D12DDB96B8C2F669ABE"
      unitRef="usdPerShare">9.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e1674-wk-Fact-907F2419D6D64060251B6B8C2F670529"
      unitRef="shares">15181100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1693-wk-Fact-223D95748C8FBC9D6F116B8C2F68B93D"
      unitRef="usdPerShare">7.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e1739-wk-Fact-B246D3B4750C5B220CAA6B8C2F6AED4A"
      unitRef="shares">2348000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1758-wk-Fact-30AD57BB2EEBF00DA8B66B8C2F60DD2E"
      unitRef="usdPerShare">14.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e1804-wk-Fact-4AC93A04508889FED89A6B8C2F62690E"
      unitRef="shares">1398000.0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1824-wk-Fact-556E2D36DCE423E4E2966B8C2F636D74"
      unitRef="usdPerShare">6.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e1870-wk-Fact-0AE2C4EE68F9D9A0C5766B8C2F67FB05"
      unitRef="shares">313100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1890-wk-Fact-05DCED1C375B010737E16B8C2F621C29"
      unitRef="usdPerShare">9.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e1936-wk-Fact-5E92F59DC82AFF7B4641F107049F41F6"
      unitRef="shares">8000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e1956-wk-Fact-66434F6085247546CD44F1070497BD32"
      unitRef="usdPerShare">10.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e2003-wk-Fact-BCC614F3A31BAD74DDABF10704A32149"
      unitRef="shares">15810000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e2022-wk-Fact-18F0E2C17DDD1785CCA56B8C2F603621"
      unitRef="usdPerShare">8.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e2068-wk-Fact-06403FBA0F323D5363ED6B8C2F66B2FC"
      unitRef="shares">4091000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e2087-wk-Fact-99F69023E684C083ED3D6B8C2F699F1D"
      unitRef="usdPerShare">10.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e2133-wk-Fact-E21317772D04BE03F5B66B8C2F6BA9A5"
      unitRef="shares">1967000.0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e2153-wk-Fact-579E3D2E91EB3AB9BACD6B8C2F6476DE"
      unitRef="usdPerShare">5.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e2199-wk-Fact-2C221FB81A0EC6B2ABA96B8C2F63009C"
      unitRef="shares">879000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e2219-wk-Fact-288930CF4C60038F10626B8C2F672866"
      unitRef="usdPerShare">11.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e2265-wk-Fact-AFDCEC4114C3560AF3FF6B8C2F66BC11"
      unitRef="shares">331000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e2285-wk-Fact-B727B5ACDBD1D3D316676B8C2F6156D3"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e2331-wk-Fact-B7CD0F2B3715033A3BD5F10704A802B4"
      unitRef="shares">16724000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e2350-wk-Fact-DC7C0A1266CFAA5A68D86B8C2F636FD8"
      unitRef="usdPerShare">9.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      id="d23321073e2364-wk-Fact-24CDBFDB1FADEFEA14C26B8C2F66FE0B">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d23321073e2380-wk-Fact-2D94BF4CEBAA15CEEC316B8C2F62FEB9"
      unitRef="usd">30800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e2395-wk-Fact-F8B2C0DE430B3FC26A8E6B8C2F65324D"
      unitRef="shares">16111200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e2414-wk-Fact-6F63F4A09D4AA3FDDC2A6B8C2F61D956"
      unitRef="usdPerShare">9.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      id="d23321073e2428-wk-Fact-2A412CA30673313E57B16B8C2F61B2E5">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d23321073e2444-wk-Fact-452E1E0C735B539386A26B8C2F64E6CB"
      unitRef="usd">30600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-2"
      id="d23321073e2459-wk-Fact-6B5099A3F2F4D22CD7A06B8C2F650A19"
      unitRef="shares">10646500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d23321073e2478-wk-Fact-FA33E95C047D425862946B8C2F681FC2"
      unitRef="usdPerShare">8.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      id="d23321073e2492-wk-Fact-2B43CA11873C7A3CC73A6B8C2F65DBB1">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d23321073e2508-wk-Fact-044AE318C987D7B20F766B8C2F66B5C1"
      unitRef="usd">27000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d23321073e2532-wk-Fact-C52AFC78286257757A326B8C2FBFD948"
      unitRef="usd">11800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d23321073e2536-wk-Fact-FCAD9C33DAB8EAC55DD26B8C2FA70507"
      unitRef="usd">11900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d23321073e2541-wk-Fact-31A2446F19E0F46853606B8C2FA6A78F"
      unitRef="usd">20800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d23321073e2557-wk-Fact-5D555EAD57689EF131F46B8C2FB82B87"
      unitRef="usd">11500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d23321073e2561-wk-Fact-8B0EBC54E03CBB6849FC6B8C2F962E5F"
      unitRef="usd">9100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d23321073e2566-wk-Fact-B32A62681747FC0946CD6B8C2F938C56"
      unitRef="usd">16300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d23321073e2574-wk-Fact-CAF2F64FEE207C986AC56B8C2FBE41AE"
      unitRef="usd">32400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      id="d23321073e2578-wk-Fact-7369085C268F31E8DC626B8C2FBB053B">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8D8648081C88943496D96B8C2FEE45BC-0-wk-Fact-1EC7FBBFC5D166DEC9166B8C2FA854A2">A summary of non-vested RSU activity under the Plan for the year ended &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-vested units as of December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,575.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,811.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(530.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(145.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-vested units as of December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,712.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,526.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(921.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(525.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-vested units as of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,792.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-2"
      id="d23321073e2791-wk-Fact-AB4DC6AF410D5387FDA26B8C2F882870"
      unitRef="shares">2575100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="2"
      id="d23321073e2810-wk-Fact-7DD21A2A94DBF4B87C3B6B8C2F9E0253"
      unitRef="usdPerShare">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-2"
      id="d23321073e2856-wk-Fact-A49FEB9988B1AB2584716B8C2FC5F4FB"
      unitRef="shares">1811900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="2"
      id="d23321073e2875-wk-Fact-E12AAD032DF6A2DB9E916B8C2FB01657"
      unitRef="usdPerShare">16.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-2"
      id="d23321073e2921-wk-Fact-FE50B2AD64E6D9CCF89F6B8C2FB871F5"
      unitRef="shares">530000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="2"
      id="d23321073e2941-wk-Fact-B3EBE060F34E3C9C85E66B8C2FD91F17"
      unitRef="usdPerShare">6.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-2"
      id="d23321073e2987-wk-Fact-DDC00EA68B64794BF6D06B8C2F7F8310"
      unitRef="shares">145000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="2"
      id="d23321073e3007-wk-Fact-82F23EBABCAF1517C85F6B8C2FA28541"
      unitRef="usdPerShare">9.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-2"
      id="d23321073e3053-wk-Fact-64470A1E4DDC79850F516B8C2F9639D8"
      unitRef="shares">3712000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="2"
      id="d23321073e3072-wk-Fact-78BDAA0022F9A4D641876B8C2FA1B8F4"
      unitRef="usdPerShare">10.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-2"
      id="d23321073e3118-wk-Fact-4157C9329DFD58F645506B8C2FA79762"
      unitRef="shares">3526000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="2"
      id="d23321073e3137-wk-Fact-933ED712907F40487C5C6B8C2FA03B99"
      unitRef="usdPerShare">10.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-2"
      id="d23321073e3183-wk-Fact-F7FA368BD79CDB060D896B8C2FA44B7B"
      unitRef="shares">921000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="2"
      id="d23321073e3203-wk-Fact-9E32FEFC38E0D29134A76B8C2F6C8E61"
      unitRef="usdPerShare">8.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-2"
      id="d23321073e3249-wk-Fact-122439D5AC571EEDCB7F6B8C2F965DD5"
      unitRef="shares">525000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="2"
      id="d23321073e3269-wk-Fact-AB77580393075F32C72E6B8C2FA188EE"
      unitRef="usdPerShare">10.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-2"
      id="d23321073e3315-wk-Fact-C874CAE23CD645A302306B8C2F86E062"
      unitRef="shares">5792000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="2"
      id="d23321073e3334-wk-Fact-27DD6F54A2C8827814CA6B8C2F7DF7BA"
      unitRef="usdPerShare">11.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      id="d23321073e3348-wk-Fact-9E47C7A5BCE8138ED98E6B8C2FA2AF6C">P2Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-5"
      id="d23321073e3364-wk-Fact-C1BF863728D52788DD2A6B8C2F68E65C"
      unitRef="usd">56400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d23321073e3382-wk-Fact-A0A054AE10824057B1516B8C2F99C1BF"
      unitRef="shares">920782</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      decimals="-5"
      id="d23321073e3390-wk-Fact-B0CD7EC1B9634E0B9C356B8C2FA675C0"
      unitRef="usd">39800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"
      id="d23321073e3394-wk-Fact-7D7E26E9159E1CB82C146B8C2FA9AB13">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0EE5A7CD52C739EB50466B8C2FEEA1A4-0-wk-Fact-82BF33F2ACDDD35FEAD46B8C2F943E37">&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity compensation expense recognized in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,328&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,855&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,520&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,773&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total equity compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,430&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d23321073e3650-wk-Fact-0EEC8328C096952DC7A76B8C2FA0AEB3"
      unitRef="usd">17575000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d23321073e3669-wk-Fact-BD51CCA018B9BA1FD8906B8C2F9C6E18"
      unitRef="usd">11740000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d23321073e3689-wk-Fact-68E2BEC4E6B7F33806FA6B8C2F9D4433"
      unitRef="usd">10328000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d23321073e3709-wk-Fact-568FD9079379AA0532DD6B8C2F9E116B"
      unitRef="usd">26855000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d23321073e3728-wk-Fact-345BA38CEC69D5757E2F6B8C2F9CFCAF"
      unitRef="usd">17520000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d23321073e3747-wk-Fact-E8B9F9C4B16BF6CDAA096B8C2FAAA537"
      unitRef="usd">12773000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321073e3778-wk-Fact-3D17075C0554D00CAE6D6B8C2F9C8DA1"
      unitRef="usd">44430000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321073e3797-wk-Fact-26AF11B40A93A84DF2846B8C2F9DF885"
      unitRef="usd">29260000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321073e3817-wk-Fact-40D99F47497183F8E95E6B8C2F9DE13A"
      unitRef="usd">23101000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EC3ACF956964C82C72FF6B8C2FEE21A0-0-wk-Fact-E930081D82B80FC20B726B8C2FD2D32C">Assets and Liabilities Measured at Fair Value&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&#160;1&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &#x2014; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&#160;2&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &#x2014; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&#160;3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &#x2014; Inputs that are unobservable for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are identified in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-back securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Government Agency Bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;314,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;314,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are identified in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.40545808966861%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;115,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;115,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-back securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240,726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240,726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;427,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;427,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s Convertible Notes falls into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the Convertible Notes at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s Senior Secured Term Loan fall into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan approximates the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company did not have any Level 3 assets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash, Money Market Funds and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. No transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy occurred during the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The contingent consideration payable resulted from the acquisition of Callidus, as discussed in "&#x2014;&#160;Note&#160;3. Acquisitions." The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Using this approach, expected future cash flows are calculated over the expected life of the agreement, are discounted, and then exercise scenario probabilities are applied. The valuation is performed quarterly. Gains and losses are included in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The contingent consideration payable for Callidus has been classified as a Level&#160;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. The Company may be required to record losses in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.64327485380117%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair value as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Valuation Technique&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Range&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.6%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;75% - 78%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Projected year of payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021 - 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company reached a clinical milestone, which was the dosing of the first patient in a Phase 3 study, related to the contingent consideration from the acquisition of Callidus. The milestone for this event was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was paid in Company common stock in the first quarter of 2019, resulting in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; impact on stockholder's equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table shows the change in the balance of contingent consideration payable for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Milestones payable, included in accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,297&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Adjustment for contingent consideration paid in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, end of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred Compensation Plan - Investment and Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Deferred Compensation Plan (the "Deferral Plan") provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant&#x2019;s base salary, bonus and director&#x2019;s fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investment&#x2019;s fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-56F1DBE1C6D650A8F66A6B8C2FEE3B4B-0-wk-Fact-FA0BBBE03090A70E039B6B8C2FD39C37">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are identified in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-back securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Government Agency Bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;314,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;314,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are identified in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.40545808966861%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;115,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;115,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-back securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240,726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240,726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;427,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;427,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&#160;3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23314355e865-wk-Fact-62D2B9935C4B76D0736E6B8C2FAF14A3"
      unitRef="usd">73710000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23314355e884-wk-Fact-FBA445FF93915393E7356B8C2FB0F89B"
      unitRef="usd">73710000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23314355e904-wk-Fact-9D22DAEB8ED75F6DAFC26B8C2FB02FD4"
      unitRef="usd">77810000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23314355e923-wk-Fact-D23316BA2ACDD59274576B8C2FB13E63"
      unitRef="usd">77810000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23314355e948-wk-Fact-CB231CD13FD9E28CE1A16B8C2FB08318"
      unitRef="usd">145991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23314355e967-wk-Fact-F43A1306B519E02282EB6B8C2FB16B09"
      unitRef="usd">145991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="d23314355e992-wk-Fact-31EFA70D78C3A4269487F51932460FC1"
      unitRef="usd">11991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="d23314355e1011-wk-Fact-5C35B3C7F6E7F515EC60F51936D40724"
      unitRef="usd">11991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23314355e1036-wk-Fact-88228F5425B592EC64416B8C2FC2DAC9"
      unitRef="usd">4768000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23314355e1055-wk-Fact-8FDA42CA2BA3FCAD58AF6B8C2FB16B2D"
      unitRef="usd">4768000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d23314355e1085-wk-Fact-306C7CF7EAB8535E7DF36B8C2FB0FD0D"
      unitRef="usd">314270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23314355e1104-wk-Fact-59E779BD08D6ADF0FD146B8C2FB250A0"
      unitRef="usd">314270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d23314355e1284-wk-Fact-A8126901DA0ED74CA5236B8C2FBE301A"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d23314355e1303-wk-Fact-AC1C14A2E15744EEC9576B8C2FD08232"
      unitRef="usd">22681000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23314355e1323-wk-Fact-043762B0B0647DE5D1E36B8C2FA51FDA"
      unitRef="usd">22681000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d23314355e1343-wk-Fact-137BB7BCEC6B7A71C9186B8C2FC55102"
      unitRef="usd">4419000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d23314355e1362-wk-Fact-7F3C403D282E06346EEC6B8C2F97DEF9"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23314355e1381-wk-Fact-CD51A036FA9AA7817B8E6B8C2FC2D26C"
      unitRef="usd">4419000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d23314355e1412-wk-Fact-0E6A72FFF324DCE980B26B8C2F952E99"
      unitRef="usd">4419000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d23314355e1431-wk-Fact-F094551D2B2367DC42296B8C2FBB2D55"
      unitRef="usd">22681000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23314355e1451-wk-Fact-C8D5B6C96E65BFC6FBE16B8C2F9AFCE0"
      unitRef="usd">27100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23314355e1591-wk-Fact-21494C4DD7EE1DD8029E6B8C2F989FD1"
      unitRef="usd">115141000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d23314355e1610-wk-Fact-F540D30470F11583D8996B8C2F9AE801"
      unitRef="usd">115141000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23314355e1630-wk-Fact-7964A76A9DD4AB4791996B8C2F9BAB85"
      unitRef="usd">68135000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d23314355e1649-wk-Fact-4C7A39899E3861A5939B6B8C2F9B07D0"
      unitRef="usd">68135000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23314355e1674-wk-Fact-FA86355F08A8A8179E1F6B8C2FA20909"
      unitRef="usd">240726000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d23314355e1693-wk-Fact-530284A611BECDC32D9B6B8C2F99BF26"
      unitRef="usd">240726000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23314355e1718-wk-Fact-CDCE02C201FAC64736E96B8C2FA50B21"
      unitRef="usd">3082000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d23314355e1737-wk-Fact-BBBD87355D902D65A0276B8C2F991BB4"
      unitRef="usd">3082000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d23314355e1767-wk-Fact-2780EFF5CE8841BA80236B8C2F98639A"
      unitRef="usd">427084000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23314355e1786-wk-Fact-DF0118932C215386FB926B8C2F9BC774"
      unitRef="usd">427084000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d23314355e1966-wk-Fact-076C70718BA9807DD34E6B8C2FC467C3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d23314355e1985-wk-Fact-C3D79DBF8DC8E250D8216B8C2F8FBED0"
      unitRef="usd">19700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23314355e2005-wk-Fact-DD91337C9F7E65E2DE886B8C2FC3FE5F"
      unitRef="usd">19700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d23314355e2025-wk-Fact-399C5AC269023A2A6AEC6B8C2FC4AA20"
      unitRef="usd">2732000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d23314355e2044-wk-Fact-1D67C75E3B1429437BAD6B8C2FC067B2"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23314355e2063-wk-Fact-9E00E9139DD05FAD37426B8C2FBF39A1"
      unitRef="usd">2732000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d23314355e2094-wk-Fact-D580D6CD7D94DF3370F46B8C2FC40EAD"
      unitRef="usd">2732000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d23314355e2113-wk-Fact-1D79A78390BD13240B5B6B8C2FC08CC2"
      unitRef="usd">19700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23314355e2133-wk-Fact-3B0BB34B55C6B627376E6B8C2FC3E94B"
      unitRef="usd">22432000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d23314355e2151-wk-Fact-B5D3E785C08D618126B46B8C2FD2A10A"
      unitRef="usd">5000000.0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CF9A1CA51A25CC5ACF9D6B8C2FEE98CC-0-wk-Fact-B506949ED8563FDE56936B8C2FD34DE2">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.64327485380117%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair value as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Valuation Technique&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Range&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.6%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;75% - 78%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Projected year of payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021 - 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember"
      decimals="3"
      id="d23314355e2382-wk-Fact-CB7D08B2553A27760399F51F8FA959D6"
      unitRef="number">0.096</fold:ContingentConsiderationMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_fold_TB200PompeProgramMember"
      decimals="-3"
      id="d23314355e2403-wk-Fact-19B1EE601DCB5A352C066B8C2FBCCBF7"
      unitRef="usd">22390000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <fold:MilestonePaymentStockIssuedAsConsideration
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d23314355e2506-wk-Fact-AF81482B9D4E0B2F2D45F5281854A0A8"
      unitRef="usd">9000000.0</fold:MilestonePaymentStockIssuedAsConsideration>
    <fold:MilestonePaymentStockIssuedAsConsideration
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d23314355e2510-wk-Fact-C32C215E245092FE298CF95B1214C8DF"
      unitRef="usd">9300000</fold:MilestonePaymentStockIssuedAsConsideration>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-97FEA1D3A39BEA57B9A96B8C2FEE2581-0-wk-Fact-5521F2C6FC13058156266B8C2FD31206">&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table shows the change in the balance of contingent consideration payable for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Milestones payable, included in accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,297&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Adjustment for contingent consideration paid in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, end of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23314355e2658-wk-Fact-340DBEA618E28155AFBC6B8C2FC2551D"
      unitRef="usd">19700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d23314355e2677-wk-Fact-B992A0290929767D0F7B6B8C2FBDBC9A"
      unitRef="usd">25400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <fold:MilestonePayableAccruedDuringPeriod
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23314355e2697-wk-Fact-E20336D039B288BF7E676B8C2FC97609"
      unitRef="usd">0</fold:MilestonePayableAccruedDuringPeriod>
    <fold:MilestonePayableAccruedDuringPeriod
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23314355e2716-wk-Fact-0D4BA3A5007CA6E174646B8C2FC38E58"
      unitRef="usd">9000000</fold:MilestonePayableAccruedDuringPeriod>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23314355e2742-wk-Fact-FB99FB171B33B0504A336B8C2FAA9303"
      unitRef="usd">-3297000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23314355e2761-wk-Fact-5BF3B505984CD70519BF6B8C2FB42BBF"
      unitRef="usd">-3300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <fold:ContingentConsiderationPaidInStockAdjustment
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23314355e2786-wk-Fact-D166FC205994C7855A326B8C2FCB74A1"
      unitRef="usd">316000</fold:ContingentConsiderationPaidInStockAdjustment>
    <fold:ContingentConsiderationPaidInStockAdjustment
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23314355e2806-wk-Fact-59F9F037EA50D56CAC3D6B8C2FCADE89"
      unitRef="usd">0</fold:ContingentConsiderationPaidInStockAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23314355e2836-wk-Fact-B390ECC61D128FFEA65D6B8C2FC22B24"
      unitRef="usd">22681000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23314355e2855-wk-Fact-340DBEA618E28155AFBC6B8C2FC2551D"
      unitRef="usd">19700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F959C5629CEE77D28E886B8C2FEF52E7-0-wk-Fact-69054EA4CAD312C074C46B8C2FCC0C37">Debt &lt;div style="line-height:120%;text-align:left;padding-left:37px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Senior Secured Term Loan due 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2018, the Company entered into a loan agreement with BioPharma Credit PLC as the lender. The loan agreement provides for a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; senior secured term loan ("Senior Secured Term Loan") with an interest rate equal to the 3-month LIBOR plus &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum and matures in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the maturity date. The Senior Secured Term Loan will be repaid in four quarterly payments equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; thereof starting on the forty-eight month anniversary of the date of the first credit extension with the balance due on the Maturity Date. Interest is payable quarterly in arrears. The Senior Secured Term Loan contains certain customary representations and warranties, affirmative and negative covenants, and events of default applicable to the Company and certain of its subsidiaries but does not include any financial covenants relating to the achievement or maintenance of revenue or cash flow. If an event of default occurs and is continuing, the lender may declare all amounts outstanding under the Senior Secured Term Loan to be immediately due and payable. The Company received net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$146.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in September 2018, after deducting fees and estimated expenses&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#661de7;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:37px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Convertible Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2016, the Company issued at par value &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; aggregate principal amount of Convertible Notes, which included the exercise in full of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; over-allotment option granted to the initial purchasers of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act (the "Note Offering"). Interest is payable semiannually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Convertible Notes are convertible at the option of the Holders, under certain circumstances and during certain periods, into cash, shares of the Company&#x2019;s common stock or a combination thereof. The net proceeds from the Note Offering were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$243.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, after deducting fees and estimated expenses. In addition, the Company used approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The Convertible Notes were initially convertible into approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock under certain circumstances prior to maturity at a conversion rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;163.3987&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share of common stock, subject to adjustment under certain conditions. Holders may convert their Convertible Notes at their option at specified times prior to the maturity date of December 15, 2023, only if: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;during any fiscal quarter commencing after March 31, 2017, if the last reported sale price of the Company&#x2019;s common stock for at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; trading days in the period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is equal to or more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the conversion price of the Convertible Notes on the last day of such preceding fiscal quarter; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;a holder submits its Convertible Notes for conversion during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business day period following any five consecutive trading day period in which the trading price for the Convertible Notes, per $1,000 principal amount of the Convertible Notes, for each such trading day was less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;98%&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the product of the last reported sale price of the Company&#x2019;s common stock and the conversion rate of the Convertible Notes on such date; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the Company issues to all or substantially all of the holders of common stock rights options or warrants entitling then them for a period of not more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; calendar days after the date of such issuance to subscribe for or purchase shares of the common stock, at a price per share less than the average of the Last Reported Sale Prices of the common stock for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance or distributes to all or substantially all holders of the common stock the Company&#x2019;s assets, debt securities or rights to purchase the Company&#x2019;s securities which distribution has a per share value of exceeding &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the Last Reported Sale Price of the common stock on the Trading Day immediately preceding the date of announcement of such distribution; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the Company enters into specified corporate transactions; or &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the Company has had a call for redemption, the holder can convert up until the second trading day immediately preceding the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Convertible Notes will be convertible, at the option of the note holders, regardless of whether any of the foregoing conditions have been satisfied, on or after September 15, 2023 at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date of December 15, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February 15, 2018, the Company entered into an underwriting agreement relating to an underwritten public offering of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock. Under the terms of the underwriting agreement, the Company granted the underwriters an option, exercisable for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days after February 16, 2018, to purchase up to an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock, which was exercised with respect to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;885,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:3px;text-align:justify;padding-left:8px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Subsequent to the underwritten public offering on February 15, 2018, the Company did not have sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the Company accounted for the portion of the bifurcated conversion feature and of the Capped Call Confirmations that would not be able to be net share settled as a current derivative liability and as a derivative asset, respectively. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at February 15, 2018 was determined to be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$507.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of which the portion that was determined to not be able to be net share settled was recorded with a corresponding impact to additional-paid-in-capital. Subsequent changes to fair value of the derivatives were recorded in the second quarter of 2018 through earnings on the Company&#x2019;s Consolidated Statements of Operations resulting in a change in fair value of derivatives for the year ended December 31, 2018 of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Following the approval by the stockholders of the Company on June 7, 2018, to increase the authorized shares of common stock to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;500,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the derivative liability and derivative asset were reclassified into additional-paid-in-capital. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at June 7, 2018 was determined to be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$88.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Capped Call Confirmations were expected generally to reduce the potential dilution to the common stock upon any conversion of the Convertible Notes and/or offset the cash payments the Company is required to make in excess of the principal amount upon conversion of the Convertible Notes in the event that the market price of the common stock was greater than the strike price of the Capped Call Confirmations (which initially corresponded to the initial conversion price of the Convertible Notes and is subject to certain adjustments under the terms of the Capped Call Confirmations), with such reduction and/or offset subject to a cap based on the cap price of the Capped Call Confirmations. The Capped Call Confirmations had an initial cap price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, which represented a premium of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; over the closing price of the Company&#x2019;s common stock on The NASDAQ Global Market on December 15, 2016 and was subject to certain adjustments under the terms of the Capped Call Confirmations. The Capped Call Confirmations covered, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes, the number of shares of common stock that underlay the Convertible Notes. The Capped Call Confirmations did not meet the criteria for separate accounting as a derivative as they were indexed to the Company&#x2019;s common stock. The premiums paid for the Capped Call Confirmations were included as a net reduction to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the first and second quarters of 2019, the Company entered into separate, privately negotiated Exchange Agreements with the Holders of the Convertible Notes. Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$247.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of Convertible Notes held by them in exchange for an aggregate of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of Company common stock, par value &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.01&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. In addition, pursuant to the Exchange Agreements, the Company made aggregate cash payments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the Holders to satisfy accrued and unpaid interest to the closing date of the transactions, along with cash in lieu of fractional shares. These transactions resulted in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$215.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in additional paid-in-capital and common stock of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the Consolidated Balance Sheets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Additionally, the Company recognized a net loss on the exchange of debt of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the Consolidated Statements of Operations during the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. During the second half of the year there were no additional debt conversion transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the first and second quarter of 2019, the Company terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for proceeds of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The last reported sale price of the Company&#x2019;s common stock was equal to or more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the conversion price of the Convertible Notes for at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; trading days of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days ending on the last day of the year. As a result, the Convertible Notes are currently convertible into the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:41px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Convertible Notes and Senior Secured Term Loan consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;152,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;400,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: debt discount &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,974&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(74,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net carrying value of the debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;149,505&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;321,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(1)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Included in the Consolidated Balance Sheets within Convertible Notes and Senior Secured Term Loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth interest expense recognized related to the Convertible Notes and Senior Secured Term Loan for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contractual interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;555&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective interest rate of the liability component, Convertible debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective interest rate of the liability component, Senior Secured Term Loan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="FI2018Q3_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d23313844e718-wk-Fact-FF6D70C0EE2C4790FC796B8C2FCC46C8"
      unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember"
      decimals="INF"
      id="d23313844e722-wk-Fact-DB8503C1C233442235606B8C2FCBE52A"
      unitRef="number">0.0750</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm
      contextRef="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember"
      id="d23313844e726-wk-Fact-22E1D6353C7B389F25CC6B8C2FC53B37">P5Y</us-gaap:DebtInstrumentTerm>
    <fold:DebtInstrumentPeriodicPaymentPrincipalPercentage
      contextRef="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="d23313844e730-wk-Fact-E6DAAB3F7AF9B9D4B9A46B8C2FC59FDE"
      unitRef="number">0.1250</fold:DebtInstrumentPeriodicPaymentPrincipalPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="D2018Q3Sep01-Sep30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d23313844e734-wk-Fact-F9D0EBDE2026DB1AEB816B8C2FCD11CB"
      unitRef="usd">146600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d23313844e751-wk-Fact-1A5BCD6FA61C935D35E46B8C2FC51676"
      unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember"
      decimals="INF"
      id="d23313844e755-wk-Fact-F738263E3F0B3159DE6F6B8C2FCA4CE5"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d23313844e759-wk-Fact-AFBDABC2B472827081366B8C2FC9F17B"
      unitRef="usd">243000000.0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <fold:PremiumsPaidForCappedCallConfirmations
      contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d23313844e763-wk-Fact-5B83B787931E7F6199DE6B8C2FC6D869"
      unitRef="usd">13500000</fold:PremiumsPaidForCappedCallConfirmations>
    <fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt
      contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d23313844e767-wk-Fact-654A998EAA6953265B3F6B8C2FC9B725"
      unitRef="shares">40800000</fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d23313844e776-wk-Fact-070D28372E735840193C6B8C2FC85BCB"
      unitRef="usdPerShare">6.12</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <fold:DebtInstrumentsConvertibleThresholdTradingDays
      contextRef="D2016Q4Dec01-Dec31_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      id="d23313844e789-wk-Fact-614A79F9919D1D48570C6B8C2FBCBD82">P20D</fold:DebtInstrumentsConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d23313844e793-wk-Fact-069AD8890E4E550C5D886B8C2FCF8CEB"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d23313844e797-wk-Fact-7CC5796764790349B7BC6B8C2FCBE7A8"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <fold:DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice
      contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      id="d23313844e824-wk-Fact-FBA1D3CE298256109EC56B8C2FCD68B4">P60D</fold:DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice>
    <fold:DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice
      contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      id="d23313844e828-wk-Fact-5FA0E637AD8AA7E2C96B6B8C2FCDC424">P10D</fold:DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice>
    <fold:DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent
      contextRef="D2016Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d23313844e832-wk-Fact-58B14D407CDD41D50F546B8C2FCEEE00"
      unitRef="number">0.10</fold:DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2018Q1Feb15-Feb15_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23313844e858-wk-Fact-B150AE12010A6F0E7FA16B8C2FC359A7"
      unitRef="shares">19400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <fold:NumberOfDaysGrantedUnderwritersForPurchaseOfShares
      contextRef="D2018Q1Feb15-Feb15_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      id="d23313844e862-wk-Fact-59D98E3469E8BE2D03CE6B8C2FCA52B0">P30D</fold:NumberOfDaysGrantedUnderwritersForPurchaseOfShares>
    <fold:MaximumNumberOfAdditionalSharesGrantedToUnderwriters
      contextRef="D2018Q1Feb16-Feb16_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="d23313844e866-wk-Fact-C01297DCB725BB446E936B8C2FCE0514"
      unitRef="shares">2900000</fold:MaximumNumberOfAdditionalSharesGrantedToUnderwriters>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2018Q1Feb16-Feb16_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d23313844e870-wk-Fact-3E0A8567ECF286FC65ED6B8C2FCC77D2"
      unitRef="shares">885000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="I2018Q1Feb15"
      decimals="-5"
      id="d23313844e879-wk-Fact-4982F8077A63ED61CD736B8C2FD42960"
      unitRef="usd">507400000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="I2018Q1Feb15"
      decimals="-5"
      id="d23313844e883-wk-Fact-2585A1F718CCFBACDC896B8C2FC83DB1"
      unitRef="usd">13600000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d23313844e887-wk-Fact-382F5C639B319DEE9E736B8C2FCB4C69"
      unitRef="usd">2700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="I2018Q2Jun07"
      decimals="INF"
      id="d23313844e896-wk-Fact-7AAFD508B95F463B58AD6B8C2FCE79B3"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="I2018Q2Jun07"
      decimals="-5"
      id="d23313844e900-wk-Fact-A300EF905825F6AFED656B8C2FC81FB5"
      unitRef="usd">88300000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="I2018Q2Jun07_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d23313844e904-wk-Fact-189ABE58A2CCA97034FA6B8C2FCFE7FD"
      unitRef="usd">2400000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <fold:DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember"
      decimals="2"
      id="d23313844e914-wk-Fact-5497BD2CA820CA3F29CCFE284125C2E6"
      unitRef="usdPerShare">7.20</fold:DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare>
    <fold:DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage
      contextRef="FD2019Q4YTD_us-gaap_FinancialInstrumentAxis_fold_CommonStockCappedCallConfirmationMember"
      decimals="INF"
      id="d23313844e918-wk-Fact-10A394F1D0D24A663F9EFE28B0DAFBF5"
      unitRef="number">0.50</fold:DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount
      contextRef="FI2019Q2"
      decimals="-5"
      id="d23313844e927-wk-Fact-B45190F1751000600DA8F95C3C463827"
      unitRef="usd">247200000</fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance
      contextRef="FI2019Q2"
      decimals="-5"
      id="d23313844e931-wk-Fact-91BBA8E21CAD8952E731F95CB2CEF06C"
      unitRef="shares">44000000.0</fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q2"
      decimals="INF"
      id="d23313844e935-wk-Fact-209D73E792B95831DFADF95D06B1901E"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d23313844e939-wk-Fact-1F5B7A94737DEA358528F5408D3044B5"
      unitRef="usd">1300000</fold:DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest>
    <fold:GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23313844e943-wk-Fact-396C28C1E94507BF0BF2F5411D5F65DD"
      unitRef="usd">215000000.0</fold:GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital>
    <fold:GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23313844e948-wk-Fact-5094DDD0E163A65FFBDAF540DD195F5A"
      unitRef="usd">400000</fold:GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23313844e956-wk-Fact-8A097E423BA39BB400C8F540FC57069F"
      unitRef="usd">-40600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d23313844e969-wk-Fact-D99DFD97B7D3360AB9D9FE28DEDC64DB"
      unitRef="usd">19900000</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d23313844e978-wk-Fact-82A399D0A8222FC4D6E06B8C2FCC4948"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <fold:DebtInstrumentsConvertibleThresholdTradingDays
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      id="d23313844e982-wk-Fact-A4E71847A9CC1F90FFB66B8C2FCBB2EE">P20D</fold:DebtInstrumentsConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d23313844e986-wk-Fact-DE8AD1F5AB7B094D94806B8C2FC5B348"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-65A3CE65A60D02E674BA6B8C2FEE2141-0-wk-Fact-BD7B287089297DB84E946B8C2FCAB8AF">&lt;div style="line-height:120%;text-align:left;padding-left:41px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Convertible Notes and Senior Secured Term Loan consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;152,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;400,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: debt discount &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,974&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(74,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net carrying value of the debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;149,505&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;321,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(1)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Included in the Consolidated Balance Sheets within Convertible Notes and Senior Secured Term Loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1124-wk-Fact-24DCFBA222D6DDC5331A6B8C2FDAB7F0"
      unitRef="usd">152825000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1143-wk-Fact-A49155D3D83F7E5189616B8C2FC6D58B"
      unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1165-wk-Fact-31776D97A1480C350A3B6B8C2FD4FD9F"
      unitRef="usd">2974000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1185-wk-Fact-AED4C09B57A701EFCE576B8C2F5D45C5"
      unitRef="usd">74145000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1213-wk-Fact-79271BE2087D91BC98256B8C2FCC81E8"
      unitRef="usd">346000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1233-wk-Fact-99CFDF4B33B0F91109976B8C2F769919"
      unitRef="usd">4115000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1264-wk-Fact-5BD150A78593854B7C036B8C2F7C736A"
      unitRef="usd">149505000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1283-wk-Fact-F9F1A4D99F1CC2367ED36B8C2F86AA44"
      unitRef="usd">321740000</us-gaap:LongTermDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-91166D466E18071C97436B8C2FEE5795-0-wk-Fact-4EBF939F978E8DDC6D8E6B8C2FAAAA73">&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth interest expense recognized related to the Convertible Notes and Senior Secured Term Loan for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contractual interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;555&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective interest rate of the liability component, Convertible debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective interest rate of the liability component, Senior Secured Term Loan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1401-wk-Fact-B633F20151B0B7E934176B8C2F8DA90A"
      unitRef="usd">16483000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1420-wk-Fact-57F52E083651E7343AF76B8C2F8E6824"
      unitRef="usd">11426000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1445-wk-Fact-F4AA3E25AED1F831FA35F558D4DDC44C"
      unitRef="usd">2381000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1464-wk-Fact-96CE3492C9F6A083E60DF558D49D26D3"
      unitRef="usd">10421000</us-gaap:AmortizationOfDebtDiscountPremium>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1489-wk-Fact-95022225BC69EB35C0C86B8C2FC6B90F"
      unitRef="usd">165000</fold:AmortizationDeferredFinancingCosts>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d23313844e1508-wk-Fact-6BF9AE3DDB2FBAD9C9D86B8C2F8DAA82"
      unitRef="usd">555000</fold:AmortizationDeferredFinancingCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="4"
      id="d23313844e1528-wk-Fact-BB3F118589D2FDE468496B8C2FC688E1"
      unitRef="number">0.1063</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="4"
      id="d23313844e1548-wk-Fact-B765D77ABDB679D3E5CA6B8C2F8ED761"
      unitRef="number">0.1085</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="4"
      id="d23313844e1574-wk-Fact-2C7F977DA607F957B1B46B8C2F8DF43A"
      unitRef="number">0.1016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="4"
      id="d23313844e1594-wk-Fact-1CBA799669C39AF5A4076B8C2F8FB7B2"
      unitRef="number">0.1048</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9BEBABECF6BAC46825B16B8C2FEF8841-0-wk-Fact-FDB0339FECC693E5F66B6B8C2FD1A2A1">Leases&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company currently has operating leases for office and research laboratory space, equipment, and vehicles under agreements expiring at various dates through 2044, which include renewal options on leases which the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, operating lease expense was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company paid &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for amounts included in the measurement of operating lease liabilities and recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$21.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of&#160;right-of-use assets and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of tenant improvements paid through lease incentives in exchange for new operating lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commitments under finance leases are not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental balance sheet information related to operating leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.270955165692%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands, except year and discount rate amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease ROU asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current portion of the operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-current portion of the operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average remaining lease terms (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the future minimum operating lease payments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.22807017543859%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,787&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;163,266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;215,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less lease incentives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(28,939&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Less imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(125,982&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the future minimum operating lease payments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.64327485380117%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,560&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,611&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,887&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Rent expense, including fees for utilities and common area maintenances under ASC 840 for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23310740e728-wk-Fact-2C1E1A67EF2F266F1A1EF5820B5A4DC1"
      unitRef="usd">10800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23310740e736-wk-Fact-CDFBD572792F40DF533DF58597568EE9"
      unitRef="usd">4900000</us-gaap:OperatingLeaseCost>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23310740e740-wk-Fact-F63CD3F91A2157E56376F58628C0D2FA"
      unitRef="usd">21800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23310740e745-wk-Fact-7A8F1CC741F0352DDED95E4386412FDB"
      unitRef="usd">19400000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A543583BC7CCFC50A412F11A0EF14EC5-0-wk-Fact-1C5B981E8951A61A6B0DF11A45D68C19">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental balance sheet information related to operating leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.270955165692%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands, except year and discount rate amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease ROU asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current portion of the operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-current portion of the operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average remaining lease terms (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e812-wk-Fact-4BD6B73A59B6BF695169F646B8B5F75E"
      unitRef="usd">33315000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e863-wk-Fact-EE5C5AABDF3F3EA76797F04F5FF883CB"
      unitRef="usd">7189000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e883-wk-Fact-27EEB08844CA532CFF47F051C35D6512"
      unitRef="usd">53531000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e913-wk-Fact-92260A302B4863A3D563F12FFDA892AC"
      unitRef="usd">60720000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q4"
      id="d23310740e959-wk-Fact-7D97FD268F4F05DE5AFBF12FFED0ED72">P18Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q4"
      decimals="3"
      id="d23310740e984-wk-Fact-6779B3EDECC548CC76A6F13000883DCD"
      unitRef="number">0.131</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D3FC531F0F6DA798EC50F11D3821DC08-0-wk-Fact-25D54E1B374D29E9D9ABF11D7103272B">&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the future minimum operating lease payments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.22807017543859%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,787&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;163,266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;215,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less lease incentives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(28,939&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Less imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(125,982&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e1065-wk-Fact-591FBE268DBA647D41D5F13193B50A99"
      unitRef="usd">9738000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e1085-wk-Fact-AB6E9B99A110471BADCEF1319461F873"
      unitRef="usd">10787000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e1110-wk-Fact-81BAD9407374C6757E17F13195030868"
      unitRef="usd">10459000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e1135-wk-Fact-A1B02EB6AFFA835280E2F13195AC74FC"
      unitRef="usd">10809000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e1160-wk-Fact-9F141E82640B9AA6C329F131967D4107"
      unitRef="usd">10582000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e1185-wk-Fact-E50DD1740E38C0C8BFE4F131974744BB"
      unitRef="usd">163266000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e1210-wk-Fact-5DD7018D8FA4A3855DA7F1319860F344"
      unitRef="usd">215641000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e1235-wk-Fact-3A0CD3ACD441D14DCF71F13199CC8FAE"
      unitRef="usd">28939000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <fold:LesseeOperatingLeaseLiabilityTenantIncentives
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e1261-wk-Fact-70C93D3BE79A79F6D9AC7881F867184F"
      unitRef="usd">125982000</fold:LesseeOperatingLeaseLiabilityTenantIncentives>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23310740e1292-wk-Fact-92260A302B4863A3D563F12FFDA892AC"
      unitRef="usd">60720000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-25093EA098ABF712041F6B8C2FEFB829-0-wk-Fact-B43E3320C99BF7745A656B8C2FCBBE62">&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the future minimum operating lease payments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.64327485380117%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,560&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,611&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,887&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23310740e1367-wk-Fact-73D409374FA0CC967FD9F128C84B1614"
      unitRef="usd">6244000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23310740e1387-wk-Fact-2A97566038DAD5A155B6F128DA6A916E"
      unitRef="usd">4063000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23310740e1412-wk-Fact-A9C9398B779ABA0F3319F128E7BB9DB4"
      unitRef="usd">3560000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23310740e1437-wk-Fact-1723A298EF75122D5B59F12900796ED3"
      unitRef="usd">3371000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23310740e1462-wk-Fact-02B2FFB3F7339C92583DF12947D5C0F8"
      unitRef="usd">3611000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23310740e1487-wk-Fact-AF2EE63D3DE760C13D6FF1298A823CB1"
      unitRef="usd">10038000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23310740e1517-wk-Fact-27BE5FEC2F3FF19B55FBF129EA73D302"
      unitRef="usd">30887000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d23310740e1538-wk-Fact-2BD4BE44BD0445A1A8686B8C2FCD7E2E"
      unitRef="usd">5700000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d23310740e1542-wk-Fact-2848F407D0CABB88D4E36B8C2FD65D1C"
      unitRef="usd">3900000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-65F2DCD53CF91B74D4EA6B8C2FF0FEE0-0-wk-Fact-16DA4D35CA075587B05D6B8C2FD551A5">Income Taxes&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For financial reporting purposes, income (loss) before income taxes includes the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(393,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(309,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(440,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(39,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(355,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(349,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(449,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Following were the components of income tax expense (benefit) for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,877&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(150,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17,389&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(165,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the statutory tax rates and the effective tax rates for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nondeductible IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign income tax rate differential&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Impact of 2017 Act&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nondeductible debt conversion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December&#160;22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASC 740, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the Tax Act's provisions, the SEC staff issued SAB&#160;118, which allows companies to record the tax effects of the Tax Act on a provisional basis based on a reasonable estimate, and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available. The measurement period ends when a company has obtained, prepared, and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from enactment. The Tax Act did not have a material impact on the Company's financial statements because its deferred temporary differences are fully offset by a valuation allowance. The Company did not have any significant offshore earnings from which to record the mandatory transition tax. During 2018 the Company operated in a consolidated loss position in its foreign operations and did not have a one-time tax on accumulated earnings of foreign subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2017, the Company provisionally recorded certain impacts of the Tax Act including the adjustment to our net deferred tax liability arising from the reduction in the federal tax rate as well as the impact of mandatory deemed repatriation. Adjustments to these provisional amounts that we recorded in 2018 did not have a significant impact on the Company's Consolidated Financial Statements. The Company's accounting for the effects of the enactment of the Tax Act are now complete.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recorded an income tax expense of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in 2019 for taxes in foreign jurisdictions and a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; tax benefit in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for taxes in U.S. federal and state jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company did not recognize interest or penalties related to income tax during the period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and did &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;t accrue for interest or penalties as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company does &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;t have an accrual for uncertain tax positions as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Tax returns for years 2015 through 2018 are open to examination by tax authorities. The Company is also subject to examination in any period for which it has net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For Years Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intellectual property&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization/depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research tax credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;141,669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96,509&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;286,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;248,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred reimbursement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-cash stock issue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest carry forward limitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;516,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;430,113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Business acquisition&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Royalty payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(46,521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(48,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16,666&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Advanced R&amp;amp;D payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,611&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;461,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;356,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(466,357&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(363,005&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded valuation allowances of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$466.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$363.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, representing an increase in the valuation allowance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$103.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;amp;D that may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had federal, state, and foreign net operating loss carry forwards ("NOLs") of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,036 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$897.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$30.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the 2017 Tax Act.&#160;Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; will expire in 2029 through 2039. The foreign NOLs are subject to differing expirations beginning in 2026. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended ( the "Code") as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past and could occur again in the future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership some of which are outside our control. We completed a detailed study of our NOLs and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on our ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company also has research and experimentation and orphan drug credit carryforwards of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$114.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, which will expire in the years 2021 through 2039. Deferred tax assets for these carryforwards are subject to a full valuation allowance.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-771DFF68B38622C834CF6B8C2FEFEA06-0-wk-Fact-985F98D9CF548B9883EC6B8C2FD5EEBC">&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For financial reporting purposes, income (loss) before income taxes includes the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(393,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(309,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(440,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(39,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(355,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(349,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(449,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321069e890-wk-Fact-1B62C5856E55328328816B8C2FC97DDE"
      unitRef="usd">-393955000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321069e910-wk-Fact-8B0AE47788918F08CACD6B8C2FD1BE99"
      unitRef="usd">-309183000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321069e931-wk-Fact-D0C3B7C2B914CE0D273D6B8C2FD1DE3A"
      unitRef="usd">-440696000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321069e952-wk-Fact-932DAB2A1D500F07D5F86B8C2FCF5C1E"
      unitRef="usd">38045000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321069e971-wk-Fact-B90A662EF7133EEC0A8B6B8C2FCB59FB"
      unitRef="usd">-39906000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321069e991-wk-Fact-BE264FA86A2454CC262E6B8C2FCDC0DE"
      unitRef="usd">-8425000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321069e1023-wk-Fact-39CB3DA7D0A5C09EE4246B8C2FAA0F9E"
      unitRef="usd">-355910000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321069e1043-wk-Fact-815848D01C88BA2101DF6B8C2FA91CFB"
      unitRef="usd">-349089000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321069e1064-wk-Fact-5152D2C671953CAC01836B8C2FB75F3C"
      unitRef="usd">-449121000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-698CDBEFF926BED040EA6B8C2FF0DA4E-0-wk-Fact-47B4792A80FE22F167F16B8C2FD702F8">&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Following were the components of income tax expense (benefit) for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,877&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(150,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17,389&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(165,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321069e1268-wk-Fact-3017EF3DD467528D67AF6B8C2FDBCB48"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321069e1287-wk-Fact-6C2D8462C980510AC0566B8C2FDCE563"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321069e1307-wk-Fact-CB91E7F12EA4CB174C106B8C2FD545BD"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321069e1327-wk-Fact-50B90BCB2AFD53BFB66D6B8C2FD682B4"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321069e1346-wk-Fact-E1693786881D256DA3FA6B8C2F5B3EE5"
      unitRef="usd">6000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321069e1365-wk-Fact-BB8CECA721E3E6027B126B8C2FD841D2"
      unitRef="usd">9000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321069e1391-wk-Fact-DBADAC90D2EC97FDAD926B8C2F5E017F"
      unitRef="usd">2877000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321069e1410-wk-Fact-1C1DD8ABDEFDD908660C6B8C2FDF0EAB"
      unitRef="usd">-100000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321069e1430-wk-Fact-CD86F9F4B51EC5932EF06B8C2FD4675E"
      unitRef="usd">2276000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321069e1523-wk-Fact-F333304494EAD4D897EE6B8C2FD38244"
      unitRef="usd">-984000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321069e1543-wk-Fact-89FF48B82C2CA89C73886B8C2FD7FB6B"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321069e1562-wk-Fact-B215553E2FCCBF8A6AF26B8C2FD922BB"
      unitRef="usd">-150015000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321069e1589-wk-Fact-15848181ADC01F902A1C6B8C2FD52239"
      unitRef="usd">-1415000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321069e1609-wk-Fact-7D11EC0D3A1915066F166B8C2FDA8E08"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321069e1628-wk-Fact-EA38FC150B6EF7F2FF5B6B8C2FD37F16"
      unitRef="usd">-17389000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321069e1655-wk-Fact-0C3143F67700DA4E00C66B8C2FDB0965"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321069e1674-wk-Fact-2E3194BADBBB0BF1202A6B8C2FD2FA1D"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321069e1693-wk-Fact-48C7A957E9810B44842D6B8C2FD10E61"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23321069e1724-wk-Fact-3855EEFA4DD61B26A72F6B8C2FB86431"
      unitRef="usd">478000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23321069e1743-wk-Fact-CECB6F05ED5CE81CFF1C6B8C2FAEB61F"
      unitRef="usd">-94000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23321069e1764-wk-Fact-741CBE90FE3A6560C1116B8C2FAF165A"
      unitRef="usd">-165119000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0DA40F01E329828AAF426B8C2FEF3BDD-0-wk-Fact-A222ECB5C7730250D4DC6B8C2FDCEFE0">&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the statutory tax rates and the effective tax rates for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nondeductible IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign income tax rate differential&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Impact of 2017 Act&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nondeductible debt conversion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d23321069e1928-wk-Fact-AA8D933C503D7D7165636B8C2FD4A315"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d23321069e1943-wk-Fact-561B46DF8FA1E7FED5E66B8C2FCFB688"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="d23321069e1958-wk-Fact-96B79A3A3C4965C6A0276B8C2FC64480"
      unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23321069e1979-wk-Fact-164FD407967FBCA3DD686B8C2FD28581"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23321069e1993-wk-Fact-3FD17995448F7480EA9D6B8C2FCD40A9"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23321069e2008-wk-Fact-7C20802DC01281574AF26B8C2FC7E5F2"
      unitRef="number">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23321069e2029-wk-Fact-8F7E3CFFA94DF87F3FE06B8C2FC490C6"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23321069e2043-wk-Fact-4FA00169E143BF5391EB6B8C2FC363D1"
      unitRef="number">-0.06</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23321069e2057-wk-Fact-415DE3AFDD493DDEFB686B8C2FD01458"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23321069e2078-wk-Fact-67ECD3733E5D98D402076B8C2FCB709C"
      unitRef="number">0</fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration>
    <fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23321069e2092-wk-Fact-788C06563B436D5D60F56B8C2FCFF233"
      unitRef="number">-0.01</fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration>
    <fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23321069e2106-wk-Fact-16AE9D2876599208D8D86B8C2FC9308D"
      unitRef="number">0.18</fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23321069e2127-wk-Fact-7D440115F0147CB9A7F46B8C2FD37B00"
      unitRef="number">-0.16</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23321069e2142-wk-Fact-AD6D85479F5FED16961F6B8C2F5E52DA"
      unitRef="number">-0.10</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23321069e2157-wk-Fact-D02D0036049D0B857DA96B8C2F5B11A2"
      unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23321069e2178-wk-Fact-2CFBEB4DCC5752AD46086B8C2FCA315D"
      unitRef="number">-0.09</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23321069e2192-wk-Fact-6E3E3F30BDC57F643AD36B8C2FD10007"
      unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23321069e2206-wk-Fact-76C2D18A6D13ECC997A56B8C2FC56659"
      unitRef="number">-0.05</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <fold:EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23321069e2226-wk-Fact-85FB580CF826B39C80466B8C2FCC87E7"
      unitRef="number">0</fold:EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent>
    <fold:EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23321069e2240-wk-Fact-FE60471FEF74411B8D946B8C2FCE6667"
      unitRef="number">0</fold:EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent>
    <fold:EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23321069e2254-wk-Fact-F75F5F279AB3842549066B8C2FD022AE"
      unitRef="number">-0.27</fold:EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent>
    <fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23321069e2274-wk-Fact-1FCC5BDCC1952E3BE704806C4173AFE3"
      unitRef="number">0.01</fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion>
    <fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23321069e2289-wk-Fact-688BF567C2646EDAD639806C4168A472"
      unitRef="number">0</fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion>
    <fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23321069e2303-wk-Fact-A34EEB2C5B9F045F0F89806C417EF5C8"
      unitRef="number">0</fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23321069e2323-wk-Fact-882E73CA7F560274E3066B8C2FCA19D6"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23321069e2337-wk-Fact-27340BF2D1ACFC4BCB206B8C2FD65A3E"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23321069e2351-wk-Fact-07C09D60DC4DC21E93B76B8C2FC69DD0"
      unitRef="number">-0.05</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23321069e2372-wk-Fact-4D3F7D15C65F60EADF7D6B8C2FC77390"
      unitRef="number">-0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23321069e2386-wk-Fact-D6422EC00323B691969D6B8C2FC89FB5"
      unitRef="number">-0.26</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23321069e2400-wk-Fact-12F92DFE772AF0C93E2A6B8C2FC9D518"
      unitRef="number">0.14</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d23321069e2421-wk-Fact-7B7933CF781616BCA3846B8C2FC89D1A"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d23321069e2436-wk-Fact-34F69AA6AD377C39C8AC6B8C2FCEDDE8"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d23321069e2451-wk-Fact-A0D3CAA093EF1472D29C6B8C2FD51D25"
      unitRef="number">0.37</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="D2017Q4Dec22-Dec22"
      decimals="INF"
      id="d23321069e2465-wk-Fact-33E7A91CB3328DEE01746B8C2FD90E91"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23321069e2485-wk-Fact-D83C88EBB3E6BADEBCAC806D686FF67A"
      unitRef="usd">2900000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23321069e2489-wk-Fact-1637E1A3A2B5DF3468835B1107EF58C6"
      unitRef="usd">-2400000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="FI2019Q4"
      decimals="0"
      id="d23321069e2504-wk-Fact-539A8AA3AF92ACCCD7266B8C2FD5A00D"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d23321069e2512-wk-Fact-C154AE221CAF6FD46CB66B8C2FDB8126"
      unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F1B00804A46C6642C9D76B8C2FF08723-0-wk-Fact-63A77C6A554A8726F1E96B8C2FDC9723">The significant components of the deferred tax assets and liabilities are as follows:&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For Years Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intellectual property&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization/depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research tax credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;141,669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96,509&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;286,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;248,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred reimbursement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-cash stock issue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest carry forward limitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;516,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;430,113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Business acquisition&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Royalty payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(46,521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(48,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16,666&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Advanced R&amp;amp;D payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,611&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;461,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;356,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(466,357&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(363,005&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <fold:DeferredTaxAssetsIntellectualProperty
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e2702-wk-Fact-771D2CDFCE34CC0AC0606B8C2F73CBE9"
      unitRef="usd">46521000</fold:DeferredTaxAssetsIntellectualProperty>
    <fold:DeferredTaxAssetsIntellectualProperty
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e2721-wk-Fact-7AB49B04AEB9AC387DE16B8C2F713AA9"
      unitRef="usd">48339000</fold:DeferredTaxAssetsIntellectualProperty>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e2741-wk-Fact-950FDD1C1EE4E7389CC66B8C2F702ADD"
      unitRef="usd">2329000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e2760-wk-Fact-915D6DC834273BF367F86B8C2F72FA30"
      unitRef="usd">3732000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e2785-wk-Fact-8D965747E3F38262C59D6B8C2F6E870E"
      unitRef="usd">141669000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e2804-wk-Fact-E27AC989C5FB9A9D8F1A6B8C2F716E4E"
      unitRef="usd">96509000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e2829-wk-Fact-76AD0CD7000D695A7EA76B8C2F717666"
      unitRef="usd">286850000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e2848-wk-Fact-4BDFB5A080BCD05C48836B8C2F6E4118"
      unitRef="usd">248398000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e2873-wk-Fact-50349FE870E9C5CB95746B8C2F6C3D2F"
      unitRef="usd">2230000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e2892-wk-Fact-4D676B30ECD5F6FF4F066B8C2F692AA1"
      unitRef="usd">4401000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <fold:DeferredTaxAssetsNonCashStockIssueNonCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e2917-wk-Fact-6E3FB4479B4A22F6CD0F6B8C2F705F6E"
      unitRef="usd">19058000</fold:DeferredTaxAssetsNonCashStockIssueNonCurrent>
    <fold:DeferredTaxAssetsNonCashStockIssueNonCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e2936-wk-Fact-1E0E903D7A04E69D55A26B8C2F6E0E1A"
      unitRef="usd">16850000</fold:DeferredTaxAssetsNonCashStockIssueNonCurrent>
    <fold:DeferredTaxAssetsInterestCarryforwardLimitation
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e2961-wk-Fact-0F35B586F2FC4A5519A86B8C2F70576D"
      unitRef="usd">2224000</fold:DeferredTaxAssetsInterestCarryforwardLimitation>
    <fold:DeferredTaxAssetsInterestCarryforwardLimitation
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e2980-wk-Fact-98D49B3AEBF4B7BDC6DC6B8C2F6D639F"
      unitRef="usd">1032000</fold:DeferredTaxAssetsInterestCarryforwardLimitation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e3005-wk-Fact-3F7781D712A988179C736B8C2F6EE5E0"
      unitRef="usd">15986000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e3024-wk-Fact-3CF879BE61D241C968FE6B8C2F73846D"
      unitRef="usd">10852000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e3050-wk-Fact-7C672B227C93287DA1826B8C2F69B385"
      unitRef="usd">516867000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e3069-wk-Fact-E4B1427FF2855D9AC6E86B8C2F702768"
      unitRef="usd">430113000</us-gaap:DeferredTaxAssetsGross>
    <fold:DeferredTaxLiabilitiesBusinessAcquisition
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e3140-wk-Fact-B68C0F160AC9B55A4C526B8C2F702690"
      unitRef="usd">5051000</fold:DeferredTaxLiabilitiesBusinessAcquisition>
    <fold:DeferredTaxLiabilitiesBusinessAcquisition
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e3160-wk-Fact-8A9D7B8D0E07FC0B6C656B8C2F6DB123"
      unitRef="usd">6465000</fold:DeferredTaxLiabilitiesBusinessAcquisition>
    <fold:DeferredTaxLiabilitiesRoyaltyPayable
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e3186-wk-Fact-00C3B260231CE4B058D86B8C2F6AAEAF"
      unitRef="usd">46521000</fold:DeferredTaxLiabilitiesRoyaltyPayable>
    <fold:DeferredTaxLiabilitiesRoyaltyPayable
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e3206-wk-Fact-46CA7336BAB2A5172E006B8C2F6F41A3"
      unitRef="usd">48339000</fold:DeferredTaxLiabilitiesRoyaltyPayable>
    <fold:DeferredTaxLiabilitiesConvertibleNotes
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e3232-wk-Fact-BF486A9101D6A25F29A56B8C2F6F68E7"
      unitRef="usd">653000</fold:DeferredTaxLiabilitiesConvertibleNotes>
    <fold:DeferredTaxLiabilitiesConvertibleNotes
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e3252-wk-Fact-F4808C0C2D06E6CE0A806B8C2F6C4037"
      unitRef="usd">16666000</fold:DeferredTaxLiabilitiesConvertibleNotes>
    <fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e3278-wk-Fact-6DDC655A3F21268CF4F26B8C2F6B6954"
      unitRef="usd">2611000</fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments>
    <fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e3298-wk-Fact-7999CD8A28AF3221C2CE6B8C2F720BA4"
      unitRef="usd">2103000</fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e3324-wk-Fact-7B40FD860DAC7E15C795806E1FE12A58"
      unitRef="usd">725000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e3344-wk-Fact-E283FCF0E2951C88FDB3806E1FF29C24"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <fold:DeferredTaxAssetsLiabilitiesGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e3369-wk-Fact-5680E77C94D4F61428266B8C2F776DBE"
      unitRef="usd">461306000</fold:DeferredTaxAssetsLiabilitiesGross>
    <fold:DeferredTaxAssetsLiabilitiesGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e3388-wk-Fact-8604C4990F7F8F1628B66B8C2F707856"
      unitRef="usd">356540000</fold:DeferredTaxAssetsLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e3413-wk-Fact-C8BD887FCE88B9FA83966B8C2F6DC6A8"
      unitRef="usd">466357000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e3433-wk-Fact-F7384C970602CB88EB406B8C2F70DEBA"
      unitRef="usd">363005000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d23321069e3464-wk-Fact-7D8351087B8D88CB6E596B8C2F71ED31"
      unitRef="usd">5051000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d23321069e3484-wk-Fact-EFD986F5DD4DD015506E6B8C2F6936D6"
      unitRef="usd">6465000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2019Q4"
      decimals="-5"
      id="d23321069e3506-wk-Fact-54D053EE631F70BD30F16B8C2FDADEA9"
      unitRef="usd">466400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2018Q4"
      decimals="-5"
      id="d23321069e3510-wk-Fact-1D727B5C50080A1FA10F6B8C2FD825BE"
      unitRef="usd">363000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d23321069e3514-wk-Fact-AA5615B419AB3FE0870C6B8C2FDF75B7"
      unitRef="usd">103400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-6"
      id="d23321069e3530-wk-Fact-86A1268CE690F76D28A66B8C2FD4B823"
      unitRef="usd">1036000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="d23321069e3534-wk-Fact-878E6FA11354F78BD9AA6B8C2FDDA479"
      unitRef="usd">897800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="d23321069e3538-wk-Fact-2BFF22EAF0794277BA446B8C2FD60226"
      unitRef="usd">30600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="FI2019Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"
      decimals="-5"
      id="d23321069e3549-wk-Fact-BA9478FDF0274A24C5CE6B8C2FD7CCF4"
      unitRef="usd">27600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="FI2019Q4_us-gaap_TaxCreditCarryforwardAxis_fold_OrphanDrugTaxCreditCarryforwardMember"
      decimals="-5"
      id="d23321069e3553-wk-Fact-CFF6089AA80D3E0AA0A46B8C2FDB1AF7"
      unitRef="usd">114000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1497BDC4FACD91DB9DC36B8C2FF0D9AE-0-wk-Fact-6CC02298C5A1E64B5CDE6B8C2F8B3CE9">Collaborative Agreements&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Penn&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2018, the Company expanded its gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDD and one additional undisclosed rare metabolic disorder. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2019, the Company further expanded the collaboration from three to six programs for rare genetic diseases and now includes specifically: NPC, MPS IIIB, as well as a next generation program in MPS IIIA. This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. Under the expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$86.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country- by-country basis. The Company will provide &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; each year during the five-year agreement to fund the discovery research program. In connection with the collaboration agreement, the Company made an upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash to Penn that was expensed to research and development expense in the Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;GlaxoSmithKline&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2013, Amicus entered into the Revised Agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus has obtained global rights to develop and commercialize Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between Amicus and GSK in July 2012 ("Expanded Collaboration Agreement"). Under the terms of the Revised Agreement, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment from Amicus to GSK. For Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as well as tiered royalties in the mid-teens in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;eight&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; major markets outside the U.S. For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company incurred approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of royalty expenses under the revised agreement with GSK.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the Revised Agreement, GSK will no longer jointly fund development costs for all formulations of Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In evaluating the impact of both the Expanded Collaboration Agreement and the Revised Agreement, the Company applied the accounting guidance regarding the impact of potential future payments it may make in its role as a vendor (i.e.,&#160;Amicus) to its customer (i.e.,&#160;GSK) and evaluated if these potential future payments could be a reduction of revenue from GSK. If the potential future payments to GSK are as follows:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;a payment for an identifiable benefit, and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the identifiable benefit is separable from the existing relationship between the Company and GSK, and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the identifiable benefit can be obtained from a party other than GSK, and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the Company can reasonably estimate the fair value of the identifiable benefit,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;then the potential future payments would be treated separately from the collaboration and research revenue. However, if all these criteria are not satisfied, then the potential future payments are treated as a reduction of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accordingly, the Company did not believe that, for accounting purposes, the new U.S. licensing rights to Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; obtained from GSK under the Expanded Collaboration Agreement, nor the ex U.S. licensing rights to Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; obtained from GSK under the Revised Agreement, represented a separate, identifiable benefit from the licenses in the Original Collaboration Agreement entered into between Amicus and GSK in 2010. The contingent amounts payable to GSK were not sufficiently separable from GSK's original license and the research and development reimbursements such that Amicus could not have entered into a similar exchange transaction with another party. Additionally, the Company cannot reasonably estimate the fair value of the worldwide licensing rights to Galafold&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the potential future payments to GSK would be treated as a reduction of revenue and that the total amount of revenue to be received under the arrangement is no longer fixed or determinable as the contingent milestone payments are subject to significant uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a result, the Company no longer recognized any of the upfront license fees and premiums on the equity purchase from GSK until such time as the arrangement consideration becomes fixed or determinable, because an indeterminable amount may ultimately be payable back to GSK. These amounts (the balance of the unrecognized upfront license fee and the premium on the equity purchases) are classified as deferred reimbursements on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, under the GSK collaboration agreements, we paid &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in sales-based milestones. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized another &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for sales-based milestones that were met, invoiced and recorded in accounts payable, accrued expenses and other current liabilities and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was recorded as deferred reimbursements in the Consolidated Balance Sheets. Additionally, the Company recognized a liability of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to royalties payable to GSK in accounts payable and accrued expenses in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The recognition of Research Revenue was also affected by the determination that the overall total arrangement consideration was no longer fixed and determinable, despite the fact that the research activities continued and that the research expense reimbursements by GSK to Amicus were received as the research activities related to the reimbursement had been completed. Therefore, the research reimbursements from GSK were recorded as deferred reimbursements on the balance sheet and would not be recognized until the total arrangement consideration becomes fixed and determinable.&lt;/span&gt;&lt;/div&gt;As a result, all revenue recognition was suspended until the total arrangement consideration would become fixed and determinable. In addition, future milestone payments made by the Company will be applied against the balance of this deferred reimbursements account. Revenue recognition for research expense reimbursements, the original upfront license fee, and the equity premiums will resume once the total arrangement consideration becomes fixed and determinable which will occur when the balance of the deferred reimbursements account is sufficient to cover all the remaining contingent milestone payments.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication
      contextRef="I2018Q3Oct31_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d23314361e721-wk-Fact-914A7A9FA001D05867236B8C2F8FED2D"
      unitRef="usd">86500000</fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication>
    <fold:CollaborationAgreementAnnualContributionByCompany
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d23314361e725-wk-Fact-13AF9A209FE6B6D3B7AE5A2F899F792B"
      unitRef="usd">10000000.0</fold:CollaborationAgreementAnnualContributionByCompany>
    <fold:PaymentsForCollaborativeArrangement
      contextRef="D2018Q4Oct_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d23314361e729-wk-Fact-5AA80ED9B4B64A5966D46B8C2F8A4025"
      unitRef="usd">7000000</fold:PaymentsForCollaborativeArrangement>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="D2013Q4Nov1-Nov30_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember"
      decimals="INF"
      id="d23314361e745-wk-Fact-4915FFA43553298649466B8C2F8CF22D"
      unitRef="usd">0</us-gaap:ProceedsFromLicenseFeesReceived>
    <fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments
      contextRef="I2013Q4Nov30_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember"
      decimals="-6"
      id="d23314361e753-wk-Fact-91880EAA908876D0BDFA6B8C2F8C056E"
      unitRef="usd">40000000</fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments>
    <fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones
      contextRef="D2013Q4Nov1-Nov30_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember"
      decimals="INF"
      id="d23314361e757-wk-Fact-97E44BF3AC9B2DE7751D6B8C2F8EE763"
      unitRef="number">8</fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember"
      decimals="-5"
      id="d23314361e766-wk-Fact-964291FBFF64F987C8E06B8C2F8CDFAC"
      unitRef="usd">15500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <fold:PaymentsForCollaborativeArrangement
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d23314361e841-wk-Fact-F6607C3E645005EFD9006B8C2F8BACF4"
      unitRef="usd">1500000</fold:PaymentsForCollaborativeArrangement>
    <fold:AccruedPaymentsForCollaborativeArrangement
      contextRef="FI2019Q4_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d23314361e849-wk-Fact-20E49CFEE805483AE05D5A2C20D3C0EA"
      unitRef="usd">4000000.0</fold:AccruedPaymentsForCollaborativeArrangement>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="FI2019Q4_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember"
      decimals="-5"
      id="d23314361e853-wk-Fact-E23A0085D26708E176FC6B8C2F8CCAB3"
      unitRef="usd">10200000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2019Q4_srt_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember"
      decimals="-5"
      id="d23314361e858-wk-Fact-F8B8CF84E363BE4B910B6B8C2F8E80C9"
      unitRef="usd">5200000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1183A685636062BAB9C06B8C2FF0EE82-0-wk-Fact-A6689DA7FF2D8776B4446B8C2F5CF69E">Basic and Diluted Net Loss per Common Share&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:16px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(356,388&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(348,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(284,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240,421,001&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;185,790,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;153,355,144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; there were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;462 thousand&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; potential common shares outstanding as a result of the Convertible Debt that were excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,724&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding warrants, convertible to common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,555&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested restricted stock units, unissued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,766&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-AB7A91445DFDCF58CA866B8C2FF0E7D6-0-wk-Fact-740F45CCD5AFF3C9DD166B8C2F5F52F2">&lt;div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:16px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(356,388&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(348,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(284,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240,421,001&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;185,790,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;153,355,144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23322176e957-wk-Fact-A12C3F3D7CBD330E74976B8C2FA8F19A"
      unitRef="usd">-356388000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23322176e977-wk-Fact-EE3BD9FBA254D383B3646B8C2FAB60A5"
      unitRef="usd">-348995000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23322176e998-wk-Fact-7624C92CE3E7F08A06F66B8C2FB8EA12"
      unitRef="usd">-284002000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q4YTD"
      decimals="0"
      id="d23322176e1086-wk-Fact-D335D27D9B7976C780C46B8C2FBC3C1B"
      unitRef="shares">240421001</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="0"
      id="d23322176e1105-wk-Fact-C04A907E3EAA92AB22546B8C2FA66E6E"
      unitRef="shares">185790021</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="0"
      id="d23322176e1124-wk-Fact-FD8F09C37B719A0A7D836B8C2FBD8BC0"
      unitRef="shares">153355144</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="-3"
      id="d23322176e1147-wk-Fact-451D251E4BC847CA86296B8C2FD73DCA"
      unitRef="shares">462000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9EE70B85AEE59FC60E9A6B8C2FF09E4A-0-wk-Fact-A8F8F06FFA1D7CA058756B8C2F5FC059">&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,724&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding warrants, convertible to common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,555&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested restricted stock units, unissued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,766&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-3"
      id="d23322176e1291-wk-Fact-B0F3B94DBA13422B52666B8C2FD65629"
      unitRef="shares">16724000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-3"
      id="d23322176e1305-wk-Fact-6AC75A5491E336EAC2576B8C2F5E631A"
      unitRef="shares">15810000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember"
      decimals="-3"
      id="d23322176e1319-wk-Fact-DC9931E8B30A4242E7926B8C2FDDCB18"
      unitRef="shares">15181000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="-3"
      id="d23322176e1339-wk-Fact-451D251E4BC847CA86296B8C2FD73DCA"
      unitRef="shares">462000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="-3"
      id="d23322176e1353-wk-Fact-B543501FDD0A78AE88E96B8C2FDD6F77"
      unitRef="shares">40850000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="-3"
      id="d23322176e1367-wk-Fact-B5B07445FBA35699ED2D6B8C2FDF0481"
      unitRef="shares">40850000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"
      decimals="-3"
      id="d23322176e1387-wk-Fact-068429365532503376166B8C2FD39D01"
      unitRef="shares">2555000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"
      decimals="-3"
      id="d23322176e1401-wk-Fact-6C7EDD7C7088D8F97D956B8C2F88392A"
      unitRef="shares">2657000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"
      decimals="-3"
      id="d23322176e1415-wk-Fact-3B34FC38F89A67D8B0436B8C2FD7D577"
      unitRef="shares">3110000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d23322176e1435-wk-Fact-A45DC495EFE4FF7EC4246B8C2F736566"
      unitRef="shares">5792000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d23322176e1449-wk-Fact-01E949B14758B2D4EBFB6B8C2F5ECE82"
      unitRef="shares">3712000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d23322176e1463-wk-Fact-1B83CD77F3BA4BA7F0346B8C2FD7D269"
      unitRef="shares">2575000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember"
      decimals="-3"
      id="d23322176e1483-wk-Fact-6988649409D0E4C870336B8C2FD2BE6A"
      unitRef="shares">186000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember"
      decimals="-3"
      id="d23322176e1497-wk-Fact-BDCD3D04D2C4C5D02E8C6B8C2F749E7B"
      unitRef="shares">91000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_VestedRestrictedStockUnitsUnissuedMember"
      decimals="-3"
      id="d23322176e1511-wk-Fact-FA31F23D13B5039940196B8C2FD50BDB"
      unitRef="shares">50000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d23322176e1531-wk-Fact-16DC22FF590D0AF5E1E96B8C2F5E7900"
      unitRef="shares">25719000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d23322176e1545-wk-Fact-1BBAF4B2EC55279EA9736B8C2FDDD346"
      unitRef="shares">63120000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d23322176e1559-wk-Fact-1F9B313FF09CAF41A2FE6B8C2F7FDF04"
      unitRef="shares">61766000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-988223644A840CFBF49B6B8C2FF071B7-0-wk-Fact-53E922A3BE245411F5D06B8C2FD86F78">Selected Quarterly Financial Data (Unaudited)&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarters Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands except per share data)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(120,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(84,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(61,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(89,729&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(61,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(159,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(78,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A29B1851B6E29EE68FC46B8C2FF1AE1F-0-wk-Fact-91EB35B5A4BEBFF93BCF6B8C2FD84F9C">&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarters Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands except per share data)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(120,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(84,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(61,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(89,729&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(61,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(159,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(78,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d23323377e1019-wk-Fact-44902E0097C5CEB0FFE28DFAB213BFF8"
      unitRef="usd">34046000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d23323377e1038-wk-Fact-7024DCA7E52B12BBE1358DFAB1E96C72"
      unitRef="usd">44130000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d23323377e1058-wk-Fact-1EE24E38CFD4F00279558DFAB1FD2307"
      unitRef="usd">48768000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q4QTD"
      decimals="-3"
      id="d23323377e1077-wk-Fact-4FAD3164B41E81BD56BB8DFAB1F98B87"
      unitRef="usd">55293000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d23323377e1102-wk-Fact-4F6C6F3770BFDE64B43A6B8C2F756313"
      unitRef="usd">-120299000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d23323377e1122-wk-Fact-F1822C751D7B6D2B708F6B8C2F72319B"
      unitRef="usd">-84551000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d23323377e1143-wk-Fact-5F683393F42F9BD1ED856B8C2F780502"
      unitRef="usd">-61809000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4QTD"
      decimals="-3"
      id="d23323377e1163-wk-Fact-1C72C39461CD96AFF4D06B8C2F767482"
      unitRef="usd">-89729000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d23323377e1191-wk-Fact-FA5B15E085FC0D8F948E6B8C2F7627C8"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d23323377e1211-wk-Fact-A0563B7683B60421C55D6B8C2F75A38D"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d23323377e1232-wk-Fact-DB6B515B1B39FB7965F26B8C2F786C03"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q4QTD"
      decimals="2"
      id="d23323377e1252-wk-Fact-CA126464B24305CA1D4E6B8C2F76B473"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d23323377e1365-wk-Fact-A8CE90D84DB95BC4D8AA8DFAB2061F50"
      unitRef="usd">16696000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d23323377e1384-wk-Fact-88A9DA73B5C16B9DCFD68DFAB20AB288"
      unitRef="usd">21309000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d23323377e1404-wk-Fact-17F49E2BE4EED94867278DFAB20276F5"
      unitRef="usd">20596000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d23323377e1423-wk-Fact-8E5F1AEF9E0BD318EB388DFAB20FE127"
      unitRef="usd">32644000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d23323377e1448-wk-Fact-050BF3C54D8FEDC1ED1E6B8C2F779697"
      unitRef="usd">-49916000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d23323377e1468-wk-Fact-46E2120879A46C1469D76B8C2F73ED0D"
      unitRef="usd">-61833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d23323377e1489-wk-Fact-CDE8CD41A6B379BC80566B8C2F7782B4"
      unitRef="usd">-159163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d23323377e1509-wk-Fact-6A3E43D826425F080B096B8C2F75F20D"
      unitRef="usd">-78083000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q1QTD"
      decimals="2"
      id="d23323377e1537-wk-Fact-7E5BBD5C2A97C85F922C6B8C2F764B3C"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d23323377e1557-wk-Fact-823B8B225542D8FCB6136B8C2F779A0C"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d23323377e1578-wk-Fact-7F6FF23300FB091E830D6B8C2F744A59"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4QTD"
      decimals="2"
      id="d23323377e1598-wk-Fact-3E6D2F9AE4C31A487F026B8C2F77F26F"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805207984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Selected Quarterly Financial Data</a></td>
<td class="text"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarters Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands except per share data)</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(120,299</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84,551</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(89,729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share&#160;</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49,916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(159,163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share&#160;</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.28</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.33</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:inherit;font-size:9pt;">Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812504944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,691</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,607</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,445</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,157</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,876</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,294</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vehicles</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,046</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,604</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,671</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,705</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805376336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Liability Components of the Convertible Notes</a></td>
<td class="text"><div style="line-height:120%;text-align:left;padding-left:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes and Senior Secured Term Loan consist of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152,825</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>400,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: debt discount </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,974</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74,145</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: deferred financing </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net carrying value of the debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149,505</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______________________________</span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in the Consolidated Balance Sheets within Convertible Notes and Senior Secured Term Loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of Total Interest Expense Recognized Related to the Convertible Notes</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth interest expense recognized related to the Convertible Notes and Senior Secured Term Loan for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,381</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of deferred financing</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective interest rate of the liability component, Convertible debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.63</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective interest rate of the liability component, Senior Secured Term Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.16</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.48</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983252592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable, Accrued Expenses, and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable, Accrued Expenses, and Other Current Liabilities</a></td>
<td class="text">Accounts Payable, Accrued Expenses, and Other Current Liabilities<div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable, accrued expenses, and other current liabilities</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">consist of the following: </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,722</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,832</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued contract manufacturing&#160;&amp; contract research costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,890</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued program fees</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued royalties </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,463</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,679</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,189</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued sales rebates and discounts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,772</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,830</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120,373</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,625</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812561296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the acquisitions, the Company initially recognized IPR&amp;D of </span><span style="font-family:inherit;font-size:10pt;"><span>$486.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and goodwill of </span><span style="font-family:inherit;font-size:10pt;"><span>$197.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. Intangible assets related to IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D assets below their respective carrying amounts.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill and intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in "&#8212;&#160;Note&#160;3. Acquisitions", in September 2017, the Company reported that top-line data from the randomized, double-blind, placebo-controlled Phase&#160;3 clinical study ("ESSENCE, SD-005") to assess the efficacy and safety of the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in participants with EB. This event led to an assessment to determine if an impairment had occurred for goodwill and IPR&amp;D. Based on tests for impairment, the Company determined that IPR&amp;D had been impaired, however goodwill was not impaired based on qualitative and market capitalization tests performed. The loss on impairment of IPR&amp;D of </span><span style="font-family:inherit;font-size:10pt;"><span>$463.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded within loss on impairment of assets in the Consolidated Statements of Operations for the year ended December 31, 2017.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the changes in IPR&amp;D for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the changes in Goodwill for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6827073200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (356,388)<span></span>
</td>
<td class="num">$ (348,995)<span></span>
</td>
<td class="num">$ (284,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and deferred financing</a></td>
<td class="nump">2,546<span></span>
</td>
<td class="nump">10,976<span></span>
</td>
<td class="nump">9,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,775<span></span>
</td>
<td class="nump">4,216<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">44,430<span></span>
</td>
<td class="nump">29,260<span></span>
</td>
<td class="nump">23,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on exchange of convertible debt</a></td>
<td class="nump">40,624<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in fair value of derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Non-cash changes in the fair value of contingent consideration payable</a></td>
<td class="nump">3,297<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="num">(234,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax', window );">Foreign currency remeasurement (gain) loss</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">3,217<span></span>
</td>
<td class="num">(5,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NonCashDeferredTaxesAndOtherTaxBenefits', window );">Non-cash deferred taxes</a></td>
<td class="num">(1,415)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(167,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Loss on impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">465,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(149)<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(11,114)<span></span>
</td>
<td class="num">(13,294)<span></span>
</td>
<td class="num">(7,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(5,114)<span></span>
</td>
<td class="num">(4,205)<span></span>
</td>
<td class="num">(897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,287)<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="num">(15,329)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, and other current liabilities</a></td>
<td class="nump">46,742<span></span>
</td>
<td class="nump">17,115<span></span>
</td>
<td class="nump">12,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities', window );">Other non-current assets and liabilities</a></td>
<td class="num">(10,117)<span></span>
</td>
<td class="num">(581)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInDeferredReimbursements', window );">Deferred reimbursements</a></td>
<td class="num">(5,500)<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
<td class="num">(12,600)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(250,416)<span></span>
</td>
<td class="num">(299,955)<span></span>
</td>
<td class="num">(213,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sale and redemption of marketable securities</a></td>
<td class="nump">499,047<span></span>
</td>
<td class="nump">463,502<span></span>
</td>
<td class="nump">323,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(383,882)<span></span>
</td>
<td class="num">(578,394)<span></span>
</td>
<td class="num">(490,468)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(20,012)<span></span>
</td>
<td class="num">(6,308)<span></span>
</td>
<td class="num">(4,526)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">95,153<span></span>
</td>
<td class="num">(121,200)<span></span>
</td>
<td class="num">(171,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants, net of issuance costs</a></td>
<td class="nump">188,994<span></span>
</td>
<td class="nump">294,584<span></span>
</td>
<td class="nump">243,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance leases</a></td>
<td class="num">(420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payment of finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334)<span></span>
</td>
<td class="num">(308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentsForRepurchaseOfRestrictedStockUnits', window );">Purchase of vested restricted stock units</a></td>
<td class="num">(3,235)<span></span>
</td>
<td class="num">(2,832)<span></span>
</td>
<td class="num">(1,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt', window );">Proceeds from termination of capped call confirmations</a></td>
<td class="nump">19,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">11,476<span></span>
</td>
<td class="nump">9,144<span></span>
</td>
<td class="nump">16,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">3,617<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from loan agreements, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">146,596<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">217,502<span></span>
</td>
<td class="nump">450,775<span></span>
</td>
<td class="nump">247,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">1,729<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">63,968<span></span>
</td>
<td class="nump">31,138<span></span>
</td>
<td class="num">(136,176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at the beginning of the year</a></td>
<td class="nump">82,375<span></span>
</td>
<td class="nump">51,237<span></span>
</td>
<td class="nump">187,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at the end of the year</a></td>
<td class="nump">146,343<span></span>
</td>
<td class="nump">82,375<span></span>
</td>
<td class="nump">51,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvements paid through lease incentive</a></td>
<td class="nump">19,388<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">16,966<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationPaidInStock', window );">Contingent consideration paid in shares</a></td>
<td class="nump">9,316<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures unpaid at the end of period</a></td>
<td class="nump">$ 1,865<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationPaidInStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration liability in stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationPaidInStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Remeasurement Gain (Loss), Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ForeignCurrencyRemeasurementGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInDeferredReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of deferred reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInDeferredReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInNoncurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NonCashDeferredTaxesAndOtherTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the non-cash component of deferred taxes and other tax benefits for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NonCashDeferredTaxesAndOtherTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the payment of contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentsForRepurchaseOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire restricted stock units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentsForRepurchaseOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807375616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (89,729)<span></span>
</td>
<td class="num">$ (61,809)<span></span>
</td>
<td class="num">$ (84,551)<span></span>
</td>
<td class="num">$ (120,299)<span></span>
</td>
<td class="num">$ (78,083)<span></span>
</td>
<td class="num">$ (159,163)<span></span>
</td>
<td class="num">$ (61,833)<span></span>
</td>
<td class="num">$ (49,916)<span></span>
</td>
<td class="num">$ (356,388)<span></span>
</td>
<td class="num">$ (348,995)<span></span>
</td>
<td class="num">$ (284,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding - basic and diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,421,001<span></span>
</td>
<td class="nump">185,790,021<span></span>
</td>
<td class="nump">153,355,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,719,000<span></span>
</td>
<td class="nump">63,120,000<span></span>
</td>
<td class="nump">61,766,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,724,000<span></span>
</td>
<td class="nump">15,810,000<span></span>
</td>
<td class="nump">15,181,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,000<span></span>
</td>
<td class="nump">40,850,000<span></span>
</td>
<td class="nump">40,850,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555,000<span></span>
</td>
<td class="nump">2,657,000<span></span>
</td>
<td class="nump">3,110,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,792,000<span></span>
</td>
<td class="nump">3,712,000<span></span>
</td>
<td class="nump">2,575,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_VestedRestrictedStockUnitsUnissuedMember', window );">Vested restricted stock units, unissued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,000<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_VestedRestrictedStockUnitsUnissuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_VestedRestrictedStockUnitsUnissuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6826611312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 182,237<span></span>
</td>
<td class="nump">$ 91,245<span></span>
</td>
<td class="nump">$ 36,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">21,963<span></span>
</td>
<td class="nump">14,404<span></span>
</td>
<td class="nump">6,236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">160,274<span></span>
</td>
<td class="nump">76,841<span></span>
</td>
<td class="nump">30,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">286,378<span></span>
</td>
<td class="nump">270,902<span></span>
</td>
<td class="nump">149,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">169,861<span></span>
</td>
<td class="nump">127,200<span></span>
</td>
<td class="nump">88,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="nump">3,297<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="num">(234,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Loss on impairment of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">465,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,775<span></span>
</td>
<td class="nump">4,216<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">464,311<span></span>
</td>
<td class="nump">405,618<span></span>
</td>
<td class="nump">472,679<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(304,037)<span></span>
</td>
<td class="num">(328,777)<span></span>
</td>
<td class="num">(441,985)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">10,249<span></span>
</td>
<td class="nump">10,461<span></span>
</td>
<td class="nump">4,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(18,872)<span></span>
</td>
<td class="num">(22,402)<span></span>
</td>
<td class="num">(17,240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on exchange of convertible notes</a></td>
<td class="num">(40,624)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,739)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(2,626)<span></span>
</td>
<td class="num">(5,632)<span></span>
</td>
<td class="nump">6,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(355,910)<span></span>
</td>
<td class="num">(349,089)<span></span>
</td>
<td class="num">(449,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(478)<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">165,119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (356,388)<span></span>
</td>
<td class="num">$ (348,995)<span></span>
</td>
<td class="num">$ (284,002)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (1.88)<span></span>
</td>
<td class="num">$ (1.85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">240,421,001<span></span>
</td>
<td class="nump">185,790,021<span></span>
</td>
<td class="nump">153,355,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6826384864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 65,309<span></span>
</td>
<td class="nump">$ 27,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(17,604)<span></span>
</td>
<td class="num">(15,671)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">47,705<span></span>
</td>
<td class="nump">11,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,185<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">14,568<span></span>
</td>
<td class="nump">8,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,157<span></span>
</td>
<td class="nump">4,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">30,294<span></span>
</td>
<td class="nump">7,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,190<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,184<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6724370016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,837,000<span></span>
</td>
<td class="nump">$ 79,749,000<span></span>
</td>
<td class="nump">$ 49,060,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">309,903,000<span></span>
</td>
<td class="nump">424,403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Debt securities, realized gain (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of available-for-sale debt securities in unrealized loss positions</a></td>
<td class="nump">$ 42,600,000<span></span>
</td>
<td class="nump">$ 403,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805138480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 21, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,476<span></span>
</td>
<td class="nump">$ 9,144<span></span>
</td>
<td class="nump">$ 16,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested and non-vested units expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting', window );">Period following separation for accelerated vesting</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | Stock Option Plan Amended Restated 2007 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested and non-vested units expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921,000.0<span></span>
</td>
<td class="nump">530,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.67<span></span>
</td>
<td class="nump">$ 10.19<span></span>
</td>
<td class="nump">$ 5.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="nump">$ 20,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6827451376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Geographical Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 55,293<span></span>
</td>
<td class="nump">$ 48,768<span></span>
</td>
<td class="nump">$ 44,130<span></span>
</td>
<td class="nump">$ 34,046<span></span>
</td>
<td class="nump">$ 32,644<span></span>
</td>
<td class="nump">$ 20,596<span></span>
</td>
<td class="nump">$ 21,309<span></span>
</td>
<td class="nump">$ 16,696<span></span>
</td>
<td class="nump">$ 182,237<span></span>
</td>
<td class="nump">$ 91,245<span></span>
</td>
<td class="nump">$ 36,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,478<span></span>
</td>
<td class="nump">7,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Ex-U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,759<span></span>
</td>
<td class="nump">$ 84,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=fold_LargestCustomerMember', window );">Largest Customer | Customer Concentration Risk | Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=fold_LargestCustomerMember', window );">Largest Customer | Customer Concentration Risk | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=fold_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=fold_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6829852608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped', window );">Number of gene therapy programs for neurologic LSDs developed | program</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Loss on impairment of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 465,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,297<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="num">(234,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,681<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fold_MilestonePaymentMember', window );">Milestone Payment | Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_FixedAssetsMember', window );">Fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Loss on impairment of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember', window );">MiaMed Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, total consideration, stock and cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentsToAcquireBusinessAssets', window );">Asset acquisition, cash consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment', window );">Asset acquisition, potential aggregate deal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ResearchExpenseForStockIssuanceInAssetAcquisition', window );">Charges to research expense for stock issued in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember', window );">MiaMed Inc | Amicus | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Consideration paid in common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationOfEnrollmentRate', window );">Enrollment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Loss on impairment of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_SellingGeneralAndAdministrativeCostsDueToWindDown', window );">Selling , general and administrative costs due to wind-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ResearchAndDevelopmentExpensesDueToWindDown', window );">Research and development expenses due to wind-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncomeTaxExpenseBenefitDueToWindDown', window );">Income tax benefit due to wind-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus | Changes in fair value of contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember', window );">Clinical, Regulatory and Commercial milestones | MiaMed Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessAssetAcquisitionContingentConsiderationMilestones', window );">Contingent consideration payable upon achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AssetAcquisitionAxis=fold_CelenexMember', window );">Celenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment', window );">Contingent consideration based on the achievement of certain milestones</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones', window );">Contingent consideration based on the achievement of regulatory milestones</a></td>
<td class="nump">262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears', window );">Maximum payment under contingent consideration</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AssetAcquisitionAxis=fold_CelenexMember', window );">Celenex | Nationwide Children's Hospital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment', window );">Contingent consideration based on the achievement of certain milestones</a></td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessAssetAcquisitionContingentConsiderationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration payable in a business asset acquisition upon achievement of certain clinical, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessAssetAcquisitionContingentConsiderationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationOfEnrollmentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The company enrollment percent achieved during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationOfEnrollmentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncomeTaxExpenseBenefitDueToWindDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit) Due To Wind-Down</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncomeTaxExpenseBenefitDueToWindDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Gene Therapy Programs For Neurologic LSDs Developed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentsToAcquireBusinessAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentsToAcquireBusinessAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ResearchAndDevelopmentExpensesDueToWindDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development expenses due to wind-down of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ResearchAndDevelopmentExpensesDueToWindDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ResearchExpenseForStockIssuanceInAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research expense charged to statement of operations for stock issued in assets acquisition transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ResearchExpenseForStockIssuanceInAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent On Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent On Submission And Approval Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Maximum Expected Payment Over Next Four Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_SellingGeneralAndAdministrativeCostsDueToWindDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of selling, general and administrative costs due to wind-down of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_SellingGeneralAndAdministrativeCostsDueToWindDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fold_MilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fold_MilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_FixedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_FixedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=fold_ChangesInFairValueOfContingentConsiderationPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=fold_ChangesInFairValueOfContingentConsiderationPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AssetAcquisitionAxis=fold_CelenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AssetAcquisitionAxis=fold_CelenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=fold_NationwideChildrensHospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=fold_NationwideChildrensHospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6809178688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Cash paid for amounts included in operating lease liabilities</a></td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">21,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU asset</a></td>
<td class="nump">33,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of the operating lease liabilities</a></td>
<td class="nump">7,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of the operating lease liabilities</a></td>
<td class="nump">53,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 60,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease terms (years)</a></td>
<td class="text">18 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 9,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">10,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">10,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">10,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">10,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">163,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">215,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less lease incentives</a></td>
<td class="num">(28,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_LesseeOperatingLeaseLiabilityTenantIncentives', window );">Less imputed interest</a></td>
<td class="num">(125,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">60,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Minimum lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense, including fees for utilities and common area maintenances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvements paid through lease incentive</a></td>
<td class="nump">$ 19,388<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_LesseeOperatingLeaseLiabilityTenantIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Incentives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_LesseeOperatingLeaseLiabilityTenantIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830082992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of the period</a></td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="nump">$ 25,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_MilestonePayableAccruedDuringPeriod', window );">Milestones payable, included in accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value during the period, included in the Consolidated Statements of Operations</a></td>
<td class="nump">3,297<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="num">$ (234,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationPaidInStockAdjustment', window );">Adjustment for contingent consideration paid in stock</a></td>
<td class="num">(316)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of the period</a></td>
<td class="nump">$ 22,681<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="nump">$ 25,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationPaidInStockAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Paid In Stock, Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationPaidInStockAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_MilestonePayableAccruedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payable Accrued During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_MilestonePayableAccruedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6747980704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Stock Option Activity (Details) - Options to purchase common stock - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">15,810,000.0<span></span>
</td>
<td class="nump">15,181,100<span></span>
</td>
<td class="nump">15,497,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted (in shares)</a></td>
<td class="nump">4,091,000.0<span></span>
</td>
<td class="nump">2,348,000.0<span></span>
</td>
<td class="nump">3,695,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="num">(1,967,000.0)<span></span>
</td>
<td class="num">(1,398,000.0)<span></span>
</td>
<td class="num">(2,878,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="num">(879,000.0)<span></span>
</td>
<td class="num">(313,100)<span></span>
</td>
<td class="num">(1,133,000.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares)</a></td>
<td class="num">(331,000.0)<span></span>
</td>
<td class="num">(8,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">16,724,000.0<span></span>
</td>
<td class="nump">15,810,000.0<span></span>
</td>
<td class="nump">15,181,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and unvested expected to vest as of the end of the period (in shares)</a></td>
<td class="nump">16,111,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">10,646,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 8.63<span></span>
</td>
<td class="nump">$ 7.48<span></span>
</td>
<td class="nump">$ 7.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share)</a></td>
<td class="nump">10.29<span></span>
</td>
<td class="nump">14.96<span></span>
</td>
<td class="nump">7.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share)</a></td>
<td class="nump">5.83<span></span>
</td>
<td class="nump">6.54<span></span>
</td>
<td class="nump">5.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share)</a></td>
<td class="nump">11.07<span></span>
</td>
<td class="nump">9.55<span></span>
</td>
<td class="nump">9.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share)</a></td>
<td class="nump">13.38<span></span>
</td>
<td class="nump">10.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">9.15<span></span>
</td>
<td class="nump">$ 8.63<span></span>
</td>
<td class="nump">$ 7.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and unvested expected to vest as of the end of the period (in dollars per share)</a></td>
<td class="nump">9.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 8.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance at the end of the period</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and unvested expected to vest at the end of the period</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the period</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 30.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options vested and unvested expected to vest</a></td>
<td class="nump">30.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">$ 27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6826642000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Transactions</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div>The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company&#8217;s Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company&#8217;s Consolidated Balance Sheets. </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The Company's accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span> have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s net product sales consist of sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2019, one customer accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>22%</span></span><span style="font-family:inherit;font-size:10pt;"> of net product sales and </span><span style="font-family:inherit;font-size:10pt;"><span>11%</span></span><span style="font-family:inherit;font-size:10pt;"> of accounts receivable from product sales.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The transaction price is determined based on fixed consideration in the Company&#8217;s customer contracts and is recorded net of estimates for variable consideration, which are third-party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories and Cost of Goods Sold</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories and Cost of Goods Sold</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Liabilities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_InterestIncomeAndInterestExpensePolicyTextBlock', window );">Interest Income and Interest Expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Income and Interest Expense</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_OtherComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of other comprehensive income (loss) include unrealized gains and losses on available-for-sale securities and gain (loss) on foreign currency transactions and are included in the Statements of Comprehensive Loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</span></div>The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods. For additional information, see " -Note 13. Leases" and "-Note 2. Summary of Significant Accounting Policies, Recent Accounting Developments - Guidance Adopted in 2019."<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NonqualifiedCashDeferralPlansPolicy', window );">Nonqualified Cash Deferral Plan</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nonqualified Cash Deferral Plan</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code (the "Code"). All of the investments held in the Deferral Plan are classified as investments held-to-maturity and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity-based Compensation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> equity-based employee compensation plans, which are described more fully in "&#8212;&#160;Note&#160;9. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Common Share</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss per Common Share</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs, and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#8212;&#160;Note&#160;17. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company currently operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> reporting unit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock', window );">Contingent Consideration Payable</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Consideration Payable</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets and Goodwill</span></div>The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Developments</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Developments - Guidance Adopted in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-02 - In February 2016, the FASB issued ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> ("ASU 2016-02"). ASU 2016-02 requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. In August 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, ("ASU 2018-11"). ASU 2018-11 provided entities with an additional transition method for adoption, whereby, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Effective January 1, 2019 the Company adopted ASU 2016-02, along with the amendments issued in 2017 and 2018, and elected the transition method in ASU 2018-11. The Company elected the package of transition provisions available for expired or existing contracts, which allowed the Company to carry forward its historical assessments of (i) whether contracts are or contain leases, (ii) lease classification and (iii) initial direct costs. In addition, the Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and will apply the practical expedient not to separate lease and non-lease components for new and modified leases commencing after adoption. The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods. Upon adoption, the Company recorded a lease liability with a corresponding right-of-use asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. The adoption did not have a material impact on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Developments - Guidance Not Yet Adopted</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2019-12 - In December 2019, the FASB issued ASU 2019-15,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following apply in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for public business entities for periods for which financial statements have not yet been issued. An entity that elects early adoption in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption should adopt all the amendments in the same period. The Company is currently assessing the impact that this standard will have on its Consolidated Financial Statements upon adoption.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2018-15 - In August 2018, the FASB issued&#160;ASU 2018-15,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)</span><span style="font-family:inherit;font-size:10pt;">: ("ASU 2018-15"), relating to a customer&#8217;s accounting for implementation, set-up, and other upfront costs incurred in a&#160;cloud computing&#160;arrangement that is hosted by a vendor. Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance does not affect the accounting for the service element of a hosting arrangement that is a service contract. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized software costs and related amortization expense and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for public companies. The Company will adopt this guidance prospectively on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2018-13 - In August 2018, the FASB issued ASU 2018-03, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement </span><span style="font-family:inherit;font-size:10pt;">("ASU 2018-13"). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on (i) changes in unrealized gains and losses, (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and (iii) the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2017-04 - In January 2017, the FASB issued ASU 2017-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </span><span style="font-family:inherit;font-size:10pt;">("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-13 - </span><span style="font-family:inherit;font-size:9pt;">I</span><span style="font-family:inherit;font-size:10pt;">n June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="font-family:inherit;font-size:10pt;">("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">basis to be presented at the net amount expected to be collected and amends guidance on the impairment of financial instruments.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13 is effective for public companies who are SEC filers for fiscal years beginning after December 15, 2019, including</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">interim periods within those years. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_InterestIncomeAndInterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest income and interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_InterestIncomeAndInterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NonqualifiedCashDeferralPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NonqualifiedCashDeferralPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_OtherComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_OtherComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812587744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For financial reporting purposes, income (loss) before income taxes includes the following components:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(393,955</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(309,183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(440,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,906</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,425</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(355,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(349,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(449,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following were the components of income tax expense (benefit) for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,877</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(100</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(984</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(150,015</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,389</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(94</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(165,119</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the statutory tax rates and the effective tax rates for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nondeductible IPR&amp;D</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign income tax rate differential</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of 2017 Act</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nondeductible debt conversion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to </span><span style="font-family:inherit;font-size:10pt;"><span>21%</span></span><span style="font-family:inherit;font-size:10pt;">, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;">, requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the Tax Act's provisions, the SEC staff issued SAB&#160;118, which allows companies to record the tax effects of the Tax Act on a provisional basis based on a reasonable estimate, and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available. The measurement period ends when a company has obtained, prepared, and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from enactment. The Tax Act did not have a material impact on the Company's financial statements because its deferred temporary differences are fully offset by a valuation allowance. The Company did not have any significant offshore earnings from which to record the mandatory transition tax. During 2018 the Company operated in a consolidated loss position in its foreign operations and did not have a one-time tax on accumulated earnings of foreign subsidiaries.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2017, the Company provisionally recorded certain impacts of the Tax Act including the adjustment to our net deferred tax liability arising from the reduction in the federal tax rate as well as the impact of mandatory deemed repatriation. Adjustments to these provisional amounts that we recorded in 2018 did not have a significant impact on the Company's Consolidated Financial Statements. The Company's accounting for the effects of the enactment of the Tax Act are now complete.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded an income tax expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2019 for taxes in foreign jurisdictions and a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> tax benefit in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> for taxes in U.S. federal and state jurisdictions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company did not recognize interest or penalties related to income tax during the period ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and did </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t accrue for interest or penalties as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company does </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t have an accrual for uncertain tax positions as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Tax returns for years 2015 through 2018 are open to examination by tax authorities. The Company is also subject to examination in any period for which it has net operating losses.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intellectual property</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization/depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research tax credit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,509</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carry forwards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred reimbursement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,401</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash stock issue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,058</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest carry forward limitation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>516,867</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>430,113</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business acquisition</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,051</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,465</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46,521</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48,339</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(653</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,666</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Advanced R&amp;D payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,103</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(725</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>461,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>356,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: valuation allowance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(466,357</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(363,005</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,051</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded valuation allowances of </span><span style="font-family:inherit;font-size:10pt;"><span>$466.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$363.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, representing an increase in the valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$103.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D that may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had federal, state, and foreign net operating loss carry forwards ("NOLs") of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1,036 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$897.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$30.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the 2017 Tax Act.&#160;Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> will expire in 2029 through 2039. The foreign NOLs are subject to differing expirations beginning in 2026. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended ( the "Code") as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past and could occur again in the future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership some of which are outside our control. We completed a detailed study of our NOLs and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on our ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also has research and experimentation and orphan drug credit carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$27.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$114.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which will expire in the years 2021 through 2039. Deferred tax assets for these carryforwards are subject to a full valuation allowance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983222560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share based Compensation</a></td>
<td class="text">Share based Compensation <div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s Equity Incentive Plans consist of the Plan and the 2007 Director Plan. The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors. advisors, and consultants at a price to be determined by the Company&#8217;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 21, 2018, the Board of Directors of the Company approved an amendment (the "Amendment") to the Plan. The Amendment provides for certain benefits to qualifying Plan Participants who separate from service with the Company due to death, disability or "Retirement" (as such term is defined under the Plan) ("Qualified Participants"). Options granted under the Plan ("Options") to a Qualified Participant shall continue to vest until the 2nd anniversary of the Qualified Participant&#8217;s separation and all vested Options held by such Qualified Participant shall remain exercisable until the earlier of the 4th anniversary of the Qualified Participant&#8217;s separation or the original expiration date of the Option. Options that are not exercised during this exercise period shall be forfeited. Time-based restricted stock units and restricted stock granted to a Qualified Participant under the Plan that was scheduled to vest within the </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> year period following the Qualified Participant's separation shall accelerate and be delivered upon such separation. Any time-based restricted stock units or restricted stock that would have vested after such </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> year period will be forfeited upon the Qualified Participant's separation. Also, per the Amendment, any performance-based restricted stock units under the Plan ("PRSUs") received by the Qualified Participant, shall remain eligible to vest after the Qualified Participant&#8217;s separation based on the actual performance of the Company through the end of the performance period applicable to any such PRSU. </span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Grants</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the fair value method of measuring stock-based compensation, using the fair value of each equity award granted. The Company chose the &#8216;&#8216;straight-line&#8217;&#8217; attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007. Beginning in the third quarter of 2017, the average expected life is determined using our actual historical data versus a &#8216;&#8216;simplified&#8217;&#8217; method used in prior quarters. The &#8216;&#8216;simplified&#8217;&#8217; method of estimating the Company did not have sufficient reliable exercise data to justify a change from the use of the &#8216;&#8216;simplified&#8217;&#8217; method of estimating the expected exercise term of employee stock option grants. The impact from this change was not material. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life of options (years) </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected annual dividend per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______________________________________</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:inherit;font-size:9pt;">The average expected life is determined using actual historical data. </span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant-date fair value per share of options granted during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$6.67</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$10.19</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.09</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company's stock options for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,497.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,695.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,878.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,133.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,181.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,348.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,398.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(313.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,810.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,091.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,967.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(879.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(331.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,724.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and unvested expected to vest, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,111.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,646.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options exercised during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$11.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$11.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$20.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively. Cash proceeds from stock options exercised during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$11.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$9.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$16.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the total unrecognized compensation cost related to non-vested stock options granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$32.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:3px;text-align:justify;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSU's")</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee&#8217;s continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average Grant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested units as of December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,575.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,811.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(530.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(145.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.65</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested units as of December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,712.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,526.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(921.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(525.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested units as of December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,792.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>920,782</span></span><span style="font-family:inherit;font-size:10pt;"> RSUs have vested and all non-vested units are expected to vest over their normal term. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$39.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.4 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation Expense Related to Equity Awards</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity compensation expense recognized in:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,328</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general, and administrative expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,855</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,773</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total equity compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,101</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812561296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consist of raw materials, work in process, and finished goods related to the manufacture of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The following table summarizes the components of inventories:</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.25341130604289%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,544</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,485</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded a reserve for inventory of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812216800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Transactions</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company&#8217;s Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company&#8217;s Consolidated Balance Sheets. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The Company's accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded an allowance for doubtful accounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s net product sales consist of sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2019, one customer accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>22%</span></span><span style="font-family:inherit;font-size:10pt;"> of net product sales and </span><span style="font-family:inherit;font-size:10pt;"><span>11%</span></span><span style="font-family:inherit;font-size:10pt;"> of accounts receivable from product sales.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The transaction price is determined based on fixed consideration in the Company&#8217;s customer contracts and is recorded net of estimates for variable consideration, which are third-party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's net product sales from Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> disaggregated by geographic area:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Year </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ex-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,022</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,930</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net product sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,930</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories and Cost of Goods Sold</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Liabilities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Income and Interest Expense</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of other comprehensive income (loss) include unrealized gains and losses on available-for-sale securities and gain (loss) on foreign currency transactions and are included in the Statements of Comprehensive Loss.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods. For additional information, see " -Note 13. Leases" and "-Note 2. Summary of Significant Accounting Policies, Recent Accounting Developments - Guidance Adopted in 2019."&#160;</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nonqualified Cash Deferral Plan</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code (the "Code"). All of the investments held in the Deferral Plan are classified as investments held-to-maturity and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity-based Compensation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> equity-based employee compensation plans, which are described more fully in "&#8212;&#160;Note&#160;9. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss per Common Share</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs, and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#8212;&#160;Note&#160;17. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company currently operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> reporting unit.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Consideration Payable</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets and Goodwill</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. No indicators of impairment were noted during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Developments - Guidance Adopted in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-02 - In February 2016, the FASB issued ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> ("ASU 2016-02"). ASU 2016-02 requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. In August 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, ("ASU 2018-11"). ASU 2018-11 provided entities with an additional transition method for adoption, whereby, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Effective January 1, 2019 the Company adopted ASU 2016-02, along with the amendments issued in 2017 and 2018, and elected the transition method in ASU 2018-11. The Company elected the package of transition provisions available for expired or existing contracts, which allowed the Company to carry forward its historical assessments of (i) whether contracts are or contain leases, (ii) lease classification and (iii) initial direct costs. In addition, the Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and will apply the practical expedient not to separate lease and non-lease components for new and modified leases commencing after adoption. The information presented for the periods prior to January 1, 2019 has not been restated and is reported under the accounting standard in effect for those periods. Upon adoption, the Company recorded a lease liability with a corresponding right-of-use asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. The adoption did not have a material impact on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Developments - Guidance Not Yet Adopted</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2019-12 - In December 2019, the FASB issued ASU 2019-15,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following apply in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for public business entities for periods for which financial statements have not yet been issued. An entity that elects early adoption in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption should adopt all the amendments in the same period. The Company is currently assessing the impact that this standard will have on its Consolidated Financial Statements upon adoption.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2018-15 - In August 2018, the FASB issued&#160;ASU 2018-15,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)</span><span style="font-family:inherit;font-size:10pt;">: ("ASU 2018-15"), relating to a customer&#8217;s accounting for implementation, set-up, and other upfront costs incurred in a&#160;cloud computing&#160;arrangement that is hosted by a vendor. Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance does not affect the accounting for the service element of a hosting arrangement that is a service contract. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized software costs and related amortization expense and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for public companies. The Company will adopt this guidance prospectively on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2018-13 - In August 2018, the FASB issued ASU 2018-03, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement </span><span style="font-family:inherit;font-size:10pt;">("ASU 2018-13"). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on (i) changes in unrealized gains and losses, (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and (iii) the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2017-04 - In January 2017, the FASB issued ASU 2017-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </span><span style="font-family:inherit;font-size:10pt;">("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-13 - </span><span style="font-family:inherit;font-size:9pt;">I</span><span style="font-family:inherit;font-size:10pt;">n June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="font-family:inherit;font-size:10pt;">("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">basis to be presented at the net amount expected to be collected and amends guidance on the impairment of financial instruments.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13 is effective for public companies who are SEC filers for fiscal years beginning after December 15, 2019, including</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">interim periods within those years. The Company will adopt this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its Consolidated Financial Statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983289184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Options</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life of options (years) </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected annual dividend per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______________________________________</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:inherit;font-size:9pt;">The average expected life is determined using actual historical data. </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company's stock options for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,497.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,695.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,878.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,133.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,181.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,348.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,398.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(313.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,810.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,091.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,967.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(879.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(331.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,724.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and unvested expected to vest, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,111.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,646.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Non-Vested RSU Activity under the Plan</a></td>
<td class="text">A summary of non-vested RSU activity under the Plan for the year ended <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average Grant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested units as of December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,575.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,811.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(530.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(145.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.65</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested units as of December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,712.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,526.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(921.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(525.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested units as of December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,792.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity Compensation Expenses</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity compensation expense recognized in:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,328</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general, and administrative expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,855</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,773</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total equity compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,101</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983175392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) before Income Taxes</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For financial reporting purposes, income (loss) before income taxes includes the following components:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(393,955</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(309,183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(440,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,906</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,425</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(355,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(349,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(449,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following were the components of income tax expense (benefit) for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,877</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(100</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(984</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(150,015</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,389</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(94</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(165,119</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the Statutory Tax Rates and the Effective Tax Rates</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the statutory tax rates and the effective tax rates for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nondeductible IPR&amp;D</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign income tax rate differential</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of 2017 Act</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nondeductible debt conversion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of the Deferred Tax Assets and Liabilities</a></td>
<td class="text">The significant components of the deferred tax assets and liabilities are as follows:<div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intellectual property</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization/depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research tax credit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,509</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carry forwards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred reimbursement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,401</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash stock issue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,058</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest carry forward limitation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>516,867</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>430,113</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business acquisition</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,051</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,465</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46,521</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48,339</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(653</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,666</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Advanced R&amp;D payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,103</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(725</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>461,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>356,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: valuation allowance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(466,357</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(363,005</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,051</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6829013328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock and Warrants (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 16, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 07, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CommonStockVotingRightsForEachShareHeld', window );">Voting right for each share held, number | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,100,000<span></span>
</td>
<td class="nump">18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross cash proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">$ 3,617<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from the issuance of common stock after deducting underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,000<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,994<span></span>
</td>
<td class="nump">$ 294,584<span></span>
</td>
<td class="nump">$ 243,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMilestonePayment', window );">Contingent consideration, milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_MilestonePaymentStockIssuedAsConsideration', window );">Milestone payment, stock issued as consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount', window );">Exchange agreement, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance', window );">Exchange agreement, authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share of common stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,787<span></span>
</td>
<td class="nump">453,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross cash proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fold_UnderwrittenOfferingMember', window );">Underwritten Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="nump">885,000<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from the issuance of common stock after deducting underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share of common stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,720,930<span></span>
</td>
<td class="nump">20,239,839<span></span>
</td>
<td class="nump">21,122,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_MilestonePaymentStockIssuedAsConsideration', window );">Milestone payment, stock issued as consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CommonStockVotingRightsForEachShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes entitled for each share held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CommonStockVotingRightsForEachShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_MilestonePaymentStockIssuedAsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Stock Issued As Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_MilestonePaymentStockIssuedAsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fold_UnderwrittenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fold_UnderwrittenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812484880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,837<span></span>
</td>
<td class="nump">$ 79,749<span></span>
</td>
<td class="nump">$ 49,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">2,626<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 146,343<span></span>
</td>
<td class="nump">$ 82,375<span></span>
</td>
<td class="nump">$ 51,237<span></span>
</td>
<td class="nump">$ 187,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812477632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Loss Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and experimentation tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 27.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=fold_OrphanDrugTaxCreditCarryforwardMember', window );">Orphan drug tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">114.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Amount of net operating loss carry forwards</a></td>
<td class="nump">1,036.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Amount of net operating loss carry forwards</a></td>
<td class="nump">897.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Amount of net operating loss carry forwards</a></td>
<td class="nump">$ 30.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=fold_OrphanDrugTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=fold_OrphanDrugTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804509056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax', window );">Foreign currency translation gain (loss), tax impact</a></td>
<td class="nump">$ 889<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Available-for-sale securities, tax expense (benefit)</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6825880256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,837<span></span>
</td>
<td class="nump">$ 79,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="nump">309,903<span></span>
</td>
<td class="nump">424,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">33,284<span></span>
</td>
<td class="nump">21,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">14,041<span></span>
</td>
<td class="nump">8,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">20,008<span></span>
</td>
<td class="nump">16,592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">520,073<span></span>
</td>
<td class="nump">551,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, less accumulated amortization of $5,342 and $0 at December 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">33,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, less accumulated depreciation of $17,604 and $15,671 at December 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">47,705<span></span>
</td>
<td class="nump">11,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research &amp; development</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="nump">197,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">28,317<span></span>
</td>
<td class="nump">6,683<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">850,207<span></span>
</td>
<td class="nump">789,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued expenses, and other current liabilities</a></td>
<td class="nump">120,373<span></span>
</td>
<td class="nump">80,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Deferred reimbursements</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">7,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">128,812<span></span>
</td>
<td class="nump">86,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="nump">8,906<span></span>
</td>
<td class="nump">10,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes</a></td>
<td class="nump">2,131<span></span>
</td>
<td class="nump">175,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Senior secured term loan</a></td>
<td class="nump">147,374<span></span>
</td>
<td class="nump">146,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">22,681<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">5,051<span></span>
</td>
<td class="nump">6,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">53,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">5,296<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">373,782<span></span>
</td>
<td class="nump">447,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value, 500,000,000 shares authorized, 255,417,869 and 189,383,924 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">2,598<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,227,225<span></span>
</td>
<td class="nump">1,740,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">2,785<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on available-for securities</a></td>
<td class="nump">40<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">13,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,768,610)<span></span>
</td>
<td class="num">(1,412,222)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">476,425<span></span>
</td>
<td class="nump">342,912<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 850,207<span></span>
</td>
<td class="nump">$ 789,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=116690757&amp;loc=SL116692626-108610<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812602304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,691</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,607</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,445</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,157</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,876</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,294</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vehicles</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,046</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,604</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,671</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,705</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983236464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Celenex</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company expanded its pipeline by acquiring the rights and related intellectual property of </span><span style="font-family:inherit;font-size:10pt;"><span>ten</span></span><span style="font-family:inherit;font-size:10pt;"> gene therapy programs through its acquisition of Celenex, Inc., ("Celenex"). Celenex is a private, clinical stage gene therapy company whose lead programs are </span><span style="font-family:inherit;font-size:10pt;"><span>ten</span></span><span style="font-family:inherit;font-size:10pt;"> gene therapy programs including CLN6 and CLN3, which are in clinical stage, and several programs in pre-clinical stage. Pursuant to the terms of the agreement, the Company acquired Celenex for cash consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has also agreed to pay up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$15 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the achievement of certain development milestones, </span><span style="font-family:inherit;font-size:10pt;"><span>$262 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the achievement of certain regulatory approval milestones across multiple programs and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$75 million</span></span><span style="font-family:inherit;font-size:10pt;"> in tiered sales milestone payments. Celenex has an exclusive license agreement with Nationwide Children&#8217;s Hospital ("NCH"). Under this license agreement, NCH is eligible to receive development and sales-based milestones of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$7.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for each product.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the Celenex transaction and concluded that the transaction did not meet the definition of a business and was an asset acquisition. Given the fact that the license has no alternative future use, the </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment was expensed to research and development expense in the Consolidated Statements of Operations for the year ended December 31, 2018</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of MiaMed,&#160;Inc</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2016, the Company entered into an Agreement and Plan of Merger (the "MiaMed Agreement") with MiaMed,&#160;Inc., ("MiaMed"). MiaMed is a pre-clinical biotechnology company focused on developing protein replacement therapy for CDD and related diseases. Under the terms of the MiaMed Agreement, the former holders of MiaMed's capital stock received an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, comprised of (i)&#160;approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash (plus MiaMed's cash and cash equivalents at closing and less any of MiaMed's unpaid third-party fees and expenses related to the transaction), and (ii)&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>825,603</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock. In addition, the Company also agreed to pay up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$83.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the achievement of certain clinical, regulatory, and commercial milestones, for a potential aggregate deal value of </span><span style="font-family:inherit;font-size:10pt;"><span>$89.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company evaluated the transaction and concluded that it only acquired inputs and did not acquire any processes. The Company will need to develop its own processes in order to produce an output. Therefore, the Company accounted for the transaction as an asset acquisition and accordingly </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> was expensed to research and development expense in the Consolidated Statements of Operation for the year ended December 31, 2016.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Scioderm,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2015, the Company acquired Scioderm&#160;Inc., ("Scioderm"), a privately-held biopharmaceutical company focused on developing innovative therapies for treating the rare disease, Epidermolysis Bullosa ("EB"). The acquisition potentially leveraged the Scioderm development team's EB expertise with the Company's global clinical infrastructure to advance SD-101toward regulatory approvals and the Company's commercial, patient advocacy, and medical affairs infrastructure to support a successful global launch. The acquisition of Scioderm was accounted for as a purchase of a business in accordance with ASC 805 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the end of the first quarter of 2017, the Company achieved </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> enrollment in the Phase&#160;3 clinical study of SD-101 and the milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:10pt;"> due for this event, was paid in April 2017. On September&#160;13, 2017, the Company reported that top-line data from the randomized, double-blind, placebo-controlled Phase&#160;3 clinical study ("ESSENCE, SD-5") to assess the efficacy and safety of the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in participants with EB. Based on these top-line data, the Company has no current plans to invest in any additional clinical studies or commercial preparation activities for SD-101. This event led the Company to assess the carrying amount of the program's tangible and intangible assets against their respective fair values. Based on the assessment, the Company recognized a loss on impairment of intangible assets in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$463.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fixed assets recorded within loss on impairment of assets within the Consolidated Statements of Operations. Since the study did not meet the primary and secondary endpoints, the Company concluded that they will not make the potential milestone payments indicated in the Asset Purchase Agreement to the former Scioderm holders. Accordingly, the Company recognized a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$254.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in changes in fair value of contingent consideration payable in the third quarter of 2017, in order to decrease the liability to zero. The Company also recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in selling, general, and administrative costs and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in research and development expenses related to the wind-down of operations for the Phase 3 ESSENCE study and ongoing extension studies SD-004 and SD-006, as well as income tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$164.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> due to the reduction of the deferred tax liability related to Scioderm IPR&amp;D, in the Consolidated Statements of Operations in the third quarter of 2017. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Callidus Biopharma,&#160;Inc.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2013, the Company acquired Callidus Biopharma, Inc., ("Callidus"), a privately-held biologics company focused on developing best-in-class ERTs for LDs with its lead ERT ATB200 for Pompe disease in late preclinical development. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the contingent acquisition consideration payments was estimated by applying a probability-based income approach utilizing an appropriate discount rate. Key assumptions include discount rate and various probability factors. This estimation was based on significant inputs that are not observable in the market, referred to as Level&#160;3 inputs. Some of the more significant assumptions used in the valuation include (i)&#160;the probability and timing related to the achievement of certain developmental milestones and (ii)&#160;and the discount rate. See "&#8212;&#160;Note&#160;11. Assets and Liabilities Measured at Fair Value", for additional discussion regarding fair value measurements of the contingent acquisition consideration payable. The Company determined the fair value of the contingent consideration to be </span><span style="font-family:inherit;font-size:10pt;"><span>$22.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which is payable beyond the next twelve months, resulting in an increase in the contingent consideration payable and related expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The expense is recorded in the Consolidated Statement of Operations within the changes in fair value of contingent consideration line item.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2018, the Company reached a clinical milestone for Callidus, which was the dosing of the first patient in a Phase 3 study. The milestone payment for this event was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> which was paid in the Company's stock during the first quarter of 2019.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For further information, see "&#8212;&#160;Note&#160;4. Goodwill and Intangible Assets."</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812589472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text">Assets and Liabilities Measured at Fair Value<div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;1</span><span style="font-family:inherit;font-size:10pt;"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;2</span><span style="font-family:inherit;font-size:10pt;"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;3</span><span style="font-family:inherit;font-size:10pt;"> &#8212; Inputs that are unobservable for the asset or liability.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are identified in the following table:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,710</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,710</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-back securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Government Agency Bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,681</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,681</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred compensation plan liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,419</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are identified in the following table:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.40545808966861%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-back securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240,726</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240,726</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred compensation plan liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s Convertible Notes falls into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the Convertible Notes at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s Senior Secured Term Loan fall into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan approximates the fair value.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company did not have any Level 3 assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Money Market Funds and Marketable Securities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. No transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy occurred during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Consideration Payable</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contingent consideration payable resulted from the acquisition of Callidus, as discussed in "&#8212;&#160;Note&#160;3. Acquisitions." The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Using this approach, expected future cash flows are calculated over the expected life of the agreement, are discounted, and then exercise scenario probabilities are applied. The valuation is performed quarterly. Gains and losses are included in the Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contingent consideration payable for Callidus has been classified as a Level&#160;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. The Company may be required to record losses in future periods.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.64327485380117%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:23%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:12%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable Input</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Range</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.6%</span></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical and regulatory milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,390</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability weighted discounted cash flow</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of achievement of milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75% - 78%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected year of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021 - 2022</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reached a clinical milestone, which was the dosing of the first patient in a Phase 3 study, related to the contingent consideration from the acquisition of Callidus. The milestone for this event was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was paid in Company common stock in the first quarter of 2019, resulting in </span><span style="font-family:inherit;font-size:10pt;"><span>$9.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> impact on stockholder's equity.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the change in the balance of contingent consideration payable for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, beginning of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones payable, included in accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,000</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in fair value during the period, included in the Consolidated Statements of Operations </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,297</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment for contingent consideration paid in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(316</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, end of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Compensation Plan - Investment and Liability</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Deferred Compensation Plan (the "Deferral Plan") provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant&#8217;s base salary, bonus and director&#8217;s fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investment&#8217;s fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812507104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable, Accrued Expenses, and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable, accrued expenses, and other current liabilities</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">consist of the following: </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,722</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,832</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued contract manufacturing&#160;&amp; contract research costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,890</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued program fees</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued royalties </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,463</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,679</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,189</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued sales rebates and discounts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,772</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,830</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120,373</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,625</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983237008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Cost</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to operating leases was as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.270955165692%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except year and discount rate amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU asset</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of the operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,189</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current portion of the operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,531</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease terms (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments, Operating Leases</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the future minimum operating lease payments were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.22807017543859%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,787</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,582</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163,266</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>215,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less lease incentives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,939</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Less imputed interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(125,982</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the future minimum operating lease payments were as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.64327485380117%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,063</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,038</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,887</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806848656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Deferred compensation investment</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fold_StockOptionPlan2007AndDirectorOptionPlan2007Member', window );">2007 Plan and 2007 Director Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Award term</a></td>
<td class="text">P10Y<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fold_StockOptionPlan2007AndDirectorOptionPlan2007Member', window );">2007 Plan and 2007 Director Plan | First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2007 Plan and 2007 Director Plan | Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance</a></td>
<td class="nump">10,667,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fold_StockOptionPlan2007AndDirectorOptionPlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fold_StockOptionPlan2007AndDirectorOptionPlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6730067872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 6,544<span></span>
</td>
<td class="nump">$ 1,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">3,660<span></span>
</td>
<td class="nump">3,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,837<span></span>
</td>
<td class="nump">3,614<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">14,041<span></span>
</td>
<td class="nump">8,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for inventory</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6827704176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,691,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 360,151<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
<td class="nump">$ 1,120,156<span></span>
</td>
<td class="nump">$ 16,076<span></span>
</td>
<td class="nump">$ 2,047<span></span>
</td>
<td class="num">$ (779,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued from exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,878,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued from exercise of stock options, net</a></td>
<td class="nump">16,301<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">16,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,122,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued from equity financing</a></td>
<td class="nump">243,037<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">242,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock tax vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock tax vesting</a></td>
<td class="num">(1,596)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,596)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">23,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding loss on available-for-sale securities</a></td>
<td class="num">(538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(3,604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(284,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(284,002)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,989,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">352,850<span></span>
</td>
<td class="nump">$ 1,721<span></span>
</td>
<td class="nump">1,400,758<span></span>
</td>
<td class="nump">16,076<span></span>
</td>
<td class="num">(2,095)<span></span>
</td>
<td class="num">(1,063,610)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued from exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,397,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued from exercise of stock options, net</a></td>
<td class="nump">9,144<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">9,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,239,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued from equity financing</a></td>
<td class="nump">294,583<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">294,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock tax vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock tax vesting</a></td>
<td class="num">(2,832)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,832)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">29,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Reclassification upon ASU 2018-02 adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(383)<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">3,617<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">6,625<span></span>
</td>
<td class="num">(3,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives', window );">Change in fair value of derivatives</a></td>
<td class="nump">2,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding loss on available-for-sale securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">2,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (348,995)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(348,995)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">189,383,924<span></span>
</td>
<td class="nump">189,383,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 342,912<span></span>
</td>
<td class="nump">$ 1,942<span></span>
</td>
<td class="nump">1,740,061<span></span>
</td>
<td class="nump">13,063<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="num">(1,412,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued from exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,967,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued from exercise of stock options, net</a></td>
<td class="nump">11,476<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">11,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,720,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued from equity financing</a></td>
<td class="nump">188,994<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">188,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock tax vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock tax vesting</a></td>
<td class="num">(3,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesContingentConsideration', window );">Stock issued for contingent consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueContingentConsideration', window );">Stock issued for contingent consideration</a></td>
<td class="nump">9,316<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">9,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">44,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="num">(676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Equity component of the convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,995,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of the convertible notes</a></td>
<td class="nump">215,476<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">215,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations', window );">Termination of capped call confirmations</a></td>
<td class="nump">19,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding loss on available-for-sale securities</a></td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (356,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(356,388)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">255,417,869<span></span>
</td>
<td class="nump">255,417,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 476,425<span></span>
</td>
<td class="nump">$ 2,598<span></span>
</td>
<td class="nump">$ 2,227,225<span></span>
</td>
<td class="nump">$ 12,387<span></span>
</td>
<td class="nump">$ 2,825<span></span>
</td>
<td class="num">$ (1,768,610)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid-In Capital, Change In Fair Value Of Derivatives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from Termination of Capped Call Confirmations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants (in shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL116659650-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805954976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccumulatedDepreciationOperatingRightOfUseLeases', window );">Accumulated depreciation and amortization, operating lease right-of-use assets</a></td>
<td class="nump">$ 5,342<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation of property and equipment</a></td>
<td class="nump">$ 17,604<span></span>
</td>
<td class="nump">$ 15,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">255,417,869<span></span>
</td>
<td class="nump">189,383,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">255,417,869<span></span>
</td>
<td class="nump">189,383,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccumulatedDepreciationOperatingRightOfUseLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated Depreciation, Operating Right-Of-Use Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccumulatedDepreciationOperatingRightOfUseLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6829042368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred and Valuation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsIntellectualProperty', window );">Intellectual property</a></td>
<td class="nump">$ 46,521<span></span>
</td>
<td class="nump">$ 48,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Amortization/depreciation</a></td>
<td class="nump">2,329<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research tax credit</a></td>
<td class="nump">141,669<span></span>
</td>
<td class="nump">96,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">286,850<span></span>
</td>
<td class="nump">248,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred reimbursement</a></td>
<td class="nump">2,230<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent', window );">Non-cash stock issue</a></td>
<td class="nump">19,058<span></span>
</td>
<td class="nump">16,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsInterestCarryforwardLimitation', window );">Interest carry forward limitation</a></td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">15,986<span></span>
</td>
<td class="nump">10,852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">516,867<span></span>
</td>
<td class="nump">430,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesBusinessAcquisition', window );">Business acquisition</a></td>
<td class="num">(5,051)<span></span>
</td>
<td class="num">(6,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesRoyaltyPayable', window );">Royalty payable</a></td>
<td class="num">(46,521)<span></span>
</td>
<td class="num">(48,339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesConvertibleNotes', window );">Convertible notes</a></td>
<td class="num">(653)<span></span>
</td>
<td class="num">(16,666)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments', window );">Advanced R&amp;D payments</a></td>
<td class="num">(2,611)<span></span>
</td>
<td class="num">(2,103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(725)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsLiabilitiesGross', window );">Total net deferred tax assets</a></td>
<td class="nump">461,306<span></span>
</td>
<td class="nump">356,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(466,357)<span></span>
</td>
<td class="num">(363,005)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">(5,051)<span></span>
</td>
<td class="num">$ (6,465)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in the valuation allowance</a></td>
<td class="nump">$ 103,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsInterestCarryforwardLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Carryforward Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsInterestCarryforwardLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carry forwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carry forwards expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsNonCashStockIssueNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from advanced Research and Development payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Business Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from royalty payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6988762880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 55,293<span></span>
</td>
<td class="nump">$ 48,768<span></span>
</td>
<td class="nump">$ 44,130<span></span>
</td>
<td class="nump">$ 34,046<span></span>
</td>
<td class="nump">$ 32,644<span></span>
</td>
<td class="nump">$ 20,596<span></span>
</td>
<td class="nump">$ 21,309<span></span>
</td>
<td class="nump">$ 16,696<span></span>
</td>
<td class="nump">$ 182,237<span></span>
</td>
<td class="nump">$ 91,245<span></span>
</td>
<td class="nump">$ 36,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (89,729)<span></span>
</td>
<td class="num">$ (61,809)<span></span>
</td>
<td class="num">$ (84,551)<span></span>
</td>
<td class="num">$ (120,299)<span></span>
</td>
<td class="num">$ (78,083)<span></span>
</td>
<td class="num">$ (159,163)<span></span>
</td>
<td class="num">$ (61,833)<span></span>
</td>
<td class="num">$ (49,916)<span></span>
</td>
<td class="num">$ (356,388)<span></span>
</td>
<td class="num">$ (348,995)<span></span>
</td>
<td class="num">$ (284,002)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (1.88)<span></span>
</td>
<td class="num">$ (1.85)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6728106464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804819472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Recent Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 60,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU asset</a></td>
<td class="nump">$ 33,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830377104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 16, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 07, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued from underwriting agreement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 507,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount', window );">Exchange agreement, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,200,000<span></span>
</td>
<td class="nump">$ 247,200,000<span></span>
</td>
<td class="nump">$ 247,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance', window );">Exchange agreement, authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000.0<span></span>
</td>
<td class="nump">44,000,000.0<span></span>
</td>
<td class="nump">44,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest', window );">Accrued and unpaid interest on exchange agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital', window );">Gain (loss) on extinguishment of debt, additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued', window );">Gain (loss) on extinguishment of debt, fair value of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on exchange of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,624,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt', window );">Proceeds from capped call confirmations, exchange of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,900,000<span></span>
</td>
<td class="num">$ (19,875,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=fold_CommonStockCappedCallConfirmationMember', window );">Common Stock Capped Call Confirmation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare', window );">Capped call confirmations, initial cap price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage', window );">Capped call confirmations, premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued from underwriting agreement (in shares) | shares</a></td>
<td class="nump">885,000<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares', window );">Number of days granted underwriters for purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters', window );">Maximum number of additional shares granted to underwriters (in shares) | shares</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | Common Stock Capped Call Confirmation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds after deducting fees and estimated expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PremiumsPaidForCappedCallConfirmations', window );">Proceeds for capped call confirmations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt', window );">Shares issued per increment of convertible debt (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt conversion ratio (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1633987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice', window );">Period following 5 consecutive trading day period, trading price less than 98% of product of sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice', window );">Period following issuance of stock rights options or warrants with price per share less than last reported sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice', window );">Period for measurement of sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent', window );">Excess of value per share for triggering event, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes | Over-allotment Option | Private Placement Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">New credit facility borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage', window );">Periodic payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Call Feature, Capped Call Confirmation, Initial Cap Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentCallFeatureCappedCallConfirmationInitialCapPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Call Feature, Capped Call Confirmation, Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentCallFeatureCappedCallConfirmationPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Restriction, Excess Of Value Per Share For Triggering Event, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleConversionRestrictionExcessOfValuePerShareForTriggeringEventPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Restriction, Period Following Issuance Of Stock Rights Options Or Warrants With Price Per Share Less Than Last Reported Sales Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleConversionRestrictionPeriodFollowingIssuanceOfStockRightsOptionsOrWarrantsWithPricePerShareLessThanLastReportedSalesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Restriction, Period For Measurement Of Sales Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleConversionRestrictionPeriodForMeasurementOfSalesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Period Following Five Consecutive Trading Day Period, Trading Price Less Than Ninety-Eight Percent Of Product Of Sales Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertiblePeriodFollowingFiveConsecutiveTradingDayPeriodTradingPriceLessThanNinetyEightPercentOfProductOfSalesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentPeriodicPaymentPrincipalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Principal Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentPeriodicPaymentPrincipalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentsConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentsConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Extinguishment Of Debt, Additional Paid-In Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Additional Shares Granted To Underwriters</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_MaximumNumberOfAdditionalSharesGrantedToUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Days Granted Underwriters For Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfDaysGrantedUnderwritersForPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares per increment of convertible debt that will be issued upon conversion. For example, X number of shares may be issued for every $1,000 of convertible debt principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PremiumsPaidForCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for premiums paid for capped call confirmations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PremiumsPaidForCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=fold_CommonStockCappedCallConfirmationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=fold_CommonStockCappedCallConfirmationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6825724096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - RSUs and PBRSUs Summary (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(920,782)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember', window );">Stock Option Plan Amended Restated 2007 Equity Incentive Plan | Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units as of the beginning of the period (in shares)</a></td>
<td class="nump">3,712,000.0<span></span>
</td>
<td class="nump">2,575,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,526,000.0<span></span>
</td>
<td class="nump">1,811,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(921,000.0)<span></span>
</td>
<td class="num">(530,000.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(525,000.0)<span></span>
</td>
<td class="num">(145,000.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units as of the end of the period (in shares)</a></td>
<td class="nump">5,792,000.0<span></span>
</td>
<td class="nump">3,712,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units as of the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 10.59<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">10.92<span></span>
</td>
<td class="nump">16.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">8.49<span></span>
</td>
<td class="nump">6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">10.52<span></span>
</td>
<td class="nump">9.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units as of the end of the period (in dollars per share)</a></td>
<td class="nump">$ 11.18<span></span>
</td>
<td class="nump">$ 10.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Non-vested units, weighted average remaining years</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Non-vested units, aggregate intrinsic value</a></td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805830832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Statutory Rate (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract', window );"><strong>Income (loss) before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393,955,000)<span></span>
</td>
<td class="num">$ (309,183,000)<span></span>
</td>
<td class="num">$ (440,696,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,045,000<span></span>
</td>
<td class="num">(39,906,000)<span></span>
</td>
<td class="num">(8,425,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(355,910,000)<span></span>
</td>
<td class="num">(349,089,000)<span></span>
</td>
<td class="num">(449,121,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,877,000<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">2,276,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(984,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(150,015,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,415,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,389,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 478,000<span></span>
</td>
<td class="num">$ (94,000)<span></span>
</td>
<td class="num">$ (165,119,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the statutory tax rates and the effective tax rates</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(18.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.00%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income tax rate differential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent', window );">Impact of 2017 Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion', window );">Nondeductible debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(37.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrual for interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Accrual for uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Current federal and state tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impact of 2017 Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812517232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue Disaggregated by Geographical Area</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's net product sales from Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> disaggregated by geographic area:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Year </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ex-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,022</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,930</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net product sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,930</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983251248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborativeArrangementDisclosureAbstract', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Penn</span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, the Company expanded its gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDD and one additional undisclosed rare metabolic disorder. </span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company further expanded the collaboration from three to six programs for rare genetic diseases and now includes specifically: NPC, MPS IIIB, as well as a next generation program in MPS IIIA. This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. Under the expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$86.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country- by-country basis. The Company will provide </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> each year during the five-year agreement to fund the discovery research program. In connection with the collaboration agreement, the Company made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash to Penn that was expensed to research and development expense in the Consolidated Statements of Operations. </span></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">GlaxoSmithKline</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2013, Amicus entered into the Revised Agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus has obtained global rights to develop and commercialize Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between Amicus and GSK in July 2012 ("Expanded Collaboration Agreement"). Under the terms of the Revised Agreement, there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment from Amicus to GSK. For Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to </span><span style="font-family:inherit;font-size:10pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:10pt;">, as well as tiered royalties in the mid-teens in </span><span style="font-family:inherit;font-size:10pt;"><span>eight</span></span><span style="font-family:inherit;font-size:10pt;"> major markets outside the U.S. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$15.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of royalty expenses under the revised agreement with GSK.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the Revised Agreement, GSK will no longer jointly fund development costs for all formulations of Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In evaluating the impact of both the Expanded Collaboration Agreement and the Revised Agreement, the Company applied the accounting guidance regarding the impact of potential future payments it may make in its role as a vendor (i.e.,&#160;Amicus) to its customer (i.e.,&#160;GSK) and evaluated if these potential future payments could be a reduction of revenue from GSK. If the potential future payments to GSK are as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a payment for an identifiable benefit, and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the identifiable benefit is separable from the existing relationship between the Company and GSK, and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the identifiable benefit can be obtained from a party other than GSK, and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Company can reasonably estimate the fair value of the identifiable benefit,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">then the potential future payments would be treated separately from the collaboration and research revenue. However, if all these criteria are not satisfied, then the potential future payments are treated as a reduction of revenue.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, the Company did not believe that, for accounting purposes, the new U.S. licensing rights to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> obtained from GSK under the Expanded Collaboration Agreement, nor the ex U.S. licensing rights to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> obtained from GSK under the Revised Agreement, represented a separate, identifiable benefit from the licenses in the Original Collaboration Agreement entered into between Amicus and GSK in 2010. The contingent amounts payable to GSK were not sufficiently separable from GSK's original license and the research and development reimbursements such that Amicus could not have entered into a similar exchange transaction with another party. Additionally, the Company cannot reasonably estimate the fair value of the worldwide licensing rights to Galafold</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that the potential future payments to GSK would be treated as a reduction of revenue and that the total amount of revenue to be received under the arrangement is no longer fixed or determinable as the contingent milestone payments are subject to significant uncertainty.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result, the Company no longer recognized any of the upfront license fees and premiums on the equity purchase from GSK until such time as the arrangement consideration becomes fixed or determinable, because an indeterminable amount may ultimately be payable back to GSK. These amounts (the balance of the unrecognized upfront license fee and the premium on the equity purchases) are classified as deferred reimbursements on the balance sheet. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, under the GSK collaboration agreements, we paid </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in sales-based milestones. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized another </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for sales-based milestones that were met, invoiced and recorded in accounts payable, accrued expenses and other current liabilities and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as deferred reimbursements in the Consolidated Balance Sheets. Additionally, the Company recognized a liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to royalties payable to GSK in accounts payable and accrued expenses in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recognition of Research Revenue was also affected by the determination that the overall total arrangement consideration was no longer fixed and determinable, despite the fact that the research activities continued and that the research expense reimbursements by GSK to Amicus were received as the research activities related to the reimbursement had been completed. Therefore, the research reimbursements from GSK were recorded as deferred reimbursements on the balance sheet and would not be recognized until the total arrangement consideration becomes fixed and determinable.</span></div>As a result, all revenue recognition was suspended until the total arrangement consideration would become fixed and determinable. In addition, future milestone payments made by the Company will be applied against the balance of this deferred reimbursements account. Revenue recognition for research expense reimbursements, the original upfront license fee, and the equity premiums will resume once the total arrangement consideration becomes fixed and determinable which will occur when the balance of the deferred reimbursements account is sufficient to cover all the remaining contingent milestone payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
